PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Savaskan, NE; Seufert, S; Hauke, J; Trankle, C; Eyupoglu, IY; Hahnen, E				Savaskan, N. E.; Seufert, S.; Hauke, J.; Traenkle, C.; Eyuepoglu, I. Y.; Hahnen, E.			Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas	ONCOGENE			English	Article						glioma; tumor microenvironment; ionotropic glutamate signaling; glutamate/cystine transporter; excitotoxicity; xCT (SLC7A11)	X(C)(-) CYSTINE/GLUTAMATE ANTIPORTER; PRIMARY BRAIN-TUMORS; AMPA RECEPTORS; CELL-PROLIFERATION; IN-VIVO; GROWTH; RNA; TRANSPORT; CANCER; MICE	Malignant glioma represents one of the most aggressive and lethal human neoplasias. A hallmark of gliomas is their rapid proliferation and destruction of vital brain tissue, a process in which excessive glutamate release by glioma cells takes center stage. Pharmacologic antagonism with glutamate signaling through ionotropic glutamate receptors attenuates glioma progression in vivo, indicating that glutamate release by glioma cells is a prerequisite for rapid glioma growth. Glutamate has been suggested to promote glioma cell proliferation in an autocrine or paracrine manner, in particular by activation of the (RS)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate (AMPA) subtype of glutamate receptors. Here, we dissect the effects of glutamate secretion on glioma progression. Glioma cells release glutamate through the amino-acid antiporter system X-c(-), a process that is mechanistically linked with cystine incorporation. We show that disrupting glutamate secretion by interfering with the system X-c(-) activity attenuates glioma cell proliferation solely cystine dependently, whereas glutamate itself does not augment glioma cell growth in vitro. Neither AMPA receptor agonism nor antagonism affects glioma growth in vitro. On a molecular level, AMPA insensitivity is concordant with a pronounced transcriptional downregulation of AMPA receptor subunits or overexpression of the fully edited GluR2 subunit, both of which block receptor activity. Strikingly, AMPA receptor inhibition in tumor-implanted brain slices resulted in markedly reduced tumor progression associated with alleviated neuronal cell death, suggesting that the ability of glutamate to promote glioma progression strictly requires the tumor microenvironment. Concerning a potential pharmacotherapy, targeting system X-c(-) activity disrupts two major pathophysiological properties of glioma cells, that is, the induction of excitotoxic neuronal cell death and incorporation of cystine required for rapid proliferation. Oncogene (2011) 30, 43-53; doi: 10.1038/onc.2010.391; published online 30 August 2010	[Savaskan, N. E.] Charite, Inst Cell Biol & Neurobiol, D-10117 Berlin, Germany; [Seufert, S.; Hauke, J.; Hahnen, E.] Univ Cologne, Inst Human Genet, D-50931 Cologne, Germany; [Seufert, S.; Hauke, J.; Hahnen, E.] Univ Cologne, Ctr Mol Med Cologne, Inst Genet, D-50931 Cologne, Germany; [Traenkle, C.] Univ Bonn, Inst Pharm, Dept Pharmacol & Toxicol, D-5300 Bonn, Germany; [Eyuepoglu, I. Y.] Univ Erlangen Nurnberg, Dept Neurosurg, Erlangen, Germany; [Hahnen, E.] Univ Hosp Erlangen, Inst Neuropathol, Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cologne; University of Cologne; University of Bonn; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Savaskan, NE (corresponding author), Charite, Inst Cell Biol & Neurobiol, Philippstr 12, D-10117 Berlin, Germany.	savaskan@gmx.net; eric.hahnen@uk-koeln.de	; Savaskan, Nicolai/D-2923-2018	Hauke, Jan/0000-0001-8236-4075; Savaskan, Nicolai/0000-0003-1348-094X	Wilhelm Sander-Stiftung; Institut Danone; International Human Frontiers Science Program; ELAN-Programm; Koln Fortune Programm; Center for Molecular Medicine Cologne (CMMC)	Wilhelm Sander-Stiftung; Institut Danone(Danone Nutricia); International Human Frontiers Science Program(Human Frontier Science Program); ELAN-Programm; Koln Fortune Programm; Center for Molecular Medicine Cologne (CMMC)	We thank Nadine Scheufler and Philip Rummel (both Erlangen) for experimental support. Jan Csupor (Berlin) is acknowledged for technical assistance. This study was supported by the 'Wilhelm Sander-Stiftung' (to EH), the 'Institut Danone' (to NES, IYE and EH), the 'International Human Frontiers Science Program' (to NES), the 'ELAN-Programm' (to IYE), the 'Koln Fortune Programm' (to EH) and the 'Center for Molecular Medicine Cologne (CMMC)' (to EH).	Behrens PF, 2000, J NEURO-ONCOL, V47, P11, DOI 10.1023/A:1006426917654; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Chung WJ, 2009, J NEUROCHEM, V110, P182, DOI 10.1111/j.1471-4159.2009.06129.x; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; De Groot JF, 2008, J NEURO-ONCOL, V88, P121, DOI 10.1007/s11060-008-9552-2; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; Eyupoglu IY, 2005, J NEUROSURG, V102, P738, DOI 10.3171/jns.2005.102.4.0738; Eyupoglu IY, 2005, J NEUROCHEM, V93, P992, DOI 10.1111/j.1471-4159.2005.03098.x; Eyupoglu LY, 2006, MOL CANCER THER, V5, P1248, DOI 10.1158/1535-7163.MCT-05-0533; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Liu RR, 2007, BIOCHEM BIOPH RES CO, V364, P528, DOI 10.1016/j.bbrc.2007.10.036; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Lu W, 2009, NEURON, V62, P254, DOI 10.1016/j.neuron.2009.02.027; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Marcus HJ, 2010, J NEURO-ONCOL, V97, P11, DOI 10.1007/s11060-009-9990-5; Mawatari C, 1996, NEUROSCIENCE, V73, P201, DOI 10.1016/0306-4522(96)00025-5; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Pham AN, 2010, J PHARMACOL EXP THER, V332, P949, DOI 10.1124/jpet.109.162248; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Robe PA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-372; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Savaskan NE, 2007, CELL MOL LIFE SCI, V64, P230, DOI 10.1007/s00018-006-6412-0; Savaskan NE, 2009, J CELL PHYSIOL, V220, P531, DOI 10.1002/jcp.21795; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Schwenk J, 2009, SCIENCE, V323, P1313, DOI 10.1126/science.1167852; Shih AY, 2006, J NEUROSCI, V26, P10514, DOI 10.1523/JNEUROSCI.3178-06.2006; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; van Vuurden DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005953; Vanhoutte N, 2009, EXP NEUROL, V218, P56, DOI 10.1016/j.expneurol.2009.04.004; Ye ZC, 1999, CANCER RES, V59, P4383; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999; Yoshida Y, 2006, PATHOL INT, V56, P262, DOI 10.1111/j.1440-1827.2006.01954.x; Zhuge J, 2006, FREE RADICAL BIO MED, V40, P63, DOI 10.1016/j.freeradbiomed.2005.08.012	42	28	31	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					43	53		10.1038/onc.2010.391	http://dx.doi.org/10.1038/onc.2010.391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802520				2022-12-28	WOS:000285959300004
J	Ythier, D; Larrieu, D; Binet, R; Binda, O; Brambilla, C; Gazzeri, S; Pedeux, R				Ythier, D.; Larrieu, D.; Binet, R.; Binda, O.; Brambilla, C.; Gazzeri, S.; Pedeux, R.			Sumoylation of ING2 regulates the transcription mediated by Sin3A	ONCOGENE			English	Article						sumoylation; Sin3A; SUMO1; transcription	DNA-REPLICATION FORKS; PHD-FINGER; EXPRESSION; PROTEIN; GENE; SUMO; GROWTH; MOTIF; P53; ACETYLATION	ING2 (inhibitor of growth 2) is a candidate tumor-suppressor gene involved in cell cycle control, apoptosis and senescence. Although the functions of ING2 within the chromatin remodeling complex Sin3A/histone deacetylase (HDAC) and in the p53 pathway have been described, how ING2 itself is regulated remains unknown. In this study we report for the first time that ING2 can be sumoylated by small ubiquitin-like modifier 1 (SUMO1) on lysine 195 both in vitro and in vivo. Strikingly, ING2 sumoylation enhances its association with Sin3a. We provide evidences that ING2 can bind to the promoter of genes to mediate their expression and that sumoylation of ING2 is required for this binding to some of these genes. Among them, we identified the gene TMEM71 (transmembrane protein 71), whose expression is regulated by ING2 sumoylation. ING2 must be sumoylated to bind to the promoter of TMEM71 and to recruit the Sin3A chromatin-modifying complex to this promoter, in order to regulate TMEM71 transcription. Hence, sumoylation of ING2 enhances its binding to the Sin3A/HDAC complex and is required to regulate gene transcriptions. Oncogene (2010) 29, 5946-5956; doi:10.1038/onc.2010.325; published online 2 August 2010	[Ythier, D.; Larrieu, D.; Binet, R.; Brambilla, C.; Gazzeri, S.; Pedeux, R.] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France; [Binda, O.] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; [Pedeux, R.] Univ Rennes 1, INSERM, U917, IFR140,Fac Med, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Pedeux, R (corresponding author), INSERM, U917 MICA, Fac Med Rennes, Batiment 2,Piece 117,2 Ave Pr Leon Bernard, F-35043 Rennes, France.	remy.pedeux@univ-rennes1.fr	Binda, Olivier/A-5941-2009; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; Binet, Romuald/I-7938-2012; PEDEUX, Rémy M/I-2603-2014	Binda, Olivier/0000-0002-1539-0828; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; Binet, Romuald/0000-0003-0636-2195; PEDEUX, Rémy M/0000-0002-2553-7934	ARC; IASLC; Marie Curie International Reintegration Grant [MIRG-CT-2006-042148]; INCa; FRM; French Ministry of Education and Research; Agir a dom	ARC(Australian Research Council); IASLC; Marie Curie International Reintegration Grant(European Commission); INCa(Institut National du Cancer (INCA) France); FRM(Fondation pour la Recherche Medicale); French Ministry of Education and Research; Agir a dom	We thank D Nissou for technical assisstance; Dr O Gozani and C Harris for antibodies, plasmids and scientific discussion, and Dr Marc Piechaczyk and Dr Guillaume Bossis for scientific discussion and advising. RP was supported by ARC, the IASLC, an 'Agir a dom' grant and a Marie Curie International Reintegration Grant (MIRG-CT-2006-042148). DY, RB and DL were funded by the INCa, ARC, the FRM (Prix Mariane Josso) and the French Ministry of Education and Research, respectively.	Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Borkosky SS, 2009, J CANCER RES CLIN, V135, P703, DOI 10.1007/s00432-008-0507-y; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Farhana L, 2009, MOL CANCER THER, V8, P1625, DOI 10.1158/1535-7163.MCT-08-0964; Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Larrieu D, 2009, CELL CYCLE, V8, P3623, DOI 10.4161/cc.8.22.9947; Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sarker KP, 2008, J BIOL CHEM, V283, P13269, DOI 10.1074/jbc.M708834200; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiseki M, 2003, CANCER RES, V63, P2373; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Terui Y, 2004, J BIOL CHEM, V279, P28257, DOI 10.1074/jbc.M403153200; Ythier D, 2008, INT J CANCER, V123, P1483, DOI 10.1002/ijc.23790; Ythier D, 2010, LUNG CANCER, V69, P180, DOI 10.1016/j.lungcan.2009.11.006; Zhang HK, 2008, CANCER LETT, V261, P183, DOI 10.1016/j.canlet.2007.11.019	33	22	24	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5946	5956		10.1038/onc.2010.325	http://dx.doi.org/10.1038/onc.2010.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20676127				2022-12-28	WOS:000283843400008
J	Erenpreisa, J; Cragg, MS				Erenpreisa, J.; Cragg, M. S.			MOS, aneuploidy and the ploidy cycle of cancer cells	ONCOGENE			English	Review						polyploidy; MOS; aneuploidy; DNA damage; tumor resistance; life cycle	MEIOSIS-SPECIFIC GENES; VIDEO TIME-LAPSE; MITOTIC CATASTROPHE; GIANT-CELLS; CHROMOSOME SEGREGATION; TUMOR-CELLS; C-MOS; UP-REGULATION; SELF-RENEWAL; POLYPLOIDY	After DNA or spindle damage, p53-defective tumor cells undergo a complex cycle of reversible polyploidy. How this process occurs and more importantly, why, has recently become the focus of several research groups, prompting this review in which we discuss two related phenomena that accompany the reversible polyploidy of tumor cells: the induction of meiosis genes such as MOS and the decrease in genomic instability observed during the reversion from polyploidy to para-diploidy. The reversible polyploidy likely provides the means through which the balance between increased chromosome instability (CIN), driving genetic variation and decreased CIN, necessary for perpetuating these malignant clones, is maintained. These concepts are integrated with recent findings that many meiotic and self-renewal genes become activated during reversible polyploidy and lead us to the hypothesis that tumor cell immortality may be achieved through germline-like transmission. Oncogene (2010) 29, 5447-5451; doi:10.1038/onc.2010.310; published online 2 August 2010	[Erenpreisa, J.] Latvian Biomed Res & Study Ctr, LV-1067 Riga, Latvia; [Cragg, M. S.] Univ Southampton, Sch Med, Gen Hosp, Tenovus Lab,Canc Sci Div, Southampton SO16 6YD, Hants, England	Latvian Biomedical Research & Study Centre; University of Southampton	Erenpreisa, J (corresponding author), Latvian Biomed Res & Study Ctr, LV-1067 Riga, Latvia.	katrina@biomed.lu.lv; msc@soton.ac.uk	Cragg, Mark S/E-5965-2010	Cragg, Mark S/0000-0003-2077-089X				Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chandhok NS, 2009, CURR OPIN GENET DEV, V19, P74, DOI 10.1016/j.gde.2008.12.004; Choi T, 1996, P NATL ACAD SCI USA, V93, P4730, DOI 10.1073/pnas.93.10.4730; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; CLEVELAND LR, 1947, SCIENCE, V105, P287, DOI 10.1126/science.105.2724.287; DELAHOZ C, 1993, J CELL SCI, V104, P31; Duesberg P, 2006, CONTRIB MICROBIOL, V13, P16, DOI 10.1159/000092963; Erenpreisa J, 2005, CELL BIOL INT, V29, P1012, DOI 10.1016/j.cellbi.2005.10.005; Erenpreisa J, 2005, CELL BIOL INT, V29, P981, DOI 10.1016/j.cellbi.2005.10.002; Erenpreisa JA, 2000, CELL BIOL INT, V24, P635, DOI 10.1006/cbir.2000.0558; Erenpreisa J, 2008, CELL BIOL INT, V32, P1044, DOI 10.1016/j.cellbi.2008.06.003; Erenpreisa J, 2007, CELL BIOL INT, V31, P1507, DOI 10.1016/j.cellbi.2007.08.013; Erenpreisa J, 2009, EXP CELL RES, V315, P2593, DOI 10.1016/j.yexcr.2009.05.011; Extavour C, 2009, CURR BIOL, V19, pR489, DOI 10.1016/j.cub.2009.05.015; Forer A, 2009, CELL BIOL INT, V33, P253, DOI 10.1016/j.cellbi.2008.11.004; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Gergely F, 2008, GENE DEV, V22, P2291, DOI 10.1101/gad.1715208; Gisselsson D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001871; Gorgoulis VG, 2001, CANCER RES, V61, P538; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642; Hoglund M, 2002, CANCER GENET CYTOGEN, V135, P103, DOI 10.1016/S0165-4608(01)00645-8; HURST LD, 1991, J THEOR BIOL, V150, P561, DOI 10.1016/S0022-5193(05)80447-3; Ianzini F, 2002, RADIAT PROT DOSIM, V99, P289, DOI 10.1093/oxfordjournals.rpd.a006787; Ianzini F, 2009, CANCER RES, V69, P2296, DOI 10.1158/0008-5472.CAN-08-3364; Illidge TM, 2000, CELL BIOL INT, V24, P621, DOI 10.1006/cbir.2000.0557; Ivanov A, 2003, J CELL SCI, V116, P4095, DOI 10.1242/jcs.00740; Kalejs M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-6; KONDRASHOV AS, 1994, NATURE, V370, P213, DOI 10.1038/370213a0; Kondrashov AS, 1997, ANNU REV ECOL SYST, V28, P391, DOI 10.1146/annurev.ecolsys.28.1.391; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lee HO, 2009, GENE DEV, V23, P2461, DOI 10.1101/gad.1829209; Ling YH, 1998, CANCER RES, V58, P3633; Martin F, 2009, CELL BIOL INT, V33, P702, DOI 10.1016/j.cellbi.2009.02.016; NAGL W, 1978, ENDOPOLYPLOIDY POLYT; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Page AW, 1997, CURR OPIN GENET DEV, V7, P23, DOI 10.1016/S0959-437X(97)80105-0; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Prieur-Carrillo G, 2003, RADIAT RES, V159, P705, DOI 10.1667/RR3009; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raikov I.B., 1982, PROTOZOAN NUCL MORPH; Rajaraman R., 2007, International Journal of Human Genetics, V7, P29; Rajaraman R, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-25; Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Therman Eeva, 1989, Critical Reviews in Oncogenesis, V1, P293; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Vitale I, 2010, EMBO J, V29, P1272, DOI 10.1038/emboj.2010.11; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Wheatley D, 2008, CELL BIOL INT, V32, P1029, DOI 10.1016/j.cellbi.2008.06.001; Wilkins AS, 2009, GENETICS, V181, P3, DOI 10.1534/genetics.108.099762; Wu JQ, 2008, J CELL SCI, V121, P3509, DOI 10.1242/jcs.036855; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	66	53	54	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5447	5451		10.1038/onc.2010.310	http://dx.doi.org/10.1038/onc.2010.310			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20676137				2022-12-28	WOS:000282945800002
J	Vilgelm, AE; Hong, SM; Washington, MK; Wei, J; Chen, H; El-Rifai, W; Zaika, A				Vilgelm, A. E.; Hong, S-M; Washington, M. K.; Wei, J.; Chen, H.; El-Rifai, W.; Zaika, A.			Characterization of Delta Np73 expression and regulation in gastric and esophageal tumors	ONCOGENE			English	Article						p73; gastric tumor; esophageal tumor	FACTOR-BINDING SITES; FEEDBACK LOOP; P53; CANCER; FAMILY; P73; PROMOTER; TAP73; DEATH; DNP73	p73 is a member of the p53 protein family. Although the tumor suppressor function of p53 is clearly defined, the role of p73 in tumorigenesis is still a matter of debate. A complex pattern of expression of p73 isoforms makes it difficult to unambiguously interpret the experimental results. Previously, we along with others have found that the N-terminally truncated isoform of p73, Delta Np73, has potent anti-apoptotic and oncogenic properties in vitro and in vivo. In this study, we analyzed, for the first time, the regulation of Delta Np73 in a large number of gastric, gastroesophageal junction and esophageal tumors. We found that expression of Delta Np73 mRNA and protein is increased in these neoplasms. Furthermore, the upregulation of the Delta Np73 protein is significantly associated with poor patient survival. Oncogenic properties of Delta Np73 were further confirmed by finding that Delta Np73 facilitates anchorage-independent growth of gastric epithelial cells in soft agar. As little is currently known about the regulation of Delta Np73 transcription, we investigated the alternative p73 gene promoter that mediates the Delta Np73 expression. Analyzing the Delta Np73 promoter in silico as well as by using chromatin immunoprecipitation, site-directed mutagenesis and deletion analyses, we identified the evolutionary conserved region within the Delta Np73 promoter that contains binding sites for HIC1 (hypermethylated in cancer) protein. We found that HIC1 negatively regulates Delta Np73 transcription in mucosal epithelial cells. This leads to a decrease in Delta Np73 protein levels and may normally control the oncogenic potential of the Delta Np73 isoform. Oncogene (2010) 29, 5861-5868; doi: 10.1038/onc.2010.319; published online 2 August 2010	[Vilgelm, A. E.; Wei, J.; El-Rifai, W.; Zaika, A.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA; [Vilgelm, A. E.; Washington, M. K.; Wei, J.; Chen, H.; El-Rifai, W.; Zaika, A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Vilgelm, A. E.] Russian Acad Sci, Dept Cell Biol, VA Engelhardt Mol Biol Inst, Moscow, Russia; [Hong, S-M] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [El-Rifai, W.; Zaika, A.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Johns Hopkins University; Johns Hopkins Medicine; Vanderbilt University; Vanderbilt University	Zaika, A (corresponding author), Dept Surg & Canc Biol, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	alexander.zaika@vanderbilt.edu		Vilgelm, Anna/0000-0002-4446-913X; Hong, Seung-Mo/0000-0002-8888-6007	National Cancer Institute [NIH CA108956]; Vanderbilt CTSA [UL1 RR024975]; NATIONAL CANCER INSTITUTE [R01CA108956, R01CA138833] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the National Cancer Institute grant NIH CA108956 and Vanderbilt CTSA grant UL1 RR024975. We thank Dr Castells and Dr Pera of University of Barcelona for their assistance.	Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Lin KW, 2004, NEOPLASIA, V6, P546, DOI 10.1593/neo.04205; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Tannapfel A, 2008, CARCINOGENESIS, V29, P211, DOI 10.1093/carcin/bgm236; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Zaika AI, 2006, CELL DEATH DIFFER, V13, P935, DOI 10.1038/sj.cdd.4401897	21	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5861	5868		10.1038/onc.2010.319	http://dx.doi.org/10.1038/onc.2010.319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20676143	Green Accepted			2022-12-28	WOS:000283586200011
J	Improgo, MRD; Scofield, MD; Tapper, AR; Gardner, PD				Improgo, M. R. D.; Scofield, M. D.; Tapper, A. R.; Gardner, P. D.			From smoking to lung cancer: the CHRNA5/A3/B4 connection	ONCOGENE			English	Review						nicotine addiction; lung cancer; nicotinic acetylcholine receptors; CHRNA5/A3/B4 gene cluster	NICOTINIC ACETYLCHOLINE-RECEPTOR; ALPHA-3 GENE PROMOTER; SUBUNIT GENE; MICE LACKING; TRANSCRIPTIONAL REGULATION; SUSCEPTIBILITY LOCUS; BETA-4 SUBUNIT; GROWTH-FACTOR; TUMOR-GROWTH; PHYSIOLOGICAL DIVERSITY	Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that modulate key physiological processes ranging from neurotransmission to cancer signaling. These receptors are activated by the neurotransmitter, acetylcholine, and the tobacco alkaloid, nicotine. Recently, the gene cluster encoding the alpha 3, alpha 5 and beta 4 nAChR subunits received heightened interest after a succession of linkage analyses and association studies identified multiple single-nucleotide polymorphisms in these genes that are associated with an increased risk for nicotine dependence and lung cancer. It is not clear whether the risk for lung cancer is direct or an effect of nicotine dependence, as evidence for both scenarios exist. In this study, we summarize the body of work implicating nAChRs in the pathogenesis of lung cancer, with special focus on the clustered nAChR subunits and their emerging role in this disease state. Oncogene (2010) 29, 4874-4884; doi: 10.1038/onc.2010.256; published online 28 June 2010	[Improgo, M. R. D.; Scofield, M. D.; Tapper, A. R.; Gardner, P. D.] Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, Worcester, MA 01604 USA	University of Massachusetts System; University of Massachusetts Worcester	Gardner, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, 303 Belmont St, Worcester, MA 01604 USA.	paul.gardner@umassmed.edu		Scofield, Michael/0000-0002-2330-6999	National Institutes of Health [NS030243, AA017656]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017656] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	Work in the authors' laboratories is supported in part by grants NS030243 (PDG) and AA017656 (ART) from the National Institutes of Health.	Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; American Cancer Society, 2009, CANC FACTS FIG 2009; Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Arneric SP, 2007, BIOCHEM PHARMACOL, V74, P1092, DOI 10.1016/j.bcp.2007.06.033; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Arredondo J, 2006, J CANCER RES CLIN, V132, P653, DOI 10.1007/s00432-006-0113-9; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; Benfante R, 2007, J BIOL CHEM, V282, P13290, DOI 10.1074/jbc.M608616200; Berrettine W, 2008, MOL PSYCHIATR, V13, P368, DOI 10.1038/sj.mp.4002154; Bierut LJ, 2008, AM J PSYCHIAT, V165, P1163, DOI 10.1176/appi.ajp.2008.07111711; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Blanchet MR, 2004, AM J RESP CRIT CARE, V169, P903, DOI 10.1164/rccm.200210-1154OC; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1997, CRIT REV TOXICOL, V27, P299, DOI 10.3109/10408449709089897; Bruschweiler-Li L, 2010, NEUROSCIENCE, V166, P864, DOI 10.1016/j.neuroscience.2010.01.026; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Caporaso N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004653; Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; Cooke JP, 2008, TRENDS CARDIOVAS MED, V18, P247, DOI 10.1016/j.tcm.2008.11.007; CORRIGALL WA, 1989, PHARMACOL BIOCHEM BE, V33, P559, DOI 10.1016/0091-3057(89)90387-0; CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Dani JA, 2001, PHARMACOL BIOCHEM BE, V70, P439, DOI 10.1016/S0091-3057(01)00652-9; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366; Davis R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007524; De Biasi M, 2008, EXP BIOL MED, V233, P917, DOI 10.3181/0712-MR-355; Di Chiara G, 2000, EUR J PHARMACOL, V393, P295, DOI 10.1016/S0014-2999(00)00122-9; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Falvella FS, 2009, CLIN CANCER RES, V15, P1837, DOI 10.1158/1078-0432.CCR-08-2107; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; Flora A, 2000, EUR J PHARMACOL, V393, P85, DOI 10.1016/S0014-2999(00)00040-6; Freathy RM, 2009, HUM MOL GENET, V18, P2922, DOI 10.1093/hmg/ddp216; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Gahring LC, 2005, AAPS J, V7, pE885, DOI 10.1208/aapsj070486; Gahring LC, 2004, J COMP NEUROL, V468, P334, DOI 10.1002/cne.10943; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Grando SA, 2008, J PHARMACOL SCI, V106, P174, DOI 10.1254/jphs.FM0070087; Greenbaum L, 2009, MOL PSYCHIATR, V14, P912, DOI 10.1038/mp.2009.59; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Improgo MRD, 2010, MOL CANCER RES, V8, P194, DOI 10.1158/1541-7786.MCR-09-0185; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Jackson KJ, 2008, J PHARMACOL EXP THER, V325, P302, DOI 10.1124/jpet.107.132977; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kawashima K, 2003, LIFE SCI, V74, P675, DOI 10.1016/j.lfs.2003.09.037; Kenny PJ, 2001, PHARMACOL BIOCHEM BE, V70, P531, DOI 10.1016/S0091-3057(01)00651-7; Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001; Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Leonard S, 2001, Nicotine Tob Res, V3, P203; Levey MS, 1996, J NEUROSCI, V16, P6878; LEVEY MS, 1995, NEURON, V14, P153, DOI 10.1016/0896-6273(95)90249-X; Linnoila RI, 2000, CANCER RES, V60, P4005; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu Q, 1999, J NEUROSCI, V19, P9747; Liu Q, 2009, J NEUROSCI, V29, P918, DOI 10.1523/JNEUROSCI.3952-08.2009; LLOYD GK, 2000, WILLIAMS M EXP THER, V292, P461; Lustig LR, 2001, GENOMICS, V73, P272, DOI 10.1006/geno.2000.6503; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MANECKJEE R, 1994, CELL GROWTH DIFFER, V5, P1033; Marubio LM, 2003, EUR J NEUROSCI, V17, P1329, DOI 10.1046/j.1460-9568.2003.02564.x; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; McKeon A, 2009, ARCH NEUROL-CHICAGO, V66, P735, DOI 10.1001/archneurol.2009.78; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; Nguyen VT, 2000, J DENT RES, V79, P939; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; Orr-Urtreger A, 2005, NEUROREPORT, V16, P1123, DOI 10.1097/00001756-200507130-00018; Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550; PATRICK J, 1993, PROG BRAIN RES, V98, P113; Perry DC, 2002, J NEUROCHEM, V82, P468, DOI 10.1046/j.1471-4159.2002.00951.x; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Portugal GS, 2008, BEHAV BRAIN RES, V193, P1, DOI 10.1016/j.bbr.2008.05.006; Portugal GS, 2008, NEUROBIOL LEARN MEM, V89, P106, DOI 10.1016/j.nlm.2007.05.002; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUNTURIERI A, 2009, SHAPIRO DUBINETT SM, V101, P554; Quick MW, 1999, NEUROPHARMACOLOGY, V38, P769, DOI 10.1016/S0028-3908(99)00024-6; Richardson CE, 2001, GASTROENTEROLOGY, V121, P350, DOI 10.1053/gast.2001.26320; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Romanelli MN, 2007, CHEMMEDCHEM, V2, P746, DOI 10.1002/cmdc.200600207; Rubin DT, 2000, EUR J GASTROEN HEPAT, V12, P855, DOI 10.1097/00042737-200012080-00004; Saccone NL, 2009, CANCER RES, V69, P6848, DOI 10.1158/0008-5472.CAN-09-0786; Saccone NL, 2009, AM J MED GENET B, V150B, P453, DOI 10.1002/ajmg.b.30828; Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438; Salas R, 2004, J NEUROSCI, V24, P10035, DOI 10.1523/JNEUROSCI.1939-04.2004; Salas R, 2004, NEUROPHARMACOLOGY, V47, P401, DOI 10.1016/j.neuropharm.2004.05.002; Salas R, 2003, J NEUROSCI, V23, P6255; Salas R, 2007, NEUROPHARMACOLOGY, V53, P863, DOI 10.1016/j.neuropharm.2007.08.017; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; Sartelet H, 2008, PATHOL RES PRACT, V204, P891, DOI 10.1016/j.prp.2008.05.006; Sasaki H, 2010, J SURG RES, V162, P75, DOI 10.1016/j.jss.2009.01.008; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schlaelpfer IR, 2008, BIOL PSYCHIAT, V63, P1039, DOI 10.1016/j.biopsych.2007.10.024; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; SCHULLER HM, 1992, CANCER RES, V52, pS2723; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; Scofield MD, 2008, NEUROREPORT, V19, P687, DOI 10.1097/WNR.0b013e3282fbcef7; Sher E, 1998, ANN NY ACAD SCI, V841, P606, DOI 10.1111/j.1749-6632.1998.tb10993.x; Sherva R, 2008, ADDICTION, V103, P1544, DOI 10.1111/j.1360-0443.2008.02279.x; Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832; Shin VY, 2004, CARCINOGENESIS, V25, P2487, DOI 10.1093/carcin/bgh266; Shivji M, 2005, J BIOL CHEM, V280, P15219, DOI 10.1074/jbc.M413946200; Song PF, 2003, CANCER RES, V63, P214; Spindel ER, 2003, AM J PHYSIOL-LUNG C, V285, pL1201, DOI 10.1152/ajplung.00251.2003; Spitz Margaret R, 2008, J Natl Cancer Inst, V100, P1552, DOI 10.1093/jnci/djn363; Stevens VL, 2008, CANCER EPIDEM BIOMAR, V17, P3517, DOI 10.1158/1055-9965.EPI-08-0585; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; Sun XJ, 2009, CANCER RES, V69, P6445, DOI 10.1158/0008-5472.CAN-09-1001; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Taly A, 2009, NAT REV DRUG DISCOV, V8, P733, DOI 10.1038/nrd2927; Tapper AR, 2007, PHYSIOL GENOMICS, V31, P422, DOI 10.1152/physiolgenomics.00063.2007; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Turner JR, 2005, J NEUROSCI, V25, P9258, DOI 10.1523/JNEUROSCI.2112-05.2005; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; Vernino S, 1998, NEUROLOGY, V50, P1806, DOI 10.1212/WNL.50.6.1806; Vernino S, 2000, NEW ENGL J MED, V343, P847, DOI 10.1056/NEJM200009213431204; WACHOLDER S, 2008, CAPORASO N, V100, P1488; Wang N, 2002, J PHYSIOL-LONDON, V542, P347, DOI 10.1113/jphysiol.2001.013456; Wang NS, 2003, MOL PHARMACOL, V63, P574, DOI 10.1124/mol.63.3.574; Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201; Weiss RB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000125; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; Xu W, 1999, J NEUROSCI, V19, P9298; Xu XH, 2006, MOL CELL BIOL, V26, P5636, DOI 10.1128/MCB.00456-06; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Ye YN, 2004, J PHARMACOL EXP THER, V308, P66, DOI 10.1124/jpet.103.058321; Zeidler R, 2007, APOPTOSIS, V12, P1927, DOI 10.1007/s10495-007-0102-8; Zhang QZ, 2007, CLIN CANCER RES, V13, P4686, DOI 10.1158/1078-0432.CCR-06-2898; Zheng Y, 2007, AM J RESP CELL MOL, V37, P681, DOI 10.1165/rcmb.2007-0051OC; Zhou YF, 1998, J NEUROBIOL, V34, P164, DOI 10.1002/(SICI)1097-4695(19980205)34:2<164::AID-NEU6>3.0.CO;2-0; Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8; Zoli M, 2002, J NEUROSCI, V22, P8785	170	42	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4874	4884		10.1038/onc.2010.256	http://dx.doi.org/10.1038/onc.2010.256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20581870	Green Accepted, Green Published			2022-12-28	WOS:000281578700002
J	Zhang, Y; Jiang, X; Qin, X; Ye, D; Yi, Z; Liu, M; Bai, O; Liu, W; Xie, X; Wang, Z; Fang, J; Chen, Y				Zhang, Y.; Jiang, X.; Qin, X.; Ye, D.; Yi, Z.; Liu, M.; Bai, O.; Liu, W.; Xie, X.; Wang, Z.; Fang, J.; Chen, Y.			RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma	ONCOGENE			English	Article						RKTG; ccRCC; angiogenesis; VEGF; HIF-1 alpha; p300	ENDOTHELIAL-GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTORS; FACTOR GENE; PROTEIN; RAF; IDENTIFICATION; TRANSDUCTION; EXPRESSION; PHOSPHORYLATION; STABILIZATION	Vascular endothelial growth factors (VEGFs) are crucial regulators of angiogenesis and vasculogenesis. The autocrine VEGF signaling is required for maintaining the homeostasis of vasculature. Dysregulation of angiogenesis is implicated in the development of many human cancers, especially in clear-cell renal cell carcinoma (ccRCC), a highly vascularized tumor. Meanwhile, antiangiogenesis has become a mainstay in the treatment of human cancers. In this study, we analyzed the functional roles of RKTG (Raf Kinase Trapping to Golgi), a negative regulator of mitogen-activated protein kinase (Raf/MEK/ERK) signaling, by sequestration of Raf kinase to the Golgi apparatus, in angiogenesis and ccRCC. Through a series of in vitro and in vivo experiments, we found that RKTG has a negative effect on cell proliferation, migration, sprouting and angiogenesis of endothelial cells. RKTG, by suppressing mitogen-activated protein kinase signaling, negatively regulates the transactivation activity of hypoxia-inducible factor 1 alpha (HIF-1 alpha) by inhibiting formation of HIF-1 alpha/p300 complex and suppressing VEGF transcription, thereby reducing hypoxia-induced VEGF production. The expression level of RKTG is significantly downregulated in clinical ccRCC tumor samples, with an inverse correlation with VEGF expression level. These results highlight the functional roles of RKTG and its regulated Raf/ERK/MEK signaling cascade in angiogenesis and autocrine VEGF signaling. In addition, this study indicates that RKTG is likely implicated in the development of ccRCC through its regulation on angiogenesis. Oncogene (2010) 29, 5404-5415; doi: 10.1038/onc.2010.270; published online 5 July 2010	[Zhang, Y.; Jiang, X.; Liu, W.; Xie, X.; Wang, Z.; Fang, J.; Chen, Y.] Chinese Acad Sci, Grad Sch, Key Lab Nutr & Metab, Inst Nutr Sci,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Qin, X.; Ye, D.] Fudan Univ, Ctr Canc, Dept Urol, Shanghai 200433, Peoples R China; [Yi, Z.; Liu, M.] E China Normal Univ, Inst Biomed Sci, Shanghai 200062, Peoples R China; [Yi, Z.; Liu, M.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Bai, O.] Jilin Univ, Hosp 1, Changchun 130023, Jilin, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; East China Normal University; East China Normal University; Jilin University	Chen, Y (corresponding author), Chinese Acad Sci, Grad Sch, Key Lab Nutr & Metab, Inst Nutr Sci,Shanghai Inst Biol Sci, 294 Taiyuan Rd,Rm307, Shanghai 200031, Peoples R China.	ychen3@sibs.ac.cn	xie, xiaoduo/B-8868-2012; Zhang, Yixuan/I-8007-2014	Zhang, Yixuan/0000-0001-7317-7235	Chinese Academy of Sciences [KSCX1-YW-02]; National Natural Science Foundation of China [30830037]; Ministry of Science and Technology of China [2007CB947100, 2006CB943900, 2010CB529506]	Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Dr George Simons and Dr Ilias Mylonis (University of Thessaly, Greece) for providing the plasmid of full-length HIF-1 alpha fused to GST; Dr William E Carson III and Dr Gregory B Lesinski (Ohio State University, USA) for discussion about the CD31 immunohistochemistry experiment; Dr Young-Guen Kwon and Yong-Sun Maeng (Yonsei University, Korea) and Dr Morag Park and Caroline Saucier (McGill University Health Centre, Quebec, Canada) for discussion about the Matrigel plug assay experiment; Dr Luisa Iruela-Arispe and Dr Tom Chen (University of California, Los Angeles, USA) for providing the experimental protocols; and Dr Jurgen Seppen (Academic Medical Centre, Amsterdam, Netherlands) for discussion about the experiment with lentivirus. This work was supported by research grants from the Chinese Academy of Sciences (Knowledge Innovation Program KSCX1-YW-02), the National Natural Science Foundation of China (30830037) and the Ministry of Science and Technology of China (2007CB947100 and 2006CB943900) to YC. This work was also supported by the Ministry of Science and Technology of China (2010CB529506) to ZW.	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Fan FJ, 2008, CARCINOGENESIS, V29, P1157, DOI 10.1093/carcin/bgn119; Feng L, 2007, P NATL ACAD SCI USA, V104, P14348, DOI 10.1073/pnas.0701298104; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haas CS, 2006, ARTHRITIS RHEUM, V54, P2402, DOI 10.1002/art.22034; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Luo X, 2008, BIOCHEM J, V414, P399, DOI 10.1042/BJ20080948; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Matsumoto T, 2006, J ATHEROSCLER THROMB, V13, P130, DOI 10.5551/jat.13.130; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Srivastava RK, 2010, MOL CELL BIOCHEM, V337, P201, DOI 10.1007/s11010-009-0300-5; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wang GG, 2008, J UNIV SCI TECHNOL B, V15, P261, DOI 10.1016/S1005-8850(08)60049-3; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Xie XD, 2008, CARCINOGENESIS, V29, P1632, DOI 10.1093/carcin/bgn139; Yi T, 2008, CANCER RES, V68, P1843, DOI 10.1158/0008-5472.CAN-07-5944	39	67	69	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5404	5415		10.1038/onc.2010.270	http://dx.doi.org/10.1038/onc.2010.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20603618				2022-12-28	WOS:000282944500007
J	Mitra, A; Radha, V				Mitra, A.; Radha, V.			F-actin-binding domain of c-Abl regulates localized phosphorylation of C3G: role of C3G in c-Abl-mediated cell death	ONCOGENE			English	Article						guanine nucleotide exchange factor; tyrosine kinase; apoptosis; c-Abl	NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-3 DOMAIN; FAMILY KINASES; INDUCED APOPTOSIS; BCR-ABL; ACTIVATION; RAP1; CRK; OVEREXPRESSION	The c-Abl tyrosine kinase maintains cellular homeostasis through its ability to regulate apoptosis and actin dynamics. In vivo, c-Abl activity is stringently regulated and mechanisms involved are not fully understood. Here, we identified the Rap1 guanine nucleotide exchange factor, C3G (RapGEF1), as a substrate and an effector of c-Abl-mediated functions. Ectopic expression of c-Abl in mammalian cell lines, known to induce apoptosis, resulted in phosphorylation of endogenous C3G on Y504 coincident with cell detachment and chromatin condensation. Phosphorylation of C3G coincided with restricted c-Abl activation in regions rich in actin, and was dependent on cellular F-actin dynamics. Unlike C3G or c-Abl, p-C3G was resistant to detergent extraction, suggesting its enhanced affinity for the cytoskeleton. Localized C3G phosphorylation and coincidence with cells undergoing cell death was dependent on F-actin-binding domain (FABD) of c-Abl. Activation of endogenous c-Abl by oxidative stress was associated with phosphorylation of cellular C3G on Y504. Inhibition of C3G expression and function using RNAi or dominant-negative approaches inhibited c-Abl-mediated cell death. These findings identify C3G as a novel target of c-Abl and also show that FABD of c-Abl is essential for regulation of its restricted activation to induce apoptosis. Oncogene (2010) 29, 4528-4542; doi: 10.1038/onc.2010.113; published online 28 June 2010	[Mitra, A.; Radha, V.] Ctr Cellular & Mol Biol, CSIR, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Radha, V (corresponding author), Ctr Cellular & Mol Biol, CSIR, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	vradha@ccmb.res.in			Council for Scientific and Industrial Research; Department of Science and Technology, Government of India	Council for Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology, Government of India(Department of Science & Technology (India))	We thank Drs PJS Stork (Oregon Health and Science University), Richard Van Etten (Tufts University), Patrick Casey (Duke University), S Tanaka (Hokkaido University School of Medicine), Bruce Mayer (University of Connecticut Health Center) for gifts of various constructs. We thank Dr Ghanshyam Swarup for support extended and for critically reading the paper. Assistance received from Ms Nandini Rangaraj during use of confocal microscopes is gratefully acknowledged. AM was supported by a fellowship from the Council for Scientific and Industrial Research. This work was supported by the Department of Science and Technology, Government of India through a grant awarded to VR.	Agami R, 1999, NATURE, V399, P809; Alvarez AR, 2004, NEUROBIOL DIS, V17, P326, DOI 10.1016/j.nbd.2004.06.007; Ba XQ, 2005, J CELL BIOCHEM, V94, P365, DOI 10.1002/jcb.20213; Balzac F, 2005, J CELL SCI, V118, P4765, DOI 10.1242/jcs.02584; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Chen CX, 2006, J BIOCHEM, V140, P229, DOI 10.1093/jb/mvj149; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chiang SH, 2006, METHOD ENZYMOL, V406, P701, DOI 10.1016/S0076-6879(06)06055-1; Cho YJ, 2005, BIOCHEM BIOPH RES CO, V333, P1276, DOI 10.1016/j.bbrc.2005.06.030; Cipres A, 2007, CELL SIGNAL, V19, P1662, DOI 10.1016/j.cellsig.2007.02.011; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Franklin-Tong VE, 2008, BIOCHEM J, V413, P389, DOI 10.1042/BJ20080320; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Grevengoed EE, 2003, J CELL BIOL, V163, P1267, DOI 10.1083/jcb.200307026; Guerrero C, 2004, ONCOGENE, V23, P4885, DOI 10.1038/sj.onc.1207622; Gutierrez-Berzal J, 2006, EXP CELL RES, V312, P938, DOI 10.1016/j.yexcr.2005.12.007; Halle M, 2007, MOL CELL BIOL, V27, P1172, DOI 10.1128/MCB.02462-05; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Holcomb M, 2006, J BIOL CHEM, V281, P2430, DOI 10.1074/jbc.M508454200; Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049; Huang XD, 2008, J CELL BIOL, V183, P711, DOI 10.1083/jcb.200801192; Huang YP, 2008, BLOOD, V112, P111, DOI 10.1182/blood-2007-10-118232; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Janji B, 2006, J CELL SCI, V119, P1947, DOI 10.1242/jcs.02874; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobayashi Y, 2006, ONCOGENE, V25, P512, DOI 10.1038/sj.onc.1209072; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; Maia V, 2009, CELL SIGNAL, V21, P1229, DOI 10.1016/j.cellsig.2009.03.015; Martin-Encabo S, 2007, EXP CELL RES, V313, P3881, DOI 10.1016/j.yexcr.2007.07.036; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nolz JC, 2008, J CELL BIOL, V182, P1231, DOI 10.1083/jcb.200801121; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Radha V, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-31; Radha V, 1999, FEBS LETT, V453, P308, DOI 10.1016/S0014-5793(99)00734-6; Radha V, 2007, EXP CELL RES, V313, P2476, DOI 10.1016/j.yexcr.2007.03.019; Radha V, 2008, J NEUROCHEM, V107, P1424, DOI 10.1111/j.1471-4159.2008.05710.x; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; SMITH JM, 2002, FRONT BIOSCI, V7, P131; Stevens TL, 2008, MOL BIOL CELL, V19, P378, DOI 10.1091/mbc.E07-01-0008; SUBHASH T, 2006, FEBS J, V273, P2766; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Woodring PJ, 2005, J BIOL CHEM, V280, P10318, DOI 10.1074/jbc.M410658200; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	64	23	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4528	4542		10.1038/onc.2010.113	http://dx.doi.org/10.1038/onc.2010.113			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20581864				2022-12-28	WOS:000280862300004
J	Chen, J; Miller, EM; Gallo, KA				Chen, J.; Miller, E. M.; Gallo, K. A.			MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells	ONCOGENE			English	Article						MLK3; JNK; migration; invasion; Bim; AP-1; breast cancer	MIXED-LINEAGE KINASE; BASEMENT-MEMBRANE CULTURES; GENE-EXPRESSION PROFILES; P38 MAPK PATHWAYS; N-TERMINAL KINASE; PROTEIN-KINASE; C-JUN; SRC-HOMOLOGY-3 DOMAIN; SIGNALING PATHWAYS; DEPENDENT PATHWAY	The malignant phenotype in breast cancer is driven by aberrant signal transduction pathways. Mixed-lineage kinase-3 (MLK3) is a mammalian mitogen-activated protein kinase kinase kinase (MAP3K) that activates multiple MAPK pathways. Depending on the cellular context, MLK3 has been implicated in apoptosis, proliferation, migration and differentiation. Here we investigated the effect of MLK3 and its signaling to MAPKs in the acquisition of malignancy in breast cancer. We show that MLK3 is highly expressed in breast cancer cells. We provide evidence that MLK3's catalytic activity and signaling to c-jun N-terminal kinase (JNK) is required for migration of highly invasive breast cancer cells and for MLK3-induced migration of mammary epithelial cells. Expression of active MLK3 is sufficient to induce the invasion of mammary epithelial cells, which requires AP-1 activity and is accompanied by the expression of several proteins corresponding to AP-1-regulated invasion genes. To assess MLK3's contribution to the breast cancer malignant phenotype in a more physiological setting, we implemented a strategy to inducibly express active MLK3 in the preformed acini of MCF10A cells grown in 3D Matrigel. Induction of MLK3 expression dramatically increases acinar size and modestly perturbs apicobasal polarity. Remarkably, MLK3 expression induces luminal repopulation and suppresses the expression of the pro-apoptotic protein BimEL, as has been observed in Her2/Neu-expressing acini. Taken together, our data show that MLK3-JNK-AP-1 signaling is critical for breast cancer cell migration and invasion. Our current study uncovers both a proliferative and novel antiapoptotic role for MLK3 in the acquisition of a malignant phenotype in mammary epithelial cells. Thus, MLK3 may be an important therapeutic target for the treatment of invasive breast cancer. Oncogene (2010) 29, 4399-4411; doi: 10.1038/onc.2010.198; published online 31 May 2010	[Miller, E. M.; Gallo, K. A.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Chen, J.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; [Gallo, K. A.] Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.	gallok@msu.edu	Wang, Limin/O-3724-2015		MSU-Health and Biomedical Research Institute [HBRI-729]; DoD [BC085020]	MSU-Health and Biomedical Research Institute; DoD(United States Department of Defense)	This work was supported by an MSU-Health and Biomedical Research Institute seed grant (KAG HBRI-729) and a DoD Breast Cancer Idea Award (KAG BC085020). Confocal microscopes were provided through the MSU Center for Advanced Microscopy. We are grateful to Cephalon Inc. for CEP-11004; Ariad Pharmaceuticals for AP21967 and for parental inducible expression vectors; Richard Mulligan (Harvard Medical School) for the 293GPG packaging cell line and Daniel DiMaio (Yale Cancer Center) for the pBabe-Tam67 construct. We thank Mauricio Reginato (Drexel University) for advice on Bim immunoblotting and Bradley Smith (Department of Physiology, MSU) for help with the morphometric analysis of the MCF10A cells grown in 3D culture. We appreciate the constructive input from the members of the MSU-Breast Cancer Signaling Networks Consortium.	BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BROWN PH, 1993, ONCOGENE, V8, P877; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Cui XJ, 2006, CANCER RES, V66, P5304, DOI 10.1158/0008-5472.CAN-05-2858; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Goicoechea SM, 2009, ONCOGENE, V28, P587, DOI 10.1038/onc.2008.408; Hall JP, 2002, J CELL BIOCHEM, V86, P1, DOI 10.1002/jcb.10187; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jacinto A, 2002, DEV CELL, V3, P9, DOI 10.1016/S1534-5807(02)00208-3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lester RD, 2005, J BIOL CHEM, V280, P39273, DOI 10.1074/jbc.M509446200; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nielsen DL, 2009, CANCER TREAT REV, V35, P121, DOI 10.1016/j.ctrv.2008.09.003; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Rizki A, 2007, CANCER RES, V67, P11106, DOI 10.1158/0008-5472.CAN-07-2348; Schachter KA, 2006, J BIOL CHEM, V281, P19134, DOI 10.1074/jbc.M603324200; Shacka JJ, 2006, CELL DEATH DIFFER, V13, P1506, DOI 10.1038/sj.cdd.4401831; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Swenson-Fields KI, 2008, MOL CELL, V32, P43, DOI 10.1016/j.molcel.2008.09.007; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Timoshenko AV, 2007, BRIT J CANCER, V97, P1090, DOI 10.1038/sj.bjc.6603993; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wilsbacher Julie L, 2006, Cell Commun Signal, V4, P5, DOI 10.1186/1478-811X-4-5; Yeh YT, 2006, INT J CANCER, V118, P2678, DOI 10.1002/ijc.21707; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	59	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2010	29	31					4399	4411		10.1038/onc.2010.198	http://dx.doi.org/10.1038/onc.2010.198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514022				2022-12-28	WOS:000280559100004
J	Yu, F; Deng, H; Yao, H; Liu, Q; Su, F; Song, E				Yu, F.; Deng, H.; Yao, H.; Liu, Q.; Su, F.; Song, E.			Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells	ONCOGENE			English	Article						microRNA; cancer stem cell; breast cancer; Ubc9; ITGB3	CANCER STEM-CELLS; IN-VITRO PROPAGATION; EXPRESSION; UBC9; MECHANISMS; INTEGRINS; ANOIKIS	Accumulating evidence indicates that a sub-population of cancer cells with stem-like properties, termed tumor-initiating cells (T-ICs), exist in many different kinds of malignancies, which have a pivotal role in tumorigenesis, tumor progression, metastasis and post-treatment relapse. However, how the stem-like properties of T-ICs are regulated remains obscure. Our previous study showed that reduction of let-7 microRNA ( miRNA) in breast tumor-initiating cells (BT-ICs) contributes to the maintenance of their self-renewal capacity and undifferentiated status. In this study we show the effect of mir-30 reduction on the stem-like features of BT-ICs. Similar to let-7, mir-30 is reduced in BT-ICs, and the protein level of Ubc9 (ubiquitin-conjugating enzyme 9) and ITGB3 ( integrin b3), the target genes of mir-30, is markedly upregulated. Enforced constitutive expression of mir-30 in BT-ICs inhibits their self-renewal capacity by reducing Ubc9, and induces apoptosis through silencing ITGB3. On the contrary, blocking the miRNA with a specific antisense oligonucleotide (ASO) in differentiated breast cancer cells revived their self-renewal capacity. Furthermore, ectopic expression of mir-30 in BT-IC xenografts reduces tumorigenesis and lung metastasis in nonobese diabetic/severe combined immunodeficient mice, whereas blocking mir-30 expression enhances tumorigenesis and metastasis. Together, our data suggest mir-30 as one of the important miRNAs in regulating the stem-like features of T-ICs. Oncogene ( 2010) 29, 4194-4204; doi: 10.1038/onc.2010.167; published online 24 May 2010	[Yu, F.; Deng, H.; Liu, Q.; Su, F.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou 510120, Guangdong, Peoples R China; [Yao, H.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Guangzhou 510120, Guangdong, Peoples R China; [Liu, Q.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Song, E.] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Harvard University; Dana-Farber Cancer Institute; Sun Yat Sen University	Song, E (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 2, Dept Breast Surg, 107 Yanjiang W Rd, Guangzhou 510120, Guangdong, Peoples R China.	songerwei02@yahoo.com.cn		Liu, Qiang/0000-0002-5451-4862	Natural Science Foundation of China [30921140312, 30830110, 30772550, 30973396, 30525022, 30671930, 30973505]; Ministry of Science and Technology of China [2010CB912800, 2009CB521706, 2005CB724605]; Natural Science Foundation of Guangdong Province [8251008901000011]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by the Natural Science Foundation of China Grant (30921140312, 30830110, 30772550, 30973396, 30525022, 30671930, 30973505), 973 (2010CB912800, 2009CB521706, 2005CB724605) Projects from the Ministry of Science and Technology of China, and Natural Science Foundation of Guangdong Province (8251008901000011).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Cho RW, 2008, CURR OPIN GENET DEV, V18, P48, DOI 10.1016/j.gde.2008.01.017; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Park SW, 2007, NAT STRUCT MOL BIOL, V14, P68, DOI 10.1038/nsmb1185; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pontier SM, 2009, J CELL SCI, V122, P207, DOI 10.1242/jcs.040394; Watanabe M, 2008, ACTA BIOCHIM POL, V55, P681; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang ZH, 2007, FASEB J, V21, P3042, DOI 10.1096/fj.06-6914com	24	254	278	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2010	29	29					4194	4204		10.1038/onc.2010.167	http://dx.doi.org/10.1038/onc.2010.167			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498642				2022-12-28	WOS:000280151500007
J	Amente, S; Bertoni, A; Morano, A; Lania, L; Avvedimento, EV; Majello, B				Amente, S.; Bertoni, A.; Morano, A.; Lania, L.; Avvedimento, E. V.; Majello, B.			LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription	ONCOGENE			English	Article						Myc; LSD1; transcription; histone; methylation; oxidative burst	AP-ENDONUCLEASE APE1/REF-1; C-MYC; BINDING; ACTIVATION; LSD1; ACETYLATION; MECHANISM; COFACTOR; GLYCOSYLASE; RECRUITS	Myc is a transcription factor that significantly contributes to cancer progression by modulating the expression of important genes through binding to a DNA sequence, CACGTG, called E-box. We find that on Myc binding to chromatin, the lysine-demethylating enzyme, LSD1, triggers a transient demethylation of lysine 4 in the histone H3. In addition, we demonstrate that Myc binds and recruits LSD1 to the E-box chromatin and the formation of this complex is stimulated by cAMP-PKA. Demethylation by LSD1 produces H2O2, which locally oxidizes guanine and induces the recruitment of 8-oxoguanine-DNA glycosylase (OGG1) and of the nuclease Ape1 on the E-box chromatin. Inhibition of oxidation or silencing of LSD1, OGG1 or Ape1 significantly reduce transcription and inhibit mRNA accumulation of Myc-target genes. Collectively, these data highlight the role of transient LSD1-mediated demethylation of H3K4 leading to local DNA oxidation as driving force in the assembly of the Myc-induced transcription initiation complex. Oncogene (2010) 29, 3691-3702; doi: 10.1038/onc.2010.120; published online 26 April 2010	[Amente, S.; Lania, L.; Majello, B.] Univ Naples Federico II, Dept Struct & Funct Biol, I-80126 Naples, Italy; [Amente, S.; Lania, L.; Avvedimento, E. V.] Naples Oncogenom Ctr CEINGE, Naples, Italy; [Bertoni, A.; Morano, A.; Avvedimento, E. V.] L Califano Univ Naples Federico II, Dept Biol Cellular & Mol Pathol, Naples, Italy	University of Naples Federico II; University of Naples Federico II	Majello, B (corresponding author), Univ Naples Federico II, Dept Struct & Funct Biol, Via Cinthia, I-80126 Naples, Italy.	majello@unina.it	Amente, Stefano/AAU-7605-2020; Morano, Annalisa/K-6955-2012	Amente, Stefano/0000-0003-0612-6096; Morano, Annalisa/0000-0002-5609-4742; Majello, Barbara/0000-0003-2789-3585	Italian Association for Cancer Research (AIRC)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank R Dalla Favera for critical reading of the paper and A Fusco for stimulating discussions and support. This work was supported by grants from the Italian Association for Cancer Research (AIRC) and by a core grant to NOGEC (AIRC). SA is a recipient of a postdoctoral fellowship from AIRC.	Anand R, 2007, J BIOL CHEM, V282, P35425, DOI 10.1074/jbc.R700027200; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Chattopadhyay R, 2008, MOL CELL BIOL, V28, P7066, DOI 10.1128/MCB.00244-08; Chen DS, 2003, J BIOL CHEM, V278, P38586, DOI 10.1074/jbc.M304286200; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gargano B, 2007, CELL CYCLE, V6, P2031, DOI 10.4161/cc.6.16.4554; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456; Kirmizis A, 2009, NAT STRUCT MOL BIOL, V16, P449, DOI 10.1038/nsmb.1569; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mantha AK, 2008, J MOL BIOL, V379, P28, DOI 10.1016/j.jmb.2008.03.052; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2007, NAT STRUCT MOL BIOL, V14, P252, DOI 10.1038/nsmb0407-252; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sidorenko VS, 2007, DNA REPAIR, V6, P317, DOI 10.1016/j.dnarep.2006.10.022; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	41	127	132	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3691	3702		10.1038/onc.2010.120	http://dx.doi.org/10.1038/onc.2010.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418916				2022-12-28	WOS:000279108600009
J	Matrone, MA; Whipple, RA; Thompson, K; Cho, EH; Vitolo, MI; Balzer, EM; Yoon, JR; Ioffe, OB; Tuttle, KC; Tan, M; Martin, SS				Matrone, M. A.; Whipple, R. A.; Thompson, K.; Cho, E. H.; Vitolo, M. I.; Balzer, E. M.; Yoon, J. R.; Ioffe, O. B.; Tuttle, K. C.; Tan, M.; Martin, S. S.			Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells	ONCOGENE			English	Article						microtentacles; tau; microtubule-associated proteins; microtubules; circulating tumor cells	MICROTUBULE-ASSOCIATED PROTEINS; PACLITAXEL SENSITIVITY; CANCER; NEURODEGENERATION; 3-REPEAT-TAU; CHEMOTHERAPY; 4-REPEAT-TAU; DYNAMICS; ADHESION; DISEASE	The cytoskeletal organization of detached and circulating tumor cells (CTCs) is currently not well defined and may provide potential targets for new therapies to limit metastatic tumor spread. In vivo, CTCs reattach in distant tissues by a mechanism that is tubulin-dependent and suppressed by polymerized actin. The cytoskeletal mechanisms that promote reattachment of CTCs match exactly with the mechanisms supporting tubulin microtentacles (McTN), which we have recently identified in detached breast tumor cells. In this study, we aimed to investigate how McTN formation is affected by the microtubule-associated protein, tau, which is expressed in a subset of chemotherapy-resistant breast cancers. We demonstrate that endogenous tau protein localizes to McTNs and is both necessary and sufficient to promote McTN extension in detached breast tumor cells. Tau-induced McTNs increase reattachment of suspended cells and retention of CTCs in lung capillaries. Analysis of patient-matched primary and metastatic tumors reveals that 52% possess tau expression in metastases and 26% display significantly increased tau expression over disease progression. Tau enrichment in metastatic tumors and the ability of tau to promote tumor cell reattachment through McTN formation support a model in which tau-induced microtubule stabilization provides a selective advantage during tumor metastasis. Oncogene (2010) 29, 3217-3227; doi: 10.1038/onc.2010.68; published online 15 March 2010	[Martin, S. S.] Univ Maryland, Greenebaum Canc Ctr, Sch Med, Program Mol Med, Baltimore, MD 21201 USA; [Whipple, R. A.; Thompson, K.; Vitolo, M. I.; Tuttle, K. C.; Tan, M.; Martin, S. S.] Univ Maryland, Marlene & Stewart Greenebaum NCI Canc Ctr, Sch Med, Baltimore, MD 21201 USA; [Yoon, J. R.; Martin, S. S.] Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA; [Ioffe, O. B.] Univ Maryland, Dept Pathol, Sch Med, Baltimore, MD 21201 USA; [Tan, M.] Univ Maryland, Dept Epidemiol & Prevent Med, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Martin, SS (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Sch Med, Program Mol Med, 655 W Baltimore St,Rm 10-029, Baltimore, MD 21201 USA.	ssmartin@som.umaryland.edu	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X; Vitolo, Michele/0000-0001-8055-9645	National Cancer Institute [R01-CA124704]; USA Medical Research and Materiel Command [BC061047]; Flight Attendants Medical Research Institute [CIA-062497]; NATIONAL CANCER INSTITUTE [K01CA096555, P30CA134274, R01CA124704] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USA Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Flight Attendants Medical Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Grant R01-CA124704 from National Cancer Institute, Breast Cancer Idea Award from USA Medical Research and Materiel Command (BC061047) and a Clinical Innovator Award from Flight Attendants Medical Research Institute (CIA-062497). We thank Dr I-Chu Tseng and the Dr Chen-Yong Lin laboratory for immunohistochemistry assistance, Dr Larry Changwan Lu for his assistance with the statistical analyses, Aric Colunga and the Dr Laure Aurelian laboratory for imaging assistance, Dr William Twaddell for assistance with pathological scoring of vimentin staining, and Dr Michele Weiss for Figure 6 assistance.	Atienza JM, 2006, ASSAY DRUG DEV TECHN, V4, P597, DOI 10.1089/adt.2006.4.597; BALZER EM, 2009, BREAST CANC RES TREA; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Bulic B, 2009, ANGEW CHEM INT EDIT, V48, P1741, DOI 10.1002/anie.200802621; Camara O, 2007, ANN ONCOL, V18, P1484, DOI 10.1093/annonc/mdm206; Cassimeris L, 2001, INT REV CYTOL, V210, P163; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Dickey CA, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-6; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ENGEL LW, 1978, CANCER RES, V38, P3352; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Goedert M, 2004, SEMIN CELL DEV BIOL, V15, P45, DOI 10.1016/j.semcdb.2003.12.015; Haier J, 2001, APMIS, V109, P241, DOI 10.1034/j.1600-0463.2001.d01-118.x; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Janni W, 2005, CANCER-AM CANCER SOC, V103, P884, DOI 10.1002/cncr.20834; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; LEE G, 1992, J CELL SCI, V102, P227; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Mialhe A, 2001, CANCER RES, V61, P5024; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Pusztai L, 2009, J CLIN ONCOL, V27, P4287, DOI 10.1200/JCO.2008.21.6887; Remmerbach TW, 2009, CANCER RES, V69, P1728, DOI 10.1158/0008-5472.CAN-08-4073; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; Schaap IAT, 2007, J STRUCT BIOL, V158, P282, DOI 10.1016/j.jsb.2006.11.010; Sharma VM, 2007, J CELL SCI, V120, P748, DOI 10.1242/jcs.03378; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wagner P, 2005, CELL CYCLE, V4, P1149, DOI 10.4161/cc.4.9.2038; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEISS L, 1991, CELL BIOPHYS, V18, P73, DOI 10.1007/BF02989807; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Whipple RA, 2007, EXP CELL RES, V313, P1326, DOI 10.1016/j.yexcr.2007.02.001; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927	41	70	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3217	3227		10.1038/onc.2010.68	http://dx.doi.org/10.1038/onc.2010.68			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20228842	Green Accepted			2022-12-28	WOS:000278321100005
J	Kongkham, PN; Northcott, PA; Croul, SE; Smith, CA; Taylor, MD; Rutka, JT				Kongkham, P. N.; Northcott, P. A.; Croul, S. E.; Smith, C. A.; Taylor, M. D.; Rutka, J. T.			The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma	ONCOGENE			English	Article						medulloblastoma; WNT signaling; epigenetics; methylation; tumor suppressor gene	BETA-CATENIN; METHYLATION; ANTAGONIST; MUTATIONS; SUBTYPES; CANCER; BRAIN; CELLS; MYC	Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Dysregulation of WNT signaling occurs in up to 20% of cases. Using a genome-wide approach, we identified the secreted frizzled-related protein 1, 2 and 3 (SFRP1, SFRP2 and SFRP3) family of WNT inhibitors as putative tumor suppressor genes silenced by promoter region methylation in MB. SFRP1, SFRP2 and SFRP3 expression increased after 5-aza-2'-deoxycytidine treatment. SFRP1, SFRP2 and SFRP3 methylation was identified in 23.5, 3.9 and 15.7% of primary MB specimens, respectively, by methylation-specific PCR. Stable SFRP1, SFRP2 and SFRP3 expression reduced phospho-DVL2 levels and hindered MB cell proliferation and colony formation in soft agar in vitro. In 60% of primary tumors, SFRP1 was expressed at levels twofold lower than that in normal cerebellum. SFRP1 expression impaired tumor formation in vivo in flank and orthotopic intracerebellar xenograft models and conferred a significant survival advantage (P<0.0001). We identify for the first time tumor suppressor gene function of SFRP genes in MB, and suggest that loss of WNT pathway inhibition due to SFRP gene silencing is an additional mechanism that may contribute to excessive WNT signaling in this disease. Oncogene (2010) 29, 3017-3024; doi:10.1038/onc.2010.32; published online 8 March 2010	[Kongkham, P. N.; Northcott, P. A.; Smith, C. A.; Taylor, M. D.; Rutka, J. T.] Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; [Kongkham, P. N.; Smith, C. A.; Rutka, J. T.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Northcott, P. A.; Taylor, M. D.] Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada; [Croul, S. E.] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Suite 1503,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Northcott, Paul A/N-4022-2018	Northcott, Paul A/0000-0002-1220-5252; Kongkham, Paul/0000-0002-1047-9305; Taylor, Michael/0000-0001-7009-3466; Croul, Sidney/0000-0002-2224-5485	Canadian Cancer Society, National Cancer Institute of Canada [019073]; Pediatric Brain Tumor Foundation; Wiley Fund at the Hospital for Sick Children and B.r.a.i.n.child; National Cancer Institute of Canada Terry Fox Foundation; Surgeon Scientist Program (University of Toronto); National Cancer Institute of Canada Terry Fox Foundation clinical research fellowship; RESTRACOMP, The Hospital for Sick Children, Toronto	Canadian Cancer Society, National Cancer Institute of Canada; Pediatric Brain Tumor Foundation; Wiley Fund at the Hospital for Sick Children and B.r.a.i.n.child; National Cancer Institute of Canada Terry Fox Foundation; Surgeon Scientist Program (University of Toronto)(University of Toronto); National Cancer Institute of Canada Terry Fox Foundation clinical research fellowship; RESTRACOMP, The Hospital for Sick Children, Toronto	This work was supported by grants from the Canadian Cancer Society, National Cancer Institute of Canada (019073), the Pediatric Brain Tumor Foundation, the Wiley Fund at the Hospital for Sick Children and B.r.a.i.n.child. James Rutka is a scientist of the Canadian Institutes of Health Research. Paul Kongkham was supported by the Surgeon Scientist Program (University of Toronto), the National Cancer Institute of Canada Terry Fox Foundation clinical research fellowship and a research studentship from RESTRACOMP, The Hospital for Sick Children, Toronto.	Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Chang Q, 2005, HUM PATHOL, V36, P1265, DOI 10.1016/j.humpath.2005.09.004; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Fan X, 2008, J CLIN ONCOL, V26, P2821, DOI 10.1200/JCO.2007.15.2264; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Katoh Y, 2006, INT J MOL MED, V17, P171; Koch A, 2007, INT J CANCER, V121, P284, DOI 10.1002/ijc.22675; Kongkham PN, 2008, CANCER RES, V68, P9945, DOI 10.1158/0008-5472.CAN-08-2169; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee Y, 2003, CANCER RES, V63, P5428; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vibhakar R, 2007, NEURO-ONCOLOGY, V9, P135, DOI 10.1215/15228517-2006-038	22	80	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					3017	3024		10.1038/onc.2010.32	http://dx.doi.org/10.1038/onc.2010.32			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208569				2022-12-28	WOS:000277890400012
J	Kim, YM; Geiger, TR; Egan, DI; Sharma, N; Nyborg, JK				Kim, Y-M; Geiger, T. R.; Egan, D. I.; Sharma, N.; Nyborg, J. K.			The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription	ONCOGENE			English	Article						CRE; cell cycle; transducer of regulated CREB; CREB-regulated transcription co-activator; CRTC	LEUKEMIA-VIRUS TYPE-1; NF-KAPPA-B; ELEMENT-BINDING PROTEIN; CAMP-RESPONSIVE ELEMENT; I TAX; COACTIVATOR CBP; GENE-EXPRESSION; T-CELLS; MOLECULAR CHARACTERIZATION; TRANSACTIVATOR TAX	Adult T-cell leukemia/lymphoma is a fatal malignancy etiologically linked to infection with the human T-cell leukemia virus (HTLV-1). The virally encoded oncoprotein Tax activates the transcription of HTLV-1 and cellular genes by cooperating with cellular transcription factors. Cyclin D1 is a pivotal regulator of cell cycle progression, and increased expression strongly correlates with malignant transformation. Here, we characterize the mechanism of Tax transactivation of cyclin D1. We find that cyclin D1 transcript levels are elevated in HTLV-1 infected cells and that Tax physically associates with the cyclin D1 gene in vivo. Tax binds the cyclin D1 promoter-proximal cyclic AMP response element (CRE) in the presence of phosphorylated CREB (pCREB) in vitro, and together the Tax-pCREB complex recruits the cellular co-activator p300 to the promoter through this unconventional Tax-responsive element. We further show that the transducer of regulated CREB 2 (TORC2) cooperates with Tax to further enhance p300 recruitment to the cyclin D1 promoter in vitro. Tax and TORC2 in combination stimulate cyclin D1 expression in vivo, demonstrating the functional outcome of the binding interactions. Together, our findings support a model in which Tax-induced accumulation of cyclin D1 shortens the G1 phase of the cell cycle, promotes mitotic replication of the virus, and drives selection and expansion of malignant T-cells. Oncogene (2010) 29, 2142-2152; doi: 10.1038/onc.2009.498; published online 25 January 2010	[Kim, Y-M; Geiger, T. R.; Egan, D. I.; Sharma, N.; Nyborg, J. K.] Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Campus Box 1870, Ft Collins, CO 80523 USA.	Jennifer.Nyborg@ColoState.Edu			National Institutes of Health [CA055035]; NATIONAL CANCER INSTITUTE [R55CA055035, R01CA055035] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs R Pestell (Thomas Jefferson University, Philadelphia, PA, USA) and A Baldwin (University of North Carolina, Chapel Hill, NC, USA) for the cyclin D1 luciferase constructs, and DY Jin (University of Hong Kong, Pokfulam, Hong Kong) for the TORC expression plasmids. We also thank Sarah Horstmann for helping with TORC2 cloning and expression and Holli Giebler for critical reading of the manuscript. This work was supported by a grant from the National Institutes of Health (CA055035).	Afonso PV, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-27; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; de la Fuente C, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-43; Fox KE, 2008, J BIOL CHEM, V283, P35096, DOI 10.1074/jbc.M806423200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Geiger TR, 2008, MOL CELL BIOL, V28, P1383, DOI 10.1128/MCB.01657-07; Georges SA, 2003, MOL CELL BIOL, V23, P3392, DOI 10.1128/MCB.23.10.3392-3404.2003; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hiraiwa N, 2003, BLOOD, V101, P3615, DOI 10.1182/blood-2002-07-2301; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kim YM, 2007, J BIOL CHEM, V282, P18750, DOI 10.1074/jbc.M700391200; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; Koga H, 2004, J BIOL CHEM, V279, P52978, DOI 10.1074/jbc.M409021200; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lemasson I, 2006, J BIOL CHEM, V281, P13075, DOI 10.1074/jbc.M512193200; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lopez DI, 2007, PROTEIN EXPRES PURIF, V55, P406, DOI 10.1016/j.pep.2007.06.011; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Ramirez JA, 2007, J MOL BIOL, V372, P958, DOI 10.1016/j.jmb.2007.06.062; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Sharma N, 2008, P NATL ACAD SCI USA, V105, P7959, DOI 10.1073/pnas.0800534105; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUZUKI T, 1994, ONCOGENE, V9, P3099; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Terme JM, 2008, J VIROL, V82, P7913, DOI 10.1128/JVI.02414-07; Trevisan R, 2006, EXP CELL RES, V312, P1390, DOI 10.1016/j.yexcr.2006.01.009; Trevisan R, 2004, EXP CELL RES, V299, P57, DOI 10.1016/j.yexcr.2004.05.024; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; Wang D, 2008, J BIOL CHEM, V283, P16299, DOI 10.1074/jbc.M706426200; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	56	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2142	2152		10.1038/onc.2009.498	http://dx.doi.org/10.1038/onc.2009.498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101207	Green Accepted			2022-12-28	WOS:000276402800012
J	Cheung, LWT; Leung, PCK; Wong, AST				Cheung, L. W. T.; Leung, P. C. K.; Wong, A. S. T.			Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; GnRH; cadherin; p120(ctn); motility	RHO-FAMILY GTPASES; BREAST-CANCER; N-CADHERIN; P-CADHERIN; EXPRESSION; RECEPTOR; ADHESION; GROWTH; PROGRESSION; PATHWAY	Gonadotropin-releasing hormone (GnRH) receptor expression is often elevated in ovarian cancer, but its potential role in ovarian cancer metastasis has just begun to be revealed. Cadherin switching is a crucial step during tumorigenesis, particularly in metastasis. Here, we showed that GnRH is an inducer of E-to P-cadherin switching, which is reminiscent of that seen during ovarian tumor progression. Overexpression of P-cadherin significantly enhanced, whereas knockdown of P-cadherin reduced migration and invasion regardless of E-cadherin expression, suggesting that inappropriate expression of P-cadherin contributes to the invasive phenotype. These effects of P-cadherin were mediated by activation of the Rho GTPases, Rac1, and Cdc42, through accumulation of p120 catenin (p120(ctn)) in the cytoplasm. The use of p120(ctn) small interfering RNA or chimeric cadherin construct to inhibit p120(ctn) expression and cytoplasmic localization, respectively, resulted in significant inhibition of cell migration and invasion, with a concomitant reduction in Rac1 and Cdc42 activation, confirming that the effect was p120(ctn) specific. Similarly, the migratory/invasive phenotype could be reversed by expression of dominant-negative Rac1 and Cdc42. These results identify for the first time cadherin switching and p120(ctn) signaling as important targets of GnRH function and as novel mediators of invasiveness and tumor progression in ovarian cancer. Oncogene (2010) 29, 2427-2440; doi:10.1038/onc.2009.523; published online 1 February 2010	[Cheung, L. W. T.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Hong Kong; University of British Columbia	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Cheung, Lydia Wai Ting/0000-0003-1137-3200; Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health; Hong Kong Research Grant Council [778108]; HKU	Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Hong Kong Research Grant Council(Hong Kong Research Grants Council); HKU(University of Hong Kong)	We thank Drs N Auersperg, A Hall, and C Gottardi for cell lines and plasmids. This work was supported by Canadian Institutes of Health Research grant (PCK Leung), and by Hong Kong Research Grant Council Grant 778108 and HKU Outstanding Young Researcher Award (AST Wong).	Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Chen CL, 2007, ENDOCRINE, V31, P311, DOI 10.1007/s12020-007-0041-8; Chen GTC, 2002, MOL REPROD DEV, V62, P289, DOI 10.1002/mrd.10121; Cheng CK, 2005, ENDOCR REV, V26, P283, DOI 10.1210/er.2003-0039; Cheung LWT, 2008, FEBS J, V275, P5479, DOI 10.1111/j.1742-4658.2008.06677.x; Cheung LWT, 2006, CANCER RES, V66, P10902, DOI 10.1158/0008-5472.CAN-06-2217; Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; EMONS G, 1989, EUR J CANCER CLIN ON, V25, P215, DOI 10.1016/0277-5379(89)90011-4; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Feltes CM, 2002, CANCER RES, V62, P6688; IRMER G, 1995, CANCER RES, V55, P817; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang SK, 2000, ENDOCRINE, V13, P297, DOI 10.1385/ENDO:13:3:297; Kim KY, 2006, ENDOCR-RELAT CANCER, V13, P211, DOI 10.1677/erc.1.01033; LI SL, 1994, ENDOCRINOLOGY, V135, P45, DOI 10.1210/en.135.1.45; Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774; Patel IS, 2003, INT J CANCER, V106, P172, DOI 10.1002/ijc.11086; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; SOMMERS CL, 1994, CANCER RES, V54, P3544; Soubry A, 2005, CANCER RES, V65, P2224, DOI 10.1158/0008-5472.CAN-04-2020; Spentzos D, 2007, ENDOCR-RELAT CANCER, V14, P781, DOI 10.1677/ERC-06-0073; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wong AST, 1999, INT J CANCER, V81, P180	35	59	60	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2427	2440		10.1038/onc.2009.523	http://dx.doi.org/10.1038/onc.2009.523			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20118984				2022-12-28	WOS:000276951500011
J	Petersen, M; Pardali, E; van der Horst, G; Cheung, H; van den Hoogen, C; van der Pluijm, G; ten Dijke, P				Petersen, M.; Pardali, E.; van der Horst, G.; Cheung, H.; van den Hoogen, C.; van der Pluijm, G.; ten Dijke, P.			Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis	ONCOGENE			English	Article						angiogenesis; breast cancer; metastasis; Smad; TGF-beta	BETA TYPE-I; TGF-BETA; SUPPRESSES METASTASIS; ENHANCES TUMORIGENESIS; MESENCHYMAL TRANSITION; KINASE INHIBITOR; VEGF PRODUCTION; MAMMARY-TUMOR; GROWTH; TGF-BETA-1	Transforming growth factor (TGF)-beta can suppress and promote breast cancer progression. How TGF-beta elicits these dichotomous functions and which roles the principle intracellular effector proteins Smad2 and Smad3 have therein, is unclear. Here, we investigated the specific functions of Smad2 and Smad3 in TGF-beta-induced responses in breast cancer cells in vitro and in a mouse model for breast cancer metastasis. We stably knocked down Smad2 or Smad3 expression in MDA-MB-231 breast cancer cells. The TGF-beta-induced Smad3-mediated transcriptional response was mitigated and enhanced by Smad3 and Smad2 knockdown, respectively. This response was also seen for TGF-beta-induced vascular endothelial growth factor (VEGF) expression. TGF-beta induction of key target genes involved in bone metastasis, were found to be dependent on Smad3 but not Smad2. Strikingly, whereas knockdown of Smad3 in MDA-MB-231 resulted in prolonged latency and delayed growth of bone metastasis, Smad2 knockdown resulted in a more aggressive phenotype compared with control MDA-MB-231 cells. Consistent with differential effects of Smad knockdown on TGF-beta-induced VEGF expression, these opposing effects of Smad2 versus Smad3 could be directly correlated with divergence in the regulation of tumor angiogenesis in vivo. Thus, Smad2 and Smad3 differentially affect breast cancer bone metastasis formation in vivo. Oncogene (2010) 29, 1351-1361; doi:10.1038/onc.2009.426; published online 14 December 2009	[Petersen, M.; Pardali, E.; ten Dijke, P.] Dept Mol Cell Biol, Leiden, Netherlands; [Petersen, M.; Pardali, E.; ten Dijke, P.] Ctr Biomed Genet, Leiden, Netherlands; [Petersen, M.; van der Horst, G.; Cheung, H.; van den Hoogen, C.; van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Urol, NL-2300 RC Leiden, Netherlands; [van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Pluijm, G (corresponding author), Leiden Univ, Med Ctr, Dept Urol & Endocrinol, J3-100,POB 9600, NL-2300 RC Leiden, Netherlands.	G.van_der_Pluijm@lumc.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; van der Horst, Geertje/0000-0003-1696-160X	Dutch Cancer Society [UL 2005-3371]; Ludwig Institute for Cancer Research; European Union [005428, 504743, 503224, 518198]	Dutch Cancer Society(KWF Kankerbestrijding); Ludwig Institute for Cancer Research; European Union(European Commission)	We thank Martine Deckers and Maarten van Dinther for their initial studies and members of our research group for help and suggestions during the course of this work. We are grateful to Lukas Hawinkels and Hein Verspaget for assistance with VEGF ELISA measurements, Kuber Sampath (Genzyme) for BMP6, Ken Iwata (OSI Pharmaceuticals) for TGF-beta 3 and Dr Philippe Clezardin for the MDA-MB-231 subclone BO2. This work was supported by the Dutch Cancer Society (UL 2005-3371), Ludwig Institute for Cancer Research and grants from the Sixth European Union Framework Programme, that is, the EpiplastCarcinoma Marie Curie RTN (project 005428), Angiotargeting (project 504743), BRECOSM (project 503224) and Tumor-Host Genomics (project 518198).	Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Desruisseau S, 2006, BRIT J CANCER, V94, P239, DOI 10.1038/sj.bjc.6602920; Donovan D, 1997, ANN SURG ONCOL, V4, P621, DOI 10.1007/BF02303745; Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078-0432.CCR-06-0162; Ghellal A, 2000, ANTICANCER RES, V20, P4413; Heffelfinger SC, 1999, CLIN CANCER RES, V5, P2867; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Isogai C, 2001, CANCER RES, V61, P5587; Ivanovic V, 2003, EUR J CANCER, V39, P454, DOI 10.1016/S0959-8049(02)00502-6; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Kirkbride KC, 2003, EXPERT OPIN BIOL TH, V3, P251; Kobayashi T, 2005, BIOCHEM BIOPH RES CO, V327, P393, DOI 10.1016/j.bbrc.2004.12.032; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; LaGamba D, 2005, DEV DYNAM, V234, P132, DOI 10.1002/dvdy.20489; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nam JS, 2008, CANCER RES, V68, P3835, DOI 10.1158/0008-5472.CAN-08-0215; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Petersen M, 2008, KIDNEY INT, V73, P705, DOI 10.1038/sj.ki.5002717; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Sheen-Chen SM, 2001, ARCH SURG-CHICAGO, V136, P937, DOI 10.1001/archsurg.136.8.937; Tannehill-Gregg SH, 2004, VET PATHOL, V41, P278, DOI 10.1354/vp.41-3-278; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Xie W, 2002, CANCER RES, V62, P497; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	51	137	140	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1351	1361		10.1038/onc.2009.426	http://dx.doi.org/10.1038/onc.2009.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20010874				2022-12-28	WOS:000275170600010
J	Djavaheri-Mergny, M; Maiuri, MC; Kroemer, G				Djavaheri-Mergny, M.; Maiuri, M. C.; Kroemer, G.			Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1	ONCOGENE			English	Review						Beclin 1; autophagy; apoptosis	BCL-2	Beclin 1 has a key role in the initiation of autophagy, a process of self-cannibalism in which cytoplasmic constituents are sequestered and targeted for lysosomal degradation. In a recent issue of Cell Death & Disease, Wirawan et al. report the significant finding that caspases can cleave Beclin 1, thereby destroying its pro-autophagic activity. Moreover, the C-terminal fragment of Beclin 1 that results from this cleavage acquires a new function and can amplify mitochondrion-mediated apoptosis. Of note, the BH3 domain of Beclin 1 remains within the N-terminal fragment, which has no detectable pro-apoptotic activity. These findings provide important insights into the molecular cross talk between autophagy and apoptosis. Oncogene (2010) 29, 1717-1719; doi:10.1038/onc.2009.519; published online 25 January 2010	[Djavaheri-Mergny, M.] INSERM, VINCO U916, Inst Bergonie, F-33076 Bordeaux, France; [Djavaheri-Mergny, M.] Univ Bordeaux, Bordeaux, France; [Maiuri, M. C.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Maiuri, M. C.; Kroemer, G.] Univ Paris 11, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Djavaheri-Mergny, M (corresponding author), INSERM, VINCO U916, Inst Bergonie, 229 Cours Argonne, F-33076 Bordeaux, France.	mojgan.mergny@inserm.fr; kroemer@orange.fr	KROEMER, Guido/B-4263-2013; Djavaheri-Mergny, Mojgan/N-6315-2017; Djavaheri-Mergny, Mojgan/L-3890-2019; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; 	EU; Ligue contre le Cancer; Agence Nationale pour la Recherche; Institut National sur le Cancer; Canceropole Ile-de-France; Fondation pour la Recherche Medicale	EU(European Commission); Ligue contre le Cancer(Ligue nationale contre le cancer); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National sur le Cancer; Canceropole Ile-de-France(Region Ile-de-France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by funds from the EU 6th and 7th Framework Programs, as well as by grants from Ligue contre le Cancer (equipe labelisee), Agence Nationale pour la Recherche, Institut National sur le Cancer, Canceropole Ile-de-France and Fondation pour la Recherche Medicale (to GK) and by grant from Ligue contre le Cancer (to MD-M).	Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Boya P, 2009, ONCOGENE, V28, P2125, DOI 10.1038/onc.2009.83; Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004; CHUA BT, 2003, NAT CELL BIOL, V11, P1241; Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Thompson J, 2008, J EXP MED, V205, P1029, DOI 10.1084/jem.20080101; WIRAWAN E, 2010, CELL DEATH IN PRESS; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Yi CH, 2009, DEV CELL, V16, P21, DOI 10.1016/j.devcel.2008.12.012; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482	16	293	317	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1717	1719		10.1038/onc.2009.519	http://dx.doi.org/10.1038/onc.2009.519			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20101204				2022-12-28	WOS:000276022800001
J	Ingemarsdotter, CK; Baird, SK; Connell, CM; Oberg, D; Hallden, G; McNeish, IA				Ingemarsdotter, C. K.; Baird, S. K.; Connell, C. M.; Oeberg, D.; Hallden, G.; McNeish, I. A.			Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer	ONCOGENE			English	Article						oncolytic adenovirus; paclitaxel; mitosis; apoptosis; microtubule	CELL-CYCLE PROGRESSION; E4ORF4 PROTEIN; GROWTH ARREST; MICROTUBULE; INFECTION; MITOSIS; DEATH; BIOLUMINESCENCE; INSTABILITY; CHECKPOINTS	The microtubule-stabilizing drug paclitaxel has activity in relapsed ovarian cancer. dl922-947, an oncolytic adenovirus with a 24-bp deletion in E1A CR2, replicates selectively within and lyses cells with a dysregulated Rb pathway and has efficacy in ovarian cancer. In the aggressive A2780CP xenograft, combination treatment with weekly dl922-947 and paclitaxel has significantly greater efficacy than either treatment alone and can produce complete tumor eradication in some animals. We investigated the mechanisms of paclitaxel's synergy with dl922-947 in ovarian cancer. The host-cell microtubule network is grossly rearranged and stabilized following adenovirus infection, but paclitaxel does not increase this significantly. Paclitaxel does not synergize by increasing infectivity, viral protein expression or virus release. However, destabilizing the microtubule network with nocodazole reduces viral exit, revealing a novel microtubule-dependent pathway for non-lytic adenoviral exit. dl922-947 can override multiple cell cycle checkpoints but induces cell death by a non-apoptotic mechanism. In combination, dl922-947 and low-dose paclitaxel induces aberrant, multipolar mitoses, mitotic slippage and multinucleation, triggering an apoptotic cell death. Oncogene (2010) 29, 6051-6063; doi:10.1038/onc.2010.335; published online 23 August 2010	[McNeish, I. A.] Queen Mary Univ London, Barts & London Sch Med, John Vane Sci Ctr, Ctr Mol Oncol & Imaging,Inst Canc, London EC1M 6BQ, England	University of London; Queen Mary University London	McNeish, IA (corresponding author), Queen Mary Univ London, Barts & London Sch Med, John Vane Sci Ctr, Ctr Mol Oncol & Imaging,Inst Canc, Charterhouse Sq, London EC1M 6BQ, England.	i.a.mcneish@qmul.ac.uk		McNeish, Iain/0000-0002-9387-7586	Medical Research Council [G0601891] Funding Source: Medline; MRC [G0601891] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Baird SK, 2008, ONCOGENE, V27, P3081, DOI 10.1038/sj.onc.1210977; BELIN MT, 1987, J VIROL, V61, P2559, DOI 10.1128/JVI.61.8.2559-2566.1987; Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07-12-1269; Chen JG, 2002, CANCER RES, V62, P1935; Cheong SC, 2008, CANCER GENE THER, V15, P40, DOI 10.1038/sj.cgt.7701099; Cherubini G, 2006, CELL CYCLE, V5, P2244, DOI 10.4161/cc.5.19.3263; Connell CM, 2008, CANCER RES, V68, P7923, DOI 10.1158/0008-5472.CAN-08-0817; De Luca A, 2003, CANCER RES, V63, P1430; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Flak MB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-175; Gartner M, 2005, CHEMBIOCHEM, V6, P1173, DOI 10.1002/cbic.200500005; Giannakakou P, 1998, INT J CANCER, V75, P57, DOI 10.1002/(SICI)1097-0215(19980105)75:1<57::AID-IJC10>3.3.CO;2-V; Hassan MAIA, 2006, CANCER GENE THER, V13, P1105, DOI 10.1038/sj.cgt.7700984; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Le LP, 2004, MOL IMAGING, V3, P105, DOI 10.1162/1535350041464874; Le T, 2006, GYNECOL ONCOL, V102, P49, DOI 10.1016/j.ygyno.2005.11.025; Leopold PL, 2007, ADV DRUG DELIVER REV, V59, P810, DOI 10.1016/j.addr.2007.06.007; Leyton J, 2006, CANCER RES, V66, P9178, DOI 10.1158/0008-5472.CAN-06-1539; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Lockley M, 2006, CANCER RES, V66, P989, DOI 10.1158/0008-5472.CAN-05-2691; Markman M, 2002, J CLIN ONCOL, V20, P2365, DOI 10.1200/JCO.2002.09.130; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; Mimori-Kiyosue Y, 2005, J CELL BIOL, V168, P141, DOI 10.1083/jcb.200405094; MURRAY JD, 1982, J CELL PHYSIOL, V111, P89, DOI 10.1002/jcp.1041110114; Paoletti A, 1997, J CELL SCI, V110, P2403; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Seidman MA, 2001, MOL THER, V4, P13, DOI 10.1006/mthe.2001.0414; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Warren JC, 2006, MOL BIOL CELL, V17, P3557, DOI 10.1091/mbc.E05-09-0850; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3	45	43	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6051	6063		10.1038/onc.2010.335	http://dx.doi.org/10.1038/onc.2010.335			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20729921	Green Published, hybrid			2022-12-28	WOS:000284108700007
J	Arias-Romero, LE; Villamar-Cruz, O; Pacheco, A; Kosoff, R; Huang, M; Muthuswamy, SK; Chernoff, J				Arias-Romero, L. E.; Villamar-Cruz, O.; Pacheco, A.; Kosoff, R.; Huang, M.; Muthuswamy, S. K.; Chernoff, J.			A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells	ONCOGENE			English	Article						transformation; small GTPase; protein kinase; ErbB2; signal transduction; breast cancer	REGULATED KINASE; P21-ACTIVATED KINASES; TAMOXIFEN RESISTANCE; ACTIVATION; PROGRESSION; VECTORS; ISOFORM; TARGETS; ERBB2	The activation of receptor tyrosine kinases, particularly ErbB2, has an important role in the genesis of breast cancer. ErbB2 kinase activity promotes Ras-mediated stimulation of downstream protein kinase cascades, including the Ras/Raf-1/MAPK/ERK kinase (Mek)/extra-cellular signal-regulated kinase (Erk) pathway, leading to tumor cell growth and migration. Signaling through the Ras-Erk pathway can be influenced by p21-activated kinase-1 (Pak1), an effector of the Rho family GTPases Rac and Cdc42. In this study, we asked if ErbB2 expression correlates with Pak1 and Erk activity in human breast cancer specimens, and if Pak1 signaling is required for ErbB2 transformation in a three-dimensional (3D) in vitro setting and in xenografts. We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human breast tumor samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and Akt pathways. Further, we found that inhibition of Pak1 by small molecules compromised activation of Erk and Akt, resulting in reversion of the malignant phenotype and restoration of normal acinar architecture. Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo. These data imply that the Rac-Pak pathway is vital to ErbB2-mediated transformation and that Pak inhibitors represent plausible drug targets in breast cancers in which ErbB2 signaling is activated. Oncogene (2010) 29, 5839-5849; doi: 10.1038/onc.2010.318; published online 16 August 2010	[Arias-Romero, L. E.; Villamar-Cruz, O.; Pacheco, A.; Huang, M.; Chernoff, J.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Kosoff, R.] Univ Penn, Canc Biol Program, Philadelphia, PA 19104 USA; [Muthuswamy, S. K.] Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada	Fox Chase Cancer Center; University of Pennsylvania; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014; Muthuswamy, Senthil K/AGY-2834-2022	Chernoff, Jonathan/0000-0002-4803-7836; Muthuswamy, Senthil K/0000-0001-6564-9634; Villamar-Cruz, Olga/0000-0003-4265-9367; Arias-Romero, Luis E./0000-0001-5676-2483	NIH [R01 CA58836, R01 CA098830, P30 CA006927]; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA058836, R56CA098830, R01CA098830] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dan Kalman (Emory University School of Medicine) and Ariad Pharmaceuticals, for their gifts of pAdlox vectors and AP1510, respectively, and Fang Zhu, of the FCCC Biostatistics Facility, for statistical analysis of TMA and xengraft data. This work was supported by grants from the NIH to JC (R01 CA58836) and SM (R01 CA098830) and to the Fox Chase Cancer Center (P30 CA006927), as well as by an appropriation from the state of Pennsylvania.	Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Li QW, 2008, NEOPLASIA, V10, P314, DOI 10.1593/neo.07970; Lightcap CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006025; Maksimoska J, 2008, J AM CHEM SOC, V130, P15764, DOI 10.1021/ja805555a; Mao K, 2008, J MOL CELL CARDIOL, V44, P429, DOI 10.1016/j.yjmcc.2007.10.016; Menard RE, 2003, CELL SIGNAL, V15, P1099, DOI 10.1016/S0898-6568(03)00087-1; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Porchia LM, 2007, MOL PHARMACOL, V72, P1124, DOI 10.1124/mol.107.037556; Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; SHALABY MR, 1992, J EXP MED, V175, P217, DOI 10.1084/jem.175.1.217; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; SOULE HD, 1990, CANCER RES, V50, P6075; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Treeck O, 2003, EUR J CANCER, V39, P1302, DOI 10.1016/S0959-8049(02)00777-3; Viaud J, 2009, MOL CANCER THER, V8, P2559, DOI 10.1158/1535-7163.MCT-09-0102; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	36	69	71	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5839	5849		10.1038/onc.2010.318	http://dx.doi.org/10.1038/onc.2010.318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20711231	Green Accepted			2022-12-28	WOS:000283586200009
J	Desch, P; Asslaber, D; Kern, D; Schnidar, H; Mangelberger, D; Alinger, B; Stoecher, M; Hofbauer, SW; Neureiter, D; Tinhofer, I; Aberger, F; Hartmann, TN; Greil, R				Desch, P.; Asslaber, D.; Kern, D.; Schnidar, H.; Mangelberger, D.; Alinger, B.; Stoecher, M.; Hofbauer, S. W.; Neureiter, D.; Tinhofer, I.; Aberger, F.; Hartmann, T. N.; Greil, R.			Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells	ONCOGENE			English	Article						chronic lymphocytic leukemia; apoptosis; hedgehog; stromal cells; GLI transcription factors	HEDGEHOG SIGNALING PATHWAY; MARROW STROMAL CELLS; SONIC HEDGEHOG; B-CELLS; ZAP-70 EXPRESSION; CD38 EXPRESSION; NEURAL-TUBE; STEM-CELLS; IN-VITRO; CANCER	The Hedgehog (Hh) pathway regulates cell proliferation and survival and contributes to tumorigenesis. We investigated the expression and function of this pathway in B-cell chronic lymphocytic leukemia (CLL) cells and in healthy B lymphocytes. Profiling of cognate Hh pathway members revealed reduced expression of two key Hh signaling effectors, Smoothened (SMOH) and GLI, in CLL cells, whereas transcription levels of other investigated members resembled normal B-lymphocyte levels. Examining the functional role of SMOH and GLI in cell survival, we found that CLL cells were hardly sensitive toward specific SMOH inhibition, but showed an unspecific decline in cell viability in response to high concentrations of the SMOH antagonist cyclopamine. In contrast, treatment with the novel GLI antagonist GANT61 reduced expression of the target gene Patched and preferentially decreased the viability of malignant cells. Specific RNA interference knockdown experiments in a CLL-derived cell line confirmed the autonomous role of GLI in malignant cell survival. GANT61-induced apoptosis in primary leukemic cells was partly attenuated by protective stromal cells, but not soluble sonic hedgehog ligand. In summary, our data show a downregulation of the classical Hh pathway in CLL and suggest an intrinsic SMOH-independent role of GLI in the ex vivo survival of CLL cells. Oncogene (2010) 29, 4885-4895; doi: 10.1038/onc.2010.243; published online 5 July 2010	[Desch, P.; Asslaber, D.; Stoecher, M.; Hofbauer, S. W.; Tinhofer, I.; Hartmann, T. N.; Greil, R.] Paracelsus Med Univ, Lab Immunol & Mol Canc Res, Med Dept Hematol Med Oncol Hemostaseol Rheumatol, A-5020 Salzburg, Austria; [Kern, D.; Schnidar, H.; Mangelberger, D.; Aberger, F.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Alinger, B.; Neureiter, D.] Paracelsus Med Univ, Inst Pathol, A-5020 Salzburg, Austria; [Tinhofer, I.] Charite, Translat Radiobiol & Radiooncol Res Lab, Clin Dept Radiotherapy CCM CVK, Berlin, Germany	Paracelsus Private Medical University; Salzburg University; Paracelsus Private Medical University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hartmann, TN (corresponding author), Paracelsus Med Univ, Lab Immunol & Mol Canc Res, Med Dept Hematol Med Oncol Hemostaseol Rheumatol, A-5020 Salzburg, Austria.	t.hartmann@salk.at; r.greil@salk.at	Hartmann, Tanja Nicole/C-9345-2017; Greil, Richard F/C-7673-2017; Aberger, Fritz/B-6357-2012; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Greil, Richard F/0000-0002-4462-3694; Aberger, Fritz/0000-0003-2009-6305; Hartmann, Tanja Nicole/0000-0002-0377-7179; Asslaber, Daniela/0000-0002-8711-016X; Tinhofer, Ingeborg/0000-0002-0512-549X; Hartmann, Tanja Nicole/0000-0002-2633-7301	Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH [P021]; ONB [13420]; PFIZER corporation Austria; Province of Salzburg; Austrian Science Fund (FWF) [W1213, P20652]; Austrian Genome programme Gen-AU	Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH; ONB; PFIZER corporation Austria; Province of Salzburg; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Genome programme Gen-AU	This work was supported by the Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH, SFB program P021 to RG, ONB research Grant 13420 to TNH., an unrestricted grant from PFIZER corporation Austria Ges.m.b.H, Vienna, and grants from the province of Salzburg. We thank Dr Reinhard Vlasak for help with the production of recombinant Shh protein. FA was supported by Austrian Science Fund (FWF) Grants W1213, P20652 and by the Austrian Genome programme Gen-AU.	Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1999, J MOL MED-JMM, V77, P266, DOI 10.1007/s001090050350; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Ecke I, 2008, MOL CARCINOGEN, V47, P361, DOI 10.1002/mc.20394; Ferretti E, 2008, EMBO J, V27, P2616, DOI 10.1038/emboj.2008.172; Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007-0167; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper Maria, 2007, V397, P67; KNUUTILA S, 1986, NEW ENGL J MED, V314, P865, DOI 10.1056/NEJM198604033141401; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee J, 1997, DEVELOPMENT, V124, P2537; Lindemann RK, 2008, CANCER RES, V68, P961, DOI 10.1158/0008-5472.CAN-07-5500; Lowrey JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/jimmunol.169.4.1869; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Matsenko NU, 2008, B EXP BIOL MED+, V145, P240, DOI 10.1007/s10517-008-0060-3; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI200523409; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; Patten PEM, 2008, BLOOD, V111, P5173, DOI 10.1182/blood-2007-08-108605; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Seiffert M, 2007, LEUKEMIA, V21, P1977, DOI 10.1038/sj.leu.2404863; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Zanotti R, 2007, LEUKEMIA, V21, P102, DOI 10.1038/sj.leu.2404458; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	60	61	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4885	4895		10.1038/onc.2010.243	http://dx.doi.org/10.1038/onc.2010.243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20603613				2022-12-28	WOS:000281578700003
J	Feng, ZJ; Gao, SB; Wu, Y; Xu, XF; Hua, X; Jin, GH				Feng, Z-J; Gao, S-B; Wu, Y.; Xu, X-F; Hua, X.; Jin, G-H			Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP beta/zeta signaling by menin	ONCOGENE			English	Article						lung cancer; migration; Men1; pleiotrophin; RPTP beta/zeta	FOCAL-ADHESION KINASE; TYROSINE-PHOSPHATASE BETA/ZETA; UP-REGULATION; GENE; PLEIOTROPHIN; INTEGRIN; FAK; METASTASIS; INVASION; PATHWAY	Menin encoded by the multiple endocrine neoplasia type 1 (MEN1) gene is associated with chromatin and the nuclear matrix and exerts multiple biological functions including regulation of cell proliferation and adhesion. Men1 mutations increase the likelihood of lung cancer development in mice. Menin expression is reduced in certain human non-small cell lung cancer cells, and reduction of menin is closely correlated with increased lung cancer metastasis to lymph nodes. However, it is poorly understood whether menin affects migration of lung cancer cells. In this study, we show that meninregulated A549 lung cancer cell migration, which was mediated by growth factor pleiotrophin (PTN) and its cell surface receptor, protein tyrosine phosphatase beta/zeta (RPTP beta/zeta). Ectopic menin expression significantly repressed PTN transcription, but indirectly inhibited RPTP beta/zeta expression through repressing PTN expression. Further studies revealed that menin-regulated cell migration through PTN/RPTP beta/zeta, in conjunction with integrin alpha(v)beta(3), focal adhesion kinase, phosphatidylinositol 3-kinase and phosphorylated extracellular signal regulated kinase 1/2. These findings provide mechanistic insights into the molecular basis for menin/PTN-mediated regulation of A549 lung cancer cell migration. Oncogene (2010) 29, 5416-5426; doi: 10.1038/onc.2010.282; published online 19 July 2010	[Feng, Z-J; Gao, S-B; Wu, Y.; Jin, G-H] Xiamen Univ, Dept Basic Med Sci, Coll Med, Xiamen 361005, Fujian, Peoples R China; [Xu, X-F] Xiamen Second Hosp, Dept Pathol, Xiamen, Fujian, Peoples R China; [Hua, X.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	Xiamen University; University of Pennsylvania	Jin, GH (corresponding author), Xiamen Univ, Dept Basic Med Sci, Coll Med, Daxue Rd 168, Xiamen 361005, Fujian, Peoples R China.	huax@mail.med.upenn.edu; ghjin@xmu.edu.cn		Feng, Zijie/0000-0002-5633-3686	NFSC [30701003]; National Cancer Institute [R01CA113962]; NATIONAL CANCER INSTITUTE [R01CA113962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK097555] Funding Source: NIH RePORTER	NFSC(National Natural Science Foundation of China (NSFC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by an NFSC grant (No. 30701003, GH Jin) and a National Cancer Institute grant (R01CA113962, XH). We appreciate the valuable comments from other members of our laboratories.	Baillat G, 2008, BBA-MOL CELL RES, V1783, P2323, DOI 10.1016/j.bbamcr.2008.08.008; Carelli S, 2006, LUNG CANCER, V53, P263, DOI 10.1016/j.lungcan.2006.06.001; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen JS, 2009, HEPATOL RES, V39, P177, DOI 10.1111/j.1872-034X.2008.00449.x; Chen YJ, 2009, J CELL PHYSIOL, V221, P98, DOI 10.1002/jcp.21835; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Duces A, 2008, MOL CANCER THER, V7, P2817, DOI 10.1158/1535-7163.MCT-08-0301; Gao SB, 2008, ANN ENDOCRINOL-PARIS, V69, P426, DOI 10.1016/j.ando.2008.06.001; Gao SB, 2009, ONCOGENE, V28, P4095, DOI 10.1038/onc.2009.273; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; Jin GH, 2007, INT J CANCER, V121, P2539, DOI 10.1002/ijc.22708; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Klein CA, 2008, SCIENCE, V321, P1785, DOI 10.1126/science.1164853; Lemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605; Liu GY, 2008, CELL BIOL INT, V32, P663, DOI 10.1016/j.cellbi.2008.01.292; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Meng XN, 2009, BRIT J CANCER, V101, P327, DOI 10.1038/sj.bjc.6605154; Mikelis C, 2009, FASEB J, V23, P1459, DOI 10.1096/fj.08-117564; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Molloy T, 2008, CURR OPIN GENET DEV, V18, P35, DOI 10.1016/j.gde.2008.01.019; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Pariser H, 2005, BIOCHEM BIOPH RES CO, V332, P664, DOI 10.1016/j.bbrc.2005.05.007; Pei XH, 2007, CANCER RES, V67, P3162, DOI 10.1158/0008-5472.CAN-06-4517; Perez-Pinera P, 2007, CELL CYCLE, V6, P2877, DOI 10.4161/cc.6.23.5090; Petzmann S, 2001, HUM PATHOL, V32, P333, DOI 10.1053/hupa.2001.22762; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Weng TT, 2009, J BIOL CHEM, V284, P28021, DOI 10.1074/jbc.M109.052530; Wu Xinjiang, 2008, Curr Mol Med, V8, P805, DOI 10.2174/156652408786733702; Yan J, 2009, ONCOGENE, V28, P973, DOI 10.1038/onc.2008.435	42	38	44	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5416	5426		10.1038/onc.2010.282	http://dx.doi.org/10.1038/onc.2010.282			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20639902	hybrid, Green Published			2022-12-28	WOS:000282944500008
J	Martin, F; Ladoire, S; Mignot, G; Apetoh, L; Ghiringhelli, F				Martin, F.; Ladoire, S.; Mignot, G.; Apetoh, L.; Ghiringhelli, F.			Human FOXP3 and cancer	ONCOGENE			English	Review						Foxp3; regulatory T cells; tumor immunity; tolerance; tumor suppressor gene	REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; EFFECTOR FUNCTIONS; PERIPHERAL-BLOOD; CARCINOMA CELLS; DENDRITIC CELLS; TUMOR-IMMUNITY; CUTTING EDGE; EXPRESSION; SURVIVAL	FOXP3 is a transcription factor necessary and sufficient for induction of the immunosuppressive functions in regulatory T lymphocytes. Its expression was first considered as specific of this cell type, but FOXP3 can also be transiently expressed in T-cell antigen receptor-activated human nonregulatory T cells. Recent data indicate that FOXP3 is also expressed by some non-lymphoid cells, in which it can repress various oncogenes that are restored following FOXP3 deletion or mutation. This review summarizes major advances in (1) the understanding of Foxp3 functions in human regulatory T cells, (2) the prognostic significance of Foxp3-expressing T cells in human malignancies and (3) the significance of Foxp3 expression in human tumor cells. Oncogene (2010) 29, 4121-4129; doi: 10.1038/onc.2010.174; published online 24 May 2010	[Ghiringhelli, F.] Univ Burgundy, Avenir Team, INSERM, Equipe Avenir,UMR 866, F-21000 Dijon, Burgundy, France; [Ladoire, S.; Ghiringhelli, F.] Ctr GF Leclerc, Dijon, France; [Apetoh, L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ghiringhelli, F (corresponding author), Univ Burgundy, Avenir Team, INSERM, Equipe Avenir,UMR 866, 7 Bd Jeanne Arc, F-21000 Dijon, Burgundy, France.	fghiringhelli@dijon.fnclcc.fr	Apetoh, Lionel/G-3310-2014; Mignot, Grégoire/R-4976-2017; Apetoh, Lionel/AIC-2384-2022	Apetoh, Lionel/0000-0002-2774-438X; Mignot, Grégoire/0000-0002-0682-0152; Apetoh, Lionel/0000-0002-2774-438X; LADOIRE, Sylvain/0000-0002-0331-9194; ghiringhelli, francois/0000-0002-5465-8305				Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Alvaro T, 2005, CLIN CANCER RES, V11, P1467, DOI 10.1158/1078-0432.CCR-04-1869; Badoual C, 2006, CLIN CANCER RES, V12, P465, DOI 10.1158/1078-0432.CCR-05-1886; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burstein HJ, 2005, NEW ENGL J MED, V353, P1652, DOI 10.1056/NEJMp058197; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2008, CURR OPIN IMMUNOL, V20, P241, DOI 10.1016/j.coi.2008.04.008; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Du JG, 2008, J IMMUNOL, V180, P4785, DOI 10.4049/jimmunol.180.7.4785; Dumitriu IE, 2009, J IMMUNOL, V182, P2795, DOI 10.4049/jimmunol.0712671; Ebert LM, 2008, CANCER RES, V68, P3001, DOI 10.1158/0008-5472.CAN-07-5664; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360; Haynes NM, 2008, CURR OPIN IMMUNOL, V20, P545, DOI 10.1016/j.coi.2008.05.008; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jordanova ES, 2008, CLIN CANCER RES, V14, P2028, DOI 10.1158/1078-0432.CCR-07-4554; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985; Koh KP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008109; LADOIRE S, 2010, BREAST CANC IN PRESS; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Liu JY, 2007, CANCER IMMUNOL IMMUN, V56, P1597, DOI 10.1007/s00262-007-0305-4; LIYANAGE UK, INT J CANC, V120, P2723; Manoukian G, 2009, EXPERT OPIN BIOL TH, V9, P1445, DOI 10.1517/14712590903348135; Medema RH, 2007, CELL, V129, P1253, DOI 10.1016/j.cell.2007.06.008; Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036; Miller AM, 2006, J IMMUNOL, V177, P7398, DOI 10.4049/jimmunol.177.10.7398; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mizukami Y, 2008, BRIT J CANCER, V98, P148, DOI 10.1038/sj.bjc.6604149; Morse MA, 2008, BLOOD, V112, P610, DOI 10.1182/blood-2008-01-135319; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077; Powell DJ, 2007, J IMMUNOL, V179, P4919, DOI 10.4049/jimmunol.179.7.4919; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189; Roux S, 2008, J CLIN INVEST, V118, P3751, DOI 10.1172/JCI35890; Rudensky AY, 2006, CELL, V126, P253, DOI 10.1016/j.cell.2006.07.005; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Siddiqui SA, 2007, CLIN CANCER RES, V13, P2075, DOI 10.1158/1078-0432.CCR-06-2139; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413; Tai XG, 2005, NAT IMMUNOL, V6, P152, DOI 10.1038/ni1160; Taieb J, 2006, J IMMUNOL, V176, P2722, DOI 10.4049/jimmunol.176.5.2722; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361; Woo EY, 2001, CANCER RES, V61, P4766; Woo YL, 2008, J CLIN PATHOL, V61, P969, DOI 10.1136/jcp.2008.056200; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yoshioka T, 2008, BRIT J CANCER, V98, P1258, DOI 10.1038/sj.bjc.6604294; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547; Zitvogel L, 2008, BLOOD, V112, P4364, DOI 10.1182/blood-2008-09-176693; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	90	95	104	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4121	4129		10.1038/onc.2010.174	http://dx.doi.org/10.1038/onc.2010.174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498631				2022-12-28	WOS:000280151500001
J	Lock, FE; Underhill-Day, N; Dunwell, T; Matallanas, D; Cooper, W; Hesson, L; Recino, A; Ward, A; Pavlova, T; Zabarovsky, E; Grant, MM; Maher, ER; Chalmers, AD; Kolch, W; Latif, F				Lock, F. E.; Underhill-Day, N.; Dunwell, T.; Matallanas, D.; Cooper, W.; Hesson, L.; Recino, A.; Ward, A.; Pavlova, T.; Zabarovsky, E.; Grant, M. M.; Maher, E. R.; Chalmers, A. D.; Kolch, W.; Latif, F.			The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappa B signaling pathways	ONCOGENE			English	Article						RASSF8; adherens junctions; lung cancer	BETA-CATENIN; GENE; INTERACTS; ADHESION; PROTEINS; DOMAIN; FAMILY	The Ras-assocation domain family (RASSF) of tumor suppressor proteins until recently contained six proteins named RASSF1-6. Recently, four novel family members, RASSF7-10, have been identified by homology searches for RA-domain-containing proteins. These additional RASSF members are divergent and structurally distinct from RASSF1-6, containing an N-terminal RA domain and lacking the Sav/RASSF/Hpo (SARAH) domain. Here, we show that RASSF8 is ubiquitously expressed throughout the murine embryo and in normal human adult tissues. Functionally, RNAi-mediated knockdown of RASSF8 in non-small-cell lung cancer (NSCLC) cell lines, increased anchorage-independent growth in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice. Furthermore, EdU staining of RASSF8-depleted cells showed growth suppression in a manner dependent on contact inhibition. We show that endogenous RASSF8 is not only found in the nucleus, but is also membrane associated at sites of cell-cell adhesion, co-localizing with the adherens junction (AJ) component beta-catenin and binding to E-cadherin. Following RASSF8 depletion in two different lung cancer cell lines using alternative small interfering RNA (siRNA) sequences, we show that AJs are destabilized and E-cadherin is lost from the cell membrane. The AJ components beta-catenin and p65 are also lost from sites of cell-cell contact and are relocalized to the nucleus with a concomitant increase in beta-catenin-dependent and nuclear factor-kappa B (NF-kappa B)-dependent signaling following RASSF8 depletion. RASSF8 may also be required to maintain actin -cytoskeletal organization since immunofluorescence analysis shows a striking disorganization of the actincytoskeleton following RASSF8 depletion. Accordingly, scratch wound healing studies show increased cellular migration in RASSF8-deficient cells. These results implicate RASSF8 as a tumor suppressor gene that is essential for maintaining AJs function in epithelial cells and have a role in epithelial cell migration. Oncogene (2010) 29, 4307-4316; doi: 10.1038/onc.2010.192; published online 31 May 2010	[Lock, F. E.; Underhill-Day, N.; Dunwell, T.; Cooper, W.; Hesson, L.; Maher, E. R.; Latif, F.] Univ Birmingham, Dept Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Matallanas, D.; Kolch, W.] Univ Coll Dublin, Dublin 2, Ireland; [Recino, A.; Ward, A.; Chalmers, A. D.] Univ Bath, Dept Biol & Biochem, Ctr Regenerat Med, Bath BA2 7AY, Avon, England; [Pavlova, T.; Zabarovsky, E.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Grant, M. M.] Univ Birmingham, Sch Dent, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University College Dublin; University of Bath; Karolinska Institutet; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Dept Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Kolch, Walter/ABF-2102-2021; MAHER, EAMONN R/A-9507-2008; Chalmers, Andrew/D-4103-2009; Grant, Melissa/A-5590-2010; gomez, david/U-9465-2019; Hesson, Luke/HDM-0311-2022; Admin, SBI/HGB-2738-2022; Zabarovsky, Eugene R/A-6645-2010	MAHER, EAMONN R/0000-0002-6226-6918; Chalmers, Andrew/0000-0003-4182-6717; Grant, Melissa/0000-0003-1154-7266; gomez, david/0000-0002-2360-3141; Ward, Andrew/0000-0001-8311-5695; Kolch, Walter/0000-0001-5777-5016; Pavlova, Tatiana/0000-0002-2857-5696; Dunwell, Thomas/0000-0001-9985-3828	Cancer Research UK; Breast Cancer Campaign; Sport Aiding Medical Research for Kids (SPARKS); MRC; Swedish Cancer Society; Swedish Research Council; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Swedish Instituteand Karolinska Institute	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Sport Aiding Medical Research for Kids (SPARKS); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Swedish Instituteand Karolinska Institute(Karolinska Institutet)	Work in FL's laboratory is supported by Cancer Research UK, Breast Cancer Campaign and Sport Aiding Medical Research for Kids (SPARKS). Work in ADC's laboratory is funded by MRC and Cancer Research UK, and AR by a Marie Curie PhD studentship. EZ was supported by research grants from the Swedish Cancer Society, the Swedish Research Council and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), the Swedish Instituteand Karolinska Institute.	Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dallol A, 2009, CURR BIOL, V19, P1227, DOI 10.1016/j.cub.2009.05.064; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Downward J, 2009, NATURE, V462, P44, DOI 10.1038/462044a; Falvella FS, 2006, ONCOGENE, V25, P3934, DOI 10.1038/sj.onc.1209422; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Rudini N, 2008, CURR BIOL, V18, pR1080, DOI 10.1016/j.cub.2008.09.018; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Sherwood V, 2008, MOL BIOL CELL, V19, P1772, DOI 10.1091/mbc.E07-07-0652; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang FL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003031	26	64	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4307	4316		10.1038/onc.2010.192	http://dx.doi.org/10.1038/onc.2010.192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514026	Green Submitted			2022-12-28	WOS:000280547900007
J	Molenaar, JJ; Ebus, ME; Koster, J; Santo, E; Geerts, D; Versteeg, R; Caron, HN				Molenaar, J. J.; Ebus, M. E.; Koster, J.; Santo, E.; Geerts, D.; Versteeg, R.; Caron, H. N.			Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells	ONCOGENE			English	Article						CCND1; ChIP; GATA3; microarray; neuroblastoma	ESTROGEN-RECEPTOR; BREAST-CANCER; AMPLIFICATION; HYDROXYLASE; EXPRESSION; FATE; GENE	Almost all neuroblastoma tumors express excess levels of Cyclin D1 (CCND1) compared to normal tissues and other tumor types. Only a small percentage of these neuroblastoma tumors have high-level amplification of the Cyclin D1 gene. The other neuroblastoma tumors have equally high Cyclin D1 expression without amplification. Silencing of Cyclin D1 expression was previously found to trigger differentiation of neuroblastoma cells. Overexpression of Cyclin D1 is therefore one of the most frequent mechanisms with a postulated function in neuroblastoma pathogenesis. The cause for the Cyclin D1 overexpression is unknown. Here we show that Cyclin D1 overexpression results from transcriptional upregulation. To identify upstream regulators, we searched in mRNA profiles of neuroblastoma tumor series for transcription factors with expression patterns correlating to Cyclin D1. GATA3 most consistently correlated to Cyclin D1 in four independent data sets. We identified a highly conserved GATA3 binding site 27 bp upstream of the Cyclin D1 transcriptional start. Chromatin immune precipitation confirmed binding of GATA3 to the Cyclin D1 promoter. Overexpression of GATA3 induced Cyclin D1 promoter activity, which decreased after site-directed mutagenesis of the GATA3 binding site in the Cyclin D1 promoter. Silencing of GATA3 resulted in reduced Cyclin D1 promoter activity and reduced Cyclin D1 mRNA and protein levels. Moreover, GATA3 silencing caused differentiation that was similar to that caused by Cyclin D1 inhibition. These finding implicate GATA3 in Cyclin D1 overexpression in neuroblastoma. Oncogene (2010) 29, 2739-2745; doi:10.1038/onc.2010.21; published online 15 February 2010	[Molenaar, J. J.; Ebus, M. E.; Koster, J.; Santo, E.; Geerts, D.; Versteeg, R.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; [Molenaar, J. J.; Caron, H. N.] Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Oncol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Molenaar, JJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, M1-132,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.j.molenaar@amc.uva.nl	Versteeg, Rogier/AAQ-1765-2020; Koster, Jan/C-5934-2008; Geerts, Dirk/K-8260-2015	Koster, Jan/0000-0002-0890-7585; Geerts, Dirk/0000-0002-6386-8187; Versteeg, Rogier/0000-0001-7172-0388	Stichting Koningin Wilhelmina Fonds; Stichting Kindergeneeskundig Kankeronderzoek; Kinderen Kankervrij	Stichting Koningin Wilhelmina Fonds; Stichting Kindergeneeskundig Kankeronderzoek; Kinderen Kankervrij	We kindly thank Dr RG Pestell for the full-length Cyclin D1 pA3 promoter construct that we used to generate our pGL3 Cyclin D1 promoter construct. The work was supported by Stichting Koningin Wilhelmina Fonds (KWF), Stichting Kindergeneeskundig Kankeronderzoek (SKK) and Kinderen Kankervrij (KiKa).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Caren H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-353; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoch RV, 1999, INT J CANCER, V84, P122; Hong SJ, 2008, NEUROCHEM RES, V33, P1821, DOI 10.1007/s11064-008-9639-3; Hong SJ, 2006, J NEUROCHEM, V98, P773, DOI 10.1111/j.1471-4159.2006.03924.x; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsarovina K, 2004, DEVELOPMENT, V131, P4775, DOI 10.1242/dev.01370; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; VANROY N, 1995, CANCER GENET CYTOGEN, V82, P151; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49	23	30	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2739	2745		10.1038/onc.2010.21	http://dx.doi.org/10.1038/onc.2010.21			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154722				2022-12-28	WOS:000277354600013
J	Sutter, R; Shakhova, O; Bhagat, H; Behesti, H; Sutter, C; Penkar, S; Santuccione, A; Bernays, R; Heppner, FL; Schuller, U; Grotzer, M; Moch, H; Schraml, P; Marino, S				Sutter, R.; Shakhova, O.; Bhagat, H.; Behesti, H.; Sutter, C.; Penkar, S.; Santuccione, A.; Bernays, R.; Heppner, F. L.; Schueller, U.; Grotzer, M.; Moch, H.; Schraml, P.; Marino, S.			Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas	ONCOGENE			English	Article						medulloblastoma; mouse model; CD133; Sox2; neural stem cells; tumor stem cells	SONIC HEDGEHOG; STEM/PROGENITOR CELLS; SOMATIC INACTIVATION; NERVOUS-SYSTEM; P53(-/-) MICE; HUMAN HOMOLOG; ADULT; EXPRESSION; PATHWAY; BRAIN	Cells with stem cell properties have been isolated from various areas of the postnatal mammalian brain, most recently from the postnatal mouse cerebellum. We show here that inactivation of the tumor suppressor genes Rb and p53 in these endogenous neural stem cells induced deregulated proliferation and resistance to apoptosis in vitro. Moreover, injection of these cells into mice formed medulloblastomas. Medulloblastomas are the most common malignant brain tumors of childhood, and despite recent advances in treatment they are associated with high morbidity and mortality. They are highly heterogeneous tumors characterized by a diverse genetic make-up and expression profile as well as variable prognosis. Here, we describe a novel ontogenetic pathway of medulloblastoma that significantly contributes to understanding their heterogeneity. Experimental medulloblastomas originating from neural stem cells preferentially expressed stem cell markers Nestin, Sox2 and Sox9, which were not expressed in medulloblastomas originating from granule-cell-restricted progenitors. Furthermore, the expression of these markers identified a subset of human medulloblastomas associated with a poorer clinical outcome. Oncogene (2010) 29, 1845-1856; doi:10.1038/onc.2009.472; published online 11 January 2010	[Sutter, R.; Shakhova, O.; Bhagat, H.; Behesti, H.; Penkar, S.; Marino, S.] Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci, London E1 2AT, England; [Sutter, C.; Santuccione, A.; Moch, H.; Schraml, P.] Univ Zurich Hosp, Dept Pathol, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Bernays, R.] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; [Heppner, F. L.] Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland; [Schueller, U.] Univ Munich, Ctr Neuropathol, Munich, Germany; [Grotzer, M.] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland	University of London; Queen Mary University London; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Munich; University Children's Hospital Zurich	Marino, S (corresponding author), Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci, 4 Newark St, London E1 2AT, England.	s.marino@qmul.ac.uk	Heppner, Frank/ABH-8393-2020; santuccione chadha, antonella/HDL-9230-2022; Sutter, Reto/D-6783-2013	Heppner, Frank/0000-0001-9816-8917; Sutter, Reto/0000-0001-6355-9838; Behesti, Hourinaz/0000-0001-9383-9929; Grotzer, Michael/0000-0002-1154-2732; Marino, Silvia/0000-0002-9612-2883; Santuccione Chadha, Antonella/0000-0002-4021-3129; Schuller, Ulrich/0000-0002-8731-1121	St Bartholomew's Charitable Foundation; Cancer Research UK; Ali's Dream and Charlie's Challenge Charities; Janggen-Pohn Foundation; Swiss National Science Foundation	St Bartholomew's Charitable Foundation; Cancer Research UK(Cancer Research UK); Ali's Dream and Charlie's Challenge Charities; Janggen-Pohn Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Rob Wechsler-Reya and James Briscoe for the gift of ptc+/- medulloblastoma pellets and Sox9 antibody respectively. We thank Gary Warnes for expert assistance with the flow cytometry analysis. This work was supported by grants of St Bartholomew's Charitable Foundation, Cancer Research UK, Ali's Dream and Charlie's Challenge Charities to SM and by personal fellowships of Janggen-Pohn Foundation and Swiss National Science Foundation to RS.	Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Behesti H, 2009, INT J BIOCHEM CELL B, V41, P435, DOI 10.1016/j.biocel.2008.06.017; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Corti S, 2007, EXP NEUROL, V205, P547, DOI 10.1016/j.expneurol.2007.03.021; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; DRESCHER DG, 1993, J NEUROCHEM, V61, P1167, DOI 10.1111/j.1471-4159.1993.tb03638.x; Eberhart CG, 2003, AM J PATHOL, V162, P7, DOI 10.1016/S0002-9440(10)63792-3; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Foroni C, 2007, CANCER RES, V67, P3725, DOI 10.1158/0008-5472.CAN-06-4577; Galli Rosselia, 2008, V438, P67, DOI 10.1007/978-1-59745-133-8_7; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee J, 1997, DEVELOPMENT, V124, P2537; Lee Y, 2003, CANCER RES, V63, P5428; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Marino S, 2000, GENE DEV, V14, P994; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Palma V, 2004, DEVELOPMENT, V131, P337, DOI 10.1242/dev.00930; Pfenninger CV, 2007, CANCER RES, V67, P5727, DOI 10.1158/0008-5472.CAN-07-0183; Phi JH, 2008, AM J SURG PATHOL, V32, P103, DOI 10.1097/PAS.0b013e31812f6ba6; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Shakhova O, 2006, CANCER RES, V66, P5190, DOI 10.1158/0008-5472.CAN-05-3545; Shu Q, 2008, STEM CELLS, V26, P1414, DOI 10.1634/stemcells.2007-1009; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sottile V, 2006, BRAIN RES, V1099, P8, DOI 10.1016/j.brainres.2006.04.127; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Weiss William A., 2002, Oncogene, V21, P7453, DOI 10.1038/sj.onc.1205936; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	49	63	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	12					1845	1856		10.1038/onc.2009.472	http://dx.doi.org/10.1038/onc.2009.472			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062081	Green Accepted			2022-12-28	WOS:000276022800013
J	Yamaguchi, K; Mandai, M; Oura, T; Matsumura, N; Hamanishi, J; Baba, T; Matsui, S; Murphy, SK; Konishi, I				Yamaguchi, K.; Mandai, M.; Oura, T.; Matsumura, N.; Hamanishi, J.; Baba, T.; Matsui, S.; Murphy, S. K.; Konishi, I.			Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes	ONCOGENE			English	Article						ovarian clear cell carcinoma; microarray; carcinogenesis; signature	EXPRESSION PROFILES; POOR-PROGNOSIS; CANCER-CELLS; MOLECULAR MARKER; BREAST-CANCER; CHEMORESISTANCE; METHYLATION; PATTERNS; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; ENDOMETRIOSIS	Ovarian clear cell carcinoma (OCCC) shows unique clinical features including an association with endometriosis and poor prognosis. We previously reported that the contents of endometriotic cysts, especially high concentrations of free iron, are a possible cause of OCCC carcinogenesis through iron-induced persistent oxidative stress. In this study, we conducted gene expression microarray analysis using 38 ovarian cancer cell lines and identified genes commonly expressed in both OCCC cell lines and clinical samples, which comprise an OCCC gene signature. The OCCC signature reproducibly predicts OCCC specimens in other microarray data sets, suggesting that this gene profile reflects the inherent biological characteristics of OCCC. The OCCC signature contains known markers of OCCC, such as hepatocyte nuclear factor-1 beta (HNF-1 beta) and versican (VCAN), and other genes that reflect oxidative stress. Expression of OCCC signature genes was induced by treatment of immortalized ovarian surface epithelial cells with the contents of endometriotic cysts, indicating that the OCCC signature is largely dependent on the tumor microenvironment. Induction of OCCC signature genes is at least in part epigenetically regulated, as we found hypomethylation of HNF-1 beta and VCAN in OCCC cell lines. This genome-wide study indicates that the tumor microenvironment induces specific gene expression profiles that contribute to the development of distinct cancer subtypes. Oncogene (2010) 29, 1741-1752; doi:10.1038/onc.2009.470; published online 11 January 2010	[Yamaguchi, K.; Mandai, M.; Matsumura, N.; Hamanishi, J.; Baba, T.; Konishi, I.] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Sakyo Ku, Kyoto 6068507, Japan; [Yamaguchi, K.; Murphy, S. K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA; [Oura, T.] Kyoto Univ, Grad Sch Publ Hlth, Dept Biostat, Sakyo Ku, Kyoto 6068507, Japan; [Matsui, S.] Inst Stat Math, Dept Data Sci, Res Org Informat & Syst, Tokyo, Japan	Kyoto University; Duke University; Kyoto University; Research Organization of Information & Systems (ROIS); Institute of Statistical Mathematics (ISM) - Japan	Mandai, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	mandai@kuhp.kyoto-u.ac.jp	Yamaguchi, Ken/Y-6633-2018; Hamanishi, Junzo/AAX-3318-2020; Murphy, Susan/R-3903-2019	Yamaguchi, Ken/0000-0002-7669-1405; Murphy, Susan/0000-0001-8298-7272; BABA, Tsukasa/0000-0003-0066-3747; Hamanishi, Junzo/0000-0002-7750-0623; Matsumura, Noriomi/0000-0002-4512-7975				Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078-0432.CCR-08-0149; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7; Cattaruzza S, 2004, FASEB J, V18, P779, DOI 10.1096/fj.03-0660fje; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Garcia-Escudero R, 2008, MOL CARCINOGEN, V47, P573, DOI 10.1002/mc.20430; Gibson G, 2008, NAT REV GENET, V9, P575, DOI 10.1038/nrg2383; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawthorne VS, 2009, MOL CANCER RES, V7, P592, DOI 10.1158/1541-7786.MCR-08-0316; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Issa JPJ, 2001, CANCER RES, V61, P3573; Itamochi H, 2008, CANCER SCI, V99, P653, DOI 10.1111/j.1349-7006.2008.00747.x; Ito M, 2007, J UROLOGY, V178, P1073, DOI 10.1016/j.juro.2007.05.012; Kato N, 2008, HISTOPATHOLOGY, V52, P682, DOI 10.1111/j.1365-2559.2008.03006.x; Lau CK, 2009, CLIN CANCER RES, V15, P3462, DOI 10.1158/1078-0432.CCR-08-2127; Lee S, 2007, GYNECOL ONCOL, V106, P311, DOI 10.1016/j.ygyno.2007.03.041; Maeda T, 2005, BRIT J CANCER, V93, P116, DOI 10.1038/sj.bjc.6602662; Marquez RT, 2005, CLIN CANCER RES, V11, P6116, DOI 10.1158/1078-0432.CCR-04-2509; Newton MA, 2007, ANN APPL STAT, V1, P85, DOI 10.1214/07-AOAS104; Osada R, 2007, HUM PATHOL, V38, P1310, DOI 10.1016/j.humpath.2007.02.010; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schwartz DR, 2002, CANCER RES, V62, P4722; Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F; Skirnisdottir I, 2005, INT J ONCOL, V26, P177; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takano M, 2006, BRIT J CANCER, V94, P1369, DOI 10.1038/sj.bjc.6603116; Takemoto Y, 2004, CLIN CANCER RES, V10, P7418, DOI 10.1158/1078-0432.CCR-04-0279; Tsuchiya A, 2003, AM J PATHOL, V163, P2503, DOI 10.1016/S0002-9440(10)63605-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamaguchi K, 2008, CLIN CANCER RES, V14, P32, DOI 10.1158/1078-0432.CCR-07-1614; Zaffanello M, 2008, MED SCI MONITOR, V14, pRA78; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	46	124	126	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1741	1752		10.1038/onc.2009.470	http://dx.doi.org/10.1038/onc.2009.470			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062075				2022-12-28	WOS:000276022800004
J	Iglesias-Ara, A; Zenarruzabeitia, O; Fernandez-Rueda, J; Sanchez-Tillo, E; Field, SJ; Celada, A; Zubiaga, AM				Iglesias-Ara, A.; Zenarruzabeitia, O.; Fernandez-Rueda, J.; Sanchez-Tillo, E.; Field, S. J.; Celada, A.; Zubiaga, A. M.			Accelerated DNA replication in E2F1-and E2F2-deficient macrophages leads to induction of the DNA damage response and p21(CIP1)-dependent senescence	ONCOGENE			English	Article						E2F; macrophage; DNA damage response; senescence; DNA hyper-replication	ONCOGENE-INDUCED SENESCENCE; T-CELL PROLIFERATION; CYCLIN-E; PROGENITOR CELLS; E2F2; EXPRESSION; TRANSCRIPTION; SUPPRESSION; MATURATION; P53	E2F1-3 proteins appear to have distinct roles in progenitor cells and in differentiating cells undergoing cell cycle exit. However, the function of these proteins in paradigms of terminal differentiation that involve continued cell division has not been examined. Using compound E2F1/E2F2-deficient mice, we have examined the effects of E2F1 and E2F2 loss on the differentiation and simultaneous proliferation of bone-marrow-derived cells toward the macrophage lineage. We show that E2F1/E2F2 deficiency results in accelerated DNA replication and cellular division during the initial cell division cycles of bone-marrow-derived cells, arguing that E2F1/E2F2 are required to restrain proliferation of pro-monocyte progenitors during their differentiation into macrophages, without promoting their cell cycle exit. Accelerated proliferation is accompanied by early expression of DNA replication and cell cycle regulators. Remarkably, rapid proliferation of E2F1/E2F2 compound mutant cultures is temporally followed by induction of a DNA damage response and the implementation of a p21(CIP1)-dependent senescence. We further show that differentiating E2F1/E2F2-knockout macrophages do not trigger a DNA damage response pathway in the absence of DNA replication. These findings underscore the relevance of E2F1 and E2F2 as suppressors of hematopoietic progenitor expansion. Our data indicate that their absence in differentiating macrophages initiates a senescence program that results from enforcement of a DNA damage response triggered by DNA hyper-replication. Oncogene (2010) 29, 5579-5590; doi:10.1038/onc.2010.296; published online 2 August 2010	[Iglesias-Ara, A.; Zenarruzabeitia, O.; Fernandez-Rueda, J.; Zubiaga, A. M.] Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, Bilbao 64448080, Spain; [Sanchez-Tillo, E.; Celada, A.] Inst Res Biomed IRB Barcelona, Macrophage Biol Grp, Barcelona, Spain; [Sanchez-Tillo, E.; Celada, A.] Univ Barcelona, Barcelona, Spain; [Field, S. J.] Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of Basque Country; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of California System; University of California San Diego	Zubiaga, AM (corresponding author), Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, Bilbao 64448080, Spain.	ana.zubiaga@ehu.es	zubiaga, ana/S-3457-2019; Iglesias, Ainhoa/H-3021-2015; Zenarruzabeitia, Olatz/AAD-6772-2019; Celada, Antonio/I-1714-2016; Iglesias, Ainhoa/AAB-8731-2022	zubiaga, ana/0000-0002-2132-9708; Iglesias, Ainhoa/0000-0002-2056-8213; Zenarruzabeitia, Olatz/0000-0002-0869-9034; Iglesias, Ainhoa/0000-0002-2056-8213; Celada, Antonio/0000-0003-3883-2171; Field, Seth/0000-0002-8893-4806	Spanish Ministry of Science and Innovation [SAF2009-12037, CSD2007-00017]; Basque Government Department of Industry [Etortek-IE06-178]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Basque Government Department of Industry(Basque Government)	We thank members of the Zubiaga laboratory for helpful discussions, Naiara Zorrilla for technical support and Dimitri Balomenos for p21<SUP>CIP1</SUP> <SUP>/</SUP> mice. AI is a recipient of the University of the Basque Country postdoctoral fellowship. OZ and JF are recipients of Basque Government fellowships for graduate students. This work was supported by grants to AMZ from the Spanish Ministry of Science and Innovation (SAF2009-12037 and Consolider-Ingenio 2010 Programme, CSD2007-00017) and the Basque Government Department of Industry (Etortek-IE06-178).	Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BRACKMAN D, 1995, J LEUKOCYTE BIOL, V58, P547, DOI 10.1002/jlb.58.5.547; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Infante A, 2008, CELL CYCLE, V7, P3915, DOI 10.4161/cc.7.24.7379; Kinross KM, 2006, BLOOD, V108, P886, DOI 10.1182/blood-2005-09-008656; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Liu Q, 1999, MOL CELL BIOL, V19, P6229; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Paulson QX, 2008, ONCOGENE, V27, P4954, DOI 10.1038/onc.2008.138; Pusapati RV, 2010, MOL CARCINOGEN, V49, P152, DOI 10.1002/mc.20584; Scheijen B, 2004, J BIOL CHEM, V279, P10476, DOI 10.1074/jbc.M313682200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001	41	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5579	5590		10.1038/onc.2010.296	http://dx.doi.org/10.1038/onc.2010.296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676136				2022-12-28	WOS:000282946900005
J	Pines, G; Huang, PH; Zwang, Y; White, FM; Yarden, Y				Pines, G.; Huang, P. H.; Zwang, Y.; White, F. M.; Yarden, Y.			EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism	ONCOGENE			English	Article						EGFR mutations; glioblastoma; growth factor; signal transduction; tyrosine kinase	EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; C-TERMINAL TAIL; HUMAN GLIOBLASTOMAS; EGF RECEPTOR; V-ERBB; DOMAIN; ACTIVATION; CELLS; MUTATIONS	Tumor cells often subvert normal regulatory mechanisms of signal transduction. This study shows this principle by studying yet uncharacterized mutants of the epidermal growth factor receptor (EGFR) previously identified in glioblastoma multiforme, which is the most aggressive brain tumor in adults. Unlike the well-characterized EGFRvIII mutant form, which lacks a portion of the ligand-binding cleft within the extracellular domain, EGFRvIVa and EGFRvIVb lack internal segments distal to the intracellular tyrosine kinase domain. By constructing the mutants and by ectopic expression in naive cells, we show that both mutants confer an oncogenic potential in vitro, as well as tumorigenic growth in animals. The underlying mechanisms entail constitutive receptor dimerization and basal activation of the kinase domain, likely through a mechanism that relieves a restraining molecular fold, along with stabilization due to association with HSP90. Phospho-proteomic analyses delineated the signaling pathways preferentially engaged by EGFRvIVb-identified unique substrates. This information, along with remarkable sensitivities to tyrosine kinase blockers and to a chaperone inhibitor, proposes strategies for pharmacological interception in brain tumors harboring EGFRvIV mutations. Oncogene (2010) 29, 5850-5860; doi: 10.1038/onc.2010.313; published online 2 August 2010	[Pines, G.; Zwang, Y.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Huang, P. H.; White, F. M.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Weizmann Institute of Science; Massachusetts Institute of Technology (MIT)	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012; Huang, Paul H./H-8591-2015	Pines, Gur/0000-0002-1757-6722; Huang, Paul H./0000-0003-3972-5087; White, Forest/0000-0002-1545-1651	Goldhirsh Foundation; US National Cancer Institute (NCI) [CA072981, CA118705, CA141556, U54-CA112967]; Israel Science Foundation; Dr Miriam and Sheldon G Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE [U54CA112967, R01CA118705, R37CA072981, U01CA141556, R01CA072981] Funding Source: NIH RePORTER	Goldhirsh Foundation; US National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Science Foundation(Israel Science Foundation); Dr Miriam and Sheldon G Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. Our work is supported by research grants from the Goldhirsh Foundation, the US National Cancer Institute (NCI; CA072981 to YY, CA118705, CA141556 and U54-CA112967 to FMW), the Israel Science Foundation and Dr Miriam and Sheldon G Adelson Medical Research Foundation.	An WG, 2000, CELL GROWTH DIFFER, V11, P355; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; Chiosis G, 2003, MOL CANCER THER, V2, P123; Clarkson RWE, 2006, MOL ENDOCRINOL, V20, P675, DOI 10.1210/me.2005-0392; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Frederick L, 2000, CANCER RES, V60, P1383; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jeuken J, 2009, BRAIN PATHOL, V19, P661, DOI 10.1111/j.1750-3639.2009.00320.x; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Ladanyi M, 2008, MODERN PATHOL, V21, pS16, DOI 10.1038/modpathol.3801018; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Li JJ, 2009, ONCOGENE, V28, P1759, DOI 10.1038/onc.2009.15; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; Nagane M, 1996, CANCER RES, V56, P5079; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang Y, 2005, MOL CELL PROTEOMICS, V4, P1240, DOI 10.1074/mcp.M500089-MCP200	39	46	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5850	5860		10.1038/onc.2010.313	http://dx.doi.org/10.1038/onc.2010.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20676128	Green Accepted, Green Published			2022-12-28	WOS:000283586200010
J	Schwarze, F; Meraner, J; Lechner, M; Loidl, A; Stasyk, T; Laich, A; Loidl, P				Schwarze, F.; Meraner, J.; Lechner, M.; Loidl, A.; Stasyk, T.; Laich, A.; Loidl, P.			Cell cycle-dependent acetylation of Rb2/p130 in NIH3T3 cells	ONCOGENE			English	Article						Rb2/p130; cell cycle; acetylation; p300; posttranslational modification	RETINOBLASTOMA TUMOR-SUPPRESSOR; FAMILY PROTEINS; POCKET PROTEINS; P130; PHOSPHORYLATION; RB	The retinoblastoma protein (pRb) and the pRb-related proteins, p130 and p107, form the 'pocket protein' family of cell cycle regulatory factors. A well characterized function of these proteins is the cell cycle-dependent regulation of E2F-responsive genes. The biological activity of pocket proteins is regulated by phosphorylation and for the founding member pRb it has been shown that acetylation also has an important role in modulating its function during the cell cycle. Here, we show that hyperphosphorylated retinoblastoma 2 (Rb2)/p130 also exists in an acetylated form in NIH3T3 cells. Acetylated p130 is present in the nucleus but not in the cytoplasm. Acetylation is cell cycle dependent, starting in S-phase and persisting until late G(2)-period. Using recombinant p130 and truncated forms for in vitro acetylation by the acetyltransferase p300, we could identify K1079 in the C-terminal part as the major acetylation site by mass spectrometry. Minor acetylation sites were pinpointed to K1068 and K1111 in the C-terminus, and K128 and K130 in the N-terminus. The human papilloma virus 16 protein-E7 preferentially binds to acetylated p130 and significantly increases in vitro p130 acetylation by p300. Oncogene (2010) 29, 5755-5760; doi:10.1038/onc.2010.311; published online 2 August 2010	[Schwarze, F.; Meraner, J.; Lechner, M.; Loidl, A.; Loidl, P.] Innsbruck Med Univ, Div Mol Biol, Bioctr, A-6020 Innsbruck, Austria; [Stasyk, T.] Innsbruck Med Univ, Div Cell Biol, Bioctr, A-6020 Innsbruck, Austria; [Laich, A.] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Loidl, P (corresponding author), Innsbruck Med Univ, Div Mol Biol, Bioctr, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Peter.Loidl@i-med.ac.at	Loidl, Alois/L-8199-2015	Loidl, Alois/0000-0002-5579-0746; Schwarze, Florian/0000-0002-1334-1301; Stasyk, Taras/0000-0003-0568-6841	Tyrolean Science Foundation	Tyrolean Science Foundation	We thank A Giordano for providing a p130 plasmid, J Kadonaga for a p300 vector, F Marx-Ladurner for PAF, G Bonn for mass spectrometry facilities and L Huber, A Lusser and M Saeed for valuable discussions. This work was supported by a grant of the Tyrolean Science Foundation to JM.	Brosch G, 2008, FEMS MICROBIOL REV, V32, P409, DOI 10.1111/j.1574-6976.2007.00100.x; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Choi CH, 2003, NATURE, V424, P965, DOI 10.1038/nature01899; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio P, 2002, GENOME BIOL, V3; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen K, 1999, ELECTROPHORESIS, V20, P372, DOI 10.1002/(SICI)1522-2683(19990201)20:2<372::AID-ELPS372>3.0.CO;2-R; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mayol X, 1996, ONCOGENE, V13, P237; Meraner J, 2006, NUCLEIC ACIDS RES, V34, P1798, DOI 10.1093/nar/gkl101; Nelson CJ, 2006, CELL, V126, P905, DOI 10.1016/j.cell.2006.07.026; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Popov B, 2005, BIOCHEM BIOPH RES CO, V336, P762, DOI 10.1016/j.bbrc.2005.08.163; Roman A, 2006, CELL CYCLE, V5, P567, DOI 10.4161/cc.5.6.2571; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; White MK, 2006, ONCOGENE, V25, P5286, DOI 10.1038/sj.onc.1209618; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	29	6	7	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5755	5760		10.1038/onc.2010.311	http://dx.doi.org/10.1038/onc.2010.311			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676144	Green Published, hybrid			2022-12-28	WOS:000283262500011
J	Weber, B; Kimhi, S; Howard, G; Eden, A; Lyko, F				Weber, B.; Kimhi, S.; Howard, G.; Eden, A.; Lyko, F.			Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription	ONCOGENE			English	Article						DNA methylation; LINE element; cMet; azacytidine; decitabine	DNA METHYLTRANSFERASE INHIBITORS; METHYLATION; CANCER; GENE; 5-AZA-2'-DEOXYCYTIDINE; HYPOMETHYLATION; ELEMENTS; EPIGENOMICS; MECHANISMS; RESISTANCE	The cytosine analogues 5-azacytidine and 5-aza-2'-deoxycytidine are currently the most advanced drugs for epigenetic cancer therapy. Both drugs function as DNA methyltransferase (DNMT) inhibitors and lead to the reactivation of epigenetically silenced tumour suppressor genes. However, not much is known about their target sequence specificity and their possible side effects on normally methylated sequences such as long interspersed nuclear element (LINE)-1 retroelements. It has been shown that demethylation and activation of the LINE-1 antisense promoter can drive the transcription of neighbouring sequences. In this study, we show that demethylation of the colon carcinoma cell line HCT116, either by treatment with DNMT inhibitors or by genetic disruption of the major DNMTs, induces the expression of an illegitimate fusion transcript between an intronic LINE-1 element and the proto-oncogene cMet (L1-cMet). Similar findings were also obtained with myeloid leukaemia cells, an established cellular model for the approved indication of azacytidine and decitabine. Interestingly, upregulation of L1-cMet transcription resulted in reduced cMet expression, which in turn led to decreased cMet receptor signalling. Our results thus provide an important paradigm for demethylation-dependent modulation of gene expression, even if the promoter of the corresponding gene is unmethylated. Oncogene (2010) 29, 5775-5784; doi: 10.1038/onc.2010.227; published online 21 June 2010	[Kimhi, S.; Howard, G.; Eden, A.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Dev Biol, IL-91904 Jerusalem, Israel; [Weber, B.; Lyko, F.] German Canc Res Ctr, DKFZ ZMBH Alliance, Div Epigenet, D-6900 Heidelberg, Germany	Hebrew University of Jerusalem; Helmholtz Association; German Cancer Research Center (DKFZ)	Eden, A (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Dev Biol, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il; f.lyko@dkfz.de			Deutsches Krebsforschungszentrum (DKFZ); Israeli Ministry of Science and Technology (MOST)	Deutsches Krebsforschungszentrum (DKFZ)(Helmholtz Association); Israeli Ministry of Science and Technology (MOST)	We thank Achim Breiling and Azeemudeen Hussain for their advice and support in chromatin immunoprecipitation and cMet signalling analysis. This work was supported by the Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ) and by the Israeli Ministry of Science and Technology (MOST).	Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172; Cruickshanks HA, 2009, GENOMICS, V94, P397, DOI 10.1016/j.ygeno.2009.08.013; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Mazo A, 2007, J CELL SCI, V120, P2755, DOI 10.1242/jcs.007633; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Mund C, 2006, EPIGENETICS-US, V1, P7; Nigumann P, 2002, GENOMICS, V79, P628, DOI 10.1006/geno.2002.6758; Novakovic B, 2010, J BIOL CHEM, V285, P9583, DOI 10.1074/jbc.M109.064956; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Schulz WA, 2006, CURR TOP MICROBIOL, V310, P211; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Stresemann C, 2008, MOL CANCER THER, V7, P2998, DOI 10.1158/1535-7163.MCT-08-0411; VESELY J, 1967, INT J CANCER, V2, P639, DOI 10.1002/ijc.2910020625; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032	40	68	73	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5775	5784		10.1038/onc.2010.227	http://dx.doi.org/10.1038/onc.2010.227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20562909				2022-12-28	WOS:000283586200003
J	Caron, C; Lestrat, C; Marsal, S; Escoffier, E; Curtet, S; Virolle, V; Barbry, P; Debernardi, A; Brambilla, C; Brambilla, E; Rousseaux, S; Khochbin, S				Caron, C.; Lestrat, C.; Marsal, S.; Escoffier, E.; Curtet, S.; Virolle, V.; Barbry, P.; Debernardi, A.; Brambilla, C.; Brambilla, E.; Rousseaux, S.; Khochbin, S.			Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers	ONCOGENE			English	Article						H4 K5ac; proteasome; chromatin; histone; epigenetics	GENE-EXPRESSION; HISTONE CODE; PROTEIN; BOUNDARY; COACTIVATOR; ATPASE; ROLES; ANCCA	Cancer cells frequently express genes normally active in male germ cells. ATAD2 is one of them encoding a conserved factor harbouring an AAA type ATPase domain and a bromodomain. We show here that ATAD2 is highly expressed in testis as well as in many cancers of different origins and that its high expression is a strong predictor of rapid mortality in lung and breast cancers. These observations suggest that ATAD2 acts on upstream and basic cellular processes to enhance oncogenesis in a variety of unrelated cell types. Accordingly, our functional studies show that ATAD2 controls chromatin dynamics, genome transcriptional activities and apoptotic cell response. We could also highlight some of the important intrinsic properties of its two regulatory domains, including a functional cross-talk between the AAA ATPase domain and the bromodomain. Altogether, these data indicate that ATAD2 overexpression in somatic cells, by acting on basic properties of chromatin, may contribute to malignant transformation. Oncogene (2010) 29, 5171-5181; doi:10.1038/onc.2010.259; published online 28 June 2010	[Caron, C.; Lestrat, C.; Marsal, S.; Escoffier, E.; Curtet, S.; Debernardi, A.; Brambilla, C.; Brambilla, E.; Rousseaux, S.; Khochbin, S.] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France; [Virolle, V.; Barbry, P.] CNRS, Sophia Antipolis, France; [Virolle, V.; Barbry, P.] Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Caron, C (corresponding author), INSERM, Inst Albert Bonniot, F-38706 La Tronche, Isere, France.	cecile.caron@ujf-grenoble.fr; khochbin@ujf-grenoble.fr	CURTET, Sandrine/E-8217-2019; Khochbin, Saadi/M-8090-2013; CURTET, Sandrine/N-3517-2013; Barbry, Pascal/O-5021-2016; Rousseaux, Sophie/G-1697-2013; debernardi, alexandra/N-4220-2013	CURTET, Sandrine/0000-0002-9419-8868; Khochbin, Saadi/0000-0002-0455-0857; Barbry, Pascal/0000-0001-9632-6483; Rousseaux, Sophie/0000-0001-5246-5350; 	ANR blanc-Episperm; INCa-DHOS; ARC-ARECA; Region Rhone-Alpes; INCa [AO 2006]; Nice-Sophia Antipolis Transcriptome Platform of the Marseille-Nice Genopole; Albert Bonniot Institute; Grenoble	ANR blanc-Episperm(French National Research Agency (ANR)); INCa-DHOS; ARC-ARECA; Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); INCa(Institut National du Cancer (INCA) France); Nice-Sophia Antipolis Transcriptome Platform of the Marseille-Nice Genopole; Albert Bonniot Institute; Grenoble(Region Auvergne-Rhone-Alpes)	This work was supported by the 'ANR blanc-Episperm', INCa-DHOS' and 'ARC-ARECA' research programs. CL and SM are supported by the PhD fellowship program of Region Rhone-Alpes and the post-doc fellowship program of INCa (AO 2006), respectively. AD salary is paid by the INCa-DHOS funds. Transcriptomic analyses of lung cancer patients were obtained thanks to the Ligue Contre le Cancer 'Carte d'identite des Tumeurs' (CIT) program. We acknowledge the support of the Nice-Sophia Antipolis Transcriptome Platform of the Marseille-Nice Genopole, in which the microarray experiments were carried out. Special thanks are due to Geraldine Rios for microarray production. We also acknowledge the support of the microscopy platform, Albert Bonniot Institute, Grenoble, and thank Catherine Souchier for her precious help in the FRAP experiments.	Boussouar F, 2008, CELL CYCLE, V7, P3499, DOI 10.4161/cc.7.22.6975; Ciro M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022; Fillingham J, 2009, MOL CELL, V35, P340, DOI 10.1016/j.molcel.2009.06.023; Gradolatto A, 2008, GENETICS, V179, P291, DOI 10.1534/genetics.107.086520; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Jambunathan N, 2005, GENETICS, V171, P913, DOI 10.1534/genetics.105.046938; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Pivot-Pajot C, 2003, MOL CELL BIOL, V23, P5354, DOI 10.1128/MCB.23.15.5354-5365.2003; Rousseaux S, 2009, EPIGENOMICS-UK, V1, P153, DOI 10.2217/EPI.09.1; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Tackett AJ, 2005, J CELL BIOL, V169, P35, DOI 10.1083/jcb.200502104; Tseng RJ, 2007, MOL GENET GENOMICS, V278, P507, DOI 10.1007/s00438-007-0265-6; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104; Zou JX, 2009, CANCER RES, V69, P3339, DOI 10.1158/0008-5472.CAN-08-3440	21	120	128	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5171	5181		10.1038/onc.2010.259	http://dx.doi.org/10.1038/onc.2010.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581866				2022-12-28	WOS:000281867200006
J	Lee, SH; Bahn, JH; Whitlock, NC; Baek, SJ				Lee, S-H; Bahn, J. H.; Whitlock, N. C.; Baek, S. J.			Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways	ONCOGENE			English	Article						Tolfenamic acid; ATF2; ATF3; apoptosis; colorectal cancer	COLORECTAL-CANCER CELLS; STRESS-INDUCIBLE GENE; RESPONSE GENE; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MAMMARY-TUMORS; BREAST-CANCER; APOPTOSIS; GROWTH; NAG-1	Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug associated with anti-tumorigenic and pro-apoptotic properties in animal and in vitro models of cancer. However, the underlying cellular mechanisms by which TA exerts its effects are only partially understood. Activating transcription factor 3 (ATF3) is a member of the ATF/CREB subfamily of the basic region-leucine zipper family and has been known as a tumor suppressor in human colorectal cancer cells. The present study was performed to observe whether ATF3 mediates TA-induced apoptosis and to elucidate the molecular mechanism of ATF3 transcription induced by TA. TA treatment and ectopic expression of ATF3 increased apoptosis, whereas knockdown of ATF3 resulted in significant repression of TA-activated apoptosis. The TA treatment also induced ATF3 promoter activity. Internal deletion and point mutation of the predicted ATF/C/EBP binding site in ATF3 promoter abolished luciferase activation by TA. Overexpression of ATF2 resulted in significant increase in ATF3 promoter activity, and electrophoretic mobility shift assay identified this region as a core sequence to which ATF2 binds. TA treatment resulted in an increase in ATF2 phosphorylation, which was followed by a subsequent increase in ATF3 transcription. Knock down of ATF2 abolished TA-induced ATF3 expression. We further provide evidence that TA leads to increases in phospho-p38 MAPK, JNK and ERK levels. Inhibition of these pathways using selective inhibitors and dominant negative constructs ameliorated TA-induced ATF3 expression and promoter activities. The current study shows that TA stimulates ATF3 expression and subsequently induces apoptosis. These pathways are mediated through phosphorylation of ATF2, which is mediated by p38 MAPK-, JNK- and ERK-dependent pathways. Oncogene (2010) 29, 5182-5192; doi:10.1038/onc.2010.251; published online 28 June 2010	[Lee, S-H; Bahn, J. H.; Whitlock, N. C.; Baek, S. J.] Univ Tennessee, Dept Pathobiol, Lab Environm Carcinogenesis, Coll Vet Med, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Baek, SJ (corresponding author), Univ Tennessee, Dept Pathobiol, Lab Environm Carcinogenesis, Coll Vet Med, 2407 River Dr, Knoxville, TN 37996 USA.	sbaek2@utk.edu	Bahn, Jae Hoon/G-7686-2016; Bahn, Jae Hoon/AAP-2672-2020; Bahn, Jae Hoon/AAA-9612-2019	Bahn, Jae Hoon/0000-0002-0365-1728; 	National Institutes of Health [R01CA108975]; University of Tennessee, Center of Excellence in Livestock Diseases and Human Health; American Cancer Society [CNE-111611]; NATIONAL CANCER INSTITUTE [R01CA108975] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Tennessee, Center of Excellence in Livestock Diseases and Human Health; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr T Hai (Ohio State University, Columbus, OH, USA) and Dr S Kitajima (Tokyo Medical and Dental University, Tokyo, Japan) for providing the pCG-ATF3 construct and ATF3 promoter, respectively. We thank Dr Philip Cohen (University of Dundee, Scotland, UK) and Dr Joo-Heon Yoon (Yonsei University, Seoul, Korea) for providing pEBG2T-GST-ATF2-6His- and CREB-expression vector, respectively. We thank Dr Melanie Cobb (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing wild type and dominant negative ERK2-expression vector. We also thank Misty Bailey for her critical reading of the paper. This work was supported by Grants from the American Cancer Society (CNE-111611), National Institutes of Health (R01CA108975) and the University of Tennessee, Center of Excellence in Livestock Diseases and Human Health to SJB.	Abdelrahim M, 2007, CANCER RES, V67, P3286, DOI 10.1158/0008-5472.CAN-06-3831; Abdelrahim M, 2006, J NATL CANCER I, V98, P855, DOI 10.1093/jnci/djj232; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Bottone FG, 2004, CARCINOGENESIS, V25, P349, DOI 10.1093/carcin/bgh016; Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chen HH, 2004, MOL PHARMACOL, V65, P1130, DOI 10.1124/mol.65.5.1130; Cho KN, 2007, EUR J CANCER, V43, P2404, DOI 10.1016/j.ejca.2007.07.020; Deng XH, 2008, CANCER RES, V68, P9663, DOI 10.1158/0008-5472.CAN-08-2229; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HANSEN PE, 1994, PHARMACOL TOXICOL, V75, P81, DOI 10.1111/j.1600-0773.1994.tb02005.x; Hao F, 2007, BBA-MOL CELL BIOL L, V1771, P883, DOI 10.1016/j.bbalip.2007.04.010; Huang XW, 2008, J BIOL CHEM, V283, P29795, DOI 10.1074/jbc.M802515200; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kashiwakura Y, 2008, CANCER RES, V68, P8333, DOI 10.1158/0008-5472.CAN-08-0080; Lee SH, 2008, MOL CANCER THER, V7, P3739, DOI 10.1158/1535-7163.MCT-08-0548; Lee SH, 2006, CARCINOGENESIS, V27, P972, DOI 10.1093/carcin/bgi268; Lee SH, 2005, BIOCHEM BIOPH RES CO, V328, P63, DOI 10.1016/j.bbrc.2004.12.138; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Maekawa T, 2008, ONCOGENE, V27, P1045, DOI 10.1038/sj.onc.1210727; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Miyazaki K, 2009, NUCLEIC ACIDS RES, V37, P1438, DOI 10.1093/nar/gkn1082; Oh YK, 2008, MOL CANCER RES, V6, P1232, DOI 10.1158/1541-7786.MCR-07-0297; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Piyanuch R, 2007, CANCER LETT, V258, P230, DOI 10.1016/j.canlet.2007.09.007; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Whitmore MM, 2007, J IMMUNOL, V179, P3622, DOI 10.4049/jimmunol.179.6.3622; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Woo IS, 2002, INT J ONCOL, V20, P527; Xue L, 2005, ONCOGENE, V24, P2343, DOI 10.1038/sj.onc.1208434; Yamaguchi K, 2006, CANCER RES, V66, P2376, DOI 10.1158/0008-5472.CAN-05-1987; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861	45	65	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5182	5192		10.1038/onc.2010.251	http://dx.doi.org/10.1038/onc.2010.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581861	Green Accepted			2022-12-28	WOS:000281867200007
J	Bobrovnikova-Marjon, E; Grigoriadou, C; Pytel, D; Zhang, F; Ye, J; Koumenis, C; Cavener, D; Diehl, JA				Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Ye, J.; Koumenis, C.; Cavener, D.; Diehl, J. A.			PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage	ONCOGENE			English	Article						PERK; Nrf2; ROS; DNA damage; cell cycle checkpoints	INTEGRATED STRESS-RESPONSE; SUBUNIT GENE-EXPRESSION; CUL3-BASED E3 LIGASE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; LUNG-CANCER; TRANSLATIONAL REGULATION; MESSENGER-RNA; COMPLEX-III; PROTEIN	To proliferate and expand in an environment with limited nutrients, cancer cells co-opt cellular regulatory pathways that facilitate adaptation and thereby maintain tumor growth and survival potential. The endoplasmic reticulum (ER) is uniquely positioned to sense nutrient deprivation stress and subsequently engage signaling pathways that promote adaptive strategies. As such, components of the ER stress-signaling pathway represent potential antineoplastic targets. However, recent investigations into the role of the ER resident protein kinase, RNA-dependent protein kinase (PKR)-like ER kinase (PERK) have paradoxically suggested both pro- and anti-tumorigenic properties. We have used animal models of mammary carcinoma to interrogate the contribution of PERK in the neoplastic process. The ablation of PERK in tumor cells resulted in impaired regeneration of intracellular antioxidants and accumulation of reactive oxygen species triggering oxidative DNA damage. Ultimately, PERK deficiency impeded progression through the cell cycle because of the activation of the DNA damage checkpoint. Our data reveal that PERK-dependent signaling is used during both tumor initiation and expansion to maintain redox homeostasis, thereby facilitating tumor growth. Oncogene (2010) 29, 3881-3895; doi:10.1038/onc.2010.153; published online 10 May 2010	[Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Diehl, J. A.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; [Ye, J.; Koumenis, C.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Cavener, D.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu	Ye, Jiangbin/A-1094-2007; Cavener, Douglas R/E-3524-2010; Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726; Ye, Jiangbin/0000-0003-1117-4869	National Institutes of Health [F32CA1238252, P01 CA104838]; Leukemia & Lymphoma Scholar award; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088140] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Scholar award(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Serge Fuchs for critical reading of the paper, Margarita Romero for outstanding technical assistance and the AFCRI histology core. This work was supported by the National Institutes of Health Grants F32CA1238252 (to EBM), P01 CA104838 and a Leukemia & Lymphoma Scholar award (to JAD).	Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Back SH, 2009, CELL METAB, V10, P13, DOI 10.1016/j.cmet.2009.06.002; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2004, CELL CYCLE, V3, P149; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Bruns CJ, 2004, CLIN CANCER RES, V10, P2109, DOI 10.1158/1078-0432.CCR-03-0502; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; Clanton TL, 2007, J APPL PHYSIOL, V102, P2379, DOI 10.1152/japplphysiol.01298.2006; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Evans, 2000, Mol Med Today, V6, P459, DOI 10.1016/S1357-4310(00)01824-4; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; FOLKMAN J, 1966, ANN SURG, V164, P491, DOI 10.1097/00000658-196609000-00012; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Lee HK, 2008, NEURO-ONCOLOGY, V10, P236, DOI 10.1215/15228517-2008-006; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; Lo SC, 2006, EMBO J, V25, P3605, DOI 10.1038/sj.emboj.7601243; Nicco C, 2005, BIOMED PHARMACOTHER, V59, P169, DOI 10.1016/j.biopha.2005.03.009; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Ranganathan AC, 2008, CANCER RES, V68, P3260, DOI 10.1158/0008-5472.CAN-07-6215; Reddy NM, 2008, ONCOGENE, V27, P5821, DOI 10.1038/onc.2008.188; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Shenvi SV, 2009, PHARMACOL RES, V60, P229, DOI 10.1016/j.phrs.2009.06.003; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shimizu Y, 2009, ANTIOXID REDOX SIGN, V11, P2317, DOI [10.1089/ars.2009.2501, 10.1089/ARS.2009.2501]; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Stracker TH, 2008, MOL CELL, V31, P21, DOI 10.1016/j.molcel.2008.04.028; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tommiska J, 2008, ONCOGENE, V27, P2501, DOI 10.1038/sj.onc.1210885; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Wu WG, 1998, CANCER RES, V58, P4082; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang F, 2006, J BIOL CHEM, V281, P30036, DOI 10.1074/jbc.M604674200; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	74	195	209	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3881	3895		10.1038/onc.2010.153	http://dx.doi.org/10.1038/onc.2010.153			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453876	Green Accepted			2022-12-28	WOS:000279603200002
J	Yamashita, Y; Yuan, J; Suetake, I; Suzuki, H; Ishikawa, Y; Choi, YL; Ueno, T; Soda, M; Hamada, T; Haruta, H; Takada, S; Miyazaki, Y; Kiyoi, H; Ito, E; Naoe, T; Tomonaga, M; Toyota, M; Tajima, S; Iwama, A; Mano, H				Yamashita, Y.; Yuan, J.; Suetake, I.; Suzuki, H.; Ishikawa, Y.; Choi, Y. L.; Ueno, T.; Soda, M.; Hamada, T.; Haruta, H.; Takada, S.; Miyazaki, Y.; Kiyoi, H.; Ito, E.; Naoe, T.; Tomonaga, M.; Toyota, M.; Tajima, S.; Iwama, A.; Mano, H.			Array-based genomic resequencing of human leukemia	ONCOGENE			English	Article						resequencing; AML; JAK3; DNMT3A	ACUTE MYELOID-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; DNA METHYLTRANSFERASES DNMT3A; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM; ACTIVATING MUTATION; JAK3 MUTATIONS; DOWN-SYNDROME; CELLS; METHYLATION	To identify oncogenes in leukemias, we performed large-scale resequencing of the leukemia genome using DNA sequence arrays that determine similar to 9 Mbp of sequence corresponding to the exons or exon-intron boundaries of 5648 protein-coding genes. Hybridization of genomic DNA from CD34-positive blasts of acute myeloid leukemia (n = 19) or myeloproliferative disorder (n = 1) with the arrays identified 9148 nonsynonymous nucleotide changes. Subsequent analysis showed that most of these changes were also present in the genomic DNA of the paired controls, with 11 somatic changes identified only in the leukemic blasts. One of these latter changes results in a Met-to-Ile substitution at amino-acid position 511 of Janus kinase 3 (JAK3), and the JAK3(M511I) protein exhibited transforming potential both in vitro and in vivo. Further screening for JAK3 mutations showed novel and known transforming changes in a total of 9 out of 286 cases of leukemia. Our experiments also showed a somatic change responsible for an Arg-to-His substitution at amino-acid position 882 of DNA methyltransferase 3A, which resulted in a loss of DNA methylation activity of >50%. Our data have thus shown a unique profile of gene mutations in human leukemia. Oncogene (2010) 29, 3723-3731; doi: 10.1038/onc.2010.117; published online 19 April 2010	[Yamashita, Y.; Choi, Y. L.; Ueno, T.; Soda, M.; Hamada, T.; Haruta, H.; Takada, S.; Mano, H.] Jichi Med Univ, Div Funct Genom, Shimotsukeshi, Tochigi 3290498, Japan; [Yuan, J.; Iwama, A.] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; [Suetake, I.; Tajima, S.] Osaka Univ, Inst Prot Res, Lab Epigenet, Osaka, Japan; [Suzuki, H.] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; [Ishikawa, Y.] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi 4648601, Japan; [Choi, Y. L.; Mano, H.] Univ Tokyo, Grad Sch Med, Dept Med Genom, Tokyo, Japan; [Miyazaki, Y.; Tomonaga, M.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Med & Hematol, Nagasaki 852, Japan; [Kiyoi, H.] Nagoya Univ, Sch Med, Dept Infect Dis, Nagoya, Aichi 466, Japan; [Ito, E.] Hirosaki Univ, Grad Sch Med, Dept Paediat, Aomori, Japan; [Toyota, M.] Sapporo Med Univ, Dept Biochem, Sapporo, Hokkaido, Japan; [Iwama, A.; Mano, H.] Japan Sci & Technol Agcy, CREST, Saitama, Japan	Jichi Medical University; Chiba University; Osaka University; Sapporo Medical University; Nagoya University; University of Tokyo; Nagasaki University; Nagoya University; Hirosaki University; Sapporo Medical University; Japan Science & Technology Agency (JST)	Mano, H (corresponding author), Jichi Med Univ, Div Funct Genom, 3311-1 Yakushiji, Shimotsukeshi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Naoe, Tomoki/I-1888-2012; Suetake, Isao/D-4326-2009; Suetake, Isao/G-3144-2013	Suetake, Isao/0000-0002-1246-8474; Takada, Shuji/0000-0002-9406-4683	Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research [22300326] Funding Source: KAKEN	Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank D Cox, KA Frazer, DG Ballinger, J Montgomery, H Tao, C Chen, L Stuve, J Kwon, J Sheehan and Y Zhan for discussion on the wafer experiments, as well as JN Ihle, T Kitamura and SB Baylin for human JAK3 cDNA, the pMX plasmid and human DNMT3A cDNA, respectively. This study was supported in part by a grant for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor, and Welfare of Japan, and by a grant for Scientific Research on Priority Areas 'Applied Genomics' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Choi YL, 2007, LEUKEMIA RES, V31, P203, DOI 10.1016/j.leukres.2006.05.006; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; El-Osta A, 2004, LEUKEMIA, V18, P233, DOI 10.1038/sj.leu.2403218; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Imanishi D, 2007, BLOOD, V110, P2231, DOI 10.1182/blood-2007-02-071423; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146; Kiyoi H, 2007, LEUKEMIA, V21, P574, DOI 10.1038/sj.leu.2404527; Koinuma K, 2005, CARCINOGENESIS, V26, P2078, DOI 10.1093/carcin/bgi184; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; Kwong YL, 1996, CANCER GENET CYTOGEN, V88, P151, DOI 10.1016/0165-4608(95)00282-0; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Nimer SD, 2004, ONCOGENE, V23, P4249, DOI 10.1038/sj.onc.1207673; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Onishi M, 1996, EXP HEMATOL, V24, P324; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sato T, 2008, BRIT J HAEMATOL, V141, P681, DOI 10.1111/j.1365-2141.2008.07081.x; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schwonzen M, 2007, LEUKEMIA RES, V31, P113, DOI 10.1016/j.leukres.2006.03.022; Shimada A, 2006, BLOOD, V107, P1806, DOI 10.1182/blood-2005-08-3408; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; Tallman Martin S, 2008, Hematology Am Soc Hematol Educ Program, P391, DOI 10.1182/asheducation-2008.1.391; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	36	196	208	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3723	3731		10.1038/onc.2010.117	http://dx.doi.org/10.1038/onc.2010.117			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20400977				2022-12-28	WOS:000279108600012
J	Kwon, IK; Wang, R; Thangaraju, M; Shuang, H; Liu, K; Dashwood, R; Dulin, N; Ganapathy, V; Browning, DD				Kwon, I-K; Wang, R.; Thangaraju, M.; Shuang, H.; Liu, K.; Dashwood, R.; Dulin, N.; Ganapathy, V.; Browning, D. D.			PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4	ONCOGENE			English	Article						PKG; cGMP; FOXO; beta-catenin; TCF; colon cancer	DEPENDENT PROTEIN-KINASE; CYCLIC-GMP; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; FUNCTIONAL-ANALYSIS; TUMOR-DEVELOPMENT; BINDING PARTNERS; BREAST-CANCER; PATHWAY	Activation of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechanisms are not fully understood. This study has examined the regulation of beta-catenin/TCF signaling, as this pathway has been highlighted as central to the anti-tumor effects of PKG. We show that PKG activation in SW620 cells results in reduced beta-catenin expression and a dramatic inhibition of TCF-dependent transcription. PKG did not affect protein stability, nor did it increase phosphorylation of the amino-terminal Ser33/37/Thr41 residues that are known to target beta-catenin for degradation. However, we found that PKG potently inhibited transcription from a luciferase reporter driven by the human CTNNB1 promoter, and this corresponded to reduced beta-catenin mRNA levels. Although PKG was able to inhibit transcription from both the CTNNB1 and TCF reporters, the effect on protein levels was less consistent. Ectopic PKG had a marginal effect on beta-catenin protein levels in SW480 and HCT116 but was able to inhibit TCF-reporter activity by over 80%. Investigation of alternative mechanisms revealed that cJun-N-terminal kinase (JNK) activation was required for the PKG-dependent regulation of TCF activity. PKG activation caused beta-catenin to bind to FOXO4 in colon cancer cells, and this required JNK. Activation of PKG was also found to increase the nuclear content of FOXO4 and increase the expression of the FOXO target genes MnSOD and catalase. FOXO4 activation was required for the inhibition of TCF activity as FOXO4-specific short-interfering RNA completely blocked the inhibitory effect of PKG. These data illustrate a dual-inhibitory effect of PKG on TCF activity in colon cancer cells that involves reduced expression of beta-catenin at the transcriptional level, and also beta-catenin sequestration by FOXO4 activation. Oncogene (2010) 29, 3423-3434; doi:10.1038/onc.2010.91; published online 29 March 2010	[Kwon, I-K; Wang, R.; Thangaraju, M.; Shuang, H.; Liu, K.; Ganapathy, V.; Browning, D. D.] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Dashwood, R.] Oregon State Univ, Linus Pauling Inst, Canc Chemoprotect Program, Corvallis, OR 97331 USA; [Dulin, N.] Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University System of Georgia; Augusta University; Oregon State University; University of Chicago	Browning, DD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, CB2605,1459 Laney Walker Blvd,1120,15th St, Augusta, GA 30912 USA.	dbrowning@mcg.edu	Dashwood, Roderick/AAF-2025-2020	Liu, Kebin/0000-0003-1965-7240; Browning, Darren/0000-0003-0497-7620; Wang, Rui/0000-0001-5794-7201	American Cancer Society [RSG-07-174-01-CSM, RSG-09-209-01-TBG]; National Institutes of Health [CA133085]; NATIONAL CANCER INSTITUTE [R01CA133085] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the American Cancer Society (RSG-07-174-01-CSM to DDB and RSG-09-209-01-TBG to KL) and the National Institutes of Health (CA133085 to KL).	Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Browning DD, 2008, EXPERT OPIN THER TAR, V12, P367, DOI 10.1517/14728222.12.3.367; Browning DD, 2001, J BIOL CHEM, V276, P13039, DOI 10.1074/jbc.M009187200; Burgering B, 2008, ONCOGENE, V27, P2258, DOI 10.1038/onc.2008.29; Burgoyne JR, 2007, SCIENCE, V317, P1393, DOI 10.1126/science.1144318; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Cen B, 2008, CANCER RES, V68, P5355, DOI 10.1158/0008-5472.CAN-07-6869; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Forte LR, 2004, PHARMACOL THERAPEUT, V104, P137, DOI 10.1016/j.pharmthera.2004.08.007; Forte LR, 2000, ANNU REV PHYSIOL, V62, P673, DOI 10.1146/annurev.physiol.62.1.673; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goluboff ET, 2001, EXPERT OPIN INV DRUG, V10, P1875, DOI 10.1517/13543784.10.10.1875; Haanen C, 2001, Curr Opin Investig Drugs, V2, P677; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200; Hoogeboom D, 2009, BBA-REV CANCER, V1796, P63, DOI 10.1016/j.bbcan.2009.02.002; Hou YL, 2006, CANCER LETT, V240, P60, DOI 10.1016/j.canlet.2005.08.035; Hou YL, 2006, CELL SIGNAL, V18, P882, DOI 10.1016/j.cellsig.2005.07.015; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kwon IK, 2008, CANCER-AM CANCER SOC, V112, P1462, DOI 10.1002/cncr.23334; Li H, 2002, CANCER BIOL THER, V1, P621, DOI 10.4161/cbt.309; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Liu L, 2001, J PHARMACOL EXP THER, V299, P583; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709; Maiese K, 2008, CELL CYCLE, V7, P3829, DOI 10.4161/cc.7.24.7231; Pitari GM, 2001, P NATL ACAD SCI USA, V98, P7846, DOI 10.1073/pnas.141124698; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769; Shailubhai K, 2000, CANCER RES, V60, P5151; Soh JW, 2008, MOL CARCINOGEN, V47, P519, DOI 10.1002/mc.20409; Soh JW, 2000, CLIN CANCER RES, V6, P4136; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Sparks AB, 1998, CANCER RES, V58, P1130; Strate LL, 2005, CANCER CAUSE CONTROL, V16, P201, DOI 10.1007/s10552-004-3488-4; Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Thompson WJ, 2000, CANCER RES, V60, P3338; Uzzau S, 2000, CELL MICROBIOL, V2, P83, DOI 10.1046/j.1462-5822.2000.00041.x; van der Vos KE, 2008, ONCOGENE, V27, P2289, DOI 10.1038/onc.2008.22; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Zhu B, 2005, J CELL BIOCHEM, V94, P336, DOI 10.1002/jcb.20286	61	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2010	29	23					3423	3434		10.1038/onc.2010.91	http://dx.doi.org/10.1038/onc.2010.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20348951	Green Accepted			2022-12-28	WOS:000278622700010
J	Richard, C; Lanner, C; Naryzhny, SN; Sherman, L; Lee, H; Lambert, PF; Zehbe, I				Richard, C.; Lanner, C.; Naryzhny, S. N.; Sherman, L.; Lee, H.; Lambert, P. F.; Zehbe, I.			The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer	ONCOGENE			English	Article						human papillomavirus; human primary foreskin keratinocytes; immortalization; transformation; cervical cancer	MAMMARY EPITHELIAL-CELLS; TYPE-16 E6; HUMAN-PAPILLOMAVIRUS-16 E6; INTRAEPITHELIAL NEOPLASIA; TELOMERASE ACTIVATION; HUMAN KERATINOCYTES; NATURAL VARIANTS; P53 DEGRADATION; E7 ONCOGENES; IN-VIVO	Persistent infection with high-risk human papillomaviruses (HPVs), especially type 16 has been undeniably linked to cervical cancer. The Asian-American (AA) variant of HPV16 is more common in the Americas than the prototype in cervical cancer. The different prevalence is based on three amino acid changes within the E6 protein denoted Q14H/H78Y/L83V. To investigate the mechanism(s) behind this observation, both E6 proteins, in the presence of E7, were evaluated for their ability to extend the life span of and transform primary human foreskin keratinocytes (PHFKs). Longterm cell culture studies resulted in death at passage 9 of vector-transduced PHFKs (negative control), but survival of both E6 PHFKs to passage 65 (and beyond). Compared with E6/E7 PHFKs, AA/E7 PHFKs were significantly faster dividing, developed larger cells in monolayer cultures, showed double the epithelial thickness and expressed cytokeratin 10 when grown as organotypic raft cultures. Telomerase activation and p53 inactivation, two hallmarks of immortalization, were not significantly different between the two populations. Both were resistant to anoikis at later passages, but only AA/E7 PHFKs acquired the capacity for in vitro transformation. Proteomic analysis revealed markedly different protein patterns between E6/E7 and AA/E7, particularly with respect to key cellular metabolic enzymes. Our results provide new insights into the reasons underlying the greater prevalence of the AA variant in cervical cancer as evidenced by characteristics associated with higher oncogenic potential. Oncogene (2010) 29, 3435-3445; doi:10.1038/onc.2010.93; published online 12 April 2010	[Zehbe, I.] Thunder Bay Reg Res Inst, Thunder Bay, ON P7B 6V4, Canada; [Richard, C.] Thunder Bay Reg Hlth Sci Ctr, Res Lab, Thunder Bay, ON, Canada; [Lanner, C.; Lee, H.] Laurentian Univ, No Ontario Sch Med, Sudbury, ON P3E 2C6, Canada; [Naryzhny, S. N.] Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada; [Naryzhny, S. N.; Lee, H.] Sudbury Reg Hosp, NE Ontario Reg Canc Program, Sudbury, ON, Canada; [Sherman, L.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel; [Lambert, P. F.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	Northern Ontario School of Medicine; Northern Ontario School of Medicine; Laurentian University; Northern Ontario School of Medicine; Laurentian University; Health Sciences North; Tel Aviv University; Sackler Faculty of Medicine; University of Wisconsin System; University of Wisconsin Madison	Zehbe, I (corresponding author), Thunder Bay Reg Res Inst, 980 Oliver Rd, Thunder Bay, ON P7B 6V4, Canada.	zehbei@tbh.net	Lambert, Paul F/F-3747-2012; Naryzhny, Stanislav/D-1683-2012	Naryzhny, Stanislav/0000-0002-4102-3423	Natural Sciences and Engineering Research Council of Canada (NSERC)	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	We are grateful to the staff from the Central Laboratory of the Thunder Bay Regional Health Sciences Centre for technical assistance and Bruce Weaver from the Northern School of Medicine, West-Campus, Thunder Bay for help with statistical analysis. This work was funded by a Discovery Grant to IZ from the Natural Sciences and Engineering Research Council of Canada (NSERC).	Allen-Hoffmann BL, 2000, J INVEST DERMATOL, V114, P444, DOI 10.1046/j.1523-1747.2000.00869.x; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; Asadurian Y, 2007, J MED VIROL, V79, P1751, DOI 10.1002/jmv.20978; Bernard HU, 2006, INT J CANCER, V118, P1071, DOI 10.1002/ijc.21655; Bernard HU, 2005, J CLIN VIROL, V32, pS1, DOI 10.1016/j.jcv.2004.10.021; Berumen J, 2001, JNCI-J NATL CANCER I, V93, P1325, DOI 10.1093/jnci/93.17.1325; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; Chen ZG, 2005, J VIROL, V79, P7014, DOI 10.1128/JVI.79.11.7014-7023.2005; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Souza PSD, 2009, FUTURE ONCOL, V5, P359, DOI [10.2217/fon.09.8, 10.2217/FON.09.8]; DeCarlo CA, 2008, ANAL BIOCHEM, V381, P59, DOI 10.1016/j.ab.2008.06.009; Fu BJ, 2003, CANCER RES, V63, P7815; Grodzki M, 2006, CANCER EPIDEM BIOMAR, V15, P820, DOI 10.1158/1055-9965.EPI-05-0864; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; James MA, 2006, INT J CANCER, V119, P1878, DOI 10.1002/ijc.22064; Ji Q, 2004, CANCER RES, V64, P7610, DOI 10.1158/0008-5472.CAN-04-1608; Kammer C, 2002, BRIT J CANCER, V86, P269, DOI 10.1038/sj.bjc.6600024; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; Kirkpatrick Katharine L, 2004, J Carcinog, V3, P1, DOI 10.1186/1477-3163-3-1; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kondoh H, 2008, EXP CELL RES, V314, P1923, DOI 10.1016/j.yexcr.2008.03.007; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Lee K, 2008, VIRUS RES, V131, P106, DOI 10.1016/j.virusres.2007.08.003; Lichtig H, 2006, VIROLOGY, V350, P216, DOI 10.1016/j.virol.2006.01.038; Maddox P, 1999, J CLIN PATHOL, V52, P41, DOI 10.1136/jcp.52.1.41; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; McMurray HR, 2004, J VIROL, V78, P5698, DOI 10.1128/JVI.78.11.5698-5706.2004; Naryzhny SN, 2007, FEBS LETT, V581, P4917, DOI 10.1016/j.febslet.2007.09.022; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; Penning TM, 2009, ANN NY ACAD SCI, V1155, P33, DOI 10.1111/j.1749-6632.2009.03700.x; Pollard PJ, 2009, SCIENCE, V324, P192, DOI 10.1126/science.1173362; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHONK DM, 1989, HUM GENET, V83, P297, DOI 10.1007/BF00285178; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; Sekaric P, 2008, J VIROL, V82, P71, DOI 10.1128/JVI.01776-07; Shamanin VA, 2008, J VIROL, V82, P3912, DOI 10.1128/JVI.02466-07; Shen ZY, 2004, ONCOL REP, V11, P647; SMEDTS F, 1992, AM J PATHOL, V141, P497; SMEDTS F, 1993, OBSTET GYNECOL, V82, P465; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Sprague DL, 2002, VIROLOGY, V301, P247, DOI 10.1006/viro.2002.1542; Stoppler MC, 1996, J VIROL, V70, P6987; Sumida T, 1999, INT J CANCER, V80, P1, DOI 10.1002/(SICI)1097-0215(19990105)80:1<1::AID-IJC1>3.0.CO;2-U; TIDY JA, 1989, LANCET, V1, P1225; WOODWORTH CD, 1988, CANCER RES, V48, P4620; Xi LF, 1998, CANCER RES, V58, P3839; Xi LF, 1997, JNCI-J NATL CANCER I, V89, P796, DOI 10.1093/jnci/89.11.796; Xi LF, 2007, CANCER EPIDEM BIOMAR, V16, P4, DOI 10.1158/1055-9965.EPI-06-0670; Xi LF, 2006, J NATL CANCER I, V98, P1045, DOI 10.1093/jnci/djj297; Zehbe I, 1999, ONCOGENE, V18, P2201, DOI 10.1038/sj.onc.1202549; Zehbe I, 2003, HUM IMMUNOL, V64, P538, DOI 10.1016/S0198-8859(03)00033-8; Zehbe I, 1998, LANCET, V352, P1441, DOI 10.1016/S0140-6736(05)61263-9; Zehbe I, 2001, INT J CANCER, V94, P711, DOI 10.1002/ijc.1520; Zehbe I, 1998, CANCER RES, V58, P829; Zehbe I, 2009, VIROLOGY, V383, P69, DOI 10.1016/j.virol.2008.09.036; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	65	54	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3435	3445		10.1038/onc.2010.93	http://dx.doi.org/10.1038/onc.2010.93			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383192				2022-12-28	WOS:000278622700011
J	Pirngruber, J; Johnsen, SA				Pirngruber, J.; Johnsen, S. A.			Induced G1 cell-cycle arrest controls replication-dependent histone mRNA 3 ' end processing through p21, NPAT and CDK9	ONCOGENE			English	Article						P53; CDK; histone; mRNA processing	S-PHASE ENTRY; GENE-EXPRESSION; DNA-DAMAGE; E/CDK2 SUBSTRATE; CAJAL BODIES; TRANSCRIPTION; P53; ACTIVATION; P220(NPAT); PHOSPHORYLATION	Proper cell cycle-dependent expression of replication-dependent histones is essential for packaging of DNA into chromatin during replication. We previously showed that cyclin-dependent kinase-9 (CDK9) controls histone H2B monoubiquitination (H2Bub1) to direct the recruitment of specific mRNA 3' end processing proteins to replication-dependent histone genes and promote proper pre-mRNA 3' end processing. We now show that p53 decreases the expression of the histone-specific transcriptional regulator Nuclear Protein, Ataxia-Telangiectasia Locus (NPAT) by inducing a G1 cell-cycle arrest, thereby affecting E2F-dependent transcription of the NPAT gene. Furthermore, NPAT is essential for histone mRNA 3' end processing and recruits CDK9 to replication-dependent histone genes. Reduced NPAT expression following p53 activation or small interfering RNA knockdown decreases CDK9 recruitment and replication-dependent histone gene transcription but increases the polyadenylation of remaining histone mRNAs. Thus, we present evidence that the induction of a G1 cell-cycle arrest (for example, following p53 accumulation) alters histone mRNA 3' end processing and uncover the first mechanism of a regulated switch in the mode of pre-mRNA 3' end processing during a normal cellular process, which may be altered during tumorigenesis. Oncogene (2010) 29, 2853-2863; doi: 10.1038/onc.2010.42; published online 1 March 2010	[Pirngruber, J.; Johnsen, S. A.] Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, D-37073 Gottingen, Lower Saxony, Germany	University of Gottingen	Johnsen, SA (corresponding author), Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, Justus von Liebig Weg 11, D-37073 Gottingen, Lower Saxony, Germany.	sjohnse@gwdg.de	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805	Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB); Forschungsforderungsprogramm at the University of Gottingen Medical Center; Deutsche Forschungsgemeinschaft [JO 815/1]	Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB); Forschungsforderungsprogramm at the University of Gottingen Medical Center; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank J Zhao for graciously providing the NPAT antibody and for helpful advice; O Karpiuk, T Prenzel and A Shchebet for suggestions, discussions and technical help; S Emmert for advice and enabling us to test some interesting medically relevant hypotheses; and M Dobbelstein for advice and extensive scientific discussions regarding the p53/RB/E2F axis. JP was supported by an Excellence Fellowship from the Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB). This work was supported by grants from the Forschungsforderungsprogramm at the University of Gottingen Medical Center and the Deutsche Forschungsgemeinschaft (JO 815/1) to SAJ.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008-5472.CAN-05-0197; COLLART D, 1991, BIOCHEMISTRY-US, V30, P1610, DOI 10.1021/bi00220a024; Deran M, 2008, MOL CELL BIOL, V28, P435, DOI 10.1128/MCB.00607-07; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; KIRSH AL, 1989, GENE DEV, V3, P2172, DOI 10.1101/gad.3.12b.2172; Kranz D, 2008, J CELL BIOL, V182, P197, DOI 10.1083/jcb.200712014; Kranz D, 2006, CANCER RES, V66, P10274, DOI 10.1158/0008-5472.CAN-06-1527; Lemm I, 2006, MOL BIOL CELL, V17, P3221, DOI 10.1091/mbc.E06-03-0247; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001; Marzluff WF, 2008, NAT REV GENET, V9, P843, DOI 10.1038/nrg2438; Narita T, 2007, MOL CELL, V26, P349, DOI 10.1016/j.molcel.2007.04.011; Pirngruber J, 2009, CELL CYCLE, V8, P3636, DOI 10.4161/cc.8.22.9890; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Simone C, 2002, ONCOGENE, V21, P4158, DOI 10.1038/sj.onc.1205511; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Takahashi Y, 2000, GENE DEV, V14, P804; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wagner EJ, 2007, MOL CELL, V28, P692, DOI 10.1016/j.molcel.2007.10.009; Wang HB, 2006, MOL CELL, V22, P383, DOI 10.1016/j.molcel.2006.03.035; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	37	32	33	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2853	2863		10.1038/onc.2010.42	http://dx.doi.org/10.1038/onc.2010.42			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190802				2022-12-28	WOS:000277591900010
J	West, NR; Watson, PH				West, N. R.; Watson, P. H.			S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer	ONCOGENE			English	Article						breast cancer; S100A7; cytokines; inflammation	CARCINOMA IN-SITU; GENE-EXPRESSION; RECEPTOR; CELLS; IL-6; BINDING; STAT3; FEATURES; JAB1; DIFFERENTIATION	S100A7 promotes aggressive features in breast cancer, although regulation of its expression is poorly understood. As S100A7 associates with inflammation in skin and breast tissue, we hypothesized that inflammatory cytokines may regulate S100A7 in breast cancer. We therefore examined the effects of several cytokines, among which oncostatin-M (OSM) and the related cytokine, interleukin (IL)-6, showed the most significant effects on S100A7 expression in breast tumor cells in vitro. Both cytokines consistently induced S100A7 expression in three cell lines (MCF7, T47D and MDA-MB-468) in a dose- and time-dependent manner. Induction of S100A7 was inhibited by blockade of STAT3, phosphatidylinositol 3 kinase (PI3K) and ERK1/2 signaling and small interference RNA (siRNA)-mediated knockdown of S100A7 eliminated the promigratory effects of OSM treatment. S100A7 mRNA levels in a case-control cohort of breast tumors (n = 20) were significantly associated with expression of the OSM receptor beta (OSMR beta) chain (P = 0.0098). This association was confirmed using publicly available microarray data from an independent breast tumor cohort (n = 201, P = 0.0005) and a correlation between S100A7 and poor patient survival was observed specifically in cases with high OSMRb expression (HR = 2.35; P = 0.0396; n = 85). We conclude that inflammatory cytokines can regulate S100A7 expression and that S100A7 may mediate some of their effects in breast cancer. Oncogene (2010) 29, 2083-2092; doi: 10.1038/onc.2009.488; published online 18 January 2010	[West, N. R.; Watson, P. H.] British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, Victoria, BC V8R 6V5, Canada; [West, N. R.; Watson, P. H.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada; [Watson, P. H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of Victoria; University of British Columbia	Watson, PH (corresponding author), British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada.	pwatson@bccancer.bc.ca		West, Nathaniel/0000-0001-9991-0503; Watson, Peter/0000-0002-1642-0638	Canadian Institutes of Health Research (CIHR) [MOP-64349, PRG80155]; Manitoba Breast Tumor Bank; US DOD	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Manitoba Breast Tumor Bank; US DOD(United States Department of Defense)	We thank Rebecca Barnes for editorial and Melanie Olson for technical assistance, Dr Robert Burke for assistance with microscopy, and Dr Jiaxu Wang, Dr Julian Lum, Eric Tran and Darin Wick for helpful discussion. We also wish to thank the investigators responsible for making the UNC microarray data set publically available. PHW holds an operating grant from the Canadian Institutes of Health Research (CIHR, grant # MOP-64349). This study was supported by the Manitoba Breast Tumor Bank (supported by CIHR grant # PRG80155), a member of the Canadian Tumor Repository Network. NRW is supported by a US DOD Breast Cancer Research Program predoctoral traineeship award.	Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Badache A, 2001, CANCER RES, V61, P383; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bando M, 2007, IMMUNOL CELL BIOL, V85, P532, DOI 10.1038/sj.icb.7100078; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Boniface K, 2007, J IMMUNOL, V178, P4615, DOI 10.4049/jimmunol.178.7.4615; Conze D, 2001, CANCER RES, V61, P8851; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2004, BREAST CANCER RES, V6, pR308, DOI 10.1186/bcr791; Emberley ED, 2004, BREAST CANCER RES, V6, P153, DOI 10.1186/bcr816; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Enerback C, 2002, CANCER RES, V62, P43; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Gazel A, 2006, J INVEST DERMATOL, V126, P2647, DOI 10.1038/sj.jid.5700461; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Hsu K, 2005, J IMMUNOL, V174, P2318, DOI 10.4049/jimmunol.174.4.2318; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Naka T, 2002, ARTHRITIS RES THER, V4, pS233, DOI 10.1186/ar565; Paruchuri V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001741; Perrier S, 2009, FEBS LETT, V583, P259, DOI 10.1016/j.febslet.2008.12.030; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Petersson S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-205; Rivard CJ, 2007, J BIOL CHEM, V282, P6644, DOI 10.1074/jbc.M609432200; Royuela M, 2004, J PATHOL, V202, P41, DOI 10.1002/path.1476; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Skliris GP, 2007, BREAST CANCER RES TR, V104, P75, DOI 10.1007/s10549-006-9390-x; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Wang J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2105; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wolf R, 2008, J IMMUNOL, V181, P1499, DOI 10.4049/jimmunol.181.2.1499; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	53	56	58	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2083	2092		10.1038/onc.2009.488	http://dx.doi.org/10.1038/onc.2009.488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101226				2022-12-28	WOS:000276402800007
J	Yamamoto, H; Oue, N; Sato, A; Hasegawa, Y; Yamamoto, H; Matsubara, A; Yasui, W; Kikuchi, A				Yamamoto, H.; Oue, N.; Sato, A.; Hasegawa, Y.; Yamamoto, H.; Matsubara, A.; Yasui, W.; Kikuchi, A.			Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase	ONCOGENE			English	Article						Wnt5a; prostate cancer; Gleason score; invasion; MMP-1	RADICAL PROSTATECTOMY; ACTIVATOR PROTEIN-1; TUMOR-FORMATION; CELL-MIGRATION; GASTRIC-CANCER; GROWTH-FACTOR; IN-VITRO; INVASION; PATHWAY; WNT-5A	Wnt5a is a representative ligand that activates the beta-catenin-independent pathway in Wnt signaling. Although it has been reported that abnormal activation of the Wnt/beta-catenin-dependent pathway is often observed in human prostate cancer, the involvement of the b-catenin-independent pathway in this cancer is unclear. Abnormal expression of Wnt5a and beta-catenin was observed in 27 (28%) and 49 (50%) of 98 prostate cancer cases, respectively, by immunohistochemical analyses. Simultaneous expression of Wnt5a and b-catenin was observed in only five cases, suggesting their exclusive expression. The positive detection of Wnt5a was correlated with high Gleason scores and biochemical relapse of prostate cancer, but that of b-catenin was not. Knockdown and overexpression of Wnt5a in human prostate cancer cell lines reduced and stimulated, respectively, their invasion activities, and the invasion activity required Frizzled2 and Ror2 as Wnt receptors. Wnt5a activated Jun-N-terminal kinase through protein kinase D (PKD) and the inhibition of PKD suppressed Wnt5a-dependent cell migration and invasion. In addition, Wnt5a induced the expression of metalloproteinase-1 through the recruitment of JunD to its promoter region. These results suggest that Wnt5a promotes the aggressiveness of prostate cancer and that its expression is involved in relapse after prostatectomy. Oncogene (2010) 29, 2036-2046; doi: 10.1038/onc.2009.496; published online 18 January 2010	[Sato, A.; Yamamoto, H.; Kikuchi, A.] Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; [Yamamoto, H.] Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Hiroshima, Japan; [Yamamoto, H.] Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Hiroshima, Japan; [Oue, N.; Yasui, W.] Hiroshima Univ, Dept Mol Pathol, Grad Sch Biomed Sci, Hiroshima, Japan; [Hasegawa, Y.; Matsubara, A.] Hiroshima Univ, Dept Urol, Grad Sch Biomed Sci, Hiroshima, Japan	Osaka University; Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University	Kikuchi, A (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp		Yamamoto, Hideki/0000-0003-4919-3483	Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009); The YASUDA Medical Foundation (2006); Uehara Memorial Foundation (2008)	Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); The YASUDA Medical Foundation (2006); Uehara Memorial Foundation (2008)(Uehara Memorial Foundation)	This work was supported by Grants-in-Aid for Scientific Research and for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009), The YASUDA Medical Foundation (2006) and Uehara Memorial Foundation (2008).	ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bernard P, 2007, INT J BIOCHEM CELL B, V39, P31, DOI 10.1016/j.biocel.2006.06.007; Cao J, 2008, J BIOL CHEM, V283, P6232, DOI 10.1074/jbc.M705759200; D'Amico AV, 2000, J CLIN ONCOL, V18, P1164, DOI 10.1200/JCO.2000.18.6.1164; Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Han M, 2003, J UROLOGY, V169, P517, DOI 10.1016/S0022-5347(05)63946-8; Hart CA, 2002, BRIT J CANCER, V86, P1136, DOI 10.1038/sj/bjc/6600207; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x; Kikuchi A, 2009, TRENDS CELL BIOL, V19, P119, DOI 10.1016/j.tcb.2009.01.003; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Kurayoshi M, 2007, BIOCHEM J, V402, P515, DOI 10.1042/BJ20061476; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Polakis P, 2000, GENE DEV, V14, P1837; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322; Sobin, 2009, UICC TNM CLASSIFICAT; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wang Q, 2007, ONCOGENE, V26, P6560, DOI 10.1038/sj.onc.1210472; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wu JY, 2006, CANCER RES, V66, P5111, DOI 10.1158/0008-5472.CAN-06-0383; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794; Zeng ZZ, 2006, CANCER RES, V66, P8091, DOI 10.1158/0008-5472.CAN-05-4400	44	175	189	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2036	2046		10.1038/onc.2009.496	http://dx.doi.org/10.1038/onc.2009.496			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101234				2022-12-28	WOS:000276402800003
J	Borgdorff, V; Lleonart, ME; Bishop, CL; Fessart, D; Bergin, AH; Overhoff, MG; Beach, DH				Borgdorff, V.; Lleonart, M. E.; Bishop, C. L.; Fessart, D.; Bergin, A. H.; Overhoff, M. G.; Beach, D. H.			Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1)	ONCOGENE			English	Article						oncogene-induced senescence; Ras; siRNA; miRNA; p21(Waf1/Cip1)	ONCOGENE-INDUCED SENESCENCE; ANCHORAGE-INDEPENDENT GROWTH; MAMMARY EPITHELIAL-CELLS; HUMAN-BREAST; CANCER; PROLIFERATION; FIBROBLASTS; P16(INK4A); P53	Overexpression of Ras(G12V) in primary cells induces a permanent growth arrest called oncogene-induced senescence (OIS) that serves as a fail-safe mechanism against malignant transformation. We have performed a genome-wide small interfering RNA (siRNA) screen and a microRNA (miRNA) screen to identify mediators of OIS and show that siRNA-mediated knockdown of p21(Waf1/Cip1) rescues from Ras(G12V)-induced senescence in human mammary epithelial cells (HMECs). Moreover, we isolated a total of 28 miRNAs that prevented Ras(G12V)-induced growth arrest, among which all of the miR-106b family members were present. In addition, we obtained a number of hits, miR-130b, miR-302a, miR-302b, miR302c, miR-302d, miR-512-3p and miR-515-3p with seed sequences very similar to miR-106b family members. We show that overexpression of all these miRNAs rescues HMECs from Ras(G12V)-induced senescence by prevention of Ras(G12V)-induced upregulation of p21(Waf1/Cip1). Our results establish an important role for the cell cycle inhibitor p21(Waf1/Cip1) in growth control of HMECs and extend the repertoire of miRNAs that modulate the activity of this tumour suppressor. Oncogene (2010) 29, 2262-2271; doi: 10.1038/onc.2009.497; published online 25 January 2010	[Borgdorff, V.; Bishop, C. L.; Fessart, D.; Bergin, A. H.; Overhoff, M. G.; Beach, D. H.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, London E1 2AT, England; [Lleonart, M. E.] Hosp Gen Valle Hebron, Inst Recerca, Dept Pathol, Barcelona, Spain	University of London; Queen Mary University London; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Beach, DH (corresponding author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, London E1 2AT, England.	dhbeach@btinternet.com	FESSART, Delphine/J-2784-2014; LLeonart, Matilde E./Q-2662-2019	FESSART, Delphine/0000-0001-7566-5670; LLeonart, Matilde E./0000-0002-6196-7405; Bishop, Cleo/0000-0002-6189-8163	Wellcome Programme [DERG1C3R]; Marato TV3 Grant [052130-TV3]; AGAUR [2007 BE-1 00296]; MRC [DERB1A4R]; CRUK [DERG1F2R]; Medical Research Council [G0500357] Funding Source: researchfish; MRC [G0500357] Funding Source: UKRI	Wellcome Programme; Marato TV3 Grant; AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by Wellcome Programme Grant DERG1C3R (Viola Borgdorff, Marita G Overhoff); Marato TV3 Grant 052130-TV3 (Matilde E Lleonart); AGAUR fellowship 2007 BE-1 00296 (Matilde E Lleonart); MRC Project Grant DERB1A4R (Cleo L Bishop, Ann-Marie H Bergin); CRUK Project Grant DERG1F2R (Delphine Fessart). MELL is a FIS (Fondo de Investigacion Sanitario) investigator (CP03/00101).	Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carbone CJ, 2007, CANCER RES, V67, P4130, DOI 10.1158/0008-5472.CAN-07-0499; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gohring UJ, 2001, J CLIN PATHOL, V54, P866, DOI 10.1136/jcp.54.11.866; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002; Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666	24	119	122	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2262	2271		10.1038/onc.2009.497	http://dx.doi.org/10.1038/onc.2009.497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101223				2022-12-28	WOS:000276685200011
J	Mishra, PJ; Ha, L; Rieker, J; Sviderskaya, EV; Bennett, DC; Oberst, MD; Kelly, K; Merlino, G				Mishra, P. J.; Ha, L.; Rieker, J.; Sviderskaya, E. V.; Bennett, D. C.; Oberst, M. D.; Kelly, K.; Merlino, G.			Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation	ONCOGENE			English	Article						anchorage-independent growth; BRaf; melanoma; NRas; PI3K; RalGEF	CELLULAR-TRANSFORMATION; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SIGNALING PATHWAYS; BRAF MUTATIONS; CANCER; GTPASES; CELLS; ACTIVATION; MIGRATION	Cutaneous malignant melanoma is considered one of the most deadly human cancers, based on both its penchant for metastatic spread and its typical resistance to currently available therapy. Long known to harbor oncogenic NRAS mutations, melanomas were more recently reported to be frequent bearers of activating mutations in BRAF, one of the effectors situated downstream of wild-type NRAS. NRAS and BRAF mutations are rarely found in the same melanoma, suggesting that they may possess important overlapping oncogenic activities. Here, we compare and contrast the oncogenic roles of the three major NRas downstream effectors, Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine exchange factor (RalGEF), using genetically engineered Arf-deficient immortalized mouse melanocytes as a model system. Although no single downstream pathway could recapitulate all of the consequences of oncogenic NRas expression, our data indicate a prominent role for BRaf and PI3K in melanocyte senescence and invasiveness, respectively. More surprisingly, we discovered that constitutive RalGEF activation had a major impact on several malignant phenotypes, particularly anchorage-independent growth, indicating that this often overlooked pathway should be more carefully evaluated as a possible therapeutic target. Oncogene (2010) 29, 2449-2456; doi:10.1038/onc.2009.521; published online 1 February 2010	[Mishra, P. J.; Ha, L.; Rieker, J.; Merlino, G.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Ha, L.] US FDA, Div Monoclonal Antibody, Ctr Drug Evaluat & Res, Bethesda, MD 20014 USA; [Sviderskaya, E. V.; Bennett, D. C.] Univ London, Div Basic Med Sci, London, England; [Oberst, M. D.; Kelly, K.] NCI, Cell & Canc Biol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); University of London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 5002,37 Convent Dr, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov	Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009	Bennett, Dorothy C/0000-0002-3639-7527; 	NCI [N01-CO-12400]; National Institutes of Health; Wellcome Trust [078327]; NATIONAL CANCER INSTITUTE [ZIABC010607, ZIABC008756] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Christopher Counter (Duke University) for useful discussions, and for communicating data before publication. We acknowledge Dr Paul Khavari (Stanford University) for gifting the NRas, PI3K and BRaf retroviral vectors, and Drs Frederique Zindy and Charles Sherr (St Jude Children's Research Hospital) for the Arf-deficient mouse skins from which the immortalized melanocytes were generated. The PEP7 and PEP8H antibodies were a gift from Dr Vince Hearing (NCI). The pEF-CAAX-Raf-1 vector was a gift from Dr Silvio J Gutkind (NIH/NIDCR). This work was supported in part by the Intramural Research Program of the NCI, National Institutes of Health, in part by NCI Contract N01-CO-12400, and in part by Wellcome Trust Program Grant 078327 (to EVS).	ALBINI A, 1987, CANCER RES, V47, P3239; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P27, DOI 10.1111/j.1755-148X.2007.00433.x; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Brose MS, 2002, CANCER RES, V62, P6997; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Gorter DJJ, 2008, BLOOD, V111, P3364, DOI 10.1182/blood-2007-08-106583; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Falsetti SC, 2007, MOL CELL BIOL, V27, P8003, DOI 10.1128/MCB.00057-07; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Freedberg DE, 2008, JNCI-J NATL CANCER I, V100, P784, DOI 10.1093/jnci/djn157; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Omholt K, 2007, MELANOMA RES, V17, P410, DOI 10.1097/CMR.0b013e3282ef4178; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Recio JA, 2002, CANCER RES, V62, P6724; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Stiles BL, 2009, INT J BIOCHEM CELL B, V41, P757, DOI 10.1016/j.biocel.2008.09.022; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Virador VM, 1999, ANAL BIOCHEM, V270, P207, DOI 10.1006/abio.1999.4090; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07	41	48	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2449	2456		10.1038/onc.2009.521	http://dx.doi.org/10.1038/onc.2009.521			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20118982	Green Accepted			2022-12-28	WOS:000276951500013
J	Uberti, B; Dentelli, P; Rosso, A; Defilippi, P; Brizzi, MF				Uberti, B.; Dentelli, P.; Rosso, A.; Defilippi, P.; Brizzi, M. F.			Inhibition of beta 1 integrin and IL-3R beta common subunit interaction hinders tumour angiogenesis	ONCOGENE			English	Article						IL-3; IL-3 receptor; beta 1 integrin; endothelial progenitor cells; tumour angiogenesis	ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR; INTERLEUKIN-3; IL-3; RECRUITMENT; VASCULATURE; EXPRESSION; RECEPTORS; SURVIVAL; PROTEIN	Integrin/cytokine receptor interaction provides permissive signals leading to neoangiogenesis, and integrins are crucial for differentiation of endothelial progenitor cells (EPCs). It is known that the inflammatory interleukin-3 (IL-3), released in the tumoral microenvironment, contributes to both angiogenesis and vasculogenic processes. Herein, we generated IL-3 receptor beta common (IL-3R beta c) extracellular domain-derived fusion proteins (Fc) to elucidate the molecular mechanisms regulating these processes. Three different Fc were generated, containing the entire extracellular domain of IL-3R beta c (Fc1.4), a fragment corresponding to domains 1-3 (Fc1.3) and a fragment corresponding to domain 4 (Fc4), respectively. The ability of the fusion proteins to interfere with IL-3R beta c/beta 1 integrin interaction was assessed on endothelial cells (ECs), EPCs and murine-derived ECs. Pull-down experiments showed that Fc1.4 and Fc4 fusion proteins specifically interacted with beta 1 integrin. Fc4 and Fc1.4 fragments prevented IL-3-mediated EPC expansion, arterial morphogenesis and tumour-derived EC migration, without affecting cell adhesion. Fc4 in vivo inhibited the IL-3-mediated vasculogenic process, as well as inflammatory and tumour vascular growth. In conclusion, these data identify the b1 integrin-interacting domain in the juxta-membrane IL-3Rbc extracellular domain, and provide the rational for targeting this interaction to impair vascular growth. Oncogene (2010) 29, 6581-6590; doi:10.1038/onc.2010.384; published online 30 August 2010	[Uberti, B.; Dentelli, P.; Rosso, A.; Brizzi, M. F.] Univ Turin, Dept Internal Med, I-10126 Turin, Italy; [Defilippi, P.] Univ Turin, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Defilippi, P.] Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy	University of Turin; University of Turin; University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	DEFILIPPI, Paola/L-2232-2014; Brizzi, Maria Felice/J-7882-2016	Defilippi, Paola/0000-0001-6427-4906	Italian Association for Cancer Research (AIRC); Association for International Cancer Research (AICR); Regione Piemonte (OncoProt, Druidi, PIStem); EU	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research (AICR); Regione Piemonte (OncoProt, Druidi, PIStem)(Regione Piemonte); EU(European Commission)	This work was supported by grants from the Italian Association for Cancer Research (AIRC) to MFB and PD, Association for International Cancer Research (AICR), Regione Piemonte (OncoProt, Druidi, PIStem) and EU FP7 Metafight to PD We thank Dr Alessandra Baragli and Dr Natalie Lassen for critical reading and final editing of the paper.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Bellik L, 2005, FEBS LETT, V579, P2731, DOI 10.1016/j.febslet.2005.04.003; Biancone L, 1999, J IMMUNOL, V162, P5263; Brizzi MF, 1999, CIRC RES, V84, P785; Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Defilippi P, 2005, J CELL BIOL, V168, P1099, DOI 10.1083/jcb.200405116; Dentelli P, 2005, ONCOGENE, V24, P6394, DOI 10.1038/sj.onc.1208786; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dentelli P, 2007, BLOOD, V109, P4264, DOI 10.1182/blood-2006-06-029603; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Furuya M, 2009, CURR PHARM DESIGN, V15, P1854, DOI 10.2174/138161209788453275; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gao DC, 2009, BBA-REV CANCER, V1796, P33, DOI 10.1016/j.bbcan.2009.05.001; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giraudo E, 1996, J IMMUNOL, V157, P2618; Groger M, 2004, J IMMUNOL, V173, P7161, DOI 10.4049/jimmunol.173.12.7161; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Makinen T, 2005, GENE DEV, V19, P397, DOI 10.1101/gad.330105; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; Naldini Antonella, 2005, Current Drug Targets - Inflammation and Allergy, V4, P3, DOI 10.2174/1568010053622830; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Schroeter MR, 2008, CIRC RES, V103, P536, DOI 10.1161/CIRCRESAHA.107.169375; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2007, CANCER RES, V67, P7055, DOI 10.1158/0008-5472.CAN-07-0905; Shojaei F, 2008, DRUG RESIST UPDATE, V11, P219, DOI 10.1016/j.drup.2008.09.001; Silva RAGD, 2008, ARTERIOSCL THROM VAS, V28, pE64; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Togliatto G, 2010, DIABETES, V59, P1016, DOI 10.2337/db09-0858; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zeoli A, 2008, BLOOD, V112, P350, DOI 10.1182/blood-2007-12-128215	45	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6581	6590		10.1038/onc.2010.384	http://dx.doi.org/10.1038/onc.2010.384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20802515				2022-12-28	WOS:000285380200007
J	Xu, K; Rajagopal, S; Klebba, I; Dong, S; Ji, Y; Liu, J; Kuperwasser, C; Garlick, JA; Naber, SP; Buchsbaum, RJ				Xu, K.; Rajagopal, S.; Klebba, I.; Dong, S.; Ji, Y.; Liu, J.; Kuperwasser, C.; Garlick, J. A.; Naber, S. P.; Buchsbaum, R. J.			The role of fibroblast Tiam1 in tumor cell invasion and metastasis	ONCOGENE			English	Article						Tiam1; Rac; tumor-associated fibroblasts; invasion; metastasis	RAC ACTIVATOR TIAM1; NUCLEOTIDE-EXCHANGE FACTORS; RHO-GTPASES; GENETIC ALTERATIONS; ACTIN CYTOSKELETON; CANCER METASTASIS; EPITHELIAL-CELLS; PROGRESSION; SKIN; PROTEINS	The co-evolution of tumors and their microenvironment involves bidirectional communication between tumor cells and tumor-associated stroma. Various cell types are present in tumor-associated stroma, of which fibroblasts are the most abundant. The Rac exchange factor Tiam1 is implicated in multiple signaling pathways in epithelial tumor cells and lack of Tiam1 in tumor cells retards tumor growth in Tiam1 knockout mouse models. Conversely, tumors arising in Tiam1 knockout mice have increased invasiveness. We have investigated the role of Tiam1 in tumor-associated fibroblasts as a modulator of tumor cell invasion and metastasis, using retroviral delivery of short hairpin RNA to suppress Tiam1 levels in three different experimental models. In spheroid co-culture of mammary epithelial cells and fibroblasts, Tiam1 silencing in fibroblasts led to increased epithelial cell outgrowth into matrix. In tissue-engineered human skin, Tiam1 silencing in dermal fibroblasts led to increased invasiveness of epidermal keratinocytes with pre-malignant features. In a model of human breast cancer in mice, co-implantation of mammary fibroblasts inhibited tumor invasion and metastasis, which was reversed by Tiam1 silencing in co-injected fibroblasts. These results suggest that stromal Tiam1 may have a role in modulating the effects of the tumor microenvironment on malignant cell invasion and metastasis. This suggests a set of pathways for further investigation, with implications for future therapeutic targets. Oncogene (2010) 29, 6533-6542; doi:10.1038/onc.2010.385; published online 30 August 2010	[Xu, K.; Rajagopal, S.; Dong, S.; Ji, Y.; Liu, J.; Buchsbaum, R. J.] Tufts Univ, Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Dong, S.; Kuperwasser, C.; Garlick, J. A.; Buchsbaum, R. J.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA; [Naber, S. P.] Tufts Univ, Tufts Med Ctr, Dept Pathol, Boston, MA 02111 USA; [Buchsbaum, R. J.] Tufts Univ, Tufts Med Ctr, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Buchsbaum, RJ (corresponding author), Tufts Univ, Tufts Med Ctr, Mol Oncol Res Inst, 800 Washington St,Box 245, Boston, MA 02111 USA.	rbuchsbaum@tuftsmedicalcenter.org			NIH [CA 095559, CA12555]; Vermont Community Foundation; Breast Cancer Research Foundation; Diane Connolly-Zaniboni Research Scholarship in Breast Cancer; Tufts Medical Center GRASP Digestive Disease Center [P30-DK34928]; Design and Data Resource Center of the Tufts Clinical; Translational Science Institute (National Center for Research Resources) [UL1 RR025752]; NATIONAL CANCER INSTITUTE [R01CA095559, R01CA125554] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vermont Community Foundation; Breast Cancer Research Foundation; Diane Connolly-Zaniboni Research Scholarship in Breast Cancer; Tufts Medical Center GRASP Digestive Disease Center; Design and Data Resource Center of the Tufts Clinical; Translational Science Institute (National Center for Research Resources)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the NIH (RB: CA 095559 and CK: CA12555), the Landmann Family Fund of the Vermont Community Foundation (RB), the Breast Cancer Research Foundation (CK), the Diane Connolly-Zaniboni Research Scholarship in Breast Cancer (RB), the Tufts Medical Center GRASP Digestive Disease Center (RB, P30-DK34928) and the Design and Data Resource Center of the Tufts Clinical and Translational Science Institute (National Center for Research Resources: UL1 RR025752).	Andriani F, 2004, INT J CANCER, V108, P348, DOI 10.1002/ijc.11525; Baines AT, 2006, METHOD ENZYMOL, V407, P556, DOI 10.1016/S0076-6879(05)07045-X; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUKAMP P, 1990, CANCER RES, V50, P2840; Buchsbaum RJ, 2007, J CELL SCI, V120, P1149, DOI 10.1242/jcs.03428; Connolly BA, 2005, MOL CELL BIOL, V25, P4602, DOI 10.1128/MCB.25.11.4602-4614.2005; Cruz-Monserrate Z, 2008, NEOPLASIA, V10, P408, DOI 10.1593/neo.07868; Cunha G R, 1989, Cancer Treat Res, V46, P159; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Fusenig NE, 1998, MOL CARCINOGEN, V23, P144, DOI 10.1002/(SICI)1098-2744(199811)23:3<144::AID-MC3>3.0.CO;2-U; Garlick JA, 2007, ADV BIOCHEM ENG BIOT, V103, P207; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hou M, 2004, ACTA BIOCH BIOPH SIN, V36, P537, DOI 10.1093/abbs/36.8.537; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; Kim JB, 2005, SEMIN CANCER BIOL, V15, P365, DOI 10.1016/j.semcancer.2005.05.002; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008-5472.CAN-04-1408; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Liu L, 2006, NEOPLASIA, V8, P917, DOI 10.1593/neo.06364; Liu L, 2005, WORLD J GASTROENTERO, V11, P705, DOI 10.3748/wjg.v11.i5.705; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Minard ME, 2005, ONCOGENE, V24, P2568, DOI 10.1038/sj.onc.1208503; Moinfar F, 2000, CANCER RES, V60, P2562; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Rajagopal S, 2010, J BIOL CHEM, V285, P18060, DOI 10.1074/jbc.M109.051490; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Rygiel TP, 2008, J CELL SCI, V121, P1183, DOI 10.1242/jcs.017194; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Segal N, 2008, MATRIX BIOL, V27, P163, DOI 10.1016/j.matbio.2007.09.002; Strumane K, 2008, LEUKEMIA RES, V32, P113, DOI 10.1016/j.leukres.2007.03.034; Supriatno, 2003, ONCOL REP, V10, P527; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; Willhauck MJ, 2007, CARCINOGENESIS, V28, P595, DOI 10.1093/carcin/bgl188; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	46	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6533	6542		10.1038/onc.2010.385	http://dx.doi.org/10.1038/onc.2010.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20802514	Green Accepted			2022-12-28	WOS:000285380200003
J	Aguilar, H; Sole, X; Bonifaci, N; Serra-Musach, J; Islam, A; Lopez-Bigas, N; Mendez-Pertuz, M; Beijersbergen, RL; Lazaro, C; Urruticoechea, A; Pujana, MA				Aguilar, H.; Sole, X.; Bonifaci, N.; Serra-Musach, J.; Islam, A.; Lopez-Bigas, N.; Mendez-Pertuz, M.; Beijersbergen, R. L.; Lazaro, C.; Urruticoechea, A.; Pujana, M. A.			Biological reprogramming in acquired resistance to endocrine therapy of breast cancer	ONCOGENE			English	Article						aromatase inhibition; breast cancer; estrogen receptor; fibroblast growth factor receptor; long-term estrogen-deprived; MCF7	ESTROGEN-RECEPTOR-ALPHA; REGULATORY FACTOR-I; ONCOLOGY TECHNOLOGY-ASSESSMENT; ACTIVATED PROTEIN-KINASE; GENOME-WIDE ASSOCIATION; ESR1 GENE AMPLIFICATION; AROMATASE INHIBITOR; TAMOXIFEN-RESISTANT; ESTRADIOL HYPERSENSITIVITY; ADAPTIVE HYPERSENSITIVITY	Endocrine therapies targeting the proliferative effect of 17 beta-estradiol through estrogen receptor alpha (ER alpha) are the most effective systemic treatment of ER alpha-positive breast cancer. However, most breast tumors initially responsive to these therapies develop resistance through molecular mechanisms that are not yet fully understood. The long-term estrogen-deprived (LTED) MCF7 cell model has been proposed to recapitulate acquired resistance to aromatase inhibitors in postmenopausal women. To elucidate this resistance, genomic, transcriptomic and molecular data were integrated into the time course of MCF7-LTED adaptation. Dynamic and widespread genomic changes were observed, including amplification of the ESR1 locus consequently linked to an increase in ER alpha. Dynamic transcriptomic profiles were also observed that correlated significantly with genomic changes and were predicted to be influenced by transcription factors known to be involved in acquired resistance or cell proliferation (for example, interferon regulatory transcription factor 1 and E2F1, respectively) but, notably, not by canonical ER alpha transcriptional function. Consistently, at the molecular level, activation of growth factor signaling pathways by EGFR/ERBB/AKT and a switch from phospho-Ser118 (pS118)- to pS167-ER alpha were observed during MCF7-LTED adaptation. Evaluation of relevant clinical settings identified significant associations between MCF7-LTED and breast tumor transcriptome profiles that characterize ER alpha-negative status, early response to letrozole and tamoxifen, and recurrence after tamoxifen treatment. In accordance with these profiles, MCF7-LTED cells showed increased sensitivity to inhibition of FGFR-mediated signaling with PD173074. This study provides mechanistic insight into acquired resistance to endocrine therapies of breast cancer and highlights a potential therapeutic strategy. Oncogene (2010) 29, 6071-6083; doi:10.1038/onc.2010.333; published online 16 August 2010	[Aguilar, H.; Urruticoechea, A.; Pujana, M. A.] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol, Translat Res Lab, Barcelona, Spain; [Sole, X.; Bonifaci, N.; Serra-Musach, J.; Pujana, M. A.] IDIBELL, Catalan Inst Oncol, Biomarkers & Susceptibil Unit, Barcelona, Spain; [Sole, X.; Bonifaci, N.; Serra-Musach, J.; Pujana, M. A.] IDIBELL, Catalan Inst Oncol, Biomed Res Ctr Network Epidemiol & Publ Hlth, Barcelona, Spain; [Islam, A.; Lopez-Bigas, N.] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Res Unit Biomed Informat, Barcelona, Spain; [Mendez-Pertuz, M.] Spanish Natl Canc Res Ctr, Mol Pathol Programme, Epithelial Carcinogenesis Grp, Madrid, Spain; [Beijersbergen, R. L.] Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Beijersbergen, R. L.] Netherlands Canc Inst, Canc Genom Ctr, Amsterdam, Netherlands; [Lazaro, C.] IDIBELL, Catalan Inst Oncol, Hereditary Canc Program, Mol Diagnost Unit, Barcelona, Spain	Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Pompeu Fabra University; Centro Nacional de Investigaciones Oncologicas (CNIO); Netherlands Cancer Institute; Netherlands Cancer Institute; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Urruticoechea, A (corresponding author), Bellvitge Inst Biomed Res, Catalan Inst Oncol, Translat Res Lab, Gran Via 199-203, Barcelona 08907, Spain.	anderu@iconcologia.net; mapujana@iconcologia.net	Lopez-Bigas, Nuria/F-6193-2011; bonifaci, nuria/B-8104-2019; Solé, Xavier/AAF-3015-2019; GARCIA, CONXI LAZARO/Q-2410-2016; Pujana, Miquel Angel/N-3127-2014; Gasull, Martina/J-4076-2019	Lopez-Bigas, Nuria/0000-0003-4925-8988; bonifaci, nuria/0000-0002-8193-6825; Solé, Xavier/0000-0002-2197-3325; GARCIA, CONXI LAZARO/0000-0002-7198-5906; Pujana, Miquel Angel/0000-0003-3222-4044; Beijersbergen, Roderick/0000-0003-0116-4130; Urruticoechea, Ander/0000-0003-0359-3641; Islam, Abul/0000-0002-7274-0855	Spanish Ministry of Health CIBERESP; Ministry of Science and Innovation (MICINN) [SAF06/05399]	Spanish Ministry of Health CIBERESP; Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This study was funded by the Spanish Ministry of Health CIBERESP and grant 06/0545 and the Ministry of Science and Innovation (MICINN) grant SAF06/05399. HA was supported by a MICINN postdoctoral fellowship and MAP was a 'Ramon y Cajal' Researcher with the MICINN.	Adelaide J, 2008, INT J CANCER, V123, P2970, DOI 10.1002/ijc.23786; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Ahn BY, 2010, CANCER RES, V70, P3013, DOI 10.1158/0008-5472.CAN-09-3108; Alvarez MJ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r143; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; Brown LA, 2008, NAT GENET, V40, P806, DOI 10.1038/ng0708-806; Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822; Chlebowski RT, 2002, J CLIN ONCOL, V20, P3328, DOI 10.1200/JCO.2002.06.029; Clarke M, 1998, LANCET, V351, P1451; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dowsett M, 2005, J STEROID BIOCHEM, V95, P167, DOI 10.1016/j.jsbmb.2005.04.022; Dowsett M, 2005, BREAST CANCER RES TR, V93, pS11, DOI 10.1007/s10549-005-9037-3; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ellis MJ, 2006, J CLIN ONCOL, V24, P3019, DOI 10.1200/JCO.2005.04.3034; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghayad SE, 2010, INT J CANCER, V126, P545, DOI 10.1002/ijc.24750; Gu ZP, 2002, CANCER RES, V62, P3428; Hoch RV, 1999, INT J CANCER, V84, P122; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Horlings HM, 2008, NAT GENET, V40, P807, DOI 10.1038/ng0708-807; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Johnston SRD, 2005, J STEROID BIOCHEM, V95, P173, DOI 10.1016/j.jsbmb.2005.04.004; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; JONAT W, 1995, EUR J CANCER, V31A, P137, DOI 10.1016/0959-8049(94)00415-2; Kanai M, 2009, GENE, V438, P49, DOI 10.1016/j.gene.2009.03.004; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lewis-Wambi JS, 2008, EUR J CANCER, V44, P1770, DOI 10.1016/j.ejca.2008.05.016; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Martin LA, 2005, ENDOCR-RELAT CANCER, V12, pS75, DOI 10.1677/erc.1.01023; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Masri S, 2008, CANCER RES, V68, P4910, DOI 10.1158/0008-5472.CAN-08-0303; Massarweh S, 2007, CLIN CANCER RES, V13, P1950, DOI 10.1158/1078-0432.CCR-06-2540; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller WR, 2007, PHARMACOGENET GENOM, V17, P813, DOI 10.1097/FPC.0b013e32820b853a; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Pique-Regi R, 2008, BIOINFORMATICS, V24, P309, DOI 10.1093/bioinformatics/btm601; Reis-Filho JS, 2008, NAT GENET, V40, P809, DOI 10.1038/ng0708-809b; Rose C, 2003, EUR J CANCER, V39, P2318, DOI 10.1016/S0959-8049(03)00630-0; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; Sadler AJ, 2009, J STEROID BIOCHEM, V114, P21, DOI 10.1016/j.jsbmb.2008.12.017; Santen R, 2001, J STEROID BIOCHEM, V79, P115, DOI 10.1016/S0960-0760(01)00151-0; Santen RJ, 2008, ADV EXP MED BIOL, V630, P19; Santen RJ, 2005, ENDOCR-RELAT CANCER, V12, pS61, DOI 10.1677/erc.1.01018; Schild-Hay LJ, 2009, CANCER RES, V69, P1150, DOI 10.1158/0008-5472.CAN-08-2806; Schones DE, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-19; Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005; Shen RL, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-28; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Sole X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004544; Song RXD, 2006, ENDOCR-RELAT CANCER, V13, pS3, DOI 10.1677/erc.1.01322; Stamm S, 2006, NUCLEIC ACIDS RES, V34, pD46, DOI 10.1093/nar/gkj031; Stephen R, 2000, BRIT J CANCER, V83, P1183, DOI 10.1054/bjoc.2000.1388; Stephen RL, 2001, J BIOL CHEM, V276, P40080, DOI 10.1074/jbc.M105892200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tashiro E, 2003, ONCOGENE, V22, P5630, DOI 10.1038/sj.onc.1206636; Tomita S, 2009, CANCER SCI, V100, P1012, DOI 10.1111/j.1349-7006.2009.01145.x; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vincent-Salomon A, 2008, NAT GENET, V40, P809, DOI 10.1038/ng0708-809a; Vuaroqueaux V, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1681; WELSHONS WV, 1987, EUR J CANCER CLIN ON, V23, P1935, DOI 10.1016/0277-5379(87)90062-9; Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yu JX, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-182; Yue W, 2005, INT J CANCER, V117, P746, DOI 10.1002/ijc.21222; Yue W, 2003, J STEROID BIOCHEM, V86, P265, DOI 10.1016/S0960-0760(03)00366-2; Zhang Z, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-331	98	53	54	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6071	6083		10.1038/onc.2010.333	http://dx.doi.org/10.1038/onc.2010.333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20711236				2022-12-28	WOS:000284108700009
J	Krig, SR; Miller, JK; Frietze, S; Beckett, LA; Neve, RM; Farnham, PJ; Yaswen, PI; Sweeney, CA				Krig, S. R.; Miller, J. K.; Frietze, S.; Beckett, L. A.; Neve, R. M.; Farnham, P. J.; Yaswen, P. I.; Sweeney, C. A.			ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells	ONCOGENE			English	Article						ZNF217; ErbB3; CtBP2; 20q13; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; TERMINAL BINDING-PROTEINS; LUNG-CANCER; TRANSCRIPTION FACTORS; TAMOXIFEN RESISTANCE; REPRESSOR COMPLEX; TUMOR-GROWTH; THERAPY; GENES; HER3	Understanding the mechanisms underlying ErbB3 overexpression in breast cancer will facilitate the rational design of therapies to disrupt ErbB2-ErbB3 oncogenic function. Although ErbB3 overexpression is frequently observed in breast cancer, the factors mediating its aberrant expression are poorly understood. In particular, the ErbB3 gene is not significantly amplified, raising the question as to how ErbB3 overexpression is achieved. In this study we showed that the ZNF217 transcription factor, amplified at 20q13 in similar to 20% of breast tumors, regulates ErbB3 expression. Analysis of a panel of human breast cancer cell lines (n=50) and primary human breast tumors (n=15) showed a strong positive correlation between ZNF217 and ErbB3 expression. Ectopic expression of ZNF217 in human mammary epithelial cells induced ErbB3 expression, whereas ZNF217 silencing in breast cancer cells resulted in decreased ErbB3 expression. Although ZNF217 has previously been linked with transcriptional repression because of its close association with C-terminal-binding protein (CtBP)1/2 repressor complexes, our results show that ZNF217 also activates gene expression. We showed that ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent and that ZNF217 and CtBP1/2 have opposite roles in regulating ErbB3 expression. In addition, we identify ErbB3 as one of the mechanisms by which ZNF217 augments PI-3K/Akt signaling. Oncogene (2010) 29, 5500-5510; doi:10.1038/onc.2010.289; published online 26 July 2010	[Krig, S. R.; Miller, J. K.; Sweeney, C. A.] Univ Calif Davis, Ctr Canc, Div Basic Sci, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Frietze, S.; Farnham, P. J.] Univ Calif Davis, Div Biostat, Dept Publ Hlth, Davis, CA 95616 USA; [Beckett, L. A.] Genentech Inc, San Francisco, CA 94080 USA; [Neve, R. M.] Univ Calif Davis, Genome Ctr, Dept Pharmacol, Davis, CA 95616 USA; [Yaswen, P. I.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; Roche Holding; Genentech; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Krig, SR (corresponding author), Univ Calif Davis, Ctr Canc, Div Basic Sci, Dept Biochem & Mol Med, Res Bldg 3,Room 1100A,4645 2nd Ave, Sacramento, CA 95817 USA.	skrig@ucdavis.edu; casweeney@ucdavis.edu		Farnham, Peggy/0000-0003-4469-7914	NIH [R01 CA118384, RO1 CA45250, U54 CA112970]; Office of Energy Research, Office of Health and Biological Research, US Department of Energy [DE-AC03-76SF00098]; NIH Center for Research Resources (NCRR) [UL1 RR024146]; DOD [W81XWH-06-1-0402]; Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024146]; NIH Roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R01CA045240, R01CA118384, P30CA093373, U54CA112970] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024146] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Energy Research, Office of Health and Biological Research, US Department of Energy(United States Department of Energy (DOE)); NIH Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); DOD(United States Department of Defense); Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by NIH grant R01 CA118384 (CS); NIH grant RO1 CA45250 (PJF); U54 CA112970 (PY, RN), and the Office of Energy Research, Office of Health and Biological Research, US Department of Energy under Contract No. DE-AC03-76SF00098 (PY) and NIH Center for Research Resources (NCRR) UL1 RR024146 (LAB). JM was a recipient of a DOD Breast Cancer Research Program Predoctoral fellowship: W81XWH-06-1-0402. We thank Dr Nelly Auersperg (U Vancouver) for the recombinant adenoviral ZNF217 construct and Jeremy Semeiks for his assistance with the adenoviral transduction experiments. We thank Dr Jeffrey Hildebrand for the CtBP2-null mef-90 fibroblasts and Dr Merlin Crossly for the CtBP2_ pcDNA_ 3.1 expression construct. We thank Dr Hongwu Chen for the pCmX vector, Dr James Trimmer for the co-REST ascites and Dr Martha Stampfer for the HMEC 184 cells. CTCS statistical support is made possible by Grant Number UL1 RR024146 from the Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. A special thank you to members of the Farnham lab for valuable discussions.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; *CORETEAM R D, 2006, R LANG ENV STAT COMP; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Folgiero V, 2007, CANCER RES, V67, P1645, DOI 10.1158/0008-5472.CAN-06-2980; Folgiero V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001592; Frank DA, 2009, IDRUGS, V12, P29; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Heidenreich Olaf, 2009, V487, P221, DOI 10.1007/978-1-60327-547-7_11; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; IWABUCHI H, 1995, CANCER RES, V55, P6172; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Lee JY, 2007, SCIENCE, V317, P206, DOI 10.1126/science.1146073; Li PX, 2007, INT J CANCER, V120, P1863, DOI 10.1002/ijc.22300; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Nonet GH, 2001, CANCER RES, V61, P1250; O'Geen H, 2006, BIOTECHNIQUES, V41, P577, DOI 10.2144/000112268; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Sassen A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1843; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; SolinasToldo S, 1996, CANCER RES, V56, P3803; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246-08; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	46	40	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5500	5510		10.1038/onc.2010.289	http://dx.doi.org/10.1038/onc.2010.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661224	Green Accepted, Green Submitted			2022-12-28	WOS:000282945800007
J	Ernst, A; Campos, B; Meier, J; Devens, F; Liesenberg, F; Wolter, M; Reifenberger, G; Herold-Mende, C; Lichter, P; Radlwimmer, B				Ernst, A.; Campos, B.; Meier, J.; Devens, F.; Liesenberg, F.; Wolter, M.; Reifenberger, G.; Herold-Mende, C.; Lichter, P.; Radlwimmer, B.			De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures	ONCOGENE			English	Article						miR-17-92; glioblastoma; retinoic acid; spheroid culture; CTGF	TUMOR-INITIATING CELLS; TRANS-RETINOIC ACID; STEM-CELLS; GROWTH-FACTOR; NEURAL PRECURSORS; PROGENITOR CELLS; GLIOMA-CELLS; IN-VITRO; EXPRESSION; MICRORNAS	All-trans retinoic acid is a potent promoter of cellular differentiation processes, which is used in cancer therapy. Glioblastoma spheroid cultures are enriched in tumor-initiating cells, and provide a model to test new treatment options in vitro. We investigated the molecular mechanisms of response to exposure to differentiation-promoting conditions in such cultures. Microarray analyses of five independent cultures showed that after induction of differentiation, inhibitors of transforming growth factor beta/bone morphogenetic protein, Wnt/beta-catenin and IGF signaling were upregulated, whereas expression of several microRNAs decreased, particularly that of the miR-17-92 cluster. In primary astrocytic gliomas (n = 82), expression of several members of miR-17-92 was significantly higher relative to those of normal brain (n = 8) and significantly increased with tumor grade progression (P < 0.05). A high-level amplification of the miR-17-92 locus was detected in one glioblastoma specimen. Transfection of inhibitors of miR-17-92 induced increased apoptosis and decreased cell proliferation in glioblastoma spheroids. Mir-17-92 inhibition was also associated with increased messenger RNA (mRNA) and/or protein expression of CDKN1A, E2F1, PTEN and CTGF. The CTGF gene was shown to be a target of miR-17-92 in glioblastoma spheroids by luciferase reporter assays. Our results suggest that miR-17-92 and its target CTGF mediate effects of differentiation-promoting treatment on glioblastoma cells through multiple regulatory pathways. Oncogene (2010) 29, 3411-3422; doi:10.1038/onc.2010.83; published online 22 March 2010	[Ernst, A.; Meier, J.; Devens, F.; Lichter, P.; Radlwimmer, B.] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; [Campos, B.; Herold-Mende, C.] Heidelberg Univ, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Liesenberg, F.; Wolter, M.; Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf	Radlwimmer, B (corresponding author), German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	b.radlwimmer@dkfz.de	Radlwimmer, Bernhard F/I-3229-2013; Reifenberger, Guido/AAE-3599-2019	Radlwimmer, Bernhard F/0000-0002-4553-7800; 	German Bundesministerium fur Bildung und Forschung [01GS0883, 01GS0884, 01GS0886]; European Union [MRTN-CT-2006-035733]; Tumorzentrum Heidelberg-Mannheim; Sibylle Assmus Foundation; Verein zur Forderung der Krebsforschung e.V	German Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); Tumorzentrum Heidelberg-Mannheim(European Commission); Sibylle Assmus Foundation; Verein zur Forderung der Krebsforschung e.V	We thank F Engel, M Zapatka, S Anders and W Huber for bioinformatic support. We also thank S Hofmann for support with array comparative genomic hybridization, A Korshunov for support with specimen analysis and B Malzkorn for sharing data. This study was supported by Grants 01GS0883, 01GS0884 and 01GS0886 of the German Bundesministerium fur Bildung und Forschung, by Grant MRTN-CT-2006-035733 from the European Union FP6 Marie Curie Research Training Network; by a Grant from the Tumorzentrum Heidelberg-Mannheim; by the Sibylle Assmus Foundation; and by the Verein zur Forderung der Krebsforschung e.V.	Aguado T, 2007, J BIOL CHEM, V282, P6854, DOI 10.1074/jbc.M608900200; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; D'Ercole AJ, 2008, ENDOCRINOLOGY, V149, P5958, DOI 10.1210/en.2008-0920; Das A, 2008, J NEURO-ONCOL, V87, P9, DOI 10.1007/s11060-007-9485-1; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Dictus C, 2007, J NEUROSCI METH, V161, P250, DOI 10.1016/j.jneumeth.2006.11.012; Ernst A, 2009, CLIN CANCER RES, V15, P6541, DOI 10.1158/1078-0432.CCR-09-0695; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; Gal H, 2008, BIOCHEM BIOPH RES CO, V376, P86, DOI 10.1016/j.bbrc.2008.08.107; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Karmakar S, 2007, APOPTOSIS, V12, P2077, DOI 10.1007/s10495-007-0116-2; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lu JR, 2008, J NEURO-ONCOL, V87, P271, DOI 10.1007/s11060-008-9518-4; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Malaterre J, 2007, FRONT BIOSCI-LANDMRK, V12, P492, DOI 10.2741/2077; MALZKORN B, 2009, BRAIN PATHO IN PRESS; Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Monzo M, 2008, CELL RES, V18, P823, DOI 10.1038/cr.2008.81; Navarro A, 2009, ONCOLOGY-BASEL, V76, P162, DOI 10.1159/000201569; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obayashi S, 2009, CELL MOL NEUROBIOL, V29, P423, DOI 10.1007/s10571-008-9338-2; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Ohgawara T, 2009, FEBS LETT, V583, P1006, DOI 10.1016/j.febslet.2009.02.025; Ohno R, 2003, LEUKEMIA, V17, P1454, DOI 10.1038/sj.leu.2403031; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfister S, 2007, GENE CHROMOSOME CANC, V46, P839, DOI 10.1002/gcc.20471; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037; Yu J, 2006, BIOCHEM BIOPH RES CO, V349, P59, DOI 10.1016/j.bbrc.2006.07.207; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zeng Y, 2009, J CLIN NEUROSCI, V16, P285, DOI 10.1016/j.jocn.2007.11.014	55	120	127	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3411	3422		10.1038/onc.2010.83	http://dx.doi.org/10.1038/onc.2010.83			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20305691				2022-12-28	WOS:000278622700009
J	Sauer, L; Gitenay, D; Vo, C; Baron, VT				Sauer, L.; Gitenay, D.; Vo, C.; Baron, V. T.			Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells	ONCOGENE			English	Article						p53; Egr-1; prostate cancer; EGF receptor; SV40 large T-antigen	GROWTH-FACTOR-BETA; EGR1 TARGET GENES; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; IMMUNE-RESPONSE; IN-VIVO; EXPRESSION; TRANSCRIPTION; LINE	Early growth response-1 (Egr-1) is overexpressed in human prostate tumors and contributes to cancer progression. On the other hand, mutation of p53 is associated with advanced prostate cancer, as well as with metastasis and hormone independence. This study shows that in prostate cell lines in culture, Egr-1 overexpression correlated with an alteration of p53 activity because of the expression of SV40 large Tantigen or because of a mutation in the TP53 gene. In cells containing altered p53 activity, Egr-1 expression was abolished by pharmacological inhibition or RNAi silencing of p53. Although forced expression of wild-type p53 was not sufficient to trigger Egr-1 transcription, four different mutants of p53 were shown to induce Egr-1. Direct binding of p53 to the EGR1 promoter could not be detected. Instead, Egr-1 transcription was driven by the ERK1/2 pathway, as it was abrogated by specific inhibitors of MEK. Egr-1 increased the transcription of HB-EGF (epidermal growth factor), amphiregulin and epiregulin, resulting in autocrine activation of the EGF receptor (EGFR) and downstream MEK/ERK cascade. Thus, mutant p53 initiates a feedback loop that involves ERK1/2-mediated transactivation of Egr-1, which in turn increases the secretion of EGFR ligands and stimulates the EGFR signaling pathway. Finally, p53 may further regulate this feedback loop by altering the level of EGFR expression. Oncogene (2010) 29, 2628-2637; doi:10.1038/onc.2010.24; published online 1 March 2010	[Sauer, L.; Gitenay, D.; Vo, C.; Baron, V. T.] VRISD, San Diego, CA 92121 USA		Baron, VT (corresponding author), VRISD, 10835 Rd Cure,Suite 150, San Diego, CA 92121 USA.	vbaron@sdibr.org		Gitenay, Delphine/0000-0002-6043-4519; Schenk, Lysann/0000-0002-5146-8485	NIH/NCI [RO1 CA102688]; NATIONAL CANCER INSTITUTE [R01CA102688] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ruth Gjerset (Torrey Pines Institute for Molecular Studies, San Diego, CA) for comments and critical reading of the paper. We are grateful to Dr Eileen Adamson and Dr Dan Mercola (University of California, Irvine, CA) for their support and many suggestions. This work was supported by a Grant from NIH/NCI-RO1 CA102688 (V Baron).	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; CAO XM, 1993, J BIOL CHEM, V268, P16949; CONNOLLY JM, 1991, PROSTATE, V19, P173, DOI 10.1002/pros.2990190210; DEB SP, 1994, ONCOGENE, V9, P1341; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Eid MA, 1998, CANCER RES, V58, P2461; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI 10.2217/FON.09.67; Gurova KV, 2003, CANCER RES, V63, P2905; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; ISAACS WB, 1991, CANCER RES, V51, P4716; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KAIGHN ME, 1979, INVEST UROL, V17, P16; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LONG SB, 1995, ANTICANCER RES, V15, P1375; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Nishi H, 2002, CANCER RES, V62, P827; PARDA DS, 1993, PROSTATE, V23, P91, DOI 10.1002/pros.2990230202; Ramsamooj P, 1997, Radiat Oncol Investig, V5, P269, DOI 10.1002/(SICI)1520-6823(1997)5:6<269::AID-ROI2>3.0.CO;2-W; Shin SY, 2006, EMBO J, V25, P1093, DOI 10.1038/sj.emboj.7600987; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Teicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yang SZ, 2003, J BIOL CHEM, V278, P39906, DOI 10.1074/jbc.M307250200; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029	40	62	64	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2628	2637		10.1038/onc.2010.24	http://dx.doi.org/10.1038/onc.2010.24			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190820	Green Accepted			2022-12-28	WOS:000277354600003
J	Barone, I; Iacopetta, D; Covington, KR; Cui, Y; Tsimelzon, A; Beyer, A; Ando, S; Fuqua, SAW				Barone, I.; Iacopetta, D.; Covington, K. R.; Cui, Y.; Tsimelzon, A.; Beyer, A.; Ando, S.; Fuqua, S. A. W.			Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity	ONCOGENE			English	Article						breast cancer; estrogen receptor; K303R mutant ER alpha; aromatase inhibitors resistance; s305 ER alpha phosphorylation; IGF-1-signaling pathway	HUMAN-BREAST-CANCER; GROWTH-FACTOR-I; TAMOXIFEN RESISTANCE; DEOXYRIBONUCLEIC-ACID; HINGE REGION; MUTATION; KINASE; CELLS; ACTIVATION; BINDING	We earlier identified a lysine to arginine transition at residue 303 (K303R) in estrogen receptor alpha (ER alpha) in invasive breast cancers, which confers resistance to the aromatase inhibitor (AI) anastrozole (Ana) when expressed in MCF-7 breast cancer cells. Here, we show that AI resistance arises through an enhanced cross talk of the insulin-like growth factor receptor-1 (IGF-1R)/insulin receptor substrate (IRS)-1/Akt pathway with ER alpha, and the serine (S) residue 305 adjacent to the K303R mutation has a key function in mediating this cross talk. The ERa S305 residue is an important site that modifies response to tamoxifen; thus, we questioned whether this site could also influence AI response. We generated stable transfectants-expressing wild-type, K303R ER alpha or a double K303R/S305A mutant receptor, and found that the AI-resistant phenotype associated with expression of the K303R mutation was dependent on activation of S305 within the receptor. Ana significantly reduced growth in K303R/S305A-expressing cells. Preventing S305 phosphorylation with a blocking peptide inhibited IGF-1R/IRS-1/Akt activation and also restored AI sensitivity. Our data suggest that the K303R mutation and the S305 ER alpha residue may be a novel determinant of AI response in breast cancer, and blockade of S305 phosphorylation represents a new therapeutic strategy for treating tumors resistant to hormone therapy. Oncogene (2010) 29, 2404-2414; doi:10.1038/onc.2009.520; published online 25 January 2010	[Fuqua, S. A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Breast Ctr, Houston, TX 77030 USA; [Barone, I.; Iacopetta, D.; Covington, K. R.; Cui, Y.; Tsimelzon, A.; Beyer, A.; Fuqua, S. A. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Barone, I.; Ando, S.] Univ Calabria, Ctr Sanit, I-87036 Cosenza, Italy; [Ando, S.] Univ Calabria, Dept Cellular Biol, I-87036 Cosenza, Italy	Baylor College of Medicine; Baylor College of Medicine; University of Calabria; University of Calabria	Fuqua, SAW (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Breast Ctr, BCM 600,1 Baylor Plaza, Houston, TX 77030 USA.	sfuqua@bcm.edu	Iacopetta, Domenico/H-4242-2014	Iacopetta, Domenico/0000-0001-5179-7118; BARONE, Ines/0000-0002-9769-1615	NCI [RO1 CA72038]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI RO1 CA72038 to SAWF. We thank Mrs. Robin Sample for excellent administrative assistance.	Agoulnik IU, 2004, J CLIN ENDOCR METAB, V89, P6340, DOI 10.1210/jc.2004-0114; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brenet F, 2009, ONCOGENE, V28, P128, DOI 10.1038/onc.2008.376; Burtrum D, 2003, CANCER RES, V63, P8912; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Conway K, 2005, BREAST CANCER RES, V7, pR871, DOI 10.1186/bcr1315; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Deeb A, 2008, J CLIN ENDOCR METAB, V93, P3691, DOI 10.1210/jc.2008-0737; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Faus H, 2006, BIOMED PHARMACOTHER, V60, P520, DOI 10.1016/j.biopha.2006.07.082; Fontenot DR, 2007, BIOCHEM BIOPH RES CO, V363, P901, DOI 10.1016/j.bbrc.2007.09.046; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Fuqua SAW, 2000, CANCER RES, V60, P4026; Giordano C, 2010, BREAST CANCER RES TR, V119, P71, DOI 10.1007/s10549-009-0334-0; Haelens A, 2007, CANCER RES, V67, P4514, DOI 10.1158/0008-5472.CAN-06-1701; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Herynk MH, 2007, CLIN CANCER RES, V13, P3235, DOI 10.1158/1078-0432.CCR-06-2608; Herynk MH, 2006, MOL CANCER THER, V5, P3023, DOI 10.1158/1535-7163.MCT-06-0394; Holm C, 2009, J PATHOL, V217, P372, DOI 10.1002/path.2455; Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; MANNING BD, 2002, SCI STKE, pPE49; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Nakajima H, 2008, BREAST CANCER-TOKYO, V15, P65, DOI 10.1007/s12282-007-0018-8; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2007, BIOMED PHARMACOTHER, V61, P408, DOI 10.1016/j.biopha.2007.05.006; Romano A, 2006, GYNECOL ONCOL, V101, P287, DOI 10.1016/j.ygyno.2005.10.040; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Salerno M, 1999, INT J CANCER, V81, P299; Santen RJ, 2005, J STEROID BIOCHEM, V95, P155, DOI 10.1016/j.jsbmb.2005.04.025; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Staka CM, 2005, ENDOCR-RELAT CANCER, V12, pS85, DOI 10.1677/erc.1.01006; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; WISEMAN LR, 1993, EUR J CANCER, V29A, P2256, DOI 10.1016/0959-8049(93)90218-5	50	48	50	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2404	2414		10.1038/onc.2009.520	http://dx.doi.org/10.1038/onc.2009.520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101208	Green Accepted			2022-12-28	WOS:000276951500009
J	Marshall, GM; Gherardi, S; Xu, N; Neiron, Z; Trahair, T; Scarlett, CJ; Chang, DK; Liu, PY; Jankowski, K; Iraci, N; Haber, M; Norris, MD; Keating, J; Sekyere, E; Jonquieres, G; Stossi, F; Katzenellenbogen, BS; Biankin, AV; Perini, G; Liu, T				Marshall, G. M.; Gherardi, S.; Xu, N.; Neiron, Z.; Trahair, T.; Scarlett, C. J.; Chang, D. K.; Liu, P. Y.; Jankowski, K.; Iraci, N.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Stossi, F.; Katzenellenbogen, B. S.; Biankin, A. V.; Perini, G.; Liu, T.			Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects	ONCOGENE			English	Article						N-Myc; c-Myc; histone deacetylase 2; cyclin G2; cell proliferation	C-MYC; CYCLIN G2; PANCREATIC-CANCER; GENOMIC TARGETS; IN-VIVO; EXPRESSION; INHIBITION; PROTEIN; CELLS; IDENTIFICATION	Myc oncoproteins and histone deacetylases (HDACs) modulate gene transcription and enhance cancer cell proliferation, and HDAC inhibitors are among the most promising new classes of anticancer drugs. Here, we show that N-Myc and c-Myc upregulated HDAC2 gene expression in neuroblastoma and pancreatic cancer cells, respectively, which contributed to N-Myc- and c-Myc-induced cell proliferation. Cyclin G2 (CCNG2) was commonly repressed by N-Myc and HDAC2 in neuroblastoma cells and by c-Myc and HDAC2 in pancreatic cancer cells, and could be reactivated by HDAC inhibitors. 5-bromo-2'-deoxyuridine incorporation assays showed that transcriptional repression of CCNG2 was, in part, responsible for N-Myc-, c-Myc- and HDAC2-induced cell proliferation. Dual crosslinking chromatin immunoprecipitation assay demonstrated that N-Myc acted as a transrepressor by recruiting the HDAC2 protein to Sp1-binding sites at the CCNG2 gene core promoter. Moreover, HDAC2 was upregulated, and CCNG2 downregulated, in pre-cancerous and neuroblastoma tissues from N-Myc transgenic mice, and c-Myc overexpression correlated with upregulation of HDAC2 and repression of CCNG2 in tumour tissues from pancreatic cancer patients. Taken together, our data indicate the critical roles of upregulation of HDAC2 and suppression of CCNG2 in Myc-induced oncogenesis, and have significant implications for the application of HDAC inhibitors in the prevention and treatment of Myc-driven cancers. Oncogene (2010) 29, 5957-5968; doi:10.1038/onc.2010.332; published online 9 August 2010	[Marshall, G. M.; Xu, N.; Neiron, Z.; Trahair, T.; Liu, P. Y.; Jankowski, K.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Liu, T.] Univ New S Wales, Childrens Canc Inst Australia Med Res, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia; [Marshall, G. M.] Univ New S Wales, Ctr Childrens Canc & Blood Disorders, Sydney Childrens Hosp, Sydney, NSW 2052, Australia; [Gherardi, S.; Iraci, N.; Perini, G.] Univ Bologna, Dept Biol, I-40126 Bologna, Italy; [Scarlett, C. J.; Chang, D. K.; Biankin, A. V.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; [Stossi, F.; Katzenellenbogen, B. S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; University of Bologna; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Illinois System; University of Illinois Urbana-Champaign	Liu, T (corresponding author), Univ New S Wales, Childrens Canc Inst Australia Med Res, Lowy Canc Res Ctr C25, POB 81, Sydney, NSW 2052, Australia.	g.marshall@unsw.edu.au; tliu@ccia.unsw.edu.au	Iraci, Nunzio/M-7451-2016; von Jonquieres, Georg/W-1781-2019; Liu, Tao/A-3922-2015	Iraci, Nunzio/0000-0003-2146-9329; von Jonquieres, Georg/0000-0002-7423-3355; Norris, Murray/0000-0002-0632-4589; Scarlett, Christopher/0000-0002-4140-7785; Liu, Tao/0000-0001-6244-7316; Haber, Michelle/0000-0003-2036-8817; Trahair, Toby/0000-0002-3295-228X; Biankin, Andrew/0000-0002-0362-5597; Chang, David/0000-0002-4821-3078	NIH; Cancer Institute NSW; NHMRC; Cancer Council NSW; Italian Association for Research on Cancer	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Institute NSW; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Italian Association for Research on Cancer(Fondazione AIRC per la ricerca sul cancro)	The authors are supported by an NIH project grant (T L), a Career Development and Support Fellowship from Cancer Institute NSW (T L and AVB), NHMRC (TL and GMM) and Cancer Council NSW (TL, AVB and CJS) project grants, NHMRC, Cancer Institute NSW and Cancer Council NSW programme grants (GMM, MH and MDN), Italian Association for Research on Cancer (GP), NHMRC Postdoctoral Training Fellowships (CJS and TT). Children's Cancer Institute Australia is affiliated with University of New South Wales and Sydney Children's Hospital.	Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Biankin AV, 2009, GASTROENTEROLOGY, V137, P558, DOI 10.1053/j.gastro.2009.04.009; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Raetz EA, 2003, CANCER, V98, P841, DOI 10.1002/cncr.11584; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312	29	65	70	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	44					5957	5968		10.1038/onc.2010.332	http://dx.doi.org/10.1038/onc.2010.332			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697349				2022-12-28	WOS:000283843400009
J	Tchaicha, JH; Mobley, AK; Hossain, MG; Aldape, KD; McCarty, JH				Tchaicha, J. H.; Mobley, A. K.; Hossain, M. G.; Aldape, K. D.; McCarty, J. H.			A mosaic mouse model of astrocytoma identifies alpha v beta 8 integrin as a negative regulator of tumor angiogenesis	ONCOGENE			English	Article						glioma; glioblastoma multiforme; itgav; itgb8; TGF beta; astrocyte	GROWTH-FACTOR RECEPTOR; ALPHA-V INTEGRINS; NEURAL STEM-CELL; NEUROVASCULAR DEVELOPMENT; GLIOBLASTOMA-MULTIFORME; RADIAL GLIA; FACTOR-BETA; IN-VITRO; ACTIVATION; GLIOMA	Angiogenesis involves a complex set of cell-cell and cell-extracellular matrix (ECM) interactions that coordinately promote and inhibit blood vessel growth and sprouting. Although many factors that promote angiogenesis have been characterized, the identities and mechanisms of action of endogenous inhibitors of angiogenesis remain unclear. Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression. Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor alpha v beta 8 integrin. Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGF beta s, resulting in impaired TGF beta receptor signaling in tumor-associated endothelial cells. These data reveal that astrocytoma cells manipulate their angiogenic balance by selectively suppressing avb8 integrin expression and function. Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors. Oncogene (2010) 29, 4460-4472; doi: 10.1038/onc.2010.199; published online 7 June 2010	[McCarty, J. H.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77030 USA; [Aldape, K. D.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	McCarty, JH (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jhmccarty@mdanderson.org			National Institutes of Neurological Disease and Stroke [R01NS059876]; National Cancer Institute [P50CA127001, CA-16672]; Ellison Medical Foundation [AG-NS-0324-06]; NATIONAL CANCER INSTITUTE [P50CA127001, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059876] Funding Source: NIH RePORTER	National Institutes of Neurological Disease and Stroke; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Nami McCarty for providing assistance with FACS analysis and Dr Russell Pieper for generously providing E6/E7 and <SUP>G12V</SUP>H-Ras plasmids. This research was supported by grants awarded to JHM from the National Institutes of Neurological Disease and Stroke (R01NS059876), the National Cancer Institute (P50CA127001) and the Ellison Medical Foundation (AG-NS-0324-06). This work was also supported in part by a National Cancer Institute core grant (CA-16672) awarded to The University of Texas MD Anderson Cancer Center.	ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bautch VL, 2009, CELL ADHES MIGR, V3, P199, DOI 10.4161/cam.3.2.8397; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; BOGLER O, 1995, CANCER RES, V55, P2746; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Kaur B, 2004, J NEURO-ONCOL, V70, P229, DOI 10.1007/s11060-004-2752-5; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCarty JH, 2005, P NATL ACAD SCI USA, V102, P13479, DOI 10.1073/pnas.0506068102; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; McCarty JH, 2002, MOL CELL BIOL, V22, P7667, DOI 10.1128/MCB.22.21.7667-7677.2002; McCarty JH, 2008, AM J PATHOL, V172, P1740, DOI 10.2353/ajpath.2008.070700; McCarty JH, 2009, CELL ADHES MIGR, V3, P211, DOI 10.4161/cam.3.2.7767; McCarty JH, 2009, CURR OPIN HEMATOL, V16, P209, DOI 10.1097/MOH.0b013e32832a07eb; Milner R, 2001, MOL CELL NEUROSCI, V18, P108, DOI 10.1006/mcne.2001.1003; Mobley AK, 2009, J CELL SCI, V122, P1842, DOI 10.1242/jcs.043257; Mori T, 2005, CURR TOP DEV BIOL, V69, P67, DOI 10.1016/S0070-2153(05)69004-7; Mu ZY, 2008, MECH DEVELOP, V125, P508, DOI 10.1016/j.mod.2008.01.003; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426; Proctor JM, 2005, J NEUROSCI, V25, P9940, DOI 10.1523/JNEUROSCI.3467-05.2005; Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533; Riemenschneider MJ, 2005, AM J PATHOL, V167, P1379, DOI 10.1016/S0002-9440(10)61225-4; Rietze RL, 2006, METHOD ENZYMOL, V419, P3, DOI 10.1016/S0076-6879(06)19001-1; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Sonoda Y, 2003, CANCER RES, V63, P1962; Sonoda Y, 2001, CANCER RES, V61, P4956; Sonoda Y, 2001, CANCER RES, V61, P6674; Stipursky J, 2007, GLIA, V55, P1023, DOI 10.1002/glia.20522; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uhrbom L, 2002, CANCER RES, V62, P5551; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhu JW, 2002, DEVELOPMENT, V129, P2891	47	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4460	4472		10.1038/onc.2010.199	http://dx.doi.org/10.1038/onc.2010.199			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20531304	Green Accepted			2022-12-28	WOS:000280559100009
J	Nakahata, S; Yamazaki, S; Nakauchi, H; Morishita, K				Nakahata, S.; Yamazaki, S.; Nakauchi, H.; Morishita, K.			Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta 1-mediated growth suppression in adult T-cell leukemia/lymphoma	ONCOGENE			English	Article						ZEB1; Smad7; ATLL	FACTOR-BETA; POTENTIAL MECHANISM; LEUKEMIA-CELLS; LEUKEMOGENESIS; EXPRESSION; RECEPTOR; GENE; TAX; COREPRESSOR; DEGRADATION	Zinc-finger E-box binding homeobox 1 (ZEB1) is a candidate tumor-suppressor gene in adult T-cell leukemia/lymphoma ( ATLL). ZEB1 binds phosphorylated Smad2/3 to enhance transforming growth factor-beta 1 (TGF-beta 1) signaling. In addition to downregulation of ZEB1 mRNA, we found overexpression of inhibitory Smad, Smad7, in resistance of ATLL cells to growth suppression by TGF-beta 1. A protein complex of Smad7 and histone deacetylase constantly bound to the promoter region of TGF-beta 1 responsive genes with the Smad-responsive element (SRE) to inhibit TGF-beta 1 signaling; however, ectopic expression of ZEB1 reactivated TGF-beta 1 signaling by binding to Smad7 and recruiting the Smad3/p300 histone acetyltransferase complex to the promoter after TGF-beta 1 stimulation in ATLL. Conversely, because ZEB1 mRNA was detected in the late stages of T-cell development, we used CTLL2 cells with ZEB1 expression, a murine peripheral T-cell lymphoma, and found that a complex of Smad3, Smad7 and ZEB1 was bound to the SRE of the p21(CDKN1A) promoter after the induction of Smad7 by TGF-beta 1 treatment. Because the duration of TGF-beta 1-induced transcriptional activation of PAI-1 and p21 was shortened in shZEB1-expressing CTLL2 cells, ZEB1 may have a role in enhancing TGF-beta 1 signaling by binding not only to Smad3 but also to Smad7 in the nucleus. Altogether, these results suggest that both ZEB1 downregulation and Smad7 overexpression contribute to resistance to TGF-beta 1-mediated growth suppression in ATLL. Oncogene ( 2010) 29, 4157-4169; doi: 10.1038/onc.2010.172; published online 31 May 2010	[Nakahata, S.; Morishita, K.] Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, Miyazaki 8891692, Japan; [Yamazaki, S.; Nakauchi, H.] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Lab Stem Cell Therapy, Tokyo, Japan	University of Miyazaki; University of Tokyo	Morishita, K (corresponding author), Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, 5200 Kihara, Miyazaki 8891692, Japan.	kmorishi@med.miyazaki-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan; Leukemia Research fund; Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST; Japan Society for the Promotion of Science [19790344]	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Leukemia Research fund; Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research of Priority Area from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Leukemia Research fund; Research fund from Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST (KM) and Young Scientists (B) (19790344) of Japan Society for the Promotion of Science (SN).	Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hidaka T, 2008, BLOOD, V112, P383, DOI 10.1182/blood-2008-01-131185; INGE TH, 1992, J IMMUNOL, V148, P3847; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; OKADA M, 1985, J IMMUNOL, V135, P3995; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; van Grunsven LA, 2001, J BONE JOINT SURG AM, V83A, pS40; Vermeer MH, 2008, CANCER RES, V68, P2689, DOI 10.1158/0008-5472.CAN-07-6398; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06	31	57	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2010	29	29					4157	4169		10.1038/onc.2010.172	http://dx.doi.org/10.1038/onc.2010.172			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20514018				2022-12-28	WOS:000280151500004
J	Grzmil, M; Rzymski, T; Milani, M; Harris, AL; Capper, RG; Saunders, NJ; Salhan, A; Ragoussis, J; Norbury, CJ				Grzmil, M.; Rzymski, T.; Milani, M.; Harris, A. L.; Capper, R. G.; Saunders, N. J.; Salhan, A.; Ragoussis, J.; Norbury, C. J.			An oncogenic role of eIF3e/INT6 in human breast cancer	ONCOGENE			English	Article						MAD2L1; BCL-XL; PLAU; urokinase-type plasminogen activator; breast cancer	INITIATION-FACTOR EIF3; MAMMARY-TUMOR VIRUS; TRANSLATION INITIATION; MESSENGER-RNA; FISSION YEAST; SUBCELLULAR-LOCALIZATION; MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; CELL-GROWTH; INT6	Altered expression of the eukaryotic translation initiation factor 3 (eIF3) subunit eIF3e/INT6 has been described in various types of human cancer, but the nature of its involvement in tumorigenesis is not yet clear. Using immunohistochemical analysis of 81 primary breast cancers, we found that high tumor grade correlated significantly with elevated cytoplasmic eIF3e level in epithelial tumor cells. Analysis of protein synthesis after siRNA-mediated knockdown in breast cancer cell lines indicated that eIF3e is not required for bulk translation. Microarray analysis of total and polysomal RNAs nonetheless identified distinct sets of mRNAs regulated either positively or negatively by eIF3e; functional classification of these revealed a marked enrichment of genes involved in cell proliferation, invasion and apoptosis. Validated mRNA targets regulated positively at the translational level by eIF3e included urokinase-type plasminogen activator and apoptotic regulator BCL-XL, whereas synthesis of proteins including the mitotic checkpoint component MAD2L1 was negatively regulated. Finally, eIF3e-depleted breast carcinoma cells showed reduced in vitro invasion and proliferation. Taken together, our study data suggest that eIF3e has a positive role in breast cancer progression. It regulates the translation, and in some cases abundance, of mRNAs involved in key aspects of cancer cell biology. Oncogene (2010) 29, 4080-4089; doi:10.1038/onc.2010.152; published online 10 May 2010	[Grzmil, M.; Capper, R. G.; Saunders, N. J.; Norbury, C. J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Rzymski, T.; Milani, M.; Harris, A. L.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX1 3RE, England; [Salhan, A.; Ragoussis, J.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Norbury, CJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	chris.norbury@path.ox.ac.uk	Ragoussis, Ioannis/AAD-9790-2022; Harris, Adrian L/ABA-3343-2020; Saunders, Nigel J/W-6745-2019	Harris, Adrian L/0000-0003-1376-8409; Grzmil, Michal/0000-0002-7866-8145; Ragoussis, Ioannis/0000-0002-8515-0934; Saunders, Nigel/0000-0002-0160-4573	Cancer Research UK; Association for International Cancer Research; Wellcome Trust [075491/Z/04]	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; Wellcome Trust(Wellcome TrustEuropean Commission)	We thank Ben Thomas and Sasha Akoulitchev for help and advice with 2D liquid chromatography, Cheng Han for help with the statistical analysis, Dan Scott and other members of the laboratory for their comments on the article. This work was supported by Cancer Research UK, the Association for International Cancer Research and the Wellcome Trust (through grant 075491/Z/04 to JR).	Ahlemann M, 2006, MOL CARCINOGEN, V45, P957, DOI 10.1002/mc.20269; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Bramham CR, 2007, NAT REV NEUROSCI, V8, P776, DOI 10.1038/nrn2150; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Buchsbaum S, 2007, ONCOGENE, V26, P5132, DOI 10.1038/sj.onc.1210314; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Chen L, 2007, J BIOL CHEM, V282, P12707, DOI 10.1074/jbc.M700423200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; De Quinto SL, 2001, RNA, V7, P1213, DOI 10.1017/S1355838201010433; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Grzmil M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000959; Han B, 2005, ONCOL REP, V14, P105; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Jivotovskaya AV, 2006, MOL CELL BIOL, V26, P1355, DOI 10.1128/MCB.26.4.1355-1372.2006; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Mavrakis KJ, 2008, CELL CYCLE, V7, P2791, DOI 10.4161/cc.7.18.6683; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; MERRICK WC, 1979, J BIOL CHEM, V254, P3708; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Paquin N, 2008, TRENDS CELL BIOL, V18, P105, DOI 10.1016/j.tcb.2007.12.004; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Rencus-Lazar S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002239; Saal LH, 2002, GENOME BIOL, V3; Savinainen KJ, 2006, PROSTATE, V66, P1144, DOI 10.1002/pros.20452; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Thumma SC, 2007, CANCER LETT, V258, P1, DOI 10.1016/j.canlet.2007.08.022; Traicoff JL, 2007, J BIOMED SCI, V14, P395, DOI 10.1007/s11373-007-9149-3; Udagawa T, 2008, J BIOL CHEM, V283, P22063, DOI 10.1074/jbc.M710017200; von Arnim AG, 2003, CURR BIOL, V13, pR323, DOI 10.1016/S0960-9822(03)00238-0; Watkins SJ, 2004, CELL PROLIFERAT, V37, P149, DOI 10.1111/j.1365-2184.2004.00305.x; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	47	42	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2010	29	28					4080	4089		10.1038/onc.2010.152	http://dx.doi.org/10.1038/onc.2010.152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453879				2022-12-28	WOS:000279892400008
J	Takizawa, M; Kim, JS; Tessarollo, L; McNeil, N; Waldschmidt, TJ; Casellas, R; Ried, T; Janz, S				Takizawa, M.; Kim, J. S.; Tessarollo, L.; McNeil, N.; Waldschmidt, T. J.; Casellas, R.; Ried, T.; Janz, S.			Genetic reporter system for oncogenic Igh-Myc translocations in mice	ONCOGENE			English	Article						mouse plasmacytoma T(12;15) translocation; human Burkitt lymphoma t(8;14)(q24;q32) translocation; green fluorescence protein	CLASS SWITCH RECOMBINATION; C-MYC; CHROMOSOMAL TRANSLOCATIONS; B-CELL; BALB/C PLASMACYTOMAS; DNA-REPAIR; IN-VIVO; T(12/15); AID; HYPERMUTATION	The Myc-deregulating chromosomal T(12; 15)(Igh-Myc) translocation, the hallmark mutation of inflammation-and interleukin 6-dependent mouse plasmacytoma (PCT), is the premier model of cancer-associated chromosomal translocations because it is the only translocation in mice that occurs spontaneously (B lymphocyte lineage) and with predictably high incidence (similar to 85% of PCT), and has a direct counterpart in humans: Burkitt lymphoma t(8;14)(q24;q32) translocation. Here, we report on the development of a genetic system for the detection of T(12;15)(Igh-Myc) translocations in plasma cells of a mouse strain in which an enhanced green fluorescent protein (GFP)-encoding reporter gene has been targeted to Myc. Four of the PCTs that developed in the newly generated translocation reporter mice, designated iGFP(5/Myc), expressed GFP consequent to naturally occurring T(12;15) translocation. GFP expression did not interfere with tumor development or the deregulation of Myc on derivative 12 of translocation, der (12), because the reporter gene was allocated to the reciprocal product of translocation, der (15). Although the described reporter gene approach requires refinement before T(12;15) translocations can be quantitatively detected in vivo, including in B lymphocyte lineage cells that have not yet completed malignant transformation, our findings provide proof of principle that reporter gene tagging of oncogenes in gene-targeted mice can be used to elucidate unresolved questions on the occurrence, distribution and trafficking of cells that have acquired cancer-causing chromosomal translocations of great relevance for humans. Oncogene (2010) 29, 4113-4120; doi:10.1038/onc.2010.150; published online 10 May 2010	[Waldschmidt, T. J.; Janz, S.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA 52246 USA; [Takizawa, M.; Kim, J. S.] NCI, Genet Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Takizawa, M.; Casellas, R.] Natl Inst Arthrit & Musculoskeletal Dis, Bethesda, MD USA; [Tessarollo, L.] NCI, Mouse Canc Genet Program, CCR, Bethesda, MD 20892 USA; [McNeil, N.; Ried, T.] NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, 500 Newton Rd,1046C ML, Iowa City, IA 52246 USA.	siegfried-janz@uiowa.edu		Waldschmidt, Thomas/0000-0001-6147-6991; McNeil, Nicole/0000-0003-1440-6880	NIH; National Cancer Institute [P50CA097274]; NATIONAL CANCER INSTITUTE [ZICBC011265, ZIABC010836, R01CA151354, P50CA097274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041149, ZIAAR041148, Z01AR041149] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank our colleagues from NCI and NIAID, NIH for their contributions to this project: Tina Willington, Vaishali Jarral and Wendy DuBois for genotyping and assistance with the mouse experiments; Eileen Southon for gene targeting; Dr Alexander L Kovalchuk for advice on PCR analysis and providing primers; Drs Sung Sup Park and Santiago Silva for contributions to early stages of this project; and Drs Michael Potter and Beverly Mock for stimulating discussion and laboratory support. For assistance with transfer, cryopreservation, maintenance and rederivation of mice under SPF conditions, we thank: Ling Hu, CCOM, Iowa City, Iowa; the staff of the Jackson Laboratory, Bar Harbor, Maine; and the Office of Animal Resources, CCOM, particularly Dr Kem Singletary and James Hynes. We also thank Lorraine Tygrett, CCOM for assistance with flow cytometry. This work was supported, in part, by the Intramural Research Program of the NIH (LT, RC, TR) and Award Number P50CA097274 from the National Cancer Institute (SJ).	ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; Cheng HL, 2009, P NATL ACAD SCI USA, V106, P2717, DOI 10.1073/pnas.0812304106; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Germain RN, 2005, SEMIN IMMUNOL, V17, P431, DOI 10.1016/j.smim.2005.09.003; Gostissa M, 2009, NATURE, V462, P803, DOI 10.1038/nature08633; Gostissa M, 2009, P NATL ACAD SCI USA, V106, P2265, DOI 10.1073/pnas.0812763106; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; Janz S, 2006, DNA REPAIR, V5, P1213, DOI 10.1016/j.dnarep.2006.05.017; Kovalchuk AL, 2000, LEUKEMIA, V14, P1127, DOI 10.1038/sj.leu.2401767; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Kovalchuk AL, 2000, LEUKEMIA, V14, P909, DOI 10.1038/sj.leu.2401676; Kovalchuk AL, 2003, ONCOGENE, V22, P2842, DOI 10.1038/sj.onc.1206345; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; Muller JR, 1997, CURR TOP MICROBIOL, V224, P251; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Silva S, 2003, CANCER RES, V63, P8656; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Wang JH, 2009, NATURE, V460, P231, DOI 10.1038/nature08159; Wessels JT, 2007, CYTOM PART A, V71A, P542, DOI 10.1002/cyto.a.20419; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822	31	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4113	4120		10.1038/onc.2010.150	http://dx.doi.org/10.1038/onc.2010.150			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453890	Green Accepted			2022-12-28	WOS:000279892400011
J	Shrestha-Bhattarai, T; Rangnekar, VM				Shrestha-Bhattarai, T.; Rangnekar, V. M.			Cancer-selective apoptotic effects of extracellular and intracellular Par-4	ONCOGENE			English	Review						Par-4; cell surface GRP78; apoptosis	TUMOR-SUPPRESSOR PAR-4; NECROSIS-FACTOR-ALPHA; PROTEIN PAR-4; ENDOPLASMIC-RETICULUM; PROSTATIC-CANCER; DOWN-REGULATION; ONCOGENIC RAS; CELLS; GENE; KINASE	Selectivity toward cancer cells is the most desirable element in cancer therapeutics. Par-4 is a cancer cell-selective proapoptotic protein that functions intracellularly in the cytoplasmic and nuclear compartments as a tumor suppressor. Moreover, recent findings indicate that the Par-4 protein is secreted by cells, and extracellular Par-4 induces cancer cell-specific apoptosis by interaction with the cell-surface receptor GRP78. This review describes the mechanisms underlying the apoptotic effects of both extracellular and intracellular Par-4 acting through its effector domain SAC. Oncogene (2010) 29, 3873-3880; doi:10.1038/onc.2010.141; published online 3 May 2010	[Rangnekar, V. M.] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; [Shrestha-Bhattarai, T.; Rangnekar, V. M.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Rangnekar, V. M.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA; [Rangnekar, V. M.] Univ Kentucky, LP Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Radiat Med, Combs Res Bldg,Room 309,800 Rose St, Lexington, KY 40536 USA.	vmrang01@email.uky.edu			NIH/NCI [CA60872, CA105453, CA84511]; NATIONAL CANCER INSTITUTE [R01CA105453, R01CA060872, R01CA116658, R01CA084511] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH/NCI grants CA60872, CA105453 and CA84511 (to VMR).	Ahmed MM, 2008, INT J CANCER, V122, P63, DOI 10.1002/ijc.23019; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Boosen M, 2009, MOL BIOL CELL, V20, P4010, DOI 10.1091/mbc.E09-02-0173; BOS JL, 1989, CANCER RES, V49, P4682; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Chakraborty M, 2001, CANCER RES, V61, P7255; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; El-Guendy N, 2003, MOL CELL BIOL, V23, P5516, DOI 10.1128/MCB.23.16.5516-5525.2003; El-Guendy N, 2003, EXP CELL RES, V283, P51, DOI 10.1016/S0014-4827(02)00016-2; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garcia-Cao I, 2005, EMBO REP, V6, P577, DOI 10.1038/sj.embor.7400421; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Gurumurthy S, 2005, MOL CELL BIOL, V25, P1146, DOI 10.1128/MCB.25.3.1146-1161.2005; Inesi G, 1998, ANN NY ACAD SCI, V853, P195, DOI 10.1111/j.1749-6632.1998.tb08267.x; ISAACS JT, 1981, CANCER RES, V41, P5070; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Johnstone RW, 1998, GENOMICS, V53, P241, DOI 10.1006/geno.1998.5494; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Kimura M, 1998, CANCER RES, V58, P2456; Kogel D, 2001, BRIT J CANCER, V85, P1801, DOI 10.1054/bjoc.2001.2158; Kukoc-Zivojnov N, 2004, EXP HEMATOL, V32, P649, DOI 10.1016/j.exphem.2004.04.004; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lucas T, 2001, MELANOMA RES, V11, P379, DOI 10.1097/00008390-200108000-00008; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200; Moreno-Bueno G, 2007, CANCER RES, V67, P1927, DOI 10.1158/0008-5472.CAN-06-2687; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Paige AJW, 2003, CELL MOL LIFE SCI, V60, P2147, DOI 10.1007/s00018-003-3027-6; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Schneider BG, 2003, J CLIN PATHOL-MOL PA, V56, P141, DOI 10.1136/mp.56.3.141; Schwarze S, 2010, CANCER BIOL THER, V9, P153, DOI 10.4161/cbt.9.2.10760; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Zapata-Benavides P, 2009, ARCH MED RES, V40, P595, DOI 10.1016/j.arcmed.2009.08.007; Zhao YM, 2007, CANCER RES, V67, P9276, DOI 10.1158/0008-5472.CAN-07-2124; Zhao YM, 2008, CANCER BIOL THER, V7, P1867, DOI 10.4161/cbt.7.12.6945; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	48	64	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3873	3880		10.1038/onc.2010.141	http://dx.doi.org/10.1038/onc.2010.141			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20440265	Green Accepted			2022-12-28	WOS:000279603200001
J	Wu, HH; Cheng, YW; Chang, JT; Wu, TC; Liu, WS; Chen, CY; Lee, H				Wu, H-H; Cheng, Y-W; Chang, J. T.; Wu, T-C; Liu, W-S; Chen, C-Y; Lee, H.			Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappa B activation	ONCOGENE			English	Article						cytoplasmic Ape1; NF-kappa B; Cox-2; lung tumor metastasis	FACTOR-I; HUMAN-MELANOMA; CANCER; EXPRESSION; APE1/REF-1; P53; APE/REF-1; ALPHA; RESVERATROL; PROGRESSION	Apurinic endonuclease 1 (Ape1) is not only involved in base excision repair, but also activates some transcriptional factors through its redox activity. However, which subcellular localization of Ape1 is involved in the activation of transcriptional factor remains unclear. We first observed that Cox-2 expression was associated with cytoplasmic Ape1 expression in lung tumors and cancer cell lines. We thus hypothesize that nuclear factor (NF)-kappa B is activated by cytoplasmic Ape1 to cause Cox-2 expression. Herein, we generated cytoplasmic and nuclear Ape1 in Ape1-knockdown lung cancer cells by exogenous expression of Ape1 containing various deletions and/or mutations of the nuclear localization sequence. It was observed that cytoplasmic Ape1, but not nuclear Ape1, induced Cox-2 expression through NF-kappa B activation. NF-kappa B activation by cytoplasmic Ape1 was diminished by the Ape1 redox activity inhibitor resveratrol. Cells expressing cytoplasmic Ape1 exhibited tumor progression and metastasis in vitro and in vivo as xenografts, but cells expressing nuclear Ape1 did not. Patients with tumors containing elevated cytoplasmic Ape1 had a poor prognosis and a 3.722-fold risk of tumor recurrence and/or metastasis. Cytoplasmic Ape1 could therefore enhance lung tumor malignancy through NF-kappa B activation, suggesting that combination of cisplatin and specific redox inhibitor could improve chemotherapeutic response in patients with tumors containing elevated cytoplasmic Ape1. Oncogene (2010) 29, 4330-4340; doi:10.1038/onc.2010.178; published online 24 May 2010	[Wu, H-H; Chang, J. T.; Lee, H.] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung 402, Taiwan; [Cheng, Y-W; Lee, H.] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan; [Wu, T-C] Chung Shan Med Univ Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan; [Liu, W-S] Chung Shan Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Lee, H.] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Health Research Institutes - Taiwan	Lee, H (corresponding author), Chung Shan Med Univ, Inst Med & Mol Toxicol, 110,Sec 1,Jianguo N Rd, Taichung 402, Taiwan.	hlee@nhri.gov.tw	Lee, Huei/B-2664-2010		National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [NSC-96-2628-B-040-002-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (NSC-96-2628-B-040-002-MY3) of Taiwan, ROC.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; Angkeow P, 2002, CELL DEATH DIFFER, V9, P717, DOI 10.1038/sj.cdd.4401025; Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025; Bapat A, 2009, ANTIOXID REDOX SIGN, V11, P651, DOI [10.1089/ars.2008.2218, 10.1089/ARS.2008.2218]; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Busso CS, 2009, ONCOGENE, V28, P1616, DOI 10.1038/onc.2009.5; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; CHENG YW, 2004, CANCER RES, V67, P10686; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dey A, 2008, NAT REV DRUG DISCOV, V7, P1031, DOI 10.1038/nrd2759; Di Maso V, 2007, MOL MED, V13, P89, DOI 10.2119/2006-00084.DiMaso; Fantini D, 2008, FREE RADICAL RES, V42, P20, DOI 10.1080/10715760701765616; Freitas S, 2003, CLIN CANCER RES, V9, P4689; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jackson EB, 2005, NUCLEIC ACIDS RES, V33, P3303, DOI 10.1093/nar/gki641; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Kakolyris S, 1998, HISTOPATHOLOGY, V33, P561; Kakolyris S, 1999, J PATHOL, V189, P351, DOI 10.1002/(SICI)1096-9896(199911)189:3<351::AID-PATH435>3.0.CO;2-1; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Moore DH, 2000, CLIN CANCER RES, V6, P602; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Pines A, 2005, NUCLEIC ACIDS RES, V33, P4379, DOI 10.1093/nar/gki751; Puglisi F, 2002, ONCOL REP, V9, P11; Puglisi F, 2001, ANTICANCER RES, V21, P4041; Qu J, 2007, NUCLEIC ACIDS RES, V35, P2522, DOI 10.1093/nar/gkl1163; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Stathopoulos GT, 2008, MOL CANCER RES, V6, P364, DOI 10.1158/1541-7786.MCR-07-0309; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wu C, 2003, J BIOL CHEM, V278, P31980, DOI 10.1074/jbc.M304278200; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Xu Y, 1997, ANTICANCER RES, V17, P3713; Yang S, 2005, MOL CANCER THER, V4, P1923, DOI 10.1158/1535-7163.MCT-05-0229; Yang Z, 2008, MOL CANCER THER, V7, P3751, DOI 10.1158/1535-7163.MCT-08-0562; Zaky A, 2008, NUCLEIC ACIDS RES, V36, P1555, DOI 10.1093/nar/gkm1173	45	38	39	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4330	4340		10.1038/onc.2010.178	http://dx.doi.org/10.1038/onc.2010.178			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498636	Bronze			2022-12-28	WOS:000280547900009
J	Rachakonda, G; Sekhar, KR; Jowhar, D; Samson, PC; Wikswo, JP; Beauchamp, RD; Datta, PK; Freeman, ML				Rachakonda, G.; Sekhar, K. R.; Jowhar, D.; Samson, P. C.; Wikswo, J. P.; Beauchamp, R. D.; Datta, P. K.; Freeman, M. L.			Increased cell migration and plasticity in Nrf2-deficient cancer cell lines	ONCOGENE			English	Article						Nrf2; TGF-beta; Smad; Cadherin; motility; oncogenesis	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR NRF2; ACTIVATOR INHIBITOR-1 PROMOTER; GENE-EXPRESSION PROFILES; UBIQUITIN LIGASE COMPLEX; FACTOR-DEFICIENT MICE; TGF-BETA; OXIDATIVE STRESS; LUNG-CANCER; BREAST-CANCER	Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) expression is deregulated in many cancers. Genetic and biochemical approaches coupled with functional assays in cultured cells were used to explore the consequences of Nrf2 repression. Nrf2 suppression by Keap1-directed ubiquitylation or the expression of independent short hairpin RNA (shRNA)/siRNA sequences enhanced cellular levels of reactive oxygen species, Smad-dependent tumor cell motility and growth in soft agar. Loss of Nrf2 was accompanied by concomitant Smad linker region/C-terminus phosphorylation, induction of the E-cadherin transcriptional repressor Slug and suppression of the cell-cell adhesion protein E-cadherin. Ectopic expression of the wildtype but not dominant-negative Nrf2 suppressed the activity of a synthetic transforming growth factor-beta 1-responsive CAGA-directed luciferase reporter. shRNA knock-down of Nrf2 enhanced the activity of the synthetic CAGA reporter, as well as the expression of the endogenous Smad target gene plasminogen activator inhibitor-1. Finally, we found that Nrf2/Smad3/Smad4 formed an immunoprecipitable nuclear complex. Thus, loss of Nrf2 increased R-Smad phosphorylation and R-Smad signaling, supporting the hypothesis that loss of Nrf2 in an oncogenic context-dependent manner can enhance cellular plasticity and motility, in part by using transforming growth factor-beta/Smad signaling. Oncogene (2010) 29, 3703-3714; doi: 10.1038/onc.2010.118; published online 3 May 2010	[Freeman, M. L.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; [Jowhar, D.; Samson, P. C.; Wikswo, J. P.] Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37232 USA; [Jowhar, D.; Samson, P. C.; Wikswo, J. P.] Vanderbilt Univ, Vanderbilt Inst Integrat Biosyst Res & Educ, Nashville, TN 37232 USA; [Wikswo, J. P.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37232 USA; [Wikswo, J. P.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Beauchamp, R. D.; Datta, P. K.] Vanderbilt Univ, Dept Surg, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Freeman, ML (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, B 902 TVC, Nashville, TN 37232 USA.	michael.freeman@vanderbilt.edu		Konjeti, Sekhar/0000-0003-2930-0739; Freeman, Michael/0000-0003-1881-366X; Beauchamp, Robert Daniel/0000-0002-8446-4114	NIH [RO1CA104590, RO1CA115556, RO1CA069457, R01DK052334, RO1CA095195, RO1CA113519, P50CA090949, U01AI061223]; Vanderbilt-Ingram Cancer Center [P30CA68485]; Vanderbilt Institute for Integrative Biosystems Research and Education; NATIONAL CANCER INSTITUTE [P50CA090949, R01CA104590, R01CA069457, R01CA115556, R01CA095195, P30CA068485, R01CA113519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052334] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt-Ingram Cancer Center; Vanderbilt Institute for Integrative Biosystems Research and Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful for the assistance provided by Dr Swati Biswas. This research was supported in part by NIH Grants RO1CA104590, RO1CA115556, RO1CA069457, R01DK052334, RO1CA095195, RO1CA113519, P50CA090949 (Project# 4), U01AI061223, the Vanderbilt-Ingram Cancer Center grant P30CA68485, and the Vanderbilt Institute for Integrative Biosystems Research and Education.	Barve A, 2009, INT J CANCER, V124, P1693, DOI 10.1002/ijc.24106; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; CHAKRABORTY AK, 1992, MELANOMA RES, V2, P315, DOI 10.1097/00008390-199212000-00004; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Grinberg AV, 2003, J BIOL CHEM, V278, P11227, DOI 10.1074/jbc.M211734200; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hirayama A, 2003, FREE RADICAL BIO MED, V34, P1236, DOI 10.1016/S0891-5849(03)00073-X; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; HUBER BE, 1987, CANCER RES, V47, P3414; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Kusano Y, 2008, BIOCHEMISTRY-US, V47, P6169, DOI 10.1021/bi800199z; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu JR, 2004, HUM GENE THER, V15, P239, DOI 10.1089/104303404322886093; Lo SC, 2006, J BIOL CHEM, V281, P37893, DOI 10.1074/jbc.M606539200; Loignon M, 2009, MOL CANCER THER, V8, P2432, DOI 10.1158/1535-7163.MCT-08-1186; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Mithani SK, 2004, J SURG RES, V117, P296, DOI 10.1016/S0022-4804(03)00335-4; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Safina AF, 2009, CELL CYCLE, V8, P284, DOI 10.4161/cc.8.2.7590; Sarsour EH, 2008, AGING CELL, V7, P405, DOI 10.1111/j.1474-9726.2008.00384.x; Sekhar KR, 2003, CANCER RES, V63, P5636; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; SUN Y, 1989, INT J CANCER, V44, P1028, DOI 10.1002/ijc.2910440615; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Weydert CJ, 2006, FREE RADICAL BIO MED, V41, P226, DOI 10.1016/j.freeradbiomed.2006.03.015; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Yu SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008579; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang Y, 2002, CANCER RES, V62, P1205	78	70	71	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3703	3714		10.1038/onc.2010.118	http://dx.doi.org/10.1038/onc.2010.118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440267	Green Accepted			2022-12-28	WOS:000279108600010
J	Morris, LGT; Veeriah, S; Chan, TA				Morris, L. G. T.; Veeriah, S.; Chan, T. A.			Genetic determinants at the interface of cancer and neurodegenerative disease	ONCOGENE			English	Review						tumor suppressor; neurodegeneration; cancer; PARK2	AMYLOID-PRECURSOR-PROTEIN; TUMOR-SUPPRESSOR GENE; RECESSIVE JUVENILE PARKINSONISM; ACUTE LYMPHOBLASTIC-LEUKEMIA; DEPENDENT KINASE INHIBITORS; NERVOUS-SYSTEM DEVELOPMENT; MITOGEN-ACTIVATED PROTEIN; AGGREGATE-PRONE PROTEINS; DNA-DAMAGING AGENTS; ATAXIA-TELANGIECTASIA	It has been hypothesized that oncogenesis and neurodegeneration may share common mechanistic foundations. Recent evidence now reveals a number of genes in which alteration leads to either carcinogenesis or neurodegeneration, depending on cellular context. Pathways that have emerged as having critical roles in both cancer and neurodegenerative disease include those involving genes such as PARK2, ATM, PTEN, PTPRD, and mTOR. A number of mechanisms have been implicated, and commonly affected cellular processes include cell cycle regulation, DNA repair, and response to oxidative stress. For example, we have recently shown that the E3 ubiquitin ligase PARK2 is mutated or deleted in many different human malignancies and helps drive loss on chromosome 6q25.2-27, a genomic region frequently deleted in cancers. Mutation in PARK2 is also the most common cause of juvenile Parkinson's disease. Mutations in PARK2 result in an upregulation of its substrate cyclin E, resulting in dysregulated entry into the cell cycle. In neurons, this process results in cell death, but in cycling cells, the result is a growth advantage. Thus, depending on whether the cell affected is a dividing cell or a post-mitotic neuron, responses to these alterations may differ, ultimately leading to varying disease phenotypes. Here, we review the substantial data implicating specific genes in both cancer and neurodegenerative disease. Oncogene (2010) 29, 3453-3464; doi:10.1038/onc.2010.127; published online 26 April 2010	[Morris, L. G. T.; Veeriah, S.; Chan, T. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Morris, L. G. T.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Chan, T. A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Chan, T. A.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave,Box 20, New York, NY 10065 USA.	chant@mskcc.org	Chan, Timothy A/ABD-5850-2021		Head and Neck Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center; National Cancer Institute [T32 CA009685]; Doris Duke Charitable Foundation; Society of Memorial Sloan-Kettering Foundation; Flight Attendant Medical Research Institute; Louis Gerstner Foundation; Memorial Sloan-Kettering Brain Tumor Center; STARR Cancer Consortium; NATIONAL CANCER INSTITUTE [T32CA009685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS086875] Funding Source: NIH RePORTER	Head and Neck Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Society of Memorial Sloan-Kettering Foundation; Flight Attendant Medical Research Institute; Louis Gerstner Foundation; Memorial Sloan-Kettering Brain Tumor Center; STARR Cancer Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the Head and Neck Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center for support (LGTM). LGTM is supported by National Cancer Institute T32 Grant CA009685. TAC is supported by the Doris Duke Charitable Foundation, the Society of Memorial Sloan-Kettering Foundation, the Flight Attendant Medical Research Institute, the Louis Gerstner Foundation, the Memorial Sloan-Kettering Brain Tumor Center, and the STARR Cancer Consortium.	Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Ackman JB, 2007, DEV NEUROSCI-BASEL, V29, P113, DOI 10.1159/000096216; Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Anandatheerthavarada HK, 2007, NEUROSCIENTIST, V13, P626, DOI 10.1177/1073858407303536; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Arvidsson Y, 2008, ENDOCR-RELAT CANCER, V15, P569, DOI 10.1677/ERC-07-0145; Auclair Y, 2008, P NATL ACAD SCI USA, V105, P17896, DOI 10.1073/pnas.0801585105; Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Ball LG, 2005, ACTA PHARMACOL SIN, V26, P897, DOI 10.1111/j.1745-7254.2005.00165.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Bixby JL, 2000, NEUROREPORT, V11, pR5, DOI 10.1097/00001756-200007140-00001; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 1996, J NEURAL TRANSM, V103, P455, DOI 10.1007/BF01276421; BRION JP, 1995, AM J PATHOL, V147, P1465; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cairns P, 1997, CANCER RES, V57, P4997; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chan TA, 2009, CELL CYCLE, V8, P3063, DOI 10.4161/cc.8.19.9455; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Connor JR, 2003, NEUROLOGY, V61, P304, DOI 10.1212/01.WNL.0000078887.16593.12; Corti O, 2005, CR BIOL, V328, P131, DOI 10.1016/j.crvi.2004.10.009; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Den Hertog J, 1999, INT J DEV BIOL, V43, P723; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FARINA L, 1994, J COMPUT ASSIST TOMO, V18, P724, DOI 10.1097/00004728-199409000-00008; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Fegan C, 1995, LEUKEMIA, V9, P2003; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gegg ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004756; Giardina SF, 2002, BRIT J PHARMACOL, V135, P1733, DOI 10.1038/sj.bjp.0704636; Gispert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005777; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; Gronbaek K, 1998, BLOOD, V91, P4388; Gumy-Pause F, 2006, LEUKEMIA, V20, P526, DOI 10.1038/sj.leu.2404091; Hampe C, 2006, HUM MOL GENET, V15, P2059, DOI 10.1093/hmg/ddl131; Hansel DE, 2003, CANCER RES, V63, P7032; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Huynh DP, 2007, EXP NEUROL, V203, P531, DOI 10.1016/j.expneurol.2006.09.009; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Inglis KJ, 2009, J BIOL CHEM, V284, P2598, DOI 10.1074/jbc.C800206200; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Inzelberg R, 2007, NEUROLOGY, V69, P1542, DOI 10.1212/01.wnl.0000277638.63767.b8; Ishiguro M, 1998, MOL BRAIN RES, V53, P24, DOI 10.1016/S0169-328X(97)00280-5; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Kerr F, 2006, FEBS LETT, V580, P3121, DOI 10.1016/j.febslet.2006.04.064; Kim RH, 2006, BRIT J CANCER, V94, P620, DOI 10.1038/sj.bjc.6602994; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Ko SY, 2004, INT J CANCER, V111, P727, DOI 10.1002/ijc.20328; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Krause K, 2008, J ENDOCRINOL, V198, P291, DOI 10.1677/JOE-08-0005; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lewis KA, 2005, CANCER RES, V65, P7091, DOI 10.1158/0008-5472.CAN-05-1019; Liang YL, 2009, WORLD J SURG, V33, P661, DOI 10.1007/s00268-008-9840-1; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marino S, 2002, DEVELOPMENT, V129, P3513; Matrone C, 2008, J ALZHEIMERS DIS, V13, P81; Matsumoto T, 2009, P NATL ACAD SCI USA, V106, P14542, DOI 10.1073/pnas.0904229106; Mavrou A, 2008, ANTICANCER RES, V28, P401; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Milne RL, 2009, GENOME MED, V1, DOI 10.1186/gm12; MOLLER H, 1995, BRIT MED J, V310, P1500, DOI 10.1136/bmj.310.6993.1500; Moore DJ, 2008, J NEUROCHEM, V105, P1806, DOI 10.1111/j.1471-4159.2008.05261.x; MORRELL D, 1986, J NATL CANCER I, V77, P89; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishimura I, 2003, EXP CELL RES, V286, P241, DOI 10.1016/S0014-4827(03)00066-1; Nouspikel T, 2003, BIOESSAYS, V25, P168, DOI 10.1002/bies.10227; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; O'Driscoll M, 2006, CELL CYCLE, V5, P2339, DOI 10.4161/cc.5.20.3358; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Olsen JH, 2005, BRIT J CANCER, V92, P201, DOI 10.1038/sj.bjc.6602279; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1997, J NEUROSCI, V17, P8975; PARKER WD, 1991, ANN NY ACAD SCI, V640, P59; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Prokopcova J, 2007, BREAST CANCER RES TR, V104, P121, DOI 10.1007/s10549-006-9406-6; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Rao KS, 2007, NAT CLIN PRACT NEURO, V3, P162, DOI 10.1038/ncpneuro0448; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Ravikumar Brinda, 2006, Molecular Aspects of Medicine, V27, P520, DOI 10.1016/j.mam.2006.08.008; Ravikumar Brinda, 2008, V445, P195, DOI 10.1007/978-1-59745-157-4_13; Rawal N, 2009, BIOCHEM BIOPH RES CO, V388, P473, DOI 10.1016/j.bbrc.2009.07.014; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Rickle A, 2006, NEUROCHEM INT, V48, P114, DOI 10.1016/j.neuint.2005.08.014; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schmitz A, 2002, HISTOCHEM CELL BIOL, V117, P171, DOI 10.1007/s00418-001-0351-5; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shineman DW, 2009, BIOCHEMISTRY-US, V48, P3787, DOI 10.1021/bi802070j; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Staropoli JF, 2008, BIOESSAYS, V30, P719, DOI 10.1002/bies.20784; Stein TD, 2002, J NEUROSCI, V22, P7380; Stepanek L, 2005, J NEUROSCI, V25, P3813, DOI 10.1523/JNEUROSCI.4531-04.2005; SWIFT M, 1986, AM J HUM GENET, V39, P573; Tabira T, 2002, FRONT BIOSCI-LANDMRK, V7, pA44, DOI 10.2741/tabira; Tanaka K, 2001, J MOL MED, V79, P482, DOI 10.1007/s001090100242; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Toma MI, 2008, NEOPLASIA, V10, P634, DOI 10.1593/neo.08160; Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040; Uetani N, 2000, EMBO J, V19, P2775, DOI 10.1093/emboj/19.12.2775; Uetani N, 2006, J NEUROSCI, V26, P5872, DOI 10.1523/JNEUROSCI.0386-06.2006; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Wang T, 2009, J CELL BIOL, V186, P703, DOI 10.1083/jcb.200904090; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; WONG KK, 2009, CURR OPIN GENET DEV; Xavier AC, 2009, J MOL DIAGN, V11, P371, DOI 10.2353/jmoldx.2009.080132; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang H, 2007, J NEUROIMMUNE PHARM, V2, P276, DOI 10.1007/s11481-007-9082-2; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhu Y, 2006, APOPTOSIS, V11, P197, DOI 10.1007/s10495-006-3714-5; Zighelboim I, 2009, J CLIN ONCOL, V27, P3091, DOI 10.1200/JCO.2008.19.9802	162	75	81	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3453	3464		10.1038/onc.2010.127	http://dx.doi.org/10.1038/onc.2010.127			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418918	Green Accepted			2022-12-28	WOS:000278835400001
J	Kang, J; Qian, PX; Pandey, V; Perry, JK; Miller, LD; Liu, ET; Zhu, T; Liu, DX; Lobie, PE				Kang, J.; Qian, P. X.; Pandey, V.; Perry, J. K.; Miller, L. D.; Liu, E. T.; Zhu, T.; Liu, D. X.; Lobie, P. E.			Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma	ONCOGENE			English	Article						artemin; antiestrogen resistance; mammary carcinoma	TAMOXIFEN-INDUCED APOPTOSIS; BREAST-CANCER CELLS; ER-BETA EXPRESSION; RECEPTOR-BETA; ENDOCRINE THERAPY; STIMULATES ONCOGENICITY; DOWN-REGULATION; MESSENGER-RNA; GROWTH; BCL-2	We have previously identified an oncogenic role of artemin (ARTN), a member of glial cell derived neurotrophic factor family of ligands, in mammary carcinoma. We herein report that ARTN is an estrogen-inducible gene. Meta-analysis of gene expression data sets showed that ARTN expression is positively correlated to estrogen receptor (ER) status in human mammary carcinoma. Furthermore, in patients with ER-positive mammary carcinoma treated with tamoxifen, high ARTN expression is significantly correlated with decreased survival. Forced expression of ARTN in ER-positive human mammary carcinoma cells increased ER transcriptional activity, promoted estrogen-independent growth and produced resistance to tamoxifen and fulvestrant in vitro and to tamoxifen in xenograft models. ARTN-stimulated resistance to tamoxifen and fulvestrant is mediated by increased BCL-2 expression. Conversely, depletion of endogenous ARTN by small-interfering RNA or functional antagonism of ARTN by antibody enhanced the efficacy of antiestrogens. Tamoxifen decreased ARTN expression in tamoxifen-sensitive mammary carcinoma cells whereas ARTN expression was increased in tamoxifen-resistant cells and not affected by tamoxifen treatment. Antibody inhibition of ARTN in tamoxifen-resistant cells improved tamoxifen sensitivity. Functional antagonism of ARTN therefore warrants consideration as an adjuvant therapy to enhance antiestrogen efficacy in ER-positive mammary carcinoma. Oncogene (2010) 29, 3228-3240; doi: 10.1038/onc.2010.71; published online 22 March 2010	[Kang, J.; Pandey, V.; Perry, J. K.; Liu, D. X.; Lobie, P. E.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; [Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Miller, L. D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Liu, E. T.] Genome Inst Singapore, Singapore, Singapore; [Lobie, P. E.] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand	University of Auckland; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Wake Forest University; Wake Forest Baptist Medical Center; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, Private Bag 92019,2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	Pandey, Vijay/P-2767-2016; Liu, Edison/C-4141-2008; Qian, Pengxu/B-9376-2016	Qian, Pengxu/0000-0001-5636-6704; Miller, Lance/0000-0003-3799-2528; Perry, Jo/0000-0002-4418-947X; Kang, Jian/0000-0001-9998-4975	Breast Cancer Research Trust; Foundation for Research, Science and Technology of New Zealand; Chinese Academy of Sciences; National Natural Science Foundation of China [30571030]; National Basic Research Program of China [2007CB914503]	Breast Cancer Research Trust; Foundation for Research, Science and Technology of New Zealand(New Zealand Foundation for Research, Science and Technology); Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	We thank Carol Chelimo (MPH) for the meta-analysis of breast cancer microarray data. This work was funded by the Breast Cancer Research Trust (NZ); the Foundation for Research, Science and Technology of New Zealand; the Hundred-Talent Scheme of Chinese Academy of Sciences, National Natural Science Foundation of China (30571030) and National Basic Research Program of China (2007CB914503).	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carmillo P, 2005, BIOCHEMISTRY-US, V44, P2545, DOI 10.1021/bi049247p; Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614; Clarke M, 1998, LANCET, V351, P1451; Diel P, 1999, BREAST CANCER RES TR, V58, P87, DOI 10.1023/A:1006338123126; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Dowsett M, 2005, BREAST CANCER RES TR, V93, pS11, DOI 10.1007/s10549-005-9037-3; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Johnston SRD, 2005, BREAST CANCER RES, V7, P119, DOI 10.1186/bcr1023; Kampa M, 2008, STEROIDS, V73, P953, DOI 10.1016/j.steroids.2007.12.009; Kang J, 2009, ONCOGENE, V28, P2034, DOI 10.1038/onc.2009.66; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Kim R, 2005, CANCER-AM CANCER SOC, V103, P2199, DOI 10.1002/cncr.21029; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levin ER, 2008, BREAST CANCER RES TR, V108, P351, DOI 10.1007/s10549-007-9618-4; Liu DX, 2007, CELL DEATH DIFFER, V14, P1893, DOI 10.1038/sj.cdd.4402209; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Murphy LC, 2006, ENDOCR-RELAT CANCER, V13, P327, DOI 10.1677/erc.1.01141; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nicholson RI, 2007, REV ENDOCR METAB DIS, V8, P241, DOI 10.1007/s11154-007-9033-5; Nicholson RI, 2005, ENDOCR-RELAT CANCER, V12, pS29, DOI 10.1677/erc.1.00991; O'Neill PA, 2004, BRIT J CANCER, V91, P1694, DOI 10.1038/sj.bjc.6602183; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pandey V, 2008, ENDOCRINOLOGY, V149, P3909, DOI 10.1210/en.2008-0286; Pandey V, 2010, ENDOCRINOLOGY, V151, P909, DOI 10.1210/en.2009-0979; Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; Riggins RB, 2005, MOL CANCER THER, V4, P33; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088; Rotolo S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002528; SARKARIA JN, 1993, CANCER RES, V53, P4413; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005; Siddiqa A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-129; Speirs V, 1999, CANCER RES, V59, P5421; Tangkeangsirisin W, 2004, CANCER RES, V64, P1737, DOI 10.1158/0008-5472.CAN-03-2364; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317	63	35	38	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3228	3240		10.1038/onc.2010.71	http://dx.doi.org/10.1038/onc.2010.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305694				2022-12-28	WOS:000278321100006
J	Kim, KW; Moretti, L; Mitchell, LR; Jung, DK; Lu, B				Kim, K. W.; Moretti, L.; Mitchell, L. R.; Jung, D. K.; Lu, B.			Endoplasmic reticulum stress mediates radiation-induced autophagy by perk-eIF2 alpha in caspase-3/7-deficient cells	ONCOGENE			English	Article						autophagy; cancer; ER stress; PERK; radiation	INDUCED APOPTOSIS; MAMMALIAN TARGET; DOWN-REGULATION; CASPASE-3; CANCER; DEATH; INHIBITION; TRANSLATION; RAPAMYCIN; CHAPERONE	As apoptosis defects limit efficacy of anticancer agents, autophagy has been proposed as a novel strategy for radiotherapy enhancement. We previously showed that caspase-3/7 inhibition induces autophagy and promotes radiosensitivity in vitro and in vivo. Therefore, we further investigated the mechanism by which radiation triggers autophagy in caspase-3/7-deficient cells, and found the involvement of endoplasmic reticulum (ER) stress. The ER activates a survival pathway, the unfolded protein response, which involves ER-localized transmembrane proteins such as protein kinase-like ER kinase (PERK), inositol-requiring enzyme-1 and activating transcription factor-6. In this study, we found that PERK is essential for radiation-induced autophagy and radiosensitivity in caspase-3/7 double-knockout cells. Irradiation of these cells increased expression of phosphorylated-eIF2 alpha. Similar results were seen after administration of tunicamycin (TM), a well-known ER stressor. Importantly, we found that the administration of TM with radiation in MCF-7 breast cancer cells, which are lacking functional caspase-3 and relatively resistant to many anticancer agents, enhances radiation sensitivity. Our findings reveal ER stress as a novel potential mechanism of radiation-induced autophagy in caspase-3/7-deficient cells and as a potential strategy to maximize efficiency of radiation therapy in breast cancer. Oncogene (2010) 29, 3241-3251; doi: 10.1038/onc.2010.74; published online 29 March 2010	[Lu, B.] Vanderbilt Univ, Dept Radiat Oncol, Vanderbilt Clin B 902, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Dept Radiat Oncol, Vanderbilt Clin B 902, Vanderbilt Ingram Canc Ctr, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI [1R01 CA125842-01A1]; DOD [BC030542]; NATIONAL CANCER INSTITUTE [R01CA125842] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NCI 1R01 CA125842-01A1 and DOD BC030542.	Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Delom F, 2007, CELL DEATH DIFFER, V14, P586, DOI 10.1038/sj.cdd.4402012; Delom F, 2007, APOPTOSIS, V12, P293, DOI 10.1007/s10495-006-0625-4; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Gelebart P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI 10.1016/j.biocel.2004.02.030; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hitomi J, 2004, NEUROSCI LETT, V357, P127, DOI 10.1016/j.neulet.2003.12.080; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kim I, 2009, J BIOL CHEM, V284, P1593, DOI 10.1074/jbc.M807308200; Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058; Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200; Kim KW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002275; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Paglin S, 2001, CANCER RES, V61, P439; Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200	39	95	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3241	3251		10.1038/onc.2010.74	http://dx.doi.org/10.1038/onc.2010.74			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20348950	Green Accepted			2022-12-28	WOS:000278321100007
J	Xu, Y; Chen, Q; Li, W; Su, X; Chen, T; Liu, Y; Zhao, Y; Yu, C				Xu, Y.; Chen, Q.; Li, W.; Su, X.; Chen, T.; Liu, Y.; Zhao, Y.; Yu, C.			Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness	ONCOGENE			English	Article						amplified in breast cancer 1; hepatocellular carcinoma; cell proliferation; cell invasion	STEROID-RECEPTOR COACTIVATOR-3; BREAST-CANCER CELLS; SIGNALING PATHWAY; GROWTH; SRC-3; EXPRESSION; MICE; GENE; ACTIVATION; AMPLIFICATION	Amplified in breast cancer 1 (AIB1) is a transcriptional coactivator for nuclear receptors and other transcription factors. AIB1 has an important role in malignancy of several cancers such as breast and prostate cancers. However, its involvement in human hepatocellular carcinoma (HCC) progression remains unclear. Here, we found that AIB1 protein was overexpressed in 23 of 34 human HCC specimens (68%). Down-regulation of AIB1 reduced HCC cell proliferation, migration, invasion, colony formation ability and tumorigenic potential in nude mice. These phenotypic changes caused by AIB1 knockdown correlated with increased expression of the cell cycle inhibitor p21(Cip1/Waf1) and decreased Akt activation and the expression of proliferating cell nuclear antigen (PCNA) and matrix metallopeptidase MMP-9. In agreement with these findings, clinical AIB1-positive HCC expressed higher levels of PCNA than AIB1-negative HCC. A positive correlation was established between the levels of AIB1 protein and PCNA protein in HCC, suggesting that AIB1 may contribute to HCC cell proliferation. In addition, MMP-9 expression in AIB1-postive HCC was significantly higher than that in AIB1-negative HCC, suggesting that AIB1-postive HCC may be more invasive. Collectively, our results show that overexpression of AIB1 promotes human HCC progression by enhancing cell proliferation and invasiveness. Therefore, AIB1 is a master regulator of human HCC growth and might be a useful molecular target for HCC prognosis and treatment. Oncogene (2010) 29, 3386-3397; doi:10.1038/onc.2010.90; published online 22 March 2010	[Xu, Y.; Su, X.; Chen, T.; Liu, Y.; Zhao, Y.; Yu, C.] Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Fujian, Peoples R China; [Chen, Q.; Li, W.; Su, X.] Xiamen Univ, Affiliated Hosp 1, Xiamen 361005, Fujian, Peoples R China	Xiamen University; Xiamen University	Yu, C (corresponding author), Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Fujian, Peoples R China.	cdyu@xmu.edu.cn	xu, yixiang/J-4297-2017	xu, yixiang/0000-0001-5793-7783	National Basic Research Program of China [2008CB517311, 2009CB522200]; National Natural Science Foundation of China [30600566, 30770455]; 111 Project [06016]; Science Planning Program of Fujian Province [2009J1010]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 Project(Ministry of Education, China - 111 Project); Science Planning Program of Fujian Province	We thank Dr Li Qin for the MMP-9-promoter/reporter plasmid and Dr Jianming Xu for critical reading of the article. This work was supported by Grants from National Basic Research Program of China (973 Program, 2008CB517311 and 2009CB522200), National Natural Science Foundation of China (30600566 and 30770455), 111 Project (06016), and the Science Planning Program of Fujian Province (2009J1010).	Adams BD, 2009, MOL ENDOCRINOL, V23, P1215, DOI 10.1210/me.2009-0062; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arii S, 1996, HEPATOLOGY, V24, P316; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chung ACK, 2007, CANCER RES, V67, P5965, DOI 10.1158/0008-5472.CAN-06-3168; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; KITAMOTO M, 1993, CANCER, V72, P1859, DOI 10.1002/1097-0142(19930915)72:6<1859::AID-CNCR2820720612>3.0.CO;2-A; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liang JA, 2009, MOL PHARMACOL, V75, P151, DOI 10.1124/mol.108.049502; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Ma CL, 2008, GASTROENTEROLOGY, V135, P947, DOI 10.1053/j.gastro.2008.05.046; Mussi P, 2006, MOL ENDOCRINOL, V20, P3105, DOI 10.1210/me.2005-0522; Nakanishi K, 2005, CANCER-AM CANCER SOC, V103, P307, DOI 10.1002/cncr.20774; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Sakakura C, 2000, INT J CANCER, V89, P217; SATO H, 1993, ONCOGENE, V8, P395; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yu CD, 2003, AM J PATHOL, V163, P1653, DOI 10.1016/S0002-9440(10)63522-5; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	44	45	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3386	3397		10.1038/onc.2010.90	http://dx.doi.org/10.1038/onc.2010.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20305690				2022-12-28	WOS:000278622700007
J	Aktary, Z; Chapman, K; Lam, L; Lo, A; Ji, C; Graham, K; Cook, L; Li, L; Mackey, JR; Pasdar, M				Aktary, Z.; Chapman, K.; Lam, L.; Lo, A.; Ji, C.; Graham, K.; Cook, L.; Li, L.; Mackey, J. R.; Pasdar, M.			Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1	ONCOGENE			English	Article						plakoglobin; tumor suppressor; Nm23; cadherin; alpha-catenin	GAMMA-CATENIN EXPRESSION; SQUAMOUS CARCINOMA-CELLS; KIDNEY EPITHELIAL-CELLS; BETA-CATENIN; E-CADHERIN; ALPHA-CATENIN; C-MYC; SUBCELLULAR-LOCALIZATION; DESMOPLAKIN ORGANIZATION; SPATIAL REGULATION	Plakoglobin (gamma-catenin) is a homolog of beta-catenin with similar dual adhesive and signaling functions. The adhesive function of these proteins is mediated by their interactions with cadherins, whereas their signaling activity is regulated by association with various intracellular partners. In this respect, beta-catenin has a well-defined oncogenic activity through its role in the Wnt signaling pathway, whereas plakoglobin acts as a tumor/metastasis suppressor through mechanisms that remain unclear. We previously expressed plakoglobin in SCC9 squamous carcinoma cells (SCC9-P) and observed a mesenchymal-to-epidermoid transition. Comparison of the protein and RNA profiles of parental SCC9 cells and SCC9-P transfectants identified various differentially expressed proteins and transcripts, including the nonmetastatic protein 23 (Nm23). In this study, we show that Nm23-H1 mRNA and Nm23-H2 protein are increased after plakoglobin expression. Coimmunoprecipitation and confocal microscopy studies using SCC9-P and various epithelial cell lines with endogenous plakoglobin expression revealed that Nm23 interacts with plakoglobin, cadherins and alpha-catenin. Furthermore, Nm23-H2 is the primary isoform involved in these interactions, which occur prominently in the cytoskeleton-associated pool of cellular proteins. In addition, we show that plakoglobin-Nm23 interaction requires the N-terminal (alpha-catenin interacting) domain of plakoglobin. Our data suggest that by increasing the expression and stability of Nm23, plakoglobin has a role in regulating the metastasis suppressor activity of Nm23, which may further provide a potential mechanism for the tumor/metastasis suppressor function of plakoglobin itself. Oncogene (2010) 29, 2118-2129; doi: 10.1038/onc.2009.495; published online 25 January 2010	[Aktary, Z.; Chapman, K.; Lam, L.; Pasdar, M.] Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; [Lo, A.; Ji, C.; Li, L.] Univ Alberta, Dept Chem, Edmonton, AB T6G 2H7, Canada; [Graham, K.; Cook, L.; Mackey, J. R.] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta	Pasdar, M (corresponding author), Univ Alberta, Dept Cell Biol, 6-24 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	mpasdar@ualberta.ca	Li, Liang/D-1822-2011	Aktary, Zackie/0000-0002-7238-3245	Alberta Cancer Research Institute; Canadian Breast Cancer Foundation-Prairies/NWT Chapter; Canadian Institutes of Health Research Frederick Banting; Charles Best Canada Graduate Scholarships; Canadian Research Chairs Program; Alberta Cancer Foundation; Killam Doctoral Award	Alberta Cancer Research Institute; Canadian Breast Cancer Foundation-Prairies/NWT Chapter; Canadian Institutes of Health Research Frederick Banting(Canadian Institutes of Health Research (CIHR)); Charles Best Canada Graduate Scholarships; Canadian Research Chairs Program(Canada Research Chairs); Alberta Cancer Foundation; Killam Doctoral Award	This work is supported by the Alberta Cancer Research Institute and the Canadian Breast Cancer Foundation-Prairies/NWT Chapter (MP) and Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarships award (ZA). LL is supported by the Canadian Research Chairs Program. JM is supported by the Alberta Cancer Research Institute and Alberta Cancer Foundation. ZA currently holds a Killam Doctoral Award.	Arnaud-Dabernat S, 2004, EXP CELL RES, V301, P293, DOI 10.1016/j.yexcr.2004.07.026; Ayabe Takanori, 2004, Ann Thorac Cardiovasc Surg, V10, P152; Bago R, 2009, MOL CARCINOGEN, V48, P779, DOI 10.1002/mc.20536; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Benjamin JM, 2008, SEMIN CANCER BIOL, V18, P53, DOI 10.1016/j.semcancer.2007.08.003; Bosnar MH, 2009, MOL CELL BIOCHEM, V329, P63, DOI 10.1007/s11010-009-0107-4; Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018; Che G, 2006, NEOPLASMA, V53, P530; Chen XF, 2005, LUNG CANCER, V48, P69, DOI 10.1016/j.lungcan.2004.09.009; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Garrod D, 2008, BIOCHEM SOC T, V36, P195, DOI 10.1042/BST0360195; Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Green KJ, 2007, J INVEST DERMATOL, V127, P2499, DOI 10.1038/sj.jid.5701015; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holthofer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Huber O, 2008, CELL CYCLE, V7, P1326, DOI 10.4161/cc.7.10.5926; IGAWA M, 1994, CANCER RES, V54, P1313; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Ji CJ, 2005, J PROTEOME RES, V4, P1419, DOI 10.1021/pr050094h; Jin L, 2009, LIFE SCI, V84, P458, DOI 10.1016/j.lfs.2009.01.010; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Jung S, 2006, ANTICANCER RES, V26, P249; Kanazawa Y, 2008, ANTICANCER RES, V28, P655; Khan MH, 2001, AM J PATHOL, V158, P1785, DOI 10.1016/S0002-9440(10)64134-X; Kim HD, 2009, MOL CELL BIOCHEM, V329, P167, DOI 10.1007/s11010-009-0109-2; Kolligs FT, 2000, GENE DEV, V14, P1319; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lam L, 2009, BREAST CANCER RES TR, V118, P605, DOI 10.1007/s10549-008-0231-y; Lee HY, 1999, CANCER LETT, V145, P93, DOI 10.1016/S0304-3835(99)00236-0; Lee MY, 2009, CANCER LETT, V275, P221, DOI 10.1016/j.canlet.2008.10.018; Li LJ, 2007, MOL CARCINOGEN, V46, P824, DOI 10.1002/mc.20310; Li Z, 1998, J CELL SCI, V111, P1005; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; McDermott WG, 2008, CLIN EXP METASTAS, V25, P131, DOI 10.1007/s10585-007-9128-0; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; MORTON RA, 1993, CANCER RES, V53, P3585; Nakanishi K, 2006, ARCH PATHOL LAB MED, V130, P1330; Narkio-Makela M, 2009, ARCH OTOLARYNGOL, V135, P1035, DOI 10.1001/archoto.2009.132; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Parker HR, 1998, CELL MOTIL CYTOSKEL, V40, P87, DOI 10.1002/(SICI)1097-0169(1998)40:1<87::AID-CM8>3.0.CO;2-C; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Rieger-Christ KM, 2005, BRIT J CANCER, V92, P2153, DOI 10.1038/sj.bjc.6602651; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Schuldiner O, 2002, GENE, V292, P91, DOI 10.1016/S0378-1119(02)00668-6; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Steeg PS, 2008, CLIN CANCER RES, V14, P5006, DOI 10.1158/1078-0432.CCR-08-0238; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; STEEG PS, 1988, CANCER RES, V48, P6550; Stemmler MP, 2008, MOL BIOSYST, V4, P835, DOI 10.1039/b719215k; Suzuki E, 2004, INT J CANCER, V108, P207, DOI 10.1002/ijc.11546; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tee Yi-Torng, 2006, Taiwan J Obstet Gynecol, V45, P107; Torlakovic E, 2002, HUM PATHOL, V33, P646, DOI 10.1053/hupa.2002.124033; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	74	44	45	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2118	2129		10.1038/onc.2009.495	http://dx.doi.org/10.1038/onc.2009.495			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101217				2022-12-28	WOS:000276402800010
J	Park, HD; Lee, Y; Oh, YK; Jung, JG; Park, YW; Myung, K; Kim, KH; Koh, SS; Lim, DS				Park, H. D.; Lee, Y.; Oh, Y. K.; Jung, J. G.; Park, Y. W.; Myung, K.; Kim, K-H; Koh, S. S.; Lim, D-S			Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation	ONCOGENE			English	Article						PAUF; TLR; CXCR4; TPL2; ERK; NF-kappa B	TOLL-LIKE RECEPTORS; TUMOR-GROWTH; CARBOHYDRATE SPECIFICITIES; STRUCTURAL BASIS; BINDING LECTINS; CANCER-CELLS; ANGIOGENESIS; LIPOPOLYSACCHARIDE; INFLAMMATION; PROGRESSION	Pancreatic adenocarcinoma upregulated factor (PAUF) is overproduced in certain types of cancer. However, little is known of the tumorigenic function of PAUF. In this study, we report the X-ray crystal structure of PAUF and reveal that PAUF is a mammalian lectin normally found in plant lectins. We also identify PAUF as an endogenous ligand of Toll-like receptor 2 (TLR2) and TLR4 by screening extracellular domain receptor pools. We further confirmed the specificity of the PAUF-TLR2 interaction. PAUF induces extracellular signal-regulated kinase (ERK) phosphorylation and activates the IKK-beta-mediated TPL2/MEK/ERK signaling pathway through TLR2. In agreement with the result of TLR2-mediated ERK activation by PAUF, PAUF induces increased expression of the protumorigenic cytokines RANTES and MIF in THP-1 cells. However, PAUF does not fully activate I kappa-B-alpha signaling pathways in THP-1 cells, and fails to translocate the p65 subunit of the nuclear factor-kappa B (NF-kappa B) complex into the nucleus, resulting in no NF-kappa B activation. Surprisingly, we found that PAUF also associated with the CXC chemokine receptor (CXCR4)-TLR2 complex and inhibited CXCR4-dependent, TLR2-mediated NF-kappa B activation. Together, these findings suggest that the new cancer-associated ligand, PAUF, may activate TLR-mediated ERK signaling to produce the protumorigenic cytokines, but inhibits TLR-mediated NF-kappa B signaling, thereby facilitating tumor growth and escape from innate immune surveillance. Oncogene (2011) 30, 201-211; doi:10.1038/onc.2010.401; published online 30 August 2010	[Lee, Y.; Jung, J. G.; Park, Y. W.; Kim, K-H; Koh, S. S.] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon, South Korea; [Park, H. D.; Lee, Y.; Lim, D-S] Natl Creat Res Initiat Ctr Cell Div & Differentia, Dept Biol Sci, Taejon, South Korea; [Park, H. D.; Oh, Y. K.] LG Life Sci, Dept Pharmacol, Taejon, South Korea; [Myung, K.] NHGRI, NIH, Bethesda, MD 20892 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); LG Life Sciences Ltd; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Koh, SS (corresponding author), Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon, South Korea.	sskoh@kribb.re.kr; daesiklim@kaist.ac.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555	National Creative Research Initiative Center; World Class University (WCU); Ministry of Education, Science and Technology in Korea; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG012003] Funding Source: NIH RePORTER	National Creative Research Initiative Center; World Class University (WCU); Ministry of Education, Science and Technology in Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by grants from the National Creative Research Initiative Center Program, World Class University (WCU) program and the 21st Century Frontier Functional Human Genome Project of the Ministry of Education, Science and Technology in Korea. We thank Sang Yong Hong for technical support with the cloning work. We thank the staff of Beamline 4A at the Pohang Accelerator Laboratory, Korea, for assistance in data collection and Dr Hyun Kyu Song of Korea University for help with MAD data analysis.	Adachi H, 2003, ACTA CRYSTALLOGR D, V59, P194, DOI 10.1107/S0907444902019741; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Azenshtein E, 2002, CANCER RES, V62, P1093; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hajishengallis G, 2008, P NATL ACAD SCI USA, V105, P13532, DOI 10.1073/pnas.0803852105; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jeyaprakash AA, 2004, J MOL BIOL, V338, P757, DOI 10.1016/j.jmb.2004.03.040; Jeyaprakash AA, 2003, J MOL BIOL, V332, P217, DOI 10.1016/S0022-2836(03)00901-X; Jouault T, 2006, J IMMUNOL, V177, P4679, DOI 10.4049/jimmunol.177.7.4679; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x; Lee Y, 2010, ONCOGENE, V29, P56, DOI 10.1038/onc.2009.298; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Li Y, 2008, J IMMUNOL, V181, P2781, DOI 10.4049/jimmunol.181.4.2781; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Miettinen M, 2008, J LEUKOCYTE BIOL, V84, P1092, DOI 10.1189/jlb.1206737; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; SHIMIZU T, 1994, EMBO J, V13, P1003, DOI 10.1002/j.1460-2075.1994.tb06348.x; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Triantafilou M, 2008, EUR J IMMUNOL, V38, P192, DOI 10.1002/eji.200636821	34	72	77	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	2					201	211		10.1038/onc.2010.401	http://dx.doi.org/10.1038/onc.2010.401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20802527	Green Accepted			2022-12-28	WOS:000286438900008
J	Madison, DL; Lundblad, JR				Madison, D. L.; Lundblad, J. R.			C-terminal binding protein and poly(ADP)ribose polymerase 1 contribute to repression of the p21(waf1/cip1) promoter	ONCOGENE			English	Article						Poly(ADP)ribose Polymerase; p21; CtBP; PARP inhibitor	ADENOVIRUS E1A; POLY(ADP-RIBOSE) POLYMERASE-1; CELLULAR PHOSPHOPROTEIN; COREPRESSOR FUNCTION; NEGATIVE MODULATION; CANCER-CELLS; TRANSCRIPTION; PARP-1; CTBP; ACTIVATION	Transcriptional repression by the C-terminal binding protein (CtBP) is proposed to require nicotinamide adenine dinucleotide dehydrogenase (NAD(H). Previous studies have implicated CtBP in transcriptional repression of the p21(waf1/cip1) gene. Similarly, the NAD-dependent poly(adenosine diphosphate) ribose polymerase 1 (PARP1) may affect p21 expression via its NAD-dependent enzymatic activity; we therefore asked if PARP1 and CtBP were functionally linked in regulating p21 transcription. We found that restraint of basal p21 transcription requires both CtBP and PARP1. PARP inhibition attenuated activation of p21 transcription by both p53-independent and p53-dependent processes, in a CtBP-dependent manner. CtBP1 + 2 or PARP1 + 2 knockdown partially activated p21 gene expression, suggesting relief of a corepressor function dependent on both proteins. We localized CtBP-responsive repression elements to the proximal promoter region, and found ZBRK1 overexpression could also overcome DNA damage-dependent, but not p53-dependent activation through this region. By chromatin immunoprecipitation we find dismissal of CtBP from the proximal promoter following DNA-damage, and that PARP1 associates with a CtBP corepressor complex in nuclear extracts. We propose a model in which both CtBP and PARP functionally interact in a corepressor complex as components of a molecular switch necessary for p21 repression, and following DNA damage signals activation of p21 transcription by corepressor dismissal and coactivator recruitment. Oncogene (2010) 29, 6027-6039; doi:10.1038/onc.2010.338; published online 16 August 2010	[Madison, D. L.; Lundblad, J. R.] Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, Portland, OR 97239 USA; [Madison, D. L.] Portland VA Med Ctr, Endocrine Sect, Dept Hosp & Specialty Med, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Madison, DL (corresponding author), Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, L-604,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	Madisond@ohsu.edu			 [NIDDK R01DK060133];  [NCI K08CA109158]; NATIONAL CANCER INSTITUTE [K08CA109158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060133] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work as supported by Grants (NIDDK R01DK060133) to JRL and DLM (NCI K08CA109158). We thank J Hildebrand (University of Pittsburgh) for the CtBP MEFs, R Klein (OHSU) for access to and assistance with real time PCR, R Kwok (University of Michigan) for the p53 expression construct and Madeleine Pham and Loren Brown for technical assistance.	Altmeyer M, 2009, NUCLEIC ACIDS RES, V37, P3723, DOI 10.1093/nar/gkp229; Ambrose HE, 2007, ONCOGENE, V26, P6244, DOI 10.1038/sj.onc.1210434; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Balasubramanian P, 2003, FEBS LETT, V537, P157, DOI 10.1016/S0014-5793(03)00119-4; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kolthur-Seetharam U, 2006, CELL CYCLE, V5, P873, DOI 10.4161/cc.5.8.2690; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200; Li M, 2004, BIOCHEM J, V382, P323, DOI 10.1042/BJ20040593; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; MOYED HS, 1983, J BACTERIOL, V155, P557, DOI 10.1128/JB.155.2.557-564.1983; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Ogino H, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-41; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Takasawa R, 2005, APOPTOSIS, V10, P1121, DOI 10.1007/s10495-005-0901-8; Tan W, 2004, J BIOL CHEM, V279, P6576, DOI 10.1074/jbc.M312270200; Tao ZH, 2009, J AM CHEM SOC, V131, P14258, DOI 10.1021/ja906135d; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang QH, 2002, SCIENCE, V295, P1895; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	52	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6027	6039		10.1038/onc.2010.338	http://dx.doi.org/10.1038/onc.2010.338			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20711239	Green Accepted			2022-12-28	WOS:000284108700005
J	Le, PU; Angers-Loustau, A; de Oliveira, RMW; Ajlan, A; Brassard, CL; Dudley, A; Brent, H; Siu, V; Trinh, G; Molenkamp, G; Wang, J; Sadr, MS; Bedell, B; Del Maestro, RF; Petrecca, K				Le, P. U.; Angers-Loustau, A.; de Oliveira, R. M. W.; Ajlan, A.; Brassard, C. L.; Dudley, A.; Brent, H.; Siu, V.; Trinh, G.; Moelenkamp, G.; Wang, J.; Sadr, M. Seyed; Bedell, B.; Del Maestro, R. F.; Petrecca, K.			DRR drives brain cancer invasion by regulating cytoskeletal-focal adhesion dynamics	ONCOGENE			English	Article						brain cancer; cytoskeleton; cell invasion	CELL INVASION; MYOSIN-II; MIGRATION; MORPHOGENESIS; MICROTUBULES; SRC	Malignant glioma invasion is a primary cause of brain cancer treatment failure, yet the molecular mechanisms underlying its regulation remain elusive. We developed a novel functional-screening strategy and identified downregulated in renal cell carcinoma (DRR) as a regulator of invasion. We show that DRR drives invasion in vitro and in vivo. We found that while DRR is not expressed in normal glial cells, it is highly expressed in the invasive component of gliomas. Exploring underlying mechanisms, we show that DRR associates with and organizes the actin and microtubular cytoskeletons and that these associations are essential for focal adhesion (FA) disassembly and cell invasion. These findings identify DRR as a new cytoskeletal crosslinker that regulates FA dynamics and cell movement. Oncogene (2010) 29, 4636-4647; doi:10.1038/onc.2010.216; published online 14 June 2010	[Le, P. U.; Angers-Loustau, A.; de Oliveira, R. M. W.; Ajlan, A.; Brassard, C. L.; Dudley, A.; Brent, H.; Siu, V.; Trinh, G.; Moelenkamp, G.; Wang, J.; Sadr, M. Seyed; Bedell, B.; Del Maestro, R. F.; Petrecca, K.] McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst & Hosp, Montreal, PQ H3A 2B4, Canada	McGill University	Petrecca, K (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst & Hosp, 3801 Univ Ave,Suite 109C, Montreal, PQ H3A 2B4, Canada.	kevin.petrecca@mcgill.ca		Angers-Loustau, Alexandre/0000-0003-1425-4143	Goals for Lily; Alex Pavanel Family; Franco Di Giovanni Funds for Brain Tumor Research; Montreal English School Board; B-Strong Foundation; Montreal Neurological Institute; Canadian Institute of Health Research; National Cancer Institute of Canada	Goals for Lily; Alex Pavanel Family; Franco Di Giovanni Funds for Brain Tumor Research; Montreal English School Board; B-Strong Foundation; Montreal Neurological Institute; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS))	We are grateful to Carmen Sabau for her technical expertise. This work was supported by Goals for Lily, the Alex Pavanel Family, the Franco Di Giovanni Funds for Brain Tumor Research, the Montreal English School Board, the B-Strong Foundation to RFDM, and the Montreal Neurological Institute to KP. RMWO was supported by the Canadian Institute of Health Research doctoral fellowship. AAL was supported by the National Cancer Institute of Canada Terry Fox sStudentship.	Beadle C, 2008, MOL BIOL CELL, V19, P3357, DOI 10.1091/mbc.E08-03-0319; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Fernandez C, 2003, NEUROSURGERY, V53, P544, DOI 10.1227/01.NEU.0000079330.01541.6E; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kleihues P, 2000, PATHOLOGY GENETICS T; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; LAUUFFENBURGER DA, 1996, CELL, V84, P359; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; PEDERSEN PH, 1995, INT J CANCER, V62, P767, DOI 10.1002/ijc.2910620620; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Salhia B, 2006, EXPERT REV MOL DIAGN, V6, P613, DOI 10.1586/14737159.6.4.613; van den Boom J, 2006, INT J CANCER, V119, P2330, DOI 10.1002/ijc.22108; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wang LM, 2008, PLOS BIOL, V6, P2496, DOI 10.1371/journal.pbio.0060289; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	29	24	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4636	4647		10.1038/onc.2010.216	http://dx.doi.org/10.1038/onc.2010.216			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543869				2022-12-28	WOS:000281127400003
J	Al-Souhibani, N; Al-Ahmadi, W; Hesketh, JE; Blackshear, PJ; Khabar, KSA				Al-Souhibani, N.; Al-Ahmadi, W.; Hesketh, J. E.; Blackshear, P. J.; Khabar, K. S. A.			The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes	ONCOGENE			English	Article						posttranscriptional control; AU-rich elements; RNA-binding proteins; RNA stability; tristetraprolin	UROKINASE PLASMINOGEN-ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; POSTTRANSCRIPTIONAL REGULATION; PROGNOSTIC-FACTOR; GENE-EXPRESSION; HUR; RECEPTOR; ELEMENTS; CELL; CYCLOOXYGENASE-2	Tristetraprolin (TTP or ZFP36) is a tandem CCCH zinc-finger RNA-binding protein that regulates the stability of certain AU-rich element (ARE) mRNAs. Recent work suggests that TTP is deficient in cancer cells when compared with normal cell types. In this study we found that TTP expression was lower in invasive breast cancer cells (MDAMB231) compared with normal breast cell lines MCF12A and MCF-10. TTP targets were probed using a novel approach by expressing the C124R zinc-finger TTP mutant that functions as dominant negative and increases target mRNA expression. In contrast to wild-type TTP, C124R TTP was able to increase certain ARE-mRNA expressions in serum-stimulated breast cancer cells. Using an ARE-gene microarray, novel targets of TTP regulation were identified, namely, urokinase plasminogen activator (uPA), uPA receptor and matrix metalloproteinase-1, all known to have prominent roles in breast cancer invasion and metastasis. Expression of these targets was upregulated in tumorigenic types, particularly in highly invasive MDAMB231. The mRNA half-lives of these TTP-regulated genes were increased in TTP-knockout embryonic mouse fibroblasts, as assessed using real-time polymerase chain reaction, whereas forced restoration of TTP by transfection led to a reduction in their mRNA levels. RNA immunoprecipitation confirmed an association of TTP, but not C124R, with these target transcripts. Moreover, TTP reduced, whereas the mutant C124R TTP increased, the activity of reporter constructs fused to target ARE. As a result of TTP regulation, invasiveness of MDAMB231 cells was reduced. The data suggest that TTP, in a 30 untranslated region- and ARE-dependent manner, regulates an important subset of cancer-related genes that are involved in cellular growth, invasion and metastasis. Oncogene ( 2010) 29, 4205-4215; doi: 10.1038/onc.2010.168; published online 24 May 2010	[Al-Souhibani, N.; Al-Ahmadi, W.; Khabar, K. S. A.] King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, Riyadh 11211, Saudi Arabia; [Hesketh, J. E.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Blackshear, P. J.] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC USA	King Faisal Specialist Hospital & Research Center; Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Khabar, KSA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, P3354, Riyadh 11211, Saudi Arabia.	khabar@kfshrc.edu.sa	Blackshear, Perry J./C-6206-2019; Khabar, Khalid/AAG-3487-2019	Blackshear, Perry J./0000-0002-9561-8529; Khabar, Khalid/0000-0003-1003-9788	King Khalid Foundation, Riyadh; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080] Funding Source: NIH RePORTER	King Khalid Foundation, Riyadh; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study is a part of the Newcastle University doctoral thesis requirements of NA-S. NA-S was supported by a PhD scholarship from King Khalid Foundation, Riyadh. We acknowledge Dr Wi S Lai for TTP plasmids and for the knockout MEF line. We also acknowledge Mr Maher Al-Saif for his technical assistance.	Al-Ahmadi W, 2009, ONCOGENE, V28, P1782, DOI 10.1038/onc.2009.16; Al-Ahmadi W, 2009, NUCLEIC ACIDS RES, V37, P3612, DOI 10.1093/nar/gkp223; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Asyali MH, 2004, NUCLEIC ACIDS RES, V32, P2323, DOI 10.1093/nar/gkh544; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Christensen L, 1996, INT J CANCER, V66, P441; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; Fisher JL, 2000, BREAST CANCER RES TR, V61, P1, DOI 10.1023/A:1006445129195; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Heinonen M, 2007, CLIN CANCER RES, V13, P6959, DOI 10.1158/1078-0432.CCR-07-1432; Iwata H, 1996, JPN J CANCER RES, V87, P602, DOI 10.1111/j.1349-7006.1996.tb00266.x; Khabar KSA, 2004, J MOL BIOL, V342, P833, DOI 10.1016/j.jmb.2004.07.065; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lai WS, 2002, J BIOL CHEM, V277, P9606, DOI 10.1074/jbc.M110395200; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Nanbu R, 1997, EUR J BIOCHEM, V247, P169, DOI 10.1111/j.1432-1033.1997.00169.x; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; QUAX PHA, 1990, CANCER RES, V50, P1488; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stoecklin G, 2008, J BIOL CHEM, V283, P11689, DOI 10.1074/jbc.M709657200; Suswam E, 2008, CANCER RES, V68, P674, DOI 10.1158/0008-5472.CAN-07-2751; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Vlasova IA, 2008, MOL CELL, V29, P263, DOI 10.1016/j.molcel.2007.11.024; Wang GJ, 1998, P NATL ACAD SCI USA, V95, P6296, DOI 10.1073/pnas.95.11.6296; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010	45	85	87	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4205	4215		10.1038/onc.2010.168	http://dx.doi.org/10.1038/onc.2010.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498646	Green Accepted			2022-12-28	WOS:000280151500008
J	Fritz, RD; Varga, Z; Radziwill, G				Fritz, R. D.; Varga, Z.; Radziwill, G.			CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis	ONCOGENE			English	Article						CNK1; Akt; FoxO; proliferation; oncogenic signalling; breast cancer	RICTOR-MTOR COMPLEX; PROTEIN-KINASE B; NF-KAPPA-B; SCAFFOLD PROTEIN; RAF ACTIVATION; CANCER; DOWNSTREAM; DROSOPHILA; PATHWAY; TARGET	The scaffold proteins connector enhancer of KSR (CNK) participate in Raf-, Rho-and NF-kappa B-dependent signalling and promote cell differentiation and invasion. In this study, we demonstrate that CNK1 downregulation inhibits, whereas CNK1 overexpression stimulates the proliferation of breast cancer cells and human embryonic kidney cells, respectively. This stimulatory effect depends on a functional phosphatidylinositol-3 kinase (PI3K) pathway because treatment of cells with the PI3K inhibitor, LY294002, abrogates CNK1-induced proliferation. CNK1 interacts with the PI3K effector Akt and knockdown of CNK1 decreases Akt activity in breast cancer cells. CNK1 controls Akt-dependent phosphorylation and transcriptional activity of FoxO, which is a negative regulator of proliferation. Consistent with this, CNK1-induced cell proliferation is blocked by FoxO overexpression. Moreover, CNK1 regulates anchorage-independent proliferation and focus formation of breast cancer cells. CNK1 is predominantly localized at the plasma membrane of breast cancer cells, whereas in non-transformed mammary epithelial cells, CNK1 is cytoplasmatic. Accordingly, CNK1 is found preferentially at the plasma membrane in carcinoma in situ and invasive breast cancer tumours compared with normal breast tissue sections. Analysis of multiple breast cancer samples reveals that CNK1-negative tumours show less Akt activity. Thus, CNK1 promotes oncogenic signalling through Akt in breast cancer cell lines and tumours. Oncogene (2010) 29, 3575-3582; doi:10.1038/onc.2010.104; published online 12 April 2010	[Fritz, R. D.; Radziwill, G.] Univ Zurich, Inst Med Virol, Zurich, Switzerland; [Varga, Z.] Univ Zurich Hosp, Inst Clin Pathol, CH-8091 Zurich, Switzerland; [Radziwill, G.] Univ Freiburg, Fac Biol, Freiburg, Germany	University of Zurich; University of Zurich; University Zurich Hospital; University of Freiburg	Radziwill, G (corresponding author), Univ Freiburg, Fac Biol Biochem, Schaenzlestr 1, D-79104 Freiburg, Germany.	gerald.radziwill@biologie.uni-freiburg.de			Cancer League of Zurich; Centre of Biological Signaling Studies (bioss)	Cancer League of Zurich; Centre of Biological Signaling Studies (bioss)	We thank Dr Thorsten Fritzius for providing the FoxO1 and Akt1 m/p expression constructs and Julia Fritz for help with fractionation experiments and critical reading of the paper. We are grateful to Dr Alexandra Trkola for providing the infrastructure. This work was supported by the Cancer League of Zurich and the Centre of Biological Signaling Studies (bioss).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Fritz RD, 2010, MOL CANCER RES, V8, P395, DOI 10.1158/1541-7786.MCR-09-0296; Fritz RD, 2005, BIOCHEM BIOPH RES CO, V338, P1906, DOI 10.1016/j.bbrc.2005.10.168; Fritzius T, 2008, EMBO J, V27, P1399, DOI 10.1038/emboj.2008.67; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kasper G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-12; Laberge G, 2005, EMBO J, V24, P487, DOI 10.1038/sj.emboj.7600558; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Lopez-Ilasaca MA, 2005, FEBS LETT, V579, P648, DOI 10.1016/j.febslet.2004.12.039; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rocheleau CE, 2005, P NATL ACAD SCI USA, V102, P11757, DOI 10.1073/pnas.0500937102; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Theurillat JP, 2007, CANCER IMMUNOL IMMUN, V56, P1723, DOI 10.1007/s00262-007-0316-1; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	33	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3575	3582		10.1038/onc.2010.104	http://dx.doi.org/10.1038/onc.2010.104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383191	Bronze			2022-12-28	WOS:000278835400012
J	Sanchez-Tillo, E; Lazaro, A; Torrent, R; Cuatrecasas, M; Vaquero, EC; Castells, A; Engel, P; Postigo, A				Sanchez-Tillo, E.; Lazaro, A.; Torrent, R.; Cuatrecasas, M.; Vaquero, E. C.; Castells, A.; Engel, P.; Postigo, A.			ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1	ONCOGENE			English	Article						BRG1; E-cadherin; epithelial-mesenchymal transition (EMT); ZEB1	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL REPRESSOR; MIR-200 FAMILY; BETA-CATENIN; CANCER-CELLS; PROMOTES METASTASIS; COLORECTAL-CANCER; GENE-EXPRESSION; INVASION FRONT; STEM-CELLS	Loss of E-cadherin is a key initial step in the transdifferentiation of epithelial cells to a mesenchymal phenotype, which occurs when tumor epithelial cells invade into surrounding tissues. Expression of the nuclear factor ZEB1 induces an epithelial-to-mesenchymal transition and confers a metastatic phenotype on carcinomas by repressing the E-cadherin gene at the transcriptional level. In this study, we show that ZEB1 interacts with the SWI/SNF chromatin-remodeling protein BRG1 to regulate E-cadherin independently of CtBP, its traditional corepressor. Blocking the interaction between ZEB1 and BRG1 induces expression of E-cadherin and downregulation of the mesenchymal marker vimentin. ZEB1 and BRG1 colocalize in E-cadherin-negative cells from cancer lines and in the stroma of normal colon. Colocalization of ZEB1 and BRG1 in epithelial cells is only found in those de-differentiated cells characterized by nuclear beta-catenin staining at the invasive edge of the tumor. Our results identify ZEB1/BRG1 as a new transcriptional mechanism regulating E-cadherin expression and epithelial-to-mesenchymal transdifferentiation that may be involved during the initial stages of tumor invasion. Oncogene (2010) 29, 3490-3500; doi:10.1038/onc.2010.102; published online 26 April 2010	[Sanchez-Tillo, E.; Postigo, A.] IDIBAPS, Dept Hematol & Oncol, Grp Transcript Regulat, Barcelona 08036, Spain; [Lazaro, A.; Engel, P.] Univ Barcelona, Sch Med, Dept Cellular Biol & Pathol, Immunol Unit, Barcelona, Spain; [Torrent, R.] Univ Pompeu Fabra, Master Program Biotechnol, Barcelona, Spain; [Cuatrecasas, M.] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain; [Vaquero, E. C.; Castells, A.] IDIBAPS, CIBEREHD, Hosp Clin, Dept Gastroenterol, Barcelona 08036, Spain; [Postigo, A.] ICREA, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Pompeu Fabra University; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA	Postigo, A (corresponding author), IDIBAPS, Dept Hematol & Oncol, Grp Transcript Regulat, Barcelona 08036, Spain.	idib412@clinic.ub.es	Cuatrecasas, Miriam/C-9156-2019; Castells, Antoni/ABC-1002-2021; Engel, Pablo/R-5907-2019	Cuatrecasas, Miriam/0000-0003-3063-0110; Castells, Antoni/0000-0001-8431-2033; Engel, Pablo/0000-0001-8410-252X; Postigo, Antonio/0000-0003-4605-2634; Vaquero, Eva C./0000-0003-0098-5295	Caixa Foundation [BM-06570]; Spanish Ministry of Science and Innovation (MICINN) [BFU2007-60302]; Olga Torres Foundation [FOT-0902]; ICREA Funding Source: Custom	Caixa Foundation(La Caixa Foundation); Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Olga Torres Foundation; ICREA(ICREA)	We also thank M Morales (Department Physiological Sciences) and staff from the Technical Science Services at the University of Barcelona for their help in confocal analysis, M Rickman (IDIBAPS) and the Pathology Department at the Hospital Clinic of Barcelona for technical advice and M Parrizas (IDIBAPS) for helpful recommendations on ChIP assays. We are also grateful to R Gasa (IDIBAPS) for critical reading of the paper and J Moore for help with English editing. We apologize to those researchers whose work was cited indirectly through reviews because of space limitations. Initial work in this study was supported by a grant from La Caixa Foundation (BM-06570) to AP. At later stages, this project was funded by the Spanish Ministry of Science and Innovation (MICINN) (BFU2007-60302) and Olga Torres Foundation (FOT-0902) to AP. EST's salary was partly funded by Grant BM-06570.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Burkhart BA, 2005, J BIOL CHEM, V280, P6349, DOI 10.1074/jbc.M411147200; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Medina PP, 2008, EPIGENETICS-US, V3, P64, DOI 10.4161/epi.3.2.6153; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peter ME, 2010, CELL STEM CELL, V6, P4, DOI 10.1016/j.stem.2009.12.006; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Postigo AA, 1999, MOL CELL BIOL, V19, P7255; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Rasband W., 2006, IMAGEJ; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Verstappen G, 2008, HUM MOL GENET, V17, P1175, DOI 10.1093/hmg/ddn007; Waldmann J, 2009, ANN SURG ONCOL, V16, P1997, DOI 10.1245/s10434-009-0480-y; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	59	321	335	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3490	3500		10.1038/onc.2010.102	http://dx.doi.org/10.1038/onc.2010.102			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418909				2022-12-28	WOS:000278835400004
J	Vigneron, S; Brioudes, E; Burgess, A; Labbe, JC; Lorca, T; Castro, A				Vigneron, S.; Brioudes, E.; Burgess, A.; Labbe, J-C; Lorca, T.; Castro, A.			RSK2 is a kinetochore-associated protein that participates in the spindle assembly checkpoint	ONCOGENE			English	Article						Rsk2; SAC; kinetochore; Mad2; CENP-E	CELL-CYCLE EXTRACTS; CENP-E; MITOTIC CHECKPOINT; MAP KINASE; ERK; ATTACHMENT; EGGS; LOCALIZATION; ACTIVATION; PATHWAY	The spindle assembly checkpoint (SAC) prevents anaphase onset until all the chromosomes have successfully attached to the spindle microtubules. The MAP kinase (MAPK) is an important player in this pathway, however its exact role is not fully understood. One major target of MAPK is the p90 ribosomal protein S6 kinase (RSKs) family. In this study, we analyse whether Rsk2 could participate in the activation of the SAC. Our data indicate that this protein is localized at the kinetochores under checkpoint conditions. Moreover, it is essential for the SAC activity in Xenopus egg extracts as its depletion prevents metaphase arrest as well as the kinetochore localization of the other SAC components. We also show that this kinase might also participate in the maintenance of the SAC in mammalian cells as Rsk2 knockdown in these cells prevents the kinetochore localization of Mad1, Mad2 and CENP-E under checkpoint conditions. Oncogene (2010) 29, 3566-3574; doi:10.1038/onc.2010.105; published online 12 April 2010	[Castro, A.] Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS, UMR 5237,IFR 122, F-34293 Montpellier 5, France; [Castro, A.] Univ Montpellier 1, Ctr Rech Biochim Macromol, CNRS, UMR 5237,IFR 122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Castro, A (corresponding author), Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS, UMR 5237,IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010; labbe, jean-claude/B-2277-2009; Burgess, Andrew/C-7952-2009; Burgess, Andrew/H-3339-2019	CASTRO, ANNA/0000-0002-3655-1352; Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Lorca, Thierry/0000-0003-2007-8924	Ligue Nationale Contre le Cancer (Equipe Labellisee)	Ligue Nationale Contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer)	We thank Dr JE Ferrell for the generous gift of the pFast-Rsk2 WT and the pFast-Rsk2 KD constructs. We thank Julian Cau from the Montpellier RIO Imaging facility (CRBM). This work was supported by the Ligue Nationale Contre le Cancer (Equipe Labellisee). AB and EB are fellows from the Fondation pour la Recherche Medicale and the Ligue Nationale Contre le Cancer, respectively.	Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Bhatt RR, 2000, J BIOL CHEM, V275, P32983, DOI 10.1074/jbc.M006386200; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nam HJ, 2008, CELL SIGNAL, V20, P1349, DOI 10.1016/j.cellsig.2008.03.008; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Nishiyama T, 2007, NATURE, V446, P1096, DOI 10.1038/nature05696; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Tanudji M, 2004, MOL BIOL CELL, V15, P3771, DOI 10.1091/mbc.E03-07-0482; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Wu JQ, 2007, P NATL ACAD SCI USA, V104, P16564, DOI 10.1073/pnas.0707537104; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	24	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3566	3574		10.1038/onc.2010.105	http://dx.doi.org/10.1038/onc.2010.105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383198	Green Published			2022-12-28	WOS:000278835400011
J	Chuang, LSH; Ito, Y				Chuang, L. S. H.; Ito, Y.			RUNX3 is multifunctional in carcinogenesis of multiple solid tumors	ONCOGENE			English	Review						RUNX3; tumor suppressor; solid tumors; functional inactivation; TGF-beta; Wnt	ONCOGENE-INDUCED SENESCENCE; PIM-1 KINASE PHOSPHORYLATES; FOXO TRANSCRIPTION FACTORS; GASTRIC EPITHELIAL-CELLS; PROMOTER HYPERMETHYLATION; GENE-EXPRESSION; PROTEIN MISLOCALIZATION; CONFERS RESISTANCE; INSERTION LOCUS; DOWN-REGULATION	The study of RUNX3 in tumor pathogenesis is a rapidly expanding area of cancer research. Functional inactivation of RUNX3-through mutation, epigenetic silencing, or cytoplasmic mislocalization-is frequently observed in solid tumors of diverse origins. This alone indicates that RUNX3 inactivation is a major risk factor in tumorigenesis and that it occurs early during progression to malignancy. Conversely, RUNX3 has also been described to have an oncogenic function in a subset of tumors. Although the mechanism of how RUNX3 switches from tumor suppressive to oncogenic activity is unclear, this is of clinical relevance with implications for cancer detection and prognosis. Recent developments have significantly contributed to our understanding of the pleiotropic tumor suppressive properties of RUNX3 that regulate major signaling pathways. This review summarizes the important findings that link RUNX3 to tumor suppression. Oncogene (2010) 29, 2605-2615; doi:10.1038/onc.2010.88; published online 29 March 2010	[Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Canc Sci Inst, Singapore 138673, Singapore; [Chuang, L. S. H.; Ito, Y.] Natl Univ Singapore, Canc Biol Program, Canc Sci Inst Singapore, Singapore 138673, Singapore; [Ito, Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Canc Sci Inst, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg			Ministry of Education (MOE); National Research Foundation (NRF), Singapore	Ministry of Education (MOE)(Ministry of Education, Singapore); National Research Foundation (NRF), Singapore(National Research Foundation, Singapore)	This work was funded by the Ministry of Education (MOE) and National Research Foundation (NRF), Singapore. We give special thanks to Dr Kazuyoshi Kohu for his contribution of Figure 2.	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bae SC, 2003, EMBO REP, V4, P538, DOI 10.1038/sj.embor.embor875; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Brady G, 2009, J CELL PHYSIOL, V221, P283, DOI 10.1002/jcp.21880; Brady G, 2009, J VIROL, V83, P6909, DOI 10.1128/JVI.00216-09; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chen PC, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000092; Chen W, 2007, GENE CHROMOSOME CANC, V46, P288, DOI 10.1002/gcc.20411; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Fukushima-Nakase Y, 2005, BLOOD, V105, P4298, DOI 10.1182/blood-2004-08-3372; Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inoue KI, 2007, J BIOL CHEM, V282, P24175, DOI 10.1074/jbc.M703746200; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2009, ONCOGENE, V28, P1379, DOI 10.1038/onc.2008.496; Ito T, 2008, ASIAN ECON POLICY R, V3, P237, DOI 10.1111/j.1748-3131.2008.00107.x; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katayama Y, 2009, BIOCHEM BIOPH RES CO, V388, P496, DOI 10.1016/j.bbrc.2009.08.003; Kilbey A, 2008, CELL CYCLE, V7, P2333; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Kim HR, 2008, J CELL BIOCHEM, V105, P1048, DOI 10.1002/jcb.21906; Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Levanon D, 2009, BLOOD CELL MOL DIS, V43, P1, DOI 10.1016/j.bcmd.2009.01.009; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Miething C, 2007, P NATL ACAD SCI USA, V104, P4594, DOI 10.1073/pnas.0604716104; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Nevadunsky NS, 2009, GYNECOL ONCOL, V112, P325, DOI 10.1016/j.ygyno.2008.09.006; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Pande S, 2009, J CELL PHYSIOL, V218, P473, DOI 10.1002/jcp.21630; Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sato K, 2006, ONCOL REP, V15, P129; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shi MJ, 1998, J IMMUNOL, V161, P6751; Snoeks L, 2009, LAB INVEST, V89, P1053, DOI 10.1038/labinvest.2009.66; Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899; Spender LC, 2005, ONCOGENE, V24, P1873, DOI 10.1038/sj.onc.1208404; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Subramaniam MM, 2009, AM J GASTROENTEROL, V104, P426, DOI 10.1038/ajg.2008.141; Tanaka Y, 2007, EXP CELL RES, V313, P3251, DOI 10.1016/j.yexcr.2007.06.012; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wolff EM, 2008, CANCER RES, V68, P6208, DOI 10.1158/0008-5472.CAN-07-6616; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yanada M, 2005, ONCOL REP, V14, P817; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang ZZ, 2008, CARCINOGENESIS, V29, P1973, DOI 10.1093/carcin/bgn183; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	102	110	125	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2605	2615		10.1038/onc.2010.88	http://dx.doi.org/10.1038/onc.2010.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20348954				2022-12-28	WOS:000277354600001
J	Athineos, D; Sansom, OJ				Athineos, D.; Sansom, O. J.			Myc heterozygosity attenuates the phenotypes of APC deficiency in the small intestine	ONCOGENE			English	Article						APC; Myc; colorectal cancer	C-MYC; COLORECTAL-CANCER; IN-VIVO; ADENOMA FORMATION; IDENTIFICATION; PROLIFERATION; INHIBITION; ACTIVATION; RS6983267; TARGET	The adenomatous polyposis coli (APC) gene encodes APC tumour suppressor protein, germline mutation of which causes familial adenomatous polyposis, an autosomal intestinal cancer syndrome. We have previously demonstrated that the proto-oncogene c-Myc is essential for all the phenotypes that occur after APC loss in the murine small intestine. One caveat to this study is that it was performed in the complete absence of c-Myc. In this study, we show that heterozygosity for Myc reduces the phenotypes of APC loss and Wnt target gene expression and slows tumourigenesis. Crucially, the levels of Myc are twofold higher than wild-type levels showing that the level of Myc induced by Wnt signalling is absolutely vital for the fate of APC-deficient cells. Taken together, this suggests that c-Myc inhibition may be a viable chemoprevention strategy for colorectal cancer. Oncogene (2010) 29, 2585-2590; doi:10.1038/onc.2010.5; published online 8 February 2010	[Athineos, D.; Sansom, O. J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk		Sansom, Owen J./0000-0001-9540-3010; Athineos, Dimitris/0000-0001-5298-7941	Cancer Research UK [12481] Funding Source: researchfish	Cancer Research UK(Cancer Research UK)		Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bommer GT, 2007, CANCER CELL, V11, P391, DOI 10.1016/j.ccr.2007.04.015; Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94; Finch AJ, 2009, MOL CELL BIOL, V29, P5306, DOI 10.1128/MCB.01745-08; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ignatenko NA, 2006, CANCER BIOL THER, V5, P1658, DOI 10.4161/cbt.5.12.3376; Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Shchors K, 2006, GENE DEV, V20, P2527, DOI 10.1101/gad.1455706; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Wilkins JA, 2008, CANCER RES, V68, P4963, DOI 10.1158/0008-5472.CAN-07-5558; Yekkala K, 2007, MOL CANCER RES, V5, P1296, DOI 10.1158/1541-7786.MCR-07-0232	24	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2585	2590		10.1038/onc.2010.5	http://dx.doi.org/10.1038/onc.2010.5			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140021				2022-12-28	WOS:000277169400013
J	Boidot, R; Vegran, F; Jacob, D; Chevrier, S; Cadouot, M; Feron, O; Solary, E; Lizard-Nacol, S				Boidot, R.; Vegran, F.; Jacob, D.; Chevrier, S.; Cadouot, M.; Feron, O.; Solary, E.; Lizard-Nacol, S.			The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism	ONCOGENE			English	Article						GATA-1; survivin promoter polymorphism; breast carcinoma	SPLICE VARIANTS; GENE-EXPRESSION; CANCER; ERYTHROPOIETIN; PHOSPHORYLATION; DIFFERENTIATION; REQUIREMENTS; ACTIVATION; APOPTOSIS; CLEAVAGE	Expression of survivin, a member of the inhibitor of apoptosis protein family, is elevated in human cancers and considered as a new therapeutic target. Mechanism upregulating survivin expression in tumour cells is poorly understood. In this study, we show that breast cancer patients harbouring a polymorphism G235A in the survivin promoter present a higher level of survivin expression. This polymorphism creates a binding site for the transcription factor GATA-1 inducing a second GATA-1-binding site in survivin promoter. At the mRNA level, GATA-1 was present in breast carcinomas and adjacent normal tissues, whereas the protein was only detected in carcinomas by western blot and immunohistochemistry. Transfection of wild-type and different constitutively active GATA-1 mutants (serine 26, 178 or 310) showed that only phospho-serine 26 GATA-1 was able to increase survivin expression. This increase was higher in G235A than in G235G cell lines. Phospho-serine 26 GATA-1 bound directly survivin promoter, with a stronger interaction in G235A than in G235G polymorphism indicating that both GATA-1-binding sites are functional. These data identify GATA-1 as a key feature in tumour aggressiveness by enhancing survivin expression and delineate its targeting as a possible new therapeutic strategy in breast carcinomas. Oncogene (2010) 29, 2577-2584; doi:10.1038/onc.2009.525; published online 25 January 2010	[Boidot, R.; Vegran, F.; Jacob, D.; Chevrier, S.; Cadouot, M.; Lizard-Nacol, S.] Ctr Georges Francois Leclerc, Mol Genet Lab, F-21034 Dijon, France; [Solary, E.] UMR INSERM, U866, IFR 100, Dijon, France	UNICANCER; Centre Georges-Francois Leclerc; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Lizard-Nacol, S (corresponding author), Ctr Georges Francois Leclerc, Mol Genet Lab, 1 Rue Prof Marion, F-21034 Dijon, France.	SLizard@dijon.fnclcc.fr	VEGRAN, Frederique/O-9986-2018; VEGRAN, Frédérique/H-4792-2017; FERON, Olivier/AAM-6395-2020	VEGRAN, Frederique/0000-0002-4377-1441; FERON, Olivier/0000-0001-5360-0286; Solary, Eric/0000-0002-8629-1341	Conseil Regional de Bourgogne; Association pour la Recherche contre le Cancer	Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer)	This work was supported by the Conseil Regional de Bourgogne and the Association pour la Recherche contre le Cancer. We thank Dr Laurent Arnould (as Pathologist) for the validation of GATA-1 immunohistochemical staining.	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri Dario C, 2003, Prog Cell Cycle Res, V5, P447; Altieri DC, 2005, IMMUNITY, V22, P534, DOI 10.1016/j.immuni.2005.05.001; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boidot R, 2008, GENE CHROMOSOME CANC, V47, P299, DOI 10.1002/gcc.20533; Boidot R, 2009, INT J MOL MED, V23, P285, DOI 10.3892/ijmm_00000129; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Connell CM, 2008, CANCER RES, V68, P7923, DOI 10.1158/0008-5472.CAN-08-0817; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; De Gobbi M, 2006, SCIENCE, V312, P1215, DOI 10.1126/science.1126431; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Kadri Z, 2005, MOL CELL BIOL, V25, P7412, DOI 10.1128/MCB.25.17.7412-7422.2005; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Nasu S, 2002, ANTICANCER RES, V22, P1839; O'Driscoll L, 2003, CURR CANCER DRUG TAR, V3, P131, DOI 10.2174/1568009033482038; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; Phillips TM, 2007, NEOPLASIA, V9, P1122, DOI 10.1593/neo.07694; Ribeil JA, 2007, NATURE, V445, P102, DOI 10.1038/nature05378; Richter M, 2003, AM J PHYSIOL-LUNG C, V285, pL719, DOI 10.1152/ajplung.00406.2002; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Sebastian S, 2002, MOL ENDOCRINOL, V16, P2243, DOI 10.1210/me.2002-0123; Towatari M, 2004, HEMATOL J, V5, P262, DOI 10.1038/sj.thj.6200345; Vegran F, 2007, ONCOGENE, V26, P290, DOI 10.1038/sj.onc.1209784; Vegran F, 2005, INT J ONCOL, V27, P1151; Wu YH, 2008, ACTA BIOCHIM POL, V55, P673; Xia F, 2006, CANCER RES, V66, P3392, DOI 10.1158/0008-5472.CAN-05-4537; Xu Y, 2004, DNA CELL BIOL, V23, P527, DOI 10.1089/dna.2004.23.527; Yu YL, 2005, J BIOL CHEM, V280, P29533, DOI 10.1074/jbc.M506514200; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516; Zhen HN, 2007, INT J ONCOL, V31, P1111; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	38	37	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2577	2584		10.1038/onc.2009.525	http://dx.doi.org/10.1038/onc.2009.525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20101202				2022-12-28	WOS:000277169400012
J	Dalton, WB; Yu, B; Yang, VW				Dalton, W. B.; Yu, B.; Yang, V. W.			p53 suppresses structural chromosome instability after mitotic arrest in human cells	ONCOGENE			English	Article						p53; cell cycle arrest; chromosomal instability; DNA damage; mitotic checkpoint; polypoidization	SPINDLE-ASSEMBLY CHECKPOINT; WILD-TYPE P53; DNA-DAMAGE; CYTOKINESIS FAILURE; CYCLE PROGRESSION; MAMMALIAN-CELLS; TP53 MUTATIONS; CANCER-CELLS; POSTMITOTIC CHECKPOINT; TELOMERE DYSFUNCTION	The p53 tumor suppressor inhibits the proliferation of cells that undergo prolonged activation of the mitotic checkpoint. However, the function of this antiproliferative response is not well defined. Here, we report that p53 suppresses structural chromosome instability after mitotic arrest in human cells. In both HCT116 colon cancer cells and normal human fibroblasts, DNA breaks occurred during mitotic arrest in a p53-independent manner, but p53 was required to suppress the proliferation and structural chromosome instability of the resulting polyploid cells. In contrast, cells made polyploid without mitotic arrest exhibited neither significant structural chromosome instability nor p53-dependent cell cycle arrest. We also observed that p53 suppressed both the frequency and structural chromosome instability of spontaneous polyploids in HCT116 cells. Furthermore, time-lapse videomicroscopy revealed that polyploidization of p53(-/-) HCT116 cells is frequently accompanied by mitotic arrest. These data suggest that a function of the p53-dependent postmitotic response is the prevention of structural chromosome instability after prolonged activation of the mitotic checkpoint. Accordingly, our study suggests a novel mechanism of tumor suppression for p53, as well as a potential function for p53 in the outcome of antimitotic chemotherapy. Oncogene (2010) 29, 1929-1940; doi:10.1038/onc.2009.477; published online 11 January 2010	[Dalton, W. B.; Yu, B.; Yang, V. W.] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; [Dalton, W. B.; Yu, B.; Yang, V. W.] Emory Univ, Sch Med, Biochem Cell & Dev Biol Grad Program, Atlanta, GA 30322 USA; [Yang, V. W.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	yu, bing/B-3078-2009; Yu, Bing/AAF-9459-2019; Dalton, William/M-7944-2017	yu, bing/0000-0002-7259-8190; Yu, Bing/0000-0002-7259-8190; Dalton, William/0000-0002-1314-0534	National Institutes of Health [DK52230, DK64399, CA84197, 5T32GM008367-18, 5T32GM008367]; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169, T32GM008367] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D Pallas, P Doetsch, D Jones, A Corbett, G Davis, and M Wiltenburg for discussion and support, and B Vogelstein for providing cell lines. This work was supported in part by grants from the National Institutes of Health to VWY (DK52230, DK64399, and CA84197) and to WBD (5T32GM008367-18). This work was supported in part by grants from the National Institutes of Health to VWY (DK52230, DK64399, and CA84197) and to WBD (5T32GM008367).	Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Curtis LJ, 2000, J PATHOL, V192, P440; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Dalton WB, 2009, FUTURE ONCOL, V5, P1363, DOI 10.2217/FON.09.118; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Di Leonardo A, 1997, CANCER RES, V57, P1013; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Galmarini CM, 2001, BRIT J CANCER, V85, P902, DOI 10.1054/bjoc.2001.2017; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Hastak K, 2008, P NATL ACAD SCI USA, V105, P6314, DOI 10.1073/pnas.0802080105; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; IKEUCHI T, 1972, J CELL BIOL, V52, P97, DOI 10.1083/jcb.52.1.97; Jong YJ, 2004, CANCER GENET CYTOGEN, V148, P55, DOI 10.1016/S0165-4608(03)00205-X; KATO H, 1967, J CELL BIOL, V34, P35, DOI 10.1083/jcb.34.1.35; Kienitz A, 2005, ONCOGENE, V24, P4301, DOI 10.1038/sj.onc.1208589; Kim KT, 2004, J BIOL CHEM, V279, P38597, DOI 10.1074/jbc.M400781200; Kleivi K, 2005, J PATHOL, V207, P14, DOI 10.1002/path.1812; Koller E, 2006, CANCER RES, V66, P2059, DOI 10.1158/0008-5472.CAN-05-1531; LALLE P, 1995, ONCOGENE, V10, P2447; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Pantic M, 2006, ONCOGENE, V25, P4413, DOI 10.1038/sj.onc.1209486; Pfleghaar K, 2005, PLOS BIOL, V3, P2127, DOI 10.1371/journal.pbio.0030416; Quignon F, 2007, ONCOGENE, V26, P165, DOI 10.1038/sj.onc.1209787; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Stevens JB, 2007, CANCER RES, V67, P7686, DOI 10.1158/0008-5472.CAN-07-0472; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Stukenberg PT, 2004, J CELL BIOL, V165, P607, DOI 10.1083/jcb.200405089; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Tao WK, 2007, MOL CELL BIOL, V27, P689, DOI 10.1128/MCB.01505-06; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang ZZ, 2007, MUTAT RES-FUND MOL M, V617, P98, DOI 10.1016/j.mrfmmm.2007.01.003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Westra JL, 2005, GENE CHROMOSOME CANC, V43, P194, DOI 10.1002/gcc.20148; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yamaguchi H, 2004, J BIOL CHEM, V279, P39431, DOI 10.1074/jbc.M401530200; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Zhang H, 2002, J BIOL CHEM, V277, P43648, DOI 10.1074/jbc.M203214200	76	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1929	1940		10.1038/onc.2009.477	http://dx.doi.org/10.1038/onc.2009.477			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062083	Green Accepted			2022-12-28	WOS:000276199600006
J	Eliasz, S; Liang, S; Chen, Y; De Marco, MA; Machek, O; Skucha, S; Miele, L; Bocchetta, M				Eliasz, S.; Liang, S.; Chen, Y.; De Marco, M. A.; Machek, O.; Skucha, S.; Miele, L.; Bocchetta, M.			Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway	ONCOGENE			English	Article						notch signaling; lung cancer; hypoxia; IGF-1R; cancer cell survival	CANCER STEM-CELLS; FACTOR-I GENE; PROTEIN-KINASE; GROWTH; INSULIN; EXPRESSION; TRANSCRIPTION; RESISTANCE; MAINTENANCE; INHIBITION	Hypoxic microenvironment supports cancer stem cell survival, causes poor response to anticancer therapy and tumor recurrence. Inhibition of Notch-1 signaling in adenocarcinoma of the lung (ACL) cells causes apoptosis ifically under hypoxia. Here, we found that Akt-1 activation is a key mediator of Notch-1 pro-survival effects under hypoxia. Notch-1 activates Akt-1 through repression of phosphatase and tensin (PTEN) homolog expression and induction of the insulin-like growth factor 1 receptor (IGF-1R). The latter seems to be the major determinant of Akt-1 stimulation, as Notch-1 signaling affects Akt-1 activation in PTEN-/- ACL cells. Both downregulation of insulin receptor substrate 1 (IRS-1) and dominant-negative IGF-1R sensitized ACL cells to c-secretase inhibitor (GSI)-induced apoptosis. Conversely, overexpression of IGF-1R protected ACL cells from GSI toxicity. Inhibition of Notch-1 caused reduced IGF-1R expression, whereas forced Notch-1 expression yielded opposite effects. Chromatin immunoprecipitation experiments suggested Notch-1 direct regulation of the IGF-1R promoter. Experiments in which human ACL cells were injected in mice confirmed elevated and specific co-expression of Notch-1IC, IGF-1R and pAkt-1 in hypoxic tumor areas. Our data provide a mechanistic explanation for Notch-1-mediated pro-survival function in hypoxic ACL tumor microenvironment. The results identify additional targets that may synergize with Notch-1 inhibition for ACL treatment. Oncogene (2010) 29, 2488-2498; doi:10.1038/onc.2010.7; published online 15 February 2010	[Eliasz, S.; Liang, S.; De Marco, M. A.; Machek, O.; Skucha, S.; Bocchetta, M.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Inst Oncol, 2160 S 1st Ave,Bldg 112,Room 204, Maywood, IL 60153 USA; [Chen, Y.] NYU, Dept Surg, Langone Med Ctr, New York, NY 10016 USA; [Miele, L.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA	Loyola University Chicago; New York University; NYU Langone Medical Center; University of Mississippi; University of Mississippi Medical Center	Bocchetta, M (corresponding author), Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Inst Oncol, 2160 S 1st Ave,Bldg 112,Room 204, Maywood, IL 60153 USA.	mbocche@lumc.edu	Machek, Ondrej/L-4203-2018	Machek, Ondrej/0000-0003-3955-7853; Miele, Lucio/0000-0002-5853-7287	American Cancer Society [RSG-05-077-MBC]; National Cancer Institute [RO1 CA134503]; Riviera Country Club and Sport Center; NATIONAL CANCER INSTITUTE [R01CA134503] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Riviera Country Club and Sport Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Patricia Simms for help with FACS analyses. Merck & CO., Inc. (Whitehouse Station, NJ, USA) kindly provided the MRK-003 compound. We thank Dr Michele Carbone for critical review of this paper. This work was supported by grants from the American Cancer Society RSG-05-077-MBC, Award Number RO1 CA134503 from the National Cancer Institute and by a grant from the Riviera Country Club and Sport Center. Financial support was from American Cancer Society grant RSG-05-077-MBC, Award Number RO1 CA134503 from the National Cancer Institute and by a grant by the Riviera Country Club and Sport Center (M Bocchetta). Merck Inc. provided the drug MRK-003.	Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Behrooz A, 1999, NEWS PHYSIOL SCI, V14, P105; Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; Carelli S, 2006, J CELL PHYSIOL, V208, P354, DOI 10.1002/jcp.20670; Chen Delphine L, 2005, Proc Am Thorac Soc, V2, P541, DOI 10.1513/pats.200507-075DS; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; HEUSON JC, 1972, CANCER RES, V32, P226; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; McLellan AS, 2006, AM J PHYSIOL-CELL PH, V291, pC300, DOI 10.1152/ajpcell.00345.2005; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Milas L, 2009, SEMIN RADIAT ONCOL, V19, P96, DOI 10.1016/j.semradonc.2008.11.004; Moromisato DY, 1996, CRIT CARE MED, V24, P919, DOI 10.1097/00003246-199606000-00008; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Ouellet J, 2008, DEVELOPMENT, V135, P2583, DOI 10.1242/dev.012435; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Schuurbiers OCJ, 2009, J THORAC ONCOL, V4, P761, DOI 10.1097/JTO.0b013e3181a1084f; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHEMER J, 1992, ENDOCRINOLOGY, V131, P2793, DOI 10.1210/en.131.6.2793; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; YOYOSHIMA Y, 2008, ENDOCRINOLOGY, V149, P5996	51	128	133	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2488	2498		10.1038/onc.2010.7	http://dx.doi.org/10.1038/onc.2010.7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154720	Green Accepted			2022-12-28	WOS:000277169400004
J	Peter, ME				Peter, M. E.			Targeting of mRNAs by multiple miRNAs: the next step	ONCOGENE			English	Review						miRNA; targeting; p21	MICRORNA TARGETS; DIFFERENTIATION; TUMORIGENESIS; PREDICTIONS; FAMILY	Micro(mi)RNAs are small noncoding RNAs that regulate expression of the majority of the genes in the genome at either the messenger RNA (mRNA) level (by degrading mRNA) or the protein level (by blocking translation). miRNAs are thought to be components of vast regulatory networks. Currently, the field is focused primarily on identifying novel targets of individual miRNAs. This focus is about to undergo a dramatic change. In a new paper by Wu et al. (2010) it is experimentally confirmed that multiple miRNAs target the same gene, suggesting that it is the combination of all these activities that determines the expression of miRNA target genes. This study ushers in a new era of miRNA research that focuses on networks more than on individual connections between miRNA and strongly predicted targets. Oncogene (2010) 29, 2161-2164; doi: 10.1038/onc.2010.59;	Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Dept Canc Res, 924 E 57th St,R112, Chicago, IL 60637 USA.	MPeter@uchicago.edu		Peter, Marcus Ernst/0000-0003-3216-036X				Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hammell M, 2008, NAT METHODS, V5, P813, DOI 10.1038/NMETH.1247; Hobert O, 2007, CELL, V131, P22, DOI 10.1016/j.cell.2007.09.031; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jiang Q, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-194; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Khan AA, 2009, NAT BIOTECHNOL, V27, P549, DOI 10.1038/nbt.1543; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003592; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Ritchie W, 2009, NAT METHODS, V6, P397, DOI 10.1038/nmeth0609-397; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Watanabe Y, 2007, METHOD ENZYMOL, V427, P65, DOI 10.1016/S0076-6879(07)27004-1; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34	23	205	216	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2161	2164		10.1038/onc.2010.59	http://dx.doi.org/10.1038/onc.2010.59			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20190803				2022-12-28	WOS:000276685200001
J	Wang, B; Hsu, SH; Majumder, S; Kutay, H; Huang, W; Jacob, ST; Ghoshal, K				Wang, B.; Hsu, S-H; Majumder, S.; Kutay, H.; Huang, W.; Jacob, S. T.; Ghoshal, K.			TGF beta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3	ONCOGENE			English	Article						miR-181b; TIMP3; hepatocarcinogenesis; CDAA diet; doxorubicin; hepatocullular carcinoma	CHOLINE-DEFICIENT; TISSUE INHIBITOR; BREAST-CANCER; IN-VIVO; MICRORNA; GENE; EXPRESSION; HSA-MIR-181B; INFLAMMATION; BIOGENESIS	To identify microRNAs (miRNAs) that may have a causal role in hepatocarcinogenesis, we used an animal model in which C57BL/6 mice fed choline-deficient and amino acid defined (CDAA) diet develop preneoplastic lesions at 65 weeks and hepatocellular carcinomas after 84 weeks. miRNA expression profiling showed significant upregulation of miR-181b and miR-181d in the livers of mice as early as 32 weeks that persisted at preneoplastic stage. The expression of tissue inhibitor of metalloprotease 3 (TIMP3), a tumor suppressor and a validated miR-181 target, was markedly suppressed in the livers of mice fed CDAA diet. Upregulation of hepatic transforming growth factor (TGF)beta and its downstream mediators Smad 2, 3 and 4 and increase in phospho-Smad2 in the liver nuclear extract correlated with elevated miR-181b/d in mice fed CDAA diet. The levels of the precursor and mature miR-181b were augmented on exposure of hepatic cells to TGF beta and were significantly reduced by small interference RNA-mediated depletion of Smad4, showing the involvement of TGFb signaling pathway in miR-181b expression. Ectopic expression and depletion of miR-181b showed that miR-181b enhanced matrix metallopeptidases (MMP)2 and MMP9 activity and promoted growth, clonogenic survival, migration and invasion of hepatocellular carcinoma (HCC) cells that could be reversed by modulating TIMP3 level. Further, depletion of miR-181b inhibited tumor growth of HCC cells in nude mice. miR-181b also enhanced resistance of HCC cells to the anticancer drug doxorubicin. On the basis of these results, we conclude that upregulation of miR-181b at early stages of feeding CDAA diet promotes hepatocarcinogenesis. Oncogene (2010) 29, 1787-1797; doi:10.1038/onc.2009.468; published online 21 December 2009	[Wang, B.; Hsu, S-H; Majumder, S.; Kutay, H.; Huang, W.; Jacob, S. T.; Ghoshal, K.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Jacob, S. T.; Ghoshal, K.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 420 W 12th Ave,646 TMRF, Columbus, OH 43210 USA.	Samson.Jacob@osumc.edu; kalpana.ghoshal@osumc.edu	Jacob, Samson/H-3135-2011; Huang, Wei/E-3270-2011; Wang, Bo/F-6519-2011	HSU, SHU-HAO/0000-0002-9444-4192; Wang, Bo/0000-0001-9234-035X	National Institutes of Health [CA086978, CA101956]; NATIONAL CANCER INSTITUTE [R01CA086978, P01CA101956] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs David P Bartel and John Taylor for pIS0 vectors and Huh-7 cells, respectively. This work was supported by the grants CA086978 and CA101956 from National Institutes of Health. Grant support: CA086978 and CA101956 from National Institutes of Health.	Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Calin GA, 2007, BEST PRACT RES CL HA, V20, P425, DOI 10.1016/j.beha.2007.02.003; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Cheung O, 2008, HEPATOLOGY, V48, P1810, DOI 10.1002/hep.22569; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Day CP, 2006, LIVER INT, V26, P1021, DOI 10.1111/j.1478-3231.2006.01323.x; Denda A, 2002, JPN J CANCER RES, V93, P125, DOI 10.1111/j.1349-7006.2002.tb01250.x; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Menghini R, 2009, GASTROENTEROLOGY, V136, P663, DOI 10.1053/j.gastro.2008.10.079; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311; Sun Q, 2008, NUCLEIC ACIDS RES, V36, P2690, DOI 10.1093/nar/gkn032; Thomas M, 2009, J GASTROENTEROL, V44, P136, DOI 10.1007/s00535-008-2252-z; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808	38	309	334	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1787	1797		10.1038/onc.2009.468	http://dx.doi.org/10.1038/onc.2009.468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023698	Green Accepted			2022-12-28	WOS:000276022800008
J	Noetzel, E; Rose, M; Sevinc, E; Hilgers, RD; Hartmann, A; Naami, A; Knuchel, R; Dahl, E				Noetzel, E.; Rose, M.; Sevinc, E.; Hilgers, R-D; Hartmann, A.; Naami, A.; Knuechel, R.; Dahl, E.			Intermediate filament dynamics and breast cancer: Aberrant promoter methylation of the Synemin gene is associated with early tumor relapse	ONCOGENE			English	Article						tumor suppressor gene; SYNM; promoter methylation; epigenetics; recurrence-free survival; pyrosequencing	PROTEIN SYNEMIN; VIMENTIN FILAMENTS; MYOEPITHELIAL CELL; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; IDENTIFICATION; MARKER; DISEASE	Synemin (SYNM) is a type IV intermediate filament that has recently been shown to interact with the LIM domain protein zyxin, thereby possibly modulating cell adhesion and cell motility. Owing to this multiplicity of potential functions relevant to cancer development, we initiated a study to decipher SYNM expression and regulation in benign human breast tissue and breast cancer. Dot blot array analysis showed significant SYNM mRNA downregulation in 86% (n = 100, P < 0.001) of breast cancers compared with their normal tissue counterparts, a result that was confirmed by real-time PCR analysis (n = 36, P < 0.0001). Immunohistochemistry analysis showed abundant SYNM protein expression in healthy myoepithelial breast cells, whereas SYNM expression loss was evident in 57% (n = 37, P < 0.001) of breast cancer specimens. Next, we analyzed methylation of the SYNM promoter to clarify whether the SYNM gene can be silenced by epigenetic means. Indeed, methylation-specific PCR analysis showed tumor-specific SYNM promoter methylation in 27% (n = 195) of breast cancers. As expected, SYNM promoter methylation was tightly associated (P < 0.0001) with SYNM expression loss. In-depth analysis of the SYNM promoter by pyrosequencing showed extensive CpG methylation of DNA elements supposed to regulate gene transcription. Demethylating treatment of SYNM methylated breast cancer cell lines with 5-aza-2-deoxycytidine clearly reestablished the SYNM expression. Statistical analysis of the patient cohort showed a close association between SYNM promoter methylation and unfavorable recurrence-free survival (hazard ratio = 2.941, P = 0.0282). Furthermore, SYNM methylation positively correlated with lymph node metastases (P = 0.0177) and advanced tumor grade (P = 0.0275), suggesting that SYNM methylation is associated with aggressive forms of breast cancer. This is the first study on the epigenetic regulation of the SYNM gene in a cancer entity. We provide first hints that SYNM could represent a novel putative breast tumor suppressor gene that is prone to epigenetic silencing. SYNM promoter methylation may become a useful predictive biomarker to stratify breast cancer patients' risk for tumor relapse. Oncogene (2010) 29, 4814-4825; doi:10.1038/onc.2010.229; published online 14 June 2010	[Noetzel, E.; Rose, M.; Sevinc, E.; Naami, A.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Fac Med, Mol Oncol Grp, Inst Pathol, Aachen, Germany; [Hilgers, R-D] Rhein Westfal TH Aachen, Dept Med Stat, Aachen, Germany; [Hartmann, A.] Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany	RWTH Aachen University; RWTH Aachen University; University of Erlangen Nuremberg	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Mol Oncol Grp, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Noetzel-Reiss, Erik/GYV-0999-2022; Hilgers, Ralf-Dieter/C-7090-2013	Noetzel-Reiss, Erik/0000-0003-3163-6848; Hilgers, Ralf-Dieter/0000-0002-5945-1119	BMBF [01KW0401]	BMBF(Federal Ministry of Education & Research (BMBF))	We thank Sonja von Serenyi and Sevim Alkaya for excellent technical assistance and Monika Klinkhammer-Schalke, as well as Armin Pauer from the Tumor Registry Regensburg for continuous help in obtaining clinical follow-up data. We are thankful to Professor Matthias Durst (Friedrich-Schiller University Jena, Germany) for kindly providing patient samples and follow-up data. This work is a research project within the German Human Genome Project and has been supported by the BMBF Grants 01KW0401 to ED.	[Anonymous], 1997, J CLIN PATHOL; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; Blake DJ, 2002, TRENDS CARDIOVAS MED, V12, P224, DOI 10.1016/S1050-1738(02)00166-4; Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433; Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Deugnier MA, 2002, BREAST CANCER RES, V4, P224, DOI 10.1186/bcr459; Dobrovic A, 1997, CANCER RES, V57, P3347; ELSTON CW, 1993, J CLIN PATHOL, V46, P189; ETIENNE J, 1990, ANN BIOL CLIN-PARIS, V48, P681; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herrmann H, 2007, NAT REV MOL CELL BIO, V8, P562, DOI 10.1038/nrm2197; Hirako Y, 2003, CELL TISSUE RES, V313, P195, DOI 10.1007/s00441-003-0732-2; Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Lakhani SR, 2001, BREAST CANCER RES, V3, P1, DOI 10.1186/bcr260; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; Mook S, 2009, BREAST CANCER RES TR, V116, P295, DOI 10.1007/s10549-008-0130-2; Nguyen M, 2000, ONCOGENE, V19, P3449, DOI 10.1038/sj.onc.1203677; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Pan YH, 2008, FASEB J, V22, P3196, DOI 10.1096/fj.08-106187; REMMELE W, 1987, PATHOLOGE, V8, P138; Schmitt-Graeff A, 2006, HUM PATHOL, V37, P1200, DOI 10.1016/j.humpath.2006.04.017; Sun N, 2010, EXP CELL RES, V316, P491, DOI 10.1016/j.yexcr.2009.10.015; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tawk M, 2003, EXP NEUROL, V183, P499, DOI 10.1016/S0014-4886(03)00240-1; Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x; Van Rossen E, 2009, HISTOCHEM CELL BIOL, V131, P313, DOI 10.1007/s00418-008-0544-2; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Wiesmann F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2319; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115	46	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4814	4825		10.1038/onc.2010.229	http://dx.doi.org/10.1038/onc.2010.229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543860				2022-12-28	WOS:000281326400007
J	Watari, A; Iwabe, N; Masuda, H; Okada, M				Watari, A.; Iwabe, N.; Masuda, H.; Okada, M.			Functional transition of Pak proto-oncogene during early evolution of metazoans	ONCOGENE			English	Article						evolution; metazoans; Pak; proto-oncogene	PROTEIN-TYROSINE KINASE; P21-ACTIVATED KINASES; MONOSIGA-BREVICOLLIS; SRC; ACTIVATION; CANCER; ONCOGENES; ANIMALS; PATHWAY; CELLS	Proto-oncogenes encode signaling molecular switches regulating cellular homeostasis in metazoans, and can be converted to oncogenes by gain-of-function mutations. To address the molecular basis for development of the regulatory system of proto-oncogenes during evolution, we screened for ancestral proto-oncogenes from the unicellular choanoflagellate Monosiga ovata by monitoring their transforming activities, and isolated a Pak gene ortholog encoding a serine/threonine kinase as a 'primitive oncogene'. We also cloned Pak orthologs from fungi and the multicellular sponge Ephydatia fluviatilis, and compared their regulatory features with that of M. ovata Pak (MoPak). MoPak is constitutively active and induces cell transformation in mammalian fibroblasts, although the Pak orthologs from multicellular animals are strictly regulated. Analyses of Pak mutants revealed that structural alteration of the auto-inhibitory domain (AID) of MoPak confers higher constitutive kinase activity, as well as greater binding ability to Rho family GTPases than the multicellular Paks, and this structural alteration is responsible for cell transformation and disruption of multicellular tissue organization. These results show that maturation of AID function was required for the development of the strict regulatory system of the Pak proto-oncogene, and suggest a potential link between the establishment of the regulatory system of proto-oncogenes and metazoan evolution. Oncogene (2010) 29, 3815-3826; doi: 10.1038/onc.2010.148; published online 10 May 2010	[Watari, A.; Masuda, H.; Okada, M.] Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; [Iwabe, N.] Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto, Japan	Osaka University; Kyoto University	Okada, M (corresponding author), Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	okadam@biken.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Drs M Matsuda, T Akagi, T Hishida, M Yutsudo and S Morita for their generous gifts of reagents. This work was supported by Grants-in-Aids for Scientific Research on Priority Areas 'Cancer' and 'Comparative Genomics', from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BISHOP JM, 1981, CELL, V23, P5; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; HIBBERD DJ, 1975, J CELL SCI, V17, P191; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHNSTON RN, 1992, BIOCHEM CELL BIOL, V70, P831, DOI 10.1139/o92-130; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li WQ, 2008, J BIOL CHEM, V283, P15491, DOI 10.1074/jbc.M800002200; Lozano E, 2008, J CELL SCI, V121, P933, DOI 10.1242/jcs.016121; Manning G, 2008, P NATL ACAD SCI USA, V105, P9674, DOI 10.1073/pnas.0801314105; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; O'Sullivan GC, 2007, INT J CANCER, V121, P1930, DOI 10.1002/ijc.22893; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Philippe H, 2004, MOL BIOL EVOL, V21, P1740, DOI 10.1093/molbev/msh182; Reeder MK, 2001, J BIOL CHEM, V276, P40606, DOI 10.1074/jbc.M103925200; Segawa Y, 2006, P NATL ACAD SCI USA, V103, P12021, DOI 10.1073/pnas.0600021103; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Suga H, 2001, GENE, V280, P195, DOI 10.1016/S0378-1119(01)00784-3; Suga H, 2008, FEBS LETT, V582, P815, DOI 10.1016/j.febslet.2008.02.002; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Todd R, 1999, ANTICANCER RES, V19, P4729; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200	38	8	8	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3815	3826		10.1038/onc.2010.148	http://dx.doi.org/10.1038/onc.2010.148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453877				2022-12-28	WOS:000279385200009
J	Xu, Y; Lee, SH; Kim, HS; Kim, NH; Piao, S; Park, SH; Jung, YS; Yook, JI; Park, BJ; Ha, NC				Xu, Y.; Lee, S-H; Kim, H. S.; Kim, N. H.; Piao, S.; Park, S-H; Jung, Y. S.; Yook, J. I.; Park, B-J; Ha, N-C			Role of CK1 in GSK3 beta-mediated phosphorylation and degradation of Snail	ONCOGENE			English	Article						snail; casein kinase 1; EMT; GSK3 beta; metastasis	CASEIN KINASE-I; EPITHELIAL-MESENCHYMAL TRANSITIONS; BETA-CATENIN; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; GENE-EXPRESSION; BREAST-CANCER; WNT; EPSILON; PROTEIN	The epithelial to mesenchymal transition (EMT) that occurs during embryonic development has begun to attract attention as a potential mechanism for tumor cell metastasis. Snail is a well-known Zn-finger transcription factor that promotes EMT by repressing E-cadherin expression. It is known that Snail is phosphorylated by GSK3 beta and degraded by beta-TrCP-mediated ubiquitination. Here we described another protein kinase, CK1, whose phosphorylation of Snail is required for the subsequent GSK3 beta phosphorylation. Specific inhibition or depletion of CK1 epsilon inhibits the phosphorylation and degradation of Snail and promotes cell migration, suggesting a central role of CK1 epsilon in the EMT process. Furthermore, our study uncovered distinct roles and steps of Snail phosphorylation by CK1 epsilon and GSK3 beta. Taken together, we identified CK1 epsilon as a new component of the Snail-mediated EMT process, providing insight into the mechanism of human cancer metastasis. Oncogene (2010) 29, 3124-3133; doi: 10.1038/onc.2010.77; published online 22 March 2010	[Xu, Y.; Piao, S.; Park, S-H; Ha, N-C] Pusan Natl Univ, Coll Pharm, Dept Mfg Pharm, Pusan 609735, South Korea; [Xu, Y.; Piao, S.; Park, S-H; Ha, N-C] Pusan Natl Univ, Res Inst Drug Dev, Pusan 609735, South Korea; [Lee, S-H; Jung, Y. S.; Park, B-J] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Kim, H. S.; Kim, N. H.; Yook, J. I.] Yonsei Univ, Coll Dent, Oral Canc Res Inst, Dept Oral Pathol, Seoul 120749, South Korea	Pusan National University; Pusan National University; Pusan National University; Yonsei University; Yonsei University Health System	Ha, NC (corresponding author), Pusan Natl Univ, Coll Pharm, Dept Mfg Pharm, 30 Jangjeon Dong, Pusan 609735, South Korea.	hnc@pusan.ac.kr		Kim, Nam Hee/0000-0002-3087-5276; Yook, Jong In/0000-0002-7318-6112; Kim, Hyun Sil/0000-0003-3614-1764	Ministry for Health, Welfare and Family affairs, Republic of Korea [0920140]	Ministry for Health, Welfare and Family affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	We thank Xiao Ling Jin for assisting in DNA construction and protein purification. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920140).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; COBB MH, 1983, J BIOL CHEM, V258, P2472; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Dahlberg CL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004766; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Santos JA, 1996, J CELL SCI, V109, P1847; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2005, CELL CYCLE, V4, P772, DOI 10.4161/cc.4.6.1744; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	44	66	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3124	3133		10.1038/onc.2010.77	http://dx.doi.org/10.1038/onc.2010.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20305697				2022-12-28	WOS:000278133100009
J	Walter, K; Cockerill, PN; Barlow, R; Clarke, D; Hoogenkamp, M; Follows, GA; Richards, SJ; Cullen, MJ; Bonifer, C; Tagoh, H				Walter, K.; Cockerill, P. N.; Barlow, R.; Clarke, D.; Hoogenkamp, M.; Follows, G. A.; Richards, S. J.; Cullen, M. J.; Bonifer, C.; Tagoh, H.			Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5	ONCOGENE			English	Article						t(8;21); mixed lineage phenotype; PAX5; CD19; chromatin structure; epigenetic regulation	ACUTE MYELOID-LEUKEMIA; B-LYMPHOPOIESIS; GENE-EXPRESSION; FUSION PROTEIN; AML1-ETO; TRANSCRIPTION; TARGET; CELLS; METHYLATION; TRANSLOCATION	Correct hematopoietic differentiation requires the tightly regulated execution of lineage-specific and stage-restricted gene expression programs. This process is disturbed in hematological malignancies that typically show incomplete differentiation but often also display a mixed lineage phenotype. Co-expression of lymphoid and myeloid molecules is a well-known feature of acute myeloblastic leukemia (AML) with t(8;21). These cells consistently express the B-cell-specific transcription factor PAX5, and the B-cell-specific cell surface protein CD19. However, the functional consequences of PAX5 expression are unknown. To address this question, we studied the chromatin features of CD19, which is a direct target of PAX5 in cells with and without the t( 8; 21) chromosomal translocation. We show that CD19 chromatin exists in a poised configuration in myeloid progenitors and that this poised chromatin structure facilitates PAX5-dependent CD19 activation. Our results also show a positive correlation between PAX5 and CD19 expression in t(8;21)-positive AML cells and demonstrate that PAX5 binds to the promoter and enhancer of CD19 gene and remodels chromatin structure at the promoter. This study shows that expression of PAX5 in leukemic cells has functional consequences and points to an important role of a progenitor-specific chromatin configuration in myeloid leukemia. Oncogene (2010) 29, 2927-2937; doi:10.1038/onc.2010.56; published online 8 March 2010	[Walter, K.; Cockerill, P. N.; Barlow, R.; Clarke, D.; Hoogenkamp, M.; Follows, G. A.; Bonifer, C.; Tagoh, H.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Mol Med, Sect Expt Haematol, Leeds, W Yorkshire, England; [Richards, S. J.; Cullen, M. J.] St Jamess Inst Oncol, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Tagoh, H (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	hiromi.tagoh@imp.ac.at	Tagoh, Hiromi/B-2954-2009	Tagoh, Hiromi/0000-0001-9905-6992; Richards, Stephen/0000-0002-8421-5353; Bonifer, Constanze/0000-0002-4267-0825; Cockerill, Peter/0000-0002-4410-8174; Hoogenkamp, Maarten/0000-0003-2429-1271	Leukaemia & Lymphoma Research; Kay Kendall Leukaemia Fund; Research Council UK	Leukaemia & Lymphoma Research; Kay Kendall Leukaemia Fund; Research Council UK(UK Research & Innovation (UKRI))	We thank M Busslinger for providing reagents including antibodies and plasmids and S Valeaux and A Ebert for technical assistance. This work was supported by Leukaemia & Lymphoma Research and by the Kay Kendall Leukaemia Fund. HT holds a Research Council UK academic fellowship.	Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Attema JL, 2007, P NATL ACAD SCI USA, V104, P12371, DOI 10.1073/pnas.0704468104; Berg T, 2008, HAEMATOL-HEMATOL J, V93, P1728, DOI 10.3324/haematol.13044; Bonifer C, 2005, CELL CYCLE, V4, P211; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Decker T, 2009, IMMUNITY, V30, P508, DOI 10.1016/j.immuni.2009.01.012; DREXLER HG, 1991, LEUKEMIA, V5, P637; DREXLER HG, 1993, LEUKEMIA, V7, P489; Elagib KE, 2007, CANCER LETT, V251, P179, DOI 10.1016/j.canlet.2006.10.010; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Gibson SE, 2006, AM J CLIN PATHOL, V126, P916, DOI 10.1309/UJUL60UPUP3YJE93; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KITA K, 1992, BLOOD, V80, P470; Kohler C, 2008, TRENDS CELL BIOL, V18, P236, DOI 10.1016/j.tcb.2008.02.005; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Kwon K, 2008, IMMUNITY, V28, P751, DOI 10.1016/j.immuni.2008.04.014; Lefevre P, 2005, J BIOL CHEM, V280, P27552, DOI 10.1074/jbc.M502422200; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Mikhail FM, 2002, CANCER GENET CYTOGEN, V135, P96, DOI 10.1016/S0165-4608(01)00633-1; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Moreau T, 2004, MOL THER, V10, P45, DOI 10.1016/j.ymthe.2004.04.005; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nishida S, 2006, BLOOD, V107, P3303, DOI 10.1182/blood-2005-04-1656; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Peterson LF, 2007, LEUKEMIA, V21, P2010, DOI 10.1038/sj.leu.2404849; Peterson LF, 2007, BLOOD, V110, P799, DOI 10.1182/blood-2006-11-019265; READING CL, 1993, BLOOD, V81, P3083; Roessler S, 2007, MOL CELL BIOL, V27, P579, DOI 10.1128/MCB.01192-06; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seet CS, 2004, J EXP MED, V199, P1689, DOI 10.1084/jem.20032202; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Tagoh H, 2006, EMBO J, V25, P1070, DOI 10.1038/sj.emboj.7600997; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tiacci E, 2004, CANCER RES, V64, P7399, DOI 10.1158/0008-5472.CAN-04-1865; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; Valbuena JR, 2006, AM J CLIN PATHOL, V126, P235, DOI 10.1309/LG0Q0VXYBETJ4VHE; Walter K, 2008, BLOOD, V112, P1673, DOI 10.1182/blood-2008-02-142786; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	49	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2927	2937		10.1038/onc.2010.56	http://dx.doi.org/10.1038/onc.2010.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208555				2022-12-28	WOS:000277890400004
J	Gabai, VL; Sherman, MY; Yaglom, JA				Gabai, V. L.; Sherman, M. Y.; Yaglom, J. A.			HSP72 depletion suppresses gamma H2AX activation by genotoxic stresses via p53/p21 signaling	ONCOGENE			English	Article						Hsp72; senescence; radiation; doxorubicine; nutlin-3	HEAT-SHOCK PROTEINS; DNA-DAMAGE; CELLS; CANCER; SENESCENCE; REPAIR; INSTABILITY; KINASES	Knockout of heat shock protein Hsp72 was shown to promote chromosomal instability and increase radiation sensitivity of mouse fibroblasts. Here, we report that downregulation of Hsp72 in human tumor cells leads to suppression of a specific branch of the DNA damage response (DDR) that facilitates DNA repair following genotoxic insults, that is, reduced accumulation of the phosphorylated form of histone H2AX (gamma H2AX). This inhibition was due to decreased expression of H2AX as well as higher rate of gamma H2AX dephosphorylation. Formation of gamma H2AX and MDC1 radiation-induced foci was impaired in Hsp72-depleted cells, which in turn enhanced DNA damage, resulting in sensitization of cells to gamma-radiation and doxorubicin. These effects of Hsp72 knockdown were dependent on activation of the p53/p21-signaling pathway. Overall, permanent activation of the p53/p21 signaling in Hsp72-depleted cells specifically impaired the gamma H2AX pathway of the DDR, enhanced DNA damage following genotoxic insults, and led to further stimulation of the p53/p21 pathway, thus creating a positive feedback loop. The resulting strong induction of p21 precipitated senescence following exposure to DNA-damaging agents, thus accounting for higher sensitivity of cells to genotoxic stresses. Oncogene (2010) 29, 1952-1962; doi:10.1038/onc.2009.480; published online 11 January 2010	[Gabai, V. L.; Sherman, M. Y.; Yaglom, J. A.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Gabai, VL (corresponding author), Boston Univ, Sch Med, Dept Biochem, 15 Stoughton St, Boston, MA 02118 USA.	gabai@bu.edu; yaglom@bu.edu	Gabai, Vladimir L/I-1650-2013; qiao, zhixin/I-3408-2012	Gabai, Vladimir L/0000-0003-4505-4718; Yaglom, Julia/0000-0002-8723-3506	American Cancer Society Institutional; NIH; Grunnen-baum Award	American Cancer Society Institutional(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grunnen-baum Award	This work was supported by American Cancer Society Institutional Grant (VLG); NIH grant (MYS) and Grunnen-baum Award (JAY).	Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Cao C, 2006, MOL CANCER THER, V5, P411, DOI 10.1158/1535-7163.MCT-05-0356; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; Gabai VL, 2008, CANCER RES, V68, P1834, DOI 10.1158/0008-5472.CAN-07-5656; Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Kabakov AE, 2006, RADIAT RES, V165, P410, DOI 10.1667/RR3514.1; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441; O'Callaghan-Sunol Cornelia, 2007, V2, P169; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2008, AGING CELL, V7, P89, DOI 10.1111/j.1474-9726.2007.00354.x; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796	24	21	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1952	1962		10.1038/onc.2009.480	http://dx.doi.org/10.1038/onc.2009.480			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062073				2022-12-28	WOS:000276199600008
J	Hagiwara, S; Murakumo, Y; Mii, S; Shigetomi, T; Yamamoto, N; Furue, H; Ueda, M; Takahashi, M				Hagiwara, S.; Murakumo, Y.; Mii, S.; Shigetomi, T.; Yamamoto, N.; Furue, H.; Ueda, M.; Takahashi, M.			Processing of CD109 by furin and its role in the regulation of TGF-beta signaling	ONCOGENE			English	Article						CD109; furin; processing; TGF-beta; cell proliferation	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMA; TRANSFORMING GROWTH-FACTOR-BETA-1; PROPROTEIN CONVERTASES; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; HUMAN CANCER; EXPRESSION; PROTEINS; MECHANISMS	CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, whose expression is upregulated in squamous cell carcinomas of the lung, esophagus, uterus and oral cavity. CD109 negatively regulates transforming growth factor (TGF)-beta signaling in keratinocytes by directly modulating receptor activity. In this study, we further characterized CD109 regulation of TGF-beta signaling and cell proliferation. We found that CD109 is produced as a 205 kDa glycoprotein, which is then processed in the Golgi apparatus into 180 kDa and 25 kDa proteins by furin (furinase). 180 kDa CD109 associated with GPI-anchored 25 kDa CD109 on the cell surface and was also secreted into the culture medium. To investigate whether furinase cleavage of CD109 is necessary for its biological activity, we mutated arginine 1273 in the CD109 furinase cleavage motif (amino acid 1270-RRRR-1273) to serine (R1273S). Interestingly, CD109 R1273S neither significantly impaired TGF-beta signaling nor affected TGF-beta-mediated suppression of cell growth, although it was expressed on the cell surface as a 205 kDa protein. Consistent with this finding, the 180 kDa and 25 kDa CD109 complex, but not CD109 R1273S, associated with the type I TGF-beta receptor. These findings indicate that processing of CD109 into 180 kDa and 25kDa proteins by furin, followed by complex formation with the type I TGF-beta receptor is required for the regulation of TGF-beta signaling in cancer cells and keratinocytes. Oncogene (2010) 29, 2181-2191; doi: 10.1038/onc.2009.506; published online 25 January 2010	[Hagiwara, S.; Murakumo, Y.; Mii, S.; Takahashi, M.] Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4648601, Japan; [Hagiwara, S.; Shigetomi, T.; Yamamoto, N.; Furue, H.; Ueda, M.] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Nagoya, Aichi 4648601, Japan; [Takahashi, M.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Pathol, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; Mii, Shinji/I-7480-2014	Takahashi, Masahide/0000-0002-2803-2683; Mii, Shinji/0000-0001-8266-3235	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Grants-in-Aid for Global Center of Excellence (GCOE) research, Scientific Research (A) and Scientific Research on Priority Area 'Cancer' commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to MT).	Arnold JN, 2006, J BIOL CHEM, V281, P6955, DOI 10.1074/jbc.M511432200; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Finnson KW, 2006, FASEB J, V20, P1525, DOI 10.1096/fj.05-5229fje; GARCIA M, 1993, J CELL SCI, V104, P1281; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Giesert C, 2003, ANN NY ACAD SCI, V996, P227, DOI 10.1111/j.1749-6632.2003.tb03250.x; GUARNACCIA SP, 1983, P NATL ACAD SCI-BIOL, V80, P1551, DOI 10.1073/pnas.80.6.1551; Hagiwara S, 2008, CANCER SCI, V99, P1916, DOI 10.1111/j.1349-7006.2008.00949.x; HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hasegawa M, 2008, PATHOL INT, V58, P288, DOI 10.1111/j.1440-1827.2008.02225.x; Hasegawa M, 2007, PATHOL INT, V57, P245, DOI 10.1111/j.1440-1827.2007.02097.x; Hashimoto M, 2004, ONCOGENE, V23, P3716, DOI 10.1038/sj.onc.1207418; Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2; KELTON JG, 1990, BLOOD, V75, P2172; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Murray LJ, 1999, EXP HEMATOL, V27, P1282, DOI 10.1016/S0301-472X(99)00071-5; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Sato T, 2007, PATHOL INT, V57, P719, DOI 10.1111/j.1440-1827.2007.02168.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; SUTHERLAND DR, 1991, BLOOD, V77, P84; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; Tam BYY, 2003, J BIOL CHEM, V278, P49610, DOI 10.1074/jbc.M308492200; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; WAECHTER CJ, 1977, ARCH BIOCHEM BIOPHYS, V181, P185, DOI 10.1016/0003-9861(77)90497-0; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang XM, 2009, MOL BIOL REP, V36, P861, DOI 10.1007/s11033-008-9256-x; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zhang JM, 2005, PATHOL INT, V55, P165, DOI 10.1111/j.1440-1827.2005.01807.x	40	58	60	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2181	2191		10.1038/onc.2009.506	http://dx.doi.org/10.1038/onc.2009.506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101215				2022-12-28	WOS:000276685200004
J	He, X; Zheng, Z; Song, T; Wei, C; Ma, H; Ma, Q; Zhang, Y; Xu, Y; Shi, W; Ye, Q; Zhong, H				He, X.; Zheng, Z.; Song, T.; Wei, C.; Ma, H.; Ma, Q.; Zhang, Y.; Xu, Y.; Shi, W.; Ye, Q.; Zhong, H.			c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation	ONCOGENE			English	Article						c-Abl nonreceptor tyrosine kinases; estrogen receptor alpha; transcriptional activity	BREAST-CANCER CELLS; ESTRADIOL-INDUCED PHOSPHORYLATION; LIGAND-INDEPENDENT ACTIVATION; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; PROTEIN-KINASE; IN-VIVO; HORMONE RECEPTORS; FAMILY KINASES	Estrogen receptors are members of the steroid hormone superfamily of nuclear receptors that act as ligand-activated transcription factors. Similar to other steroid hormone receptors, estrogen receptor alpha (ER alpha) is a substrate for protein kinases, and phosphorylation has profound effects on the function of this receptor. In this study, we show that ER alpha associates with c-Abl nonreceptor tyrosine kinase. The direct interaction is mediated by two PXXP motifs of ER alpha and the c-Abl SH3 domain. Mutational analysis and in vitro kinase assays show that ER alpha can be phosphorylated on two sites, tyrosine 52 (Y-52) and tyrosine 219 (Y-219). ER alpha phosphorylation by c-Abl stabilizes ER alpha, resulting in enhanced ER alpha transcriptional activity and increased expression of endogenous ER alpha target genes. Furthermore, ER alpha phosphorylation at the Y-219 site affects DNA binding and dimerization by ER alpha. Both the c-Abl inhibitor and the c-Abl kinase dead mutation abolish the c-Abl-induced accumulation of ER alpha and enhancement of ER alpha transcriptional activity, indicating that c-Abl kinase activity is required for regulation of the ER alpha function. Moreover, the ER alpha (Y52,219F) mutant shows reduced breast cancer cell growth and invasion. Taken together, these results show that c-Abl is a novel kinase that upregulates ER alpha expression and promotes breast cancer cell proliferation, suggesting a great potential for this kinase to function as a therapeutic target for breast cancer. Oncogene (2010) 29, 2238-2251; doi: 10.1038/onc.2009.513; published online 25 January 2010	[He, X.; Zheng, Z.; Song, T.; Wei, C.; Ma, H.; Ma, Q.; Ye, Q.; Zhong, H.] Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, Beijing 100850, Peoples R China; [Xu, Y.; Shi, W.] Jilin Univ, Key Lab Mol Enzymol, Changchun 130023, Peoples R China; [He, X.] Inst Dis Control & Prevent, Beijing, Peoples R China	Jilin University	Zhong, H (corresponding author), Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, 841 E Dist Bldg,27 Taipinglu, Beijing 100850, Peoples R China.	yeqn66@yahoo.com; towall@yahoo.com			National Natural Science Foundation [30772605, 30700413, 30870500, 30871276, 30530320]; Beijing Natural Science Foundation [7092081]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported in part by the National Natural Science Foundation (30772605, 30700413, 30870500, 30871276 and 30530320) and by the Beijing Natural Science Foundation (7092081).	Acconcia F, 2006, CANCER RES, V66, P11030, DOI 10.1158/0008-5472.CAN-06-2676; Agami R, 1999, NATURE, V399, P809; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Castano E, 1997, BIOCHEM J, V326, P149, DOI 10.1042/bj3260149; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; DEBORAH AL, 2003, STEROIDS, V68, P1; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Frech MS, 2005, CANCER RES, V65, P681; Han JQ, 2006, NUCLEIC ACIDS RES, V34, P3095, DOI 10.1093/nar/gkl389; He X, 2009, APOPTOSIS, V14, P268, DOI 10.1007/s10495-009-0313-2; HIROKO Y, 2005, BREAST CANCER RES, V7, P753; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kim HJ, 2004, AM J HEMATOL, V76, P360, DOI 10.1002/ajh.20117; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Liu X, 2006, MOL CELL, V22, P317, DOI 10.1016/j.molcel.2006.04.007; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Nagano K, 2006, ONCOGENE, V25, P493, DOI 10.1038/sj.onc.1208996; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; SENAD M, 2005, J BIOL CHEM, V280, P33006; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tsai KKC, 2003, CANCER RES, V63, P3418; van Diest PJ, 2004, J CLIN PATHOL, V57, P675, DOI 10.1136/jcp.2003.010777; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	61	42	43	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2238	2251		10.1038/onc.2009.513	http://dx.doi.org/10.1038/onc.2009.513			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101225				2022-12-28	WOS:000276685200009
J	Muller, T; Stein, U; Poletti, A; Garzia, L; Rothley, M; Plaumann, D; Thiele, W; Bauer, M; Galasso, A; Schlag, P; Pankratz, M; Zollo, M; Sleeman, JP				Mueller, T.; Stein, U.; Poletti, A.; Garzia, L.; Rothley, M.; Plaumann, D.; Thiele, W.; Bauer, M.; Galasso, A.; Schlag, P.; Pankratz, M.; Zollo, M.; Sleeman, J. P.			ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients	ONCOGENE			English	Article						ASAP1; metastasis; ARF-GAP; motility; invasion	GTPASE-ACTIVATING PROTEIN; SMOOTH-MUSCLE-CELLS; PODOSOME FORMATION; BINDING-PROTEIN; EXPRESSION; SRC; PHOSPHORYLATION; INVASION; ARF1; GAP	We have previously performed an unbiased screen to identify genes whose expression is associated with the metastatic phenotype. Secondary screening of these genes using custom microarray chips identified ASAP1, a multidomain adaptor protein with ADP-ribosylation factor-GAP activity, as being potentially involved in tumor progression. Here, we show that at least three different splice forms of ASAP1 are upregulated in rodent tumor models in a manner that correlates with metastatic potential. In human cancers, we found that ASAP1 expression is strongly upregulated in a variety of tumors in comparison with normal tissue and that this expression correlates with poor metastasis-free survival and prognosis in colorectal cancer patients. Using loss and gain of function approaches, we were able to show that ASAP1 promotes metastasis formation in vivo and stimulates tumor cell motility, invasiveness, and adhesiveness in vitro. Furthermore, we show that ASAP1 interacts with the metastasis-promoting protein h-prune and stimulates its phosphodiesterase activity. In addition, ASAP1 binds to the SH3 domains of several proteins, including SLK with which it co-immunoprecipitates. These data support the notion that ASAP1 can contribute to the dissemination of a variety of tumor types and represent a potential target for cancer therapy. Oncogene (2010) 29, 2393-2403; doi:10.1038/onc.2010.6; published online 15 February 2010	[Poletti, A.; Rothley, M.; Thiele, W.; Sleeman, J. P.] Univ Heidelberg, Univ Med Mannheim, D-68167 Mannheim, Germany; [Mueller, T.; Rothley, M.; Plaumann, D.; Thiele, W.; Bauer, M.; Pankratz, M.; Sleeman, J. P.] Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; [Stein, U.] Max Delbruck Ctr Mol Med, Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany; [Garzia, L.; Galasso, A.; Zollo, M.] Ctr Ingn Genet & Biotecnol Avanzate CEINGE, Naples, Italy; [Schlag, P.] Charite Comprehens Canc Ctr, Berlin, Germany; [Zollo, M.] Univ Naples Federico 2, Fac Biotechnol Sci, Dipartimento Biochim & Biotecnol Med, Naples, Italy	Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; CEINGE Biotecnologie Avanzate; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Naples Federico II	Sleeman, JP (corresponding author), Univ Heidelberg, Univ Med Mannheim, Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	sleeman@medma.uni-heidelberg.de	Sleeman, Jonathan P/H-2515-2013; Thiele, Wilko/AAF-7856-2020	Sleeman, Jonathan P/0000-0003-1718-7687; Thiele, Wilko/0000-0002-8978-4192; Stein, Ulrike/0000-0001-7006-282X; Galasso, Alessia/0000-0001-7110-9925	BMBF; European Union [LSHC-CT-2004-503224]; AIRC [2007-2010]; Association for International Cancer Research (AICR) [08-0015]	BMBF(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); AIRC(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research (AICR)	This work was supported by grants to JPS and US from the BMBF NGFN2 CancerNet Program, to JPS from the European Union (FP6 STREP project BRECOSM, contract no. LSHC-CT-2004-503224), to MZ from AIRC 2007-2010 and to JPS and MZ from the Association for International Cancer Research (AICR, grant no. 08-0015). We thank Norma Howells and Selma Huber for animal care and Paul Randazzo, Craig Furman, and Margaret Frame for providing expression contructs. The contribution of Franziska Arlt Pia Hermann and Markus Niederstrasser is also gratefully acknowledged.	Andreev J, 1999, MOL CELL BIOL, V19, P2338; Bharti S, 2007, MOL CELL BIOL, V27, P8271, DOI 10.1128/MCB.01781-06; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Buffart TE, 2005, CELL ONCOL, V27, P57; Cougoule C, 2005, TRAFFIC, V6, P682, DOI 10.1111/j.1600-0854.2005.00307.x; D'Angelo A, 2004, CANCER CELL, V5, P137, DOI 10.1016/S1535-6108(04)00021-2; Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Harlow E., 1988, ANTIBODIES LAB MANUA; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hofmann M, 1998, J CELL SCI, V111, P1673; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kruljac-Letunic A, 2003, J BIOL CHEM, V278, P29560, DOI 10.1074/jbc.M302278200; Lin D, 2008, CANCER RES, V68, P4352, DOI 10.1158/0008-5472.CAN-07-5237; Liu YH, 2005, J BIOL CHEM, V280, P8884, DOI 10.1074/jbc.M412200200; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Marino N, 2007, CLIN EXP METASTAS, V24, P637, DOI 10.1007/s10585-007-9109-3; Mengwasser J, 2004, ONCOGENE, V23, P7430, DOI 10.1038/sj.onc.1207987; Nam JM, 2007, EMBO J, V26, P647, DOI 10.1038/sj.emboj.7601534; Nestl A, 2001, CANCER RES, V61, P1569; Nie ZZ, 2006, CURR BIOL, V16, P130, DOI 10.1016/j.cub.2005.11.069; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; Oda A, 2003, J BIOL CHEM, V278, P6456, DOI 10.1074/jbc.M210817200; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Oshiro T, 2002, J BIOL CHEM, V277, P38618, DOI 10.1074/jbc.M203453200; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Webb BA, 2005, AM J PHYSIOL-CELL PH, V289, pC898, DOI 10.1152/ajpcell.00095.2005; Zhou ST, 2006, AM J PHYSIOL-CELL PH, V290, pC463, DOI 10.1152/ajpcell.00350.2005	37	65	68	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2393	2403		10.1038/onc.2010.6	http://dx.doi.org/10.1038/onc.2010.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20154719				2022-12-28	WOS:000276951500008
J	Dudnakova, T; Spraggon, L; Slight, J; Hastie, N				Dudnakova, T.; Spraggon, L.; Slight, J.; Hastie, N.			Actin: a novel interaction partner of WT1 influencing its cell dynamic properties	ONCOGENE			English	Article						WT1; actin; nucleo-cytoplasmic shuttling	WILMS-TUMOR GENE; PROTEIN; TRANSCRIPTS; EXPRESSION; NUCLEUS; MYOSIN	The Wilms' tumour suppressor, WT1, is a zinc finger protein with key roles in normal development of the genitourinary system and tumourigenesis. Mutations or deletion of WT1 result in a spectrum of developmental disorders and susceptibility to Wilms' tumour in children. Ectopic expression of Wt1 associated with oncogenic functions has been observed in a large number of malignancies, including haematological and solid cancers. Although Wt1 is predominantly a nuclear protein in normal tissues, it is mostly cytoplasmic in the majority of Wt1-expressing tumours. Actin was identified in this study as a new WT1 interaction partner both in the nucleus and in the cytoplasm. We confirmed this interaction both in vitro and in vivo and started to explore its functional significance. Perturbation of the actin cytoskeleton moved Wt1 off the polysome fraction in the cytoplasm, cancelled its nucleo-cytoplasmic shuttling and altered Wt1 DNA- and RNA-binding abilities. These data have implications for Wt1 functions in relation to RNA metabolism and response to cytoskeletal alterations in cancer cells. Thus, our findings could shed more light on the functions of both these proteins and possibly pave way for the development of new cancer therapies. Oncogene (2010) 29, 1085-1092; doi:10.1038/onc.2009.444; published online 7 December 2009	[Dudnakova, T.; Spraggon, L.; Slight, J.; Hastie, N.] Western Gen Hosp, MRC Human Genet Unit, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland; [Spraggon, L.] Univ Newcastle, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne, Tyne & Wear, England	University of Edinburgh; Newcastle University - UK	Hastie, N (corresponding author), Western Gen Hosp, MRC Human Genet Unit, Inst Genet & Mol Med, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	nick.hastie@hgu.mrc.ac.uk	Spraggon, Lee/E-5900-2012	Dudnakova, Tatyana/0000-0002-8388-8871	MRC; EU; MRC [MC_U127527180] Funding Source: UKRI; Medical Research Council [MC_U127527180] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EU(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Drs J Caceres and S Guil for their useful advice and GFP-hnRNP A1 and GFP-SF2 expressing constructs and anti-hnRNP A1 antibody. We also thank Mr Nick Tomczyk from the Chemistry Department at the University of Edinburgh for carrying out MALDI-TOF analysis. This study was funded by a core grant from the MRC and an EU Marie Curie Fellowship to TD.	Bing ZY, 2008, APPL IMMUNOHISTO M M, V16, P316, DOI 10.1097/PAI.0b013e31815c2e02; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; de Lanerolle P, 2005, NAT STRUCT MOL BIOL, V12, P742, DOI 10.1038/nsmb983; Discenza MT, 1997, NUCLEIC ACIDS RES, V25, P4314, DOI 10.1093/nar/25.21.4314; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Gimona M, 2008, SEMIN CANCER BIOL, V18, P23, DOI 10.1016/j.semcancer.2007.08.005; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Ladomery M, 2003, J CELL SCI, V116, P1539, DOI 10.1242/jcs.00324; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Louvet E, 2009, INT REV CEL MOL BIO, V272, P107, DOI 10.1016/S1937-6448(08)01603-1; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Rao JY, 2004, CURR CANCER DRUG TAR, V4, P345, DOI 10.2174/1568009043332998; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; Spraggon L, 2007, ONCOGENE, V26, P1484, DOI 10.1038/sj.onc.1209922; TELLMANN G, 2006, BIOCHEMICA MANNHEIM, V4, P16; Vajjhala PR, 2003, FEBS LETT, V554, P143, DOI 10.1016/S0014-5793(03)01144-X; Viney RL, 2007, PROTEOMICS, V7, P804, DOI 10.1002/pmic.200600666	22	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1085	1092		10.1038/onc.2009.444	http://dx.doi.org/10.1038/onc.2009.444			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19966868				2022-12-28	WOS:000274604400014
J	Nevo, J; Mai, A; Tuomi, S; Pellinen, T; Pentikainen, OT; Heikkila, P; Lundin, J; Joensuu, H; Bono, P; Ivaska, J				Nevo, J.; Mai, A.; Tuomi, S.; Pellinen, T.; Pentikainen, O. T.; Heikkila, P.; Lundin, J.; Joensuu, H.; Bono, P.; Ivaska, J.			Mammary-derived growth inhibitor (MDGI) interacts with integrin alpha-subunits and suppresses integrin activity and invasion	ONCOGENE			English	Article						integrin; MDGI; breast cancer; adhesion; migration; invasion	FATTY-ACID-BINDING; BREAST-CANCER; PROXIMITY LIGATION; BETA(1) INTEGRIN; CELL-MIGRATION; IN-SITU; ACTIVATION; PROTEIN; ADHESION; TALIN	The majority of mortality associated with cancer is due to formation of metastases from the primary tumor. Adhesion mediated by different integrin heterodimers has an important role during cell migration and invasion. Protein interactions with the beta 1-integrin cytoplasmic tail are known to influence integrin affinity for extracellular ligands, but regulating binding partners for the alpha-subunit cytoplasmic tails have remained elusive. In this study, we show that mammary-derived growth inhibitor (MDGI) (also known as FABP-3 or H-FABP) binds directly to the cytoplasmic tail of integrin alpha-subunits and its expression inhibits integrin activity. In breast cancer cell lines, MDGI expression correlates with suppression of the active conformation of integrins. This results in reduced integrin adhesion to type I collagen and fibronectin and inhibition of cell migration and invasion. In tissue microarray of 1331 breast cancer patients, patients with MDGI-positive tumors had more favorable 10-year distant disease-free survival compared with patients with MDGI-negative tumors. Our data indicate that MDGI is a novel interacting partner for integrin alpha-subunits, and its expression modulates integrin activity and suppresses cell invasion in breast cancer patients. Retained MDGI expression is associated with favorable prognosis. Oncogene (2010) 29, 6452-6463; doi:10.1038/onc.2010.376; published online 30 August 2010	[Ivaska, J.] Univ Turku, VTT Med Biotechnol, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Nevo, J.; Mai, A.; Tuomi, S.; Pellinen, T.; Ivaska, J.] VTT Tech Res Ctr Finland, Turku, Finland; [Nevo, J.; Mai, A.; Tuomi, S.; Pellinen, T.; Ivaska, J.] Abo Akad Univ, Turku, Finland; [Pentikainen, O. T.] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland; [Pentikainen, O. T.] Univ Jyvaskyla, Nanosci Ctr, Jyvaskyla, Finland; [Heikkila, P.] Helsinki Univ Hosp, Dept Pathol, Helsinki, Finland; [Lundin, J.; Joensuu, H.; Bono, P.] Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland; [Ivaska, J.] Univ Turku, Dept Biochem & Food Chem, FIN-20520 Turku, Finland	University of Turku; VTT Technical Research Center Finland; VTT Technical Research Center Finland; Abo Akademi University; University of Jyvaskyla; University of Jyvaskyla; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Turku	Ivaska, J (corresponding author), Univ Turku, VTT Med Biotechnol, Turku Ctr Biotechnol, Itainen Pitkakatu 4C, FIN-20520 Turku, Finland.	johanna.ivaska@vtt.fi	Lundin, Johan/I-1843-2018; Lundin, Johan/AAC-8510-2020; Pentikäinen, Olli T/E-1980-2012	Lundin, Johan/0000-0002-2681-4139; Lundin, Johan/0000-0002-2681-4139; Pentikäinen, Olli T/0000-0001-7188-4016; Joensuu, Heikki/0000-0003-0281-2507; Ivaska, Johanna/0000-0002-6295-6556	Academy of Finland; ERC; Sigrid Juselius Foundation; EMBO YIP Cancer Organization; Finnish Cancer Organization; Maud Kuistila Memorial Foundation; Turku University Foundation; Turku Graduate School of Biomedical Sciences; Drug Discovery Graduate School	Academy of Finland(Academy of Finland); ERC(European Research Council (ERC)European Commission); Sigrid Juselius Foundation(Sigrid Juselius Foundation); EMBO YIP Cancer Organization; Finnish Cancer Organization; Maud Kuistila Memorial Foundation; Turku University Foundation; Turku Graduate School of Biomedical Sciences; Drug Discovery Graduate School	We thank Professor J Ylanne and Professor M Salmi for critically reviewing the paper; J Siivonen, H Marttila, O Levalampi and P Terho for the excellent technical assistance. This study has been supported by Academy of Finland, ERC Starting Grant, Sigrid Juselius Foundation, EMBO YIP and Finnish Cancer Organizations. JN has been supported by Maud Kuistila Memorial Foundation and Turku University Foundation. JN, ST and TP were supported by Turku Graduate School of Biomedical Sciences and AM by Drug Discovery Graduate School.	Anthis NJ, 2009, EMBO J, V28, P3623, DOI 10.1038/emboj.2009.287; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bottcher RT, 2009, CURR OPIN CELL BIOL, V21, P670, DOI 10.1016/j.ceb.2009.05.008; Bouaouina M, 2008, J BIOL CHEM, V283, P6118, DOI 10.1074/jbc.M709527200; Bouvard D, 2003, J BIOL CHEM, V278, P6567, DOI 10.1074/jbc.M211258200; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Byron A, 2009, J CELL SCI, V122, P4009, DOI 10.1242/jcs.056770; Clark AJ, 2000, TRANSGENIC RES, V9, P439, DOI 10.1023/A:1026552629493; Czuchra A, 2006, J CELL BIOL, V174, P889, DOI 10.1083/jcb.200604060; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Harburger DS, 2009, J BIOL CHEM, V284, P11485, DOI 10.1074/jbc.M809233200; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Huynh H, 1997, CLIN CANCER RES, V3, P2151; Huynh H, 1996, CANCER RES, V56, P4865; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jarvius M, 2007, MOL CELL PROTEOMICS, V6, P1500, DOI 10.1074/mcp.M700166-MCP200; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; Lau TL, 2009, EMBO J, V28, P1351, DOI 10.1038/emboj.2009.63; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Lucke C, 2001, BIOCHEM J, V354, P259, DOI 10.1042/0264-6021:3540259; Lundin J, 2001, J CLIN ONCOL, V19, P28, DOI 10.1200/JCO.2001.19.1.28; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Millon-Fremillon A, 2008, J CELL BIOL, V180, P427, DOI 10.1083/jcb.200707142; Nevo J, 2009, CLIN CANCER RES, V15, P6570, DOI 10.1158/1078-0432.CCR-09-0773; Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Shi XH, 2007, J BIOL CHEM, V282, P20455, DOI 10.1074/jbc.M611680200; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takala H, 2008, BLOOD, V112, P1853, DOI 10.1182/blood-2007-12-127795; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Wang HL, 2000, ONCOGENE, V19, P2455, DOI 10.1038/sj.onc.1203575; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wegener KL, 2007, CELL, V128, P171, DOI 10.1016/j.cell.2006.10.048; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765	47	35	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6452	6463		10.1038/onc.2010.376	http://dx.doi.org/10.1038/onc.2010.376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802519				2022-12-28	WOS:000285138900005
J	Okamoto, J; Hirata, T; Chen, Z; Zhou, HM; Mikami, I; Li, H; Beltran, A; Johansson, M; Coussens, LM; Clement, G; Shi, Y; Zhang, F; Koizumi, K; Shimizu, K; Jablons, D; He, B				Okamoto, J.; Hirata, T.; Chen, Z.; Zhou, H-M; Mikami, I.; Li, H.; Beltran, A.; Johansson, M.; Coussens, L. M.; Clement, G.; Shi, Y.; Zhang, F.; Koizumi, K.; Shimizu, K.; Jablons, D.; He, B.			EMX2 is epigenetically silenced and suppresses growth in human lung cancer	ONCOGENE			English	Article						EMX2; methylation; lung cancer; WNT signaling; tumor suppression	INHIBITORY FACTOR-I; PROMOTER HYPERMETHYLATION; S100 PROTEINS; EXPRESSION; METHYLATION; GENE; METASTASIS; PATHOLOGY; FAMILY; TARGET	Lung cancer is a common cancer and the leading cause of cancer-related death worldwide. Aberrant activation of WNT signaling is implicated in lung carcinogenesis. EMX2, a human homologue of the Drosophila empty spiracles gene is a homeodomain-containing transcription factor. The function of EMX2 has been linked to the WNT signaling pathway during embryonic patterning in mice. However, little is known about the role of EMX2 in human tumorigenesis. In this study, we found that EMX2 was dramatically downregulated in lung cancer tissue samples and this downregulation was associated with methylation of the EMX2 promoter. Restoration of EMX2 expression in lung cancer cells lacking endogenous EMX2 expression suppressed cell proliferation and invasive phenotypes, inhibited canonical WNT signaling, and sensitized lung cancer cells to the treatment of the chemo cytotoxic drug cisplatin. On the other hand, knockdown of EMX2 expression in lung cancer cells expressing endogenous EMX2 promoted cell proliferation, invasive phenotypes and canonical WNT signaling. Taken together, our study suggests that EMX2 may have important roles as a novel suppressor in human lung cancer. Oncogene (2010) 29, 5969-5975; doi:10.1038/onc.2010.330; published online 9 August 2010	[Okamoto, J.; Hirata, T.; Chen, Z.; Mikami, I.; Li, H.; Beltran, A.; Clement, G.; Shi, Y.; Zhang, F.; Jablons, D.; He, B.] Univ Calif San Francisco, Thorac Oncol Program, Dept Surg, San Francisco, CA 94115 USA; [Okamoto, J.; Hirata, T.; Mikami, I.; Koizumi, K.; Shimizu, K.] Nippon Med Sch, Div Thorac Surg, Dept Surg, Tokyo 113, Japan; [Chen, Z.; Zhou, H-M] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; [Johansson, M.; Coussens, L. M.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA; [Johansson, M.; Coussens, L. M.; Jablons, D.; He, B.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA; [Shi, Y.] SRI Int, Biosci Div, Menlo Pk, CA 94025 USA	University of California System; University of California San Francisco; Nippon Medical School; Tsinghua University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; SRI International	He, B (corresponding author), Univ Calif San Francisco, Thorac Oncol Program, Dept Surg, 2340 Sutter St,Room N222, San Francisco, CA 94115 USA.	biao.he@ucsfmedctr.org	Coussens, Lisa/ABH-9834-2020		Joan's Legacy: uniting against Lung Cancer Research Grant; NIH/NCI [R01CA125030, R01CA130980, R01CA13256]; Eileen D Ludwig endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan foundation; McClain foundation; Abrams foundation; Fernandez foundation; Lyons foundation; Greenwood foundation; Harley and Oberman Foundation; Barbara Isackson Lung Cancer Research Fund; Swedish Cancer Institute; DOD [W81XWH-06-1-0416]; NATIONAL CANCER INSTITUTE [R01CA125030, R01CA132566, R01CA130980] Funding Source: NIH RePORTER	Joan's Legacy: uniting against Lung Cancer Research Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eileen D Ludwig endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan foundation; McClain foundation; Abrams foundation; Fernandez foundation; Lyons foundation; Greenwood foundation; Harley and Oberman Foundation; Barbara Isackson Lung Cancer Research Fund; Swedish Cancer Institute; DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grant from Joan's Legacy: uniting against Lung Cancer Research Grant, NIH/NCI grant R01CA125030 and the Eileen D Ludwig endowed for Thoracic Oncology Research (to BH); the Bonnie J Addario Lung Cancer Foundation, the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation and the Barbara Isackson Lung Cancer Research Fund (DJ); Swedish Cancer Institute (MJ); NIH/NCI grants R01CA130980, R01CA13256 and DOD BCRP Era of Hope Scholar Award (W81XWH-06-1-0416) (to LMC). Microarray profiling was done by the UCSF Shared Microarray Core Facilities. We thank M Roshni Ray for editing this paper.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; American Cancer Society, 2008, CANC FACTS FIG; BOERSMA CJ, 1999, MOL CELL BIOL RES CO, V2, P117; Clement G, 2008, CANCER SCI, V99, P46, DOI 10.1111/j.1349-7006.2007.00663.x; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341; Fong KM, 2003, THORAX, V58, P892, DOI 10.1136/thorax.58.10.892; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; Galli R, 2002, DEVELOPMENT, V129, P1633; Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517; Grote HJ, 2006, CANCER CYTOPATHOL, V108, P129, DOI 10.1002/cncr.21717; Grote HJ, 2005, INT J CANCER, V116, P720, DOI 10.1002/ijc.21090; He B, 2005, CANCER RES, V65, P743; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Ligon KL, 2003, DEVELOPMENT, V130, P2275, DOI 10.1242/dev.00421; Lind GE, 2006, J PATHOL, V210, P441, DOI 10.1002/path.2064; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Noonan FC, 2003, GENOMICS, V81, P58, DOI 10.1016/S0888-7543(02)00023-X; Noonan FC, 2001, GENOMICS, V76, P37, DOI 10.1006/geno.2001.6590; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Raz DJ, 2008, CLIN CANCER RES, V14, P5565, DOI 10.1158/1078-0432.CCR-08-0544; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Taylor HS, 2005, MOL ENDOCRINOL, V19, P2839, DOI 10.1210/me.2005-0130; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297; Zochbauer-Muller S, 2000, Clin Lung Cancer, V2, P141, DOI 10.3816/CLC.2000.n.027	36	43	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5969	5975		10.1038/onc.2010.330	http://dx.doi.org/10.1038/onc.2010.330			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697358	Green Accepted			2022-12-28	WOS:000283843400010
J	Pan, J; Nakade, K; Huang, YC; Zhu, ZW; Masuzaki, S; Hasegawa, H; Murata, T; Yoshiki, A; Yamaguchi, N; Lee, CH; Yang, WC; Tsai, EM; Obata, Y; Yokoyama, KK				Pan, J.; Nakade, K.; Huang, Y-C; Zhu, Z-W; Masuzaki, S.; Hasegawa, H.; Murata, T.; Yoshiki, A.; Yamaguchi, N.; Lee, C-H; Yang, W-C; Tsai, E-M; Obata, Y.; Yokoyama, K. K.			Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2	ONCOGENE			English	Article						cyclin-A2; cell proliferation; JDP2; epidermal thickness; cell-cycle arrest	INSERTIONAL MUTAGENESIS; AP-1 REPRESSOR; TRANSCRIPTION FACTOR; DIFFERENTIATION; IDENTIFICATION; TRANSFORMATION; FIBROBLASTS; ACTIVATION; INHIBITORS; DISTINCT	We report here a novel role for Jun dimerization protein-2 (JDP2) as a regulator of the progression of normal cells through the cell cycle. To determine the role of JDP2 in vivo, we generated Jdp2-knockout (Jdp2KO) mice by targeting exon-1 to disrupt the site of initiation of transcription. The epidermal thickening of skin from the Jdp2KO mice after treatment with 12-O-tetradecanoyl-phorbol 13-acetate (TPA) proceeded more rapidly than that of control mice, and more proliferating cells were found at the epidermis. Fibroblasts derived from embryos of Jdp2KO mice proliferated faster and formed more colonies than fibroblasts from wild-type mice. JDP2 was recruited to the promoter of the gene for cyclin-A2 (ccna2) at the AP-1 site. Cells lacking Jdp2 had elevated levels of cyclin-A2 mRNA. Furthermore, reintroduction of JDP2 resulted in the repression of transcription of ccna2 and of cell-cycle progression. Thus, transcription of the gene for cyclin-A2 appears to be a direct target of JDP2 in the suppression of cell proliferation. Oncogene (2010) 29, 6245-6256; doi:10.1038/onc.2010.355; published online 30 August 2010	[Huang, Y-C; Lee, C-H; Tsai, E-M; Yokoyama, K. K.] Kaohsiung Med Univ, Grad Inst Med, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan; [Pan, J.; Nakade, K.; Masuzaki, S.; Murata, T.; Yoshiki, A.; Obata, Y.; Yokoyama, K. K.] RIKEN BioResource Ctr, Ibaraki, Japan; [Pan, J.; Zhu, Z-W] Zhejiang Acad Agr Sci, Inst Anim Husb & Vet, Hangzhou, Zhejiang, Peoples R China; [Hasegawa, H.; Yamaguchi, N.] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cell Biol, Chiba, Japan; [Lee, C-H] Kaohsiung Municipal Hsiaokang Hosp, Kaohsiung, Taiwan; [Yang, W-C] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Yokoyama, K. K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo, Japan	Kaohsiung Medical University; RIKEN; Zhejiang Academy of Agricultural Sciences; Chiba University; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Academia Sinica - Taiwan; University of Tokyo	Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan.	kazu@kmu.edu.tw	Lee, Chih-Hung/AAJ-5551-2020; Obata, Yuichi/A-5300-2016; Lee, Chih-Hung/B-4081-2010; Yoshiki, Atsushi/O-6162-2019; Yang, Wen-Chin/D-3441-2015	Lee, Chih-Hung/0000-0001-9804-3874; Obata, Yuichi/0000-0003-1839-4709; Yoshiki, Atsushi/0000-0002-9450-5151; Yang, Wen-Chin/0000-0001-6410-2581	RIKEN; Ministry of Education, Culture, Sports, Science and Technology of Japan; Kaohsiung Medical University, Taiwan [KMU-EM-99-3]	RIKEN; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kaohsiung Medical University, Taiwan	We thank S Itohara, C Jin, R Chiu, K Itakura, T Kondo, S Takahashi, P Kourilsky and G Gachelin for discussion, and L-H Lee, M Hirose and K Inabe for technical support. This work was supported by grants from the RIKEN Bioresource Project (to AY, YO and KKY), the Ministry of Education, Culture, Sports, Science and Technology of Japan (to KN, NY and KKY) and Kaohsiung Medical University, Taiwan (KMU-EM-99-3, to KKY, C-HL and ET).	Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bitton-Worms K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-54; Blazek E, 2003, ONCOGENE, V22, P2151, DOI 10.1038/sj.onc.1206312; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Caldon CE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-2; Chaudhry HW, 2004, J BIOL CHEM, V279, P35858, DOI 10.1074/jbc.M404975200; Cherasse Y, 2008, FEBS LETT, V582, P1537, DOI 10.1016/j.febslet.2008.03.050; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GRANA X, 1995, ONCOGENE, V11, P211; Heinrich R, 2004, J BIOL CHEM, V279, P5708, DOI 10.1074/jbc.M307608200; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Jin CY, 2006, NAT STRUCT MOL BIOL, V13, P331, DOI 10.1038/nsmb1063; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Kalaszczynska I, 2009, CELL, V138, P352, DOI 10.1016/j.cell.2009.04.062; Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321; Lerdrup M, 2005, BBA-MOL CELL RES, V1745, P29, DOI 10.1016/j.bbamcr.2005.06.008; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mateo F, 2009, ONCOGENE, V28, P2654, DOI 10.1038/onc.2009.127; Nakade K, 2007, CELL DEATH DIFFER, V14, P1398, DOI 10.1038/sj.cdd.4402129; Nakade K, 2009, J BIOL CHEM, V284, P10808, DOI 10.1074/jbc.M808333200; Nakamura Y, 1998, CANCER RES, V58, P4832; Ostrovsky O, 2002, J BIOL CHEM, V277, P40043, DOI 10.1074/jbc.M205494200; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Polisetty N, 2008, MOL VIS, V14, P431; Rasmussen MH, 2009, NUCLEIC ACIDS RES, V37, P4657, DOI 10.1093/nar/gkp469; Rasmussen MH, 2005, VIROLOGY, V337, P353, DOI 10.1016/j.virol.2005.04.027; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stewart M, 2007, CANCER RES, V67, P5126, DOI 10.1158/0008-5472.CAN-07-0433; Sweeney C, 1996, DEVELOPMENT, V122, P53; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weidenfeld-Baranboim K, 2008, NUCLEIC ACIDS RES, V36, P3608, DOI 10.1093/nar/gkn268; Weidenfeld-Baranboim K, 2009, NUCLEIC ACIDS RES, V37, P2194, DOI 10.1093/nar/gkp083	36	37	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6245	6256		10.1038/onc.2010.355	http://dx.doi.org/10.1038/onc.2010.355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802531	hybrid, Green Published			2022-12-28	WOS:000284601700006
J	Li, L; Wei, XH; Pan, YP; Li, HC; Yang, H; He, QH; Pang, Y; Shan, Y; Xiong, FX; Shao, GZ; Zhou, RL				Li, L.; Wei, X. H.; Pan, Y. P.; Li, H. C.; Yang, H.; He, Q. H.; Pang, Y.; Shan, Y.; Xiong, F. X.; Shao, G. Z.; Zhou, R. L.			LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling	ONCOGENE			English	Article						LAPTM4B; multidrug resistance; drug efflux; PI3K-AKT signaling	P-GLYCOPROTEIN; TETRATRANSMEMBRANE PROTEIN; MEMBRANE-PROTEIN; DRUG-RESISTANCE; EXPRESSION; OVEREXPRESSION; MECHANISMS; INHIBITOR; MARKER; GROWTH	LAPTM4B (lysosomal protein transmembrane 4 beta) is a newly identified cancer-associated gene. Both of its mRNA and the encoded LAPTM4B-35 protein are significantly upregulated with more than 70% frequency in a wide variety of cancers. The LAPTM4B-35 level in cancer is evidenced to be an independent prognostic factor and its upregulation promotes cell proliferation, migration and invasion, as well as tumorigenesis in nude mice. In contrary, knockdown of LAPTM4B-35 expression by RNA interference (RNAi) reverses all of the above malignant phenotypes. We herein reveal a new role of LAPTM4B-35 in promoting multidrug resistance of cancer cells. Upregulation of LAPTM4B-35 motivates multidrug resistance by enhancement of efflux from cancer cells of a variety of chemodrugs with variant structures and properties, including doxorubicin, paclitaxel and cisplatin through colocalization and interaction of LAPTM4B-35 with multidrug resistance (MDR) 1 (P-glycoprotein, P-gp), and also by activation of PI3K/AKT signaling pathway through interaction of PPRP motif contained in the N-terminus of LAPTM4B-35 with the p85 alpha regulatory subunit of PI3K. The specific inhibitors of PI3K and knockdown of LAPTM4B-35 expression by RNAi eliminate the multidrug resistance effect motivated by upregulation of LAPTM4B-35. In conclusion, LAPTM4B-35 motivates multidrug resistance of cancer cells by promoting drug efflux through colocalization and interaction with P-gp, and anti-apoptosis by activating PI3K/AKT signaling. These findings provide a promising novel strategy for sensitizing chemical therapy of cancers and increasing the chemotherapeutic efficacy through knockdown LAPTM4B-35 expression by RNAi. Oncogene (2010) 29, 5785-5795; doi: 10.1038/onc.2010.303; published online 16 August 2010	[Li, L.; Wei, X. H.; Pan, Y. P.; Li, H. C.; Yang, H.; He, Q. H.; Pang, Y.; Shan, Y.; Xiong, F. X.; Shao, G. Z.; Zhou, R. L.] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing 100191, Peoples R China	Peking University	Zhou, RL (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Cell Biol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	rlzhou@bjmu.edu.cn	Shan, Yi/E-3862-2016	Li, Li/0000-0002-8630-3699	211 and 985 Foundation of Peking University; National High-tech R&D Program (863 Program) [2006AA02A305]; 248 major R&D program of Beijing [H020220020310]; NNSFC [90408018]	211 and 985 Foundation of Peking University; National High-tech R&D Program (863 Program)(National High Technology Research and Development Program of China); 248 major R&D program of Beijing; NNSFC(National Natural Science Foundation of China (NSFC))	This work was supported by grants from 211 and 985 Foundation of Peking University, National High-tech R&D Program (863 Program) (2006AA02A305), 248 major R&D program of Beijing (H020220020310) and NNSFC (90408018).	Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006; Cabrita MA, 1999, CANCER RES, V59, P4890; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; Duvvuri M, 2005, BIOCHEMISTRY-US, V44, P15743, DOI 10.1021/bi051759w; Fu D, 2007, AM J PHYSIOL-CELL PH, V292, pC1543, DOI 10.1152/ajpcell.00068.2006; GARCIA MG, 2008, LEUKEMIA RES, V33, P288; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; He Jing, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P348; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 1999, J BIOL CHEM, V274, P12877, DOI 10.1074/jbc.274.18.12877; Kasper G, 2005, CANCER LETT, V224, P93, DOI 10.1016/j.canlet.2004.10.004; Kim H, 1997, AM J PHYSIOL-CELL PH, V273, pC687, DOI 10.1152/ajpcell.1997.273.2.C687; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liu XR, 2004, WORLD J GASTROENTERO, V10, P1555, DOI 10.3748/wjg.v10.i11.1555; Liu XR, 2009, CANCER SCI, V100, P2335, DOI 10.1111/j.1349-7006.2009.01346.x; Morris DG, 2005, EUR J ENDOCRINOL, V153, P143, DOI 10.1530/eje.1.01937; Peng C, 2005, WORLD J GASTROENTERO, V11, P2704, DOI 10.3748/wjg.v11.i18.2704; Shao GZ, 2003, ONCOGENE, V22, P5060, DOI 10.1038/sj.onc.1206832; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Yang H, 2010, CANCER LETT, V294, P236, DOI 10.1016/j.canlet.2010.02.006; Yang H, 2010, J CANCER RES CLIN, V136, P275, DOI 10.1007/s00432-009-0659-4; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; Yang Y, 2008, ONCOL REP, V20, P1077, DOI 10.3892/or_00000112; Zhang XY, 2008, EUR J OBSTET GYN R B, V139, P237, DOI 10.1016/j.ejogrb.2007.12.021; Zhou L, 2008, CANCER LETT, V264, P209, DOI 10.1016/j.canlet.2008.01.025; Zhou L, 2007, EUR J CANCER, V43, P809, DOI 10.1016/j.ejca.2006.10.025	31	95	105	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5785	5795		10.1038/onc.2010.303	http://dx.doi.org/10.1038/onc.2010.303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20711237				2022-12-28	WOS:000283586200004
J	Lu, C; Everhart, L; Tilan, J; Kuo, L; Sun, CCJ; Munivenkatappa, RB; Jonsson-Rylander, AC; Sun, J; Kuan-Celarier, A; Li, L; Abe, K; Zukowska, Z; Toretsky, JA; Kitlinska, J				Lu, C.; Everhart, L.; Tilan, J.; Kuo, L.; Sun, C-C J.; Munivenkatappa, R. B.; Jonsson-Rylander, A.-C.; Sun, J.; Kuan-Celarier, A.; Li, L.; Abe, K.; Zukowska, Z.; Toretsky, J. A.; Kitlinska, J.			Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy	ONCOGENE			English	Article						neuropeptide Y; neuroblastoma; angiogenesis	BAX-DEPENDENT APOPTOSIS; SMOOTH-MUSCLE-CELLS; INDUCED ANGIOGENESIS; NEURO-BLASTOMA; ADRENAL-GLAND; YY2 RECEPTOR; EXPRESSION; BIM; TUMORS; PHOSPHORYLATION	Neuroblastomas are pediatric tumors that develop from sympathetic precursors and express neuronal proteins, such as neuropeptide Y (NPY). NPY is a sympathetic neurotransmitter acting via multiple receptors (Y1-Y5R). Both NPY and Y2Rs are commonly expressed in neuroblastoma cell lines and tissues. The peptide secreted from neuroblastomas stimulates tumor cell proliferation and angiogenesis. As both processes are Y2R-mediated, the aim of this study was to assess Y2R as a potential therapeutic target for neuroblastoma. In vitro, Y2R antagonist (BIIE0246) prevented activation of p44/42 mitogen-activated protein kinase (MAPK) induced by endogenous NPY, which resulted in decreased proliferation and induction of Bim-mediated apoptosis. Similar growth-inhibitory effects were achieved with NPY small interfering RNA (siRNA) and Y2R siRNA. In vivo, Y2R antagonist significantly inhibited growth of SK-N-BE(2) and SK-N-AS xenografts, which was associated with decreased activation of p44/42 MAPK, as well as reduced proliferation (Ki67) and increased apoptosis (TdT-mediated dUTP nick end labeling; TUNEL). The Y2R antagonist also exerted an antiangiogenic effect. In vitro, it reduced the proliferation of endothelial cells induced by neuroblastoma-conditioned media. Consequently, the Y2R antagonist-treated xenografts had decreased vascularization and a high degree of focal fibrosis. In human neuroblastoma tissues, the expression of Y2R was observed in both tumor and endothelial cells, while NPY was predominantly expressed in neuroblastoma cells. In summary, Y2R is a promising new target for neuroblastoma therapy affecting both cancer cells and tumor vasculature. Oncogene (2010) 29, 5630-5642; doi:10.1038/onc.2010.301; published online 2 August 2010	[Lu, C.; Everhart, L.; Tilan, J.; Kuo, L.; Kuan-Celarier, A.; Li, L.; Zukowska, Z.; Kitlinska, J.] Georgetown Univ, Dept Physiol & Biophys, Washington, DC 20057 USA; [Sun, C-C J.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Munivenkatappa, R. B.] Univ Maryland, Sch Med, Dept Surg, Div Transplantat, Baltimore, MD 21201 USA; [Jonsson-Rylander, A.-C.] AstraZeneca, Dept Biosci, Molndal, Sweden; [Sun, J.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA; [Abe, K.] NHLBI, NIH, Bethesda, MD 20892 USA; [Toretsky, J. A.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; AstraZeneca; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Kitlinska, J (corresponding author), Georgetown Univ, Dept Physiol & Biophys, BSB 231A,3900 Reservoir Rd NW, Washington, DC 20057 USA.	jbk4@georgetown.edu	Lu, Congyi/G-3984-2013		NIH [1R01CA123211-01]; Children's Cancer Foundation (Baltimore, MD, USA); NATIONAL CANCER INSTITUTE [R01CA123211] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Cancer Foundation (Baltimore, MD, USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant 1R01CA123211-01 and funding from Children's Cancer Foundation (Baltimore, MD, USA) to Joanna Kitlinska. The authors would like to thank John Styliaris and David Hur for help in performing experiments. We also thank the Flow Cytometry/Cell Sorting Shared Resources of Lombardi Comprehensive Cancer Center for technical assistance and Children's Oncology Group for providing human samples.	BIEDLER JL, 1978, CANCER RES, V38, P3751; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; COHEN PS, 1990, CANCER RES, V50, P6055; Dotsch J, 1998, REGUL PEPTIDES, V75-6, P185, DOI 10.1016/S0167-0115(98)00067-6; Ekstrand AJ, 2003, P NATL ACAD SCI USA, V100, P6033, DOI 10.1073/pnas.1135965100; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; Jonsson-Rylander AC, 2003, PEPTIDES, V24, P255, DOI 10.1016/S0196-9781(03)00041-X; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Kitlinska J, 2002, PEPTIDES, V23, P71, DOI 10.1016/S0196-9781(01)00581-2; KOGNER P, 1994, ACTA PAEDIATR, V83, P423, DOI 10.1111/j.1651-2227.1994.tb18134.x; Korner M, 2004, CLIN CANCER RES, V10, P8426, DOI 10.1158/1078-0432.CCR-04-0821; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Lee EW, 2003, PEPTIDES, V24, P99, DOI 10.1016/S0196-9781(02)00281-4; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Magni P, 2000, NEUROPHARMACOLOGY, V39, P1628, DOI 10.1016/S0028-3908(99)00231-2; Malmstrom RE, 2001, BRIT J PHARMACOL, V133, P1073, DOI 10.1038/sj.bjp.0704171; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05-4770fje; Naveilhan P, 1999, NAT MED, V5, P1188, DOI 10.1038/13514; OHARE MMT, 1989, CANCER RES, V49, P7015; OHARE MMT, 1989, CANCER RES, V49, P7010; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Pons J, 2008, CAN J PHYSIOL PHARM, V86, P438, DOI [10.1139/Y08-054, 10.1139/y08-054]; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ribattia Domenico, 2005, Cancer Treatment Reviews, V31, P27, DOI 10.1016/j.ctrv.2004.09.006; Rossler J, 2008, EUR J CANCER, V44, P1645, DOI 10.1016/j.ejca.2008.05.015; Sheriff' S, 1998, REGUL PEPTIDES, V75-6, P309, DOI 10.1016/S0167-0115(98)00083-4; Shusterman S, 2005, CANCER LETT, V228, P171, DOI 10.1016/j.canlet.2005.01.049; Uddman R, 2002, PEPTIDES, V23, P927, DOI 10.1016/S0196-9781(02)00003-7; Wassberg E, 1999, UPSALA J MED SCI, V104, P1; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yoon HZ, 2002, CLIN EXP OPHTHALMOL, V30, P424, DOI 10.1046/j.1442-9071.2002.00573.x; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; ZUKOWSKAGROJEC Z, 1993, PEPTIDES, V14, P263, DOI 10.1016/0196-9781(93)90040-N	42	42	44	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5630	5642		10.1038/onc.2010.301	http://dx.doi.org/10.1038/onc.2010.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676138	Green Accepted			2022-12-28	WOS:000282946900009
J	Santonico, E; Belleudi, F; Panni, S; Torrisi, MR; Cesareni, G; Castagnoli, L				Santonico, E.; Belleudi, F.; Panni, S.; Torrisi, M. R.; Cesareni, G.; Castagnoli, L.			Multiple modification and protein interaction signals drive the Ring finger protein 11 (RNF11) E3 ligase to the endosomal compartment	ONCOGENE			English	Article						RING E3-ligase; acylation; endosome compartment; ubiquitination	LIPID RAFTS; BREAST-CANCER; WW DOMAIN; STABILITY; HRS; UBIQUITINATION; ENZYMOLOGY; EXPRESSION; PROTEOMICS; CAVEOLAE	Ring finger protein 11 (RNF11) is a small RING E3-ligase overexpressed in numerous human prostate, colon and invasive breast cancers. Although functional studies have implicated RNF11 in a variety of biological processes, including signal transduction and apoptosis, the molecular mechanisms underlying its function are still poorly understood. In this study we show that RNF11 is a membrane-associated E3 ligase co-localizing with markers of both the early and the recycling endosomes. Several modification and protein interaction signals in the RNF11 sequence are shown to affect its compartmentalization. Membrane binding requires two acylation motifs driving the myristoylation of Gly2 and the S-palmitoylation of Cys4. Accordingly, genetic removal of the myristoylating signal results in diffuse staining, whereas an RNF11 protein mutated in the palmitoylation signal is retained in compartments of the early secretory pathway. However, amino-terminal fusion to green fluorescent protein of a 10-residue peptide containing both acylation signals re-localizes the chimera to the plasma membrane, but it is not sufficient to direct it to the recycling compartment suggesting that additional signals contribute to the correct localization. In addition, we show that membrane anchoring through acylation is necessary for RNF11 to be post-translationally modified by the addition of several ubiquitin moieties and that loss of acylation severely impairs the in vivo ubiquitination mediated by the HECT E3-ligases Itch and Nedd4. Finally, in cells transfected with RNF11 we observe a correlation between high RNF11 expression, as in tumor cells, and a swelling of the endosomal compartment suggesting a possible role of the dysregulation of the endosome compartment in tumorigenesis. Oncogene (2010) 29, 5604-5618; doi:10.1038/onc.2010.294; published online 2 August 2010	[Santonico, E.; Cesareni, G.; Castagnoli, L.] Univ Roma Tor Vergata, Dept Mol Biol, I-00133 Rome, Italy; [Belleudi, F.; Torrisi, M. R.] Univ Roma La Sapienza, Dept Mol & Clin Med, Inst Pasteur, Fdn Cenci Bolognetti, Rome, Italy; [Panni, S.] Univ Calabria, Dept Cell Biol, Calabria, Italy; [Torrisi, M. R.] Azienda Osped S Andrea, Rome, Italy; [Cesareni, G.] IRCCS Fdn S Lucia, Rome, Italy	University of Rome Tor Vergata; Fondazione Cenci Bolognetti; Sapienza University Rome; University of Calabria; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Santa Lucia	Santonico, E (corresponding author), Univ Roma Tor Vergata, Dept Mol Biol, Via Ric Sci, I-00133 Rome, Italy.	Elena.Santonico@uniroma2.it; Cesareni@uniroma2.it; Castagnoli@uniroma2.it	Santonico, Elena/ABB-8919-2020; Cesareni, Gianni/AAW-1382-2020	Santonico, Elena/0000-0002-3897-8990; Castagnoli, Luisa/0000-0001-5283-8671; panni, simona/0000-0002-7500-4028	AIRC (Italian Association for Cancer Research)	AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro)	The work described in this study has been supported by AIRC (Italian Association for Cancer Research). We thank Dr Maurizio Mattei for RNF11 antibody production and Dr Palma Mattioli for helpful suggestions and support with microscopy.	Anderson LR, 2007, J NEUROPATH EXP NEUR, V66, P955, DOI 10.1097/nen.0b013e3181567f17; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Azmi PB, 2009, ANTICANCER RES, V29, P2253; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Burger A, 1998, ONCOGENE, V16, P327, DOI 10.1038/sj.onc.1201517; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Chen C, 2008, ONCOGENE, V27, P6845, DOI 10.1038/onc.2008.288; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Doray B, 2002, J BIOL CHEM, V277, P18477, DOI 10.1074/jbc.M201879200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Jacque E, 2009, EMBO J, V28, P455, DOI 10.1038/emboj.2009.18; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RESH MD, 2006, SCI STKE, pRE14, DOI DOI 10.1126/STKE.3592006RE14; Santonico Elena, 2007, BMC Biochemistry, V8, P29, DOI 10.1186/1471-2091-8-29; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scialpi F, 2008, BIOCHEM PHARMACOL, V76, P1515, DOI 10.1016/j.bcp.2008.07.028; Seki N, 1999, BBA-GENE STRUCT EXPR, V1489, P421, DOI 10.1016/S0167-4781(99)00190-6; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Xue Y, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-458	38	23	28	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5604	5618		10.1038/onc.2010.294	http://dx.doi.org/10.1038/onc.2010.294			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676133				2022-12-28	WOS:000282946900007
J	Shibata, T; Kokubu, A; Miyamoto, M; Hosoda, F; Gotoh, M; Tsuta, K; Asamura, H; Matsuno, Y; Kondo, T; Imoto, I; Inazawa, J; Hirohashi, S				Shibata, T.; Kokubu, A.; Miyamoto, M.; Hosoda, F.; Gotoh, M.; Tsuta, K.; Asamura, H.; Matsuno, Y.; Kondo, T.; Imoto, I.; Inazawa, J.; Hirohashi, S.			DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung	ONCOGENE			English	Article						lung cancer; cancer stem cell; DEK; neuroendocrine	COMPARATIVE GENOMIC HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; CANCER STEM-CELLS; CHROMOSOMAL TRANSLOCATION; PROTEIN DEK; HEPATOCELLULAR-CARCINOMA; PROTOONCOGENE; EXPRESSION; CHROMATIN; DIFFERENTIATION	Lung cancer shows diverse histological subtypes. Large-cell neuroendocrine cell carcinoma and small-cell lung carcinoma show similar histological features and clinical behaviors, and can be classified as high-grade neuroendocrine carcinoma (HGNEC) of the lung. Here we elucidated the molecular classification of pulmonary endocrine tumors by copy-number profiling. We compared alterations of copy number with the clinical outcome of HGNEC and identified a chromosomal gain of the DEK oncogene locus (6p22.3) that was significantly associated with poor prognosis. We further confirmed that DEK overexpression was associated with poor prognosis in a larger set of HGNEC. Downregulation of DEK by small hairpin RNA led to a marked reduction of in vitro colony formation, in vivo tumorigenicity and chemo-resistance, and was associated with loss of lung cancer stem cell markers. Gene expression profiling revealed that DEK downregulation was associated with altered expression of transcriptional regulators, which specifically include known targets of interchromosomal translocations in hematopoietic tumors, and knockdown of these epigenetic modifiers affected colony formation activity. Our study showed that DEK overexpression, partly through an increase in its gene dose, mediates the activity of global transcriptional regulators and is associated with tumor initiation activity and poor prognosis in HGNEC. Oncogene (2010) 29, 4671-4681; doi:10.1038/onc.2010.217; published online 14 June 2010	[Shibata, T.; Kokubu, A.; Miyamoto, M.; Hosoda, F.; Hirohashi, S.] Natl Canc Ctr, Canc Genom Project, Res Inst, Chuo Ku, Tokyo 1040045, Japan; [Shibata, T.; Gotoh, M.; Hirohashi, S.] Natl Canc Ctr, Div Pathol, Res Inst, Chuo Ku, Tokyo 1040045, Japan; [Tsuta, K.] Natl Canc Ctr, Clin Lab Div, Chuo Ku, Tokyo, Japan; [Asamura, H.] Natl Canc Ctr, Div Thorac Surg, Chuo Ku, Tokyo, Japan; [Matsuno, Y.] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan; [Kondo, T.] Natl Canc Ctr, Proteome Bioinfomat Project, Res Inst, Chuo Ku, Tokyo 1040045, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Grad Sch Biomed Sci, Tokyo, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Ctr Excellence Program Frontier Res Mol Destruct, Tokyo, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Hokkaido University; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Shibata, T (corresponding author), Natl Canc Ctr, Canc Genom Project, Res Inst, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tashibat@ncc.go.jp	imoto, Issei/D-8065-2012; Shibata, Tatsuhiro/AAO-1278-2021; Kondo, Tadashi/I-4819-2019; Imoto, Issei/AAD-5799-2020; Shibata, Tatsuhiro/ABA-8234-2020	Kondo, Tadashi/0000-0001-6405-7792; 	Ministry of Health, Labor and Welfare of Japan; New Energy and Industrial Technology Development Organization (NEDO), Japan; National Institute of Biomedical Innovation (NiBio)	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); New Energy and Industrial Technology Development Organization (NEDO), Japan(New Energy and Industrial Technology Development Organization (NEDO)); National Institute of Biomedical Innovation (NiBio)(National Institute of Biomedical Innovation)	We thank Dr Weixia Peng for the initial work of array CGH and Dr Yukihiro Yoshida for the help of clinical data analysis. We thank Dr S Diane Hayward at the Johns Hopkins University for generously providing the CBF1 reporter constructs (4xwtCBF1Luc and 4xmtCBF1Luc). This work was supported in part by Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan, a grant from the New Energy and Industrial Technology Development Organization (NEDO), Japan and a grant for the program for promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio).	Alexiadis V, 2000, GENE DEV, V14, P1308; Asamura H, 2006, J CLIN ONCOL, V24, P70, DOI 10.1200/JCO.2005.04.1202; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; Cavellan E, 2006, J BIOL CHEM, V281, P16264, DOI 10.1074/jbc.M600233200; Cleary J, 2005, J BIOL CHEM, V280, P31760, DOI 10.1074/jbc.M500884200; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; D'Adda T, 2005, MODERN PATHOL, V18, P795, DOI 10.1038/modpathol.3800353; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Fujita K, 2009, J HUM GENET, V54, P355, DOI 10.1038/jhg.2009.40; Gamble MJ, 2007, NAT STRUCT MOL BIOL, V14, P548, DOI 10.1038/nsmb1248; Glinsky GV, 2008, J CLIN ONCOL, V26, P2846, DOI 10.1200/JCO.2008.17.0266; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gustafsson BI, 2008, CANCER-AM CANCER SOC, V113, P5, DOI 10.1002/cncr.23542; Han SY, 2009, PATHOL INT, V59, P443, DOI 10.1111/j.1440-1827.2009.02392.x; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Jiang TY, 2009, CANCER RES, V69, P845, DOI 10.1158/0008-5472.CAN-08-2762; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Kappes F, 2004, MOL CELL BIOL, V24, P6011, DOI 10.1128/MCB.24.13.6011-6020.2004; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Ko SI, 2006, FEBS LETT, V580, P3217, DOI 10.1016/j.febslet.2006.04.081; Kondoh N, 1999, CANCER RES, V59, P4990; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Soares LMM, 2006, SCIENCE, V312, P1961, DOI 10.1126/science.1128659; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Peacock CD, 2008, J CLIN ONCOL, V26, P2883, DOI 10.1200/JCO.2007.15.2702; Peng WX, 2005, CANCER SCI, V96, P661, DOI 10.1111/j.1349-7006.2005.00092.x; Pina C, 2008, CELL STEM CELL, V2, P264, DOI 10.1016/j.stem.2008.01.013; Righi L, 2007, VIRCHOWS ARCH, V451, pS51, DOI 10.1007/s00428-007-0445-0; Sammons M, 2006, J BIOL CHEM, V281, P26802, DOI 10.1074/jbc.M600915200; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200; Shibata T, 2005, CLIN CANCER RES, V11, P6177, DOI 10.1158/1078-0432.CCR-05-0293; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Sriuranpong V, 2001, CANCER RES, V61, P3200; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Travis W.D., 2004, PATHOLOGY GENETICS T, P341; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Walch AK, 1998, AM J PATHOL, V153, P1089, DOI 10.1016/S0002-9440(10)65653-2; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330	54	50	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4671	4681		10.1038/onc.2010.217	http://dx.doi.org/10.1038/onc.2010.217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543864				2022-12-28	WOS:000281127400006
J	Deisenroth, C; Zhang, Y				Deisenroth, C.; Zhang, Y.			Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway	ONCOGENE			English	Review						ribosome biogenesis; ribosomal protein; Mdm2; p53; nucleolar stress	POLYMERASE-III TRANSCRIPTION; DIAMOND-BLACKFAN ANEMIA; NUCLEOLAR PROTEIN BOP1; RNA-SYNTHESIS; P53-DEPENDENT CHECKPOINT; CELL-PROLIFERATION; SACCHAROMYCES-CEREVISIAE; I TRANSCRIPTION; P53 ACTIVATION; DNA-DAMAGE	The dynamic processes of cell growth and cell division remain under constant surveillance. As one of the primary 'gatekeepers' of the cell, p53 has a major role in sensing a variety of stressors to maintain cellular homeostasis. Growth is driven by new protein synthesis, a process that requires robust manufacture of ribosomes in the nucleolus. Ribosome biogenesis is a complex process comprising transcription, modification, and processing of ribosomal RNA, production of ribosomal proteins (RPs) and auxiliary factors, and coordinated assembly of ribonucleoprotein particles to produce mature ribosomes. As the major function of the nucleolus, ribosome biogenesis demands a considerable amount of resources and must be maintained in a coordinated manner to ensure fidelity of the process. Perturbations to many aspects of ribosome biogenesis are thought to contribute to 'nucleolar stress' and trigger a RP-Mdm2-p53 stress response pathway. In this review, we will clarify how disruption to three major components of ribosome biogenesis can trigger nucleolar stress and activate p53, thereby lending support to a RP-Mdm2-p53 ribosome biogenesis surveillance pathway. Oncogene (2010) 29, 4253-4260; doi: 10.1038/onc.2010.189; published online 24 May 2010	[Deisenroth, C.; Zhang, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27514 USA; [Deisenroth, C.; Zhang, Y.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27514 USA; [Zhang, Y.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27514 USA; [Deisenroth, C.; Zhang, Y.] Univ N Carolina, Dept Radiat Oncol, Sch Med, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Box 7512,101 Manning Dr, Chapel Hill, NC 27514 USA.	ypzhang@med.unc.edu		Zhang, Yi/0000-0002-2789-0811	NCI NIH HHS [R01 CA127770, R01 CA100302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100302, R01CA127770] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Ayrault O, 2006, ONCOGENE, V25, P7577, DOI 10.1038/sj.onc.1209743; Azuma M, 2006, J BIOL CHEM, V281, P13309, DOI 10.1074/jbc.M601892200; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chakraborty A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004152; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Ellis SR, 2008, CURR TOP DEV BIOL, V82, P217, DOI 10.1016/S0070-2153(07)00008-7; Fujii K, 2009, GENE DEV, V23, P963, DOI 10.1101/gad.1775609; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Holzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141; Huang M, 2008, LEUKEMIA RES, V32, P131, DOI 10.1016/j.leukres.2007.03.025; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lai K, 2009, DEV DYNAM, V238, P76, DOI 10.1002/dvdy.21815; Lempiainen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Lindstrom MS, 2008, J BIOL CHEM, V283, P15568, DOI 10.1074/jbc.M801151200; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Liu JJ, 2006, J CELL PHYSIOL, V207, P287, DOI 10.1002/jcp.20589; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Luft F, 2010, J MOL MED-JMM, V88, P1, DOI 10.1007/s00109-009-0570-0; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARIA FC, 2008, HUM MUTAT, V29, P911; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Meek DW, 2003, MOL CANCER RES, V1, P1017; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Panic L, 2006, MOL CELL BIOL, V26, P8880, DOI 10.1128/MCB.00751-06; Parlato R, 2008, J NEUROSCI, V28, P12759, DOI 10.1523/JNEUROSCI.2439-08.2008; PERRY RP, 1963, EXP CELL RES, V29, P400, DOI 10.1016/S0014-4827(63)80003-8; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Skarie JM, 2008, HUM MOL GENET, V17, P2474, DOI 10.1093/hmg/ddn147; SOBELL HM, 1971, NATURE-NEW BIOL, V231, P200, DOI 10.1038/newbio231200a0; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Szymanski M, 2003, BIOCHEM J, V371, P641, DOI 10.1042/BJ20020872; Tang Q, 1999, DEV BIOL, V207, P239, DOI 10.1006/dbio.1998.9142; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang C, 2005, MOL CELL BIOL, V25, P6899, DOI 10.1128/MCB.25.16.6899-6911.2005; Zhang J, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-115; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	77	220	222	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4253	4260		10.1038/onc.2010.189	http://dx.doi.org/10.1038/onc.2010.189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498634				2022-12-28	WOS:000280547900002
J	Guo, G; Qiu, X; Wang, S; Chen, Y; Rothman, PB; Wang, Z; Chen, Y; Wang, G; Chen, JL				Guo, G.; Qiu, X.; Wang, S.; Chen, Y.; Rothman, P. B.; Wang, Z.; Chen, Y.; Wang, G.; Chen, J-L			Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells	ONCOGENE			English	Article						AKT1; v-Abl; Pim; mutation; cancer	SERINE/THREONINE KINASE PIM-1; HEMATOPOIETIC-CELLS; LEUKEMIA-CELLS; HUMAN CANCER; DOWNSTREAM; APOPTOSIS; PATHWAY; GROWTH; PHOSPHORYLATION; LEUKEMOGENESIS	Abl-mediated transformation requires the activation of multiple pathways involved in the cellular proliferation and survival, including PI3K/AKT and JAK/STAT-dependent Pim kinases. Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice. However, this mutation has not been identified in Abl-transformed cells. We investigated the presence of the AKT1(E17K) mutation in v-Abl-transformed cell clones. AKT1(E17K) was detected in 3 (2.6%) of 116 specimens examined. To show the involvement of AKT1(E17K) directly in v-Abl-mediated tumorigenesis, we infected bone marrow cells from mice with bicistronic retroviruses encoding v-Abl and either wild-type or the mutant AKT1. Interestingly, we found that E17K mutant greatly increased the v-Abl transformation efficiency as compared with wild-type AKT1. Ectopic expression of E17K mutant increased the expression levels of antiapoptotic protein BCL2 and phosphorylation levels of proapoptotic protein BAD. This correlated with an increased protection from imatinib-induced apoptosis in Abl transformants. Furthermore, AKT1(E17K) promotes survival of the Pim-deficient cells, indicating a functional link between AKT and Pim in v-Abl transformation. In addition, AKT1(E17K) delays loss of Pim-1 and Pim-2 protein levels on v-Abl inactivation, which suggests that there exists reciprocal signaling between AKT and Pim in v-Abl transformants. Oncogene (2010) 29, 3845-3853; doi: 10.1038/onc.2010.149; published online 3 May 2010	[Guo, G.; Qiu, X.; Wang, S.; Chen, Y.; Chen, J-L] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China; [Rothman, P. B.] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Wang, Z.; Chen, Y.] China Agr Univ, Coll Anim Med, Dept Cell Biol & Anat, Beijing 100094, Peoples R China; [Wang, G.] Louisiana State Univ, Hlth Sci Ctr, Dept Med & Genet, Gene Therapy Program, New Orleans, LA USA	Chinese Academy of Sciences; Institute of Microbiology, CAS; University of Iowa; China Agricultural University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Chen, JL (corresponding author), Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, W Beichen Rd, Beijing 100101, Peoples R China.	chenjl@im.ac.cn	Chen, Ji-Long/AAJ-2134-2021	Chen, Ji-Long/0000-0002-4274-0563; Guo, Guijie/0000-0002-9031-1915	Natural Science Foundation of China [30971476]; National Basic Research Program (973) of China [2009CB918902, 2010CB534004]; Chinese Academy of Sciences	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program (973) of China(National Basic Research Program of China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank members of Chen laboratory for helpful discussions. This work was supported by Natural Science Foundation of China (30971476), National Basic Research Program (973) of China (2009CB918902, 2010CB534004) and Hundreds of Talents Program of Chinese Academy of Sciences 2009-2014.	AHMED NN, 1993, ONCOGENE, V8, P1957; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Banerjee A, 1998, J IMMUNOL, V161, P4611; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen JL, 2008, BLOOD, V111, P1677, DOI 10.1182/blood-2007-04-083808; Cheng GD, 2005, COLD REG SCI TECHNOL, V42, P169, DOI 10.1016/j.coldregions.2005.01.002; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Deutsch AJA, 2007, BLOOD, V109, P3500, DOI 10.1182/blood-2006-06-030494; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gong L, 2004, J VIROL, V78, P1636, DOI 10.1128/JVI.78.4.1636-1644.2004; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Horn S, 2008, ONCOGENE, V27, P4096, DOI 10.1038/onc.2008.40; Hu XF, 2009, J CLIN INVEST, V119, P362, DOI 10.1172/JCI33216; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Mahmoud IS, 2008, BRIT J CANCER, V99, P488, DOI 10.1038/sj.bjc.6604512; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mohamedali A, 2008, TECHNOL CANCER RES T, V7, P407, DOI 10.1177/153303460800700509; Muraski JA, 2007, NAT MED, V13, P1467, DOI 10.1038/nm1671; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Riener MO, 2008, BRIT J CANCER, V99, P836, DOI 10.1038/sj.bjc.6604498; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tao WJ, 2008, ONCOGENE, V27, P3194, DOI 10.1038/sj.onc.1210979; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Zenz T, 2008, BRIT J HAEMATOL, V141, P742, DOI 10.1111/j.1365-2141.2008.07113.x; Zhang F, 2009, CANCER BIOL THER, V8, P846, DOI 10.4161/cbt.8.9.8210; Zilberman DE, 2009, CANCER GENET CYTOGEN, V191, P34, DOI 10.1016/j.cancergencyto.2009.01.009	41	32	33	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3845	3853		10.1038/onc.2010.149	http://dx.doi.org/10.1038/onc.2010.149			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440266				2022-12-28	WOS:000279385200012
J	Su, L; Cheng, H; Sampaio, AV; Nielsen, TO; Underhill, TM				Su, L.; Cheng, H.; Sampaio, A. V.; Nielsen, T. O.; Underhill, T. M.			EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor	ONCOGENE			English	Article						HDAC inhibitors; synovial sarcoma; EGR1; PTEN; apoptosis	TRANSCRIPTION FACTOR; CANCER CELLS; INDUCED APOPTOSIS; IN-VITRO; GROWTH; EXPRESSION; PROTEIN; P53; TRANSFORMATION; TRICHOSTATIN	Synovial sarcoma is a high-grade soft tissue malignancy, for which current cytotoxic chemotherapies provide limited benefit. Although histone deacetylase (HDAC) inhibitors are known to suppress synovial sarcoma in vitro and in vivo, the exact mechanism is not clear. In this study, we report a central role of the transcription factor, early growth response-1 (EGR1), in the regulation of HDAC inhibitor-induced apoptotic cell death in synovial sarcoma. The SS18-SSX oncoprotein, characteristic of synovial sarcoma, maintains EGR1 expression at low levels, whereas it is significantly increased after HDAC inhibitor treatment. On the contrary, EGR1 knockdown leads to a decrease in HDAC inhibitor-induced apoptosis. Moreover, we find that under these conditions phosphatase and tensin homolog deleted in chromosome 10 (PTEN) is upregulated and this occurs through direct binding of EGR1 to an element upstream of the PTEN promoter. Using a combination of gain-and loss-of-function approaches, we show that EGR1 modulation of PTEN contributes to HDAC inhibitor-induced apoptosis in synovial sarcoma. Finally, restoration of EGR1 or PTEN expression is sufficient to induce synovial sarcoma cell death. Taken together, our findings indicate that SS18-SSX-mediated attenuation of an EGR1-PTEN network regulates synovial sarcoma cell survival, and that HDAC inhibitor-mediated apoptosis operates at least in part through reactivation of this pathway. Oncogene (2010) 29, 4352-4361; doi: 10.1038/onc.2010.204; published online 31 May 2010	[Underhill, T. M.] Univ British Columbia, Biomed Res Ctr, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; [Cheng, H.; Nielsen, T. O.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Nielsen, TO (corresponding author), Vancouver Coastal Hlth Res Inst, Room JP1502,855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.	torsten@interchange.ubc.ca; tunderhi@brc.ubc.ca			Canadian Cancer Society Research Institute [018355]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	We thank Dr Diederik RH de Bruijn (Radbound University Nijmegen Medical Centre, Nijmegen, the Netherlands) for the gift of rabbit polyclonal antibody against SS18-SSX. This work was supported by a grant from the Canadian Cancer Society Research Institute (Grant #018355). Dr TO Nielsen is a scholar of the Michael Smith Foundation for Health Research, and Dr TM Underhill is an Arthritis Society Investigator.	Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bozzi F, 2008, TRANSL ONCOL, V1, P95, DOI 10.1593/tlo.08121; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Calogero A, 1996, ONCOGENE, V13, P2105; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Condorelli F, 2008, BRIT J PHARMACOL, V153, P657, DOI 10.1038/sj.bjp.0707608; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Gan YH, 2009, ORAL ONCOL, V45, pE150, DOI 10.1016/j.oraloncology.2009.05.563; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Habold C, 2008, J CELL MOL MED, V12, P607, DOI 10.1111/j.1582-4934.2007.00136.x; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Italiano A, 2009, ANN ONCOL, V20, P425, DOI 10.1093/annonc/mdn678; Ito T, 2005, CANCER LETT, V224, P311, DOI 10.1016/j.canlet.2004.10.030; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kim J, 2006, CANCER RES, V66, P784, DOI 10.1158/0008-5472.CAN-05-1316; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Liu J, 2001, INT J ONCOL, V18, P863; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Ma DZ, 2005, WORLD J GASTROENTERO, V11, P4472, DOI 10.3748/wjg.v11.i29.4472; Medina V, 1997, CANCER RES, V57, P3697; Moradei O, 2008, CURR TOP MED CHEM, V8, P841, DOI 10.2174/156802608784911581; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Okcu MF, 2003, J CLIN ONCOL, V21, P1602, DOI 10.1200/JCO.2003.07.008; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Roeb W, 2008, CELL CYCLE, V7, P837, DOI 10.4161/cc.7.7.5652; Roeb W, 2007, P NATL ACAD SCI USA, V104, P18085, DOI 10.1073/pnas.0708910104; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Stimson L, 2009, ANN ONCOL, V20, P1293, DOI 10.1093/annonc/mdn792; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	48	42	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4352	4361		10.1038/onc.2010.204	http://dx.doi.org/10.1038/onc.2010.204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514024				2022-12-28	WOS:000280547900011
J	Wiman, KG				Wiman, K. G.			Pharmacological reactivation of mutant p53: from protein structure to the cancer patient	ONCOGENE			English	Review						mutant p53; drug discovery; reactivation; apoptosis; cancer therapy	TUMOR-SUPPRESSOR; LEUKEMIA CELLS; RESCUE; RESTORATION; ACTIVATION; APOPTOSIS; MUTATIONS; CP-31398; PRIMA-1; GROWTH	The p53 tumor suppressor pathway blocks tumor development by triggering apoptosis or cellular senescence in response to oncogenic stress. A large fraction of human tumors carry p53 mutations that disrupt DNA binding of p53 and transcriptional regulation of target genes. Reconstitution of wild-type p53 in vivo triggers rapid elimination of tumors. Therefore, pharmacological reactivation of mutant p53 is a promising strategy for novel cancer therapy. Several approaches for identification of small molecules that target mutant p53 have been applied, including rational design and screening of chemical libraries. The compound PhiKan083 binds with high affinity to a crevice created by the Y220C mutation in p53 and stabilizes the mutant protein. The compound PRIMA-1 (p53 reactivation and induction of massive apoptosis) restores wild-type conformation to mutant p53 by binding to the core and induces apoptosis in human tumor cells. The PRIMA-1 analog APR-246 is currently tested in a clinical trial. Successful development of mutant p53-reactivating anticancer drugs should have a major impact on the treatment of cancer. Oncogene (2010) 29, 4245-4252; doi: 10.1038/onc.2010.188; published online 24 May 2010	Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X	Swedish Cancer Society; Swedish Medical Research Council; Cancer Society of Stockholm; EU	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Cancer Society of Stockholm; EU(European Commission)	I thank the Swedish Cancer Society (Cancerfonden), the Swedish Medical Research Council (VR), the Cancer Society of Stockholm (Cancerforeningen) and the EU 6th Framework Program for generous support. I am cofounder and shareholder of Aprea AB, a company that develops p53-based cancer therapy, and member of its board.	Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Bykov VJN, 2009, CELL CYCLE, V8, P2509, DOI 10.4161/cc.8.16.9382; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Huang C, 2009, CANCER BIOL THER, V8, P2185, DOI 10.4161/cbt.8.22.10446; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nahi H, 2006, BRIT J HAEMATOL, V132, P230, DOI 10.1111/j.1365-2141.2005.05851.x; Nahi H, 2004, BRIT J HAEMATOL, V127, P285, DOI 10.1111/j.1365-2141.2004.05210.x; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Olivier M, 2005, 25 YEARS OF P53 RESEARCH, P321, DOI 10.1007/1-4020-2922-5_14; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shi LM, 1998, MOL PHARMACOL, V53, P241, DOI 10.1124/mol.53.2.241; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Weinmann L, 2008, CELL DEATH DIFFER, V15, P718, DOI 10.1038/sj.cdd.4402301; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zache N, 2008, CELL ONCOL, V30, P411, DOI 10.3233/CLO-2008-0440; Zache N, 2008, MOL ONCOL, V2, P70, DOI 10.1016/j.molonc.2008.02.004	55	110	116	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4245	4252		10.1038/onc.2010.188	http://dx.doi.org/10.1038/onc.2010.188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498645				2022-12-28	WOS:000280547900001
J	Honaker, Y; Piwnica-Worms, H				Honaker, Y.; Piwnica-Worms, H.			Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction	ONCOGENE			English	Article						cell cycle; Chk1; beta-TrCP; ubiquitin	BETA-TRCP; S-PHASE; DNA-DAMAGE; MEDIATED DEGRADATION; PHOSPHATASE; PHOSPHORYLATION; CHECKPOINT; INHIBITOR; TRANSITION; PATHWAY	The Cdc25A protein phosphatase drives cell-cycle transitions by activating cyclin-dependent protein kinases. Failure to regulate Cdc25A leads to deregulated cell-cycle progression, bypass of cell-cycle checkpoints and genome instability. Ubiquitin-mediated proteolysis has an important role in balancing Cdc25A levels. Cdc25A contains a DS(82)G motif whose phosphorylation is targeted by beta-TrCP E3 ligase during interphase. Targeting beta-TrCP to Cdc25A requires phosphorylation of serines 79 (S79) and 82 (S82). Here, we report that casein kinase 1 alpha (CK1 alpha) phosphorylates Cdc25A on both S79 and S82 in a hierarchical manner requiring prior phosphorylation of S76 by Chk1 or GSK-3 beta. This facilitates beta-TrCP binding and ubiquitin-mediated proteolysis of Cdc25A throughout interphase and after exposure to genotoxic stress. The priming of Cdc25A by at least three kinases (Chk1, GSK-3 beta, CK1 alpha), some of which also require priming, ensures diverse extra- and intracellular signals interface with Cdc25A to precisely control cell division. Oncogene (2010) 29, 3324-3334; doi:10.1038/onc.2010.96; published online 29 March 2010	[Honaker, Y.; Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Piwnica-Worms, H.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Piwnica-Worms, H.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Campus Box 8228, St Louis, MO 63110 USA.	hpiwnica@cellbiology.wustl.edu	Piwnica-Worms, Helen/C-5214-2012		National Institutes of Health [GM047017, P50 CA94056]; NCI Cancer Center [P30 CA91842]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [P50CA094056, P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Van Leung-Pineda and Dr Tiebang Kang for helpful suggestions. We also thank Chris Ryan for editorial assistance. We thank Chris Ryan, Yonghao Hou, Mei-Shya Chen, Dr Jiandong Chen and Dr Binhua P Zhou for providing expression plasmids. This work was supported by grants from the National Institutes of Health (GM047017 and P50 CA94056). We acknowledge the p50 Molecular Imaging Center and the Alvin J. Siteman Cancer Center at Washington University School of Medicine for the use of the High Throughput Core. The Siteman Cancer Center was supported in part by an NCI Cancer Center Support Grant No. P30 CA91842. H.P.-W. is an Investigator of the Howard Hughes Medical Institute.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Donzelli M, 2004, CELL CYCLE, V3, P469; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ray D, 2005, MOL CELL BIOL, V25, P3338, DOI 10.1128/MCB.25.8.3338-3347.2005; Ray D, 2008, CANCER RES, V68, P1251, DOI 10.1158/0008-5472.CAN-07-5983; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	38	42	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2010	29	23					3324	3334		10.1038/onc.2010.96	http://dx.doi.org/10.1038/onc.2010.96			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20348946	Green Accepted			2022-12-28	WOS:000278622700002
J	Bafna, S; Kaur, S; Batra, SK				Bafna, S.; Kaur, S.; Batra, S. K.			Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells	ONCOGENE			English	Review						MUC4; MUC1; MUC16 (CA125); cancer; cell survival; apoptosis	INTRAMEMBRANE ERBB2 LIGAND; MUC4 MUCIN; MUC4/SIALOMUCIN COMPLEX; GENE-EXPRESSION; FACTOR RECEPTOR; MAMMARY-GLAND; TRANSMEMBRANE MUCIN; PROGNOSTIC-FACTOR; EPITHELIAL-CELLS; C-ABL	Mucins (MUC) are high molecular weight O-linked glycoproteins whose primary functions are to hydrate, protect, and lubricate the epithelial luminal surfaces of the ducts within the human body. The MUC family is comprised of large secreted gel forming and transmembrane (TM) mucins. MUC1, MUC4, and MUC16 are the well-characterized TM mucins and have been shown to be aberrantly overexpressed in various malignancies including cystic fibrosis, asthma, and cancer. Recent studies have uncovered the unique roles of these mucins in the pathogenesis of cancer. These mucins possess specific domains that can make complex associations with various signaling pathways, impacting cell survival through alterations of cell growth, proliferation, death, and autophagy. The cytoplasmic domain of MUC1 serves as a scaffold for interaction with various signaling proteins. On the other hand, MUC4 mediates its effect by stabilizing and enhancing the activity of growth factor receptor ErbB2. MUC16, previously known as CA125, is a well-known serum marker for the diagnosis of ovarian cancer and has a key role in stimulation and dissemination of ovarian cancer cells by interacting with mesothelin and galectin. Therefore, herein we discuss the function and divergent mechanisms of MUC1, MUC4, and MUC16 in carcinogenesis in the context of alteration in cell growth and survival. Oncogene (2010) 29, 2893-2904; doi:10.1038/onc.2010.87; published online 29 March 2010	[Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu			National Institutes of Health [CA78590, CA111294, CA133774, CA131944]; Department of Defense [BC074639]; NATIONAL CANCER INSTITUTE [R01CA133774, R01CA131944, R01CA078590, U01CA111294] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors on this work are supported by grants from the National Institutes of Health (CA78590, CA111294, CA133774, and CA131944) and Department of Defense grant (BC074639). We thank Kristi L Berger for the paper editing and Dr Shantibhusan Senapati for editing figures.	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Argueso P, 2003, INVEST OPHTH VIS SCI, V44, P2487, DOI 10.1167/iovs.02-0862; Aubert S, 2009, CANCER RES, V69, P5707, DOI 10.1158/0008-5472.CAN-08-4905; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Bafna S, 2008, CANCER RES, V68, P9231, DOI 10.1158/0008-5472.CAN-08-3135; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Bitler BG, 2009, CLIN CANCER RES, V15, P100, DOI 10.1158/1078-0432.CCR-08-1745; Blalock TD, 2007, INVEST OPHTH VIS SCI, V48, P4509, DOI 10.1167/iovs.07-0430; Boivin M, 2009, GYNECOL ONCOL, V115, P407, DOI 10.1016/j.ygyno.2009.08.007; Buisine MP, 2001, GUT, V49, P544, DOI 10.1136/gut.49.4.544; CAPSTICK V, 1991, International Journal of Biological Markers, V6, P129; Carraway KL, 2007, CURR TOP DEV BIOL, V78, P1, DOI 10.1016/S0070-2153(06)78001-2; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Copin MC, 2001, HUM PATHOL, V32, P274, DOI 10.1053/hupa.2001.22752; Corfield AP, 2001, FRONT BIOSCI-LANDMRK, V6, pD1321, DOI 10.2741/Corfield; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; Davidson B, 2007, DIAGN CYTOPATHOL, V35, P756, DOI 10.1002/dc.20771; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Gipson IK, 2005, E SCHERING RES FDN W, V52, P219; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Gubbels JAA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-11; Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011; Hanaoka J, 2001, CANCER-AM CANCER SOC, V92, P2148, DOI 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO;2-6; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Hattrup CL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1515; Higuchi T, 2004, MOL CELL BIOL, V24, P7456, DOI 10.1128/MCB.24.17.7456-7468.2004; Higuchi T, 2004, J BIOL CHEM, V279, P1968, DOI 10.1074/jbc.M304558200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Hu YP, 2003, BIOCHEM PHARMACOL, V65, P1419, DOI 10.1016/S0006-2952(03)00086-8; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Itoh Y, 2008, GLYCOBIOLOGY, V18, P74, DOI 10.1093/glycob/cwm118; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Kawano T, 2008, INT J ONCOL, V33, P153; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; KUI WN, 2003, J BIOL CHEM, V278, P28619, DOI DOI 10.1074/JBC.M302741200; LAN MS, 1990, J BIOL CHEM, V265, P15294; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li Gui-sen, 2005, Zhonghua Yi Xue Za Zhi, V85, P1333; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Mall AS, 2008, J CLIN PATHOL, V61, P1018, DOI 10.1136/jcp.2008.058057; Malmberg EK, 2008, BIOCHEM J, V410, P283, DOI 10.1042/BJ20071068; MATSUOKA Y, 1990, CANCER, V65, P506, DOI 10.1002/1097-0142(19900201)65:3<506::AID-CNCR2820650322>3.0.CO;2-0; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Moniaux N, 2006, J BIOL CHEM, V281, P23676, DOI 10.1074/jbc.M600302200; Nakamura T, 2007, CANCER RES, V67, P7597, DOI 10.1158/0008-5472.CAN-07-0874; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; Pallesen LT, 2002, EUR J BIOCHEM, V269, P2755, DOI 10.1046/j.1432-1033.2002.02949.x; Park HU, 2003, PANCREAS, V26, pe48; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Price-Schiavi SA, 2005, J CELL PHYSIOL, V203, P44, DOI 10.1002/jcp.20200; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rump A, 2004, J BIOL CHEM, V279, P9190, DOI 10.1074/jbc.M312372200; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scholler N, 2007, CANCER LETT, V247, P130, DOI 10.1016/j.canlet.2006.03.029; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shyu MK, 2007, HUM REPROD, V22, P2723, DOI 10.1093/humrep/dem249; Singh AP, 2006, PROSTATE, V66, P421, DOI 10.1002/pros.20372; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tamada S, 2006, CLIN CANCER RES, V12, P4257, DOI 10.1158/1078-0432.CCR-05-2814; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Tsutsumida H, 2007, LUNG CANCER, V55, P195, DOI 10.1016/j.lungcan.2006.10.013; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Workman HC, 2009, CANCER RES, V69, P2845, DOI 10.1158/0008-5472.CAN-08-2089; Yin L, 2004, J BIOL CHEM, V279, P45721, DOI 10.1074/jbc.M408027200; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2009, INT J ONCOL, V34, P1691, DOI 10.3892/ijo_00000300; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Zeimet AG, 1998, TUMOR BIOL, V19, P275, DOI 10.1159/000030018; Zhao QC, 2009, CANCER RES, V69, P6799, DOI 10.1158/0008-5472.CAN-09-1096	105	272	287	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2893	2904		10.1038/onc.2010.87	http://dx.doi.org/10.1038/onc.2010.87			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20348949	Green Accepted			2022-12-28	WOS:000277890400001
J	Millour, J; Constantinidou, D; Stavropoulou, AV; Wilson, MSC; Myatt, SS; Kwok, JMM; Sivanandan, K; Coombes, RC; Medema, RH; Hartman, J; Lykkesfeldt, AE; Lam, EWF				Millour, J.; Constantinidou, D.; Stavropoulou, A. V.; Wilson, M. S. C.; Myatt, S. S.; Kwok, J. M-M; Sivanandan, K.; Coombes, R. C.; Medema, R. H.; Hartman, J.; Lykkesfeldt, A. E.; Lam, E. W-F			FOXM1 is a transcriptional target of ER alpha and has a critical role in breast cancer endocrine sensitivity and resistance	ONCOGENE			English	Article						breast cancer; forkhead; estrogen receptor; FOXM1; endocrine resistance; transcription	ESTROGEN-RECEPTOR-ALPHA; CYCLIN D1; HEPATOCYTE ENTRY; REGULATED GENES; FACTOR HFH-11B; GROWTH-FACTOR; CELL-LINES; S-PHASE; EXPRESSION; MOUSE	In this study, we investigated the regulation of FOXM1 expression by estrogen receptor alpha (ER alpha) and its role in hormonal therapy and endocrine resistance. FOXM1 protein and mRNA expression was regulated by ER-ligands, including estrogen, tamoxifen (OHT) and fulvestrant (ICI182780; ICI) in breast carcinoma cell lines. Depletion of ER alpha by RNA interference (RNAi) in MCF-7 cells downregulated FOXM1 expression. Reporter gene assays showed that ER alpha activates FOXM1 transcription through an estrogen-response element ( ERE) located within the proximal promoter region. The direct binding of ER alpha to the FOXM1 promoter was confirmed in vitro by mobility shift and DNA pull-down assays and in vivo by chromatin immunoprecipitation (ChIP) analysis. Our data also revealed that upon OHT treatment ER alpha recruits histone deacetylases to the ERE site of the FOXM1 promoter, which is associated with a decrease in histone acetylation and transcription activity. Importantly, silencing of FOXM1 by RNAi abolished estrogen-induced MCF-7 cell proliferation and overcame acquired tamoxifen resistance. Conversely, ectopic expression of FOXM1 abrogated the cell cycle arrest mediated by the antiestrogen OHT. OHT repressed FOXM1 expression in endocrine sensitive but not resistant breast carcinoma cell lines. Furthermore, qRT-PCR analysis of breast cancer patient samples revealed that there was a strong and significant positive correlation between ERa and FOXM1 mRNA expression. Collectively, these results show FOXM1 to be a key mediator of the mitogenic functions of ER alpha and estrogen in breast cancer cells, and also suggest that the deregulation of FOXM1 may contribute to anti-estrogen insensitivity. Oncogene (2010) 29, 2983-2995; doi:10.1038/onc.2010.47; published online 8 March 2010	[Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, CR UK Labs, Dept Surg & Canc, London W12 0NN, England; [Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Hartman, J.] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden; [Lykkesfeldt, A. E.] Danish Canc Soc, Inst Canc Biol, Dept Breast Canc Res, Copenhagen, Denmark	Imperial College London; Utrecht University; Utrecht University Medical Center; Karolinska Institutet; Danish Cancer Society	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, CR UK Labs, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Wilson, Miranda/W-1453-2019; Medema, Rene H/E-2981-2013; Hartman, Johan/N-1406-2015; Medema, Rene H/G-5415-2011; Teh, Muy-Teck/B-9284-2016; Lam, Eric W-F/AAW-8566-2020	Wilson, Miranda/0000-0001-7521-4036; Hartman, Johan/0000-0002-6500-8527; Teh, Muy-Teck/0000-0002-7725-8355; Lam, Eric W-F/0000-0003-1274-3576; Coombes, Raoul Charles/0000-0002-4811-1100	Breast Cancer Campaign; Cancer Research UK; Biotechnology and Biological Sciences Research Council; Cancer Research UK [12011] Funding Source: researchfish	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK)	Grant support was given by Breast Cancer Campaign (J Millour and EW-F Lam), Cancer Research UK (SS Myatt, K-K Ho, RC Coombes, EW-F Lam), Biotechnology and Biological Sciences Research Council (MSC Wilson and EW-F Lam).	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; BRUNNER N, 1989, CANCER CELL-MON REV, V1, P81; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; DIAZARIAS AA, 1993, DIAGN CYTOPATHOL, V9, P516, DOI 10.1002/dc.2840090509; Elkak AE, 2001, CURR MED RES OPIN, V17, P282, DOI 10.1185/030079901753403180; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essafi Abdelkader, 2009, V462, P201, DOI 10.1007/978-1-60327-115-8_13; Fellowes VS, 2004, INT J ONCOL, V24, P861; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; GAPINSKI PV, 1980, SURGERY, V88, P386; Goss PE, 2008, CLIN BREAST CANCER, V8, P411, DOI 10.3816/CBC.2008.n.049; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kothari MS, 2003, BRIT J CANCER, V88, P1071, DOI 10.1038/sj.bjc.6600866; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Laoukili J, 2008, MOL CELL BIOL, V28, P3076, DOI 10.1128/MCB.01710-07; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150; Luscher-Firzlaff JM, 2006, FEBS LETT, V580, P1716, DOI 10.1016/j.febslet.2006.02.021; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1986, BREAST CANCER RES TR, V7, P83; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Madsen MW, 1997, CANCER RES, V57, P585; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Myatt SS, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-6; OSBORNE CK, 1979, B CANCER, V66, P203; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Schug Jonathan, 2008, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0206s21; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Wang Y, 2008, CANCER RES, V68, P5628, DOI 10.1158/0008-5472.CAN-07-3170; Wierstra I, 2006, BIOCHEM BIOPH RES CO, V348, P99, DOI 10.1016/j.bbrc.2006.07.008; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; Yamashita H, 2008, INT J CLIN ONCOL, V13, P380, DOI 10.1007/s10147-008-0818-7; Yamashita H, 2009, CANCER SCI, V100, P2028, DOI 10.1111/j.1349-7006.2009.01274.x; Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Zwart W, 2009, MOL ENDOCRINOL, V23, P1335, DOI 10.1210/me.2008-0268	54	112	119	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2983	2995		10.1038/onc.2010.47	http://dx.doi.org/10.1038/onc.2010.47			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208560	Green Accepted, Green Submitted			2022-12-28	WOS:000277890400009
J	Zanella, F; Renner, O; Garcia, B; Callejas, S; Dopazo, A; Peregrina, S; Carnero, A; Link, W				Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W.			Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells	ONCOGENE			English	Article						TRIB2; FOXO; melanoma; RNAi; screening	TRANSCRIPTION FACTORS; PROTEINS; TRIBBLES; SCREEN; MORPHOGENESIS; METASTASIS; EXPRESSION; DROSOPHILA; SURVIVAL; LINEAGE	FOXO transcription factors are evolutionarily conserved proteins that orchestrate gene expression programs known to control a variety of cellular processes such as cell cycle, apoptosis, DNA repair and protection from oxidative stress. As the abrogation of FOXO function is a key feature of many tumor cells, regulation of FOXO factors is receiving increasing attention in cancer research. In order to discover genes involved in the regulation of FOXO activity, we performed a large-scale RNA-mediated interference (RNAi) screen using cell-based reporter systems that monitor transcriptional activity and subcellular localization of FOXO. We identified genes previously implicated in phosphoinositide 3-kinase/Akt signaling events, which are known to be important for FOXO function. In addition, we discovered a previously unrecognized FOXO-repressor function of TRIB2, the mammalian homolog of the Drosophila gene tribbles. A cancer-profiling array revealed specific overexpression of TRIB2 in malignant melanoma, but not in other types of skin cancer. We provide experimental evidence that TRIB2 transcript levels correlate with the degree of cytoplasmic localization of FOXO3a. Moreover, we show that TRIB2 is important in the maintenance of the oncogenic properties of melanoma cells, as its silencing reduces cell proliferation, colony formation and wound healing. Tumor growth was also substantially reduced upon RNAi-mediated TRIB2 knockdown in an in vivo melanoma xenograft model. Our studies suggest that TRIB2 provides the melanoma cells with growth and survival advantages through the abrogation of FOXO function. Altogether, our results show the potential of large-scale cell-based RNAi screens to identify promising diagnostic markers and therapeutic targets. Oncogene (2010) 29, 2973-2982; doi:10.1038/onc.2010.58; published online 8 March 2010	[Zanella, F.; Renner, O.; Garcia, B.; Peregrina, S.; Carnero, A.; Link, W.] CNIO, Expt Therapeut Program, Madrid 28029, Spain; [Callejas, S.; Dopazo, A.] CNIC, Genom Unit, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Link, W (corresponding author), CNIO, Expt Therapeut Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	wlink@cnio.es	Renner, Oliver/M-7002-2015; Dopazo, Ana/N-1159-2014; Link, Wolfgang/F-4435-2012; IBIS, CANCER/P-3323-2015	Renner, Oliver/0000-0002-4046-0517; Dopazo, Ana/0000-0002-4910-1684; Link, Wolfgang/0000-0002-3340-5165; Callejas, Sergio/0000-0003-3351-4940; Carnero, Amancio/0000-0003-4357-3979	Spanish MEC [BIO2006-02432]; Marie Curie Fellowship	Spanish MEC(Spanish Government); Marie Curie Fellowship(European Commission)	This work was supported by a grant from the Spanish MEC (project BIO2006-02432). FZ is the recipient of a Marie Curie Fellowship. We acknowledge the expert technical assistance of D Megias, J C Cigudosa, J Monsech and O Dominguez. We thank M Hu, T Unterman and E Kiss-Toth for providing plasmids and JF Martinez for helpful discussions and critical reading of this paper. We are indebted to R Bernards for advice and for providing us with the NKI shRNA library.	Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hegedus Z, 2006, CELL MOL LIFE SCI, V63, P1632, DOI 10.1007/s00018-006-6007-9; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hilmi C, 2008, PIGM CELL MELANOMA R, V21, P139, DOI 10.1111/j.1755-148X.2008.00440.x; Hou L, 2000, DEVELOPMENT, V127, P5379; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Meier F, 2007, BRIT J DERMATOL, V156, P1204, DOI 10.1111/j.1365-2133.2007.07821.x; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Rosado A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001823; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Zanella F, 2008, CHEMBIOCHEM, V9, P2229, DOI 10.1002/cbic.200800255; Zanella F, 2007, ASSAY DRUG DEV TECHN, V5, P333, DOI 10.1089/adt.2007.058; Zanella F, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-14	28	82	83	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					2973	2982		10.1038/onc.2010.58	http://dx.doi.org/10.1038/onc.2010.58			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208562				2022-12-28	WOS:000277890400008
J	Dong, F; Soubeyrand, S; Hache, RJG				Dong, F.; Soubeyrand, S.; Hache, R. J. G.			Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5	ONCOGENE			English	Article						Ku antigen; PARP-1; protein phosphatase 5; DNA repair; bleomycin	DOUBLE-STRAND BREAKS; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE-1; SERINE/THREONINE PHOSPHATASE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; KINASE-C; IN-VITRO; PHOSPHORYLATION; IDENTIFICATION	Poly (ADP-ribose) polymerase-1 (PARP-1) has an important role in the cellular response to a broad spectrum of DNA lesions. PARP-1 is strongly activated in response to double-stranded DNA breaks (DSBs), yet its contribution to the DSB response is poorly understood. Here we used bleomycin, a radiomimetic that generates DSBs with high specificity to focus on the response of PARP-1 to DSBs. We report that the induction of PARP-1 activity by bleomycin depends on the Ku antigen, a nonhomologous-DNA-End-Joining factor and protein phosphatase 5 (PP5). PARP-1 activation in response to bleomycin was reduced over 10-fold in Ku-deficient cells, whereas its activation in response to U. V. was unaffected. PARP-1 activation was rescued by reexpression of Ku, but was refractory to manipulation of DNA-dependent protein kinase or ATM. Similarly, PARP-1 activation subsequent to bleomycin was reduced 2-fold on ablation of PP5 and was increased 5-fold when PP5 was overexpressed. PP5 seemed to act directly on PARP-1, as its basal phosphorylation was reduced on overexpression of PP5, and PP5 dephosphorylated PARP-1 in vitro. These results highlight the functional importance of Ku antigen and PP5 for PARP-1 activity subsequent to DSBs. Oncogene (2010) 29, 2093-2103; doi: 10.1038/onc.2009.492; published online 25 January 2010	[Dong, F.; Soubeyrand, S.; Hache, R. J. G.] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Hache, R. J. G.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Hache, R. J. G.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Hache, RJG (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr, Calgary, AB T2N 1N4, Canada.	rjhache@ucalgary.ca		soubeyrand, sebastien/0000-0002-9317-301X	Canadian Institutes of Health Research [CIHR MT 13412]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We are very grateful to Dr V Schreiber and Dr G de Murcia for providing the PARP-deficient and control mouse fibroblasts. We would also like to thank Dr Y Shiloh for providing us with the ATM-restored and AT fibroblast cell lines (PEBS-YZ5 and PEBS, respectively). Finally, we are grateful to L Pope for her logistical support. This work was funded by an operating grant from the Canadian Institutes of Health Research (CIHR MT 13412) to RJGH. RJGH was a University of Ottawa Health Research Chair.	Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Audebert M, 2006, J MOL BIOL, V356, P257, DOI 10.1016/j.jmb.2005.11.028; BAUER PI, 1992, BIOCHEM BIOPH RES CO, V187, P730, DOI 10.1016/0006-291X(92)91256-P; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; CANTONI O, 1986, BIOCHIM BIOPHYS ACTA, V867, P135, DOI 10.1016/0167-4781(86)90073-4; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; Cole A, 1975, Basic Life Sci, V5B, P665; Douglas P, 2005, DNA REPAIR, V4, P1006, DOI 10.1016/j.dnarep.2005.05.003; Errami A, 1996, MOL CELL BIOL, V16, P1519; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Golden TA, 2003, METHOD ENZYMOL, V366, P372; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grote J, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-48; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hossain MB, 2009, J BIOL CHEM, V284, P8612, DOI 10.1074/jbc.M807198200; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Idogawa M, 2007, CANCER RES, V67, P911, DOI 10.1158/0008-5472.CAN-06-2360; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kang Y, 2009, J BIOL CHEM, V284, P9845, DOI 10.1074/jbc.M809272200; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Lis JT, 2006, CELL, V125, P1225, DOI 10.1016/j.cell.2006.06.016; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Midorikawa R, 2006, CELL, V125, P371, DOI 10.1016/j.cell.2006.02.039; Mitsuhashi S, 2001, BIOCHEM BIOPH RES CO, V287, P328, DOI 10.1006/bbrc.2001.5596; OGATA N, 1981, J BIOL CHEM, V256, P4135; OKAYAMA H, 1977, J BIOL CHEM, V252, P7000; Perrault R, 2004, J CELL BIOCHEM, V92, P781, DOI 10.1002/jcb.20104; Pion E, 2005, BIOCHEMISTRY-US, V44, P14670, DOI 10.1021/bi050755o; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Postow L, 2008, J CELL BIOL, V182, P467, DOI 10.1083/jcb.200802146; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P5808, DOI 10.1021/bi00440a016; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Rivera-Calzada A, 2007, EMBO REP, V8, P56, DOI 10.1038/sj.embor.7400847; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; TANAKA Y, 1987, BIOCHEM BIOPH RES CO, V148, P709, DOI 10.1016/0006-291X(87)90934-X; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Yin H, 2006, J BIOL CHEM, V281, P11496, DOI 10.1074/jbc.M511138200; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	55	13	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2093	2103		10.1038/onc.2009.492	http://dx.doi.org/10.1038/onc.2009.492			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101203				2022-12-28	WOS:000276402800008
J	Hofstetter, G; Berger, A; Fiegl, H; Slade, N; Zoric, A; Holzer, B; Schuster, E; Mobus, VJ; Reimer, D; Daxenbichler, G; Marth, C; Zeimet, AG; Concin, N; Zeillinger, R				Hofstetter, G.; Berger, A.; Fiegl, H.; Slade, N.; Zoric, A.; Holzer, B.; Schuster, E.; Mobus, V. J.; Reimer, D.; Daxenbichler, G.; Marth, C.; Zeimet, A. G.; Concin, N.; Zeillinger, R.			Alternative splicing of p53 and p73: the novel p53 splice variant p53 delta is an independent prognostic marker in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; p53; p73; splice variants	SITE MUTATION; EXPRESSION; ISOFORMS; CARCINOMA; DELTA-NP73; GENE	Similar to p73, the tumor suppressor gene p53 is subject to alternative splicing. Besides p53 Delta E6 and p53 beta, we identified p53 zeta, p53 delta and p53 epsilon, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53 delta expression was associated with impaired response to primary platinum-based chemotherapy (P = 0.032). Also, p53 delta expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121-3.065, P = 0.016; and hazard ratio 1.937, 95% confidence interval 1.177-3.186, P = 0.009, respectively). p53 beta expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P = 0.002 and P = 0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P = 0.049). Delta N'p73 constituted the main N-terminally truncated p73 isoform and was preferentially found in ovarian cancer cell lines showing functionally active p53, supporting our hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of p53 protein function. Oncogene (2010) 29, 1997-2004; doi:10.1038/onc.2009.482; published online 18 January 2010	[Holzer, B.; Schuster, E.; Zeillinger, R.] Med Univ Vienna, Dept Obstet & Gynecol, Mol Oncol Grp, A-1090 Vienna, Austria; [Hofstetter, G.; Berger, A.; Fiegl, H.; Reimer, D.; Daxenbichler, G.; Marth, C.; Zeimet, A. G.; Concin, N.] Innsbruck Med Univ, Dept Gynecol & Obstet, Innsbruck, Austria; [Slade, N.; Zoric, A.] Rudjer Boskovic Inst, Dept Mol Med, Mol Oncol Lab, Zagreb, Croatia; [Mobus, V. J.] Staedt Kliniken, Dept Obstet & Gynecol, Frankfurt, Germany; [Zeillinger, R.] Ludwig Boltzmann Gesell, Cluster Translat Oncol, Vienna, Austria	Medical University of Vienna; Medical University of Innsbruck; Rudjer Boskovic Institute; Ludwig Boltzmann Institute	Zeillinger, R (corresponding author), Med Univ Vienna, Dept Obstet & Gynecol, Mol Oncol Grp, Waehringer Guertel 18-20,5Q, A-1090 Vienna, Austria.	robert.zeillinger@meduniwien.ac.at	Zeillinger, Robert/AAI-6164-2020; Fiegl, Heidi/K-4445-2017	Zeillinger, Robert/0000-0001-6771-4591; Concin, Nicole/0000-0002-9795-2643; Hofstetter, Gerda/0000-0001-8912-3725; Fiegl, Heidi/0000-0002-1236-6806				Anczukow O, 2008, HUM MUTAT, V29, P65, DOI 10.1002/humu.20590; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Concin N, 2003, INT J ONCOL, V22, P51; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; Ebrahimi M, 2008, ORAL ONCOL, V44, P156, DOI 10.1016/j.oraloncology.2007.01.014; Fischer DC, 2004, ONCOL REP, V11, P1085; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Graupner V, 2009, CELL CYCLE, V8, P1238, DOI 10.4161/cc.8.8.8251; Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Janicke RU, 2009, BIOL CHEM, V390, P951, DOI 10.1515/BC.2009.093; JOLLY KW, 1994, ONCOGENE, V9, P97; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Marabese M, 2008, EUR J CANCER, V44, P131, DOI 10.1016/j.ejca.2007.10.011; MOBUS V, 1992, INT J CANCER, V52, P76, DOI 10.1002/ijc.2910520115; Oswald C, 2008, CELL CYCLE, V7, P1726, DOI 10.4161/cc.7.12.6148; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Slade N, 2004, CELL DEATH DIFFER, V11, P357, DOI 10.1038/sj.cdd.4401335; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029	31	54	56	4	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1997	2004		10.1038/onc.2009.482	http://dx.doi.org/10.1038/onc.2009.482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101229				2022-12-28	WOS:000276199600012
J	Lam, S; Lodder, K; Teunisse, AFAS; Rabelink, MJWE; Schutte, M; Jochemsen, AG				Lam, S.; Lodder, K.; Teunisse, A. F. A. S.; Rabelink, M. J. W. E.; Schutte, M.; Jochemsen, A. G.			Role of Mdm4 in drug sensitivity of breast cancer cells	ONCOGENE			English	Article						Mdm4; p53; cancer; Nutlin; doxorubicin	P53 ACTIVATION; TUMOR-CELLS; POLY(ADP-RIBOSE) POLYMERASE; P53-BINDING PROTEIN; MALIGNANT GLIOMAS; DNA-DAMAGE; HDMX; AMPLIFICATION; INHIBITION; EXPRESSION	The p53 tumor suppressor protein is frequently mutated in human tumors. It is thought that the p53 pathway is indirectly impaired in the remaining tumors, for example by overexpression of its important regulators Mdm2 and Mdm4, making them attractive targets for the development of anti-cancer agents. Recent studies have suggested that Mdm4 levels determine the sensitivity of tumor cells for anti-cancer therapy. To investigate this possibility, we studied the drug sensitivity of several breast cancer cell lines containing wild-type p53, but expressing different Mdm4 levels. We show that endogenous Mdm4 levels can affect the sensitivity of breast cancer cells to anti-cancer agents, but in a cell line-dependent manner and depending on an intact apoptotic response. Furthermore, treatment with the non-genotoxic agent Nutlin-3 sensitizes cells for doxorubicin, showing that activation of p53 by targeting its regulators is an efficient strategy to decrease cell viability of breast cancer cells. These results confirm a function of Mdm4 in determining the efficacy of chemotherapeutic agents to induce apoptosis of cancer cells in a p53-dependent manner, although additional undetermined factors also influence the drug response. Targeting Mdm4 to sensitize tumor cells for chemotherapeutic drugs might be a strategy to effectively treat tumors harboring wild-type p53. Oncogene (2010) 29, 2415-2426; doi:10.1038/onc.2009.522; published online 8 February 2010	[Lam, S.; Lodder, K.; Teunisse, A. F. A. S.; Rabelink, M. J. W. E.; Jochemsen, A. G.] Leiden Univ, Dept Mol Cell Biol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Schutte, M.] Erasmus Univ, Dept Med Oncol, Josephine Nefkens Inst, Med Ctr, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	Jochemsen, AG (corresponding author), Leiden Univ, Dept Mol Cell Biol, Med Ctr, POB 9600,Postal Zone S1-P, NL-2300 RC Leiden, Netherlands.	A.G.Jochemsen@lumc.nl		Rabelink, Martijn/0000-0002-3274-7825	Association for International Cancer [05-273]; EC [503576]	Association for International Cancer; EC(European CommissionEuropean Commission Joint Research Centre)	We thank Dr G Selivanova for providing RITA, Dr A Levine and Dr G Peters for providing anti-Mdm2 and anti-p16 antibodies, respectively. This study was supported by grants from the Association for International Cancer Research (grant 05-273) and by EC FP6 funding (contract 503576) to AG Jochemsen. This publication reflects the authors' views and not necessarily those of the European Community. The EC is not liable for any use that may be made of the information contained.	Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao C, 2006, MOL CANCER THER, V5, P411, DOI 10.1158/1535-7163.MCT-05-0356; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLESTELLE A, 2009, BREAST CANC IN PRESS; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2008, CELL CYCLE, V7, P1973, DOI 10.4161/cc.7.13.6072; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wasielewski M, 2006, BREAST CANCER RES TR, V99, P97, DOI 10.1007/s10549-006-9186-z	42	42	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2415	2426		10.1038/onc.2009.522	http://dx.doi.org/10.1038/onc.2009.522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20140020				2022-12-28	WOS:000276951500010
J	Thalappilly, S; Soubeyran, P; Iovanna, JL; Dusetti, NJ				Thalappilly, S.; Soubeyran, P.; Iovanna, J. L.; Dusetti, N. J.			VAV2 regulates epidermal growth factor receptor endocytosis and degradation	ONCOGENE			English	Article						VAV2; EGFR; endosome; receptor internalization	NUCLEOTIDE EXCHANGE FACTOR; EGF RECEPTOR; C-CBL; PANCREATIC-CANCER; TRAFFICKING; ACTIVATION; PROTEIN; RAC1; FAMILY; CDC42	Vav proteins are guanine nucleotide exchange factors for Rho GTPases that regulate cell adhesion, motility, spreading and proliferation in response to growth factor signalling. In this work, we show that Vav2 expression delayed epidermal growth factor receptor (EGFR) internalization and degradation, and enhanced EGFR, ERK and Akt phosphorylations. This effect of Vav2 on EGFR degradation is dependent on its guanine nucleotide exchange function. Knockdown of Vav2 in HeLa cells enhanced EGFR degradation and reduced cell proliferation. epidermal growth factor stimulation led to colocalization of Vav2 with EGFR and Rab5 in endosomes. We further show that the effect of Vav2 on EGFR stability is modulated by its interaction with two endosome-associated proteins and require RhoA function. Thus, in this work, we report for the first time that Vav2 can regulate growth factors receptor signalling by slowing receptor internalization and degradation through its interaction with endosome-associated proteins. Oncogene (2010) 29, 2528-2539; doi:10.1038/onc.2010.1; published online 8 February 2010	[Thalappilly, S.; Soubeyran, P.; Iovanna, J. L.; Dusetti, N. J.] INSERM, U624, F-13288 Marseille, France; [Thalappilly, S.; Soubeyran, P.; Iovanna, J. L.; Dusetti, N. J.] Aix Marseille Univ, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Dusetti, NJ (corresponding author), INSERM, U624, Parc Sci Luminy,Case 915, F-13288 Marseille, France.	nelson.dusetti@inserm.fr	Iovanna, Juan/M-9805-2017; Soubeyran, Philippe/P-1758-2018; Dusetti, Nelson/O-7919-2017	Iovanna, Juan/0000-0003-1822-2237; Dusetti, Nelson/0000-0002-6161-8483; Thalappilly, Subhash/0000-0003-1766-3057; Soubeyran, Philippe/0000-0002-5876-3217	INSERM; Ligue Contre le Cancer; ARC (Association pour la Recherche sur le Cancer)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Contre le Cancer(Ligue nationale contre le cancer); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer)	We gratefully acknowledge M Seux for help throughout the work and P Spotto for technical help. Dr Alan Saltiel (University of Michigan, Ann Arbor, MI, USA) kindly provided Gapvd1 constructs and Dr Laszlo Buday (Semmelweis University, Budapest, Hungary) Vav2-GFP plasmids. This work was supported in part by INSERM and grants from the Ligue Contre le Cancer. ST was supported by a postdoctoral fellowship from ARC (Association pour la Recherche sur le Cancer).	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; BUSTELO XR, 1994, ONCOGENE, V9, P2405; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Cowan CW, 2005, NEURON, V46, P205, DOI 10.1016/j.neuron.2005.03.019; de Melker AA, 2001, J CELL SCI, V114, P2167; Donepudi M, 2008, CELL SIGNAL, V20, P1359, DOI 10.1016/j.cellsig.2008.03.007; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Franco M, 2006, MOL CELL BIOL, V26, P1932, DOI 10.1128/MCB.26.5.1932-1947.2006; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Goel S, 2007, J EXP THER ONCOL, V6, P305; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Hunker CM, 2006, BIOCHEM BIOPH RES CO, V340, P967, DOI 10.1016/j.bbrc.2005.12.099; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lodhi IJ, 2007, CELL METAB, V5, P59, DOI 10.1016/j.cmet.2006.12.006; Marcoux N, 2003, ONCOGENE, V22, P6100, DOI 10.1038/sj.onc.1206712; Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Narumiya S, 2006, CURR OPIN CELL BIOL, V18, P199, DOI 10.1016/j.ceb.2006.02.002; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Patel V, 2007, CARCINOGENESIS, V28, P1145, DOI 10.1093/carcin/bgm008; Peng FF, 2010, CELL SIGNAL, V22, P34, DOI 10.1016/j.cellsig.2009.09.003; Puertollano R, 2005, J BIOL CHEM, V280, P9258, DOI 10.1074/jbc.M412481200; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Schuebel KE, 1996, ONCOGENE, V13, P363; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stuffers S, 2009, EXP CELL RES, V315, P1619, DOI 10.1016/j.yexcr.2008.10.013; Su X, 2007, J BIOL CHEM, V282, P21278, DOI 10.1074/jbc.M703725200; Swat W, 2005, IMMUNOL RES, V32, P259, DOI 10.1385/IR:32:1-3:259; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Thalappilly S, 2008, PROTEOMICS, V8, P3071, DOI 10.1002/pmic.200701157; Tu S, 2003, J BIOL CHEM, V278, P49293, DOI 10.1074/jbc.M307021200; Umebayashi K, 2008, MOL BIOL CELL, V19, P3454, DOI 10.1091/mbc.E07-10-0988; Ung CY, 2008, FEBS LETT, V582, P2283, DOI 10.1016/j.febslet.2008.05.026; Wadsworth P, 2005, CURR BIOL, V15, pR871, DOI 10.1016/j.cub.2005.10.021; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Yamazaki T, 2002, J CELL SCI, V115, P1791; Yanagida-Ishizaki Y, 2008, CELL STRUCT FUNCT, V33, P91, DOI 10.1247/csf.07037; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	57	33	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2528	2539		10.1038/onc.2010.1	http://dx.doi.org/10.1038/onc.2010.1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140013				2022-12-28	WOS:000277169400008
J	Periyasamy, S; Hinds, T; Shemshedini, L; Shou, W; Sanchez, ER				Periyasamy, S.; Hinds, T., Jr.; Shemshedini, L.; Shou, W.; Sanchez, E. R.			FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A	ONCOGENE			English	Article						transcription; prostate cancer; androgen receptor; Cyp40; FKBP51; FKBP52	NF-KAPPA-B; PEPTIDYL-PROLYL ISOMERASE; IMMUNOPHILIN FKBP51; IDIOPATHIC MYELOFIBROSIS; GLUCOCORTICOID-RECEPTOR; INSENSITIVITY SYNDROME; MOLECULAR-MECHANISMS; MEDIATED REGULATION; FACTOR INDEPENDENCE; SQUIRREL-MONKEY	Prostate cancer (PCa) growth is dependent on androgens and on the androgen receptor (AR), which acts by modulating gene transcription. Tetratricopeptide repeat (TPR) proteins (FKBP52, FKBP51 and Cyp40) interact with AR in PCa cells, suggesting roles in AR-mediated gene transcription and cell growth. We report here that FKBP51 and Cyp40, but not FKBP52, are significantly elevated in PCa tissues and in androgen-dependent (AD) and androgen-independent (AI) cell lines. Overexpression of FKBP51 in AD LNCaP cells increased AR transcriptional activity in the presence and absence of androgen, whereas siRNA knockdown of FKBP51 dramatically decreased AD gene transcription and proliferation. Knockdown of Cyp40 also inhibited androgen-mediated transcription and growth in LNCaP cells. However, disruption of FKBP51 and Cyp40 in AI C4-2 cells caused only a small reduction in proliferation, indicating that Cyp40 and FKBP51 predominantly regulate AD cell proliferation. Under knockdown conditions, the inhibitory effects of TPR ligands, cyclosporine A (CsA) and FK506, on AR activity were not observed, indicating that Cyp40 and FKBP51 are the targets of CsA and FK506, respectively. Our findings show that FKBP51 and Cyp40 are positive regulators of AR that can be selectively targeted by CsA and FK506 to achieve inhibition of androgen-induced cell proliferation. These proteins and their cognate ligands thus provide new strategies in the treatment of PCa. Oncogene (2010) 29, 1691-1701; doi:10.1038/onc.2009.458; published online 21 December 2009	[Shemshedini, L.] Univ Toledo Main Campus, Dept Biol Sci, Toledo, OH USA; [Shou, W.] Indiana Univ, Sch Med, Dept Pediat, Pediat Cardiol Sect,Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Periyasamy, S.; Hinds, T., Jr.; Sanchez, E. R.] Univ Toledo, Coll Med, Dept Physiol & Pharmacol, CeDER, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University of Toledo Health Science Campus; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; University of Toledo	Periyasamy, S (corresponding author), Univ Toledo Hlth Sci Campus, Dept Physiol & Pharmacol, 3000 Arlington Ave,Mail Stop 1008, Toledo, OH 43614 USA.	sumudra.periyasamy@utoledo.edu	Hinds, Terry/B-8495-2015	Hinds, Terry/0000-0002-7599-1529	National Institutes of Health [DK73402, DK70127]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK084958, R01DK073402, R01DK070127] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Theo Rein (Max Planck Institute of Psychiatry) and Marianne Sadar (British Columbia Cancer Agency) for the generous gift of Flag-tagged FKBP51 and PSA-luciferase reporter plasmid, respectively. This study was supported in part by National Institutes of Health grants DK73402 to WS and DK70127 to ERS.	Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; Amler LC, 2000, CANCER RES, V60, P6134; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Banerjee A, 2008, BIOCHEMISTRY-US, V47, P10471, DOI 10.1021/bi8011862; BATCH JA, 1992, HUM MOL GENET, V1, P497, DOI 10.1093/hmg/1.7.497; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Cinar B, 2004, BIOCHEM J, V379, P421, DOI 10.1042/BJ20031661; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Dehm SM, 2007, CANCER RES, V67, P10067, DOI 10.1158/0008-5472.CAN-07-1267; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Febbo PG, 2005, J UROLOGY, V173, P1772, DOI 10.1097/01.ju.0000155845.44729.ba; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Giraudier S, 2002, BLOOD, V100, P2932, DOI 10.1182/blood-2002-02-0485; Gregory CW, 2001, CANCER RES, V61, P4315; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hubler TR, 2003, ENDOCRINOLOGY, V144, P2380, DOI 10.1210/en.2003-0092; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang W, 2008, NEOPLASIA, V10, P235, DOI 10.1593/neo.07929; Komura E, 2003, EXP HEMATOL, V31, P622, DOI 10.1016/S0301-472X(03)00085-7; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lavery DN, 2005, BIOCHEM J, V391, P449, DOI 10.1042/BJ20050872; Lee SO, 2005, PROSTATE, V64, P160, DOI 10.1002/pros.20218; Li TH, 2007, NUCLEIC ACIDS RES, V35, P2767, DOI 10.1093/nar/gkm198; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Makkonen H, 2009, NUCLEIC ACIDS RES, V37, P4135, DOI 10.1093/nar/gkp352; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; Periyasamy S, 2007, ENDOCRINOLOGY, V148, P4716, DOI 10.1210/en.2007-0145; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Riggs DL, 2007, MOL CELL BIOL, V27, P8658, DOI 10.1128/MCB.00985-07; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Romano MF, 2004, EUR J CANCER, V40, P2829, DOI 10.1016/j.ejca.2004.08.017; Scherr D, 2003, UROLOGY, V61, P14, DOI 10.1016/S0090-4295(02)02395-6; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Thalmann GN, 2000, PROSTATE, V44, P91; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Yong WD, 2007, J BIOL CHEM, V282, P5026, DOI 10.1074/jbc.M609360200; Zhu W, 2001, CARCINOGENESIS, V22, P1399, DOI 10.1093/carcin/22.9.1399	64	90	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1691	1701		10.1038/onc.2009.458	http://dx.doi.org/10.1038/onc.2009.458			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20023700	Green Accepted			2022-12-28	WOS:000275694700014
J	Licchesi, JDF; Van Neste, L; Tiwari, VK; Cope, L; Lin, X; Baylin, SB; Herman, JG				Licchesi, J. D. F.; Van Neste, L.; Tiwari, V. K.; Cope, L.; Lin, X.; Baylin, S. B.; Herman, J. G.			Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc	ONCOGENE			English	Article						WIF-1; Wnt signaling; c-Myc; Miz-1; DNA methylation	C-MYC; EPIGENETIC INACTIVATION; DNA METHYLATION; CANCER; PROMOTER; GENE; EXPRESSION; MIZ-1; REPRESSES; PROTEIN	The Wnt signaling pathway is capable of self-regulation through positive and negative feedback mechanisms. For example, the oncoprotein c-Myc, which is upregulated by Wnt signaling activity, participates in a positive feedback loop of canonical Wnt signaling through repression of Wnt antagonists DKK1 and SFRP1. In this study, we investigated the mechanism of Wnt inhibitory factor-1 (WIF-1) silencing. Mapping of CpG island methylation of the WIF-1 promoter reveals regional methylation (-295 to -95 bp from the transcription start site) that correlates with transcriptional silencing. We identified Miz-1 as a direct activator of WIF-1 transcriptional activity, which is found at WIF-1 promoter. In addition, we show that c-Myc contributes to WIF-1 transcriptional repression in a Miz-1-dependent manner. Although the transient repression mediated by Miz-1/c-Myc is independent of de novo methylation, the stable repression by this complex is associated with CpG island methylation of the critical -295 to -95-bp region of the WIF-1 promoter. Importantly, Miz-1 and c-Myc are found at WIF-1 promoter in WIF-1 non-expressing cell lines DLD-1 and 209myc. Transient knockdown or somatic knockout of c-Myc in DLD-1 failed to restore WIF-1 expression suggesting that c-Myc is involved in initiating rather than maintaining WIF-1 epigenetic silencing. In a genome-wide screen, DNAJA4, TGF beta-induced and TRIM59 were repressed by c-Myc overexpression and DNA promoter hypermethylation. Our data reveal novel insights into c-Myc-mediated DNA methylation-dependent transcriptional silencing, a mechanism that might contribute to the dysregulation of Wnt signaling in cancer. Oncogene (2010) 29, 5923-5934; doi:10.1038/onc.2010.322; published online 9 August 2010	[Licchesi, J. D. F.] MRC Lab Mol Biol, Cambridge CB2 0QH, England; [Licchesi, J. D. F.; Tiwari, V. K.; Cope, L.; Baylin, S. B.; Herman, J. G.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Canc Biol Program, Baltimore, MD 21231 USA; [Van Neste, L.] Univ Ghent, Dept Mol Biotechnol, Fac Biosci Engn, B-9000 Ghent, Belgium; [Lin, X.] Johns Hopkins Univ, Dept Appl Math & Stat, Whiting Sch Engn, Baltimore, MD USA	MRC Laboratory Molecular Biology; Johns Hopkins University; Johns Hopkins Medicine; Ghent University; Johns Hopkins University	Licchesi, JDF (corresponding author), MRC Lab Mol Biol, Hills Rd, Cambridge CB2 0QH, England.	jlicchesi@yahoo.com; hermanji@jhmi.edu		Licchesi, Julien/0000-0003-3786-3013	NCI [CA058184, P30 CA06973-44]; AICR [07-0040]; Medical Research Council [MC_U105192713, MC_U105184273] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA006973, P50CA058184] Funding Source: NIH RePORTER; MRC [MC_U105184273, MC_U105192713] Funding Source: UKRI	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AICR; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge Dr Martin Eilers (Marbourg University, Germany), Dr Arthur Riggs (Beckman Research Institute, Duarte, CA, USA) and Dr Bert Vogelstein (Johns Hopkins School of Medicine, USA) for plasmids, Dr Kurt Bachman (University of Maryland, USA) for the DLD-1 c-Myc -/- DNA and cDNA. We are grateful to Dr Wayne Yu at the Johns Hopkins Microarray Core facility, Dr Kornel Schuebel for his help with the microarray experiment and Dr Mariann Bienz for her support. Finally, we thank all the members of the Baylin/Herman laboratory for useful discussions and Kathy Bender for administrative assistance. This study was supported by NCI/SPORE grant CA058184 to James G Herman, AICR grant 07-0040 to Mariann Bienz (MRC-LMB) and NCI grant P30 CA06973-44 to Leslie Cope.	Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Barr LF, 2000, CANCER RES, V60, P143; Benanti JA, 2007, MOL CANCER RES, V5, P1181, DOI 10.1158/1541-7786.MCR-06-0372; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547; Chen ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/jcb.20447; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; de la Roche M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-199; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Finlan LE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000039; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Guarda A, 2009, EXP CELL RES, V315, P1895, DOI 10.1016/j.yexcr.2009.01.019; GUJRAL TS, 2009, SCI SIGNAL, V2, pNIL6; Halaban R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004563; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ikegaki N, 2007, CLIN CANCER RES, V13, P6001, DOI 10.1158/1078-0432.CCR-07-0071; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Li ZJ, 2009, CANCER RES, V69, P1109, DOI 10.1158/0008-5472.CAN-08-3381; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Patel JH, 2006, J BIOL CHEM, V281, P3283, DOI 10.1074/jbc.M513038200; Perini G, 2005, P NATL ACAD SCI USA, V102, P12117, DOI 10.1073/pnas.0409097102; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shah JN, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-284; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Zhang Y, 2009, CANCER RES, V69, P37, DOI 10.1158/0008-5472.CAN-08-1648; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	52	35	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5923	5934		10.1038/onc.2010.322	http://dx.doi.org/10.1038/onc.2010.322			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697356	Green Accepted			2022-12-28	WOS:000283843400006
J	Oleinik, NV; Krupenko, NI; Krupenko, SA				Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.			ALDH1L1 inhibits cell motility via dephosphorylation of cofilin by PP1 and PP2A	ONCOGENE			English	Article						ALDH1L1; cofilin; phosphatases; actin; folate	ACTIN-BINDING PROTEINS; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; REGULATES COFILIN; GENE-EXPRESSION; CARCINOMA-CELLS; DIETARY-FOLATE; BREAST-CANCER; DYNAMICS; MIGRATION; INVASION	Here we report that ALDH1L1 (FDH, a folate enzyme with tumor suppressor-like properties) inhibits cell motility. The underlying mechanism involves F-actin stabilization, re-distribution of cytoplasmic actin toward strong preponderance of filamentous actin and formation of actin stress fibers. A549 cells expressing FDH showed a much slower recovery of green fluorescent protein-actin fluorescence in a fluorescence recovery after photobleaching assay, as well as an increase in G-actin polymerization and a decrease in F-actin depolymerization rates in pyren-actin fluorescence assays indicating the inhibition of actin dynamics. These effects were associated with robust dephosphorylation of the actin depolymerizing factor cofilin by PP1 and PP2A serine/threonine protein phosphatases, but not the cofilin-specific phosphatases slingshot and chronophin. In fact, the PP1/PP2A inhibitor calyculin prevented cofilin dephosphorylation and restored motility. Inhibition of FDH-induced apoptosis by the Jun N-terminal kinase inhibitor SP600125 or the pan-caspase inhibitor zVAD-fmk did not restore motility or levels of phosphor-cofilin, indicating that the observed effects are independent of FDH function in apoptosis. Interestingly, cofilin small interfering RNA or expression of phosphorylation-deficient S3A cofilin mutant resulted in a decrease of G-actin and the actin stress fiber formation, the effects seen upon FDH expression. In contrast, the expression of S3D mutant, mimicking constitutive phosphorylation, prevented these effects further supporting the cofilin-dependent mechanism. Dephosphorylation of cofilin and inhibition of motility in response to FDH can also be prevented by the increased folate in media. Furthermore, folate depletion itself, in the absence of FDH, resulted in cofilin dephosphorylation and inhibition of motility in several cell lines. Our experiments showed that these effects were folate specific and not a general response to nutrient starvation. Overall, this study shows the presence of distinct intracellular signaling pathways regulating motility in response to folate status and points toward mechanisms involving folates in promoting a malignant phenotype. Oncogene (2010) 29, 6233-6244; doi:10.1038/onc.2010.356; published online 23 August 2010	[Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,Room 512-B BSB, Charleston, SC 29425 USA.	krupenko@musc.edu			National Institutes of Health [DK054388, CA095030]; NATIONAL CANCER INSTITUTE [R01CA095030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054388] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The construct for expression of GFP/actin fusion was a kind gift from Dr Imhof. Vectors for expression of S3A and S3D cofilin mutants were generous gifts from Dr Shieh. The authors would like to thank Dr Condeelis for the helpful discussion. This work was supported by National Institutes of Health Grants DK054388 and CA095030.	Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Ananthakrishnan R, 2007, INT J BIOL SCI, V3, P303; Ballestrem C, 1998, J CELL SCI, V111, P1649; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Chanson A, 2005, J NUTR, V135, P2524, DOI 10.1093/jn/135.11.2524; Chhabra D, 2005, BIOPHYS J, V89, P1902, DOI 10.1529/biophysj.105.062083; Cohen PTW, 2002, J CELL SCI, V115, P241; Crott JW, 2008, J NUTR BIOCHEM, V19, P328, DOI 10.1016/j.jnutbio.2007.05.003; Crott JW, 2004, CARCINOGENESIS, V25, P69, DOI 10.1093/carcin/bgg150; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Fox JT, 2008, VITAM HORM, V79, P1, DOI 10.1016/S0083-6729(08)00401-9; Franco C, 2006, AM J PATHOL, V168, P1697, DOI 10.2353/ajpath.2006.050613; Ghose S, 2009, MOL CANCER RES, V7, P99, DOI 10.1158/1541-7786.MCR-08-0309; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Jhaveri MS, 2001, MOL PHARMACOL, V60, P1288, DOI 10.1124/mol.60.6.1288; Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Lai FP, 2008, EMBO J, V27, P982, DOI 10.1038/emboj.2008.34; Lewis CM, 1998, CANCER RES, V58, P2952; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Montell DJ, 2008, SCIENCE, V322, P1502, DOI 10.1126/science.1164073; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Oleinik NV, 2006, BIOCHEM PHARMACOL, V72, P256, DOI 10.1016/j.bcp.2006.04.005; Oleinik NV, 2005, BIOCHEM J, V391, P503, DOI 10.1042/BJ20050533; Oleinik NV, 2003, MOL CANCER RES, V1, P577; Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Song XY, 2006, J CELL SCI, V119, P2871, DOI 10.1242/jcs.03017; Turner DP, 2007, CANCER RES, V67, P1618, DOI 10.1158/0008-5472.CAN-06-2913; Tyagi SC, 1996, J CELL PHYSIOL, V167, P137, DOI 10.1002/(SICI)1097-4652(199604)167:1<137::AID-JCP16>3.0.CO;2-8; Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206; van Rheenen J, 2009, J CELL SCI, V122, P305, DOI 10.1242/jcs.031146; Wagner C, 1995, FOLATE HLTH DIS, P23; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wiggan O, 2005, NAT CELL BIOL, V7, P8, DOI 10.1038/ncb0105-8; Williams MJ, 2006, J CELL SCI, V119, P2015, DOI 10.1242/jcs.02920; Winder SJ, 2005, J CELL SCI, V118, P651, DOI 10.1242/jcs.01670; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhan Q, 2003, CELL MOTIL CYTOSKEL, V54, P1, DOI 10.1002/cm.10079; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946; Zhao RB, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000969; Zhu HP, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-128	56	57	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	47					6233	6244		10.1038/onc.2010.356	http://dx.doi.org/10.1038/onc.2010.356			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729910	Green Accepted			2022-12-28	WOS:000284601700005
J	Rabson, AB				Rabson, A. B.			Trisomy 21 leukemias: finding the hits that matter	ONCOGENE			English	Editorial Material							DOWN-SYNDROME; MOUSE MODEL; LEUKEMOGENESIS; GATA1; ERG	Down syndrome is associated with a markedly increased risk of childhood leukemias, and identification of chromosome 21 sequences that have a role in leukemogenesis may provide insights into critical pathways and suggest targets for therapy and prevention. A study in this issue of Oncogene, defines human chromosome 21 sequences that alter hematopoiesis and induce expression of leukemia-associated markers. Oncogene (2010) 29, 6099-6101; doi:10.1038/onc.2010.353; published online 16 August 2010	[Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rabson, AB (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, 89 French St, New Brunswick, NJ 08901 USA.	rabsonab@umdnj.edu						Alford KA, 2010, BLOOD, V115, P2928, DOI 10.1182/blood-2009-06-227629; Chou ST, 2008, BLOOD, V112, P4503, DOI 10.1182/blood-2008-05-157859; De Vita S, 2010, ONCOGENE, V29, P6102, DOI 10.1038/onc.2010.351; Izraeli S, 2007, BLOOD CELL MOL DIS, V39, P156, DOI 10.1016/j.bcmd.2007.04.004; Kirsammer G, 2008, BLOOD, V111, P767, DOI 10.1182/blood-2007-04-085670; Klusmann JH, 2010, GENE DEV, V24, P478, DOI 10.1101/gad.1856210; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; Malinge S, 2009, BLOOD, V113, P2619, DOI 10.1182/blood-2008-11-163501; Ng AP, 2010, BLOOD, V115, P3966, DOI 10.1182/blood-2009-09-242107; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Tunstall-Pedoe O, 2008, BLOOD, V112, P4507, DOI 10.1182/blood-2008-04-152967; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675	12	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	46					6099	6101		10.1038/onc.2010.353	http://dx.doi.org/10.1038/onc.2010.353			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20711238				2022-12-28	WOS:000284356500002
J	Herrero-Gonzalez, S; Gangoso, E; Giaume, C; Naus, CC; Medina, JM; Tabernero, A				Herrero-Gonzalez, S.; Gangoso, E.; Giaume, C.; Naus, C. C.; Medina, J. M.; Tabernero, A.			Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells	ONCOGENE			English	Article						cell cycle; CNS; gap junctions; glia; proliferation	GAP-JUNCTION PROTEIN; INTERCELLULAR COMMUNICATION; TYROSINE PHOSPHORYLATION; CULTURED ASTROCYTES; CYCLIN D1; GROWTH; EXPRESSION; PROLIFERATION; GENE; TRANSCRIPTION	One of the characteristics of gliomas is a decrease in the expression of connexin43, a protein that forms gap junctions. Restoring connexin43 expression in glioma cells reduces their exacerbated rate of cell growth, although it is not yet known how connexin43 modifies the expression of genes involved in cell proliferation. Here, we show that restoring connexin43 to C6 glioma cells impedes their progression from G0/G1 to the S phase of the cell cycle by reducing retinoblastoma phosphorylation and cyclin E expression through the upregulation of p21 and p27. Interestingly, connexin43 diminishes the oncogenic activity of c-Src exhibited by glioma cells. By studying a Tyr247 and Tyr265 mutant connexin43, we show that these residues are required for connexin43 to inhibit c-Src activity and cell proliferation. In conclusion, by acting as a substrate of c-Src, connexin43 reduces its oncogenic activity and decreases the rate of glioma cell proliferation, potentially an early step in the antiproliferative effects of connexin43. Although c-Src is known to phosphorylate connexin43, this study provides the first evidence that connexin43 can also inhibit c-Src activity. Oncogene (2010) 29, 5712-5723; doi:10.1038/onc.2010.299; published online 2 August 2010	[Herrero-Gonzalez, S.; Gangoso, E.; Medina, J. M.; Tabernero, A.] Univ Salamanca, Dept Bioquim & Biol Mol, INCYL, Salamanca 37007, Spain; [Giaume, C.] Coll France, INSERM, U840, F-75231 Paris, France; [Naus, C. C.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada	University of Salamanca; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; University of British Columbia	Tabernero, A (corresponding author), Univ Salamanca, Dept Bioquim & Biol Mol, INCYL, C Pintor Fernando Gallego 1, Salamanca 37007, Spain.	ataber@usal.es	Tabernero, Arantxa/K-5950-2014; IBSAL, Secretaría/H-3719-2011; Gangoso, Ester/B-4825-2016; Gangoso, Ester/J-2604-2019	Tabernero, Arantxa/0000-0001-6302-6134; Gangoso, Ester/0000-0003-4851-9680; Gangoso, Ester/0000-0003-4851-9680	Ministerio de Educacion y Ciencia [SAF2007-64161]; Junta de Castilla y Leon [SA043A09]	Ministerio de Educacion y Ciencia(Spanish Government); Junta de Castilla y Leon(Junta de Castilla y Leon)	This work was supported by the Ministerio de Educacion y Ciencia, FEDER SAF2007-64161, the Junta de Castilla y Leon SA043A09. S Herrero-Gonzalez and E Gangoso were recipient of a fellowship from the Ministerio de Educacion y Ciencia. We are grateful for the technical assistance of T del Rey and we thank M Sefton for help in preparing the paper.	Bates DC, 2007, GLIA, V55, P1554, DOI 10.1002/glia.20569; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Campbell EJ, 2008, BRIT J CANCER, V99, P1769, DOI 10.1038/sj.bjc.6604768; Cavalla P, 1998, ACTA NEUROPATHOL, V95, P131, DOI 10.1007/s004010050776; Chakrabarty A, 1996, NEUROPATH APPL NEURO, V22, P311, DOI 10.1111/j.1365-2990.1996.tb01109.x; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cina C, 2009, J NEUROSCI, V29, P2009, DOI 10.1523/JNEUROSCI.5025-08.2009; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Geng Y, 1996, ONCOGENE, V12, P1173; Giepmans BNG, 2006, ADV CARDIOL, V42, P41, DOI 10.1159/000092561; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Gilleron J, 2008, J CELL SCI, V121, P4069, DOI 10.1242/jcs.033373; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Herrero-Gonzalez S, 2009, GLIA, V57, P222, DOI 10.1002/glia.20748; Herve JC, 2007, PROG BIOPHYS MOL BIO, V94, P29, DOI 10.1016/j.pbiomolbio.2007.03.010; Huang RP, 1998, CANCER RES, V58, P5089; Huang RP, 1999, J SURG ONCOL, V70, P21, DOI 10.1002/(SICI)1096-9098(199901)70:1<21::AID-JSO4>3.3.CO;2-S; Kanemitsu MY, 1998, CELL GROWTH DIFFER, V9, P13; Kardami E, 2007, PROG BIOPHYS MOL BIO, V94, P245, DOI 10.1016/j.pbiomolbio.2007.03.009; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Lai CPK, 2009, ONCOGENE, V28, P4402, DOI 10.1038/onc.2009.283; Lai CPK, 2007, CANCER RES, V67, P1545, DOI 10.1158/0008-5472.CAN-06-1396; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Li W, 2005, J BIOL CHEM, V280, P7941, DOI 10.1074/jbc.M410548200; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; Lin R, 2006, CELL COMMUN ADHES, V13, P199, DOI 10.1080/15419060600848516; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; Naus CCG, 1997, J NEUROSCI RES, V49, P528, DOI 10.1002/(SICI)1097-4547(19970901)49:5<528::AID-JNR3>3.0.CO;2-D; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Pahujaa M, 2007, EXP CELL RES, V313, P4083, DOI 10.1016/j.yexcr.2007.09.010; Penuela S, 2007, J CELL SCI, V120, P3772, DOI 10.1242/jcs.009514; Prochnow N, 2008, HISTOCHEM CELL BIOL, V130, P71, DOI 10.1007/s00418-008-0434-7; Pu PY, 2004, CLIN NEUROL NEUROSUR, V107, P49, DOI 10.1016/j.clineuro.2004.03.006; Rouach N, 2008, SCIENCE, V322, P1551, DOI 10.1126/science.1164022; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shinoura N, 1996, J NEUROSURG, V84, P839, DOI 10.3171/jns.1996.84.5.0839; Sin WC, 2008, J CELL BIOCHEM, V103, P1772, DOI 10.1002/jcb.21571; Solan JL, 2009, BIOCHEM J, V419, P261, DOI 10.1042/BJ20082319; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Suadicani SO, 2009, ASN NEURO, V1, DOI 10.1042/AN20090001; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Tabernero A, 2006, J NEUROCHEM, V96, P973, DOI 10.1111/j.1471-4159.2005.03623.x; Tabernero A, 1996, GLIA, V16, P187, DOI 10.1002/(SICI)1098-1136(199603)16:3<187::AID-GLIA1>3.0.CO;2-#; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Warn-Cramer BJ, 2003, CELL COMMUN ADHES, V10, P299, DOI 10.1080/714040443; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Zhang X, 2005, J CLIN NEUROSCI, V12, P166, DOI 10.1016/j.jocn.2004.03.036; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	60	45	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5712	5723		10.1038/onc.2010.299	http://dx.doi.org/10.1038/onc.2010.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676131				2022-12-28	WOS:000283262500007
J	Cooke, SL; Ng, CKY; Melnyk, N; Garcia, MJ; Hardcastle, T; Temple, J; Langdon, S; Huntsman, D; Brenton, JD				Cooke, S. L.; Ng, C. K. Y.; Melnyk, N.; Garcia, M. J.; Hardcastle, T.; Temple, J.; Langdon, S.; Huntsman, D.; Brenton, J. D.			Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma	ONCOGENE			English	Article						ovarian cancer; heterogeneity; evolution; chemotherapy	ACUTE LYMPHOBLASTIC-LEUKEMIA; CANCER CELL-LINES; BREAST-CANCER; CHROMOSOMAL INSTABILITY; TUMOR HETEROGENEITY; DISEASE PROGRESSION; COPY NUMBER; MUTATIONS; EXPRESSION; RESISTANCE	Resistance to chemotherapy in ovarian cancer is poorly understood. Evolutionary models of cancer predict that, following treatment, resistance emerges either because of outgrowth of an intrinsically resistant sub-clone or evolves in residual disease under the selective pressure of treatment. To investigate genetic evolution in high-grade serous (HGS) ovarian cancers, we first analysed cell line series derived from three cases of HGS carcinoma before and after platinum resistance had developed (PEO1, PEO4 and PEO6; PEA1 and PEA2; and PEO14 and PEO23). Analysis with 24-colour fluorescence in situ hybridisation and single nucleotide polymorphism (SNP) array comparative genomic hybridisation (CGH) showed mutually exclusive endoreduplication and loss of heterozygosity events in clones present at different time points in the same individual. This implies that platinum-sensitive and -resistant disease was not linearly related, but shared a common ancestor at an early stage of tumour development. Array CGH analysis of six paired pre- and post-neoadjuvant treatment HGS samples from the CTCR-OV01 clinical study did not show extensive copy number differences, suggesting that one clone was strongly dominant at presentation. These data show that cisplatin resistance in HGS carcinoma develops from pre-existing minor clones but that enrichment for these clones is not apparent during short-term chemotherapy treatment. Oncogene (2010) 29, 4905-4913; doi: 10.1038/onc.2010.245; published online 28 June 2010	[Cooke, S. L.; Ng, C. K. Y.; Garcia, M. J.; Hardcastle, T.; Temple, J.; Brenton, J. D.] Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Cambridge, England; [Melnyk, N.; Huntsman, D.] British Columbia Canc Agcy, Ctr Translat & Appl Genom, Vancouver, BC V5Z 4E6, Canada; [Langdon, S.] Univ Edinburgh, Div Pathol, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland	Cancer Research UK; CRUK Cambridge Institute; British Columbia Cancer Agency; University of Edinburgh	Brenton, JD (corresponding author), Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge, England.	james.brenton@cancer.org.uk	Brenton, James D/B-3174-2008; Ng, Charlotte K Y/AAA-1670-2020; Huntsman, David/ABE-6082-2020; García, María J/G-1361-2016; Ng, Charlotte K Y/AAY-3178-2021	Brenton, James D/0000-0002-5738-6683; García, María J/0000-0002-2236-9912; Ng, Charlotte K Y/0000-0002-6100-0026; Hardcastle, Thomas/0000-0002-9328-5011	Cancer Research UK; University of Cambridge; Hutchison Whampoa Ltd; Cambridge Experimental Cancer Medicine Centre; NIHR Biomedical Research Centre; Cancer Research UK [19556] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); University of Cambridge(University of Cambridge); Hutchison Whampoa Ltd; Cambridge Experimental Cancer Medicine Centre; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK)	We thank Paul Edwards for helpful discussion of the paper. We thank our patients and members of the Gynaecological Oncology Multidisciplinary Team at Cambridge University Hospitals NHS Foundation Trust for their participation in the CTCR-OV01 clinical study. This work was funded by Cancer Research UK. We acknowledge the support of the University of Cambridge, Hutchison Whampoa Ltd, the Cambridge Experimental Cancer Medicine Centre and the NIHR Biomedical Research Centre.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bayani J, 2002, CANCER RES, V62, P3466; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Curto M, 2008, BRIT J CANCER, V98, P256, DOI 10.1038/sj.bjc.6604002; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzog TJ, 2006, NAT CLIN PRACT ONCOL, V3, P604, DOI 10.1038/ncponc0637; Herzog TJ, 2004, CLIN CANCER RES, V10, P7439, DOI 10.1158/1078-0432.CCR-04-0683; Hofmann WK, 2003, BLOOD, V102, P659, DOI 10.1182/blood-2002-06-1756; KAMB A, 1994, SCIENCE, V264, P440; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khalique L, 2007, J PATHOL, V211, P286, DOI 10.1002/path.2112; Koebel Martin, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S146239940800077X; LANGDON SP, 1988, CANCER RES, V48, P6166; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; MARKMAN M, 1991, J CLIN ONCOL, V9, P389, DOI 10.1200/JCO.1991.9.3.389; McAlpine JN, 2008, GYNECOL ONCOL, V110, P360, DOI 10.1016/j.ygyno.2008.05.019; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ouellet V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-152; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Ruijter ET, 1996, J PATHOL, V180, P295; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Schulmann K, 2005, GASTROENTEROLOGY, V129, P74, DOI 10.1053/j.gastro.2005.04.011; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shibata K, 1998, BIOCHEM BIOPH RES CO, V246, P205, DOI 10.1006/bbrc.1998.8581; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Torres L, 2007, BREAST CANCER RES TR, V102, P143, DOI 10.1007/s10549-006-9317-6; Toyoda M, 2003, DEV CELL, V5, P85, DOI 10.1016/S1534-5807(03)00189-8; Trofatter J A, 1993, Cell, V75, P826; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Zhu YM, 1999, BRIT J CANCER, V79, P1151, DOI 10.1038/sj.bjc.6690183	41	118	122	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4905	4913		10.1038/onc.2010.245	http://dx.doi.org/10.1038/onc.2010.245			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20581869	Green Accepted			2022-12-28	WOS:000281578700005
J	Craik, AC; Veldhoen, RA; Czernick, M; Buckland, TW; Kyselytzia, K; Ghosh, S; Lai, R; Damaraju, S; Underhill, DA; Mackey, JR; Goping, IS				Craik, A. C.; Veldhoen, R. A.; Czernick, M.; Buckland, T. W.; Kyselytzia, K.; Ghosh, S.; Lai, R.; Damaraju, S.; Underhill, D. A.; Mackey, J. R.; Goping, I. S.			The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism	ONCOGENE			English	Article						Bad; taxane; paclitaxel; docetaxel; apoptosis; breast cancer	CELL-SURVIVAL; BH3 DOMAIN; EXPRESSION PATTERNS; MAMMARY-GLAND; MITOTIC BLOCK; APOPTOSIS; PHOSPHORYLATION; BCL-2; DEATH; PACLITAXEL	Antimitotic agents such as taxanes (paclitaxel and docetaxel) have greatly advanced the treatment of breast cancer, although variable patient response and drug toxicity are major limitations. Lack of validated predictive markers for taxane responsiveness precludes a priori identification of patients who are most likely to respond to treatment; thus, a subset of patients endure toxic side effects with marginal benefit. Mechanistic insights into taxane therapeutic activity may lead to rational therapeutic improvements. In this paper we report that the proapoptotic BH3-only protein Bad has a major role in taxane-induced cell death in vitro, and clinically is a prognostic indicator for overall survival of breast cancer patients after adjuvant taxane chemotherapy. Unexpectedly, Bad did not induce the mitochondrial apoptotic machinery in response to taxane treatment. Instead, Bad indirectly facilitated cell death by stimulating cellular proliferation. As dividing cells are the targets of taxane therapy, Bad-stimulated proliferation may be a marker of taxane sensitivity. Our studies indicate that quantification of Bad protein levels may have value as a diagnostic tool. They also suggest that cells expressing Bad are more sensitive to taxanes because of their altered cell cycle dynamics and reveal a clinically relevant proliferative role of Bad in breast cancer. Oncogene (2010) 29, 5381-5391; doi: 10.1038/onc.2010.272; published online 5 July 2010	[Craik, A. C.; Veldhoen, R. A.; Czernick, M.; Buckland, T. W.; Kyselytzia, K.; Goping, I. S.] Univ Alberta, Dept Biochem, Sch Mol & Syst Med, Edmonton, AB T6G 2H7, Canada; [Ghosh, S.; Underhill, D. A.; Mackey, J. R.; Goping, I. S.] Univ Alberta, Dept Oncol, Sch Canc Engn & Imaging Sci Med, Edmonton, AB T6G 2H7, Canada; [Lai, R.; Damaraju, S.] Univ Alberta, Dept Lab Med & Pathol, Sch Clin & Lab Sci, Edmonton, AB T6G 2H7, Canada; [Damaraju, S.; Mackey, J. R.] Cross Canc Inst, Alberta Hlth Serv, PolyomX Program, Edmonton, AB T6G 1Z2, Canada; [Underhill, D. A.] Univ Alberta, Dept Med Genet, Sch Human Dev, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta; Alberta Health Services (AHS); University of Alberta; University of Alberta	Goping, IS (corresponding author), Univ Alberta, Dept Biochem, Sch Mol & Syst Med, 5-73 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	igoping@ualberta.ca	Veldhoen, Richard/M-8168-2019	Veldhoen, Richard/0000-0003-4643-2960; Underhill, Darrell/0000-0003-0957-7407	QEII; Mary Johnston Melanoma Research Chair; Alberta Cancer Research Institute; Canadian Breast Cancer Foundation	QEII; Mary Johnston Melanoma Research Chair; Alberta Cancer Research Institute; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS))	We thank Drs Thomas Simmen, Roseline Godbout and Simonetta Sipione for helpful discussions, Ms Yisu Li for assistance with gene expression microarray analysis and Ms Cheryl Santos for excellent technical input. We also thank the anonymous reviewers for insightful suggestions that improved this study. ACC is a recipient of a QEII Graduate Scholarship. DAU is supported by the Mary Johnston Melanoma Research Chair. ISG is a recipient of a Recruitment Award from the Alberta Cancer Research Institute. This work was supported by operating grants from the Alberta Cancer Research Institute and the Canadian Breast Cancer Foundation awarded to ISG.	Aapro MS, 2001, ONCOLOGIST, V6, P36, DOI 10.1634/theoncologist.6-4-376; Al-Bazz YO, 2009, EUR J CANCER, V45, P694, DOI 10.1016/j.ejca.2008.11.044; Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Chang JC, 2008, BREAST CANCER RES TR, V108, P233, DOI 10.1007/s10549-007-9590-z; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Derry WB, 1998, CANCER RES, V58, P1177; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Fernando R, 2007, J BIOL CHEM, V282, P28864, DOI 10.1074/jbc.M700785200; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janumyan Y, 2008, J BIOL CHEM, V283, P34108, DOI 10.1074/jbc.M806294200; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitada S, 1998, AM J PATHOL, V152, P51; Klumpp S, 2003, NEUROCHEM INT, V42, P555, DOI 10.1016/S0197-0186(02)00174-2; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Noguchi S, 2006, CANCER SCI, V97, P813, DOI 10.1111/j.1349-7006.2006.00265.x; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Pellegrini F, 2005, CANCER INVEST, V23, P264, DOI 10.1081/CNV-200055970; Perez EA, 1999, SEMIN ONCOL, V26, P1; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Roy SS, 2009, MOL CELL, V33, P377, DOI 10.1016/j.molcel.2009.01.018; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Smith AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006224; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Upreti M, 2008, J BIOL CHEM, V283, P35517, DOI 10.1074/jbc.M805019200; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	66	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5381	5391		10.1038/onc.2010.272	http://dx.doi.org/10.1038/onc.2010.272			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20603619				2022-12-28	WOS:000282944500005
J	Wolf, MJ; Seleznik, GM; Zeller, N; Heikenwalder, M				Wolf, M. J.; Seleznik, G. M.; Zeller, N.; Heikenwalder, M.			The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development	ONCOGENE			English	Review						lymphotoxin beta receptor signaling; inflammation-induced carcinogenesis; NF-kappa B signaling; lymphotoxin alpha; lymphotoxin beta	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FACTOR TNF-ALPHA; LT-ALPHA; GENE-EXPRESSION; IKK-ALPHA; T-CELLS; SURFACE LYMPHOTOXIN; SJOGRENS-SYNDROME	The cytokines lymphotoxin (LT) alpha, beta and their receptor (LT beta R) belong to the tumor necrosis factor (TNF) superfamily, whose founder-TNF alpha-was initially discovered due to its tumor necrotizing activity. LT beta R signaling serves pleiotropic functions including the control of lymphoid organ development, support of efficient immune responses against pathogens due to maintenance of intact lymphoid structures, induction of tertiary lymphoid organs, liver regeneration or control of lipid homeostasis. Signaling through LTbR comprises the noncanonical/canonical nuclear factor-kappa B (NF-kappa B) pathways thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Blocking LT beta R signaling or Fc gamma-receptor mediated immunoablation of LT-expressing cells was demonstrated to be beneficial in various infectious or noninfectious inflammatory or autoimmune disorders. Only recently, LT beta R signaling was shown to initiate inflammation-induced carcinogenesis, to influence primary tumorigenesis and to control reemergence of carcinoma in various cancer models through distinct mechanisms. Indeed, LT beta R signaling inhibition has already been used as efficient anti-inflammatory, anti-cancer therapy in some experimental models. Here, we review the pleiotropic functions attributed to LT, the effects of its deregulation and extensively discuss the recent literature on LT's link to carcinogenesis. Oncogene (2010) 29, 5006-5018; doi:10.1038/onc.2010.260; published online 5 July 2010	[Wolf, M. J.; Seleznik, G. M.; Zeller, N.; Heikenwalder, M.] Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, CH-8091 Zurich, Switzerland; [Heikenwalder, M.] Tech Univ Munich, Inst Virol, Helmholtz Zentrum Munchen, Munich, Germany	University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Heikenwalder, M (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	mathias.heikenwaelder@usz.ch	Heikenwalder, Mathias/AAA-2269-2020		Biogen Idec; Oncosuisse foundation [OCS 02113-08-2007]; Novartis Stiftung fur Biologisch-Medizinische Forschung [09C62]; Stiftung zur Schweizerischen Krebsbekampfung; Helmholtz-foundation; Research foundation at the Medical Faculty Zurich; Julius-Muller foundation; Kurt und Senta Hermann Stiftung; Roche Research Foundation	Biogen Idec(Biogen); Oncosuisse foundation; Novartis Stiftung fur Biologisch-Medizinische Forschung; Stiftung zur Schweizerischen Krebsbekampfung; Helmholtz-foundation(Helmholtz Association); Research foundation at the Medical Faculty Zurich; Julius-Muller foundation; Kurt und Senta Hermann Stiftung; Roche Research Foundation	Dr Mathias Heikenwalder is in the process of designing a clinical trial using LTBR-Ig (baminercept) in hepatitis C virus-infected patients, which would be partially funded by Biogen Idec. The planned trial is not yet approved. Dr Nicolas Zeller, Monika Wolf and Gitta Seleznik declare no conflict of interest.; We thank Dr Tracy O'Connor, Dr Barbara Stecher, Jay Tracy and Lukas Frick for critically reading this paper. MH was supported by grants of the Oncosuisse foundation (OCS 02113-08-2007), the Novartis Stiftung fur Biologisch-Medizinische Forschung (Nr. 09C62), the 'Stiftung zur Schweizerischen Krebsbekampfung', the Helmholtz-foundation, the research foundation at the Medical Faculty Zurich, the Julius-Muller foundation and the 'Kurt und Senta Hermann Stiftung'. MJW was supported by a grant of the Roche Research Foundation. MH is a fellow of the Professor Dr Max Cloetta foundation.	AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; An MM, 2006, BIOL PHARM BULL, V29, P2025, DOI 10.1248/bpb.29.2025; An MM, 2005, PHARMACOL RES, V52, P234, DOI 10.1016/j.phrs.2005.03.009; Anand S, 2006, J CLIN INVEST, V116, P1045, DOI 10.1172/JCI27083; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Armengol MP, 2003, J IMMUNOL, V170, P6320, DOI 10.4049/jimmunol.170.12.6320; Aust G, 2004, EUR J ENDOCRINOL, V150, P225, DOI 10.1530/eje.0.1500225; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Britanova LV, 2008, BIOCHEM BIOPH RES CO, V365, P583, DOI 10.1016/j.bbrc.2007.10.200; Browning JL, 2008, IMMUNOL REV, V223, P202, DOI 10.1111/j.1600-065X.2008.00633.x; Browning JL, 2005, IMMUNITY, V23, P539, DOI 10.1016/j.immuni.2005.10.002; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CAVENDER DE, 1989, AM J PATHOL, V134, P551; Chae YS, 2010, CANCER CHEMOTH PHARM, V65, P571, DOI 10.1007/s00280-009-1066-x; Chiang EY, 2009, NAT MED, V15, P766, DOI 10.1038/nm.1984; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Columba-Cabezas S, 2006, J NEUROIMMUNOL, V179, P76, DOI 10.1016/j.jneuroim.2006.06.015; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cuff CA, 1998, J IMMUNOL, V161, P6853; Cuff CA, 1999, J IMMUNOL, V162, P5965; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Ettinger R, 2001, J EXP MED, V193, P1333, DOI 10.1084/jem.193.11.1333; Fava RA, 2003, J IMMUNOL, V171, P115, DOI 10.4049/jimmunol.171.1.115; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Fu YX, 2000, J IMMUNOL, V164, P2508, DOI 10.4049/jimmunol.164.5.2508; Fu YX, 1997, J EXP MED, V185, P2111, DOI 10.1084/jem.185.12.2111; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gatumu MK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2617; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; Ghosh S, 2005, J IMMUNOL, V174, P2860, DOI 10.4049/jimmunol.174.5.2860; Gommerman JL, 2003, NAT REV IMMUNOL, V3, P642, DOI 10.1038/nri1151; Gommerman JL, 2003, J CLIN INVEST, V112, P755, DOI 10.1172/JCI200318648; Grabner R, 2009, J EXP MED, V206, P233, DOI 10.1084/jem.20080752; GRANGER GA, 1968, NATURE, V218, P1253, DOI 10.1038/2181253a0; GRANGER GA, 1969, NATURE, V221, P1155, DOI 10.1038/2211155a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; He GB, 2010, CANCER CELL, V17, P286, DOI 10.1016/j.ccr.2009.12.048; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Hehlgans T, 2002, CANCER RES, V62, P4034; Heikenwalder M, 2005, SCIENCE, V307, P1107, DOI 10.1126/science.1106460; Heikenwalder M, 2008, AM J PATHOL, V172, P1555, DOI 10.2353/ajpath.2008.070572; HISERODT JC, 1977, CELL IMMUNOL, V34, P326, DOI 10.1016/0008-8749(77)90255-6; Hjelmervik TOR, 2005, ARTHRITIS RHEUM, V52, P1534, DOI 10.1002/art.21006; Ito D, 1999, J IMMUNOL, V163, P2809; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kobayashi M, 2004, P NATL ACAD SCI USA, V101, P17807, DOI 10.1073/pnas.0407503101; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Kuprash DV, 2008, CANCER LETT, V268, P70, DOI 10.1016/j.canlet.2008.03.023; Lee Y, 2006, IMMUNITY, V25, P499, DOI 10.1016/j.immuni.2006.06.016; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lo JC, 2007, SCIENCE, V316, P285, DOI 10.1126/science.1137221; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Lukashev M, 2006, CANCER RES, V66, P9617, DOI 10.1158/0008-5472.CAN-06-0217; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Markey KA, 2010, BLOOD, V115, P122, DOI 10.1182/blood-2009-01-199927; Martin AP, 2004, J IMMUNOL, V173, P4791, DOI 10.4049/jimmunol.173.8.4791; McCarthy DA, 2006, IMMUNOL RES, V35, P41, DOI 10.1385/IR:35:1:41; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; MULLER U, 1987, NATURE, V325, P265, DOI 10.1038/325265a0; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; NEDWIN GE, 1985, J CELL BIOCHEM, V29, P171, DOI 10.1002/jcb.240290302; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Norris PS, 2007, ADV EXP MED BIOL, V597, P160; Or YYY, 2010, J PATHOL, V220, P97, DOI 10.1002/path.2609; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Plant SR, 2007, J NEUROSCI, V27, P7429, DOI 10.1523/JNEUROSCI.1307-07.2007; POBER JS, 1987, J IMMUNOL, V138, P3319; POBER JS, 1987, CIBA F SYMP, V131, P170; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; PRINEAS JW, 1979, SCIENCE, V203, P1123, DOI 10.1126/science.424741; Puglielli MT, 1999, NAT MED, V5, P1370; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497; Ruddell RG, 2009, HEPATOLOGY, V49, P227, DOI 10.1002/hep.22597; RUDDLE NH, 1967, SCIENCE, V157, P1060, DOI 10.1126/science.157.3792.1060; RUDDLE NH, 1968, J EXP MED, V128, P1267, DOI 10.1084/jem.128.6.1267; Schneider K, 2004, IMMUNOL REV, V202, P49, DOI 10.1111/j.0105-2896.2004.00206.x; Schreyer SA, 2002, J BIOL CHEM, V277, P12364, DOI 10.1074/jbc.M111727200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Shao H, 2003, EUR J IMMUNOL, V33, P1736, DOI 10.1002/eji.200323745; STEERE AC, 1988, ARTHRITIS RHEUM, V31, P487, DOI 10.1002/art.1780310405; Stopfer P, 2004, J IMMUNOL, V172, P7459, DOI 10.4049/jimmunol.172.12.7459; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; Tamada K, 2000, NAT MED, V6, P283; Tamada K, 2002, J CLIN INVEST, V109, P549, DOI 10.1172/JCI200213604; Tumanov AV, 2007, CURR MOL MED, V7, P567, DOI 10.2174/156652407781695701; Tumanov AV, 2009, GASTROENTEROLOGY, V136, P694, DOI 10.1053/j.gastro.2008.09.015; Villanueva A, 2009, CANCER CELL, V16, P272, DOI 10.1016/j.ccr.2009.09.012; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719; WARE CF, 1979, J IMMUNOL, V122, P1763; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883; Wu Q, 2004, J IMMUNOL, V172, P1630, DOI 10.4049/jimmunol.172.3.1630; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; YOUNG CL, 1984, ARTHRITIS RHEUM, V27, P32, DOI 10.1002/art.1780270106; Young J, 2010, CYTOKINE, V51, P78, DOI 10.1016/j.cyto.2010.03.003; Zhou PH, 2009, P NATL ACAD SCI USA, V106, P17134, DOI 10.1073/pnas.0905707106	129	70	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5006	5018		10.1038/onc.2010.260	http://dx.doi.org/10.1038/onc.2010.260			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20603617				2022-12-28	WOS:000281620100002
J	Zipfel, PA; Brady, DC; Kashatus, DF; Ancrile, BD; Tyler, DS; Counter, CM				Zipfel, P. A.; Brady, D. C.; Kashatus, D. F.; Ancrile, B. D.; Tyler, D. S.; Counter, C. M.			Ral activation promotes melanomagenesis	ONCOGENE			English	Article						melanoma; RalA; RalB; NRas	GTPASES; CANCER; PATHWAYS; EXPRESSION; FAMILY; GROWTH; RAIA	Up to one-third of human melanomas are characterized by an oncogenic mutation in the gene encoding the small guanosine triphosphatase (GTPase) NRAS. Ras proteins activate three primary classes of effectors, namely, Rafs, phosphatidyl-inositol-3-kinases (PI3Ks) and Ral guanine exchange factors (RalGEFs). In melanomas lacking NRAS mutations, the first two effectors can still be activated through an oncogenic BRAF mutation coupled with a loss of the PI3K negative regulator PTEN. This suggests that Ras effectors promote melanoma, regardless of whether they are activated by oncogenic NRas. The only major Ras effector pathway not explored for its role in melanoma is the RalGEF-Ral pathway, in which Ras activation of RalGEFs converts the small GTPases RalA and RalB to an active guanosine triphosphate-bound state. We report that RalA is activated in several human melanoma cancer cell lines harboring an oncogenic NRAS allele, an oncogenic BRAF allele or wild-type NRAS and BRAF alleles. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of RalA, and to a lesser extent of RalB, variably inhibited the tumorigenic growth of melanoma cell lines having these three genotypes. Thus, as is the case for Raf and PI3K signaling, Rals also contribute to melanoma tumorigenesis. Oncogene (2010) 29, 4859-4864; doi:10.1038/onc.2010.224; published online 21 June 2010	[Zipfel, P. A.; Tyler, D. S.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Zipfel, P. A.; Tyler, D. S.] Durham VA Med Ctr, Durham, NC USA; [Brady, D. C.; Kashatus, D. F.; Ancrile, B. D.; Counter, C. M.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Counter, C. M.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University	Tyler, DS (corresponding author), Duke Univ, Med Ctr, Dept Surg, LSRC Bldg Room C225,Res Dr, Durham, NC 27710 USA.	tyler002@mc.duke.edu; count004@mc.duke.edu	Kashatus, David F/D-8299-2012; Brady, Donita/E-3801-2012	Kashatus, David F/0000-0001-8007-0612; Counter, Christopher M/0000-0003-0748-3079	American Cancer Society; National Institutes of Health [CA94184]; Leukemia & Lymphoma Fellowship; Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA094184] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Fellowship; Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by an American Cancer Society Grant to PAZ, a Leukemia & Lymphoma Fellowship to DFK, a Veterans Affairs Merit Review Grant to DST and a National Institutes of Health grant (CA94184) to CMC. We thank Dr Hillard Siegler (Duke University Medical Center) for all melanoma cell lines except SKMel28 cells.	Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bodempudi V, 2009, MOL CELL BIOL, V29, P3964, DOI 10.1128/MCB.01153-08; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; de Gorter DJJ, 2008, BLOOD, V111, P3364, DOI 10.1182/blood-2007-08-106583; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Falsetti SC, 2007, MOL CELL BIOL, V27, P8003, DOI 10.1128/MCB.00057-07; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Lim KH, 2010, MOL CELL BIOL, V30, P508, DOI 10.1128/MCB.00916-08; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Sowalsky AG, 2010, ONCOGENE, V29, P45, DOI 10.1038/onc.2009.307; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07	28	30	32	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4859	4864		10.1038/onc.2010.224	http://dx.doi.org/10.1038/onc.2010.224			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562921	Green Accepted			2022-12-28	WOS:000281326400011
J	Wang, YN; Yamaguchi, H; Hsu, JM; Hung, MC				Wang, Y-N; Yamaguchi, H.; Hsu, J-M; Hung, M-C			Nuclear trafficking of the epidermal growth factor receptor family membrane proteins	ONCOGENE			English	Review						EGFR family receptors; nuclear trafficking; integral membrane proteins	TYROSINE KINASE INHIBITORS; CLATHRIN-INDEPENDENT ENDOCYTOSIS; CELL-SURFACE RECEPTORS; BREAST-CANCER; INTRACELLULAR DOMAIN; NUCLEOCYTOPLASMIC TRANSPORT; GENE-EXPRESSION; EGF RECEPTOR; LUNG-CANCER; SIGNAL-TRANSDUCTION	Multiple membrane-bound receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR) and ErbB-2, have been reported to be localized in the nucleus, where emerging evidence suggests that they are involved in transcriptional regulation, cell proliferation, DNA repair and chemo-and radio-resistance. Recent studies have shown that endocytosis and endosomal sorting are involved in the nuclear transport of cell surface RTKs. However, the detailed mechanism by which the full-length receptors embedded in the endosomal membrane travel all the way from the cell surface to the early endosomes and pass through the nuclear pore complexes is unknown. This important area has been overlooked for decades, which has hindered progress in our understanding of nuclear RTKs' functions. Here, we discuss the putative mechanisms by which EGFR family RTKs are shuttled into the nucleus. Understanding the trafficking mechanisms as to how RTKs are transported from the cell surface to the nucleus will significantly contribute to understanding the functions of the nuclear RTKs. Oncogene (2010) 29, 3997-4006; doi:10.1038/onc.2010.157; published online 17 May 2010	[Wang, Y-N; Yamaguchi, H.; Hsu, J-M; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hsu, J-M; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 079, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Hsu, Jung-Mao/AAP-8045-2020; Hsu, Jung-Mao/AAC-9527-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Ying-Nai/0000-0002-5275-6729	National Institutes of Health [RO1 109311]; National Breast Cancer Foundation Inc.; China Medical University Hospital; Cancer Center Research of Excellence Taiwan [DOH TD-C-111-005]; National Science Council Taiwan [TMS-94-2B-001]; MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P01CA099031, R01CA109311] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation Inc.; China Medical University Hospital; Cancer Center Research of Excellence Taiwan; National Science Council Taiwan(Ministry of Science and Technology, Taiwan); MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Institutes of Health Grants RO1 109311; the National Breast Cancer Foundation Inc.; the Sister Institutional fund from China Medical University Hospital and MD Anderson Cancer Center; Cancer Center Research of Excellence DOH TD-C-111-005 (Taiwan) (to M-CH), and National Science Council Taiwan Merit Postdoctoral Scholarship TMS-94-2B-001 (to Y-NW). In memoriam, Mrs Serena Lin-Guo for her courageous battle in breast cancer.	Adam RM, 2003, CANCER RES, V63, P484; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bailey KE, 2007, J NUCL MED, V48, P1562, DOI 10.2967/jnumed.107.044073; Baldys A, 2009, BIOCHEMISTRY-US, V48, P9321, DOI 10.1021/bi900865u; Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Bueter W, 2006, CYTOKINE, V36, P267, DOI 10.1016/j.cyto.2007.02.002; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Ceresa BP, 2006, J BIOL CHEM, V281, P1099, DOI 10.1074/jbc.M504175200; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cook A, 2007, ANNU REV BIOCHEM, V76, P647, DOI 10.1146/annurev.biochem.76.052705.161529; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2005, RADIOTHER ONCOL, V76, P157, DOI 10.1016/j.radonc.2005.06.022; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Klaus HD, 2008, INT J RADIAT ONCOL, V70, P203, DOI 10.1016/j.ijrobp.2007.08.065; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Edwards J, 2006, CLIN CANCER RES, V12, P123, DOI 10.1158/1078-0432.CCR-05-1445; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Fang XH, 2005, J BIOL CHEM, V280, P28451, DOI 10.1074/jbc.M504400200; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755; Grasl-Kraupp B, 2002, HEPATOLOGY, V35, P1372, DOI 10.1053/jhep.2002.33203; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Hieda M, 2008, J CELL BIOL, V180, P763, DOI 10.1083/jcb.200710022; Higashiyama S, 2008, CANCER SCI, V99, P214, DOI 10.1111/j.1349-7006.2007.00676.x; Hoelz A, 2004, NATURE, V432, P815, DOI 10.1038/432815a; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Irmer D, 2007, ONCOGENE, V26, P5693, DOI 10.1038/sj.onc.1210383; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johannes L, 2008, CELL, V135, P1175, DOI 10.1016/j.cell.2008.12.009; Jones FE, 2008, J MAMMARY GLAND BIOL, V13, P247, DOI 10.1007/s10911-008-9076-6; Kim HP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005933; Kim J, 2007, CANCER RES, V67, P9229, DOI 10.1158/0008-5472.CAN-07-1333; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; Klein C, 2004, BIOCHEMISTRY-US, V43, P15873, DOI 10.1021/bi048604t; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lusk CP, 2007, NAT REV MOL CELL BIO, V8, P414, DOI 10.1038/nrm2165; MARTI U, 1995, J HEPATOL, V23, P318, DOI 10.1016/S0168-8278(95)80011-5; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Marti Ulrich, 2000, Molecular Cell Biology Research Communications, V3, P8, DOI 10.1006/mcbr.2000.0177; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mills IG, 2005, J CELL BIOL, V170, P191, DOI 10.1083/jcb.200503106; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Muraoka-Cook RS, 2008, J MAMMARY GLAND BIOL, V13, P235, DOI 10.1007/s10911-008-9080-x; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Pilecka I, 2007, EUR J CELL BIOL, V86, P533, DOI 10.1016/j.ejcb.2007.04.004; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; RAPER SE, 1987, GASTROENTEROLOGY, V92, P1243, DOI 10.1016/S0016-5085(87)91084-5; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Saksena S, 2006, NAT STRUCT MOL BIOL, V13, P500, DOI 10.1038/nsmb1098; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Sequist LV, 2008, ANNU REV MED, V59, P429, DOI 10.1146/annurev.med.59.090506.202405; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Spooner RA, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-26; Stachowiak MK, 2007, DNA CELL BIOL, V26, P811, DOI 10.1089/dna.2007.0664; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Stewart CL, 2007, SCIENCE, V318, P1408, DOI 10.1126/science.1142034; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Terry LJ, 2007, SCIENCE, V318, P1412, DOI 10.1126/science.1142204; Thompson M, 2007, BRAIN RES, V1139, P95, DOI 10.1016/j.brainres.2006.11.047; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang ZH, 1998, ANTICANCER RES, V18, P4329; Wanner G, 2008, RADIOTHER ONCOL, V86, P383, DOI 10.1016/j.radonc.2007.10.041; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162; Woodman P, 2009, BIOCHEM SOC T, V37, P146, DOI 10.1042/BST0370146; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Xu YR, 2009, J CELL BIOCHEM, V107, P873, DOI 10.1002/jcb.22195; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zuleger N, 2008, BIOCHEM SOC T, V36, P1373, DOI 10.1042/BST0361373	121	158	167	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2010	29	28					3997	4006		10.1038/onc.2010.157	http://dx.doi.org/10.1038/onc.2010.157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473332	Green Accepted			2022-12-28	WOS:000279892400001
J	Brem, R; Li, F; Montaner, B; Reelfs, O; Karran, P				Brem, R.; Li, F.; Montaner, B.; Reelfs, O.; Karran, P.			DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation	ONCOGENE			English	Article						thiopurines; UVA; skin cancer; DNA breakage; cell cycle checkpoints	DOUBLE-STRAND BREAKS; TRANSPLANT RECIPIENTS; MEDIATED DAMAGE; REPAIR; AZATHIOPRINE; SKIN; MECHANISMS; PROTECTION; MUTATIONS; CANCERS	The frequency of squamous cell skin carcinoma in organ transplant patients is around 100-fold higher than normal. This dramatic example of therapy-related cancer reflects exposure to sunlight and to immunosuppressive drugs. Here, we show that the interaction between low doses of UVA, the major ultraviolet component of incident sunlight, and 6-TG, a UVA chromophore that is introduced into DNA by one of the most widely prescribed immunosuppressive drugs, causes DNA single- and double-strand breaks (DSB). S phase cells are particularly vulnerable to this DNA breakage and cells defective in rejoining of S-phase DSB are hypersensitive to the combination of low-dose UVA and DNA 6-TG. 6-TG/UVA-induced DNA lesions provoke canonical DNA damage responses involving activation of the ATM/Chk2 and ATR/Chk1 pathways and appropriate cell cycle checkpoints. Higher levels of photochemical DNA damage induce a proteasome-mediated degradation of Chk1 and checkpoint abrogation that is consistent with persistent unrepaired DNA damage. These findings indicate that the interaction between UVA and an immunosuppressant drug causes photochemical DNA lesions, including DNA breaks, and can compromise cell cycle checkpoints. These two properties could contribute to the high risk of sunlight-related skin cancer in long-term immunosuppressed patients. Oncogene (2010) 29, 3953-3963; doi:10.1038/onc.2010.140; published online 3 May 2010	[Brem, R.; Li, F.; Montaner, B.; Karran, P.] Canc Res UK London Res Inst, Mammalian DNA Repair Lab, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; [Reelfs, O.] Guys Hosp, Kings Coll Sch Med, St Johns Inst Dermatol, London SE1 9RT, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Karran, P (corresponding author), Canc Res UK London Res Inst, Mammalian DNA Repair Lab, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	peter.karran@cancer.org.uk	/AAD-1866-2020	Montaner, Beatriz/0000-0001-9877-7317	Cancer Research UK [A3558] Funding Source: Medline; Cancer Research UK [11584] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Brem R, 2009, NUCLEIC ACIDS RES, V37, P1951, DOI 10.1093/nar/gkp070; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Cahill MA, 1996, BIOCHEM BIOPH RES CO, V229, P170, DOI 10.1006/bbrc.1996.1775; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Cooke MS, 2008, DNA REPAIR, V7, P1982, DOI 10.1016/j.dnarep.2008.08.007; Daehn I, 2009, CANCER RES, V69, P2393, DOI 10.1158/0008-5472.CAN-08-4264; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Grosse Y, 2009, LANCET ONCOL, V10, P13, DOI 10.1016/S1470-2045(08)70286-9; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Karran P, 2008, NAT REV CANCER, V8, P24, DOI 10.1038/nrc2292; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kerzendorfer C, 2009, DNA REPAIR, V8, P1139, DOI 10.1016/j.dnarep.2009.04.018; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Kumar SS, 2000, MUTAT RES-GEN TOX EN, V469, P207, DOI 10.1016/S1383-5718(00)00074-7; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; LJUNGMAN M, 1992, MOL CARCINOGEN, V5, P264, DOI 10.1002/mc.2940050406; LJUNGMAN M, 1991, RADIAT RES, V127, P171, DOI 10.2307/3577962; Montaner B, 2007, EMBO REP, V8, P1074, DOI 10.1038/sj.embor.7401084; O'Donovan P, 2005, SCIENCE, V309, P1871, DOI 10.1126/science.1114233; ORMEROD MG, 2000, FLOW CYTOMETRY PRACT, P159; Penn I, 1994, Transplant Sci, V4, P23; Perrett CM, 2008, BRIT J DERMATOL, V159, P198, DOI 10.1111/j.1365-2133.2008.08610.x; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Smith CC, 1999, ENVIRON MOL MUTAGEN, V34, P131, DOI 10.1002/(SICI)1098-2280(1999)34:2/3<131::AID-EM12>3.3.CO;2-B; Toyooka T, 2006, ENVIRON MOL MUTAGEN, V47, P38, DOI 10.1002/em.20166; WARREN DJ, 1995, CANCER RES, V55, P1670; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955; Zhang XH, 2007, DNA REPAIR, V6, P344, DOI 10.1016/j.dnarep.2006.11.003; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	39	34	34	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3953	3963		10.1038/onc.2010.140	http://dx.doi.org/10.1038/onc.2010.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20440263	Green Accepted			2022-12-28	WOS:000279603200008
J	Hecker, RM; Amstutz, RA; Wachtel, M; Walter, D; Niggli, FK; Schafer, BW				Hecker, R. M.; Amstutz, R. A.; Wachtel, M.; Walter, D.; Niggli, F. K.; Schaefer, B. W.			p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment	ONCOGENE			English	Article						rhabdomyosarcoma; PAX3/FKHR; p21; combination treatment	HISTONE DEACETYLASE INHIBITOR; RHABDOMYOSARCOMA STUDY-GROUP; HUMAN COLON-CANCER; INTERGROUP RHABDOMYOSARCOMA; P21(WAF1/CIP1) EXPRESSION; TRANSCRIPTION FACTOR; CELL-LINES; GROWTH; ADOLESCENTS; EXPERIENCE	A number of drugs developed against cancer-specific molecular targets have been shown to offer survival benefits alone or in combination with standard treatments, especially for those cases in which tumor pathogenesis is dominated by a single molecular abnormality. One example for such a tumor type is alveolar rhabdomyosarcoma (aRMS), which is characterized by a specific translocation creating the oncogenic PAX3/FKHR transcription factor, believed to be the molecular basis of the disease. Recently, we were able to show that the small molecule inhibitor PKC412 (midostaurin) shows strong antitumor activity against aRMS by reducing the transcriptional activity of PAX3/FKHR. In this study, we screened for combination strategies that are superior to PKC412-only treatment and found that the combination of PKC412 with histone deacetylase inhibitors like valproic acid (VPA) synergistically induced apoptosis resulting in suppressed aRMS tumor growth in vivo. We provide evidence that the antitumor effect on combination treatment is achieved by VPA-induced reactivation of p21, which is downregulated in aRMS cells by destabilization of the transcriptional regulator EGR1 by PAX3/FKHR. Our study highlights a possible mechanism behind the increased efficacy and indicates that different arms of PAX3/FKHR oncogenicity can be exploited therapeutically by the specific combination of drugs to increase their therapeutic potential. Oncogene (2010) 29, 3942-3952; doi:10.1038/onc.2010.145; published online 10 May 2010	[Hecker, R. M.; Amstutz, R. A.; Wachtel, M.; Walter, D.; Niggli, F. K.; Schaefer, B. W.] Univ Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich	Schafer, BW (corresponding author), Univ Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	beat.schaefer@kispi.uzh.ch	Niggli, Felix/L-6547-2017	Niggli, Felix/0000-0002-7553-3712; Wachtel, Marco/0000-0002-6077-3692; Schafer, Beat/0000-0001-5988-2915	Swiss National Science Foundation (SNF) [3100-109837, 3100-122562]	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF))	We thank professor Soon Young Shin for providing constructs encoding EGR1 and p21 luciferase reporter plasmid, Silvia Behnke for her help with the stainings of tumor sections and Sarah Steinbacher for her graphical support in designing Figure 6. This work was supported by grants (3100-109837 and 3100-122562) from the Swiss National Science Foundation (SNF).	Amstutz R, 2008, CANCER RES, V68, P3767, DOI 10.1158/0008-5472.CAN-07-2447; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bali P, 2004, CLIN CANCER RES, V10, P4991, DOI 10.1158/1078-0432.CCR-04-0210; Barlow JW, 2006, PEDIATR BLOOD CANCER, V47, P773, DOI 10.1002/pbc.20650; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Choi BH, 2008, CANCER RES, V68, P1369, DOI 10.1158/0008-5472.CAN-07-5222; Della Ragione F, 2003, J BIOL CHEM, V278, P23360, DOI 10.1074/jbc.M300771200; Ebauer M, 2007, ONCOGENE, V26, P7267, DOI 10.1038/sj.onc.1210525; Furukawa Y, 2007, LEUKEMIA, V21, P1005, DOI 10.1038/sj.leu.2404593; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Genini M, 1996, INT J CANCER, V66, P571; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Kim JS, 2001, BIOCHEM BIOPH RES CO, V281, P866, DOI 10.1006/bbrc.2001.4434; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; Pappo AS, 1999, J CLIN ONCOL, V17, P3487, DOI 10.1200/JCO.1999.17.11.3487; Raney RB, 2001, J PEDIAT HEMATOL ONC, V23, P215, DOI 10.1097/00043426-200105000-00008; Roeb W, 2008, CELL CYCLE, V7, P837, DOI 10.4161/cc.7.7.5652; Roeb W, 2007, P NATL ACAD SCI USA, V104, P18085, DOI 10.1073/pnas.0708910104; Smith LM, 2001, J CLIN ONCOL, V19, P4058, DOI 10.1200/JCO.2001.19.20.4058; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200	28	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3942	3952		10.1038/onc.2010.145	http://dx.doi.org/10.1038/onc.2010.145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453878	Green Accepted			2022-12-28	WOS:000279603200007
J	Santhanam, AN; Baker, AR; Hegamyer, G; Kirschmann, DA; Colburn, NH				Santhanam, A. N.; Baker, A. R.; Hegamyer, G.; Kirschmann, D. A.; Colburn, N. H.			Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion	ONCOGENE			English	Article						PDCD4; lysyl oxidase; breast cancer; hypoxia	TRANSFORMATION SUPPRESSOR PDCD4; TUMOR-SUPPRESSOR; PROTEIN PDCD4; INDUCIBLE FACTOR-1-ALPHA; EUKARYOTIC TRANSLATION; GENE-EXPRESSION; CARCINOMA; AKT; METASTASIS; ACTIVATION	Metastasis to bone, liver and lungs is the primary cause of death in breast cancer patients. Our studies have revealed that the novel tumor suppressor Pdcd4 inhibits breast cancer cell migration and invasion in vitro. Loss of Pdcd4 in human nonmetastatic breast cancer cells increased the expression of lysyl oxidase (LOX) mRNA. LOX is a hypoxia-inducible amine oxidase, the activity of which enhances breast cancer cell invasion in vitro and in vivo. Specific inhibition of LOX activity by beta-aminopropionitrile or small interfering RNA decreased the invasiveness of T47D and MCF7 breast cancer cells attenuated for Pdcd4 function. Most significantly, loss of Pdcd4 augments hypoxia induction of LOX as well. Conversely, overexpression of Pdcd4 significantly reversed the hypoxia induction of LOX expression in T47D cells attenuated for Pdcd4. However, Pdcd4 did not affect hypoxia-inducible factor-1 (HIF-1) protein expression or HIF-1-responsive element-luciferase activity in response to hypoxia, suggesting that Pdcd4 regulation of LOX occurs through an HIF-independent mechanism. Nevertheless, the loss of Pdcd4 early in cancer progression may have an important role in the increased sensitivity of cancer cells to hypoxia through increased LOX activity and concomitant enhanced invasiveness. Oncogene (2010) 29, 3921-3932; doi:10.1038/onc.2010.158; published online 24 May 2010	[Santhanam, A. N.; Baker, A. R.; Hegamyer, G.; Colburn, N. H.] NCI, Gene Regulat Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21702 USA; [Kirschmann, D. A.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Childrens Mem Res Ctr,Canc Biol & Epigen Program, Chicago, IL 60611 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Santhanam, AN (corresponding author), NCI, Gene Regulat Sect, Lab Canc Prevent, Ctr Canc Res, Boyles St, Frederick, MD 21702 USA.	santhanama@ncifcrf.gov			NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010026] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Giovanni Melillo and Annamaria Rapisarda (Tumor Hypoxia Laboratory, NCI-Frederick) for helpful suggestions and for the use of reagents and hypoxia chambers. We also thank members of the Gene Regulation Section, Laboratory of Cancer Prevention, for helpful discussions. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Atsawasuwan P, 2008, J BIOL CHEM, V283, P34229, DOI 10.1074/jbc.M803142200; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Chen HHW, 2007, BREAST CANCER RES TR, V103, P167, DOI 10.1007/s10549-006-9360-3; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Csiszar K, 1996, MOL BIOL REP, V23, P97, DOI 10.1007/BF00424435; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Goke R, 2004, AM J PHYSIOL-CELL PH, V287, pC1541, DOI 10.1152/ajpcell.00025.2004; Ivan M, 2008, J CELL MOL MED, V12, P1426, DOI 10.1111/j.1582-4934.2008.00398.x; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; Kang YB, 2005, EXPERT REV MOL DIAGN, V5, P385, DOI 10.1586/14737159.5.3.385; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kronblad A, 2006, INT J CANCER, V118, P2609, DOI 10.1002/ijc.21676; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008-5472.CAN-04-1284; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lundgren K, 2007, CELL MOL LIFE SCI, V64, P3233, DOI 10.1007/s00018-007-7390-6; Melillo G, 1999, CANCER RES, V59, P5433; Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; PASTOREK J, 1994, ONCOGENE, V9, P2877; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Postovit LM, 2008, J CELL BIOCHEM, V103, P1369, DOI 10.1002/jcb.21517; Rucker RB, 1998, AM J CLIN NUTR, V67, p996S, DOI 10.1093/ajcn/67.5.996S; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Tan RSP, 1996, CANCER RES, V56, P2417; van der Groep P, 2008, BREAST CANCER RES TR, V111, P475, DOI 10.1007/s10549-007-9817-z; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Wen YH, 2007, ONCOL REP, V18, P1387; Yagata H, 2003, PATHOL INT, V53, P501, DOI 10.1046/j.1440-1827.2003.01514.x; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	62	53	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3921	3932		10.1038/onc.2010.158	http://dx.doi.org/10.1038/onc.2010.158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20498644	Green Accepted			2022-12-28	WOS:000279603200005
J	Asnaghi, L; Vass, WC; Quadri, R; Day, PM; Qian, X; Braverman, R; Papageorge, AG; Lowy, DR				Asnaghi, L.; Vass, W. C.; Quadri, R.; Day, P. M.; Qian, X.; Braverman, R.; Papageorge, A. G.; Lowy, D. R.			E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases	ONCOGENE			English	Article						E-cadherin; NSCLC; tumorigenesis; cell migration; Rho-family GTPases	BETA-CATENIN; FACTOR RECEPTOR; FAMILY GTPASES; BREAST-CANCER; ACTIVATING PROTEIN; REDUCED EXPRESSION; TISSUE MICROARRAY; TUMOR PROGRESSION; TYROSINE KINASES; ALPHA-CATENIN	Non-small cell lung cancers (NSCLC) that express the cell surface adhesion protein E-cadherin may carry a better prognosis than E-cadherin-negative tumors. Here, we found substantial inhibition of anchorage-independent growth in soft agar and cell migration in each of four NSCLC lines stably transfected with E-cadherin. The inhibitory effects were independent of the EGFR and beta-catenin/Wnt-signaling pathways. However, E-cadherin expression was associated with an adhesion-dependent reduction in the activity of Rho family proteins, RhoA in two lines and Cdc42 in the other two. The reduction of RhoA activity was dependent on DLC-1 Rho-GAP and p190 Rho-GAP and associated with an increase in a membrane-associated p190 Rho-GAP/p120 Ras-GAP complex. In parental cells with high levels of RhoAGTP, siRNA-mediated knock-down of RhoA reduced cell migration and agar growth in a manner analogous to E-cadherin. In parental cells with high levels of Cdc42-GTP, transfection of a Cdc42 dominant-negative mutant reduced cell growth and migration similarly to cells expressing E-cadherin. Thus, E-cadherin can negatively regulate cell proliferation and migration in NSCLC by reducing the level of the predominant active form of Rho family protein, RhoA or Cdc42. These proteins can be considered downstream effectors of E-cadherin and might represent therapeutic targets in some NSCLC. Oncogene (2010) 29, 2760-2771; doi: 10.1038/onc. 2010.39; published online 15 March 2010	[Asnaghi, L.; Vass, W. C.; Quadri, R.; Day, P. M.; Qian, X.; Braverman, R.; Papageorge, A. G.; Lowy, D. R.] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lowy, DR (corresponding author), NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, 37 Convent Dr MSC 4264,Bldg 37,Rm 4106,37 Convent, Bethesda, MD 20892 USA.	lowyd@mail.nih.gov			National Institutes of Health; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC008905] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Margaret Wheelock, Wen Jin Wu, Dianne Hirsch and Silvio Gutkind for providing plasmids, Drs Curt Harris and Terry Moody for providing NSCLC cell lines, Dr Cynthia Masison and Mike Radanovich for technical assistance and Dr Giovanna Tosato for helpful discussions. This research has been supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254-004-0034-4; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; BOHM M, 1994, CLIN EXP METASTAS, V12, P55, DOI 10.1007/BF01784334; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; CAPUZZO F, 2005, J NATL CANCER I, V97, P743; Chong IW, 2007, ONCOL REP, V18, P17; Deeb G, 2004, MODERN PATHOL, V17, P430, DOI 10.1038/modpathol.3800041; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Fei QY, 2002, LUNG CANCER, V37, P147, DOI 10.1016/S0169-5002(02)00077-6; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukata M, 1999, J CELL SCI, V112, P4491; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grewal T, 2006, BIOESSAYS, V28, P1211, DOI 10.1002/bies.20503; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hajra KM, 2002, CANCER RES, V62, P1613; Heijink IH, 2007, J IMMUNOL, V178, P7678, DOI 10.4049/jimmunol.178.12.7678; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hlubek F, 2007, FRONT BIOSCI, V12, P458, DOI 10.2741/2075; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kris MG, 2005, ONCOLOGIST, V10, P23, DOI 10.1634/theoncologist.10-90002-23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lock JG, 2005, TRAFFIC, V6, P1142, DOI 10.1111/j.1600-0854.2005.00349.x; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Pirinen RT, 2001, J CLIN PATHOL, V54, P391, DOI 10.1136/jcp.54.5.391; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Toyoyama H, 1999, ONCOL REP, V6, P81; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; van de Wetering M, 2001, CANCER RES, V61, P278; Vincan E, 2008, CLIN EXP METASTAS, V25, P657, DOI 10.1007/s10585-008-9156-4; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	66	54	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2760	2771		10.1038/onc.2010.39	http://dx.doi.org/10.1038/onc.2010.39			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20228844	Green Accepted, Green Submitted			2022-12-28	WOS:000277591900002
J	Albano, F; Anelli, L; Zagaria, A; Coccaro, N; D'Addabbo, P; Liso, V; Rocchi, M; Specchia, G				Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; D'Addabbo, P.; Liso, V.; Rocchi, M.; Specchia, G.			Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia	ONCOGENE			English	Article						segmental duplications; chronic myeloid leukemia; microdeletions	DERIVATIVE CHROMOSOME-9 DELETIONS; BREAKPOINT; REGION; TRANSLOCATION; HYBRIDIZATION; ARCHITECTURE; COMMON; GENE	A crucial role of segmental duplications (SDs) of the human genome has been shown in chromosomal rearrangements associated with several genomic disorders. Limited knowledge is yet available on the molecular processes resulting in chromosomal rearrangements in tumors. The t(9;22)(q34;q11) rearrangement causing the 5'BCR/3'ABL gene formation has been detected in more than 90% of cases with chronic myeloid leukemia (CML). In 10-18% of patients with CML, genomic deletions were detected on der(9) chromosome next to translocation breakpoints. The molecular mechanism triggering the t(9; 22) and deletions on der(9) is still speculative. Here we report a molecular cytogenetic analysis of a large series of patients with CML with der(9) deletions, revealing an evident breakpoint clustering in two regions located proximally to ABL and distally to BCR, containing an interchromosomal duplication block (SD_9/22). The deletions breakpoints distribution appeared to be strictly related to the distance from the SD_9/22. Moreover, bioinformatic analyses of the regions surrounding the SD_9/22 revealed a high Alu frequency and a poor gene density, reflecting genomic instability and susceptibility to rearrangements. On the basis of our results, we propose a three-step model for t(9; 22) formation consisting of alignment of chromosomes 9 and 22 mediated by SD_9/22, spontaneous chromosome breakages and misjoining of DNA broken ends. Oncogene (2010) 29, 2509-2516; doi:10.1038/onc.2009.524; published online 25 January 2010	[Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; Liso, V.; Specchia, G.] Univ Bari, Dept Hematol, I-70124 Bari, Italy; [D'Addabbo, P.; Rocchi, M.] Univ Bari, Dept Genet & Microbiol, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Albano, F (corresponding author), Univ Bari, Azienda Osped Univ Policlin, Dept Hematol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	f.albano@ematba.uniba.it	Albano, Francesco/J-2352-2016; D'Addabbo, Pietro/AAC-7731-2020; D'Addabbo, Pietro/D-8551-2016; Anelli, Luisa/K-2661-2016; Zagaria, Antonella/K-2995-2016; Specchia, Giorgina/K-3084-2016	Albano, Francesco/0000-0001-7926-6052; D'Addabbo, Pietro/0000-0003-3325-4931; Anelli, Luisa/0000-0002-9185-724X; Coccaro, Nicoletta/0000-0003-1327-8186; Zagaria, Antonella/0000-0002-0135-6661; Specchia, Giorgina/0000-0002-2479-9529; Rocchi, Mariano/0000-0002-9451-5616	Associazione Italiana contro le Leucemie (AIL)-BARI	Associazione Italiana contro le Leucemie (AIL)-BARI	We thank Ms MVC Pragnell for language revision of the paper. The financial support of Associazione Italiana contro le Leucemie (AIL)-BARI is gratefully acknowledged.	Albano F, 2007, CANCER GENET CYTOGEN, V174, P121, DOI 10.1016/j.cancergencyto.2006.09.025; Bailey JA, 2006, NAT REV GENET, V7, P552, DOI 10.1038/nrg1895; Barbouti A, 2004, AM J HUM GENET, V74, P1, DOI 10.1086/380648; Darai-Ramqvist E, 2008, GENOME RES, V18, P370, DOI 10.1101/gr.7010208; de Campos MGV, 2007, CANCER GENET CYTOGEN, V178, P49, DOI 10.1016/j.cancergencyto.2007.06.013; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Fourouclas N, 2006, HAEMATOL-HEMATOL J, V91, P952; Gibcus JH, 2007, HUM GENET, V121, P187, DOI 10.1007/s00439-006-0299-6; Gu Wenli, 2008, Pathogenetics, V1, P4, DOI 10.1186/1755-8417-1-4; Huntly BJP, 2001, BLOOD, V98, P1732, DOI 10.1182/blood.V98.6.1732; Kim PM, 2008, GENOME RES, V18, P1865, DOI 10.1101/gr.081422.108; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; Kreil S, 2007, BLOOD, V110, P1283, DOI 10.1182/blood-2007-02-074252; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITZ CE, 1993, BLOOD, V81, P1567; Lomiento M, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r173; Mefford HC, 2009, CURR OPIN GENET DEV, V19, P196, DOI 10.1016/j.gde.2009.04.003; Saglio G, 2002, P NATL ACAD SCI USA, V99, P9882, DOI 10.1073/pnas.152171299; Sharp AJ, 2006, NAT GENET, V38, P1038, DOI 10.1038/ng1862; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Specchia G, 2004, LEUKEMIA LYMPHOMA, V45, P689, DOI 10.1080/10428190310001623900; Storlazzi CT, 2002, GENE CHROMOSOME CANC, V35, P271, DOI 10.1002/gcc.10116; Yatsenko SA, 2009, HUM MOL GENET, V18, P1924, DOI 10.1093/hmg/ddp114	24	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2509	2516		10.1038/onc.2009.524	http://dx.doi.org/10.1038/onc.2009.524			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20101201				2022-12-28	WOS:000277169400006
J	Chung, H; Lopez, CG; Young, DJ; Lai, JF; Holmstrom, J; Ream-Robinson, D; Cabrera, BL; Carethers, JM				Chung, H.; Lopez, C. G.; Young, D. J.; Lai, J. F.; Holmstrom, J.; Ream-Robinson, D.; Cabrera, B. L.; Carethers, J. M.			Flanking sequence specificity determines coding microsatellite heteroduplex and mutation rates with defective DNA mismatch repair (MMR)	ONCOGENE			English	Article							NONPOLYPOSIS COLON-CANCER; COLORECTAL-CANCER; INSTABILITY; GENE; RECEPTOR; INACTIVATION; ACTIVIN; BETA; HOMOLOG; GROWTH	The activin type II receptor (ACVR2) contains two identical microsatellites in exons 3 and 10, but only the exon 10 microsatellite is frameshifted in mismatch repair (MMR)-defective colonic tumors. The reason for this selectivity is not known. We hypothesized that ACVR2 frameshifts were influenced by DNA sequences surrounding the microsatellite. We constructed plasmids in which exons 3 or 10 of ACVR2 were cloned vertical bar 1 bp out of frame of enhanced green fluorescent protein (EGFP), allowing -1 bp frameshift to express EGFP. Plasmids were stably transfected into MMR-deficient cells, and subsequent non-fluorescent cells were sorted, cultured and harvested for mutation analysis. We swapped DNA sequences flanking the exon 3 and 10 microsatellites to test our hypothesis. Native ACVR2 exon 3 and 10 microsatellites underwent heteroduplex formation (A7/T8) in hMLH1(-/-) cells, but only exon 10 microsatellites fully mutated (A7/T7) in both hMLH1(-/-) and hMSH6(-/-) backgrounds, showing selectivity for exon 10 frameshifts and inability of exon 3 heteroduplexes to fully mutate. Substituting nucleotides flanking the exon 3 microsatellite for nucleotides flanking the exon 10 microsatellite significantly reduced heteroduplex and full mutation in hMLH1(-/-) cells. When the exon 3 microsatellite was flanked by nucleotides normally surrounding the exon 10 microsatellite, fully mutant exon 3 frameshifts appeared. Mutation selectivity for ACVR2 lies partly with flanking nucleotides surrounding each microsatellite. Oncogene (2010) 29, 2172-2180; doi: 10.1038/onc.2009.508; published online 8 February 2010	[Chung, H.; Lopez, C. G.; Lai, J. F.; Holmstrom, J.; Ream-Robinson, D.; Cabrera, B. L.; Carethers, J. M.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Young, D. J.; Carethers, J. M.] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, San Diego, CA 92103 USA; [Carethers, J. M.] VA San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Carethers, JM (corresponding author), Univ Michigan, Dept Internal Med, 3100A Taubman Ctr,1500 E Med Ctr Dr,SPC 5368, Ann Arbor, MI 48109 USA.	jcarethe@umich.edu			United States Public Health Service [DK067287]; UCSD Digestive Diseases Research Development Center [DK080506]; VA Research Service; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067287, R24DK080506] Funding Source: NIH RePORTER	United States Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); UCSD Digestive Diseases Research Development Center; VA Research Service(US Department of Veterans Affairs); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the United States Public Health Service (DK067287 to JMC), the UCSD Digestive Diseases Research Development Center (DK080506), and the VA Research Service (Merit Review Award to JMC). We thank the support of Moores UCSD Cancer Center Flow Cytometry and DNA Sequencing Shared Resources.	Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Akiyama Y, 1997, CANCER RES, V57, P3920; Barbara JT, 2006, INT J CANCER, V118, P2509, DOI 10.1002/ijc.21710; Carethers JM, 1999, GASTROENTEROLOGY, V117, P123, DOI 10.1016/S0016-5085(99)70558-5; Chung H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003463; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Harrington JA, 2007, MOL CELL BIOL, V27, P6546, DOI 10.1128/MCB.00855-07; Hempen PM, 2003, CANCER RES, V63, P994; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Jung B, 2004, GASTROENTEROLOGY, V126, P654, DOI 10.1053/j.gastro.2004.01.008; Jung BH, 2007, GASTROENTEROLOGY, V132, P633, DOI 10.1053/j.gastro.2006.11.018; Luria SE, 1943, GENETICS, V28, P491; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Modrich P, 2006, J BIOL CHEM, V281, P30305, DOI 10.1074/jbc.R600022200; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456	23	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2172	2180		10.1038/onc.2009.508	http://dx.doi.org/10.1038/onc.2009.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20140012	Green Accepted			2022-12-28	WOS:000276685200003
J	Cheung, M; Pei, J; Pei, Y; Jhanwar, SC; Pass, HI; Testa, JR				Cheung, M.; Pei, J.; Pei, Y.; Jhanwar, S. C.; Pass, H. I.; Testa, J. R.			The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival	ONCOGENE			English	Article						mesothelioma; PLZF; genomic imbalances; tumor suppressors; transcription factor	METHYLTHIOADENOSINE PHOSPHORYLASE; GROWTH SUPPRESSION; TUMOR-SUPPRESSOR; PROTEIN PLZF; EXPRESSION; DELETION; TRANSLOCATION; REPRESSION; MECHANISM; APOPTOSIS	DNA copy number analysis was performed, using single-nucleotide polymorphism mapping arrays, to. ne map genomic imbalances in human malignant mesothelioma (MM) cell lines derived from primary tumors. Chromosomal losses accounted for the majority of genomic imbalances. All 22 cell lines examined showed homozygous deletions of 9p21.3, centering at the CDKN2A/ARF and CDKN2B loci. Other commonly underrepresented segments included 1p36, 1p22, 3p21-22, 4q13, 4q34, 11q23, 13q12-13, 14q32, 15q15, 18q12, and 22q12, each observed in 55-90% of cell lines. Focal deletions of 11q23 encompassed the transcriptional repressor gene promyelocytic leukemia zinc finger (PLZF), which was validated by analysis of genomic DNA using real-time polymerase chain reaction (PCR). Semi-quantitative RT PCR and immunoblot analysis revealed that PLZF is greatly downregulated in MM cell lines compared with non-malignant mesothelial cells. Ectopic expression of PLZF in PLZF-deficient MM cells resulted in decreased cell viability, reduced colony formation, as well as increased apoptosis, the latter based on results of various cell death assays and the observation of increased cleavage of caspase 3, PARP, and Mcl-1. These data indicate that deletions of PLZF are a common occurrence in MM and that downregulation of PLZF may contribute to MM pathogenesis by promoting cell survival. Oncogene (2010) 29, 1633-1640; doi:10.1038/onc.2009.455; published online 14 December 2009	[Cheung, M.; Pei, J.; Pei, Y.; Testa, J. R.] Fox Chase Canc Ctr, Canc Genet & Signaling Program, Philadelphia, PA 19111 USA; [Jhanwar, S. C.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Pass, H. I.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; New York University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Canc Genet & Signaling Program, 333 Cottman Ave,P3032, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu		Pass, Harvey/0000-0003-3222-3471	National Cancer Institute [CA-114047, CA-06927]; Commonwealth of Pennsylvania; International Association of Heat and Frost Insulators Allied Workers; NATIONAL CANCER INSTITUTE [P30CA006927, P01CA114047] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth of Pennsylvania; International Association of Heat and Frost Insulators Allied Workers; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Craig Menges for helpful suggestions about some of the experiments and Jin Fang for technical assistance on some of the array hybridizations. This work was supported by National Cancer Institute Grants CA-114047 and CA-06927, by an appropriation from the Commonwealth of Pennsylvania, and by a gift from the Local #14 Mesothelioma Fund of the International Association of Heat and Frost Insulators & Allied Workers in memory of Hank Vaughan and Alice Haas. The following Fox Chase Cancer Center shared facilities were used in the course of this work: Cell Culture, Genomics, Flow Cytometry, and DNA Synthesis Facilities.	Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Balsara BR, 1999, CANCER RES, V59, P450; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Bernardo MV, 2007, BIOCHEM BIOPH RES CO, V359, P317, DOI 10.1016/j.bbrc.2007.05.085; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Christopher SA, 2002, CANCER RES, V62, P6639; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Frizelle SP, 1998, ONCOGENE, V16, P3087, DOI 10.1038/sj.onc.1201870; Greshock J, 2007, CANCER RES, V67, P10173, DOI 10.1158/0008-5472.CAN-07-2102; Illei PB, 2003, CLIN CANCER RES, V9, P2108; McConnell MJ, 2007, CURR TOP MICROBIOL, V313, P31; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Musti M, 2006, CANCER GENET CYTOGEN, V170, P9, DOI 10.1016/j.cancergencyto.2006.04.011; Pei JM, 2006, CANCER GENET CYTOGEN, V170, P65, DOI 10.1016/j.cancergencyto.2006.05.002; Rho SB, 2007, J CELL BIOCHEM, V101, P57, DOI 10.1002/jcb.21127; Shiraishi K, 2007, ONCOGENE, V26, P339, DOI 10.1038/sj.onc.1209800; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; TAGUCHI T, 1993, CANCER RES, V53, P4349; WAGNER J C, 1960, Br J Ind Med, V17, P260; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	29	43	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1633	1640		10.1038/onc.2009.455	http://dx.doi.org/10.1038/onc.2009.455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20010871	Green Accepted			2022-12-28	WOS:000275694700008
J	Varela, E; Blasco, MA				Varela, E.; Blasco, M. A.			2009 Nobel Prize in Physiology or Medicine: telomeres and telomerase	ONCOGENE			English	Editorial Material							DYSFUNCTIONAL TELOMERES; EPIGENETIC REGULATION; TERMINAL TRANSFERASE; MAMMALIAN TELOMERES; YEAST TELOMERES; DEFICIENT MICE; HUMAN-DISEASE; HUMAN CANCER; LIFE-SPAN; CELLS		[Varela, E.; Blasco, M. A.] CNIO, Spanish Natl Canc Ctr, Telomeres & Telomerase Grp, Mol Oncol Program, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Varela, E (corresponding author), CNIO, Spanish Natl Canc Ctr, Telomeres & Telomerase Grp, Mol Oncol Program, Madrid, Spain.	mblasco@cnio.es	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Azzalin CM, 2008, CELL CYCLE, V7, P1161, DOI 10.4161/cc.7.9.5836; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; BATEMAN AJ, 1975, NATURE, V253, P379, DOI 10.1038/253379a0; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bell DR, 2004, ONCOGENE, V23, P7290, DOI 10.1038/sj.onc.1207949; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2005, NATURE, V436, P922, DOI 10.1038/436922a; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; CAVALIER.T, 1974, NATURE, V250, P467, DOI 10.1038/250467a0; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Choudhury AR, 2007, NAT GENET, V39, P99, DOI 10.1038/ng1937; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DANCIS BM, 1979, J THEOR BIOL, V78, P211, DOI 10.1016/0022-5193(79)90265-0; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hayflick Leonard, 1998, Keio Journal of Medicine, V47, P174; HERMANN MT, 2001, CELL, V107, P67; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200; Luke B, 2009, EMBO J, V28, P2503, DOI 10.1038/emboj.2009.166; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Mason PJ, 2005, CURR MOL MED, V5, P159, DOI 10.2174/1566524053586581; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morrish TA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000357; Muller H.J., 1938, COLLECTING NET, V13, P181; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; SCHOEFTNER S, 2009, SEMIN CELL DEV BIOL; Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685; Schoeftner S, 2009, EMBO J, V28, P2323, DOI 10.1038/emboj.2009.197; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Shete S, 2009, NAT GENET, V41, P899, DOI 10.1038/ng.407; Siegl-Cachedenier I, 2007, GENE DEV, V21, P2234, DOI 10.1101/gad.430107; Stacey SN, 2009, NAT GENET, V41, P909, DOI 10.1038/ng.412; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Tomas-Loba A, 2008, CELL, V135, P609, DOI 10.1016/j.cell.2008.09.034; Vera E, 2008, ONCOGENE, V27, P6817, DOI 10.1038/onc.2008.289; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	83	26	27	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1561	1565		10.1038/onc.2010.15	http://dx.doi.org/10.1038/onc.2010.15			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20237481				2022-12-28	WOS:000275694700001
J	See, WL; Miller, JP; Squatrito, M; Holland, E; Resh, MD; Koff, A				See, W. L.; Miller, J. P.; Squatrito, M.; Holland, E.; Resh, M. D.; Koff, A.			Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas	ONCOGENE			English	Article						p27; tumor suppressor; DNA repair; glioma; mouse model	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; TUMOR SUPPRESSION; NUCLEAR FOCI; FACTOR-B; P27(KIP1); P27; EXPRESSION; DAMAGE	The tumor suppressive activities of the Kip-family of cyclin-dependent kinase (cdk) inhibitors often go beyond their role directly regulating the cell cycle. In this study, we show that p27 enhances Rad51 accumulation during repair of double-strand DNA breaks. Progression of platelet-derived growth factor (PDGF)-induced oligodendrogliomas was accelerated in mice lacking the cyclin-cdk binding activities of p27(kip1). To understand how p27 deficiency contributes, cell lines were developed from RCAS-PDGF infection of nestin-tv-a brain progenitor cells in culture. p27 deficiency did not affect cell proliferation in early passage cell lines; however, the absence of p27 affected chromosomal stability. In p27-deficient cells, the activation of Atm and Chk2 and the accumulation of gamma-H2AX was unaffected when compared with wild-type cells, and the number of phospho-histone H3 staining mitotic cells was decreased, consistent with G2/M checkpoint activation. However, the percentage of Rad51 foci-positive cells was decreased, and the kinase activity that targets the C-terminus of BRCA2, regulating BRCA2/Rad51 interactions, was increased in lysates derived from p27-deficient cells. Increased numbers of chromatid breaks in p27-deficient cells that adapted to the checkpoint were also observed. These findings suggest that Rad51-dependent repair of double-stranded breaks was hindered in p27-deficient cells, leading to chromosomal instability, a hallmark of cancers with poor prognosis. Oncogene (2010) 29, 1720-1731; doi:10.1038/onc.2009.465; published online 11 January 2010	[See, W. L.; Resh, M. D.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; [Miller, J. P.; Koff, A.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; [Squatrito, M.; Holland, E.] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, RRL917C,Box 207,1275 York Ave, New York, NY 10021 USA.	m-resh@ski.mskcc.org; a-koff@ski.mskcc.org	Squatrito, Massimo/F-4149-2016	Squatrito, Massimo/0000-0002-4593-3790; Resh, Marilyn/0000-0001-6118-9466; Koff, Andrew/0000-0003-3271-3067	US National Institutes of Health [CA96582, CA89563]; Golfers Against Cancer Foundation; Institutional Core Grant; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA096582, R01CA089563] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Golfers Against Cancer Foundation; Institutional Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Travis Stracker, John Petrini, Yossi Shiloh, Yuhui Liu, Nancy Yeh, Daniel Ciznadija, Dolores Hambardzumyan, Oren Becher, Elena Fomchenko, and Robert Finney, Katia Manova, Lei Zhang, Kalyani Chadalavada, Margaret Leversha, Jan Hendrix and Diane Domingo. This research was supported by the US National Institutes of Health Grant CA96582 (to MR, AK and EH), CA89563 (to AK) and funds from The Golfers Against Cancer Foundation (to AK). Additional support was provided by an Institutional Core Grant to Memorial Sloan-Kettering Cancer Center.	Anantha RW, 2007, J BIOL CHEM, V282, P35910, DOI 10.1074/jbc.M704645200; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Aylon Y, 2004, EMBO J, V23, P4868, DOI 10.1038/sj.emboj.7600469; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Becher OJ, 2008, CANCER RES, V68, P2241, DOI 10.1158/0008-5472.CAN-07-6350; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cavalla P, 1999, ACTA NEUROPATHOL, V98, P629, DOI 10.1007/s004010051128; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Cipriano SC, 2001, MOL ENDOCRINOL, V15, P985, DOI 10.1210/me.15.6.985; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Doetsch F, 1997, J NEUROSCI, V17, P5046; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kamiya M, 2002, CLIN NEUROPATHOL, V21, P52; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Koff A, 2006, CANCER CELL, V9, P75, DOI 10.1016/j.ccr.2006.01.020; Korshunov A, 2002, J NEURO-ONCOL, V58, P237, DOI 10.1023/A:1016270101321; Liu Y, 2007, EMBO J, V26, P4683, DOI 10.1038/sj.emboj.7601886; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Musgrove EA, 2004, J MAMMARY GLAND BIOL, V9, P55, DOI 10.1023/B:JOMG.0000023588.55733.84; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Powell SN, 2009, DNA REPAIR, V8, P1153, DOI 10.1016/j.dnarep.2009.04.011; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Uhrbom L, 2001, J NEURO-ONCOL, V53, P297, DOI 10.1023/A:1012208314436; Uhrbom L, 1998, CANCER RES, V58, P5275; Weinstock DM, 2006, DNA REPAIR, V5, P1065, DOI 10.1016/j.dnarep.2006.05.028	52	30	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1720	1731		10.1038/onc.2009.465	http://dx.doi.org/10.1038/onc.2009.465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062078	Bronze, Green Accepted			2022-12-28	WOS:000276022800002
J	Yao, Z; Duan, S; Hou, D; Wang, W; Wang, G; Liu, Y; Wen, L; Wu, M				Yao, Z.; Duan, S.; Hou, D.; Wang, W.; Wang, G.; Liu, Y.; Wen, L.; Wu, M.			B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1	ONCOGENE			English	Article						B23/NPM; hnRNPs; nucleolar stress; cell survival; apoptosis	MESSENGER-RNA; PROTEIN; NUCLEOPHOSMIN; A1; ACTINOMYCIN; P53	The nucleolus is one of the functional nuclear compartments in which the ribosome biogenesis takes place. Proteomic analysis revealed a large number of nucleolar proteins that are involved in diverse cellular processes, including biogenesis of ribonucleoprotein particles, stress responses, cell proliferation and cell cycle progression. Here, we report that in response to transcription repression-induced nucleolar segregation, B23, a nucleolar protein required for rRNA processing, is localized to the cytoplasm and forms a complex with the mRNA-binding proteins hnRNPU and hnRNPA1 in a sequential manner. In addition, RNA Polymerase I, but not RNA Polymerase II inhibition, was found to account for the translocation-dependent assembly of B23/hnRNPU/hnRNPA1. We also showed that interactions among these proteins are regulated by hnRNPU-bound mRNAs such as the 30-untranslated region (UTR) of Bcl-xL mRNA. Ectopically expressed 30-UTR of Bcl-xL mRNA, which disrupted the interactions among B23, hnRNPU and hnRNPA1, led to enhanced cell apoptosis induced by either actinomycin D treatment or mitotic arrest. Overall, these data highlight a novel function of B23 as a stress sensor in the assembly of B23/hnRNPU/hnRNPA1 complex to promote cell survival. Oncogene (2010) 29, 1821-1834; doi:10.1038/onc.2009.473; published online 18 January 2010	[Yao, Z.; Duan, S.; Hou, D.; Wang, W.; Wang, G.; Wen, L.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Liu, Y.] Univ Sci & Technol China, Sch Life Sci, Ctr Tech Serv Life Sci, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wu, M (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Yao, Zhan/AAK-6756-2020; Wu, Mian/H-2494-2018; Yao, Zhan/K-1839-2013	Wen, Longping/0000-0003-0384-4578; YAO, ZHAN/0000-0001-5391-5691; Wu, Mian/0000-0002-2714-0500; WANG, Wenyu/0000-0001-8947-4867	National Natural Science Foundation of China [30530200, 30871290, 30728003]; Ministry of Science and Technology of China [2006CB933300, 2006CB910300]; Chinese Academy of Sciences [KSCX1-YW-R-57]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We are grateful to Dr Yinon Ben-Neriah (The Hebrew University-Hadassah Medical School, Israel) for kindly providing the pFLAG-CMV-2-hnRNPU plasmid. This research was supported by grants from the National Natural Science Foundation of China (30530200, 30871290 and 30728003), the Ministry of Science and Technology of China (2006CB933300 and 2006CB910300) and the Chinese Academy of Sciences (KSCX1-YW-R-57).	Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Duan SS, 2007, EMBO J, V26, P3062, DOI 10.1038/sj.emboj.7601749; FREI E, 1974, CANCER CHEMOTH REP 1, V58, P49; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Johnson RF, 2006, J VIROL, V80, P5135, DOI 10.1128/JVI.01857-05; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Okuwaki M, 2008, J BIOCHEM, V143, P441, DOI 10.1093/jb/mvm222; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Wu MH, 2002, INT J CANCER, V97, P297, DOI 10.1002/ijc.1606; Yugami M, 2007, FEBS LETT, V581, P1, DOI 10.1016/j.febslet.2006.11.062; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8	22	41	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1821	1834		10.1038/onc.2009.473	http://dx.doi.org/10.1038/onc.2009.473			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20101230				2022-12-28	WOS:000276022800011
J	Chen, TH; Chan, PC; Chen, CL; Chen, HC				Chen, T-H; Chan, P-C; Chen, C-L; Chen, H-C			Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition	ONCOGENE			English	Article						FAK; Met; RTK; FERM; autoinhibition	GROWTH-FACTOR; FERM DOMAIN; IN-VITRO; PROTEIN; IDENTIFICATION; PP125(FAK); CELLS; FAK; ASSOCIATION; PP60(SRC)	Focal adhesion kinase (FAK) has a crucial role in integration of signals from integrins and growth factor receptors. In this study, we demonstrate that growth factor receptors including hepatocyte growth factor receptor Met, epidermal growth factor receptor, and platelet-derived growth factor receptor directly phosphorylate FAK on Tyr194 in the FERM domain (band 4.1 and ezrin/radixin/moesin homology domain). Upon binding to Met or phosphoinositides, FAK may undergo conformational changes, which renders Tyr194 accessible for phosphorylation. Substitution of Tyr194 with Phe significantly suppresses the activation of FAK by Met. In contrast, substitution of Tyr194 with Glu (Y194E substitution) leads to constitutive activation of FAK. The phosphorylation of FAK on Tyr194 may cause conformational changes in the FERM domain, which disrupts the intramolecular inhibitory interaction between the FERM and kinase domains of FAK. Moreover, substitution of the basic residues in the (216)KAKTLRK(222) patch in the FERM domain with Ala antagonizes the effect of the Y194E substitution on FAK activation, thus suggesting that the interactions between the phosphorylated Tyr194 and the basic resides in the (216)KAKTLRK(222) patch may allow FAK to be activated through relief of its autoinhibition. Collectively, this study provides the first example to explain how FAK is activated by receptor tyrosine kinases. Oncogene (2011) 30, 153-166; doi:10.1038/onc.2010.398; published online 30 August 2010	[Chen, T-H; Chen, C-L; Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Chan, P-C; Chen, H-C] Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan; [Chen, H-C] China Med Univ, Dept Nutr, Taichung, Taiwan	National Chung Hsing University; National Chung Hsing University; China Medical University Taiwan	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hcchen@nchu.edu.tw			National Science Council, Taiwan [NSC97-3112-B-005-001, NSC97-2628-B-005-001-MY3]; National Health Research Institutes, Taiwan [NHRI-EX97-9730BI]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	This work is supported by Grants NSC97-3112-B-005-001 and NSC97-2628-B-005-001-MY3 from the National Science Council, Taiwan and NHRI-EX97-9730BI from the National Health Research Institutes, Taiwan.	Cai XM, 2008, MOL CELL BIOL, V28, P201, DOI 10.1128/MCB.01324-07; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chan PC, 2002, J BIOL CHEM, V277, P50373, DOI 10.1074/jbc.M204691200; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cohen LA, 2005, J BIOL CHEM, V280, P8197, DOI 10.1074/jbc.M412021200; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Dunty JM, 2004, MOL CELL BIOL, V24, P5353, DOI 10.1128/MCB.24.12.5353-5368.2004; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Jacamo RO, 2005, BIOCHEM BIOPH RES CO, V334, P1299, DOI 10.1016/j.bbrc.2005.07.034; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Lietha D, 2007, CELL, V129, P1177, DOI 10.1016/j.cell.2007.05.041; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; RANKIN S, 1994, J BIOL CHEM, V269, P704; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	31	31	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					153	166		10.1038/onc.2010.398	http://dx.doi.org/10.1038/onc.2010.398			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20802513				2022-12-28	WOS:000286438900004
J	Yu, J; Ma, X; Cheung, KF; Li, X; Tian, L; Wang, S; Wu, CW; Wu, WKK; He, M; Wang, M; Ng, SSM; Sung, JJY				Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Tian, L.; Wang, S.; Wu, C. W.; Wu, W. K. K.; He, M.; Wang, M.; Ng, S. S. M.; Sung, J. J. Y.			Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer	ONCOGENE			English	Article						T-box transcription factor 5; colon cancer; tumor suppressor gene; epigenetic alteration; prognosis	SYNUCLEIN-GAMMA-GENE; COLORECTAL-CANCER; GASTRIC-CANCER; BREAST-CANCER; DNA METHYLATION; CPG ISLAND; APOPTOSIS; METASTASIS; EXPRESSION; SURVIVAL	T-box transcription factor 5 (TBX5) is a member of a phylogenetically conserved family of genes involved in the regulation of developmental processes. The function of TBX5 in cancer development is largely unclear. We identified that TBX5 was preferentially methylated in cancer using methylation-sensitive arbitrarily primed PCR. We aim to clarify the epigenetic inactivation, biological function and clinical significance of TBX5 in colon cancer. Promoter methylation was evaluated by combined bisulfite restriction analysis and bisulfite genomic sequencing. Cell proliferation was examined by cell viability assay and colony formation assay, apoptosis by flow cytometry and cell migration by wound-healing assay. TBX5 target genes were identified by cDNA microarray analysis. Cox regression model and log-rank test were used to identify independent predictors of prognosis. TBX5 was silenced or downregulated in 88% (7/8) colon cancer cell lines, but was expressed in normal colon tissues. Loss of gene expression was associated with promoter methylation. The biological function of TBX5 in human colon cancer cells was examined. Re-expression of TBX5 in silenced colon cancer cell lines suppressed colony formation (P<0.001), proliferation (P<0.001), migration and induced apoptosis (P<0.01). Induction of apoptosis was mediated through cross-talk of extrinsic apoptosis pathway, apoptotic BCL2-associated X protein and Granzyme A signaling cascades. TBX5 suppressed tumor cell proliferation and metastasis through the upregulation of cyclin-dependent kinase inhibitor 2A, metastasis suppressor 1 and downregulation of synuclein gamma and metastasis-associated protein 1 family member 2. TBX5 methylation was detected in 68% (71/105) of primary colon tumors. Multivariate analysis showed that patients with TBX5 methylation had a significantly poor overall survival (P=0.0007). In conclusion, we identified a novel functional tumor suppressor gene TBX5 inactivated by promoter methylation in colon cancer. Detection of methylated TBX5 may serve as a potential biomarker for the prognosis of this malignancy. Oncogene (2010) 29, 6464-6474; doi:10.1038/onc.2010.370; published online 30 August 2010	[Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Wang, S.; Wu, C. W.; Wu, W. K. K.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Wang, S.; Wu, C. W.; Wu, W. K. K.; Sung, J. J. Y.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Ma, X.; Wang, M.] Hebei Med Univ, Dept Neurol, Hosp 1, Shijiazhuang, Peoples R China; [He, M.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China; [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Hebei Medical University; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Pillay, Nischalan/F-9536-2012; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Tian, Linwei/A-9736-2009; HE, Ming-Liang/AAG-3397-2022; wu, william/HII-5817-2022; Ng, Simon S. M./M-1219-2018; HE, Ming-Liang/AFK-4738-2022; Li, Xiao-xing/B-9114-2008; Wu, William K.K./A-3277-2009	Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Tian, Linwei/0000-0002-4739-1534; Ng, Simon S. M./0000-0002-5389-9297; Li, Xiao-xing/0000-0001-8791-7505; Wu, William K.K./0000-0002-5662-5240; Tian, Linwei/0000-0003-2240-8886; He, Ming-Liang/0000-0002-4317-2836; HE, Mingliang/0000-0002-9942-9151	Council Competitive Earmarked Research Grant CUHK [473008]	Council Competitive Earmarked Research Grant CUHK	This work was supported by research grant of Council Competitive Earmarked Research Grant CUHK (473008).	Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017; Cai CL, 2005, DEVELOPMENT, V132, P2475, DOI 10.1242/dev.01832; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Cullen SP, 2010, CELL DEATH DIFFER, V17, P616, DOI 10.1038/cdd.2009.206; Finotto Susetta, 2008, V94, P83, DOI 10.1159/000154869; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Gupta A, 2003, CANCER RES, V63, P664; He ML, 2002, BIOCHEM BIOPH RES CO, V297, P185, DOI 10.1016/S0006-291X(02)02142-3; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Hu H, 2009, CLIN CANCER RES, V15, P5485, DOI 10.1158/1078-0432.CCR-08-2491; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000; Maitra M, 2009, DEV BIOL, V326, P368, DOI 10.1016/j.ydbio.2008.11.004; Mori AD, 2006, DEV BIOL, V297, P566, DOI 10.1016/j.ydbio.2006.05.023; Nemer M, 2008, CARDIOVASC PATHOL, V17, P48, DOI 10.1016/j.carpath.2007.06.005; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Page D.L., 2002, TNM CLASSIFICATION M, V6th; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Plageman TF, 2006, DEV DYNAM, V235, P2868, DOI 10.1002/dvdy.20923; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8; Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107; Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967	34	68	72	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6464	6474		10.1038/onc.2010.370	http://dx.doi.org/10.1038/onc.2010.370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802524				2022-12-28	WOS:000285138900006
J	Bralten, LBC; Gravendeel, AM; Kloosterhof, NK; Sacchetti, A; Vrijenhoek, T; Veltman, JA; van den Bent, MJ; Kros, JM; Hoogenraad, CC; Smitt, PAES; French, PJ				Bralten, L. B. C.; Gravendeel, A. M.; Kloosterhof, N. K.; Sacchetti, A.; Vrijenhoek, T.; Veltman, J. A.; van den Bent, M. J.; Kros, J. M.; Hoogenraad, C. C.; Smitt, P. A. E. Sillevis; French, P. J.			The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma	ONCOGENE			English	Article						CASPR2; CNTNAP2; glioma; tumor suppressor gene; NCOAI; translocation	FRAGILE SITE GENES; NEUREXIN SUPERFAMILY; MYELINATED AXONS; EXPRESSION; CNTNAP2; BRAIN; AUTISM; JUXTAPARANODES; CHANNELS; FUSION	Genomic translocations have been implicated in cancer. In this study, we performed a screen for genetic translocations in gliomas based on exon-level expression profiles. We identified a translocation in the contactin-associated protein-like 2 (CASPR2) gene, encoding a cell adhesion molecule. CASPR2 mRNA was fused to an expressed sequence tag that likely is part of the nuclear receptor coactivator 1 gene. Despite high mRNA expression levels, no CASPR2 fusion protein was detected. In a set of 25 glioblastomas and 22 oligodendrogliomas, mutation analysis identified two additional samples with genetic alterations in the CASPR2 gene and all three identified genetic alterations are likely to reduce CASPR2 protein expression levels. Methylation of the CASPR2 gene was also observed in gliomas and glioma cell lines. CASPR2-overexpressing cells showed decreased proliferation rates, likely because of an increase in apoptosis. Moreover, high CASPR2 mRNA expression level is positively correlated with survival and is an independent prognostic factor. These results indicate that CASPR2 acts as a tumor suppressor gene in glioma. Oncogene (2010) 29, 6138-6148; doi:10.1038/onc.2010.342; published online 16 August 2010	[Bralten, L. B. C.; Gravendeel, A. M.; Kloosterhof, N. K.; van den Bent, M. J.; Smitt, P. A. E. Sillevis; French, P. J.] Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Kloosterhof, N. K.] Erasmus MC, Dept Pediat Oncol & Hematol, NL-3000 CA Rotterdam, Netherlands; [Sacchetti, A.; Kros, J. M.] Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands; [Vrijenhoek, T.; Veltman, J. A.] Radboud Univ Nijmegen, Dept Human Genet, Nijmegen Ctr Mol Life Sci, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Hoogenraad, C. C.] Erasmus MC, Dept Neurosci, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC	French, PJ (corresponding author), Erasmus MC, Dept Neurol, Room Be 462A,POB 2040, NL-3000 CA Rotterdam, Netherlands.	p.french@erasmusmc.nl	Veltman, Joris A/F-5128-2010; Hoogenraad, Casper/B-8866-2011; Sacchetti, Andrea/H-8763-2019	Veltman, Joris A/0000-0002-3218-8250; Hoogenraad, Casper/0000-0002-2666-0758; van den Bent, Martin/0000-0001-5710-5127; French, Pim/0000-0002-0668-9529				Alarcon M, 2008, AM J HUM GENET, V82, P150, DOI 10.1016/j.ajhg.2007.09.005; Arking DE, 2008, AM J HUM GENET, V82, P160, DOI 10.1016/j.ajhg.2007.09.015; Bakkaloglu B, 2008, AM J HUM GENET, V82, P165, DOI 10.1016/j.ajhg.2007.09.017; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Bralten LBC, 2010, GENE CHROMOSOME CANC, V49, P509, DOI 10.1002/gcc.20760; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Clark TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r64; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Freire P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004076; French PJ, 2007, CANCER RES, V67, P5635, DOI 10.1158/0008-5472.CAN-06-2869; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Friedman JI, 2008, MOL PSYCHIATR, V13, P261, DOI 10.1038/sj.mp.4002049; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Horresh I, 2008, J NEUROSCI, V28, P14213, DOI 10.1523/JNEUROSCI.3398-08.2008; Jackman C, 2009, PEDIATR NEUROL, V40, P310, DOI 10.1016/j.pediatrneurol.2008.10.013; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Kleihues P, 2000, PATHOLOGY GENETICS T; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Lieberoth A, 2009, J NEUROSCI, V29, P6677, DOI 10.1523/JNEUROSCI.4361-08.2009; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; McAvoy S, 2007, CYTOGENET GENOME RES, V118, P260, DOI 10.1159/000108309; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Poliak S, 2003, J CELL BIOL, V162, P1149, DOI 10.1083/jcb.200305018; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Schutte M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003007; Smith DI, 2007, SEMIN CANCER BIOL, V17, P31, DOI 10.1016/j.semcancer.2006.10.003; Strauss KA, 2006, NEW ENGL J MED, V354, P1370, DOI 10.1056/NEJMoa052773; Thorell K, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-53; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Verkerk AJMH, 2003, GENOMICS, V82, P1, DOI 10.1016/S0888-7543(03)00097-1; Vernes SC, 2008, NEW ENGL J MED, V359, P2337, DOI 10.1056/NEJMoa0802828; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zecchini S, 2010, ADV EXP MED BIOL, V663, P319, DOI 10.1007/978-1-4419-1170-4_20	43	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6138	6148		10.1038/onc.2010.342	http://dx.doi.org/10.1038/onc.2010.342			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20711234				2022-12-28	WOS:000284356500006
J	Maniati, E; Soper, R; Hagemann, T				Maniati, E.; Soper, R.; Hagemann, T.			Up for Mischief? IL-17/Th17 in the tumour microenvironment	ONCOGENE			English	Review						IL-17; Th17; cancer; inflammation; tumour microenvironment	REGULATORY T-CELLS; GROWTH-FACTOR-BETA; ROR-GAMMA-T; CANCER-RELATED INFLAMMATION; BRONCHIAL EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; AIRWAYS IN-VIVO; TH17 CELLS; CUTTING EDGE; TGF-BETA	The role of interleukin (IL)-17 and the IL-17-producing T helper (Th)17 cells in cancer has recently become the focus of extensive investigation. An expanding body of literature implicates Th17 cells and their hallmark cytokine in both pro-and anti-tumourigenic processes. In this review we describe their biological activities and outline the reciprocal interactions between Th17 cells and other cells of the immune system. We also discuss the evidence regarding their dual role in the tumour microenvironment. An understanding of the processes that regulate the pro-or anti-tumour activities of Th17 cell and IL-17 will allow the development of more effective means for cancer immunotherapy. Oncogene (2010) 29, 5653-5662; doi:10.1038/onc.2010.367; published online 23 August 2010	[Maniati, E.; Soper, R.; Hagemann, T.] Queen Mary Univ London, Ctr Canc & Inflammat, Inst Canc, Barts & London Sch Med & Dent, London EC1M 6BQ, England	University of London; Queen Mary University London	Hagemann, T (corresponding author), Queen Mary Univ London, Ctr Canc & Inflammat, Inst Canc, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.	t.hagemann@qmul.ac.uk	Maniati, Eleni/ABC-4551-2020		Medical Research Council; Cancer Research UK; MRC [G0601867] Funding Source: UKRI; Medical Research Council [G0601867] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council (to T Hagemann and R Soper) and Cancer Research UK (to T Hagemann and E Maniati).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Aspord C, 2007, J EXP MED, V204, P1037, DOI 10.1084/jem.20061120; Ayyoub M, 2009, P NATL ACAD SCI USA, V106, P8635, DOI 10.1073/pnas.0900621106; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deknuydt F, 2009, CLIN IMMUNOL, V131, P298, DOI 10.1016/j.clim.2008.12.008; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Derhovanessian E, 2009, INT J CANCER, V125, P1372, DOI 10.1002/ijc.24497; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Ghadjar P, 2009, INT J CANCER, V125, P741, DOI 10.1002/ijc.24468; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Haudenschild D, 2002, J BIOL CHEM, V277, P4309, DOI 10.1074/jbc.M109372200; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; Hinrichs CS, 2009, BLOOD, V114, P596, DOI 10.1182/blood-2009-02-203935; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Horlock C, 2009, BRIT J CANCER, V100, P1061, DOI 10.1038/sj.bjc.6604963; Hoshino H, 1999, AM J RESP CRIT CARE, V159, P1423, DOI 10.1164/ajrccm.159.5.9806008; Hoshino H, 2000, J ALLERGY CLIN IMMUN, V105, P143, DOI 10.1016/S0091-6749(00)90189-1; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Huang SH, 2004, ALLERGY ASTHMA PROC, V25, P17; Huang XM, 2003, FRONT BIOSCI-LANDMRK, V8, pS740, DOI 10.2741/1093; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kolls JK, 2003, AM J RESP CELL MOL, V28, P9, DOI 10.1165/rcmb.2002-0255PS; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kryczek I, 2005, CANCER RES, V65, P465; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Laan M, 2003, EUR RESPIR J, V21, P387, DOI 10.1183/09031936.03.00303503; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Laan M, 1999, J IMMUNOL, V162, P2347; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Leveque L, 2009, J IMMUNOTHER, V32, P101, DOI 10.1097/CJI.0b013e318195b59e; Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111; Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105; Miyamoto M, 2003, J IMMUNOL, V170, P4665, DOI 10.4049/jimmunol.170.9.4665; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Ngiow SF, 2010, BLOOD, V115, P2554, DOI 10.1182/blood-2009-11-254607; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Nurieva R, 2009, J IMMUNOL, V182, P2565, DOI 10.4049/jimmunol.0803931; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Prause O, 2004, THORAX, V59, P313, DOI 10.1136/thx.2003.008854; Roberts SJ, 2007, P NATL ACAD SCI USA, V104, P6770, DOI 10.1073/pnas.0604982104; Rubie C, 2006, SCAND J IMMUNOL, V63, P468, DOI 10.1111/j.1365-3083.2006.001766.x; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Sfanos KS, 2008, CLIN CANCER RES, V14, P3254, DOI 10.1158/1078-0432.CCR-07-5164; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Steiner GE, 2003, PROSTATE, V56, P171, DOI 10.1002/pros.10238; Su XM, 2010, J IMMUNOL, V184, P1630, DOI 10.4049/jimmunol.0902813; Tartour E, 1999, CANCER RES, V59, P3698; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; von Euw E, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-35; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Yang ZZ, 2009, CANCER RES, V69, P5522, DOI 10.1158/0008-5472.CAN-09-0266; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang B, 2008, BIOCHEM BIOPH RES CO, V374, P533, DOI 10.1016/j.bbrc.2008.07.060; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhou Q, 2005, INFECT IMMUN, V73, P935, DOI 10.1128/IAI.73.2.935-943.2005; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	106	85	92	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5653	5662		10.1038/onc.2010.367	http://dx.doi.org/10.1038/onc.2010.367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20729908	Green Accepted			2022-12-28	WOS:000283262500001
J	Imam, JS; Buddavarapu, K; Lee-Chang, JS; Ganapathy, S; Camosy, C; Chen, Y; Rao, MK				Imam, J. S.; Buddavarapu, K.; Lee-Chang, J. S.; Ganapathy, S.; Camosy, C.; Chen, Y.; Rao, M. K.			MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers	ONCOGENE			English	Article						Cancer; Six1; microRNA; miR-185; tumor suppressor	HOMEOPROTEIN SIX1; GENE-EXPRESSION; OVEREXPRESSION; APOPTOSIS; RESISTANCE; MECHANISM; CARCINOMA; TRAIL; EZRIN	Homeobox genes encode transcription factors that are essential for normal development and are often dysregulated in cancers. The molecular mechanisms that cause their misregulation in cancers are largely unknown. In this study, we investigate the mechanism by which the Six1 homeobox protein, which has a crucial role during development, is frequently deregulated in several poor outcome, aggressive, metastatic adult human cancers, including breast cancer, ovarian cancer, hepatocellular carcinoma and pediatric malignancies such as rhabdomyosarcoma and Wilms' tumor. Our results reveal that miRNA-185 translationally represses Six1 by binding to its 3'-untranslated region. Analyses of ovarian cancers, pediatric renal tumors and multiple breast cancer cell lines showed decreased miR-185 expression, paralleling an increase in Six1 levels. Further investigation revealed that miR-185 impedes anchorage-independent growth and cell migration, in addition to suppressing tumor growth in vivo, implicating it to be a potent tumor suppressor. Our results indicate that miR-185 mediates its tumor suppressor function by regulating cell-cycle proteins and Six1 transcriptional targets c-myc and cyclin A1. Furthermore, we show that miR-185 sensitizes Six1-overexpressing resistant cancer cells to apoptosis in general and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in particular. Together, our findings suggest that the altered expression of the novel tumor suppressor miR-185 may be one of the central events that leads to dysregulation of oncogenic protein Six1 in human cancers. Oncogene (2010) 29, 4971-4979; doi: 10.1038/onc.2010.233; published online 5 July 2010	[Rao, M. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Ganapathy, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, San Antonio, TX 78229 USA; [Chen, Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Rao, MK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	RaoM@uthscsa.edu	Ganapathy, Suthakar/C-1266-2013	Ganapathy, Suthakar/0000-0003-3828-5382; Imam, J Saadi/0000-0003-3463-838X	San Antonio Area Foundation; GCCRI	San Antonio Area Foundation; GCCRI	We thank Jennifer Rebeles and Tiffany Jones for their assistance in flow cytometry and data analysis; Dr Yao-Fu-Chang for his suggestions in the preparation of this paper; Drs James Garbe and Martha Stampfer of Lawrence Berkeley National Laboratory for kindly providing us normal HMEC RNA samples; the Children's Oncology Group for providing Wilms' tumor and matched control kidney tissues; Dr Russell Broaddus and Ovarian Cancer Translational Research Tumor Bank, MD Anderson Cancer Center for normal and ovarian cancer tissues; and Dr Padmanabhan Swami, UT Health Science Center, San Antonio for recombinant human TRAIL. Financial support: This work was supported by San Antonio Area Foundation Grant (JSI and MKR) and GCCRI startup fund (MKR).	Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Grifone R, 2005, DEVELOPMENT, V132, P2235, DOI 10.1242/dev.01773; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Ozaki H, 2004, DEVELOPMENT, V131, P551, DOI 10.1242/dev.00943; Radisky DC, 2009, J CLIN INVEST, V119, P2528, DOI 10.1172/JCI40555; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; Shen C, 2008, BIOLOGICALS, V36, P263, DOI 10.1016/j.biologicals.2008.02.002; Shin MS, 2001, CANCER RES, V61, P4942; Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600-0609.2009.01348.x; Wan F, 2008, INT J CANCER, V123, P32, DOI 10.1002/ijc.23463; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628	25	144	158	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4971	4979		10.1038/onc.2010.233	http://dx.doi.org/10.1038/onc.2010.233			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20603620				2022-12-28	WOS:000281578700011
J	Li, C; Xin, W; Sy, MS				Li, C.; Xin, W.; Sy, M-S			Binding of pro-prion to filamin A: by design or an unfortunate blunder	ONCOGENE			English	Review						prion protein; filamins; cancer	COMPARATIVE GENOMIC HYBRIDIZATION; GPI TRANSAMIDASE SUBUNITS; GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; CENTRAL-NERVOUS-SYSTEM; GLYCOPROTEIN-IB-ALPHA; CARBONIC-ANHYDRASE-IV; RESOLUTION ARRAY CGH; CHROMOSOME ARM 20Q; DNA COPY NUMBER	Over the last decades, cancer research has focused on tumor suppressor genes and oncogenes. Genes in other cellular pathways has received less attention. Between 0.5% to 1% of the mammalian genome encodes for proteins that are tethered on the cell membrane via a glycosylphosphatidylinositol (GPI)-anchor. The GPI modification pathway is complex and not completely understood. Prion (PrP), a GPI-anchored protein, is infamous for being the only normal protein that when misfolded can cause and transmit a deadly disease. Though widely expressed and highly conserved, little is known about the functions of PrP. Pancreatic cancer and melanoma cell lines express PrP. However, in these cell lines the PrP exists as a proPrP as defined by retaining its GPI anchor peptide signal sequence (GPI-PSS). Unexpectedly, the GPI-PSS of PrP has a filamin A (FLNA) binding motif and binds FLNA. FLNA is a cytolinker protein, and an integrator of cell mechanics and signaling. Binding of pro-PrP to FLNA disrupts the normal FLNA functions. Although normal pancreatic ductal cells lack PrP, about 40% of patients with pancreatic ductal cell adenocarcinoma express PrP in their cancers. These patients have significantly shorter survival time compared with patients whose cancers lack PrP. Pro-PrP is also detected in melanoma in situ but is undetectable in normal melanocyte, and invasive melanoma expresses more pro-PrP. In this review, we will discuss the underlying mechanisms by which binding of pro-PrP to FLNA disrupts normal cellular physiology and contributes to tumorigenesis, and the potential mechanisms that cause the accumulation of pro-PrP in cancer cells. Oncogene (2010) 29, 5329-5345; doi: 10.1038/onc.2010.307; published online 9 August 2010	[Li, C.; Sy, M-S] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Xin, W.] Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, Wolstein Res Bldg,Room 5131, Cleveland, OH 44106 USA.	man-sun.sy@case.edu			Department of Pathology; NIH [R21-CA133559-01, 5P30AR039750]; SDRC; NATIONAL CANCER INSTITUTE [R21CA133559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	Department of Pathology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SDRC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank all the collaborators who have contributed to these studies, and Pearl Ling for careful reading of the paper, suggestion and editorial assistant. Start-up funds from the Department of Pathology to WX. Supported by R21-CA133559-01 from NIH and a pilot Grant from SDRC#5P30AR039750 from NIH.	Abujiang P, 1998, ONCOGENE, V17, P3029, DOI 10.1038/sj.onc.1202230; ADAMSON R, 1994, ONCOGENE, V9, P2077; Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Alper O, 2009, CANCER SCI, V100, P1748, DOI 10.1111/j.1349-7006.2009.01244.x; Amundadottir L, 2009, NAT GENET, V41, P986, DOI 10.1038/ng.429; Anantharam V, 2008, FREE RADICAL BIO MED, V45, P1530, DOI 10.1016/j.freeradbiomed.2008.08.028; Antonacopoulou AG, 2008, ANTICANCER RES, V28, P1221; Argos M, 2008, CANCER GENET CYTOGEN, V182, P69, DOI 10.1016/j.cancergencyto.2008.01.001; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Bedolla RG, 2009, CLIN CANCER RES, V15, P788, DOI 10.1158/1078-0432.CCR-08-1402; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bempt IV, 2006, J PATHOL, V208, P486, DOI 10.1002/path.1911; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bisgaard ML, 2001, SCAND J GASTROENTERO, V36, P405, DOI 10.1080/003655201300051252; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; BOSCHMAN CR, 1994, AM J PATHOL, V145, P1291; BOUFFARD D, 1994, HUM PATHOL, V25, P709, DOI 10.1016/0046-8177(94)90305-0; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brown KM, 2008, NAT GENET, V40, P838, DOI 10.1038/ng.163; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BYERS HR, 1991, AM J PATHOL, V139, P423; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Campana V, 2005, TRENDS CELL BIOL, V15, P102, DOI 10.1016/j.tcb.2004.12.002; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Chen R, 2002, J CELL BIOCHEM, V84, P68, DOI 10.1002/jcb.1267; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Choi YW, 2007, INT J GYNECOL CANCER, V17, P687, DOI 10.1111/j.1525-1438.2007.00834.x; Creutzfeldt HG, 1920, Z GESAMTE NEUROL PSY, V57, P1, DOI 10.1007/BF02866081; Cukier IH, 2007, FEBS LETT, V581, P1661, DOI 10.1016/j.febslet.2007.03.041; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Daley D, 2008, AM J HUM GENET, V82, P723, DOI 10.1016/j.ajhg.2008.01.007; Davies P, 2008, BIOCHEM J, V410, P237, DOI 10.1042/BJ20071477; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; Dimova I, 2009, TUMORI, V95, P357; Dohna M, 2000, GENE CHROMOSOME CANC, V28, P145, DOI 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.0.CO;2-7; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119; Fanjul M, 2004, HISTOCHEM CELL BIOL, V121, P91, DOI 10.1007/s00418-003-0616-2; Fanjul M, 2007, J HISTOCHEM CYTOCHEM, V55, P783, DOI 10.1369/jhc.6A7112.2007; Feng SJ, 2003, BLOOD, V102, P2122, DOI 10.1182/blood-2002-12-3805; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Fiori JL, 2009, ENDOCRINOLOGY, V150, P2551, DOI 10.1210/en.2008-1344; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Franscini N, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000071; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; Fujita Y, 2003, HEPATO-GASTROENTEROL, V50, P1857; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Gajdusek DC, 2008, PHILOS T R SOC B, V363, P3697, DOI 10.1098/rstb.2008.0070; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; Garcea G, 2005, EUR J CANCER, V41, P2213, DOI 10.1016/j.ejca.2005.04.044; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; GOLDFARB LG, 1994, PHILOS T R SOC B, V343, P379, DOI 10.1098/rstb.1994.0032; Goldmann WH, 2002, CELL BIOL INT, V26, P567, DOI 10.1006/cbir.2002.0900; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GREIG JR, 1950, J COMP PATHOL THERAP, V60, P263, DOI 10.1016/S0368-1742(50)80024-3; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Guan Y, 2008, INT J CANCER, V122, P1820, DOI 10.1002/ijc.23297; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Guled M, 2008, MODERN PATHOL, V21, P770, DOI 10.1038/modpathol.2008.57; Guo ZM, 2004, NAT MED, V10, P374, DOI 10.1038/nm1010; Han HY, 2002, CANCER RES, V62, P2890; Hart AW, 2006, HUM MOL GENET, V15, P2457, DOI 10.1093/hmg/ddl168; He HJ, 2003, J BIOL CHEM, V278, P27096, DOI 10.1074/jbc.M301003200; He XQ, 2000, MOL IMMUNOL, V37, P603, DOI 10.1016/S0161-5890(00)00070-5; Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7; Helfand BT, 2009, J UROLOGY, V181, P2502, DOI 10.1016/j.juro.2009.01.109; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidaka S, 2003, ANTICANCER RES, V23, P3353; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; Ho JC, 2006, INT J CANCER, V119, P1330, DOI 10.1002/ijc.22005; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; Hruban RH, 2009, ARCH PATHOL LAB MED, V133, P347, DOI 10.1043/1543-2165-133.3.347; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; Hulsebos TJM, 1997, GENE CHROMOSOME CANC, V18, P279, DOI 10.1002/(SICI)1098-2264(199704)18:4<279::AID-GCC5>3.0.CO;2-Y; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Ishihara T, 2008, CANCER SCI, V99, P1940, DOI 10.1111/j.1349-7006.2008.00900.x; Ishkanian AS, 2009, PROSTATE, V69, P1091, DOI 10.1002/pros.20959; Ittmann M, 2009, NEOPLASIA, V11, P305, DOI 10.1593/neo.81530; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang WW, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-74; Johnson-Pais TL, 2003, INT J CANCER, V105, P285, DOI 10.1002/ijc.11070; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Kamochi N, 2008, CANCER SCI, V99, P2417, DOI 10.1111/j.1349-7006.2008.00978.x; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Kayed H, 2006, INT J ONCOL, V29, P1139; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Keshet GI, 2000, J NEUROCHEM, V75, P1889, DOI 10.1046/j.1471-4159.2000.0751889.x; Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011; Kim H, 2008, EXP CELL RES, V314, P834, DOI 10.1016/j.yexcr.2007.11.022; Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kinoshita T, 2008, J BIOCHEM, V144, P287, DOI 10.1093/jb/mvn090; Kley RA, 2007, BRAIN, V130, P3250, DOI 10.1093/brain/awm271; Krakow D, 2004, NAT GENET, V36, P405, DOI 10.1038/ng1319; Kresse SH, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-39; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lad Y, 2007, EMBO J, V26, P3993, DOI 10.1038/sj.emboj.7601827; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; LI C, 2010, J BIOL CHEM; Li CY, 2007, BIOCHEM J, V406, P333, DOI 10.1042/BJ20061857; Li CY, 2009, J CLIN INVEST, V119, P2725, DOI 10.1172/JCI39542; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li M, 2002, BIOCHEM PHARMACOL, V63, P859, DOI 10.1016/S0006-2952(01)00932-7; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Li RL, 2003, BIOCHEM BIOPH RES CO, V303, P446, DOI 10.1016/S0006-291X(03)00354-1; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Liang J, 2009, FEBS J, V276, P685, DOI 10.1111/j.1742-4658.2008.06816.x; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Lindholm PM, 2007, CYTOGENET GENOME RES, V119, P46, DOI 10.1159/000109618; Liu ET, 2008, CURR OPIN GENET DEV, V18, P251, DOI 10.1016/j.gde.2008.07.014; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Logsdon CD, 2003, CANCER RES, V63, P2649; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Lu J, 2005, EPILEPSY BEHAV, V7, P143, DOI 10.1016/j.yebeh.2005.05.001; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Ma J, 2006, J PATHOL, V210, P205, DOI 10.1002/path.2050; Maeda Y, 2006, METHOD ENZYMOL, V416, P182, DOI 10.1016/S0076-6879(06)16012-7; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; Maqani N, 2006, MOL CANCER RES, V4, P449, DOI 10.1158/1541-7786.MCR-06-0058; Mastracci TL, 2006, GENE CHROMOSOME CANC, V45, P1007, DOI 10.1002/gcc.20368; Mhawech-Fauceglia P, 2008, INT J GYNECOL PATHOL, V27, P539, DOI 10.1097/PGP.0b013e31816bcda4; Millhauser GL, 2007, ANNU REV PHYS CHEM, V58, P299, DOI 10.1146/annurev.physchem.58.032806.104657; Miozzo M, 2000, INT J CANCER, V87, P68, DOI 10.1002/1097-0215(20000701)87:1<68::AID-IJC10>3.0.CO;2-V; Miyoshi E, 2008, J BIOCHEM, V143, P725, DOI 10.1093/jb/mvn011; Morel E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003000; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Myllykangas S, 2008, INT J CANCER, V123, P817, DOI 10.1002/ijc.23574; Naghibalhossaini F, 2007, MOL BIOL CELL, V18, P1366, DOI 10.1091/mbc.E06-10-0884; Nagpal JK, 2008, MODERN PATHOL, V21, P979, DOI 10.1038/modpathol.2008.76; Nakamura F, 2006, BLOOD, V107, P1925, DOI 10.1182/blood-2005-10-3964; Nakamura F, 2007, J CELL BIOL, V179, P1011, DOI 10.1083/jcb.200707073; Nakanishi H, 2009, CANCER RES, V69, P1615, DOI 10.1158/0008-5472.CAN-08-3218; Narang HK, 2005, EXP BIOL MED, V230, P343, DOI 10.1177/153537020523000508; Narayan G, 2007, GENE CHROMOSOME CANC, V46, P373, DOI 10.1002/gcc.20418; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nicholson TB, 2007, J CELL BIOL, V177, P211, DOI 10.1083/jcb.200701158; Nomachi A, 2008, J BIOL CHEM, V283, P27973, DOI 10.1074/jbc.M802325200; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Notterman DA, 2001, CANCER RES, V61, P3124; Nowak NJ, 2005, CANCER GENET CYTOGEN, V161, P36, DOI 10.1016/j.cancergencyto.2005.01.009; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Ottenhof NA, 2009, ARCH PATHOL LAB MED, V133, P375, DOI 10.1043/1543-2165-133.3.375; Paitel E, 2004, J BIOL CHEM, V279, P612, DOI 10.1074/jbc.M310453200; Paladino S, 2008, J CELL SCI, V121, P4001, DOI 10.1242/jcs.036038; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; PERIS K, 1995, J INVEST DERMATOL, V105, P625, DOI 10.1111/1523-1747.ep12323809; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ravid D, 2008, EXP CELL RES, V314, P2762, DOI 10.1016/j.yexcr.2008.06.004; Robertson SP, 2005, CURR OPIN GENET DEV, V15, P301, DOI 10.1016/j.gde.2005.04.001; Sahar S, 2009, NAT REV CANCER, V9, P886, DOI 10.1038/nrc2747; Saito S, 2006, ONCOL REP, V16, P949; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Schmitt-Ulms G, 2004, NAT BIOTECHNOL, V22, P724, DOI 10.1038/nbt969; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Selvarajah S, 2008, CYTOGENET GENOME RES, V122, P5, DOI 10.1159/000151310; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Sharom FJ, 2002, BIOCHEM CELL BIOL, V80, P535, DOI 10.1139/O02-146; Shi CJ, 2008, ADV ANAT PATHOL, V15, P185, DOI 10.1097/PAP.0b013e31817bf57d; Shivapurkar N, 1999, CANCER RES, V59, P3576; Sibley K, 2000, GENE CHROMOSOME CANC, V29, P378, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1045>3.0.CO;2-K; Simoneau S, 2003, BIOL CHEM, V384, P243, DOI 10.1515/BC.2003.027; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200; Stanford JL, 2009, HUM MOL GENET, V18, P1839, DOI 10.1093/hmg/ddp100; Steele AD, 2009, PRION, V3, P240, DOI 10.4161/pri.3.4.10135; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Sun JL, 2008, PROSTATE, V68, P691, DOI 10.1002/pros.20754; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Sverdlov M, 2009, MOL BIOL CELL, V20, P4531, DOI 10.1091/mbc.E08-10-0997; Taylor DR, 2006, MOL MEMBR BIOL, V23, P89, DOI 10.1080/09687860500449994; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Thelin WR, 2007, J CLIN INVEST, V117, P364, DOI 10.1172/JCI30376; Thomassen M, 2009, BREAST CANCER RES TR, V113, P239, DOI 10.1007/s10549-008-9927-2; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Torring N, 2007, BRIT J CANCER, V96, P499, DOI 10.1038/sj.bjc.6603476; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van Dartel M, 2002, CANCER GENET CYTOGEN, V139, P91, DOI 10.1016/S0165-4608(02)00627-1; VANDUI, 2007, CYTOGENET GENOME RES, V118, P130; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wang Y, 2007, ONCOGENE, V26, P6061, DOI 10.1038/sj.onc.1210435; Wescott MP, 2008, CANCER PREV RES, V1, P503, DOI 10.1158/1940-6207.CAPR-08-0195; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200; Wong N, 2003, J HEPATOL, V38, P298, DOI 10.1016/S0168-8278(02)00412-9; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; Wu GJ, 2006, CANCER RES, V66, P9829, DOI 10.1158/0008-5472.CAN-06-0506; Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650; Yin S, 2008, J BIOL CHEM, V283, P25446, DOI 10.1074/jbc.M800814200; Yu JC, 2008, HEPATO-GASTROENTEROL, V55, P1487; Yue JY, 2009, CANCER RES, V69, P7978, DOI 10.1158/0008-5472.CAN-09-2177; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812; Zhu TN, 2007, J BIOL CHEM, V282, P14816, DOI 10.1074/jbc.M611430200; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	228	14	15	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5329	5345		10.1038/onc.2010.307	http://dx.doi.org/10.1038/onc.2010.307			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20697352	Green Accepted			2022-12-28	WOS:000282944500001
J	Liss, AS; Tiwari, R; Kralova, J; Bose, HR				Liss, A. S.; Tiwari, R.; Kralova, J.; Bose, H. R., Jr.			Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappa B oncogenesis	ONCOGENE			English	Article						v-Rel; Rel/NF-kappa B; oncogenesis; AP-1; Ras; MAPK	DNA-BINDING; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTORS; TRANSDUCTION PATHWAY; HUMAN CANCER; ATF-2; PHOSPHORYLATION; EXPRESSION; KINASE	Cell transformation by the v-rel oncogene is mediated by the aberrant expression of genes that are normally tightly regulated by other Rel/NF-kappa B family members. Although a number of genes inappropriately activated or suppressed by v-Rel have been identified, their contributions to the v-Rel transformation process have been poorly characterized. Here, we examine the role of individual AP-1 proteins in v-Rel-mediated transformation. v-Rel-transformed cells exhibit elevated RNA and protein expression of c-Fos, c-Jun and ATF2 and sustained repression of Fra-2. c-Fos and c-Jun are essential in both the initiation and maintenance of v-Rel-mediated transformation, whereas Fra-2 is dispensable. By employing a c-Jun dimerization mutant, we further identified Fos/Jun heterodimers as major contributors to the v-Rel transformation process. The inability of c-Rel to induce the expression of c-Fos and c-Jun contributes to its weaker oncogenic potential relative to v-Rel. Our studies also demonstrate that v-Rel may induce AP-1 members by directly upregulating gene expression (c-fos and ATF2) and by activating pathways that stimulate AP-1 activity. Although elevated expression of ATF2 is also required for v-Rel-mediated transformation, its ectopic overexpression is inhibitory. Investigating the mode of ATF2 regulation revealed a positive feedback mechanism whereby ATF2 induces p38 MAPK phosphorylation to further induce its own activity. In addition, these studies identified Ha-Ras as an effector of v-Rel-mediated transformation and reveal a novel role for ATF2 in the inhibition of the Ras-Raf-MEK-ERK signaling pathway. Overall, these studies reveal distinct and complex roles of AP-1 proteins in Rel/NF-kappa B oncogenesis. Oncogene (2010) 29, 4925-4937; doi: 10.1038/onc.2010.239; published online 21 June 2010	[Liss, A. S.; Tiwari, R.; Kralova, J.; Bose, H. R., Jr.] Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	National Cancer Institute [CA33192, CA098151]; NATIONAL CANCER INSTITUTE [R01CA033192, R01CA098151] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ashley Sims for her technical assistance and Marc Castellazzi for providing the Coll and Jun2 luciferase reporter vectors. This study was supported by Public Health Service Grants CA33192 and CA098151 from the National Cancer Institute.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Breitwieser W, 2007, GENE DEV, V21, P2069, DOI 10.1101/gad.430207; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Das RM, 2006, DEV BIOL, V294, P554, DOI 10.1016/j.ydbio.2006.02.020; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Ewert D, 1999, ACTA VIROL, V43, P133; Fujii Masahiro, 1997, Leukemia (Basingstoke), V11, P402; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; HOWE LR, 1993, ONCOGENE, V8, P2583; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Lewis JS, 2005, ONCOL RES, V15, P113, DOI 10.3727/096504005776367924; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; LISS AS, 2008, ENCY VIROLOGY, P412; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; Mathas S, 2005, BLOOD, V106, P4287, DOI 10.1182/blood-2004-09-3620; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morton S, 2004, FEBS LETT, V572, P177, DOI 10.1016/j.febslet.2004.07.031; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricote M, 2006, J PATHOL, V208, P401, DOI 10.1002/path.1910; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vlahopoulos SA, 2008, BIOESSAYS, V30, P314, DOI 10.1002/bies.20734; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	46	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4925	4937		10.1038/onc.2010.239	http://dx.doi.org/10.1038/onc.2010.239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562914	Green Accepted			2022-12-28	WOS:000281578700007
J	Meng, L; Gabai, VL; Sherman, MY				Meng, L.; Gabai, V. L.; Sherman, M. Y.			Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis	ONCOGENE			English	Article						HSF1; HER2; growth arrest; senescence; p21; survivin	CANCER-CELLS; MOLECULAR CHAPERONES; SENESCENCE PATHWAYS; PROTEIN HSP72; GENE; ONCOGENESIS; EXPRESSION; APOPTOSIS; SURVIVIN; DEATH	The heat-shock transcription factor HSF1 was recently shown to have a key role in the development of tumors associated with activation of Ras or inactivation of p53. Here, we show that HSF1 is required for the cell transformation and tumorigenesis induced by the human epidermal growth factor receptor-2 (HER2) oncogene responsible for aggressive breast tumors. Upon expression of HER2, untransformed human mammary epithelial MCF-10A cells underwent neoplastic transformation, formed foci in culture and tumors in nude mouse xenografts. However, expression of HER2 in MCF-10A cells with knockdown of HSF1 did not cause either foci formation or tumor growth in xenografts. The antitumorigenic effect of downregulation of HSF1 was associated with HER2-induced accumulation of the cyclin-dependent kinase inhibitor p21 and decrease in the mitotic regulator survivin, which resulted in growth inhibition and cell senescence. In fact, either knockout of p21 or overexpression of survivin alleviated these effects of HSF1 knockdown. The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest. Similar effects were observed with a small-molecular-weight inhibitor of the heat-shock response NZ28. The effects of HSF1 knockdown on the growth arrest and senescence of HER2-expressing cells were associated with downregulation of heat-shock protein (Hsp) 72 and Hsp27. Therefore, HSF1 is critical for proliferation of HER2-expressing cells, most likely because it maintains the levels of HSPs, which in turn control regulators of senescence p21 and survivin. Oncogene (2010) 29, 5204-5213; doi:10.1038/onc.2010.277; published online 12 July 2010	[Meng, L.; Gabai, V. L.; Sherman, M. Y.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 72 E Concord St,K-323, Boston, MA 02118 USA.	gabai@bu.edu; sherma1@bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Sherman, Michael/0000-0003-3345-073X	National Institute of Health [CA081244]; NATIONAL CANCER INSTITUTE [R01CA081244] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institute of Health CA081244. We thank Dr B Park and Dr C Spangenberg for their kind supply of MCF-10A cells and HER2-overexpressing retroviral vector.	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Cahill CM, 1997, ADV EXP MED BIOL, V400, P625; Cai L, 2003, CELL RES, V13, P93, DOI 10.1038/sj.cr.7290154; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Roninson IB, 2003, CANCER RES, V63, P2705; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Trost TM, 2005, CANCER RES, V65, P840; Wu GJ, 2005, CANCER RES, V65, P758; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Xie Y, 2002, BIOCHEM BIOPH RES CO, V291, P1071, DOI 10.1006/bbrc.2002.6562; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692	31	106	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5204	5213		10.1038/onc.2010.277	http://dx.doi.org/10.1038/onc.2010.277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622894	Green Accepted			2022-12-28	WOS:000281867200009
J	Xiong, J; Du, Q; Liang, Z				Xiong, J.; Du, Q.; Liang, Z.			Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein	ONCOGENE			English	Article						microRNA; c-Myc binding protein; MYCBP; miR-22; cancer; cell growth	CELL-PROLIFERATION; AMY-1; IDENTIFICATION; EXPRESSION; REPRESSION; S-AKAP84; SUBUNIT; NETWORK; COMPLEX; KINASE	Oncogenic c-Myc has been described to modulate the expression of a subset of microRNAs (miRNAs), which include miR-22; however, the mechanism through which a miRNA controls c-Myc activity remains unclear. Here we report a novel anti-c-Myc function mediated by miR-22. Ectopically expressed miR-22 inhibited cell proliferation and anchorage-independent growth of human cancer cell lines. Microarray screening and western analyses revealed that miR-22 repressed the c-Myc-binding protein MYCBP, a positive regulator of c-Myc. Consistent with this, reporter assays showed that miR-22-mediated MYCBP gene suppression largely depends on the conserved miR-22 target site within the MYCBP 3'-untranslational region (3'UTR), implying that MYCBP mRNA is a direct miR-22 target. Depletion of MYCBP using small interfering RNA (siRNA) recapitulated the miR-22-induced anti-growth effect on tumor cells, whereas ectopically expressed MYCBP rescued cells from the growth suppression mediated by miR-22. Moreover, repression of MYCBP by miR-22 downregulated a panel of E-box-containing c-Myc target genes. Our results suggest that miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities. As c-Myc inhibits the expression of miR-22, we propose a novel positive feedback loop formed by oncogenic c-Myc to accelerate cell proliferation by suppressing miR-22, a potent inhibitor of MYCBP. Oncogene (2010) 29, 4980-4988; doi: 10.1038/onc.2010.241; published online 21 June 2010	[Liang, Z.] Peking Univ, Inst Mol Med, Lab Nucle Acid Technol, Beijing 100871, Peoples R China	Peking University	Liang, Z (corresponding author), Peking Univ, Inst Mol Med, Lab Nucle Acid Technol, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.	liangz@pku.edu.cn	Xiong, Jianhua/D-6099-2015; Liang, Zicai/A-2646-2013	Xiong, Jianhua/0000-0002-2740-4027; 	National High-tech R&D Program of China [2007AA02Z165, 2008DFA30770]; National Basic Research Program of China [2007CB512100]; National Natural Science Foundation of China [30873187, 30771085, 30871385]; Department of Education of China [20070001011, 200800010019]	National High-tech R&D Program of China(National High Technology Research and Development Program of China); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Education of China	We thank Tianjing Cai for excellent technical assistance, and Dr Iain C Bruce for critical reading of the paper. This work was supported by the National High-tech R&D Program of China (2007AA02Z165, 2008DFA30770), the National Basic Research Program of China (2007CB512100), the National Natural Science Foundation of China (30873187, 30771085 and 30871385) and by grants from the Department of Education of China (20070001011 and 200800010019).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Furusawa M, 2002, J BIOL CHEM, V277, P50885, DOI 10.1074/jbc.M206387200; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Ishizaki R, 2006, GENES CELLS, V11, P949, DOI 10.1111/j.1365-2443.2006.00991.x; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lei CX, 2009, HUM REPROD, V24, P2879, DOI 10.1093/humrep/dep250; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Neely LA, 2006, NAT METHODS, V3, P41, DOI 10.1038/NMETH825; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yukitake H, 2002, J BIOL CHEM, V277, P45480, DOI 10.1074/jbc.M206201200	37	113	118	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4980	4988		10.1038/onc.2010.241	http://dx.doi.org/10.1038/onc.2010.241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562918				2022-12-28	WOS:000281578700012
J	Singh, J; Aaronson, SA; Mlodzik, M				Singh, J.; Aaronson, S. A.; Mlodzik, M.			Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways	ONCOGENE			English	Article						Drosophila; Abl; Src; kinase; cell invasive behavior	ABL TYROSINE KINASE; BREAST-CANCER CELLS; BINDING PROTEIN RAC; C-ABL; SIGNALING PATHWAY; FAMILY KINASES; DISC EVERSION; BCR-ABL; SRC; JNK	The Abelson (Abl) family of non-receptor tyrosine kinases has an important role in cell morphogenesis, motility, and proliferation. Although the function of Abl has been extensively studied in leukemia, its role in epithelial cell invasion remains obscure. Using the Drosophila wing epithelium as an in vivo model system, we show that overexpression (activation) of Drosophila Abl (dAbl) causes loss of epithelial apical/basal cell polarity and secretion of matrix metalloproteinases, resulting in a cellular invasion and apoptosis. Our in vivo data indicate that dAbl acts downstream of the Src kinases, which are known regulators of cell adhesion and invasion. Downstream of dAbl, Rac GTPases activate two distinct MAPK pathways: c-Jun N-terminal kinase signaling (required for cell invasion and apoptosis) and ERK signaling (inducing cell proliferation). Activated Abl also increases the activity of Src members through a positive feedback loop leading to signal amplification. Thus, targeting Src-Abl, using available dual inhibitors, could be of therapeutic importance in tumor cell metastasis. Oncogene (2010) 29, 4033-4045; doi:10.1038/onc.2010.155; published online 10 May 2010	[Singh, J.; Mlodzik, M.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA; [Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Mlodzik, M (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	marek.mlodzik@mssm.edu			NIH/NCI; NIH/National Eye Institute [R01 EY14597]; NATIONAL EYE INSTITUTE [R01EY014597, R01EY013256] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank the Bloomington Stock Center, DSHB, Ed Giniger, and Ross Cagan for fly stocks and antibodies. We are grateful to members of the Mlodzik lab for helpful suggestions, discussions, and criticism, Ross Cagan and members of the Cagan lab for discussion and reagents, in particular Tirtha Das. We also thank William Gault for critical reading of the manuscript, Nadinath Nillegoda, and Maneesha Chhikara for helpful comments and suggestions, and Joyce Lau, Sophy Okello, and Andrea Blitzer for technical help. Confocal laser microscopy was performed at the MSSM Microscopy SRF, supported by an NIH/NCI shared instrumentation grant. This research was supported by NIH/National Eye Institute Grant R01 EY14597 to MM.	Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; BRAND AH, 1993, DEVELOPMENT, V118, P401; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Golas JM, 2003, CANCER RES, V63, P375; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDEN N, 1995, DEVELOPMENT, V121, P903; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Pastor-Pareja JC, 2004, DEV CELL, V7, P387, DOI 10.1016/j.devcel.2004.07.022; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Shindo M, 2008, DEVELOPMENT, V135, P1355, DOI 10.1242/dev.015982; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Stevens TL, 2008, MOL BIOL CELL, V19, P378, DOI 10.1091/mbc.E07-01-0008; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yang JH, 2008, BIOCHEM BIOPH RES CO, V374, P512, DOI 10.1016/j.bbrc.2008.07.057	48	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4033	4045		10.1038/onc.2010.155	http://dx.doi.org/10.1038/onc.2010.155			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453880	Green Accepted			2022-12-28	WOS:000279892400004
J	Lane, D; Goncharenko-Khaider, N; Rancourt, C; Piche, A				Lane, D.; Goncharenko-Khaider, N.; Rancourt, C.; Piche, A.			Ovarian cancer ascites protects from TRAIL-induced cell death through alpha v beta 5 integrin-mediated focal adhesion kinase and Akt activation	ONCOGENE			English	Article						integrins; death receptors; ovarian carcinoma; ascites; PI3K/Akt pathway; TRAIL	LYSOPHOSPHATIDIC ACID LPA; GROWTH-FACTOR RECEPTOR; INDUCED APOPTOSIS; COUPLED RECEPTOR; EXPRESSION; CARCINOMA; MIGRATION; PATHWAY; LIGAND; IDENTIFICATION	Interactions between ovarian cancer cells and the surrounding tumor microenvironment are not well characterized. We have earlier shown that ovarian cancer ascites induces Akt activation and protect tumor cells from TRAIL-induced apoptosis. Here, we investigated the mechanism by which ascites activates Akt. The ability of ovarian cancer ascites to activate Akt and inhibit TRAIL-induced cell death and caspase activity was decreased by heat inactivation, but was retained in ascites fractions >5 kDa. The survival promoting activity of ascites was not affected by inhibitors of growth factor receptor including epidermal growth factor receptor (EGFR), VEGFR, FGFR, Her2/neu, and IGF-R1. However, this activity was inhibited by an alpha v beta 5 integrin-blocking antibody, but not by blocking antibodies against alpha v beta 3, beta 1, or beta 3 integrins. alpha v beta 5 integrin-blocking antibodies also inhibited ascites-induced Akt phosphorylation and c-FLIPs up-regulation. Ovarian cancer ascites induced a rapid phosphorylation of focal adhesion kinase (FAK), which closely correlated with the phosphorylation of Akt overtime. FAK phosphorylation was strongly inhibited by alpha v beta 5 integrin-blocking antibodies. Depletion of FAK content by RNA interference was also associated with inhibition of ascites-mediated Akt activation and survival. These results suggest that ovarian cancer ascites induces FAK and Akt activation in an alpha v beta 5 integrin-dependent pathway, which confers protection from TRAIL-induced cell death and caspase activation. Oncogene (2010) 29, 3519-3531; doi:10.1038/onc.2010.107; published online 19 April 2010	[Lane, D.; Goncharenko-Khaider, N.; Rancourt, C.; Piche, A.] Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Piche, A (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, 3001,12Ieme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Alain.Piche@USherbrooke.ca			Cancer Research Society	Cancer Research Society	Funding for this study was provided by the Cancer Research Society. We thank the Tumor Bank from the 'Reseau de Recherche en Cancer du Fond de Recherche en Sante du Quebec' for providing the ovarian cancer ascites.	Abendstein B, 2000, CYTOKINE, V12, P1115, DOI 10.1006/cyto.1999.0632; Alper O, 2001, J NATL CANCER I, V93, P1375, DOI 10.1093/jnci/93.18.1375; Carreiras F, 1999, INT J CANCER, V80, P285; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Damiano JS, 2002, CURR CANCER DRUG TAR, V2, P37, DOI 10.2174/1568009023334033; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Davidson B, 2006, CLIN CANCER RES, V12, P791, DOI 10.1158/1078-0432.CCR-05-2516; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fraser M, 2003, CANCER RES, V63, P7081; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gillan L, 2002, CANCER RES, V62, P5358; Goetzl EJ, 1999, CANCER RES, V59, P5370; Graves LE, 2004, CANCER RES, V64, P7045, DOI 10.1158/0008-5472.CAN-04-1800; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kandasamy K, 2002, CANCER RES, V62, P4929; Kang YC, 2004, CELL DEATH DIFFER, V11, P1287, DOI 10.1038/sj.cdd.4401489; Kobayashi-Sakamoto M, 2008, MICROVASC RES, V76, P139, DOI 10.1016/j.mvr.2008.06.004; KOHLER M, 1989, ANTICANCER RES, V9, P1537; KOHLER M, 1992, EUR J CANCER, V28A, P1432, DOI 10.1016/0959-8049(92)90538-D; Lane D, 2008, INT J GYNECOL CANCER, V18, P670, DOI 10.1111/j.1525-1438.2007.01062.x; Lane D, 2007, INT J CANCER, V121, P1227, DOI 10.1002/ijc.22840; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; MILLS GB, 1988, CANCER RES, V48, P1066; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Puls LE, 1996, GYNECOL ONCOL, V61, P109, DOI 10.1006/gyno.1996.0106; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Saltzman AK, 1999, GYNECOL OBSTET INVES, V47, P200, DOI 10.1159/000010095; Shen-Gunther J, 2002, GYNECOL ONCOL, V87, P77, DOI 10.1006/gyno.2002.6800; Sivaprasad U, 2007, CELL DEATH DIFFER, V14, P851, DOI 10.1038/sj.cdd.4402077; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	43	66	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3519	3531		10.1038/onc.2010.107	http://dx.doi.org/10.1038/onc.2010.107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400979				2022-12-28	WOS:000278835400007
J	Pontier, SM; Huck, L; White, DE; Rayment, J; Sanguin-Gendreau, V; Hennessy, B; Zuo, D; St-Arnaud, R; Mills, GB; Dedhar, S; Marshall, CJ; Muller, WJ				Pontier, S. M.; Huck, L.; White, D. E.; Rayment, J.; Sanguin-Gendreau, V.; Hennessy, B.; Zuo, D.; St-Arnaud, R.; Mills, G. B.; Dedhar, S.; Marshall, C. J.; Muller, W. J.			Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer	ONCOGENE			English	Article						integrin-linked kinase; ErbB2; mammary tumorigenesis	EPITHELIAL-SPECIFIC DISRUPTION; GLYCOGEN-SYNTHASE KINASE; TRANSGENIC MOUSE MODEL; PROTEIN-KINASE; CELL-SURVIVAL; GROWTH-FACTOR; THERAPEUTIC TARGET; MET AMPLIFICATION; B/AKT ACTIVATION; LUNG-CANCER	Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction. Oncogene (2010) 29, 3374-3385; doi:10.1038/onc.2010.86; published online 22 March 2010	[Pontier, S. M.; Huck, L.; Rayment, J.; Sanguin-Gendreau, V.; Zuo, D.; Muller, W. J.] McGill Univ, Goodman Canc Ctr, Dept Med, Montreal, PQ H3A 1A3, Canada; [White, D. E.; Marshall, C. J.] Canc Res UK Ctr Cell & Mol Biol, Inst Canc Res, London, England; [Hennessy, B.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [St-Arnaud, R.] Shriners Hosp Crippled Children, Genet Unit, Montreal, PQ, Canada; [Dedhar, S.] Univ British Columbia, BC Canc Agcy, Dept Biochem, Vancouver, BC, Canada	McGill University; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Texas System; UTMD Anderson Cancer Center; McGill University; British Columbia Cancer Agency; University of British Columbia	Muller, WJ (corresponding author), McGill Univ, Goodman Canc Ctr, Dept Med, 1160 Ave Pins Ouest,Room 509, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca	Pontier, Stéphanie/A-3836-2015	Pontier, Stéphanie/0000-0002-9124-9228; Rayment, Jonathan/0000-0003-4955-8876; Hennessy, Bryan/0000-0002-7871-6477; Dedhar, Shoukat/0000-0003-4355-1657	The Terry Fox Foundation through an award from the National Cancer Institute of Canada (NCIC); US Department of Defense (BCRP/CDMRP Era of Hope Postdoctoral award); Cancer Research UK; Canadian Institutes of Health Research (CIHR)/Canadian Breast Cancer Research Alliance (CBCRA) [64280]; National Institutes of Health [5PO1GA-099031-05]	The Terry Fox Foundation through an award from the National Cancer Institute of Canada (NCIC); US Department of Defense (BCRP/CDMRP Era of Hope Postdoctoral award)(United States Department of Defense); Cancer Research UK(Cancer Research UK); Canadian Institutes of Health Research (CIHR)/Canadian Breast Cancer Research Alliance (CBCRA)(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to Cynthia Lavoie, Vassilios Papavassiliou, Celine Champigny and Kay Savage for excellent technical help during the project. We also thank all members of the Muller laboratory for their critical commentaries as well as Richard Lamb and Maria Cerone for critical discussions and reading. SMP was funded by a fellowship of The Terry Fox Foundation through an award from the National Cancer Institute of Canada (NCIC). DW was funded by the US Department of Defense (BCRP/CDMRP Era of Hope Postdoctoral award) as well as JR. CJM is a Cancer Research UK Gibb Fellow. WJM was supported by CRC Chair in Molecular Oncology. This work was supported by grants from Cancer Research UK, the Canadian Institutes of Health Research (CIHR)/Canadian Breast Cancer Research Alliance (CBCRA) (#64280), the US Department of Defense and the National Institutes of Health 5PO1GA-099031-05.	Ahmed F, 2002, CANCER RES, V62, P7166; Akhtar N, 2009, DEVELOPMENT, V136, P1019, DOI 10.1242/dev.028423; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hennessy BT, 2007, CLIN CANCER RES, V13, P7421, DOI 10.1158/1078-0432.CCR-07-0760; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Mongroo PS, 2004, ONCOGENE, V23, P8959, DOI 10.1038/sj.onc.1208112; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Somasiri A, 2001, J CELL SCI, V114, P1125; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; White DE, 2006, GENE DEV, V20, P2355, DOI 10.1101/gad.1458906; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078	47	36	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3374	3385		10.1038/onc.2010.86	http://dx.doi.org/10.1038/onc.2010.86			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20305688				2022-12-28	WOS:000278622700006
J	Trong-Tue, N; Thao, DTP; Yamaguchi, M				Trong-Tue, N.; Thao, D. T. P.; Yamaguchi, M.			Role of DREF in transcriptional regulation of the Drosophila p53 gene	ONCOGENE			English	Article						Drosophila; DREF; p53; transcriptional regulation	REPLICATION-RELATED ELEMENT; DNA-REPLICATION; BINDING-FACTOR; CELL-PROLIFERATION; P53 HOMOLOG; IDENTIFICATION; MELANOGASTER; EXPRESSION; PROMOTER; SYSTEM	The tumor suppressor protein p53 has a critical role in safeguarding the integrity of the genome. Its functions are well understood but factors responsible for the transcriptional regulation of the p53 gene are almost entirely unknown. The DNA replication-related element (DRE)/DNA replication-related element-binding factor (DREF) transcriptional regulatory system is established as a master key to cell proliferation in Drosophila. DREF binds specifically to DRE sequences in the Drosophila p53 (dmp53) gene promoter as shown using anti-DREF antibodies in chromatin immunoprecipitation assays. Furthermore, a rough eye phenotype because of overexpression of DREF in Drosophila eye imaginal disks could be suppressed by half dose reduction of the dmp53 gene. In addition, the level of mRNA of dmp53 was decreased in DREF-knockdown cells and transient expression of the luciferase gene under control of the wild-type dmp53 gene promoter showed strong promoter activity in S2 cells, but this was almost completely abrogated with a DRE-mutated promoter. Requirement of DREs for dmp53 promoter activity was further confirmed by anti-beta-galactosidase antibody-staining of various tissues from transgenic flies carrying dmp53 promoter-lacZ fusion genes. These results indicate that DREF is necessary for dmp53 gene promoter activity. Oncogene (2010) 29, 2060-2069; doi: 10.1038/onc.2009.483; published online 18 January 2010	[Trong-Tue, N.; Thao, D. T. P.; Yamaguchi, M.] Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan; [Yamaguchi, M.] Kyoto Inst Technol, Sakyo Ku, Insect Biomed Res Ctr, Kyoto 6068585, Japan	Kyoto Institute of Technology; Kyoto Institute of Technology	Yamaguchi, M (corresponding author), Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.	myamaguc@kit.ac.jp	Dang, Thao/AFC-0112-2022	Yamaguchi, Masamitsu/0000-0002-6321-9750; Dang, Thao/0000-0002-5713-323X	KIT	KIT	We are grateful to Dr M Abrams for dmp53 mutant stock, Dr Dean P Smith for kindly providing the casper-nls-LacZ plasmid, Dr Fumiko Hirose for the anti-DREF monoclonal antibodies and Dr Malcolm Moore for comments on the English language in the paper. This study was partially supported by a scholarship and grants from the KIT.	Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Choi TY, 2000, FEBS LETT, V483, P71, DOI 10.1016/S0014-5793(00)02085-8; Galindo K, 2001, GENETICS, V159, P1059; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Hayashi Y, 2006, BBA-GENE STRUCT EXPR, V1759, P359, DOI 10.1016/j.bbaexp.2006.07.002; Hirose F, 1996, J BIOL CHEM, V271, P3930; Hirose F, 2001, MOL CELL BIOL, V21, P7231, DOI 10.1128/MCB.21.21.7231-7242.2001; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hirose F, 1999, MOL CELL BIOL, V19, P6020; Hyun JY, 2005, MOL CELL BIOL, V25, P5590, DOI 10.1128/MCB.25.13.5590-5598.2005; Ida H, 2007, EXP CELL RES, V313, P4208, DOI 10.1016/j.yexcr.2007.08.016; Ida H, 2009, NUCLEIC ACIDS RES, V37, P1423, DOI 10.1093/nar/gkn1068; Jasper H, 2002, DEV CELL, V3, P511, DOI 10.1016/S1534-5807(02)00297-6; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Kim YS, 2007, GENES CELLS, V12, P569, DOI 10.1111/j.1365-2443.2007.01075.x; Matsukage A, 2008, BBA-GENE REGUL MECH, V1779, P81, DOI 10.1016/j.bbagrm.2007.11.011; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nakamura K, 2008, NUCLEIC ACIDS RES, V36, P3905, DOI 10.1093/nar/gkn291; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; Ohshima N, 2003, J BIOL CHEM, V278, P22928, DOI 10.1074/jbc.M303109200; Okudaira K, 2005, BBA-GENE STRUCT EXPR, V1732, P23, DOI 10.1016/j.bbaexp.2005.10.009; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Rebollar E, 2006, FEBS LETT, V580, P642, DOI 10.1016/j.febslet.2005.12.083; ROBERTSON HM, 1988, GENETICS, V118, P461; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Seto H, 2006, GENES CELLS, V11, P499, DOI 10.1111/j.1365-2443.2006.00956.x; Sharpless NE, 2002, CANCER RES, V62, P2761; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Spradling A. C, 1986, DROSOPHILA PRACTICAL; Suyari O, 2009, EXP CELL RES, V315, P1403, DOI 10.1016/j.yexcr.2008.12.017; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Takahashi Y, 1999, NUCLEIC ACIDS RES, V27, P510, DOI 10.1093/nar/27.2.510; Thao DTP, 2006, EXP CELL RES, V312, P3641, DOI DOI 10.1016/J.YEXCR.2006.08.005; Tsuchiya A, 2007, FEBS J, V274, P1818, DOI 10.1111/j.1742-4658.2007.05730.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; Yamashita D, 2007, MOL CELL BIOL, V27, P2003, DOI 10.1128/MCB.01462-06; Yoshida H, 2004, GENES CELLS, V9, P935, DOI 10.1111/j.1365-2443.2004.00775.x; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	45	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2060	2069		10.1038/onc.2009.483	http://dx.doi.org/10.1038/onc.2009.483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101238				2022-12-28	WOS:000276402800005
J	Goldschneider, D; Mehlen, P				Goldschneider, D.; Mehlen, P.			Dependence receptors: a new paradigm in cell signaling and cancer therapy	ONCOGENE			English	Review						dependence receptors; apoptosis; caspase; tumor progression; cancer therapy	NERVE GROWTH-FACTOR; REPULSIVE GUIDANCE MOLECULE; P75 NEUROTROPHIN RECEPTOR; TUMOR-SUPPRESSOR GENE; FOREBRAIN CHOLINERGIC NEURONS; ANAPLASTIC LYMPHOMA KINASE; AMYLOID PRECURSOR PROTEIN; PRODUCT INDUCES APOPTOSIS; LIPID RAFT LOCALIZATION; AFFINITY NGF RECEPTOR	Dependence receptors (DRs) now form a family of more than a dozen membrane receptors that are not linked by their structure, but by common functional traits. The most notable is their ability to trigger two opposite signaling pathways: in the presence of ligand, these receptors activate classic signaling pathways implicated in cell survival, migration and differentiation. In the absence of ligand, they do not stay inactive, rather they elicit an apoptotic signal. Thus, cells expressing this kind of receptor are dependent on the presence of ligand in the extracellular environment to survive. This review will recapitulate the increasing data regarding the molecular mechanisms associated with DRs, their potential implication during development, as well as their deregulation during tumorigenesis and, finally, their emergence as new possible therapeutic targets for cancer treatment. Oncogene (2010) 29, 1865-1882; doi:10.1038/onc.2010.13; published online 22 February 2010	[Goldschneider, D.; Mehlen, P.] Univ Lyon, Ctr Leon Berard, Canc & Dev Lab, Equipe Labellisee La Ligue,CNRS,UMR5238, F-69008 Lyon, Rhone, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Leon Berard	Mehlen, P (corresponding author), Univ Lyon, Ctr Leon Berard, Canc & Dev Lab, Equipe Labellisee La Ligue,CNRS,UMR5238, 28 Rue Laennec, F-69008 Lyon, Rhone, France.	mehlen@lyon.fnclcc.fr						Allouche M, 2007, CELL CYCLE, V6, P1533, DOI 10.4161/cc.6.13.4433; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Bazigou E, 2007, CELL, V128, P961, DOI 10.1016/j.cell.2007.02.024; Bernet A, 2007, GASTROENTEROLOGY, V133, P1840, DOI 10.1053/j.gastro.2007.08.009; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Castets M, 2009, DEV CELL, V16, P614, DOI 10.1016/j.devcel.2009.02.006; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; Charrier JB, 1999, DEVELOPMENT, V126, P4771; Charrier JB, 2001, DEVELOPMENT, V128, P4011; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Clark Peter E, 2003, Methods Mol Med, V81, P255; Cohen LY, 2005, CELL DEATH DIFFER, V12, P243, DOI 10.1038/sj.cdd.4401568; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Delloye-Bourgeois C, 2009, J EXP MED, V206, P833, DOI 10.1084/jem.20082299; Delloye-Bourgeois C, 2009, JNCI-J NATL CANCER I, V101, P237, DOI 10.1093/jnci/djn491; Depaepe V, 2005, NATURE, V435, P1244, DOI 10.1038/nature03651; Desmond JC, 2007, LEUKEMIA, V21, P1026, DOI 10.1038/sj.leu.2404611; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Fitamant J, 2008, P NATL ACAD SCI USA, V105, P4850, DOI 10.1073/pnas.0709810105; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Foveau B, 2007, CELL DEATH DIFFER, V14, P752, DOI 10.1038/sj.cdd.4402080; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Frade JM, 1996, NATURE, V383, P166; Fujita Y, 2008, CELL DEATH DIFFER, V15, P1593, DOI 10.1038/cdd.2008.92; Furne C, 2006, P NATL ACAD SCI USA, V103, P4128, DOI 10.1073/pnas.0507864103; Furne C, 2008, P NATL ACAD SCI USA, V105, P14465, DOI 10.1073/pnas.0803645105; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; Geisbrecht BV, 2003, J BIOL CHEM, V278, P32561, DOI 10.1074/jbc.M302943200; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Grady WM, 2007, GASTROENTEROLOGY, V133, P2045, DOI 10.1053/j.gastro.2007.10.034; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kato H, 2000, BRIT J CANCER, V82, P459, DOI 10.1054/bjoc.1999.0943; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95; Koike C, 2002, ONCOGENE, V21, P2670, DOI 10.1038/sj.onc.1205370; Kong WJ, 2005, LARYNGOSCOPE, V115, P1395, DOI 10.1097/01.MLG.0000166708.23673.3A; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Lee DK, 2003, J STEROID BIOCHEM, V84, P41, DOI 10.1016/S0960-0760(03)00005-0; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lejmi E, 2008, P NATL ACAD SCI USA, V105, P12491, DOI 10.1073/pnas.0804008105; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Link BC, 2007, ANN SURG ONCOL, V14, P2591, DOI 10.1245/s10434-007-9469-6; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Lourenco FC, 2009, CELL DEATH DIFFER, V16, P655, DOI 10.1038/cdd.2008.191; Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080; Lykissas MG, 2007, CURR NEUROVASC RES, V4, P143, DOI 10.2174/156720207780637216; Maisse C, 2008, EXP CELL RES, V314, P2544, DOI 10.1016/j.yexcr.2008.06.001; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; Mehlen P, 2005, CELL MOL LIFE SCI, V62, P2599, DOI 10.1007/s00018-005-5191-3; Mehlen P, 2004, J CLIN ONCOL, V22, P3420, DOI 10.1200/JCO.2004.02.019; Mehlen P, 2004, CELL MOL LIFE SCI, V61, P1854, DOI 10.1007/s00018-004-3467-7; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mehlen P, 2003, BIOL CELL, V95, P425, DOI 10.1016/S0248-4900(03)00072-8; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Mille F, 2009, CELL DEATH DIFFER, V16, P1344, DOI 10.1038/cdd.2009.75; Mille F, 2009, NAT CELL BIOL, V11, P739, DOI 10.1038/ncb1880; Minichiello L, 1995, DEVELOPMENT, V121, P4067; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Nelson KA, 2002, AM J EPIDEMIOL, V155, P883, DOI 10.1093/aje/155.10.883; Nguyen TVV, 2008, J NEUROCHEM, V104, P1065, DOI 10.1111/j.1471-4159.2007.05031.x; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Paradisi A, 2008, GASTROENTEROLOGY, V135, P1248, DOI 10.1053/j.gastro.2008.06.080; Paradisi A, 2009, P NATL ACAD SCI USA, V106, P17146, DOI 10.1073/pnas.0901767106; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Peterziel H, 2007, J NEUROCHEM, V103, P2491, DOI 10.1111/j.1471-4159.2007.04962.x; Pflug B, 1998, MOL CARCINOGEN, V23, P106, DOI 10.1002/(SICI)1098-2744(199810)23:2<106::AID-MC7>3.0.CO;2-W; Puschel AW, 1999, MECH DEVELOP, V83, P65, DOI 10.1016/S0925-4773(99)00035-0; Qin ST, 2007, MOL CELL NEUROSCI, V34, P243, DOI 10.1016/j.mcn.2006.11.002; Rabizadeh S, 2000, J MOL NEUROSCI, V15, P215, DOI 10.1385/JMN:15:3:215; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Rajasekharan S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-239; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002; Rodrigues S, 2007, ONCOGENE, V26, P5615, DOI 10.1038/sj.onc.1210347; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Saito M, 1999, ONCOLOGY-BASEL, V56, P134, DOI 10.1159/000011954; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SANTISTEBAN DA, 1994, J CHILD ADOLES SUBST, V3, P9, DOI 10.1300/J029v03n02_02; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; Shin SK, 2007, GASTROENTEROLOGY, V133, P1849, DOI 10.1053/j.gastro.2007.08.074; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Sieber OM, 2000, MOL MED TODAY, V6, P462; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Stupack D.G., 2002, SCI STKE, P7; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2005, CELL DEATH DIFFER, V12, P1021, DOI 10.1038/sj.cdd.4401658; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun XF, 1999, J CLIN ONCOL, V17, P1745, DOI 10.1200/JCO.1999.17.6.1745; Tang XL, 2008, NAT CELL BIOL, V10, P698, DOI 10.1038/ncb1732; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Velcich A, 1999, ONCOGENE, V18, P2599, DOI 10.1038/sj.onc.1202610; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152; Wang JJL, 2000, J NEUROSCI RES, V60, P587, DOI 10.1002/(SICI)1097-4547(20000601)60:5<587::AID-JNR3>3.0.CO;2-1; Wang R, 2009, MOL CELL, V33, P692, DOI 10.1016/j.molcel.2009.02.016; Wicking C, 2001, CANCER LETT, V173, P1, DOI 10.1016/S0304-3835(01)00676-0; Williams ME, 2003, J BIOL CHEM, V278, P17483, DOI 10.1074/jbc.M300415200; Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Yeo TT, 1997, J NEUROSCI, V17, P7594	177	124	131	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1865	1882		10.1038/onc.2010.13	http://dx.doi.org/10.1038/onc.2010.13			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20173780				2022-12-28	WOS:000276199600001
J	Yamasaki, N; Miyazaki, K; Nagamachi, A; Koller, R; Oda, H; Miyazaki, M; Sasaki, T; Honda, Z; Wolff, L; Inaba, T; Honda, H				Yamasaki, N.; Miyazaki, K.; Nagamachi, A.; Koller, R.; Oda, H.; Miyazaki, M.; Sasaki, T.; Honda, Z-i; Wolff, L.; Inaba, T.; Honda, H.			Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia	ONCOGENE			English	Article						E2A-HLF; inducible knock-in mice; retrovirus insertional mutagenesis; Zfp521/ZNF521	RETROVIRAL INSERTIONAL MUTAGENESIS; DOWNSTREAM TARGET; CELL DEVELOPMENT; BLAST CRISIS; E2A GENE; EXPRESSION; TRANSFORMATION; MYC; DIFFERENTIATION; LYMPHOMAGENESIS	E2A-hepatic leukemia factor (HLF) is a chimeric protein found B-lineage acute lymphoblastic leukemia (ALL) with t(17;19). To analyze the leukemogenic process and to create model mice for t(17;19)-positive leukemia, we generated inducible knock-in (iKI) mice for E2A-HLF. Despite the induced expression of E2A-HLF in the hematopoietic tissues, no disease was developed during the long observation period, indicating that additional gene alterations are required to develop leukemia. To elucidate this process, E2A-HLF iKI and control littermates were subjected to retroviral insertional mutagenesis. Virus infection induced acute leukemias in E2A-HLF iKI mice with higher morbidity and mortality than in control mice. Inverse PCR detected three common integration sites specific for E2A-HLF iKI leukemic mice, which induced overexpression of zinc-finger transcription factors: growth factor independent 1 (Gfi1), zinc-finger protein subfamily 1A1 isoform a (Zfp1a1, also known as Ikaros) and zinc-finger protein 521 (Zfp521). Interestingly, tumors with Zfp521 integration exclusively showed B-lineage ALL, which corresponds to the phenotype of human t(17;19)-positive leukemia. In addition, ZNF521 (human counterpart of Zfp521) was found to be over-expressed in human leukemic cell lines harboring t(17;19). Moreover, both iKI for E2A-HLF and transgenic for Zfp521 mice frequently developed B-lineage ALL. These results indicate that a set of transcription factors promote leukemic transformation of E2A-HLF-expressing hematopoietic progenitors and suggest that aberrant expression of Zfp521/ZNF521 may be clinically relevant to t(17;19)positive B-lineage ALL. Oncogene (2010) 29, 1963-1975; doi:10.1038/onc.2009.475; published online 11 January 2010	[Yamasaki, N.; Miyazaki, K.; Sasaki, T.; Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol, Minami Ku, Hiroshima 7348553, Japan; [Nagamachi, A.; Inaba, T.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Minami Ku, Hiroshima 7348553, Japan; [Koller, R.; Wolff, L.] NCI, Leukemogenosis Sect, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, Tokyo, Japan; [Miyazaki, M.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Immunol, Minami Ku, Hiroshima 7348553, Japan; [Honda, Z-i] Univ Tokyo, Grad Sch Med, Fac Med, Dept Allergy & Rheumatol,Bunkyo Ku, Tokyo, Japan	Hiroshima University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tokyo Women's Medical University; Hiroshima University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp			Ministry of Education, Science and Culture of Japan; Ministry of Health, Labour and Welfare of Japan [13-2]; Takeda Science Foundation; Astellas Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); Astellas Foundation(Astellas Pharmaceuticals)	We thank Yuki Sakai, Kayoko Hashimoto, Yuko Tsukawaki and Rika Tai, for the care of the mice and technical assistance, Dr Nobuaki Yoshida for E14 ES cells, Dr Soren Warming, Dr Neal G Copeland and Dr Nancy A Jenkins for mouse Zfp521 cDNA, Dr Koichi Ikuta for mouse TCRJb probe, Dr Hirotaka Matsui for statistical analysis and Dr Takuro Nakamura for helpful discussion. This work was in part supported by a grant-in-aid from the Ministry of Education, Science and Culture of Japan, a grant-in-aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (13-2), Takeda Science Foundation, Astellas Foundation for Research on Metabolic Disorders, the Japan Leukaemia Research Fund and Tsuchiya Foundation.	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Aspland SE, 2001, ONCOGENE, V20, P5708, DOI 10.1038/sj.onc.1204592; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Bond HM, 2008, INT J BIOCHEM CELL B, V40, P848, DOI 10.1016/j.biocel.2007.04.006; Dang JJ, 2001, MOL CELL BIOL, V21, P5935, DOI 10.1128/MCB.21.17.5935-5945.2001; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Hentges KE, 2005, ONCOGENE, V24, P1220, DOI 10.1038/sj.onc.1208243; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Honda H, 1999, BLOOD, V93, P2780; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inukai T, 1997, MOL CELL BIOL, V17, P1417, DOI 10.1128/MCB.17.3.1417; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Matsunaga T, 2004, BLOOD, V103, P3185, DOI 10.1182/blood-2003-09-3022; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Miyazaki K, 2009, BLOOD, V113, P4702, DOI 10.1182/blood-2007-05-088724; Mizuno T, 2008, ONCOGENE, V27, P3465, DOI 10.1038/sj.onc.1211007; Nakamura T, 2005, CANCER SCI, V96, P7, DOI 10.1111/j.1349-7006.2005.00011.x; Nakayama H, 1999, CANCER RES, V59, P3931; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Seidel MG, 2001, ONCOGENE, V20, P5718, DOI 10.1038/sj.onc.1204591; SHINTO Y, 1995, ONCOGENE, V11, P1729; Smith KS, 2002, MOL CELL BIOL, V22, P7678, DOI 10.1128/MCB.22.21.7678-7688.2002; Smith KS, 1999, MOL CELL BIOL, V19, P4443; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zornig M, 1996, ONCOGENE, V12, P1789	43	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1963	1975		10.1038/onc.2009.475	http://dx.doi.org/10.1038/onc.2009.475			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062079				2022-12-28	WOS:000276199600009
J	Zhu, S; Sachdeva, M; Wu, F; Lu, Z; Mo, YY				Zhu, S.; Sachdeva, M.; Wu, F.; Lu, Z.; Mo, Y-Y			Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner	ONCOGENE			English	Article						cell invasion; metastasis; miRNA; miR-224; CXCR4; Ubc9	CANCER-CELLS; REPRESSORS ZEB1; RT-PCR; SUMO; MICRORNAS; PROTEIN; ALPHA; EXPRESSION; INDUCTION; RECEPTOR	Ubc9 is an E2-conjugating enzyme that transfers the activated small ubiquitin-like modifier (SUMO) to protein substrates, and thus it has an important function in sumoylation-mediated cellular pathways. We have earlier reported that Ubc9 promotes tumor growth in the xenograft mouse model using breast cancer cell line MCF-7 in part through regulation of Bcl-2 expression. In this study, we show that ectopic expression of wild-type Ubc9 (Ubc9-WT) promotes cell invasion and metastasis. Surprisingly, the dominant negative mutant Ubc9 (Ubc9-DN) also causes the same phenotype, indicating that the ability of Ubc9 to promote invasion and metastasis is distinct from its ability to conjugate SUMO to protein substrates. Of considerable interest, several microRNAs such as miR-224 are regulated by Ubc9. Although ectopic expression of Ubc9 causes downregulation of miR-224, suppression of Ubc9 by Ubc9-siRNAs leads to its upregulation. We further show that miR-224 can inhibit cell invasion and directly targets CDC42 and CXCR4, and that suppression of CDC42 and CXCR4 by RNAi causes inhibition of Ubc9-mediated invasion. Together, these results show a molecular link between Ubc9 and the metastasis genes such as CDC42 and CXCR4, and thus provide new insight into the mechanism by which Ubc9 promotes tumor invasion and metastasis. Oncogene (2010) 29, 1763-1772; doi:10.1038/onc.2009.459; published online 21 December 2009	[Zhu, S.; Sachdeva, M.; Wu, F.; Lu, Z.; Mo, Y-Y] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 825 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/B-6141-2011; zhu, shoumin/F-4564-2011; Mo, Yin-Yuan/R-8255-2019		NCI [CA102630]; Illinois Department of Public Health; NATIONAL CANCER INSTITUTE [R01CA102630] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Illinois Department of Public Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Joan Massague for providing LM2-4142 cells. This study is supported by grants CA102630 from NCI and postdoctoral fellowship award from Illinois Department of Public Health.	Baek SH, 2006, CELL CYCLE, V5, P1492, DOI 10.4161/cc.5.14.3008; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Guo YG, 2008, BIOCHEM BIOPH RES CO, V374, P570, DOI 10.1016/j.bbrc.2008.07.064; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Kim JH, 2006, NAT CELL BIOL, V8, P631, DOI 10.1038/ncb1415; Kobayashi S, 2004, ENDOCR RES, V30, P617, DOI 10.1081/ERC-200043789; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; Lao KQ, 2006, BIOCHEM BIOPH RES CO, V343, P85, DOI 10.1016/j.bbrc.2006.02.106; Liu LB, 2007, DIABETES, V56, P1977, DOI 10.2337/db06-1100; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu ZH, 2006, EXP CELL RES, V312, P1865, DOI 10.1016/j.yexcr.2006.02.017; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 2005, EXPERT OPIN THER TAR, V9, P1203, DOI 10.1517/14728222.9.6.1203; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Singh SK, 2008, NATURE, V453, P223, DOI 10.1038/nature06863; Tomoiu A, 2006, J VIROL, V80, P10218, DOI 10.1128/JVI.00375-06; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wilke K, 1997, GENOMICS, V45, P1, DOI 10.1006/geno.1997.4885; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	41	94	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1763	1772		10.1038/onc.2009.459	http://dx.doi.org/10.1038/onc.2009.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023705	Green Accepted			2022-12-28	WOS:000276022800006
J	Chen, KF; Liu, CY; Lin, YC; Yu, HC; Liu, TH; Hou, DR; Chen, PJ; Cheng, AL				Chen, K-F; Liu, C-Y; Lin, Y-C; Yu, H-C; Liu, T-H; Hou, D-R; Chen, P-J; Cheng, A-L			CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells	ONCOGENE			English	Article						HCC; CIP2A; bortezomib; proteasome inhibitor; PP2A; apoptosis	PROTEASOME INHIBITORS; CANCER; PP2A; PHOSPHATASES; MECHANISMS; SORAFENIB; MYC	Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein phosphatase 2A (PP2A), mediates the apoptotic effect of bortezomib in HCC. Silencing PP2A by small interference RNA (siRNA) abolishes bortezomib-induced down-regulation of phospho-Akt and apoptosis. Bortezomib increases PP2A activity in sensitive HCC cells, including Sk-Hep1, Hep3B and Huh-7, but not in resistant PLC5 cells. Bortezomib down-regulates CIP2A in a dose-and time-dependent manner in all sensitive HCC cells, whereas no alterations in CIP2A were found in resistant PLC5 cells. Knockdown of CIP2A by siRNA restored bortezomib's effects on apoptosis and PP2A activity in PLC5 cells. Moreover, over-expression of CIP2A up-regulated phospho-Akt and protected Sk-Hep1 cells from bortezomib-induced apoptosis. It is significant that, ectopic expression of CIP2A decreased Akt-related PP2A activity, whereas silencing CIP2A increased this activity, indicating that CIP2A negatively regulates Akt-related PP2A activity in HCC cells, furthermore, our in vivo data showed that bortezomib down-regulates CIP2A and up-regulates PP2A activity in Huh-7 tumors, but not in PLC5 tumors. In conclusion, inhibition of CIP2A determines the effects of bortezomib on apoptosis and PP2A-dependent Akt inactivation in HCC. Oncogene (2010) 29, 6257-6266; doi:10.1038/onc.2010.357; published online 23 August 2010	[Cheng, A-L] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; [Cheng, A-L] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan; [Chen, K-F; Yu, H-C; Liu, T-H; Chen, P-J] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 10016, Taiwan; [Chen, K-F; Yu, H-C; Liu, T-H; Chen, P-J] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan; [Chen, K-F; Yu, H-C; Liu, T-H; Chen, P-J; Cheng, A-L] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei 10016, Taiwan; [Liu, C-Y] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Liu, C-Y] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Lin, Y-C] Far Eastern Mem Hosp, Dept Internal Med, Taipei, Taiwan; [Hou, D-R] Natl Cent Univ, Dept Chem, Tao Yuan, Taiwan; [Cheng, A-L] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; [Cheng, A-L] Natl Taiwan Univ, Coll Med, Dept Oncol, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Far Eastern Memorial Hospital; National Central University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	alcheng@ntu.edu.tw	Liu, Tsung-Hao/D-3357-2016	Liu, Tsung-Hao/0000-0002-8891-4426; Chen, Kuen-Feng/0000-0002-4686-7019; Cheng, Ann-Lii/0000-0002-9152-6512; Chen, Pei-Jer/0000-0001-8316-3785; HOU, Duen-Ren/0000-0003-1072-2915	National Taiwan University Hospital [NTUH98P03, NTUH98FTN21]; National Science Council, Taiwan [NSC97-2314-B-002-182, NSC98-2314-B-002-067-MY3, NSC98-3112-B-002-037]	National Taiwan University Hospital(National Taiwan University); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	Supported by NTUH98P03, NTUH98FTN21 from National Taiwan University Hospital and NSC97-2314-B-002-182, NSC98-2314-B-002-067-MY3, NSC98-3112-B-002-037 from the National Science Council, Taiwan.	Bielinski VA, 2007, EXP CELL RES, V313, P3117, DOI 10.1016/j.yexcr.2007.05.008; Chen KF, 2008, CANCER RES, V68, P6698, DOI 10.1158/0008-5472.CAN-08-0257; Chen KF, 2010, J HEPATOL, V52, P88, DOI 10.1016/j.jhep.2009.10.011; Chen KF, 2009, J BIOL CHEM, V284, P11121, DOI 10.1074/jbc.M806268200; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Davis NB, 2004, J CLIN ONCOL, V22, P115, DOI 10.1200/JCO.2004.07.165; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; McConkey DJ, 2008, DRUG RESIST UPDATE, V11, P164, DOI 10.1016/j.drup.2008.08.002; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Richardson P, 2008, ASH ANN M, V112, P870; Verslype C, 2009, ANN ONCOL, V20, P1, DOI 10.1093/annonc/mdp281; Voorhees PM, 2006, ANNU REV PHARMACOL, V46, P189, DOI 10.1146/annurev.pharmtox.46.120604.141300; Yu CR, 2006, MOL CANCER THER, V5, P2378, DOI 10.1158/1535-7163.MCT-06-0235	24	133	143	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6257	6266		10.1038/onc.2010.357	http://dx.doi.org/10.1038/onc.2010.357			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729919				2022-12-28	WOS:000284601700007
J	Olsen, BB; Issinger, OG; Guerra, B				Olsen, B. B.; Issinger, O-G; Guerra, B.			Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells	ONCOGENE			English	Article						DNA-PK; CK2; autophosphorylation; DNA repair; glioblastoma cells	DOUBLE-STRAND BREAKS; CATALYTIC SUBUNIT; IN-VIVO; IONIZING-RADIATION; CYCLE ARREST; AUTOPHOSPHORYLATION; REPAIR; DAMAGE; PHOSPHORYLATION; APOPTOSIS	The DNA-dependent protein kinase (DNA-PK) is a nuclear serine/threonine protein kinase composed of a large catalytic subunit (DNA-PKcs) and a heterodimeric DNA-targeting subunit Ku. DNA-PK is a major component of the nonhomologous end-joining pathway of DNA double-strand breaks repair. Although DNA-PK has been biochemically characterized in vitro, relatively little is known about its functions in the context of DNA repair and how its kinase activity is precisely regulated in vivo. Here, we report that cellular depletion of the individual catalytic subunits of protein kinase CK2 by RNA interference leads to significant cell death in M059K human glioblastoma cells expressing DNA-PKcs, but not in their isogenic counterpart, that is M059J cells, devoid of DNA-PKcs. The lack of CK2 results in enhanced DNA-PKcs activity and strongly inhibits DNA damage-induced autophosphorylation of DNA-PKcs at S2056 as well as repair of DNA double-strand breaks. By the application of the in situ proximity ligation assay, we show that CK2 interacts with DNA-PKcs in normal growing cells and that the association increases upon DNA damage. These results indicate that CK2 has an important role in the modulation of DNA-PKcs activity and its phosphorylation status providing important insights into the mechanisms by which DNA-PKcs is regulated in vivo. Oncogene (2010) 29, 6016-6026; doi:10.1038/onc.2010.337; published online 16 August 2010	[Olsen, B. B.; Issinger, O-G; Guerra, B.] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Fyn, Denmark	University of Southern Denmark	Guerra, B (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Fyn, Denmark.	bag@bmb.sdu.dk	Olsen, Birgitte B/U-2382-2017	Olsen, Birgitte B/0000-0002-6130-0387; Guerra, Barbara/0000-0003-1136-2413	Danish Cancer Society [DP08152, DP06083, DP07109]; Danish Natural Science Research Council [272-07-0258]	Danish Cancer Society(Danish Cancer Society); Danish Natural Science Research Council(Danish Natural Science Research Council)	This study was supported by grants from the Danish Cancer Society (DP08152) and the Danish Natural Science Research Council (272-07-0258) to BG. BBO and OGI were supported by grants from the Danish Cancer Society (DP06083, DP07109).	Achari Y, 2000, METH MOL B, V99, P85; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Bibby AC, 2005, INT J BIOL SCI, V1, P67; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Douglas P, 2007, MOL CELL BIOL, V27, P1581, DOI 10.1128/MCB.01962-06; Guerra B, 2008, CURR MED CHEM, V15, P1870, DOI 10.2174/092986708785132933; Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Kuo LJ, 2008, IN VIVO, V22, P305; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Matsumoto Y, 1997, BIOCHEM BIOPH RES CO, V234, P568, DOI 10.1006/bbrc.1997.6689; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Niefind K, 2000, ACTA CRYSTALLOGR D, V56, P1680, DOI 10.1107/S0907444900013627; Olsen BB, 2008, MOL CELL BIOCHEM, V316, P115, DOI 10.1007/s11010-008-9817-2; Olsen BB, 2008, MOL CELL BIOCHEM, V316, P37, DOI 10.1007/s11010-008-9824-3; Olsen BB, 2006, PROTEIN EXPRES PURIF, V47, P651, DOI 10.1016/j.pep.2005.12.001; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Sandholt IS, 2009, ANTI-CANCER DRUG, V20, P238, DOI 10.1097/CAD.0b013e328326472e; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; St-Denis NA, 2009, CELL MOL LIFE SCI, V66, P1817, DOI 10.1007/s00018-009-9150-2; Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y; Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Weterings E, 2007, J CELL BIOL, V179, P183, DOI 10.1083/jcb.200705106; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378; Yde CW, 2007, MOL CANCER THER, V6, P1869, DOI 10.1158/1535-7163.MCT-07-0072; Zhan YH, 2009, BIOCHEM BIOPH RES CO, V378, P273, DOI 10.1016/j.bbrc.2008.11.038	39	35	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6016	6026		10.1038/onc.2010.337	http://dx.doi.org/10.1038/onc.2010.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20711232				2022-12-28	WOS:000284108700004
J	Olivares-Illana, V; Fahraeus, R				Olivares-Illana, V.; Fahraeus, R.			p53 isoforms gain functions	ONCOGENE			English	Review						p53; endoplasmic reticulum stress; senescence; alternative gene expression	ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA TRANSLATION; UNFOLDED PROTEIN RESPONSE; RIBOSOME ENTRY SITE; ONCOGENE-INDUCED SENESCENCE; TUMOR-SUPPRESSOR; ER STRESS; CELLULAR SENESCENCE; DNA-DAMAGE; MDM2	Many different cell stress pathways converge on p53 to induce a number of distinct cell biological responses such as G1 or G2 arrest, senescence or apoptosis. One of the outstanding questions with regard to p53 is how the cells can differentiate between different stresses so that p53 activation leads to the correct response. It has been known for some time that the p53 gene expresses isoforms that carry unique domains and properties, and more recent works have started to reveal some of their functions. The alternative mRNA translation product p53/47, which lacks the first 40 codons, including the first of p53's two trans-activation domains, is being linked to endoplasmic reticulum stress and the unfolded protein response to which it causes a specific G2 arrest. On the other hand, p53 itself induces G1 arrest and has no effect on the G2. The two isoforms Delta 133p53, which lacks the first 133 amino acids, and p53 beta, which carries an alternative C-terminus, are derived from alternative promoter usage or splicing, respectively, and are together implied in controlling cellular senescence. Hence, through different mechanisms of gene expression control, alternative levels of p53 isoforms help the cell to differentiate between p53 activation and the response to diverse stresses. This holds promise to a better understanding of how upstream and downstream p53 pathways have evolved relative to specific p53 domains. Oncogene (2010) 29, 5113-5119; doi:10.1038/onc.2010.266; published online 12 July 2010	[Olivares-Illana, V.; Fahraeus, R.] Univ Paris 07, Inst Genet Mol, INSERM Cibles Therapeut, Hop St Louis, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fahraeus, R (corresponding author), Univ Paris 07, Inst Genet Mol, INSERM Cibles Therapeut, Hop St Louis, 27 Rue Juliette Dodu, F-75010 Paris, France.	robin.fahraeus@inserm.fr	Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Olivares-Illana, Vanesa/0000-0001-6949-5986	La Ligue Contre le Cancer; French National Cancer Institute (INCa)	La Ligue Contre le Cancer(Ligue nationale contre le cancer); French National Cancer Institute (INCa)(Institut National du Cancer (INCA) France)	We apologize to those whose works have not been cited in this article owing to lack of space. This article is supported by the La Ligue Contre le Cancer and the French National Cancer Institute (INCa).	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lane DP, 2010, CELL CYCLE, V9, P748, DOI 10.4161/cc.9.4.10616; Ledoux S, 2003, CANCER RES, V63, P7284; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Moll UM, 2004, MOL CANCER RES, V2, P371; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Sivan G, 2008, CELL CYCLE, V7, P741, DOI 10.4161/cc.7.6.5596; Urano F, 2000, J CELL SCI, V113, P3697; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	56	39	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5113	5119		10.1038/onc.2010.266	http://dx.doi.org/10.1038/onc.2010.266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622898				2022-12-28	WOS:000281867200001
J	Wheeler, SE; Suzuki, S; Thomas, SM; Sen, M; Leeman-Neill, RJ; Chiosea, SI; Kuan, CT; Bigner, DD; Gooding, WE; Lai, SY; Grandis, JR				Wheeler, S. E.; Suzuki, S.; Thomas, S. M.; Sen, M.; Leeman-Neill, R. J.; Chiosea, S. I.; Kuan, C-T; Bigner, D. D.; Gooding, W. E.; Lai, S. Y.; Grandis, J. R.			Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation	ONCOGENE			English	Article						head and neck cancer; epidermal growth factor receptor; EGFRvIII; STAT3; cancer cell invasion	CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCERS; MOUSE FIBROBLASTS; EXPRESSION; EGFR; CARCINOMA; TRANSCRIPTION-3; RESISTANCE; PROMOTES; KINASE	Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth. EGFR variant III (EGFRvIII) is the most commonly altered form of EGFR and contains a truncated ligand-binding domain. We previously reported that EGFRvIII is expressed in up to 40% of HNSCC tumors where it is associated with increased proliferation, tumor growth and chemoresistance to antitumor drugs including the EGFR-targeting monoclonal antibody cetuximab. Cetuximab was FDA-approved in 2006 for HNSCC but has not been shown to prevent invasion or metastasis. This study was undertaken to evaluate the mechanisms of EGFRvIII-mediated cell motility and invasion in HNSCC. We found that EGFRvIII induced HNSCC cell migration and invasion in conjunction with increased signal transducer and activator of transcription 3 (STAT3) activation, which was not abrogated by cetuximab treatment. Further investigation showed that EGF-induced expression of the STAT3 target gene HIF1-alpha, was abolished by cetuximab in HNSCC cells expressing wild-type EGFR under hypoxic conditions, but not in EGFRvIII-expressing HNSCC cells. These results suggest that EGFRvIII mediates HNSCC cell migration and invasion by increased STAT3 activation and induction of HIF1-alpha, which contribute to cetuximab resistance in EGFRvIII-expressing HNSCC tumors. Oncogene (2010) 29, 5135-5145; doi:10.1038/onc.2009.279; published online 12 July 2010	[Wheeler, S. E.; Suzuki, S.; Thomas, S. M.; Sen, M.; Lai, S. Y.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA; [Wheeler, S. E.; Suzuki, S.; Thomas, S. M.; Sen, M.; Leeman-Neill, R. J.; Chiosea, S. I.; Gooding, W. E.; Lai, S. Y.; Grandis, J. R.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Leeman-Neill, R. J.; Chiosea, S. I.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Kuan, C-T; Bigner, D. D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Gooding, W. E.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Univ Pittsburgh, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu	Thomas, Sufi Mary/AFR-1642-2022; Thomas, Sufi/O-1487-2018	Thomas, Sufi Mary/0000-0001-5370-0842; Thomas, Sufi/0000-0001-5370-0842; Chiosea, Simion/0000-0002-5766-8779; Lai, Stephen/0000-0001-8301-7286; Wheeler, Sarah/0000-0002-7851-9836	American Cancer Society [CRP-08-229-01]; NIH [EY08098];  [RO1 CA77308];  [RO1 CA101840];  [P50 CA097190]; NATIONAL CANCER INSTITUTE [R01CA077308, R01CA101840, R37CA011898, P50CA097190] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by Grants RO1 CA77308, RO1 CA101840 and P50 CA097190, and an American Cancer Society Clinical Research professorship CRP-08-229-01 (to JRG) and the NIH core Grant EY08098.	Andersen P, 2008, INT J CANCER, V122, P342, DOI 10.1002/ijc.23109; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Besser D, 1999, MOL CELL BIOL, V19, P1401; BIGNER SH, 1990, CANCER RES, V50, P8017; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; DIEDRICH U, 1995, J NEUROL, V242, P683, DOI 10.1007/BF00866920; GARCIA DP, 1993, CANCER RES, V53, P3217; Germain D, 2007, CLIN CANCER RES, V13, P5665, DOI 10.1158/1078-0432.CCR-06-2491; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, J CELL BIOCHEM, P188; Huang M, 2002, ONCOGENE, V21, P8804, DOI 10.1038/sj.onc.1206028; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; Lal A, 2002, CANCER RES, V62, P3335; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Li DN, 2007, J CLIN INVEST, V117, P346, DOI 10.1172/JCI30446; Masuda M, 2002, CANCER RES, V62, P3351; Mizoguchi M, 2006, J NEUROPATH EXP NEUR, V65, P1181, DOI 10.1097/01.jnen.0000248549.14962.b2; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Qiu ZJ, 2007, CANCER SCI, V98, P1099, DOI 10.1111/j.1349-7006.2007.00485.x; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sen M, 2009, CANCER CHEMOTH PHARM, V63, P983, DOI 10.1007/s00280-008-0823-6; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Sriuranpong V, 2003, CANCER RES, V63, P2948; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CY, 2000, J PHARMACOL EXP THER, V293, P453; Thomas SM, 2003, CANCER RES, V63, P5629; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Weppler SA, 2007, RADIOTHER ONCOL, V83, P333, DOI 10.1016/j.radonc.2007.04.025; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504	49	81	90	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	37					5135	5145		10.1038/onc.2009.279	http://dx.doi.org/10.1038/onc.2009.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622897	Green Submitted, Green Accepted			2022-12-28	WOS:000281867200003
J	Suraneni, MV; Schneider-Broussard, R; Moore, JR; Davis, TC; Maldonado, CJ; Li, H; Newman, RA; Kusewitt, D; Hu, J; Yang, P; Tang, DG				Suraneni, M. V.; Schneider-Broussard, R.; Moore, J. R.; Davis, T. C.; Maldonado, C. J.; Li, H.; Newman, R. A.; Kusewitt, D.; Hu, J.; Yang, P.; Tang, D. G.			Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence	ONCOGENE			English	Article						15-lipoxygenase 2; prostate; hyperplasia; senescence; tumor suppression; stem cells	FUNCTIONAL TUMOR-SUPPRESSOR; ACTIVATED RECEPTOR-GAMMA; HUMAN BREAST-CANCER; INTRAEPITHELIAL NEOPLASIA; STEM-CELL; ELEVATED EXPRESSION; EPITHELIAL-CELLS; PROGENITOR CELLS; GENE-EXPRESSION; IN-VITRO	15-Lipoxygenase 2 (15-LOX2), a lipid-peroxidizing enzyme, is mainly expressed in the luminal compartment of the normal human prostate, and is often decreased or lost in prostate cancer. Previous studies from our lab implicate 15-LOX2 as a functional tumor suppressor. To better understand the biological role of 15-LOX2 in vivo, we generated prostate-specific 15-LOX2 transgenic mice using the ARR2PB promoter. Unexpectedly, transgenic expression of 15-LOX2 or 15-LOX2sv-b, a splice variant that lacks arachidonic acid-metabolizing activity, resulted in age-dependent prostatic hyperplasia and enlargement of the prostate. Prostatic hyperplasia induced by both 15-LOX2 and 15-LOX2sv-b was associated with an increase in luminal and Ki-67(+) cells; however, 15-LOX2-transgenic prostates also showed a prominent increase in basal cells. Microarray analysis revealed distinct gene expression profiles that could help explain the prostate phenotypes. Strikingly, 15-LOX2, but not 15-LOX2sv-b, transgenic prostate showed upregulation of several well-known stem or progenitor cell molecules including Sca-1, Trop2, p63, Nkx3.1 and Psca. Prostatic hyperplasia caused by both 15-LOX2 and 15-LOX2sv-b did not progress to prostatic intraprostate neoplasia or carcinoma and, mechanistically, prostate lobes (especially those of 15-LOX2 mice) showed a dramatic increase in senescent cells as revealed by increased SA-beta gal, p27(Kip1) and heterochromatin protein 1 gamma staining. Collectively, our results suggest that 15-LOX2 expression in mouse prostate leads to hyperplasia and also induces cell senescence, which may, in turn, function as a barrier to tumor development. Oncogene (2010) 29, 4261-4275; doi: 10.1038/onc.2010.197; published online 31 May 2010	[Suraneni, M. V.; Schneider-Broussard, R.; Moore, J. R.; Davis, T. C.; Maldonado, C. J.; Li, H.; Kusewitt, D.; Tang, D. G.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; [Newman, R. A.; Yang, P.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hu, J.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Tang, D. G.] Univ Texas Grad Sch Biomed Sci, Program Mol Carcinogenesis, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd,1C, Smithville, TX 78957 USA.	dtang@mdanderson.org	Kusewitt, Donna F/E-8107-2011; Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174	NIH [R01-AG023374, R01-ES015888, R21-ES015893-01A1]; American Cancer Society [RSG MGO-105961]; Department of Defense [W81XWH-07-1-0616, W81XWH-08-1-0472]; Elsa Pardee Foundation; Center Grants [CCSG-5 P30 CA016672, ES07784]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES015893, P30ES007784, R01ES015888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Department of Defense(United States Department of Defense); Elsa Pardee Foundation; Center Grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr R Matusik (Vanderbilt University) for providing the ARR2PB promoter, D Holowell for transgenic studies, Dr H Thames and K Lin for assistance in statistics, the Histology Core for help in IHC, Animal Facility Core for animal-related experiments, Molecular Biology Core, especially J Repass, for assistance in qPCR analysis, C Perez for assistance in LCM, S Gaddis, L Shen and S Tsavachidis for assistance in microarray analysis, Drs S Fischer and C Jeter for critically reading the paper and other members of the Tang lab for support and helpful discussions. This work was supported in part by grants from NIH (R01-AG023374, R01-ES015888 and R21-ES015893-01A1), American Cancer Society (RSG MGO-105961), Department of Defense (W81XWH-07-1-0616 and W81XWH-08-1-0472) and Elsa Pardee Foundation (DGT) and by two Center Grants (CCSG-5 P30 CA016672 and ES07784).	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Allred DC, 1998, MODERN PATHOL, V11, P155; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Bhatia B, 2008, J BIOL CHEM, V283, P27957, DOI 10.1074/jbc.M803467200; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Chano T, 2002, ONCOGENE, V21, P1295, DOI 10.1038/sj.onc.1205178; Chen GG, 2003, INT J CANCER, V107, P837, DOI 10.1002/ijc.11447; Chen X, 2009, DIFFERENTIATION, V77, P324, DOI 10.1016/j.diff.2008.10.011; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Dillner K, 2003, ENDOCRINOLOGY, V144, P4955, DOI 10.1210/en.2003-0415; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fang H, 2009, METHODS MOL BIOL, V563, P379, DOI 10.1007/978-1-60761-175-2_20; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Gonzalez AL, 2004, HUM PATHOL, V35, P840, DOI 10.1016/j.humpath.2004.04.001; Ibaragi S, 2009, MOL CANCER RES, V7, P415, DOI 10.1158/1541-7786.MCR-08-0137; Ikebuchi K, 2009, INT J CANCER, V125, P861, DOI 10.1002/ijc.24466; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kasper S, 1998, LAB INVEST, V78, pI; Katona TM, 2005, CLIN CANCER RES, V11, P8358, DOI 10.1158/1078-0432.CCR-05-0962; Kelavkar UP, 2006, NEOPLASIA, V8, P510, DOI 10.1593/neo.06202; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kim E, 2005, ONCOGENE, V24, P1174, DOI 10.1038/sj.onc.1208269; Kindblom J, 2003, ENDOCRINOLOGY, V144, P2269, DOI 10.1210/en.2002-0187; Lawson DA, 2007, J CLIN INVEST, V117, P2044, DOI 10.1172/JCI32810; Mahipal SVK, 2007, BIOCHEM PHARMACOL, V74, P202, DOI 10.1016/j.bcp.2007.04.005; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Masumori N, 2001, CANCER RES, V61, P2239; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Schweiger D, 2007, J LIPID RES, V48, P553, DOI 10.1194/jlr.M600311-JLR200; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shappell SB, 2003, CANCER RES, V63, P2256; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Spindler SA, 1997, BIOCHEM BIOPH RES CO, V239, P775, DOI 10.1006/bbrc.1997.7471; Subbarayan V, 2006, ONCOGENE, V25, P6015, DOI 10.1038/sj.onc.1209617; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Tang DG, 2007, PROSTAG OTH LIPID M, V82, P135, DOI 10.1016/j.prostaglandins.2006.05.022; Tang DG, 2007, MOL CARCINOGEN, V46, P1, DOI 10.1002/mc.20255; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Tang Y, 2009, INT J CANCER, V124, P1545, DOI 10.1002/ijc.24118; Tran CP, 2002, MOL CANCER RES, V1, P113; Wang D, 2006, TUMOR BIOL, V27, P261, DOI 10.1159/000094761; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Xu XC, 2003, NEOPLASIA, V5, P121, DOI 10.1016/S1476-5586(03)80003-9; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	54	29	30	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4261	4275		10.1038/onc.2010.197	http://dx.doi.org/10.1038/onc.2010.197			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514017	Green Accepted			2022-12-28	WOS:000280547900003
J	Haller, D; Mackiewicz, M; Gerber, S; Beyer, D; Kullmann, B; Schneider, I; Ahmed, JS; Seitzer, U				Haller, D.; Mackiewicz, M.; Gerber, S.; Beyer, D.; Kullmann, B.; Schneider, I.; Ahmed, J. S.; Seitzer, U.			Cytoplasmic sequestration of p53 promotes survival in leukocytes transformed by Theileria	ONCOGENE			English	Article						apoptosis; cytoplasmic sequestration; p53; Theileria annulata	WILD-TYPE P53; PARASITE THEILERIA; NUCLEAR EXCLUSION; COLORECTAL ADENOCARCINOMA; PROTEIN; CELLS; ACTIVATION; PARVA; LYMPHOCYTES; ONCOPROTEIN	The function of the p53 protein as the central effector molecule of the p53 apoptotic pathway was investigated in a reversible model of epigenetic transformation. The infection of bovine leukocytes by the intracellular protozoan parasite Theileria annulata results in parasite-dependent transformation and proliferation of the host cells. We found p53 to be largely localized in the host cell cytoplasm and associated with the parasite membrane of isolated schizonts. Curing infected cells of the parasite with the theilericidal drug buparvaquone resulted in a time-dependent translocation of p53 into the host cell nucleus and the upregulation of the proapoptotic Bax and Apaf-1 and the downregulation of the anti-apoptotic Bcl-2 proteins. Although buparvaquone treatment led to apoptosis of the host cell, inhibition of either p53 or Bax significantly reduced buparvaquone-induced apoptosis of the transformed cells. Thus, the p53 apoptotic pathway of host cells is not induced by infection and transformation with Theileria by a mechanism involving cytoplasmic sequestration of p53. The close association of host cell p53 with the parasite membrane implies that the parasite either interacts directly with p53 or mediates cytoplasmic sequestration of p53 by interacting with other host cell proteins regulating p53 localization. Oncogene (2010) 29, 3079-3086; doi: 10.1038/onc.2010.61; published online 8 March 2010	[Haller, D.; Mackiewicz, M.; Gerber, S.; Beyer, D.; Kullmann, B.; Schneider, I.; Ahmed, J. S.; Seitzer, U.] Res Ctr Borstel, Dept Immunol & Cell Biol, Div Vet Infect Biol & Immunol, D-23845 Borstel, Schleswig Holst, Germany	Forschungszentrum Borstel	Seitzer, U (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, Div Vet Infect Biol & Immunol, Pk Allee 22, D-23845 Borstel, Schleswig Holst, Germany.	useitzer@fz-borstel.de			European Commission [ICA4-CT-2000-30028]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported in part by a grant from the European Commission INCO-DEV Program (Contract Grant Number: ICA4-CT-2000-30028).	Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Ahmed JS, 1999, PARASITOL RES, V85, P527, DOI 10.1007/s004360050592; AHMED JS, 1989, J VET MED B, V36, P584, DOI 10.1111/j.1439-0450.1989.tb00649.x; Bakheit MA, 2006, PARASITOL RES, V100, P161, DOI 10.1007/s00436-006-0255-3; Bakheit MA, 2006, ANN NY ACAD SCI, V1081, P453, DOI 10.1196/annals.1373.064; BOSARI S, 1995, AM J PATHOL, V147, P790; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; DOBBELAERE DAE, 1988, P NATL ACAD SCI USA, V85, P4730, DOI 10.1073/pnas.85.13.4730; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Galley Y, 1997, P NATL ACAD SCI USA, V94, P5119, DOI 10.1073/pnas.94.10.5119; Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439; Guergnon J, 2003, BIOCHIMIE, V85, P771, DOI 10.1016/j.biochi.2003.09.013; Heussler VT, 2001, CELL MICROBIOL, V3, P537, DOI 10.1046/j.1462-5822.2001.00134.x; Heussler VT, 2002, SCIENCE, V298, P1033, DOI 10.1126/science.1075462; Knippschild U, 1996, ONCOGENE, V12, P1755; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; McHardy N., 1985, Immunization against theileriosis in Africa. Proceedings of a Joint Workshop, 1-5 October 1984, Nairobi, Kenya, ILRAD & FAO., P88; MCHARDY N, 1985, RES VET SCI, V39, P1; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schneider I, 2004, PARASITOL RES, V94, P405, DOI 10.1007/s00436-004-1226-1; Seitzer U, 2006, ANN NY ACAD SCI, V1081, P473, DOI 10.1196/annals.1373.069; Shayan P, 1999, PARASITOL RES, V85, P613, DOI 10.1007/s004360050605; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Toye P, 1996, INFECT IMMUN, V64, P1832, DOI 10.1128/IAI.64.5.1832-1838.1996; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	39	27	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3079	3086		10.1038/onc.2010.61	http://dx.doi.org/10.1038/onc.2010.61			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20208567				2022-12-28	WOS:000278133100005
J	Krndija, D; Schmid, H; Eismann, JL; Lother, U; Adler, G; Oswald, F; Seufferlein, T; von Wichert, G				Krndija, D.; Schmid, H.; Eismann, J-L; Lother, U.; Adler, G.; Oswald, F.; Seufferlein, T.; von Wichert, G.			Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility	ONCOGENE			English	Article						spreading; force; colon cancer; tyrosine-phosphatase; contractility; invasion	SRC-FAMILY KINASES; RPTP-ALPHA; MECHANICAL FORCE; LEADING-EDGE; PTP-ALPHA; FIBROBLASTS; EXPRESSION; ADHESION; MATRIX; ACTIVATION	Microenvironmental clues are critical to cell behavior. One of the key elements of migration is the generation and response to forces. Up to now, there is no definitive concept on how the generation and responses to cellular forces influence cancer-cell behavior. Here, we show that expression of receptor-type tyrosine-protein phosphatase alpha (RPTP alpha) in human SW480 colon cancer cells sets a threshold for the response to matrix forces by changing cellular contractility. This can be explained as an RPTP alpha-mediated increase in contractility with a consecutive increase in number and size of adhesion sites and stress fibers. These effects are mediated through myosin light chain kinase and largely independent of Rho/Rho-kinase (ROCK) signaling. In addition, we report that RPTPa influences spreading on low-rigidity surfaces, binding of collagen-coated beads and expression of RPTPa is required for invasion into the chorioallantoic membrane. These data suggest that force-responsive proteins such as RPTPa can influence cancer-cell behavior and identify potential targets for cancer therapy. Oncogene (2010) 29, 2724-2738; doi:10.1038/onc.2010.25; published online 8 March 2010	[Krndija, D.; Schmid, H.; Eismann, J-L; Lother, U.; Adler, G.; Oswald, F.; Seufferlein, T.; von Wichert, G.] Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Baden Wuerttemb, Germany	Ulm University	von Wichert, G (corresponding author), Univ Ulm, Dept Internal Med 1, Albert Einstein Allee 23, D-89081 Ulm, Baden Wuerttemb, Germany.	goetz.wichert@uniklinik-ulm.de	Krndija, Denis/AAR-5918-2020; Seufferlein, Thomas TW/P-7147-2018; Oswald, Franz/AAO-9584-2020	Krndija, Denis/0000-0001-8686-7542; 	DFG; Deutsche Krebshilfe	DFG(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by the DFG to GvW and FO and the Deutsche Krebshilfe to GvW and TS.	Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Benoliel AM, 2003, ANTICANCER RES, V23, P4891; Berndt A, 1999, HISTOCHEM CELL BIOL, V111, P399, DOI 10.1007/s004180050373; Bodrikov V, 2005, J CELL BIOL, V168, P127, DOI 10.1083/jcb.200405073; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333; Jiang GY, 2006, BIOPHYS J, V90, P1804, DOI 10.1529/biophysj.105.072462; Kostic A, 2006, MOL BIOL CELL, V17, P2684, DOI 10.1091/mbc.E05-12-1161; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; Munevar S, 2001, BIOPHYS J, V80, P1744, DOI 10.1016/S0006-3495(01)76145-0; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petrone A, 2000, J CELL SCI, V113, P2345; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wang YL, 1998, METHOD ENZYMOL, V298, P489, DOI 10.1016/S0076-6879(98)98041-7; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Wells RG, 2008, HEPATOLOGY, V47, P1394, DOI 10.1002/hep.22193; Wozniak MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010; Wu CW, 2006, CANCER LETT, V242, P95, DOI 10.1016/j.canlet.2005.10.046; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	34	37	38	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2724	2738		10.1038/onc.2010.25	http://dx.doi.org/10.1038/onc.2010.25			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20208566				2022-12-28	WOS:000277354600012
J	Zhu, XG; Zhao, L; Willingham, MC; Cheng, SY				Zhu, X-G; Zhao, L.; Willingham, M. C.; Cheng, S-Y			Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma	ONCOGENE			English	Article						thyroid cancer; mouse model; mutations of thyroid hormone receptors	DOMINANT-NEGATIVE ACTIVITY; SECRETING PITUITARY-TUMOR; TRANSFORMING GENE PTTG; CLEAR-CELL CARCINOMA; LINKED KINASE ILK; BETA-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTORS; TRANSGENIC MICE; V-ERBA	Aberrant expression and mutations of thyroid hormone receptor genes (TRs) are closely associated with several types of human cancers. To test the hypothesis that TRs could function as tumor suppressors, we took advantage of mice with deletion of all functional TRs (TR alpha 1(-/-)TR beta(-/-) mice). As these mice aged, they spontaneously developed follicular thyroid carcinoma with pathological progression from hyperplasia to capsular invasion, vascular invasion, anaplasia and metastasis to the lung, similar to human thyroid cancer. Detailed molecular analysis revealed that known tumor promoters such as pituitary tumor-transforming gene were activated and tumor suppressors such as peroxisome proliferator-activated receptor gamma and p53 were suppressed during carcinogenesis. In addition, consistent with the human cancer, AKT-mTOR-p70(S6K) signaling and vascular growth factor and its receptor were activated to facilitate tumor progression. This report presents in vivo evidence that functional loss of both TR alpha 1 and TR beta genes promotes tumor development and metastasis. Thus, TRs could function as tumor suppressors in a mouse model of metastatic follicular thyroid cancer. Oncogene (2010) 29, 1909-1919; doi:10.1038/onc.2009.476; published online 11 January 2010	[Zhu, X-G; Zhao, L.; Cheng, S-Y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC008752, ZIABC011191] Funding Source: NIH RePORTER	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. We thank Drs H Ying and Y Kato for the analyses of survival curves and thyroid growth in the early phase of the present work.	Ando S, 2001, MOL ENDOCRINOL, V15, P1529, DOI 10.1210/me.15.9.1529; Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Davis PJ, 2008, FRONT NEUROENDOCRIN, V29, P211, DOI 10.1016/j.yfrne.2007.09.003; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2009, STEROIDS, V74, P628, DOI 10.1016/j.steroids.2008.10.009; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Kim DS, 2006, J CLIN ENDOCR METAB, V91, P4603, DOI 10.1210/jc.2006-1291; Kim DS, 2003, CLIN OTOLARYNGOL, V28, P386, DOI 10.1046/j.1365-2273.2003.00732.x; Lawal O, 2001, EUR J SURG ONCOL, V27, P157, DOI 10.1053/ejso.2000.1085; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Li Z, 2002, CANCER RES, V62, P1939; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; MAEDA K, 1995, J CLIN ONCOL, V13, P477, DOI 10.1200/JCO.1995.13.2.477; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miyakawa M, 2003, ENDOCR J, V50, P77, DOI 10.1507/endocrj.50.77; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Puzianowska-Kuznicka M, 2000, CANCER LETT, V155, P145, DOI 10.1016/S0304-3835(00)00416-X; Puzianowska-Kuznicka M, 2006, ACTA BIOCHIM POL, V53, P641, DOI 10.18388/abp.2006_3292; Ringel MD, 2001, CANCER RES, V61, P6105; Safer JD, 2001, THYROID, V11, P281, DOI 10.1089/105072501750159750; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shen WT, 2005, THYROID, V15, P594, DOI 10.1089/thy.2005.15.594; Suzuki H, 2003, MOL ENDOCRINOL, V17, P895, DOI 10.1210/me.2002-0326; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Takano T, 2003, J CLIN ENDOCR METAB, V88, P3447, DOI 10.1210/jc.2003-030012; Teresi RE, 2008, PPAR RES, V2008, DOI 10.1155/2008/932632; Thormeyer D, 1999, INT J MOL MED, V4, P351; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014; Ward J M, 1986, Adv Exp Med Biol, V206, P529; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Weiss R E, 2000, Rev Endocr Metab Disord, V1, P97, DOI 10.1023/A:1010072605757; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; YEN PM, 1994, J BIOL CHEM, V269, P903; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Ying H, 2006, J CLIN INVEST, V116, P2972, DOI 10.1172/JCI28598; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133; Zhang XY, 2002, MOL ENDOCRINOL, V16, P2077, DOI 10.1210/me.2002-0080; Zimonjic DB, 2005, CANCER GENET CYTOGEN, V161, P104, DOI 10.1016/j.cancergencyto.2005.02.007	63	41	42	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1909	1919		10.1038/onc.2009.476	http://dx.doi.org/10.1038/onc.2009.476			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062085	Green Accepted			2022-12-28	WOS:000276199600004
J	Heinrich, C; Keller, C; Boulay, A; Vecchi, M; Bianchi, M; Sack, R; Lienhard, S; Duss, S; Hofsteenge, J; Hynes, NE				Heinrich, C.; Keller, C.; Boulay, A.; Vecchi, M.; Bianchi, M.; Sack, R.; Lienhard, S.; Duss, S.; Hofsteenge, J.; Hynes, N. E.			Copine-III interacts with ErbB2 and promotes tumor cell migration	ONCOGENE			English	Article						quantitative mass spectrometry; ErbB2; HRG; Copine-III; FRET acceptor photobleaching; cell migration	BREAST-CANCER; C2 DOMAIN; AUTOPHOSPHORYLATION SITES; PROTEIN; RECEPTOR; IDENTIFICATION; KINASE; RACK1; ADHESION; FAMILY	ErbB2 amplification and overexpression in breast cancer correlates with aggressive disease and poor prognosis. To find novel ErbB2-interacting proteins, we used stable isotope labeling of amino acids in cell culture followed by peptide affinity pull-downs and identified specific binders using relative quanti. cation by mass spectrometry. Copine-III, a member of a Ca2+-dependent phospholipid-binding protein family, was identified as binding to phosphorylated Tyr1248 of ErbB2. In breast cancer cells, Copine-III requires Ca2+ for binding to the plasma membrane, where it interacts with ErbB2 upon receptor stimulation, an interaction that is dependent on receptor activity. Copine-III also binds receptor of activated C kinase 1 and colocalizes with phosphorylated focal adhesion kinase at the leading edge of migrating cells. Importantly, knockdown of Copine-III in T47D breast cancer cells causes a decrease in Src kinase activation and ErbB2-dependent wound healing. Our data suggest that Copine-III is a novel player in the regulation of ErbB2-dependent cancer cell motility. In primary breast tumors, high CPNE3 RNA levels significantly correlate with ERBB2 amplification. Moreover, in an in situ tissue microarray analysis, we detected differential protein expression of Copine-III in normal versus breast, prostate and ovarian tumors, suggesting a more general role for Copine-III in carcinogenesis. Oncogene (2010) 29, 1598-1610; doi:10.1038/onc.2009.456; published online 14 December 2009	[Heinrich, C.; Keller, C.; Boulay, A.; Sack, R.; Lienhard, S.; Duss, S.; Hofsteenge, J.; Hynes, N. E.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Vecchi, M.; Bianchi, M.] IFOM, FIRC Inst Mol Oncol Fdn, Milan, Italy	Friedrich Miescher Institute for Biomedical Research; IFOM - FIRC Institute of Molecular Oncology	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66,WRO 1066-206, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch	Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160; Sack, Ragna/0000-0003-0963-8089; Keller Valsecchi, Claudia Isabelle/0000-0003-4135-5927; Duss, Stephan/0000-0002-0521-162X	TRANSFOG FP6 IP [LSHC-CT-2004-503438]; Novartis Research Foundation	TRANSFOG FP6 IP; Novartis Research Foundation	We thank Elizabeth A Grimm for the polyclonal Copine-III antibody, Martin Spiess for the transferrin receptor antibody, Susanne Schenk for help in generating the Copine-III monoclonal antibody, Laurent Gelman for help with FRET, Michael Rebhan for some bioinformatic analyses and Gwen MacDonald and Julien Dey for helpful discussions. We also thank Daniel Hess and Florence Dalvai for help with establishing the 'MRM buddy'. The work of CH, MV and MB was partially supported by TRANSFOG FP6 IP funding (LSHC-CT-2004-503438). The laboratories of NEH and JH are supported by the Novartis Research Foundation.	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Church DL, 2003, GENETICS, V165, P563; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gharbi S, 2002, MOL CELL PROTEOMICS, V1, P91, DOI 10.1074/mcp.T100007-MCP200; Gottschalk A, 2005, EMBO J, V24, P2566, DOI 10.1038/sj.emboj.7600741; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guerrero-Valero M, 2007, J MOL BIOL, V371, P608, DOI 10.1016/j.jmb.2007.05.086; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hua J, 2001, GENE DEV, V15, P2263, DOI 10.1101/gad.918101; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kheifets V, 2007, PHARMACOL RES, V55, P467, DOI 10.1016/j.phrs.2007.04.014; Kiely PA, 2009, J BIOL CHEM, V284, P20263, DOI 10.1074/jbc.M109.017640; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Meira M, 2009, J CELL SCI, V122, P787, DOI 10.1242/jcs.032094; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; Nagy P, 1998, CYTOMETRY, V32, P120, DOI 10.1002/(SICI)1097-0320(19980601)32:2<120::AID-CYTO7>3.0.CO;2-P; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; Tomsig JL, 2003, J BIOL CHEM, V278, P10048, DOI 10.1074/jbc.M212632200; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; White SL, 2004, BRIT J CANCER, V90, P173, DOI 10.1038/sj.bjc.6601458; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	49	42	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1598	1610		10.1038/onc.2009.456	http://dx.doi.org/10.1038/onc.2009.456			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20010870	Green Submitted			2022-12-28	WOS:000275694700005
J	El-Kalla, M; Onyskiw, C; Baksh, S				El-Kalla, M.; Onyskiw, C.; Baksh, S.			Functional importance of RASSF1A microtubule localization and polymorphisms	ONCOGENE			English	Article						RASSF1A; microtubule; polymorphism; Tubulin; tumor suppressor gene	TUMOR-SUPPRESSOR RASSF1A; TRANSCRIPTION FACTOR P120(E4F); DEATH INDUCER C19ORF5; CELL-DEATH; BINDING PROTEIN; SPINDLE POLES; GAMMA-TUBULIN; RAS; ASSOCIATION; FAMILY	Ras association domain family protein 1A (RASSF1A) is one of the more heavily methylated genes in human cancers. In addition to promoter-specific methylation, RASSF1A polymorphisms have been identified in cancer patients. RASSF1A is a tumor suppressor protein involved in death receptor-dependent apoptosis and it is localized to microtubules. Currently, the biological importance of RASSF1A microtubule localization and the functional consequences of RASSF1A polymorphisms is not under-stood. In this study, we have investigated both RASSF1A microtubule association and polymorphisms. Loss of RASSF1A microtubule association resulted in the nuclear appearance of RASSF1A and the loss of association with alpha-, gamma-and beta-tubulin. Moreover, the loss of microtubule localization of RASSF1A resulted in enhanced tumor-promoting potential, as determined by a xenograft transplantation model in nude mice. It is surprising that, several RASSF1A polymorphisms also lost the ability to associate with alpha-, gamma-and beta-tubulin and lost the ability to prevent tumor formation in a xenograft nude mouse model when compared with wild-type RASSF1A. Our results demonstrate a role for RASSF1A microtubule localization in eliciting its tumor suppressor function. In addition, some RASSF1A polymorphisms lack the tumor suppressor function of RASSF1A and, if present in patients, may be tumorigenic. Oncogene (2010) 29, 5729-5740; doi:10.1038/onc.2010.316; published online 9 August 2010	[El-Kalla, M.; Onyskiw, C.; Baksh, S.] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB T6G 2N8, Canada	University of Alberta	Baksh, S (corresponding author), Univ Alberta, Fac Med & Dent, Dept Pediat, Room B066 Dent Pharm Bldg, Edmonton, AB T6G 2N8, Canada.	sbaksh@ualberta.ca	Baksh, Shairaz/GRX-2106-2022		CIHR [MOP-79494]; Women and Children's Health Research Institute [WCO14]; Stollery Children's Hospital Foundation [PD946]; Alberta Heritage Foundation for Medical Research [G220170170]; Canadian Foundation for Innovation [13118]	CIHR(Canadian Institutes of Health Research (CIHR)); Women and Children's Health Research Institute; Stollery Children's Hospital Foundation; Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Canadian Foundation for Innovation(Canada Foundation for Innovation)	We thank Dr Haya Abu Ghazaleh for her helpful discussions, Adrienne DeCorby-Baksh for her excellent technical assistance with our confocal imaging, Dr Victor Yu and Naiyang Fu for the MOAP-1 expression construct. This work was supported by grants from CIHR (MOP-79494) (MEK), the Women and Children's Health Research Institute (WCO14) (MEK), the Stollery Children's Hospital Foundation Donation Grant (PD946) (SB and MEK), Alberta Heritage Foundation for Medical Research (G220170170) (SB), and Canadian Foundation for Innovation/Alberta Small Equipment Grants Program (#13118).	Abu Ghazaleh H, 2010, APOPTOSIS, V15, P117, DOI 10.1007/s10495-009-0451-6; Adachi M, 2003, FEBS LETT, V551, P147, DOI 10.1016/S0014-5793(03)00915-3; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Allen NPC, 2007, ONCOGENE, V26, P6203, DOI 10.1038/sj.onc.1210440; Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Brameier M, 2007, BIOINFORMATICS, V23, P1159, DOI 10.1093/bioinformatics/btm066; Cuschieri L, 2007, CELL CYCLE, V6, P2788, DOI 10.4161/cc.6.22.4941; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dallol A, 2007, CANCER RES, V67, P492, DOI 10.1158/0008-5472.CAN-06-3604; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07; Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183; Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Moshnikova A, 2006, J BIOL CHEM, V281, P8143, DOI 10.1074/jbc.M511837200; Moshnikova Anna, 2008, BMC Res Notes, V1, P13, DOI 10.1186/1756-0500-1-13; Parvin JD, 2009, ENVIRON MOL MUTAGEN, V50, P649, DOI 10.1002/em.20475; Pihan G, 2003, CANCER CELL, V4, P89, DOI 10.1016/S1535-6108(03)00195-8; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Raynaud-Messina B, 2007, CURR OPIN CELL BIOL, V19, P24, DOI 10.1016/j.ceb.2006.12.008; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Senda Takao, 2005, Anatomical Science International, V80, P121, DOI 10.1111/j.1447-073x.2005.00106.x; Sherwood V, 2008, MOL BIOL CELL, V19, P1772, DOI 10.1091/mbc.E07-07-0652; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; van der Weyden L, 2008, ONCOGENE, V27, P4503, DOI 10.1038/onc.2008.94; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wade RH, 2009, MOL BIOTECHNOL, V43, P177, DOI 10.1007/s12033-009-9193-5	46	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5729	5740		10.1038/onc.2010.316	http://dx.doi.org/10.1038/onc.2010.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20697344				2022-12-28	WOS:000283262500009
J	Hu, F; Gartenhaus, RB; Eichberg, D; Liu, Z; Fang, HB; Rapoport, AP				Hu, F.; Gartenhaus, R. B.; Eichberg, D.; Liu, Z.; Fang, H-B; Rapoport, A. P.			PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21	ONCOGENE			English	Article						PDZ-binding kinase; tumor suppressor p53; cyclin-dependent kinase inhibitor p21WAF1; PBK/TOPK	ORIGINATED PROTEIN-KINASE; PDZ-BINDING KINASE; DNA-DAMAGE; MITOTIC KINASE; MUTANT P53; HUMAN HOMOLOG; GLIOMA-CELLS; WILD-TYPE; APOPTOSIS; TOPK	PBK/TOPK (PDZ-binding kinase, T-LAK-cell-originated protein kinase) is a serine-threonine kinase that is overexpressed in a variety of tumor cells but its role in oncogenesis remains unclear. Here we show, by co-immunoprecipitation experiments and yeast two-hybrid analysis, that PBK/TOPK physically interacts with the tumor suppressor p53 through its DNA-binding (DBD) domain in HCT116 colorectal carcinoma cells that express wild-type p53. PBK also binds to p53 mutants carrying five common point mutations in the DBD domain. The PBK-p53 interaction appears to down-modulate p53 transactivation function as indicated by PBK/TOPK knockdown experiments, which show upregulated expression of the key p53 target gene and cyclin-dependent kinase inhibitor p21 in HCT116 cells, particularly after genotoxic damage from doxorubicin. Furthermore, stable PBK/TOPK knockdown cell lines (derived from HCT116 and MCF-7 cells) showed increased apoptosis, G(2)/M arrest and slower growth as compared to stable empty vector-transfected control cell lines. Gene microarray studies identified additional p53 target genes involved in apoptosis or cell cycling, which were differentially regulated by PBK knockdown. Together, these data suggest that increased levels of PBK/TOPK may contribute to tumor cell development and progression through suppression of p53 function and consequent reductions in the cell-cycle regulatory proteins such as p21. PBK/TOPK may therefore be a valid target for antineoplastic kinase inhibitors to sensitize tumor cells to chemotherapy-induced apoptosis and growth suppression. Oncogene (2010) 29, 5464-5474; doi:10.1038/onc.2010.275; published online 12 July 2010	[Hu, F.; Gartenhaus, R. B.; Eichberg, D.; Liu, Z.; Fang, H-B; Rapoport, A. P.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Rapoport, AP (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	arapoport@umm.edu			Marlene and Stewart Greenebaum Cancer Center	Marlene and Stewart Greenebaum Cancer Center	This work was supported in part by philanthropic gifts from Mr Willard Hackerman, Mr and Mrs Robert Becker, and Mr and Mrs Gaylord Christle. Additional funds were provided by the Marlene and Stewart Greenebaum Cancer Center.	Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Abe Y, 2007, J MOL BIOL, V370, P231, DOI 10.1016/j.jmb.2007.04.067; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; Brooks WS, 2008, J BIOL CHEM, V283, P22304, DOI 10.1074/jbc.M803238200; Brooks WS, 2007, EXP CELL RES, V313, P665, DOI 10.1016/j.yexcr.2006.11.020; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Dougherty JD, 2005, J NEUROSCI, V25, P10773, DOI 10.1523/JNEUROSCI.3207-05.2005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Guo NH, 1997, CANCER RES, V57, P1735; Hagn F, 2010, J BIOL CHEM, V285, P3439, DOI 10.1074/jbc.M109.065391; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Patel S, 2008, NUCLEIC ACIDS RES, V36, P5139, DOI 10.1093/nar/gkn490; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Rikhof B, 2003, CANCER BIOL THER, V2, P707; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Sot B, 2007, J BIOL CHEM, V282, P29193, DOI 10.1074/jbc.M705544200; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Soussi T, 2006, CLIN CANCER RES, V12, P62, DOI 10.1158/1078-0432.CCR-05-0413; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048; Zykova TA, 2006, CLIN CANCER RES, V12, P6884, DOI 10.1158/1078-0432.CCR-06-0410	42	88	92	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5464	5474		10.1038/onc.2010.275	http://dx.doi.org/10.1038/onc.2010.275			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20622899				2022-12-28	WOS:000282945800004
J	Wilson, CH; McIntyre, RE; Arends, MJ; Adams, DJ				Wilson, C. H.; McIntyre, R. E.; Arends, M. J.; Adams, D. J.			The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways	ONCOGENE			English	Article						cAMP; colorectal cancer; GNAS	MCCUNE-ALBRIGHT-SYNDROME; STIMULATORY G-PROTEIN; K-RAS; ADRENAL-HYPERPLASIA; COLORECTAL-CANCER; HUMAN BREAST; CELL-GROWTH; A33 ANTIGEN; EXPRESSION; CAMP	Somatically acquired, activating mutations of GNAS, the gene encoding the stimulatory G-protein Gsa subunit, have been identified in kidney, thyroid, pituitary, leydig cell, adrenocortical and, more recently, in colorectal tumours, suggesting that mutations such as R201C may be oncogenic in these tissues. To study the role of GNAS in intestinal tumourigenesis, we placed GNAS R201C under the control of the A33-antigen promoter (Gpa33), which is almost exclusively expressed in the intestines. The GNAS R201C mutation has been shown to result in the constitutive activation of Gs alpha and adenylate cyclase and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP). Gpa33(tm1(GnasR201C) Wtsi/+) mice showed significantly elevated cAMP levels and a compensatory upregulation of cAMP-specific phosphodiesterases in the intestinal epithelium. GNAS R201C alone was not sufficient to induce tumourigenesis by 12 months, but there was a significant increase in adenoma formation when Gpa(33tm1(GnasR201C) Wtsi/+) mice were bred onto an Apc(Min/+) background. GNAS R201C expression was associated with elevated expression of Wnt and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) pathway target genes, increased phosphorylation of ERK1/2 MAPK and increased immunostaining for the proliferation marker Ki67. Furthermore, the effects of GNAS R201C on the Wnt pathway were additive to the inactivation of Apc. Our data strongly suggest that activating mutations of GNAS cooperate with inactivation of APC and are likely to contribute to colorectal tumourigenesis. Oncogene (2010) 29, 4567-4575; doi: 10.1038/onc.2010.202; published online 7 June 2010	[Wilson, C. H.; McIntyre, R. E.; Adams, D. J.] Sanger Inst, Wellcome Trust, Hinxton CB10 1SA, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England	Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Adams, DJ (corresponding author), Sanger Inst, Wellcome Trust, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	da1@sanger.ac.uk		Adams, David/0000-0001-9490-0306; Wilson, Catherine/0000-0002-5333-0295	Cancer Research UK (CR-UK); Wellcome Trust	Cancer Research UK (CR-UK)(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)	Work in the DJ Adams Laboratory and the MJ Arends Laboratory is funded by Cancer Research UK (CR-UK) and the Wellcome Trust. We thank Dr Mattias Ernst for providing the Gpa33 targeting vector.	Abud HE, 2000, MECH DEVELOP, V98, P111, DOI 10.1016/S0925-4773(00)00438-X; Araki Y, 2003, CANCER RES, V63, P728; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen CJ, 2004, J PEDIATR ENDOCR MET, V17, P365; Collins MT, 2003, J CLIN ENDOCR METAB, V88, P4413, DOI 10.1210/jc.2002-021642; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074, DOI 10.1210/jc.83.6.2074; Fragoso MCBV, 2003, J CLIN ENDOCR METAB, V88, P2147, DOI 10.1210/jc.2002-021362; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; HAPPLE R, 1986, CLIN GENET, V29, P321; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; Horvath A, 2008, EUR J HUM GENET, V16, P1245, DOI 10.1038/ejhg.2008.85; Horvath A, 2006, NAT GENET, V38, P794, DOI 10.1038/ng1809; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Johnstone CN, 2000, AM J PHYSIOL-GASTR L, V279, pG500, DOI 10.1152/ajpgi.2000.279.3.G500; Kalfa N, 2006, J UROLOGY, V176, P891, DOI 10.1016/j.juro.2006.04.023; Kirk JMW, 1999, J PEDIATR-US, V134, P789, DOI 10.1016/S0022-3476(99)70302-1; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kotoula V, 2009, ENDOCR-RELAT CANCER, V16, P565, DOI 10.1677/ERC-08-0101; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVY DB, 1994, CANCER RES, V54, P5953; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo F, 2007, ONCOGENE, V26, P4415, DOI 10.1038/sj.onc.1210231; Luo FJ, 2009, INT J EXP PATHOL, V90, P558, DOI 10.1111/j.1365-2613.2009.00667.x; MacMahon H E, 1971, Pathol Annu, V6, P81; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orner GA, 2002, MUTAT RES-FUND MOL M, V506, P121, DOI 10.1016/S0027-5107(02)00158-6; Palos-Paz F, 2008, EUR J ENDOCRINOL, V159, P623, DOI 10.1530/EJE-08-0313; Plagge A, 2008, J ENDOCRINOL, V196, P193, DOI 10.1677/JOE-07-0544; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rudolph JA, 2004, J BIOL CHEM, V279, P14828, DOI 10.1074/jbc.M310289200; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sieber OM, 2000, MOL MED TODAY, V6, P462; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stratakis CA, 2003, TRENDS ENDOCRIN MET, V14, P404, DOI 10.1016/j.tem.2003.08.005; Su H, 2002, GENESIS, V32, P187, DOI 10.1002/gene.10043; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taboada GF, 2009, PITUITARY, V12, P165, DOI 10.1007/s11102-008-0136-0; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Wilkins JA, 2008, CANCER RES, V68, P4963, DOI 10.1158/0008-5472.CAN-07-5558; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yang GCH, 1999, MODERN PATHOL, V12, P969; Zhang T, 2001, CANCER RES, V61, P8664	54	81	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4567	4575		10.1038/onc.2010.202	http://dx.doi.org/10.1038/onc.2010.202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531296	Green Accepted, Green Submitted			2022-12-28	WOS:000280862300007
J	Chu, WK; Hanada, K; Kanaar, R; Hickson, ID				Chu, W. K.; Hanada, K.; Kanaar, R.; Hickson, I. D.			BLM has early and late functions in homologous recombination repair in mouse embryonic stem cells	ONCOGENE			English	Article						Rad54; gene targeting; mitomycin C; sister chromatid exchanges; DNA crosslinking agents	SISTER-CHROMATID EXCHANGES; BLOOMS-SYNDROME HELICASE; DNA-DAMAGE; RESECT DNA; D-LOOPS; RAD54; PROTEIN; PROMOTES; SGS1; DISRUPTION	BLM is a RecQ family helicase that is defective in individuals with the cancer predisposition disorder, Bloom's syndrome (BS). At the cellular level, BS is characterized by hyper-recombination manifested as excessive sister chromatid exchange and loss of heterozygosity. However, the precise function of BLM remains unclear. Multiple roles have been proposed for BLM in the homologous recombination (HR) repair pathway, including 'early' functions, such as the stimulation of resection of DNA double-strand break ends or displacement of the invading strand of DNA displacement loops, and 'late' roles, such as dissolution of double Holliday junctions. However, most of the evidence for these putative roles comes from in vitro biochemical data. In this study, we report the characterization of mouse embryonic stem cells with disruption of Blm and/or Rad54 genes. We show that Blm has roles both upstream and downstream of the Rad54 protein, a core HR factor. Disruption of Rad54 in the Blm-mutant background reduced the elevated level of gene targeting and of sister chromatid exchanges, implying that Blm primarily functions downstream of Rad54 in the HR pathway. Conversely, however, mutation of Blm in Rad54(-/-) cells rescued their mitomycin C (MMC) sensitivity, and decreased both the level of DNA damage and cell cycle perturbation induced by MMC, suggesting an early role for Blm. Our data are consistent with Blm having at least two roles in HR repair in mammalian cells. Oncogene (2010) 29, 4705-4714; doi:10.1038/onc.2010.214; published online 7 June 2010	[Chu, W. K.; Hanada, K.; Hickson, I. D.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England; [Hanada, K.; Kanaar, R.] Erasmus MC, Dept Cell Biol & Genet, Canc Genom Ctr, Dept Radiat Oncol, Rotterdam, Netherlands; [Hickson, I. D.] Univ Copenhagen, Panum Inst, Dept Cellular & Mol Med, DK-2200 Copenhagen N, Denmark	University of Oxford; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Copenhagen	Hickson, ID (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England.	hickson@imm.ox.ac.uk	Chu, Wai Kit/F-9405-2016; Hickson, Ian/AAJ-7548-2020	Chu, Wai Kit/0000-0003-2903-3247; Hanada, Katsuhiro/0000-0003-0429-1899; Hickson, Ian/0000-0002-0583-566X	Cancer Research UK; Bloom's Syndrome Foundation; Netherlands Genomic Initiative/The Netherlands Organization for Scientific Research; Anita Mui 'True Heart' Charity Foundation; K P Tin Foundation Limited; China Oxford Scholarship	Cancer Research UK(Cancer Research UK); Bloom's Syndrome Foundation; Netherlands Genomic Initiative/The Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Anita Mui 'True Heart' Charity Foundation; K P Tin Foundation Limited; China Oxford Scholarship	We thank Dr A Bradley for Blm<SUP>m3/m4</SUP> cells, and Drs H te Riele and D Adams for the targeting vectors. We also thank Drs L Wu, P McHugh and CZ Bachrati for helpful comments on the paper, Mr PS North for advice on SCE assays and Miss P White for preparing the paper. This work was supported by Cancer Research UK and by The Bloom's Syndrome Foundation (IDH), and by The Netherlands Genomic Initiative/The Netherlands Organization for Scientific Research (RK). WK Chu was supported by the Anita Mui 'True Heart' Charity Foundation, the K P Tin Foundation Limited and the China Oxford Scholarship Fund.	Amitani I, 2006, MOL CELL, V23, P143, DOI 10.1016/j.molcel.2006.05.009; Bachrati CZ, 2006, NUCLEIC ACIDS RES, V34, P2269, DOI 10.1093/nar/gkl258; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Bugreev DV, 2006, NATURE, V442, P590, DOI 10.1038/nature04889; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Li X, 2009, MOL CELL, V36, P704, DOI 10.1016/j.molcel.2009.09.036; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mankouri HW, 2007, MOL BIOL CELL, V18, P4062, DOI 10.1091/mbc.E07-05-0490; Marple T, 2006, MUTAT RES-FUND MOL M, V602, P110, DOI 10.1016/j.mrfmmm.2006.08.005; Mazina OM, 2008, P NATL ACAD SCI USA, V105, P18249, DOI 10.1073/pnas.0807016105; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Otsuki M, 2007, J CELL BIOL, V179, P53, DOI 10.1083/jcb.200702183; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Singh TR, 2008, GENE DEV, V22, P2856, DOI 10.1101/gad.1725108; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wesoly J, 2006, MOL CELL BIOL, V26, P976, DOI 10.1128/MCB.26.3.976-989.2006; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Xu DY, 2008, GENE DEV, V22, P2843, DOI 10.1101/gad.1708608; Zhang R, 2005, CANCER RES, V65, P2526, DOI 10.1158/0008-5472.CAN-04-2421; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	46	30	30	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4705	4714		10.1038/onc.2010.214	http://dx.doi.org/10.1038/onc.2010.214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531307				2022-12-28	WOS:000281127400009
J	Hrstka, R; Nenutil, R; Fourtouna, A; Maslon, MM; Naughton, C; Langdon, S; Murray, E; Larionov, A; Petrakova, K; Muller, P; Dixon, MJ; Hupp, TR; Vojtesek, B				Hrstka, R.; Nenutil, R.; Fourtouna, A.; Maslon, M. M.; Naughton, C.; Langdon, S.; Murray, E.; Larionov, A.; Petrakova, K.; Muller, P.; Dixon, M. J.; Hupp, T. R.; Vojtesek, B.			The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers	ONCOGENE			English	Article						AGR2; tamoxifen; letrozole; estrogen receptor; breast cancer	HUMAN ESTROGEN-RECEPTOR; PROGESTERONE RECEPTORS; RESPONSE ELEMENT; HUMAN HOMOLOG; GENE XAG-2; CELL-LINES; EXPRESSION; AGR2; RESISTANCE; HYBRIDIZATION	Transcriptomic screens in breast cancer cell lines have identified a protein named anterior gradient-2 (AGR2) as a potentially novel oncogene overexpressed in estrogen receptor (ER) positive tumours. As targeting the ER is responsible for major improvements in cure rates and prevention of breast cancers, we have evaluated the prooncogenic function of AGR2 in anti-hormone therapeutic responses. We show that AGR2 expression promotes cancer cell survival in clonogenic assays and increases cell proliferation and viability in a range of cancer cell lines. Chromatin immunoprecipitation and reporter assays indicate that AGR2 is transcriptionally activated by estrogen through ER alpha. However, we also found that AGR2 expression is elevated rather than inhibited in response to tamoxifen, thus identifying a novel mechanism to account for an agonistic effect of the drug on a specific pro-oncogenic pathway. Consistent with these data, clinical analysis indicates that AGR2 expression is related to treatment failure in ER alpha-positive breast cancers treated with tamoxifen. In contrast, AGR2 is one of the most highly suppressed genes in cancers of responding patients treated with the anti-hormonal drug letrozole. These data indicate that the AGR2 pathway represents a novel pro-oncogenic pathway for evaluation as anti-cancer drug developments, especially therapies that by-pass the agonist effects of tamoxifen. Oncogene (2010) 29, 4838-4847; doi:10.1038/onc.2010.228; published online 7 June 2010	[Hrstka, R.; Nenutil, R.; Petrakova, K.; Muller, P.; Vojtesek, B.] Masaryk Mem Canc Inst, Dept Oncol & Expt Pathol, Brno 65653, Czech Republic; [Fourtouna, A.; Maslon, M. M.; Naughton, C.; Langdon, S.; Murray, E.; Hupp, T. R.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Fourtouna, A.; Maslon, M. M.; Naughton, C.; Langdon, S.; Murray, E.; Hupp, T. R.] Univ Edinburgh, Canc Res UK Signal Transduct Labs P53, Edinburgh, Midlothian, Scotland; [Larionov, A.; Dixon, M. J.] Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Masaryk Memorial Cancer Institute; University of Edinburgh; University of Edinburgh; University of Edinburgh	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Dept Oncol & Expt Pathol, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Hrstka, Roman/AAM-4430-2020; RASOR, Scotland/A-3274-2011; Muller, Petr/F-7762-2015; Maslon, Magdalena/AAC-4790-2022; Larionov, Alexey/A-5088-2010; Muller, Petr/AAK-5014-2021; Maslon, Magdalena/AAB-9609-2020	Hrstka, Roman/0000-0002-6139-2664; Muller, Petr/0000-0002-8404-4494; Larionov, Alexey/0000-0001-6374-9391; Muller, Petr/0000-0002-8404-4494; Naughton, Catherine/0000-0002-9576-5983; Maslon, Magdalena/0000-0002-1050-1306; Nenutil, Rudolf/0000-0003-0068-9760	GACR [P301/10/1615]; IGA MZCR [NS/9812-4, MZ0MOU2005]; Cancer Research UK [C483/A10706, C483/A6354]; Breast Cancer Campaign Garfield Weston PhD studentship on AGR2 pathway regulation; BBSRC; Breakthrough Breast Cancer	GACR(Grant Agency of the Czech Republic); IGA MZCR; Cancer Research UK(Cancer Research UK); Breast Cancer Campaign Garfield Weston PhD studentship on AGR2 pathway regulation; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Breakthrough Breast Cancer	We thank Tamara Smerdova and Sona Babcanova for their excellent technical assistance and Larry Hayward for critical discussions. This work was supported by the GACR P301/10/1615, IGA MZCR NS/9812-4 and MZ0MOU2005. Ted Hupp was supported by grants C483/A10706 and C483/A6354 from the Cancer Research UK, a Breast Cancer Campaign Garfield Weston PhD studentship on AGR2 pathway regulation (AF), and the BBSRC (EM). Mike Dixon was supported by Breakthrough Breast Cancer.	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Anderson I, 2000, BIOCHEMISTRY-US, V39, P3842, DOI 10.1021/bi9924516; Barraclough DL, 2009, AM J PATHOL, V175, P1848, DOI 10.2353/ajpath.2009.090246; Barraclough DL, 2010, CELL ONCOL, V32, P87, DOI 10.3233/CLO-2009-0499; Brunner N, 1997, CANCER RES, V57, P3486; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fritzsche FR, 2006, CLIN CANCER RES, V12, P1728, DOI 10.1158/1078-0432.CCR-05-2057; Goetz MP, 2003, JNCI-J NATL CANCER I, V95, P1734, DOI 10.1093/jnci/djg129; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; Gunthert AR, 2005, EUR J ENDOCRINOL, V153, P613, DOI 10.1530/eje.1.01996; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Innes HE, 2006, BRIT J CANCER, V94, P1057, DOI 10.1038/sj.bjc.6603065; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Kim NS, 2007, J BIOCHEM MOL BIOL, V40, P212; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Kondrakhin Yury V, 2008, In Silico Biol, V8, P383; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lee S, 2006, ONCOL REP, V16, P747; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Mackay A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1732; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Robertson JFR, 1996, INT J BIOL MARKER, V11, P29, DOI 10.1177/172460089601100106; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; Stendahl M, 2004, BRIT J CANCER, V90, P1942, DOI 10.1038/sj.bjc.6601831; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Tyulmenkov VV, 2001, MOL CELL ENDOCRINOL, V182, P109, DOI 10.1016/S0303-7207(01)00508-1; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Zhang Y, 2007, PROSTATE CANCER P D, V10, P293, DOI 10.1038/sj.pcan.4500960; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263; Zhu H, 2007, CANCER LETT, V245, P303, DOI 10.1016/j.canlet.2006.01.020; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	43	76	79	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4838	4847		10.1038/onc.2010.228	http://dx.doi.org/10.1038/onc.2010.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20531310				2022-12-28	WOS:000281326400009
J	Jones, RA; Petrik, JJ; Moorehead, RA				Jones, R. A.; Petrik, J. J.; Moorehead, R. A.			Preneoplastic changes persist after IGF-IR downregulation and tumor regression	ONCOGENE			English	Article						mammary tumorigenesis; IGF-IR; tumor regression; tumor recurrence; dormant tumor cells	BREAST-CANCER-CELLS; TRANSGENIC MICE; NEOADJUVANT CHEMOTHERAPY; SOMATOMEDIN RECEPTOR; MAMMARY-TUMORS; GROWTH; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION; RESISTANCE	Despite our incomplete understanding of the function of the type I insulin-like growth factor receptor (IGF-IR) in tumorigenesis, IGF-IR targeting agents have entered clinical trials for the treatment of human cancers. Previously, we have shown that downregulation of IGF-IR transgene in mammary tumors in MTB-IGFIR transengic mice results in tumor regression in a majority of the mice and most of these mice do not develop recurrent mammary tumors. In this study, we examined mammary tissue of mice that did not develop recurrent tumors. Areas of tumor regression were visible macroscopically and microscopically these lesions contained cell debris, individual cells, lipofuscin and doxycycline crystals. Three of the 12 mice also presented with considerable lobuloalveolar development. The re-expression of the IGF-IR transgene in mammary tissue with stably regressed tumors resulted in the rapid re-emergence of mammary tumors, some of which seemed to originate from the regressed mammary lesions. Thus, despite stable tumor regression after IGF-IR downregulation, mammary tissue contained preneoplastic lesions and tumors rapidly re-appear upon re-overexpression of IGF-IR transgene. Therefore, IGF-IR-targeting agents may be effective at regressing mammary tumors expressing IGF-IR, but these agents will not completely eradicate all tumor cells or restore the mammary stromal environment. Oncogene (2010) 29, 4779-4786; doi:10.1038/onc.2010.231; published online 14 June 2010	[Jones, R. A.; Petrik, J. J.; Moorehead, R. A.] Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, Guelph, ON N5A 7Z1, Canada	University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, 50 Stone Rd E, Guelph, ON N5A 7Z1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295; Jones, Robert/0000-0001-7665-9301	Cancer Research Society; Canadian Institutes of Health Research	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by a Cancer Research Society grant and a Canadian Institutes of Health Research grant to RAM.	ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; ARTEAGA CL, 1989, CANCER RES, V49, P6237; Bahri S, 2009, ANN SURG ONCOL, V16, P1619, DOI 10.1245/s10434-009-0441-5; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; Denys H, 2009, CURR PHARM DESIGN, V15, P1373, DOI 10.2174/138161209787846711; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Ghajar CM, 2008, HISTOCHEM CELL BIOL, V130, P1105, DOI 10.1007/s00418-008-0537-1; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Kaplan-Lefko PJ, 2008, ONCOGENE, V27, P2868, DOI 10.1038/sj.onc.1210943; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Linnerth NM, 2009, NEOPLASIA, V11, P672, DOI 10.1593/neo.09310; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Miranda MB, 2008, LEUKEMIA, V22, P1624, DOI 10.1038/leu.2008.28; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; Morris GJ, 2010, SEMIN ONCOL, V37, P1, DOI 10.1053/j.seminoncol.2009.12.001; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Peintinger F, 2008, BRIT J SURG, V95, P433, DOI 10.1002/bjs.6044; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Pure E, 2009, EXPERT OPIN THER TAR, V13, P967, DOI 10.1517/14728220903103841; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Wise TL, 2006, CANCER RES, V66, P1327, DOI 10.1158/0008-5472.CAN-05-3107; Zhang DW, 2009, CLIN CANCER RES, V15, P6639, DOI 10.1158/1078-0432.CCR-09-0951	36	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4779	4786		10.1038/onc.2010.231	http://dx.doi.org/10.1038/onc.2010.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543862				2022-12-28	WOS:000281326400004
J	Kim, EH; Park, AK; Dong, SM; Ahn, JH; Park, WY				Kim, E-H; Park, A-K; Dong, S. M.; Ahn, J-H; Park, W-Y			Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines	ONCOGENE			English	Article						CpG methylation; ionizing radiation; microarray; radiosensitivity	DNA METHYLATION; PROSTATE-CANCER; ATM PROMOTER; EXPRESSION; RADIORESISTANCE; CARCINOMA; MASPIN; BASONUCLIN; DISCOVERY; BREAST	Epigenetic regulation by CpG methylation has an important role in tumorigenesis as well as in the response to cancer therapy. To analyze the mechanism of epigenetic control of radiosensitivity, the CpG methylation profiles of radiosensitive H460 and radioresistant H1299 human non-small cell lung cancer (NSCLC) cell lines were analyzed using microarray profiling. These analyses revealed 1091 differentially methylated genes (DMG) (absolute difference of mean beta-values, |Delta(beta) over bar > 0.5), including genes involved in cell adhesion, cell communication, signal transduction and transcriptional regulation. Among the 747 genes hypermethylated in radioresistant H1299 cells, CpG methylation of SERPINB5 and S100A6 in radioresistant H1299 cells was confirmed by methylation-specific PCR. Reverse transcriptase-PCR showed higher expression of these two genes in radiosensitive H460 cells compared with radioresistant H1299 cells. Downregulation of SERPINB5 or S100A6 by small interfering RNA in H460 cells increased the resistance of these cells to ionizing radiation. In contrast, promoter CpG sites of 344 genes, including CAT and BNC1, were hypomethylated in radioresistant H1299 cells. Suppression of CAT or BNC1 mRNA expression in H1299 cells also reduced the resistance of these cells to ionizing radiation. Thus, we identified DMGs by genome-wide CpG methylation profiling in two NSCLC cell lines with different responses to ionizing radiation, and our data indicated that these differences may be critical for epigenetic regulation of radiosensitivity in lung cancer cells. Oncogene (2010) 29, 4725-4731; doi:10.1038/onc.2010.223; published online 7 June 2010	[Kim, E-H; Park, A-K; Park, W-Y] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea; [Kim, E-H; Park, A-K; Park, W-Y] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea; [Park, A-K; Park, W-Y] Seoul Natl Univ, Coll Med, Genom Core Lab, Seoul 110799, South Korea; [Dong, S. M.] Natl Canc Ctr, Div Translat & Clin Res 1, Res Inst, Seoul, South Korea; [Ahn, J-H] Ewha Womans Univ, Dept Biochem, Sch Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC); Ewha Womans University	Park, WY (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehakro, Seoul 110799, South Korea.	wypark@snu.ac.kr	park, woongyang/D-5727-2012; Kim, Eunhye/ABG-2184-2021	Kim, Eunhye/0000-0002-9225-5865	Korea Science and Engineering Foundation (KOSEF); Ministry of Education, Science and Technology, Korea [M20706000020- 07M0600-02010]; Brain Korea21 (BK21) Program	Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation); Ministry of Education, Science and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); Brain Korea21 (BK21) Program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea)	This research was supported by a grant from the Korea Science and Engineering Foundation (KOSEF), the Ministry of Education, Science and Technology, Korea (M20706000020- 07M0600-02010 to WYP), and the Brain Korea21 (BK21) Program (WYP).	Amundson SA, 2005, ONCOGENE, V24, P4572, DOI 10.1038/sj.onc.1208653; An JH, 2006, J RADIAT RES, V47, P147, DOI 10.1269/jrr.47.147; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Ding S, 2004, WORLD J GASTROENTERO, V10, P3433; Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Epperly MW, 2009, RADIAT RES, V171, P588, DOI 10.1667/RR1424.1; Esteller M, 2002, SCIENCE, V297, P1807; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang KH, 2009, CLIN CANCER RES, V15, P4174, DOI 10.1158/1078-0432.CCR-08-2929; Jeong SH, 2009, EXP MOL MED, V41, P912, DOI 10.3858/emm.2009.41.12.097; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109; Kron K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004830; Maass N, 2000, ACTA ONCOL, V39, P931; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Nagtegaal ID, 2005, VIRCHOWS ARCH, V446, P127, DOI 10.1007/s00428-004-1160-8; Orre LM, 2007, MOL CELL PROTEOMICS, V6, P2122, DOI 10.1074/mcp.M700202-MCP200; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Rehman I, 2004, BRIT J CANCER, V91, P739, DOI 10.1038/sj.bjc.6602034; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222; Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Skvortsova I, 2008, PROTEOMICS, V8, P4521, DOI 10.1002/pmic.200800113; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; Wang L, 2008, MOL PHARMACOL, V73, P119, DOI 10.1124/mol.107.040873; Zhang XH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001087; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	32	42	48	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4725	4731		10.1038/onc.2010.223	http://dx.doi.org/10.1038/onc.2010.223			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531302				2022-12-28	WOS:000281127400011
J	Wang, Y; Ngo, VN; Marani, M; Yang, Y; Wright, G; Staudt, LM; Downward, J				Wang, Y.; Ngo, V. N.; Marani, M.; Yang, Y.; Wright, G.; Staudt, L. M.; Downward, J.			Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells	ONCOGENE			English	Article						KRAS; synthetic lethal; oncogene addiction; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; RNA INTERFERENCE; P53-MEDIATED APOPTOSIS; TUMOR PROGRESSION; CANCER-CELLS; FACTOR SLUG; LINES; GROWTH; GENE	Activating mutations in the KRAS gene are among the most prevalent genetic changes in human cancers. To identify synthetic lethal interactions in cancer cells harbouring mutant KRAS, we performed a large-scale screen in isogenic paired colon cancer cell lines that differ by a single allele of mutant KRAS using an inducible short hairpin RNA interference library. Snail2, a zinc finger transcriptional repressor encoded by the SNAI2 gene, was found to be selectively required for the long-term survival of cancer cells with mutant KRAS that have undergone epithelial-mesenchymal transition (EMT), a transdifferentiation event that is frequently seen in advanced tumours and is promoted by RAS activation. Snail2 expression is regulated by the RAS pathway and is required for EMT. Our findings support Snail2 as a possible target for the treatment of the broad spectrum of human cancers of epithelial origin with mutant RAS that have undergone EMT and are characterized by a high degree of chemoresistance and radioresistance. Oncogene (2010) 29, 4658-4670; doi:10.1038/onc.2010.218; published online 21 June 2010	[Wang, Y.; Marani, M.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; [Ngo, V. N.; Yang, Y.; Staudt, L. M.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Wright, G.] NCI, Biometr Res Branch, DCTD, NIH, Bethesda, MD 20892 USA	Cancer Research UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julian.downward@cancer.org.uk	Downward, Julian/A-3251-2012; Wright, George W/M-1660-2017; Staudt, Louis/AAC-5324-2019	Wang, Yihua/0000-0001-5561-0648; Ngo, Vu/0000-0002-9501-6990; Downward, Julian/0000-0002-2331-4729	Cancer Research UK; NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011008, ZIABC011007] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alberto Bardelli for providing SW48 and SW48 KRAS G13D cells and Senji Shirasawa for providing HCT-116, HKe-3 and HKh-2 cells. This work was supported by funding from Cancer Research UK and from the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Bernards R, 2006, NAT METHODS, V3, P701, DOI 10.1038/NMETH921; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Cully M, 2008, CELL, V133, P1292, DOI 10.1016/j.cell.2008.06.020; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Di Nicolantonio F, 2008, P NATL ACAD SCI USA, V105, P20864, DOI 10.1073/pnas.0808757105; DOBZHANSKY T, 1946, GENETICS, V31, P269; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hajra KM, 2002, CANCER RES, V62, P1613; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; Joyce T, 2009, CLIN EXP METASTAS, V26, P569, DOI 10.1007/s10585-009-9256-9; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Katoh M, 2005, ONCOL REP, V14, P1083; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018; Schmidt CR, 2005, SURGERY, V138, P306, DOI 10.1016/j.surg.2005.06.007; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Vannini I, 2007, CELL ONCOL, V29, P279; Vitali R, 2008, CLIN CANCER RES, V14, P4622, DOI 10.1158/1078-0432.CCR-07-5210; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang Z, 2007, ONCOGENE, V26, P1222, DOI 10.1038/sj.onc.1209902; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029	50	86	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4658	4670		10.1038/onc.2010.218	http://dx.doi.org/10.1038/onc.2010.218			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20562906	Green Accepted			2022-12-28	WOS:000281127400005
J	Kim, TH; Franco, HL; Jung, SY; Qin, J; Broaddus, RR; Lydon, JP; Jeong, JW				Kim, T. H.; Franco, H. L.; Jung, S. Y.; Qin, J.; Broaddus, R. R.; Lydon, J. P.; Jeong, J-W			The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression	ONCOGENE			English	Article						Mig-6; Pten; uterus; endometrial cancer	APOPTOSIS-INHIBITORY PROTEIN; ESTROGEN-RECEPTOR-ALPHA; TUMOR-SUPPRESSOR GENE; PROGESTERONE-RECEPTOR; AKT-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EXPRESSION; CARCINOMA; ACTIVATION; STRESS	Ablation of Mig-6 in the murine uterus leads to the development of endometrial hyperplasia and estrogen-induced endometrial cancer. An additional endometrial cancer mouse model is generated by the ablation of phosphatase and tensin homolog deleted from chromosome 10 (Pten) (either as heterozygotes or by conditional uterine ablation). To determine the interplay between Mig-6 and the PTEN/phosphoinositide 3-kinase signaling pathway during endometrial tumorigenesis, we generated mice with Mig-6 and Pten conditionally ablated in progesterone receptor-positive cells (PR(cre/+)Mig-6(f/f)Pten(f/f); Mig-6(d/d)Pten(d/d)). The ablation of both Mig-6 and Pten dramatically accelerated the development of endometrial cancer compared with the single ablation of either gene. The epithelium of Mig-6(d/d)Pten(d/d) mice showed a significant decrease in the number of apoptotic cells compared with Pten(d/d) mice. The expression of the estrogen-induced apoptotic inhibitors Birc1 was significantly increased in Mig-6(d/d)Pten(d/d) mice. We identified extracellular signal-regulated kinase 2 (ERK2) as an MIG-6 interacting protein by coimmunoprecipitation and demonstrated that the level of ERK2 phosphorylation was increased upon Mig-6 ablation either singly or in combination with Pten ablation. These results suggest that Mig-6 exerts a tumor-suppressor function in endometrial cancer by promoting epithelial cell apoptosis through the downregulation of the estrogen-induced apoptosis inhibitors Birc1 and the inhibition of ERK2 phosphorylation. Oncogene (2010) 29, 3770-3780; doi: 10.1038/onc.2010.126; published online 26 April 2010	[Kim, T. H.; Franco, H. L.; Jung, S. Y.; Qin, J.; Lydon, J. P.; Jeong, J-W] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Jung, S. Y.; Qin, J.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Jeong, JW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,M725, Houston, TX 77030 USA.	jjeong@bcm.edu		Jung, Sung Yun/0000-0003-1521-7977	Reproductive Biology Training [T32HD007165]; Baylor Research Advocates for Student Scientists; NIH [R01CA77530, P50CA098258, R01HD057873]; Dan Duncan Cancer Center in Baylor College of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165, R01HD057873] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA077530, P30CA016672] Funding Source: NIH RePORTER	Reproductive Biology Training; Baylor Research Advocates for Student Scientists; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dan Duncan Cancer Center in Baylor College of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Francesco J DeMayo for fruitful discussion; Jinghua Li for technical assistance; Cory A Rubel, MS and Michael J Large for manuscript preparation. We also thank Dr Hong Wu for the floxed Pten mice. This work was supported by the Reproductive Biology Training Grant T32HD007165 and a scholarship from Baylor Research Advocates for Student Scientists (to HLF), NIH R01CA77530 (to JPL), NIH P50CA098258 (to RRB) and NIH R01HD057873 (to J-WJ). We thank the support of the pathway discovery core of the Dan Duncan Cancer Center in Baylor College of Medicine for proteomic work.	Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Boland R, 2008, STEROIDS, V73, P859, DOI 10.1016/j.steroids.2007.12.027; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; Ejskjaer K, 2007, GYNECOL ONCOL, V104, P158, DOI 10.1016/j.ygyno.2006.07.015; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; Endrizzi MG, 2000, GENOME RES, V10, P1095, DOI 10.1101/gr.10.8.1095; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gesty-Palmer D, 2005, J BIOL CHEM, V280, P32157, DOI 10.1074/jbc.M507460200; Ito K, 2007, ENDOCR J, V54, P667, DOI 10.1507/endocrj.KR-114; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jeong JW, 2009, P NATL ACAD SCI USA, V106, P8677, DOI 10.1073/pnas.0903632106; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Jin N, 2007, GENESIS, V45, P716, DOI 10.1002/dvg.20348; Jung SY, 2008, ANAL CHEM, V80, P1721, DOI 10.1021/ac7021025; Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476; Kakinuma N, 2008, J CELL BIOL, V181, P537, DOI 10.1083/jcb.200707022; Kanamori Y, 2001, CLIN CANCER RES, V7, P892; KHALIFA MA, 1994, GYNECOL ONCOL, V53, P84, DOI 10.1006/gyno.1994.1092; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Levine RL, 1998, CANCER RES, V58, P3254; Lian ZL, 2006, J CELL PHYSIOL, V208, P255, DOI 10.1002/jcp.20681; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Malathi K, 2005, P NATL ACAD SCI USA, V102, P14533, DOI 10.1073/pnas.0507551102; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Sivridis E, 2004, INT J SURG PATHOL, V12, P99, DOI 10.1177/106689690401200202; Slaets H, 2008, PROTEOMICS, V8, P1237, DOI 10.1002/pmic.200700641; SMITH WL, 2000, ANNU REV BIOCHEM, V145, P182; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; Vilgelm A, 2006, CANCER RES, V66, P3375, DOI 10.1158/0008-5472.CAN-05-4019; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin Y, 2008, MOL ENDOCRINOL, V22, P113, DOI 10.1210/me.2007-0295; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790; Zhang YW, 2007, CELL CYCLE, V6, P507, DOI 10.4161/cc.6.5.3928	61	45	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3770	3780		10.1038/onc.2010.126	http://dx.doi.org/10.1038/onc.2010.126			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418913	Bronze, Green Accepted			2022-12-28	WOS:000279385200005
J	Uhlmann, S; Zhang, JD; Schwager, A; Mannsperger, H; Riazalhosseini, Y; Burmester, S; Ward, A; Korf, U; Wiemann, S; Sahin, O				Uhlmann, S.; Zhang, J. D.; Schwaeger, A.; Mannsperger, H.; Riazalhosseini, Y.; Burmester, S.; Ward, A.; Korf, U.; Wiemann, S.; Sahin, Oe			miR-200bc/429 cluster targets PLC gamma 1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer	ONCOGENE			English	Article						miR-200 family; PLC gamma 1; invasion; cell proliferation; tumor suppressor; breast cancer	MESENCHYMAL TRANSITION; GROWTH; MICRORNAS; CONTRIBUTES; SENSITIVITY; ACTIVATION; RESISTANCE; ARREST; FAMILY	The genes encoding microRNAs of the human miR-200 family map to fragile chromosomal regions and are frequently downregulated upon tumor progression. Although having been reported to regulate epithelial-to-mesenchymal transition and transforming growth factor-beta- driven cell invasion, the role of the miR-200 family in EGF-driven breast cancer cell invasion, viability, apoptosis and cell cycle progression is still unknown. In particular, there is no study comparing the roles of the two clusters of this miRNA family. In this study, we show for the first time that miR-200 family members differentially regulate EGF-driven invasion, viability, apoptosis and cell cycle progression of breast cancer cells. We showed that, all miR-200 family members regulate EGF-driven invasion, with the miR-200bc/429 cluster showing stronger effects than the miR-200a/141 cluster. Furthermore, expression of the miR-200a/141 cluster results in G1 arrest supported by increased p27/Kip1 and decreased cyclin dependent kinase 6 expression. In contrast, expression of the 200bc/429 cluster decreases G1 population and increases G2/M phase, in line with the observed reduction of p27/Kip1 and upregulation of the inhibitory phosphorylation of Cdc25C, respectively. To test the hypothesis that phenotypical differences observed between the two clusters are caused by differential targeting spectrums, we performed genome-wide microarray profiling in combination with gain-of-function studies. This identified phospholipase C gamma 1 (PLCG1), which was downregulated only by the miR-200bc/429 cluster, as a potential candidate contributing to these phenotypical differences. Luciferase reporter assays validated PLCG1 as a direct functional target of miR-200bc/429 cluster, but not of miR-200a/141 cluster. Finally, loss of PLCG1 in part mimicked the effect of miR-200bc/429 overexpression in viability, apoptosis and EGF-driven cell invasion of breast cancer cells. Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion, viability and cell cycle progression in breast cancer. Oncogene (2010) 29, 4297-4306; doi: 10.1038/onc.2010.201; published online 31 May 2010	[Uhlmann, S.; Zhang, J. D.; Schwaeger, A.; Mannsperger, H.; Burmester, S.; Ward, A.; Korf, U.; Wiemann, S.; Sahin, Oe] German Canc Res Ctr, Div Mol Genome Anal, D-6900 Heidelberg, Germany; [Riazalhosseini, Y.] German Canc Res Ctr, Div Funct Genome Anal, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Sahin, O (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	oe.sahin@dkfz-heidelberg.de	Sahin, Özgür/F-4403-2014; Wiemann, Stefan/E-4424-2013; Korf, Ulrike/G-2795-2013	Sahin, Özgür/0000-0002-8033-7089; Wiemann, Stefan/0000-0003-4683-3174; Fullgrabe, Anja/0000-0002-8674-0039; Ward Gahlawat, Aoife/0000-0001-7854-7207	National Genome Research Network of the Federal Ministry of Education and Research (BMBF) [01GS0864]; Wilhelm-Sander Stiftung [2009.051.1]; DKFZ International PhD Program	National Genome Research Network of the Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Wilhelm-Sander Stiftung; DKFZ International PhD Program	This work was supported in part by the National Genome Research Network (Contract No. 01GS0864) of the Federal Ministry of Education and Research (BMBF) and by Wilhelm-Sander Stiftung (Contract No. 2009.051.1). JDZ is supported by the DKFZ International PhD Program. We thank Moritz Kublbeck, Christian Schmidt and Ute Ernst for their excellent technical assistance.	Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Browaeys-Poly E, 2009, ANTICANCER RES, V29, P4965; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cochrane DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/821717; DiPaola RS, 2002, CLIN CANCER RES, V8, P3311; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Hyun S, 2009, CELL, V139, P1096, DOI 10.1016/j.cell.2009.11.020; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li SW, 2009, MOL ENDOCRINOL, V23, P901, DOI 10.1210/me.2008-0368; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Markova B, 2010, ONCOGENE, V29, P739, DOI 10.1038/onc.2009.374; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sahin O, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-1; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Sala G, 2008, CANCER RES, V68, P10187, DOI 10.1158/0008-5472.CAN-08-1181; Sato Y, 2001, LEUKEMIA, V15, P1193, DOI 10.1038/sj.leu.2402188; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	33	171	188	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4297	4306		10.1038/onc.2010.201	http://dx.doi.org/10.1038/onc.2010.201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514023				2022-12-28	WOS:000280547900006
J	Suvasini, R; Somasundaram, K				Suvasini, R.; Somasundaram, K.			Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy	ONCOGENE			English	Article						p53; PI3-kinase; chemosensitivity; chemotherapy	PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; DNA-DAMAGE; BREAST-CANCER; TUMOR-CELLS; P53; AKT; INHIBITION; PHOSPHORYLATION; ACTIVATION; APOPTOSIS	The PI3-kinase pathway is the target of inactivation in achieving better cancer chemotherapy. Here, we report that p53-mediated transcription is inhibited by pharmacological inhibitors and a dominant-negative mutant of PI3-kinase, and this inhibition was relieved by a constitutively active mutant of PI3-kinase. Akt/PKB and mTOR, the downstream effectors of PI3-kinase, were also found to be essential. LY294002 (PI3-kinase inhibitor) pre-treatment altered the post-translational modifications and the sub-cellular localization of p53. Although LY294002 increased the chemosensitivity of cells to low concentrations of adriamycin (adriamycin-low), it protected the cells from cytotoxicity induced by high concentrations of adriamycin (adriamycin-high) in a p53-dependent manner. Further, we found that LY294002 completely abolished the activation of p53 target genes (particularly pro-apoptotic) under adriamycin-high conditions, whereas it only marginally repressed the p53 target genes under adriamycin-low conditions; in fact, it further activated the transcription of NOXA, HRK, APAF1 and CASP5 genes. Thus, the differential effect of PI3-kinase on p53 functions seems to be responsible for the differential regulation of DNA damage-induced cytotoxicity and cell death by PI3-kinase. Our finding becomes relevant in the light of ongoing combination chemotherapy trials with the PI3-kinase pathway inhibitors and underscores the importance of p53 status in the careful formulation of combination chemotherapies. Oncogene (2010) 29, 3605-3618; doi: 10.1038/onc.2010.123; published online 26 April 2010	[Suvasini, R.; Somasundaram, K.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in			ICMR; DBT; DST; UGC	ICMR(Indian Council of Medical Research (ICMR)); DBT(Department of Biotechnology (DBT) India); DST(Department of Science & Technology (India)); UGC(University Grants Commission, India)	KS is a Wellcome Trust International Senior Research Fellow. Infrastructural support by funding from ICMR, DBT, DST and UGC to MCB is acknowledged. RS gratefully acknowledges SRF from CSIR.	Bar J, 2005, CELL DEATH DIFFER, V12, P1578, DOI 10.1038/sj.cdd.4401677; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172; Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li XQ, 2005, BREAST CANCER RES, V7, pR589, DOI 10.1186/bcr1259; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meek DW, 1997, PATHOL BIOL, V45, P804; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Price BD, 1996, CANCER RES, V56, P246; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reddy SP, 2008, CLIN CANCER RES, V14, P2978, DOI 10.1158/1078-0432.CCR-07-4821; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3605	3618		10.1038/onc.2010.123	http://dx.doi.org/10.1038/onc.2010.123			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418912				2022-12-28	WOS:000279108600002
J	Mestdagh, P; Fredlund, E; Pattyn, F; Rihani, A; Van Maerken, T; Vermeulen, J; Kumps, C; Menten, B; De Preter, K; Schramm, A; Schulte, J; Noguera, R; Schleiermacher, G; Janoueix-Lerosey, I; Laureys, G; Powel, R; Nittner, D; Marine, JC; Ringner, M; Speleman, F; Vandesompele, J				Mestdagh, P.; Fredlund, E.; Pattyn, F.; Rihani, A.; Van Maerken, T.; Vermeulen, J.; Kumps, C.; Menten, B.; De Preter, K.; Schramm, A.; Schulte, J.; Noguera, R.; Schleiermacher, G.; Janoueix-Lerosey, I.; Laureys, G.; Powel, R.; Nittner, D.; Marine, J-C; Ringner, M.; Speleman, F.; Vandesompele, J.			An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours	ONCOGENE			English	Article						neuroblastoma; T-UCR; non-coding RNA	NONCODING RNAS; MICRORNAS; PCR; ANTAGONISTS; ASSOCIATE; PATHWAY; MAPS	Different classes of non-coding RNAs, including microRNAs, have recently been implicated in the process of tumourigenesis. In this study, we examined the expression and putative functions of a novel class of non-coding RNAs known as transcribed ultraconserved regions (T-UCRs) in neuroblastoma. Genome-wide expression pro. ling revealed correlations between specific T-UCR expression levels and important clinicogenetic parameters such as MYCN amplification status. A functional genomics approach based on the integration of multi-level transcriptome data was adapted to gain insights into T-UCR functions. Assignments of T-UCRs to cellular processes such as TP53 response, differentiation and proliferation were verified using various cellular model systems. For the first time, our results de. ne a T-UCR expression landscape in neuroblastoma and suggest widespread T-UCR involvement in diverse cellular processes that are deregulated in the process of tumourigenesis. Oncogene (2010) 29, 3583-3592; doi:10.1038/onc.2010.106; published online 12 April 2010	[Vandesompele, J.] Ghent Univ Hosp, Ctr Med Genet, MRB, B-9000 Ghent, East Flanders, Belgium; [Fredlund, E.; Ringner, M.] Lund Univ, Dept Oncol, Lund, Sweden; [Fredlund, E.; Ringner, M.] Lund Univ, Strateg Ctr Translat Canc Res, CREATE Hlth, Lund, Sweden; [Schramm, A.; Schulte, J.] Univ Hosp Essen, Essen, Germany; [Noguera, R.] Med Sch Valencia, Valencia, Spain; [Schleiermacher, G.] Inst Curie, Dept Paediat Oncol, Paris, France; [Schleiermacher, G.; Janoueix-Lerosey, I.] Inst Curie, INSERM, U830, Paris, France; [Laureys, G.] Ghent Univ Hosp, Dept Pediat Oncol, B-9000 Ghent, Belgium; [Powel, R.] PrimerDesign, Southampton, Hants, England; [Nittner, D.; Marine, J-C] VIB UGent, Lab Mol Canc Biol, Ghent, Belgium	Ghent University; Ghent University Hospital; Lund University; Lund University; University of Duisburg Essen; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University	Vandesompele, J (corresponding author), Ghent Univ Hosp, Ctr Med Genet, MRB, Pintelaan 185, B-9000 Ghent, East Flanders, Belgium.	Joke.Vandesompele@UGent.be	Janoueix-Lerosey, Isabelle/G-1758-2018; De Preter, Katleen/I-7135-2013; Marine, Jean Christophe/J-2237-2015; speleman, frank/AAR-5184-2020; Schleiermacher, Gudrun/AAN-4711-2021; Pattyn, Filip/A-4164-2015; Rihani, Ali/R-6608-2019; Schramm, Alexander/G-5688-2010; laureys, genevieve/AAG-2390-2021; Schulte, Johannes H/G-3981-2010; Marine, Jean-Christophe/K-3292-2016; Menten, Björn/B-3072-2013; Ringnér, Markus/G-3641-2011; Vandesompele, Jo/W-3411-2018	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; De Preter, Katleen/0000-0002-7726-5096; speleman, frank/0000-0002-6628-8559; Schleiermacher, Gudrun/0000-0002-0133-5879; Pattyn, Filip/0000-0003-0858-6651; Rihani, Ali/0000-0002-6176-0519; Schramm, Alexander/0000-0001-7670-7529; Marine, Jean-Christophe/0000-0003-2433-9837; Ringnér, Markus/0000-0001-5469-8940; Vandesompele, Jo/0000-0001-6274-0184; Schulte, Johannes Hubertus/0000-0003-0671-1201; Nittner, David/0000-0002-2939-2453; Mestdagh, Pieter/0000-0001-7821-9684	Gent University [BOF 01D31406, BOF 01F07207, BOF 01Z09407]; Belgian Kid's Fund; Fondation pour la recherche Nuovo-Soldati; RTICC/ISCIII [RD06/0020/0102]; American Cancer Association; Swedish Cancer Society; Fund for Scientific Research [G.0198.08, 31511809]; Belgian Foundation Against Cancer [SCIE2006-25]; Fund for Scientific Research-Flanders; Institute for the Promotion of Innovation by Science and Technology in Flanders [IWT - 081373]; European Community [037260, 201102]	Gent University; Belgian Kid's Fund; Fondation pour la recherche Nuovo-Soldati(Fondation pour la Recherche Medicale); RTICC/ISCIII(Instituto de Salud Carlos III); American Cancer Association; Swedish Cancer Society(Swedish Cancer Society); Fund for Scientific Research; Belgian Foundation Against Cancer; Fund for Scientific Research-Flanders(FWO); Institute for the Promotion of Innovation by Science and Technology in Flanders(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); European Community(European Commission)	We are indebted to all the members of the SIOPEN and the GPOH for providing tumour samples or the clinical history of patients. This research was funded by the Gent University Research Fund (BOF 01D31406 to PM, BOF 01F07207 to FP, BOF 01Z09407 to J Vandesompele), the Belgian Kid's Fund and the Fondation pour la recherche Nuovo-Soldati (J Vermeulen), RD06/0020/0102 from RTICC/ISCIII to RN, the American Cancer Association to EF, the Swedish Cancer Society to MR, the Fund for Scientific Research (grant number: G.0198.08 and 31511809) and the Belgian Foundation Against Cancer, found of public interest (project SCIE2006-25). KDP is a postdoctoral researcher with the Fund for Scientific Research-Flanders. CK is supported by a doctoral grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT - 081373). We acknowledge the support of the European Community under the FP6 (project: STREP: EET-pipeline, number: 037260) and FP7 (ONCOMIRS, grant agreement number 201102). This publication reflects only authors' views; the commission is not liable for any use that may be made of the information herein. This article presents research results of the Belgian programme of Interuniversity Poles of Attraction, initiated by the Belgian State, Prime Minister's Office, Science Policy Programming.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lazcoz P, 2007, CANCER GENET CYTOGEN, V174, P1, DOI 10.1016/j.cancergencyto.2006.08.014; Lefever S, 2009, NUCLEIC ACIDS RES, V37, pD942, DOI 10.1093/nar/gkn777; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pruitt KD, 2009, NUCLEIC ACIDS RES, V37, pD32, DOI 10.1093/nar/gkn721; Rozen S, 2000, Methods Mol Biol, V132, P365; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	32	109	118	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3583	3592		10.1038/onc.2010.106	http://dx.doi.org/10.1038/onc.2010.106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383195				2022-12-28	WOS:000278835400013
J	Ochiai, H; Takenobu, H; Nakagawa, A; Yamaguchi, Y; Kimura, M; Ohira, M; Okimoto, Y; Fujimura, Y; Koseki, H; Kohno, Y; Nakagawara, A; Kamijo, T				Ochiai, H.; Takenobu, H.; Nakagawa, A.; Yamaguchi, Y.; Kimura, M.; Ohira, M.; Okimoto, Y.; Fujimura, Y.; Koseki, H.; Kohno, Y.; Nakagawara, A.; Kamijo, T.			Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1B beta and TSLC1 in neuroblastoma	ONCOGENE			English	Article						Bmi1; MYCN; neuroblastoma; TSLC1; KIF1B beta	SELF-RENEWAL; STEM-CELLS; N-MYC; EXPRESSION; CANCER; METHYLATION; PROTEINS; HYPERMETHYLATION; PROLIFERATION; AMPLIFICATION	Recent advances in neuroblastoma (NB) research addressed that epigenetic alterations such as hypermethylation of promoter sequences, with consequent silencing of tumor-suppressor genes, can have significant roles in the tumorigenesis of NB. However, the exact role of epigenetic alterations, except for DNA hypermethylation, remains to be elucidated in NB research. In this paper, we clarified the direct binding of MYCN to Bmi1 promoter and upregulation of Bmi1 transcription by MYCN. Mutation introduction into an MYCN binding site in the Bmi1 promoter suggests that MYCN has more important roles in the transcription of Bmi1 than E2F-related Bmi1 regulation. A correlation between MYCN and polycomb protein Bmi1 expression was observed in primary NB tumors. Expression of Bmi1 resulted in the acceleration of proliferation and colony formation in NB cells. Bmi1-related inhibition of NB cell differentiation was confirmed by neurite extension assay and analysis of differentiation marker molecules. Intriguingly, the above-mentioned Bmi1-related regulation of the NB cell phenotype seems not to be mediated only by p14ARF/p16INK4a in NB cells. Expression profiling analysis using a tumor-specific cDNA microarray addressed the Bmi1-dependent repression of KIF1B beta and TSLC1, which have important roles in predicting the prognosis of NB. Chromatin immunoprecipitation assay showed that KIF1Bb and TSLC1 are direct targets of Bmi1 in NB cells. These findings suggest that MYCN induces Bmi1 expression, resulting in the repression of tumor suppressors through Polycomb group gene-mediated epigenetic chromosome modification. NB cell proliferation and differentiation seem to be partially dependent on the MYCN/Bmi1/tumor-suppressor pathways. Oncogene (2010) 29, 2681-2690; doi:10.1038/onc.2010.22; published online 1 March 2010	[Kamijo, T.] Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, Chiba 2608717, Japan; [Ochiai, H.; Kohno, Y.] Chiba Univ, Dept Pediat, Grad Sch Med, Chiba, Japan; [Nakagawa, A.] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan; [Ohira, M.] Chiba Canc Ctr, Res Inst, Lab Canc Genom, Chiba 2608717, Japan; [Okimoto, Y.] Chiba Childrens Hosp, Dept Hematol & Oncol, Chiba, Japan; [Fujimura, Y.; Koseki, H.] RIKEN, Res Ctr Allergy & Immunol, Dev Genet Grp, Yokohama, Kanagawa, Japan; [Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Innovat Canc Therapeut, Chiba 2608717, Japan	Chiba Cancer Center; Chiba University; National Center for Child Health & Development - Japan; Chiba Cancer Center; Chiba Children's Hospital; RIKEN; Chiba Cancer Center	Kamijo, T (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854; Takenobu, Hisanori/0000-0001-7355-1565	Sankyo Foundation of Life Science; Ministry of Health, Labor, and Welfare; Ministry of Health, Labor, and Welfare of Japan [20-13]; Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Sankyo Foundation of Life Science; Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank K Sakurai for technical assistance, and Daniel Mrozek, Medical English Service, for editorial assistance. This study was supported in part by a grant-in-aid from the Sankyo Foundation of Life Science, a grant-in-aid from the Ministry of Health, Labor, and Welfare for Third Term Comprehensive Control Research for Cancer, a grant-in-aid for Cancer Research (20-13) from the Ministry of Health, Labor, and Welfare of Japan, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Ando K, 2008, INT J CANCER, V123, P2087, DOI 10.1002/ijc.23776; Atsuta T, 2001, HYBRIDOMA, V20, P43, DOI 10.1089/027245701300060427; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Caren H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-10; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Cui HJ, 2006, J BIOL CHEM, V281, P34696, DOI 10.1074/jbc.M604009200; Easton J, 1998, CANCER RES, V58, P2624; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fujimura Y, 2006, DEVELOPMENT, V133, P2371, DOI 10.1242/dev.02405; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kamminga LM, 2006, STEM CELLS, V24, P1143, DOI 10.1634/stemcells.2005-0345; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Lutz W, 1996, ONCOGENE, V13, P803; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Munirajan AK, 2008, J BIOL CHEM, V283, P24426, DOI 10.1074/jbc.M802316200; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004; Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608; Schwartz YB, 2008, CURR OPIN CELL BIOL, V20, P266, DOI 10.1016/j.ceb.2008.03.002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Sugino Y, 2007, ONCOGENE, V26, P7401, DOI 10.1038/sj.onc.1210550; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Yan P, 2003, GENE CHROMOSOME CANC, V36, P129, DOI 10.1002/gcc.10150; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331; Yang QW, 2003, CANCER RES, V63, P6299	46	64	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2681	2690		10.1038/onc.2010.22	http://dx.doi.org/10.1038/onc.2010.22			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190806				2022-12-28	WOS:000277354600008
J	Pommier, AJC; Alves, G; Viennois, E; Bernard, S; Communal, Y; Sion, B; Marceau, G; Damon, C; Mouzat, K; Caira, F; Baron, S; Lobaccaro, JMA				Pommier, A. J. C.; Alves, G.; Viennois, E.; Bernard, S.; Communal, Y.; Sion, B.; Marceau, G.; Damon, C.; Mouzat, K.; Caira, F.; Baron, S.; Lobaccaro, J. M. A.			Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells	ONCOGENE			English	Article						LXRs; cholesterol; lipid rafts; apoptosis; prostate	FATTY-ACID SYNTHASE; AKT/PROTEIN KINASE-B; TUMOR-GROWTH; NUCLEAR RECEPTORS; PLASMA-MEMBRANE; ATHYMIC MICE; CHOLESTEROL; INHIBITION; PROLIFERATION; EXPRESSION	Cholesterol is a structural component of lipid rafts within the plasma membrane. These domains, used as platforms for various signaling molecules, regulate cellular processes including cell survival. Cholesterol contents are tightly correlated with the structure and function of lipid rafts. Liver X receptors (LXRs) have a central role in the regulation of cholesterol homeostasis within the cell. Therefore, we investigated whether these nuclear receptors could modulate lipid raft signaling and consequently alter prostate cancer (PCa) cell survival. Treatment with the synthetic LXR agonist T0901317 downregulated the AKT survival pathway and thus induced apoptosis of LNCaP PCa cells in both xenografted nude mice and cell culture. The decrease in tumor cholesterol content resulted from the upregulation of ABCG1 and the subsequent increase in reverse cholesterol transport. RNA interference experiments showed that these effects were mediated by LXRs. Atomic force microscopy scanning of the inner plasma membrane sheet showed smaller and thinner lipid rafts after LXR stimulation, associated with the downregulation of AKT phosphorylation in these lipid rafts. Replenishment of cell membranes with exogenous cholesterol antagonized these effects, showing that cholesterol is a key modulator in this process. Altogether, pharmacological modulation of LXR activity could thus reduce prostate tumor growth by enhancing apoptosis in a lipid raft-dependent manner. Oncogene (2010) 29, 2712-2723; doi:10.1038/onc.2010.30; published online 1 March 2010	[Lobaccaro, J. M. A.] Clermont Univ, CNRS, GReD, UMR 6247, F-63177 Aubiere, France; [Pommier, A. J. C.; Alves, G.; Viennois, E.; Damon, C.; Caira, F.; Baron, S.; Lobaccaro, J. M. A.] Univ Clermont Ferrand, Clermont Univ, Clermont Ferrand, France; [Pommier, A. J. C.; Alves, G.; Viennois, E.; Caira, F.; Baron, S.; Lobaccaro, J. M. A.] Ctr Rech Nutr Humaine Auvergne, Clermont Ferrand, France; [Bernard, S.] Univ Paris 05, CNRS, UPR 2228, Paris, France; [Communal, Y.] Ctr Jean Perrin, Dept Oncogenet, Clermont Ferrand, France; [Sion, B.] Univ Auvergne, Equipe Accueil EA975, Clermont Ferrand, France; [Marceau, G.] Univ Auvergne, Clermont Univ, Clermont Ferrand, France; [Marceau, G.] Ctr Hosp Univ, Serv Biochim, Clermont Ferrand, France; [Mouzat, K.] Ctr Hosp Univ, Serv Biochim, Nimes, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; Universite de Montpellier; CHU de Nimes	Lobaccaro, JMA (corresponding author), Clermont Univ, CNRS, GReD, UMR 6247, Campus Cezeaux,24 Ave Landais, F-63177 Aubiere, France.	j-marc.lobaccaro@univ-bpclermont.fr	Lobaccaro, Jean-Marc/Q-3926-2019; Sion, Benoit/K-2268-2015; LOBACCARO, Jean-Marc/L-6151-2015	Lobaccaro, Jean-Marc/0000-0001-9890-2392; MARCEAU, GEOFFROY/0000-0003-4713-7162; Viennois, Emilie/0000-0002-3104-620X	Association de Recherche sur les Tumeurs Prostatiques; Ligue Allier contre le Cancer; FRM; Fondation BNP-Paribas; MNERT and Region Auvergne; Region Auvergne	Association de Recherche sur les Tumeurs Prostatiques; Ligue Allier contre le Cancer; FRM(Fondation pour la Recherche Medicale); Fondation BNP-Paribas; MNERT and Region Auvergne(Region Auvergne-Rhone-Alpes); Region Auvergne(Region Auvergne-Rhone-Alpes)	This study was supported by Association de Recherche sur les Tumeurs Prostatiques, Ligue Allier contre le Cancer, FRM and Fondation BNP-Paribas research grants. A Pommier and E Viennois are funded by MNERT and Region Auvergne grants, respectively, and G Alves is funded by Region Auvergne program. We are grateful to ICCF-Imagerie Confocale Clermont-Ferrand-for the help in confocal analyses. We thank JP Saru and A De Haze for molecular biology technical assistance, and C Puchol and S Plantade for animal facilities. We also thank Dr P Val, Dr A Martinez, Dr L Morel and Dr C White for their help in the editing of the paper and for fruitful scientific discussions.	Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Beckers A, 2007, CANCER RES, V67, P8180, DOI 10.1158/0008-5472.CAN-07-0389; Bravi F, 2006, ANN ONCOL, V17, P1014, DOI 10.1093/annonc/mdl080; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Brusselmans K, 2007, J BIOL CHEM, V282, P18777, DOI 10.1074/jbc.M611763200; Carson JP, 1999, CANCER RES, V59, P1449; Choe SS, 2007, DIABETES, V56, P1534, DOI 10.2337/db06-1059; Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008-5472.CAN-06-0632; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Frankel DJ, 2006, BIOPHYS J, V90, P2404, DOI 10.1529/biophysj.105.073692; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Fukuchi J, 2004, CANCER RES, V64, P7682, DOI 10.1158/0008-5472.CAN-04-2647; Fukuchi J, 2004, CANCER RES, V64, P7686, DOI 10.1158/0008-5472.CAN-04-2332; Grizard G, 2000, J CHROMATOGR B, V740, P101, DOI 10.1016/S0378-4347(00)00039-6; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kim HJ, 2009, P NATL ACAD SCI USA, V106, P558, DOI 10.1073/pnas.0811295106; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Magura L, 2008, CANCER CAUSE CONTROL, V19, P1259, DOI 10.1007/s10552-008-9197-7; Meng ZX, 2009, DIABETOLOGIA, V52, P125, DOI 10.1007/s00125-008-1174-x; Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701; Mouzat K, 2009, ENDOCRINOLOGY, V150, P3369, DOI 10.1210/en.2008-1519; Murtola TJ, 2008, NAT CLIN PRACT UROL, V5, P376, DOI 10.1038/ncpuro1146; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Rossi S, 2003, MOL CANCER RES, V1, P707; Rusinol AE, 2004, J BIOL CHEM, V279, P1392, DOI 10.1074/jbc.M308619200; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sekine Y, 2008, BIOCHEM BIOPH RES CO, V372, P356, DOI 10.1016/j.bbrc.2008.05.043; Shannon J, 2005, AM J EPIDEMIOL, V162, P318, DOI 10.1093/aje/kwi203; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Swyer GIM, 1942, CANCER RES, V2, P372; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Volle DH, 2007, MOL CELL ENDOCRINOL, V265, P183, DOI 10.1016/j.mce.2006.12.018; Walczak R, 2004, J BIOL CHEM, V279, P9905, DOI 10.1074/jbc.M310587200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White CP, 1909, J PATHOL BACTERIOL, V13, P3, DOI 10.1002/path.1700130103; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang L, 2000, BIOCHEM BIOPH RES CO, V278, P557, DOI 10.1006/bbrc.2000.3855; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zhuang LY, 2005, J CLIN INVEST, V115, P959	52	144	153	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2712	2723		10.1038/onc.2010.30	http://dx.doi.org/10.1038/onc.2010.30			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190811				2022-12-28	WOS:000277354600011
J	Sato, T; Nakashima, A; Guo, L; Coffman, K; Tamanoi, F				Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F.			Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer	ONCOGENE			English	Article						mTORC1; rapamycin; cancer genome database; kinase activity	CDC25 PHOSPHATASES; SIGNALING NETWORK; PROTEIN; GROWTH; RAPAMYCIN; PATHWAY; TARGET	Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates a variety of cellular functions such as growth, proliferation and autophagy. In a variety of cancer cells, overactivation of mTOR has been reported. In addition, mTOR inhibitors, such as rapamycin and its derivatives, are being evaluated in clinical trials as anticancer drugs. However, no active mutants of mTOR have been identified in human cancer. Here, we report that two different point mutations, S2215Y and R2505P, identified in human cancer genome database confer constitutive activation of mTOR signaling even under nutrient starvation conditions. S2215Y was identified in large intestine adenocarcinoma whereas R2505P was identified in renal cell carcinoma. mTOR complex 1 prepared from cells expressing the mutant mTOR after nutrient starvation still retains the activity to phosphorylate 4E-BP1 in vitro. The cells expressing the mTOR mutant show increased percentage of S-phase cells and exhibit resistance to cell size decrease by amino-acid starvation. The activated mutants are still sensitive to rapamycin. However, they show increased resistance to 1-butanol. Our study points to the idea that mTOR activating mutations can be identified in a wide range of human cancer. Oncogene (2010) 29, 2746-2752; doi:10.1038/onc.2010.28; published online 1 March 2010	[Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Jonsson Comprehens Canc Ctr, 1602 Mol Sci Bldg,609 Charles E Young Dr E, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu			National Institutes of Health [CA41996]; NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant CA41996.	Aressy B, 2008, ANTI-CANCER AGENT ME, V8, P818, DOI 10.2174/187152008786847756; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Kranenburg O, 2005, BBA-REV CANCER, V1756, P81, DOI 10.1016/j.bbcan.2005.10.001; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Ohne Y, 2008, J BIOL CHEM, V283, P31861, DOI 10.1074/jbc.M801546200; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Ray D, 2007, CELL CYCLE, V6, P3039, DOI 10.4161/cc.6.24.5104; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Robb VA, 2007, J UROLOGY, V177, P346, DOI 10.1016/j.juro.2006.08.076; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sato T, 2009, J BIOL CHEM, V284, P12783, DOI 10.1074/jbc.M809207200; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	23	153	162	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2746	2752		10.1038/onc.2010.28	http://dx.doi.org/10.1038/onc.2010.28			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190810	Green Accepted			2022-12-28	WOS:000277354600014
J	Nicolas, L; Martinez, C; Baro, C; Rodriguez, M; Baroja-Mazo, A; Sole, F; Flores, JM; Ampurdanes, C; Dantzer, F; Martin-Caballero, J; Aparicio, P; Yelamos, J				Nicolas, L.; Martinez, C.; Baro, C.; Rodriguez, M.; Baroja-Mazo, A.; Sole, F.; Flores, J. M.; Ampurdanes, C.; Dantzer, F.; Martin-Caballero, J.; Aparicio, P.; Yelamos, J.			Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice	ONCOGENE			English	Article						Parp-2; p53; tumour development; thymocytes; V(D)J recombination; double-strand breaks	DOUBLE-STRAND BREAKS; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; GENOMIC STABILITY; REPAIR; P53; RECOMBINATION; TUMORIGENESIS; INHIBITION; DEFICIENCY	Poly(ADP-ribose) polymerase-2 (Parp-2) belongs to a family of enzymes that catalyse poly(ADP-ribosyl) ation of proteins. Parp-2 deficiency in mice (Parp-2(-/-)) results in reduced thymic cellularity associated with increased apoptosis in thymocytes, defining Parp-2 as an important mediator of T-cell survival during thymopoiesis. To determine whether there is a link between Parp-2 and the p53 DNA-damage-dependent apoptotic response, we have generated Parp-2/p53-double-null mutant mice. We found that p53(-/-) backgrounds completely restored the survival and development of Parp-2(-/-) thymocytes. However, Parp-2-deficient thymocytes accumulated high levels of DNA double-strand breaks (DSB), independently of the p53 status, in line with a function of Parp-2 as a caretaker promoting genomic stability during thymocytes development. Although Parp-2(-/-) mice do not have spontaneous tumours, Parp-2 deficiency accelerated spontaneous tumour development in p53-null mice, mainly T-cell lymphomas. These data suggest a synergistic interaction between Parp-2 and p53 in tumour suppression through the role of Parp-2 in DNA-damage response and genome integrity surveillance, and point to the potential importance of examining human tumours for the status of both genes. Oncogene (2010) 29, 2877-2883; doi: 10.1038/onc.2010.11; published online 15 February 2010	[Nicolas, L.; Ampurdanes, C.; Martin-Caballero, J.; Yelamos, J.] IMIM Hosp Mar, Barcelona Biomed Res Pk PRBB, Dept Immunol, Barcelona 08003, Spain; [Nicolas, L.; Aparicio, P.] Univ Murcia, Dept Biochem Mol Biol & Immunol, Sch Med, Murcia, Spain; [Martinez, C.; Baroja-Mazo, A.] Univ Murcia, Dept Surg, CIBERehd, Univ Hosp Virgen de la Arrixaca, Murcia, Spain; [Baro, C.; Rodriguez, M.; Sole, F.] IMIM Hosp Mar, Barcelona Biomed Res Pk, Dept Pathol, Barcelona 08003, Spain; [Flores, J. M.] Univ Complutense, Dept Anim Surg & Med, Sch Vet, E-28040 Madrid, Spain; [Dantzer, F.] ESBS, IREBS FRE3211, Strasbourg, France	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; University of Murcia; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Hospital Clinico Universitario Virgen de la Arrixaca; University of Murcia; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Complutense University of Madrid	Yelamos, J (corresponding author), IMIM Hosp Mar, Barcelona Biomed Res Pk PRBB, Dept Immunol, C Dr Aiguader,88, Barcelona 08003, Spain.	jyelamos@imim.es	Solé, Francesc/K-8373-2012; Dantzer, Françoise/O-2126-2016; sole, francesc/A-2430-2011; Baroja-Mazo, Alberto/E-6270-2016; Martinez, Carlos M./E-4986-2016; Yelamos, Jose/N-2842-2016	Solé, Francesc/0000-0002-3251-2161; Baroja-Mazo, Alberto/0000-0001-5212-5006; Martinez, Carlos M./0000-0003-3307-1326; Aparicio, Pedro/0000-0001-9162-1563; Yelamos, Jose/0000-0003-1195-1496; Dantzer, Francoise/0000-0003-0945-8483	Spanish Ministerio de Ciencia e Innovacion [SAF2008-01572]; Generalitat de Catalunya [2009/SGR/524]; Instituto de Salud Carlos III [PI081150]; Fundacion Seneca [08643/PI/08]; Centre National de la Recherche Scientifique, Association pour la Recherche contre le Cancer, Electricite de France, Comite du Haut-Rhin de la Ligue Nationale Contre le Cancer and Commissariat a l'Energie Atomique; Spanish Ministerio de Ciencia e Innovacion; Instituto de Salud Carlos III (Madrid, Spain); FFIS (Murcia, Spain)	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Generalitat de Catalunya(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fundacion Seneca(Fundacion Seneca); Centre National de la Recherche Scientifique, Association pour la Recherche contre le Cancer, Electricite de France, Comite du Haut-Rhin de la Ligue Nationale Contre le Cancer and Commissariat a l'Energie Atomique(Centre National de la Recherche Scientifique (CNRS)); Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Instituto de Salud Carlos III (Madrid, Spain)(Instituto de Salud Carlos III); FFIS (Murcia, Spain)	We thank Katherine Papageorgiou for assistance with handling the mice and Sergi Mojal for statistical analysis support. This work was supported by Spanish Ministerio de Ciencia e Innovacion (Grant SAF2008-01572 to JY); Generalitat de Catalunya (Grant 2009/SGR/524 to JY); Instituto de Salud Carlos III (Grant PI081150 to PA); Fundacion Seneca (Grant 08643/PI/08 to PA); and funds from Centre National de la Recherche Scientifique, Association pour la Recherche contre le Cancer, Electricite de France, Comite du Haut-Rhin de la Ligue Nationale Contre le Cancer and Commissariat a l'Energie Atomique (VS, FD). LN is supported by the Spanish Ministerio de Ciencia e Innovacion and AB-M is supported by Instituto de Salud Carlos III (Madrid, Spain) and the FFIS (Murcia, Spain).	Bai P, 2007, J BIOL CHEM, V282, P37738, DOI 10.1074/jbc.M701021200; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Beneke R, 2001, ONCOGENE, V20, P8136, DOI 10.1038/sj.onc.1205056; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; Dantzer F, 2006, P NATL ACAD SCI USA, V103, P14854, DOI 10.1073/pnas.0604252103; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; Hawwari A, 2005, NAT IMMUNOL, V6, P481, DOI 10.1038/ni1189; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PETRIE HT, 1993, J EXP MED, V178, P615, DOI 10.1084/jem.178.2.615; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robert I, 2009, J EXP MED, V206, P1047, DOI 10.1084/jem.20082468; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tentori L, 2008, EUR J CANCER, V44, P1302, DOI 10.1016/j.ejca.2008.03.019; Tong WM, 2007, ONCOGENE, V26, P3857, DOI 10.1038/sj.onc.1210156; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2002, CANCER RES, V62, P6990; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Xu M, 2008, MOL CELL BIOL, V28, P1713, DOI 10.1128/MCB.01360-07; Yelamos J, 2008, TRENDS MOL MED, V14, P169, DOI 10.1016/j.molmed.2008.02.003; Yelamos J, 2006, EMBO J, V25, P4350, DOI 10.1038/sj.emboj.7601301	39	44	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2877	2883		10.1038/onc.2010.11	http://dx.doi.org/10.1038/onc.2010.11			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20154718				2022-12-28	WOS:000277591900012
J	Li, J; Lu, Y; Zhang, J; Kang, H; Qin, Z; Chen, C				Li, J.; Lu, Y.; Zhang, J.; Kang, H.; Qin, Z.; Chen, C.			PI4KII alpha is a novel regulator of tumor growth by its action on angiogenesis and HIF-1 alpha regulation	ONCOGENE			English	Article						phosphatidylinositol 4-kinase type II alpha (PI4KII alpha); tumor; angiogenesis; hypoxia-inducible factor-1 alpha (HIF-1 alpha)	HYPOXIA-INDUCIBLE FACTOR; II PHOSPHATIDYLINOSITOL 4-KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; NITRIC-OXIDE; FACTOR-1; PATHWAY; ALPHA; PROGRESSION; MODULATION	Tumor growth is the orchestration of various oncogenes and tumor suppressors, and the regulation of these genes offers a rational therapeutic approach to cancer treatment. In this study, we found a new regulator of tumor growth, phosphatidylinositol 4-kinase type II alpha (PI4KII alpha), the mechanism of which is involved in angiogenesis and hypoxia-inducible factor HIF-1 alpha regulation. Results obtained from a human cancer tissue microarray showed that PI4KII alpha protein expression increases markedly in seven types of cancers compared with normal tissues. Suppression of PI4KII alpha leads to retarded tumor growth in nude mice. Downregulation of PI4KII alpha in cancer cells eliminates tumor cell-induced endothelial cell tubulogenesis and migration, and results in impaired angiogenesis. Further investigation showed that PI4KII alpha can directly regulate HIF-1 alpha expression and that the expression of these two proteins is correlated in vivo. At the same time, downregulation of PI4KII alpha markedly reduces HER-2 autophosphorylation, and PI4KII alpha specifically triggers HIF-1 alpha accumulation through a phosphatidylinositol 3-kinase (PI3K)- and extracellular signal-regulated protein kinase (ERK)-dependent pathway, suggesting that PI4KII alpha may regulate HIF-1 alpha through the HER-2/PI3K, ERK cascade. In summary, we discovered a pivotal role for PI4KII alpha in the regulation of tumor growth. Our results shed new light on understanding the novel functions of PI4KII alpha in cancer and suggest that PI4KII alpha may be a promising specific target for tumor therapy. Oncogene (2010) 29, 2550 - 2559; doi:10.1038/onc.2010.14; published online 15 February 2010	[Li, J.; Lu, Y.; Zhang, J.; Qin, Z.; Chen, C.] Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China; [Lu, Y.; Zhang, J.; Qin, Z.] Chinese Acad Sci, Univ Tokyo Joint Lab Struct Virol & Immunol, Inst Biophys, Beijing, Peoples R China; [Kang, H.] Capital Med Univ, Dept Gen Surg, Xuanwu Hosp, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Capital Medical University	Chen, C (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, 15 Datun Rd, Beijing 100101, Peoples R China.	zhihai@ibp.ac.cn; changchen@moon.ibp.ac.cn		Zhang, Jinhua/0000-0001-8957-8893	'863' National High-Technology Development Program of China [0A200202D03]; National Basic Research Program of China [2006CB911001, 2005CB522804]; National Natural Science Foundation of China [90606020, 30770512]	'863' National High-Technology Development Program of China(National High Technology Research and Development Program of China); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Shane Minogue and Konstantin V Kandror for gifted plasmids and Pietro De Camilli for PI4KII alpha antibody, Wei Liang, Xiyun Yan and Yi Zhu for sharing materials, and Guoheng Xu and Qinwei Yin for valuable discussions. We are grateful to Nanping Wang for his great support. We also thank Junfeng Hao and Xudong Zhao for technical assistance. The work was supported by the '863' National High-Technology Development Program of China (0A200202D03), the National Basic Research Program of China (2006CB911001, 2005CB522804) and the National Natural Science Foundation of China (90606020, 30770512).	Craige B, 2008, MOL BIOL CELL, V19, P1415, DOI 10.1091/mbc.E07-12-1239; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DRABKIN DL, 1949, AM J MED SCI, V217, P710; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Garcia-Cardena G, 1998, J NATL CANCER I, V90, P560, DOI 10.1093/jnci/90.8.560; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; Guo J, 2003, P NATL ACAD SCI USA, V100, P3995, DOI 10.1073/pnas.0230488100; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heilmeyer LMG, 2003, IUBMB LIFE, V55, P59, DOI 10.1080/1521654031000090896; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; Koesters R, 2003, CANCER LETT, V198, P123, DOI 10.1016/S0304-3835(03)00367-7; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Minogue S, 2006, J CELL SCI, V119, P571, DOI 10.1242/jcs.02752; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Qin YB, 2009, J BIOL CHEM, V284, P22544, DOI 10.1074/jbc.M109.014399; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Salazar G, 2009, J BIOL CHEM, V284, P1790, DOI 10.1074/jbc.M805991200; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Simonton DK, 2009, PERSPECT PSYCHOL SCI, V4, P2, DOI 10.1111/j.1745-6924.2009.01093.x; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Waugh MG, 2003, BIOCHEM J, V373, P57, DOI 10.1042/BJ20030089; Weber G, 1996, ANTICANCER RES, V16, P3271; Xu Z, 2006, MOL ENDOCRINOL, V20, P2890, DOI 10.1210/me.2006-0193; Yamamoto S, 2004, ANN SURG ONCOL, V11, P697, DOI 10.1245/ASO.2004.10.018; Zhong H, 2000, CANCER RES, V60, P1541	41	40	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2550	2559		10.1038/onc.2010.14	http://dx.doi.org/10.1038/onc.2010.14			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154717				2022-12-28	WOS:000277169400010
J	Wu, J; Zhang, YC; Suo, WH; Liu, XB; Shen, WW; Tian, H; Fu, GH				Wu, J.; Zhang, Y-C; Suo, W-H; Liu, X-B; Shen, W-W; Tian, H.; Fu, G-H			Induction of anion exchanger-1 translation and its opposite roles in the carcinogenesis of gastric cancer cells and differentiation of K562 cells	ONCOGENE			English	Article						anion exchanger-1; band-3; miR-24; erythropoiesis; gastric carcinogenesis	ERYTHROID-DIFFERENTIATION; NONERYTHROID CELLS; PROGENITOR CELLS; ALPHA-SPECTRIN; BETA-SPECTRIN; KIDNEY BAND-3; PROTEIN 4.1; AE1 GENE; EXPRESSION; CLONING	Anion exchanger-1 (AE1), an erythroid-specific membrane protein, mediates the Cl(-)/HCO(3)(-) exchange across the plasma membrane and regulates intracellular pH. We have found that AE1 was unexpectedly expressed in gastric cancer cells and participated in the tumorigenesis of the cancer. Here, we focus on the induction of AE1 expression and its role in gastric carcinogenesis as well as in the differentiation of K562 cells. The results show that expression of AE1 is not related to genetic mutation or the mRNA level, but rather, that it is modulated by miR-24. miR-24 decreases the expression of AE1 through binding to the 3'UTR of AE1 mRNA. Transfection of an miR-24 into gastric cancer cells reduced the elevation of the AE1 protein, which resulted in return of AE1-sequestrated p16 to the nucleus, thereby inhibiting proliferation of the cells. Furthermore, the miR-24 inhibitor cooperated with hemin to induce the expression of AE1 in K562 cells and differentiation of the cells, which is consistent with results obtained from the cells cultured at pH 7.6 or from forced stable expression of AE1. These findings establish a novel regulation of miR-24-related AE1 expression in gastric carcinogenesis and erythropoiesis. Oncogene (2010) 29, 1987-1996; doi:10.1038/onc.2009.481; published online 11 January 2010	[Wu, J.; Zhang, Y-C; Suo, W-H; Shen, W-W; Tian, H.; Fu, G-H] Shanghai Jiao Tong Univ, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Sch Med,Inst Med Sci,Dept Pathol, Shanghai 200025, Peoples R China; [Liu, X-B] Harbin Med Coll, Oncol Affiliated Hosp 2, Radiat Dept, Harbin, Peoples R China	Shanghai Jiao Tong University; Harbin Medical University	Fu, GH (corresponding author), Shanghai Jiao Tong Univ, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Sch Med,Inst Med Sci,Dept Pathol, 280 S Chong Qing Rd, Shanghai 200025, Peoples R China.	fuguhu@263.net		Wu, Jun/0000-0003-2515-6418	National Natural Science Foundation of China [NO30570697, NO30770960]; National High Technology Research and Development Program of China [NO2008AA02Z120]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	This work was supported in part by the National Natural Science Foundation of China (NO30570697, NO30770960) and National High Technology Research and Development Program of China (863 Program) (NO2008AA02Z120).	ALPER SL, 1994, J CLIN INVEST, V93, P1430, DOI 10.1172/JCI117120; An XL, 2005, BIOCHEMISTRY-US, V44, P10681, DOI 10.1021/bi047331z; Durham JT, 2009, MICROVASC RES, V77, P281, DOI 10.1016/j.mvr.2008.12.003; ENDO T, 1994, LEUKEMIA RES, V18, P49, DOI 10.1016/0145-2126(94)90008-6; Friis-Hansen L, 2006, SCAND J CLIN LAB INV, V66, P607, DOI 10.1080/00365510600873894; Fu GH, 2005, FEBS LETT, V579, P2105, DOI 10.1016/j.febslet.2005.02.063; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Galluzzi L, 2001, FEBS LETT, V489, P254, DOI 10.1016/S0014-5793(00)02333-4; Gascard P, 2000, CURR OPIN HEMATOL, V7, P123, DOI 10.1097/00062752-200003000-00009; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Huo XF, 2006, MOL CELL BIOCHEM, V292, P155, DOI 10.1007/s11010-006-9229-0; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; Lal A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001864; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; McAdams TA, 1998, BRIT J HAEMATOL, V103, P317, DOI 10.1046/j.1365-2141.1998.00975.x; McAdams TA, 1997, BRIT J HAEMATOL, V97, P889, DOI 10.1046/j.1365-2141.1997.1372951.x; Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600-0609.2008.01111.x; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Richards SM, 1999, J CELL SCI, V112, P1519; Ruan K, 2009, CANCER LETT, V285, P116, DOI 10.1016/j.canlet.2009.04.031; SAHR KE, 1994, GENOMICS, V24, P491, DOI 10.1006/geno.1994.1658; SCHOFIELD AE, 1994, BLOOD, V84, P2000; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; Shen WW, 2007, NEOPLASIA, V9, P812, DOI 10.1593/neo.07403; SHOWE L C, 1987, Genomics, V1, P71, DOI 10.1016/0888-7543(87)90107-8; Takakuwa Y, 2000, INT J HEMATOL, V72, P298; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; Wang JY, 2009, J CELL PHYSIOL, V219, P617, DOI 10.1002/jcp.21711; Wang Q, 2008, BLOOD, V111, P588, DOI 10.1182/blood-2007-05-092718; Xu WQ, 2009, J CANCER RES CLIN, V135, P1323, DOI 10.1007/s00432-009-0573-9; Yang GH, 2009, J CELL BIOCHEM, V107, P548, DOI 10.1002/jcb.22156	35	30	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1987	1996		10.1038/onc.2009.481	http://dx.doi.org/10.1038/onc.2009.481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062076				2022-12-28	WOS:000276199600011
J	Peschiaroli, A; Skaar, JR; Pagano, M; Melino, G				Peschiaroli, A.; Skaar, J. R.; Pagano, M.; Melino, G.			The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival	ONCOGENE			English	Article						ubiquitin; F-box proteins; beta-Trcp; degradation	F-BOX PROTEINS; KAPPA-B-ALPHA; REPEAT-CONTAINING PROTEIN; MEDIATED DEGRADATION; LIGASE; INHIBITION; BETA-TRCP1; PATHWAY; PLAYERS; CDC25A	Ubiquitin-specific proteases (USPs) are a subclass of cysteine proteases that catalyze the removal of ubiquitin (either monomeric or chains) from substrates, thus counteracting the activity of E3 ubiquitin ligases. Although the importance of USPs in a multitude of processes, from hereditary cancer to neurodegeneration, is well established, our knowledge on their mode of regulation, substrate specificity and biological function is quite limited. In this study we identify USP47 as a novel interactor of the E3 ubiquitin ligase, Skp1/Cul1/F-box protein beta-transducin repeat-containing protein (SCF beta-Trcp). We found that both beta-Trcp1 and beta-Trcp2 bind specifically to USP47, and point mutations in the beta-Trcp WD-repeat region completely abolished USP47 binding, indicating an E3-substrate-type interaction. However, unlike canonical beta-Trcp substrates, USP47 protein levels were neither affected by silencing of beta-Trcp nor modulated in a variety of processes, such as cell-cycle progression, DNA damage checkpoint responses or tumor necrosis factor (TNF) pathway activation. Notably, genetic or siRNA-mediated depletion of USP47 induced accumulation of Cdc25A, decreased cell survival and augmented the cytotoxic effects of anticancer drugs. In conclusion, we showed that USP47, a novel beta-Trcp interactor, regulates cell growth and survival, potentially providing a novel target for anticancer therapies. Oncogene (2010) 29, 1384-1393; doi:10.1038/onc.2009.430; published online 7 December 2009	[Peschiaroli, A.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, IDI IRCCS Biochem Lab, I-00173 Rome, Italy; [Skaar, J. R.; Pagano, M.] NYU, Sch Med, Dept Pathol, NYU Canc Inst, New York, NY USA; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA; [Melino, G.] Univ Leicester, Toxicol Unit, MRC, Leicester, Leics, England	University of Rome Tor Vergata; New York University; Howard Hughes Medical Institute; New York University; University of Leicester	Melino, G (corresponding author), Univ Rome, Dept Expt Med & Biochem Sci, IDI IRCCS Biochem Lab, Via Montpellier, I-00133 Rome, RM, Italy.	gerry.melino@uniroma2.it		PESCHIAROLI, ANGELO/0000-0001-6311-2382; pagano, michele/0000-0003-3210-2442	EU [LSHB-CT-019067]; Alleanza contro il Cancro [ACC12/6]; MIUR/PRIN [RBIP06LCA9_0023]; AIRC [2008-2010_33-08]; ISS 'Program Italia-USA' [N526D5]; Italian Human ProteomeNet [RBRN07BMCT_007]; Telethon; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research Foundation; Philip Morris USA Inc.; Philip Morris International; American Cancer Society; MRC [MC_U132670600] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R21CA125173, R37CA076584, R21CA161108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; Medical Research Council [MC_U132670600] Funding Source: researchfish	EU(European Commission); Alleanza contro il Cancro; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); ISS 'Program Italia-USA'; Italian Human ProteomeNet; Telethon(Fondazione Telethon); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research Foundation; Philip Morris USA Inc.; Philip Morris International; American Cancer Society(American Cancer Society); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by grants from EU EPISTEM (LSHB-CT-019067), 'Alleanza contro il Cancro' (ACC12/6), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-2010_33-08), ISS 'Program Italia-USA' N526D5, Italian Human ProteomeNet RBRN07BMCT_007 and Telethon to GM; and grants from the National Institutes of Health (R01-GM57587, R37-CA76584 and R21-CA125173) and Multiple Myeloma Research Foundation to MP. Research described in this article was also supported in part by Philip Morris USA Inc. and Philip Morris International to GM. JRS was supported by the American Cancer Society-Mr and Mrs William G Campbell Postdoctoral Fellowship in Memory of Carolyn Cabott. MP is an Investigator with the Howard Hughes Medical Institute.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Lantinga-van Leeuwen IS, 2004, HUM MOL GENET, V13, P3069, DOI 10.1093/hmg/ddh336; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Syljuasen RG, 2004, CANCER RES, V64, P9035, DOI 10.1158/0008-5472.CAN-04-2434; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	39	58	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1384	1393		10.1038/onc.2009.430	http://dx.doi.org/10.1038/onc.2009.430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19966869	Green Accepted			2022-12-28	WOS:000275170600013
J	Masuda, K; Ishikawa, Y; Onoyama, I; Unno, M; de Alboran, IM; Nakayama, KI; Nakayama, K				Masuda, K.; Ishikawa, Y.; Onoyama, I.; Unno, M.; de Alboran, I. M.; Nakayama, K. I.; Nakayama, K.			Complex regulation of cell-cycle inhibitors by Fbxw7 in mouse embryonic fibroblasts	ONCOGENE			English	Article						cell cycle; CDK inhibitor; ubiquitin ligase; SCF complex; Notch; conditional knockout mouse	F-BOX PROTEIN; FBW7 UBIQUITIN LIGASE; C-MYC; TUMOR-SUPPRESSOR; MICE LACKING; P27(KIP1); NUCLEOPHOSMIN; DEGRADATION; P57(KIP2); EXIT	The F-box protein Fbxw7 (also known as Fbw7, SEL-10, hCdc4 or hAgo) mediates the ubiquitylation and thereby contributes to the degradation of proteins that positively regulate cell cycle. Conditional ablation of Fbxw7 in mouse embryonic fibroblasts (MEFs) induces cell-cycle arrest accompanied by abnormal accumulation of the intracellular domain of Notch1 (NICD1) and c-Myc. However, the molecular mechanisms by which the accumulation of NICD1 and c-Myc induces cell-cycle arrest have remained unclear. We have now examined the expression of cell-cycle inhibitors in Fbxw7-deficient MEFs and found that the abundance of p27(Kip1) and p57(Kip2) is paradoxically decreased. This phenomenon appears to be attributable to the accumulation of NICD1, given that it was recapitulated by overexpression of NICD1 and blocked by ablation of RBP-J. Conversely, the expression of p16(Ink4a) and p19(ARF) was increased in an NICD1-independent manner in Fbxw7-null MEFs. The increased expression of p19(ARF) was recapitulated by overexpression of c-Myc and abolished by ablation of c-Myc, suggesting that the accumulation of c-Myc is primarily responsible for that of p19(ARF). In contrast, the upregulation of p16(Ink4a) appeared to be independent of c-Myc. These results indicate that cell-cycle inhibitors undergo complex regulation by the Fbxw7-mediated proteolytic system. Oncogene (2010) 29, 1798-1809; doi:10.1038/onc.2009.469; published online 21 December 2009	[Masuda, K.; Ishikawa, Y.; Nakayama, K.] Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Masuda, K.; Unno, M.] Tohoku Univ, Grad Sch Med, Dept Surg, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Masuda, K.; Ishikawa, Y.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Onoyama, I.; Nakayama, K. I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan; [de Alboran, I. M.] CSIC, Dept Immunol & Oncol, Natl Biotechnol Ctr, Madrid, Spain	Tohoku University; Tohoku University; Japan Science & Technology Agency (JST); Kyushu University; Consejo Superior de Investigaciones Cientificas (CSIC)	Nakayama, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	nakayak2@mail.tains.tohoku.ac.jp	Moreno de Alboran, Ignacio/K-1044-2017; Unno, Michiaki/AAX-5246-2020; Unno, Michiaki/A-8633-2010	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Honjo for providing Rbpj<SUP>F/F</SUP> mice; R Tsunematsu for an NICD1 plasmid; T Kitamura for pMX-puro and Plat-E cells; T Senga, Y Ono and N Kobayashi for technical assistance; and N Yanagihara, N Ishida and other laboratory members for helpful discussion and Y Akaida for help in preparation of the paper. This study was supported in part by a Grant-in-Aid and the Network Medicine Global COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; de Alboran IM, 2004, CELL DEATH DIFFER, V11, P61, DOI 10.1038/sj.cdd.4401319; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Georgia S, 2006, DEV BIOL, V298, P22, DOI 10.1016/j.ydbio.2006.05.036; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Ishikawa Y, 2008, ONCOGENE, V27, P6164, DOI 10.1038/onc.2008.216; Jia JL, 2007, MOL CELL BIOL, V27, P7236, DOI 10.1128/MCB.00780-07; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Lomas J, 2008, FRONT BIOSCI-LANDMRK, V13, P5071, DOI 10.2741/3065; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Onoyama I, 2008, CELL CYCLE, V7, P3307, DOI 10.4161/cc.7.21.6931; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Solomon DA, 2008, CANCER RES, V68, P8657, DOI 10.1158/0008-5472.CAN-08-2084; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUNDARAM M, 1993, GENETICS, V135, P765; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Vernon AE, 2006, EMBO REP, V7, P643, DOI 10.1038/sj.embor.7400691; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1798	1809		10.1038/onc.2009.469	http://dx.doi.org/10.1038/onc.2009.469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023701				2022-12-28	WOS:000276022800009
J	Sheridan, C; Brumatti, G; Elgendy, M; Brunet, M; Martin, SJ				Sheridan, C.; Brumatti, G.; Elgendy, M.; Brunet, M.; Martin, S. J.			An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs	ONCOGENE			English	Article						apoptosis; cisplatin; Noxa; BH3-only; ERK; Ras	CISPLATIN-INDUCED APOPTOSIS; BH3-ONLY PROTEINS; MITOCHONDRIAL APOPTOSIS; PROTEASOME INHIBITION; SIGNALING PATHWAY; BCL-2 FAMILY; HL-60 CELLS; CANCER; ACTIVATION; BIM	Cisplatin is a widely used cancer chemotherapeutic that promotes DNA damage-associated apoptosis. Although platinum compounds are known to form DNA adducts and provoke DNA damage, the molecular mechanism of cisplatin-induced cell death remains unclear. In this article, we show that the BH3-only protein Noxa is strongly transcriptionally upregulated in response to cisplatin and related platinum compounds. Cisplatin-induced Noxa expression was ERK dependent, but p53 independent, and inhibition of ERK activation markedly attenuated cisplatin-induced cell death, as well as Noxa expression. Furthermore, siRNA-mediated ablation of Noxa expression also inhibited cisplatin-induced cell death and permitted clonogenic survival. These observations reveal a novel ERK-regulated route to Noxa expression that is important for the cell killing activity of platinum-based chemotherapeutic drugs. Oncogene (2010) 29, 6428-6441; doi:10.1038/onc.2010.380; published online 30 August 2010	[Sheridan, C.; Brumatti, G.; Elgendy, M.; Brunet, M.; Martin, S. J.] Trinity Coll Dublin, Mol Cell Biol Lab, Dept Genet, Smurfit Inst, Dublin D2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Trinity Coll Dublin, Mol Cell Biol Lab, Dept Genet, Smurfit Inst, Dublin D2, Ireland.	martinsj@tcd.ie		Martin, Seamus/0000-0002-8539-3143	Science Foundation Ireland [08/IN.1/B203]; Irish Cancer Society [CRP08MAR]; IRCSET	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Irish Cancer Society; IRCSET(Irish Research Council for Science, Engineering and Technology)	We thank Dr Julian Downward, Dr Richard Marais and Dr Maria Soengas for provision of Ras, B-Raf and Bax/Bak shRNA expression plasmids, respectively; Dr Eric Eldering for provision of shRNA constructs against Noxa and Mcl-1; Dr Dean Fennell for provision of H460 cells and for very useful discussions; Dr Yihong Ye for provision of shRNA constructs against ATF4 and Dr Hans van Dam for provision of shRNA constructs against Fra1 and ATF3. We thank Science Foundation Ireland (08/IN.1/B203) and The Irish Cancer Society (CRP08MAR) for support of this work. GB was supported, in part, by an IRCSET post-doctoral fellowship. CS was supported, in part, by an IRCSET PhD studentship. SJM is a Science Foundation Ireland Principal Investigator.	Adrain C, 2006, SCIENCE, V311, P785, DOI 10.1126/science.1124154; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Amran D, 2005, BBA-MOL CELL RES, V1743, P269, DOI 10.1016/j.bbamcr.2004.10.009; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI SS, 1995, ONCOGENE, V11, P1693; Cosaert J, 2002, BRIT J CANCER, V87, P825, DOI 10.1038/sj.bjc.6600540; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gong JG, 1999, NATURE, V399, P806; Hao D, 2006, SEMIN RADIAT ONCOL, V16, P10, DOI 10.1016/j.semradonc.2005.08.002; Kim GP, 2007, EXPERT OPIN DRUG MET, V3, P281, DOI 10.1517/17425255.3.2.281; Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kollmannsberger C, 2006, CANCER-AM CANCER SOC, V106, P1217, DOI 10.1002/cncr.21742; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; Muggia F, 2009, GYNECOL ONCOL, V112, P275, DOI 10.1016/j.ygyno.2008.09.034; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; O'Reilly LA, 2009, J IMMUNOL, V183, P261, DOI 10.4049/jimmunol.0803853; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pectasides D, 2008, CANCER TREAT REV, V34, P603, DOI 10.1016/j.ctrv.2008.05.006; Petit T, 2003, MOL CANCER THER, V2, P165; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Schimmer AD, 2008, CLIN CANCER RES, V14, P8295, DOI 10.1158/1078-0432.CCR-08-0999; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schweyer S, 2004, BRIT J CANCER, V91, P589, DOI 10.1038/sj.bjc.6601919; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; von Kriegsheim A, 2009, NAT CELL BIOL, V11, P1458, DOI 10.1038/ncb1994; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937	49	71	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6428	6441		10.1038/onc.2010.380	http://dx.doi.org/10.1038/onc.2010.380			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802529				2022-12-28	WOS:000285138900003
J	Cheng, L; Zhou, Z; Flesken-Nikitin, A; Toshkov, IA; Wang, W; Camps, J; Ried, T; Nikitin, AY				Cheng, L.; Zhou, Z.; Flesken-Nikitin, A.; Toshkov, I. A.; Wang, W.; Camps, J.; Ried, T.; Nikitin, A. Y.			Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency	ONCOGENE			English	Article						breast cancer; genomic maintenance; mouse; models of cancer; oncogenomics; tumor suppressor	CONDITIONAL MOUSE MODEL; TUMOR-SUPPRESSOR; BREAST-CANCER; SOMATIC INACTIVATION; HIGH-FREQUENCY; DNA-DAMAGE; CYCLIN D1; IN-VIVO; MICE; EXPRESSION	Genetically defined mouse models offer an important tool to identify critical secondary genetic alterations with relevance to human cancer pathogenesis. We used newly generated MMTV-Cre105Ayn mice to inactivate p53 and/or Rb strictly in the mammary epithelium, and to determine recurrent genomic changes associated with deficiencies of these genes. p53 inactivation led to formation of estrogen receptor-positive raloxifene-responsive mammary carcinomas with features of luminal subtype B. Rb deficiency was insufficient to initiate carcinogenesis but promoted genomic instability and growth rate of neoplasms associated with p53 inactivation. Genome-wide analysis of mammary carcinomas identified a recurrent amplification at chromosome band 9A1, a locus orthologous to human 11q22, which contains protooncogenes cIAP1 (Birc2), cIAP2 (Birc3) and Yap1. It is interesting that this amplicon was preferentially detected in carcinomas carrying wild-type Rb. However, all three genes were overexpressed in carcinomas with p53 and Rb inactivation, likely due to E2F-mediated transactivation, and cooperated in carcinogenesis according to gene knockdown experiments. These findings establish a model of luminal subtype B mammary carcinoma, identify critical role of cIAP1, cIAP2 and Yap1 co-expression in mammary carcinogenesis and provide an explanation for the lack of recurrent amplifications of cIAP1, cIAP2 and Yap1 in some tumors with frequent Rb deficiency, such as mammary carcinoma. Oncogene (2010) 29, 5700-5711; doi:10.1038/onc.2010.300; published online 2 August 2010	[Cheng, L.; Zhou, Z.; Flesken-Nikitin, A.; Toshkov, I. A.; Nikitin, A. Y.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; [Wang, W.] Cornell Univ, Microarray Core Facil, Ithaca, NY 14853 USA; [Camps, J.; Ried, T.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA	Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nikitin, AY (corresponding author), Cornell Univ, Dept Biomed Sci, T2 014A VRT Campus Rd, Ithaca, NY 14853 USA.	an58@cornell.edu	Camps, Jordi/AAG-3080-2020	Camps, Jordi/0000-0002-3165-3640	NIH/NCI [R01 CA96823]; NYSTEM [C023050]; NATIONAL CANCER INSTITUTE [ZIABC010836, R01CA096823] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NYSTEM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank David C Corney for critical reading of this paper and Dr Anton Berns (Netherlands Cancer Institute, Amsterdam, The Netherlands) for the generous gift of the p53<SUP>floxP/floxP</SUP> and Rb<SUP>floxP/floxP</SUP> mice. This work was supported by grants R01 CA96823 (NIH/NCI) and C023050 (NYSTEM) to AYN.	Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chai Y, 2000, DEVELOPMENT, V127, P1671; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Geradts J, 1996, AM J PATHOL, V149, P15; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Knudsen ES, 2006, CURR MOL MED, V6, P749; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Ma O, 2009, CANCER RES, V69, P2559, DOI 10.1158/0008-5472.CAN-08-2929; MALKIN D, 1994, ANNU REV GENET, V28, P443; Marino S, 2000, GENE DEV, V14, P994; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Reed CA, 2009, ONCOGENE, V28, P4434, DOI 10.1038/onc.2009.303; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robinson GW, 2001, ONCOGENE, V20, P7115, DOI 10.1038/sj.onc.1204888; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Scambia G, 2006, ONCOGENE, V25, P5302, DOI 10.1038/sj.onc.1209620; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sporn MB, 2004, CLIN THER, V26, P830, DOI 10.1016/S0149-2918(04)90127-0; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wijnhoven SWP, 2005, CANCER RES, V65, P8166, DOI 10.1158/0008-5472.CAN-05-1650; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	50	33	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5700	5711		10.1038/onc.2010.300	http://dx.doi.org/10.1038/onc.2010.300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676140	Green Accepted			2022-12-28	WOS:000283262500006
J	Iadevaia, V; Caldarola, S; Biondini, L; Gismondi, A; Karlsson, S; Dianzani, I; Loreni, F				Iadevaia, V.; Caldarola, S.; Biondini, L.; Gismondi, A.; Karlsson, S.; Dianzani, I.; Loreni, F.			PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression	ONCOGENE			English	Article						ribosome synthesis; cell cycle arrest; erythroleukemia cells; PIM1; RPS19; p27(Kip1)	DIAMOND-BLACKFAN ANEMIA; ACTIVATION; P53; PROTEINS; PROLIFERATION; BIOGENESIS; DISRUPTION; REGULATORS; P27(KIP1); STABILITY	PIM1 is a constitutively active serine/threonine kinase regulated by cytokines, growth factors and hormones. It has been implicated in the control of cell cycle progression and apoptosis and its overexpression has been associated with various kinds of lymphoid and hematopoietic malignancies. The activity of PIM1 is dependent on the phosphorylation of several targets involved in transcription, cell cycle and apoptosis. We have recently observed that PIM1 interacts with ribosomal protein (RP) S19 and cosediments with ribosomes. Defects in ribosome synthesis (ribosomal stress) have been shown to activate a p53-dependent growth arrest response. To investigate if PIM1 could have a role in the response to ribosomal stress, we induced ribosome synthesis alterations in TF-1 and K562 erythroid cell lines. We found that RP deficiency, induced by RNA interference or treatment with inhibitor of nucleolar functions, causes a drastic destabilization of PIM1. The lower level of PIM1 induces an increase in the cell cycle inhibitor p27(Kip1) and blocks cell proliferation even in the absence of p53. Notably, restoring PIM1 level by transfection causes a recovery of cell growth. Our data indicate that PIM1 may act as a sensor for ribosomal stress independently of or in concert with the known p53-dependent mechanisms. Oncogene (2010) 29, 5490-5499; doi:10.1038/onc.2010.279; published online 19 July 2010	[Iadevaia, V.; Caldarola, S.; Biondini, L.; Gismondi, A.; Loreni, F.] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; [Karlsson, S.] Univ Lund Hosp, Lund Stem Cell Ctr, Dept Mol Med & Gene Therapy, S-22185 Lund, Sweden; [Dianzani, I.] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy	University of Rome Tor Vergata; Lund University; Skane University Hospital; University of Eastern Piedmont Amedeo Avogadro	Loreni, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	loreni@uniroma2.it	Iadevaia, Valentina/J-8613-2017; Gismondi, Angelo/N-4264-2015; Iadevaia, Valentina/H-2950-2019	Iadevaia, Valentina/0000-0002-8393-8541; Gismondi, Angelo/0000-0002-9257-9667; Iadevaia, Valentina/0000-0002-8393-8541	Telethon, Italy [GGP07242]; Diamond Blackfan Anemia Foundation Inc.; Italian Ministry for University and Research (MIUR)	Telethon, Italy(Fondazione Telethon); Diamond Blackfan Anemia Foundation Inc.; Italian Ministry for University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank Marcello Giorgi for expert technical assistance. The financial support of Telethon, Italy (Grant No. GGP07242) is gratefully acknowledged. This work was also supported by grants from Diamond Blackfan Anemia Foundation Inc. and the Italian Ministry for University and Research (MIUR) FIRB and PRIN.	Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Badhai J, 2009, FEBS LETT, V583, P2049, DOI 10.1016/j.febslet.2009.05.023; Caldarola S, 2009, FEBS J, V276, P3199, DOI 10.1111/j.1742-4658.2009.07036.x; Chiocchetti A, 2005, HAEMATOLOGICA, V90, P1453; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Idol RA, 2007, BLOOD CELL MOL DIS, V39, P35, DOI 10.1016/j.bcmd.2007.02.001; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Losman JA, 2003, J BIOL CHEM, V278, P4800, DOI 10.1074/jbc.M208246200; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Miyake K, 2005, MOL THER, V11, P627, DOI 10.1016/j.ymthe.2004.12.001; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Orru S, 2007, MOL CELL PROTEOMICS, V6, P382, DOI 10.1074/mcp.M600156-MCP200; Panic L, 2007, CELL CYCLE, V6, P20, DOI 10.4161/cc.6.1.3666; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shah N, 2008, EUR J CANCER, V44, P2144, DOI 10.1016/j.ejca.2008.06.044; Shay KP, 2005, MOL CANCER RES, V3, P170; Soeiro I, 2006, MOL CELL BIOL, V26, P6170, DOI 10.1128/MCB.02182-05; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Urashima M, 1998, BLOOD, V92, P959, DOI 10.1182/blood.V92.3.959.414k21_959_967; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wang Z, 2001, J Vet Sci, V2, P167; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	34	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5490	5499		10.1038/onc.2010.279	http://dx.doi.org/10.1038/onc.2010.279			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20639905				2022-12-28	WOS:000282945800006
J	Kufe, D				Kufe, D.			Oncogenic function of the MUC1 receptor subunit in gene regulation	ONCOGENE			English	Editorial Material						MUC1; MUC1-C subunit; nuclear localization; transcriptional regulation; Wnt/beta-catenin; p53	BETA-CATENIN; BREAST; TUMORIGENICITY; CARCINOMA; CANCER	The mucin 1 (MUC1) oncoprotein is overexpressed by diverse human cancers; however, it has remained largely unclear how MUC1 contributes to tumorigenesis. In this issue of Oncogene and in concert with published work, Behrens et al. report that the MUC1 receptor subunit activates genes involved in invasion, angiogenesis and metastasis. Oncogene (2010) 29, 5663-5666; doi:10.1038/onc.2010.334; published online 16 August 2010	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Room D830, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA097098, R01CA042802] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097098-01, R01 CA097098, R01 CA042802, R01 CA042802-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008	10	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	42					5663	5666		10.1038/onc.2010.334	http://dx.doi.org/10.1038/onc.2010.334			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20711235	Green Accepted			2022-12-28	WOS:000283262500002
J	Lin, T; Ponn, A; Hu, X; Law, BK; Lu, J				Lin, T.; Ponn, A.; Hu, X.; Law, B. K.; Lu, J.			Requirement of the histone demethylase LSD1 in Snail-mediated transcriptional repression during epithelial-mesenchymal transition	ONCOGENE			English	Article						EMT; E-cadherin; Snail; histone modifications; LSD1; bivalent	E-CADHERIN REPRESSION; LYSINE DEMETHYLASES; TUMOR PROGRESSION; GENE-EXPRESSION; CHROMATIN; PROTEIN; DIFFERENTIATION; METHYLATION; DISEASE; COMPLEX	Epithelial-mesenchymal transition (EMT) has pivotal roles during embryonic development and carcinoma progression. Members of the Snai1 family of zinc finger transcription factors are central mediators of EMT and induce EMT in part by directly repressing epithelial markers such as E-cadherin, a gatekeeper of the epithelial phenotype and a suppressor of tumor invasion. However, the molecular mechanism underlying Snai1-mediated transcriptional repression remains incompletely understood. Here we show that Snai1 physically interacts with and recruits the histone demethylase LSD1 (KDM1A) to epithelial gene promoters. LSD1 removes dimethylation of lysine 4 on histone H3 (H3K4m2), a covalent histone modification associated with active chromatin. Importantly, LSD1 is essential for Snai1-mediated transcriptional repression and for maintenance of the silenced state of Snai1 target genes in invasive cancer cells. In the absence of LSD1, Snai1 fails to repress E-cadherin. In cancer cells in which E-cadherin is silenced, depletion of LSD1 results in partial de-repression of epithelial genes and elevated H3K4m2 levels at the E-cadherin promoter. These results underline the critical role of LSD1 in Snai1-dependent transcriptional repression of epithelial markers and suggest that the LSD1 complex could be a potential therapeutic target for prevention of EMT-associated tumor invasion. Oncogene (2010) 29, 4896-4904; doi: 10.1038/onc.2010.234; published online 21 June 2010	[Lin, T.; Ponn, A.; Hu, X.; Lu, J.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Law, B. K.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Hu, X.] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Jilin University	Lu, J (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, POB 103633, Gainesville, FL 32610 USA.	jrlu@ufl.edu	Lin, Tong/G-4105-2012; Law, Brian/L-6043-2019; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	Stop! Children's Cancer, Florida Bankhead-Coley Cancer Research Program [09BN-12-23092]; The National Cancer Institute [R01CA137021]; University of Florida, Gainesville, FL, USA; NATIONAL CANCER INSTITUTE [R01CA137021] Funding Source: NIH RePORTER	Stop! Children's Cancer, Florida Bankhead-Coley Cancer Research Program; The National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Florida, Gainesville, FL, USA(University of Florida); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate technical assistance from Linbao Ai and Heiman Wang. We are grateful to Mien-Chie Hung (MD Anderson Cancer Center, Texas, USA), M Angela Nieto (Instituto de Neurociencias CSIC-UMH, Spain), Suming Huang, Yi Qiu and Lizi Wu for kindly providing reagents. We thank Mike Kilberg and Jorg Bungert for critical reading of the paper. This study was supported by grants to JL from Stop! Children's Cancer, Florida Bankhead-Coley Cancer Research Program (09BN-12-23092), The National Cancer Institute (R01CA137021) and to AP from the University Scholars Program at University of Florida, Gainesville, FL, USA.	Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	33	205	219	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4896	4904		10.1038/onc.2010.234	http://dx.doi.org/10.1038/onc.2010.234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562920	Green Accepted			2022-12-28	WOS:000281578700004
J	Santos, J; Gonzalez-Sanchez, L; Villa-Morales, M; Ors, I; Lopez-Nieva, P; Vaquero, C; Gonzalez-Gugel, E; Fernandez-Navarro, P; Roncero, AM; Guenet, JL; Montagutelli, X; Fernandez-Piqueras, J				Santos, J.; Gonzalez-Sanchez, L.; Villa-Morales, M.; Ors, I.; Lopez-Nieva, P.; Vaquero, C.; Gonzalez-Gugel, E.; Fernandez-Navarro, P.; Roncero, A. M.; Guenet, J-L; Montagutelli, X.; Fernandez-Piqueras, J.			The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with gamma-radiation-induced T-cell lymphoblastic lymphomas	ONCOGENE			English	Article						T-cell lymphoblastic lymphoma; gamma-irradiation; survival; thymus stroma; Cd274 gene	RECOMBINANT CONGENIC STRAINS; INDUCED THYMIC LYMPHOMAS; NON-HODGKINS-LYMPHOMA; TUMOR-SUSCEPTIBILITY; POSITIVE SELECTION; POTENTIAL MECHANISM; BREAST-CANCER; MOUSE MODELS; BONE-MARROW; B7-H1	Using an inter-specific subcongenic strain, Nested Recombinant Haplotype 3 (NRH3), generated between two mouse strains showing extreme differences in gamma-radiation-induced thymic lymphoma susceptibility (SEG/Pas and C57BL/6J), we have identified a critical region on chromosome 19 that regulates survival of mice suffering from T-cell lymphoblastic lymphomas. Mapped on this region, the gene encoding the Cd274 ligand is able to trigger an inhibitory effect that modulates T-cell receptor (TCR) signalling and affects thymocyte maturation. Interestingly, this gene shows differential expression between thymic stromal cells from both strains in early response to a single sublethal c-ray dose, but is inhibited in T-cell lymphoblastic lymphomas. Furthermore, we have identified several polymorphisms in the complementary DNA sequence of this gene that affect the affinity for its Cd279 receptor and are able to induce a differential rate of thymocyte apoptosis. Taken together, our data are consistent with Cd274 acting as a genetic modifier that influences the survival of c-radiation-induced T-cell lymphoma-bearing mice. The data similarly support the idea of a co-evolution of tumour cells and associated stromal cells to generate a favourable microenvironment for T-cell lymphoma growth. Oncogene (2010) 29, 5265-5273; doi:10.1038/onc.2010.280; published online 19 July 2010	[Santos, J.; Gonzalez-Sanchez, L.; Villa-Morales, M.; Ors, I.; Vaquero, C.; Gonzalez-Gugel, E.; Roncero, A. M.; Fernandez-Piqueras, J.] Univ Autonoma Madrid, CSIC, Dept Biol Celular & Inmunol, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; [Santos, J.; Gonzalez-Sanchez, L.; Villa-Morales, M.; Ors, I.; Vaquero, C.; Gonzalez-Gugel, E.; Fernandez-Piqueras, J.] MICINN, ISCIII, Madrid, Spain; [Lopez-Nieva, P.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain; [Fernandez-Navarro, P.] Inst Salud Carlos III, Area Epidemiol Ambiental & Canc, Ctr Nacl Epidemiol, Madrid, Spain; [Fernandez-Navarro, P.] Minist Sanidad & Consumo, Madrid, Spain; [Guenet, J-L; Montagutelli, X.] Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Instituto de Salud Carlos III; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, CSIC, Dept Biol Celular & Inmunol, Ctr Biol Mol Severo Ochoa, Nicolas Cabrera 1, E-28049 Madrid, Spain.	jfpiqueras@cbm.uam.es	Santos, Javier/ABF-5755-2021; Navarro, Pablo Fernandez/E-8893-2018; VILLA-MORALES, MARIA C./H-8797-2015; Nieva, Pilar López/R-9516-2019	Santos, Javier/0000-0002-4168-6251; Navarro, Pablo Fernandez/0000-0001-9427-2581; VILLA-MORALES, MARIA C./0000-0001-7906-0169; Nieva, Pilar López/0000-0001-6369-2444; Gonzalez-Sanchez, Laura/0000-0002-4749-2423; RONCERO SANCHEZ, ANA MARIA/0000-0002-2542-9028	European Commission [FI6R-CT2003-508842]; Spanish Ministry of Education and Science [SAF-2006-09437, SAF2009-11426]	European Commission(European CommissionEuropean Commission Joint Research Centre); Spanish Ministry of Education and Science(Spanish Government)	This work was supported by the European Commission contract number FI6R-CT2003-508842 to JS and by the Spanish Ministry of Education and Science contract number SAF-2006-09437 and SAF2009-11426 to JFP. We thank Arturo Morales for the critical reading of the paper.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Bian YS, 2007, HUM MOL GENET, V16, P3128, DOI 10.1093/hmg/ddm274; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; BRATHWAITE O, 1992, CANCER RES, V52, P3791; Burgio G, 2007, GENETICS, V177, P2321, DOI 10.1534/genetics.107.078006; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIAMOND LE, 1988, IMMUNOGENETICS, V28, P71, DOI 10.1007/BF00346154; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Elahi E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004388; Gray DHD, 2002, J IMMUNOL METHODS, V260, P15, DOI 10.1016/S0022-1759(01)00493-8; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hare KJ, 1999, J IMMUNOL, V162, P3978; Inman BA, 2007, CANCER-AM CANCER SOC, V109, P1499, DOI 10.1002/cncr.22588; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jawad M, 2007, BLOOD CELL MOL DIS, V38, P69, DOI 10.1016/j.bcmd.2006.10.009; Keir ME, 2005, J IMMUNOL, V175, P7372, DOI 10.4049/jimmunol.175.11.7372; Kodama Y, 2004, CARCINOGENESIS, V25, P143, DOI 10.1093/carcin/bgg177; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Liang SC, 2003, EUR J IMMUNOL, V33, P2706, DOI 10.1002/eji.200324228; Lwin T, 2007, LEUKEMIA, V21, P1521, DOI 10.1038/sj.leu.2404723; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; Mori N, 2000, J RADIAT RES, V41, P367, DOI 10.1269/jrr.41.367; Muhlbauer M, 2006, J HEPATOL, V45, P520, DOI 10.1016/j.jhep.2006.05.007; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Ochiai Y, 2003, ONCOGENE, V22, P1098, DOI 10.1038/sj.onc.1206202; Ogawa K, 2007, CANCER RES, V67, P4016, DOI 10.1158/0008-5472.CAN-06-4498; Oka S, 1999, J VET MED SCI, V61, P709, DOI 10.1292/jvms.61.709; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pelham RJ, 2006, P NATL ACAD SCI USA, V103, P19848, DOI 10.1073/pnas.0609635104; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Santos J, 2009, CANCER RES, V69, P2577, DOI 10.1158/0008-5472.CAN-08-1821; Villa-Morales M, 2006, ONCOGENE, V25, P2022, DOI 10.1038/sj.onc.1209234; Villa-Morales M, 2007, CANCER RES, V67, P5107, DOI 10.1158/0008-5472.CAN-06-4006; Wang M, 2003, CANCER RES, V63, P3317; Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752; Wintterle S, 2003, CANCER RES, V63, P7462	48	5	7	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5265	5273		10.1038/onc.2010.280	http://dx.doi.org/10.1038/onc.2010.280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20639904				2022-12-28	WOS:000282089100005
J	Luker, KE; Steele, JM; Mihalko, LA; Ray, P; Luker, GD				Luker, K. E.; Steele, J. M.; Mihalko, L. A.; Ray, P.; Luker, G. D.			Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands	ONCOGENE			English	Article						breast cancer; chemokines; chemokine receptors; bioluminescence imaging; luciferase; protein fragment complementation	TUMOR-GROWTH; RECEPTOR; PROTEIN; MIGRATION; CXCL12; DIMERIZATION; CHEMOTAXIS; INHIBITION; EXPRESSION; SURFACE	CXCR7 is a receptor for chemokines including CXCL12 (stromal-derived factor-1), a molecule that promotes tumor growth and metastasis in breast cancer and other malignancies. Building on the recent observation that CXCR7 sequesters CXCL12, we investigated mechanisms for CXCR7-dependent uptake of chemokines. Breast cancer cells expressing CXCR7 accumulated chemokines CXCL12 and CXC11 present at concentrations < 1ng/ml, unlike cells expressing CXCR4. CXCR7-dependent accumulation of chemokines was reduced by inhibitors of clathrin-mediated endocytosis. After CXCR7-mediated internalization, CXCL12 trafficked to lysosomes and was degraded, although levels of CXCR7 remained stable. CXCR7 reduced CXCL12 in the extracellular space, limiting the amounts of chemokine available to acutely stimulate signaling through CXCR4. CXCR7 constitutively internalized and recycled to the cell membrane even in the absence of ligand, and addition of chemokines did not significantly enhance receptor internalization. Chemokines at concentrations less than the Kd values for ligand-receptor binding did not alter levels of CXCR7 at the cell surface. Higher concentrations of chemokine ligands reduced the total cell surface expression of CXCR7 without affecting receptor internalization, indicating that receptor recycling was inhibited. CXCR7dependent uptake of chemokines and receptor trafficking were regulated by beta-arrestin 2. These studies establish mechanisms through which CXCR7 regulates the availability of chemokine ligands in the extracellular space. Oncogene (2010) 29, 4599-4610; doi: 10.1038/onc.2010.212; published online 7 June 2010	[Luker, G. D.] Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ctr Mol Imaging, Ann Arbor, MI 48109 USA; [Luker, K. E.; Steele, J. M.; Mihalko, L. A.; Ray, P.; Luker, G. D.] Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ctr Mol Imaging, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		luker, gary/0000-0001-6832-2581	NIH [R01CA136553, R01CA136829, P50CA093990]; NATIONAL CANCER INSTITUTE [P50CA093990, R01CA136829, R01CA136553] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research was supported by NIH grants R01CA136553, R01CA136829 and P50CA093990. We thank ChemoCentryx for mAb 11G8 and CCX733.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Atanackovic D, 2008, TUMOR BIOL, V29, P93, DOI 10.1159/000135689; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Cox JH, 2008, J BIOL CHEM, V283, P19389, DOI 10.1074/jbc.M800266200; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; Fermas S, 2008, GLYCOBIOLOGY, V18, P1054, DOI 10.1093/glycob/cwn088; Furuya M, 2007, HUM PATHOL, V38, P1676, DOI 10.1016/j.humpath.2007.03.023; Galliera E, 2004, J BIOL CHEM, V279, P25590, DOI 10.1074/jbc.M400363200; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hansell CAH, 2006, BIOCHEM SOC T, V34, P1009, DOI 10.1042/BST0341009; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KELLY K, 2006, MOL IMAGING BIOL, V8, P1536; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kollmar O, 2007, NEOPLASIA, V9, P862, DOI 10.1593/neo.07559; Laguri C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001110; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker KE, 2008, ANAL CHEM, V80, P5565, DOI 10.1021/ac8005457; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Luker KE, 2009, NEOPLASIA, V11, P1022, DOI 10.1593/neo.09724; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Luker KE, 2009, FASEB J, V23, P823, DOI 10.1096/fj.08-116749; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200; Sharma V, 1996, J MED CHEM, V39, P3483, DOI 10.1021/jm950823c; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; van Weert AWM, 2000, EUR J CELL BIOL, V79, P394, DOI 10.1078/0171-9335-00062; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Weber M, 2004, MOL BIOL CELL, V15, P2492, DOI 10.1091/mbc.E03-09-0634; Wu FY, 2008, MOL CANCER RES, V6, P1276, DOI 10.1158/1541-7786.MCR-07-2108; Yang XL, 2006, VACCINE, V24, P2966, DOI 10.1016/j.vaccine.2005.12.004; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang GB, 2007, CHINA COMMUN, V4, P46; Zhao M, 2008, BREAST CANCER RES TR, V110, P211, DOI 10.1007/s10549-007-9712-7	53	170	170	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4599	4610		10.1038/onc.2010.212	http://dx.doi.org/10.1038/onc.2010.212			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531309	Green Accepted			2022-12-28	WOS:000280862300010
J	Zhao, TT; Le Francois, BG; Goss, G; Ding, K; Bradbury, PA; Dimitroulakos, J				Zhao, T. T.; Le Francois, B. G.; Goss, G.; Ding, K.; Bradbury, P. A.; Dimitroulakos, J.			Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins	ONCOGENE			English	Article						epidermal growth factor receptor mevalonate pathway; AKT; lovastatin; rho GTPases	GROWTH-FACTOR RECEPTOR; MEVALONATE PATHWAY; MTOR INHIBITORS; LUNG-CANCER; PHASE-III; COMBINATION; ERLOTINIB; GTPASES; TRIALS; RAS	We recently showed the ability of lovastatin to inhibit the function of the epidermal growth factor receptor (EGFR) and its downstream signaling of the phosphatidylinositol-3 kinase/AKT pathway. Combining lovastatin with gefitinib, a potent EGFR inhibitor, induced synergistic cytotoxicity in various tumor-derived cell lines. In this study, lovastatin treatment was found to inhibit ligand-induced EGFR dimerization in squamous cell carcinoma cells and its activation of AKT and its downstream targets 4E-binding protein 1 and S6 kinase 1. This inhibition was associated with global protein translational inhibition shown by a decrease in RNA associated polysome fractions. The effects of lovastatin on EGFR function were reversed by the addition of geranylgeranyl pyrophosphate, which functions as a protein membrane anchor. Lovastatin treatment induced actin cytoskeletal disorganization and the expression of geranylgeranylated rho family proteins that regulate the actin cytoskeleton, including rhoA. Lovastatin-induced rhoA was inactive as EGF stimulation failed to activate rhoA and inhibition of the rho-associated kinase, a target and mediator of rhoA function, with Y-27632 also showed inhibitory effects on EGFR dimerization. The ability of lovastatin to inhibit EGFR dimerization is a novel exploitable mechanism regulating this therapeutically relevant target. To explore the potential clinical significance of this combination, we evaluated the effect of statin on the overall survival (OS) and disease-specific survival (DSS) of patients with advanced non-small-cell lung cancer enrolled in the NCIC Clinical Trials Group phase III clinical trials BR21 (EGFR tyrosine kinase inhibitor erlotinib versus placebo) and BR18 (carboplatin and paclitaxel with or without the metalloproteinase inhibitor BMS275291). In BR18, use of statin did not affect OS or DSS. In BR21, patients showed a trend for improvement in OS (HR: 0.69, P = 0.098) and DSS (HR: 0.62, P = 0.048), but there was no statin x treatment interaction effect (P = 0.34 and P = 0.51 for OS and DSS, respectively). Oncogene (2010) 29, 4682-4692; doi:10.1038/onc.2010.219; published online 21 June 2010	[Zhao, T. T.; Le Francois, B. G.; Dimitroulakos, J.] Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; [Zhao, T. T.; Goss, G.] Ottawa Hosp, Res Inst, Dept Med Oncol, Ottawa, ON K1H 1C4, Canada; [Dimitroulakos, J.] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Dimitroulakos, J.] Univ Ottawa, Dept Biochem, Ottawa, ON, Canada; [Ding, K.; Bradbury, P. A.] Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Queens University - Canada; Canadian Cancer Trials Group	Dimitroulakos, J (corresponding author), Ottawa Hosp, Res Inst, Ctr Canc Therapeut, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 1C4, Canada.	jdimitroulakos@ohri.ca	Dimitroulakos, Jim/AAK-3398-2020		Canadian Institute of Health Research; Ontario Institute for Cancer Research	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research	Research support from the Canadian Institute of Health Research (JD) and the Ontario Institute for Cancer Research (JD) is greatly appreciated. We thank Dr D. Gray, Apotex Canada and AstraZeneca UK for generously providing the reagents used in this study.	Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Boulougouris P, 2001, ANTICANCER RES, V21, P2769; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Cabebe Elwyn, 2007, Curr Treat Options Oncol, V8, P15, DOI 10.1007/s11864-007-0022-4; Cicha I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.a3; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Dann SG, 2006, FEBS LETT, V580, P2821, DOI 10.1016/j.febslet.2006.04.068; Darenfed H, 2007, CELL MOTIL CYTOSKEL, V64, P97, DOI 10.1002/cm.20168; Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247; Dimitroulakos J, 2006, CLIN CANCER RES, V12, p4426S, DOI 10.1158/1078-0432.CCR-06-0089; Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Herbst RS, 2003, SEMIN ONCOL, V30, P34, DOI 10.1016/S0093-7754(03)00184-2; Herbst RS, 2002, EXPERT OPIN INV DRUG, V11, P837, DOI 10.1517/13543784.11.6.837; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; Mantha AJ, 2005, CLIN CANCER RES, V11, P2398, DOI 10.1158/1078-0432.CCR-04-1951; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Niknejad N, 2007, J BIOL CHEM, V282, P29748, DOI 10.1074/jbc.M705859200; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Pallet N, 2006, M S-MED SCI, V22, P947, DOI 10.1051/medsci/20062211947; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Thibault A, 1996, CLIN CANCER RES, V2, P483; Thomas AL, 2003, SEMIN ONCOL, V30, P32, DOI 10.1016/S0093-7754(03)00123-4	36	49	49	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4682	4692		10.1038/onc.2010.219	http://dx.doi.org/10.1038/onc.2010.219			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20562912	Bronze			2022-12-28	WOS:000281127400007
J	Shouse, GP; Nobumori, Y; Liu, X				Shouse, G. P.; Nobumori, Y.; Liu, X.			A B56 gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A	ONCOGENE			English	Article						p53; PP2A; B56 gamma; Thr55 phosphorylation; lung cancer	A-BETA-SUBUNIT; REGULATORY SUBUNIT; P53; GENE; HOLOENZYME; COMPLEXES; COLON	Earlier studies have shown both p53-dependent and -independent tumor-suppressive functions of B56 gamma-specific protein phosphatase 2A (B56 gamma-PP2A). In the absence of p53, B56 gamma-PP2A can inhibit cell proliferation and cell transformation by an unknown mechanism. In the presence of p53, on DNA damage, a complex including B56 gamma-PP2A and p53 is formed, which leads to Thr55 dephosphorylation of p53, induction of the p53 transcriptional target p21 and inhibition of cell proliferation. In spite of its significance in inhibition of cell proliferation, no B56 gamma mutations have been linked to human cancer to date. In this study, we first differentiate between the p53-dependent and -independent functions of B56 gamma-PP2A by identifying a domain of the B56 gamma protein required for interaction with p53. Within this region, we identify a B56 gamma mutation, F395C, in lung cancer that disrupts the B56 gamma-p53 interaction. More importantly, we show that F395C is unable to promote p53 Thr55 dephosphorylation, transcriptional activation of p21 and the p53-dependent tumor-suppressive function of PP2A. This finding provides a mechanistic basis for the p53-dependent and -independent functions of B56 gamma-PP2A and establishes a critical link between B56 gamma-PP2A p53-dependent tumor-suppressive function and tumorigenesis. Oncogene (2010) 29, 3933-3941; doi:10.1038/onc.2010.161; published online 17 May 2010	[Shouse, G. P.; Nobumori, Y.; Liu, X.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Liu, X (corresponding author), Univ Calif Riverside, Dept Biochem, 5414 Boyce Hall, Riverside, CA 92521 USA.	xuan.liu@ucr.edu		Shouse, Geoffrey/0000-0002-7917-5713	NIH, National Institute of Cancer [CA075180]; NATIONAL CANCER INSTITUTE [R01CA075180, R29CA075180] Funding Source: NIH RePORTER	NIH, National Institute of Cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr B Shen at the City of Hope for assistance in searching public databases for mutations in the B56 gamma gene and to P Podlesny for generating B56 gamma mutant plasmid constructs. We thank all members of our laboratory for many helpful discussions. This work was supported by NIH grant CA075180 from the National Institute of Cancer.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Esplin ED, 2006, GENE CHROMOSOME CANC, V45, P182, DOI 10.1002/gcc.20284; Forester CM, 2007, P NATL ACAD SCI USA, V104, P19867, DOI 10.1073/pnas.0709879104; Grochola LF, 2009, CLIN CANCER RES, V15, P6301, DOI 10.1158/1078-0432.CCR-09-0797; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; NETO E, 2006, P NATL ACAD SCI USA, V97, P3491; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Suzuki Y, 2004, GENOME RES, V14, P1711, DOI 10.1101/gr.2435604; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033	27	39	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3933	3941		10.1038/onc.2010.161	http://dx.doi.org/10.1038/onc.2010.161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20473327	Green Accepted			2022-12-28	WOS:000279603200006
J	Wang, SE; Yu, Y; Criswell, TL; DeBusk, LM; Lin, PC; Zent, R; Johnson, DH; Ren, X; Arteaga, CL				Wang, S. E.; Yu, Y.; Criswell, T. L.; DeBusk, L. M.; Lin, P. C.; Zent, R.; Johnson, D. H.; Ren, X.; Arteaga, C. L.			Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators	ONCOGENE			English	Article						HER2/ErbB2; Ras; TGF-beta; VEGF; EGFR ligands; tumor microenvironment	TYROSINE KINASE INHIBITOR; FACTOR-BETA; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; SOMATIC MUTATIONS; CELL-MIGRATION; IN-VITRO; H-RAS; RECEPTOR; ERBB2	Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared with wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and exhibit an attenuated response to the HER2 antibody trastuzumab. We investigated herein pathways through which mutant HER2 alters the extracellular environment, potentially leading to drug resistance and the effect of simultaneously targeting HER2 and the tumor cell microenvironment with a therapeutic intent. Expression of mutant HER2 in mammary epithelial cells activated autocrine transforming growth factor (TGF) beta 1 signaling through a mechanism involving Rac1 and c-Jun N-terminal kinase-activating protein 1-dependent transcription. Cells transformed by an activating mutant of H-Ras (G12V) also expressed higher TGF-beta 1 level through Rac1 activation. In addition, mutant HER2 induced the EGFR ligands TGF-alpha and amphiregulin at the mRNA and protein levels. Vascular endothelial growth factor, a target of the TGF-beta-Smad transcriptional regulation, was also induced as a result of expression of mutant HER2. Inhibition of TGF-beta signaling with the Alk5 small molecule inhibitor LY2109761 reduced growth and invasiveness of cells expressing mutant HER2. Combined inhibition of intracellular and paracrine effects of mutant HER2 by trastuzumab and the EGFR antibody cetuximab were more efficient than single-agent therapies. These data suggest that mutations in oncogenes such as HER2 and Ras not only alter intracellular signaling but also influence on other components of the tumor microenvironment by inducing several pro-invasive growth factors. In turn, these serve as extracellular targets of novel therapeutic strategies directed at both cancer-driving oncogenes and the modified tumor microenvironment. Oncogene (2010) 29, 3335-3348; doi:10.1038/onc.2010.112; published online 12 April 2010	[Wang, S. E.] Beckman Res Inst City Hope, Div Tumor Cell Biol, Duarte, CA 91010 USA; [Yu, Y.; Ren, X.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol & Biotherapy, Tianjin, PR, Peoples R China; [Criswell, T. L.; DeBusk, L. M.; Lin, P. C.; Zent, R.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [DeBusk, L. M.; Lin, P. C.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [Zent, R.; Johnson, D. H.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [Arteaga, C. L.] Vanderbilt Univ, Sch Med, Breast Canc Res Program, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA	City of Hope; Beckman Research Institute of City of Hope; Tianjin Medical University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Wang, SE (corresponding author), Beckman Res Inst City Hope, Div Tumor Cell Biol, 1500 E Duarte Rd,KCRB Room 2007, Duarte, CA 91010 USA.	ewang@coh.org; carlos.arteaga@vanderbilt.edu			NCI [K99/R00 CA125892, NCI R01 CA62212, R01 CA80195]; ACS [CRP-07-234]; Breast Cancer Specialized Program of Research Excellence (SPORE) [P50 CA98131]; Vanderbilt-Ingram Comprehensive Cancer Center [P30 CA68485]; NATIONAL CANCER INSTITUTE [K99CA125892, ZIABC011390, P30CA068485, R01CA080195, R00CA125892, T32CA009592, R01CA062212, P50CA098131] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); Breast Cancer Specialized Program of Research Excellence (SPORE); Vanderbilt-Ingram Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI K99/R00 CA125892 (SEW), NCI R01 CA62212 (CLA), R01 CA80195 (CLA), ACS Clinical Research Professorship Grant CRP-07-234 (CLA), Breast Cancer Specialized Program of Research Excellence (SPORE) P50 CA98131, and Vanderbilt-Ingram Comprehensive Cancer Center Support Grant P30 CA68485.	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2002, J CELL SCI, V115, P3193; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DeBusk LM, 2004, EXP CELL RES, V298, P167, DOI 10.1016/j.yexcr.2004.04.013; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Erdogan M, 2007, J BIOL CHEM, V282, P27713, DOI 10.1074/jbc.M703037200; Fahey MS, 1996, BRIT J CANCER, V74, P1074, DOI 10.1038/bjc.1996.492; Fong TAT, 1999, CANCER RES, V59, P99; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Heasley LE, 2006, MOL CELLS, V21, P167; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Josko J, 2004, MED SCI MONITOR, V10, pRA89; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Maity A, 2000, CANCER RES, V60, P5879; MALIPIERO U, 1990, BIOCHEM BIOPH RES CO, V171, P1145, DOI 10.1016/0006-291X(90)90804-V; Moulder SL, 2001, CANCER RES, V61, P8887; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Peng SB, 2005, BIOCHEMISTRY-US, V44, P2293, DOI 10.1021/bi048851x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	55	35	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3335	3348		10.1038/onc.2010.112	http://dx.doi.org/10.1038/onc.2010.112			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383197	Green Accepted			2022-12-28	WOS:000278622700003
J	Gao, MQ; Choi, YP; Kang, S; Youn, JH; Cho, NH				Gao, M-Q; Choi, Y-P; Kang, S.; Youn, J. H.; Cho, N-H			CD24(+) cells from hierarchically organized ovarian cancer are enriched in cancer stem cells	ONCOGENE			English	Article						CD24; ovarian cancer; cancer stem cell; tumorigenicity	PROSPECTIVE IDENTIFICATION; SIDE POPULATION; CD133; RESISTANCE; INSIGHTS; MARKERS; GROWTH	Cancer stem cells (CSCs) have been identified in solid tumors and cancer cell lines. In this study, we isolated a series of cancer cell clones, which were heterogeneous in growth rate, cell cycle distribution and expression profile of genes and proteins, from ovarian tumor specimens of a patient and identified a sub-population enriched for ovarian CSCs defined by CD24 phenotype. Experiments in vitro demonstrated CD24(+) sub-population possessed stem cell-like characteristics of remaining quiescence and more chemoresistant compared with CD24(-) fraction, as well as a specific capacity for self-renewal and differentiation. In addition, injection of 5 x 10(3) CD24(+) cells was able to form tumor xenografts in nude mice, whereas equal number of CD24(-) cells remained nontumorigenic. We also found that CD24(+) cells expressed higher mRNA levels of some 'stemness' genes, including Nestin, beta-catenin, Bmi-1, Oct4, Oct3/4, Notch1 and Notch4 which were involved in modulating many functions of stem cells, and lower E-cadherin mRNA level than CD24(-) cells. Altogether, these observations suggest human ovarian tumor cells are organized as a hierarchy and CD24 demarcates an ovarian cancer-initiating cell population. These findings will have important clinical applications for developing effective therapeutic strategies to treat ovarian cancer. Oncogene (2010) 29, 2672-2680; doi:10.1038/onc.2010.35; published online 1 March 2010	[Choi, Y-P; Kang, S.; Cho, N-H] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea; [Gao, M-Q] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120749, South Korea; [Youn, J. H.] Yonsei Univ, Coll Med, Res Ctr Human Nat Def Syst, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, NH (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, 134 Shinchon Dong, Seoul 120749, South Korea.	cho1988@yuhs.ac		KANG, SUKI/0000-0002-9957-3479; jo, namhun/0000-0002-0045-6441	Ministry for Health, Welfare and Family Affairs, Republic of Korea [A062598]; National Research Foundation of Korea (NRF); Korea Government (MEST) [20090079165]	Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea Government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A062598; NHC) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (No. 20090079165; CNH).	Ahn SM, 2008, PROTEOMICS, V8, P4946, DOI 10.1002/pmic.200800312; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Cheng T, 2004, ONCOGENE, V23, P7256, DOI 10.1038/sj.onc.1207945; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; DEININGER M, 2004, CELL CYCLE GROWTH 5, P667; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Ferrandina G, 2008, INT J GYNECOL CANCER, V18, P506, DOI 10.1111/j.1525-1438.2007.01056.x; Friel AM, 2008, CELL CYCLE, V7, P242, DOI 10.4161/cc.7.2.5207; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Goranov AI, 2009, GENE DEV, V23, P1408, DOI 10.1101/gad.1777309; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jaksch M, 2008, CANCER RES, V68, P7882, DOI 10.1158/0008-5472.CAN-08-0723; Kristiansen G, 2002, AM J PATHOL, V161, P1215, DOI 10.1016/S0002-9440(10)64398-2; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Seigel GM, 2007, MOL VIS, V13, P823; Song J, 2007, CLIN CANCER RES, V13, P6842, DOI 10.1158/1078-0432.CCR-07-0569; Stupp R, 2007, NAT BIOTECHNOL, V25, P193, DOI 10.1038/nbt0207-193; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	30	280	294	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2672	2680		10.1038/onc.2010.35	http://dx.doi.org/10.1038/onc.2010.35			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190812				2022-12-28	WOS:000277354600007
J	Loayza-Puch, F; Yoshida, Y; Matsuzaki, T; Takahashi, C; Kitayama, H; Noda, M				Loayza-Puch, F.; Yoshida, Y.; Matsuzaki, T.; Takahashi, C.; Kitayama, H.; Noda, M.			Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs	ONCOGENE			English	Article						RECK; invasion; metastasis; MMP; hypoxia; RAS	GENE-EXPRESSION; MESENCHYMAL TRANSITION; INVASION; MIR-21; METASTASIS; INVOLVEMENT; GROWTH; INHIBITION; APOPTOSIS; CELLS	Cancer cells show characteristic gene expression profiles. Recent studies support the potential importance of microRNA (miRNA) expression signatures as biomarkers and therapeutic targets. The membrane-anchored protease regulator RECK is downregulated in many cancers, and forced expression of RECK in tumor cells results in decreased malignancy in animal models. RECK is also essential for mammalian development. In this study, we found that RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373); that RECK mutants lacking the target sites for these miRNA show augmented tumor/metastasis-suppressor activities; and that miR-372/373 are upregulated in response to hypoxia through HIF1 alpha and TWIST1, whereas miR-21 is upregulated by RAS/ERK signaling. These data indicate that the hypoxia- and RAS-signaling pathways converge on RECK through miRNAs, cooperatively downregulating this tumor suppressor and thereby promoting malignant cell behavior. Oncogene (2010) 29, 2638-2648; doi:10.1038/onc.2010.23; published online 15 February 2010	[Noda, M.] Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Noda, M (corresponding author), Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp		Loayza-Puch, Fabricio/0000-0002-2999-8594	JSPS; MEXT; Grants-in-Aid for Scientific Research [22501010] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Takao Miki, EPS Chandana and Awad Shamma for valuable discussion; Masahiro Sonoshita for advice on animal experiments; Aiko Nishimoto and Hai-Ou Gu for technical support; Aki Miyazaki for secretarial assistance and David B Alexander and Oana Maria Cusen for critical reading of the paper. This work was supported by a Grant-in-Aid for Creative Scientific Research from JSPS. FL has been supported by fellowships from MEXT and the Global COE Program, JSPS.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Hsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200; Hu SJ, 2008, J BIOL CHEM, V283, P23473, DOI 10.1074/jbc.M800406200; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawada K, 2007, ONCOGENE, V26, P4679, DOI 10.1038/sj.onc.1210267; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; WANG GL, 1993, BLOOD, V82, P3610; Yang L, 2008, WD SCI P COMP ENG, V1, P295, DOI 10.1142/9789812799470_0048; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	43	90	93	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2638	2648		10.1038/onc.2010.23	http://dx.doi.org/10.1038/onc.2010.23			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154725	Green Submitted			2022-12-28	WOS:000277354600004
J	Soto-Reyes, E; Recillas-Targa, F				Soto-Reyes, E.; Recillas-Targa, F.			Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines	ONCOGENE			English	Article						tumor suppressor gene; CTCF; epigenetics; DNA methylation; p53 human promoter and histone covalent modifications	TUMOR-SUPPRESSOR; DNA METHYLATION; HUMAN GENOME; PROTEIN CTCF; CANCER; BINDING; EXPRESSION; INSULATOR; REGION; DOMAIN	Epigenetic silencing of tumor suppressor gene promoters has become a more frequent phenomenon in cancer than previously anticipated. In this study we addressed the mechanisms involved in the protection of the p53 tumor suppressor gene against epigenetic silencing in human transformed cell lines. We characterized a binding site for the CCCTC-binding factor (CTCF) in the human p53 gene promoter that contributes to its transcriptional expression, and has the ability to maintain this regulatory element in a local open chromatin configuration. In the absence of CTCF we observe the incorporation of repressive histone marks, such as H3K9me3, H3K27me3 and H4K20me3, in different sub-domains of the upstream regulatory sequence. This evidence suggests that CTCF protects the p53 gene promoter against repressive histone marks. Notably, no apparent direct correlation between repression and DNA hypermethylation has been detected. Together, we present evidence supporting the relevant role of CTCF in the epigenetic regulation of tumor suppressor genes and cancer. We propose that CTCF is a strategic component responsible for the maintenance and segregation of epigenetic traits. Oncogene (2010) 29, 2217-2227; doi: 10.1038/onc.2009.509; published online 25 January 2010	[Soto-Reyes, E.; Recillas-Targa, F.] Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Recillas-Targa, F (corresponding author), Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Apartado Postal 70-242, Mexico City 04510, DF, Mexico.	frecilla@ifc.unam.mx	Xie, Huangming/B-2260-2012	Soto-Reyes, Ernesto/0000-0002-4219-6406	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Mexico [IN209403, IN214407]; Consejo Nacional de Ciencia y Tecnologia (CONACyT) [42653-Q, 58767, 181389]; Fundacion Miguel Aleman, AC; Direccion General de estudios de Posgrado-Universidad Nacional Autonoma de Mexico (DGEP); Doctorado en Ciencias Biomedicas	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Mexico(Universidad Nacional Autonoma de Mexico); Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Fundacion Miguel Aleman, AC; Direccion General de estudios de Posgrado-Universidad Nacional Autonoma de Mexico (DGEP)(Universidad Nacional Autonoma de Mexico); Doctorado en Ciencias Biomedicas	We thank Inti Alberto de la Rosa-Velazquez, Catherine Farrell, Mayra Furlan-Magaril, Francisco Antequera, Abrahan Hernandez-Hernandez, Martin Escamilla-del-Arenal and Hector Rincon-Arano for suggestions and constant scientific discussions. We are particularly indebted with the excellent technical assistance of Georgina Guerrero Avendano, members of the Felix Recillas-Targa laboratory, Dr JA Garcia-Sainz and the Instituto de Fisiologia Celular, UNAM. We thank L Ongay, G Codiz and M Mora from the Unidad de Biologia Molecular, IFC-UNAM, for DNA sequencing. This work was supported by the Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Mexico (IN209403 and IN214407), Consejo Nacional de Ciencia y Tecnologia (CONACyT: 42653-Q and 58767) and Fundacion Miguel Aleman, AC. E Soto-Reyes is supported by a PhD fellowship from CONACyT (181389) and Direccion General de estudios de Posgrado-Universidad Nacional Autonoma de Mexico (DGEP). Additional support was provided by the PhD Graduate Program of Doctorado en Ciencias Biomedicas.	Amatya VJ, 2005, ACTA NEUROPATHOL, V110, P178, DOI 10.1007/s00401-005-1041-5; Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002; Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Docquier F, 2009, CLIN CANCER RES, V15, P5762, DOI 10.1158/1078-0432.CCR-09-0329; El-Kady A, 2005, FEBS LETT, V579, P1424, DOI 10.1016/j.febslet.2005.01.044; Escamilla-Del-Arenal M, 2008, MOL CELL BIOL, V28, P575, DOI 10.1128/MCB.00943-07; Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3; Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jelinic P, 2006, PLOS BIOL, V4, P1910, DOI 10.1371/journal.pbio.0040355; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Nguyen P, 2008, CANCER RES, V68, P5546, DOI 10.1158/0008-5472.CAN-08-1005; Pogribny IP, 2000, CANCER RES, V60, P588; Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Su CH, 2009, MOL CELL BIOL, V29, P93, DOI 10.1128/MCB.00704-08; Sun LC, 2008, CANCER RES, V68, P2726, DOI 10.1158/0008-5472.CAN-07-6654; Valadez-Graham V, 2004, NUCLEIC ACIDS RES, V32, P1354, DOI 10.1093/nar/gkh301; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Williams A, 2008, J EXP MED, V205, P747, DOI 10.1084/jem.20080066; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426	41	76	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2217	2227		10.1038/onc.2009.509	http://dx.doi.org/10.1038/onc.2009.509			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101205				2022-12-28	WOS:000276685200007
J	Schmidt, S; Schneider, L; Essmann, F; Cirstea, IC; Kuck, F; Kletke, A; Janicke, RU; Wiek, C; Hanenberg, H; Ahmadian, MR; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schmidt, S.; Schneider, L.; Essmann, F.; Cirstea, I. C.; Kuck, F.; Kletke, A.; Jaenicke, R. U.; Wiek, C.; Hanenberg, H.; Ahmadian, M. R.; Schulze-Osthoff, K.; Nuernberg, B.; Piekorz, R. P.			The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program	ONCOGENE			English	Article						centrosome; mitosis; paclitaxel; p21(WAF); premature senescence; TACC3	SPINDLE POLE ORGANIZATION; CELLULAR SENESCENCE; BREAST-CANCER; AURORA-A; APOPTOSIS; CELLS; ERK; P53; PHOSPHORYLATION; CHECKPOINT	Microtubule-interfering cancer drugs such as paclitaxel (PTX) often cause chemoresistance and severe side effects, including neurotoxicity. To explore potentially novel antineoplastic molecular targets, we investigated the cellular response of breast carcinoma cells to short hairpin(sh)RNA-mediated depletion of the centrosomal protein transforming acidic coiled coil (TACC) 3, an Aurora A kinase target expressed during mitosis. Unlike PTX, knockdown of TACC3 did not trigger a cell death response, but instead resulted in a progressive loss of the pro-apoptotic Bcl-2 protein Bim that links microtubule integrity to spindle poison-induced cell death. Interestingly, TACC3-depleted cells arrested in G(1) through a cellular senescence program characterized by the upregulation of nuclear p21(WAF), downregulation of the retinoblastoma protein and extracellular signal-regulated kinase 1/2, formation of HP1 gamma (phospho-Ser83)-positive senescence-associated heterochromatic foci and increased senescence-associated beta-galactosidase activity. Remarkably, the onset of senescence following TACC3 knockdown was strongly accelerated in the presence of non-toxic PTX concentrations. Thus, we conclude that mitotic spindle stress is a major trigger of premature senescence and propose that the combined targeting of the centrosomal Aurora A-TACC3 axis together with drugs interfering with microtubule dynamics may efficiently improve the chemosensitivity of cancer cells. Oncogene (2010) 29, 6184-6192; doi:10.1038/onc.2010.354; published online 23 August 2010	[Schmidt, S.; Schneider, L.; Cirstea, I. C.; Kuck, F.; Ahmadian, M. R.; Nuernberg, B.; Piekorz, R. P.] Univ Dusseldorf, Inst Biochem & Mol Biol 2, Univ Klinikum, D-40225 Dusseldorf, Germany; [Jaenicke, R. U.] Univ Dusseldorf, Klin Strahlentherapie & Radioonkol, Univ Klinikum, D-40225 Dusseldorf, Germany; [Wiek, C.; Hanenberg, H.] Univ Dusseldorf, Klin Kinder Onkol Hamatol & Klin Immunol, Univ Klinikum, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Tubingen, Abt Mol Med, IFIB, Tubingen, Germany; [Hanenberg, H.] Indiana Univ Sch Med, Riley Hosp Children, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN USA; [Nuernberg, B.] Klinikum Eberhard Karls Univ, Inst Expt & Klin Pharmakol, Tubingen, Germany; [Nuernberg, B.] Klinikum Eberhard Karls Univ, Interfak Zentrum Pharmakogenom & Arzneimittelfors, Tubingen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Eberhard Karls University of Tubingen; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Piekorz, RP (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 2, Univ Klinikum, D-40225 Dusseldorf, Germany.	roland.piekorz@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Schneider, Leonid/H-3275-2013; Schulze-Osthoff, Klaus/N-9025-2013; Cirstea, Ion Cristian/AAQ-7670-2020	Essmann, Frank/0000-0003-4369-8456; Schneider, Leonid/0000-0002-6204-9470; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Cirstea, Ion Cristian/0000-0003-3204-1598; Nurnberg, Bernd/0000-0002-5995-6555; Wiek, Constanze/0000-0003-2214-8148	Collaborative Research Centers of the Deutsche Forschungsgemeinschaft [SFB728, SFB773, SPP1230]; Forschungskommission (Medizinische Fakultat) of the Heinrich-Heine-Universitat; NGFNplus program [01GS08100]; Bundesministerium fur Bildung und Forschung	Collaborative Research Centers of the Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Forschungskommission (Medizinische Fakultat) of the Heinrich-Heine-Universitat; NGFNplus program; Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	Grant support: Collaborative Research Centers SFB728 (RUJ, RPP), SFB773 (FE, KSO), and SPP1230 (HH) of the Deutsche Forschungsgemeinschaft; Forschungskommission (Medizinische Fakultat) of the Heinrich-Heine-Universitat (ICC, MRA, RUJ, RPP); and the NGFNplus program (grant 01GS08100 to MRA) and the network for bone marrow failure syndromes (bmfs to HH) of the Bundesministerium fur Bildung und Forschung.	Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Blagosklonny MV, 2006, J CELL PHYSIOL, V209, P592, DOI 10.1002/jcp.20750; Blagosklonny MV, 2006, CELL CYCLE, V5, P1574, DOI 10.4161/cc.5.14.3113; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Broude EV, 2007, ONCOGENE, V26, P6954, DOI 10.1038/sj.onc.1210516; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kadura S, 2005, CELL MOTIL CYTOSKEL, V61, P145, DOI 10.1002/cm.20072; Khodjakov Alexey, 2009, Journal of Biology (London), V8, P1, DOI 10.1186/jbiol195; Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Maehara K, 2010, MOL CELL BIOL, V30, P2090, DOI 10.1128/MCB.01318-09; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Pajalunga D, 2007, J CELL BIOL, V176, P807, DOI 10.1083/jcb.200608109; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Prencipe M, 2009, BRIT J CANCER, V101, P1900, DOI 10.1038/sj.bjc.6605419; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schneider L, 2008, ONCOGENE, V27, P116, DOI 10.1038/sj.onc.1210628; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Srsen V, 2006, J CELL BIOL, V174, P625, DOI 10.1083/jcb.200606051; Tierno MB, 2009, J PHARMACOL EXP THER, V328, P715, DOI 10.1124/jpet.108.147330; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Tresini M, 2007, J BIOL CHEM, V282, P4136, DOI 10.1074/jbc.M604955200; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang RG, 2007, MOL CELL BIOL, V27, P949, DOI 10.1128/MCB.01639-06; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	55	35	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6184	6192		10.1038/onc.2010.354	http://dx.doi.org/10.1038/onc.2010.354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729911				2022-12-28	WOS:000284356500010
J	Tian, L; Peng, G; Parant, JM; Leventaki, V; Drakos, E; Zhang, Q; Parker-Thornburg, J; Shackleford, TJ; Dai, H; Lin, SY; Lozano, G; Rassidakis, GZ; Claret, FX				Tian, L.; Peng, G.; Parant, J. M.; Leventaki, V.; Drakos, E.; Zhang, Q.; Parker-Thornburg, J.; Shackleford, T. J.; Dai, H.; Lin, S-Y; Lozano, G.; Rassidakis, G. Z.; Claret, F. X.			Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair	ONCOGENE			English	Article						DNA repair; DNA damage; null mutation; embryonic lethality; Rad51	RAD51 RECOMBINATION PROTEIN; HOMOLOGOUS RECOMBINATION; EXPRESSION; P53; DEGRADATION; ACTIVATION; P27(KIP1); OVEREXPRESSION; PROLIFERATION; LOCALIZATION	Jun activation domain-binding protein 1 (JAB1) is a multifunctional protein that participates in the control of cell proliferation and the stability of multiple proteins. JAB1 overexpression has been implicated in the pathogenesis of human cancer. JAB1 regulates several key proteins and thereby produces varied effects on cell cycle progression, genome stability and cell survival. However, the biological significance of JAB1 activity in these cellular signaling pathways is unclear. Therefore, we developed mice that were deficient in Jab1 and analyzed the null embryos and heterozygous cells. This disruption of Jab1 in mice resulted in early embryonic lethality due to accelerated apoptosis. Loss of Jab1 expression sensitized both mouse primary embryonic fibroblasts and osteosarcoma cells to gamma-radiation-induced apoptosis, with an increase in spontaneous DNA damage and homologous recombination (HR) defects, both of which correlated with reduced levels of the DNA repair protein Rad51 and elevated levels of p53. Furthermore, the accumulated p53 directly binds to Rad51 promoter, inhibits its activity and represents a major mechanism underlying the HR repair defect in Jab1-deficient cells. These results indicate that Jab1 is essential for efficient DNA repair and mechanistically link Jab1 to the maintenance of genome integrity and to cell survival. Oncogene (2010) 29, 6125-6137; doi:10.1038/onc.2010.345; published online 30 August 2010	[Tian, L.; Peng, G.; Zhang, Q.; Shackleford, T. J.; Dai, H.; Lin, S-Y; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Peng, G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Leventaki, V.; Drakos, E.; Rassidakis, G. Z.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Parker-Thornburg, J.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Claret, FX (corresponding author), Univ Texas MD Anderson, Dept Syst Biol, Div Canc Med, 7435 Fannin St,Unit 950, Houston, TX 77054 USA.	fxclaret@mdanderson.org	Rassidakis, George/V-9553-2019; Claret, Francois X/R-2104-2016; Leventaki, Vasiliki/N-8175-2018	Claret, Francois X/0000-0003-4629-6495; Shackleford, Terry/0000-0002-3621-2289	National Institutes of Health [RO1 CA90853, CA16672]; Susan G Komen for the Cure; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jeffrey Medeiros's laboratory for providing technical help, Dina Lev and Zhi-Xiang Xu for kindly providing the pRad51-luciferase reporter, Rad51 and p53 constructs and Dr Bert Vogelstein for sharing PG13-luc and MG15-Luc plasmids. We also thank Christine Wogan for assistance with the manuscript preparation. This research was supported by the National Institutes of Health Grant RO1 CA90853, the Susan G Komen for the Cure and the NIH Core Grant CA16672.	Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Dong YY, 2005, CLIN CANCER RES, V11, P259; Doronkin S, 2002, DEVELOPMENT, V129, P5053; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; Harada K, 2006, ANTICANCER RES, V26, P1615; Harari-Steinberg O, 2007, GENES CELLS, V12, P183, DOI 10.1111/j.1365-2443.2007.01049.x; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kouvaraki MA, 2003, CANCER RES, V63, P2977; KOUVARAKI MA, 2006, CANCER RES, V66, P6589; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Oron E, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100150; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Pierce AJ, 2005, METH MOL B, V291, P373; Raderschall E, 2002, CANCER RES, V62, P219; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Russell JS, 2003, CANCER RES, V63, P7377; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2004, J BIOL CHEM, V279, P43013, DOI 10.1074/jbc.M406559200; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Zhang QX, 2005, FEBS LETT, V579, P3932, DOI 10.1016/j.febslet.2005.06.012	47	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6125	6137		10.1038/onc.2010.345	http://dx.doi.org/10.1038/onc.2010.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20802511	Green Accepted			2022-12-28	WOS:000284356500005
J	Ponnusamy, MP; Lakshmanan, I; Jain, M; Das, S; Chakraborty, S; Dey, P; Batra, SK				Ponnusamy, M. P.; Lakshmanan, I.; Jain, M.; Das, S.; Chakraborty, S.; Dey, P.; Batra, S. K.			MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells	ONCOGENE			English	Article						MUC4; EMT; E-cadherin; N-cadherin; metastasis and ovarian cancer	N-CADHERIN; DIAGNOSTIC-SIGNIFICANCE; SURFACE EPITHELIUM; TUMOR PROGRESSION; GENE-EXPRESSION; ADHESION; GROWTH; REQUIREMENT; CARCINOMA; MOTILITY	The acquisition of invasiveness in ovarian cancer (OC) is accompanied by the process of epithelial-to-mesenchymal transition (EMT). The MUC4 mucin is overexpressed in ovarian tumors and has a role in the invasiveness of OC cells. The present study was aimed at evaluating the potential involvement of MUC4 in the metastasis of OC cells by inducing EMT. Ectopic overexpression of MUC4 in OC cells (SKOV3-MUC4) resulted in morphological alterations along with a decreased expression of epithelial markers (E-cadherin and cytokeratin (CK)-18) and an increased expression of mesenchymal markers (N-cadherin and vimentin) compared with the control cells (SKOV3-vector). Also, pro-EMT transcription factors TWIST1, TWIST2 and SNAIL showed an upregulation in SKOV3-MUC4 cells. We further investigated the pathways upstream of N-cadherin, such as focal adhesion kinase (FAK), MKK7, JNK1/2 and c-Jun, which were also activated in the SKOV3-MUC4 cells compared with SKOV3-vector cells. Inhibition of phospho-FAK (pFAK) and pJNK1/2 decreased N-cadherin expression in the MUC4-overexpressing cells, which further led to a significant decrease in cellular motility. Knockdown of N-cadherin decreased the activation of extracellular signal-regulated kinase-1/2 (ERK1/2), AKT and matrix metalloproteinase 9 (MMP9), and inhibited the motility in the SKOV3-MUC4 cells. Upon in vivo tumorigenesis and metastasis analysis, the SKOV3-MUC4 cells produced significantly larger tumors and demonstrated a higher incidence of metastasis to distance organs (peritoneal wall, colon, intestine, stomach, lymph nodes, liver and diaphragm). Taken together, our study reveals a novel role for MUC4 in inducing EMT through the upregulation of N-cadherin and promoting metastasis of OC cells. Oncogene (2010) 29, 5741-5754; doi:10.1038/onc.2010.309; published online 9 August 2010	[Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	chakraborty, subhankar/B-6550-2012	Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; lakshmanan, Imayavaramban/0000-0003-1733-2223	National Institutes of Health [CA78590, CA111294, CA127297, CA133774, CA131944]; Department of Defense [BC074639]; Susan G Komen Foundation [KG070826]; NATIONAL CANCER INSTITUTE [R01CA131944, U01CA111294, P50CA127297, R01CA133774, R01CA078590] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work are supported by the grants from the National Institutes of Health (CA78590, CA111294, CA127297, CA133774 and CA131944), Department of Defense (BC074639) and the Susan G Komen Foundation (KG070826). We thank Ms Kristi L Berger for editing the paper. The authors acknowledge the invaluable technical support from Mr Erik Moore and Mrs Kavita Mallya. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at the UNMC for their support.	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BEHRENS J, 1994, ACTA ANAT, V149, P165; Boman F, 2001, J PATHOL, V193, P339, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH798>3.0.CO;2-9; Carraway KL, 2001, J MAMMARY GLAND BIOL, V6, P323, DOI 10.1023/A:1011327708973; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646; Chen HY, 1997, J CELL SCI, V110, P345; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; Giuntoli RL, 1998, CANCER RES, V58, P5546; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Horn G, 2009, EXP CELL RES, V315, P1490, DOI 10.1016/j.yexcr.2009.02.011; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kolosionek E, 2009, MOL BIOL CELL, V20, P4751, DOI 10.1091/mbc.E09-01-0019; Kondo K, 1998, CANCER RES, V58, P2014; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Lopez-Ferrer A, 2001, HUM PATHOL, V32, P1197, DOI 10.1053/hupa.2001.28938; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Shintani Y, 2008, J CELL BIOL, V180, P1277, DOI 10.1083/jcb.200708137; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sommers CL, 1996, J MAMMARY GLAND BIOL, V1, P219, DOI 10.1007/BF02013645; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011	38	111	117	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5741	5754		10.1038/onc.2010.309	http://dx.doi.org/10.1038/onc.2010.309			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20697346	Green Accepted			2022-12-28	WOS:000283262500010
J	Munro, AF; Cameron, DA; Bartlett, JMS				Munro, A. F.; Cameron, D. A.; Bartlett, J. M. S.			Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge	ONCOGENE			English	Review						HER2; TOP2A; anthracyclines; breast cancer	TOPOISOMERASE-II-ALPHA; IN-SITU HYBRIDIZATION; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; TISSUE INHIBITOR; RANDOMIZED-TRIAL; PREMENOPAUSAL WOMEN; HIGH-RISK; EXPRESSION; HER2	The search for a predictive marker of sensitivity to anthracycline-based chemotherapy has proven challenging. Despite human epidermal growth factor receptor 2 (HER2) being a strong prognostic marker in breast cancer, the only therapies with which there is a recognized functional link to the HER2 oncogene are those directly targeting the molecule itself. Despite this, HER2 has been extensively assessed as a predictive marker in a variety of chemotherapy regimens including anthracyclines. Analysis of anthracycline response in patients with HER2 amplification has given conflicting results. This led to the suggestion that HER2 amplification was acting as a surrogate for the gene encoding topoisomerase II alpha (TOP2A), a direct cellular target of anthracyclines. Despite an attractive functional link between TOP2A and anthracyclines, published studies have failed to show strong evidence of an interaction between TOP2A genetic aberrations and anthracycline response. A number of other biomarkers have also been assessed for their role in predicting anthracycline response, including TP53 (tumour protein 53) and BRCA1 (breast cancer 1, early onset), together with an increasing emergence of gene expression profiling to produce predictive signatures of response. Moreover, recent evidence has emerged from presentations suggesting new candidate markers of response that warrant further investigation: Chr17CEP duplication and tissue inhibitor of metalloproteases 1. This review will discuss research into HER2 and TOP2A as predictive markers of anthracycline response and will focus on current research into other possible candidate predictive markers. Oncogene (2010) 29, 5231-5240; doi:10.1038/onc.2010.286; published online 2 August 2010	[Munro, A. F.; Cameron, D. A.; Bartlett, J. M. S.] Western Gen Hosp, Edinburgh Canc Res Ctr, Endocrine Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland	University of Edinburgh	Bartlett, JMS (corresponding author), Western Gen Hosp, Edinburgh Canc Res Ctr, Endocrine Canc Grp, Crewe Rd S, Edinburgh EH4 2XR, Midlothian, Scotland.	John.Bartlett@ed.ac.uk	Cameron, David A/C-7781-2013	Cameron, David A/0000-0002-2717-7979				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2; Arriola E, 2008, LAB INVEST, V88, P491, DOI 10.1038/labinvest.2008.19; Bartlett J, 2009, CANCER RES, V69, P45; BARTLETT JM, 2009, CANCER RES, V69, P6059; Bartlett JMS, 2001, J PATHOL, V195, P422, DOI 10.1002/path.971; BARTLETT JMS, 2008, J CLIN ONCOL, V26, P1; Bartlett JMS, 2010, LANCET ONCOL, V11, P266, DOI 10.1016/S1470-2045(10)70006-1; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Bhargava R, 2005, AM J CLIN PATHOL, V123, P889, DOI 10.1309/PCFK8YTQPYWD534F; Bidard FC, 2008, ANN ONCOL, V19, P1261, DOI 10.1093/annonc/mdn039; Biganzoli L, 2007, CRIT REV ONCOL HEMAT, V62, P1, DOI 10.1016/j.critrevonc.2006.10.004; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; BORG A, 1991, ONCOGENE, V6, P137; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; CERSOSIMO RJ, 1986, J CLIN ONCOL, V4, P425, DOI 10.1200/JCO.1986.4.3.425; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Cortes-Funes H, 2007, CARDIOVASC TOXICOL, V7, P56, DOI 10.1007/s12012-007-0015-3; Davidsen ML, 2006, BRIT J CANCER, V95, P1114, DOI 10.1038/sj.bjc.6603378; Del Mastro L, 2005, BRIT J CANCER, V93, P7, DOI 10.1038/sj.bjc.6602660; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Di Leo A, 2007, ANN ONCOL, V18, P997, DOI 10.1093/annonc/mdm075; Di Leo A, 2004, BREAST CANCER RES TR, V86, P197, DOI 10.1023/B:BREA.0000036783.88387.47; Di Leo A, 2002, CLIN CANCER RES, V8, P1107; Di Leo A, 2001, ANN ONCOL, V12, P1081, DOI 10.1023/A:1011669223035; Di Leo A, 2009, CANCER RES, V69, P705; Di Leo Angelo, 2003, Clin Breast Cancer, V4, P179; Du YL, 2006, BIOCHEM BIOPH RES CO, V345, P1092, DOI 10.1016/j.bbrc.2006.04.172; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; Ejlertsen B, 2010, J CLIN ONCOL, V28, P984, DOI 10.1200/JCO.2009.24.1166; Fedier A, 2003, INT J ONCOL, V22, P1169; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fraser JA, 2003, BRIT J CANCER, V88, P1263, DOI 10.1038/sj.bjc.6600863; Fung MKL, 2006, BRIT J CANCER, V95, P475, DOI 10.1038/sj.bjc.6603284; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Greenberg RA, 2008, CHROMOSOMA, V117, P305, DOI 10.1007/s00412-008-0154-8; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Holten-Andersen MN, 2000, CLIN CANCER RES, V6, P4292; Hutchins LF, 2005, J CLIN ONCOL, V23, P8313, DOI 10.1200/JCO.2005.08.071; Jarvinen TAH, 2003, CYTOPATHOLOGY, V14, P309, DOI 10.1046/j.0956-5507.2003.00105.x; Jarvinen TAH, 1999, GENE CHROMOSOME CANC, V26, P142; Jarvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; JOHN RG, 2003, CANCER, V97, P527; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kim HT, 2008, MOL CELLS, V25, P457; KLIJN JGM, 1993, ANN NY ACAD SCI, V698, P85, DOI 10.1111/j.1749-6632.1993.tb17193.x; Knoop AS, 2005, J CLIN ONCOL, V23, P7483, DOI 10.1200/JCO.2005.11.007; Levine MN, 2005, J CLIN ONCOL, V23, P5166, DOI 10.1200/JCO.2005.09.423; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Lipton A, 2008, J CLIN ONCOL, V26, P2653, DOI 10.1200/JCO.2007.15.4336; McArthur HL, 2009, CANCER RES, V69, P2023; McClendon AK, 2007, MUTAT RES-FUND MOL M, V623, P83, DOI 10.1016/j.mrfmmm.2007.06.009; McCullough Shaun D., 2007, V11, P31; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Murphy CG, 2010, CANCER J, V16, P39, DOI 10.1097/PPO.0b013e3181cf0204; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nielsen KV, 2008, ACTA ONCOL, V47, P725, DOI 10.1080/02841860801995396; Norton Larry, 2008, Breast Dis, V29, P27; O'Malley FP, 2009, JNCI-J NATL CANCER I, V101, P644, DOI 10.1093/jnci/djp067; Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69; OMALLEY FP, 2006, ASCO M, V24, P533; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Pritchard KI, 2008, J CLIN ONCOL, V26, P736, DOI 10.1200/JCO.2007.15.4716; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Rahko E, 2003, EUR J CANCER, V39, P447, DOI 10.1016/S0959-8049(02)00499-9; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Reinholz MM, 2007, BREAST CANCER RES TR, V106, pS11; RIED T, 1995, CANCER RES, V55, P5415; Schmidt M, 2009, CANCER RES, V69, P2695, DOI 10.1158/0008-5472.CAN-08-4013; Schrohl AS, 2006, CLIN CANCER RES, V12, P7054, DOI 10.1158/1078-0432.CCR-06-0950; Schrohl AS, 2004, CLIN CANCER RES, V10, P2289, DOI 10.1158/1078-0432.CCR-03-0360; Slamon D, 2005, BREAST CANCER RES TR, V94, pS5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Small GW, 2003, J PHARMACOL EXP THER, V307, P861, DOI 10.1124/jpet.103.055806; Spencer DMS, 2003, ONCOL RES, V13, P479, DOI 10.3727/000000003108748009; Taatjes DJ, 1999, CHEM RES TOXICOL, V12, P588, DOI 10.1021/tx990008q; Tanner M, 2006, J CLIN ONCOL, V24, P2428, DOI 10.1200/JCO.2005.02.9264; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Todorovic-Rakovic N, 2009, DIS MARKERS, V26, P171, DOI 10.3233/DMA-2009-0628; Tordai A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2088; Tovey SM, 2004, BREAST CANCER RES, V6, pR246, DOI 10.1186/bcr783; Vincent-Salomon A, 2004, EUR J CANCER, V40, P1502, DOI 10.1016/j.ejca.2004.03.014; Wurtz SO, 2008, ACTA ONCOL, V47, P580, DOI 10.1080/02841860802022976	91	24	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5231	5240		10.1038/onc.2010.286	http://dx.doi.org/10.1038/onc.2010.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20676126				2022-12-28	WOS:000282089100002
J	Yu, J; Cao, Q; Yu, J; Wu, L; Dallol, A; Li, J; Chen, G; Grasso, C; Cao, X; Lonigro, RJ; Varambally, S; Mehra, R; Palanisamy, N; Wu, JY; Latif, F; Chinnaiyan, AM				Yu, J.; Cao, Q.; Yu, J.; Wu, L.; Dallol, A.; Li, J.; Chen, G.; Grasso, C.; Cao, X.; Lonigro, R. J.; Varambally, S.; Mehra, R.; Palanisamy, N.; Wu, J. Y.; Latif, F.; Chinnaiyan, A. M.			The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer	ONCOGENE			English	Article						polycomb group proteins; EZH2; SLIT2; prostate cancer; epigenetic silencing; DNA hypermethylation	FREQUENT EPIGENETIC INACTIVATION; GROUP PROTEIN EZH2; CONTROL CELL FATE; EXPRESSION SIGNATURE; SQUAMOUS-CELL; BETA-CATENIN; E-CADHERIN; GENE; POLYCOMB; TUMOR	The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer. Oncogene (2010) 29, 5370-5380; doi: 10.1038/onc.2010.269; published online 12 July 2010	[Chinnaiyan, A. M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Pathol & Urol, Ann Arbor, MI 48109 USA; [Yu, J.; Wu, L.; Wu, J. Y.] Northwestern Univ, Div Hematol Oncol, Dept Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, J.; Cao, Q.; Yu, J.; Li, J.; Chen, G.; Grasso, C.; Cao, X.; Lonigro, R. J.; Varambally, S.; Mehra, R.; Palanisamy, N.; Chinnaiyan, A. M.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Yu, J.; Cao, Q.; Grasso, C.; Cao, X.; Varambally, S.; Mehra, R.; Palanisamy, N.; Chinnaiyan, A. M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Yu, J.; Lonigro, R. J.; Chinnaiyan, A. M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Dallol, A.; Latif, F.] Univ Birmingham, Inst Biomed Res, Dept Med & Mol Genet, Edgbaston, England; [Chinnaiyan, A. M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Wu, J. Y.] Northwestern Univ, Dept Neurol, Lurie Comprehens Canc Ctr, Ctr Genet Med, Chicago, IL 60611 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Birmingham; University of Michigan System; University of Michigan; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Pathol & Urol, 1500 E Med Ctr Dr,5410 CCGC, Ann Arbor, MI 48109 USA.	jindan-yu@northwestern.edu; arul@umich.edu	Palanisamy, Nallasivam/ABC-8844-2020; Dallol, Ashraf/H-8661-2012; WU, Longtao/G-6477-2014; Cao, Qi/A-5517-2010; Chen, Guoan/J-9140-2018	Palanisamy, Nallasivam/0000-0002-0633-9772; Dallol, Ashraf/0000-0002-8803-228X; WU, Longtao/0000-0003-3463-4127; Cao, Qi/0000-0002-5140-3681; Chen, Guoan/0000-0001-5608-6761; Varambally, Sooryanarayana/0000-0002-2277-1127	NIH [P50CA69568, P50CA090386, 1R01CA132874-01A1, CA114197, CA107193, K99CA129565-01A1]; Early Detection Research Network [UO1 111275]; US Department of Defense [PC051081, PC080665]; James S McDonnell Foundation; Searle Foundation; Doris Duke Charitable Foundation; Prostate Cancer Foundation; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA107193, R01CA132874, K99CA129565, R01CA114197, P50CA090386, R00CA129565, P50CA069568, U01CA111275] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Early Detection Research Network; US Department of Defense(United States Department of Defense); James S McDonnell Foundation; Searle Foundation; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Prostate Cancer Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the NIH Prostate Specialized Program of Research Excellence Grants P50CA69568 and P50CA090386, Early Detection Research Network Grant UO1 111275 (to AMC), the NIH 1R01CA132874-01A1 (to AMC), CA114197 and CA107193 (to JYW) and K99CA129565-01A1 (to JY), the US Department of Defense PC051081 (to AMC) and PC080665 (to JY), and the James S McDonnell Foundation Grant JSMF (to JYW) and Searle Foundation (to JYW). AMC is supported by a Burroughs Welcome Foundation Award in Clinical Translational Research, a Doris Duke Charitable Foundation Distinguished Clinical Investigator Award, the Prostate Cancer Foundation and the Howard Hughes Medical Institute. AMC is an American Cancer Society Research Professor.	Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022; Kanno R, 2008, CANCER SCI, V99, P1077, DOI 10.1111/j.1349-7006.2008.00797.x; Kim HK, 2008, NEOPLASIA, V10, P1411, DOI 10.1593/neo.08804; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200; Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Werbowetski-Ogilvie TE, 2006, ONCOGENE, V25, P5103, DOI 10.1038/sj.onc.1209524; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	46	63	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5370	5380		10.1038/onc.2010.269	http://dx.doi.org/10.1038/onc.2010.269			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20622896	Green Accepted			2022-12-28	WOS:000282944500004
J	Gao, X; Pang, J; Li, LY; Liu, WP; Di, JM; Sun, QP; Fang, YQ; Liu, XP; Pu, XY; He, D; Li, MT; Su, ZL; Li, BY				Gao, X.; Pang, J.; Li, L-Y; Liu, W-P; Di, J-M; Sun, Q-P; Fang, Y-Q; Liu, X-P; Pu, X-Y; He, D.; Li, M-T; Su, Z-L; Li, B-Y			Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer	ONCOGENE			English	Article						prostate cancer; proteomics; collapsin response mediator protein-4; metastasis-suppressor gene; methylation	UNC-33-LIKE PHOSPHOPROTEIN GENE; LYMPH-NODE METASTASIS; GROWTH CONE COLLAPSE; TRANSCRIPTION FACTORS; METHYLATION; PROMOTER; INVASION; CELLS; MICROMETASTASES; NEUROBLASTOMA	Metastasis is the chief cause of mortality from cancer, but the mechanisms leading to metastasis are poorly understood. We used a proteomics approach to screen for metastasis-associated proteins and found that collapsin response mediator protein-4 (CRMP4) expression was inversely associated with the lymph node metastasis of prostate cancer (PCa). Subsequent in vitro and in vivo studies revealed that overexpression of CRMP4 not only suppressed the invasion ability of PCa cells, but also strongly inhibited tumor metastasis in an animal model. Furthermore, methylation of a CpG island within the promoter region of the CRMP4 gene is responsible for downregulation of CRMP4 expression. Thus, in this study, we show new function of CRMP4 as a metastasis-suppressor in PCa. The findings provide new mechanistic insights into metastasis and therapeutic potential for this most common male cancer. Oncogene (2010) 29, 4555-4566; doi: 10.1038/onc.2010.213; published online 14 June 2010	[Gao, X.; Pang, J.; Li, L-Y; Liu, W-P; Di, J-M; Sun, Q-P; Fang, Y-Q; Liu, X-P; Pu, X-Y] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China; [He, D.; Su, Z-L] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China; [Li, M-T] Sun Yat Sen Univ, Prote Ctr, Zhongshan Sch Medcine, Guangzhou 510275, Guangdong, Peoples R China; [Li, B-Y] Univ Kansas, Med Ctr, Dept Urol, Kansas City, KS 66103 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Kansas; University of Kansas Medical Center	Gao, X (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Tianhe Rd 600, Guangzhou 510630, Guangdong, Peoples R China.	Xin.Gao.zsu@gmail.com	Pang, Jun/AAY-3407-2021	Pang, Jun/0000-0003-0024-9415; li, liaoyuan/0000-0002-5328-6802	Chinese National Natural Science Foundation [30772178, 30973011, 30901496]; Guangdong Provincial Science and Technology Research [7117362]; Chinese Ministry of Health; Chinese National Hi-Tech Research and Development Program [2007AA021906]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Research; Chinese Ministry of Health; Chinese National Hi-Tech Research and Development Program(National High Technology Research and Development Program of China)	We thank Professor Quentin Liu (State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University) for providing excellent technical assistances. Special thanks to Professor Zhou Zhu (Johns Hopkins University, School of Medicine, USA) for valuable suggestions and critical reading of this paper. This work was supported by Chinese National Natural Science Foundation 30772178, 30973011, 30901496, Key Project of Guangdong Provincial Science and Technology Research 7117362, Key Project of Chinese Ministry of Health and Chinese National Hi-Tech Research and Development Program 2007AA021906.	Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433; Burton JB, 2008, NAT MED, V14, P882, DOI 10.1038/nm.1727; Cai CQ, 2008, ONCOGENE, V27, P3201, DOI 10.1038/sj.onc.1210983; Cathcart MC, 2008, J PHARMACOL EXP THER, V326, P51, DOI 10.1124/jpet.107.134221; Chi AS, 2009, ONCOLOGIST, V14, P621, DOI 10.1634/theoncologist.2008-0272; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de Boer M, 2009, NEW ENGL J MED, V361, P653, DOI 10.1056/NEJMoa0904832; Deo RC, 2004, EMBO J, V23, P9, DOI 10.1038/sj.emboj.7600021; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fu HJ, 2007, J PROTEOME RES, V6, P2435, DOI 10.1021/pr060615g; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jackson D, 2006, PROTEOMICS, V6, P3901, DOI 10.1002/pmic.200500794; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Klein CA, 2008, SCIENCE, V321, P1785, DOI 10.1126/science.1164853; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Matsuo T, 2000, J BIOL CHEM, V275, P16560, DOI 10.1074/jbc.M001312200; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Miyake H, 2007, CLIN CANCER RES, V13, P1192, DOI 10.1158/1078-0432.CCR-05-2706; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Paris PL, 2004, HUM MOL GENET, V13, P1303, DOI 10.1093/hmg/ddh155; Rinker-Schaeffer CW, 2006, CLIN CANCER RES, V12, P3882, DOI 10.1158/1078-0432.CCR-06-1014; Rosslenbroich V, 2005, EXP CELL RES, V310, P434, DOI 10.1016/j.yexcr.2005.08.005; Schewe DM, 2005, CLIN CANCER RES, V11, P8538, DOI 10.1158/1078-0432.CCR-05-0786; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Shaffer DR, 2006, NAT MED, V12, P14, DOI 10.1038/nm0106-14; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Shih JY, 2003, CLIN EXP METASTAS, V20, P69, DOI 10.1023/A:1022598604565; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Uzawa K, 2002, CLIN CANCER RES, V8, P828; Wang LH, 1997, J NEUROCHEM, V69, P2261; Yacoub M, 2009, HISTOPATHOLOGY, V55, P392, DOI 10.1111/j.1365-2559.2009.03406.x; Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105; Zilberman D, 2007, NAT GENET, V39, P442, DOI 10.1038/ng0407-442	47	50	53	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2010	29	32					4555	4566		10.1038/onc.2010.213	http://dx.doi.org/10.1038/onc.2010.213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20543870				2022-12-28	WOS:000280862300006
J	Salmeen, A; Park, BO; Meyer, T				Salmeen, A.; Park, B. O.; Meyer, T.			The NADPH oxidases NOX4 and DUOX2 regulate cell cycle entry via a p53-dependent pathway	ONCOGENE			English	Article						NADPH oxidases; redox signaling; p53; NOX4; DUOX2	SMOOTH-MUSCLE-CELLS; EPIDERMAL-GROWTH-FACTOR; REACTIVE OXYGEN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION REPRESSION; RETINOBLASTOMA PROTEIN; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; NAD(P)H OXIDASE	Reactive oxygen species (ROS) are produced in growth factor-signaling pathways leading to cell proliferation, but the mechanisms leading to ROS generation and the targets of ROS signals are not well understood. Using a focused siRNA screen to identify redox-related proteins required for growth factor-induced cell cycle entry, we show that two ROS-generating proteins, the NADPH oxidases NOX4 and DUOX2, are required for platelet-derived growth factor (PDGF) induced retinoblastoma protein (Rb) phosphorylation in normal human fibroblasts. Unexpectedly, NOX4 and DUOX2 knockdown did not inhibit the early signaling pathways leading to cyclin D1 upregulation. However, hours after growth factor stimulation, NOX4 and DUOX2 knockdown reduced ERK1 phosphorylation and increased levels of the tumor suppressor protein p53 and a cell cycle inhibitor protein p21 (Waf1/Cip1) that is transcriptionally regulated by p53. Co-knockdown of NOX4 or DUOX2 with either p53 or with p21 overcame the inhibition of Rb phosphorylation that occurred with NOX4 or DUOX2 knockdown alone. Our results argue that rather than primarily affecting growth factor receptor signaling, NOX4 and DUOX2 regulate cell cycle entry as part of a p53-dependent checkpoint for proliferation. Oncogene (2010) 29, 4473-4484; doi: 10.1038/onc.2010.200; published online 7 June 2010	[Salmeen, A.; Park, B. O.; Meyer, T.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Clark Ctr W200, Stanford, CA 94305 USA	Stanford University	Salmeen, A (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Clark Ctr W200, 318 Campus Dr, Stanford, CA 94305 USA.	tobias1@stanford.edu		Meyer, Tobias/0000-0003-4339-3804	Burroughs Wellcome Fund; Helen Hay Whitney Foundation/Paul Sigler Agouron Institute; NIH [R33 CA 120732]; NATIONAL CANCER INSTITUTE [R33CA120732] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); Helen Hay Whitney Foundation/Paul Sigler Agouron Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Won Do Heo for his assistance with the cell cycle entry assay, Dr Dan Kaplan, Dr Sean Collins and Dr Karlene Cimprich for their critical reading of the article and members of the Meyer lab and Renee Paulsen for helpful discussions. This work was supported by a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund (AS), by a Helen Hay Whitney Foundation/Paul Sigler Agouron Institute post-doctoral fellowship (AS) and by an NIH grant R33 CA 120732 (TM).	Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Burch PM, 2005, ANTIOXID REDOX SIGN, V7, P741, DOI 10.1089/ars.2005.7.741; Burhans WC, 2009, FREE RADICAL BIO MED, V47, P1282, DOI 10.1016/j.freeradbiomed.2009.05.026; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Laurent E, 2008, INT J CANCER, V123, P100, DOI 10.1002/ijc.23423; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu YX, 2008, MOL CANCER RES, V6, P624, DOI 10.1158/1541-7786.MCR-07-2019; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Park HS, 2005, DIABETES, V54, P3175, DOI 10.2337/diabetes.54.11.3175; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Petry A, 2006, ANTIOXID REDOX SIGN, V8, P1473, DOI 10.1089/ars.2006.8.1473; Ranjan P, 2006, ANTIOXID REDOX SIGN, V8, P1447, DOI 10.1089/ars.2006.8.1447; Rhee S G, 2000, Sci STKE, V2000, ppe1; Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005; Sturrock A, 2007, AM J PHYSIOL-LUNG C, V292, pL1543, DOI 10.1152/ajplung.00430.2006; Sun XZ, 2003, ANTIOXID REDOX SIGN, V5, P655, DOI 10.1089/152308603770310338; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Ward JPT, 2008, BBA-BIOENERGETICS, V1777, P1, DOI 10.1016/j.bbabio.2007.10.010; Wilkinson DS, 2008, MOL CELL BIOL, V28, P1988, DOI 10.1128/MCB.01442-07; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Winterbourn CC, 2008, FREE RADICAL BIO MED, V45, P549, DOI 10.1016/j.freeradbiomed.2008.05.004; Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yamaura M, 2009, CANCER RES, V69, P2647, DOI 10.1158/0008-5472.CAN-08-3745; Yao G, 2008, NAT CELL BIOL, V10, P476, DOI 10.1038/ncb1711; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	43	38	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4473	4484		10.1038/onc.2010.200	http://dx.doi.org/10.1038/onc.2010.200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20531308	Green Accepted			2022-12-28	WOS:000280559100010
J	Shimura, T; Kakuda, S; Ochiai, Y; Nakagawa, H; Kuwahara, Y; Takai, Y; Kobayashi, J; Komatsu, K; Fukumoto, M				Shimura, T.; Kakuda, S.; Ochiai, Y.; Nakagawa, H.; Kuwahara, Y.; Takai, Y.; Kobayashi, J.; Komatsu, K.; Fukumoto, M.			Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3 beta-mediated cyclin D1 overexpression	ONCOGENE			English	Article						cyclin D1; AKT; fractionated-radiation; radioresistance; DNA-PK	STRAND BREAK RESPONSE; CANCER STEM-CELLS; DNA-DAMAGE; NUCLEAR EXPORT; MAMMALIAN-CELLS; PROTEIN-KINASE; PHOSPHORYLATION; REPAIR; REPLICATION; INHIBITION	Recurrence is frequently associated with the acquisition of radioresistance by tumors and resulting failures in radiotherapy. We report, in this study, that long-term fractionated radiation (FR) exposures conferred radioresistance to the human tumor cells, HepG2 and HeLa with cyclin D1 overexpression. A positive feedback loop was responsible for the cyclin D1 overexpression in which constitutively active AKT was involved. AKT is known to inactivate glycogen synthase kinase-3 beta (GSK3 beta), which is essential for the proteasomal degradation of cyclin D1. The resulting cyclin D1 overexpression led to the forced progression of S-phase with the induction of DNA double strand breaks. Cyclin D1-dependent DNA damage activated DNA-dependent protein kinase (DNA-PK), which in turn activated AKT and inactivated GSK3 beta, thus completing a positive feedback loop of cyclin D1 overproduction. Cyclin D1 overexpression led to the activation of DNA damage response (DDR) consisted of ataxia telangiectasia mutated (ATM)- and Chk1-dependent DNA damage checkpoint and homologous recombination repair (HRR). Long-term FR cells repaired radiation-induced DNA damage faster than non-FR cells. Thus, acquired radioresistance of long-term FR cells was the result of alterations in DDR mediated by cyclin D1 overexpression. Inhibition of the AKT/GSK3 beta/cyclin D1/Cdk4 pathway by the AKT inhibitor, Cdk4 inhibitor or cyclin D1 targeting small interfering RNA (siRNA) suppressed the radioresistance. Present observations give a mechanistic insight for acquired radioresistance of tumor cells by cyclin D1 overexpression, and provide novel therapeutic targets for recurrent radioresistant tumors. Oncogene (2010) 29, 4826-4837; doi:10.1038/onc.2010.238; published online 21 June 2010	[Shimura, T.; Kakuda, S.; Ochiai, Y.; Nakagawa, H.; Kuwahara, Y.; Fukumoto, M.] Tohoku Univ, Dept Pathol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; [Kakuda, S.; Takai, Y.] Tohoku Univ, Grad Sch Med, Dept Therapeut Radiol, Sendai, Miyagi 9808575, Japan; [Kobayashi, J.; Komatsu, K.] Kyoto Univ, Dept Genome Dynam, Ctr Radiat Biol, Kyoto, Japan	Tohoku University; Tohoku University; Kyoto University	Fukumoto, M (corresponding author), Tohoku Univ, Dept Pathol, Inst Dev Aging & Canc, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	fukumoto@idac.tohoku.ac.jp	Kobayashi, Junya/AAX-6390-2021; Fukumoto, Manabu/L-1444-2019	Kobayashi, Junya/0000-0003-4645-7500; 	Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare of Japan; Interdisciplinary Research, Tohoku University;  [Start-up-20810003];  [Wakate-B-21710054]	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Interdisciplinary Research, Tohoku University; ; 	We thank Dr Ohtsura Niwa and Dr Keiko Nakayama for their critical reading of the paper. We thank Dr J Alan Diehl for providing pFleX-cyclin D1 expression vectors. We thank Dr Shuntaro Ikawa for providing some chemicals. This study was in part supported by the Grant-in-Aid for young scientists (Start-up-20810003) and (Wakate-B-21710054), by the Grant-in-Aid from Ministry of Education, Culture, Sports, Science and Technology, by grants from the Ministry of Health, Labour and Welfare of Japan, and by the 'Frontier Science Research Program' in the Center for Interdisciplinary Research, Tohoku University.	Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Cann KL, 2007, BIOCHEM CELL BIOL, V85, P663, DOI 10.1139/O07-135; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang AR, 2008, HEAD NECK-J SCI SPEC, V30, P852, DOI 10.1002/hed.20788; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; FILMUS J, 1994, ONCOGENE, V9, P3627; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; GILLETT C, 1994, CANCER RES, V54, P1812; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Higuchl E, 2007, HEAD NECK-J SCI SPEC, V29, P940, DOI 10.1002/hed.20632; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shimura T, 2008, J MOL BIOL, V375, P1152, DOI 10.1016/j.jmb.2007.11.006; Shimura T, 2007, J MOL BIOL, V367, P665, DOI 10.1016/j.jmb.2007.01.018; Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Veuger SJ, 2003, CANCER RES, V63, P6008; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343	48	109	114	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4826	4837		10.1038/onc.2010.238	http://dx.doi.org/10.1038/onc.2010.238			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562919				2022-12-28	WOS:000281326400008
J	Julian, E; Dave, RK; Robson, JP; Hallahan, AR; Wainwright, BJ				Julian, E.; Dave, R. K.; Robson, J. P.; Hallahan, A. R.; Wainwright, B. J.			Canonical Notch signaling is not required for the growth of Hedgehog pathway-induced medulloblastoma	ONCOGENE			English	Article						medulloblastoma; Notch; Hedgehog; therapy; RBP-J	GRANULE NEURON PRECURSORS; POSTNATAL MOUSE-BRAIN; BASAL-CELL CARCINOMA; SONIC-HEDGEHOG; STEM-CELLS; HUMAN HOMOLOG; MUTANT MICE; GLIAL DIFFERENTIATION; GENETIC ALTERATIONS; FATE DETERMINATION	Current treatment for medulloblastoma is successful in more than half of all cases but results in substantial disability in survivors. Accordingly, there is considerable interest in drugs that may target specific signaling pathways activated in the tumors, with inhibitors of both the Hedgehog and Notch pathways currently proposed as possible therapeutics. Here, we tested the hypothesis that Notch pathway inhibition in vivo may block the formation of Hedgehog-dependent medulloblastoma. We took the general approach of using a cre recombinase under the control of the GFAP promoter to generate medulloblastoma in mice carrying a conditional Ptc1 allele and introduced a conditional RBP-J allele to ablate canonical Notch signaling. Loss of RBP-J from the developing cerebellum led to a modest loss of stem cells and an overall developmental delay. These phenotypes could be partially compensated by activation of the Hedgehog pathway. Hedgehog-dependent medulloblastoma were not blocked by loss of RBP-J, indicating that canonical Notch signaling is not required for tumor initiation and growth in this model. Oncogene (2010) 29, 3465-3476; doi:10.1038/onc.2010.101; published online 26 April 2010	[Julian, E.; Dave, R. K.; Robson, J. P.; Wainwright, B. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Hallahan, A. R.] Univ Queensland, Dept Paediat & Child Hlth, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Wainwright, BJ (corresponding author), Univ Queensland, Inst Mol Biosci, Bldg 80,St Lucia Campus, Brisbane, Qld 4072, Australia.	b.wainwright@imb.uq.edu.au	Hallahan, Andrew R/F-1757-2010	Wainwright, Brandon/0000-0003-0406-2092	National Health and Medical Research Council of Australia; John Trivett Foundation; ARC Special Research Centre for Functional and Applied Genomics; Australian Cancer Research Fund	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); John Trivett Foundation; ARC Special Research Centre for Functional and Applied Genomics(Australian Research Council); Australian Cancer Research Fund	E Julian is an ANZ Trustees Research Scholar. This work was supported by funds from the National Health and Medical Research Council of Australia, The John Trivett Foundation, the ARC Special Research Centre for Functional and Applied Genomics and the Australian Cancer Research Fund. We thank Professor Tasuku Honjo for RBP-J mice and Professor Ryoichiro Kageyama and Dr Zeng-jie Yang for helpful discussions.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Adolphe C, 2004, DEVELOPMENT, V131, P5009, DOI 10.1242/dev.01367; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Binning MJ, 2008, CANCER RES, V68, P7838, DOI 10.1158/0008-5472.CAN-08-1899; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Corbin JG, 2008, J NEUROCHEM, V106, P2272, DOI 10.1111/j.1471-4159.2008.05522.x; Dakubo GD, 2006, J NEURO-ONCOL, V79, P221, DOI 10.1007/s11060-006-9132-2; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dong J, 2000, Hum Mutat, V16, P89, DOI 10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.3.CO;2-Z; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Frappart PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703; Fujikura J, 2006, CELL METAB, V3, P59, DOI 10.1016/j.cmet.2005.12.005; Galli R, 2002, DEVELOPMENT, V129, P1633; Gao F, 2009, MOL CELL NEUROSCI, V40, P442, DOI 10.1016/j.mcn.2008.12.008; Garzia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004998; Gazit R, 2004, DEVELOPMENT, V131, P903, DOI 10.1242/dev.00982; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hurlbut GD, 2007, CURR OPIN CELL BIOL, V19, P166, DOI 10.1016/j.ceb.2007.02.012; Imayoshi I, 2008, DEVELOPMENT, V135, P2531, DOI 10.1242/dev.021535; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Irvin DK, 2004, J NEUROSCI RES, V75, P330, DOI 10.1002/jnr.10843; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Klein AL, 2004, DEV BIOL, V266, P161, DOI 10.1016/j.ydbio.2003.10.017; Komine O, 2007, DEV BIOL, V311, P238, DOI 10.1016/j.ydbio.2007.08.042; Koo BK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001221; Lelievre V, 2008, DEV BIOL, V313, P359, DOI 10.1016/j.ydbio.2007.10.031; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Lutolf S, 2002, DEVELOPMENT, V129, P373; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Marino S, 2000, GENE DEV, V14, P994; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; Packer Roger J., 1994, Current Opinion in Oncology, V6, P240, DOI 10.1097/00001622-199405000-00004; Pazzaglia S, 2006, ONCOGENE, V25, P5575, DOI 10.1038/sj.onc.1209544; Pietsch T, 1997, CANCER RES, V57, P2085; Purow B, 2009, CURR PHARM BIOTECHNO, V10, P154, DOI 10.2174/138920109787315060; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008-5472.CAN-05-0481; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saran A, 2009, CURR MOL MED, V9, P1046, DOI 10.2174/156652409789839080; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sasai K, 2007, CANCER RES, V67, P3871, DOI 10.1158/0008-5472.CAN-07-0493; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Sottile V, 2006, BRAIN RES, V1099, P8, DOI 10.1016/j.brainres.2006.04.127; Stump G, 2002, MECH DEVELOP, V114, P153, DOI 10.1016/S0925-4773(02)00043-6; Sweeney C, 2004, FASEB J, V18, P1421, DOI 10.1096/fj.04-1700fje; Talora C, 2008, BBA-MOL BASIS DIS, V1782, P489, DOI 10.1016/j.bbadis.2008.06.008; Tanaka M, 1999, J NEUROBIOL, V41, P524, DOI 10.1002/(SICI)1097-4695(199912)41:4<524::AID-NEU8>3.3.CO;2-9; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Tanori M, 2008, CARCINOGENESIS, V29, P1911, DOI 10.1093/carcin/bgn174; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wall DS, 2009, CELL CYCLE, V8, P1301, DOI 10.4161/cc.8.9.8284; Wall DS, 2009, J CELL BIOL, V184, P101, DOI 10.1083/jcb.200805155; Wang JP, 2003, J CLIN INVEST, V112, P535, DOI 10.1172/JCI200318637; Weller M, 2006, DEV NEUROSCI-BASEL, V28, P70, DOI 10.1159/000090754; Wetmore C, 2001, CANCER RES, V61, P513; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008; Zindy F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418	71	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3465	3476		10.1038/onc.2010.101	http://dx.doi.org/10.1038/onc.2010.101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418906				2022-12-28	WOS:000278835400002
J	Vichalkovski, A; Gresko, E; Hess, D; Restuccia, DF; Hemmings, BA				Vichalkovski, A.; Gresko, E.; Hess, D.; Restuccia, D. F.; Hemmings, B. A.			PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage	ONCOGENE			English	Article						PKB/Akt; Twist-1 transcription factor; DNA damage; cancer	PROTEIN-KINASE B/AKT; SAETHRE-CHOTZEN-SYNDROME; BREAST-CANCER CELLS; TUMOR SUPPRESSION; UP-REGULATION; EXPRESSION; METASTASIS; SURVIVAL; RESISTANCE; INVASION	Protein kinase B (PKB/Akt) is ubiquitously expressed in cells. Phosphorylation of its multiple targets in response to various stimuli, including growth factors or cytokines, promotes cell survival and inhibits apoptosis. PKB is upregulated in many different cancers and a significant amount of the enzyme is present in its activated form. Here we show that PKB phosphorylates one of the anti-apoptotic proteins-transcription factor Twist-1 at Ser42. Cells expressing Twist-1 displayed inefficient p53 upregulation in response to DNA damage induced by gamma-irradiation or the genotoxic drug adriamycin. This influenced the activation of p53 target genes such as p21(Waf1) and Bax and led to aberrant cell-cycle regulation and the inhibition of apoptosis. The impaired induction of these p53 effector molecules is likely to be mediated by PKB-dependent phosphorylation of Twist-1 because, unlike the wild-type mutant, the Twist-1 S42A mutant did not confer cell resistance to DNA damage. Moreover, phosphorylation of Twist-1 at Ser42 was shown in vivo in various human cancer tissues, suggesting that this post-translational modi. cation ensures functional activation of Twist-1 after promotion of survival during carcinogenesis. Oncogene (2010) 29, 3554-3565; doi:10.1038/onc.2010.115; published online 19 April 2010	[Vichalkovski, A.; Gresko, E.; Hess, D.; Restuccia, D. F.; Hemmings, B. A.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch	Restuccia, David/D-7114-2012	Restuccia, David/0000-0001-7131-8065	Novartis Research Foundation; Swiss Cancer League Grant [OCS 01667-02-2005]	Novartis Research Foundation; Swiss Cancer League Grant	We thank S Bichet and A Bogucki for their help with immunohistochemistry and P King for critical comments on the article. This work was supported by the Novartis Research Foundation and the Swiss Cancer League Grant OCS 01667-02-2005 (to EG).	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Cai JL, 2005, BIOESSAYS, V27, P1102, DOI 10.1002/bies.20313; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Firulli AB, 2008, CURR MED CHEM, V15, P2641, DOI 10.2174/092986708785908987; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Funato N, 2005, HUM MUTAT, V25, P550, DOI 10.1002/humu.20176; GHOUZZI V, 2001, FEBS LETT, V492, P112; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Guenou H, 2006, AM J PATHOL, V169, P1303, DOI 10.2353/ajpath.2006.060102; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067; Hess D, 2008, J BIOL CHEM, V283, P7354, DOI 10.1074/jbc.M710251200; Hosono S, 2007, BRIT J CANCER, V96, P314, DOI 10.1038/sj.bjc.6603533; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Kyo S, 2006, HUM PATHOL, V37, P431, DOI 10.1016/j.humpath.2005.12.021; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Restuccia DF, 2009, SCIENCE, V325, P1083, DOI 10.1126/science.1179972; Shibata K, 2008, ANN ONCOL, V19, P81, DOI 10.1093/annonc/mdm344; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Singh S, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-47; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Zhang XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	54	98	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3554	3565		10.1038/onc.2010.115	http://dx.doi.org/10.1038/onc.2010.115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400976				2022-12-28	WOS:000278835400010
J	Danese, S; Mantovani, A				Danese, S.; Mantovani, A.			Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer	ONCOGENE			English	Review						inflammation; colon cancer; chemokines	TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; IKK/NF-KAPPA-B; BLOCKING TNF-ALPHA; COLON-CANCER; ULCERATIVE-COLITIS; COLORECTAL-CANCER; EPITHELIAL-CELLS; MOUSE MODEL; INTERLEUKIN-10-DEFICIENT MICE	Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor kappa B, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factor beta, toll-like receptor and the IL-1 receptor inhibitor TIR8/SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies. Oncogene (2010) 29, 3313-3323; doi:10.1038/onc.2010.109; published online 19 April 2010	[Mantovani, A.] Ist Clin Humanitas IRCCS, Lab Inflammat & Immunol, I-20089 Milan, Italy; [Danese, S.] Div Gastroenterol, Inflammatory Bowel Dis Unit, Milan, Italy	IRCCS Humanitas Research Hospital	Mantovani, A (corresponding author), Ist Clin Humanitas IRCCS, Lab Inflammat & Immunol, Via Manzoni56, I-20089 Milan, Italy.	sdanese@hotmail.com; alberto.mantovani@humanitasresearch.it	Danese, Silvio/ABH-9571-2020; Mantovani, Alberto/HCI-7449-2022	Danese, Silvio/0000-0001-7341-1351; Mantovani, Alberto/0000-0001-5578-236X	Broad Medical Research Program,; Italian Ministery of Health (Ricerca Finalizzata) [72]; Bando Giovani Ricercatori; Fondazione Cariplo; Italian Association for Cancer Research (AIRC); European Community [518167]; Ministero dell'Istruzione dell'Universita e della Ricerca (Rome, Italy) [2002061255, RBIN04EKC]; Fondazione Cariplo (Milan, Italy); Fondazione Humanitas per la Ricerca (Rozzano, Italy)	Broad Medical Research Program,; Italian Ministery of Health (Ricerca Finalizzata); Bando Giovani Ricercatori; Fondazione Cariplo(Fondazione Cariplo); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); European Community(European Commission); Ministero dell'Istruzione dell'Universita e della Ricerca (Rome, Italy)(Ministry of Education, Universities and Research (MIUR)); Fondazione Cariplo (Milan, Italy)(Fondazione Cariplo); Fondazione Humanitas per la Ricerca (Rozzano, Italy)	This study was supported by grants from the Broad Medical Research Program, the Italian Ministery of Health (Ricerca Finalizzata 2006, n.72 and Bando Giovani Ricercatori), Fondazione Cariplo and the Italian Association for Cancer Research (My first AIRC Grant) to SD, and the European Community (INNOCHEM project 518167), the Ministero dell'Istruzione dell'Universita e della Ricerca (Rome, Italy; PRIN project 2002061255; FIRB project RBIN04EKCX) and Fondazione Cariplo (Milan, Italy; NOBEL project). This work was conducted in the context and with the support of the Fondazione Humanitas per la Ricerca (Rozzano, Italy).	Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Attiga FA, 2000, CANCER RES, V60, P4629; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Beaugerie L, 2009, LANCET, V374, P1617, DOI 10.1016/S0140-6736(09)61302-7; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Becker C, 2006, CYTOKINE GROWTH F R, V17, P97, DOI 10.1016/j.cytogfr.2005.09.004; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Betti M, 2006, ANN ONCOL, V17, P235; Biancone L, 2009, GUT, V58, P1703, DOI 10.1136/gut.2008.176461; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bonecchi R, 2004, J IMMUNOL, V172, P4972, DOI 10.4049/jimmunol.172.8.4972; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bos CL, 2006, CARCINOGENESIS, V27, P2371, DOI 10.1093/carcin/bgl071; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Burstein E, 2008, J CLIN INVEST, V118, P464, DOI [10.1172/JC134831, 10.1172/JCI34831]; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; Chung YC, 2003, J SURG ONCOL, V83, P222, DOI 10.1002/jso.10269; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; de la Torre YM, 2007, P NATL ACAD SCI USA, V104, P2319, DOI 10.1073/pnas.0607514104; Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Fantini MC, 2009, GASTROENTEROLOGY, V136, P1308, DOI 10.1053/j.gastro.2008.12.053; Fukata M, 2008, ONCOGENE, V27, P234, DOI 10.1038/sj.onc.1210908; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Garlanda C, 2004, P NATL ACAD SCI USA, V101, P3522, DOI 10.1073/pnas.0308680101; Garlanda C, 2007, CANCER RES, V67, P6017, DOI 10.1158/0008-5472.CAN-07-0560; Garlanda C, 2009, TRENDS IMMUNOL, V30, P439, DOI 10.1016/j.it.2009.06.001; Garrett WS, 2009, CANCER CELL, V16, P208, DOI 10.1016/j.ccr.2009.07.015; Gasche C, 2004, ALIMENT PHARM THER, V20, P31, DOI 10.1111/j.1365-2036.2004.02045.x; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; GYDE S, 1982, GASTROENTEROLOGY, V83, P36; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Jacoby RF, 2000, CANCER RES, V60, P5040; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Kai H, 2005, ANTICANCER RES, V25, P709; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002; Laghi L, 2009, LANCET ONCOL, V10, P877, DOI 10.1016/S1470-2045(09)70186-X; Li GP, 2002, BIOCHEM BIOPH RES CO, V299, P886, DOI 10.1016/S0006-291X(02)02707-9; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mantovani A, 2004, J LEUKOCYTE BIOL, V75, P738, DOI 10.1189/jlb.1003473; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Matuk R, 2004, INFLAMM BOWEL DIS, V10, P352, DOI 10.1097/00054725-200407000-00005; Mazzucchelli L, 1996, J PATHOL, V178, P201, DOI 10.1002/(SICI)1096-9896(199602)178:2<201::AID-PATH440>3.0.CO;2-4; McLoughlin RM, 2003, J CLIN INVEST, V112, P598, DOI 10.1172/JCI200317129; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murphy PM, 2000, PHARMACOL REV, V52, P145; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nakamura K, 2006, WORLD J GASTROENTERO, V12, P4628, DOI 10.3748/wjg.v12.i29.4628; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nibbs RJB, 2001, AM J PATHOL, V158, P867, DOI 10.1016/S0002-9440(10)64035-7; Nibbs RJB, 2007, J CLIN INVEST, V117, P1884, DOI 10.1172/JCI30068; NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833; Noguchi M, 1998, GUT, V43, P203, DOI 10.1136/gut.43.2.203; Okayasu I, 2002, J GASTROEN HEPATOL, V17, P1078, DOI 10.1046/j.1440-1746.2002.02853.x; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Osawa E, 2006, INT J CANCER, V118, P2232, DOI 10.1002/ijc.21639; Oshima M, 2001, CANCER RES, V61, P1733; Pasparakis M, 2008, MUCOSAL IMMUNOL, V1, pS54, DOI 10.1038/mi.2008.53; PESKAR BM, 1987, DIGEST DIS SCI, V32, pS51, DOI 10.1007/BF01312464; Polentarutti N, 2003, EUR CYTOKINE NETW, V14, P211; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; REINECKER HC, 1995, GASTROENTEROLOGY, V108, P40, DOI 10.1016/0016-5085(95)90006-3; Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286; Roessner A, 2008, PATHOL RES PRACT, V204, P511, DOI 10.1016/j.prp.2008.04.011; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sinicrope FA, 2004, CANCER METAST REV, V23, P63, DOI 10.1023/A:1025863029529; Stolfi C, 2008, WORLD J GASTROENTERO, V14, P4434, DOI 10.3748/wjg.14.4434; Stolfi C, 2008, BIOCHEM PHARMACOL, V75, P668, DOI 10.1016/j.bcp.2007.09.020; Sun YJ, 2002, CANCER RES, V62, P6323; Szlosarek P, 2006, EUR J CANCER, V42, P745, DOI 10.1016/j.ejca.2006.01.012; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Vetrano S, 2010, GUT, V59, P197, DOI 10.1136/gut.2009.183772; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Waldner M, 2006, WORLD J GASTROENTERO, V12, P7233, DOI 10.3748/wjg.v12.i45.7233; Wang H., 2003, CYTOKINE HDB, V4th ed., P837; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012	114	153	158	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3313	3323		10.1038/onc.2010.109	http://dx.doi.org/10.1038/onc.2010.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20400974				2022-12-28	WOS:000278622700001
J	Behren, A; Muhlen, S; Sanhueza, GAA; Schwager, C; Plinkert, PK; Huber, PE; Abdollahi, A; Simon, C				Behren, A.; Muehlen, S.; Sanhueza, G. A. Acuna; Schwager, C.; Plinkert, P. K.; Huber, P. E.; Abdollahi, A.; Simon, C.			Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion	ONCOGENE			English	Article						MAPK; p38; ras; invasion; FOXM1; MKK3	ACTIVATED PROTEIN-KINASES; BREAST EPITHELIAL-CELLS; SIGNALING PATHWAYS; GENE-EXPRESSION; TRANSGENIC MICE; RAS; P38; CARCINOMA; FIBROBLASTS; SENESCENCE	The Ras oncogene is known to activate three major MAPK pathways, ERK, JNK, p38 and exert distinct cellular phenotypes, that is, apoptosis and invasion through the Ras-MKK3-p38-signaling cascade. We attempted to identify the molecular targets of this pathway that selectively govern the invasive phenotype. Stable transfection of NIH3T3 fibroblasts with MKK3(act) cDNA construct revealed similar p38-dependent in vitro characteristics observed in Ha-Ras(EJ)-transformed NIH3T3 cells, including enhanced invasiveness and anchorage-independent growth correlating with p38 phosphorylation status. To identify the consensus downstream targets of the Ras-MKK3-p38 cascade involved in invasion, in vitro invasion assays were used to isolate highly invasive cells from both, MKK3 and Ha-Ras(EJ) transgenic cell lines. Subsequently a genome-wide transcriptome analysis was employed to investigate differentially regulated genes in invasive Ha-Ras(EJ)- and MKK3(act)-transfected NIH3T3 fibroblasts. Using this phenotype-assisted approach combined with system level protein-interaction network analysis, we identified FOXM1, PLK1 and CDK1 to be differentially regulated in invasive Ha-Ras(EJ)- NIH3T3 and MKK3(act)-NIH3T3 cells. Finally, a FOXM1 RNA-knockdown approach revealed its requirement for both invasion and anchorage-independent growth of Ha-Ras(EJ)- and MKK3(act)-NIH3T3 cells. Together, we identified FOXM1 as a key downstream target of Ras and MKK3-induced cellular in vitro invasion and anchorage-independent growth signaling. Oncogene (2010) 29, 1519-1530; doi:10.1038/onc.2009.436; published online 21 December 2009	[Behren, A.] Ludwig Inst Canc Res Ltd, Melbourne Ctr Clin Sci, Canc Vaccine, Heidelberg, Vic, Australia; [Muehlen, S.] Univ Newcastle, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne, Tyne & Wear, England; [Behren, A.; Muehlen, S.; Plinkert, P. K.; Simon, C.] Univ Heidelberg Hosp, Dept Otolaryngol Head & Neck Surg, Heidelberg, Germany; [Sanhueza, G. A. Acuna] DKFZ, German Canc Res Ctr, Div Signal Transduct & Growth Control, Heidelberg, Germany; [Schwager, C.; Huber, P. E.; Abdollahi, A.] DKFZ, German Canc Res Ctr, Dept Radiat Oncol, Heidelberg, Germany; [Abdollahi, A.] Tufts Univ, Sch Med, Ctr Canc Syst Biol, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USA; [Abdollahi, A.] Harvard Univ, Sch Med, Dept Surg, Karp Family Res Labs,Vasc Biol Program, Boston, MA 02115 USA	Ludwig Institute for Cancer Research; Newcastle University - UK; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); St. Elizabeth's Medical Center; Tufts University; Harvard University; Harvard Medical School	Simon, C (corresponding author), Univ Heidelberg, Dept Otolaryngol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	csimon1407@aol.com	Behren, Andreas/ABZ-2615-2022	Muehlen, Sabrina/0000-0001-7474-705X; Behren, Andreas/0000-0001-5329-280X	German Krebshilfe (Deutsche Krebshilfe) [107691]; NSCOR [NNJ04HJ12G]; DFG [SPP1190, Si634-5/1]	German Krebshilfe (Deutsche Krebshilfe)(Deutsche Krebshilfe); NSCOR; DFG(German Research Foundation (DFG))	We thank Thomas Regiert (DKFZ) for excellent technical assistance with microarray analysis. We also thank J Han (Scripps Research Institute) for providing us with the MKK3(b) expression construct and RH Medema (Laboratory of Experimental Oncology, University Medical Center Utrecht) for the FoxM1 promoter construct. This work was supported by the German Krebshilfe (Deutsche Krebshilfe, 107691, to CS, PH, PP and AA), NSCOR NNJ04HJ12G and DFG-SPP1190 (to AA and PH) and DFG-Si634-5/1 (to CS and PP).	Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820; Behren A, 2005, EXP CELL RES, V303, P321, DOI 10.1016/j.yexcr.2004.10.004; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Haq R, 2002, CANCER RES, V62, P5076; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jin K, 2005, J BIOL CHEM, V280, P42097, DOI 10.1074/jbc.M507301200; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinina OA, 2003, ONCOGENE, V22, P6266, DOI 10.1038/sj.onc.1206640; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moon A, 2006, ARCH PHARM RES, V29, P113, DOI 10.1007/BF02974271; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schwacke JH, 2007, J THEOR BIOL, V246, P604, DOI 10.1016/j.jtbi.2006.12.035; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; ZHANG JY, 1992, CANCER RES, V52, P6682	39	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1519	1530		10.1038/onc.2009.436	http://dx.doi.org/10.1038/onc.2009.436			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20023695				2022-12-28	WOS:000275392400010
J	Lujambio, A; Portela, A; Liz, J; Melo, SA; Rossi, S; Spizzo, R; Croce, CM; Calin, GA; Esteller, M				Lujambio, A.; Portela, A.; Liz, J.; Melo, S. A.; Rossi, S.; Spizzo, R.; Croce, C. M.; Calin, G. A.; Esteller, M.			CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer	ONCOGENE			English	Article						DNA methylation; CpG island; non-coding RNA; epigenetics	MICRORNA; GENES; METHYLATION; EPIGENETICS; SITES; CONTRIBUTES; EPIGENOMICS; SIGNATURES; MUTATIONS; ELEMENTS	Although only 1.5% of the human genome appears to code for proteins, much effort in cancer research has been devoted to this minimal fraction of our DNA. However, the last few years have witnessed the realization that a large class of non-coding RNAs (ncRNAs), named microRNAs, contribute to cancer development and progression by acting as oncogenes or tumor suppressor genes. Recent studies have also shown that epigenetic silencing of microRNAs with tumor suppressor features by CpG island hypermethylation is a common hallmark of human tumors. Thus, we wondered whether there were other ncRNAs undergoing aberrant DNA methylation-associated silencing in transformed cells. We focused on the transcribed-ultraconserved regions (T-UCRs), a subset of DNA sequences that are absolutely conserved between orthologous regions of the human, rat and mouse genomes and that are located in both intra-and intergenic regions. We used a pharmacological and genomic approach to reveal the possible existence of an aberrant epigenetic silencing pattern of T-UCRs by treating cancer cells with a DNA-demethylating agent followed by hybridization to an expression microarray containing these sequences. We observed that DNA hypomethylation induces release of T-UCR silencing in cancer cells. Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues. The analysis of a large set of primary human tumors (n = 283) demonstrated that hypermethylation of the described T-UCR CpG islands was a common event among the various tumor types. Our finding that, in addition to microRNAs, another class of ncRNAs (T-UCRs) undergoes DNA methylation-associated inactivation in transformed cells supports a model in which epigenetic and genetic alterations in coding and non-coding sequences cooperate in human tumorigenesis. Oncogene (2010) 29, 6390-6401; doi:10.1038/onc.2010.361; published online 30 August 2010	[Esteller, M.] Hosp Duran & Reynals, Bellvitge Inst Biomed Res IDI BELL, Canc Epigenet & Biol Program, Barcelona 08907, Catalonia, Spain; [Rossi, S.; Spizzo, R.; Calin, G. A.] Texas State Univ, MD Anderson Canc Ctr, Houston, TX USA; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Texas State University System; Texas State University San Marcos; University of Texas System; UTMD Anderson Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Inst Biomed Res IDI BELL, Canc Epigenet & Biol Program, 08907 Hosp,3rd Floor,Avda Gran Via 199-203, Barcelona 08907, Catalonia, Spain.	mesteller@iconcologia.net	Calin, George/E-9390-2011; MELO, SONIA/H-8972-2013; Esteller, Manel/L-5956-2014; Spizzo, Riccardo/V-1057-2019; Young, Richard A/F-6495-2012	MELO, SONIA/0000-0002-2291-4263; Esteller, Manel/0000-0003-4490-6093; Spizzo, Riccardo/0000-0001-7772-0960; Young, Richard A/0000-0001-8855-8647; Portela, Anna/0000-0003-2184-2584; Calin, George/0000-0001-6704-5615; Lujambio, Amaia/0000-0002-2798-1481	Consolider [CSD2006-49]; CANCERDIP [HEALTH-F2-2007-200620]; Dr Josef Steiner Cancer Research Foundation; FPU;  [SAF2007-00027-65134]; ICREA Funding Source: Custom	Consolider(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CANCERDIP; Dr Josef Steiner Cancer Research Foundation; FPU(Spanish Government); ; ICREA(ICREA)	This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, CANCERDIP HEALTH-F2-2007-200620 and the Dr Josef Steiner Cancer Research Foundation. AL is supported by a FPU Fellowship. AP is a Sara Borell Postdoctoral Fellow. ME is an ICREA Research Professor.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bejerano G, 2006, NATURE, V441, P87, DOI 10.1038/nature04696; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Hammond SM, 2007, NAT GENET, V39, P582, DOI 10.1038/ng0507-582; Han L, 2007, CANCER BIOL THER, V6, P1284; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Henikoff S, 2008, NAT REV GENET, V9, P15, DOI 10.1038/nrg2206; Henikoff S, 2007, CANCER CELL, V12, P407, DOI 10.1016/j.ccr.2007.10.024; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Iwama H, 2007, FEBS LETT, V581, P1805, DOI 10.1016/j.febslet.2007.03.066; Jacinto FV, 2009, ONCOGENE, V28, P4212, DOI 10.1038/onc.2009.267; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katzman S, 2007, SCIENCE, V317, P915, DOI 10.1126/science.1142430; Lareau LF, 2007, NATURE, V446, P926, DOI 10.1038/nature05676; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CELL CYCLE, V6, P1455; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nguyen CT, 2002, CANCER RES, V62, P6456; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rossi S, 2008, MAMM GENOME, V19, P526, DOI 10.1007/s00335-008-9119-8; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040; Takai Daiya, 2003, In Silico Biology, V3, P235; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Velculescu VE, 2008, CARCINOGENESIS, V29, P1087, DOI 10.1093/carcin/bgn096; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	60	145	151	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6390	6401		10.1038/onc.2010.361	http://dx.doi.org/10.1038/onc.2010.361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20802525	Green Published, hybrid			2022-12-28	WOS:000284874700009
J	Monahan, KB; Rozenberg, GI; Krishnamurthy, J; Johnson, SM; Liu, W; Bradford, MK; Horner, J; DePinho, RA; Sharpless, NE				Monahan, K. B.; Rozenberg, G. I.; Krishnamurthy, J.; Johnson, S. M.; Liu, W.; Bradford, M. K.; Horner, J.; DePinho, R. A.; Sharpless, N. E.			Somatic p16(INK4a) loss accelerates melanomagenesis	ONCOGENE			English	Article						melanoma; RAS; p16(INK4a)	TUMOR-SUPPRESSOR PTEN; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; CELL-MIGRATION; P53 GENE; GERMLINE MUTATIONS; MELANOCYTIC NEVI; ONCOGENIC RAS; SUN EXPOSURE; IN-VIVO	Loss of p16(INK4a)-RB and ARF-p53 tumor suppressor pathways, as well as activation of RAS-RAF signaling, is seen in a majority of human melanomas. Although heterozygous germline mutations of p16(INK4a) are associated with familial melanoma, most melanomas result from somatic genetic events: often p16(INK4a) loss and N-RAS or B-RAF mutational activation, with a minority possessing alternative genetic alterations such as activating mutations in K-RAS and/or p53 inactivation. To generate a murine model of melanoma featuring some of these somatic genetic events, we engineered a novel conditional p16(INK4a)-null allele and combined this allele with a melanocyte-specific, inducible CRE recombinase strain, a conditional p53-null allele and a loxP-stop-loxP activatable oncogenic K-Ras allele. We found potent synergy between melanocyte-specific activation of K-Ras and loss of p16(INK4a) and/or p53 in melanomagenesis. Mice harboring melanocyte-specific activated K-Ras and loss of p16(INK4a) and/or p53 developed invasive, unpigmented and nonmetastatic melanomas with short latency and high penetrance. In addition, the capacity of these somatic genetic events to rapidly induce melanomas in adult mice suggests that melanocytes remain susceptible to transformation throughout adulthood. Oncogene (2010) 29, 5809-5817; doi: 10.1038/onc.2010.314; published online 9 August 2010	[Monahan, K. B.; Rozenberg, G. I.; Krishnamurthy, J.; Johnson, S. M.; Liu, W.; Bradford, M. K.; Sharpless, N. E.] Univ N Carolina, Sch Med, Ctr Environm Hlth & Susceptibil, Dept Med,Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Monahan, K. B.; Rozenberg, G. I.; Krishnamurthy, J.; Johnson, S. M.; Liu, W.; Bradford, M. K.; Sharpless, N. E.] Univ N Carolina, Sch Med, Ctr Environm Hlth & Susceptibil, Dept Genet,Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Horner, J.; DePinho, R. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci,Dept Med Oncol, Boston, MA 02115 USA; [Horner, J.; DePinho, R. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci,Dept Med, Boston, MA 02115 USA; [Horner, J.; DePinho, R. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci,Dept Genet, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sharpless, NE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, CB 7295,Mason Farm Rd, Chapel Hill, NC 27599 USA.	nes@med.unc.edu		Sharpless, Norman/0000-0001-7078-9455; DePinho, Ronald/0000-0002-5625-577X	NIH [AG024379, ES14635]; American Federation of Aging; Golfers Against Cancer Foundation; Sidney Kimmel Foundation; National Cancer Center; NATIONAL CANCER INSTITUTE [R01CA163896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES014635, P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024379] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Federation of Aging; Golfers Against Cancer Foundation; Sidney Kimmel Foundation; National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Eric Brown, Marcus Bosenberg, Vincent Hearing for advice and reagents. This work was supported by Grants from NIH (AG024379 and ES14635), as well as from the American Federation of Aging (to KJ), the Golfers Against Cancer Foundation, the Sidney Kimmel Foundation and the National Cancer Center (to KBM).	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Akslen LA, 1998, INT J CANCER, V79, P91; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; BADER JL, 1985, AM J PEDIAT HEMATOL, V7, P341; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; English DR, 2005, CANCER EPIDEM BIOMAR, V14, P2873, DOI 10.1158/1055-9965.EPI-05-0520; Evan GI, 2009, CURR OPIN GENET DEV, V19, P25, DOI 10.1016/j.gde.2008.11.009; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; HARRISON SL, 1994, LANCET, V344, P1529, DOI 10.1016/S0140-6736(94)90348-4; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Marino S, 2002, DEVELOPMENT, V129, P3513; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Petermann KB, 2007, J CLIN INVEST, V117, P3922, DOI 10.1172/JCI32163; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramsey MR, 2007, CANCER RES, V67, P4732, DOI 10.1158/0008-5472.CAN-06-3437; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Sharpless NE, 2002, CANCER RES, V62, P2761; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shields JM, 2007, CANCER RES, V67, P1502, DOI 10.1158/0008-5472.CAN-06-3311; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; SPARROW LE, 1995, MELANOMA RES, V5, P93, DOI 10.1097/00008390-199504000-00004; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	55	44	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5809	5817		10.1038/onc.2010.314	http://dx.doi.org/10.1038/onc.2010.314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20697345	Green Published, hybrid			2022-12-28	WOS:000283586200006
J	Crusio, KM; King, B; Reavie, LB; Aifantis, I				Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.			The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformation	ONCOGENE			English	Review						Fbw7; ubiquitin-proteasome system; GSK-3 beta; p53	F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE-RESPONSE; CELL SELF-RENEWAL; C-MYC PROTEIN; TUMOR-SUPPRESSOR; CYCLIN-E; CHROMOSOMAL INSTABILITY; FBXW7 ACTS	The ubiquitin-proteasome system (UPS) is a multi-subunit pathway that allows for ubiquitin modification of proteins and leads to either degradation or other non-proteolytic processes such as trafficking or transcriptional activation. Given its role as a regulator of cellular homeostasis it is not surprising that members of the UPS are frequently aberrantly expressed in a number of disease states including cancer. This review will focus on one member of the UPS, the F-box protein, Fbw7 (also known as Sel-10, Ago, hCDC4) and mechanisms by which Fbw7 interacts with its substrates in the context of development and tumorigenesis will be discussed. In addition, antagonists of this pathway as well as current and future therapeutics for the UPS will be examined. Oncogene (2010) 29, 4865-4873; doi: 10.1038/onc.2010.222; published online 14 June 2010	[Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.] NYU, Sch Med, Howard Hughes Med Inst, Dept Pathol, New York, NY 10016 USA; [Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.] NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA; [Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.] NYU, Sch Med, Helen & Martin S Kimmel Stem Cell Ctr, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University; New York University	Aifantis, I (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, Dept Pathol, 550 1st Ave,MSB 504, New York, NY 10016 USA.	iannis.aifantis@nyumc.org			National Institutes of Health [RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, P30CA016087]; American Cancer Society [RSG0806801]; Edward Mallinckrodt Jr Foundation; Irma T Hirschl Trust; Alex's Lemonade Stand Foundation; NYU [5T32CA009161]; NATIONAL CANCER INSTITUTE [R01CA133379, T32CA009161, R21CA141399, R01CA149655, R01CA105129, P30CA016087] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Edward Mallinckrodt Jr Foundation; Irma T Hirschl Trust; Alex's Lemonade Stand Foundation; NYU; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Aifantis Lab for advice and illuminating discussions. Supported by the National Institutes of Health (RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655 and P30CA016087), the American Cancer Society (RSG0806801), the Edward Mallinckrodt Jr Foundation, the Irma T Hirschl Trust, the Alex's Lemonade Stand Foundation (all to IA), NYU Molecular Oncology and Immunology/Ruth L Kirchstein Institutional Training Grant (5T32CA009161 to KC), NYU Cell and Molecular Biology/Ruth L Kirchstein Institutional Traning Grant (BK). IA is a Leukemia & Lymphoma Society Scholar and an Early Career Scientist at the Howard Hughes Medical Institute.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Bechard M, 2009, MOL CELL BIOL, V29, P2092, DOI 10.1128/MCB.01405-08; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Finkin S, 2008, ONCOGENE, V27, P4411, DOI 10.1038/onc.2008.77; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; HARTWELL LH, 1973, GENETICS, V74, P267; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Ishikawa Y, 2008, ONCOGENE, V27, P6164, DOI 10.1038/onc.2008.216; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Kanei-Ishii C, 2008, J BIOL CHEM, V283, P30540, DOI 10.1074/jbc.M804340200; Kitagawa K, 2009, ONCOGENE, V28, P2393, DOI 10.1038/onc.2009.111; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Masuda K, 2010, ONCOGENE, V29, P1798, DOI 10.1038/onc.2009.469; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Petroski MD, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S7; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reavie L, 2010, NAT IMMUNOL, V11, P207, DOI 10.1038/ni.1839; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SIEGERT W, 1990, EUR J CANCER, V26, P733, DOI 10.1016/0277-5379(90)90130-L; Skaar JR, 2009, CURR OPIN CELL BIOL, V21, P816, DOI 10.1016/j.ceb.2009.08.004; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Song L, 2008, CURR OPIN CELL BIOL, V20, P156, DOI 10.1016/j.ceb.2008.01.012; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YANO T, 1993, ONCOGENE, V8, P2741; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	80	95	106	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4865	4873		10.1038/onc.2010.222	http://dx.doi.org/10.1038/onc.2010.222			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20543859	Green Accepted			2022-12-28	WOS:000281578700001
J	Kong, B; Michalski, CW; Hong, X; Valkovskaya, N; Rieder, S; Abiatari, I; Streit, S; Erkan, M; Esposito, I; Friess, H; Kleeff, J				Kong, B.; Michalski, C. W.; Hong, X.; Valkovskaya, N.; Rieder, S.; Abiatari, I.; Streit, S.; Erkan, M.; Esposito, I.; Friess, H.; Kleeff, J.			AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-beta-mediated ERK signaling	ONCOGENE			English	Article						pancreatic cancer; AZGP1; EMT; MET; transdifferentiation; transforming growth factor-beta	GROWTH-FACTOR-BETA; K-RAS; CELL-LINE; CONFERS RESISTANCE; GENE-EXPRESSION; STELLATE CELLS; INDUCTION; ZN-ALPHA-2-GLYCOPROTEIN; PROGRESSION; ACTIVATION	Epithelial-to-mesenchymal transdifferentiation (EMT) mediated by transforming growth factor-beta (TGF-beta) signaling leads to aggressive cancer progression. In this study, we identified zinc-alpha 2-glycoprotein (AZGP1, ZAG) as a tumor suppressor in pancreatic ductal adenocarcinoma whose expression is lost due to histone deacetylation. In vitro, ZAG silencing strikingly increased invasiveness of pancreatic cancer cells accompanied by the induction of a mesenchymal phenotype. Expression analysis of a set of EMT markers showed an increase in the expression of mesenchymal markers (vimentin (VIM) and integrin-alpha 5) and a concomitant reduction in the expression of epithelial markers (cadherin 1 (CDH1), desmoplakin and keratin-19). Blockade of endogenous TGF-beta signaling inhibited these morphological changes and the downregulation of CDH1, as elicited by ZAG silencing. In a ZAG-negative cell line, human recombinant ZAG (rZAG) specifically inhibited exogenous TGF-beta-mediated tumor cell invasion and VIM expression. Furthermore, rZAG blocked TGF-beta-mediated ERK2 phosphorylation. PCR array analysis revealed that ZAG-induced epithelial transdifferentiation was accompanied by a series of concerted cellular events including a shift in the energy metabolism and prosurvival signals. Thus, epigenetically regulated ZAG is a novel tumor suppressor essential for maintaining an epithelial phenotype. Oncogene (2010) 29, 5146-5158; doi:10.1038/onc.2010.258; published online 28 June 2010	[Kong, B.; Michalski, C. W.; Hong, X.; Valkovskaya, N.; Rieder, S.; Abiatari, I.; Streit, S.; Erkan, M.; Friess, H.; Kleeff, J.] Tech Univ Munich, Dept Surg, D-81675 Munich, Germany; [Esposito, I.] Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich	Kleeff, J (corresponding author), Tech Univ Munich, Dept Surg, Ismaningerstr 22, D-81675 Munich, Germany.	kleeff@chir.med.tu-muenchen.de	Kleeff, Jorg/B-2124-2009; Michalski, Christoph/U-9167-2019; Abiatari, Ivane/ABC-6247-2021	Kleeff, Jorg/0000-0003-3432-6669; Abiatari, Ivane/0000-0002-1118-3477	European Union; Commission for Clinical Research of the TU Munich; Ministry of Education of China	European Union(European Commission); Commission for Clinical Research of the TU Munich; Ministry of Education of China(Ministry of Education, China)	We thank Felicitas Altmayr, Tanja Rossmann-Bloeck, Manja Thorwirth and Carmen Marthen for excellent technical support. This study was in part supported by the European Union (within the framework of the 'MolDiagPaca' project; to JK, CWM and HF) and by the commission for clinical research of the TU Munich (KKF). BK received a fellowship from the Scholarship Council of the Ministry of Education of China.	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Benfield AP, 2007, ARCH BIOCHEM BIOPHYS, V462, P47, DOI 10.1016/j.abb.2007.03.010; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Bing C, 2004, P NATL ACAD SCI USA, V101, P2500, DOI 10.1073/pnas.0308647100; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; BUERGI W, 1961, J BIOL CHEM, V236, P1066; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dembinski JL, 2009, CLIN EXP METASTAS, V26, P611, DOI 10.1007/s10585-009-9260-0; DIEZITZA I, 1993, EUR J CANCER, V29A, P1256, DOI 10.1016/0959-8049(93)90068-Q; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Ellenrieder V, 2001, CANCER RES, V61, P4222; Esposito I, 2007, J CLIN PATHOL, V60, P885, DOI 10.1136/jcp.2006.038257; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; Finkel E, 1996, LANCET, V347, P1034, DOI 10.1016/S0140-6736(96)90163-4; Freemantle SJ, 2007, J CELL BIOCHEM, V102, P869, DOI 10.1002/jcb.21519; FRENETTE G, 1987, PROSTATE, V11, P257, DOI 10.1002/pros.2990110306; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hale LP, 2001, CLIN CANCER RES, V7, P846; Hamada S, 2007, J CELL PHYSIOL, V213, P768, DOI 10.1002/jcp.21148; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Ketterer K, 2009, CANCER LETT, V277, P72, DOI 10.1016/j.canlet.2008.11.028; Khasawneh J, 2009, P NATL ACAD SCI USA, V106, P3354, DOI 10.1073/pnas.0802864106; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lecanda J, 2009, CELL CYCLE, V8, P742, DOI 10.4161/cc.8.5.7871; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; Lim JH, 2008, J CELL BIOCHEM, V105, P1117, DOI 10.1002/jcb.21914; Longnecker DS, 1998, PANCREAS, V17, P323, DOI 10.1097/00006676-199811000-00001; Lung FDT, 2003, BIOPOLYMERS, V71, P132, DOI 10.1002/bip.10396; Marrades MP, 2008, J PHYSIOL BIOCHEM, V64, P61, DOI 10.1007/BF03168235; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Michalski CW, 2007, ANN SURG, V246, P786, DOI 10.1097/SLA.0b013e318070d56e; Michalski CW, 2007, GASTROENTEROLOGY, V132, P1968, DOI 10.1053/j.gastro.2007.02.035; Michalski CW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001701; Michaud DS, 2001, JAMA-J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921; OHKUBO I, 1990, BIOCHIM BIOPHYS ACTA, V1034, P152, DOI 10.1016/0304-4165(90)90069-9; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Robson EJD, 2006, DIFFERENTIATION, V74, P254, DOI 10.1111/j.1432-0436.2006.00075.x; Rolli V, 2007, FEBS LETT, V581, P394, DOI 10.1016/j.febslet.2006.12.047; Russell ST, 2004, BBA-MOL CELL BIOL L, V1636, P59, DOI 10.1016/j.bbalip.2003.12.004; Russell ST, 2010, ENDOCRINOLOGY, V151, P948, DOI 10.1210/en.2009-0827; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Subramanian G, 2004, CANCER RES, V64, P5200, DOI 10.1158/0008-5472.CAN-04-0018; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wan M, 2005, AM J PATHOL, V166, P1379, DOI 10.1016/S0002-9440(10)62356-5; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Zhang WW, 2007, CANCER BIOL THER, V6, P218, DOI 10.4161/cbt.6.2.3623	55	64	69	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	37					5146	5158		10.1038/onc.2010.258	http://dx.doi.org/10.1038/onc.2010.258			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581862				2022-12-28	WOS:000281867200004
J	Staub, E; Buhr, HJ; Grone, J				Staub, E.; Buhr, H-J; Groene, J.			Predicting the site of origin of tumors by a gene expression signature derived from normal tissues	ONCOGENE			English	Article						gene expression signature; CUP; cancer type; expression profiling; microarray	CHAIN-REACTION ASSAY; UNKNOWN PRIMARY; MOLECULAR CLASSIFICATION; MICROARRAY; CANCER; CARCINOMA; IDENTIFICATION; DIAGNOSIS; IDENTIFY; MARKERS	Multiple expression signatures for the prediction of the site of origin of metastatic cancer of unknown primary origin (CUP) have been developed. Owing to their limited coverage of tumor types and suboptimal prediction accuracy on distinct tumors, there is still room for alternative CUP gene expression signatures. Whereas in past studies, CUP classifiers were trained solely on data from tumor samples, we now use expression patterns from normal tissues for classifier training. This approach potentially avoids pitfalls related to the representation of genetically heterogeneous tumor subtypes during classifier training. Two expression data sets of normal human tissues have been reanalyzed to derive an expression signature for liver, prostate, kidney, ovarian and lung tissues. In reciprocal validation, classifiers trained on either data set achieved overall accuracies greater than 97%. Classifiers trained on combined expression data from both normal tissue data sets were able to predict the site of origin in a cohort of 652 primary tumors with similar to 90% accuracy. Prediction accuracies of primary cancer-based classifiers were in the same range, as determined by cross-validation on this cohort. For individual tumor types, normal tissue-based classifiers achieved sensitivities in the range of 64-99% and specificities in the range of 92-100%. Primary origins for 12 of 20 metastases were predicted correctly, with false predictions highlighting the need for accurate sample preparation to avoid contaminations by metastases-surrounding tissue. We conclude that gene expression patterns of normal tissues harbor phenotypic information that is retained in tumors and can be sufficient to recover the type of primary tumor from expression patterns alone. Oncogene (2010) 29, 4485-4492; doi: 10.1038/onc.2010.196; published online 31 May 2010	[Staub, E.] Merck KGaA, Merck Serono, Drug Discovery Informat, Darmstadt, Germany; [Buhr, H-J; Groene, J.] Charite, Dept Gen Vasc & Thorac Surg, Berlin, Germany	Merck KGaA; EMD Serono Inc.; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Staub, E (corresponding author), Merck KGaA, Merck Serono, Drug Discovery Informat, Darmstadt, Germany.	eike.staub@merck.de	Staub, Eike/B-9801-2009	Staub, Eike/0000-0002-5039-3098				ABBRUZZESE JL, 1994, J CLIN ONCOL, V12, P1272, DOI 10.1200/JCO.1994.12.6.1272; Bloom G, 2004, AM J PATHOL, V164, P9, DOI 10.1016/S0002-9440(10)63090-8; Bridgewater J, 2008, BRIT J CANCER, V98, P1425, DOI 10.1038/sj.bjc.6604315; Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236; Dennis JL, 2005, CLIN CANCER RES, V11, P3766, DOI 10.1158/1078-0432.CCR-04-2236; Dennis JL, 2002, CANCER RES, V62, P5999; Dumur CI, 2008, J MOL DIAGN, V10, P67, DOI 10.2353/jmoldx.2008.070099; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; Horlings HM, 2008, J CLIN ONCOL, V26, P4435, DOI 10.1200/JCO.2007.14.6969; Ma XJ, 2006, ARCH PATHOL LAB MED, V130, P465; Monzon FA, 2009, J CLIN ONCOL, V27, P2503, DOI 10.1200/JCO.2008.17.9762; Oien KA, 2008, J CLIN ONCOL, V26, P4373, DOI 10.1200/JCO.2008.17.6156; Pentheroudakis G, 2007, EUR J CANCER, V43, P2026, DOI 10.1016/j.ejca.2007.06.023; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2001, CANCER RES, V61, P7388; Talantov D, 2006, J MOL DIAGN, V8, P320, DOI 10.2353/jmoldx.2006.050136; Tothill RW, 2005, CANCER RES, V65, P4031, DOI 10.1158/0008-5472.CAN-04-3617; van de Wouw AJ, 2002, EUR J CANCER, V38, P409, DOI 10.1016/S0959-8049(01)00378-1; van Laar RK, 2009, INT J CANCER, V125, P1390, DOI 10.1002/ijc.24504; Varadhachary GR, 2008, J CLIN ONCOL, V26, P4442, DOI 10.1200/JCO.2007.14.4378; YEANG CH, 2001, BIOINFORMATICS, V17, P316	24	8	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2010	29	31					4485	4492		10.1038/onc.2010.196	http://dx.doi.org/10.1038/onc.2010.196			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514016				2022-12-28	WOS:000280559100011
J	Breig, O; Theoleyre, O; Douablin, A; Baklouti, F				Breig, O.; Theoleyre, O.; Douablin, A.; Baklouti, F.			Subtle distinct regulations of late erythroid molecular events by PI3K/AKT- mediated activation of Spi-1/PU.1 oncogene autoregulation loop	ONCOGENE			English	Article						erythroleukemia; mRNA splicing; cell differentiation; cell signaling	PRE-MESSENGER-RNA; TRANSCRIPTION FACTOR PU.1; FOCUS-FORMING VIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; FRIEND-ERYTHROLEUKEMIA; PHOSPHOINOSITIDE 3-KINASE; TARGET GENES; ERYTHROPOIETIN; KINASE; PHOSPHORYLATION	Spi-1/PU.1 oncogene is downregulated as proerythroblasts undergo terminal differentiation. Insertion of the Friend virus upstream of the Spi-1/PU.1 locus leads to the constitutive upregulation of Spi-1/PU.1, and a subsequent block in the differentiation of the affected erythroblasts. We have shown that sustained overexpression of Spi-1/PU.1 also inhibits the erythroid splicing of protein 4.1R exon 16, irrespective of chemical induction of differentiation. Here, we show a positive feedback loop that couples constitutive phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling to high expression of Spi-1/PU.1 in Friend erythroleukemia cells. Inhibition of PI3K/AKT results in Spi-1/PU.1 downregulation in a stepwise manner and induces cell differentiation. Chromatin immunoprecipitation assays further supported the positive autoregulatory effect of Spi-1/PU.1. Mutational analysis indicated that Ser41, but not Ser148, is necessary for Spi1/PU.1-mediated repression of hemoglobin expression, whereas both Ser residues are required for Spi-1/PU.1 inhibition of the erythroid splicing event. We further show that inhibition of the erythroid transcriptional and splicing events are strictly dependent on distinct Spi-1/PU.1 phosphorylation modifications rather than Spi-1/PU.1 expression level per se. Our data further support the fact that Spi-1/PU.1 inhibits 4.1R erythroid splicing through two different pathways, and bring new insights into the extracellular signal impact triggered by erythropoietin on late erythroid regulatory program, including pre-mRNA splicing. Oncogene (2010) 29, 2807-2816; doi: 10.1038/onc.2010.29; published online 1 March 2010	[Breig, O.; Theoleyre, O.; Douablin, A.; Baklouti, F.] Univ Lyon 1, mRNA Metab Normal & Pathol Cells, CGMC, CNRS,UMR 5534, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Baklouti, F (corresponding author), Univ Lyon 1, mRNA Metab Normal & Pathol Cells, CGMC, CNRS,UMR 5534, Bat Gregor Mendel,16,Rue R, F-69622 Villeurbanne, France.	faouzi.baklouti@univ-lyon1.fr	BAKLOUTI, Faouzi/E-7670-2013	BAKLOUTI, Faouzi/0000-0002-2830-292X	Ligue contre le Cancer, Comite de la Loire; INSERM; Ligue contre le Cancer, Comite du Doubs	Ligue contre le Cancer, Comite de la Loire; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue contre le Cancer, Comite du Doubs	We thank Dr I Merida (Department of Immunology and Oncology, Centro Nacional de Biotecnologia, Madrid, Spain) for pEFbosEGFP_C1 plasmid, Dr F Moreau-Gachelin (Inserm U830, Institut Curie, Paris, France) for anti-Spi-1/PU.1 antibody, G Giraud for helping with the ChIP assay and Dr G Mouchiroud and Dr F Morle (CGMC, Villeurbanne, France) for sharing reagents, including anti-p85 antibody. This work was supported by grants from the 'Ligue contre le Cancer, Comite de la Loire'. Authors were supported by the INSERM, the 'Ligue contre le Cancer, Comite de la Loire', the 'Ligue contre le Cancer, Comite du Doubs'	Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; Back J, 2004, BLOOD, V103, P3615, DOI 10.1182/blood-2003-11-4089; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Barnache S, 2001, BLOOD, V98, P2372, DOI 10.1182/blood.V98.8.2372; Bavelloni A, 2000, CELL DEATH DIFFER, V7, P112, DOI 10.1038/sj.cdd.4400591; Blaustein M, 2005, NAT STRUCT MOL BIOL, V12, P1037, DOI 10.1038/nsmb1020; Blaustein M, 2007, INT J BIOCHEM CELL B, V39, P2031, DOI 10.1016/j.biocel.2007.04.004; Blaybel R, 2008, CELL RES, V18, P834, DOI 10.1038/cr.2008.68; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Cataldi A, 2000, CELL SIGNAL, V12, P667, DOI 10.1016/S0898-6568(00)00109-1; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DELGADO MD, 1994, ONCOGENE, V9, P1723; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fisher RC, 2004, LEUKEMIA RES, V28, P83, DOI 10.1016/S0145-2126(03)00178-4; Ghaffari S, 2003, MIL DRUG TH, P65; Jelkmann W, 2007, EUR J HAEMATOL, V78, P183, DOI 10.1111/j.1600-0609.2007.00818.x; Juban G, 2009, MOL CELL BIOL, V29, P2852, DOI 10.1128/MCB.01435-08; Maillet P, 1996, HUM MUTAT, V7, P61, DOI 10.1002/(SICI)1098-1004(1996)7:1<61::AID-HUMU9>3.3.CO;2-T; Moreau-Gachelin F, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-99; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Myklebust JH, 2002, EXP HEMATOL, V30, P990, DOI 10.1016/S0301-472X(02)00868-8; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Nishigaki K, 2006, J VIROL, V80, P5678, DOI 10.1128/JVI.02651-05; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Patel NA, 2005, J BIOL CHEM, V280, P14302, DOI 10.1074/jbc.M411485200; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rieske P, 2001, J BIOL CHEM, V276, P8460, DOI 10.1074/jbc.M007482200; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sivertsen EA, 2006, BRIT J HAEMATOL, V135, P117, DOI 10.1111/j.1365-2141.2006.06252.x; Tarn WY, 2007, J BIOMED SCI, V14, P517, DOI 10.1007/s11373-007-9161-7; Theoleyre O, 2004, ONCOGENE, V23, P920, DOI 10.1038/sj.onc.1207206; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	43	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2807	2816		10.1038/onc.2010.29	http://dx.doi.org/10.1038/onc.2010.29			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190819				2022-12-28	WOS:000277591900006
J	Lee, GH; Yan, C; Shin, SJ; Hong, SC; Ahn, T; Moon, A; Park, SJ; Lee, YC; Yoo, WH; Kim, HT; Kim, DS; Chae, SW; Kim, HR; Chae, HJ				Lee, G-H; Yan, C.; Shin, S-J; Hong, S-C; Ahn, T.; Moon, A.; Park, S. J.; Lee, Y. C.; Yoo, W. H.; Kim, H-T; Kim, D-S; Chae, S-W; Kim, H-R; Chae, H-J			BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function	ONCOGENE			English	Article						BI-1; cancer; metastasis; NHE; acidic pH	INTRACELLULAR PH REGULATION; NA+/H+ EXCHANGER; EXTRACELLULAR PH; EPITHELIAL-CELLS; MATRIX-METALLOPROTEINASE; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; PROSTATE-CANCER; SKELETAL-MUSCLE; DOWN-REGULATION	The anti-apoptotic protein, BAX inhibitor-1 (BI-1), has a role in cancer/tumor progression. BI-1-overexpressing HT1080 and B16F10 cells produced higher lung weights and tumor volumes after injection into the tail veins of mice. Transfection of BI-1 siRNA into cells before injection blocked lung metastasis. in vitro, the overexpression of BI-1 increased cell mobility and invasiveness, with highly increased glucose consumption and cytosolic accumulation of lactate and pyruvate, but decreased mitochondrial O(2) consumption and ATP production. Glucose metabolism-associated extracellular pH also decreased as cells excreted more H(+), and sodium hydrogen exchanger (NHE) activity increased, probably as a homeostatic mechanism for intracellular pH. These alterations activated MMP 2/9 and cell mobility and invasiveness, which were reversed by the NHE inhibitor, 5-(N-ethyl-N-isopropyl) amiloride (EIPA), suggesting a role for NHE in cancer metastasis. In both in vitro and in vivo experiments, C-terminal deleted (CDBI-1) cells showed similar results to control cells, suggesting that the C-terminal motif is required for BI-1-associated alterations of glucose metabolism, NHE activation and cancer metastasis. These findings strongly suggest that BI-1 reduces extracellular pH and regulates metastasis by altering glucose metabolism and activating NHE, with the C-terminal tail having a pivotal role in these processes. Oncogene (2010) 29, 2130-2141; doi: 10.1038/onc.2009.491; published online 1 February 2010	[Chae, H-J] Chonbuk Natl Univ, Dept Pharmacol & Res, Sch Med, Res Ctr Pulm Disorder, Jeonju 561181, Chonbuk, South Korea; [Lee, G-H; Yan, C.; Kim, D-S; Chae, S-W; Chae, H-J] Chonbuk Natl Univ, Dept Pharmacol & Cardiovasc Res Ctr, Jeonju 561181, Chonbuk, South Korea; [Shin, S-J; Hong, S-C] Chonbuk Natl Univ, Dept Microbiol, Sch Med, Jeonju 561181, Chonbuk, South Korea; [Ahn, T.] Chonnam Natl Univ, Coll Vet Med, Dept Biochem, Kwangju, South Korea; [Moon, A.] Duksung Womens Univ, Sch Pharm, Seoul, South Korea; [Park, S. J.; Lee, Y. C.] Chonbuk Natl Univ, Dept Internal Med, Jeonju 561181, Chonbuk, South Korea; [Park, S. J.; Lee, Y. C.] Chonbuk Natl Univ, Airway Remodeling Lab, Sch Med, Jeonju 561181, Chonbuk, South Korea; [Yoo, W. H.] Chonbuk Natl Univ, Dept Internal Med, Div Rheumatol, Jeonju 561181, Chonbuk, South Korea; [Kim, H-T] Chonbuk Natl Univ, Sch Med, Dept Anat, Jeonju 561181, Chonbuk, South Korea; [Kim, H-R] Wonkwang Univ, Sch Dent, Dept Dent Pharmacol, Iksan, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Chonnam National University; Duksung Women's University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Wonkwang University	Chae, HJ (corresponding author), Chonbuk Natl Univ, Dept Pharmacol & Res, Sch Med, Res Ctr Pulm Disorder, San2-20, Jeonju 561181, Chonbuk, South Korea.	hrkimdp@wonkwang.ac.kr; hjchae@chonbuk.ac.kr		Hong, Seong-Tshool/0000-0001-8254-6581; HyoungTae, Kim/0000-0002-2482-6064	Ministry of Education, Science and Technology, South Korea; Ministry for Health, Welfare and Family Affairs, Republic of Korea [A084144]	Ministry of Education, Science and Technology, South Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by the Research Program for New Drug Target Discovery grant from the Ministry of Education, Science and Technology, South Korea and partly supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084144).	Alrefai WA, 2001, AM J PHYSIOL-CELL PH, V281, pC1551, DOI 10.1152/ajpcell.2001.281.5.C1551; BENNETT AF, 1982, BIOCHEMISTRY-US, V21, P4407, DOI 10.1021/bi00261a033; BEREITERHAHN J, 1988, CELL MOTIL CYTOSKEL, V10, P528, DOI 10.1002/cm.970100409; Bhujwalla ZM, 2002, NMR BIOMED, V15, P114, DOI 10.1002/nbm.743; Bolduc N, 2002, FEBS LETT, V532, P111, DOI 10.1016/S0014-5793(02)03650-5; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Boyd RS, 1999, BRIT J CANCER, V80, P315, DOI 10.1038/sj.bjc.6690357; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DELCARMEN G, 2005, EUR J GYNAECOL ONCOL, V26, P501; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Dohm CP, 2006, J MOL NEUROSCI, V29, P1, DOI 10.1385/JMN:29:1:1; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; Harguindey S, 2005, BBA-REV CANCER, V1756, P1, DOI 10.1016/j.bbcan.2005.06.004; Harima Y, 2004, INT J RADIAT ONCOL, V60, P237, DOI 10.1016/j.ijrobp.2004.02.047; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Hille C, 2007, J EXP BIOL, V210, P1463, DOI 10.1242/jeb.001529; Honegger KJ, 2006, P NATL ACAD SCI USA, V103, P803, DOI 10.1073/pnas.0503562103; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jones LE, 2004, CLIN CANCER RES, V10, P2832, DOI 10.1158/1078-0432.CCR-1157-03; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kim MS, 2003, CANCER RES, V63, P5454; Klein M, 2000, J GEN PHYSIOL, V115, P599, DOI 10.1085/jgp.115.5.599; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LAGARDE AE, 1988, J CELL BIOCHEM, V36, P249, DOI 10.1002/jcb.240360306; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Provent P, 2007, CANCER RES, V67, P7638, DOI 10.1158/0008-5472.CAN-06-3459; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623, DOI 10.1152/ajpcell.1994.267.6.C1623; ROTIN D, 1989, CANCER RES, V49, P205; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Schornack PA, 2003, NEOPLASIA, V5, P135, DOI 10.1016/S1476-5586(03)80005-2; Stacpoole Peter W., 2003, Current Gene Therapy, V3, P239, DOI 10.2174/1566523034578320; Steffan JJ, 2009, TRAFFIC, V10, P737, DOI 10.1111/j.1600-0854.2009.00904.x; Stellingwerff T, 2003, AM J PHYSIOL-ENDOC M, V284, pE589, DOI 10.1152/ajpendo.00418.2002; Stephens FB, 2007, J PHYSIOL-LONDON, V581, P431, DOI 10.1113/jphysiol.2006.125799; TANNOCK IF, 1989, CANCER RES, V49, P4373; Thomas SH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002103; Wahl ML, 2000, J CELL PHYSIOL, V183, P373, DOI 10.1002/(SICI)1097-4652(200006)183:3<373::AID-JCP10>3.0.CO;2-S; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9	55	51	52	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2130	2141		10.1038/onc.2009.491	http://dx.doi.org/10.1038/onc.2009.491			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20118983				2022-12-28	WOS:000276402800011
J	Peng, S; Maihle, NJ; Huang, Y				Peng, S.; Maihle, N. J.; Huang, Y.			Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer	ONCOGENE			English	Article						Lin28; Oct4; ovarian cancer; cancer stem cell; gene therapy; molecular diagnostics	MESSENGER-RNA; LIN-28; EXPRESSION; BIOGENESIS; SUPPRESSES; PROMOTES; MARKER	Lin28 and Oct4 are highly expressed in human embryonic stem (ES) cells and, along with two other stem cell marker proteins (Nanog and Sox2), together can convert human somatic cells to pluripotency. As an RNA-binding protein, Lin28 acts to stimulate the translation of a specific subset of mRNAs, and to inhibit the biogenesis of a group of microRNAs. Oct4 is a transcription factor essential for the maintenance of pluripotency and survival of ES cells. In this study, we report that a sub-population of epithelial ovarian cancer (EOC) cells co-expresses Lin28 and Oct4 as demonstrated in the analyses of both cell lines and patient tumor samples. We also observe that the combined expression of these proteins in tumor samples is correlated with advanced tumor grade. Intriguingly, when the expression of these two proteins is repressed in the same cells using RNA interference, there is significant reduction in cell growth and survival. We thus propose that Lin28 and Oct4 may have important roles in the initiation and/or progression of EOC, and consequently may serve as important molecular diagnostics and/or therapeutic targets for the development of novel treatment strategies in EOC patients. Oncogene (2010) 29, 2153-2159; doi: 10.1038/onc.2009.500; published online 25 January 2010	[Peng, S.; Maihle, N. J.; Huang, Y.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06510 USA; [Maihle, N. J.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Maihle, N. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Huang, Y (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 310 Cedar St,LSOG 205C, New Haven, CT 06510 USA.	yingqun.huang@yale.edu			Fannie E Rippel Foundation; CT Stem Cell Grant [09SCAYALE14]; Yale School of Medicine 'Senior Women in Medicine' Professorship; NIH [CA 79808]; NATIONAL CANCER INSTITUTE [R01CA079808] Funding Source: NIH RePORTER	Fannie E Rippel Foundation; CT Stem Cell Grant; Yale School of Medicine 'Senior Women in Medicine' Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jianyu Jin for technical assistance, Jill Reiter for extracts from ovarian cancer cells and insightful scientific discussions, Philip Low and Gil Mor for cell lines and Jason Wilken for critical discussions and reading of this paper. This study was supported by the Fannie E Rippel Foundation and a CT Stem Cell Grant 09SCAYALE14 to YH, and a Yale School of Medicine 'Senior Women in Medicine' Professorship, and NIH CA 79808 to NJM.	Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Assou S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-10; BENARD J, 1985, CANCER RES, V45, P4970; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270; Cheng L, 2007, J PATHOL, V211, P1, DOI 10.1002/path.2105; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Darr H, 2009, STEM CELLS, V27, P352, DOI 10.1634/stemcells.2008-0720; Fodde R, 2009, CANCER CELL, V15, P87, DOI 10.1016/j.ccr.2009.01.011; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Jinawath N, 2009, ONCOGENE, V28, P1941, DOI 10.1038/onc.2009.37; Jordan CT, 2009, CELL STEM CELL, V4, P203, DOI 10.1016/j.stem.2009.02.003; Lu LG, 2009, EUR J CANCER, V45, P2212, DOI 10.1016/j.ejca.2009.05.003; Mlarotta LLC, 2009, CURR OPIN GENET DEV, V19, P44, DOI 10.1016/j.gde.2008.12.003; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Pei DQ, 2009, J BIOL CHEM, V284, P3365, DOI 10.1074/jbc.R800063200; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Trabucchi M, 2009, NATURE, V459, P1010, DOI 10.1038/nature08025; Vasey PA, 2008, ANN ONCOL, V19, P61, DOI 10.1093/annonc/mdn479; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Xu BS, 2009, NUCLEIC ACIDS RES, V37, P4256, DOI 10.1093/nar/gkp372; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Yang DH, 2003, GENE EXPR PATTERNS, V3, P719, DOI 10.1016/S1567-133X(03)00140-6; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang KX, 2008, RNA, V14, P577, DOI 10.1261/rna.739308; Zhang M, 2007, PLACENTA, V28, P779, DOI 10.1016/j.placenta.2007.01.012	34	207	219	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2153	2159		10.1038/onc.2009.500	http://dx.doi.org/10.1038/onc.2009.500			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101213				2022-12-28	WOS:000276402800013
J	Puhlmann, J; Puehler, F; Mumberg, D; Boukamp, P; Beier, R				Puhlmann, J.; Puehler, F.; Mumberg, D.; Boukamp, P.; Beier, R.			Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus	ONCOGENE			English	Article						Newcastle disease virus; transformation; oncolytic; Rac1; Ras; interferon	NEWCASTLE-DISEASE-VIRUS; RAS SIGNALING PATHWAY; TUMOR PROGRESSION; INTERFERON RESPONSE; ACTIVATION; INFECTION; TRANSFORMATION; EXPRESSION; GTPASE; PERMISSIVENESS	Oncolytic Newcastle disease virus (NDV) replicates selectively in most human tumor cells but not in normal cells. The relationship between tumorigenesis and the selective susceptibility of most tumor cells to oncolytic NDV replication is poorly understood. A multistage skin carcinogenesis model derived from non-tumorigenic HaCaT cells was used to systematically investigate the molecular mechanisms involved in the oncolytic NDV-sensitivity associated with tumorigenic transformation. No significant differences in interferon signaling were observed between the virus-sensitive tumor cells and the virus-resistant non-tumorigenic parental cells. Oncogenic H-Ras, which had been used for tumorigenic transformation, was shown to be necessary for virus replication but was not sufficient to render cells susceptible to NDV replication. By using an siRNA screening approach to search for virus-sensitizing genes in the tumorigenic cells, we could identify the small GTPase Rac1 as an oncogenic protein that is essential for NDV replication and anchorage-independent growth in tumorigenic cells. Furthermore, Rac1 expression was sufficient to render non-tumorigenic cells susceptible to NDV replication and to oncolytic cytotoxicity. This study establishes Rac1 as a link between tumorigenesis and oncolytic virus sensitivity in the HaCaT multistage skin carcinogenesis model. Oncogene (2010) 29, 2205-2216; doi: 10.1038/onc.2009.507; published online 25 January 2010	[Beier, R.] Bayer Schering Pharma AG, TRG Oncol, Global Drug Discovery, D-13342 Berlin, Germany; [Puhlmann, J.] FU Berlin, Inst Biol, Berlin, Germany; [Boukamp, P.] Deutsch Krebsforschungszentrum, Div Genet Skin Carcinogenesis, D-6900 Heidelberg, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Beier, R (corresponding author), Bayer Schering Pharma AG, TRG Oncol, Global Drug Discovery, Mullerstr 178, D-13342 Berlin, Germany.	Rudolf.Beier@bayerhealthcare.com			Tumorzentrum Heidelberg-Mannheim	Tumorzentrum Heidelberg-Mannheim(European Commission)	The authors thank Katja Kockritz, Steve Baethge, Anica Hoegner and Andreas Jung for their excellent technical assistance and Sanna-Maria Kakonen and David Light for carefully reading this paper. This work was in part supported by a grant from the Tumorzentrum Heidelberg-Mannheim to Petra Boukamp.	Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Bergmann M, 2001, CANCER RES, V61, P8188; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CASSEL WA, 1965, CANCER, V18, P863, DOI 10.1002/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Espina C, 2008, AM J PATHOL, V172, P156, DOI 10.2353/ajpath.2008.070561; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Fiola C, 2006, INT J CANCER, V119, P328, DOI 10.1002/ijc.21821; Fusenig NE, 1998, MOL CARCINOGEN, V23, P144, DOI 10.1002/(SICI)1098-2744(199811)23:3<144::AID-MC3>3.0.CO;2-U; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gros A, 2008, CANCER RES, V68, P8928, DOI 10.1158/0008-5472.CAN-08-1145; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hoppe S, 2006, J GEN VIROL, V87, P3483, DOI 10.1099/vir.0.82231-0; Hotte SJ, 2007, CLIN CANCER RES, V13, P977, DOI 10.1158/1078-0432.CCR-06-1817; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Krishnamurthy S, 2006, J VIROL, V80, P5145, DOI 10.1128/JVI.02618-05; Kwei KA, 2006, CANCER LETT, V231, P326, DOI 10.1016/j.canlet.2005.02.031; LORENCE RM, 1994, CANCER RES, V54, P6017; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; Mueller MM, 2001, AM J PATHOL, V159, P1567, DOI 10.1016/S0002-9440(10)62541-2; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Noser JA, 2007, MOL THER, V15, P1531, DOI 10.1038/sj.mt.6300193; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Puhler F, 2008, GENE THER, V15, P371, DOI 10.1038/sj.gt.3303095; REICHARD KW, 1992, J SURG RES, V52, P448, DOI 10.1016/0022-4804(92)90310-V; Saeed MF, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000141; Schirrmacher Volker, 2009, V542, P565, DOI 10.1007/978-1-59745-561-9_30; Schowalter RM, 2006, VIROLOGY, V350, P323, DOI 10.1016/j.virol.2006.01.033; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sinkovics JG, 2000, J CLIN VIROL, V16, P1, DOI 10.1016/S1386-6532(99)00072-4; Smith KD, 2006, J VIROL, V80, P1110, DOI 10.1128/JVI.80.3.1110-1120.2006; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Tang Y, 1999, MOL CELL BIOL, V19, P1881; WHEELOCK EF, 1964, NEW ENGL J MED, V271, P645, DOI 10.1056/NEJM196409242711302; Wilden H, 2009, INT J ONCOL, V34, P971, DOI 10.3892/ijo_00000223	42	43	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2205	2216		10.1038/onc.2009.507	http://dx.doi.org/10.1038/onc.2009.507			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101224				2022-12-28	WOS:000276685200006
J	Tajima, K; Ohashi, R; Sekido, Y; Hida, T; Nara, T; Hashimoto, M; Iwakami, S; Minakata, K; Yae, T; Takahashi, F; Saya, H; Takahashi, K				Tajima, K.; Ohashi, R.; Sekido, Y.; Hida, T.; Nara, T.; Hashimoto, M.; Iwakami, S.; Minakata, K.; Yae, T.; Takahashi, F.; Saya, H.; Takahashi, K.			Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells	ONCOGENE			English	Article						osteopontin; mesothelioma; multidrug resistance; hyaluronan; CD44	MALIGNANT PLEURAL MESOTHELIOMA; RANDOMIZED PHASE-II; LUNG-CANCER CELLS; LEUKEMIA GROUP-B; EPITHELIAL-CELLS; PROGNOSTIC-FACTORS; NONSMALL CELL; TUMOR-CELLS; APOPTOSIS; LINES	Malignant pleural mesothelioma (MPM) is resistant to chemotherapy and thus shows a dismal prognosis. Osteopontin (OPN), a secreted noncollagenous and phosphoprotein, is suggested to be involved in the pathogenesis of MPM. However, the precise role of OPN, especially in the multidrug resistance of MPM, remains to be elucidated. We therefore established stable transfectants (ACC-MESO-1/OPN), which constitutively express OPN, to determine its role in the chemoresistance observed in MPM. The introduction of the OPN gene provides MPM cells with upregulated multidrug resistance through the mechanism of enhanced hyaluronate (HA) binding. The expression of CD44 variant isoforms, which inhibit HA binding, significantly decreased in ACC-MESO-1/OPN cells in comparison to control transfectants. Interestingly, the inhibition of the HA-CD44 interaction abrogated multidrug resistance in the ACC-MESO-1/OPN, thus suggesting the involvement of the surviving signal emanating from the HA-CD44 interaction. An enhanced level of the p-Akt in ACCMESO-1/OPN cells was observed, and was diminished by CD44 siRNA. Inhibition of the Akt phosphorylation increased in number of the cells underwent apoptosis induced by NVB, VP-16 and GEM. Collectively, these results indicate that OPN is strongly involved in multidrug resistance by enhancing the CD44 binding to HA. Oncogene (2010) 29, 1941-1951; doi:10.1038/onc.2009.478; published online 18 January 2010	[Tajima, K.; Ohashi, R.; Minakata, K.; Yae, T.; Takahashi, F.; Takahashi, K.] Juntendo Univ, Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138421, Japan; [Tajima, K.; Ohashi, R.; Minakata, K.; Takahashi, F.; Takahashi, K.] Juntendo Univ, Sch Med, Res Inst Dis Old Ages, Bunkyo Ku, Tokyo 1138421, Japan; [Sekido, Y.; Hida, T.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan; [Nara, T.; Hashimoto, M.] Juntendo Univ, Sch Med, Dept Mol & Cellular Parasitol, Bunkyo Ku, Tokyo 1138421, Japan; [Iwakami, S.] Juntendo Univ, Shizuoka Hosp, Dept Resp Med, Shizuoka, Japan; [Iwakami, S.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo, Japan	Juntendo University; Juntendo University; Aichi Cancer Center; Juntendo University; Juntendo University; Keio University	Tajima, K (corresponding author), Juntendo Univ, Sch Med, Dept Resp Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	tajiken@juntendo.ac.jp	Sekido, Yoshitaka/P-9756-2015; Hashimoto, Muneaki/L-6386-2018; Saya, Hideyuki/J-4325-2013	Hashimoto, Muneaki/0000-0001-7215-7558; Saya, Hideyuki/0000-0001-6610-1902; Sekido, Yoshitaka/0000-0002-2428-3848	Ministry of Education, Culture, Sports, Science and Technology of Japan [19590914]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by a Grants-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (K.T. No 19590914).	Boutin C, 1998, EUR RESPIR J, V12, P972, DOI 10.1183/09031936.98.12040972; CHAHINIAN AP, 1993, J CLIN ONCOL, V11, P1559, DOI 10.1200/JCO.1993.11.8.1559; Cook AC, 2006, J BIOL CHEM, V281, P24381, DOI 10.1074/jbc.M602694200; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Elliott Tony, 2002, Expert Rev Anticancer Ther, V2, P449, DOI 10.1586/14737140.2.4.449; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Graessmann M, 2007, ONCOGENE, V26, P2840, DOI 10.1038/sj.onc.1210096; Grigoriu BD, 2007, CLIN CANCER RES, V13, P2928, DOI 10.1158/1078-0432.CCR-06-2144; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hughes A, 2002, J CLIN ONCOL, V20, P3533, DOI 10.1200/JCO.2002.10.073; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; Jackman DM, 2008, CANCER-AM CANCER SOC, V113, P808, DOI 10.1002/cncr.23617; Khan SA, 2005, CLIN EXP METASTAS, V22, P663, DOI 10.1007/s10585-006-9007-0; Kindler HL, 2001, LUNG CANCER-J IASLC, V31, P311, DOI 10.1016/S0169-5002(00)00166-5; Kouniavsky G, 2002, CLIN EXP METASTAS, V19, P55, DOI 10.1023/A:1013880326925; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Lokeshwar VB, 1997, CANCER RES, V57, P773; MANZINI VD, 1993, CANCER-AM CANCER SOC, V72, P410, DOI 10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Ohashi R, 2007, CANCER LETT, V252, P225, DOI 10.1016/j.canlet.2006.12.025; Ohashi R, 2009, ANTICANCER RES, V29, P2205; Pass HI, 2005, NEW ENGL J MED, V353, P1564, DOI 10.1056/NEJMoa051185; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; RUFFIE P A, 1991, Current Opinion in Oncology, V3, P328, DOI 10.1097/00001622-199104000-00014; Rusch VW, 1999, ANN THORAC SURG, V68, P1799, DOI 10.1016/S0003-4975(99)01038-3; Russo RIC, 2008, INT J CANCER, V122, P1012, DOI 10.1002/ijc.23122; SAMSON MK, 1987, J CLIN ONCOL, V5, P86, DOI 10.1200/JCO.1987.5.1.86; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Sugarbaker DJ, 1996, ANN SURG, V224, P288, DOI 10.1097/00000658-199609000-00005; Takahashi F, 2002, INT J CANCER, V98, P707, DOI 10.1002/ijc.10261; Takahashi K, 2003, LUNG CANCER-J IASLC, V41, P145, DOI 10.1016/S0169-5002(03)00224-1; Thylen A, 1997, EUR RESPIR J, V10, P404, DOI 10.1183/09031936.97.10020404; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Usami N, 2006, CANCER SCI, V97, P387, DOI 10.1111/j.1349-7006.2006.00184.x; White SC, 2000, ANN ONCOL, V11, P201, DOI 10.1023/A:1008328605413; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	40	38	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1941	1951		10.1038/onc.2009.478	http://dx.doi.org/10.1038/onc.2009.478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101228				2022-12-28	WOS:000276199600007
J	Bauer, M; Su, G; Casper, C; He, R; Rehrauer, W; Friedl, A				Bauer, M.; Su, G.; Casper, C.; He, R.; Rehrauer, W.; Friedl, A.			Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast	ONCOGENE			English	Article						breast neoplasms; tumor stroma; fibroblasts; invasion	CANCER-ASSOCIATED FIBROBLASTS; TISSUE GROWTH-FACTOR; TUMOR-STROMA; STEM-CELLS; AUTOCRINE; TP53; MICROENVIRONMENT; TRANSFORMATION; MUTATIONS	Breast carcinoma invasion is associated with prominent alterations in stromal fibroblasts. Carcinoma-associated fibroblasts (CAF) support and promote tumorigenesis, whereas normal mammary fibroblasts (NF) are thought to suppress tumor progression. Little is known about the difference in gene expression between CAF and NF or the patient-to-patient variability in gene expression. Paired CAF and NF were isolated from six primary human breast carcinoma specimens. RNA was extracted from low-passage cultures of CAF and NF and analyzed with Affymetrix Human Genome U133 Plus 2.0 arrays. The array data were examined with an empirical Bayes model and filtered according to the posterior probability of equivalent expression and fold difference in expression. Twenty-one genes (27 probe sets) were up-regulated in CAF, as compared with NF. Known functions of these genes relate to paracrine or intracellular signaling, transcriptional regulation, extracellular matrix and cell adhesion/migration. Ten genes (14 probe sets) were down-regulated in CAF, including the pluripotency transcription factor KLF4. Quantitative RT-PCR analysis of 10 genes validated the array results. Immunohistochemical staining for three gene products confirmed stromal expression in terms of location and relative quantity. Surprisingly, the variability of gene expression was slightly higher in NF than in CAF, suggesting inter-individual heterogeneity of normal stroma. Oncogene (2010) 29, 1732-1740; doi:10.1038/onc.2009.463; published online 11 January 2010	[Bauer, M.; Su, G.; He, R.; Rehrauer, W.; Friedl, A.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; [Casper, C.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1111 Highland Ave,6051 WIMR,Mailcode 2275, Madison, WI 53706 USA.	afriedl@wisc.edu			Dr Mildred Scheel Stiftung; National Institutes of Health [RO1 CA107012]; Wisconsin Partnership program; NATIONAL CANCER INSTITUTE [R01CA107012] Funding Source: NIH RePORTER	Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wisconsin Partnership program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Christina Kendziorski for help with the array analyses and Dr Korise Rasmusson for her assistance with the manuscript preparation. Maret Bauer was supported by a scholarship from the Dr Mildred Scheel Stiftung. This research was funded by National Institutes of Health grant RO1 CA107012 and a grant from the Wisconsin Partnership program.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Briand P, 1996, CANCER RES, V56, P2039; Campbell IG, 2008, NEW ENGL J MED, V358, P1634, DOI 10.1056/NEJMc086024; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Chang CF, 2007, FRONT BIOSCI-LANDMRK, V12, P4393, DOI 10.2741/2396; De Jong JS, 1998, J PATHOL, V184, P44; Duque JL, 2001, J UROLOGY, V165, P284, DOI 10.1097/00005392-200101000-00080; Erickson AC, 2003, EXPERT OPIN THER TAR, V7, P71, DOI 10.1517/14728222.7.1.71; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Iacobuzio-Donahue CA, 2002, CANCER RES, V62, P5351; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ji Q, 2004, CANCER RES, V64, P7610, DOI 10.1158/0008-5472.CAN-04-1608; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kendziorski CM, 2003, STAT MED, V22, P3899, DOI 10.1002/sim.1548; Kim YC, 2008, CANCER RES, V68, P10145, DOI 10.1158/0008-5472.CAN-08-2992; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LeWitt PA, 2004, CLIN NEUROPHARMACOL, V27, P1, DOI 10.1097/00002826-200401000-00001; Massague J, 2007, NEW ENGL J MED, V356, P294, DOI 10.1056/NEJMe068292; Mercier I, 2008, CANCER BIOL THER, V7, P1212, DOI 10.4161/cbt.7.8.6220; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nakagawa H, 2004, ONCOGENE, V23, P7366, DOI 10.1038/sj.onc.1208013; Narita K, 2007, J BIOL CHEM, V282, P14413, DOI 10.1074/jbc.M611395200; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; R Development Core Team, 2008, LANG ENV STAT COMP; Roukos DH, 2008, NEW ENGL J MED, V358, P1636; Singer CF, 2002, BREAST CANCER RES TR, V72, P69, DOI 10.1023/A:1014918512569; Singer CF, 2008, BREAST CANCER RES TR, V110, P273, DOI 10.1007/s10549-007-9725-2; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sutmuller M, 1997, HISTOL HISTOPATHOL, V12, P557; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tang Y, 2004, MOL CANCER RES, V2, P73; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Xie D, 2001, CANCER RES, V61, P8917; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006	45	120	131	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1732	1740		10.1038/onc.2009.463	http://dx.doi.org/10.1038/onc.2009.463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062080	Green Accepted			2022-12-28	WOS:000276022800003
J	Hadfield, KD; Smith, MJ; Urquhart, JE; Wallace, AJ; Bowers, NL; King, AT; Rutherford, SA; Trump, D; Newman, WG; Evans, DG				Hadfield, K. D.; Smith, M. J.; Urquhart, J. E.; Wallace, A. J.; Bowers, N. L.; King, A. T.; Rutherford, S. A.; Trump, D.; Newman, W. G.; Evans, D. G.			Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas	ONCOGENE			English	Article						mitotic recombination; schwannomatosis; SMARCB1; NF2; vestibular schwannoma	COMPARATIVE GENOMIC HYBRIDIZATION; FAMILIAL SCHWANNOMATOSIS; SMARCB1; IDENTIFICATION; NEUROFIBROMAS; METHYLATION; MUTATION; GENE; DNA	Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. Oncogene (2010) 29, 6216-6221; doi:10.1038/onc.2010.363; published online 23 August 2010	[Hadfield, K. D.; Smith, M. J.; Urquhart, J. E.; Wallace, A. J.; Bowers, N. L.; Trump, D.; Newman, W. G.; Evans, D. G.] Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Med Genet, Manchester M13 9WL, Lancs, England; [King, A. T.; Rutherford, S. A.] Hope Hosp, Dept Neurosurg, Manchester, Lancs, England	University of Manchester	Evans, DG (corresponding author), Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Med Genet, Manchester M13 9WL, Lancs, England.	gareth.evans@cmft.nhs.uk	Evans, D Gareth/AAB-4308-2022; Rutherford, Scott/GMX-2404-2022; Smith, Miriam/J-4001-2015; Urquhart, Jill/G-2282-2015; King, Andrew/AAR-1656-2020	Evans, D Gareth/0000-0002-8482-5784; Smith, Miriam/0000-0002-3184-0817; Urquhart, Jill/0000-0002-5788-5511; King, Andrew/0000-0002-6546-7248; Newman, William/0000-0002-6382-4678; Rutherford, Scott/0000-0002-6749-2295	Children's Tumor Foundation; NIHR Manchester Biomedical Research Centre	Children's Tumor Foundation; NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR))	This work was supported by a grant from the Children's Tumor Foundation. The Department of Genetic Medicine is supported by the NIHR Manchester Biomedical Research Centre. We also thank all the patients who provided samples for the study.	Boyd C, 2008, CLIN GENET, V74, P358, DOI 10.1111/j.1399-0004.2008.01060.x; Carbone L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000538; De Raedt T, 2006, GENE CHROMOSOME CANC, V45, P893, DOI 10.1002/gcc.20353; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; EVANS DGR, 1992, Q J MED, V84, P603; Gonzalez-Gomez P, 2003, CLIN CANCER RES, V9, P5601; Hadfield KD, 2008, J MED GENET, V45, P332, DOI 10.1136/jmg.2007.056499; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; James L, 1996, CHROMOSOME RES, V4, P163, DOI 10.1007/BF02259711; James LA, 1999, BRIT J CANCER, V81, P300, DOI 10.1038/sj.bjc.6990691; KAPLAN JC, 1987, J MED GENET, V24, P65, DOI 10.1136/jmg.24.2.65; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; MacCollin M, 2003, NEUROLOGY, V60, P1968, DOI 10.1212/01.WNL.0000070184.08740.E0; Serra E, 2001, NAT GENET, V28, P294, DOI 10.1038/90148; Sestini R, 2008, HUM MUTAT, V29, P227, DOI 10.1002/humu.20679; Warren C, 2003, J MED GENET, V40, P802, DOI 10.1136/jmg.40.11.802	17	74	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6216	6221		10.1038/onc.2010.363	http://dx.doi.org/10.1038/onc.2010.363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729918	Bronze			2022-12-28	WOS:000284601700003
J	Lau, KM; Chan, QKY; Pang, JCS; Li, KKW; Yeung, WW; Chung, NYF; Lui, PC; Tam, YS; Li, HM; Zhou, L; Wang, Y; Mao, Y; Ng, HK				Lau, K-M; Chan, Q. K. Y.; Pang, J. C. S.; Li, K. K. W.; Yeung, W. W.; Chung, N. Y. F.; Lui, P. C.; Tam, Y-S; Li, H-M; Zhou, L.; Wang, Y.; Mao, Y.; Ng, H-K			Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion	ONCOGENE			English	Article						medulloblastoma; MCM2; MCM3; MCM7; migration; invasion	COMPARATIVE GENOMIC HYBRIDIZATION; PRIMITIVE NEUROECTODERMAL TUMORS; DNA-REPLICATION; MCM PROTEINS; PROLIFERATION MARKER; PEDIATRIC MEDULLOBLASTOMAS; INDEPENDENT PREDICTOR; CHECKPOINT KINASES; PROSTATE-CANCER; S-PHASE	Minichromosome maintenance (MCM) proteins 2-7 are important in DNA replication licensing. Functional roles beyond licensing are speculated. In addition, significances in medulloblastoma (MB) remain unclear. In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples. Moreover, DAOY and ONS76 and the clinical samples expressed elevated MCM7 transcripts with genomic gain of the gene. Immunopositivity restricted to tumor cells was found in 41, 37 and 53 out of 73 MB cases for MCM2, MCM3 and MCM7, respectively. High-MCM3 expression was associated with poor prognosis. Knockdowns of these MCMs significantly inhibited anchorage-dependent and -independent MB cell growth. The inhibition of MCM3 expression by small interfering RNA knockdown was related to G1 arrest with reduced cyclin A expression, whereas the MCM2- and MCM7-knocked-down cells arrested at G2/M with increased cyclin A expression. Interestingly, we demonstrated the links of these MCMs with cell migration and invasion using wound-healing and Transwell migration/invasion assays. Exogenous overexpression of MCM2, MCM3 and MCM7 increased anchorage-independent cell growth, and also cell migration and invasion capabilities in MB cells. The knockdown reduced the number of filopodial cells and the cells with intense stress fibers by blocking cdc42 and Rho activation. Taken together, deregulation of MCM2, MCM3 and MCM7 expression might be involved in MB tumorigenesis and we revealed undefined roles of these MCMs in control of MB cell migration and invasion. Oncogene (2010) 29, 5475-5489; doi:10.1038/onc.2010.287; published online 26 July 2010	[Lau, K-M; Chan, Q. K. Y.; Pang, J. C. S.; Li, K. K. W.; Yeung, W. W.; Chung, N. Y. F.; Lui, P. C.; Tam, Y-S; Li, H-M; Ng, H-K] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; [Lau, K-M; Pang, J. C. S.; Ng, H-K] Chinese Univ Hong Kong, State Key Lab So China Oncol, Shatin, Hong Kong, Peoples R China; [Zhou, L.; Mao, Y.] Fudan Univ, Hua Shan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China; [Wang, Y.] Fudan Univ, Hua Shan Hosp, Dept Neuropathol, Shanghai 200433, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Fudan University; Fudan University	Lau, KM (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Room 38018,Clinical Sci Bldg, Shatin, Hong Kong, Peoples R China.	kmlau@cuhk.edu.hk; hkng@cuhk.edu.hk	Ng, Ho Keung/I-3952-2015	Mao, Ying/0000-0001-8055-115X; Lau, Kin-Mang/0000-0001-5888-1937	Hong Kong Research Grants Council [472307]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	This work was supported by the Hong Kong Research Grants Council General Research Fund 472307.	Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Bailis JM, 2004, CURR OPIN GENET DEV, V14, P17, DOI 10.1016/j.gde.2003.11.002; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Crevel G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000833; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; De Bortoli M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-223; Dudderidge TJ, 2007, BRIT J CANCER, V96, P1384, DOI 10.1038/sj.bjc.6603718; Dudderidge TJ, 2005, CLIN CANCER RES, V11, P2510, DOI 10.1158/1078-0432.CCR-04-1776; Eberhart CG, 2002, BRAIN PATHOL, V12, P36, DOI 10.1111/j.1750-3639.2002.tb00420.x; Endl E, 2001, J PATHOL, V195, P457, DOI 10.1002/path.978; Feng DR, 2003, CANCER RES, V63, P7356; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Freeman A, 1999, CLIN CANCER RES, V5, P2121; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; Giordana MT, 1998, CHILD NERV SYST, V14, P256, DOI 10.1007/s003810050221; Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Ha SA, 2004, CLIN CANCER RES, V10, P8386, DOI 10.1158/1078-0432.CCR-04-1029; Hanna-Morris A, 2009, J CLIN PATHOL, V62, P325, DOI 10.1136/jcp.2007.054643; Haverty PM, 2002, NUCLEIC ACIDS RES, V30, P214, DOI 10.1093/nar/30.1.214; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Hui ABY, 2005, CLIN CANCER RES, V11, P4707, DOI 10.1158/1078-0432.CCR-05-0128; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Kato H, 2003, J SURG ONCOL, V84, P24, DOI 10.1002/jso.10287; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Korkolopoulou P, 2005, HUM PATHOL, V36, P899, DOI 10.1016/j.humpath.2005.06.008; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Lei M, 1996, MOL CELL BIOL, V16, P5081; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meng MV, 2001, CLIN CANCER RES, V7, P2712; Nicholson JC, 1999, BRIT J CANCER, V80, P1322, DOI 10.1038/sj.bjc.6690525; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Nishizaki T, 1999, PEDIATR NEUROSURG, V31, P27, DOI 10.1159/000028827; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Polkinghorn WR, 2007, NAT CLIN PRACT ONCOL, V4, P295, DOI 10.1038/ncponc0794; Ramnath N, 2001, J CLIN ONCOL, V19, P4259, DOI 10.1200/JCO.2001.19.22.4259; Reardon DA, 1997, CANCER RES, V57, P4042; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Rodins K, 2002, CLIN CANCER RES, V8, P1075; Rossi MR, 2006, GENE CHROMOSOME CANC, V45, P290, DOI 10.1002/gcc.20292; Schrader C, 2005, BRIT J CANCER, V93, P939, DOI 10.1038/sj.bjc.6602795; Scott WC, 2005, AM J DRUG ALCOHOL AB, V31, P455, DOI 10.1081/ADA-200056807; Shechter D, 2004, P NATL ACAD SCI USA, V101, P10845, DOI 10.1073/pnas.0404143101; Stoeber K, 2001, J CELL SCI, V114, P2027; Tachibana KEK, 2005, J PATHOL, V205, P123, DOI 10.1002/path.1708; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187; Wharton SB, 2007, ACTA NEUROPATHOL, V113, P119, DOI 10.1007/s00401-006-0177-2; Wharton SB, 2001, NEUROPATH APPL NEURO, V27, P305, DOI 10.1046/j.0305-1846.2001.00333.x; Williams GH, 2007, CURR OPIN CELL BIOL, V19, P672, DOI 10.1016/j.ceb.2007.10.005; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Yu ZL, 2004, J MOL BIOL, V340, P1197, DOI 10.1016/j.jmb.2004.05.024	60	72	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5475	5489		10.1038/onc.2010.287	http://dx.doi.org/10.1038/onc.2010.287			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661220				2022-12-28	WOS:000282945800005
J	Weisberg, E; Sattler, M; Ray, A; Griffin, JD				Weisberg, E.; Sattler, M.; Ray, A.; Griffin, J. D.			Drug resistance in mutant FLT3-positive AML	ONCOGENE			English	Review						drug resistance; AML; FLT3; combination therapy; stroma	ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; INTERNAL TANDEM DUPLICATION; CONSTITUTIVELY ACTIVATED FLT3; ACQUIRED UNIPARENTAL DISOMY; BCR-ABL; IN-VITRO; C-CBL; PTK INHIBITORS; ANTILEUKEMIC THERAPIES	Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with standard therapies. However, the transient and partial responses observed in AML patients treated with FLT3 inhibitors, coupled with the discovery of drug-resistant leukemic blast cells in AML patients, have made resistance to FLT3 inhibitors a growing concern. In this study, we provide an overview of the role of mutant FLT3 in AML, FLT3 inhibitors under clinical and preclinical investigation, mechanisms of resistance to FLT3 inhibitors, and possible therapeutic approaches to overcoming this resistance. Oncogene (2010) 29, 5120-5134; doi:10.1038/onc.2010.273; published online 12 July 2010	[Weisberg, E.; Sattler, M.; Ray, A.; Griffin, J. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol Hematol Neoplasia, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Weisberg, E (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	Ellen_Weisberg@dfci.harvard.edu			National Institutes of Health [CA134660-02, CA36167, DK50654]; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [R37CA036167, R01CA134660, R01CA036167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported in part by the National Institutes of Health Grants (CA134660-02, MS; and CA36167 and DK50654, JDG), and a Leukemia and Lymphoma Society SCOR grant (JDG).	Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Al Shaer L, 2008, BRIT J HAEMATOL, V141, P483, DOI 10.1111/j.1365-2141.2008.07053.x; Albert DH, 2006, MOL CANCER THER, V5, P995, DOI 10.1158/1535-7163.MCT-05-0410; ASHLEY DM, 1994, LEUKEMIA RES, V18, P337, DOI 10.1016/0145-2126(94)90017-5; Auclair D, 2007, LEUKEMIA, V21, P439, DOI 10.1038/sj.leu.2404508; Bagrintseva K, 2005, BLOOD, V105, P3679, DOI 10.1182/blood-2004-06-2459; Bagrintseva K, 2004, BLOOD, V103, P2266, DOI 10.1182/blood-2003-05-1653; Bang SM, 2008, J KOREAN MED SCI, V23, P833, DOI 10.3346/jkms.2008.23.5.833; Barry EV, 2007, BLOOD, V110, P4476, DOI 10.1182/blood-2007-07-101238; Bojko P, 2002, ANN HEMATOL, V81, P522, DOI 10.1007/s00277-002-0535-7; Bradstock K, 1996, LEUKEMIA, V10, P813; Brandts CH, 2005, CANCER RES, V65, P9643, DOI 10.1158/0008-5472.CAN-05-0422; Breitenbuecher F, 2009, BLOOD, V113, P4063, DOI 10.1182/blood-2007-11-126664; Brown P, 2004, BLOOD, V104, P1841, DOI 10.1182/blood-2004-03-1034; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Caligiuri MA, 2007, BLOOD, V110, P1022, DOI 10.1182/blood-2006-12-061176; Chao Q, 2009, J MED CHEM, V52, P7808, DOI 10.1021/jm9007533; Cheng Y, 2008, IDRUGS, V11, P46; Chu SH, 2009, DRUG RESIST UPDATE, V12, P8, DOI 10.1016/j.drup.2008.12.001; Clark JJ, 2004, BLOOD, V104, P2867, DOI 10.1182/blood-2003-12-4446; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; CORTES J, 2008, BLOOD, V2967; Cramer K, 2008, CANCER RES, V68, P6884, DOI 10.1158/0008-5472.CAN-08-1101; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; de Menezes DEL, 2005, CLIN CANCER RES, V11, P5281, DOI 10.1158/1078-0432.CCR-05-0358; Deininger MWN, 2005, BLOOD, V106, p204A; Despars G, 2006, STEM CELLS, V24, P1496, DOI 10.1634/stemcells.2005-0530; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; Fernandes MS, 2009, BLOOD, V114, P1813, DOI 10.1182/blood-2008-07-172148; Fiedler W, 2005, BLOOD, V105, P986, DOI 10.1182/blood-2004-05-1846; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Galban S, 2009, BIOCHEM J, V417, P765, DOI 10.1042/BJ20081677; Gaul MD, 2007, BIOORG MED CHEM LETT, V17, P4861, DOI 10.1016/j.bmcl.2007.06.046; Gazit A, 2003, BIOORGAN MED CHEM, V11, P2007, DOI 10.1016/S0968-0896(03)00048-8; Giles FJ, 2003, BLOOD, V102, P795, DOI 10.1182/blood-2002-10-3023; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gracias V, 2008, BIOORG MED CHEM LETT, V18, P2691, DOI 10.1016/j.bmcl.2008.03.021; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Guerrouahen BS, 2010, CLIN CANCER RES, V16, P1149, DOI 10.1158/1078-0432.CCR-09-2416; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Hunter HM, 2004, BRIT J HAEMATOL, V127, P26, DOI 10.1111/j.1365-2141.2004.05145.x; Ikezoe T, 2006, MOL CANCER THER, V5, P2522, DOI 10.1158/1535-7163.MCT-06-0071; Ishida H, 2008, BIOORG MED CHEM LETT, V18, P5472, DOI 10.1016/j.bmcl.2008.09.031; Jiang JR, 2004, BLOOD, V104, P1855, DOI 10.1182/blood-2004-02-0712; Jin GL, 2009, BIOCHEM BIOPH RES CO, V390, P1001, DOI 10.1016/j.bbrc.2009.10.094; Kancha RK, 2007, EXP HEMATOL, V35, P1522, DOI 10.1016/j.exphem.2007.07.008; Kasper S, 2008, LEUKEMIA RES, V32, P1698, DOI 10.1016/j.leukres.2008.05.003; Kayser S, 2009, BLOOD, V114, P2386, DOI 10.1182/blood-2009-03-209999; Keller O, 2002, SINGLE MOL, V3, P5, DOI 10.1002/1438-5171(200204)3:1<5::AID-SIMO5>3.0.CO;2-6; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Kindler T, 2005, BLOOD, V105, P335, DOI 10.1182/blood-2004-02-0660; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Kiyoi H, 2007, CLIN CANCER RES, V13, P4575, DOI 10.1158/1078-0432.CCR-07-0225; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kohl TM, 2007, LEUKEMIA, V21, P1763, DOI 10.1038/sj.leu.2404776; Komeno Y, 2005, LEUKEMIA, V19, P930, DOI 10.1038/sj.leu.2403736; Kondo M, 1999, MED PEDIATR ONCOL, V33, P525; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Kornblau SM, 2006, BLOOD, V108, P2358, DOI 10.1182/blood-2006-02-003475; Kornblau SM, 2010, CLIN CANCER RES, V16, P1865, DOI 10.1158/1078-0432.CCR-09-2551; Kumagai MA, 1996, J CLIN INVEST, V97, P755, DOI 10.1172/JCI118474; Kurokawa M, 2008, MOL CELL BIOL, V28, P5494, DOI 10.1128/MCB.00265-08; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lagneaux L, 1999, LEUKEMIA LYMPHOMA, V35, P445, DOI 10.1080/10428199909169609; Lee BD, 2007, LEUKEMIA RES, V31, P1131, DOI 10.1016/j.leukres.2006.11.012; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Libura M, 2003, BLOOD, V102, P2198, DOI 10.1182/blood-2003-01-0162; Lierman E, 2007, HAEMATOL-HEMATOL J, V92, P27, DOI 10.3324/haematol.10692; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Loh ML, 2009, BLOOD, V114, P1859, DOI 10.1182/blood-2009-01-198416; LYMAN SD, 1995, BLOOD, V86, P4091, DOI 10.1182/blood.V86.11.4091.bloodjournal86114091; Makishima H, 2009, J CLIN ONCOL, V27, P6109, DOI 10.1200/JCO.2009.23.7503; Melnick JS, 2006, P NATL ACAD SCI USA, V103, P3153, DOI 10.1073/pnas.0511292103; Meshinchi S, 2003, BLOOD, V102, P1474, DOI 10.1182/blood-2003-01-0137; Meshinchi S, 2008, BLOOD, V111, P4930, DOI 10.1182/blood-2008-01-117770; Meshinchi S, 2006, BLOOD, V108, P3654, DOI 10.1182/blood-2006-03-009233; Metzelder S, 2009, BLOOD, V113, P6567, DOI 10.1182/blood-2009-03-208298; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Mollgard L, 2008, CANCER CHEMOTH PHARM, V62, P439, DOI 10.1007/s00280-007-0623-4; Molyneux G, 2008, INT J EXP PATHOL, V89, P159, DOI 10.1111/j.1365-2613.2008.00580.x; Mony U, 2008, LEUKEMIA, V22, P1395, DOI 10.1038/leu.2008.125; Murata K, 2003, J BIOL CHEM, V278, P32892, DOI 10.1074/jbc.M210405200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nakao M, 1996, LEUKEMIA, V10, P1911; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Nishioka C, 2008, LEUKEMIA RES, V32, P865, DOI 10.1016/j.leukres.2007.09.017; Nishiyama U, 2006, LEUKEMIA RES, V30, P1541, DOI 10.1016/j.leukres.2006.02.028; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; O'Farrell AM, 2003, CLIN CANCER RES, V9, P5465; O'Hare T, 2005, CLIN CANCER RES, V11, P6987, DOI 10.1158/1078-0432.CCR-05-0622; Olsson I, 1996, EUR J HAEMATOL, V57, P1; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paraguassu-Braga FH, 2003, CELL DEATH DIFFER, V10, P1101, DOI 10.1038/sj.cdd.4401279; Patch RJ, 2006, BIOORG MED CHEM LETT, V16, P3282, DOI 10.1016/j.bmcl.2006.03.032; Piloto O, 2007, BLOOD, V109, P1643, DOI 10.1182/blood-2006-05-023804; Pollard JA, 2006, BLOOD, V108, P2764, DOI 10.1182/blood-2006-04-012260; Pratz K, 2008, LEUKEMIA LYMPHOMA, V49, P852, DOI 10.1080/10428190801895352; Pratz KW, 2010, BLOOD, V115, P1425, DOI 10.1182/blood-2009-09-242859; Pratz KW, 2009, BLOOD, V113, P3938, DOI 10.1182/blood-2008-09-177030; Ray A, 2007, BLOOD, V109, P5011, DOI 10.1182/blood-2006-01-015347; Recher C, 2005, BLOOD, V105, P2527, DOI 10.1182/blood-2004-06-2494; Reindl C, 2006, BLOOD, V107, P3700, DOI 10.1182/blood-2005-06-2596; Reindl C, 2009, CLIN CANCER RES, V15, P2238, DOI 10.1158/1078-0432.CCR-08-1325; Rivera VM, 2008, BLOOD, V112, P1008; Rocnik JL, 2006, BLOOD, V108, P1339, DOI 10.1182/blood-2005-11-011429; Rodrigues MS, 2008, ANTIOXID REDOX SIGN, V10, P1813, DOI 10.1089/ars.2008.2071; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Sargin B, 2007, BLOOD, V110, P1004, DOI 10.1182/blood-2007-01-066076; Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456; Seedhouse CH, 2006, LEUKEMIA, V20, P2130, DOI 10.1038/sj.leu.2404439; Sensintaffar J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-11; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shaked Y, 2005, BLOOD, V105, P4500, DOI 10.1182/blood-2004-08-3210; Shankar DB, 2007, BLOOD, V109, P3400, DOI 10.1182/blood-2006-06-029579; Shiotsu Y, 2009, BLOOD, V114, P1607, DOI 10.1182/blood-2009-01-199307; Siendones E, 2007, HEMATOL ONCOL, V25, P30, DOI 10.1002/hon.805; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Stolzel F, 2010, ANN HEMATOL, V89, P653, DOI 10.1007/s00277-009-0889-1; Stone R. M., 2004, Annals of Hematology, V83, pS89; Stone RM, 2005, BLOOD, V106, p121A; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; TANAKA T, 1997, LEUKEMIA, V1111, P299; Teller S, 2002, LEUKEMIA, V16, P1528, DOI 10.1038/sj.leu.2402630; Thien CBF, 2005, GROWTH FACTORS, V23, P161, DOI 10.1080/08977190500153763; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Tse KF, 2002, LEUKEMIA, V16, P2027, DOI 10.1038/sj.leu.2402674; Tse KF, 2001, LEUKEMIA, V15, P1001, DOI 10.1038/sj.leu.2402199; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; von Bubnoff N, 2009, CANCER RES, V69, P3032, DOI 10.1158/0008-5472.CAN-08-2923; Walters DK, 2005, BLOOD, V105, P2952, DOI 10.1182/blood-2004-07-2758; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Weisberg E, 2008, MOL CANCER THER, V7, P1121, DOI 10.1158/1535-7163.MCT-07-2331; Weisberg E, 2008, BLOOD, V111, P3723, DOI 10.1182/blood-2007-09-114454; Weisberg E, 2007, MOL CANCER THER, V6, P1951, DOI 10.1158/1535-7163.MCT-06-0810; Weisberg E, 2009, DRUG RESIST UPDATE, V12, P81, DOI 10.1016/j.drup.2009.04.001; Weisberg E, 2008, BLOOD, V112, P5161, DOI 10.1182/blood-2008-02-138065; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186; WodnarFilipowicz A, 1996, BLOOD, V88, P4493, DOI 10.1182/blood.V88.12.4493.bloodjournal88124493; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Youssoufian H, 2010, CANCER-AM CANCER SOC, V116, P1013, DOI 10.1002/cncr.24787; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zeng ZH, 2006, CANCER RES, V66, P3737, DOI 10.1158/0008-5472.CAN-05-1278; Zeng Z, 2006, MOL CANCER THER, V5, P3113, DOI 10.1158/1535-7163.MCT-06-0228; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Zhang WG, 2008, JNCI-J NATL CANCER I, V100, P184, DOI 10.1093/jnci/djm328; Zhou JB, 2008, LEUKEMIA RES, V32, P1091, DOI 10.1016/j.leukres.2007.11.025; Zhou JB, 2009, BLOOD, V113, P4052, DOI 10.1182/blood-2008-05-156422; Zwaan CM, 2003, BLOOD, V102, P2387, DOI 10.1182/blood-2002-12-3627; Zwierzina H, 1999, LEUKEMIA, V13, P553, DOI 10.1038/sj.leu.2401378	164	79	82	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	37					5120	5134		10.1038/onc.2010.273	http://dx.doi.org/10.1038/onc.2010.273			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622902				2022-12-28	WOS:000281867200002
J	Fritz, V; Fajas, L				Fritz, V.; Fajas, L.			Metabolism and proliferation share common regulatory pathways in cancer cells	ONCOGENE			English	Review						cancer; metabolism; cell-cycle regulators; glycolysis; de novo lipogenesis	FATTY-ACID SYNTHASE; ATP-CITRATE LYASE; RESPONSIVE TRANSCRIPTION FACTOR; ACTIVATED-RECEPTOR-GAMMA; C-MYC; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; MITOCHONDRIAL BIOGENESIS; PROMOTES ADIPOGENESIS; HISTONE DEACETYLASE	Cancer development involves major alterations in cells' metabolism. Enhanced glycolysis and de novo fatty acids synthesis are indeed characteristic features of cancer. Cell proliferation and metabolism are tightly linked cellular processes. Others and we have previously shown a close relationship between metabolic responses and proliferative stimuli. In addition to trigger proliferative and survival signaling pathways, most oncoproteins also trigger metabolic changes to transform the cell. We present herein the view that participation of cell-cycle regulators and oncogenic proteins to cancer development extend beyond the control of cell proliferation, and discuss how these new functions may be implicated in metabolic alterations concomitant to the pathogenesis of human cancers. Oncogene (2010) 29, 4369-4377; doi: 10.1038/onc.2010.182; published online 31 May 2010	[Fritz, V.; Fajas, L.] INSERM, U896, Montpellier, France; [Fritz, V.; Fajas, L.] Univ Montpellier I, Montpellier, France; [Fritz, V.; Fajas, L.] IRCM, CRLC Val Aurelle Paul Lamarque, Montpellier, France; [Fritz, V.; Fajas, L.] Inst Rech Cancerol Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Fajas, L (corresponding author), IRCM, CRLC Val Aurelle, Parc Euromed, F-34298 Montpellier, France.	lluis.fajas@inserm.fr	Coll, Lluis Fajas/C-8567-2014	Fajas, Lluis/0000-0002-1283-9503	Fajas' lab; Agence Nationale pour la Recherche (ANR physio); Association pour la Recherche contre le Cancer; Institut National du Cancer (INCA); Fondation pour la Recherche Medicale	Fajas' lab; Agence Nationale pour la Recherche (ANR physio)(French National Research Agency (ANR)); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Members of the Fajas' lab are acknowledged for support and discussions. This work was supported by grants from Agence Nationale pour la Recherche (ANR physio), Association pour la Recherche contre le Cancer, Institut National du Cancer (INCA) and Fondation pour la Recherche Medicale. VF was supported by a grant from the INCA.	Abella A, 2005, CELL METAB, V2, P239, DOI 10.1016/j.cmet.2005.09.003; Annicotte JS, 2009, NAT CELL BIOL, V11, P1017, DOI 10.1038/ncb1915; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528; Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denechaud PD, 2008, FEBS LETT, V582, P68, DOI 10.1016/j.febslet.2007.07.084; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Fajas L, 2004, J CLIN INVEST, V113, P1288, DOI 10.1172/JCI200418555; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITZ V, 2010, MOL CANC TH IN PRESS; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Iankova I, 2006, MOL ENDOCRINOL, V20, P1494, DOI 10.1210/me.2005-0222; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Jezek P, 2010, INT J BIOCHEM CELL B, V42, P604, DOI 10.1016/j.biocel.2009.11.008; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lewis BC, 2000, CANCER RES, V60, P6178; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li FX, 2003, P NATL ACAD SCI USA, V100, P12935, DOI 10.1073/pnas.2231861100; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722; Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2005, MED HYPOTHESES, V64, P342, DOI 10.1016/j.mehy.2004.07.022; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Moon YA, 1999, EXP MOL MED, V31, P108, DOI 10.1038/emm.1999.18; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Nadolski MJ, 2007, FEBS J, V274, P5202, DOI 10.1111/j.1742-4658.2007.06056.x; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; Porstmann T, 2009, BIOCHEM SOC T, V37, P278, DOI 10.1042/BST0370278; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; SABINE JR, 1967, CANCER RES, V27, P793; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tong XM, 2009, P NATL ACAD SCI USA, V106, P21660, DOI 10.1073/pnas.0911316106; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wofford JA, 2008, BLOOD, V111, P2101, DOI 10.1182/blood-2007-06-096297; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600	79	137	141	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4369	4377		10.1038/onc.2010.182	http://dx.doi.org/10.1038/onc.2010.182			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514019	Green Accepted, Green Submitted			2022-12-28	WOS:000280559100001
J	Kapoor, GS; O'Rourke, DM				Kapoor, G. S.; O'Rourke, D. M.			SIRP alpha 1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration	ONCOGENE			English	Article						SIRP alpha 1; EGFRvIII; SHP-2; glioblastoma; migration	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; ONCOGENIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID; G(2)/M ARREST; IN-VIVO; SHP-2; ACTIVATION; PHOSPHORYLATION	EGFRvIII, a frequent genetic alteration of the epidermal growth factor receptor ( EGFR), has been shown to increase the migratory potential of tumor cells and normal fibroblasts. Previously, we showed that signal regulatory protein alpha 1 (SIRP alpha 1) receptors interact with SHP-2 to inhibit wild-type (wt) EGFR-mediated tumor migration, survival and cell transformation. However, the effects of SIRP alpha 1 inhibitory receptors on EGFRvIII-mediated phenotypes are unclear. The aim of this study was to investigate the effect of SIRP alpha 1 receptor on the EGFRvIII signalosome and phenotypes. Overexpression of SIRP alpha 1 in U87MG. EGFRvIII cells inhibited transformation and migration in a MAPK-dependent manner, and is independent of the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway. We observed reduced EGFRvIII/SHP-2/Gab1/Grb2/Sos-1 interaction and enhanced SIRP/SHP-2 association in U87MG. EGFRvIII/SIRP alpha 1 cells when compared with empty vector control cells. Interestingly, SIRP alpha 1 overexpression differentially modulated SHP-2 phosphorylation at tyrosyl 542 and 580 residues, which may regulate Erk1/2 activity and the EGFRvIII phenotype. In addition, SIRP alpha 1-expressing cells exhibited reduced focal adhesion kinase (FAK) phosphorylation and its recruitment to the EGFRvIII/Grb2/Sos-1/Gab1/SHP-2 complex. Collectively, our data indicate that SIRP alpha 1 specifically affects the SHP-2/FAK/Grb2/Sos-1/MAPK activation loop to downmodulate EGFRvIII-mediated migration and transformation. Further understanding of the molecular interactions between the SIRP alpha 1 inhibitory receptor and the EGFRvIII signalosome may facilitate the identification of novel targets to inhibit the EGFRvIII glioblastoma phenotype. Oncogene (2010) 29, 4130-4144; doi: 10.1038/onc.2010.164; published online 17 May 2010	[Kapoor, G. S.; O'Rourke, D. M.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [O'Rourke, D. M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.	donald.orourke@uphs.upenn.edu	O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314	National Institutes of Health [R01 CA-90586, R01 2R56CA0905896-06A1]; Terri Ann for a Cure and For Pete's Sake Funds to the University of Pennsylvania; NATIONAL CANCER INSTITUTE [R01CA090586, T32CA009058] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Terri Ann for a Cure and For Pete's Sake Funds to the University of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants to DMO from the National Institutes of Health R01 CA-90586, R01 2R56CA0905896-06A1 and from the Terri Ann for a Cure and For Pete's Sake Funds to the University of Pennsylvania.	Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Boudot C, 2002, CELL SIGNAL, V14, P869, DOI 10.1016/S0898-6568(02)00036-0; Cetin S, 2007, AM J PHYSIOL-GASTR L, V292, pG1347, DOI 10.1152/ajpgi.00375.2006; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Dai HY, 2008, MOL CARCINOGEN, V47, P956, DOI 10.1002/mc.20448; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Dong LW, 2008, MOL IMMUNOL, V45, P3025, DOI 10.1016/j.molimm.2008.03.012; Eminaga S, 2008, J BIOL CHEM, V283, P15328, DOI 10.1074/jbc.M801382200; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; GARCIA DP, 1993, CANCER RES, V53, P3217; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guo HB, 2007, J BIOL CHEM, V282, P22150, DOI 10.1074/jbc.M611518200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Kapoor GS, 2004, CANCER RES, V64, P6444, DOI 10.1158/0008-5472.CAN-04-0256; Kapoor GS, 2004, MOL CELL BIOL, V24, P823, DOI 10.1128/MCB.24.2.823-836.2004; Kapoor GS, 2007, CANCER BIOL THER, V6, P571, DOI 10.4161/cbt.6.4.3852; Keegan K, 1996, ONCOGENE, V12, P1537; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lorimer IAJ, 2001, BBA-MOL CELL RES, V1538, P1, DOI 10.1016/S0167-4889(00)00129-4; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Luo Y, 2009, BIOCHEMISTRY-US, V48, P1838, DOI 10.1021/bi8020789; Madan R, 2006, HUM PATHOL, V37, P9, DOI 10.1016/j.humpath.2005.09.024; Malchinkhuu E, 2005, ONCOGENE, V24, P6676, DOI 10.1038/sj.onc.1208805; Minoo P, 2003, CELL SIGNAL, V15, P319, DOI 10.1016/S0898-6568(02)00122-5; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Qin Jian-Min, 2006, Hepatobiliary Pancreat Dis Int, V5, P246; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sampaio C, 2008, MOL CELL BIOL, V28, P587, DOI 10.1128/MCB.01318-07; Sampson JH, 2008, SEMIN IMMUNOL, V20, P267, DOI 10.1016/j.smim.2008.04.001; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yan HX, 2004, HEPATOLOGY, V40, P618, DOI 10.1002/hep.20360; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yuan LP, 2005, J BIOL CHEM, V280, P42701, DOI 10.1074/jbc.M506768200; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhan Y, 2004, CANCER RES, V64, P8292, DOI 10.1158/0008-5472.CAN-03-3143; Zhan Y, 2009, EXP CELL RES, V315, P2343, DOI 10.1016/j.yexcr.2009.05.001	64	9	10	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4130	4144		10.1038/onc.2010.164	http://dx.doi.org/10.1038/onc.2010.164			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20473329				2022-12-28	WOS:000280151500002
J	Boukerche, H; Aissaoui, H; Prevost, C; Hirbec, H; Das, SK; Su, ZZ; Sarkar, D; Fisher, PB				Boukerche, H.; Aissaoui, H.; Prevost, C.; Hirbec, H.; Das, S. K.; Su, Z-Z; Sarkar, D.; Fisher, P. B.			Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappa B	ONCOGENE			English	Article						mda-9/syntenin; src; NF-kappa B	HUMAN-MELANOMA CELLS; PROTEIN-KINASE; PDZ DOMAINS; C-SRC; METASTATIC PHENOTYPE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS; TYROSINE KINASE; FAMILY KINASES	The scaffolding postsynaptic density-95/disks large/zonula occludens-1 (PDZ) domain-containing protein melanoma differentiation associated gene-9 (MDA-9)/syntenin is a tandem PDZ protein overexpressed in human melanoma, and breast and gastric cancer cells. MDA-9/syntenin affects cancer cell motility and invasion through distinct biochemical and signaling pathways, including focal adhesion kinase and p38 mitogen-activated protein kinase (MAPK), resulting in activation of the nuclear factor (NF)-kappa B pathway. MDA-9/syntenin also promotes melanoma metastasis by activating c-Src, but how c-Src regulates NF-kappa B activation is unclear. Using a human melanoma model, we document that MDA-9/synteninc-Src interactions are positive regulators of NF-kappa B activation. Inhibition of c-Src by PP2 treatment, by blocking c-Src or mda-9/syntenin expression with small interfering RNA, or in c-Src (-/-) knockout cell lines, reduces NF-kappa B activation following overexpression of mda-9/syntenin or c-Src. Deletion or point mutations of the PDZ binding motif preventing MDA-9/syntenin association with c-Src reveals that both PDZ domains, with PDZ2 being the dominant module, are required for activating downstream signaling pathways, including p38 MAPK and NF-kappa B. We also document that MDA-9/syntenin-c-Src complexes functionally cooperate with NF-kappa B to promote anchorage-independent growth, motility and invasion of melanoma cells. These findings underscore PDZ domains of MDA-9/syntenin as promising potential therapeutic targets for intervening in a decisive component of cancer progression, namely, metastatic tumor spread. Oncogene (2010) 29, 3054-3066; doi: 10.1038/onc.2010.65; published online 15 March 2010	[Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Boukerche, H.] Univ Lyon 1, INSERM, Fac Med Rene Laennec, Unite Rech Hematol,EA4174, F-69372 Lyon 08, France; [Hirbec, H.] INSERM, U583, Montpellier, France; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	habib.boukerche@sante.univ-lyon1.fr; pbfisher@vcu.edu	Hirbec, Helene/ABE-4188-2021	Hirbec, Helene/0000-0002-5593-5255	National Institutes of Health, National Cancer Institute [R01 CA035675, CA097318]; Samuel Waxman Cancer Research Foundation (SWCRF); National Foundation for Cancer Research (NFCR); Goldhirsh Foundation; Dana Foundation; Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer [1019]; NATIONAL CANCER INSTITUTE [R01CA097318, R01CA035675] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Samuel Waxman Cancer Research Foundation (SWCRF); National Foundation for Cancer Research (NFCR); Goldhirsh Foundation; Dana Foundation; Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health, National Cancer Institute Grants R01 CA035675 and CA097318, the Samuel Waxman Cancer Research Foundation (SWCRF), the National Foundation for Cancer Research (NFCR) (PBF); the Goldhirsh Foundation and the Dana Foundation (DS); and the Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer grant 1019 (HB). DS is the Harrison Endowed Scholar in Cancer Research and PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center. PBF is a SWCRF Investigator.	Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Baril P, 2002, INT J CANCER, V99, P315, DOI 10.1002/ijc.10324; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Boukerche H, 2000, CANCER RES, V60, P5848; Boukerche H, 2005, CANCER RES, V65, P10901, DOI 10.1158/0008-5472.CAN-05-1614; Boukerche H, 2004, GENE, V343, P191, DOI 10.1016/j.gene.2004.09.002; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Boukerche H, 2007, CANCER RES, V67, P1812, DOI 10.1158/0008-5472.CAN-06-3875; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chu Quincy S C, 2007, Invest New Drugs, V25, P359, DOI 10.1007/s10637-006-9031-6; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; FIDLER IJ, 1991, ANTICANCER RES, V11, P17; Funakoshi-Tago M, 2005, J BIOCHEM, V137, P189, DOI 10.1093/jb/mvi018; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Helmke BM, 2004, ONCOL REP, V12, P221; Hirbec H, 2005, MOL CELL NEUROSCI, V28, P737, DOI 10.1016/j.mcn.2004.12.005; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Liu AMF, 2005, J BIOL CHEM, V280, P34617, DOI 10.1074/jbc.M504264200; Matsuo Y, 2006, J BIOL CHEM, V281, P36767, DOI 10.1074/jbc.M604371200; Meerschaert K, 2007, EXP CELL RES, V313, P1790, DOI 10.1016/j.yexcr.2007.03.014; Mikami F, 2005, J BIOL CHEM, V280, P36185, DOI 10.1074/jbc.M503941200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Perez DG, 2009, CANCER-AM CANCER SOC, V115, P119, DOI 10.1002/cncr.23987; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Sarkar D, 2004, PHARMACOL THERAPEUT, V104, P101, DOI 10.1016/j.pharmthera.2004.08.004; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Sarkar FH, 2008, INT REV IMMUNOL, V27, P293, DOI 10.1080/08830180802276179; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sulka B, 2009, J BIOL CHEM, V284, P10659, DOI 10.1074/jbc.M807643200; Ten RM, 1999, J IMMUNOL, V163, P3851; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Warmuth M, 2003, CURR PHARM DESIGN, V9, P2043, DOI 10.2174/1381612033454126; Zhang Q, 2001, J BIOL CHEM, V276, P43216, DOI 10.1074/jbc.M105996200; Zhou J, 2004, INVEST OPHTH VIS SCI, V45, P2314, DOI 10.1167/iovs.03-1210	50	57	61	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3054	3066		10.1038/onc.2010.65	http://dx.doi.org/10.1038/onc.2010.65			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20228839	Green Submitted, Green Accepted			2022-12-28	WOS:000278133100003
J	Hsu, FF; Lin, TY; Chen, JY; Shieh, SY				Hsu, F-F; Lin, T-Y; Chen, J-Y; Shieh, S-Y			p53-Mediated transactivation of LIMK2b links actin dynamics to cell cycle checkpoint control	ONCOGENE			English	Article						cell cycle checkpoint; LIMK2; p53	TISSUE-SPECIFIC EXPRESSION; PROTEIN-KINASE; COFILIN PHOSPHORYLATION; ALTERNATIVE TRANSCRIPTS; DEPOLYMERIZING FACTOR; TARGET-GENE; P53; ROCK; RHO; ACTIVATION	The p53 tumor suppressor protein is widely known for its role as a sequence-specific transcription factor that regulates the expression of stress response genes. Here, we report the identification of LIMK2, which encodes a kinase that regulates actin dynamics through phosphorylation of cofilin, as a p53 target upregulated by DNA damage. Interestingly, the splice variant LIMK2b, but not LIMK2a, was induced in a p53-dependent manner through an intronic consensus p53-binding site. Depletion of LIMK2b leads to early exit of G2/M arrest after DNA damage, whereas its overexpression prolongs the arrest. These responses are recapitulated by ectopic expression of the active cofilin S3A mutant and the inactive cofilin S3D mutant, respectively, suggesting that LIMK2b may modulate G2/M arrest through cofilin phosphorylation. Furthermore, in support of its potential role as a tumor suppressor, LIMK2b was downregulated in esophageal and thyroid cancers, as well as in a number of established cancer cell lines, and its expression suppresses cancer cell migration. Taken together, our results unveil a novel pathway whereby LIMK2b, acting downstream of p53, ensures proper execution of checkpoint arrest by modulating the dynamics of actin polymerization. Oncogene (2010) 29, 2864-2876; doi: 10.1038/onc.2010.40; published online 1 March 2010	[Hsu, F-F; Lin, T-Y; Chen, J-Y; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Hsu, F-F] Natl Yang Ming Univ, Program Mol Med, Inst Biochem & Mol Biol, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018; Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	Academia Sinica	Academia Sinica(Academia Sinica - Taiwan)	We thank Hsiu-Ting Lin for her expert technical assistance with the RT-PCR. This work was supported by funding from Academia Sinica to S-Y Shieh.	Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Lu Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001149; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nomoto S, 1999, GENE, V236, P259, DOI 10.1016/S0378-1119(99)00280-2; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Ongusaha PP, 2006, CURR BIOL, V16, P2466, DOI 10.1016/j.cub.2006.10.056; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Smolich B, 1997, J BIOCHEM-TOKYO, V121, P382; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Takahashi T, 2001, DEV BIOL, V229, P554, DOI 10.1006/dbio.2000.9999; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Zhu Y, 2006, ONCOGENE, V25, P2901, DOI 10.1038/sj.onc.1209314	39	33	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2864	2876		10.1038/onc.2010.40	http://dx.doi.org/10.1038/onc.2010.40			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190821				2022-12-28	WOS:000277591900011
J	Lin, Y; Chen, NT; Shih, YP; Liao, YC; Xue, L; Lo, SH				Lin, Y.; Chen, N-T; Shih, Y-P; Liao, Y-C; Xue, L.; Lo, S. H.			DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration	ONCOGENE			English	Article						DLC2; RhoGAP; tumor suppressor; angiogenesis	GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; LIVER; CANCER; EXPRESSION; GROWTH; LOCALIZATION; INHIBITION; RHOGAP	Deleted in liver cancer 1 (DLC1) is a RhoGTPase activation protein-containing tumor suppressor that associates with various types of cancer. Although DLC2 shares a similar domain structure with that of DLC1, the function of DLC2 is not well characterized. Here, we describe the expression and ablation of DLC2 in mice using a reporter-knockout approach. DLC2 is expressed in several tissues and in endothelial cells (ECs) of blood vessels. Although ECs and blood vessels show no histological abnormalities and mice appear overall healthy, DLC2-mutant mice display enhanced angiogenic responses induced by matrigel and by tumor cells. Silencing of DLC2 in human ECs has reduced cell attachment, increased migration, and tube formation. These changes are rescued by silencing of RhoA, suggesting that the process is RhoA pathway dependent. These results indicate that DLC2 is not required for mouse development and normal vessel formation, but may protect mouse from unwanted angiogenesis induced by, for example, tumor cells. Oncogene (2010) 29, 3010-3016; doi:10.1038/onc.2010.54; published online 8 March 2010	[Lin, Y.; Chen, N-T; Shih, Y-P; Liao, Y-C; Lo, S. H.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Lin, Y.; Xue, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China	University of California System; University of California Davis; Sun Yat Sen University	Lo, SH (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, 4635 2nd Ave,Room 3002, Sacramento, CA 95817 USA.	shlo@ucdavis.edu	Hsiao, Wei-Hung/B-9931-2013; Liao, Yi-Chun/H-2383-2014	Liao, Yi-Chun/0000-0002-0399-0201; Lo, Su Hao/0000-0002-2675-9387	National Institutes of Health [CA102537]; NATIONAL CANCER INSTITUTE [R01CA102537, R56CA102537] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Knockout Mouse Project Repository for DLC2 ES cells. This work is supported in part by grants from the National Institutes of Health (CA102537) to SHL.	Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Li XR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-205; Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042; Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Testa G, 2004, GENESIS, V38, P151, DOI 10.1002/gene.20012; Ullmannova V, 2006, INT J ONCOL, V29, P1127; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yau TO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006566; Yuan BZ, 1998, CANCER RES, V58, P2196	17	31	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					3010	3016		10.1038/onc.2010.54	http://dx.doi.org/10.1038/onc.2010.54			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208559	Green Accepted, Green Submitted			2022-12-28	WOS:000277890400011
J	Hajji, N; Wallenborg, K; Vlachos, P; Fullgrabe, J; Hermanson, O; Joseph, B				Hajji, N.; Wallenborg, K.; Vlachos, P.; Fullgrabe, J.; Hermanson, O.; Joseph, B.			Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide	ONCOGENE			English	Article						cell death; topoisomerase inhibitor; HDAC inhibitor; hMOF; SIRT1; H4K16 acetylation	HISTONE DEACETYLASE INHIBITORS; CELL LUNG CARCINOMAS; DNA-DAMAGE; ANTICANCER AGENTS; H4 LYSINE-16; CANCER; PROTEIN; APOPTOSIS; ACETYLTRANSFERASE; RESPONSES	Various inhibitors of histone deacetylase (HDAC) activity can sensitize drug resistant cancer cells to chemotherapeutic agents. However, the mechanisms underlying such effects of distinct HDAC inhibitors (HDACi) remain poorly understood. Here we show that both the HDACi trichostatin A and valproic acid induced a sensitization of multidrug-resistant cancer cells to the topoisomerase II inhibitor etoposide/VP16. This effect was associated with increased acetylation of certain lysines on histones H3 and H4, including lysine 16 on histone H4 (H4K16). Overexpression of the histone acetyltransferase hMOF, known to target H4K16, was sufficient to mimic HDACi treatment on sensitization and H4K16 acetylation, and importantly, small-interfering RNA (siRNA)-mediated knockdown of hMOF abolished the HDACi-mediated sensitizing effects as well as the increase in H4K16 acetylation. Conversely, siRNA-mediated knockdown of the H4K16 deacetylase SIRT1 mimicked HDACi treatment whereas overexpression of SIRT1 abolished H4K16 acetylation and significantly reduced the sensitizing effects of HDACi. Interestingly, the effects of hMOF on H4K16 acetylation and sensitization to the topoisomerase II inhibitor could be directly counteracted by exogenous expression of increasing amounts of SIRT1 and vice versa. Our study results suggest that hMOF and SIRT1 activities are critical parameters in HDACi-mediated sensitization of multidrug-resistant cancer cells to topoisomerase II inhibitor and increased H4K16 acetylation. Oncogene (2010) 29, 2192-2204; doi: 10.1038/onc.2009.505; published online 1 February 2010	[Hajji, N.; Vlachos, P.; Fullgrabe, J.; Joseph, B.] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden; [Wallenborg, K.; Hermanson, O.] Karolinska Inst, CoE Dev Biol CEDB DBRM, Dept Neurosci, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, R8 03, S-17176 Stockholm, Sweden.	bertrand.joseph@ki.se	, Ola/AAF-5126-2021; hajji, nabil/AAV-1435-2020	Fullgrabe, Jens/0000-0003-0047-4719; Hermanson, Ola/0000-0001-9320-7921; Joseph, Bertrand/0000-0001-5655-9979	Swedish Research Council; Swedish Cancer Society; Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer); Swedish Children's Cancer Foundation; Medical Research Council [G0801056B] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer)(Karolinska Institutet); Swedish Children's Cancer Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank RG Roeder (The Rockefeller University), L Guarente (Massachusetts Institute of Technology) and M Henriksson (Karolinska Institutet) for providing us with hMOF DNA construct, SIRT1 DNA construct and SK-N-BE(2) cell line, respectively, and S Orrenius, T Perlmann and members of Hermanson and Joseph's labs for helpful comments. This work was supported by the Swedish Research Council, the Swedish Cancer Society, the Ake Wiberg Foundation, the Swedish Medical Society, the Karolinska Institutet Foundations (KI Cancer) (BJ and OH), SSF (CEDB & OBOE) and the Swedish Children's Cancer Foundation (OH).	Andersson T, 2009, J BIOL CHEM, V284, P3672, DOI 10.1074/jbc.M808119200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417; Keshelava N, 1998, CANCER RES, V58, P5396; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Nyman U, 2009, MOL CELL BIOL, V29, P1814, DOI 10.1128/MCB.00585-08; Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029	42	57	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2192	2204		10.1038/onc.2009.505	http://dx.doi.org/10.1038/onc.2009.505			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20118981				2022-12-28	WOS:000276685200005
J	Kitzing, TM; Wang, Y; Pertz, O; Copeland, JW; Grosse, R				Kitzing, T. M.; Wang, Y.; Pertz, O.; Copeland, J. W.; Grosse, R.			Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC	ONCOGENE			English	Article						cancer cell invasion; Diaphanous formins; RhoC; FMNL2; actin	GENOMIC ANALYSIS; ACTIVATION; GTPASES; G-ALPHA(12/13); METASTASIS; TRANSITION; MECHANISM; MIGRATION; INHIBIT; LARG	Invasive cell migration is a key step for cancer metastasis and involves Rho GTPase-controlled reorganization of the actin cytoskeleton. Altered Rho GTPase expression is found in various malignancies. Particularly, the closely related GTPases RhoA and RhoC are upregulated in many aggressive tumours, but specific effectors that distinguish between these two GTPases to explain mechanistic differences have not been identified. The formins are by far the largest family of Rho GTPase effectors and are characterized by the actin-nucleating formin homology 2 domain. Using siRNA-based screening against all 15 human formins, we systematically analysed their functions in 3D cell motility using three different cancer cell lines. These results reveal distinct requirements for specific formins in amoeboid versus mesenchymal invasive cell migration. Importantly, by knocking down all Rho proteins, we identified formin-like 2 ( FMNL2) as a specific RhoC effector, showing selective interaction of FMNL2 with active RhoC, but not RhoA or RhoB. Functional analysis shows that RhoC regulates auto-inhibition of FMNL2, whereas suppression of FMNL2 inhibits RhoC-, but not RhoA-dependent, rounded invasive cell migration. Thus, our data uncover a novel regulatory and functional interaction between RhoC and FMNL2 for modulating cell shape and invasiveness and provide mechanistic insight into RhoC-specific signalling events. Oncogene (2010) 29, 2441-2448; doi:10.1038/onc.2009.515; published online 25 January 2010	[Grosse, R.] Univ Marburg, Inst Pharmacol, D-35032 Marburg, Hessen, Germany; [Kitzing, T. M.; Wang, Y.] Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany; [Wang, Y.] Heidelberg Univ, HBIGS, Heidelberg, Germany; [Pertz, O.] Univ Basel, Ctr Biomed, Basel, Switzerland; [Copeland, J. W.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada	Philipps University Marburg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Basel; University of Ottawa	Grosse, R (corresponding author), Univ Marburg, Inst Pharmacol, Karl von Frisch Str 1, D-35032 Marburg, Hessen, Germany.	robert.grosse@staff.uni-marburg.de		Wang, Ying/0000-0001-8699-5974; Grosse, Robert/0000-0002-3380-5273; pertz, olivier/0000-0001-8579-4919	Deutsche Krebshilfe e. V. [108293]; C.H.S.-Foundation; Heart and Stroke Foundation of Ontario [T6317]; Krebsliga beider Basel	Deutsche Krebshilfe e. V.(Deutsche Krebshilfe); C.H.S.-Foundation; Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Krebsliga beider Basel	We thank Erik Sahai for supplying siRNAs against human Rho proteins. We thank Barbara Di Ventura for comments on the paper, Philippe Chavrier for discussions and Anke Niemann for excellent technical assistance. This work was funded by the Deutsche Krebshilfe e. V. (108293) and a group leader fellowship from the C.H.S.-Foundation to RG. JWC is supported by the Heart and Stroke Foundation of Ontario (T6317) and OP by grants from the Krebsliga beider Basel.	Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Chesarone M, 2009, DEV CELL, V16, P292, DOI 10.1016/j.devcel.2008.12.001; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001; Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Goulimari P, 2008, MOL BIOL CELL, V19, P30, DOI 10.1091/mbc.E06-11-1045; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ji P, 2008, NAT CELL BIOL, V10, P314, DOI 10.1038/ncb1693; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Vaillant DC, 2008, J BIOL CHEM, V283, P33750, DOI 10.1074/jbc.M803156200; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Zhu XL, 2008, INT J COLORECTAL DIS, V23, P1041, DOI 10.1007/s00384-008-0520-2	33	103	108	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2441	2448		10.1038/onc.2009.515	http://dx.doi.org/10.1038/onc.2009.515			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101212				2022-12-28	WOS:000276951500012
J	Liu, G; Xirodimas, DP				Liu, G.; Xirodimas, D. P.			NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways	ONCOGENE			English	Article						NEDDylation; ubiquitination; NUB1; p53; Mdm2; cytoplasmic localization	RING-FINGER DOMAIN; NUCLEAR; NEDDYLATION; DEGRADATION; BINDING; PROTEIN; MDM2; AUTOPHAGY	Non-covalent recognition of ubiquitin (Ub) and ubiquitin-like molecules (Ubls) by interacting proteins has an important role in the regulation of protein function and initiation of signalling events. In addition, growing evidence suggests that regulation of p53 subcellular localization contributes to the biological outcome of the p53 response. Cytoplasmic p53 is shown to promote apoptosis and inhibit the induction of autophagy. In this study we show that NEDD8 ultimate buster 1 (NUB1), a non-covalent interactor of the Ubl NEDD8 (neural precursor cell expressed, developmentally downregulated 8), controls the localization of p53. Expression of NUB1 leads to decreased modification of p53 with NEDD8 and stimulation of p53 ubiquitination. The biological outcome is the cytoplasmic localization and inhibition of the transcriptional activity of p53. Although the effects of NUB1 on p53 depend on NEDDylation and the murine double minute 2 (Mdm2) E3-ligase, the cooperation of NEDD8 with ubiquitin is required. The data identify a role for NEDD8 in controlling p53 localization and suggest that NEDD8 can control protein function through its non-covalent recognition by interacting proteins. Oncogene (2010) 29, 2252-2261; doi: 10.1038/onc.2009.494; published online 25 January 2010	[Xirodimas, D. P.] Univ Dundee, Sch Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Div Gene Regulat & Express,Coll Life Sci, Dundee DD1 5EH, Angus, Scotland	University of Dundee	Xirodimas, DP (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Div Gene Regulat & Express,Coll Life Sci, Dow St, Dundee DD1 5EH, Angus, Scotland.	d.xirodimas@dundee.ac.uk		Liu, Geng/0000-0002-9293-0461; Xirodimas, Dimitris/0000-0001-9275-1140				Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Carter S, 2009, CURR OPIN GENET DEV, V19, P18, DOI 10.1016/j.gde.2008.11.010; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Coutts AS, 2009, DNA REPAIR, V8, P483, DOI 10.1016/j.dnarep.2009.01.008; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dohmesen C, 2008, CELL CYCLE, V7, P222, DOI 10.4161/cc.7.2.5185; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; Laine A, 2006, MOL CELL BIOL, V26, P8901, DOI 10.1128/MCB.01156-06; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; LEE KAW, 1994, CELL BIOL LAB HDB, V1, P668; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Schmidtke G, 2006, J BIOL CHEM, V281, P20045, DOI 10.1074/jbc.M603063200; Speidel D, 2006, ONCOGENE, V25, P940, DOI 10.1038/sj.onc.1209126; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tanji K, 2005, BIOCHEM BIOPH RES CO, V337, P116, DOI 10.1016/j.bbrc.2005.09.014; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314	44	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2252	2261		10.1038/onc.2009.494	http://dx.doi.org/10.1038/onc.2009.494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101219				2022-12-28	WOS:000276685200010
J	Murayama-Hosokawa, S; Oda, K; Nakagawa, S; Ishikawa, S; Yamamoto, S; Shoji, K; Ikeda, Y; Uehara, Y; Fukayama, M; McCormick, F; Yano, T; Taketani, Y; Aburatani, H				Murayama-Hosokawa, S.; Oda, K.; Nakagawa, S.; Ishikawa, S.; Yamamoto, S.; Shoji, K.; Ikeda, Y.; Uehara, Y.; Fukayama, M.; McCormick, F.; Yano, T.; Taketani, Y.; Aburatani, H.			Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway	ONCOGENE			English	Article						chromosomal instability; microsatellite instability; copy number neutral LOH; homozygous deletions; Ras-PI3K pathway; endometrial carcinoma	ACQUIRED UNIPARENTAL DISOMY; PLECKSTRIN HOMOLOGY DOMAIN; ACUTE MYELOID LEUKEMIAS; RESOLUTION COPY NUMBER; MICROSATELLITE INSTABILITY; OVARIAN-CANCER; MUTATIONS; HETEROZYGOSITY; PIK3CA; GENES	Endometrial cancer is one of the tumor types in which either chromosomal instability (CIN) or microsatellite instability (MSI) may occur. It is known to possess mutations frequently in the Ras-PI3K (phosphatidylinositol 30-kinase) pathway. We performed a comprehensive genomic survey in 31 endometrial carcinomas with paired DNA for chromosomal imbalances (25 by the 50K and 6 by the 250K single-nucleotide polymorphism (SNP) array), and screened 25 of the 31 samples for MSI status and mutational status in the Ras-PI3K pathway genes. We detected five or more copy number changes (classified as CIN-extensive) in 9 (29%), 1 to 4 changes (CIN-intermediate) in 17 (55%) and no changes (CIN-negative) in 5 (16%) tumors. Positive MSI was less common in CIN-extensive tumors (14%), compared with CIN-intermediate/negative tumors (50%), and multivariate analysis showed that CIN-extensive is an independent poor prognostic factor. SNP array analysis unveiled copy number neutral LOH at 54 loci in 13 tumors (42%), including four at the locus of PTEN. In addition to eight (26%) tumors with PTEN deletions, we detected chromosomal imbalances of NF1, K-Ras and PIK3CA in four (13%), four (13%) and six (19%) tumors, respectively. In all, 7 of the 9 CIN-extensive tumors harbor deletions in the loci of PTEN and/or NF1, whereas all the 10 MSI-positive tumors possess PTEN, PIK3CA and/or K-Ras mutations. Our results showed that genomic alterations in the Ras-PI3K pathway are remarkably widespread in endometrial carcinomas, regardless of the type of genomic instability, and suggest that the degree of CIN is a useful biomarker for prognosis in endometrial carcinomas. Oncogene (2010) 29, 1897-1908; doi:10.1038/onc.2009.474; published online 11 January 2010	[Aburatani, H.] Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; [Murayama-Hosokawa, S.; Oda, K.; Nakagawa, S.; Shoji, K.; Ikeda, Y.; Uehara, Y.; Yano, T.; Taketani, Y.] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan; [Ishikawa, S.; Fukayama, M.] Univ Tokyo, Dept Pathol, Tokyo, Japan; [McCormick, F.] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [McCormick, F.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of Tokyo; University of Tokyo; University of Tokyo; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Aburatani, H (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Komaba 4-6-1, Tokyo 1538904, Japan.	haburata-tky@umin.ac.jp			Ministry of Education, Science, Sports and Culture [16101006, 17015008]; Ministry of Education, Culture, Sports, Science and Technology of Japan [20014007, 19599005, 21791544, 20018005]; Core Research for Evolutional Science and Technology (CREST); Japan Science and Technology Agency (JST); New Energy and Industrial Technology Development Organization (NEDO) of Japan	Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Core Research for Evolutional Science and Technology (CREST)(Core Research for Evolutional Science and Technology (CREST)); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); New Energy and Industrial Technology Development Organization (NEDO) of Japan(New Energy and Industrial Technology Development Organization (NEDO))	We thank Hiroko Meguro, Akira Watanabe, Jennifer Okada, Toshiharu Yasugi, Kei Kawana, Takahide Arimoto, Akira Tsuchiya, Osamu Hiraike-Wada, Kenbun Sone, Yuichiro Miyamoto, Haruko Hiraike, Katsuyuki Adachi, Shiho Miura and Ayako Tomio for support and assistance. This work was supported by the Ministry of Education, Science, Sports and Culture Grant Number: Scientific Research (S) 16101006, Scientific Research on Priority Areas 17015008, Ministry of Education, Culture, Sports, Science and Technology of Japan on Priority Area; Grant Number: 20014007, and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST) (to H Aburatani); by the Grant-in-Aid for Scientific Research (C), Grant Number 19599005 and the Grant-in-Aid for Young Scientists (B), Grant Number 21791544 from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to K Oda); by the Grant-in-Aid for Scientific Research on Priority Areas 'Applied Genomics', Grant Number 20018005, from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Industrial Technology Research Grant Program from New Energy and Industrial Technology Development Organization (NEDO) of Japan (to S Ishikawa).	An HJ, 2004, MODERN PATHOL, V17, P530, DOI 10.1038/modpathol.3800057; Arabi H, 2009, GYNECOL ONCOL, V113, P153, DOI 10.1016/j.ygyno.2009.02.004; Atkin NB, 2001, CYTOGENET CELL GENET, V92, P177, DOI 10.1159/000056898; Bacolod MD, 2009, CANCER RES, V69, P723, DOI 10.1158/0008-5472.CAN-08-3543; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; Black D, 2006, J CLIN ONCOL, V24, P1745, DOI 10.1200/JCO.2005.04.1574; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi SW, 2002, CLIN CANCER RES, V8, P2311; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Doll A, 2008, J STEROID BIOCHEM, V108, P221, DOI 10.1016/j.jsbmb.2007.09.020; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; ENOMOTO T, 1991, CANCER RES, V51, P5308; Fitzgibbon J, 2005, CANCER RES, V65, P9152, DOI 10.1158/0008-5472.CAN-05-2017; Flotho C, 2007, ONCOGENE, V26, P5816, DOI 10.1038/sj.onc.1210361; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gorringe KL, 2008, GENE CHROMOSOME CANC, V47, P933, DOI 10.1002/gcc.20595; Gorringe KL, 2007, CLIN CANCER RES, V13, P4731, DOI 10.1158/1078-0432.CCR-07-0502; Gorringe KL, 2009, GENE CHROMOSOME CANC, V48, P931, DOI 10.1002/gcc.20694; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Hirasawa A, 2003, CLIN CANCER RES, V9, P5675; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Kawamata N, 2008, BLOOD, V111, P776, DOI 10.1182/blood-2007-05-088310; Komura D, 2006, GENOME RES, V16, P1575, DOI 10.1101/gr.5629106; Kong D, 2008, CANCER SCI, V99, P1734, DOI 10.1111/j.1349-7006.2008.00891.x; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kratz CP, 2007, HUM MOL GENET, V16, P374, DOI 10.1093/hmg/ddl458; Levan K, 2006, CYTOGENET GENOME RES, V115, P16, DOI 10.1159/000094796; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loukola A, 2001, CANCER RES, V61, P4545; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maira SM, 2009, BIOCHEM SOC T, V37, P265, DOI 10.1042/BST0370265; MCCONNELL JD, 1995, BR J UROL S, V1, P5; Melcher R, 2007, CYTOGENET GENOME RES, V118, P214, DOI 10.1159/000108303; Micci F, 2004, GENE CHROMOSOME CANC, V40, P229, DOI 10.1002/gcc.20038; Midorikawa Y, 2006, ONCOGENE, V25, P5581, DOI 10.1038/sj.onc.1209537; Minaguchi T, 2001, CLIN CANCER RES, V7, P2636; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Onda T, 1997, BRIT J CANCER, V75, P1836, DOI 10.1038/bjc.1997.313; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Raghavan M, 2005, CANCER RES, V65, P375; Rowan A, 2005, CLIN GASTROENTEROL H, V3, P1115, DOI 10.1016/S1542-3565(05)00618-X; Ryan AJ, 2005, CELL TISSUE RES, V322, P53, DOI 10.1007/s00441-005-1109-5; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Sirchia SM, 2000, CANCER GENET CYTOGEN, V121, P156, DOI 10.1016/S0165-4608(00)00240-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suehiro Y, 2000, GENE CHROMOSOME CANC, V29, P75, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1010>3.3.CO;2-T; Tashiro H, 1997, AM J PATHOL, V150, P75; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; Toda T, 2001, CANCER GENET CYTOGEN, V126, P120, DOI 10.1016/S0165-4608(00)00400-3; Tuna M, 2009, TRENDS MOL MED, V15, P120, DOI 10.1016/j.molmed.2009.01.005; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walsh CS, 2008, CLIN CANCER RES, V14, P7645, DOI 10.1158/1078-0432.CCR-08-1291; Weber JC, 2007, INT J CANCER, V120, P524, DOI 10.1002/ijc.22343; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421	62	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1897	1908		10.1038/onc.2009.474	http://dx.doi.org/10.1038/onc.2009.474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062086				2022-12-28	WOS:000276199600003
J	Nasarre, C; Roth, M; Jacob, L; Roth, L; Koncina, E; Thien, A; Labourdette, G; Poulet, P; Hubert, P; Cremel, G; Roussel, G; Aunis, D; Bagnard, D				Nasarre, C.; Roth, M.; Jacob, L.; Roth, L.; Koncina, E.; Thien, A.; Labourdette, G.; Poulet, P.; Hubert, P.; Cremel, G.; Roussel, G.; Aunis, D.; Bagnard, D.			Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo	ONCOGENE			English	Article						neuropilin; glioma; angiogenesis; peptide; tumour growth	POINT MUTATION; BREAST-CANCER; MOUSE MODEL; CELLS; RECEPTORS; BINDING; ANGIOGENESIS; ACTIVATION; PROTEIN; PROGRESSION	Angiogenesis in glioblastoma is largely dependent on vascular endothelial growth factor (VEGF) signalling. Consistently, the VEGF coreceptor NRP1 promotes angiogenesis and tumour growth in gliomas. Here, we provide data showing that an innovative peptidic tool targeting the transmembrane domain of NRP1 efficiently blocks rat and human glioma growth in vivo. We show both in vivo and in vitro that the antitumour effect results from the anti-proliferative, anti-migratory and anti-angiogenic properties of the compound. The proposed NRP1 antagonizing peptide is therefore a promising novel class of anti-angiogenic drugs that might prolong glioma patient survival. Our results finally show for the first time that the transmembrane domain of important signalling receptors can be antagonized in vivo thereby providing a new avenue towards the development of atypical antagonists with strong therapeutic potential. Oncogene (2010) 29, 2381-2392; doi:10.1038/onc.2010.9; published online 8 February 2010	[Nasarre, C.; Roth, M.; Jacob, L.; Roth, L.; Koncina, E.; Thien, A.; Labourdette, G.; Cremel, G.; Roussel, G.; Aunis, D.; Bagnard, D.] INSERM, U575, F-67200 Strasbourg, France; [Poulet, P.] Inst Phys Biol, Lab Neuroimagerie & Neurosci Cognit, Strasbourg, France; [Hubert, P.] CNRS, LISM, UPR 9027, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Bagnard, D (corresponding author), INSERM, U682, 3 Ave Moliere, F-67200 Strasbourg, France.	dominique.bagnard@inserm.u-strasbg.fr	Hubert, Pierre/C-6678-2013; Poulet, Patrick/AAD-1438-2020; Poulet, Patrick/A-2001-2012; Poulet, Patrick/AAG-7783-2021; Dominique, Aunis/W-1419-2019; Bagnard, Dominique/I-6535-2013	Hubert, Pierre/0000-0002-7549-8910; JACOB, Laurent/0000-0003-4767-0442; Poulet, Patrick/0000-0001-7998-9672; Roth, Lise/0000-0001-7555-2916; Bagnard, Dominique/0000-0002-5261-902X	INSERM; ACI JC [5327]; ARC; ANR Emergence bio; FRC/Rotary international; Pharmaxon; La Ligue Contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ACI JC; ARC(Australian Research Council); ANR Emergence bio(French National Research Agency (ANR)); FRC/Rotary international; Pharmaxon; La Ligue Contre le Cancer(Ligue nationale contre le cancer)	We thank Dr Sophie Reibel-Foisset and Mr Nicolas Lethenet for excellent assistance with in vivo experiments and animal care. This work was supported by INSERM, ACI JC (No. 5327), ARC, ANR Emergence bio, FRC/Rotary international to Dominique Bagnard. Cecile Nasarre was supported by Pharmaxon and La Ligue Contre le Cancer.	Bagci T, 2009, ONCOGENE, V28, P3537, DOI 10.1038/onc.2009.204; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Bedjeguelal K, 2006, BIOORG MED CHEM LETT, V16, P3998, DOI 10.1016/j.bmcl.2006.05.014; Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gamse JT, 2002, NAT GENET, V30, P117, DOI 10.1038/ng793; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; Giordano RJ, 2005, CHEM BIOL, V12, P1075, DOI 10.1016/j.chembiol.2005.07.008; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; JOCIC Z, 1993, BRAIN COGNITION, V23, P222, DOI 10.1006/brcg.1993.1056; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; Kienlen-Campard P, 2008, J BIOL CHEM, V283, P7733, DOI 10.1074/jbc.M707142200; KLOSEN P, 1993, J HISTOCHEM CYTOCHEM, V41, P455, DOI 10.1177/41.3.8429209; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462; Nasarre C, 2009, CELL ADHES MIGR, V3, P383, DOI 10.4161/cam.3.4.9934; Nasarre P, 2005, NEOPLASIA, V7, P180, DOI 10.1593/neo.04481; Orian-Rousseau V, 2008, ADV CANCER RES, V101, P63, DOI 10.1016/S0065-230X(08)00404-1; Roth L, 2008, MOL BIOL CELL, V19, P646, DOI 10.1091/mbc.E07-06-0625; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Slimani H, 2006, J DRUG TARGET, V14, P694, DOI 10.1080/10611860600947607; Starzec A, 2006, LIFE SCI, V79, P2370, DOI 10.1016/j.lfs.2006.08.005; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tessitore A, 1999, J CLIN ENDOCR METAB, V84, P3522, DOI 10.1210/jc.84.10.3522; Tirand L, 2006, J CONTROL RELEASE, V111, P153, DOI 10.1016/j.jconrel.2005.11.017; Uitenbroek, 1997, BINOMIAL SISA; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams G, 2005, J NEUROCHEM, V92, P1180, DOI 10.1111/j.1471-4159.2004.02950.x; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099	42	85	90	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2381	2392		10.1038/onc.2010.9	http://dx.doi.org/10.1038/onc.2010.9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20140015				2022-12-28	WOS:000276951500007
J	Wu, Y; Wang, YY; Nakamoto, Y; Li, YY; Baba, T; Kaneko, S; Fujii, C; Mukaida, N				Wu, Y.; Wang, Y. Y.; Nakamoto, Y.; Li, Y-Y; Baba, T.; Kaneko, S.; Fujii, C.; Mukaida, N.			Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver	ONCOGENE			English	Article						serine/threonine kinase; apoptosis; cell cycle; Bad	NF-KAPPA-B; SERINE/THREONINE KINASE-ACTIVITY; BAD-MEDIATED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CHEMICAL HEPATOCARCINOGENESIS; PROTEIN-KINASE; GROWTH-FACTOR; CANCER CELLS; C-MYC; ACTIVATION	Pim-3, a proto-oncogene with serine/threonine kinase activity, was enhanced in hepatocellular carcinoma (HCC) tissues. To address the roles of Pim-3 in HCC development, we prepared transgenic mice that express human Pim-3 selectively in liver. The mice were born at a Mendelian ratio, were fertile and did not exhibit any apparent pathological changes in the liver until 1 year after birth. Pim-3-transgenic mouse-derived hepatocytes exhibited accelerated cell cycle progression. The administration of a potent hepatocarcinogen, diethylnitrosamine (DEN), induced accelerated proliferation of liver cells in Pim-3 transgenic mice in the early phase, compared with that observed for wild-type mice. Treatment with DEN induced lipid droplet accumulation with increased proliferating cell numbers 6 months after the treatment. Eventually, wild-type mice developed HCC with a frequency of 40% until 10 month after the treatment. Lipid accumulation was accelerated in Pim-3 transgenic mice with higher proliferating cell numbers, compared with that observed for wild-type mice. Pim-3 transgenic mice developed HCC with a higher incidence (80%) and a heavier burden, together with enhanced intratumoral CD31-positive vascular areas, compared with that observed for wild-type mice. These observations indicate that Pim-3 alone cannot cause, but can accelerate HCC development when induced by a hepatocarcinogen, such as DEN. Oncogene (2010) 29, 2228-2237; doi: 10.1038/onc.2009.504; published online 18 January 2010	[Wu, Y.; Wang, Y. Y.; Li, Y-Y; Baba, T.; Fujii, C.; Mukaida, N.] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9200934, Japan; [Wu, Y.] Sichuan Univ, W China Hosp, Dept Hematol, Chengdu 610064, Sichuan, Peoples R China; [Wu, Y.] Sichuan Univ, W China Hosp, Hematol Res Lab, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China; [Wu, Y.] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610064, Sichuan, Peoples R China; [Nakamoto, Y.; Kaneko, S.] Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa 9200934, Japan; [Li, Y-Y] Fudan Univ, Canc Hosp, Researcher Ctr, Shanghai 200433, Peoples R China	Kanazawa University; Sichuan University; Sichuan University; Sichuan University; Kanazawa University; Fudan University	Mukaida, N (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	naofumim@kenroku.kanazawa-u.ac.jp	Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851; Fujii, Chifumi/0000-0001-8735-5274				Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; BRAUN L, 1989, CANCER RES, V49, P1554; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chung J, 2007, LAB INVEST, V87, P540, DOI 10.1038/labinvest.3700550; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Fujii C, 2005, INT J CANCER, V114, P209, DOI 10.1002/ijc.20719; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; HOSONO S, 1993, ONCOGENE, V8, P491; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Li YY, 2006, CANCER RES, V66, P6741, DOI 10.1158/0008-5472.CAN-05-4272; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Manna SK, 2000, J IMMUNOL, V165, P5962, DOI 10.4049/jimmunol.165.10.5962; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Otani K, 2005, GASTROENTEROLOGY, V128, P96, DOI 10.1053/j.gastro.2004.10.045; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Popivanova BK, 2007, CANCER SCI, V98, P321, DOI 10.1111/j.1349-7006.2007.00390.x; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; ROBERTS RA, 1999, CARCINOGENESIS, V20, P1297; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Udalova IA, 2001, BIOCHEM BIOPH RES CO, V289, P25, DOI 10.1006/bbrc.2001.5929; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; Wang Y, 2009, INT J CANCER, V124, P540, DOI 10.1002/ijc.23995; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Wu Y, 2008, J IMMUNOL, V181, P6384, DOI 10.4049/jimmunol.181.9.6384; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang XQ, 2006, INT J CANCER, V118, P1869, DOI 10.1002/ijc.21596; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zheng HC, 2008, J CANCER RES CLIN, V134, P481, DOI 10.1007/s00432-007-0310-1; Zheng YY, 2007, HEPATOLOGY, V45, P16, DOI 10.1002/hep.21445	43	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2228	2237		10.1038/onc.2009.504	http://dx.doi.org/10.1038/onc.2009.504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101231	Green Submitted			2022-12-28	WOS:000276685200008
J	Ibanez de Caceres, I; Cortes-Sempere, M; Moratilla, C; Machado-Pinilla, R; Rodriguez-Fanjul, V; Manguan-Garcia, C; Cejas, P; Lopez-Rios, F; Paz-Ares, L; de CastroCarpeno, J; Nistal, M; Belda-Iniesta, C; Perona, R				Ibanez de Caceres, I.; Cortes-Sempere, M.; Moratilla, C.; Machado-Pinilla, R.; Rodriguez-Fanjul, V.; Manguan-Garcia, C.; Cejas, P.; Lopez-Rios, F.; Paz-Ares, L.; de CastroCarpeno, J.; Nistal, M.; Belda-Iniesta, C.; Perona, R.			IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer	ONCOGENE			English	Article						CDDP-resistance; IGFBP-3; NSCLC; hypermethylation	INDUCED DNA HYPERMETHYLATION; EPITHELIAL OVARIAN-CANCER; DRUG-RESISTANCE; BINDING PROTEIN-3; PROMOTER HYPERMETHYLATION; ACQUIRED-RESISTANCE; CPG ISLAND; METHYLATION; GROWTH; GENE	Cisplatin-based chemotherapy is the paradigm of non-small-cell lung cancer (NSCLC) treatment; however, it also induces de novo DNA-hypermethylation, a process that may be involved in the development of drug-resistant phenotypes by inactivating genes required for drug-cytotoxicity. By using an expression microarray analysis, we aimed to identify those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Results revealed specific silencing by promoter hypermethylation of IGFBP-3 in CDDP resistant cells, whereas IGFBP-3 siRNA interference, induced resistance to CDDP in sensitive cells (P<0.001). In addition, we found a strong correlation between methylation status and CDDP response in tumor specimens (P<0.001). Thus, stage I patients, whose tumors harbor an unmethylated promoter, had a trend towards increased disease-free survival (DFS). We report that a loss of IGFBP-3 expression, mediated by promoter-hypermethylation, results in a reduction of tumor cell sensitivity to cisplatin in NSCLC. Basal methylation status of IGFBP-3 before treatment may be a clinical biomarker and a predictor of the chemotherapy outcome, helping to identify patients who are most likely to benefit from CDDP therapy alone or in combination with epigenetic treatment. Oncogene (2010) 29, 1681-1690; doi:10.1038/onc.2009.454; published online 21 December 2009	[Ibanez de Caceres, I.] FIB La Paz Univ Hosp, Oncol Res Lab, Inst Invest Biomed Madrid, Res Unit, Madrid 28029, Spain; [Cortes-Sempere, M.; Moratilla, C.; Machado-Pinilla, R.; Rodriguez-Fanjul, V.; Manguan-Garcia, C.; Perona, R.] UAM, Translat Oncol Unit, CSIC H La Paz, Inst Invest Biomed CSIC, Madrid, Spain; [Cejas, P.; de CastroCarpeno, J.; Belda-Iniesta, C.] La Paz Univ Hosp, Translat Oncol Unit, CSIC H La Paz, Dept Med Oncol, Madrid, Spain; [Lopez-Rios, F.] Hosp 12 Octubre, Dept Pathol, E-28041 Madrid, Spain; [Paz-Ares, L.] Hosp 12 Octubre, Dept Med Oncol, E-28041 Madrid, Spain; [Nistal, M.] La Paz Univ Hosp, Dept Pathol, Madrid, Spain	Autonomous University of Madrid; Hospital Universitario La Paz; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario La Paz	Ibanez de Caceres, I (corresponding author), FIB La Paz Univ Hosp, Oncol Res Lab, Inst Invest Biomed Madrid, Res Unit, C Arturo Duperier 4, Madrid 28029, Spain.	inma.ibanezca@salud.madrid.org	Fanjul, Vanessa VRF Rodriguez/K-8417-2017; Rodríguez, Ferran A. A/H-4892-2011; Paz-Ares, Luis/AAH-2750-2019	Fanjul, Vanessa VRF Rodriguez/0000-0002-3386-5874; Rodríguez, Ferran A. A/0000-0002-2280-8962; Belda Iniesta, Cristobal/0000-0003-3254-7492	Fondo de Investigacion Sanitaria (ISCIII) [CP08/000689; PI-717, PI06-1234, PI08-1485, PS09/00472]; Fundacion Medica Mutua Madrilena	Fondo de Investigacion Sanitaria (ISCIII)(Instituto de Salud Carlos III); Fundacion Medica Mutua Madrilena(Instituto de Salud Carlos III)	We gratefully acknowledge Javier Perez for the artwork and to J Siegfried, for the English correction of the manuscript. Ibanez de Caceres was partially supported by the Fondo de Investigacion Sanitaria (ISCIII) through the 'Miguel Servet' program (CP08/000689; PI-717). Note: Supported by FIS PI06-1234, PI08-1485, PS09/00472 and Fundacion Medica Mutua Madrilena.	Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 2003, CANCER RES, V63, P7089; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Esteller M, 1999, CANCER RES, V59, P793; Gosepath EM, 2008, INT J CANCER, V123, P2013, DOI 10.1002/ijc.23721; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018; Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Leyland-Jones B, 1999, AM J PATHOL, V155, P77, DOI 10.1016/S0002-9440(10)65102-4; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; MCKEAGE MJ, 1995, DRUG SAFETY, V13, P228, DOI 10.2165/00002018-199513040-00003; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; NYCE J, 1989, CANCER RES, V49, P5829; Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8; Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767; Plasencia C, 2006, INT J ONCOL, V29, P225; Plumb JA, 2000, CANCER RES, V60, P6039; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Riedel RF, 2008, MOL CANCER THER, V7, P3141, DOI 10.1158/1535-7163.MCT-08-0642; Roninson IB, 2003, CANCER RES, V63, P2705; Shen DW, 2004, BRIT J CANCER, V91, P270, DOI 10.1038/sj.bjc.6601956; Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; 2003, CENT EUR J PUBLIC HL, V11, P177	43	89	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1681	1690		10.1038/onc.2009.454	http://dx.doi.org/10.1038/onc.2009.454			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20023704				2022-12-28	WOS:000275694700013
J	Brown, JAL; Bourke, E; Liptrot, C; Dockery, P; Morrison, CG				Brown, J. A. L.; Bourke, E.; Liptrot, C.; Dockery, P.; Morrison, C. G.			MCPH1/BRIT1 limits ionizing radiation-induced centrosome amplification	ONCOGENE			English	Article						Mcph1/Brit1; centrosome; DNA damage response; checkpoint; ionizing radiation	DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; CHROMOSOME CONDENSATION; MITOTIC ENTRY; MICROCEPHALIN; PROTEIN; CANCER; ACTIVATION; CHECKPOINT	Microcephalin (MCPH1/BRIT1) is a potential tumour suppressor that localizes to the centrosome, forms ionizing radiation-induced nuclear foci (IRIF) and is involved in the DNA damage checkpoints that ensure genome stability. Here, we report the impact of Mcph1 disruption in the hyper-recombinogenic DT40 cell line. Mcph1(-/-) cells were viable and proliferated at the same rate as wildtype controls. Mcph1-deficient cells had intact G2-to-M checkpoint responses after ionizing radiation (IR) treatment, but showed moderate radiosensitivity. Light and electron microscopy indicated normal centrosome structures in Mcph1 null cells, but IR induced massive amplification of centrosome numbers in the absence of Mcph1. Mcph1 null cells formed gamma-H2AX and Rad51 IRIF, but resolved them more slowly than wild-type cells. Mcph1 deficiency caused sustained Chk1 phosphorylation after IR, dysregulating Cdk2 activity. These findings show that Mcph1 controls centrosome numbers after DNA damage, which may indicate a novel tumour suppressive mechanism for microcephalin. Oncogene (2010) 29, 5537-5544; doi:10.1038/onc.2010.302; published online 26 July 2010	[Brown, J. A. L.; Bourke, E.; Morrison, C. G.] Natl Univ Ireland Galway, Sch Nat Sci, Ctr Chromosome Biol, Galway, Ireland; [Liptrot, C.; Dockery, P.] Natl Univ Ireland Galway, Sch Med, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Sch Nat Sci, Ctr Chromosome Biol, Univ Rd, Galway, Ireland.	Ciaran.Morrison@nuigalway.ie	Morrison, Ciaran/AAH-2034-2019; Liptrot, Catherine/D-7056-2012; Morrison, Ciaran/B-6568-2008; Brown, James/H-3437-2019	Morrison, Ciaran/0000-0003-2401-7029; Liptrot, Catherine/0000-0003-3882-8084; Morrison, Ciaran/0000-0003-2401-7029; Brown, James/0000-0002-3155-0334; Bourke, Emer/0000-0002-2218-3114; Dockery, Peter/0000-0001-5103-6589	National Biophotonics and Imaging Platform; HEA [PRTLI4]; Health Research Board project [RP/2006/36]; Science Foundation Ireland [08/IN.1/B1029]	National Biophotonics and Imaging Platform; HEA; Health Research Board project; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We thank William Tsang and Brian Dynlacht for the Cep76 antibody, Andrew Jackson and Andrea Robertson for the MCPH1 mutant lymphoblastoid cells, Tiago Dantas for help with the EM and Noel Lowndes for critical reading of the paper. CL was funded by the National Biophotonics and Imaging Platform funded by the HEA under PRTLI4. This work was supported by the Health Research Board project grant RP/2006/36 and Science Foundation Ireland Principal Investigator award 08/IN.1/B1029.	Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brunk K, 2007, J CELL SCI, V120, P3578, DOI 10.1242/jcs.014290; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jeffers LJ, 2008, ONCOGENE, V27, P139, DOI 10.1038/sj.onc.1210595; Liang YL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000826; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; LIPTROT C, 1992, ANIMAL CELL TECHNOLOGY : DEVELOPMENTS, PROCESSES AND PRODUCTS, P653; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Rai R, 2008, CELL CYCLE, V7, P2225, DOI 10.4161/cc.7.14.6303; Rai R, 2006, CANCER CELL, V10, P145, DOI 10.1016/j.ccr.2006.07.002; Rickmyre JL, 2007, J CELL SCI, V120, P3565, DOI 10.1242/jcs.016626; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tibelius A, 2009, J CELL BIOL, V185, P1149, DOI 10.1083/jcb.200810159; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Trimborn M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009242; Tsang WY, 2009, DEV CELL, V16, P649, DOI 10.1016/j.devcel.2009.03.004; Wood JL, 2008, J BIOL CHEM, V283, P29586, DOI 10.1074/jbc.M804080200; Wood JL, 2007, J BIOL CHEM, V282, P35416, DOI 10.1074/jbc.M705245200; Wu XL, 2009, CANCER RES, V69, P5531, DOI 10.1158/0008-5472.CAN-08-4834; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128	34	27	29	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	40					5537	5544		10.1038/onc.2010.302	http://dx.doi.org/10.1038/onc.2010.302			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661222				2022-12-28	WOS:000282945800010
J	Tsang, YH; Lamb, A; Romero-Gallo, J; Huang, B; Ito, K; Peek, RM; Ito, Y; Chen, LF				Tsang, Y. H.; Lamb, A.; Romero-Gallo, J.; Huang, B.; Ito, K.; Peek, R. M., Jr.; Ito, Y.; Chen, L. F.			Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation	ONCOGENE			English	Article						CagA; degradation; H. pylori; RUNX3; ubiquitination	GROWTH-FACTOR; EPITHELIAL-CELLS; BETA-CATENIN; EXPRESSION; CANCER; RISK; METHYLATION; COOPERATION; MECHANISMS; INFECTION	Chronic infection with cagA-positive Helicobacter pylori is the strongest risk factor for the development of gastric adenocarcinoma. The cagA gene product CagA is injected into gastric epithelial cells and disturbs cellular functions by physically interacting with and deregulating a variety of cellular signaling molecules. RUNX3 is a tumor suppressor in many tissues, and it is frequently inactivated in gastric cancer. In this study, we show that H. pylori infection inactivates the gastric tumor suppressor RUNX3 in a CagA-dependent manner. CagA directly associates with RUNX3 through a specific recognition of the PY motif of RUNX3 by a WW domain of CagA. Deletion of the WW domains of CagA or mutation of the PY motif in RUNX3 abolishes the ability of CagA to induce the ubiquitination and degradation of RUNX3, thereby extinguishing its ability to inhibit the transcriptional activation of RUNX3. Our studies identify RUNX3 as a novel cellular target of H. pylori CagA and also reveal a mechanism by which CagA functions as an oncoprotein by blocking the activity of gastric tumor suppressor RUNX3. Oncogene (2010) 29, 5643-5650; doi:10.1038/onc.2010.304; published online 2 August 2010	[Tsang, Y. H.; Lamb, A.; Huang, B.; Chen, L. F.] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; [Tsang, Y. H.; Ito, Y.] Inst Mol & Cell Biol, Proteos, Singapore; [Romero-Gallo, J.; Peek, R. M., Jr.] Vanderbilt Univ, Sch Med, Dept Med & Canc Biol, Div Gastroenterol, Nashville, TN 37212 USA; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 852, Japan	University of Illinois System; University of Illinois Urbana-Champaign; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Vanderbilt University; Nagasaki University	Chen, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem, MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu			UIUC; NIH [DK-085158, DK-58587, CA-77955, CA-116087]; CMB-TG; NATIONAL CANCER INSTITUTE [P01CA116087, R29CA077955, R01CA077955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, R01DK085158, P30DK058404] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CMB-TG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Hatakeyama (University of Tokyo, Japan) for providing the expression vector for CagA-HA and CagA-PRHA. This work is supported in part by ICR provided by UIUC and NIH Grants DK-085158 (to LFC) and DK-58587, CA-77955 and CA-116087 (to RMP). AL is a recipient of the CMB-TG. YHT is an A*STAR-Illinois Partnership fellow.	BLASER MJ, 1995, CANCER RES, V55, P2111; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2008, CURR OPIN MICROBIOL, V11, P30, DOI 10.1016/j.mib.2007.12.003; Hatakeyama M, 2009, J GASTROENTEROL, V44, P239, DOI 10.1007/s00535-009-0014-1; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hsu PI, 2009, ANN SURG ONCOL, V16, P1686, DOI 10.1245/s10434-009-0428-2; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Katayama Y, 2009, BIOCHEM BIOPH RES CO, V388, P496, DOI 10.1016/j.bbrc.2009.08.003; Kitajima Y, 2008, ONCOL REP, V19, P197; Lamb A, 2009, EMBO REP, V10, P1242, DOI 10.1038/embor.2009.210; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek Richard M Jr, 2005, Sci STKE, V2005, ppe14; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sugiura H, 2008, ONCOL REP, V19, P713; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	32	72	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5643	5650		10.1038/onc.2010.304	http://dx.doi.org/10.1038/onc.2010.304			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676134	Green Accepted			2022-12-28	WOS:000282946900010
J	Rzymski, T; Milani, M; Pike, L; Buffa, F; Mellor, HR; Winchester, L; Pires, I; Hammond, E; Ragoussis, I; Harris, AL				Rzymski, T.; Milani, M.; Pike, L.; Buffa, F.; Mellor, H. R.; Winchester, L.; Pires, I.; Hammond, E.; Ragoussis, I.; Harris, A. L.			Regulation of autophagy by ATF4 in response to severe hypoxia	ONCOGENE			English	Article						autophagy; UPR; cancer; hypoxia; anoxia; tumour	CELL-SURVIVAL; TRANSLATIONAL REGULATION; MOLECULAR-CLONING; PHOSPHORYLATION; RESISTANCE; DEATH; PERK; STABILIZATION; LYSOSOMES; INDUCTION	Activating transcription factor 4 (ATF4) is a transcription factor induced under severe hypoxia and a component of the PERK pathway involved in the unfolded protein response (UPR), a process that protects cells from the negative consequences of endoplasmic reticulum (ER) stress. In this study, we have used small interfering RNA (siRNA) and microarray analysis to provide the first whole-genome analysis of genes regulated by ATF4 in cancer cells in response to severe and prolonged hypoxic stress. We show that ATF4 is required for ER stress and hypoxia-induced expansion of autophagy. MAP1LC3B (LC3B) is a key component of the autophagosomal membrane, and in this study we demonstrate that ATF4 facilitates autophagy through direct binding to a cyclic AMP response element binding site in the LC3B promoter, resulting in LC3B upregulation. Previously, we have shown that Bortezomib-induced ATF4 stabilization, which then upregulated LC3B expression and had a critical role in activating autophagy, protecting cells from Bortezomib-induced cell death. We also showed that severe hypoxia stabilizes ATF4. In this study, we demonstrate that severe hypoxia leads to ER stress and induces ATF4-dependent autophagy through LC3 as a survival mechanism. In summary, we show that ATF4 has a key role in the regulation of autophagy in response to ER stress and provide a direct mechanistic link between the UPR and the autophagic machinery. Oncogene (2010) 29, 4424-4435; doi: 10.1038/onc.2010.191; published online 31 May 2010	[Rzymski, T.; Milani, M.; Pike, L.; Buffa, F.; Mellor, H. R.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Growth Factor Grp,Mol Oncol Labs, Canc Res UK,Weatherall Inst Mol Med, Oxford OX3 9DU, England; [Winchester, L.; Ragoussis, I.] Wellcome Trust Ctr Human Genet, Genom Lab, Oxford, England; [Pires, I.; Hammond, E.] Univ Oxford, Canc Res UK, MRC Gray Inst Radiat Oncol & Biol, Churchill Hosp, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Growth Factor Grp,Mol Oncol Labs, Canc Res UK,Weatherall Inst Mol Med, Oxford OX3 9DU, England.	aharris.lab@imm.ox.ac.uk	Ragoussis, Ioannis/AAD-9790-2022; Buffa, Francesca/D-2574-2013; Harris, Adrian L/ABA-3343-2020	Buffa, Francesca/0000-0003-0409-406X; Harris, Adrian L/0000-0003-1376-8409; Hammond, Ester/0000-0002-2335-3146; Ragoussis, Ioannis/0000-0002-8515-0934; Pires, Isabel/0000-0002-0417-2710				Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mujcic H, 2009, RADIOTHER ONCOL, V92, P450, DOI 10.1016/j.radonc.2009.08.017; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Olive PL, 2002, RADIAT RES, V158, P159, DOI 10.1667/0033-7587(2002)158[0159:TROOIS]2.0.CO;2; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rzymski T, 2008, ONCOGENE, V27, P4532, DOI 10.1038/onc.2008.100; Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2008, AUTOPHAGY, V4, P534, DOI 10.4161/auto.5956; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Wenger RH, 1996, NATURE, V380, P100, DOI 10.1038/380100d0; Wouters BG, 1997, RADIAT RES, V147, P541, DOI 10.2307/3579620; Wu JX, 2006, BIOCHEM BIOPH RES CO, V339, P437, DOI 10.1016/j.bbrc.2005.10.211; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200	41	261	265	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4424	4435		10.1038/onc.2010.191	http://dx.doi.org/10.1038/onc.2010.191			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514020				2022-12-28	WOS:000280559100006
J	Bower, JJ; Karaca, GF; Zhou, Y; Simpson, DA; Cordeiro-Stone, M; Kaufmann, WK				Bower, J. J.; Karaca, G. F.; Zhou, Y.; Simpson, D. A.; Cordeiro-Stone, M.; Kaufmann, W. K.			Topoisomerase II alpha maintains genomic stability through decatenation G(2) checkpoint signaling	ONCOGENE			English	Article						decatenation; G(2) checkpoint; topoisomerase II alpha; topoisomerase II beta; chromosomal instability	CELL-CYCLE; DNA TOPOISOMERASES; BREAST-CANCER; CHROMOSOME SEGREGATION; IONIZING-RADIATION; GENE-EXPRESSION; BETA; POISONS; ROLES; BISDIOXOPIPERAZINES	Topoisomerase II alpha (topoII alpha) is an essential mammalian enzyme that topologically modifies DNA and is required for chromosome segregation during mitosis. Previous research suggests that inhibition of topoII decatenatory activity triggers a G(2) checkpoint response, which delays mitotic entry because of insufficient decatenation of daughter chromatids. Here we examine the effects of both topoII alpha and topoII beta on decatenatory activity in cell extracts, DNA damage and decatenation G(2) checkpoint function, and the frequencies of p16(INK4A) allele loss and gain. In diploid human fibroblast lines, depletion of topoII alpha by small-interfering RNA was associated with severely reduced decatenatory activity, delayed progression from G(2) into mitosis and insensitivity to G(2) arrest induced by the topoII catalytic inhibitor ICRF-193. Furthermore, interphase nuclei of topoII alpha-depleted cells showed increased frequencies of losses and gains of the tumor suppressor genetic locus p16(INK4A). This study shows that the topoII alpha protein is required for decatenation G(2) checkpoint function, and inactivation of decatenation and the decatenation G(2) checkpoint leads to abnormal chromosome segregation and genomic instability. Oncogene (2010) 29, 4787-4799; doi:10.1038/onc.2010.232; published online 21 June 2010	[Bower, J. J.; Karaca, G. F.; Zhou, Y.; Simpson, D. A.; Cordeiro-Stone, M.; Kaufmann, W. K.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Bower, J. J.; Cordeiro-Stone, M.; Kaufmann, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Cordeiro-Stone, M.; Kaufmann, W. K.] Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kaufmann, WK (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Rm 31-345 Lineberger Comprehens Canc Ctr,CB 7295, Chapel Hill, NC 27599 USA.	bill_kaufmann@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022; Ariel, Pablo/AGJ-4118-2022		NIH-NCI Ruth L. Kirschstein National Research Service [1F32CA134155-01]; PHS [CA81343, P30-ES10126]; NATIONAL CANCER INSTITUTE [R01CA081343, F32CA134155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	NIH-NCI Ruth L. Kirschstein National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Financial Support: This work was supported by an NIH-NCI Ruth L. Kirschstein National Research Service Award Grant # 1F32CA134155-01 (JJ Bower) and PHS grants CA81343 and P30-ES10126 (WK Kaufmann).	Akimitsu N, 2003, GENES CELLS, V8, P393, DOI 10.1046/j.1365-2443.2003.00643.x; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Bandele OJ, 2008, CHEM RES TOXICOL, V21, P936, DOI 10.1021/tx700434v; Bandele OJ, 2007, BIOCHEMISTRY-US, V46, P6097, DOI 10.1021/bi7000664; Baxter J, 2008, MOL CELL, V30, P790, DOI 10.1016/j.molcel.2008.04.019; Beser AR, 2007, PATHOL ONCOL RES, V13, P180, DOI 10.1007/BF02893497; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Bower JJ, 2010, CELL CYCLE, V9, P1617, DOI 10.4161/cc.9.8.11470; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; Carpenter AJ, 2004, MOL BIOL CELL, V15, P5700, DOI 10.1091/mbc.E04-08-0732; Coelho PA, 2008, PLOS BIOL, V6, P1758, DOI 10.1371/journal.pbio.0060207; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; Damelin M, 2005, CANCER CELL, V8, P479, DOI 10.1016/j.ccr.2005.11.004; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; Deming PB, 2002, J BIOL CHEM, V277, P36832, DOI 10.1074/jbc.M206109200; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; Doherty SC, 2003, J NATL CANCER I, V95, P1859, DOI 10.1093/jnci/djg120; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Emmons M, 2006, BIOCHEM PHARMACOL, V72, P11, DOI 10.1016/j.bcp.2006.03.017; Franchitto A, 2003, CANCER RES, V63, P3289; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Gromova I, 1998, BIOCHEMISTRY-US, V37, P16645, DOI 10.1021/bi981391l; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Jarvinen TAH, 1996, AM J PATHOL, V148, P2073; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Johnson M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp480; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Larsen A K, 1996, Prog Cell Cycle Res, V2, P229; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Lorusso V, 2007, ANN ONCOL, V18, P70, DOI 10.1093/annonc/mdm229; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Lyu YL, 2007, CANCER RES, V67, P8839, DOI 10.1158/0008-5472.CAN-07-1649; Maeshima K, 2005, CHROMOSOMA, V114, P365, DOI 10.1007/s00412-005-0023-7; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Nakagawa T, 2004, CANCER RES, V64, P4826, DOI 10.1158/0008-5472.CAN-04-0871; Park I, 2006, EXP CELL RES, V312, P1996, DOI 10.1016/j.yexcr.2006.02.029; Robinson HMR, 2007, CELL CYCLE, V6, P1265, DOI 10.4161/cc.6.10.4225; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Sehested M, 1996, BIOCHEM PHARMACOL, V51, P879, DOI 10.1016/0006-2952(95)02241-4; Simpson Dennis A, 2005, J Carcinog, V4, P18, DOI 10.1186/1477-3163-4-18; van Doorn-Khosrovani SBV, 2007, CARCINOGENESIS, V28, P1703, DOI 10.1093/carcin/bgm102; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang LHC, 2008, CHROMOSOMA, V117, P123, DOI 10.1007/s00412-007-0131-7; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100; Zhou T, 2006, ENVIRON HEALTH PERSP, V114, P553, DOI 10.1289/ehp.8026	51	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4787	4799		10.1038/onc.2010.232	http://dx.doi.org/10.1038/onc.2010.232			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562910	Green Submitted, Green Accepted			2022-12-28	WOS:000281326400005
J	Xu, Y; Yan, W; Chen, X				Xu, Y.; Yan, W.; Chen, X.			SNF5, a core component of the SWI/SNF complex, is necessary for p53 expression and cell survival, in part through eIF4E	ONCOGENE			English	Article						p53; SNF5; chromatin remodeling; Mdm2; eIF4E; AMPK	CHROMATIN REMODELING COMPLEXES; MALIGNANT RHABDOID TUMORS; DNA-DAMAGE; CYCLE PROGRESSION; SUPPRESSOR; CANCER; MUTATIONS; FAMILY; TRANSCRIPTION; CHECKPOINT	SNF5, a core component of the SWI/SNF chromatin remodeling complex, is expressed as two isoforms, SNF5a and SNF5b. SNF5 is a tumor suppressor, as mutation of SNF5 leads to tumor formation and cooperates with p53 deficiency to enhance cancer susceptibility. Interestingly, lack of SNF5 inhibits cell survival and embryonic development, potentially through abnormal activation of p53. To further examine this, we generated cell lines in which SNF5a, SNF5b or both can be inducibly knocked down. We found that SNF5 knockdown leads to cell-cycle arrest in G1, and SNF5a and SNF5b are functionally redundant. We also showed that SNF5 knockdown impairs p53-dependent transcription of p21 and murine double minute 2. However, contrary to earlier reports that p53 is activated by SNF5 knockout in murine cells, SNF5 knockdown leads to decreased, but not increased, expression of both basal and stress-induced p53 in multiple human cell lines. In addition, we showed that SNF5 knockdown induces adenosine monophosphate-activated protein kinase activation and inhibits eIF4E expression. Finally, we showed that SNF5 knockdown inhibits p53 translation by eIF4E and replacement of eIF4E in SNF5 knockdown cells restores p53 expression and cell survival. Together, our study results suggest that the p53 pathway is regulated by, and mediates the activity of, SNF5 in tumor suppression and prosurvival. Oncogene (2010) 29, 4090-4100; doi:10.1038/onc.2010.159; published online 17 May 2010	[Xu, Y.; Yan, W.; Chen, X.] Univ Calif Davis, Ctr Comparat Oncol, VM Surg & Radiol Sci, Davis, CA 95616 USA; [Xu, Y.] Zhejiang Univ, Dept Hematol, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China	University of California System; University of California Davis; Zhejiang University	Chen, X (corresponding author), Univ Calif Davis, Ctr Comparat Oncol, VM Surg & Radiol Sci, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NIH [CA081237, CA076069, CA102188]; NATIONAL CANCER INSTITUTE [R01CA102188, R29CA076069, R01CA081237, R01CA121137, R01CA076069] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH Grants CA081237, CA076069 and CA102188.	Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Chai JJ, 2007, CANCER RES, V67, P3002, DOI 10.1158/0008-5472.CAN-06-4207; CHEN XB, 1995, CANCER RES, V55, P4257; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2004, J BIOL CHEM, V279, P4180, DOI 10.1074/jbc.M312043200; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Peters Charles R., 1996, Kaupia Darmstaedter Beitraege zur Naturgeschichte, V6, P175; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Scoumanne A, 2008, HISTOL HISTOPATHOL, V23, P1143, DOI 10.14670/HH-23.1143; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	41	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4090	4100		10.1038/onc.2010.159	http://dx.doi.org/10.1038/onc.2010.159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473326	Green Accepted			2022-12-28	WOS:000279892400009
J	Kim, M; Williamson, CT; Prudhomme, J; Bebb, DG; Riabowol, K; Lee, PWK; Lees-Miller, SP; Mori, Y; Rahman, MM; McFadden, G; Johnston, RN				Kim, M.; Williamson, C. T.; Prudhomme, J.; Bebb, D. G.; Riabowol, K.; Lee, P. W. K.; Lees-Miller, S. P.; Mori, Y.; Rahman, M. M.; McFadden, G.; Johnston, R. N.			The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status	ONCOGENE			English	Article						reovirus; myxoma virus; tumor suppressor; oncolytic virus; anticancer therapy	ACTIVATED RAS PATHWAY; SIGNALING PATHWAY; CANCER-THERAPY; PHASE-I; CELLS; P53; INFECTION; INTERFERON; REPLICATION; VIROTHERAPY	Replication-competent oncolytic viruses hold great potential for the clinical treatment of many cancers. Importantly, many oncolytic virus candidates, such as reovirus and myxoma virus, preferentially infect cancer cells bearing abnormal cellular signaling pathways. Reovirus and myxoma virus are highly responsive to activated Ras and Akt signaling pathways, respectively, for their specificity for viral oncolysis. However, considering the complexity of cancer cell populations, it is possible that other tumor-specific signaling pathways may also contribute to viral discrimination between normal versus cancer cells. Because carcinogenesis is a multistep process involving the accumulation of both oncogene activations and the inactivation of tumor suppressor genes, we speculated that not only oncogenes but also tumor suppressor genes may have an important role in determining the tropism of these viruses for cancer cells. It has been previously shown that many cellular tumor suppressor genes, such as p53, ATM and Rb, are important for maintaining genomic stability; dysfunction of these tumor suppressors may disrupt intact cellular antiviral activity due to the accumulation of genomic instability or due to interference with apoptotic signaling. Therefore, we speculated that cells with dysfunctional tumor suppressors may display enhanced susceptibility to challenge with these oncolytic viruses, as previously seen with adenovirus. We report here that both reovirus and myxoma virus preferentially infect cancer cells bearing dysfunctional or deleted p53, ATM and Rb tumor suppressor genes compared to cells retaining normal counterparts of these genes. Thus, oncolysis by these viruses may be influenced by both oncogenic activation and tumor suppressor status. Oncogene (2010) 29, 3990-3996; doi:10.1038/onc.2010.137; published online 17 May 2010	[Kim, M.; Williamson, C. T.; Prudhomme, J.; Riabowol, K.; Lees-Miller, S. P.; Mori, Y.; Johnston, R. N.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; [Kim, M.; Rahman, M. M.; McFadden, G.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Bebb, D. G.] Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; [Lee, P. W. K.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	University of Calgary; State University System of Florida; University of Florida; University of Calgary; Dalhousie University	Johnston, RN (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Room HMRB 307,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rnjohnst@ucalgary.ca	Johnston, Randal/B-9247-2009	Lees-Miller, Susan/0000-0001-5809-2516; McFadden, Grant/0000-0002-2556-3526	Canadian Institutes of Health Research; Canadian Breast Cancer Foundation; University of Florida College of Medicine; NIH [R01 CA138541]; NATIONAL CANCER INSTITUTE [R01CA138541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080607] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); University of Florida College of Medicine(University of Florida); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by funding from the Canadian Institutes of Health Research and the Canadian Breast Cancer Foundation (to RNJ) and a start-up grant from the University of Florida College of Medicine and NIH grant R01 CA138541 (to GM). GM is an International Scholar of the Howard Hughes Medical Institute.	Abou El Hassan MAI, 2004, J VIROL, V78, P12243, DOI 10.1128/JVI.78.22.12243-12251.2004; Alain T, 2002, BLOOD, V100, P4146, DOI 10.1182/blood-2002-02-0503; Bea S, 2009, BLOOD, V113, P3059, DOI 10.1182/blood-2008-07-170183; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Duursma AM, 2003, SEMIN CANCER BIOL, V13, P267, DOI 10.1016/S1044-579X(03)00040-3; Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Huang S, 2004, CELL CYCLE, V3, P1043; Johnston JB, 2003, J VIROL, V77, P5877, DOI 10.1128/JVI.77.10.5877-5888.2003; Kim M, 2007, ONCOGENE, V26, P4124, DOI 10.1038/sj.onc.1210189; Kim M, 2009, LEUKEMIA, V23, P2313, DOI 10.1038/leu.2009.219; KIM M, 2007, AM SOC VIR ASV 2007; Kitagawa R, 2005, COLD SH Q B, V70, P99, DOI 10.1101/sqb.2005.70.002; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Lun XQ, 2005, CANCER RES, V65, P9982, DOI 10.1158/0008-5472.CAN-05-1201; Lun XQ, 2007, CANCER RES, V67, P8818, DOI 10.1158/0008-5472.CAN-07-1214; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; McFadden G, 2005, NAT REV MICROBIOL, V3, P201, DOI 10.1038/nrmicro1099; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Munoz-Fontela C, 2008, J EXP MED, V205, P1929, DOI 10.1084/jem.20080383; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; Royds JA, 2006, ONCOGENE, V25, P1509, DOI 10.1038/sj.onc.1209185; Shmulevitz M, 2010, CANCER GENE THER, V17, P69, DOI 10.1038/cgt.2009.46; Song L, 2009, CANCER GENE THER, V16, P382, DOI 10.1038/cgt.2008.84; Stanford MM, 2008, MOL THER, V16, P52, DOI 10.1038/sj.mt.6300348; Stanford MM, 2007, EXPERT OPIN BIOL TH, V7, P1415, DOI 10.1517/14712598.7.9.1415; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; STRONG JE, 1993, VIROLOGY, V197, P405, DOI 10.1006/viro.1993.1602; Sypula J., 2004, GENE THER MOL BIOL, V8, P103; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tucker CA, 2006, LEUKEMIA RES, V30, P449, DOI 10.1016/j.leukres.2005.08.016; Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524; Wang F, 2009, J VIROL, V83, P5928, DOI 10.1128/JVI.02587-08; Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0	44	45	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3990	3996		10.1038/onc.2010.137	http://dx.doi.org/10.1038/onc.2010.137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20473328	Green Accepted			2022-12-28	WOS:000279603200011
J	Leone, V; Mansueto, G; Pierantoni, GM; Tornincasa, M; Merolla, F; Cerrato, A; Santoro, M; Grieco, M; Scaloni, A; Celetti, A; Fusco, A				Leone, V.; Mansueto, G.; Pierantoni, G. M.; Tornincasa, M.; Merolla, F.; Cerrato, A.; Santoro, M.; Grieco, M.; Scaloni, A.; Celetti, A.; Fusco, A.			CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1	ONCOGENE			English	Article						CREB1; CCDC6; HDAC1; RET/PTC1; papillary thyroid carcinomas	PAPILLARY THYROID-CARCINOMA; FACTOR RECEPTOR-BETA; GROWTH-FACTOR; GENE-TRANSCRIPTION; TRANSGENIC MICE; CELL-LINE; EXPRESSION; RET; REARRANGEMENTS; H4(D10S170)	RET/papillary thyroid carcinoma 1 (PTC1) oncogene is frequently activated in human PTCs. It is characterized by the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of CCDC6. The aim of our work is to characterize the function of the CCDC6 protein to better understand the function of its truncation, that results in the loss of the expression of one allele, in the process of thyroid carcinogenesis. Here, we report that CCDC6 interacts with CREB1 and represses its transcriptional activity by recruiting histone deacetylase 1 and protein phosphatase 1 proteins at the CRE site of the CREB1 target genes. Finally, we show an increased CREB1 phosphorylation and activity in PTCs carrying the RET/PTC1 oncogene. Consistently, an increased expression of two known CREB1 target genes, AREG and cyclin A, was observed in this subgroup of thyroid papillary carcinomas. Therefore, the repression of CREB1 activity by CCDC6 has a critical function in the development of human thyroid papillary carcinomas carrying RET/PTC1 activation. Oncogene (2010) 29, 4341-4351; doi:10.1038/onc.2010.179; published online 24 May 2010	[Fusco, A.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, Fac Med & Chirurg Napoli,CNR, I-80131 Naples, Italy; [Leone, V.; Mansueto, G.; Fusco, A.] Biotechnol Avanzate Napoli, NOGEC, CEINGE, Naples, Italy; [Leone, V.; Mansueto, G.; Fusco, A.] European Sch Mol Med, SEMM, Naples, Italy; [Scaloni, A.] CNR, Prote & Mass Spectrometry Lab, ISPAAM, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Fusco, A (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, Fac Med & Chirurg Napoli,CNR, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Celetti, Angela/AAY-7172-2020; Mansueto, Gelsomina/AAD-6317-2021; Pierantoni, Giovanna Maria/O-7527-2015; Cerrato, Aniello/AAY-1484-2020	Mansueto, Gelsomina/0000-0002-0544-5100; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197; Scaloni, Andrea/0000-0001-9362-8515	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [CCPKRP_002]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC) and from the Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) (MERIT and PRIN 2008 CCPKRP_002). We are grateful to Konstantina Vergadou (Scientific Communication) for editing the text and Mario Berardone for artwork.	Bennett D, 2005, BIOCHEM SOC T, V33, P1444, DOI 10.1042/BST0331444; Berasain C, 2007, CANCER LETT, V254, P30, DOI 10.1016/j.canlet.2007.01.015; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; De Angelis R, 2003, FEBS LETT, V547, P15, DOI 10.1016/S0014-5793(03)00659-8; De Martino I, 2009, CANCER RES, V69, P1844, DOI 10.1158/0008-5472.CAN-08-4133; Dettori T, 2004, CANCER GENET CYTOGEN, V151, P171, DOI 10.1016/j.cancergencyto.2003.09.023; Drechsler M, 2007, ANN HEMATOL, V86, P353, DOI 10.1007/s00277-006-0247-5; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Gao JX, 2009, BIOCHEM BIOPH RES CO, V379, P1, DOI 10.1016/j.bbrc.2008.11.135; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Han YB, 2007, ARCH ANDROLOGY, V53, P169, DOI 10.1080/01485010701314032; Hu XD, 2006, J NEUROCHEM, V98, P1841, DOI 10.1111/j.1471-4159.2006.04070.x; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kulkarni S, 2000, CANCER RES, V60, P3592; Luciani P, 2003, EUR J ENDOCRINOL, V148, P579, DOI 10.1530/eje.0.1480579; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Merolla F, 2007, ONCOGENE, V26, P6167, DOI 10.1038/sj.onc.1210446; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839; Pierantoni GM, 2007, PROTEOMICS, V7, P3735, DOI 10.1002/pmic.200700148; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Puxeddu E, 2005, MUTAT RES-FUND MOL M, V570, P17, DOI 10.1016/j.mrfmmm.2004.09.010; SANTISTEBAN DA, 1994, J CHILD ADOLES SUBST, V3, P9, DOI 10.1300/J029v03n02_02; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro M, 2006, EUR J ENDOCRINOL, V155, P645, DOI 10.1530/eje.1.02289; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Talamo F, 2003, PROTEOMICS, V3, P440, DOI 10.1002/pmic.200390059; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Trinkle-Mulcahy L, 2006, CURR OPIN CELL BIOL, V18, P623, DOI 10.1016/j.ceb.2006.09.001; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wang BJ, 2008, SCI CHINA SER C, V51, P487, DOI 10.1007/s11427-008-0068-y	40	29	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4341	4351		10.1038/onc.2010.179	http://dx.doi.org/10.1038/onc.2010.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498639				2022-12-28	WOS:000280547900010
J	Greenhough, A; Wallam, CA; Hicks, DJ; Moorghen, M; Williams, AC; Paraskeva, C				Greenhough, A.; Wallam, C. A.; Hicks, D. J.; Moorghen, M.; Williams, A. C.; Paraskeva, C.			The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells	ONCOGENE			English	Article						Bim; COX-2; ERK; colorectal cancer; apoptosis; PGE2	CARCINOMA CELLS; BAX ACTIVATION; KEY ROLES; IN-VITRO; BCL-X; APOPTOSIS; PROMOTES; GROWTH; EXPRESSION; SURVIVAL	Overexpression of cyclooxygenase-2 (COX-2) and elevated levels of its enzymatic product prostaglandin E2 (PGE(2)) occur in the majority of colorectal cancers and have important roles in colorectal tumorigenesis. However, despite the established prosurvival role of PGE(2) in cancer, the underlying mechanisms are not fully understood. Here, we have shown that PGE(2) suppresses apoptosis via repression of the proapoptotic BH3-only protein Bim in human colorectal adenoma cells. Repression of Bim expression was dependent upon PGE(2)-mediated activation of the Raf-MEK-ERK1/2 pathway, which promoted Bim phosphorylation and proteasomal degradation. Reduction of Bim expression using RNA interference reduced spontaneous apoptosis in adenoma cells and abrogated PGE(2)-dependent apoptosis suppression. Treatment of COX-2-expressing colorectal carcinoma cells with COX-2-selective NSAIDs-induced Bim expression, suggesting that Bim repression via PGE(2) signalling may be opposed by COX-2 inhibition. Examination of Bim expression in two established in vitro models of the adenoma-carcinoma sequence revealed that downregulation of Bim expression was associated with tumour progression towards an anchorage-independent phenotype. Finally, immunohistochemical analyses revealed that Bim expression is markedly reduced in approximately 40% of human colorectal carcinomas in vivo. These observations highlight the COX-2/PGE(2) pathway as an important negative regulator of Bim expression in colorectal tumours and suggest that Bim repression may be an important step during colorectal cancer tumorigenesis. Oncogene (2010) 29, 3398-3410; doi:10.1038/onc.2010.94; published online 29 March 2010	[Greenhough, A.; Wallam, C. A.; Hicks, D. J.; Williams, A. C.; Paraskeva, C.] Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Canc Res UK Colorectal Tumour Biol Grp, Bristol BS8 1TD, Avon, England; [Moorghen, M.] Bristol Royal Infirm & Gen Hosp, Dept Clin Pathol, Bristol, Avon, England	University of Bristol; Bristol Royal Infirmary	Greenhough, A (corresponding author), Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Canc Res UK Colorectal Tumour Biol Grp, Bristol BS8 1TD, Avon, England.	a.greenhough@bristol.ac.uk	Greenhough, Alexander/Y-6728-2019; Greenhough, Alexander/J-9308-2012	Greenhough, Alexander/0000-0002-8306-811X; Greenhough, Alexander/0000-0002-8306-811X; Williams, Ann/0000-0002-6009-7137	Citrina Foundation; John James Bristol Foundation; Cancer Research UK programme	Citrina Foundation; John James Bristol Foundation; Cancer Research UK programme(Cancer Research UK)	We thank Debbie Martin and Gini Tilly for help with histology; David Huang for provision of Bim wild-type and null iMEF cells; Andy Silver and Nirosha Suraweera for sequencing analysis; Andy Herman for help with flow cytometry, and members of the CP group for useful discussion. This work was funded by the Citrina Foundation, the John James Bristol Foundation, and by a Cancer Research UK programme grant.	Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; BEDI A, 1995, CANCER RES, V55, P1811; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cartlidge RA, 2008, PIGM CELL MELANOMA R, V21, P534, DOI 10.1111/j.1755-148X.2008.00491.x; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chell SD, 2006, CANCER RES, V66, P3106, DOI 10.1158/0008-5472.CAN-05-3702; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clemo NK, 2008, CARCINOGENESIS, V29, P849, DOI 10.1093/carcin/bgn004; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Crew TE, 2000, CARCINOGENESIS, V21, P69, DOI 10.1093/carcin/21.1.69; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Elder DJE, 2002, J PATHOL, V198, P428, DOI 10.1002/path.1232; Elder DJE, 1998, NAT MED, V4, P392, DOI 10.1038/nm0498-392; Elder DJE, 1996, CANCER RES, V56, P2273; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gallenne T, 2009, J CELL BIOL, V185, P279, DOI 10.1083/jcb.200809153; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Greenhough A, 2007, INT J CANCER, V121, P2172, DOI 10.1002/ijc.22917; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL PA, 1994, J CELL SCI, V107, P3569; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hawcroft G, 2007, ONCOGENE, V26, P3006, DOI 10.1038/sj.onc.1210113; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Krajewska M, 1996, CANCER RES, V56, P2422; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Loveridge CJ, 2008, ONCOGENE, V27, P2648, DOI 10.1038/sj.onc.1210891; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; PARASKEVA C, 1989, CANCER RES, V49, P1282; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rice PL, 2004, CANCER RES, V64, P8148, DOI 10.1158/0008-5472.CAN-04-1517; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Wickenden JA, 2008, ONCOGENE, V27, P7150, DOI 10.1038/onc.2008.335; Williams AC, 2007, CELL DEATH DIFFER, V14, P137, DOI 10.1038/sj.cdd.4401919; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Yang F, 2009, J VIB CONTROL, V15, P233, DOI 10.1177/1077546308091220; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	74	35	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3398	3410		10.1038/onc.2010.94	http://dx.doi.org/10.1038/onc.2010.94			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20348947	Green Accepted			2022-12-28	WOS:000278622700008
J	Liu, ZB; Hou, YF; Zhu, J; Hu, DL; Jin, W; Ou, ZL; Di, GH; Wu, J; Shen, ZZ; Shao, ZM				Liu, Z-B; Hou, Y-F; Zhu, J.; Hu, D-L; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M			Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner	ONCOGENE			English	Article						PA-MSHA vaccine; breast tumor; EGFR; mannose; sugar binding	UROPATHOGENIC ESCHERICHIA-COLI; GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELLS; IN-VITRO; CARBOHYDRATE INTERACTIONS; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; ADHERENCE	To identify more therapeutic targets and clarify the detailed mechanisms of Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) on breast cancer cells both in vitro and in vivo. PA-MSHA was administered to epidermal growth factor receptor (EGFR)positive human breast cancer cell lines MDA-MB-231HM and MDA-MB-468 in vitro and to mice bearing tumor xenografts. The mannose cocultured test was used to detect the effect of mannose on PA-MSHA-induced cell proliferation, cell cycle arrest, apoptosis, and EGFR pathway signaling. We found that cells stimulated with PA-MSHA exhibited a downregulation of EGFR signaling. The addition of mannose partially inhibited the PA-MSHA-stimulated cell anti-proliferative effect, cell apoptosis, cell cycle arrest, activation of apoptosis-associated caspases, and even downregulation of the EGFR signaling pathway. In vivo, PA-MSHA treatment significantly suppressed mammary tumorigenesis in xenografts in mice and decreased lung metastasis in MDA-MB-231HM cell-transplanted mice. Tumor sample analyses confirmed inhibition of the EGFR pathway in the PA-MSHA-treated mice. In conclusion, this study showed that the involvement of the mannose-mediated EGFR pathway has a critical function in the preclinical rationale for the development of PA-MSHA for the treatment of human breast cancer. It also suggests the potentially beneficial use of PA-MSHA in adjuvant therapy for breast tumors with EGFR overexpression. Oncogene (2010) 29, 2996-3009; doi:10.1038/onc.2010.70; published online 15 March 2010	[Liu, Z-B; Hou, Y-F; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M] Fudan Univ, Dept Breast Surg, Breast Canc Inst, Canc Hosp, Shanghai 200032, Peoples R China; [Liu, Z-B; Hou, Y-F; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Liu, Z-B; Hou, Y-F; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Zhu, J.; Hu, D-L] Shanghai Homejoy Pharmaceut Co Ltd, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University	Shao, ZM (corresponding author), Fudan Univ, Dept Breast Surg, Breast Canc Inst, Canc Hosp, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com		Di, Genhong/0000-0003-1171-7907	Fudan University [EHF159201]; National Basic Research Program of China [2006CB910501]; National Natural Science Foundation of China [30371580, 30572109]; Shanghai Science and Technology Committee [06DJ14004, 06DZ19504, 08ZR1403500]	Fudan University; National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	We are grateful to Professor Xi-Liang Zha for providing technical assistance. This work was supported in part by the Key Discipline Innovation Personnel Training Program of Fudan University (Contract grant number: EHF159201), National Basic Research Program of China (Contract grant number: 2006CB910501), the National Natural Science Foundation of China (Contract grant numbers: 30371580 and 30572109), and the Shanghai Science and Technology Committee (Contract grant numbers: 06DJ14004, 06DZ19504, and 08ZR1403500).	Capdevila J, 2009, CANCER TREAT REV, V35, P354, DOI 10.1016/j.ctrv.2009.02.001; DUGUID JAMES P., 1968, ARCH IMMUNOL THER EXP, V16, P173; Duncan MJ, 2005, J BIOL CHEM, V280, P37707, DOI 10.1074/jbc.M501249200; ESHDAT Y, 1984, BIOL CELL, V51, P259, DOI 10.1111/j.1768-322X.1984.tb00307.x; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; HARPER M, 1978, J MED MICROBIOL, V11, P117, DOI 10.1099/00222615-11-2-117; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598; Johns TG, 2005, FASEB J, V19, P780, DOI 10.1096/fj.04-1766fje; Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932; Karlsson KA, 2001, ADV EXP MED BIOL, V491, P431; Kawashima N, 2009, J BIOL CHEM, V284, P6147, DOI 10.1074/jbc.M808171200; King SS, 2000, AM J VET RES, V61, P446, DOI 10.2460/ajvr.2000.61.446; Klumpp DJ, 2006, INFECT IMMUN, V74, P5106, DOI 10.1128/IAI.00376-06; KORHONEN TK, 1980, J BACTERIOL, V144, P800, DOI 10.1128/JB.144.2.800-805.1980; KORHONEN TK, 1981, INFECT IMMUN, V32, P796, DOI 10.1128/IAI.32.2.796-804.1981; Lage A, 2003, ANN MED, V35, P327, DOI 10.1080/07853890310010889; Liu B, 2009, AUTOPHAGY, V5, P432, DOI 10.4161/auto.5.3.7924; Liu B, 2009, AUTOPHAGY, V5, P253, DOI 10.4161/auto.5.2.7561; Liu ZB, 2009, J CELL BIOCHEM, V108, P195, DOI 10.1002/jcb.22241; McEwan NA, 2008, VET DERMATOL, V19, P221, DOI 10.1111/j.1365-3164.2008.00678.x; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; OFEK I, 1978, INFECT IMMUN, V22, P247, DOI 10.1128/IAI.22.1.247-254.1978; Schaerli P, 1998, CELL MOL LIFE SCI, V54, P129, DOI 10.1007/s000180050132; Schilling JD, 2001, J INFECT DIS, V183, pS36, DOI 10.1086/318855; Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; STEPINSKA M, 1995, FEMS IMMUNOL MED MIC, V12, P187, DOI 10.1016/0928-8244(95)00066-6; Wang JS, 2008, MOL CANCER RES, V6, P372, DOI 10.1158/1541-7786.MCR-07-0162; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278	31	28	42	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					2996	3009		10.1038/onc.2010.70	http://dx.doi.org/10.1038/onc.2010.70			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20228837				2022-12-28	WOS:000277890400010
J	Luo, P; Yang, X; Ying, M; Chaudhry, P; Wang, A; Shimada, H; May, WA; Adams, GB; Mock, D; Triche, TJ; He, Q; Wu, L				Luo, P.; Yang, X.; Ying, M.; Chaudhry, P.; Wang, A.; Shimada, H.; May, W. A.; Adams, G. B.; Mock, D.; Triche, T. J.; He, Q.; Wu, L.			Retinoid-suppressed phosphorylation of RAR alpha mediates the differentiation pathway of osteosarcoma cells	ONCOGENE			English	Article						RA response pathways; decreased CAK phosphorylation of RAR alpha; cell-cycle G(1) exit; RA-RAR alpha-FGF8f signaling; transcriptional expression of RA target genes	KINASE-ACTIVATING KINASE; ACID RECEPTOR-ALPHA; FGF SIGNALING PATHWAYS; IN-VITRO; HUMAN OSTEOBLASTS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GROWTH-FACTOR; CYCLE CONTROL; TARGET GENES	Although retinoic acid (RA) is a potent agent that coordinates inhibition of proliferation with differentiation of many cell types, RA-mediated signaling pathways in osteosarcoma cell differentiation are uncharacterized. In this study, we show that in human U2OS osteosarcoma cells, decreased phosphorylation of RA receptor alpha (RAR alpha) by RA treatment or overexpressing a phosphorylation- defective mutant RAR alpha S77A results in the inhibition of proliferation and induction of differentiation, and that U2OS cells transduced with RAR alpha S77A suppresses tumor formation in nude mice. Moreover, using different human primary osteosarcoma cells and human mesenchymal stem cells for gene expression analysis, we found that either RA or RAR alpha S77A induces many of the same differentiation response pathways and signaling molecules involved in U2OS cell differentiation. In addition, overexpression of the fibroblast growth factor 8f (FGF8f), one of the downstream targets induced by both RA and RAR alpha S77A in U2OS cells, inhibits proliferation and induces expression of osteoblastic differentiation regulators. Hence, these data strongly suggest that RA-suppressed phosphorylation of RAR alpha induces FGF8f expression to mediate differentiation response pathway in U2OS osteosarcoma cells. Oncogene (2010) 29, 2772-2783; doi: 10.1038/onc.2010.50; published online 1 March 2010	[Wu, L.] Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA; [Luo, P.; Yang, X.; Ying, M.; Chaudhry, P.; Wang, A.; Shimada, H.; Mock, D.; Triche, T. J.; Wu, L.] Childrens Hosp Los Angeles, Dept Pathol, Saban Res Inst, Los Angeles, CA 90027 USA; [May, W. A.] Childrens Hosp Los Angeles, Dept Pediat, Saban Res Inst, Los Angeles, CA 90027 USA; [Adams, G. B.] Univ So Calif, Keck Sch Med, Ctr Stem Cell & Regenerat Med, Los Angeles, CA 90027 USA; [He, Q.] Zhejiang Univ, Inst Pharmacol & Toxicol, Sch Pharmaceut Sci, Hangzhou 310003, Zhejiang, Peoples R China	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; Zhejiang University	Wu, L (corresponding author), Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu	he, qiaojun/F-3198-2010; Chaudhry, Parvesh/I-4417-2015		National Institutes of Health [R21 CA111440, R01 CA120512, 1 UO1 CA114757-01]; NATIONAL CANCER INSTITUTE [R21CA111440, U01CA114757, R21CA137485, R01CA120512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Grants from the National Institutes of Health R21 CA111440 and R01 CA120512 to L Wu, and 1 UO1 CA114757-01 to TJ Triche.	Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bacci G, 2001, EUR J CANCER, V37, P32, DOI 10.1016/S0959-8049(00)00361-0; Barroga E, 1999, J VET MED A, V46, P573, DOI 10.1046/j.1439-0442.1999.00251.x; Barroga EF, 2000, VET J, V159, P186, DOI 10.1053/tvjl.1999.0441; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BEERE HM, 1993, ANTI-CANCER DRUG DES, V8, P299; BENAYAHU D, 1994, J CELL BIOCHEM, V56, P62, DOI 10.1002/jcb.240560111; Brondani V, 2000, BIOCHEM BIOPH RES CO, V272, P98, DOI 10.1006/bbrc.2000.2740; Brondani V, 2002, J MOL BIOL, V319, P715, DOI 10.1016/S0022-2836(02)00376-5; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Crowe David L, 2002, Cancer Cell Int, V2, P15, DOI 10.1186/1475-2867-2-15; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; He QJ, 2004, FASEB J, V18, P1734, DOI 10.1096/fj.04-2182fje; Hoffman UM, 2003, J BONE JOINT SURG AM, V85A, P124, DOI 10.2106/00004623-200300002-00017; Hong SH, 2000, RES VET SCI, V68, P57, DOI 10.1053/rvsc.1999.0338; Hong SH, 2000, AM J VET RES, V61, P69, DOI 10.2460/ajvr.2000.61.69; Horowitz MC, 2005, IMMUNOL REV, V208, P141, DOI 10.1111/j.0105-2896.2005.00328.x; Jackson RA, 2006, GENE, V379, P79, DOI 10.1016/j.gene.2006.04.028; Jacobson A, 2004, BIOCHEM BIOPH RES CO, V322, P162, DOI 10.1016/j.bbrc.2004.07.092; Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li ZX, 2006, TRENDS BIOCHEM SCI, V31, P589, DOI 10.1016/j.tibs.2006.08.001; Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011; Luo PH, 2007, STEM CELLS, V25, P2628, DOI 10.1634/stemcells.2007-0264; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mattila MA, 2007, CYTOKINE GROWTH F R, V18, P257, DOI 10.1016/j.cytogfr.2007.04.010; Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood-2008-01-133710; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Orimo H, 2005, BONE, V36, P866, DOI 10.1016/j.bone.2005.02.010; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SONG LN, 1994, ONCOL RES, V6, P111; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850; TRAIANEDES K, 1993, J CELL PHYSIOL, V157, P243, DOI 10.1002/jcp.1041570206; WANG A, 2009, FASEB J; Wang JG, 2006, FASEB J, V20, P2142, DOI 10.1096/fj.06-5900fje; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; Wang XD, 2005, ALCOHOL, V35, P251, DOI 10.1016/j.alcohol.2005.04.006; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; WU LT, 1994, ONCOGENE, V9, P2089; Zhang SN, 2004, CANCER RES, V64, P2977, DOI 10.1158/0008-5472.CAN-03-4018; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	57	30	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2772	2783		10.1038/onc.2010.50	http://dx.doi.org/10.1038/onc.2010.50			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190807				2022-12-28	WOS:000277591900003
J	Zhang, P; Yang, Y; Nolo, R; Zweidler-McKay, PA; Hughes, DPM				Zhang, P.; Yang, Y.; Nolo, R.; Zweidler-McKay, P. A.; Hughes, D. P. M.			Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness	ONCOGENE			English	Article						NOTCH; HES1; Deltex1(DTX1); osteosarcoma; invasion	UBIQUITIN LIGASE; CELL; ACTIVATION; RECEPTOR; SUPPRESSOR; REPRESSION; PROMOTER; PATHWAY; DOMAIN	The highly conserved NOTCH signaling pathway has many essential functions in the development of diverse cells, tissues and organs from Drosophila to humans, and dysregulated NOTCH signaling contributes to several disorders, including vascular and bone defects, as well as several cancers. Here we describe a novel mechanism of NOTCH regulation by reciprocal inhibition of two NOTCH downstream effectors: Deltex1 and HES1. This mechanism appears to regulate invasion of osteosarcoma cells, as Deltex1 blocks osteosarcoma invasiveness by downregulating NOTCH/HES1 signaling. The inhibitory effect of endogenous Deltex1 on NOTCH signaling is mediated through binding with the intracellular domain of NOTCH and ubiquitination and degradation of NOTCH receptors. Conversely, we show that the NOTCH target gene HES1 causes transcriptional inhibition of Deltex1 by directly binding to the promoter of Deltex1. An HES1 binding site is identified 400 bp upstream of the transcription start site of Deltex1. HES1-mediated repression of Deltex1 requires the C-terminal H3/H4 and WRPW domains of HES1, which associate with the TLE/Groucho corepressors. Taken together, we define a molecular mechanism regulating NOTCH signaling by reciprocal inhibition of the NOTCH target genes HES1 and Deltex1 in mammalian cells. This mechanism may have important clinical implications for targeting NOTCH signaling in osteosarcoma and other cancers. Oncogene (2010) 29, 2916-2926; doi:10.1038/onc.2010.62; published online 8 March 2010	[Zhang, P.; Yang, Y.; Nolo, R.; Zweidler-McKay, P. A.; Hughes, D. P. M.] Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Childrens Canc Hosp, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hughes, DPM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Childrens Canc Hosp, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dphughes@mdanderson.org		Zweidler-McKay, Patrick/0000-0001-6621-523X	UT MD Anderson Cancer Center; NIH [K08CA118730-04]; Jori Zemel Children's Bone Cancer Foundation; Hope Street Kids Foundation; NATIONAL CANCER INSTITUTE [K08CA118730] Funding Source: NIH RePORTER	UT MD Anderson Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jori Zemel Children's Bone Cancer Foundation; Hope Street Kids Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tetsuo Sudo, Dr Anders Strom and Dr Iannis Aifantis for providing reagents, and to Dr Shufang Jia and Dr Wendy Fang for technical assistance. This work was supported by Physician Scientist Awards from UT MD Anderson Cancer Center to Dr D Hughes and Dr P Zweidler-McKay and by NIH Grant K08CA118730-04 to Dr Dennis Hughes. Dr P Zhang was supported by the Jori Zemel Children's Bone Cancer Foundation (www.JoriZemel.com) and Hope Street Kids Foundation (www.hopestreetkids.org).	Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelson H, 2004, CANCER LETT, V204, P171, DOI 10.1016/S0304-3835(03)00453-1; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Cinnamon E, 2008, CURR OPIN GENET DEV, V18, P435, DOI 10.1016/j.gde.2008.07.010; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Hori K, 2004, DEVELOPMENT, V131, P5527, DOI 10.1242/dev.01448; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Liu WH, 2005, MOL CELL BIOL, V25, P1367, DOI 10.1128/MCB.25.4.1367-1378.2005; Matsuno K, 2002, DEVELOPMENT, V129, P1049; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Mukherjee A, 2005, NAT CELL BIOL, V7, P1191, DOI 10.1038/ncb1327; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilkin M, 2008, DEV CELL, V15, P762, DOI 10.1016/j.devcel.2008.09.002; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078-0432.CCR-07-1992; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355; Zweidler-McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012; Zweifel ME, 2005, STRUCTURE, V13, P1599, DOI 10.1016/j.str.2005.07.015	30	76	79	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2916	2926		10.1038/onc.2010.62	http://dx.doi.org/10.1038/onc.2010.62			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208568	Green Accepted			2022-12-28	WOS:000277890400003
J	Serrano, J; Fernandez, AP; Martinez-Murillo, R; Martinez, A				Serrano, J.; Fernandez, A. P.; Martinez-Murillo, R.; Martinez, A.			High sensitivity to carcinogens in the brain of a mouse model of Alzheimer's disease	ONCOGENE			English	Article						brain tumors; Alzheimer's disease; tumor microenvironment; inflammatory mediators; carcinogenesis	ELDERLY-PATIENTS; TUMOR MICROENVIRONMENT; INFLAMMATORY RESPONSE; CEREBRAL-CORTEX; STEM-CELLS; EXPRESSION; GLIOBLASTOMA; DEMENTIA; COMORBIDITY; CANCER	Cancer and Alzheimer's disease (AD) are commonly found among elderly patients. Chronic inflammation is the characteristic of both diseases. Amyloid-beta peptide is the main inducer of inflammation in AD. Moreover, chronic inflammation promotes cancer, suggesting that AD patients may be more prone to develop cancer than non-demented people. To test this hypothesis, we injected the carcinogen 20-methylcholanthrene in the brain of transgenic mice overexpressing the mutant forms of amyloid precursor protein (APP) and presenilin 1 (PS1), as a model of AD, and their wild-type (WT) littermates. Mutant mice developed tumors faster and with higher incidence than their WT counterparts. Expression of the inflammatory markers interleukin (IL)-1 alpha, IL-1 beta, IL-6, IP-10 and tumor necrosis factor-alpha (TNF-alpha) was measured in AD and WT mice of 3 and 12 months of age that had not been exposed to the carcinogen. These cytokines were elevated in older AD mice, indicating the existence of a highly inflammatory milieu in these animals. We also found elevated expression of a mutated form of p53 in older AD mice, suggesting an alternative mechanism for the predisposition of AD brains to develop brain tumors. Clinical studies reporting comorbidity of AD and brain cancer are needed to understand whether our observations hold true for humans. Oncogene (2010) 29, 2165-2171; doi: 10.1038/onc.2009.503; published online 25 January 2010	[Serrano, J.; Fernandez, A. P.; Martinez-Murillo, R.] CSIC, Inst Cajal, Dept Mol Cellular & Dev Neurobiol, E-28002 Madrid, Spain; [Martinez, A.] Ctr Biomed Res La Rioja CIBIR, Logrono, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Martinez-Murillo, R (corresponding author), CSIC, Inst Cajal, Dept Cellular Mol & Dev Neurobiol, Avda Doctor Arce 37, E-28002 Madrid, Spain.	r.martinez@cajal.csic.es	Fernández, Ana Patricia/K-7901-2014; Martinez, Alfredo/GQH-5998-2022; Martinez-Murillo, Ricardo/K-7596-2014	Fernández, Ana Patricia/0000-0002-3843-4715; Martinez, Alfredo/0000-0003-4882-4044; Martinez-Murillo, Ricardo/0000-0003-3657-3890	Spanish Ministry of Science and Innovation [SAF2007-60010]; Instituto de Salud Carlos III [RD06/0026/1001]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission)	We gratefully acknowledge Professor Ignacio Torres (Instituto Cajal, Madrid, Spain) for the breeding pairs to initiate the mouse colony. We are also grateful to Dr Josune Garcia-Sanmartin (CIBIR, Logrono, Spain) for her valuable help in statistical analysis. This work was supported by Spanish Ministry of Science and Innovation Grant SAF2007-60010, and Instituto de Salud Carlos III Grant RD06/0026/1001.	Anisimov Vladimir N, 2007, Cancer Control, V14, P23; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Beard CM, 1996, ANN EPIDEMIOL, V6, P195, DOI 10.1016/1047-2797(95)00068-2; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Chang CY, 2005, J CLIN NEUROSCI, V12, P930, DOI 10.1016/j.jocn.2004.11.017; Chicoine MR, 1997, J NEURO-ONCOL, V35, P249, DOI 10.1023/A:1005808315821; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Domenico F, 2009, NEUROCHEM RES, V34, P727, DOI 10.1007/s11064-009-9924-9; Driver JA, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2467; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Formiga F, 2008, REV NEUROLOGIA, V46, P72, DOI 10.33588/rn.4602.2007490; Formiga F, 2007, REV CLIN ESP, V207, P495, DOI 10.1157/13111547; Gambassi G, 1999, NEUROLOGY, V53, P508, DOI 10.1212/WNL.53.3.508; Gasper Mason C, 2005, Am J Geriatr Pharmacother, V3, P1, DOI 10.1016/j.amjopharm.2005.02.001; Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740; Hong SH, 2000, FASEB J, V14, P1499, DOI 10.1096/fj.99-0802com; Hoozemans JJM, 2008, CURR PHARM DESIGN, V14, P1419, DOI 10.2174/138161208784480171; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu M, 2008, EUR J CANCER, V44, P2760, DOI 10.1016/j.ejca.2008.09.038; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Kamer AR, 2008, J ALZHEIMERS DIS, V13, P437; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Lanni C, 2008, CURR PHARM DESIGN, V14, P2665, DOI 10.2174/138161208786264133; Leonard BE, 2007, NEUROCHEM RES, V32, P1749, DOI 10.1007/s11064-007-9385-y; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Murat A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005947; Nelson JS, 2002, ARCH PATHOL LAB MED, V126, P1515; Paugh BS, 2009, J BIOL CHEM, V284, P3408, DOI 10.1074/jbc.M807170200; Peebles KA, 2007, EXPERT REV ANTICANC, V7, P1405, DOI 10.1586/14737140.7.10.1405; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Quante M, 2008, PHYSIOLOGY, V23, P350, DOI 10.1152/physiol.00031.2008; Ribatti D, 2006, CLIN EXP MED, V6, P145, DOI 10.1007/s10238-006-0117-4; Rodrigo J, 2004, NEUROSCIENCE, V128, P73, DOI 10.1016/j.neuroscience.2004.06.030; Roe CM, 2005, NEUROLOGY, V64, P895, DOI 10.1212/01.WNL.0000152889.94785.51; Rogers J, 2008, J PERIODONTOL, V79, P1535, DOI 10.1902/jop.2008.080171; Saetre P, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-46; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Sanders P, 2007, BRAIN RES REV, V54, P274, DOI 10.1016/j.brainresrev.2007.03.001; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Serrano J, 2008, BRAIN PATHOL, V18, P434, DOI 10.1111/j.1750-3639.2008.00142.x; Steinman L, 2008, J CLIN INVEST, V118, P3557, DOI 10.1172/JCI36532; Stock D, 2008, UROL CLIN N AM, V35, P117, DOI 10.1016/j.ucl.2007.09.006; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Tansey MG, 2008, FRONT BIOSCI-LANDMRK, V13, P709, DOI 10.2741/2713; Uberti D, 2008, NEURODEGENER DIS, V5, P209, DOI 10.1159/000113704; Vesce S, 2007, INT REV NEUROBIOL, V82, P57, DOI 10.1016/S0074-7742(07)82003-4; Wang Y, 2009, CANCER CELL, V15, P514, DOI 10.1016/j.ccr.2009.04.001; Yamada M, 1999, J AM GERIATR SOC, V47, P189, DOI 10.1111/j.1532-5415.1999.tb04577.x; Yeruva S, 2008, INT J COLORECTAL DIS, V23, P305, DOI 10.1007/s00384-007-0396-6; Zimmerman HM, 1941, CANCER RES, V1, P919	54	25	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2165	2171		10.1038/onc.2009.503	http://dx.doi.org/10.1038/onc.2009.503			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101216				2022-12-28	WOS:000276685200002
J	Janoueix-Lerosey, I; Schleiermacher, G; Delattre, O				Janoueix-Lerosey, I.; Schleiermacher, G.; Delattre, O.			Molecular pathogenesis of peripheral neuroblastic tumors	ONCOGENE			English	Review						neuroblastoma; genetic alterations; susceptibility; ALK mutations; expression profiling; progression	ANAPLASTIC LYMPHOMA KINASE; HIGH-RESOLUTION ANALYSIS; HOMEOBOX GENE PHOX2B; B-CELL LYMPHOMA; N-MYC GENE; NPM-ALK; PROGNOSTIC-SIGNIFICANCE; MALIGNANT PROGRESSION; ACTIVATING MUTATIONS; GENOMIC ALTERATIONS	Neuroblastoma (NB) is an embryonal cancer of the sympathetic nervous system observed in early childhood, characterized by a broad spectrum of clinical behaviors, ranging from spontaneous regression to fatal outcome despite aggressive therapies. NB accounts for 8-10% of pediatric cancers and 15% of the deaths attributable to malignant conditions in children. Interestingly, NB may occur in various contexts, being mostly sporadic but also familial or syndromic. This review focuses on recent advances in the identification of the genes and mechanisms implicated in NB pathogenesis. Although the extensive characterization of the genomic aberrations recurrently observed in sporadic NBs provides important insights into the understanding of the clinical heterogeneity of this neoplasm, analysis of familial and syndromic cases also unravels essential clues on the genetic bases of NB. Recently, the ALK gene emerged as an important NB gene, being implicated both in sporadic and familial cases. The identification of gene expression signatures associated with patient's outcome points out the potential of using gene expression profiling to improve clinical management of patients suffering from NB. Finally, based on recent observations integrating genomic analyses, biological data and clinical information, we discuss possible evolution/progression schemes in NB. Oncogene (2010) 29, 1566-1579; doi:10.1038/onc.2009.518; published online 25 January 2010	[Janoueix-Lerosey, I.; Schleiermacher, G.; Delattre, O.] Inst Curie, INSERM, Lab Genet & Biol Canc, U830, F-75248 Paris 05, France; [Schleiermacher, G.] Inst Curie, Dept Pediat, F-75248 Paris 05, France; [Delattre, O.] Inst Curie, Unite Genet Somat, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Janoueix-Lerosey, I (corresponding author), Inst Curie, INSERM, Lab Genet & Biol Canc, U830, 26 Rue Ulm, F-75248 Paris 05, France.	janoueix@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Schleiermacher, Gudrun/AAN-4711-2021	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Schleiermacher, Gudrun/0000-0002-0133-5879; delattre, olivier/0000-0002-8730-2276	Agence Nationale pour la Recherche; Institut National du Cancer; Ligue Nationale contre le Cancer; APAESIC (Association des Parents et des Amis des Enfants Soignes a l'Institut Curie); Association Hubert Gouin; Les Bagouz a Manon; les amis de Claire and Enfance et Sante	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); APAESIC (Association des Parents et des Amis des Enfants Soignes a l'Institut Curie); Association Hubert Gouin; Les Bagouz a Manon; les amis de Claire and Enfance et Sante	We thank V Marty, P Vielh and G Vassal from the Institut Gustave Roussy for providing the image of ALK immunohistochemistry. We are grateful to F Bourdeaut for critical reading of the paper. Our work was supported by grants from the Agence Nationale pour la Recherche, the Institut National du Cancer, the Ligue Nationale contre le Cancer (Equipe labellisee), the APAESIC (Association des Parents et des Amis des Enfants Soignes a l'Institut Curie), the Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante	Adam P, 2003, AM J SURG PATHOL, V27, P1473, DOI 10.1097/00000478-200311000-00012; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Barrette SP, 2006, J CLIN ONCOL, V24, P1542, DOI 10.1200/JCO.2005.04.4602; Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bilsland JG, 2008, NEUROPSYCHOPHARMACOL, V33, P685, DOI 10.1038/sj.npp.1301446; Bourdeaut F, 2008, ONCOGENE, V27, P3066, DOI 10.1038/sj.onc.1210965; Bourdeaut F, 2009, J PATHOL, V219, P463, DOI 10.1002/path.2614; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Capasso M, 2009, NAT GENET, V41, P718, DOI 10.1038/ng.374; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; CARON H, 1994, AM J HUM GENET, V55, P341; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Carr J, 2007, CANCER GENET CYTOGEN, V172, P127, DOI 10.1016/j.cancergencyto.2006.08.012; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Denayer E, 2008, J MED GENET, V45, P695, DOI 10.1136/jmg.2007.055772; Diskin SJ, 2009, NATURE, V459, P987, DOI 10.1038/nature08035; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Fix A, 2008, GENE CHROMOSOME CANC, V47, P819, DOI 10.1002/gcc.20583; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; FUKUDA Y, 2005, NUCL ACIDS S SER, V49, P341, DOI DOI 10.1093/NASS/49.1.341; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; George RE, 1997, EUR J CANCER, V33, P2037, DOI 10.1016/S0959-8049(97)00206-2; Griffin CA, 1999, CANCER RES, V59, P2776; Heck JE, 2009, PAEDIATR PERINAT EP, V23, P125, DOI 10.1111/j.1365-3016.2008.00983.x; Hiyama E, 2008, LANCET, V371, P1173, DOI 10.1016/S0140-6736(08)60523-1; Janoueix-Lerosey I, 2005, CELL CYCLE, V4, P1842, DOI 10.4161/cc.4.12.2257; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; JINBO T, 1989, JPN J CANCER RES, V80, P299, DOI 10.1111/j.1349-7006.1989.tb02309.x; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Krasnoselsky AL, 2005, ONCOGENE, V24, P1533, DOI 10.1038/sj.onc.1208341; Ladenstein R, 2001, MED PEDIATR ONCOL, V36, P83; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Laneve P, 2007, P NATL ACAD SCI USA, V104, P7957, DOI 10.1073/pnas.0700071104; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marcelis CLM, 2008, HUM MUTAT, V29, P1125, DOI 10.1002/humu.20750; Maris JM, 2008, NEW ENGL J MED, V358, P2585, DOI 10.1056/NEJMoa0708698; Maris JM, 2008, LANCET, V371, P1142, DOI 10.1016/S0140-6736(08)60500-0; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McConville C, 2006, AM J MED GENET A, V140A, P1297, DOI 10.1002/ajmg.a.31278; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse Y, 2003, LANCET ONCOL, V4, P769, DOI 10.1016/S1470-2045(03)01283-X; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Munzer C, 2008, INT J CANCER, V122, P2315, DOI 10.1002/ijc.23301; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Onciu M, 2003, BLOOD, V102, P2642, DOI 10.1182/blood-2003-04-1095; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Plantaz D, 2001, INT J CANCER, V91, P680, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rothenberg AB, 2009, PEDIATR RADIOL, V39, P155, DOI 10.1007/s00247-008-1062-z; Satge D, 2003, CANCER GENET CYTOGEN, V147, P89, DOI 10.1016/S0165-4608(03)00203-6; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; Schleiermacher G, 2004, GENE CHROMOSOME CANC, V39, P143, DOI 10.1002/gcc.10313; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Schneiderman J, 2008, J CLIN ONCOL, V26, P913, DOI 10.1200/JCO.2007.13.9493; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Shojaei-Brosseau T, 2004, PEDIATR BLOOD CANCER, V42, P99, DOI 10.1002/pbc.10381; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105; Spitz R, 2006, GENE CHROMOSOME CANC, V45, P1130, DOI 10.1002/gcc.20376; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Su WT, 2004, CANCER GENET CYTOGEN, V154, P131, DOI 10.1016/j.cancergencyto.2004.02.009; Tomioka N, 2008, ONCOGENE, V27, P441, DOI 10.1038/sj.onc.1210661; Trochet D, 2005, HUM MOL GENET, V14, P3697, DOI 10.1093/hmg/ddi401; Trochet D, 2005, AM J HUM GENET, V76, P421, DOI 10.1086/428366; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; Trochet D, 2009, HUM MUTAT, V30, pE421, DOI 10.1002/humu.20923; Turner SD, 2003, ONCOGENE, V22, P7750, DOI 10.1038/sj.onc.1207048; van Bokhoven H, 2005, NAT GENET, V37, P465, DOI 10.1038/ng1546; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Van Roy N, 2001, GENE CHROMOSOME CANC, V32, P126, DOI 10.1002/gcc.1174; Van Roy N, 2006, GENE CHROMOSOME CANC, V45, P107, DOI 10.1002/gcc.20272; Vandepoele K, 2005, MOL BIOL EVOL, V22, P2265, DOI 10.1093/molbev/msi222; Vandepoele K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002207; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Webb TR, 2009, EXPERT REV ANTICANC, V9, P331, DOI 10.1586/14737140.9.3.331; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287; Yamamoto K, 2002, J CLIN ONCOL, V20, P1209, DOI 10.1200/JCO.2002.20.5.1209; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	133	64	67	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1566	1579		10.1038/onc.2009.518	http://dx.doi.org/10.1038/onc.2009.518			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20101209				2022-12-28	WOS:000275694700002
J	Kim, JA; Lee, J; Margolis, RL; Fotedar, R				Kim, J. A.; Lee, J.; Margolis, R. L.; Fotedar, R.			SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition	ONCOGENE			English	Article						Cdk1 activation; endoreplication; G2/M progression; JNK; polyploidy; SP600125	POLO-LIKE KINASES; CELL-CYCLE PROGRESSION; N-TERMINAL KINASE; DNA-REPLICATION; DEPENDENT KINASE; MAMMALIAN-CELLS; AURORA-A; CANCER-CELLS; HISTONE H3; MITOSIS	Cell cycle controls ensure that DNA replication (S phase) follows mitosis resulting in two precise copies of the genome. A failure of the control mechanisms can result in multiple rounds of DNA replication without cell division. In endoreplication, cells with replicated genomes bypass mitosis, then replicate their DNA again, resulting in polyploidy. Endoreplication from G2 phase lacks all hallmarks of mitosis. Using synchronized cells, we show that the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, prevents the entry of cells into mitosis and leads to endoreplication of DNA from G2 phase. We show that cells proceed from G2 phase to replicate their DNA in the absence of mitosis. This effect of SP600125 is independent of its suppression of JNK activity. Instead, the inhibitory effect of SP600125 on mitotic entry predominantly occurs upstream of Aurora A kinase and Polo-like kinase 1, resulting in a failure to remove the inhibitory phosphorylation of Cdk1. Importantly, our results directly show that the inhibition of Cdk1 activity and the persistence of Cdk2 activity in G2 cells induces endoreplication without mitosis. Furthermore, endoreplication from G2 phase is independent of p53 control. Oncogene (2010) 29, 1702-1716; doi:10.1038/onc.2009.464; published online 11 January 2010	[Margolis, R. L.; Fotedar, R.] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Kim, J. A.; Lee, J.; Margolis, R. L.; Fotedar, R.] Sidney Kimmel Canc Ctr, San Diego, CA USA	Sanford Burnham Prebys Medical Discovery Institute	Fotedar, R (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rfotedar@burnham.org			National Institutes of Health [CA108947, CA101810, GM068107, GM088716]; NATIONAL CANCER INSTITUTE [R01CA101810, R01CA108947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088716, R01GM068107] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We dedicate this paper in fond memory of Arun Fotedar, a colleague and friend, whose laughter infected us all. We thank Kristian Helin (European Institute of Oncology, Italy) for Cdc6 antibody, Hideo Nishitani (Kyushu University) for Cdt1 antibody and Robert J Schultz (NCI, Bethesda, MD) for UCN-01. This work was supported by grants from the National Institutes of Health to RF (CA108947 and CA101810) and to RM (GM068107 and GM088716).	ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Arias EE, 2007, GENE DEV, V21, P497, DOI 10.1101/gad.1508907; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Busby EC, 2000, CANCER RES, V60, P2108; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Di Fiore B, 2007, J CELL BIOL, V177, P425, DOI 10.1083/jcb.200611166; Diffley JFX, 2002, J CELL SCI, V115, P869; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Georgatos SD, 1997, J CELL SCI, V110, P2129; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HAMILTON BT, 1982, EUR J CELL BIOL, V28, P190; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hochegger H, 2007, J CELL BIOL, V178, P257, DOI 10.1083/jcb.200702034; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Kiang L, 2009, MOL CELL BIOL, V29, P4025, DOI 10.1128/MCB.00185-09; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; L'Italien L, 2006, CELL CYCLE, V5, P984, DOI 10.4161/cc.5.9.2721; Laronne A, 2003, MOL BIOL CELL, V14, P3730, DOI 10.1091/mbc.E02-12-0850; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; MacCorkle RA, 2004, J BIOL CHEM, V279, P40112, DOI 10.1074/jbc.M405481200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; Miyamoto-Yamasaki Y, 2007, CELL BIOL INT, V31, P1501, DOI 10.1016/j.cellbi.2007.07.002; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Farrell PH, 2001, TRENDS CELL BIOL, V11, P512, DOI 10.1016/S0962-8924(01)02142-0; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Schmidt M, 2005, EMBO REP, V6, P866, DOI 10.1038/sj.embor.7400483; Sclafani RA, 2007, ANNU REV GENET, V41, P237, DOI 10.1146/annurev.genet.41.110306.130308; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang M, 2009, J PATHOL, V218, P95, DOI 10.1002/path.2521; Yu Q, 2002, CANCER RES, V62, P5743; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	60	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1702	1716		10.1038/onc.2009.464	http://dx.doi.org/10.1038/onc.2009.464			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20062077	Green Accepted			2022-12-28	WOS:000275694700015
J	Cheung, AF; Carter, AM; Kostova, KK; Woodruff, JF; Crowley, D; Bronson, RT; Haigis, KM; Jacks, T				Cheung, A. F.; Carter, A. M.; Kostova, K. K.; Woodruff, J. F.; Crowley, D.; Bronson, R. T.; Haigis, K. M.; Jacks, T.			Complete deletion of Apc results in severe polyposis in mice	ONCOGENE			English	Article						Apc truncation; Apc null; colon cancer; mouse model	FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN; MOUSE MODEL; MUTATION; ACTIVATION; REGULATOR; PHENOTYPE; PROTEIN; SITE; RAS	The adenomatous polyposis coli (APC) gene product is mutated in the vast majority of human colorectal cancers. APC negatively regulates the WNT pathway by aiding in the degradation of beta-catenin, which is the transcription factor activated downstream of WNT signaling. APC mutations result in beta-catenin stabilization and constitutive WNT pathway activation, leading to aberrant cellular proliferation. APC mutations associated with colorectal cancer commonly fall in a region of the gene termed the mutation cluster region and result in expression of an N-terminal fragment of the APC protein. Biochemical and molecular studies have revealed localization of APC/Apc to different sub-cellular compartments and various proteins outside of the WNT pathway that associate with truncated APC/Apc. These observations and genotype-phenotype correlations have led to the suggestion that truncated APC bears neomorphic and/or dominant-negative function that support tumor development. To analyze this possibility, we have generated a novel allele of Apc in the mouse that yields complete loss of Apc protein. Our studies reveal that whole-gene deletion of Apc results in more rapid tumor development than the APC multiple intestinal neoplasia (Apc(Min)) truncation. Furthermore, we found that adenomas bearing truncated Apc had increased beta-catenin activity when compared with tumors lacking Apc protein, which could lead to context-dependent inhibition of tumorigenesis. Oncogene (2010) 29, 1857-1864; doi:10.1038/onc.2009.457; published online 14 December 2009	[Cheung, A. F.; Carter, A. M.; Kostova, K. K.; Woodruff, J. F.; Crowley, D.; Jacks, T.] MIT, Robert Koch Inst, Cambridge, MA 02139 USA; [Cheung, A. F.; Carter, A. M.; Kostova, K. K.; Woodruff, J. F.; Crowley, D.; Jacks, T.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Crowley, D.; Jacks, T.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Bronson, R. T.] Tufts Univ, Sch Med & Vet Med, Dept Pathol, Boston, MA 02111 USA; [Haigis, K. M.] Harvard Univ, Sch Med, Dept Pathol, Masschusetts Gen Hosp,Canc Ctr, Charlestown, MA USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Tufts University; Harvard University	Jacks, T (corresponding author), MIT, Robert Koch Inst, 77 Massachusetts Ave,E17-517, Cambridge, MA 02139 USA.	tjacks@mit.edu	Kostova, Kamena/AAK-9431-2020	Kostova, Kamena/0000-0001-9973-401X	Howard Hughes Medical Institute; National Cancer Institute [P30-CA14051]; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Jacks labs, Keara Lane in particular, for experimental advice and assistance. This work was supported by the Howard Hughes Medical Institute and partially by the Cancer Center Support (core) Grant P30-CA14051 from the National Cancer Institute. TJ is a Howard Hughes Investigator and a Daniel K Ludwig Scholar.	Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Haigis KM, 2004, P NATL ACAD SCI USA, V101, P9769, DOI 10.1073/pnas.0403338101; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; McCartney BM, 2008, CURR OPIN CELL BIOL, V20, P186, DOI 10.1016/j.ceb.2008.02.001; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nathke I, 2004, J CELL SCI, V117, P4873, DOI 10.1242/jcs.01313; Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollard P, 2009, GASTROENTEROLOGY, V136, P2204, DOI 10.1053/j.gastro.2009.02.058; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P2954, DOI 10.1073/pnas.042699199; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Takacs CM, 2008, SCIENCE, V319, P333, DOI 10.1126/science.1151232; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2	32	54	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1857	1864		10.1038/onc.2009.457	http://dx.doi.org/10.1038/onc.2009.457			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20010873	Green Accepted, Green Submitted			2022-12-28	WOS:000276022800014
J	Lee, JH; Kang, Y; Khare, V; Jin, ZY; Kang, MY; Yoon, Y; Hyun, JW; Chung, MH; Cho, SI; Jun, JY; Chang, IY; You, HJ				Lee, J-H; Kang, Y.; Khare, V.; Jin, Z-Y; Kang, M-Y; Yoon, Y.; Hyun, J-W; Chung, M-H; Cho, S-I; Jun, J. Y.; Chang, I-Y; You, H. J.			The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage	ONCOGENE			English	Article						PIG3; DNA damage response; DNA damage checkpoint; gamma-H2AX; DNA repair	DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; HISTONE H2AX; ATAXIA-TELANGIECTASIA; ATM ACTIVATION; MRE11-RAD50-NBS1 COMPLEX; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; STRESS RESPONSES; GENOTOXIC STRESS	The p53-inducible gene 3 (PIG3) is originally isolated as a p53 downstream target gene, but its function remains unknown. Here, we report a role of PIG3 in the activation of DNA damage checkpoints, after UV irradiation or radiomimetic drug neocarzinostatin (NCS). We show that depletion of endogenous PIG3 sensitizes cells to DNA damage agents, and impaired DNA repair. PIG3 depletion also allows for UV- and NCS-resistant DNA synthesis and permits cells to progress into mitosis, indicating that PIG3 knockdown can suppress intra-S phase and G2/M checkpoints. PIG3-depleted cells show reduced Chk1 and Chk2 phosphorylation after DNA damage, which may directly contribute to checkpoint bypass. PIG3 exhibited diffuse nuclear staining in the majority of untreated cells and forms discrete nuclear foci in response to DNA damage. PIG3 colocalizes with gamma-H2AX and 53BP1 to sites of DNA damage after DNA damage, and binds to a gamma-H2AX. Notably, PIG3 depletion decreases the efficient induction and maintenance of H2AX phosphorylation after DNA damage. Moreover, PIG3 contributes to the recruitment of 53BP1, Mre11, Rad50 and Nbs1 to the sites of DNA break lesions in response to DNA damage. Our combined results suggest that PIG3 is a critical component of the DNA damage response pathway and has a direct role in the transmission of the DNA damage signal from damaged DNA to the intra-S and G2/M checkpoint machinery in human cells. Oncogene (2010) 29, 1431-1450; doi:10.1038/onc.2009.438; published online 21 December 2009	[Lee, J-H; Kang, Y.; Khare, V.; Jin, Z-Y; Kang, M-Y; Yoon, Y.; You, H. J.] Chosun Univ, Dept Biomat, DNA Repair Res Ctr, Kwangju 501759, South Korea; [Lee, J-H; Kang, Y.; Kang, M-Y; Yoon, Y.; You, H. J.] Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; [Hyun, J-W] Cheju Natl Univ, Sch Med, Dept Biochem, Jeju Si, South Korea; [Chung, M-H] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea; [Cho, S-I] Chosun Univ, Sch Med, Dept Otorhinolaryngol, Kwangju 501759, South Korea; [Jun, J. Y.] Chosun Univ, Sch Med, Dept Physiol, Kwangju 501759, South Korea; [Chang, I-Y] Chosun Univ, Sch Med, Dept Anat, Kwangju 501759, South Korea	Chosun University; Chosun University; Jeju National University; Seoul National University (SNU); Chosun University; Chosun University; Chosun University	You, HJ (corresponding author), 2F Chosun Univ, Sch Med, Dept Pharmacol, DNA Repair Res Ctr & Bioengn BD, 375 Seosuk Dong, Kwangju 501759, Chonnam, South Korea.	hjyou@chosun.ac.kr		You, Ho Jin/0000-0002-0530-4017; Lee, Jung-Hee/0000-0002-6889-9126	Ministry of Education, Science and Technology [M 2009-0065519, M 20706000032]; Korean government; Chosun University	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean government(Korean Government); Chosun University	This research was supported by grants (M 2009-0065519 and M 20706000032) from the Ministry of Education, Science and Technology, the Korean government and from the Chosun University, 2002.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2000, CANCER RES, V60, P5934; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garg R, 2004, MOL CANCER RES, V2, P362; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Jazayeri A, 2008, EMBO J, V27, P1953, DOI 10.1038/emboj.2008.128; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Nicholls CD, 2004, J BIOL CHEM, V279, P24171, DOI 10.1074/jbc.M401049200; Nicholls CD, 2008, BBA-GENE REGUL MECH, V1779, P838, DOI 10.1016/j.bbagrm.2008.08.009; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porte S, 2009, J BIOL CHEM, V284, P17194, DOI 10.1074/jbc.M109.001800; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Su TT, 2006, ANNU REV GENET, V40, P187, DOI 10.1146/annurev.genet.40.110405.090428; Tanaka T, 2007, CELL, V130, P638, DOI 10.1016/j.cell.2007.08.001; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	63	58	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1431	1450		10.1038/onc.2009.438	http://dx.doi.org/10.1038/onc.2009.438			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20023697				2022-12-28	WOS:000275392400003
J	Ji, C; Yang, B; Yang, YL; He, SH; Miao, DS; He, L; Bi, ZG				Ji, C.; Yang, B.; Yang, Y-L; He, S-H; Miao, D-S; He, L.; Bi, Z-G			Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition	ONCOGENE			English	Article						C6 ceramide; cancer chemotherapy; Doxorubicin; AMPK; mTORC1 and apoptosis	HEPATOCELLULAR-CARCINOMA CELLS; PROTEIN-KINASE; IN-VITRO; GROWTH; DEATH; METABOLISM; EXPRESSION; PACLITAXEL; INDUCTION; MECHANISM	New chemotherapy-enhancing strategies are needed for better cancer therapy. Previous studies suggest that exogenous cell-permeable C6 ceramide may be a useful adjunct to the anti-tumor effects of chemotherapeutic agents (such as Taxol) against multiple cancers. Here we demonstrate that exogenous cell-permeable C6 ceramide largely sensitizes multiple progressive cancer cell lines to Doxorubicin-induced cell death and apoptosis. We found for the first time that Doxorubicin induces AMP-activated protein kinase (AMPK) activation in a reactive oxygen species-dependent manner. Activation of AMPK contributes to Doxorubicin-induced cancer cell death and apoptosis. Inhibition of AMPK by small interfering RNA knockdown or a pharmacological inhibitor reduces Doxorubicin-induced cancer cell apoptosis, whereas AMPK activator AICAR enhances it. Importantly, we found that C6 ceramide largely enhances Doxorubicin-induced activation of AMPK, which leads to mTOR complex 1 inhibition and chemo-sensitization. Our data suggest that the combination of C6 ceramide with traditional chemotherapy drugs such as Doxorubicin may have the potential to be used as a new therapeutic intervention against multiple cancers. Oncogene (2010) 29, 6557-6568; doi:10.1038/onc.2010.379; published online 30 August 2010	[Bi, Z-G] Nanjing Med Univ, Affiliated BenQ Hosp, Dept Dermatol, Nanjing 210019, Jiangsu, Peoples R China; [Ji, C.] Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, Nanjing 210024, Jiangsu, Peoples R China; [Yang, B.] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China; [Yang, Y-L] Nanjing Med Univ, Affiliated Hosp 1, Dept Otolaryngol, Nanjing, Jiangsu, Peoples R China; [He, S-H] Nanjing Med Univ, Affiliated Hosp 1, Clin Expt Ctr, Nanjing, Jiangsu, Peoples R China; [Miao, D-S] Nanjing Med Univ, Dept Human Anat, Nanjing, Jiangsu, Peoples R China; [He, L.] Kunming Med Univ, Yunnan Prov Inst Dermatol, Affiliated Hosp 1, Dept Dermatol, Kunming, Yunnan, Peoples R China	Nanjing Medical University; Nanjing Medical University; Fudan University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Kunming Medical University	Bi, ZG (corresponding author), Nanjing Med Univ, Affiliated BenQ Hosp, Dept Dermatol, Nanjing 210019, Jiangsu, Peoples R China.	surpassing_ji@yahoo.com.cn; heli2662@163.com; eltonbibenqhospital@yahoo.com.cn		Miao, Dengshun/0000-0002-2682-3502	National Natural Science Foundation of China [30271195, 30671894]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported in part by grants from the National Natural Science Foundation of China (30271195 and 30671894).	Arad M, 2007, CIRC RES, V100, P474, DOI 10.1161/01.RES.0000258446.23525.37; Auzenne E, 1998, MELANOMA RES, V8, P227, DOI 10.1097/00008390-199806000-00005; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cao C, 2008, J BIOL CHEM, V283, P28897, DOI 10.1074/jbc.M804144200; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chiang PC, 2010, BIOCHEM PHARMACOL, V79, P162, DOI 10.1016/j.bcp.2009.08.022; Grunwald V, 2002, CANCER RES, V62, P6141; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jaswal JS, 2006, AM J PHYSIOL-HEART C, V291, pH1883, DOI 10.1152/ajpheart.01147.2005; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim do Y, 2009, J AGR FOOD CHEM, V57, P10573; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Mehta S, 2000, CANCER CHEMOTH PHARM, V46, P85, DOI 10.1007/s002800000140; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Nithipongvanitch R, 2007, ANTIOXID REDOX SIGN, V9, P1001, DOI 10.1089/ars.2007.1632; Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200; Piguet AC, 2008, J HEPATOL, V49, P78, DOI 10.1016/j.jhep.2008.03.024; Qiu LH, 2006, ONCOL REP, V16, P907; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Rath G, 2009, INT J BIOCHEM CELL B, V41, P1165, DOI 10.1016/j.biocel.2008.10.021; Ravid A, 1999, CANCER RES, V59, P862; Romano MF, 2004, EUR J CANCER, V40, P2829, DOI 10.1016/j.ejca.2004.08.017; Ruderman NB, 2006, DIABETES, V55, pS48, DOI 10.2337/db06-S007; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Yamauchi M, 2008, MOL ENDOCRINOL, V22, P893, DOI 10.1210/me.2007-0249; Yoon H, 2008, BIOCHEM BIOPH RES CO, V371, P495, DOI 10.1016/j.bbrc.2008.04.102; Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322; Zhang JF, 2007, TRANSPL IMMUNOL, V17, P162, DOI 10.1016/j.trim.2006.12.003; Zhu WQ, 2009, CIRCULATION, V119, P99, DOI 10.1161/CIRCULATIONAHA.108.799700	34	109	112	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6557	6568		10.1038/onc.2010.379	http://dx.doi.org/10.1038/onc.2010.379			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20802518				2022-12-28	WOS:000285380200005
J	Marshall, GM; Bell, JL; Koach, J; Tan, O; Kim, P; Malyukova, A; Thomas, W; Sekyere, EO; Liu, T; Cunningham, AM; Tobias, V; Norris, MD; Haber, M; Kavallaris, M; Cheung, BB				Marshall, G. M.; Bell, J. L.; Koach, J.; Tan, O.; Kim, P.; Malyukova, A.; Thomas, W.; Sekyere, E. O.; Liu, T.; Cunningham, A. M.; Tobias, V.; Norris, M. D.; Haber, M.; Kavallaris, M.; Cheung, B. B.			TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells	ONCOGENE			English	Article						TRIM16; EBBP; neuroblastoma; vimentin; E2F1; tumour suppressor	B-BOX PROTEIN; HIGH-RISK NEUROBLASTOMA; RING FINGER; 13-CIS-RETINOIC ACID; UBIQUITIN LIGASE; BINDING DOMAIN; RETINOIC ACID; BREAST-CANCER; EXPRESSION; FAMILY	The family of tripartite-motif (TRIM) proteins are involved in diverse cellular processes, but are often characterized by critical protein-protein interactions necessary for their function. TRIM16 is induced in different cancer types, when the cancer cell is forced to proceed down a differentiation pathway. We have identified TRIM16 as a DNA-binding protein with histone acetylase activity, which is required for the retinoic acid receptor beta(2) transcriptional response in retinoid-treated cancer cells. In this study, we show that overexpressed TRIM16 reduced neuroblastoma cell growth, enhanced retinoid-induced differentiation and reduced tumourigenicity in vivo. TRIM16 was only expressed in the differentiated ganglion cell component of primary human neuroblastoma tumour tissues. TRIM16 bound directly to cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. TRIM16 reduced cell motility and this required downregulation of vimentin. Retinoid treatment and enforced overexpression caused TRIM16 to translocate to the nucleus, and bind to and downregulate nuclear E2F1, required for cell replication. This study, for the first time, demonstrates that TRIM16 acts as a tumour suppressor, affecting neuritic differentiation, cell migration and replication through interactions with cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. Oncogene (2010) 29, 6172-6183; doi:10.1038/onc.2010.340; published online 23 August 2010	[Marshall, G. M.; Bell, J. L.; Koach, J.; Tan, O.; Kim, P.; Malyukova, A.; Thomas, W.; Sekyere, E. O.; Liu, T.; Norris, M. D.; Haber, M.; Kavallaris, M.; Cheung, B. B.] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia; [Marshall, G. M.] Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW, Australia; [Cunningham, A. M.] UNSW, Sch Womens & Childrens Hlth, Fac Med, Kensington, NSW, Australia; [Tobias, V.] Sydney Childrens Hosp, S Eastern Area Lab Serv, Randwick, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney	Cheung, BB (corresponding author), Univ NSW, Lowy Canc Res Ctr, Mol Carcinogenesis Program, Childrens Canc Inst Australia, High St,POB 81, Randwick, NSW 2031, Australia.	bcheung@ccia.unsw.edu.au	Liu, Tao/A-3922-2015; Kavallaris, Maria/J-5240-2014	Tan, Owen/0000-0002-0303-7138; Haber, Michelle/0000-0003-2036-8817; Norris, Murray/0000-0002-0632-4589; Liu, Tao/0000-0001-6244-7316; Bell, Jessica/0000-0002-8875-0943; Cheung, Belamy/0000-0001-8784-860X	National Health and Medical Research Council, Australia; Cancer Institute NSW	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW	This research was supported by programme grants from the National Health and Medical Research Council, Australia. This research project was also supported by an Early Career Development Fellowship from the Cancer Institute NSW. The Children's Cancer Institute Australia for Medical Research is affiliated with the University of NSW and Sydney Children's Hospital. We thank Ms Tala Kaplinovsky of the Westfield Research Laboratory at Sydney Children's Hospital for help with using confocal microscopy. We thank Mr Andrew Gayagay of the Paediatric Anatomical Pathology, SEALS for help with preparation of patient samples.	Beer HD, 2002, J BIOL CHEM, V277, P20740, DOI 10.1074/jbc.M111233200; BORDEN KLB, 1993, FEBS LETT, V335, P255, DOI 10.1016/0014-5793(93)80741-C; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Cao TY, 1998, J CELL SCI, V111, P1319; Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Cheung BB, 2006, J BIOL CHEM, V281, P18246, DOI 10.1074/jbc.M600879200; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson DG, 2006, CURR MOL MED, V6, P731; Joshi VV, 2000, PEDIATR DEVEL PATHOL, V3, P184, DOI 10.1007/s100240050024; KATSETOS CD, 1991, LAB INVEST, V64, P45; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lalonde JP, 2004, J BIOL CHEM, V279, P8181, DOI 10.1074/jbc.M306751200; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Liu HLC, 1998, MOL ENDOCRINOL, V12, P1733, DOI 10.1210/me.12.11.1733; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Mrosek M, 2008, BIOCHEMISTRY-US, V47, P10722, DOI 10.1021/bi800733z; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Muley PD, 2008, DEV NEUROBIOL, V68, P1441, DOI 10.1002/dneu.20670; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Raif A, 2009, CANCER LETT, V277, P82, DOI 10.1016/j.canlet.2008.11.030; Rexhepaj E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2187; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vichi A, 2005, P NATL ACAD SCI USA, V102, P1945, DOI 10.1073/pnas.0409800102; Vora HH, 2009, INT J BIOL MARKER, V24, P38, DOI 10.1177/172460080902400106; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yabe JT, 2003, CELL MOTIL CYTOSKEL, V56, P193, DOI 10.1002/cm.10137	39	51	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	46					6172	6183		10.1038/onc.2010.340	http://dx.doi.org/10.1038/onc.2010.340			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729920	Green Published, hybrid			2022-12-28	WOS:000284356500009
J	Davies, MA; Samuels, Y				Davies, M. A.; Samuels, Y.			Analysis of the genome to personalize therapy for melanoma	ONCOGENE			English	Review						BRAF; NRAS; C-KIT; ERBB4; GN alpha Q	MULTIKINASE INHIBITOR SORAFENIB; PHASE-II TRIAL; RECOMBINANT INTERLEUKIN-2 THERAPY; COOPERATIVE-ONCOLOGY-GROUP; KIT PROTEIN EXPRESSION; ACUTE MYELOID-LEUKEMIA; PRIMARY UVEAL MELANOMA; METASTATIC MELANOMA; CUTANEOUS MELANOMA; BRAF MUTATIONS	The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease. Oncogene (2010) 29, 5545-5555; doi:10.1038/onc.2010.323; published online 9 August 2010	[Samuels, Y.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Samuels, Y (corresponding author), NHGRI, Canc Genet Branch, NIH, 50 South Dr,MSC 8000,Bldg 50,Room 5140, Bethesda, MD 20892 USA.	samuelsy@mail.nih.gov	Davies, Michael/GWV-2527-2022		ASCO; M D Anderson Cancer Center SPORE in Melanoma [5 P50 CA093459 03 PP-DRP3]; National Human Genome Research Institute, National Institutes of Health, USA; NATIONAL CANCER INSTITUTE [P50CA093459] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200337] Funding Source: NIH RePORTER	ASCO; M D Anderson Cancer Center SPORE in Melanoma; National Human Genome Research Institute, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Darryl Leja for graphical expertize and Nature Genetics for permission to use figures from paper doi:10.1038/ng.438. This work was supported by grants from ASCO (Young Investigator Award) and M D Anderson Cancer Center SPORE in Melanoma (Developmental Research Grant; 5 P50 CA093459 03 PP-DRP3; to MAD) and the Intramural Research Programs of the National Human Genome Research Institute, National Institutes of Health, USA (to YS).	Akslen LA, 2008, MELANOMA RES, V18, P29, DOI 10.1097/CMR.0b013e3282f32517; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Antonescu CR, 2007, INT J CANCER, V121, P257, DOI 10.1002/ijc.22681; Ashida A, 2009, INT J CANCER, V124, P862, DOI 10.1002/ijc.24048; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Baguley BC, 2010, METHODS MOL BIOL, V596, P1, DOI 10.1007/978-1-60761-416-6_1; Baker M, 2008, NATURE, V454, P556, DOI [10.1038/454556a, 10.1038/456553a]; Bastian BC, 1998, CANCER RES, V58, P2170; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brose MS, 2002, CANCER RES, V62, P6997; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Cruz F, 2003, CANCER RES, V63, P5761; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies M, 2006, EXPERT OPIN PHARMACO, V7, P2243, DOI 10.1517/14656566.7.16.2243; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Ernst DS, 2005, INVEST NEW DRUG, V23, P569, DOI 10.1007/s10637-005-1157-4; Fisher D E, 2010, Pigment Cell Melanoma Res, V23, P14, DOI 10.1111/j.1755-148X.2009.00655.x; Flaherty KT, 2008, CLIN CANCER RES, V14, P4836, DOI 10.1158/1078-0432.CCR-07-4123; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guldberg P, 1997, CANCER RES, V57, P3660; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Handolias D, 2010, PIGM CELL MELANOMA R, V23, P210, DOI 10.1111/j.1755-148X.2010.00671.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2008, CANCER-AM CANCER SOC, V112, P982, DOI 10.1002/cncr.23251; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hingorani SR, 2003, CANCER RES, V63, P5198; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Huang SY, 1996, ONCOGENE, V13, P2339; Inman JL, 2003, J SURG ONCOL, V84, P82, DOI 10.1002/jso.10297; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kim KB, 2008, BRIT J CANCER, V99, P734, DOI 10.1038/sj.bjc.6604482; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; LASSAM N, 1992, ONCOGENE, V7, P51; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maat W, 2008, INVEST OPHTH VIS SCI, V49, P23, DOI 10.1167/iovs.07-0722; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Margolin K, 2005, CANCER-AM CANCER SOC, V104, P1045, DOI 10.1002/cncr.21265; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Omholt K, 2006, MELANOMA RES, V16, P197, DOI 10.1097/01.cmr.0000200488.77970.e3; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Phan GQ, 2001, J CLIN ONCOL, V19, P3477, DOI 10.1200/JCO.2001.19.15.3477; Philp AJ, 2001, CANCER RES, V61, P7426; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintas-Cardama A, 2008, NAT CLIN PRACT ONCOL, V5, P737, DOI 10.1038/ncponc1251; Rimoldi D, 2003, CANCER RES, V63, P5712; Rivera RS, 2008, VIRCHOWS ARCH, V452, P27, DOI 10.1007/s00428-007-0524-2; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schwartz RN, 2002, ONCOLOGY-NY, V16, P11; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; SUAREZ HG, 1988, ONCOGENE, V2, P403; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; Torres-Cabala CA, 2009, MODERN PATHOL, V22, P1446, DOI 10.1038/modpathol.2009.116; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Turner EH, 2009, NAT METHODS, V6, P315, DOI 10.1038/nmeth.f.248; Ugurel S, 2005, BRIT J CANCER, V92, P1398, DOI 10.1038/sj.bjc.6602529; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Woodman SE, 2009, MOL CANCER THER, V8, P2079, DOI 10.1158/1535-7163.MCT-09-0459; Wyman K, 2006, CANCER-AM CANCER SOC, V106, P2005, DOI 10.1002/cncr.21834; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	119	87	93	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5545	5555		10.1038/onc.2010.323	http://dx.doi.org/10.1038/onc.2010.323			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20697348	Green Accepted			2022-12-28	WOS:000282946900001
J	Goncharenko-Khaider, N; Lane, D; Matte, I; Rancourt, C; Piche, A				Goncharenko-Khaider, N.; Lane, D.; Matte, I.; Rancourt, C.; Piche, A.			The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells	ONCOGENE			English	Article						death receptors; ovarian carcinoma; resistance; PI3K/Akt pathway; TRAIL; Bid	CISPLATIN-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; X-LINKED INHIBITOR; MEDIATED APOPTOSIS; KINASE; DEATH; PROTEIN; PHOSPHORYLATION; CHEMOTHERAPY; CLEAVAGE	Epithelial ovarian cancer (EOC) cells often show increased activity of the PI3K/Akt pathway. In addition, we have previously shown that EOC ascites induce Akt activation in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-sensitive EOC cell line, CaOV3, leading to TRAIL-mediated apoptosis inhibition. In this study, we investigated the role of Akt in intrinsic resistance to TRAIL, which is common in EOC cells. We report that Akt activation reduces the sensitivity of EOC cells to TRAIL. TRAIL-resistant SKOV3ip1 and COV2 cells were sensitized to TRAIL-induced apoptosis by PI3K or Akt inhibitors although inhibition of PI3K/Akt signaling pathway did not interfere with the recruitment and processing of caspase-8 to the death-inducing signaling complex. Conversely, overexpression of Akt1 in TRAIL-sensitive cells promoted resistance to TRAIL. Although the fact that TRAIL-induced caspase-8 activation was observed in both sensitive and resistant cell lines, Bid cleavage occurred only in sensitive cells or in SKOV3ip1 cells treated with LY294002. Bid expression was low in resistant cells and Akt activation down-regulated its expression. Depletion of Bid by siRNA in OVCAR3 cells was associated with a decrease in TRAIL-mediated apoptosis. Overexpression of Bid only in SKOV3ip1 cells enhanced TRAIL-induced apoptosis. Simultaneous blockade of Akt pathway further increased TRAIL-induced apoptosis. Thus, Akt acts upstream of mitochondria and inhibits TRAIL-induced apoptosis by decreasing Bid protein levels and possibly inhibiting its cleavage. Oncogene (2010) 29, 5523-5536; doi:10.1038/onc.2010.288; published online 26 July 2010	[Goncharenko-Khaider, N.; Lane, D.; Matte, I.; Rancourt, C.; Piche, A.] Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Piche, A (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, 3001 12Ieme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Alain.Piche@USherbrooke.ca			Cancer Research Society	Cancer Research Society	This study was supported by a Grant from the Cancer Research Society (A.P.). We wish to thank the Tumor Bank from the Reseau de Recherche en Cancer du Fond de Recherche en Sante du Quebec, Canada for providing the primary tumor cell samples. We also thank Dr Louis Valiquette for his assistance with the statistical analyses.	Asselin E, 2001, CANCER RES, V61, P1862; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Cuello M, 2004, CELL DEATH DIFFER, V11, P527, DOI 10.1038/sj.cdd.4401387; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fraser M, 2003, CANCER RES, V63, P7081; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hu LM, 2002, CANCER RES, V62, P1087; Izeradjene K, 2005, ONCOGENE, V24, P2050, DOI 10.1038/sj.onc.1208397; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Kandasamy K, 2002, CANCER RES, V62, P4929; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kang YC, 2004, CELL DEATH DIFFER, V11, P1287, DOI 10.1038/sj.cdd.4401489; Kim KM, 2005, J CELL BIOCHEM, V96, P376, DOI 10.1002/jcb.20512; Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278; Kim YH, 2007, J CELL BIOCHEM, V100, P998, DOI 10.1002/jcb.21098; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klinck R, 2008, CANCER RES, V68, P657, DOI 10.1158/0008-5472.CAN-07-2580; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lane D, 2008, INT J GYNECOL CANCER, V18, P670, DOI 10.1111/j.1525-1438.2007.01062.x; Lane D, 2004, GYNECOL ONCOL, V93, P594, DOI 10.1016/j.ygyno.2004.03.029; Lane D, 2006, MOL CANCER THER, V5, P509, DOI 10.1158/1535-7163.MCT-05-0362; Lane D, 2010, ONCOGENE, V29, P3519, DOI 10.1038/onc.2010.107; Lane D, 2007, INT J CANCER, V121, P1227, DOI 10.1002/ijc.22840; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Page C, 2000, ANTICANCER RES, V20, P407; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Siervo-Sassi RR, 2003, CANCER LETT, V190, P61, DOI 10.1016/S0304-3835(02)00579-7; Westfall SD, 2005, MOL CANCER THER, V4, P1764, DOI 10.1158/1535-7163.MCT-05-0192; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	48	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5523	5536		10.1038/onc.2010.288	http://dx.doi.org/10.1038/onc.2010.288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661217	hybrid, Green Published			2022-12-28	WOS:000282945800009
J	Bengoechea-Alonso, MT; Ericsson, J				Bengoechea-Alonso, M. T.; Ericsson, J.			Tumor suppressor Fbxw7 regulates TGF beta signaling by targeting TGIF1 for degradation	ONCOGENE			English	Article						TGF beta; TGIF; Fbxw7; ubiquitin; tumor suppressor; protein degradation	SMAD TRANSCRIPTIONAL COREPRESSOR; F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; FBW7 UBIQUITIN LIGASE; CYCLIN-E; C-MYC; GROWTH; TRANSDUCTION; SCFFBW7; CANCER	Transforming growth factor-beta (TGF beta) signaling regulates multiple cellular processes, including extracellular matrix production, cell growth, apoptosis and differentiation. Dysfunction of TGF beta signaling has been implicated in various human disorders ranging from vascular diseases to cancer. TGF beta signaling is negatively regulated by the transcriptional repressor TGF beta-induced factor 1 (TGIF1). The tumor suppressor Fbxw7 is the substrate-recognition factor of a ubiquitin ligase that targets multiple proteins for degradation, including c-Myc, cyclin E, c-Jun and Notch. Here, we describe that TGIF1 is targeted for degradation by Fbxw7 in a phosphorylation-dependent manner. Inactivation of Fbxw7 results in the accumulation of phosphorylated TGIF1 molecules and repression of TGF beta-dependent transcription. Cancer cell lines with inactivating mutations in Fbxw7 show enhanced levels of TGIF1 and attenuated TGF beta-dependent signaling. Importantly, inactivation of Fbxw7 attenuates TGF beta-dependent regulation of cell growth and migration. Taken together, our results suggest that Fbxw7 is a novel regulator of TGF beta signaling. Oncogene (2010) 29, 5322-5328; doi: 10.1038/onc.2010.278; published online 12 July 2010	[Bengoechea-Alonso, M. T.; Ericsson, J.] Univ Coll Dublin, UCD Conway Inst, Sch Med & Med Sci, Dublin D4, Ireland	University College Dublin	Ericsson, J (corresponding author), Univ Coll Dublin, UCD Conway Inst, Sch Med & Med Sci, Dublin D4, Ireland.	johan.ericsson@ucd.ie	Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	Ludwig Institute for Cancer Research Ltd.; Science Foundation Ireland [07/SK/B1242b]	Ludwig Institute for Cancer Research Ltd.; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We thank Ulla Engstrom for peptide synthesis and antibody purification, and Aris Moustakas, Lars van der Heide and Peter Lonn for plasmids, antibodies and advice. This work was supported by a grant from the Ludwig Institute for Cancer Research Ltd. JE is the recipient of a Science Foundation Ireland Stokes Professorship Award (07/SK/B1242b).	Bartholin L, 2006, MOL CELL BIOL, V26, P990, DOI 10.1128/MCB.26.3.990-1001.2006; Bengoechea-Alonso MT, 2009, J BIOL CHEM, V284, P5885, DOI 10.1074/jbc.M807906200; Faresse N, 2008, EMBO J, V27, P1804, DOI 10.1038/emboj.2008.109; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Onoyama I, 2008, CELL CYCLE, V7, P3307, DOI 10.4161/cc.7.21.6931; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	26	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5322	5328		10.1038/onc.2010.278	http://dx.doi.org/10.1038/onc.2010.278			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622901				2022-12-28	WOS:000282089100010
J	Yang, WL; Zhang, X; Lin, HK				Yang, W-L; Zhang, X.; Lin, H-K			Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development	ONCOGENE			English	Review						protein kinase; ubiquitination; phosphorylation; Akt; TRAF6; tumorigenesis	NF-KAPPA-B; CYCLIN D1; ONCOGENIC FUNCTION; AKT ACTIVATION; RECEPTOR; LIGASE; PTEN; P53; POLYUBIQUITINATION; BINDING	Ubiquitination is an important post-translational modification that has a pivotal role in numerous biological functions, such as cell growth, proliferation, apoptosis, DNA damage response, innate immune response and neuron degeneration. Although ubiquitination is thought to achieve these functions by targeting proteins for proteasome-dependent degradation, recent studies suggest that ubiquitination also has nonproteolytic functions, such as protein trafficking, kinase and phosphatase activation, which are involved in cell survival and cancer development. These progresses have advanced our current understanding of the novel functions of ubiquitination in signal transduction pathways and may provide novel paradigms for the treatment of human cancers. Oncogene (2010) 29, 4493-4503; doi: 10.1038/onc.2010.190; published online 7 June 2010	[Yang, W-L; Zhang, X.; Lin, H-K] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Yang, W-L; Zhang, X.; Lin, H-K] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Lin, HK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	hklin@mdanderson.org	Yang, Wei-Lei/E-2598-2012	Zhang, Xian/0000-0001-9674-7886	NCI; Department of Defense; MD Anderson Research Trust; NATIONAL CANCER INSTITUTE [R01CA149321] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); MD Anderson Research Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Lin's laboratory for their comments and suggestions. We extend our special thanks to Yuan Gao for her critical reading and for editing the paper. We apologize to many investigators whose important works were not cited here due to space limitations. This work is supported by the MD Anderson Research Trust Scholar Fund, a RO1 grant from NCI, and New Investigator Award from the Department of Defense to HK Lin.	Adhikari A, 2009, DEV CELL, V16, P485, DOI 10.1016/j.devcel.2009.04.001; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Amati B, 2007, NAT CELL BIOL, V9, P729, DOI 10.1038/ncb0707-729; Ashida H, 2010, NAT CELL BIOL, V12, P66, DOI 10.1038/ncb2006; Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brooks CL, 2007, ONCOGENE, V26, P7262, DOI 10.1038/sj.onc.1210531; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Conze DB, 2008, MOL CELL BIOL, V28, P3538, DOI 10.1128/MCB.02098-07; Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Schutter J, 2009, J BIOL CHEM, V284, P36062, DOI 10.1074/jbc.M109.064923; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fallon L, 2006, NAT CELL BIOL, V8, P834, DOI 10.1038/ncb1441; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962; Heemers HV, 2009, CANCER CELL, V15, P245, DOI 10.1016/j.ccr.2009.03.009; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Inohara N, 2000, J BIOL CHEM, V275, P27823; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Klein S, 2009, CURR OPIN CELL BIOL, V21, P185, DOI 10.1016/j.ceb.2008.12.006; Kon N, 2010, ONCOGENE, V29, P1270, DOI 10.1038/onc.2009.427; Kong M, 2007, J BIOL CHEM, V282, P29712, DOI 10.1074/jbc.M703159200; Korchnak AC, 2009, CELL SIGNAL, V21, P1620, DOI 10.1016/j.cellsig.2009.06.008; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lazar DF, 2006, NAT REV DRUG DISCOV, V5, P333, DOI 10.1038/nrd2007; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lynch OT, 2004, MOL INTERV, V4, P144, DOI 10.1112/4.3.3; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; McConnell JL, 2010, BIOCHEMISTRY-US, V49, P1713, DOI 10.1021/bi901837h; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Monami G, 2008, J CELL PHYSIOL, V216, P426, DOI 10.1002/jcp.21405; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Rong SB, 2001, J MED CHEM, V44, P898, DOI 10.1021/jm000493i; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Solit DB, 2003, CANCER RES, V63, P2139; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Sun SC, 2008, NAT REV IMMUNOL, V8, P501, DOI 10.1038/nri2337; [孙雪涛 Sun Xuetao], 2004, [中国工程科学, Engineering science], V6, P1; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Toker A, 2009, DEV CELL, V17, P752, DOI 10.1016/j.devcel.2009.12.003; Tremblay ML, 2008, CELL METAB, V7, P101, DOI 10.1016/j.cmet.2008.01.004; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Varghese B, 2008, MOL CELL BIOL, V28, P5275, DOI 10.1128/MCB.00350-08; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yamazaki K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000387; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	107	58	64	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4493	4503		10.1038/onc.2010.190	http://dx.doi.org/10.1038/onc.2010.190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531303	Green Accepted			2022-12-28	WOS:000280862300001
J	Jeninga, EH; Schoonjans, K; Auwerx, J				Jeninga, E. H.; Schoonjans, K.; Auwerx, J.			Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility	ONCOGENE			English	Review						AMPK; ATP citrate lyase; GCN5; mitochondria; PGC-1 alpha; SIRT1	CONTROLLING MITOCHONDRIAL BIOGENESIS; GLOBAL HISTONE ACETYLATION; FATTY-ACID OXIDATION; LIFE-SPAN EXTENSION; HUMAN BREAST-CANCER; TRANSCRIPTIONAL COACTIVATOR; SACCHAROMYCES-CEREVISIAE; PPAR-GAMMA; HEPATIC GLUCONEOGENESIS; CALORIE RESTRICTION	Organisms adapt their metabolism to meet ever changing environmental conditions. This metabolic adaptation involves at a cellular level the fine tuning of mitochondrial function, which is mainly under the control of the transcriptional co-activator proliferator-activated receptor gamma co-activator (PGC)-1 alpha. Changes in PGC-1 alpha activity coordinate a transcriptional response, which boosts mitochondrial activity in times of energy needs and attenuates it when energy demands are low. Reversible acetylation has emerged as a key way to alter PGC-1 alpha activity. Although it is well established that PGC-1 alpha is deacetylated and activated by Sirt1 and acetylated and inhibited by GCN5, less is known regarding how these enzymes themselves are regulated. Recently, it became clear that the energy sensor, AMP-activated kinase (AMPK) translates the effects of energy stress into altered Sirt1 activity by regulating the intracellular level of its co-substrate nicotinamide adenine dinucleotide (NAD)(+). Conversely, the enzyme ATP citrate lyase (ACL), relates energy balance to GCN5, through the control of the nuclear production of acetyl-CoA, the substrate for GCN5's acetyltransferase activity. We review here how these metabolic signaling pathways, affecting GCN5 and Sirt1 activity, allow the reversible acetylation-deacetylation of PGC-1 alpha and the adaptation of mitochondrial energy homeostasis to energy levels. Oncogene (2010) 29, 4617-4624; doi:10.1038/onc.2010.206; published online 7 June 2010	[Jeninga, E. H.; Schoonjans, K.; Auwerx, J.] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Auwerx, J (corresponding author), Ecole Polytech Fed Lausanne, EPFL SV IBI1 LISP NCEM1, Batiment AI AI 1-145,Stn 15, CH-1015 Lausanne, Switzerland.	admin.auwerx@epfl.ch	Auwerx, Johan/ABE-9307-2021	Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393	Ecole Polytechnique Federale de Lausanne; Swiss National Science Foundation; NIH [DK59820]; European Research Council [ERC-2008-AdG23118]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER	Ecole Polytechnique Federale de Lausanne; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Research Council(European Research Council (ERC)European Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Ecole Polytechnique Federale de Lausanne, Swiss National Science Foundation, NIH (DK59820) and the European Research Council Ideas programme (Sirtuins; ERC-2008-AdG23118).	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Bracha AL, 2010, NAT CHEM BIOL, V6, P202, DOI 10.1038/NCHEMBIO.301; Brown WJ, 2007, AM J PREV MED, V33, P404, DOI 10.1016/j.amepre.2007.07.029; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Coste A, 2008, P NATL ACAD SCI USA, V105, P17187, DOI 10.1073/pnas.0808207105; COSTFORD SR, 2009, AM J PHYSIOL-ENDOC M, V298, P117; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Feilchenfeldt J, 2004, CANCER LETT, V203, P25, DOI 10.1016/j.canlet.2003.08.024; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Friis RMN, 2009, NUCLEIC ACIDS RES, V37, P3969, DOI 10.1093/nar/gkp270; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Houtkooper RH, 2010, ENDOCR REV, V31, P194, DOI 10.1210/er.2009-0026; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kals M, 2005, YEAST, V22, P213, DOI 10.1002/yea.1204; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kelly TJ, 2009, J BIOL CHEM, V284, P19945, DOI 10.1074/jbc.M109.015164; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Leriche M., 1926, MEM SOC GEOL NORD, V32, P365; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208; Ortolan E, 2002, CELL BIOCHEM FUNCT, V20, P309, DOI 10.1002/cbf.978; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; SZUTOWICZ A, 1979, BRIT J CANCER, V39, P681, DOI 10.1038/bjc.1979.120; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Turyn J, 2003, HORM METAB RES, V35, P565, DOI 10.1055/s-2003-43500; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Watkins G, 2004, ONCOL REP, V12, P483; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yin PH, 2004, BRIT J CANCER, V90, P2390, DOI 10.1038/sj.bjc.6601838; Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhang Y, 2007, CELL RES, V17, P363, DOI 10.1038/cr.2007.11	72	117	127	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4617	4624		10.1038/onc.2010.206	http://dx.doi.org/10.1038/onc.2010.206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531298	Green Accepted			2022-12-28	WOS:000281127400001
J	Singh, A; Settleman, J				Singh, A.; Settleman, J.			EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer	ONCOGENE			English	Review						EMT; cancer; cancer stem cells; drug resistance	EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; MIR-200 FAMILY; E-CADHERIN; LUNG-CANCER; REPRESSORS ZEB1; SMAD PROTEINS	Tumors are cellularly and molecularly heterogeneous, with subsets of undifferentiated cancer cells exhibiting stem cell-like features (CSCs). Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. The EMT process can be regulated by a diverse array of cytokines and growth factors, such as transforming growth factor (TGF)-beta, whose activities are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in the acquisition of invasive and metastatic properties. Recent reports indicate that the emergence of CSCs occurs in part as a result of EMT, for example, through cues from tumor stromal components. Recent evidence now indicates that EMT of tumor cells not only causes increased metastasis, but also contributes to drug resistance. In this review, we will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs. We will also highlight recent studies implicating the function of TGF-beta-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal. Finally we will discuss how EMT and CSCs may contribute to drug resistance, as well as therapeutic strategies to overcome this clinically. Oncogene (2010) 29, 4741-4751; doi: 10.1038/onc.2010.215; published online 7 June 2010	[Settleman, J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Settleman, J (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, 149 13th St, Charlestown, MA 02129 USA.	settleman@HELIX.MGH.HARVARD.EDU	Singh, Anurag/C-7347-2014	Singh, Anurag/0000-0003-4705-8683	NCI NIH HHS [K99 CA149169, K99 CA149169-01, K99 CA149169-02, R00 CA149169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K99CA149169, R00CA149169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Baulcombe DC, 2006, COLD SPRING HARB SYM, V71, P13, DOI 10.1101/sqb.2006.71.052; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chng ZZ, 2010, CELL STEM CELL, V6, P59, DOI 10.1016/j.stem.2009.11.015; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Deonarain MP, 2009, MABS-AUSTIN, V1, P12, DOI 10.4161/mabs.1.1.7347; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Feuring-Buske M, 2001, BLOOD, V97, P3882, DOI 10.1182/blood.V97.12.3882; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kuhnle M, 2009, J MED CHEM, V52, P1190, DOI 10.1021/jm8013822; LaGamba D, 2005, DEV DYNAM, V234, P132, DOI 10.1002/dvdy.20489; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEDER A, 1975, SCIENCE, V190, P893, DOI 10.1126/science.1059262; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu YQ, 2009, CELL STEM CELL, V4, P336, DOI 10.1016/j.stem.2009.02.015; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MCCAUGHAN F, 2010, AM J RESP CRIT CARE; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peacock CD, 2008, J CLIN ONCOL, V26, P2883, DOI 10.1200/JCO.2007.15.2702; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; Robey RW, 2007, MOL CANCER THER, V6, P1877, DOI 10.1158/1535-7163.MCT-06-0811; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Sayan AE, 2009, P NATL ACAD SCI USA, V106, P14884, DOI 10.1073/pnas.0902042106; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yuan P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009112; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	102	1920	2000	7	480	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4741	4751		10.1038/onc.2010.215	http://dx.doi.org/10.1038/onc.2010.215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20531305	Green Accepted			2022-12-28	WOS:000281326400001
J	Beilke, S; Oswald, F; Genze, F; Wirth, T; Adler, G; Wagner, M				Beilke, S.; Oswald, F.; Genze, F.; Wirth, T.; Adler, G.; Wagner, M.			The zinc-finger protein KCMF1 is overexpressed during pancreatic cancer development and downregulation of KCMF1 inhibits pancreatic cancer development in mice	ONCOGENE			English	Article						cancer; pancreas; KCMF1; gene trap mice; mouse model; tumor progression	TRANSFORMING-GROWTH-FACTOR; EWINGS-SARCOMA; FACTOR-ALPHA; CYCLIN D1; IN-VIVO; CELLS; MOUSE; EXPRESSION; ADENOCARCINOMA; TUMORIGENESIS	Potassium channel modulatory factor 1 (KCMF1) was found upregulated in a differential screen in the metaplastic epithelium in the pancreas of transforming growth factor (TGF)-alpha transgenic mice. Expression analysis indicated broad overexpression in human cancer tissues. Therefore, we investigated the hypothesis that KCMF1 promotes metaplastic changes and tumor development. KCMF1 represents an evolutionarily highly conserved protein with a 95% identity between human and zebrafish. KCMF1 is expressed during embryonic development and in the majority of adult tissues investigated. Upregulation of nuclear KCMF1 expression is evident in preneoplastic lesions and in several epithelial malignancies, such as pancreatic cancer in mice and humans. In cell culture and in the chicken chorioallantoic membrane model, KCMF1 enhances proliferation, migration and invasion of HEK-293 and Panc1 cells. In crossbreeding experiments, KCMF1-knockdown gene trap mice showed a reduced number and size of premalignant lesions and absence of pancreatic cancer formation in TGF-alpha transgenic mice. This effect is related to the decreased expression of G1 to S cell-cycle regulators such as cyclin D and cyclin-dependent kinase (CDK) 4. Our data support the hypothesis that KCMF1 mediates pro-oncogenic functions in vitro and in vivo and downregulation of KCMF1 results in the inhibition of pancreatic cancer formation in mice. These effects are mediated through downregulation of cell-cycle control genes such as cyclin D and CDK4. Oncogene (2010) 29, 4058-4067; doi:10.1038/onc.2010.156; published online 17 May 2010	[Beilke, S.; Oswald, F.; Adler, G.; Wagner, M.] Univ Hosp Ulm, Dept Internal Med 1, Ctr Internal Med, D-89083 Ulm, Baden Wuerttemb, Germany; [Genze, F.] Univ Ulm, Inst Pharmacol Nat Prod, Ulm, Germany; [Wirth, T.] Univ Ulm, Dept Physiol Chem, Ulm, Germany	Ulm University; Ulm University; Ulm University	Wagner, M (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Ctr Internal Med, Albert Einstein Allee 23, D-89083 Ulm, Baden Wuerttemb, Germany.	martin.wagner@uni-ulm.de	Oswald, Franz/AAO-9584-2020; Wirth, Thomas/X-7172-2019		Deutsche Forschungsgemeinschaft [SFB518: A10, A18, B23]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Jessica Wegele and Uschi Mohnle for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (SFB518: A10 to MW, A18 to FO and B23 to TW). We thank all the participating members of the SFB518 for helpful discussions, advices and materials.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; CALDAS C, 1994, CANCER RES, V54, P3568; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; de Alava E, 2007, CLIN TRANSL ONCOL, V9, P130, DOI 10.1007/s12094-007-0027-2; Ghaneh P, 2006, BEST PRACT RES CL GA, V20, P383, DOI 10.1016/j.bpg.2005.11.008; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Hahn SA, 1996, CANCER RES, V56, P490; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jang JH, 2004, FEBS LETT, V578, P21, DOI 10.1016/j.febslet.2004.10.071; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Khasawneh J, 2009, P NATL ACAD SCI USA, V106, P3354, DOI 10.1073/pnas.0802864106; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Li ZX, 2003, BIOCHEM BIOPH RES CO, V306, P623, DOI 10.1016/S0006-291X(03)00875-1; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mendez J, 2009, CRIT REV BIOCHEM MOL, V44, P343, DOI 10.1080/10409230903232618; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Nakhai LA, 2007, EVID-BASED COMPL ALT, V4, P43, DOI 10.1093/ecam/nel051; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tosh D, 2002, NAT REV MOL CELL BIO, V3, P187, DOI 10.1038/nrm761; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; Wagner M, 2002, GASTROENTEROLOGY, V122, P1898, DOI 10.1053/gast.2002.33594; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; Yamamoto M, 2006, MOL CARCINOGEN, V45, P901, DOI 10.1002/mc.20204	33	13	16	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4058	4067		10.1038/onc.2010.156	http://dx.doi.org/10.1038/onc.2010.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473331				2022-12-28	WOS:000279892400006
J	Dean, JL; Thangavel, C; McClendon, AK; Reed, CA; Knudsen, ES				Dean, J. L.; Thangavel, C.; McClendon, A. K.; Reed, C. A.; Knudsen, E. S.			Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure	ONCOGENE			English	Article						breast cancer; CDK4/6; RB; PD-0332991; cyclin D; E2F	CELL-CYCLE; RETINOBLASTOMA GENE; ESTROGEN-RECEPTOR; DEPENDENT KINASES; LUNG-CANCER; EXPRESSION; PROTEIN; RB; PHOSPHORYLATION; OVEREXPRESSION	A hallmark of cancer is the deregulation of cell-cycle machinery, ultimately facilitating aberrant proliferation that fuels tumorigenesis and disease progression. Particularly, in breast cancers, cyclin D1 has a crucial role in the development of disease. Recently, a highly specific inhibitor of CDK4/6 activity (PD-0332991) has been developed that may have efficacy in the treatment of breast cancer. To interrogate the utility of PD-0332991 in treating breast cancers, therapeutic response was evaluated on a panel of breast cancer cell lines. These analyses showed that the chronic loss of Rb is specifically associated with evolution to a CDK4/6-independent state and, ultimately, resistance to PD-0332991. However, to interrogate the functional consequence of Rb directly, knockdown experiments were performed in models that represent immortalized mammary epithelia and multiple subtypes of breast cancer. These studies showed a highly specific role for Rb in mediating the response to CDK4/6 inhibition that was dependent on transcriptional repression manifest through E2F, and the ability to attenuate CDK2 activity. Acquired resistance to PD-03322991 was specifically associated with attenuation of CDK2 inhibitors, indicating that redundancy in CDK functions represents a determinant of therapeutic failure. Despite these caveats, in specific models, PD-0332991 was a particularly effective therapy, which induced Rb-dependent cytostasis. Combined, these findings indicate the critical importance of fully understanding cell-cycle regulatory pathways in directing the utilization of CDK inhibitors in the clinic. Oncogene (2010) 29, 4018-4032; doi:10.1038/onc.2010.154; published online 17 May 2010	[Dean, J. L.; Thangavel, C.; McClendon, A. K.; Reed, C. A.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, BLSB Room 1002,233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org						Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Alle KM, 1998, CLIN CANCER RES, V4, P847; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483; Barker Stewart, 2003, Curr Opin Investig Drugs, V4, P652; BORG A, 1992, CANCER RES, V52, P2991; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; Buzdar AU, 2009, ANN ONCOL, V20, P993, DOI 10.1093/annonc/mdn739; Dannenberg Jan-Hermen, 2006, V42, P183, DOI 10.1007/002; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fry DW, 2004, MOL CANCER THER, V3, P1427; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GILLETT C, 1994, CANCER RES, V54, P1812; Halaban R, 1998, INT J MOL MED, V1, P419; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Loden M, 2002, ONCOGENE, V21, P4680, DOI 10.1038/sj.onc.1205578; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; OKAMOTO A, 1994, COLD SPRING HARB SYM, V59, P49, DOI 10.1101/SQB.1994.059.01.008; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Rizzi F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003617; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stengel KR, 2009, J BIOL CHEM, V284, P19265, DOI 10.1074/jbc.M808740200; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Vivar OI, 2009, BIOCHEM PHARMACOL, V78, P469, DOI 10.1016/j.bcp.2009.05.008; Wakimoto N, 2008, CANCER RES, V68, P6978, DOI 10.1158/0008-5472.CAN-07-5675; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; YEAGER T, 1995, CANCER RES, V55, P493; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753	60	270	276	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4018	4032		10.1038/onc.2010.154	http://dx.doi.org/10.1038/onc.2010.154			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473330	Bronze			2022-12-28	WOS:000279892400003
J	Lee, CC; Jan, HJ; Lai, JH; Ma, HI; Hueng, DY; Lee, YCG; Cheng, YY; Liu, LW; Wei, HW; Lee, HM				Lee, C-C; Jan, H-J; Lai, J-H; Ma, H-I; Hueng, D-Y; Lee, Y-C Gladys; Cheng, Y-Y; Liu, L-W; Wei, H-W; Lee, H-M			Nodal promotes growth and invasion in human gliomas	ONCOGENE			English	Article						glioma; invasion; MMP-2; Nodal	EMBRYONIC STEM-CELLS; HUMAN GLIOBLASTOMA; GENE-EXPRESSION; FACTOR-BETA; CANCER-CELLS; TUMOR-GROWTH; BRAIN-TUMOR; IN-VITRO; DIFFERENTIATION; PROLIFERATION	Uncontrolled growth and diffused invasion are major causes of mortality in patients with malignant gliomas. Nodal has been shown to have a central role in the tumorigenic signaling pathways of malignant melanoma. In this study, we show that grade IV human glioma cell lines expressed different levels of Nodal, paralleled to the potential for cell invasiveness. Treatment of glioma cell lines with recombinant Nodal (rNodal) increased matrix metalloproteinase 2 (MMP-2) secretion and cell invasiveness. The ectopic expression of Nodal in GBM glioma cells that expressed Nodal at low level resulted in increased MMP-2 secretion, enhanced cell invasiveness, raised cell proliferation rates in vitro, increased tumor growth in vivo, and was associated with poor survival in a mice xenograft model. In contrast, the knockdown of Nodal expression in U87MG glioma cells with high Nodal expression level had reduced MMP-2 secretion, less cell invasiveness, lower tumor growth in vivo and longer lifespan in mice with U87MG/shNodal cell xenografts. In addition, Nodal knockdown promoted the reversion of malignant glioma cells toward a differentiated astrocytic phenotype. Furthermore, our data support the notion that Nodal may regulate glioma progression through the induction of the leukemia inhibitory factor (LIF) and Cripto-1 through activated Smad. Oncogene (2010) 29, 3110-3123; doi: 10.1038/onc.2010.55; published online 12 April 2010	[Jan, H-J; Lai, J-H; Cheng, Y-Y; Liu, L-W; Lee, H-M] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan; [Lee, C-C] Shin Kong Mem Hosp, Dept Pathol, Taipei, Taiwan; [Lee, C-C] Taipei Med Univ, Dept Pathol, Taipei 110, Taiwan; [Lee, C-C] Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan; [Ma, H-I; Hueng, D-Y] Triserv Gen Hosp, Natl Def Med Ctr, Dept Neurol Surg, Taipei, Taiwan; [Lee, Y-C Gladys] Taipei Med Univ, Grad Inst Biomed Informat, Taipei 110, Taiwan; [Wei, H-W] Natl Taiwan Univ, Dept Anim Sci & Technol, Taipei 10764, Taiwan; [Lee, H-M] Cent Taiwan Univ Sci & Technol, Inst Pharmaceut Sci & Technol, Taichung, Taiwan; [Lee, H-M] Taipei Med Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Taipei 110, Taiwan	Taipei Medical University; Shin Kong Wu Ho Su Memorial Hospital; Taipei Medical University; Fu Jen Catholic University; National Defense Medical Center; Tri-Service General Hospital; Taipei Medical University; National Taiwan University; Central Taiwan University Science & Technology; Taipei Medical University	Lee, HM (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.	leehorng@tmu.edu.tw	Hueng, Dueng-Yuan/AAM-7807-2021	Hueng, Dueng-Yuan/0000-0001-7868-3161; WEI, HEN-WEI/0000-0001-9096-1013				Bennett JT, 2007, NATURE, V450, pE1, DOI 10.1038/nature06314; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Candolfi M, 2007, J NEURO-ONCOL, V85, P133, DOI 10.1007/s11060-007-9400-9; Chakravarti Arnab, 2008, P173; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013; Kargiotis O, 2008, ONCOGENE, V27, P4830, DOI 10.1038/onc.2008.122; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Ma HI, 2002, CANCER RES, V62, P756; Ma HI, 2002, GENE THER, V9, P2, DOI 10.1038/sj.gt.3301616; Mancino M, 2008, J CELL PHYSIOL, V215, P192, DOI 10.1002/jcp.21301; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Postovit LM, 2008, PIGM CELL MELANOMA R, V21, P348, DOI 10.1111/j.1755-148X.2008.00463.x; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Rooprai HK, 2000, BRIT J CANCER, V82, P52, DOI 10.1054/bjoc.1999.0876; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Saha S, 2008, BIOPHYS J, V94, P4123, DOI 10.1529/biophysj.107.119891; Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003; Strizzi Luigi, 2008, Breast Dis, V29, P91; Strizzi L, 2009, CANCER RES, V69, P7131, DOI 10.1158/0008-5472.CAN-09-1199; Strojnik T, 2006, ANTICANCER RES, V26, P2887; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Svechnikova I, 2008, INT J ONCOL, V32, P821; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; Wick W, 2006, CURR PHARM DESIGN, V12, P341, DOI 10.2174/138161206775201901; Zhou RX, 2000, EXP CELL RES, V254, P269, DOI 10.1006/excr.1999.4762	35	87	95	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3110	3123		10.1038/onc.2010.55	http://dx.doi.org/10.1038/onc.2010.55			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20383200	Green Submitted			2022-12-28	WOS:000278133100008
J	Marcel, V; Vijayakumar, V; Fernandez-Cuesta, L; Hafsi, H; Sagne, C; Hautefeuille, A; Olivier, M; Hainaut, P				Marcel, V.; Vijayakumar, V.; Fernandez-Cuesta, L.; Hafsi, H.; Sagne, C.; Hautefeuille, A.; Olivier, M.; Hainaut, P.			p53 regulates the transcription of its Delta 133p53 isoform through specific response elements contained within the TP53 P2 internal promoter	ONCOGENE			English	Article						p53; Delta 133p53 isoform; promoter; transcriptional regulation; genotoxic stress	CANCER-CELLS; GENE; ACTIVATION; ZEBRAFISH; DIFFERENTIATION; DELTA-113P53; SUPPRESSION; EXPRESSION; DELTA-NP73; MUTATIONS	The tumor suppressor p53 protein is activated by genotoxic stress and regulates genes involved in senescence, apoptosis and cell-cycle arrest. Nine p53 isoforms have been described that may modulate suppressive functions of the canonical p53 protein. Among them, Delta 133p53 lacks the 132 proximal residues and has been shown to modulate p53-induced apoptosis and cell-cycle arrest. Delta 133p53 is expressed from a specific mRNA, p53I4, driven by an alternative promoter P2 located between intron 1 and exon 5 of TP53 gene. Here, we report that the P2 promoter is regulated in a p53-dependent manner. Delta 133p53 expression is increased in response to DNA damage by doxorubicin in p53 wild-type cell lines, but not in p53-mutated cells. Chromatin immunoprecipitation and luciferase assays using P2 promoter deletion constructs indicate that p53 binds functional response elements located within the P2 promoter. We also show that Delta 133p53 does not bind specifically to p53 consensus DNA sequence in vitro, but competes with wild-type p53 in specific DNA-binding assays. Finally, we report that Delta 133p53 counteracts p53-dependent growth suppression in clonogenic assays. These observations indicate that D133p53 is a novel target of p53 that may participate in a negative feedback loop controlling p53 function. Oncogene (2010) 29, 2691-2700; doi:10.1038/onc.2010.26; published online 1 March 2010	[Marcel, V.; Vijayakumar, V.; Fernandez-Cuesta, L.; Hafsi, H.; Sagne, C.; Hautefeuille, A.; Olivier, M.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon 08, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Fernandez-Cuesta, Lynnette/O-2415-2017; MARCEL, Virginie/ABF-1904-2020; Fernandez-Cuesta, Lynnette/Z-1875-2019; Marcel, Virginie/H-3037-2011; Olivier, Magali/G-3728-2010; Hainaut, Pierre/B-6018-2012	Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; MARCEL, Virginie/0000-0002-9557-8221; Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Marcel, Virginie/0000-0002-9557-8221; Olivier, Magali/0000-0002-8202-342X; Hainaut, Pierre/0000-0002-1303-1610; Vijayakumar, Vineetha/0000-0002-4295-7009	Association for International Cancer Research (AICR); Ligue Regionale du Rhone Contre le Cancer	Association for International Cancer Research (AICR); Ligue Regionale du Rhone Contre le Cancer	VM is supported by la Ligue National Contre le Cancer. LF-C is supported by The Association for International Cancer Research (AICR). This project is funded by la Ligue Regionale du Rhone Contre le Cancer.	Bacus SS, 1996, ONCOGENE, V12, P2535; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Ishimoto O, 2002, CANCER RES, V62, P636; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Menendez D, 2007, ONCOGENE, V26, P2191, DOI 10.1038/sj.onc.1210277; MIYASHITA T, 1995, CELL, V80, P293; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	31	53	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2691	2700		10.1038/onc.2010.26	http://dx.doi.org/10.1038/onc.2010.26			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190805				2022-12-28	WOS:000277354600009
J	El Hour, M; Moncada-Pazos, A; Blacher, S; Masset, A; Cal, S; Berndt, S; Detilleux, J; Host, L; Obaya, AJ; Maillard, C; Foidart, JM; Ectors, F; Noel, A; Lopez-Otin, C				El Hour, M.; Moncada-Pazos, A.; Blacher, S.; Masset, A.; Cal, S.; Berndt, S.; Detilleux, J.; Host, L.; Obaya, A. J.; Maillard, C.; Foidart, J. M.; Ectors, F.; Noel, A.; Lopez-Otin, C.			Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis	ONCOGENE			English	Article						ADAMTS-12; angiogenesis; tumor suppression	MATRIX METALLOPROTEINASES; ADAMTS METALLOPROTEINASES; EMERGING ROLES; CANCER; VASCULARIZATION; SUSCEPTIBILITY; PROGRESSION; EXPRESSION; PROTEASES; STROMA	ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin motifs) constitute a family of endopeptidases related to matrix metalloproteinases. These proteases have been largely implicated in tissue remodeling and angiogenesis associated with physiological and pathological processes. To elucidate the in vivo functions of ADAMTS-12, we have generated a knockout mouse strain (Adamts12(-/-)) in which Adamts12 gene was deleted. The mutant mice had normal gestations and no apparent defects in growth, life span and fertility. By applying three different in vivo models of angiogenesis (malignant keratinocyte transplantation, Matrigel plug and aortic ring assays) to Adamts12(-/-) mice, we provide evidence for a protective effect of this host enzyme toward angiogenesis and cancer progression. In the absence of Adamts-12, both the angiogenic response and tumor invasion into host tissue were increased. Complementing results were obtained by using medium conditioned by cells overexpressing human ADAMTS-12, which inhibited vessel outgrowth in the aortic ring assay. This angioinhibitory effect of ADAMTS-12 was independent of its enzymatic activity as a mutated inactive form of the enzyme was similarly efficient in inhibiting endothelial cell sprouting in the aortic ring assay than the wild-type form. Altogether, our results show that ADAMTS-12 displays antiangiogenic properties and protect the host toward tumor progression. Oncogene (2010) 29, 3025-3032; doi:10.1038/onc.2010.49; published online 8 March 2010	[Noel, A.] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, CHU Sart Tilman, B-4000 Liege, Belgium; [Moncada-Pazos, A.; Cal, S.; Obaya, A. J.; Lopez-Otin, C.] Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, Asturias, Spain; [Ectors, F.] Univ Liege, GIGA Transgenesis, B-4000 Liege, Belgium	University of Liege; University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Liege	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, CHU Sart Tilman, Tour Pathol B23, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	López-Otín, Carlos/AAB-2106-2020; Obaya, Alvaro J./AAQ-6115-2021	López-Otín, Carlos/0000-0001-6964-1904; Obaya, Alvaro J./0000-0002-4163-2173; Noel, Agnes/0000-0002-7670-6179; MONCADA PAZOS, ANGELA/0000-0002-3871-2965	Ministerio de Ciencia e Innovacion, Fundacion M. Botin (Spain) [201279]; FP7-HEALTH-2007-A [201279]; Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium); Foundation against Cancer; DGTRE from the SPW (Region Wallonne, Belgium); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)	Ministerio de Ciencia e Innovacion, Fundacion M. Botin (Spain)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); FP7-HEALTH-2007-A; Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Foundation against Cancer; DGTRE from the SPW (Region Wallonne, Belgium); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office)	The authors acknowledge F Olivier, G Roland and L Volders for their excellent technical assistance. This work was supported by grants from Ministerio de Ciencia e Innovacion, Fundacion M. Botin (Spain), the FP7-HEALTH-2007-A-Project No. 201279 'MICROENVIMET', the Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium), the Foundation against Cancer (foundation of public interest, Belgium), the DGTRE from the SPW (Region Wallonne, Belgium), the Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium). MEH, AM, JD, LH and FE are recipients of grants from the Fonds de la Recherche Scientifique (FRS-FNRS, Belgium).	Bai XH, 2009, CELL MOL LIFE SCI, V66, P667, DOI 10.1007/s00018-008-8633-x; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Berndt S, 2006, FASEB J, V20, P2630, DOI 10.1096/fj.06-5885fje; Berndt Sarah, 2008, P305, DOI 10.1007/978-0-387-69057-5_16; Blacher S, 2008, MICROVASC RES, V75, P169, DOI 10.1016/j.mvr.2007.09.002; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Cauwe B, 2007, CRIT REV BIOCHEM MOL, V42, P113, DOI 10.1080/10409230701340019; Dunn JR, 2006, BRIT J CANCER, V94, P1186, DOI 10.1038/sj.bjc.6603006; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FUSENIG NE, 1983, J INVEST DERMATOL, V81, P168; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Jost M, 2007, AM J PATHOL, V171, P1369, DOI 10.2353/ajpath.2007.070074; Jost M, 2006, CANCER RES, V66, P5234, DOI 10.1158/0008-5472.CAN-05-4315; Jost Maud, 2008, P327, DOI 10.1007/978-0-387-69057-5_17; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Llamazares M, 2007, J CELL SCI, V120, P3544, DOI 10.1242/jcs.005751; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Moncada-Pazos A, 2009, J CELL SCI, V122, P2906, DOI 10.1242/jcs.050468; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Noel A, 2008, SEMIN CELL DEV BIOL, V19, P52, DOI 10.1016/j.semcdb.2007.05.011; Nyberg P, 2008, FRONT BIOSCI, V13, P6537, DOI 10.2741/3173; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349	30	69	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					3025	3032		10.1038/onc.2010.49	http://dx.doi.org/10.1038/onc.2010.49			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208563	Green Published, Green Submitted			2022-12-28	WOS:000277890400013
J	Kupferman, ME; Jiffar, T; El-Naggar, A; Yilmaz, T; Zhou, G; Xie, T; Feng, L; Wang, J; Holsinger, FC; Yu, D; Myers, JN				Kupferman, M. E.; Jiffar, T.; El-Naggar, A.; Yilmaz, T.; Zhou, G.; Xie, T.; Feng, L.; Wang, J.; Holsinger, F. C.; Yu, D.; Myers, J. N.			TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma	ONCOGENE			English	Article						TrkB; squamous cell carcinoma; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; NEUROTROPHIC FACTOR ACTIVATION; PROTECTS NEUROBLASTOMA-CELLS; ORAL-CAVITY; CANCER STATISTICS; TUMOR PROGRESSION; RECEPTOR TRKA; IN-VITRO; EXPRESSION; METASTASIS	Head and neck squamous cell carcinoma (HNSCC) remains a significant public health problem, accounting for over 5% of all cancer-related deaths, and these deaths primarily result from metastatic disease. The molecular processes involved in HNSCC pathogenesis and progression are poorly understood, and here we present experimental evidence for a direct role of the cell surface receptor tyrosine kinase, TrkB, in HNSCC tumor progression. Using immunohistochemical analysis and transcriptional profiling of archival HNSCC tumor specimens, we found that TrkB and its secreted ligand, brain-derived neurotrophic factor (BDNF), are expresses in greater than 50% of human HNSCC tumors, but not in normal upper aerodigestive tract (UADT) epithelia. Studies with HNSCC cell lines reveal that in vitro stimulation with BDNF, the ligand for TrkB, upregulates the migration and invasion of HNSCC cells, and both transient and stable suppressions of TrkB result in significant abrogation of constitutive and ligand-mediated migration and invasion. Furthermore, enforced overexpression of TrkB results in altered expression of molecular mediators of epithelial-to-mesenchymal transition (EMT), including downregulation of E-cadherin and upregulation of Twist. Using an in vivo mouse model of HNSCC, we were able to show that downregulation of TrkB suppresses tumor growth. These results directly implicate TrkB in EMT and the invasive behavior of HNSCC, and correlate with the in vivo overexpression of TrkB in human HNSCC. Taken together, these data suggest that the TrkB receptor may be a critical component in the multi-step tumor progression of HNSCC, and may be an attractive target for much needed new therapies for this disease. Oncogene (2010) 29, 2047-2059; doi: 10.1038/onc.2009.486; published online 18 January 2010	[Kupferman, M. E.; Jiffar, T.; Yilmaz, T.; Zhou, G.; Xie, T.; Holsinger, F. C.; Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [El-Naggar, A.] Dept Pathol, Houston, TX USA; [Feng, L.] Dept Biostat, Houston, TX USA; [Wang, J.] Dept Bioinformat, Houston, TX USA; [Yu, D.] Dept Mol & Cellular Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Kupferman, ME (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1400 Pressler St Unit 1445, Houston, TX 77030 USA.	mekupfer@mdanderson.org		Wang, Jennifer Rui/0000-0002-0807-3832; Yu, Dihua/0000-0001-6231-9381	American Head and Neck Society; Young Investigator Award (MEK); MDACC (MEK); NIH [CA16672]; NIDCR (MEK) [K08 DE019185]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE019185] Funding Source: NIH RePORTER	American Head and Neck Society; Young Investigator Award (MEK); MDACC (MEK); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDCR (MEK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank S Jasser, MS, for technical assistance, T Astin for administrative assistance and X Wu, PhD, for critical review of the paper. This study was supported by the following funding sources: American Head and Neck Society; Young Investigator Award (MEK); Head and Neck SPORE ProgramCareer Development Award, MDACC (MEK); and the MD Anderson Cancer Center Physician-Scientist Program (MEK). NIH Cancer Center Support Grant CA16672 (MDACC) and Grant K08 DE019185 from the NIDCR (MEK).	Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Armistead PM, 2007, CANCER, V110, P2293, DOI 10.1002/cncr.23038; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Chao MV, 2004, J ALZHEIMERS DIS, V6, pS7; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Ho R, 2002, CANCER RES, V62, P6462; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jaboin J, 2002, CANCER RES, V62, P6756; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Karamouzis MV, 2007, JAMA-J AM MED ASSOC, V298, P70, DOI 10.1001/jama.298.1.70; Ketterer K, 2003, CLIN CANCER RES, V9, P5127; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; Kupferman ME, 2006, OTOLARYNG CLIN N AM, V39, P229, DOI 10.1016/j.otc.2005.11.003; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Luikart BW, 2008, J NEUROSCI, V28, P7006, DOI 10.1523/JNEUROSCI.0195-08.2008; Martens LK, 2007, J BIOL CHEM, V282, P14379, DOI 10.1074/jbc.M609857200; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Nakashima T, 2000, BBA-GENE STRUCT EXPR, V1492, P441, DOI 10.1016/S0167-4781(00)00100-7; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929; Yigitbasi OG, 2004, CANCER RES, V64, P7977, DOI 10.1158/0008-5472.CAN-04-1477; Zhou G, 2008, ONCOGENE, V27, P3527, DOI 10.1038/sj.onc.1211015	41	147	150	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2047	2059		10.1038/onc.2009.486	http://dx.doi.org/10.1038/onc.2009.486			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101235	Green Accepted			2022-12-28	WOS:000276402800004
J	Fougere, M; Gaudineau, B; Barbier, J; Guaddachi, F; Feugeas, JP; Auboeuf, D; Jauliac, S				Fougere, M.; Gaudineau, B.; Barbier, J.; Guaddachi, F.; Feugeas, J-P; Auboeuf, D.; Jauliac, S.			NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene	ONCOGENE			English	Article						NFAT3; LCN2; estrogen receptor alpha; motility; breast	GELATINASE-ASSOCIATED LIPOCALIN; ESTROGEN-RECEPTOR-ALPHA; T-CELLS; PANCREATIC-CANCER; NUCLEAR FACTOR; EXPRESSION; NGAL; IDENTIFICATION; INVASION; PROTEIN	NFAT1 and NFAT5 act as pro-invasive and promigratory transcription factors in breast carcinoma, contributing to the formation of metastases. We report that NFAT3 is specifically expressed in estrogen receptor a positive (ERA +) breast cancer cells. We show that NFAT3 inhibits by itself the invasion capacity of ERA + breast cancer cells and needs to cooperate with ERA to inhibit their migration. Conversely, NFAT3 downregulation results in actin reorganization associated with increased migration and invasion capabilities. NFAT3 signaling reduces migration through inhibition of Lipocalin 2 (LCN2) gene expression. Collectively, our study unravels an earlier unknown NFAT3/LCN2 axis that critically controls motility in breast cancer. Oncogene (2010) 29, 2292-2301; doi: 10.1038/onc.2009.499; published online 25 January 2010	[Fougere, M.; Gaudineau, B.; Guaddachi, F.; Feugeas, J-P; Jauliac, S.] Univ Paris Diderot, Hop St Louis, Inst Hematol, CNRS,UMR7212,INSERM,U944, F-75475 Paris 10, France; [Barbier, J.; Auboeuf, D.] Hop St Louis, INSERM, Inst Hematol, U685,AVENIR,Ctr Hayem, Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jauliac, S (corresponding author), Univ Paris Diderot, Hop St Louis, Inst Hematol, CNRS,UMR7212,INSERM,U944, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	sebastien.jauliac@inserm.fr	Jauliac, Sebastien/B-7847-2010; Auboeuf, Didier/M-4610-2014	Jauliac, Sebastien/0000-0002-1712-3416; Auboeuf, Didier/0000-0002-3757-0002	Conseil Regional d'Ile-de-France; Ministere de la Recherche; INSERM Region Ile-de-France; ARC; Canceropole Ile-de-France; Research Ministry; INSERM AVENIR; Ligue Nationale contre le Cancer; Comitede Paris of Ligue Nationale contre le Cancer; Comite Tumeurs de la Fondation de France	Conseil Regional d'Ile-de-France(Region Ile-de-France); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); INSERM Region Ile-de-France(Region Ile-de-France); ARC(Australian Research Council); Canceropole Ile-de-France(Region Ile-de-France); Research Ministry; INSERM AVENIR(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Comitede Paris of Ligue Nationale contre le Cancer; Comite Tumeurs de la Fondation de France	We thank H de The, D Auboeuf and members of their laboratories for insightful discussions. We thank E Turpin, P Bertheau for providing their microarray data. We thank J L Poyet for providing the T7-pcDNA3 vector and G lazennec for the ER alpha expression vector. We thank T Hoey for providing the human NFAT3 expression vector. We thank J-C Gluckman for reading the paper. We thank N Setterblad at the Service Commun d'Imagerie Cellulaire et Moleculaire of the Institut Universitaire d'Hematologie IFR105 for confocal microscopy. The Service Commun d'Imagerie Cellulaire et Moleculaire is supported by grants from the Conseil Regional d'Ile-de-France and the Ministere de la Recherche. M Fougere was supported by a doctoral grant from INSERM Region Ile-de-France and an ARC fellowship. B Gaudineau was supported by a grant from the Canceropole Ile-de-France and J Barbier by a grant from the Research Ministry. This work was supported by the INSERM AVENIR Program and grants from Ligue Nationale contre le Cancer, the Comitede Paris of Ligue Nationale contre le Cancer, ARC, and the Comite Tumeurs de la Fondation de France and the Canceropole Ile-de-France.	Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3; Benedito AB, 2005, J BIOL CHEM, V280, P2818, DOI 10.1074/jbc.M408741200; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; Flower DR, 1996, BIOCHEM J, V318, P1; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; Gruvberger S, 2001, CANCER RES, V61, P5979; Gwira JA, 2005, J BIOL CHEM, V280, P7875, DOI 10.1074/jbc.M413192200; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Leng X, 2008, ONCOGENE, V27, P6110, DOI 10.1038/onc.2008.209; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Li CI, 2001, J NATL CANCER I, V93, P1008, DOI 10.1093/jnci/93.13.1008; Lim R, 2007, INT J CANCER, V120, P2426, DOI 10.1002/ijc.22352; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Playford RJ, 2006, GASTROENTEROLOGY, V131, P809, DOI 10.1053/j.gastro.2006.05.051; PRICE JE, 1990, CANCER RES, V50, P717; Provatopoulou X, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-390; Qin X, 2008, CELL MOL LIFE SCI, V65, P2752, DOI 10.1007/s00018-008-8273-1; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shi H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-83; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; THOMPSON EW, 1988, CANCER RES, V48, P6764; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang H, 2005, J BIOL CHEM, V280, P43188, DOI 10.1074/jbc.M506598200; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420; Zhong L, 2004, PROTEOMICS, V4, P1216, DOI 10.1002/pmic.200200679	47	39	42	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2292	2301		10.1038/onc.2009.499	http://dx.doi.org/10.1038/onc.2009.499			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101218				2022-12-28	WOS:000276685200014
J	Santo, L; Vallet, S; Hideshima, T; Cirstea, D; Ikeda, H; Pozzi, S; Patel, K; Okawa, Y; Gorgun, G; Perrone, G; Calabrese, E; Yule, M; Squires, M; Ladetto, M; Boccadoro, M; Richardson, PG; Munshi, NC; Anderson, KC; Raje, N				Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Patel, K.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Yule, M.; Squires, M.; Ladetto, M.; Boccadoro, M.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N.			AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3 beta activation and RNA polymerase II inhibition	ONCOGENE			English	Article						myeloma; cyclin-dependent kinase; GSK-3 beta; RNA pol II	GLYCOGEN-SYNTHASE KINASE-3; DOWN-REGULATION; CELL-CYCLE; PROTEIN-KINASE; SELICICLIB CYC202; R-ROSCOVITINE; CANCER-CELLS; KAPPA-B; TRANSCRIPTION; SURVIVAL	Dysregulated cell cycling is a universal hallmark of cancer and is often mediated by abnormal activation of cyclin-dependent kinases (CDKs) and their cyclin partners. Overexpression of individual complexes are reported in multiple myeloma (MM), making them attractive therapeutic targets. In this study, we investigate the preclinical activity of a novel small-molecule multi-CDK inhibitor, AT7519, in MM. We show the anti-MM activity of AT7519 displaying potent cytotoxicity and apoptosis; associated with in vivo tumor growth inhibition and prolonged survival. At the molecular level, AT7519 inhibited RNA polymerase II (RNA pol II) phosphorylation, a CDK9, 7 substrate, associated with decreased RNA synthesis confirmed by [(3)H] Uridine incorporation. In addition, AT7519 inhibited glycogen synthase kinase 3 beta (GSK-3 beta) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3 beta knockdown restored MM survival, suggesting the involvement of GSK-3 beta in AT7519-induced apoptosis. GSK-3 beta activation was independent of RNA pol II dephosphorylation confirmed by alpha-amanitin, a specific RNA pol II inihibitor, showing potent inhibition of RNA pol II phosphorylation without corresponding effects on GSK-3 beta phosphorylation. These results offer new insights into the crucial, yet controversial role of GSK-3 beta in MM and show significant anti-MM activity of AT7519, providing the rationale for its clinical evaluation in MM. Oncogene (2010) 29, 2325-2336; doi:10.1038/onc.2009.510; published online 25 January 2010	[Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N.] Harvard Univ, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Sch Med, Boston, MA 02115 USA; [Vallet, S.; Pozzi, S.; Patel, K.; Raje, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA; [Yule, M.; Squires, M.] Astex Therapeut Ltd, Cambridge, England; [Ladetto, M.; Boccadoro, M.] Univ Turin, Div Ematol, Turin, Italy	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Astex Pharmaceuticals; University of Turin	Santo, L (corresponding author), Harvard Univ, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Sch Med, 44 Binney St, Boston, MA 02115 USA.	loredana_santo@dfci.harvard.edu	Perrone, Giulia/L-4565-2017; Pozzi, Samantha/A-7617-2012; Vallet, Sonia/AHE-3935-2022; Munshi, Nikhil/ABE-2338-2021; ladetto, marco/AAA-5546-2022	Perrone, Giulia/0000-0002-4312-0577; Pozzi, Samantha/0000-0001-7917-1774; Vallet, Sonia/0000-0003-0146-8089; ladetto, marco/0000-0002-8283-2681; Boccadoro, Mario/0000-0001-8130-5209; Patel, Kishan/0000-0002-5526-2900	ASCO CDA; Multiple Myeloma Research Foundation (MMRF); International Myeloma Foundation (IMF); Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [P50CA100707, P01CA078378] Funding Source: NIH RePORTER	ASCO CDA; Multiple Myeloma Research Foundation (MMRF); International Myeloma Foundation (IMF); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by ASCO CDA, Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF) and Leukemia and Lymphoma Society Clinical Scholar Award.	Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; G-Amlak M, 2002, BIOCHEM BIOPH RES CO, V297, P760, DOI 10.1016/S0006-291X(02)02278-7; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Grimes CA, 2001, PROG NEUROBIOL, V65, P497, DOI 10.1016/S0301-0082(01)00024-7; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hideshima T, 2007, BRIT J HAEMATOL, V138, P783, DOI 10.1111/j.1365-2141.2007.06714.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Loyer P, 2005, CELL SIGNAL, V17, P1033, DOI 10.1016/j.cellsig.2005.02.005; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McInnes C, 2008, DRUG DISCOV TODAY, V13, P875, DOI 10.1016/j.drudis.2008.06.012; Menu E, 2008, CANCER RES, V68, P5519, DOI 10.1158/0008-5472.CAN-07-6404; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Nakagawa Y, 2006, AM J HEMATOL, V81, P824, DOI 10.1002/ajh.20656; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Neri A, 2008, LEUKEMIA LYMPHOMA, V49, P1374, DOI 10.1080/10428190802078289; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Raje N, 2009, LEUKEMIA, V23, P961, DOI 10.1038/leu.2008.378; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Squires MS, 2009, MOL CANCER THER, V8, P324, DOI 10.1158/1535-7163.MCT-08-0890; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tu YP, 2000, CANCER RES, V60, P6763; Vene R, 2008, CANCER RES, V68, P6987, DOI 10.1158/0008-5472.CAN-07-6362; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; WIELAND T, 1991, EXPERIENTIA, V47, P1186, DOI 10.1007/BF01918382; Wyatt PG, 2008, J MED CHEM, V51, P4986, DOI 10.1021/jm800382h; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	45	100	105	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2325	2336		10.1038/onc.2009.510	http://dx.doi.org/10.1038/onc.2009.510			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101221	Green Accepted			2022-12-28	WOS:000276951500002
J	Ehsanian, R; Brown, M; Lu, H; Yang, XP; Pattatheyil, A; Yan, B; Duggal, P; Chuang, R; Doondeea, J; Feller, S; Sudol, M; Chen, Z; Van Waes, C				Ehsanian, R.; Brown, M.; Lu, H.; Yang, X. P.; Pattatheyil, A.; Yan, B.; Duggal, P.; Chuang, R.; Doondeea, J.; Feller, S.; Sudol, M.; Chen, Z.; Van Waes, C.			YAP dysregulation by phosphorylation or Delta Np63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets	ONCOGENE			English	Article						YAP; p53; Delta Np63; p73; apoptosis; cancer	SQUAMOUS-CELL CARCINOMA; YES-ASSOCIATED PROTEIN; NF-KAPPA-B; GROWTH-FACTOR-RECEPTOR; TUMOR-SUPPRESSOR; WW DOMAIN; PROANGIOGENIC CYTOKINES; HIPPO PATHWAY; DNA-DAMAGE; ACTIVATION	Overexpression of the Yes-associated protein (YAP), and TP53 family members Delta Np63 and p73, have been independently detected in subsets of head and neck squamous cell carcinomas (HNSCCs). YAP may serve as a nuclear cofactor with Delta Np63 and p73, but the functional role of YAP and their potential relationship in HNSCCs are unknown. In this study, we show that in a subset of HNSCC lines and tumors, YAP expression is increased but localized in the cytoplasm in association with increased AKT and YAP phosphorylation, and with decreased expression of Delta Np63 and p73. In another subset, YAP expression is decreased but detectable in the nucleus in association with lower AKT and YAP phosphorylation, and with increased Delta Np63 and p73 expression. Inhibiting AKT decreased serine-127 phosphorylation and enhanced nuclear translocation of YAP. Delta Np63 bound to the YAP promoter and suppressed its expression. Transfection of a YAP-serine-127-alanine phosphoacceptor-site mutant or Delta Np63 knockdown significantly increased nuclear YAP and cell death. Conversely, YAP knockdown enhanced cell proliferation, survival, migration and cisplatin chemoresistance. Thus, YAP function as a tumor suppressor may alternatively be dysregulated by AKT phosphorylation at serine-127 and cytoplasmic sequestration, or by transcriptional repression by Delta Np63, in different subsets of HNSCC. AKT and/or Delta Np63 are potential targets for enhancing YAP-mediated apoptosis and chemosensitivity in HNSCCs. Oncogene (2010) 29, 6160-6171; doi:10.1038/onc.2010.339; published online 23 August 2010	[Ehsanian, R.; Brown, M.; Lu, H.; Yang, X. P.; Pattatheyil, A.; Yan, B.; Duggal, P.; Chuang, R.; Chen, Z.; Van Waes, C.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD USA; [Ehsanian, R.] Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Bethesda, MD 20817 USA; [Ehsanian, R.] NIH Oxford Univ Stanford Univ, Sch Med, Grad Partnership Program, NIH, Bethesda, MD USA; [Brown, M.] NIH, NIH Pfizer Clin Res Training Program, Bethesda, MD USA; [Doondeea, J.; Feller, S.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England; [Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; Pfizer; University of Oxford; Icahn School of Medicine at Mount Sinai	Van Waes, C (corresponding author), NIDCD, Head & Neck Surg Branch, NIH, 10-5D55,MSC 1419, Bethesda, MD 20892 USA.	vanwaesc@nidcd.nih.gov		Brown, Matthew/0000-0003-0575-3696; Lu, Hai/0000-0002-4212-3282; /0000-0002-2168-3379	NIDCD [Z1ADC-000073, Z1ADC-000074]; Head and Neck Cancer Charity; Pennsylvania Department of Health; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073] Funding Source: NIH RePORTER	NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Head and Neck Cancer Charity; Pennsylvania Department of Health; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Drs Tsutomu Oka, Maie St John and Ms Cindy Clark for their critical review; Ning Yeh, Dr Liesl Nottingham, Dr Jay Friedman, Dr Yansong Bian and Jonah Cohen for technical assistance; and Dr Paul Albert for assistance with statistical analysis. This study was supported by the NIDCD Intramural project Z1ADC-000073, Z1ADC-000074, Head and Neck Cancer Charity Grant and the Breast Cancer Coalition Grant from the Pennsylvania Department of Health.	Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Amornphimoltham P, 2008, CLIN CANCER RES, V14, P8094, DOI 10.1158/1078-0432.CCR-08-0703; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; CAREY TE, 1993, ANTICANCER RES, V13, P2561; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Danovi SA, 2008, CELL DEATH DIFFER, V15, P217, DOI 10.1038/sj.cdd.4402226; Dong G, 1997, J CELL BIOCHEM, P90; Dong G, 2001, CANCER RES, V61, P4797; Dong G, 2001, CANCER RES, V61, P5911; Downward J, 2008, MOL CELL, V32, P749, DOI 10.1016/j.molcel.2008.12.002; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Friedman J, 2007, CLIN CANCER RES, V13, P6568, DOI 10.1158/1078-0432.CCR-07-1591; Howell M, 2004, J BIOL CHEM, V279, P26300, DOI 10.1074/jbc.M401070200; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee TL, 2008, INT J CANCER, V122, P1987, DOI 10.1002/ijc.23324; Lee TL, 2007, CLIN CANCER RES, V13, P5680, DOI 10.1158/1078-0432.CCR-07-0670; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Massarelli E, 2005, CANCER-AM CANCER SOC, V104, P2430, DOI 10.1002/cncr.21476; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Rocco JW, 2006, CELL CYCLE, V5, P936, DOI 10.4161/cc.5.9.2716; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Thimmaiah KN, 2005, J BIOL CHEM, V280, P31924, DOI 10.1074/jbc.M507057200; Thurfjell N, 2005, INT J MOL MED, V16, P1065; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Worden B, 2005, CANCER RES, V65, P7071, DOI 10.1158/0008-5472.CAN-04-0989; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Yu M, 2006, CANCER RES, V66, P6722, DOI 10.1158/0008-5472.CAN-05-3758; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	52	79	83	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6160	6171		10.1038/onc.2010.339	http://dx.doi.org/10.1038/onc.2010.339			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729916	Green Accepted			2022-12-28	WOS:000284356500008
J	Chakrabarty, A; Rexer, BN; Wang, SE; Cook, RS; Engelman, JA; Arteaga, CL				Chakrabarty, A.; Rexer, B. N.; Wang, S. E.; Cook, R. S.; Engelman, J. A.; Arteaga, C. L.			H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3	ONCOGENE			English	Article						PIK3CA mutations; HER2 overexpression; HER3; heregulin; breast cancer	HUMAN BREAST-CANCER; TYROSINE KINASE INHIBITORS; GROWTH-FACTOR RECEPTOR; PIK3CA MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; TRASTUZUMAB RESISTANCE; EPITHELIAL-CELLS; HIGH-FREQUENCY; PI3K PATHWAY	Hyperactivation of phosphatidylinositol-3 kinase (PI3K) can occur as a result of somatic mutations in PIK3CA, the gene encoding the p110 alpha subunit of PI3K. The HER2 oncogene is amplified in 25% of all breast cancers and some of these tumors also harbor PIK3CA mutations. We examined mechanisms by which mutant PI3K can enhance transformation and confer resistance to HER2-directed therapies. We introduced the PI3K mutations E545K and H1047R in MCF10A human mammary epithelial cells that also overexpress HER2. Both mutants conferred a gain of function to MCF10A/HER2 cells. Expression of H1047R PI3K, but not E545K PI3K, markedly upregulated the HER3/HER4 ligand heregulin (HRG). HRG siRNA inhibited growth of H1047R but not E545K-expressing cells and synergized with the HER2 inhibitors trastuzumab and lapatinib. The PI3K inhibitor BEZ235 markedly inhibited HRG and pAKT levels and, in combination with lapatinib, completely inhibited growth of cells expressing H1047R PI3K. These observations suggest that PI3K mutants enhance HER2-mediated transformation by amplifying the ligand-induced signaling output of the ErbB network. This also counteracts the full effect of therapeutic inhibitors of HER2. These data also suggest that mammary tumors that contain both HER2 gene amplification and PIK3CA mutations should be treated with a combination of HER2 and PI3K inhibitors. Oncogene (2010) 29, 5193-5203; doi:10.1038/onc.2010.257; published online 28 June 2010	[Chakrabarty, A.; Rexer, B. N.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Wang, S. E.; Cook, R. S.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Cook, R. S.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Breast Canc Res Program, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Engelman, J. A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Canc Ctr,Dept Med, Charlestown, MA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Massachusetts General Hospital	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Canc Ctr, 777 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu		Wang, Shizhen Emily/0000-0002-5036-8175	ACS Clinical Research [CRP-07-234]; Breast Cancer Specialized Program of Research Excellence (SPORE) [P50 CA98131]; Vanderbilt-Ingram Comprehensive Cancer Center [P30 CA68485];  [R01 CA80195]; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA080195, P50CA098131] Funding Source: NIH RePORTER	ACS Clinical Research; Breast Cancer Specialized Program of Research Excellence (SPORE); Vanderbilt-Ingram Comprehensive Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr H Shelton Earp III and Dr Carlos Garcia-Echeverria for providing the HER4 antibody and NVP-BEZ235, respectively. This work was supported by R01 CA80195 (CLA), ACS Clinical Research Professorship Grant CRP-07-234 (CLA), Breast Cancer Specialized Program of Research Excellence (SPORE) P50 CA98131 and Vanderbilt-Ingram Comprehensive Cancer Center Support Grant P30 CA68485.	Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Geering B, 2007, BIOCHEM SOC T, V35, P199, DOI 10.1042/BST0350199; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lai YL, 2008, ANN SURG ONCOL, V15, P1064, DOI 10.1245/s10434-007-9751-7; Lee JY, 2007, SCIENCE, V317, P206, DOI 10.1126/science.1146073; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lerma E, 2008, VIRCHOWS ARCH, V453, P133, DOI 10.1007/s00428-008-0643-4; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li SY, 2006, BREAST CANCER RES TR, V96, P91, DOI 10.1007/s10549-005-9048-0; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Medina PJ, 2008, CLIN THER, V30, P1426, DOI 10.1016/j.clinthera.2008.08.008; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	52	78	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5193	5203		10.1038/onc.2010.257	http://dx.doi.org/10.1038/onc.2010.257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581867	Green Accepted			2022-12-28	WOS:000281867200008
J	Gan, Y; Shi, C; Inge, L; Hibner, M; Balducci, J; Huang, Y				Gan, Y.; Shi, C.; Inge, L.; Hibner, M.; Balducci, J.; Huang, Y.			Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells	ONCOGENE			English	Article						EGFR; ERK; Akt; phosphorylation; signaling; cell migration	GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; FOCAL ADHESION PROTEIN; E-CADHERIN EXPRESSION; DOWN-REGULATION; TUMOR PROGRESSION; ERBB RECEPTORS; BETA-CATENIN; C-CBL	Upregulation of epidermal growth factor receptor (EGFR) and subsequent increases in extracellular-regulated kinase (ERK) and Akt signaling are implicated in prostate cancer progression. Impaired endocytic downregulation of EGFR also contributes to oncogenic phenotypes such as metastasis. Thus, understanding the roles of divergent signaling pathways in the regulation of EGFR trafficking and EGFR-driven invasive migration may enable the development of more effective therapies. In this study, we use the human prostate cancer cell lines, DU145 and PC3, to investigate the effects of both the ERK and Akt pathways on epidermal growth factor (EGF)-mediated EGFR signaling, trafficking and cell motility. We show that DU145 and PC3 cells overexpress EGFR and migrate in a ligand (EGF)dependent manner. Next, we show that pharmacological inhibition of ERK (but not Akt) signaling enhances EGF-induced EGFR activation, ubiquitination and downregulation, and may lead to enhanced receptor turnover. These findings negatively correlate with ERK-mediated threonine phosphorylation of EGFR, implicating it as a possible mechanism. Further, we uncover that EGF promotes disassembly of cell-cell junctions, downregulation of E-cadherin and upregulation of the transcriptional repressor, Snail, typical characteristics of epithelial-mesenchymal transition (EMT). These effects are dependent on activation of Akt, as inhibition of Akt signaling abolishes EGF/EGFR-driven cell migration and EMT. Knockdown of endogenous Snail also prevents EGFR-mediated downregulation of E-cadherin, EMT and cell migration. Surprisingly, inhibition of the ERK pathway augments EGFR-dependent motility, occurring concomitantly with elevation of EGF-induced Akt activity. Collectively, our results suggest that EGF-triggered ERK activation has profound feedback on EGFR signaling and trafficking by EGFR threonine phosphorylation, and Akt has a pivotal role in EGFR-mediated cell migration by activating EMT. More important, our results also suggest that therapeutic targeting of ERK signaling may have undesirable outcomes (for example, augmenting EGFR-driven motility). Oncogene (2010) 29, 4947-4958; doi: 10.1038/onc.2010.240; published online 21 June 2010	[Gan, Y.; Shi, C.; Hibner, M.; Balducci, J.; Huang, Y.] St Josephs Hosp, Dept Obstet & Gynecol, Phoenix, AZ 85004 USA; [Inge, L.] St Josephs Hosp, Heart & Lung Inst, Phoenix, AZ 85004 USA; [Shi, C.] Huazhong Univ Sci & Technol, Dept Pathogen Biol, Tongji Med Coll, Wuhan 430074, Peoples R China	St. Joseph's Hospital and Medical Center; St. Joseph's Hospital and Medical Center; Huazhong University of Science & Technology	Huang, Y (corresponding author), St Josephs Hosp, Dept Obstet & Gynecol, 445 N 5th St,Suite 110, Phoenix, AZ 85004 USA.	yhuang@chw.edu	高, 雨莉/HGU-8187-2022		St Joseph's Foundation	St Joseph's Foundation	We thank Prof. Michael Croft for generously providing retroviral expression vector for constitutively active (myristoylated) Akt. This work was supported by a St Joseph's Foundation Startup Fund (to YH). Part of this work was presented at the 91st Endocrine Society Annual Meeting in Washington DC, USA, 2009.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Deng L, 2007, MOL ENDOCRINOL, V21, P1537, DOI 10.1210/me.2007-0138; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hipp S, 2009, J CELL MOL MED, V13, P3858, DOI 10.1111/j.1582-4934.2008.00526.x; Huang Y, 2006, ONCOGENE, V25, P7565, DOI 10.1038/sj.onc.1209740; Huang Y, 2004, ENDOCRINOLOGY, V145, P3297, DOI 10.1210/en.2003-1658; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kambhampati S, 2005, FRONT BIOSCI-LANDMRK, V10, P1355, DOI 10.2741/1625; Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ma FX, 2009, GENES CELLS, V14, P281, DOI 10.1111/j.1365-2443.2008.01267.x; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Schlessinger K, 2004, NAT CELL BIOL, V6, P913, DOI 10.1038/ncb1004-913; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Traish AM, 2009, BRIT J CANCER, V101, P1949, DOI 10.1038/sj.bjc.6605376; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; UMBAS R, 1994, CANCER RES, V54, P3929; UMBAS R, 1992, CANCER RES, V52, P5104; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yang CC, 2009, CANCER CELL, V15, P355, DOI 10.1016/j.ccr.2009.04.003; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	48	220	228	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4947	4958		10.1038/onc.2010.240	http://dx.doi.org/10.1038/onc.2010.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562913				2022-12-28	WOS:000281578700009
J	Nagasaka, K; Pim, D; Massimi, P; Thomas, M; Tomaic, V; Subbaiah, VK; Kranjec, C; Nakagawa, S; Yano, T; Taketani, Y; Myers, M; Banks, L				Nagasaka, K.; Pim, D.; Massimi, P.; Thomas, M.; Tomaic, V.; Subbaiah, V. K.; Kranjec, C.; Nakagawa, S.; Yano, T.; Taketani, Y.; Myers, M.; Banks, L.			The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction	ONCOGENE			English	Article						hScrib; phosphorylation; ERK; protein kinase A	LARGE TUMOR-SUPPRESSOR; PAPILLOMAVIRUS E6 PROTEINS; MAP KINASE KINASE; DISCS LARGE; HUMAN SCRIBBLE; NUCLEAR TRANSLOCATION; MEDIATED DEGRADATION; CYCLE PROGRESSION; DOCKING SITES; HUMAN HOMOLOG	The cell polarity regulator, human Scribble (hScrib), is a potential tumour suppressor whose loss is a frequent event in late-stage cancer development. Little is yet known about the mode of action of hScrib, although recent reports suggest its role in the regulation of cell signalling. In this study we show that hScrib is a direct regulator of extracellular signal-regulated kinase (ERK). In human keratinocytes, loss of hScrib results in elevated phospho-ERK levels and concomitant increased nuclear translocation of phospho-ERK. We also show that hScrib interacts with ERK through two well-conserved kinase interaction motif (KIM) docking sites, both of which are also required for ERK-induced phosphorylation of hScrib on two distinct residues. Although wild-type hScrib can downregulate activation of ERK and oncogenic Ras co-transforming activity, an hScrib mutant that lacks the carboxy terminal KIM docking site has no such effects. These results provide a clear mechanistic explanation of how hScrib can regulate ERK signalling and begin to explain how loss of hScrib during cancer development can contribute to disease progression. Oncogene (2010) 29, 5311-5321; doi:10.1038/onc.2010.265; published online 12 July 2010	[Nagasaka, K.; Pim, D.; Massimi, P.; Thomas, M.; Tomaic, V.; Subbaiah, V. K.; Kranjec, C.; Myers, M.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Nagasaka, K.; Nakagawa, S.; Yano, T.; Taketani, Y.] Univ Tokyo, Dept Obstet & Gynecol, Grad Sch Med, Tokyo, Japan	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Tokyo	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	nagasaka@icgeb.org; banks@icgeb.org	Kranjec, Christian/ABA-9194-2021; Nagasaka, Kazunori/AAM-4311-2020; , Subbaiah/AAB-9747-2021	Nagasaka, Kazunori/0000-0002-0696-5175; Krishna, Vanitha/0000-0002-0444-531X; Kranjec, Christian/0000-0001-9713-7406	Yoshida (YKK) Scholarship Foundation; Associazione Italiana per la Ricerca sul Cancro	Yoshida (YKK) Scholarship Foundation; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Yoshida (YKK) Scholarship Foundation (to KN) and by a research grant from the Associazione Italiana per la Ricerca sul Cancro (to LB). We are also very grateful to David Allen (Nextgen Sciences) for his kind support and advice on the phospho-mapping analyses.	Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Massimi P, 2008, EXP CELL RES, V314, P3306, DOI 10.1016/j.yexcr.2008.08.016; Nagasaka K, 2006, CANCER SCI, V97, P1217, DOI 10.1111/j.1349-7006.2006.00315.x; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	41	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5311	5321		10.1038/onc.2010.265	http://dx.doi.org/10.1038/onc.2010.265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622900				2022-12-28	WOS:000282089100009
J	Kiefel, H; Bondong, S; Erbe-Hoffmann, N; Hazin, J; Riedle, S; Wolf, J; Pfeifer, M; Arlt, A; Schafer, H; Muerkoster, SS; Altevogt, P				Kiefel, H.; Bondong, S.; Erbe-Hoffmann, N.; Hazin, J.; Riedle, S.; Wolf, J.; Pfeifer, M.; Arlt, A.; Schaefer, H.; Mueerkoester, S. Sebens; Altevogt, P.			L1CAM-integrin interaction induces constitutive NF-kappa B activation in pancreatic adenocarcinoma cells by enhancing IL-1 beta expression	ONCOGENE			English	Article						pancreatic tumour; L1CAM signalling; integrins	ADHESION MOLECULE L1; INTEGRIN-LINKED KINASE; CARCINOMA-CELLS; PRESENILIN/GAMMA-SECRETASE; THERAPEUTIC ANTIBODIES; MALIGNANT-MELANOMA; OVARIAN CARCINOMAS; COLORECTAL-CANCER; GENE-EXPRESSION; MIGRATION	L1 cell adhesion molecule (L1CAM) overexpression is often associated with bad prognosis in various human carcinomas. Recent studies also suggest a role of L1CAM in pancreatic ductal adenocarcinomas (PDAC). To further address its contribution, we expressed functional domains of L1CAM in PT45-P1 PDAC cells. We found that L1CAM that is full length (L1-FL), but neither the soluble ectodomain (L1ecto) nor the cytoplasmic part (L1cyt), could enhance cell proliferation or tumour growth in mice. Expression of L1-FL resulted in constitutive activation of NF-kappa B, which was abolished by L1CAM knockdown. We showed that the expression of IL-1 beta was selectively upregulated by L1-FL, and increased IL-1 beta levels were instrumental for sustained NF-kappa B activation. IL-1 beta production and NF-kappa B activation were abolished by knockdown of alpha 5-integrin and integrin-linked kinase, but insensitive to depletion of L1CAM cleavage proteinases. Supporting these data, PT45-P1 cells transduced with an L1CAM mutant deficient in integrin binding (L1-RGE) did not support the described L1-FL functions. Our results suggest that membranous L1CAM interacts with RGD-binding integrins, leading to sustained NF-kappa B activation by IL-1 beta production and autocrine/paracrine signalling. The unravelling of this novel mechanism sheds new light on the important role of L1CAM expression in PDAC cells. Oncogene (2010) 29, 4766-4778; doi:10.1038/onc.2010.230; published online 14 June 2010	[Kiefel, H.; Bondong, S.; Erbe-Hoffmann, N.; Hazin, J.; Riedle, S.; Wolf, J.; Pfeifer, M.; Altevogt, P.] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Arlt, A.; Schaefer, H.; Mueerkoester, S. Sebens] Univ Kiel, Clin Internal Med, Lab Mol Gastroenterol & Hepatol, Kiel, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Kiel	Altevogt, P (corresponding author), German Canc Res Ctr, D015,Neuenheimer Feld 280, D-69120 Baden Wurtemberg, Germany.	P.Altevogt@dkfz.de	Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010	Arlt, Alexander/0000-0002-6160-1059; 	Deutsche Krebshilfe (Schwerpunktprogramm: Invasion and Migration); Deutsche Forschungsgemeinschaft [SE-1831/2-1]; EU [PE-14034]; Medigene Inc. (Munich)	Deutsche Krebshilfe (Schwerpunktprogramm: Invasion and Migration)(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); EU(European Commission); Medigene Inc. (Munich)	We acknowledge the competent help of Dr Alex Stoeck (University of Michigan, Ann Arbor) in retroviral expression in the early phase of the study. We also thank Ramona Straub and Dagmar Leisner for excellent technical assistance. This study was supported by grants from Deutsche Krebshilfe (Schwerpunktprogramm: Invasion and Migration), the Deutsche Forschungsgemeinschaft project nr. SE-1831/2-1 to S.S. and the EU-FP6 framework program OVCAD project nr. PE-14034 to PA. Further financial support was received from a collaborative research grant from Medigene Inc. (Munich) to PA.	Arlt A, 2002, CANCER RES, V62, P910; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bao SD, 2008, CANCER RES, V68, P6043, DOI 10.1158/0008-5472.CAN-08-1079; Boo YJ, 2007, ANN SURG ONCOL, V14, P1703, DOI 10.1245/s10434-006-9281-8; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gast D, 2008, ONCOGENE, V27, P1281, DOI 10.1038/sj.onc.1210747; Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869; Gast D, 2008, EXP CELL RES, V314, P2411, DOI 10.1016/j.yexcr.2008.04.004; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Gouveia RM, 2008, J BIOL CHEM, V283, P28038, DOI 10.1074/jbc.M804991200; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Issa Y, 2009, J MOL MED, V87, P99, DOI 10.1007/s00109-008-0410-7; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kaifi JT, 2007, MODERN PATHOL, V20, P1183, DOI 10.1038/modpathol.3800955; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Maddaluno L, 2009, J EXP MED, V206, P623, DOI 10.1084/jem.20081211; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Muerkoester SS, 2009, INT J ONCOL, V34, P243, DOI 10.3892/ijo_00000146; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Novak-Hofer I, 2008, CANCER LETT, V261, P193, DOI 10.1016/j.canlet.2007.11.012; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Reidy M, 2006, J BIOMED MATER RES A, V77A, P542, DOI 10.1002/jbm.a.30590; Riedle S, 2009, BIOCHEM J, V420, P391, DOI 10.1042/BJ20081625; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Schniewind B, 2007, ONCOGENE, V26, P4850, DOI 10.1038/sj.onc.1210272; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Stoeck A, 2006, CANCER LETT, V239, P212, DOI 10.1016/j.canlet.2005.08.005; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3; Wolterink S, 2010, CANCER RES, V70, P2504, DOI 10.1158/0008-5472.CAN-09-3730	47	49	53	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4766	4778		10.1038/onc.2010.230	http://dx.doi.org/10.1038/onc.2010.230			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543863				2022-12-28	WOS:000281326400003
J	Talotta, F; Mega, T; Bossis, G; Casalino, L; Basbous, J; Jariel-Encontre, I; Piechaczyk, M; Verde, P				Talotta, F.; Mega, T.; Bossis, G.; Casalino, L.; Basbous, J.; Jariel-Encontre, I.; Piechaczyk, M.; Verde, P.			Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein	ONCOGENE			English	Article						c-Jun stability; FRA-1; heterodimerization; RAS transformation	TRANSCRIPTIONAL ACTIVATION; PROTEASOMAL DEGRADATION; THYROID-CELLS; AP-1; FOS; PHOSPHORYLATION; JNK; UBIQUITINATION; TRANSFORMATION; INVASIVENESS	Multiple tumorigenic pathways converge on the activating protein-1 (AP-1) family of dimeric transcription complexes by affecting transcription, mRNA decay, posttranslational modifications, as well as stability of its JUN and FOS components. Several mechanisms have been implicated in the phosphorylation-and ubiquitylation-dependent control of c-Jun protein stability. Although its dimer composition has a major role in the regulation of AP-1, little is known about the influence of heterodimerization partners on the half-life of c-Jun. The FOS family member Fra-1 is overexpressed in various tumors and cancer cell lines wherein it controls motility, invasiveness, cell survival and cell division. Oncogene-induced accumulation of Fra-1 results from both increased transcription and phosphorylation-dependent stabilization of the protein. In this report, we describe a novel role of Fra-1 as a posttranslational regulator of c-Jun. By using both constitutively and inducible transformed rat thyroid cell lines, we found that c-Jun is stabilized in response to RAS oncoprotein expression. This stabilization requires the activity of the extracellular signal-related kinase (ERK) pathway, along with c-Jun heterodimerization with Fra-1. In particular, heterodimerization with Fra-1 inhibits c-Jun breakdown by a mechanism dependent on the phosphorylation of the Fra-1 C-terminal domain that positively controls the stability of the protein in response to ERK signaling. Therefore, Fra-1 modulates AP-1 dimer composition by promoting the accumulation of c-Jun in response to oncogenic RAS signaling. Oncogene (2010) 29, 4732-4740; doi:10.1038/onc.2010.211; published online 14 June 2010	[Talotta, F.; Mega, T.; Casalino, L.; Verde, P.] CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy; [Bossis, G.; Basbous, J.; Jariel-Encontre, I.; Piechaczyk, M.] Univ Montpellier I & II, Inst Genet Mol Montpellier, CNRS, UMR 5535, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Verde, P (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy.	verde@igb.cnr.it	Basbous, Jihane/AAQ-2040-2021; Casalino, Laura/C-1506-2015; PIECHACZYK, Marc/E-7896-2013; Bossis, Guillaume/C-7172-2012	Basbous, Jihane/0000-0002-3943-627X; Casalino, Laura/0000-0002-2557-0443; PIECHACZYK, Marc/0000-0003-1367-2597; bossis, guillaume/0000-0002-3349-8250	AIRC (Associazione Italiana per la Ricerca sul Cancro); AICR (Association for International Cancer Research, UK); MIUR (Ministero dell'Istruzione, Universita e Ricerca); INCA; PAI 'Galileo'	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AICR (Association for International Cancer Research, UK); MIUR (Ministero dell'Istruzione, Universita e Ricerca)(Ministry of Education, Universities and Research (MIUR)); INCA(Institut National du Cancer (INCA) France); PAI 'Galileo'	We thank Roberto Di Lauro for the FRTL-5<SUP>ER-RAS</SUP> cell line, and Dirk Bohmann, Claus Nerlov and Latifa Bakiri for expression vectors encoding various c-Jun derivatives. We also thank Ingram Iaccarino for critical reading of this paper. This work was supported by grants to Pasquale Verde from AIRC (Associazione Italiana per la Ricerca sul Cancro), AICR (Association for International Cancer Research, UK) and PRIN-MIUR (Ministero dell'Istruzione, Universita e Ricerca). Marc Piechaczyk's group is an 'Equipe Labellisee' of the French 'Ligue Nationale contre le Cancer'. Jihane Basbous was supported by an INCA contract. Exchanges between the two laboratories received support of the PAI 'Galileo'.	Adiseshaiah P, 2008, BIOCHEM BIOPH RES CO, V371, P304, DOI 10.1016/j.bbrc.2008.04.063; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Debinski W, 2005, MOL CANCER RES, V3, P237; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; ELBAHASSI M, 2004, CLIN EXP METASTAS, V21, P293; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Malnou CE, 2007, J BIOL CHEM, V282, P31046, DOI 10.1074/jbc.M702833200; Malnou CE, 2010, J BIOL CHEM, V285, P6552, DOI 10.1074/jbc.M109.032680; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005	37	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4732	4740		10.1038/onc.2010.211	http://dx.doi.org/10.1038/onc.2010.211			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543861				2022-12-28	WOS:000281127400012
J	Sauzeau, V; Berenjeno, IM; Citterio, C; Bustelo, XR				Sauzeau, V.; Berenjeno, I. M.; Citterio, C.; Bustelo, X. R.			A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeleton	ONCOGENE			English	Article						RhoA; c-Myc; Pak; integrin; stress fibers; gene expression	GTP-BINDING PROTEINS; ROCK-I; KINASE; ACTIVATION; GTPASES; DEGRADATION; DISTINCT; MYOSIN; FAMILY; TARGET	The GTPase RhoA participates in a number of cellular processes, including cytoskeletal organization, mitogenesis and tumorigenesis. We have previously shown that the transforming activity of an oncogenic version of RhoA (Q63L mutant) was highly dependent on the transcriptional factor c-Myc. In contrast to these positive effects in the RhoA route, we show here that c-Myc affects negatively the F-actin cytoskeleton induced by RhoA(Q63L) and its downstream effector, the serine/threonine kinase Rock. This effect entails the activation of a transcriptional program that requires synergistic interactions with RhoA-derived signals and that includes the upregulation of the GTPase Cdc42 and its downstream element Pak1 as well as the repression of specific integrin subunits. The negative effects of c-Myc in the F-actin cytoskeleton are eliminated by the establishment of cell-to-cell contacts, an effect associated with the rescue of Pak1 and integrin levels at the post-transcriptional and transcriptional levels, respectively. These results reveal the presence of a hitherto unknown signaling feed-back loop between RhoA and c-Myc oncogenes that can contribute to maintain fluid cytoskeletal dynamics in cancer cells. Oncogene (2010) 29, 3781-3792; doi: 10.1038/onc.2010.134; published online 10 May 2010	[Sauzeau, V.; Berenjeno, I. M.; Citterio, C.; Bustelo, X. R.] Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; [Sauzeau, V.; Berenjeno, I. M.; Citterio, C.; Bustelo, X. R.] Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Sauzeau, Vincent/D-3548-2015; Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Sauzeau, Vincent/0000-0002-6187-0312	NIH [5R01CA73735]; Spanish Ministry of Science and Innovation [SAF2006-01789, GEN2003-20239-C06-01]; Red Tematica de Investigacion Cooperativa en Cancer [RD06/0020/0001]; Castilla y Leon Autonomous Government [GR97]; European Union [FP7-HEALTH-2007-A-201862]; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Red Tematica de Investigacion Cooperativa en Cancer; Castilla y Leon Autonomous Government; European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Blazquez for technical help. XRB work is supported by grants from the NIH (5R01CA73735), the Spanish Ministry of Science and Innovation (SAF2006-01789, GEN2003-20239-C06-01), the Red Tematica de Investigacion Cooperativa en Cancer (RD06/0020/0001), the Castilla y Leon Autonomous Government (GR97), and the 7th Framework European Union Program (FP7-HEALTH-2007-A-201862).	Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Berenjeno IM, 2007, ONCOGENE, V26, P4295, DOI 10.1038/sj.onc.1210194; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Croft DR, 2004, CANCER RES, V64, P8994, DOI 10.1158/0008-5472.CAN-04-2052; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Hatzoglou A, 2007, MOL BIOL CELL, V18, P1242, DOI 10.1091/mbc.E06-06-0510; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lee HH, 2008, J CELL BIOL, V181, P999, DOI 10.1083/jcb.200710187; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ongusaha PP, 2006, CURR BIOL, V16, P2466, DOI 10.1016/j.cub.2006.10.056; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8	30	17	18	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3781	3792		10.1038/onc.2010.134	http://dx.doi.org/10.1038/onc.2010.134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453885	Green Accepted, Green Submitted			2022-12-28	WOS:000279385200006
J	Ji, P; Smith, SM; Wang, Y; Jiang, R; Song, SW; Li, B; Sawaya, R; Bruner, JM; Kuang, J; Yu, H; Fuller, GN; Zhang, W				Ji, P.; Smith, S. M.; Wang, Y.; Jiang, R.; Song, S. W.; Li, B.; Sawaya, R.; Bruner, J. M.; Kuang, J.; Yu, H.; Fuller, G. N.; Zhang, W.			Inhibition of gliomagenesis and attenuation of mitotic transition by MIIP	ONCOGENE			English	Article						MIIP; mitotic transition; gliomagenesis; APC/C(Cdc20); centrosome; mitotic catastrophe	ANAPHASE-PROMOTING COMPLEX; PRIMARY BRAIN-TUMORS; CELL-MIGRATION; SPINDLE CHECKPOINT; CYCLIN-B; CDC20; GLIOMA; DESTRUCTION; DEGRADATION; INVASION	The migration and invasion inhibitor protein (MIIP, also known as IIp45) was discovered as a negative regulator of cell migration and invasion in glioma. Our previous studies have shown that the MIIP protein was reduced or undetectable in some tissue samples obtained from patients with glioblastoma. The significance of MIIP in gliomagenesis is unknown. In this study, we report that MIIP has an important role in the inhibition of gliomagenesis and attenuation of mitotic transition. Increased MIIP expression levels inhibited colony formation and cell growth of glioma cell lines in vitro, whereas decreased expression by specific small interfering RNA for MIIP resulted in increased cell growth. Expression of MIIP in a glial-specific mouse model blocked glioma development and progression, thus showing that MIIP is an inhibitor of gliomagenesis. Furthermore, we show that MIIP attenuates mitotic transition and results in increased mitotic catastrophe. The biochemical mechanism of MIIP in this process is associated with its regulation of anaphase-promoting complex (APC/C) activity. MIIP interacts directly with Cdc20, and the interaction of MIIP with Cdc20 inhibits APC/C-mediated degradation of cyclin B1. Thus, MIIP attenuates mitotic transition and increases mitotic catastrophe, thereby inhibiting glioma development and progression. Oncogene (2010) 29, 3501-3508; doi:10.1038/onc.2010.114; published online 26 April 2010	[Ji, P.; Smith, S. M.; Wang, Y.; Jiang, R.; Song, S. W.; Bruner, J. M.; Fuller, G. N.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Smith, S. M.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA; [Wang, Y.] Tianjin Med Univ, Gen Hosp, Dept Gynecol, Tianjin, Peoples R China; [Wang, Y.] Tianjin Med Univ, Gen Hosp, Dept Obstet, Tianjin, Peoples R China; [Jiang, R.] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Song, S. W.] Capital Med Univ, Beijing Shijitan Hosp, Canc Res Lab, Beijing, Peoples R China; [Li, B.; Yu, H.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Sawaya, R.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Kuang, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Capital Medical University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA.	wzhang@mdanderson.org		Wang, Yingmei/0000-0001-6457-3420; Fuller, Gregory/0000-0001-9447-2647; Yu, Hongtao/0000-0002-8861-049X	Texas Higher Education Coordinating Board; Anthony Bullock Brain Tumor Research Fund; NIH [RO1 CA98503]; National Foundation for Cancer Research; Goldhirsh Foundation; James S McDonnell Foundation; Oreffice Foundation; American Legion Fellowship; NATIONAL CANCER INSTITUTE [R01CA098503] Funding Source: NIH RePORTER	Texas Higher Education Coordinating Board; Anthony Bullock Brain Tumor Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Foundation for Cancer Research; Goldhirsh Foundation; James S McDonnell Foundation; Oreffice Foundation; American Legion Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kanchana Natarajan-Mendes for her contribution to the cell-cycle assays in this study, and Hong Zheng for her technical assistance. We thank Drs Ying Wu, Limei Hu and Paul Chiao for critically reviewing the manuscript and providing valuable comments. We gratefully thank Dr Kate J Newberry at the Department of Scientific Publications of MD Anderson Cancer Center for editing this paper. This study was partially supported by an ARP Grant from the Texas Higher Education Coordinating Board, the Anthony Bullock Brain Tumor Research Fund and NIH grant RO1 CA98503 (to WZ and GNF). We also thank the National Foundation for Cancer Research, the Goldhirsh Foundation, the James S McDonnell Foundation and the Oreffice Foundation for their support. Sarah M Smith (formerly Sarah M Dunlap) was supported by an NIH Pharmacoinformatics Training Fellowship and an American Legion Fellowship.	Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287; Hoffman S, 2006, NEURO-ONCOLOGY, V8, P27, DOI 10.1215/S1522851705000323; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Homer HA, 2005, REPRODUCTION, V130, P829, DOI 10.1530/rep.1.00856; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Munirajan AK, 2008, J BIOL CHEM, V283, P24426, DOI 10.1074/jbc.M802316200; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Song FF, 2010, CANCER RES, V70, P1024, DOI 10.1158/0008-5472.CAN-09-3742; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Song SW, 2005, CANCER RES, V65, P3562, DOI 10.1158/0008-5472.CAN-04-3392; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027; Wu Y, 2010, J BIOL CHEM, V285, P3554, DOI 10.1074/jbc.M109.063354; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009	30	30	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3501	3508		10.1038/onc.2010.114	http://dx.doi.org/10.1038/onc.2010.114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418911				2022-12-28	WOS:000278835400005
J	Lee, KS; Lee, YS; Lee, JM; Ito, K; Cinghu, S; Kim, JH; Jang, JW; Li, YH; Goh, YM; Chi, XZ; Wee, H; Lee, HW; Hosoya, A; Chung, JH; Jang, JJ; Kundu, JK; Surh, YJ; Kim, WJ; Ito, Y; Jung, HS; Bae, SC				Lee, K-S; Lee, Y-S; Lee, J-M; Ito, K.; Cinghu, S.; Kim, J-H; Jang, J-W; Li, Y-H; Goh, Y-M; Chi, X-Z; Wee, H.; Lee, H-W; Hosoya, A.; Chung, J-H; Jang, J-J; Kundu, J. K.; Surh, Y-J; Kim, W-J; Ito, Y.; Jung, H-S; Bae, S-C			Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer	ONCOGENE			English	Article						RUNX3; lung; adenocarcinoma; adenoma; tumor suppressor	ATYPICAL ADENOMATOUS HYPERPLASIA; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; GASTRIC-CANCER; STEM-CELLS; GENE; EXPRESSION; GROWTH	Human lung adenocarcinoma, the most prevalent form of lung cancer, is characterized by many molecular abnormalities. K-ras mutations are associated with the initiation of lung adenocarcinomas, but K-ras-independent mechanisms may also initiate lung tumors. Here, we find that the runt-related transcription factor Runx3 is essential for normal murine lung development and is a tumor suppressor that prevents lung adenocarcinoma. Runx3-/- mice, which die soon after birth, exhibit alveolar hyperplasia. Importantly, Runx3-/- bronchioli exhibit impaired differentiation, as evidenced by the accumulation of epithelial cells containing specific markers for both alveolar (that is SP-B) and bronchiolar (that is CC10) lineages. Runx3-/- epithelial cells also express Bmi1, which supports self-renewal of stem cells. Lung adenomas spontaneously develop in aging Runx3+/- mice (similar to 18 months after birth) and invariably exhibit reduced levels of Runx3. As K-ras mutations are very rare in these adenomas, Runx3+/- mice provide an animal model for lung tumorigenesis that recapitulates the preneoplastic stage of human lung adenocarcinoma development, which is independent of K-Ras mutation. We conclude that Runx3 is essential for lung epithelial cell differentiation, and that downregulation of Runx3 is causally linked to the preneoplastic stage of lung adenocarcinoma. Oncogene (2010) 29, 3349-3361; doi:10.1038/onc.2010.79; published online 15 March 2010	[Lee, K-S] Chungbuk Natl Univ, Dept Biochem, Tumor Res Ctr, Sch Med,Inst Tumor Res,Coll Med, Cheongju 361763, Chungbuk, South Korea; [Lee, J-M; Jung, H-S] Yonsei Univ, Div Anat & Dev Biol, Coll Dent, Seoul 120749, South Korea; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Sakamoto Nagasaki, Japan; [Lee, H-W] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Lab Anim Res Ctr, Seoul 120749, South Korea; [Hosoya, A.] Matsumoto Dent Univ, Dept Oral Histol, Shiojiri Nagano, Japan; [Chung, J-H; Jang, J-J] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; [Kundu, J. K.; Surh, Y-J] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Kim, W-J] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 361763, Chungbuk, South Korea; [Kim, W-J] Inst Tumor Res, Cheongju, South Korea; [Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Chungbuk National University; Yonsei University; Yonsei University Health System; Nagasaki University; Yonsei University; Matsumoto Dental University; Seoul National University (SNU); Seoul National University (SNU); Chungbuk National University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lee, KS (corresponding author), Chungbuk Natl Univ, Dept Biochem, Tumor Res Ctr, Sch Med,Inst Tumor Res,Coll Med, Cheongju 361763, Chungbuk, South Korea.	klee-2005@chungbuk.ac.kr; scbae@chungbuk.ac.kr	Jung, Han-Sung/I-3848-2012; Jang, JaJune/F-6647-2011; Chung, Jin-Haeng/F-3706-2011; Kundu, Joydeb/E-6004-2010	Lee, Jong-Min/0000-0002-9466-7644; Jung, Han-Sung/0000-0003-2795-531X; Jung, Han Sung/0000-0002-5563-7039	Korea Science and Engineering Foundation [R16-2003-002-0100102006, R13-2003-013-05001-0]; Korea Research Foundation [KRF-2005-217-E00002]	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Korea Research Foundation(National Research Foundation of Korea)	This work was supported by research grants from the Korea Science and Engineering Foundation (R16-2003-002-0100102006 to S-C Bae and R13-2003-013-05001-0 to H-S Jung) and a grant from the Basic Research Promotion Fund of the Korea Research Foundation (KRF-2005-217-E00002 to K-S Lee).	Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Bea S, 2001, CANCER RES, V61, P2409; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Cazorla M, 1998, MOL CARCINOGEN, V21, P251, DOI 10.1002/(SICI)1098-2744(199804)21:4<251::AID-MC4>3.0.CO;2-N; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Collins LG, 2007, AM FAM PHYSICIAN, V75, P56; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Dimri GP, 2002, CANCER RES, V62, P4736; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Goel A, 2004, INT J CANCER, V112, P754, DOI 10.1002/ijc.20472; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2009, ONCOGENE, V28, P1379, DOI 10.1038/onc.2008.496; Ito T, 2008, ASIAN ECON POLICY R, V3, P237, DOI 10.1111/j.1748-3131.2008.00107.x; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Mori M, 1998, ULTRASTRUCT PATHOL, V22, P459, DOI 10.3109/01913129809032282; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Okuda, 1996, Mol Diagn, V1, P139, DOI 10.1016/S1084-8592(96)70029-2; Osanai M, 2001, ULTRASTRUCT PATHOL, V25, P367, DOI 10.1080/019131201317101243; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Peacock CD, 2008, J CLIN ONCOL, V26, P2883, DOI 10.1200/JCO.2007.15.2702; Petersen I, 2001, ANAL CELL PATHOL, V22, P111, DOI 10.1155/2001/374304; Reddy R, 2004, AM J PHYSIOL-LUNG C, V286, pL658, DOI 10.1152/ajplung.00159.2003; Sato K, 2006, ONCOL REP, V15, P129; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Westra WH, 1996, CANCER RES, V56, P2224; Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wuenschell CW, 1996, J HISTOCHEM CYTOCHEM, V44, P113, DOI 10.1177/44.2.8609367; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zochbauer-Muller S, 2000, Chest Surg Clin N Am, V10, P691	57	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3349	3361		10.1038/onc.2010.79	http://dx.doi.org/10.1038/onc.2010.79			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20228843				2022-12-28	WOS:000278622700004
J	Gascoyne, DM; Dunne, J; Behjati, S; Sebire, NJ; Anderson, J; Latchman, DS				Gascoyne, D. M.; Dunne, J.; Behjati, S.; Sebire, N. J.; Anderson, J.; Latchman, D. S.			EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A	ONCOGENE			English	Article						EWS/ETS; Ewing's sarcoma; EFT; BRN3A; POU4F1	EWINGS-SARCOMA; DNA-BINDING; GENE-EXPRESSION; FUSION PROTEIN; NEUROECTODERMAL TUMORS; INHIBITS PROLIFERATION; EWS-FLI1 ONCOPROTEIN; SENSORY NEURONS; TARGET GENE; CELL-LINES	Ewing's sarcoma family tumors (ESFTs or EFTs) express neuronal markers, which indicates they may originate from cells at least partly committed to neuronal lineage. However, recent publications suggest EFT originates in mesenchymal stem cells, and EWS/ETS fusion proteins characteristic of EFT activate neuronal marker expression to confer a neural phenotype on EFT. Here we show that the neuronal marker BRN3A/POU4F1 is expressed abundantly at the protein level in primary EFT but not in rhabdomyosarcoma and neuroblastoma, and EFT cells exhibit high activity of the BRN3A proximal autoregulatory region. EWS/FLI-1 siRNA reduces BRN3A expression and promoter activity and EWS/ETS proteins are bound to the BRN3A locus, suggesting a direct function for EWS/ETS proteins in control of BRN3A expression. Differentiation-associated and autoregulatory activities of BRN3A are respectively impaired and altered in EFT cells, and EWS/FLI-1 siRNA can restore some BRN3A function. A potentially novel function for BRN3A in EFT cells is identified. These results extend the hypothesis that EWS/ETS proteins induce expression of neuronal markers such as BRN3A in EFT by showing that the function of those same markers may be restricted or controlled in an EWS/ETS-dependent manner. Oncogene (2010) 29, 3134-3145; doi: 10.1038/onc.2010.72; published online 29 March 2010	[Gascoyne, D. M.; Behjati, S.; Anderson, J.] UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London, England; [Dunne, J.] Barts & London Queen Marys Sch Med & Dent, Canc Res UK Med Oncol Lab, London, England; [Sebire, N. J.] Great Ormond St Hosp Sick Children, Dept Paediat Pathol, London WC1N 3JH, England; [Latchman, D. S.] Univ London, Birkbeck Coll, London, England	University of London; University College London; Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; Birkbeck University London	Gascoyne, DM (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Level 4 Acad Block, Oxford OX3 9DU, England.	duncan.gascoyne@ndcls.ox.ac.uk		Anderson, William/0000-0001-7509-3203; Sebire, Neil/0000-0001-5348-9063	MRC; BBSRC; CR-UK; Great Ormond Street Hospital Childrens Charity [V0907] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CR-UK(Cancer Research UK); Great Ormond Street Hospital Childrens Charity	We thank Sue Burchill (Leeds, UK) and Peter Houghton (Memphis, USA) for cell lines, Eric Turner (San Diego, USA) for alpha-Brn3a antiserum, Seong-Jin Kim (Bethesda, USA) for TGFbRII (-1670/+36), Sian Gibson and Dyanne Rampling for technical assistance and James Diss for PC-3 cells and useful discussions. Funding was provided by MRC and BBSRC (DMG and DSL), and CR-UK (JD).	Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Eng SR, 2001, J NEUROSCI, V21, P541, DOI 10.1523/JNEUROSCI.21-02-00541.2001; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; Frass B, 2002, BBA-GENE STRUCT EXPR, V1579, P207, DOI 10.1016/S0167-4781(02)00540-7; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gascoyne DM, 2004, ONCOGENE, V23, P3830, DOI 10.1038/sj.onc.1207497; Gonzalez I, 2004, CLIN CANCER RES, V10, P751, DOI 10.1158/1078-0432.CCR-0778-03; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hippenmeyer S, 2005, PLOS BIOL, V3, P878, DOI 10.1371/journal.pbio.0030159; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Landuzzi L, 2000, AM J PATHOL, V157, P2123, DOI 10.1016/S0002-9440(10)64850-X; Lanier J, 2007, DEV BIOL, V302, P703, DOI 10.1016/j.ydbio.2006.10.050; LeblondFrancillard M, 1997, J CLIN ENDOCR METAB, V82, P89, DOI 10.1210/jc.82.1.89; Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078-0432.CCR-06-1518; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THIELE CJ, 1990, CANCER INVEST, V8, P629, DOI 10.3109/07357909009018932; Torchia EC, 2003, CANCER RES, V63, P3464; Trieu M, 1999, J NEUROSCI, V19, P6549; Trieu M, 2003, DEVELOPMENT, V130, P111, DOI 10.1242/dev.00194; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yamaki K, 2005, MENT RETARD, V43, P1, DOI 10.1352/0047-6765(2005)43<1:BWSAAW>2.0.CO;2; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594	50	1	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3134	3145		10.1038/onc.2010.72	http://dx.doi.org/10.1038/onc.2010.72			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20348952				2022-12-28	WOS:000278133100010
J	Ercan, D; Zejnullahu, K; Yonesaka, K; Xiao, Y; Capelletti, M; Rogers, A; Lifshits, E; Brown, A; Lee, C; Christensen, JG; Kwiatkowski, DJ; Engelman, JA; Janne, PA				Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Xiao, Y.; Capelletti, M.; Rogers, A.; Lifshits, E.; Brown, A.; Lee, C.; Christensen, J. G.; Kwiatkowski, D. J.; Engelman, J. A.; Jaenne, P. A.			Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor	ONCOGENE			English	Article						epidermal growth factor receptor; drug resistance; EGFR T790M; amplification; tyrosine kinase inhibitor; non-small cell lung cancer	GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; NERATINIB HKI-272; GENE MUTATION; BLAST CRISIS; GEFITINIB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the gatekeeper residue. Irreversible EGFR inhibitors, including PF00299804, are effective in vitro and in vivo against EGFR mutant tumors that contain EGFR T790M and are currently under clinical development. In this study, we generate models of resistance to PF00299804, using cell lines with EGFR T790M and show that the PF00299804-resistant models develop focal amplification of EGFR that preferentially involves the T790M-containing allele. These PF00299804-resistant cell lines remain dependent on EGFR for growth as downregulation of EGFR by shRNA compromises their viability. We show that resistance to PF00299804 arises, at least in part, through selection of a pre-existing EGFR T790M-amplified clone both in vitro and using a xenograft model in vivo. Our findings show that EGFR T790M is a common resistance mechanism to both reversible, and when amplified, the irreversible EGFR kinase inhibitors further emphasizing the need to develop more potent therapies against EGFR T790M. These findings can be used to guide studies of patient tumor specimens from ongoing clinical trials of irreversible EGFR kinase inhibitors. Oncogene (2010) 29, 2346-2356; doi:10.1038/onc.2009.526; published online 1 February 2010	[Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Capelletti, M.; Rogers, A.; Jaenne, P. A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA; [Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Capelletti, M.; Rogers, A.; Jaenne, P. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Xiao, Y.; Lee, C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Lifshits, E.; Engelman, J. A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Brown, A.] Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Cambridge, MA 02138 USA; [Christensen, J. G.] Pfizer Global Res & Dev, Dept Res Pharmacol, La Jolla Labs, La Jolla, CA USA; [Kwiatkowski, D. J.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA; [Jaenne, P. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Pfizer; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Janne, PA (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, D820,44 Binney St, Boston, MA 02115 USA.	pjanne@partners.org	Capelletti, Marzia/L-6317-2016	Capelletti, Marzia/0000-0001-5095-7060	National Institutes of Health [RO1CA114465-04, R01CA135257-01, R01CA137008-01]; National Cancer Institute [P50CA090578]; American Cancer Society [RSG0610201]; Hazel and Samuel Bellin research fund; NATIONAL CANCER INSTITUTE [R01CA137008, P50CA090578, R01CA135257, K08CA120060, R01CA114465] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Hazel and Samuel Bellin research fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Institutes of Health RO1CA114465-04 (PAJ), R01CA135257-01 (PAJ, JAE, CL), R01CA137008-01 (JAE, PAJ), National Cancer Institute Lung SPORE P50CA090578 (PAJ, JAE and DJK), American Cancer Society RSG0610201CCE (PAJ, JAE), and the Hazel and Samuel Bellin research fund (PAJ).	Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Besse B, 2008, EJC SUPPL, V6, P64, DOI 10.1016/S1359-6349(08)72135-9; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guo T, 2007, CLIN CANCER RES, V13, P4874, DOI 10.1158/1078-0432.CCR-07-0484; Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692; Janne PA, 2008, J CLIN ONCOL, V26; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ono M, 2004, MOL CANCER THER, V3, P465; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Quintas-Cardama A, 2008, CLIN CANCER RES, V14, P4392, DOI 10.1158/1078-0432.CCR-08-0117; Rothenberg SM, 2008, P NATL ACAD SCI USA, V105, P12480, DOI 10.1073/pnas.0803217105; Sawai A, 2008, CANCER RES, V68, P589, DOI 10.1158/0008-5472.CAN-07-1570; Schellens JH, 2007, J CLIN ONCOL, V25; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shimamura T, 2008, CANCER RES, V68, P5827, DOI 10.1158/0008-5472.CAN-07-5428; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Wong KK, 2009, CLIN CANCER RES, V15, P2552, DOI 10.1158/1078-0432.CCR-08-1978; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yuza Y, 2007, CANCER BIOL THER, V6, P661, DOI 10.4161/cbt.6.5.4003; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	44	186	198	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2346	2356		10.1038/onc.2009.526	http://dx.doi.org/10.1038/onc.2009.526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20118985	Green Accepted			2022-12-28	WOS:000276951500004
J	Liddiard, K; Hills, R; Burnett, AK; Darley, RL; Tonks, A				Liddiard, K.; Hills, R.; Burnett, A. K.; Darley, R. L.; Tonks, A.			OGG1 is a novel prognostic indicator in acute myeloid leukaemia	ONCOGENE			English	Article						OGG1; acute myeloid leukaemia; prognosis; DNA repair	ACUTE MYELOGENOUS LEUKEMIA; DNA GLYCOSYLASE; EMBRYONIC LETHALITY; PROGENITOR CELLS; EXPRESSION; GENE; DAMAGE; REPAIR; FUSION; AML1-ETO	OGG1 (8-oxoguanine DNA glycosylase) constitutes a key component of the DNA base excision repair pathway, catalysing the removal of 8-oxoguanine nucleotides from DNA, thereby suppressing mutagenesis and cell death. We found that OGG1 expression was significantly downregulated by the RUNX1-ETO fusion protein product of the t(8;21) chromosome translocation in normal haematopoietic progenitor cells and in patients with acute myeloid leukaemia (AML). Further examination of OGG1 expression in 174 AML trial patients using Affymetrix microarrays showed that the prevalence rate of OGG1 expression was 33% and correlated strongly with adverse cytogenetics. OGG1-expressing patients had a worse relapse-free survival and overall survival and an increased risk of relapse at 5-years of follow-up. There remained a trend towards increased relapse rate among OGG1-expressing patients, even after adjusting for other known risk factors in comprehensive stratified analyses. We also determined a trend for OGG1 expression to have a more adverse impact on disease outcome in the context of the FLT3-ITD mutation. This study highlights OGG1 as a valuable prognostic marker that could be used to sub-stratify AML patients to predict those likely to fail conventional chemotherapies but those likely to benefit from novel therapeutic approaches that modulate DNA repair activity. Oncogene (2010) 29, 2005-2012; doi:10.1038/onc.2009.462; published online 21 December 2009	[Liddiard, K.; Hills, R.; Burnett, A. K.; Darley, R. L.; Tonks, A.] Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Tonks, A (corresponding author), Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF14 4XN, S Glam, Wales.	tonksa@cf.ac.uk	Tonks, Alex/Y-8301-2019; Tonks, Alex/C-1174-2012; DARLEY, RICHARD/J-8563-2013	Tonks, Alex/0000-0002-6073-4976; Tonks, Alex/0000-0002-6073-4976; Hills, Robert/0000-0003-0166-0062	Wales Office of Research and Development (Welsh Assembly Government); Medical Research Council UK; Leukaemia Research UK	Wales Office of Research and Development (Welsh Assembly Government); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Leukaemia Research UK	This study was supported by the Wales Office of Research and Development (Welsh Assembly Government) and the Medical Research Council UK. Dr A Tonks is also supported by Leukaemia Research UK. We thank Amanda Gilkes and Megan Musson (Cardiff University) for their technical assistance in processing microarray samples. We also thank Professor Ken Mills (Queen's University, Belfast) for help in microarray analyses. We acknowledge the MRC for access to patient sample material enrolled in the NCRI clinical trials.	Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bullinger L, 2007, BLOOD, V110, P1291, DOI 10.1182/blood-2006-10-049783; Chatterjee A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-235; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; ERICKSON P, 1992, BLOOD, V80, P1825; Fishel ML, 2003, CANCER RES, V63, P608; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x; Grignani F, 1998, CANCER RES, V58, P14; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gustafson SA, 2009, AM J CLIN PATHOL, V131, P647, DOI 10.1309/AJCP5ETHDXO6NCGZ; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hill JW, 2007, CANCER DETECT PREV, V31, P237, DOI 10.1016/j.cdp.2007.05.001; Husain A, 1998, CANCER RES, V58, P1120; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; Hyun JW, 2006, INT J CANCER, V118, P302, DOI 10.1002/ijc.21329; Ishchenko A, 2003, MED SCI MONITOR, V9, pBR16; Jankowska AM, 2008, LEUKEMIA, V22, P551, DOI 10.1038/sj.leu.2405055; KEATING MJ, 1988, LEUKEMIA, V2, P403; Kinsella TJ, 2009, CLIN CANCER RES, V15, P1853, DOI 10.1158/1078-0432.CCR-08-1307; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krejci O, 2008, BLOOD, V111, P2190, DOI 10.1182/blood-2007-06-093682; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OSHIMURA M, 1982, GANN, V73, P212; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; QUESNEL B, 1993, J CLIN ONCOL, V11, P2370, DOI 10.1200/JCO.1993.11.12.2370; Radyuk SN, 2006, FREE RADICAL BIO MED, V41, P757, DOI 10.1016/j.freeradbiomed.2006.05.021; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; Saebo M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-208; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Sunaga N, 2001, CARCINOGENESIS, V22, P1355, DOI 10.1093/carcin/22.9.1355; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; Tonks A, 2004, LEUKEMIA, V18, P1238, DOI 10.1038/sj.leu.2403396; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	48	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					2005	2012		10.1038/onc.2009.462	http://dx.doi.org/10.1038/onc.2009.462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20023702				2022-12-28	WOS:000276199600013
J	Tsai, WL; Chung, RT				Tsai, W-L; Chung, R. T.			Viral hepatocarcinogenesis	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis B virus; hepatitis C virus; genomics; signaling pathways pathogenesis	HEPATITIS-B-VIRUS; HCV CORE PROTEIN; COMPARATIVE GENOMIC HYBRIDIZATION; NONSTRUCTURAL 5A PROTEIN; CHRONIC LIVER-DISEASE; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA RISK; ENDOPLASMIC-RETICULUM STRESS; INDUCED OXIDATIVE STRESS; C-VIRUS	Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Despite recent advances in the diagnosis and treatment of HCC, its prognosis remains dismal. Infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major risk factors for HCC. Although both are hepatotropic viral infections, there are important differences between the oncogenic mechanisms of these two viruses. In addition to the oncogenic potential of its viral proteins, HBV, as a DNA virus, can integrate into host DNA and directly transform hepatocytes. In contrast, HCV, an RNA virus, is unable to integrate into the host genome, and viral protein expression has a more critical function in hepatocarcinogenesis. Both HBV and HCV proteins have been implicated in disrupting cellular signal transduction pathways that lead to unchecked cell growth. Most HCC develops in the cirrhotic liver, but the linkage between cirrhosis and HCC is likely multifactorial. In this review, we summarize current knowledge regarding the pathogenetic mechanisms of viral HCC. Oncogene (2010) 29, 2309-2324; doi:10.1038/onc.2010.36; published online 15 March 2010	[Tsai, W-L; Chung, R. T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit,Dept Med, Boston, MA 02114 USA; [Tsai, W-L] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan	Harvard University; Harvard Medical School; Massachusetts General Hospital; Kaohsiung Veterans General Hospital	Chung, RT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit,Dept Med, 55 Fruit St,Warren 1007, Boston, MA 02114 USA.	rtchung@partners.org			NIH [DK078772, AI069939]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK078772] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH Grants DK078772 and AI069939 (both to RTC).	Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Arora P, 2008, CANCER LETT, V261, P244, DOI 10.1016/j.canlet.2007.11.033; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; Barth H, 2008, J HEPATOL, V49, P134, DOI 10.1016/j.jhep.2008.03.012; Bassett SE, 1999, HEPATOLOGY, V29, P1884, DOI 10.1002/hep.510290623; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bonte D, 2004, ARCH VIROL, V149, P1353, DOI 10.1007/s00705-003-0291-6; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Branda M, 2006, HEPATOLOGY, V43, P891, DOI 10.1002/hep.21196; BRECHOT C, 1980, NATURE, V286, P533, DOI 10.1038/286533a0; Bureau C, 2001, J BIOL CHEM, V276, P23077, DOI 10.1074/jbc.M100698200; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Caldwell S, 2009, J GASTROENTEROL, V44, P96, DOI 10.1007/s00535-008-2258-6; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; Cassiman D, 2001, HEPATOLOGY, V33, P148, DOI 10.1053/jhep.2001.20793; Chami M, 2006, BBA-MOL CELL RES, V1763, P1344, DOI 10.1016/j.bbamcr.2006.09.025; Chan HLY, 2008, J CLIN ONCOL, V26, P177, DOI 10.1200/JCO.2007.13.2043; Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324; Chen CH, 2007, AM J TROP MED HYG, V77, P747, DOI 10.4269/ajtmh.2007.77.747; Chen CJ, 2009, HEPATOLOGY, V49, pS72, DOI 10.1002/hep.22884; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chen J, 2007, J VIROL, V81, P6757, DOI 10.1128/JVI.00172-07; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chiu CM, 2007, P NATL ACAD SCI USA, V104, P2571, DOI 10.1073/pnas.0609498104; Cho JW, 2001, BBA-MOL CELL RES, V1538, P59, DOI 10.1016/S0167-4889(00)00137-3; Choi J, 2006, AM J PHYSIOL-GASTR L, V290, pG847, DOI 10.1152/ajpgi.00522.2005; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Chou YC, 2008, GUT, V57, P91, DOI 10.1136/gut.2006.114066; Chu CJ, 2002, GASTROENTEROLOGY, V122, P1756, DOI 10.1053/gast.2002.33588; Chung YL, 2003, INT J CANCER, V107, P65, DOI 10.1002/ijc.11303; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Czaja MJ, 2007, SEMIN LIVER DIS, V27, P378, DOI 10.1055/s-2007-991514; Dandri M, 2002, HEPATOLOGY, V35, P217, DOI 10.1053/jhep.2002.30203; de Lucas S, 2003, ANTIVIR RES, V60, P117, DOI 10.1016/j.antiviral.2003.08.006; Deng L, 2006, J GEN VIROL, V87, P1703, DOI 10.1099/vir.0.81735-0; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323; Ebara M, 2003, ONCOLOGY-BASEL, V65, P323, DOI 10.1159/000074645; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Fang ZL, 2008, AM J GASTROENTEROL, V103, P2254, DOI 10.1111/j.1572-0241.2008.01974.x; Fattovich G, 2003, SEMIN LIVER DIS, V23, P47, DOI 10.1055/s-2003-37590; Feitelson MA, 2007, CANCER LETT, V252, P157, DOI 10.1016/j.canlet.2006.11.010; Feitelson MA, 2009, CANCER LETT, V286, P69, DOI 10.1016/j.canlet.2008.12.010; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; Fujie H, 2001, GASTROENTEROLOGY, V120, P1564, DOI 10.1053/gast.2001.24501; FUJIO K, 1994, LAB INVEST, V70, P511; Fukutomi T, 2005, HEPATOLOGY, V41, P1096, DOI 10.1002/hep.20668; Furutani T, 2006, GASTROENTEROLOGY, V130, P2087, DOI 10.1053/j.gastro.2006.02.060; Gaudio E, 2009, DIGEST LIVER DIS, V41, P455, DOI 10.1016/j.dld.2009.03.009; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gu X, 2010, HUM GENET, V127, P75, DOI 10.1007/s00439-009-0750-6; Guerrero RB, 2005, J HEPATOL, V42, P760, DOI 10.1016/j.jhep.2005.02.005; Hassan M, 2005, VIROLOGY, V333, P324, DOI 10.1016/j.virol.2005.01.008; Hassan M, 2007, CELL SIGNAL, V19, P301, DOI 10.1016/j.cellsig.2006.07.002; Hassan M, 2009, HEPATOLOGY, V49, P1469, DOI 10.1002/hep.22849; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Hirankarn N, 2006, WORLD J GASTROENTERO, V12, P776, DOI 10.3748/wjg.v12.i5.776; Honda M, 2006, HEPATOLOGY, V44, P1122, DOI 10.1002/hep.21383; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Hourigan LF, 1999, HEPATOLOGY, V29, P1215, DOI 10.1002/hep.510290401; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Iizuka N, 2002, CANCER RES, V62, P3939; Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016; Irshad M, 2006, MED PRIN PRACT, V15, P405, DOI 10.1159/000095485; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kamegaya Y, 2005, HEPATOLOGY, V41, P660, DOI 10.1002/hep.20621; Kanda T, 2008, J VIROL, V82, P11066, DOI 10.1128/JVI.01300-08; Kao JH, 2000, GASTROENTEROLOGY, V118, P554, DOI 10.1016/S0016-5085(00)70261-7; Kao JH, 2003, GASTROENTEROLOGY, V124, P327, DOI 10.1053/gast.2003.50053; Kato J, 2007, J GASTROENTEROL, V42, P830, DOI 10.1007/s00535-007-2095-z; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Keasler VV, 2007, J VIROL, V81, P2656, DOI 10.1128/JVI.02020-06; Kew MC, 2009, CANCER LETT, V286, P38, DOI 10.1016/j.canlet.2008.11.001; Kidd-Ljunggren K, 2002, J GEN VIROL, V83, P1267, DOI 10.1099/0022-1317-83-6-1267; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim KH, 2007, GASTROENTEROLOGY, V132, P1955, DOI 10.1053/j.gastro.2007.03.039; Kim K, 2008, BIOCHEM J, V416, P219, DOI 10.1042/BJ20081336; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; Koike K, 2007, HEPATOL RES, V37, pS115, DOI 10.1111/j.1872-034X.2007.00173.x; Koike K, 2009, J GASTROENTEROL, V44, P82, DOI 10.1007/s00535-008-2276-4; Kordes C, 2007, BIOCHEM BIOPH RES CO, V352, P410, DOI 10.1016/j.bbrc.2006.11.029; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Kremsdorf D, 2006, ONCOGENE, V25, P3823, DOI 10.1038/sj.onc.1209559; Kummee P, 2007, J VIRAL HEPATITIS, V14, P841, DOI 10.1111/j.1365-2893.2007.00880.x; Kuo MT, 2006, MOL CARCINOGEN, V45, P701, DOI 10.1002/mc.20240; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Kusano N, 2002, CANCER, V94, P746, DOI 10.1002/cncr.10254; Kwun HJ, 2003, J VIRAL HEPATITIS, V10, P249, DOI 10.1046/j.1365-2893.2003.00434.x; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Leenders MWH, 2008, WORLD J GASTROENTERO, V14, P6915, DOI 10.3748/wjg.14.6915; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li BZ, 2007, VIRUS RES, V124, P44, DOI 10.1016/j.virusres.2006.09.011; Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu CJ, 2005, LIVER INT, V25, P1097, DOI 10.1111/j.1478-3231.2005.01177.x; Liu H, 2007, BIOCHEM BIOPH RES CO, V355, P379, DOI 10.1016/j.bbrc.2007.01.160; Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Locarnini S, 2003, SEMIN LIVER DIS, V23, P5, DOI 10.1055/s-2003-37587; Lonardo A, 2004, GASTROENTEROLOGY, V126, P586, DOI 10.1053/j.gastro.2003.11.020; Longato L, 2009, HEPATOLOGY, V49, P1935, DOI 10.1002/hep.22856; Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361; Luber B, 1996, ONCOGENE, V12, P1597; Machida K, 2006, J VIROL, V80, P7199, DOI 10.1128/JVI.00321-06; Mahmood S, 2004, ANTIOXID REDOX SIGN, V6, P19, DOI 10.1089/152308604771978318; Majumder M, 2003, FEBS LETT, V555, P528, DOI 10.1016/S0014-5793(03)01337-1; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Martin-Lluesma S, 2008, HEPATOLOGY, V48, P1467, DOI 10.1002/hep.22542; Martin-Vilchez S, 2008, HEPATOLOGY, V47, P1872, DOI 10.1002/hep.22265; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110; Matsuzaki K, 2007, HEPATOLOGY, V46, P48, DOI 10.1002/hep.21672; Matsuzaki K, 2009, FRONT BIOSCI-LANDMRK, V14, P2923, DOI 10.2741/3423; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; Missiha SB, 2008, GASTROENTEROLOGY, V134, P1699, DOI 10.1053/j.gastro.2008.02.069; Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Moriyama M, 2006, DIGEST DIS SCI, V51, P1967, DOI 10.1007/s10620-005-9051-7; Murakami Y, 2005, GUT, V54, P1162, DOI 10.1136/gut.2004.054452; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Myung SJ, 2007, FEBS LETT, V581, P2954, DOI 10.1016/j.febslet.2007.05.050; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; Naas T, 2005, J GEN VIROL, V86, P2185, DOI 10.1099/vir.0.80969-0; Newell P, 2008, J HEPATOL, V48, P858, DOI 10.1016/j.jhep.2008.01.008; Niki T, 1999, HEPATOLOGY, V29, P520, DOI 10.1002/hep.510290232; Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Oh JC, 2003, EXP MOL MED, V35, P301, DOI 10.1038/emm.2003.41; Ohata K, 2003, CANCER-AM CANCER SOC, V97, P3036, DOI 10.1002/cncr.11427; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Okabe H, 2001, CANCER RES, V61, P2129; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Pang R, 2007, GASTROENTEROLOGY, V132, P1088, DOI 10.1053/j.gastro.2006.12.030; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parsons CJ, 2007, J GASTROEN HEPATOL, V22, pS79, DOI 10.1111/j.1440-1746.2006.04659.x; Pekow JR, 2007, CANCER-AM CANCER SOC, V109, P2490, DOI 10.1002/cncr.22701; Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013; Pinzani M, 1996, AM J PATHOL, V148, P785; Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014; Qadri I, 2004, BIOCHEM J, V378, P919, DOI 10.1042/BJ20031587; QADRI I, 2002, BIOCHIM BIOPHYS ACTA, V21, P193; Qi P, 2009, CANCER IMMUNOL IMMUN, V58, P1433, DOI 10.1007/s00262-009-0660-4; Ray RB, 1997, J BIOL CHEM, V272, P10983; Roskams T, 2006, J HEPATOL, V45, P1, DOI 10.1016/j.jhep.2006.05.002; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Schaefer S, 2005, J VIRAL HEPATITIS, V12, P111, DOI 10.1111/j.1365-2893.2005.00584.x; SCHLUTER V, 1994, ONCOGENE, V9, P3335; Severi T, 2007, CHEM-BIOL INTERACT, V168, P128, DOI 10.1016/j.cbi.2007.03.006; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; Shin HD, 2003, HUM MOL GENET, V12, P901, DOI 10.1093/hmg/ddg104; Shin JY, 2005, EXP MOL MED, V37, P138, DOI 10.1038/emm.2005.19; Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sorrell MF, 2009, HEPATOLOGY, V49, pS4, DOI 10.1002/hep.22946; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su PF, 2007, INT J CANCER, V121, P1257, DOI 10.1002/ijc.22849; SUMIDA Y, 2000, J HEPATOL, V13, P159; Sy SMH, 2005, MODERN PATHOL, V18, P686, DOI 10.1038/modpathol.3800345; Tai AW, 2009, J HEPATOL, V50, P412, DOI 10.1016/j.jhep.2008.11.010; Tai PC, 2002, VIROLOGY, V292, P44, DOI 10.1006/viro.2001.1239; Takeya R, 2006, ANTIOXID REDOX SIGN, V8, P1523, DOI 10.1089/ars.2006.8.1523; Tanaka N, 2008, J CLIN INVEST, V118, P683, DOI 10.1172/JCI33594; Tanaka N, 2008, INT J CANCER, V122, P124, DOI 10.1002/ijc.23056; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581; Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Tennant BC, 2004, GASTROENTEROLOGY, V127, pS283, DOI 10.1053/j.gastro.2004.09.043; Thakur V, 2002, J GASTROEN HEPATOL, V17, P165, DOI 10.1046/j.1440-1746.2002.02605.x; Tsuchiya H, 2009, GASTROENTEROLOGY, V136, P341, DOI 10.1053/j.gastro.2008.09.027; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Villanueva A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171; Wang HC, 2006, CANCER SCI, V97, P683, DOI 10.1111/j.1349-7006.2006.00235.x; WANG J, 1992, ONCOGENE, V7, P1653; Wang T, 2006, J GASTROEN HEPATOL, V21, pS34, DOI 10.1111/j.1440-1746.2006.04591.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wong CM, 2008, LIVER INT, V28, P160, DOI 10.1111/j.1478-3231.2007.01637.x; Wu CF, 2008, CARCINOGENESIS, V29, P106, DOI 10.1093/carcin/bgm252; Wu SC, 2008, J BIOL CHEM, V283, P29396, DOI 10.1074/jbc.M802821200; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P528, DOI 10.1016/S0006-291X(02)00508-9; Yanagitani A, 2004, HEPATOLOGY, V40, P366, DOI 10.1002/hep.20335; Yang HI, 2008, JNCI-J NATL CANCER I, V100, P1134, DOI 10.1093/jnci/djn243; Yang JC, 2009, HEPATOLOGY, V49, P1962, DOI 10.1002/hep.22889; Yang L, 2008, J HEPATOL, V48, P98, DOI 10.1016/j.jhep.2007.07.032; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yu MW, 2005, JNCI-J NATL CANCER I, V97, P265, DOI 10.1093/jnci/dji043; Yu MW, 1999, AM J EPIDEMIOL, V150, P367, DOI 10.1093/oxfordjournals.aje.a010016; Yu MW, 2003, J NATL CANCER I, V95, P1485, DOI 10.1093/jnci/djg051; Yu MW, 2001, J NATL CANCER I, V93, P1644, DOI 10.1093/jnci/93.21.1644; Yuan JM, 2006, JNCI-J NATL CANCER I, V98, P482, DOI 10.1093/jnci/djj104; YUAN JM, 2009, CANCER EPIDEM BIOMAR, V18, P1762; Zemel R, 2001, J VIRAL HEPATITIS, V8, P96, DOI 10.1046/j.1365-2893.2001.00283.x; Zhao LJ, 2005, EXP CELL RES, V305, P23, DOI 10.1016/j.yexcr.2004.12.024; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	234	198	212	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2309	2324		10.1038/onc.2010.36	http://dx.doi.org/10.1038/onc.2010.36			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20228847	Green Accepted			2022-12-28	WOS:000276951500001
J	Zhang, H; Fagan, DH; Zeng, X; Freeman, KT; Sachdev, D; Yee, D				Zhang, H.; Fagan, D. H.; Zeng, X.; Freeman, K. T.; Sachdev, D.; Yee, D.			Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation	ONCOGENE			English	Article						insulin receptor; angiogenesis; lymphangiogenesis; metastasis	GROWTH-FACTOR-RECEPTOR; HUMAN-BREAST-CANCER; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; IGF-I RECEPTORS; M14 MELANOMA; VIVO; EXPRESSION; LINES; MICE; ACTIVATION	Insulin receptor (IR) and the type I IGF receptor (IGF1R) are structurally and functionally related. The function of IGF1R in cancer has been well documented and anti-IGF1R strategies to treat cancer have shown initial positive results. However, the role of IR in tumor biology, independent of IGF1R, is less clear. To address this issue, short hairpin RNA (shRNA) was used to specifically downregulate IR in two cancer cell lines, LCC6 and T47D. Cells with reduced IR showed reduced insulin-stimulated Akt activation, without affecting IGF1R activation. Cells with reduced IR formed fewer colonies in anchorage-independent conditions. LCC6 IR shRNA xenograft tumors in mice had reduced growth, angiogenesis and lymphangiogensis when compared with LCC6 wild-type cells. Accordingly, LCC6 IR shRNA clones produced less hypoxia-inducible factor-1 alpha, vascular endothelial growth factor (VEGF)-A and VEGF-D. Furthermore, LCC6 IR shRNA cells formed fewer pulmonary metastases when compared with LCC6 wild-type cells. Using in vivo luciferase imaging, we have shown that LCC6 IR shRNA cells have less seeding and colonization potential in the lung and liver of mice than LCC6 cells. In conclusion, downregulation of IR inhibited cancer cell proliferation, angiogenesis, lymphangiogenesis and metastasis. Our data argue that IR should also be targeted in cancer therapy. Oncogene (2010) 29, 2517-2527; doi:10.1038/onc.2010.17; published online 15 February 2010	[Zhang, H.; Freeman, K. T.; Sachdev, D.; Yee, D.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Fagan, D. H.; Zeng, X.; Yee, D.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Sachdev, D.; Yee, D.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Yee, D (corresponding author), Univ Minnesota, Masonic Canc Ctr, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	yeexx006@umn.edu		Yee, Douglas/0000-0002-3387-4009	Department of Defense [BC050548]; National Institutes of Health [R01CA74285]; National Cancer Institute Cancer Center [P30 077598]; NATIONAL CANCER INSTITUTE [P30CA077598, R01CA074285] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Colleen Forster for the technical service on immunohistochemistry staining of tumor and lung tissue. We thank Dr Ilze Matise from the Masonic Cancer Center Comparative Pathology Shared Resource for valuable advice. We thank Dr Yunfang Li and Dr Kalpna Gupta from Masonic Cancer Center for detailed protocol of LYVE-1 and CD31 staining in tumor samples. We appreciate Dr Minghai Shao and Dr Daniela E Matei from Indiana University School of Medicine for providing the retroviral vector expressing luciferase. We acknowledge the assistance of the Flow Cytometry Core Shared Resource of the Masonic Cancer Center. Animal imaging was performed at the Biomedical Image Processing laboratory at University of Minnesota. This work was supported by Department of Defense Breast Cancer Research Program post-doctoral Grant BC050548 to HZ, National Institutes of Health R01CA74285 to DY and National Cancer Institute Cancer Center Support Grant P30 077598.	Ademuyiwa FO, 2008, CLIN BREAST CANCER, V8, pS151, DOI 10.3816/CBC.2008.s.011; Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102; Byron SA, 2006, BRIT J CANCER, V95, P1220, DOI 10.1038/sj.bjc.6603354; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dunn SE, 1998, CANCER RES, V58, P3353; Eccles S, 2007, CLIN EXP METASTAS, V24, P619, DOI 10.1007/s10585-007-9123-5; Feldser D, 1999, CANCER RES, V59, P3915; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Frasca Francesco, 2003, Breast Dis, V17, P73; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Haluska P, 2006, CANCER RES, V66, P362, DOI 10.1158/0008-5472.CAN-05-1107; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HEUSON JC, 1972, CANCER RES, V32, P226; Hewish M, 2009, RECENT PAT ANTI-CANC, V4, P54, DOI 10.2174/157489209787002515; Ji QS, 2007, MOL CANCER THER, V6, P2158, DOI 10.1158/1535-7163.MCT-07-0070; KAREY KP, 1988, CANCER RES, V48, P4083; KASUYA J, 1993, BIOCHEMISTRY-US, V32, P13531, DOI 10.1021/bi00212a019; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Li JG, 2006, PHYSIOL GENOMICS, V25, P450, DOI 10.1152/physiolgenomics.00293.2005; Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Novosyadlyy R, 2009, ONCOGENE, V28, P3477, DOI 10.1038/onc.2009.209; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2003, CANCER RES, V63, P627; Sachdev D, 2006, J MAMMARY GLAND BIOL, V11, P27, DOI 10.1007/s10911-006-9010-8; Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8; Tang YC, 2003, CANCER RES, V63, P1166; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wang JQ, 2006, BIOORG MED CHEM LETT, V16, P331, DOI 10.1016/j.bmcl.2005.09.082; Weroha S, 2008, J MAMMARY GLAND BIOL, V13, P471, DOI 10.1007/s10911-008-9104-6; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhang H, 2006, CLIN CANCER RES, V12, P6323, DOI 10.1158/1078-0432.CCR-06-1707	43	97	106	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2517	2527		10.1038/onc.2010.17	http://dx.doi.org/10.1038/onc.2010.17			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154728	Green Accepted			2022-12-28	WOS:000277169400007
J	Saether, T; Pattabiraman, DR; Alm-Kristiansen, AH; Vogt-Kielland, LT; Gonda, TJ; Gabrielsen, OS				Saether, T.; Pattabiraman, D. R.; Alm-Kristiansen, A. H.; Vogt-Kielland, L. T.; Gonda, T. J.; Gabrielsen, O. S.			A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability	ONCOGENE			English	Article						c-Myb; SUMO; SUMO-interacting motif; myeloid; transformation; hematopoiesis	UBIQUITIN-LIKE PROTEINS; TRANSCRIPTION-FACTOR; V-MYB; SACCHAROMYCES-CEREVISIAE; BINDING MOTIF; DNA-BINDING; NF-M; COACTIVATOR; ACTIVATION; LEUKEMIA	c-Myb is an essential hematopoietic transcription factor that controls proliferation and differentiation of progenitors during blood cell development. Whereas sumoylation of the C-terminal regulatory domain (CRD) is known to have a major impact on the activity of c-Myb, no role for noncovalent binding of small ubiquitin-like modifier (SUMO) to c-Myb has been described. Based on the consensus SUMO-interacting motif (SIM), we identified and examined putative SIMs in human c-Myb. Interaction and reporter assays showed that the SIM in the in the transactivation domain of c-Myb (V(267)NIV) is functional. This motif is necessary for c-Myb to be able to interact noncovalently with SUMO, preferentially SUMO2/3. Destroying the SUMO-binding properties by mutation resulted in a large increase in the transactivation potential of c-Myb. Mutational analysis and overexpression of conjugation-defective SUMO argued against intramolecular repression caused by sumoylated CRD and in favor of SUMO-dependent repression in trans. Using both a myeloid cell line-based assay and a primary hematopoietic cell assay, we addressed the transforming abilities of SUMO binding and conjugation mutants. Interestingly, only loss of SUMO binding, and not SUMO conjugation, enhanced the myeloid transformational potential of c-Myb. c-Myb with the SIM mutated conferred a higher proliferative ability than the wild-type and caused an effective differentiation block. This establishes SUMO binding as a mechanism involved in modulating the transactivation activity of c-Myb, and responsible for keeping the transforming potential of the oncoprotein in check. Oncogene (2011) 30, 212-222; doi:10.1038/onc.2010.397; published online 30 August 2010	[Saether, T.; Alm-Kristiansen, A. H.; Vogt-Kielland, L. T.; Gabrielsen, O. S.] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; [Pattabiraman, D. R.; Gonda, T. J.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia	University of Oslo; University of Queensland	Saether, T (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041 Blindern, N-0316 Oslo, Norway.	thomas.sather@imbv.uio.no	Pattabiraman, Diwakar/AAE-6338-2020; Gonda, Thomas J/A-3620-2012	Pattabiraman, Diwakar/0000-0002-2418-6458; Gonda, Thomas/0000-0002-8792-3021; Saether, Thomas/0000-0003-4976-3810	Norwegian Cancer Society; Norwegian Research Council; Leukaemia Foundation	Norwegian Cancer Society(Norwegian Cancer Society); Norwegian Research Council(Research Council of NorwayEuropean Commission); Leukaemia Foundation	We thank Marit Ledsaak for excellent technical assistance and Professor D Livingston, Professor G Del Sal, Professor RT Hay, Professor R Grosschedl and Professor ET Yeh for providing us with relevant expression constructs. This work was supported by the Norwegian Cancer Society (TS) and the FUGE program of the Norwegian Research Council. DRP was supported by a scholarship from The Leukaemia Foundation (Australia).	Alm-Kristiansen AH, 2008, ONCOGENE, V27, P4644, DOI 10.1038/onc.2008.105; Andersson KB, 2003, J BIOL CHEM, V278, P3816, DOI 10.1074/jbc.M209404200; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Brown AL, 2006, J LEUKOCYTE BIOL, V80, P433, DOI 10.1189/jlb.0206112; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hecker CM, 2006, J BIOL CHEM, V281, P16117, DOI 10.1074/jbc.M512757200; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; HU YL, 1991, ONCOGENE, V6, P1549; Jin SH, 2010, J CLIN INVEST, V120, P593, DOI 10.1172/JCI38030; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; McCormack MP, 2000, BLOOD, V95, P120, DOI 10.1182/blood.V95.1.120.001k08_120_127; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Molvaersmyr AK, 2010, NUCLEIC ACIDS RES, V38, P4970, DOI 10.1093/nar/gkq245; Murati A, 2009, LEUKEMIA, V23, P85, DOI 10.1038/leu.2008.257; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pattabiraman DR, 2009, MOL CANCER RES, V7, P1477, DOI 10.1158/1541-7786.MCR-09-0070; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saether T, 2007, J BIOL CHEM, V282, P13994, DOI 10.1074/jbc.M700755200; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sramko M, 2006, J BIOL CHEM, V281, P40065, DOI 10.1074/jbc.M609404200; Takahashi H, 2005, J BIOL CHEM, V280, P5611, DOI 10.1074/jbc.M408130200; Tatham MH, 2005, NAT STRUCT MOL BIOL, V12, P67, DOI 10.1038/nsmb878; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466	47	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	2					212	222		10.1038/onc.2010.397	http://dx.doi.org/10.1038/onc.2010.397			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20802522				2022-12-28	WOS:000286438900009
J	Radulescu, S; Ridgway, RA; Appleton, P; Kroboth, K; Patel, S; Woodgett, J; Taylor, S; Nathke, IS; Sansom, OJ				Radulescu, S.; Ridgway, R. A.; Appleton, P.; Kroboth, K.; Patel, S.; Woodgett, J.; Taylor, S.; Nathke, I. S.; Sansom, O. J.			Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol	ONCOGENE			English	Article						APC; WNT signalling; Taxol; mitotic spindle assembly checkpoint	POLYPOSIS-COLI PROTEIN; SUPPRESSOR GENE; CANCER; EXPRESSION; MUTATIONS; PROLIFERATION; MICROTUBULE; HOMEOSTASIS; INSTABILITY; PROGRESSION	Mutations in the adenomatous polyposis coli (APC) tumour suppressor are the key initiating event of colorectal cancer. Although the control of WNT signalling is well established as a central tumour-suppressive function, the significance of APC in regulating chromosome instability is less well established. In this study, we test whether APC-deficient cells have a functional spindle assembly checkpoint (SAC) in vivo by examining the response of these cells to Taxol and Vinorelbine. We also show for the first time that APC deficiency compromises the arrest response to Taxol in vivo. This effect is independent of the role that APC has in WNT signalling. At higher levels of Taxol, APC-deficient cells arrest as efficiently as wild-type cells. Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in models of benign (APC(Min/+) mouse) and invasive (AhCreER(+) APC(fl/+) PTENfl/fl) cancer. In contrast to intestinal enterocytes with a general SAC defect because of Bub1 (budding uninhibited by benzimidazole 1) deletion, APC-deficient enterocytes arrest equivalently to wild type when treated with Vinorelbine. This suggests that the failed arrest in response to Taxol is because of a specific defect in microtubule stabilization following Taxol treatment rather than a general role of the APC protein in the mitotic spindle checkpoint. In summary, this study clarifies the role of APC as a mitotic spindle checkpoint protein in vivo and shows that APC-deficient cells have a compromised response to Taxol. Oncogene (2010) 29, 6418-6427; doi:10.1038/onc.2010.373; published online 23 August 2010	[Radulescu, S.; Ridgway, R. A.; Sansom, O. J.] CR UK Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Appleton, P.; Kroboth, K.; Nathke, I. S.] Univ Dundee, WTB MSI, Dundee, Scotland; [Patel, S.; Woodgett, J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Taylor, S.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	Beatson Institute; University of Dundee; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Manchester	Sansom, OJ (corresponding author), CR UK Beatson Inst Canc Res, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Woodgett, Jim/F-1087-2010; Taylor, Stephen/GZL-6499-2022	Woodgett, Jim/0000-0003-3731-5797; Sansom, Owen J./0000-0001-9540-3010; Taylor, Stephen/0000-0003-4621-9326; Nathke, Inke/0000-0003-2420-4385	CR-UK; AICR; Cancer Research UK [11913, 12481, 11243] Funding Source: researchfish	CR-UK(Cancer Research UK); AICR; Cancer Research UK(Cancer Research UK)	This work was funded by the CR-UK project and programme grants to Inke Nathke and Owen Sansom. Sorina Radulescu was funded by an AICR grant. Help from Colin Nixon with histology and from Derek Miller and Tom Hamilton with transgenic work was much appreciated.	Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Dikovskaya D, 2001, TRENDS CELL BIOL, V11, P378, DOI 10.1016/S0962-8924(01)02069-4; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Green RA, 2005, MOL BIOL CELL, V16, P4609, DOI 10.1091/mbc.E05-03-0259; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; KRIKORIAN A, 1991, ONKOLOGIE, V14, P7; Kroboth K, 2007, MOL BIOL CELL, V18, P910, DOI 10.1091/mbc.E06-03-0179; LINN SC, 1995, EUR J CANCER, V31A, P1291, DOI 10.1016/0959-8049(95)00278-Q; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Perera D, 2007, DEV CELL, V13, P566, DOI 10.1016/j.devcel.2007.08.008; RADULESCU S, BUB1 HAPLOINSU UNPUB; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SU LK, 1995, CANCER RES, V55, P2972; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014	32	24	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6418	6427		10.1038/onc.2010.373	http://dx.doi.org/10.1038/onc.2010.373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20729907	Green Accepted			2022-12-28	WOS:000285138900002
J	De Vita, S; Canzonetta, C; Mulligan, C; Delom, F; Groet, J; Baldo, C; Vanes, L; Dagna-Bricarelli, F; Hoischen, A; Veltman, J; Fisher, EMC; Tybulewicz, VLJ; Nizetic, D				De Vita, S.; Canzonetta, C.; Mulligan, C.; Delom, F.; Groet, J.; Baldo, C.; Vanes, L.; Dagna-Bricarelli, F.; Hoischen, A.; Veltman, J.; Fisher, E. M. C.; Tybulewicz, V. L. J.; Nizetic, D.			Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome	ONCOGENE			English	Article						chromosome 21; trisomy 21; gene expression; Down's syndrome; leukaemia; mouse models	ACUTE LYMPHOBLASTIC LEUKEMIAS; IN-VITRO DIFFERENTIATION; MEGAKARYOBLASTIC LEUKEMIA; TRANSCRIPTION FACTOR; MOUSE MODEL; MYELOID PROGENITOR; ACQUIRED MUTATIONS; FETAL LIVER; EXPRESSION; TRANSIENT	Children with Down's syndrome (DS) have 20-50-fold higher incidence of all leukaemias (lymphoid and myeloid), for reasons not understood. As incidence of many solid tumours is much lower in DS, we speculated that disturbed early haematopoietic differentiation could be the cause of increased leukaemia risk. If a common mechanism is behind the risk of both major leukaemia types, it would have to arise before the bifurcation to myeloid and lymphoid lineages. Using the transchromosomic system (mouse embryonic stem cells (ESCs)) bearing an extra human chromosome 21 (HSA21)) we analyzed the early stages of haematopoietic commitment (mesodermal colony formation) in vitro. We observed that trisomy 21 (T21) causes increased production of haemogenic endothelial cells, haematopoietic stem cell precursors and increased colony forming potential, with significantly increased immature progenitors. Transchromosomic colonies showed increased expression of Gata-2, c-Kit and Tie-2. A panel of partial T21 ESCs allowed us to assign these effects to HSA21 sub-regions, mapped by 3.5 kbp-resolution tiling arrays. The Gata-2 increase on one side, and c-Kit and Tie-2 increases on the other, could be attributed to two different, non-overlapping HSA21 regions. Using human-specific small interfering RNA silencing, we could demonstrate that an extra copy of RUNX1, but not ETS-2 or ERG, causes an increase in Tie-2/c-Kit levels. Finally, we detected significantly increased levels of RUNX1, C-KIT and PU.1 in human foetal livers with T21. We conclude that overdose of more than one HSA21 gene contributes to the disturbance of early haematopoiesis in DS, and that one of the contributors is RUNX1. As the observed T21-driven hyperproduction of multipotential immature precursors precedes the bifurcation to lymphoid and myeloid lineages, we speculate that this could create conditions of increased chance for acquisition of pre-leukaemogenic rearrangements/mutations in both lymphoid and myeloid lineages foetal haematopoiesis, contributing to the increased risk of both leukaemia types in DS. Oncogene (2010) 29, 6102-6114; doi:10.1038/onc.2010.351; published online 9 August 2010	[De Vita, S.; Canzonetta, C.; Mulligan, C.; Delom, F.; Groet, J.; Nizetic, D.] Queen Mary Univ London, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, Ctr Paediat, London, England; [Baldo, C.; Dagna-Bricarelli, F.] Galliera Hosp, Human Genet Lab, Genoa, Italy; [Vanes, L.; Tybulewicz, V. L. J.] MRC Natl Inst Med Res, London, England; [Hoischen, A.; Veltman, J.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Fisher, E. M. C.] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England	University of London; Queen Mary University London; Ente Ospedaliero Ospedali Galliera; MRC National Institute for Medical Research; Radboud University Nijmegen; University of London; University College London	Nizetic, D (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Paediat, Blizard Inst Cell & Mol Sci, 4 Newark St, London E1 2AT, England.	d.nizetic@qmul.ac.uk	Nizetic, Dean/F-9509-2015; Hoischen, Alexander/D-1282-2013; Baldo, Chiara/AAB-1435-2020; Veltman, Joris A/F-5128-2010; Delom, Frederic/J-2782-2014; Hoischen, Alexander/AGF-7293-2022; Fisher, Elizabeth MC/C-2168-2008	Hoischen, Alexander/0000-0002-8072-4476; Baldo, Chiara/0000-0001-7508-3953; Veltman, Joris A/0000-0002-3218-8250; Delom, Frederic/0000-0002-4600-7633; Hoischen, Alexander/0000-0002-8072-4476; Fisher, Elizabeth MC/0000-0003-2850-9936; Canzonetta, Claudia/0000-0002-8928-5537; Nizetic, Dean/0000-0001-5486-5761	EU Commission; Leukaemia Research Fund-UK [05075, 06003]; Italian Telethon [GTB07001]; MRC [U117527252]; MRC [MC_U117527252, G0601056] Funding Source: UKRI; Medical Research Council [MC_U117527252, G0601056] Funding Source: researchfish	EU Commission(European CommissionEuropean Commission Joint Research Centre); Leukaemia Research Fund-UK; Italian Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Gary Warnes for help with FACS analysis and Mike Kirwan for technical advice. This work was supported by the 'Aneuploidy' Grant from Framework Programme 6 from the EU Commission, and by the Gordon Piller Studentship (05075) and the specialist programme Grant (06003) from the Leukaemia Research Fund-UK. For FL material, we thank the MRC-Foetal Tissue Bank, and The Galliera Genetic Bank-'Telethon Genetic Biobank Network', which is supported by Italian Telethon Grants (Project no. GTB07001). We would also like to thank MRC funding number U117527252.	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Al-Kasim F, 2002, J PEDIAT HEMATOL ONC, V24, P9, DOI 10.1097/00043426-200201000-00004; Alford KA, 2010, BLOOD, V115, P2928, DOI 10.1182/blood-2009-06-227629; Bahn S, 2002, LANCET, V359, P310, DOI 10.1016/S0140-6736(02)07497-4; Bercovich D, 2008, LANCET, V372, P1484, DOI 10.1016/S0140-6736(08)61341-0; Broxmeyer HE, 2003, P NATL ACAD SCI USA, V100, P645, DOI 10.1073/pnas.0237086100; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012; Carmichael CL, 2009, BLOOD, V113, P1929, DOI 10.1182/blood-2008-06-161422; Cavani S, 1998, BRIT J HAEMATOL, V103, P213, DOI 10.1046/j.1365-2141.1998.00924.x; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Choi K, 1998, DEVELOPMENT, V125, P725; Chou ST, 2008, BLOOD, V112, P4503, DOI 10.1182/blood-2008-05-157859; De Vita S, 2008, BRIT J HAEMATOL, V143, P300, DOI 10.1111/j.1365-2141.2008.07332.x; Delom F, 2007, CELL DEATH DIFFER, V14, P586, DOI 10.1038/sj.cdd.4402012; Era T, 2000, BLOOD, V95, P870, DOI 10.1182/blood.V95.3.870.003k44_870_878; Eto K, 2003, METHOD ENZYMOL, V365, P142; Forestier E, 2008, BLOOD, V111, P1575, DOI 10.1182/blood-2007-09-114231; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hernandez D, 1999, HUM MOL GENET, V8, P923, DOI 10.1093/hmg/8.5.923; Hertzberg L, 2010, BLOOD, V115, P1006, DOI 10.1182/blood-2009-08-235408; Hitzler JK, 2005, NAT REV CANCER, V5, P11, DOI 10.1038/nrc1525; Jaffredo T, 2005, EXP HEMATOL, V33, P1029, DOI 10.1016/j.exphem.2005.06.005; Kearney L, 2009, BLOOD, V113, P646, DOI 10.1182/blood-2008-08-170928; Kirsammer G, 2008, BLOOD, V111, P767, DOI 10.1182/blood-2007-04-085670; Kitajima K, 2003, METHOD ENZYMOL, V365, P72; Kitajima K, 2006, BLOOD, V107, P1857, DOI 10.1182/blood-2005-06-2527; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; Klusmann JH, 2010, GENE DEV, V24, P478, DOI 10.1101/gad.1856210; Korbel JO, 2009, P NATL ACAD SCI USA, V106, P12031, DOI 10.1073/pnas.0813248106; KRIVIT W, 1957, AMA J DIS CHILD, V94, P289, DOI 10.1001/archpedi.1957.04030040075012; Lancrin C, 2009, NATURE, V457, P892, DOI 10.1038/nature07679; Lepagnol-Bestel AM, 2009, HUM MOL GENET, V18, P1405, DOI 10.1093/hmg/ddp047; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; Lugus JJ, 2007, DEVELOPMENT, V134, P393, DOI 10.1242/dev.02731; Lugus JJ, 2009, BLOOD, V113, P563, DOI 10.1182/blood-2008-06-162750; Lundin C, 2009, BRIT J HAEMATOL, V146, P113, DOI 10.1111/j.1365-2141.2009.07689.x; Malinge S, 2009, BLOOD, V113, P2619, DOI 10.1182/blood-2008-11-163501; McElwaine S, 2004, BRIT J HAEMATOL, V125, P729, DOI 10.1111/j.1365-2141.2004.04982.x; Mensah A, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-131; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Ng AP, 2010, BLOOD, V115, P3966, DOI 10.1182/blood-2009-09-242107; NIIKAWA N, 1991, HUM GENET, V87, P561; Nottingham WT, 2007, BLOOD, V110, P4188, DOI 10.1182/blood-2007-07-100883; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; Ohta T, 1996, AM J HUM GENET, V58, P544; Olson LE, 2004, DEV DYNAM, V230, P581, DOI 10.1002/dvdy.20079; Park C, 2005, EXP HEMATOL, V33, P965, DOI 10.1016/j.exphem.2005.06.003; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Prandini P, 2007, AM J HUM GENET, V81, P252, DOI 10.1086/519248; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Rainis L, 2003, BLOOD, V102, P981, DOI 10.1182/blood-2002-11-3599; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Sakai E, 2009, EXP HEMATOL, V37, P334, DOI 10.1016/j.exphem.2008.11.007; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Satge D, 1998, CANCER RES, V58, P448; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHEN JJ, 1995, AM J HUM GENET, V56, P915; Stankiewicz MJ, 2009, BLOOD, V113, P3337, DOI 10.1182/blood-2008-08-174813; Sussan TE, 2008, NATURE, V451, P73, DOI 10.1038/nature06446; Taub JW, 2002, J PEDIAT HEMATOL ONC, V24, P6, DOI 10.1097/00043426-200201000-00003; Teyssier-Le Discorde M, 1999, BRIT J HAEMATOL, V107, P247, DOI 10.1046/j.1365-2141.1999.01725.x; Toki T, 2005, BLOOD, V105, P3100, DOI 10.1182/blood-2004-07-2826; Toki T, 2009, LEUKEMIA, V23, P95, DOI 10.1038/leu.2008.267; Tunstall-Pedoe O, 2008, BLOOD, V112, P4507, DOI 10.1182/blood-2008-04-152967; Wang Y, 2009, MOL CELL PROTEOMICS, V8, P585, DOI 10.1074/mcp.M800256-MCP200; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3; ZIPURSKY A, 1994, LEUKEMIA RES, V18, P163, DOI 10.1016/0145-2126(94)90111-2; Zovein AC, 2008, CELL STEM CELL, V3, P625, DOI 10.1016/j.stem.2008.09.018	73	31	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6102	6114		10.1038/onc.2010.351	http://dx.doi.org/10.1038/onc.2010.351			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20697343	hybrid, Green Published			2022-12-28	WOS:000284356500003
J	Fukunaga-Kalabis, M; Martinez, G; Nguyen, TK; Kim, D; Santiago-Walker, A; Roesch, A; Herlyn, M				Fukunaga-Kalabis, M.; Martinez, G.; Nguyen, T. K.; Kim, D.; Santiago-Walker, A.; Roesch, A.; Herlyn, M.			Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population	ONCOGENE			English	Article						tenascin; ABCB5; side population	STEM-CELLS; MATRICELLULAR PROTEINS; GENE-EXPRESSION; CANCER CELLS; GROWTH; RESISTANCE; SURVIVAL; IDENTIFICATION; SUBPOPULATION; ACTIVATION	Tenascin-C (TNC) is highly expressed in melanoma; however, little is known about its functions. Recent studies indicate that TNC has a role within the stem cell niche. We hypothesized that TNC creates a specific environment for melanoma cells to show a stem cell-like phenotype, promoting tumor growth and evading conventional therapies. TNC expression was strongly upregulated in melanoma cells grown as 3D spheres (enriched for stem-like cells) when compared to adherent cells. Down-modulation of TNC by shRNA lentiviruses significantly decreased the growth of melanoma spheres. The incidence of pulmonary metastases after intravenous injection of TNC knockdown cells was significantly lower in NOD/SCID IL2R gamma(null) mice compared with control cells. Melanoma spheres contain an increased number of side population (SP) cells, which show stem cell characteristics, and have the potential for drug resistance due to their high efflux capacity. Knockdown of TNC dramatically decreased the SP fraction in melanoma spheres and lowered their resistance to doxorubicin treatment, likely because of the downregulation of multiple ATP-binding cassette (ABC) transporters, including ABCB5. These data suggest that TNC is critical in melanoma progression as it mediates protective signals in the therapy-resistant population of melanoma. Oncogene (2010) 29, 6115-6124; doi:10.1038/onc.2010.350; published online 23 August 2010	[Fukunaga-Kalabis, M.; Martinez, G.; Nguyen, T. K.; Kim, D.; Santiago-Walker, A.; Roesch, A.; Herlyn, M.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Div Mol & Cellular Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Div Mol & Cellular Biol, 3601 Spruce St,489 WISTAR, Philadelphia, PA 19104 USA.	herlynm@wistar.org			NCI [CA25874, CA47159, CA93372, CA10815]; NATIONAL CANCER INSTITUTE [P50CA093372, P30CA010815, R01CA047159, R01CA225874, P01CA025874, R01CA076674] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the NCI (CA25874, CA47159, CA93372, CA10815). We thank Angela Cipolla, Sarah Telson and Kate M Belser for technical assistance. This work was also supported by Ellen Heber-Katz, James Hayden and Frederick Keeney (The Wistar Microscopy Facility), Russell Delgiacco (The Wistar Histotechnology Facility), Jonni Moore and Hank Fletcher (University of Pennsylvania, Flow Cytometry Core Facility) and The Wistar Animal Facility.	Bidard FC, 2008, CANCER METAST REV, V27, P5, DOI 10.1007/s10555-007-9103-x; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Cohen ED, 2009, J CLIN INVEST, V119, P2538, DOI 10.1172/JCI38079; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Fukunaga-Kalabis M, 2006, J CELL BIOL, V175, P563, DOI 10.1083/jcb.200602132; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555; HERLYN M, 1991, CANCER RES, V51, P4853; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Jang JH, 2005, CANCER LETT, V229, P101, DOI 10.1016/j.canlet.2004.12.012; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Jonker JW, 2005, STEM CELLS, V23, P1059, DOI 10.1634/stemcells.2005-0150; Kabashima A, 2009, INT J CANCER, V124, P2771, DOI 10.1002/ijc.24349; Katoh SY, 2008, J BIOCHEM, V143, P517, DOI 10.1093/jb/mvm242; Kloepper JE, 2008, EXP DERMATOL, V17, P592, DOI 10.1111/j.1600-0625.2008.00720.x; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Marchionini DM, 2003, J COMP NEUROL, V464, P172, DOI 10.1002/cne.10785; Matsuzaki Y, 2008, AM J RESP CELL MOL, V38, P551, DOI 10.1165/rcmb.2007-0311OC; Mouthon MA, 2006, J NEUROCHEM, V99, P807, DOI 10.1111/j.1471-4159.2006.04118.x; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nakanishi T, 2006, BLOOD, V108, P678, DOI 10.1182/blood-2005-10-4020; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Refaeli Y, 2009, EMBO REP, V10, P965, DOI 10.1038/embor.2009.184; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Susanto J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004023; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; TUOMINEN H, 1994, J CUTAN PATHOL, V21, P424, DOI 10.1111/j.1600-0560.1994.tb00284.x; Villuendas R, 2006, LEUKEMIA, V20, P1047, DOI 10.1038/sj.leu.2404197; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	46	65	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6115	6124		10.1038/onc.2010.350	http://dx.doi.org/10.1038/onc.2010.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729912	Green Accepted			2022-12-28	WOS:000284356500004
J	Melillo, RM; Guarino, V; Avilla, E; Galdiero, MR; Liotti, F; Prevete, N; Rossi, FW; Basolo, F; Ugolini, C; de Paulis, A; Santoro, M; Marone, G				Melillo, R. M.; Guarino, V.; Avilla, E.; Galdiero, M. R.; Liotti, F.; Prevete, N.; Rossi, F. W.; Basolo, F.; Ugolini, C.; de Paulis, A.; Santoro, M.; Marone, G.			Mast cells have a protumorigenic role in human thyroid cancer	ONCOGENE			English	Article						chemokine; mast cell; thyroid cancer	ENDOTHELIAL GROWTH-FACTOR; PAPILLARY CARCINOMA; FOLLICULAR CELLS; TUMOR-GROWTH; INFLAMMATION; EXPRESSION; LINES; BRAF; ANGIOGENESIS; ACTIVATION	In different human carcinoma types, mast cell infiltrate increases with respect to normal tissue and mast cell density correlates with a bad prognosis. To assess the role of mast cells in human thyroid cancer, we compared the density of tryptase-positive mast cells in 96 papillary thyroid carcinomas (PTCs) versus normal thyroid tissue from 14 healthy individuals. Mast cell density was higher in 95% of PTCs (n - 91) than in control tissue. Mast cell infiltrate correlated with extrathyroidal extension (P = 0.0005) of PTCs. We show that thyroid cancer cell-line-derived soluble factors induce mast cell activation and chemoattraction in vitro. Different mast cell lines (HMC-1 and LAD2) and primary human lung mast cells induced thyroid cancer cell invasive ability, survival and DNA synthesis in vitro. The latter effect was mainly mediated by three mast-cell-derived mediators: histamine, and chemokines CXCL1/GRO alpha and CXCL10/IP10. We show that xenografts of thyroid carcinoma cells (8505-C) could recruit mast cells injected into the tail vein of mice. Co-injection of human mast cells accelerated the growth of thyroid cancer cell (8505-C) xenografts in athymic mice. This effect was mediated by increased tumor vascularization and proliferation, and was reverted by treating mice with sodium cromoglycate (Cromolyn), a specific mast cell inhibitor. In conclusion, our study data suggest that mast cells are recruited into thyroid carcinomas and promote proliferation, survival and invasive ability of cancer cells, thereby contributing to thyroid carcinoma growth and invasiveness. Oncogene (2010) 29, 6203-6215; doi:10.1038/onc.2010.348; published online 23 August 2010	[Melillo, R. M.; Guarino, V.; Avilla, E.; Liotti, F.; Santoro, M.] Univ Naples Federico 2, DBPCM, IEOS, CNR, I-80131 Naples, Italy; [Galdiero, M. R.; Prevete, N.; Rossi, F. W.; de Paulis, A.; Marone, G.] Univ Naples Federico 2, Div Immunol Clin & Allergol, Ctr Interdipartimentale Ric Sci Immunol Base & Cl, I-80131 Naples, Italy; [Melillo, R. M.] Fac Sci Biotecnol, Naples, Italy; [Basolo, F.; Ugolini, C.] Univ Pisa, Dipartimento Chirurg, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Pisa	Melillo, RM (corresponding author), Univ Naples Federico 2, DBPCM, IEOS, CNR, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	UGOLINI, Clara/AAG-1760-2019; Basolo, Fulvio/AAC-2727-2019; Liotti, Federica/AAC-1614-2019; UGOLINI, CLARA/AAI-6489-2021; melillo, rosa marina/O-5255-2015; GALDIERO, MARIA ROSARIA/J-6869-2018	UGOLINI, Clara/0000-0002-3489-8280; Basolo, Fulvio/0000-0003-1657-5020; Liotti, Federica/0000-0002-0145-988X; GALDIERO, MARIA ROSARIA/0000-0002-8086-9130; de Paulis, Amato/0000-0003-0347-2540; MELILLO, Rosa Marina/0000-0002-9233-5275	Associazione Italiana per la Ricerca sul Cancro (AIRC); Istituto Superiore di Oncologia (ISO); Project 'Applicazioni Biotecnologiche dalle molecole all'uomo' (MoMa); EC [03695]; Project 'Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale' (ACC); Project 'Molecular diagnostic and prognostic markers of thyroid neoplasis' [RF-CAM-353005]	Associazione Italiana per la Ricerca sul Cancro (AIRC); Istituto Superiore di Oncologia (ISO); Project 'Applicazioni Biotecnologiche dalle molecole all'uomo' (MoMa); EC(European CommissionEuropean Commission Joint Research Centre); Project 'Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale' (ACC); Project 'Molecular diagnostic and prognostic markers of thyroid neoplasis'	We would like to dedicate this paper to the memory of Professor Gaetano Salvatore, who continues to inspire our work. We are indebted to AS Kirshenbaum and JH Butterfield for the LAD2 and HMC-1 cell lines, respectively and to F Curcio for the P5 primary thyroid culture. We thank Mario Galgani and Salvatore De Simone for PBMC purification and 8505-C GFP-expressing cell sorting. We also thank Jean Ann Gilder for text editing. This study was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC), the Istituto Superiore di Oncologia (ISO), the Project 'Applicazioni Biotecnologiche dalle molecole all'uomo' (MoMa), the EC Contract 03695 (GenRisk-T), the Project 'Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale' (ACC) and the Project 'Molecular diagnostic and prognostic markers of thyroid neoplasis' RF-CAM-353005 of the Health Ministry. VG was a fellow of the Fondazione Italiana per la Ricerca sul Cancro (FIRC).	Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Borrello MG, 2008, CANCER LETT, V267, P262, DOI 10.1016/j.canlet.2008.03.060; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Castellone MD, 2004, ONCOGENE, V23, P5958, DOI 10.1038/sj.onc.1207790; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; de la Torre NG, 2006, ENDOCR-RELAT CANCER, V13, P931, DOI 10.1677/erc.1.01210; de Paulis A, 2006, J IMMUNOL, V177, P7322, DOI 10.4049/jimmunol.177.10.7322; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Di Pasquale M, 2001, HUM PATHOL, V32, P24, DOI 10.1053/hupa.2001.21138; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Jo YS, 2006, J CLIN ENDOCR METAB, V91, P3667, DOI 10.1210/jc.2005-2836; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marone G, 2005, ADV IMMUNOL, V88, P97, DOI 10.1016/S0065-2776(05)88004-6; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Parsons ME, 2006, BRIT J PHARMACOL, V147, pS127, DOI 10.1038/sj.bjp.0706440; Pufnock JS, 2009, J IMMUNOL, V182, P5498, DOI 10.4049/jimmunol.0801284; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Rivera ES, 2000, SEMIN CANCER BIOL, V10, P15, DOI 10.1006/scbi.2000.0303; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Welsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041	39	148	153	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	47					6203	6215		10.1038/onc.2010.348	http://dx.doi.org/10.1038/onc.2010.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729915				2022-12-28	WOS:000284601700002
J	Debnath, J				Debnath, J.			p66(Shc) and Ras: controlling anoikis from the inside-out	ONCOGENE			English	Editorial Material							APOPTOSIS; DEATH; LIFE	Protection from detachment-induced cell death, termed anoikis, facilitates metastasis. Though anoikis is largely attributed to the loss of integrin-related 'outside-in' survival signals, Terada and colleagues demonstrate a novel 'insideout' attachment sensing role for the adapter protein p66(Shc) in promoting anoikis and suppressing metastasis via Ras-dependent control of proliferation and survival. Oncogene (2010) 29, 5556-5558; doi:10.1038/onc.2010.347; published online 16 August 2010	[Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Debnath, J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW450B Box 0502, San Francisco, CA 94143 USA.	Jayanta.Debnath@ucsf.edu		Debnath, Jayanta/0000-0002-8745-4069	NCI NIH HHS [R01CA126792, CA126792-S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA126792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Ma Z, 2010, ONCOGENE, V29, P5559, DOI 10.1038/onc.2010.326; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Pinton P, 2008, CELL CYCLE, V7, P304, DOI 10.4161/cc.7.3.5360; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537	10	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5556	5558		10.1038/onc.2010.347	http://dx.doi.org/10.1038/onc.2010.347			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20711240				2022-12-28	WOS:000282946900002
J	Carter, CL; Lin, C; Liu, CY; Yang, L; Liu, ZR				Carter, C. L.; Lin, C.; Liu, C-Y; Yang, L.; Liu, Z-R			Phosphorylated p68 RNA helicase activates snail1 transcription by promoting HDAC1 dissociation from the snail1 promoter	ONCOGENE			English	Article						p68 RNA helicase; Snail1; transcription activation; HDAC1; Mi-2/NuRD	EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; E-CADHERIN EXPRESSION; HISTONE ACETYLATION; TUMOR PROGRESSION; BETA-CATENIN; CHROMATIN; PROTEIN; COMPLEX; CANCER	The nuclear p68 RNA helicase is a prototypical member of the DEAD-box family of RNA helicases. p68 RNA helicase has been implicated in cell proliferation and early organ development and maturation. However, the functional role of p68 RNA helicase in these biological processes at the molecular level is not well understood. We previously reported that tyrosine phosphorylation of p68 RNA helicase mediates the effects of platelet-derived growth factor (PDGF) in induction of epithelial mesenchymal transition by promoting beta-catenin nuclear translocation. Here, we report that phosphorylation of p68 RNA helicase at Y593 upregulates transcription of the Snail1 gene. The phosphorylated p68 activates transcription of the Snail1 gene by promoting histone deacetylase (HDAC) 1 dissociation from the Snail1 promoter. Our results showed that p68 interacted with the nuclear remodeling and deacetylation complex MBD3:Mi-2/NuRD. Thus, our data suggested that a DEAD-box RNA unwindase could potentially regulate gene expression by functioning as a protein 'displacer' to modulate protein-protein interactions at the chromatin-remodeling complex. Oncogene (2010) 29, 5427-5436; doi: 10.1038/onc.2010.276; published online 2 August 2010	[Carter, C. L.; Lin, C.; Liu, C-Y; Yang, L.; Liu, Z-R] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Plaza,24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		National Institute of Health [GM063874, CA118113]; Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE [R01CA118113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Roger Bridgeman for antibody p68-rgg production. We also thank Birgit Neuhaus for assistance in confocal imaging. This paper is greatly improved by critical comments from Jenny Yang, Mike Kirberger, Julian A. Johnson and Heena Dey. This study is supported in part by Research Grants from National Institute of Health (GM063874), (CA118113) and Georgia Cancer Coalition to ZR Liu.	Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Buszczak M, 2006, GENE DEV, V20, P977, DOI 10.1101/gad.1396306; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Liu ZR, 1998, MOL CELL BIOL, V18, P6910, DOI 10.1128/MCB.18.12.6910; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyoshi A, 2005, BRIT J CANCER, V92, P252, DOI 10.1038/sj.bjc.6602266; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wei Y, 2001, Yi Chuan Xue Bao, V28, P991; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, CELL SIGNAL, V17, P1495, DOI 10.1016/j.cellsig.2005.03.008; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yang LQ, 2004, PROTEIN EXPRES PURIF, V35, P327, DOI 10.1016/j.pep.2004.02.004; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	48	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5427	5436		10.1038/onc.2010.276	http://dx.doi.org/10.1038/onc.2010.276			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20676135	Green Accepted			2022-12-28	WOS:000282944500009
J	Merdzhanova, G; Gout, S; Keramidas, M; Edmond, V; Coll, JL; Brambilla, C; Brambilla, E; Gazzeri, S; Eymin, B				Merdzhanova, G.; Gout, S.; Keramidas, M.; Edmond, V.; Coll, J-L; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.			The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo	ONCOGENE			English	Article						alternative splicing; angiogenesis; cancer; E2F1; SC35; VEGF-A	METASTATIC COLORECTAL-CANCER; TUMOR ANGIOGENESIS; SPLICE VARIANTS; LUNG-TUMORS; VEGF; EXPRESSION; VEGF(165)B; CARCINOMA; RECEPTORS; DEATH	The transcription factor E2F1 has a crucial role in the control of cell growth and has been shown to regulate neoangiogenesis in a p53-dependent manner through inhibition of activity of the VEGF-A (vascular endothelial growth factor) promoter. Besides being regulated by transcription, VEGF-A is also highly regulated by pre-mRNA alternative splicing, resulting in the expression of several VEGF isoforms with either pro-(VEGF(xxx)) or anti-(VEGF(xxx)b) angiogenic properties. Recently, we identified the SR (Ser-Rich/Arg) protein SC35, a splicing factor, as a new transcriptional target of E2F1. Here, we show that E2F1 downregulates the activity of the VEGF-A promoter in tumour cells independently of p53, leading to a strong decrease in VEGFxxx mRNA levels. We further show that, strikingly, E2F1 alters the ratio of pro-VEGF(xxx) versus anti-VEGF(xxx)b angiogenic isoforms, favouring the anti-angiogenic isoforms, by a mechanism involving the induction of SC35 expression. Finally, using lung tumour xenografts in nude mice, we provide evidence that E2F1 and SC35 proteins increase the VEGF165b/VEGF ratio and decrease tumour neovascularization in vivo. Overall, these findings highlight E2F1 and SC35 as two regulators of the VEGF(xxx)/VEGF(xxx)b angiogenic switch in human cancer cells, a role that could be crucial during tumour progression, as well as in tumour response to antiangiogenic therapies. Oncogene (2010) 29, 5392-5403; doi: 10.1038/onc. 2010.281; published online 19 July 2010	[Merdzhanova, G.; Gout, S.; Keramidas, M.; Edmond, V.; Coll, J-L; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.] Univ Grenoble 1, Inst Albert Bonniot, Grenoble, France; [Keramidas, M.; Coll, J-L] INSERM, U823, Equipe Cibles Therapeurt & Diagnost & Vectoris Dr, Grenoble, France; [Merdzhanova, G.; Gout, S.; Edmond, V.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.] INSERM, Equipe Bases Mol Progress Canc Poumon 2, Inst Albert Bonniot, U823, F-38042 Grenoble 09, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Eymin, B (corresponding author), INSERM, Equipe Bases Mol Progress Canc Poumon 2, Inst Albert Bonniot, U823, BP170, F-38042 Grenoble 09, France.	Beatrice.Eymin@ujf-grenoble.fr	Eymin, Beatrice/M-1962-2013; Coll, Jean-Luc/G-2520-2013; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019; gazzeri, sylvie/U-4669-2019	Eymin, Beatrice/0000-0002-7311-3810; Coll, Jean-Luc/0000-0002-2453-3552; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839	Ligue Nationale contre le Cancer; Conseil Scientifique National d'AGIR a dom; Research French Ministry; Fondation pour la Recherche Medicale (FRM); Association pour la Recherche Contre le Cancer (ARC); Conseil Scientifique National d'AGIR	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Conseil Scientifique National d'AGIR a dom; Research French Ministry; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Association pour la Recherche Contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); Conseil Scientifique National d'AGIR	We thank Patricia Betton, Pascal Perron and Celine Lampreia for technical assistance. This work was supported by the Ligue Nationale contre le Cancer (Equipe Labellisee Ligue 2007) and by the Conseil Scientifique National d'AGIR a dom. Galina Merdzhanova was supported by fellowships from the Research French Ministry and the Fondation pour la Recherche Medicale (FRM). Stephanie Gout was supported by a fellowship from Association pour la Recherche Contre le Cancer (ARC). Valerie Edmond was supported by a grant from the Conseil Scientifique National d'AGIR a dom.	Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2002, CANCER RES, V62, P7203; Bates DO, 2006, CLIN SCI, V110, P575, DOI 10.1042/CS20050292; Bates DO, 2002, CANCER RES, V62, P4123; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Catena R, 2007, INT J CANCER, V120, P2096, DOI 10.1002/ijc.22461; Cheung N, 1998, HUM PATHOL, V29, P910, DOI 10.1016/S0046-8177(98)90195-2; Cohen CD, 2005, J AM SOC NEPHROL, V16, P1958, DOI 10.1681/ASN.2005020204; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Elias AP, 2008, CANCER MICROENVIRON, V1, P131, DOI 10.1007/s12307-008-0013-4; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; Jiang SX, 2007, MOL CELL BIOL, V27, P1696, DOI 10.1128/MCB.01760-06; Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; RAK J, 1995, CANCER RES, V55, P4575; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Robinson CJ, 2001, J CELL SCI, V114, P853; Salon C, 2007, ONCOGENE, V26, P6927, DOI 10.1038/sj.onc.1210499; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Zhang LL, 2000, CANCER RES, V60, P3655	34	68	70	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5392	5403		10.1038/onc.2010.281	http://dx.doi.org/10.1038/onc.2010.281			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20639906	Green Submitted			2022-12-28	WOS:000282944500006
J	Sakamoto, K; Triplett, AA; Schuler, LA; Wagner, KU				Sakamoto, K.; Triplett, A. A.; Schuler, L. A.; Wagner, K-U			Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer	ONCOGENE			English	Article						prolactin; Janus kinase 2; Stat5; gene targeting; transgenic; breast cancer	GROWTH-FACTOR-ALPHA; BREAST-CANCER; EPITHELIAL-CELLS; SIGNAL TRANSDUCER; ER-ALPHA; EXPRESSION; ACTIVATION; RECEPTOR; STAT5A; GENE	The prolactin receptor (PRLR), its associated Janus kinase 2 (Jak2) and the signal transducer and activator of transcription 5 (Stat5) are essential for normal mammary gland development. Owing to the upregulation of the PRLR and the local synthesis of its ligand in neoplastic cells, it has been proposed that PRL can act as a local growth factor in human breast cancers. This notion is supported by experimental evidence in transgenic mice, which showed that the mammary-specific expression of PRL contributes to carcinogenesis in vivo. To assess the importance of Jak2/Stat5 signaling during mammary cancer initiation and progression, we generated a PRL-induced mammary cancer model that allows the functional ablation of the Jak2 gene in the mammary epithelium before and after neoplastic transformation. Collectively, the results of this study show that the functional ablation of Jak2 protects against the onset of PRL-induced mammary tumorigenesis, suggesting that targeting this kinase is a relevant strategy for mammary cancer prevention. Surprisingly, Jak2 deficiency did not affect the growth and survival of PRL-induced mammary cancer cells in culture and in vivo. Consequently, Jak2 cannot be a sole therapeutic target to treat the established disease. PRL-induced mammary cancers exhibited an upregulation of ErbB2 and other ErbB receptor tyrosine kinases that may supersede the functionality of PRLR signaling through Jak2. Oncogene (2010) 29, 5359-5369; doi: 10.1038/onc.2010.274; published online 19 July 2010	[Sakamoto, K.; Triplett, A. A.; Wagner, K-U] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Schuler, L. A.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; [Wagner, K-U] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Nebraska System; University of Nebraska Medical Center	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, DRCII Room 5033, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	National Cancer Institute [CA117930, CA78312]; Nebraska Cancer and Smoking Disease Research Program [NE DHHS LB506 2009-45]; Susan G Komen Breast Cancer Foundation [PDF0600835]; NATIONAL CANCER INSTITUTE [R01CA117930, R01CA078312] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Cancer and Smoking Disease Research Program; Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Public Health Service Grant CA117930 (to K-UW) as well as Grant CA78312 (to LAS) from the National Cancer Institute. Additional financial support provided to K-UW by the Nebraska Cancer and Smoking Disease Research Program (NE DHHS LB506 2009-45) was imperative to finance the maintenance of the Jak2 conditional knockout model. KS received a postdoctoral fellowship from the Susan G Komen Breast Cancer Foundation (PDF0600835).	AOUIJAMALI MA, 2003, CANCER RES, V63, P3764; Arendt LM, 2008, AM J PATHOL, V172, P194, DOI 10.2353/ajpath.2008.070597; Arendt LM, 2006, AM J PATHOL, V168, P1365, DOI 10.2353/ajpath.2006.050861; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Brockman JL, 2005, MOL CELL ENDOCRINOL, V239, P45, DOI 10.1016/j.mce.2005.04.006; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Cardiff RD, 1998, J MAMMARY GLAND BIOL, V3, P3, DOI 10.1023/A:1018714016205; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; GINSBURG E, 1995, CANCER RES, V55, P2591; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Kim A, 2005, BREAST CANCER RES, V7, pR708, DOI 10.1186/bcr1281; Krempler A, 2004, GENESIS, V40, P52, DOI 10.1002/gene.20063; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Garcia-Martinez JM, 2010, CELL SIGNAL, V22, P415, DOI 10.1016/j.cellsig.2009.10.013; Matulka LA, 2005, DRUG DISCOV TODAY, V2, P1, DOI DOI 10.1016/J.DDMOD.2005.05.008; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Miermont AM, 2010, CARCINOGENESIS, V31, P1124, DOI 10.1093/carcin/bgq048; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Oakes SR, 2007, ONCOGENE, V26, P543, DOI 10.1038/sj.onc.1209838; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Pardanani A, 2008, LEUKEMIA, V22, P23, DOI 10.1038/sj.leu.2404948; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Sakamoto K, 2007, MOL ENDOCRINOL, V21, P1877, DOI 10.1210/me.2006-0316; Sakamoto K, 2009, CANCER RES, V69, P6642, DOI 10.1158/0008-5472.CAN-09-0746; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P563, DOI 10.1210/me.16.3.563; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tang JZ, 2010, ENDOCRINOLOGY, V151, P43, DOI 10.1210/en.2009-0651; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; Tran TH, 2010, CANCER RES, V70, P1711, DOI 10.1158/0008-5472.CAN-09-2314; Triplett AA, 2008, NEOPLASIA, V10, P1325, DOI 10.1593/neo.08524; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Wagner Kay-Uwe, 1997, Genes and Function, V1, P233; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	52	41	42	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5359	5369		10.1038/onc.2010.274	http://dx.doi.org/10.1038/onc.2010.274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20639901	Green Accepted			2022-12-28	WOS:000282944500003
J	Lyngaa, R; Norregaard, K; Kristensen, M; Kubale, V; Rosenkilde, MM; Kledal, TN				Lyngaa, R.; Norregaard, K.; Kristensen, M.; Kubale, V.; Rosenkilde, M. M.; Kledal, T. N.			Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling	ONCOGENE			English	Article						Epstein-Barr virus; cell transformation; G protein-coupled receptor; constitutive activity; signaling; VEGF	SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; KAPOSIS-SARCOMA; 7-TRANSMEMBRANE RECEPTOR; LYTIC INFECTION; CHEMOKINE; EXPRESSION; GENE; US28	Epstein-Barr virus (EBV) open reading frame BILF1 encodes a seven trans-membrane (TM) G protein-coupled receptor that signals with high constitutive activity through G alpha(i) (Beisser et al., 2005; Paulsen et al., 2005). In this paper, the transforming potential of BILF1 is investigated in vitro in a foci formation assay using retrovirally transduced NIH3T3 cells, as well as in vivo by using nude mice. BILF1 revealed a substantial transforming potential that was dependent on constitutive signaling, as a signaling-deficient mutant completely lost its ability to transform cells in vitro, and an intermediately active triple-mutated receptor possessed an intermediate transforming potential. Furthermore, BILF1 expression induced vascular endothelial growth factor secretion in a constitutively active manner. In nude mice, BILF1 promoted tumor formation in 90% of cases, ORF74 (from Kaposi's sarcoma-associated herpes virus) in 100% of cases, whereas the signaling-deficient receptor resulted in tumor establishment in 40% of cases. These data suggest that BILF1, when expressed during EBV infection, could indeed be involved in the pathogenesis of EBV-associated diseases and malignancies. Furthermore, the correlation between receptor activity and the ability to mediate cell transformation in vitro and tumor formation in vivo supports the idea that inverse agonists for BILF1 could inhibit cell transformation and be relevant therapeutic candidates. Oncogene (2010) 29, 4388-4398; doi: 10.1038/onc.2010.173; published online 14 June 2010	[Lyngaa, R.; Kristensen, M.; Kledal, T. N.] Danish Tech Univ, Lab Cell Biol & Virol, DTU Nanotech, Dept Micro & Nanotechnol, DK-4000 Roskilde, Denmark; [Norregaard, K.; Kubale, V.; Rosenkilde, M. M.] Univ Copenhagen, Mol Pharmacol Lab, Dept Neurosci & Pharmacol, Fac Hlth Sci, Copenhagen, Denmark	Technical University of Denmark; University of Copenhagen	Kledal, TN (corresponding author), Danish Tech Univ, Virol Dept Micro & Nanotechnol, DTU Nanotech, Frederiksborgvej 399,Build 330, DK-4000 Roskilde, Denmark.	tnkl@risoe.dtu.dk		Rosenkilde, Mette Marie/0000-0001-9600-3254				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 2005, J VIROL, V79, P441, DOI 10.1128/JVI.79.1.441-449.2005; Beisser PS, 1999, J VIROL, V73, P7218, DOI 10.1128/JVI.73.9.7218-7230.1999; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Hong GK, 2005, J VIROL, V79, P13984, DOI 10.1128/JVI.79.22.13984-13992.2005; Hong GK, 2005, J VIROL, V79, P13993, DOI 10.1128/JVI.79.22.13993-14003.2005; Kieff E, 2007, FIELDS VIROLOGY, P2603; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Krishna SM, 2006, VIRUS RES, V115, P85, DOI 10.1016/j.virusres.2005.07.010; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; McLean KA, 2004, VIROLOGY, V325, P241, DOI 10.1016/j.virol.2004.04.027; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montone KT, 1996, MODERN PATHOL, V9, P621; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; O'Neil JD, 2008, J GEN VIROL, V89, P2833, DOI 10.1099/vir.0.2008/003392-0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Paydas S, 2008, LEUKEMIA RES, V32, P1424, DOI 10.1016/j.leukres.2008.01.008; Pleskoff O, 2005, FEBS J, V272, P4163, DOI 10.1111/j.1742-4658.2005.04829.x; Rajagopal K, 2005, J CLIN INVEST, V115, P2971, DOI 10.1172/JCI26950; Rosenkilde MM, 2008, BRIT J PHARMACOL, V153, pS154, DOI 10.1038/sj.bjp.0707660; Rosenkilde MM, 2006, J BIOL CHEM, V281, P13199, DOI 10.1074/jbc.M602245200; Rosenkilde MM, 2006, CURR DRUG TARGETS, V7, P103, DOI 10.2174/138945006775270259; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2000, CANCER RES, V60, P4873; Streblow DN, 2003, J BIOL CHEM, V278, P50456, DOI 10.1074/jbc.M307936200; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Vischer HF, 2008, BIOCHEM BIOPH RES CO, V377, P93, DOI 10.1016/j.bbrc.2008.09.082; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Walling DM, 2003, J INFECT DIS, V188, P883, DOI 10.1086/378072; Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zuo JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000255	47	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4388	4398		10.1038/onc.2010.173	http://dx.doi.org/10.1038/onc.2010.173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20543866				2022-12-28	WOS:000280559100003
J	Eramo, A; Haas, TL; De Maria, R				Eramo, A.; Haas, T. L.; De Maria, R.			Lung cancer stem cells: tools and targets to fight lung cancer	ONCOGENE			English	Review						lung cancer; cancer stem cells; therapy; stem cells	TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; ALDEHYDE DEHYDROGENASE 1; BREAST-CANCER; PROGENITOR CELLS; SARS CORONAVIRUS; MARKER CD133; SOLID TUMORS; BASAL-CELLS; IDENTIFICATION	Cancer stem cell (CSC) theory states that tumors are organized in a similar hierarchical manner as normal tissues, with a sub-population of tumorigenic stem-like cells that generate the more differentiated nontumorigenic tumor cells. CSCs are chemoresistant and seem to be responsible for tumor recurrence and formation of metastases. Therefore, the study of these cells may lead to crucial advances in the understanding of tumor biology as well as to innovative and more effective therapies. Lung cancer represents the leading cause of cancer-related mortality worldwide. Despite improvements in medical and surgical management, patient survival rates remain stable at similar to 15%, calling for innovative strategies that may contribute to improve patient outcome. The discovery of lung CSCs and the possibility to characterize their biological properties may provide powerful translational tools to improve the clinical outcome of patients with lung cancer. In this report, we review what is known about lung CSCs and discuss the diagnostic, prognostic and therapeutic prospective of these findings. Oncogene (2010) 29, 4625-4635; doi:10.1038/onc.2010.207; published online 7 June 2010	[Eramo, A.; Haas, T. L.; De Maria, R.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Haas, T. L.; De Maria, R.] Mediterranean Inst Oncol, Catania, Italy	Istituto Superiore di Sanita (ISS); Mediterranean Institute of Oncology	De Maria, R (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	demaria@iss.it	De Maria, Ruggero/S-6385-2019; Eramo, Adriana/K-6694-2016	De Maria, Ruggero/0000-0003-2255-0583; Eramo, Adriana/0000-0002-0814-6683; Haas, Tobias/0000-0003-2336-0263	Italian Association for Cancer Research (AIRC); Marie Curie network [MRTN-CT-2006-035624]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Marie Curie network(European Commission)	We thank Giuseppe Loreto for technical assistance with figures and tables. We thank the Italian Association for Cancer Research (AIRC) and the Marie Curie network project 'ApopTrain' (MRTN-CT-2006-035624) for supporting the lung cancer stem cell research.	Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bianchi F, 2008, CELL CYCLE, V7, P729, DOI 10.4161/cc.7.6.5591; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BLENKINSOPP WK, 1967, EXP CELL RES, V46, P144, DOI 10.1016/0014-4827(67)90416-8; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borczuk Alain C, 2009, Proc Am Thorac Soc, V6, P152, DOI 10.1513/pats.200807-076LC; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chen YX, 2007, J EXP MED, V204, P2529, DOI 10.1084/jem.20070462; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins LG, 2007, AM FAM PHYSICIAN, V75, P56; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dubey S, 2008, AM J RESP CRIT CARE, V177, P941, DOI 10.1164/rccm.200801-107UP; Dubey S, 2009, AM J RESP CRIT CARE, V179, P860, DOI 10.1164/rccm.200902-0289UP; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Giangreco A, 2007, AM J RESP CRIT CARE, V175, P547, DOI 10.1164/rccm.200607-984PP; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Hong KU, 2004, AM J PHYSIOL-LUNG C, V286, pL643, DOI 10.1152/ajplung.00155.2003; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lantuejoul S, 2009, HISTOPATHOLOGY, V54, P43, DOI 10.1111/j.1365-2559.2008.03182.x; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103; Maeda S, 2008, BRIT J CANCER, V98, P1389, DOI 10.1038/sj.bjc.6604307; MAHVI D, 1977, AM J PATHOL, V86, P559; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Pallini R, 2008, CLIN CANCER RES, V14, P8205, DOI 10.1158/1078-0432.CCR-08-0644; Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Rawlins Emma L, 2008, Proc Am Thorac Soc, V5, P675, DOI 10.1513/pats.200801-006AW; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Ross JS, 2009, AM J CLIN PATHOL, V132, P237, DOI 10.1309/AJCPJI7DEOLKCS6F; Scagliotti G, 2009, ONCOLOGIST, V14, P253, DOI 10.1634/theoncologist.2008-0232; Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sholl LM, 2010, APPL IMMUNOHISTO M M, V18, P55, DOI 10.1097/PAI.0b013e3181b16b88; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song W, 2008, INT J CLIN PRACT, V62, P1212, DOI 10.1111/j.1742-1241.2008.01777.x; Storms RW, 1999, P NATL ACAD SCI USA, V96, P9118, DOI 10.1073/pnas.96.16.9118; Stripp Barry R, 2008, Proc Am Thorac Soc, V5, P328, DOI 10.1513/pats.200711-167DR; Stripp BR, 1995, AM J PHYSIOL-LUNG C, V269, pL791, DOI 10.1152/ajplung.1995.269.6.L791; Theodoropoulos PA, 2010, CANCER LETT, V288, P99, DOI 10.1016/j.canlet.2009.06.027; Tiseo M, 2009, EXPERT REV ANTICANC, V9, P425, DOI 10.1586/ERA.09.3; Todaro M, 2008, CELL CYCLE, V7, P309, DOI 10.4161/cc.7.3.5389; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; vanWinkle LS, 1995, AM J PHYSIOL-LUNG C, V269, pL800, DOI 10.1152/ajplung.1995.269.6.L800; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	103	104	112	4	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4625	4635		10.1038/onc.2010.207	http://dx.doi.org/10.1038/onc.2010.207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531299				2022-12-28	WOS:000281127400002
J	Oh, W; Lee, EW; Lee, D; Yang, MR; Ko, A; Yoon, CH; Lee, HW; Bae, YS; Choi, CY; Song, J				Oh, W.; Lee, E-W; Lee, D.; Yang, M-R; Ko, A.; Yoon, C-H; Lee, H-W; Bae, Y-S; Choi, C. Y.; Song, J.			Hdm2 negatively regulates telomerase activity by functioning as an E3 ligase of hTERT	ONCOGENE			English	Article						Hdm2; telomerase; hTERT; p53; ubiquitination	HUMAN TUMOR-CELLS; DOWN-REGULATION; LIFE-SPAN; P53; CANCER; APOPTOSIS; EXPRESSION; DEGRADATION; GROWTH; MDM2	In this study, we identified posttranslational regulation of human telomerase reverse-transcriptase (hTERT) by the E3 ligase Hdm2. The telomerase activity generated by exogenous hTERT in U2OS cells was reduced on adriamycin treatment. The overexpressed levels of hTERT were also decreased under the same conditions. These processes were reversed by treatment with a proteasome inhibitor or depletion of Hdm2. Furthermore, intrinsic telomerase activity was increased in HCT116 cells with ablation of Hdm2. Immunoprecipitation analyses showed that hTERT and Hdm2 bound to each other in multiple domains. Ubiquitination analyses showed that Hdm2 could polyubiquitinate hTERT principally at the N-terminus, which was further degraded in a proteasome-dependent manner. An hTERT mutant with all five lysine residues at the N-terminus of hTERT that mutated to arginine became resistant to Hdm2-mediated ubiquitination and degradation. In U2OS cells, depletion of Hdm2 or addition of the Hdm2-resistant hTERT mutant strengthened the cellular protective effects against apoptosis. Similar results were obtained with the Hdm2-stable H1299 cell line. These observations indicate that Hdm2 is an E3 ligase of hTERT. Oncogene (2010) 29, 4101-4112; doi:10.1038/onc.2010.160; published online 10 May 2010	[Oh, W.; Lee, E-W; Yang, M-R; Ko, A.; Song, J.] Sungkyunkwan Univ, Dept Biotechnol & Bioengn, Suwon 440746, South Korea; [Lee, D.; Yoon, C-H; Bae, Y-S; Choi, C. Y.] Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; [Lee, H-W] Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Yonsei University	Song, J (corresponding author), Sungkyunkwan Univ, Dept Biotechnol & Bioengn, Suwon 440746, South Korea.	jso678@skku.edu	Lee, Eun-Woo/AAP-9603-2020	Song, Jaewhan/0000-0001-8152-9210; Ko, Aram/0000-0003-4997-3092; Lee, Eun-Woo/0000-0002-5156-0003	Ministry of Health and Welfare, Republic of Korea [0820110, A080333]	Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (0820110) and by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A080333).	Akiyama M, 2002, CANCER RES, V62, P3876; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Blasco MA, 2003, CURR OPIN GENET DEV, V13, P70, DOI 10.1016/S0959-437X(02)00011-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bouska A, 2009, TRENDS BIOCHEM SCI, V34, P279, DOI 10.1016/j.tibs.2009.02.006; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025; Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Carroll VA, 2008, CANCER RES, V68, P545, DOI 10.1158/0008-5472.CAN-06-4738; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.onc.1210452; Dalla Torre CA, 2002, BRAZ J MED BIOL RES, V35, P65, DOI 10.1590/S0100-879X2002000100009; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dimri GP, 2002, CANCER RES, V62, P4736; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Froment P, 2008, CELL CYCLE, V7, P3098, DOI 10.4161/cc.7.19.6807; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Oh W, 2009, J CELL SCI, V122, P2613, DOI 10.1242/jcs.048066; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	44	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4101	4112		10.1038/onc.2010.160	http://dx.doi.org/10.1038/onc.2010.160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453884				2022-12-28	WOS:000279892400010
J	Salem, H; Rachmin, I; Yissachar, N; Cohen, S; Amiel, A; Haffner, R; Lavi, L; Motro, B				Salem, H.; Rachmin, I.; Yissachar, N.; Cohen, S.; Amiel, A.; Haffner, R.; Lavi, L.; Motro, B.			Nek7 kinase targeting leads to early mortality, cytokinesis disturbance and polyploidy	ONCOGENE			English	Article						NIMA; kinase; gene targeting; early lethality; cytokinesis; mitosis	NIMA-FAMILY KINASE; POLYCYSTIC KIDNEY-DISEASE; MITOTIC SPINDLE FORMATION; CELL-CYCLE; PROTEIN-KINASES; ASPERGILLUS-NIDULANS; MAMMALIAN-CELLS; MURINE KINASES; PRIMARY CILIA; CENTROSOME	The mammalian NIMA-related kinases (Neks) are commonly referred to as mitotic kinases, although a definitive in vivo verification of this definition is largely missing. Reduction in the activity of Nek7 or its close paralog, Nek6, has previously been shown to arrest cells in mitosis, mainly at metaphase. In this study, we investigate the developmental and cellular roles of Nek7 kinase through the generation and analysis of Nek7-deficient mice. We show that absence of Nek7 leads to lethality in late embryogenesis or at early post-natal stages and to severe growth retardation. Mouse embryonic fibroblasts (MEFs) derived from Nek7(-/-) embryos show increase tendency for chromosomal lagging, micronuclei formation and cytokinesis failure. Tetraploidy and aneuploidy were commonly observed and their prevalence arises with MEFs passages. The frequency of multicentrosomal cells in the mutant's MEF cells was higher, and it commonly occurred concurrently with a binuclear phenotype, suggesting cytokinesis failure etiology. Lastly, the percentage of mutant MEF cells bearing primary cilia (PC) was low, whereas a cell population having two cilia appeared in the mutant MEFs. Taken together, these results confirm Nek7 as a regulator of cell division, and reveal it as an essential component for mammalian growth and survival. The intimate connection between tetraploidy, aneuploidy and cancer development suggests that Nek7 deregulation can induce oncogenesis. Oncogene (2010) 29, 4046-4057; doi:10.1038/onc.2010.162; published online 17 May 2010	[Salem, H.; Rachmin, I.; Yissachar, N.; Cohen, S.; Amiel, A.; Lavi, L.; Motro, B.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel; [Amiel, A.] Meir Med Ctr, Genet Inst, Kefar Sava, Israel; [Haffner, R.] Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel	Bar Ilan University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Motro, B (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	motro@mail.biu.ac.il	/ABF-8487-2022	Yissachar, Nissan/0000-0002-7647-9754	Bar-Ilan Rector	Bar-Ilan Rector	We thank G Damari and A Berkovitz from the Transgenic Unit of the Weizmann Institute for generation of chimeras. We also thank S Madar, Weizmann Institute, for real time RT-PCR analyses; R Palmiter, University of Washington, for providing the pNeoZTK2 vector. This study is supported by funds from Bar-Ilan Rector.	Akhter S, 2004, MOL CELL BIOL, V24, P10448, DOI 10.1128/MCB.24.23.10448-10455.2004; Aleem Eiman, 2006, V42, P271, DOI 10.1007/023; Alieva IB, 2004, CELL BIOL INT, V28, P139, DOI 10.1016/j.cellbi.2003.11.013; Barr FA, 2007, CELL, V131, P847, DOI 10.1016/j.cell.2007.11.011; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Castillo A, 2007, CANCER RES, V67, P10138, DOI 10.1158/0008-5472.CAN-07-0326; De Souza CPC, 2003, GENETICS, V165, P1071; EPSTEIN CJ, 1967, P NATL ACAD SCI USA, V57, P327, DOI 10.1073/pnas.57.2.327; Feige E, 2002, MECH DEVELOP, V110, P219, DOI 10.1016/S0925-4773(01)00573-1; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kim S, 2007, BIOCHEM BIOPH RES CO, V360, P56, DOI 10.1016/j.bbrc.2007.05.206; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lee MY, 2008, CELL CYCLE, V7, P2705, DOI 10.4161/cc.7.17.6551; Liu SM, 2002, DEVELOPMENT, V129, P5839, DOI 10.1242/dev.00173; Mahjoub MR, 2005, J AM SOC NEPHROL, V16, P3485, DOI 10.1681/ASN.2005080824; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; O'Regan L, 2009, MOL CELL BIOL, V29, P3975, DOI 10.1128/MCB.01867-08; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; Parker JDK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001076; Rapley J, 2008, J CELL SCI, V121, P3912, DOI 10.1242/jcs.035360; Roig J, 2005, MOL BIOL CELL, V16, P4827, DOI 10.1091/mbc.E05-04-0315; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shalom O, 2008, FEBS LETT, V582, P1465, DOI 10.1016/j.febslet.2008.03.036; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smith LA, 2006, J AM SOC NEPHROL, V17, P2821, DOI 10.1681/ASN.2006020136; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; White MC, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-29; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yin MJ, 2003, J BIOL CHEM, V278, P52454, DOI 10.1074/jbc.M308080200; Yissachar N, 2006, FEBS LETT, V580, P6489, DOI 10.1016/j.febslet.2006.10.069	45	53	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4046	4057		10.1038/onc.2010.162	http://dx.doi.org/10.1038/onc.2010.162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473324				2022-12-28	WOS:000279892400005
J	Hatton, BA; Villavicencio, EH; Pritchard, J; LeBlanc, M; Hansen, S; Ulrich, M; Ditzler, S; Pullar, B; Stroud, MR; Olson, JM				Hatton, B. A.; Villavicencio, E. H.; Pritchard, J.; LeBlanc, M.; Hansen, S.; Ulrich, M.; Ditzler, S.; Pullar, B.; Stroud, M. R.; Olson, J. M.			Notch signaling is not essential in sonic hedgehog-activated medulloblastoma	ONCOGENE			English	Article						medulloblastoma; notch; sonic hedgehog; gamma secretase inhibitor	GAMMA-SECRETASE INHIBITORS; EMBRYONAL BRAIN-TUMORS; PATHWAY; CELLS; GROWTH; MODEL; CORE; MICE	Dysregulated signal transduction through the notch pathway has been noted in human and mouse medulloblastoma studies. Gamma secretase inhibitors (GSIs) impair notch signaling by preventing the cleavage of transmembrane notch proteins into their active intracellular domain fragments. Previous studies have shown that GSI treatment caused apoptosis and impaired medulloblastoma cell engraftment in xenograft systems. In this study, we used in vivo genetic and pharmacologic approaches to quantify the contribution of notch signaling to sonic hedgehog (shh)-activated mouse medulloblastoma models. In contrast to prior in vitro studies, pharmacologic inhibition of notch pathways did not reduce the efficiency of medulloblastoma xenotransplantation nor did systemic therapy impact tumor size, proliferation, or apoptosis in genetically engineered mouse medulloblastoma models. The incidence and pathology of medulloblastomas driven by the SmoA1 transgene was unchanged by the bi-allelic absence of Notch1, Notch2, or Hes5 genes. These data show that notch signaling is not essential for the initiation, engraftment, or maintenance of sonic hedgehog pathway-driven medulloblastomas. Oncogene (2010) 29, 3865-3872; doi: 10.1038/onc.2010.142; published online 3 May 2010	[Hatton, B. A.; Villavicencio, E. H.; Pritchard, J.; LeBlanc, M.; Hansen, S.; Ulrich, M.; Ditzler, S.; Pullar, B.; Stroud, M. R.; Olson, J. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Olson, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	jolson@fhcrc.org			NIH [5R01CA112350-04, 5R01CA114567-04, 5T32CA009351, 5K12CA076930]; NATIONAL CANCER INSTITUTE [R01CA114567, T32CA009351, K12CA076930, R01CA112350] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Francois Guillemot for providing the Hes5-null mice, to Freddy Radtke for the notch1 conditional knockout mice, to Thomas Gridley for the notch2 conditional knockout mice, and to Dr Irwin Bernstein for providing the 18G anti-Notch antibody and advice. The gamma secretase inhibitor MRK-003 was provided by Merck Research Laboratories, which also provided partial funding for the studies. This work was supported by NIH Grants 5R01CA112350-04, 5R01CA114567-04, 5T32CA009351, and 5K12CA076930.	Cau E, 2000, DEVELOPMENT, V127, P2323; Eberhart CG, 2007, NEUROSURG CLIN N AM, V18, P59, DOI 10.1016/j.nec.2006.10.005; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Julian E, 2010, ONCOGENE, V29, P3465, DOI 10.1038/onc.2010.101; Lewis SJ, 2005, BIOORG MED CHEM LETT, V15, P373, DOI 10.1016/j.bmcl.2004.10.062; McCright B, 2006, GENESIS, V44, P29, DOI 10.1002/gene.20181; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Schouwey K, 2008, HISTOL HISTOPATHOL, V23, P609, DOI 10.14670/HH-23.609; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Sparey T, 2005, BIOORG MED CHEM LETT, V15, P4212, DOI 10.1016/j.bmcl.2005.06.084; Wall DS, 2009, J CELL BIOL, V184, P101, DOI 10.1083/jcb.200805155; Weiner HL, 2002, CANCER RES, V62, P6385; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832	22	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3865	3872		10.1038/onc.2010.142	http://dx.doi.org/10.1038/onc.2010.142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440271	Green Accepted			2022-12-28	WOS:000279385200014
J	Vizioli, MG; Sensi, M; Miranda, C; Cleris, L; Formelli, F; Anania, MC; Pierotti, MA; Greco, A				Vizioli, M. G.; Sensi, M.; Miranda, C.; Cleris, L.; Formelli, F.; Anania, M. C.; Pierotti, M. A.; Greco, A.			IGFBP7: an oncosuppressor gene in thyroid carcinogenesis	ONCOGENE			English	Article						IGFBP7; thyroid tumors; PTC	EXPRESSION PROFILES; COLORECTAL-CANCER; TUMOR-GROWTH; PAPILLARY; PROTEIN; CARCINOMA; SENESCENCE; BRAF	Insulin-like growth factor-binding protein 7 (IGFBP7) is a secreted protein involved in several cellular processes, including proliferation, senescence and apoptosis. Loss of IGFBP7 expression is a critical step in the development of human tumors, including melanoma and colon cancer. By microarray gene expression studies, we have detected downregulation of IGFBP7 gene expression in follicular and papillary thyroid tumors in comparison with normal thyroid tissue. Evaluation of publicly available PTC microarray gene expression data sets confirmed, in a consistent fraction of tumors, the downregulation of IGFBP7 transcript levels. The functional consequence of IGFBP7 downregulation was addressed in the PTC-derived NIM1 cell line in which IGFBP7 expression is repressed by promoter hypermethylation. Exposure to soluble IGFBP7 protein or restoration of IGFBP7 expression by complementary DNA transfection reduced growth rate, migration, anchorage-independent growth and tumorigenicity of NIM1 cells. We show that the effects of IGFBP7 are related to apoptosis. Our data suggest that loss of IGFBP7 expression has a functional role in thyroid carcinogenesis, and it may represent a possible basis for therapeutic strategies. Oncogene (2010) 29, 3835-3844; doi: 10.1038/onc.2010.136; published online 3 May 2010	[Vizioli, M. G.; Miranda, C.; Anania, M. C.; Greco, A.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Mol Mech Unit, I-20133 Milan, Italy; [Sensi, M.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, I-20133 Milan, Italy; [Cleris, L.; Formelli, F.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Chemoprevent Unit, I-20133 Milan, Italy; [Pierotti, M. A.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Sci Directorate, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Greco, A (corresponding author), Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Mol Mech Unit, Via Venezian 1, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Anania, Maria Chiara/N-4853-2019; Cleris, Loredana/T-3144-2018; Greco, Angela/C-1953-2017; Sensi, Marialuisa/K-5631-2014; Anania, Maria Chiara/B-9339-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Anania, Maria Chiara/0000-0003-4012-1870; Cleris, Loredana/0000-0001-8778-7931; Greco, Angela/0000-0003-2994-0349; Sensi, Marialuisa/0000-0002-7643-0248; Anania, Maria Chiara/0000-0003-4012-1870; Pierotti, Marco Alessandro/0000-0002-7431-8332	AIRC [4472]; ACC; Ministry of Health	AIRC(Fondazione AIRC per la ricerca sul cancro); ACC; Ministry of Health	The authors thank Mrs Sonia Pagliardini for technical assistance and Mrs Cristina Mazzadi for editing and secretarial help. This work was supported by AIRC grant N. 4472, ACC and Ministry of Health.	Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; [Anonymous], 1988, BRIT J CANCER, V58, P109, DOI 10.1038/bjc.1988.174; Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023; Chen Y, 2007, J PATHOL, V211, P431, DOI 10.1002/path.2132; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Ferrario C, 2008, LAB INVEST, V88, P474, DOI 10.1038/labinvest.2008.17; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Greco A, 2009, Q J NUCL MED MOL IM, V53, P440; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hinoue T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008357; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kanemitsu N, 2000, BIOCHEM BIOPH RES CO, V279, P251, DOI 10.1006/bbrc.2000.3944; Latini FRM, 2008, ENDOCR-RELAT CANCER, V15, P787, DOI 10.1677/ERC-08-0079; Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Ruan Wen-jing, 2006, J Zhejiang Univ Sci B, V7, P929, DOI 10.1631/jzus.2006.B0929; Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702; Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x; Schrama D, 2010, J INVEST DERMATOL, V130, P897, DOI 10.1038/jid.2009.304; Sprenger CC, 1999, CANCER RES, V59, P2370; Suzuki H, 2010, CARCINOGENESIS, V31, P342, DOI 10.1093/carcin/bgp179; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wajapeyee N, 2009, MOL CANCER THER, V8, P3009, DOI 10.1158/1535-7163.MCT-09-0470; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127	31	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3835	3844		10.1038/onc.2010.136	http://dx.doi.org/10.1038/onc.2010.136			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440262				2022-12-28	WOS:000279385200011
J	Liu, F; Killian, JK; Yang, M; Walker, RL; Hong, JA; Zhang, M; Davis, S; Zhang, Y; Hussain, M; Xi, S; Rao, M; Meltzer, PA; Schrump, DS				Liu, F.; Killian, J. K.; Yang, M.; Walker, R. L.; Hong, J. A.; Zhang, M.; Davis, S.; Zhang, Y.; Hussain, M.; Xi, S.; Rao, M.; Meltzer, P. A.; Schrump, D. S.			Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate	ONCOGENE			English	Article						tobacco smoke; lung cancer; epigenetics; respiratory epithelial cells	CELL LUNG-CANCER; MODIFICATIONS PREDICT PROGNOSIS; IN-VITRO; METHYLTRANSFERASES CONTRIBUTES; MAINSTREAM SMOKE; POOR-PROGNOSIS; UP-REGULATION; MAGE-A; METHYLATION; ACTIVATION	Limited information is available regarding epigenomic events mediating initiation and progression of tobacco-induced lung cancers. In this study, we established an in vitro system to examine epigenomic effects of cigarette smoke in respiratory epithelia. Normal human small airway epithelial cells and cdk-4/hTERT-immortalized human bronchial epithelial cells (HBEC) were cultured in normal media with or without cigarette smoke condensate (CSC) for up to 9 months under potentially relevant exposure conditions. Western blot analysis showed that CSC mediated dose- and time-dependent diminution of H4K16Ac and H4K20Me3, while increasing relative levels of H3K27Me3; these histone alterations coincided with decreased DNA methyltransferase 1 (DNMT1) and increased DNMT3b expression. Pyrosequencing and quantitative RT-PCR experiments revealed time-dependent hypomethylation of D4Z4, NBL2, and LINE-1 repetitive DNA sequences; up-regulation of H19, IGF2, MAGE-A1, and MAGE-A3; activation of Wnt signaling; and hypermethylation of tumor suppressor genes such as RASSF1A and RAR-beta, which are frequently silenced in human lung cancers. Array-based DNA methylation profiling identified additional novel DNA methylation targets in soft-agar clones derived from CSC-exposed HBEC; a CSC gene expression signature was also identified in these cells. Progressive genomic hypomethylation and locoregional DNA hypermethylation induced by CSC coincided with a dramatic increase in soft-agar clonogenicity. Collectively, these data indicate that cigarette smoke induces 'cancer-associated' epigenomic alterations in cultured respiratory epithelia. This in vitro model may prove useful for delineating early epigenetic mechanisms regulating gene expression during pulmonary carcinogenesis. Oncogene ( 2010) 29, 3650-3664; doi: 10.1038/onc.2010.129; published online 3 May 2010	[Liu, F.; Yang, M.; Hong, J. A.; Zhang, M.; Zhang, Y.; Hussain, M.; Xi, S.; Rao, M.; Schrump, D. S.] NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Killian, J. K.; Walker, R. L.; Davis, S.; Meltzer, P. A.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res, 10 Ctr Dr,Bldg 10,Room 4-3940, Bethesda, MD 20892 USA.	David_Schrump@nih.gov	Davis, Sean/AAD-1801-2021	Davis, Sean/0000-0002-8991-6458; Walker, Robert/0000-0001-8235-4686	NATIONAL CANCER INSTITUTE [ZIABC011122, ZICBC011040, ZIABC011091] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC011115-09, ZIA BC011122-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622; Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Cho Hearn J, 2006, Cancer Immun, V6, P12; D'Alessio AC, 2006, BIOCHEM CELL BIOL, V84, P463, DOI 10.1139/O06-090; Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Fields WR, 2005, TOXICOL SCI, V86, P84, DOI 10.1093/toxsci/kfi179; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019; Hoogeboom D, 2009, BBA-REV CANCER, V1796, P63, DOI 10.1016/j.bbcan.2009.02.002; Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Jensen TJ, 2009, TOXICOL APPL PHARM, V235, P39, DOI 10.1016/j.taap.2008.10.013; Jin Q, 2008, CARCINOGENESIS, V29, P1614, DOI 10.1093/carcin/bgm234; Jorgensen ED, 2004, CELL CYCLE, V3, P1154; Kang Y, 2007, ONCOGENE, V26, P4394, DOI 10.1038/sj.onc.1210218; Kaplan R, 2003, CANCER RES, V63, P1475; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Killian JK, 2009, CANCER RES, V69, P758, DOI 10.1158/0008-5472.CAN-08-2984; Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087; LE FN, 2005, FASEB J, V19, P144; Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Malusecka E, 2008, ANTICANCER RES, V28, P501; Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002; McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Schrump DS, 2007, CANCER J, V13, P56, DOI 10.1097/PPO.0b013e31803c74cf; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seng TJ, 2008, BRIT J CANCER, V99, P375, DOI 10.1038/sj.bjc.6604452; Sexton K, 2008, PHARMACOGENET GENOM, V18, P853, DOI 10.1097/FPC.0b013e328307bddf; Shin HJ, 2009, FOOD CHEM TOXICOL, V47, P192, DOI 10.1016/j.fct.2008.10.028; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Smith CJ, 2003, FOOD CHEM TOXICOL, V41, P807, DOI 10.1016/S0278-6915(03)00021-8; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; Vrzalikova K, 2008, J CANCER RES CLIN, V134, P1037, DOI 10.1007/s00432-008-0361-y; Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200; Wu JP, 2009, TOXICOL SCI, V107, P385, DOI 10.1093/toxsci/kfn239; Xing J, 2008, BRIT J CANCER, V98, P1716, DOI 10.1038/sj.bjc.6604343; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478; Zhou X, 2009, TOXICOL APPL PHARM, V236, P78, DOI 10.1016/j.taap.2009.01.009	51	202	218	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3650	3664		10.1038/onc.2010.129	http://dx.doi.org/10.1038/onc.2010.129			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440268	Green Accepted			2022-12-28	WOS:000279108600006
J	Lee, YC; Huang, CF; Murshed, M; Chu, K; Araujo, JC; Ye, X; deCrombrugghe, B; Yu-Lee, LY; Gallick, GE; Lin, SH				Lee, Y-C; Huang, C-F; Murshed, M.; Chu, K.; Araujo, J. C.; Ye, X.; deCrombrugghe, B.; Yu-Lee, L-Y; Gallick, G. E.; Lin, S-H			Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts	ONCOGENE			English	Article						dasatinib; Src family kinase; osteoblast; prostate cancer; bone metastasis	FIBROBLAST-GROWTH-FACTOR; PROSTATE-CANCER CELLS; BONE-FORMATION; COLLAGEN-SYNTHESIS; TUMOR PROGRESSION; SECRETED ISOFORM; PROTEIN-KINASE; EXPRESSION; PP60C-SRC; METASTASIS	Dasatinib, a dual Src family kinase and Abl inhibitor, is being tested clinically for the treatment of prostate cancer bone metastasis. Bidirectional interactions between osteoblasts and prostate cancer cells are critical in the progression of prostate cancer in bone, but the effect of dasatinib on osteoblasts is unknown. We found that dasatinib inhibited proliferation of primary mouse osteoblasts isolated from mouse calvaria and the immortalized MC3T3-E1 cell line. In calvarial osteoblasts from Col-luc transgenic mice carrying osteoblast-specific Col1 alpha 1 promoter reporter, luciferase activity was inhibited. Dasatinib also inhibited fibroblast growth factor-2-induced osteoblast proliferation, but strongly promoted osteoblast differentiation, as reflected by stimulation of alkaline phosphatase activity, osteocalcin secretion and osteoblast mineralization. To determine how dasatinib blocks proliferative signaling in osteoblasts, we analyzed the expression of a panel of tyrosine kinases, including Src, Lyn, Fyn, Yes and Abl, in osteoblasts. In the Src family kinases, only Src was activated at a high level. Abl was expressed at a low level in osteoblasts. Phosphorylation of Src-Y419 or Abl-Y245 was inhibited by dasatinib treatment. Knockdown of either Src or Abl by lenti-shRNA in osteoblasts enhances osteoblast differentiation, suggesting that dasatinib enhances osteoblast differentiation through inhibition of both Src and Abl. Oncogene (2010) 29, 3196-3207; doi: 10.1038/onc.2010.73; published online 15 March 2010	[Lee, Y-C; Huang, C-F; Ye, X.; Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Huang, C-F] Natl Taiwan Univ, Coll Med, Grad Inst Pharm, Natl Taiwan Univ Hosp,Dept Pharm, Taipei 10764, Taiwan; [Murshed, M.; Chu, K.; Araujo, J. C.; Gallick, G. E.; Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [deCrombrugghe, B.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; [Yu-Lee, L-Y] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Taiwan University; National Taiwan University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77030 USA.	slin@mdanderson.org		Huang, Chih-Fen/0000-0003-1311-8828	National Institutes of Health [CA111479, P50 CA140388, DK53176]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [P50CA140388, R01CA111479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Karen Philips for editing the paper. This study was supported by National Institutes of Health Grants CA111479 (SH Lin), P50 CA140388 (SH Lin, GE Gallick) and DK53176 (LY Yu-Lee), and by the Prostate Cancer Foundation (SH Lin).	Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BELLOWS CG, 1989, DEV BIOL, V133, P8, DOI 10.1016/0012-1606(89)90291-1; Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Brownlow N, 2009, LEUKEMIA, V23, P590, DOI 10.1038/leu.2008.237; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HANNON RA, 2009, J BONE MINER RES; Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224; Jacob K, 1999, CANCER RES, V59, P4453; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lin SH, 2008, ONCOGENE, V27, P5195, DOI 10.1038/onc.2008.156; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583; MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo-125-4-2118; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Nelson JB, 1999, UROLOGY, V53, P1063, DOI 10.1016/S0090-4295(98)00658-X; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Ye XC, 2007, FRONT BIOSCI, V12, P3273, DOI 10.2741/2311	48	66	68	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3196	3207		10.1038/onc.2010.73	http://dx.doi.org/10.1038/onc.2010.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20228840	Green Accepted			2022-12-28	WOS:000278321100003
J	Denes, V; Pilichowska, M; Makarovskiy, A; Carpinito, G; Geck, P				Denes, V.; Pilichowska, M.; Makarovskiy, A.; Carpinito, G.; Geck, P.			Loss of a cohesin-linked suppressor APRIN (Pds5b) disrupts stem cell programs in embryonal carcinoma: an emerging cohesin role in tumor suppression	ONCOGENE			English	Article						APRIN; stem cells; differentiation; cancer; Pds5b; cohesins	PROSTATE-CANCER CELLS; DE-LANGE-SYNDROME; NEURAL DIFFERENTIATION; GENE-EXPRESSION; AT-HOOK; AS3; PROLIFERATION; PATTERNS; NEURONS; PROTEIN	Cohesins appear to have critical functions beyond mitotic cohesion. Our data on a cohesin-associated Pds5-paralog, APRIN, indicate a novel cohesin role in stem cell differentiation. APRIN/Pds5B is lost in many cancers and it is a putative tumor suppressor. Its mutations in the germ line, however, generate birth defects. We reasoned that as both cancer and birth defects share disrupted stem cell differentiation, the data suggest an APRIN/Pds5B cohesin function in stem cells. We used an embryonal carcinoma stem cell model and show here that (i) APRIN expression is precisely coordinated with stem cell differentiation; (ii) this coordination involves surface-contact and endocrine pathways; and (iii) APRIN/Pds5b coordination is critical in stem/progenitor exit decisions. APRIN knockdown disrupted Oct4, Nanog and SOX2 patterns, differentiation failed and the resulting immature proliferative cells did not progress beyond proneural progenitor phase. Furthermore, the phenotype-blocked progenitor exit (Mash-1(+)); failed E-cadherin exit (E-Cadh(low+));incomplete N-cadherin transition (N-Cadh(low+)); retained proliferative capacity (c-myc(+)); irregular stemness (SOX2(late++)) and lost response to contact and hormonal cues-shares similarities with cancer-initiating cells. The data suggest novel APRIN/Pds5B-linked cohesin roles in stem/progenitor programs and a new mechanism in tumor suppression. Oncogene (2010) 29, 3446-3452; doi:10.1038/onc.2010.100; published online 12 April 2010	[Denes, V.; Geck, P.] Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA; [Pilichowska, M.] Tufts Med Ctr, Dept Pathol, Boston, MA USA; [Makarovskiy, A.; Carpinito, G.] Tufts Med Ctr, Dept Urol, Boston, MA USA	Tufts University; Tufts Medical Center; Tufts Medical Center	Geck, P (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cell Biol, Harrison Ave, Boston, MA 02111 USA.	peter.geck@tufts.edu			The Susan G Komen Breast Cancer Foundation [BCTR0403214, W81XWH-08-1-0575, W81XWH-09-1-0411]; Sanofi-Aventis [IST10257];  [DOD-DAMD17-01-1-0430];  [DOD-DAMD1703-1-0266]	The Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Sanofi-Aventis(Sanofi-Aventis); ; 	We are grateful to Grace Gill, Karina Meiri and Natasha Kreder for critical review of the paper. The technical assistance of Shu Ling Liang and Byung Kyu Kim is greatly appreciated. This work was supported by the following awards: DOD-DAMD17-01-1-0430 (PG); DOD-DAMD1703-1-0266 (PG); The Susan G Komen Breast Cancer Foundation BCTR0403214 (PG); W81XWH-08-1-0575 (PG); W81XWH-09-1-0411 (PG) and Sanofi-Aventis award IST10257 (AM).	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Berney C, 2006, P ROY SOC B-BIOL SCI, V273, P1867, DOI 10.1098/rspb.2006.3537; Cattaruzzi G, 2007, NUCLEIC ACIDS RES, V35, P1751, DOI 10.1093/nar/gkl1106; DuVall GA, 1996, J CLIN GASTROENTEROL, V22, P131, DOI 10.1097/00004836-199603000-00012; Gao X, 2001, BIOCHEM BIOPH RES CO, V284, P1098, DOI 10.1006/bbrc.2001.5089; Geck P, 1999, J STEROID BIOCHEM, V68, P41, DOI 10.1016/S0960-0760(98)00165-4; Geck P, 1997, J STEROID BIOCHEM, V63, P211, DOI 10.1016/S0960-0760(97)00122-2; Geck P, 2001, AM J HUM GENET, V69, P461, DOI 10.1086/321968; Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185; Gohlke JM, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-15; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Harada H, 2001, INT J ONCOL, V18, P1003; Itoh F, 1997, TOHOKU J EXP MED, V182, P327, DOI 10.1620/tjem.182.327; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Kumar D, 2004, GENE, V328, P187, DOI 10.1016/j.gene.2003.12.013; Liu J, 2009, CLIN GENET, V76, P303, DOI 10.1111/j.1399-0004.2009.01271.x; Losada A, 2005, J CELL SCI, V118, P2133, DOI 10.1242/jcs.02355; Maffini M, 2008, J STEROID BIOCHEM, V108, P32, DOI 10.1016/j.jsbmb.2007.05.034; Maffini MV, 2002, ENDOCRINOLOGY, V143, P2708, DOI 10.1210/en.143.7.2708; Mani S, 2001, MOL CELL NEUROSCI, V17, P54, DOI 10.1006/mcne.2000.0931; MARUIWA M, 1988, VIRCHOWS ARCH A, V413, P463, DOI 10.1007/BF00716995; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MUMMERY CL, 1991, DIFFERENTIATION, V46, P51, DOI 10.1111/j.1432-0436.1991.tb00865.x; Murthy S, 2005, PROSTATE, V64, P362, DOI 10.1002/pros.20251; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okita Keisuke, 2006, Curr Stem Cell Res Ther, V1, P103, DOI 10.2174/157488806775269061; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Reis EM, 2005, CANCER RES, V65, P1693, DOI 10.1158/0008-5472.CAN-04-3506; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; SATO A, 1986, ACTA PATHOL JAPON, V36, P143; Seo MJ, 2005, GYNECOL ONCOL, V96, P621, DOI 10.1016/j.ygyno.2004.11.032; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; SUGITA K, 1986, BRAIN DEV-JPN, V8, P541, DOI 10.1016/S0387-7604(86)80101-2; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Teramoto S, 2005, ONCOL REP, V14, P1231; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Xia CH, 2007, DIFFERENTIATION, V75, P912, DOI 10.1111/j.1432-0436.2007.00188.x; Zhang B, 2007, DEVELOPMENT, V134, P3191, DOI 10.1242/dev.005884; Zhang B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005232; Zhang Y, 2008, J GENET GENOMICS, V35, P267, DOI 10.1016/S1673-8527(08)60038-7; Zheng MZ, 2008, J CANCER RES CLIN, V134, P453, DOI 10.1007/s00432-007-0306-x	49	18	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2010	29	23					3446	3452		10.1038/onc.2010.100	http://dx.doi.org/10.1038/onc.2010.100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383194				2022-12-28	WOS:000278622700012
J	Xu, L; Nilsson, MB; Saintigny, P; Cascone, T; Herynk, MH; Du, Z; Nikolinakos, PG; Yang, Y; Prudkin, L; Liu, D; Lee, JJ; Johnson, FM; Wong, KK; Girard, L; Gazdar, AF; Minna, JD; Kurie, JM; Wistuba, II; Heymach, JV				Xu, L.; Nilsson, M. B.; Saintigny, P.; Cascone, T.; Herynk, M. H.; Du, Z.; Nikolinakos, P. G.; Yang, Y.; Prudkin, L.; Liu, D.; Lee, J. J.; Johnson, F. M.; Wong, K-K; Girard, L.; Gazdar, A. F.; Minna, J. D.; Kurie, J. M.; Wistuba, I. I.; Heymach, J. V.			Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1 alpha in non-small cell lung cancer cells	ONCOGENE			English	Article						EGFR; MET; non-small cell lung cancer; HIF-1 alpha; invasiveness	PREVIOUSLY TREATED PATIENTS; KINASE DOMAIN MUTATIONS; FACTOR SCATTER FACTOR; IN-VITRO INVASION; C-MET; TYROSINE KINASE; FACTOR-ALPHA; CROSS-TALK; SIGNALING PATHWAY; EGF RECEPTOR	Recent studies have established that amplification of the MET proto-oncogene can cause resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) cell lines with EGFR-activating mutations. The role of non-amplified MET in EGFR-dependent signaling before TKI resistance, however, is not well understood. Using NSCLC cell lines and transgenic models, we demonstrate here that EGFR activation by either mutation or ligand binding increases MET gene expression and protein levels. Our analysis of 202 NSCLC patient specimens was consistent with these observations: levels of MET were significantly higher in NSCLC with EGFR mutations than in NSCLC with wild-type EGFR. EGFR regulation of MET levels in cell lines occurred through the hypoxia-inducible factor (HIF)-1 alpha pathway in a hypoxia-independent manner. This regulation was lost, however, after MET gene amplification or overexpression of a constitutively active form of HIF-1 alpha. EGFR- and hypoxia-induced invasiveness of NSCLC cells, but not cell survival, were found to be MET dependent. These findings establish that, absent MET amplification, EGFR signaling can regulate MET levels through HIF-1 alpha and that MET is a key downstream mediator of EGFR- induced invasiveness in EGFR- dependent NSCLC cells. Oncogene (2010) 29, 2616-2627; doi:10.1038/onc.2010.16; published online 15 February 2010	[Xu, L.; Nilsson, M. B.; Saintigny, P.; Cascone, T.; Herynk, M. H.; Nikolinakos, P. G.; Yang, Y.; Johnson, F. M.; Kurie, J. M.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Du, Z.; Wistuba, I. I.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Prudkin, L.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Liu, D.; Lee, J. J.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; [Wong, K-K] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Hamon Ctr Therapeut Oncol Res, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Heymach, JV (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA.	jheymach@mdanderson.org	Lee, Jack/P-7331-2019; Heymach, John/AAG-2361-2019; Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Yang, Yanan/F-1592-2010	Lee, Jack/0000-0002-4584-929X; Heymach, John/0000-0001-9068-8942; Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Saintigny, Pierre/0000-0002-8090-9323	NIH [P50 CA70907, P01 CA06294]; Department of Defense [W81XWH-07-1-0306 01]; Metastasis Foundation; Physician-Scientist Program; American Society for Clinical Oncology Career Development Award; Damon Runyon Cancer Research Foundation [CI 24-04]; NATIONAL CANCER INSTITUTE [P50CA070907, P01CA006294] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Metastasis Foundation; Physician-Scientist Program; American Society for Clinical Oncology Career Development Award; Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Mien-Chie Hung, Scott Lippman, and Kian Ang for their critical review, Dr Jeffrey Engelman for the EGFR-transfected NIH 3T3 cell lines, and Joseph Munch for editorial assistance. Supported in part by the NIH Lung Cancer SPORE grant P50 CA70907, NIH Grant P01 CA06294, Department of Defense Grant W81XWH-07-1-0306 01, awards from the Metastasis Foundation, the Physician-Scientist Program, and the American Society for Clinical Oncology Career Development Award (JVH). JVH is a Damon Runyon-Lilly Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI 24-04).	Beadsmoore CJ, 2003, EUR J RADIOL, V45, P8, DOI 10.1016/S0720-048X(02)00287-5; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Bredin CG, 2003, ANTICANCER RES, V23, P4877; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; Damstrup L, 1998, BRIT J CANCER, V78, P631, DOI 10.1038/bjc.1998.553; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; HAMADA J, 1995, CANCER LETT, V89, P161, DOI 10.1016/0304-3835(95)03686-Q; Hirami Y, 2004, CANCER LETT, V214, P157, DOI 10.1016/j.canlet.2004.04.028; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Ide T, 2006, INT J CANCER, V119, P2750, DOI 10.1002/ijc.22178; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; LIU C, 1993, AM J PATHOL, V142, P1155; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Luwor RB, 2005, ONCOGENE, V24, P4433, DOI 10.1038/sj.onc.1208625; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349-7006.2007.00493.x; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Qiao H, 2002, J CELL BIOCHEM, V86, P665, DOI 10.1002/jcb.10239; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shimazaki K, 2003, BRAIN RES, V962, P105, DOI 10.1016/S0006-8993(02)03975-6; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Stabile LP, 2004, GENE THER, V11, P325, DOI 10.1038/sj.gt.3302169; Swinson DEB, 2006, CLIN LUNG CANCER, V7, P250, DOI 10.3816/CLC.2006.n.002; Swinson DEB, 2004, INT J CANCER, V111, P43, DOI 10.1002/ijc.20052; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Weinberger PM, 2005, ARCH OTOLARYNGOL, V131, P707, DOI 10.1001/archotol.131.8.707; Yang Y, 2008, MOL CANCER THER, V7, P952, DOI 10.1158/1535-7163.MCT-07-2045; Yi S, 1998, BRIT J CANCER, V77, P2162, DOI 10.1038/bjc.1998.361; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603; Zhong H, 2000, CANCER RES, V60, P1541; Zhou QC, 2006, ZEBRAFISH, V3, P39, DOI 10.1089/zeb.2006.3.39	60	69	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2616	2627		10.1038/onc.2010.16	http://dx.doi.org/10.1038/onc.2010.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154724	Green Accepted			2022-12-28	WOS:000277354600002
J	Bosco, EE; Nakai, Y; Hennigan, RF; Ratner, N; Zheng, Y				Bosco, E. E.; Nakai, Y.; Hennigan, R. F.; Ratner, N.; Zheng, Y.			NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation	ONCOGENE			English	Article						Rac1; NF2/merlin; neurofibromatosis type 2; Wnt signaling; contact inhibition; proliferation	NF2 TUMOR-SUPPRESSOR; BETA-CATENIN; EXCHANGE FACTOR; INCREASED EXPRESSION; SCHWANNOMA CELLS; GENE-PRODUCT; RHO-GTPASES; MERLIN; COMPLEX; GROWTH	The neuro. bromatosis type 2 (NF2) tumor suppressor gene encodes merlin, a membrane/cytoskeleton protein necessary for the maintenance of contact inhibition of growth in cells. Bi-allelic inactivation of NF2 is known to cause multiple cancers in both humans and mice. However, the mechanism through which merlin exerts its tumor-suppressive function remains obscure. In this report, we show that NF2 knockout mouse embryonic fibroblasts lost contact inhibition of cell proliferation and contained significantly increased canonical Wnt signaling. Inhibition of Rac1, the activity of which is inversely regulated by NF2, through the use of a dominant-negative mutant, small hairpin RNA or a small molecule inhibitor in NF2-deficient cells, was able to suppress elevated Wnt signals as shown by reduced activity of the T-cell factor 4 (TCF4) transcription factor. Dominant-negative TCF4 or Rac1 mutant, as well as a small molecule inhibition of Wnt, were able to curb NF2 deficiency-elicited cell proliferation at the confluent state. Thus, Rac1-mediated canonical Wnt signaling is essential for the loss of contact inhibition in NF2-deficient cells. Oncogene (2010) 29, 2540-2549; doi:10.1038/onc.2010.20; published online 15 February 2010	[Bosco, E. E.; Nakai, Y.; Ratner, N.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH USA; [Hennigan, R. F.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Yi.Zheng@cchmc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; RATNER, NANCY/0000-0001-5030-9354; Nakai-Futatsugi, Yoko/0000-0003-4187-6060	NIH [R01 CA125658, R01 CA118032, T32 CA117846]; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA118032, R01CA141341, R01CA125658] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Zheng laboratory for thought-provoking discussions. This study was supported by NIH R01 CA125658 (YZ), NIH R01 CA118032 (NR) and NIH T32 CA117846 (EEB). EEB and YN performed experiments, analyzed results and made the figures; RFH provided key reagents, NR collaborated on experimental design, EEB and YZ designed the research and wrote the paper.	Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Colomba A, 2008, ONCOGENE, V27, P2728, DOI 10.1038/sj.onc.1210921; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giovannini M, 2000, GENE DEV, V14, P1617; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600-0609.2008.01188.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sampietro J, 2006, MOL CELL, V24, P293, DOI 10.1016/j.molcel.2006.09.001; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	35	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2540	2549		10.1038/onc.2010.20	http://dx.doi.org/10.1038/onc.2010.20			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154721	Green Accepted			2022-12-28	WOS:000277169400009
J	Kim, DH; Kim, EH; Na, HK; Sun, Y; Surh, YJ				Kim, D-H; Kim, E-H; Na, H-K; Sun, Y.; Surh, Y-J			15-Deoxy-Delta(12,14)-prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue	ONCOGENE			English	Article						cyclopentenone prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J(2); p53; thiol modification	WILD-TYPE P53; NF-KAPPA-B; PROLIFERATOR-ACTIVATED RECEPTOR; BREAST-CANCER CELLS; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; CYCLOPENTENONE PROSTAGLANDINS; MOUSE SKIN; COVALENT MODIFICATION; OXIDATIVE STRESS	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a representative cyclopentenone prostaglandin, has many interesting biological effects. In this study, treatment of human breast cancer cells (MCF-7) with 15d-PGJ(2) led to accumulation of p53 protein. However, the p53 DNA binding and its transcriptional activity were significantly reduced. 15d-PGJ(2) directly modified p53 as verified by reacting recombinant p53 with biotinylated 15d-PGJ(2). 9,10-Dihydro-15-deoxy-Delta(12,14)-prostaglandin J(2) lacking the electrophilic alpha,beta-unsaturated functionality failed to inhibit p53 DNA binding as well as to modify p53. Moreover, by conducting an in vitro [S-35]-labeled p53 translation assay, we identified cysteine 277 as a putative site of p53 modification by 15d-PGJ(2). The DNA-binding ability of a mutant p53 in which cysteine 277 was substituted by alanine was virtually unaffected by 15d-PGJ(2). Likewise, p53 binding activity of biotinylated 15d-PGJ(2) was abolished in mutant cells. In addition, cells expressing wild-type p53 exhibited p53 protein stability to a greater extent than mutant C277A cells. In conclusion, 15d-PGJ(2) can undergo nucleophilic addition to p53, presumably at the cysteine 277 residue, rendering this tumor suppressor less susceptible to proteasomal degradation. Oncogene (2010) 29, 2560-2576; doi:10.1038/onc.2010.8; published online 8 March 2010	[Kim, D-H; Kim, E-H; Surh, Y-J] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Na, H-K] Sungshin Womens Univ, Dept Food & Nutr, Seoul, South Korea; [Sun, Y.] Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Surh, Y-J] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul 151742, South Korea; [Surh, Y-J] Seoul Natl Univ, Canc Res Inst, Seoul 151742, South Korea	Seoul National University (SNU); Sungshin Women's University; University of Michigan System; University of Michigan; Seoul National University (SNU); Seoul National University (SNU)	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, 599 Kwanak Ro, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr			IDRC [R11-2007-107-01002-0]; WCU, National Research Foundation, Republic of Korea [R31-008-000-10103-0]	IDRC; WCU, National Research Foundation, Republic of Korea	This work was supported by the Outstanding Scholar Support grant, IDRC Grant (R11-2007-107-01002-0), and the WCU project Grant (R31-008-000-10103-0) from the National Research Foundation, Republic of Korea.	Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Asher G, 2006, ISR MED ASSOC J, V8, P229; ATSMON J, 1990, CANCER RES, V50, P1879; Azuma Y, 2004, J PHARMACOL SCI, V94, P261, DOI 10.1254/jphs.94.261; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Biramijamal F, 2001, CANCER RES, V61, P3119; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2007, J BIOL CHEM, V282, P22804, DOI 10.1074/jbc.M700961200; Bureau F, 2002, J IMMUNOL, V168, P5318, DOI 10.4049/jimmunol.168.10.5318; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; CAGEN LM, 1975, BIOCHIM BIOPHYS ACTA, V398, P205, DOI 10.1016/0005-2760(75)90184-8; Calmels S, 1997, CANCER RES, V57, P3365; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chene P, 1999, BIOCHEM BIOPH RES CO, V263, P1, DOI 10.1006/bbrc.1999.1294; Chinery R, 1999, CANCER RES, V59, P2739; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clay CE, 2001, J BIOL CHEM, V276, P47131, DOI 10.1074/jbc.C100339200; de Moraes E, 2007, INT J CANCER, V121, P929, DOI 10.1002/ijc.22899; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Emi M, 2004, BIOCHEM PHARMACOL, V67, P1259, DOI 10.1016/j.bcp.2003.10.037; Fischer Susan M., 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P183; Furstenberger G, 2003, PROG EXP TUMOR RES, V37, P72; Gayarre J, 2005, FEBS LETT, V579, P5803, DOI 10.1016/j.febslet.2005.09.069; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; HAINAUT P, 1993, CANCER RES, V53, P4469; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HOSODA S, 1974, J BIOL CHEM, V249, P6416; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kim EH, 2008, CARCINOGENESIS, V29, P688, DOI 10.1093/carcin/bgm299; Kim EH, 2006, ANN NY ACAD SCI, V1090, P375, DOI 10.1196/annals.1378.041; Kim EH, 2008, BIOCHEM PHARMACOL, V76, P1544, DOI 10.1016/j.bcp.2008.07.043; Kim HJ, 2007, CANCER RES, V67, P2595, DOI 10.1158/0008-5472.CAN-06-3043; Kim WJ, 2007, EMBO J, V26, P5020, DOI 10.1038/sj.emboj.7601920; Klatt P, 2002, METHOD ENZYMOL, V348, P157, DOI 10.1016/S0076-6879(02)48635-1; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kundu JK, 2006, CARCINOGENESIS, V27, P1465, DOI 10.1093/carcin/bgi349; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Millan O, 2006, CARCINOGENESIS, V27, P328, DOI 10.1093/carcin/bgi213; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; Oh JY, 2008, BIOCHEM J, V411, P297, DOI [10.1042/BJ20071189, 10.1042/bj20071189]; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Pande V, 2005, BIOORG MED CHEM LETT, V15, P4057, DOI 10.1016/j.bmcl.2005.06.025; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Pignatelli M, 2005, CARCINOGENESIS, V26, P81, DOI 10.1093/carcin/bgh308; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Scher JU, 2009, J INVEST MED, V57, P703, DOI 10.2310/JIM.0b013e31819aaa76; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Shigemasa K, 2003, INT J ONCOL, V22, P99; Shiraki T, 2005, J BIOL CHEM, V280, P14145, DOI 10.1074/jbc.M500901200; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Tiano HF, 2002, CANCER RES, V62, P3395; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wu H.H., 1999, GEN THER MOL BIOL, V4, P119; Wu HH, 2000, BIOCHEM J, V351, P87, DOI 10.1042/0264-6021:3510087; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	81	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2560	2576		10.1038/onc.2010.8	http://dx.doi.org/10.1038/onc.2010.8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20208557				2022-12-28	WOS:000277169400011
J	Mejias-Luque, R; Linden, SK; Garrido, M; Tye, H; Najdovska, M; Jenkins, BJ; Iglesias, M; Ernst, M; de Bolos, C				Mejias-Luque, R.; Linden, S. K.; Garrido, M.; Tye, H.; Najdovska, M.; Jenkins, B. J.; Iglesias, M.; Ernst, M.; de Bolos, C.			Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors	ONCOGENE			English	Article						gastric tumors; intestinal mucins; inflammatory cytokines; IL-6/gp130	LEWIS ANTIGEN-EXPRESSION; GP130 MUTANT MICE; CANCER-CELLS; HELICOBACTER-PYLORI; HUMAN STOMACH; KAPPA-B; MUC5AC; ACTIVATION; CARCINOMA; GROWTH	Infection of gastric mucosa by Helicobacter pylori induces an inflammatory response with increased levels of proinflammatory cytokines. Among them, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 induce the activation of signaling pathways that regulate genes expression, such as MUC2 and MUC4 intestinal mucins ectopically detected in gastric tumors. This study evaluated if the predominant inflammatory cell type correlates with MUC2 and MUC4 expression in human intestinal gastric tumors (n = 78). In addition, we analyzed the regulatory effects of the associated inflammatory signaling pathways on their expression in gastric cancer cell lines, and in a mouse model with hyperactivated STAT3 signaling pathway. Tumors with predominant lymphoplasmocytic infiltrate (chronic inflammation), presented higher levels of MUC2 and were more differentiated than tumors with predominant polymorphonuclear infiltrate (acute inflammation). These differences can be attributed to specific cytokines, because TNF-alpha and IL-1 beta induced MUC2 but no MUC4 expression in gastric cancer cell lines. The two groups of tumors expressed similar levels of MUC4 that correlated with the expression of STAT3 transcription factor, implicated in the activation of genes through the IL-6 pathway. In gastric tissues from gp130(+/+), gp130(Y757F/Y757F) and gp130(Y757F/Y757F) Stat3(-/+) mice, Muc2 was not detected, whereas Muc4 was found in the gastric tumors developed in the gp130(Y757F/Y757F) mice, with hyperactivated STAT3. These data indicate that the signaling pathways associated with the inflammatory response can modulate the expression of MUC2 and MUC4 intestinal mucin genes, in human and mouse gastric tumors. Oncogene (2010) 29, 1753-1762; doi:10.1038/onc.2009.467; published online 11 January 2010	[Mejias-Luque, R.; Garrido, M.; Iglesias, M.; de Bolos, C.] IMIM Hosp Mar, Programa Recerca Canc, Barcelona 08003, Spain; [Linden, S. K.] Gothenburg Univ, Sahlgrenska Acad, Mucosal Immunobiol & Vaccine Ctr, Gothenburg, Sweden; [Tye, H.; Najdovska, M.; Jenkins, B. J.] Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Gothenburg; Monash University	de Bolos, C (corresponding author), IMIM Hosp Mar, Programa Recerca Canc, Parc Recerca Biomed Barcelona,Dr Aiguader 88, Barcelona 08003, Spain.	cbolos@imim.es	Ernst, Matthias/D-5111-2012; jenkins, brendan/J-7854-2012; Lindén, Sara K/A-3271-2011	Ernst, Matthias/0000-0002-6399-1177; Lindén, Sara K/0000-0002-7751-9586; Jenkins, Brendan/0000-0002-7552-4656; Mejias-Luque, Raquel/0000-0002-4602-4927	Marato de TV3 [050930]; Instituto de Investigacion Carlos III [PI061421]; Swedish Cancer Foundation and Research Counsil (Cancerfonden and Vetenskapsradet); Jeansson foundation; Sylvia and Charles Viertel Charitable Foundation; Monash University; Cancer Council of Victoria; Association for International Cancer Research	Marato de TV3; Instituto de Investigacion Carlos III(Instituto de Salud Carlos III); Swedish Cancer Foundation and Research Counsil (Cancerfonden and Vetenskapsradet); Jeansson foundation; Sylvia and Charles Viertel Charitable Foundation; Monash University(Monash University); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Association for International Cancer Research	We thank the scientists providing the antibodies, Sergi Mojal for statistical analysis, and M Pera, A Dalmases, P Navarro and J Gunnarsson for helpful contributions. This work was supported by Marato de TV3 (050930), Instituto de Investigacion Carlos III (PI061421), the Swedish Cancer Foundation and Research Counsil (Cancerfonden and Vetenskapsradet) and the Jeansson foundation, Sylvia and Charles Viertel Charitable Foundation Senior Medical Research Fellowship, Monash University Fellowship, Cancer Council of Victoria Grant-in-aid, and the Association for International Cancer Research Grant awarded to BJJ.	Ahn DH, 2005, CELL PHYSIOL BIOCHEM, V15, P29, DOI 10.1159/000083636; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gartner F, 1996, VIRCHOWS ARCH, V428, P91; Gong WD, 2005, CLIN CANCER RES, V11, P1386, DOI 10.1158/1078-0432.CCR-04-0487; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim DY, 2004, PHARMACOLOGY, V72, P6, DOI 10.1159/000078626; Kimura YN, 2007, CANCER SCI, V98, P2009, DOI 10.1111/j.1349-7006.2007.00633.x; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Leung WK, 2002, J PATHOL, V197, P582, DOI 10.1002/path.1147; Lidell ME, 2008, FEBS J, V275, P481, DOI 10.1111/j.1742-4658.2007.06215.x; Linden SK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003952; Lopez-Ferrer A, 2000, GUT, V47, P349, DOI 10.1136/gut.47.3.349; Lopez-Ferrer A, 2002, GLYCOCONJUGATE J, V19, P13, DOI 10.1023/A:1022576712961; Lopez-Ferrer A, 2001, AM J RESP CELL MOL, V24, P22, DOI 10.1165/ajrcmb.24.1.4294; Matsuda K, 2008, SCAND J GASTROENTERO, V43, P25, DOI 10.1080/00365520701579795; Mejias-Luque R, 2008, BBA-MOL CELL RES, V1783, P1728, DOI 10.1016/j.bbamcr.2008.05.020; Peek RM, 2006, J PATHOL, V208, P233, DOI 10.1002/path.1868; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Reis CA, 1999, CANCER RES, V59, P1003; Sell S., 2001, IMMUNOLOGY IMMUNOPAT; Senapati S, 2008, HISTOL HISTOPATHOL, V23, P1541, DOI 10.14670/HH-23.1541; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Yakata Y, 2007, INT J ONCOL, V30, P437; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	33	56	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	12					1753	1762		10.1038/onc.2009.467	http://dx.doi.org/10.1038/onc.2009.467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062084				2022-12-28	WOS:000276022800005
J	Bui-Nguyen, TM; Pakala, SB; Sirigiri, RD; Xia, W; Hung, MC; Sarin, SK; Kumar, V; Slagle, BL; Kumar, R				Bui-Nguyen, T. M.; Pakala, S. B.; Sirigiri, R. D.; Xia, W.; Hung, M-C; Sarin, S. K.; Kumar, V.; Slagle, B. L.; Kumar, R.			NF-kappa B signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx	ONCOGENE			English	Article						MTA1; hepatitis B virus; HBx; signaling; MTA coregulator; liver cancer	X-PROTEIN; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; CELL-LINES; EXPRESSION; TRANSCRIPTION; GENE; CANCER; COREGULATORS; COREPRESSOR	Metastasis-associated protein 1 (MTA1), a master chromatin modi. er, has been shown to regulate cancer progression and is widely upregulated in human cancer, including hepatitis B virus-associated hepatocellular carcinomas (HCCs). Here we provide evidence that hepatitis B virus transactivator protein HBx stimulates the expression of MTA1 but not of MTA2 or MTA3. The underlying mechanism of HBx stimulation of MTA1 involves HBx targeting of transcription factor nuclear factor (NF)-kappa B and the recruitment of HBx/p65 complex to the NF-kappa B consensus motif on the relaxed MTA1 gene chromatin. We also discovered that MTA1 depletion in HBx-expressing cells severely impairs the ability of HBx to stimulate NF-kappa B signaling and the expression of target proinflammatory molecules. Furthermore, the presence of HBx in HBx-infected HCCs correlated well with increased MTA1 and NF-kappa B-p65. Collectively, these findings revealed a previously unrecognized integral role of MTA1 in HBx stimulation of NF-kappa B signaling and consequently, the expression of NF-kappa B targets gene products with functions in inflammation and tumorigenesis. Oncogene (2010) 29, 1179-1189; doi: 10.1038/onc.2009.404; published online 14 December 2009	[Bui-Nguyen, T. M.; Pakala, S. B.; Sirigiri, R. D.; Kumar, R.] George Washington Univ, Dept Biochem & Mol Biol, Inst Coregulator Biol, Washington, DC 20037 USA; [Xia, W.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Ctr Mol Med, Taichung, Taiwan; [Sarin, S. K.] GB Pant Hosp, Dept Gastroenterol, Inst Liver & Biliary Sci, New Delhi, India; [Sarin, S. K.] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi, India; [Kumar, V.] Int Ctr Genet Engn & Biotechnol, Virol Lab, New Delhi, India; [Slagle, B. L.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	George Washington University; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Govind Ballabh Pant Institute of Postgraduate Medical Education & Research; Institute of Liver & Biliary Sciences (ILBS); Institute of Liver & Biliary Sciences (ILBS); Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Baylor College of Medicine	Kumar, R (corresponding author), George Washington Univ, Dept Biochem & Mol Biol, Inst Coregulator Biol, 2300 1 St, Washington, DC 20037 USA.	bcmrxk@gwumc.edu	Hung, Mien-Chie/ABD-5911-2021; Kumar, Rakesh/ABD-1065-2020; sirigiri, divijendranathareddy/A-9857-2010	Hung, Mien-Chie/0000-0003-4317-4740; Kumar, Rakesh/0000-0001-7664-0803; Pakala, Suresh Babu/0000-0002-5679-4837	NIH [CA98823, 95388]; NATIONAL CANCER INSTITUTE [R01CA098823] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Aleem Siddiqui for pCMVXF and pCMV-Core constructs, Ranjit Banerjee for the HVC core plasmid, Amanda J Hodgson for technical assistance and Xuemei Wang for statistical analysis. The work was supported by NIH Grant CA98823 (RK). Work in Dr Betty L Slagle laboratory is supported by the NIH Grant 95388.	Anderson P, 2007, MOL CELL, V25, P796, DOI 10.1016/j.molcel.2007.03.005; Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Cheng ASL, 2004, MODERN PATHOL, V17, P1169, DOI 10.1038/modpathol.3800196; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Dvorchik I, 2007, CURR PHARM DESIGN, V13, P1527, DOI 10.2174/138161207780765846; Giannini R, 2005, ANTICANCER RES, V25, P4287; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Hamatsu T, 2003, ONCOL REP, V10, P599; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Keasler VV, 2007, J VIROL, V81, P2656, DOI 10.1128/JVI.02020-06; Kidd M, 2006, ANN SURG ONCOL, V13, P253, DOI 10.1245/ASO.2006.12.011; Kim SY, 2008, BMB REP, V41, P158, DOI 10.5483/BMBRep.2008.41.2.158; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010; Manavathi B, 2007, P NATL ACAD SCI USA, V104, P13128, DOI 10.1073/pnas.0705878104; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ryu SH, 2008, HEPATOLOGY, V47, P929, DOI 10.1002/hep.22124; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SLAGLE BL, 1991, CANCER RES, V51, P49; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Weil R, 1999, MOL CELL BIOL, V19, P6345; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	38	54	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1179	1189		10.1038/onc.2009.404	http://dx.doi.org/10.1038/onc.2009.404			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	20010875	Green Accepted			2022-12-28	WOS:000274912100009
J	Salvati, E; Scarsella, M; Porru, M; Rizzo, A; Iachettini, S; Tentori, L; Graziani, G; D'Incalci, M; Stevens, MFG; Orlandi, A; Passeri, D; Gilson, E; Zupi, G; Leonetti, C; Biroccio, A				Salvati, E.; Scarsella, M.; Porru, M.; Rizzo, A.; Iachettini, S.; Tentori, L.; Graziani, G.; D'Incalci, M.; Stevens, M. F. G.; Orlandi, A.; Passeri, D.; Gilson, E.; Zupi, G.; Leonetti, C.; Biroccio, A.			PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy	ONCOGENE			English	Article						PARP1; G4 ligand; combination therapy	POLY(ADP-RIBOSE) POLYMERASE-2 PARP-2; QUADRUPLEX LIGAND RHPS4; DNA-REPAIR; ANTITUMOR-ACTIVITY; HUMAN-CHROMOSOMES; CANCER-THERAPY; DAMAGE; INHIBITORS; CELLS; TRF2	New anti-telomere strategies represent important goals for the development of selective cancer therapies. In this study, we reported that uncapped telomeres, resulting from pharmacological stabilization of quadruplex DNA by RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino [4,3,2-kl] acridinium methosulfate), trigger specific recruitment and activation of poly-adenosine diphosphate (ADP) ribose polymerase I (PARP1) at the telomeres, forming several ADP-ribose polymers that co-localize with the telomeric repeat binding factor 1 protein and are inhibited by selective PARP(s) inhibitors or PARP1-specific small interfering RNAs. The knockdown of PARP1 prevents repairing of RHPS4-induced telomere DNA breaks, leading to increases in chromosome abnormalities and eventually to the inhibition of tumor cell growth both in vitro and in xenografts. More interestingly, the integration of a TOPO1 inhibitor on the combination treatment proved to have a high therapeutic efficacy ensuing a complete regression of the tumor as well as a significant increase in overall survival and cure of mice even when treatments started at a very late stage of tumor growth. Overall, this work reveals the unexplored link between the PARP1 and G-quadruplex ligands and demonstrates the excellent efficacy of a multi-component strategy based on the use of PARP inhibitors in telomere-based therapy. Oncogene (2010) 29, 6280-6293; doi:10.1038/onc.2010.344; published online 30 August 2010	[Salvati, E.; Scarsella, M.; Porru, M.; Rizzo, A.; Iachettini, S.; Zupi, G.; Leonetti, C.; Biroccio, A.] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; [Tentori, L.; Graziani, G.] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; [D'Incalci, M.] Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, Italy; [Stevens, M. F. G.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England; [Orlandi, A.; Passeri, D.] Univ Roma Tor Vergata, Dept Biopathol & Image Diagnost, Inst Pathol Anat, Rome, Italy; [Gilson, E.] Univ Nice Sophia Antipolis, Fac Med, INSERM, Lab Biol & Pathol Genomes,CNRS, Nice, France; CHU Nice, Archet Hosp 2, Dept Med Genet, Nice, France	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Nottingham; University of Rome Tor Vergata; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Biroccio, A (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Doro 156, I-00158 Rome, Italy.	leonetti@ifo.it; biroccio@ifo.it	PORRU, MANUELA/K-4809-2018; Rizzo, Angela/ABH-6753-2020; Biroccio, Annamaria/B-2861-2018; Leonetti, Carlo/B-2860-2018; Scarsella, Marco/AAA-1486-2020; Porru, Manuela/AAA-5510-2021; Graziani, Grazia/G-5747-2012; Orlandi, Augusto/AHE-8753-2022; IACHETTINI, SARA/AAY-6180-2021; D'Incalci, Maurizio/AAA-9021-2020	PORRU, MANUELA/0000-0002-6614-9110; Rizzo, Angela/0000-0001-5421-3085; Biroccio, Annamaria/0000-0003-3198-3532; Leonetti, Carlo/0000-0002-3526-7827; Porru, Manuela/0000-0002-6614-9110; Graziani, Grazia/0000-0002-0221-768X; IACHETTINI, SARA/0000-0002-9442-0326; D'Incalci, Maurizio/0000-0001-8784-1360; Salvati, Erica/0000-0002-3373-7442; TENTORI, LUCIO/0000-0002-7691-527X; Scarsella, Marco/0000-0002-3386-9664; orlandi, augusto/0000-0001-7202-5854	Italian Association for Cancer Research (AIRC); Ministero della Salute; Ligue Nationale contre le Cancer (EG equipe labellisee); Italian Foundation for Cancer Research (FIRC)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Ligue Nationale contre le Cancer (EG equipe labellisee); Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Italian Association for Cancer Research (AIRC), Ministero della Salute and Ligue Nationale contre le Cancer (EG equipe labellisee). ES and MP are recipients of fellowships from the Italian Foundation for Cancer Research (FIRC). We thank Mrs Carmen D'Angelo for generating HT29 cells that express the luciferase gene and Mrs Adele Petricca for her helpful assistance in typing the manuscript. We are also grateful to Tania Merlino for the English revision.	Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bakondi E, 2002, J HISTOCHEM CYTOCHEM, V50, P91, DOI 10.1177/002215540205000110; Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Brunori M, 2006, ONCOGENE, V25, P990, DOI 10.1038/sj.onc.1209135; BURKLE A, 2005, POLY ADP RIBOSYL ATI; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Donigian JR, 2007, J BIOL CHEM, V282, P22662, DOI 10.1074/jbc.M702620200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gagne JP, 2006, CURR OPIN CELL BIOL, V18, P145, DOI 10.1016/j.ceb.2006.02.013; Gavathiotis E, 2003, J MOL BIOL, V334, P25, DOI 10.1016/j.jmb.2003.09.018; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Gomez M, 2006, MOL BIOL CELL, V17, P1686, DOI 10.1091/mbc.E05-07-0672; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kelland L, 2007, CLIN CANCER RES, V13, P4960, DOI 10.1158/1078-0432.CCR-07-0422; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Leonetti C, 2008, CLIN CANCER RES, V14, P7284, DOI 10.1158/1078-0432.CCR-08-0941; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Malanga M, 2005, BIOCHEM CELL BIOL, V83, P354, DOI 10.1139/o05-038; Marcellini M, 2006, AM J PATHOL, V169, P643, DOI 10.2353/ajpath.2006.051041; Oganesian L, 2007, BIOESSAYS, V29, P155, DOI 10.1002/bies.20523; Orlandi A, 2008, CELL CYCLE, V7, P3889, DOI 10.4161/cc.7.24.7323; Pisano C, 2008, MOL CANCER THER, V7, P2051, DOI 10.1158/1535-7163.MCT-08-0266; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Plummer ER, 2007, CLIN CANCER RES, V13, P6252, DOI 10.1158/1078-0432.CCR-07-0617; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Rippmann JF, 2002, J MOL BIOL, V323, P217, DOI 10.1016/S0022-2836(02)00946-4; Rizzo A, 2009, NUCLEIC ACIDS RES, V37, P5353, DOI 10.1093/nar/gkp582; Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Smith S, 1999, J CELL SCI, V112, P3649; Sugimura K, 2008, J CELL BIOL, V183, P1203, DOI 10.1083/jcb.200806068; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tentori L, 2005, PHARMACOL RES, V52, P25, DOI 10.1016/j.phrs.2005.02.010; Tentori L, 2006, FASEB J, V20, P1709, DOI 10.1096/fj.06-5916fje; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801	43	87	91	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6280	6293		10.1038/onc.2010.344	http://dx.doi.org/10.1038/onc.2010.344			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802516				2022-12-28	WOS:000284601700009
J	Alessio, N; Squillaro, T; Cipollaro, M; Bagella, L; Giordano, A; Galderisi, U				Alessio, N.; Squillaro, T.; Cipollaro, M.; Bagella, L.; Giordano, A.; Galderisi, U.			The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways	ONCOGENE			English	Article						stem cells; senescence; apoptosis; p53; retinoblastoma; chromatin	RETINOBLASTOMA PROTEIN; STROMAL CELLS; DNA-REPAIR; TUMOR-SUPPRESSOR; GROWTH ARREST; P53; DIFFERENTIATION; APOPTOSIS; BINDING; GENE	We focused our attention on brahma-related gene 1 (BRG1), the ATPase subunit of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex, and analyzed its role in mesenchymal stem cell (MSC) biology. We hypothesized that deviation from the correct concentration of these proteins, which act at the highest level of gene regulation, may be deleterious for cells. We wanted to know what would happen if a cell had to cope with altered regulation of gene expression, either by upregulation or downregulation of BRG1. We assumed that cells would try to restore homeostasis or, alternatively, that the event could trigger senescence/apoptosis phenomena. To this end, in MSCs, we silenced BRG1gene. Knockdown of BRG1 expression induced a significant increase in senescent cells and decrease in apoptotic cells. It is interesting that BRG1 downregulation also induced an increase in heterochromatin. At the molecular level, these phenomena were associated with activation of retinoblastoma-like protein 2 (RB2)/P130-and P53-related pathways. Senescence was accompanied by reduced expression of some stemness-related genes. This is consistent with our previous research, which showed that BRG1 upregulation by ectopic expression also induced senescence processes. Together, these data suggest that BRG1 belongs to a class of genes whose expression is tightly regulated; hence, subtle alterations in BRG1 activity seem to negatively affect mechanisms regulating chromatin status and, in turn, impair cellular physiology. Oncogene (2010) 29, 5452-5463; doi:10.1038/onc.2010.285; published online 9 August 2010	[Cipollaro, M.; Galderisi, U.] Univ Naples 2, Biotechnol & Mol Biol Sect, Dept Expt Med, I-80138 Naples, Italy; [Alessio, N.; Squillaro, T.; Bagella, L.; Giordano, A.; Galderisi, U.] Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Alessio, N.; Bagella, L.] Univ Sassari, Dept Biomed Sci, Div Biochem & Biophys, I-07100 Sassari, Italy; [Squillaro, T.] Univ Siena, I-53100 Siena, Italy; [Giordano, A.] Univ Siena, Human Pathol & Oncol Dept, I-53100 Siena, Italy; [Giordano, A.] Human Hlth Fdn, Spoleto, Italy	Universita della Campania Vanvitelli; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Sassari; University of Siena; University of Siena	Galderisi, U (corresponding author), Univ Naples 2, Biotechnol & Mol Biol Sect, Dept Expt Med, Via Costantinopoli 16, I-80138 Naples, Italy.	umberto.galderisi@unina2.it	Giordano, Antonio/F-1927-2010; Alessio, Nicola/K-2119-2018	Giordano, Antonio/0000-0002-5959-016X; Alessio, Nicola/0000-0002-5019-2130; GALDERISI, Umberto/0000-0003-0909-7403; BAGELLA, Luigi/0000-0003-2815-037X; Cipollaro, Marilena/0000-0003-4350-4324	SHRO	SHRO	This work was partially supported by SHRO funds to UG and AG. We thank Maria Rosaria Cipollaro for technical assistance. We thank Dr Francesca Pentimalli for helpful discussion.; Author contributions: Tiziana Squillaro: conception and design, performed experiments; Nicola Alessio: conception and design, performed experiments; Marilena Cipollaro: assembly of data, data analysis and interpretation; Luigi Bagella: provision of study material, data analysis and interpretation and financial support; Antonio Giordano: conception and design, data analysis and interpretation and financial support; Umberto Galderisi: conception and design, data analysis and interpretation, paper writing and financial support.	Alves H, 2009, J CELL MOL MED; Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Diggle CP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng083; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Fotedar R, 2004, CELL CYCLE, V3, P134; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hill R, 2008, CELL CYCLE, V7, P2535; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Marsden VS, 2006, BLOOD, V107, P1872, DOI 10.1182/blood-2005-05-2160; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matoba R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000026; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Morales M, 2005, GENE DEV, V19, P3043, DOI 10.1101/gad.1373705; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MULLERSIEBURG CE, 1995, STEM CELLS, V13, P477, DOI 10.1002/stem.5530130505; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Oberdoerffer P, 2007, NAT REV MOL CELL BIO, V8, P692, DOI 10.1038/nrm2238; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; Wesierska-Gadek J, 2005, CELL MOL BIOL LETT, V10, P439; Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	67	37	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5452	5463		10.1038/onc.2010.285	http://dx.doi.org/10.1038/onc.2010.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20697355				2022-12-28	WOS:000282945800003
J	Qian, T; Lee, JY; Park, JH; Kim, HJ; Kong, G				Qian, T.; Lee, J-Y; Park, J-H; Kim, H-J; Kong, G.			Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex	ONCOGENE			English	Article						Id1; polycomb group proteins; E3 ubiquitin ligase	CELL-CYCLE PROGRESSION; ESOPHAGEAL CANCER-CELLS; NF-KAPPA-B; BREAST-CANCER; PROTEASOME PATHWAY; STEM-CELLS; TRANSCRIPTIONAL REPRESSION; H2A UBIQUITYLATION; SIGNALING PATHWAY; DEPENDENT MANNER	The helix-loop-helix inhibitor of differentiation and DNA binding (Id1) is well known as an oncogene in various tumors. Although it has been reported that Id1 promotes several oncogenic processes, it is still unclear whether Id1 functions through epigenetic transcriptional regulation. In this study, we examined the effect of Id1 on polycomb group (PcG) proteins, which are crucial epigenetic gene silencers, and found that Id1 regulated the expression of Mel-18 and Bmi-1, both of which belong to polycomb repressive complex 1. We also confirmed that Id1 induced Mel-18 downregulation, which was mediated by the Akt pathway, and consequently upregulated the transcription of its target gene, c-Myc. Using a promoter-reporter, we demonstrated that Id1 regulated Bmi-1 transcription through c-Myc binding to its E-box in the promoter. Finally, we examined the activity of E3 ligase RING1b, whose catalytic activity is increased by binding with the RING finger protein Bmi-1, and found that Id1 overexpression enhanced RING1b E3 ligase activity leading to accumulation of H2A ubiquitination and ubiquitin/proteasome-mediated degradation of geminin. Taken together, our study provided a novel link between Id1 and PcG proteins and suggested that Id1 may contribute to tumor development through PcG-mediated epigenetic regulation. Oncogene (2010) 29, 5818-5827; doi: 10.1038/onc.2010.317; published online 9 August 2010	[Qian, T.; Park, J-H; Kim, H-J; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, Seoul 133791, South Korea; [Lee, J-Y; Kong, G.] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea	Hanyang University; Hanyang University	Kong, G (corresponding author), Hanyang Univ, Dept Pathol, Coll Med, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr			Korean Government (MOEHRD) [KRF-2007-314-E00041]; Korean government (MEST) [20090081874]	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a Korea Research Foundation Grant (KRF-2007-314-E00041) funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) and a Korea Science and Engineering Foundation grant funded by the Korean government (MEST) (No. 20090081874).	Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Calses C, 2008, MOL CELL BIOL, V28, P1018, DOI 10.1128/MCB.01136-07; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Choi YS, 2005, MOL CELLS, V20, P241; Elderkin S, 2007, MOL CELL, V28, P107, DOI 10.1016/j.molcel.2007.08.009; Gao HD, 2007, MOL CELL BIOCHEM, V305, P35, DOI 10.1007/s11010-007-9525-3; Geng H, 2010, CANCER RES, V70, P3239, DOI 10.1158/0008-5472.CAN-09-3186; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Hattori T, 2003, GENES CELLS, V8, P889, DOI 10.1046/j.1365-2443.2003.00684.x; Jang KS, 2006, CANCER LETT, V244, P203, DOI 10.1016/j.canlet.2005.12.016; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Kroll KL, 2007, FRONT BIOSCI, V12, P1395, DOI 10.2741/2156; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee JY, 2009, ONCOGENE, V28, P824, DOI 10.1038/onc.2008.451; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Li B, 2009, INT J CANCER, V125, P2576, DOI 10.1002/ijc.24675; Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200; Lin JZ, 2010, CLIN CANCER RES, V16, P77, DOI 10.1158/1078-0432.CCR-08-2362; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Matsuo Fumie, 2002, Breast Cancer, V9, P33, DOI 10.1007/BF02967544; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Saxena S, 2005, MUTAT RES-FUND MOL M, V569, P111, DOI 10.1016/j.mrfmmm.2004.05.026; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200; Zaaroor-Regev D, 2010, P NATL ACAD SCI USA, V107, P6788, DOI 10.1073/pnas.1003108107; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	46	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5818	5827		10.1038/onc.2010.317	http://dx.doi.org/10.1038/onc.2010.317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20697353				2022-12-28	WOS:000283586200007
J	Yamaguchi, H; Chen, CT; Chou, CK; Pal, A; Bornmann, W; Hortobagyi, GN; Hung, MC				Yamaguchi, H.; Chen, C-T; Chou, C-K; Pal, A.; Bornmann, W.; Hortobagyi, G. N.; Hung, M-C			Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation	ONCOGENE			English	Article						HDAC inhibitors; E1A; apoptosis; Bim; gene therapy	OVARIAN-CANCER CELLS; HUMAN BREAST-CANCER; GENE-THERAPY; CLINICAL-TRIAL; HER-2/NEU-OVEREXPRESSING BREAST; E1A-LIPOSOME COMPLEX; TUMOR-CELLS; IN-VIVO; EXPRESSION; DELIVERY	Histone deacetylase inhibitors (HDACi) are potent anticancer agents for variety of cancer types. Suberoylanilide hydroxamic acid (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi and other agents have been actively tested in many clinical trials. Adenovirus 5 early region 1A (E1A) has been shown to exhibit high tumor suppressor activity, and gene therapy using E1A has been tested in clinical trials. Here, we showed that proapoptotic activity of HDACi was robustly enhanced by E1A in multiple cancer cells, but not in normal cells. Moreover, we showed that combination of E1A gene therapy and SAHA showed high therapeutic efficacy with low toxicity in vivo ovarian and breast xenograft models. SAHA downregulated Bcl-XL and upregulated proapoptotic BH3-only protein Bim, whose expression was further enhanced by E1A in cancer cells. These alterations of Bcl-2 family proteins were critical for apoptosis induced by the combination in cancer cells. SAHA enhanced acetylation of histone H3 in Bim promoter region, while E1A upregulated Egr-1, which was directly involved in Bim transactivation. Together, our results provide not only a novel insight into the mechanisms underlying anti-tumor activity of E1A, but also a rationale for the combined HDACi and E1A gene therapy in future clinical trials. Oncogene (2010) 29, 5619-5629; doi:10.1038/onc.2010.295; published online 2 August 2010	[Yamaguchi, H.; Chen, C-T; Chou, C-K; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, C-T; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Pal, A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Diagnost Imaging, Houston, TX 77030 USA; [Bornmann, W.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 079, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; CHOU, CHAO-KAI/0000-0001-5231-5264	SPORE Grant in ovarian cancer and breast cancer [P50 CA83639, PO50 CA116199]; National Breast Cancer Foundation; MDACC China Medical University and Hospital Sister Institution; Cancer Center [CA16672]; Cancer Research Center of Excellence [DOH99-TD-C-111-005]; Taiwan Department of Health; MARCUS Foundation; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639, P01CA099031, R01CA109311, P50CA116199] Funding Source: NIH RePORTER	SPORE Grant in ovarian cancer and breast cancer; National Breast Cancer Foundation; MDACC China Medical University and Hospital Sister Institution; Cancer Center; Cancer Research Center of Excellence; Taiwan Department of Health; MARCUS Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Jingwen Liu (Palo Alto Health Care System) and Thomas E Eling (National Institute of Health) for Egr-1 dominant negative expression plasmid and Egr-1 luciferase plasmid, respectively. We thank Dr Yongkun Wei for help in carrying out statistical analysis of xenograft experiments. We thank Drs Jennifer L. Hsu and Stephanie Miller for help in preparation of this paper. This work was supported by a SPORE Grant in ovarian cancer and breast cancer (P50 CA83639 and PO50 CA116199), the National Breast Cancer Foundation, MDACC China Medical University and Hospital Sister Institution Fund, Cancer Center Support Grant CA16672, DOH99-TD-C-111-005 Cancer Research Center of Excellence, Taiwan Department of Health, and the MARCUS Foundation. In memoriam, Mrs Serena Lin-Guo for her courageous fight against breast cancer.	Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; BYRD PJ, 1988, ONCOGENE, V2, P477; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chou CK, 2009, MOL CARCINOGEN, V48, P1048, DOI 10.1002/mc.20557; Cook JL, 2005, FRONT BIOSCI-LANDMRK, V10, P1396, DOI 10.2741/1628; Day CP, 2006, CANCER GENE THER, V13, P706, DOI 10.1038/sj.cgt.7700945; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2004, CLIN CANCER RES, V10, P2905, DOI 10.1158/1078-0432.CCR-04-0644; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hubberstey AV, 2002, CANCER GENE THER, V9, P321, DOI 10.1038/sj.cgt.7700436; Hung MC, 2000, ADV EXP MED BIOL, V465, P171; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Liao Y, 2004, CANCER GENE THER, V11, P594, DOI 10.1038/sj.cgt.7700743; Liao Y, 2007, ADV EXP MED BIOL, V608, P144; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; Lo HW, 2005, ADV GENET, V54, P235, DOI 10.1016/S0065-2660(05)54010-0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Madhusudan S, 2004, CLIN CANCER RES, V10, P2986, DOI 10.1158/1078-0432.CCR-03-0291; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Pirollo KF, 2008, CANCER RES, V68, P1247, DOI 10.1158/0008-5472.CAN-07-5810; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Stoff-Khalili MA, 2006, CANCER GENE THER, V13, P633, DOI 10.1038/sj.cgt.7700929; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Ueno NT, 2002, CANCER RES, V62, P6712; Ueno NT, 2000, CLIN CANCER RES, V6, P250; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Villaret D, 2002, HEAD NECK-J SCI SPEC, V24, P661, DOI 10.1002/hed.10107; Wang YN, 2006, MOL PHARMACOL, V69, P85, DOI 10.1124/mol.105.016220; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XM, 2009, MOL CANCER THER, V8, P2375, DOI 10.1158/1535-7163.MCT-09-0056; Xing X, 1997, GENE THER, V4, P238, DOI 10.1038/sj.gt.3300376; Xing X, 1998, GENE THER, V5, P1538, DOI 10.1038/sj.gt.3300771; Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103; Yamaguchi H, 2003, CANCER RES, V63, P1483; YAN DH, 1991, ONCOGENE, V6, P343; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1995, ONCOGENE, V11, P1383; Zhang F, 2003, J BIOL CHEM, V278, P44246, DOI 10.1074/jbc.M305564200	58	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5619	5629		10.1038/onc.2010.295	http://dx.doi.org/10.1038/onc.2010.295			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676141	Green Accepted			2022-12-28	WOS:000282946900008
J	Das, PM; Thor, AD; Edgerton, SM; Barry, SK; Chen, DF; Jones, FE				Das, P. M.; Thor, A. D.; Edgerton, S. M.; Barry, S. K.; Chen, D. F.; Jones, F. E.			Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells	ONCOGENE			English	Article						breast cancer; EGFR-family; epigenetics; apoptosis; heregulin	INTRACELLULAR DOMAIN 4ICD; ESTROGEN-RECEPTOR; BH3-ONLY PROTEIN; GENE-EXPRESSION; MAMMARY-GLAND; CANCER; ERBB4; METHYLATION; HER4; DIFFERENTIATION	Experimental and clinical data support a growth inhibitory role for HER4 in breast cancer. Clinically HER4 expression is extinguished during breast tumorigenesis supporting a tumor suppressor function for HER4, however, a molecular mechanism to explain the selective loss of HER4 expression has remained elusive. Epigenetic mechanisms, for example, aberrant gene promoter hypermethylation, have been shown to ablate tumor suppressor gene expression in breast carcinomas. We identified a CpG island within the HER4 promoter and show by pyrosequencing of bisulfite-treated DNA an inverse correlation between HER4 expression and the extent of promoter methylation. Treatment of the HER4-negative BT20 cell line with the DNA demethylating agent 5-aza-2'-deoxycytidine (DAC)-enhanced HER4 expression, confirming a role for DNA methylation in suppressed HER4 expression. DAC treatment to reactive HER4 expression in combination with the HER4 ligand heregulin-beta 1 (HRG) resulted in apoptosis of BT20 cells providing a novel therapeutic strategy for triple-negative tumors. The BT20 cells were rescued from apoptosis when preincubated with HER4 small interfering RNA, thereby confirming a role for HER4 in DAC/HRG-induced apoptosis. We verified HER4 promoter methylation in primary breast carcinomas and detected a significant increase in HER4 promoter methylation in HER4-negative breast tumors (P < 0.001). Furthermore, increased levels of HER4 promoter methylation were significantly associated with worse patient prognosis (P = 0.0234). Taken together, our data support a tumor suppressor function for HER4, which is epigenetically suppressed in breast tumors through promoter hypermethylation. Oncogene (2010) 29, 5214-5219; doi:10.1038/onc.2010.271; published online 5 July 2010	[Das, P. M.; Jones, F. E.] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; [Thor, A. D.; Edgerton, S. M.] Univ Colorado Denver, Dept Pathol, Aurora, CO USA; [Barry, S. K.; Chen, D. F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Tulane University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Tulane University	Jones, FE (corresponding author), Tulane Univ, Dept Cell & Mol Biol, 6400 Freret St, New Orleans, LA 70118 USA.	fjones3@tulane.edu	Das, Partha/C-6898-2012		National Cancer Institute/National Institutes of Health [RO1CA95783, RO1CA96717]; NATIONAL CANCER INSTITUTE [R01CA095783, R01CA096717] Funding Source: NIH RePORTER	National Cancer Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank June Allison for excellent lab management and other members of the Jones lab for valuable input. This work is dedicated to the loving memory of June Allison who will no longer be subjected to the hardships of breast cancer. This work was supported by National Cancer Institute/National Institutes of Health Grants RO1CA95783 (FEJ) and RO1CA96717 (FEJ).	Chua YL, 2009, ONCOGENE, V28, P4041, DOI 10.1038/onc.2009.259; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2008, J MAMMARY GLAND BIOL, V13, P247, DOI 10.1007/s10911-008-9076-6; KREIKE B, 2009, BREAST CANC RES TREA; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05; Muraoka-Cook RS, 2009, MOL CELL BIOL, V29, P4935, DOI 10.1128/MCB.01705-08; Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rokavec M, 2007, CLIN CANCER RES, V13, P7506, DOI 10.1158/1078-0432.CCR-07-0457; Sassen A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2339; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Thor AD, 2009, AM J PATHOL, V175, P1802, DOI 10.2353/ajpath.2009.090204; Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200; Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	29	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5214	5219		10.1038/onc.2010.271	http://dx.doi.org/10.1038/onc.2010.271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20603612	hybrid, Green Published			2022-12-28	WOS:000281867200010
J	Paggetti, J; Largeot, A; Aucagne, R; Jacquel, A; Lagrange, B; Yang, XJ; Solary, E; Bastie, JN; Delva, L				Paggetti, J.; Largeot, A.; Aucagne, R.; Jacquel, A.; Lagrange, B.; Yang, X-J; Solary, E.; Bastie, J-N; Delva, L.			Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+cells	ONCOGENE			English	Article						MOZ; MLL; HOX genes; human CD34+cells	HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; ZINC-FINGER PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEXES; CREB-BINDING-PROTEIN; HOMEOBOX GENES; TRANSCRIPTIONAL REGULATION; METHYLATION; H3; METHYLTRANSFERASE	MOZ and MLL, encoding a histone acetyltransferase (HAT) and a histone methyltransferase, respectively, are targets for recurrent chromosomal translocations found in acute myeloblastic or lymphoblastic leukemia. In MOZ (MOnocytic leukemia Zinc-finger protein)/CBP- or mixed lineage leukemia (MLL)-rearranged leukemias, abnormal levels of HOX transcription factors have been found to be critical for leukemogenesis. We show that MOZ and MLL cooperate to regulate these key genes in human cord blood CD34+ cells. These chromatin-modifying enzymes interact, colocalize and functionally cooperate, and both are recruited to multiple HOX promoters. We also found that WDR5, an adaptor protein essential for lysine 4 trimethylation of histone H3 (H3K4me3) by MLL, colocalizes and interacts with MOZ. We detected the binding of the HAT MOZ to H3K4me3, thus linking histone methylation to acetylation. In CD34+ cells, depletion of MLL causes release of MOZ from HOX promoters, which is correlated to defective histone activation marks, leading to repression of HOX gene expression and alteration of commitment of CD34+ cells into myeloid progenitors. Thus, our results unveil the role of the interaction between MOZ and MLL in CD34+ cells in which both proteins have a critical role in hematopoietic cell-fate decision, suggesting a new molecular mechanism by which MOZ or MLL deregulation leads to leukemogenesis. Oncogene (2010) 29, 5019-5031; doi:10.1038/onc.2010.254; published online 28 June 2010	[Paggetti, J.; Largeot, A.; Aucagne, R.; Jacquel, A.; Lagrange, B.; Bastie, J-N; Delva, L.] Univ Burgundy, Fac Med, INSERM, UMR 866, Dijon, France; [Yang, X-J] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ, Canada; [Solary, E.] Inst Gustave Roussy, INSERM, UMR 1009, F-94805 Villejuif, France; [Bastie, J-N] Univ Hosp CHU, Dept Clin Hematol, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CHU Dijon Bourgogne	Delva, L (corresponding author), Univ Bourgogne, Fac Med, IFR Sante STIC, INSERM,Ctr Rech,UMR 866, 7 Blvd Jeanne dArc, F-21000 Dijon, France.	Laurent.Delva@u-bourgogne.fr	Paggetti, Jerome/I-2786-2019; Jacquel, Arnaud/O-1928-2017; Jacquel, Arnaud/AAJ-4760-2021	Paggetti, Jerome/0000-0001-9460-5876; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Aucagne, Romain/0000-0002-5644-3287; Solary, Eric/0000-0002-8629-1341; DELVA, Laurent/0000-0002-1086-3964; Largeot, Anne/0000-0002-9388-8461; Lagrange, Brice/0000-0002-4131-5995	Fondation de France (Leukemia Committee); Ligue contre le Cancer (Cote d'Or committee); Ligue contre le Cancer (Rhone committee); Conseil Regional de Bourgogne (FABER); Faculty of Medicine, Dijon; National Institute of Cancer; Ligue Nationale contre le Cancer; Agence Nationale de la Recherche of France; Canadian Cancer Society; Ministere de l'Enseignement Superieur et de la Recherche of France; Association pour la Recherche sur le Cancer (ARC); Inserm; Region Bourgogne; Ligue contre le Cancer; Saone-et-Loire committee; National committee	Fondation de France (Leukemia Committee)(Fondation de France); Ligue contre le Cancer (Cote d'Or committee); Ligue contre le Cancer (Rhone committee); Conseil Regional de Bourgogne (FABER)(Region Bourgogne-Franche-Comte); Faculty of Medicine, Dijon; National Institute of Cancer; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche of France(French National Research Agency (ANR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Ministere de l'Enseignement Superieur et de la Recherche of France; Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Region Bourgogne(Region Bourgogne-Franche-Comte); Ligue contre le Cancer(Ligue nationale contre le cancer); Saone-et-Loire committee; National committee	We gratefully acknowledge Amandine Bataille, Amandine Chlemaire and Franck Menetrier for immunocytofluorescence assays; Andre Bouchot for epifluorescence microscopy; and Christine Arnould for confocal analysis (SERCOBIO, Universite de Bourgogne), and the Etablissement Francais du Sang (EFS) of Bourgogne Franche-Comte, which kindly supplied the cord blood buffy coats. We also thank Mustapha Oulad-Abdelghani for producing the anti-MOZ antibody. We thank Robert Slany, Issai Kitabayashi, Paul Shore, Michael Cleary and Edward Chan for providing plasmids. We appreciate the fine work performed by Magali Belt in correction of English text. This work was supported by funds from the Fondation de France (Leukemia Committee to LD), the Ligue contre le Cancer (Cote d'Or committee to LD), the Ligue contre le Cancer (Rhone committee to LD), the Conseil Regional de Bourgogne (FABER to LD), the Faculty of Medicine (to J-NB) in Dijon, the National Institute of Cancer (to ES), the Ligue Nationale contre le Cancer (Label to ES), the Agence Nationale de la Recherche of France (to ES and LD) and the Canadian Cancer Society (to XJY). JP was supported by fellowships from the Ministere de l'Enseignement Superieur et de la Recherche of France and the Association pour la Recherche sur le Cancer (ARC). AL was supported by fellowships from the Inserm and the Region Bourgogne. RA and AJ were supported by fellowships from the Ligue contre le Cancer, Saone-et-Loire committee and national committee, respectively. BL was supported by fellowships from the Ministere de l'Enseignement Superieur et de la Recherche of France.	Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; BORRESEN B, 1996, P 10 INT S MOLT SALT, V7, P11; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chan EM, 2007, EXP HEMATOL, V35, P1782, DOI 10.1016/j.exphem.2007.07.015; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Huang G, 2008, BLOOD, V112, P110; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Kohlmann A, 2005, LEUKEMIA, V19, P953, DOI 10.1038/sj.leu.2403746; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McMahon KA, 2007, CELL STEM CELL, V1, P338, DOI 10.1016/j.stem.2007.07.002; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nabirochkina E, 2002, MECH DEVELOP, V114, P119, DOI 10.1016/S0925-4773(02)00035-7; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ohta K, 2005, J HEALTH SCI, V51, P253, DOI 10.1248/jhs.51.253; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; Rokudai S, 2009, J BIOL CHEM, V284, P237, DOI 10.1074/jbc.M805101200; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Tyagi S, 2007, MOL CELL, V27, P107, DOI 10.1016/j.molcel.2007.05.030; Ullah M, 2008, MOL CELL BIOL, V28, P6828, DOI 10.1128/MCB.01297-08; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yang XJ, 2007, ONCOGENE, V26, P5408, DOI 10.1038/sj.onc.1210609; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	62	40	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	36					5019	5031		10.1038/onc.2010.254	http://dx.doi.org/10.1038/onc.2010.254			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581860				2022-12-28	WOS:000281620100003
J	Tang, D; Kang, R; Cheh, CW; Livesey, KM; Liang, X; Schapiro, NE; Benschop, R; Sparvero, LJ; Amoscato, AA; Tracey, KJ; Zeh, HJ; Lotze, MT				Tang, D.; Kang, R.; Cheh, C-W; Livesey, K. M.; Liang, X.; Schapiro, N. E.; Benschop, R.; Sparvero, L. J.; Amoscato, A. A.; Tracey, K. J.; Zeh, H. J.; Lotze, M. T.			HMGB1 release and redox regulates autophagy and apoptosis in cancer cells	ONCOGENE			English	Article						HMGB1; apoptosis; autophagy; Beclin 1; redox; chemotheraphy	MOBILITY GROUP BOX-1; CHROMATIN PROTEIN HMGB1; MEDIATED APOPTOSIS; TUMOR-CELLS; INFLAMMATION; RECEPTOR; DNA; HEAT-SHOCK-PROTEIN-72; MACROPHAGES; DEATH	The functional relationship and cross-regulation between autophagy and apoptosis is complex. In this study we show that the high-mobility group box 1 protein (HMGB1) is a redox-sensitive regulator of the balance between autophagy and apoptosis. In cancer cells, anticancer agents enhanced autophagy and apoptosis, as well as HMGB1 release. HMGB1 release may be a prosurvival signal for residual cells after various cytotoxic cancer treatments. Diminished HMGB1 by short hairpin RNA transfection or inhibition of HMGB1 release by ethyl pyruvate or other small molecules led predominantly to apoptosis and decreased autophagy in stressed cancer cells. In this setting, reducible HMGB1 binds to the receptor for advanced glycation end products (RAGEs), but not to Toll-like receptor 4, induces Beclin1-dependent autophagy and promotes tumor resistance to alkylators (melphalan), tubulin disrupting agents (paclitaxel), DNA crosslinkers (ultraviolet light) and DNA intercalators (oxaliplatin or adriamycin). On the contrary, oxidized HMGB1 increases the cytotoxicity of these agents and induces apoptosis mediated by the caspase-9/-3 intrinsic pathway. HMGB1 release, as well as its redox state, thus links autophagy and apoptosis, representing a suitable target when coupled with conventional tumor treatments. Oncogene (2010) 29, 5299-5310; doi:10.1038/onc.2010.261; published online 12 July 2010	[Tang, D.] Univ Pittsburgh, Sch Med, Dept Surg, DAMP Lab,Hillman Canc Ctr,Canc Inst, Pittsburgh, PA 15213 USA; [Benschop, R.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; [Tracey, K. J.] NYU, N Shore Univ Hosp, Sch Med, Manhasset, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Eli Lilly; New York University; Northwell Health; North Shore University Hospital	Tang, D (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, DAMP Lab,Hillman Canc Ctr,Canc Inst, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	tangd2@upmc.edu; zehh@upmc.edu; lotzemt@upmc.edu	Kang, Rui/ABD-5291-2021; li, tao/B-2402-2008; Tang, Daolin/B-2905-2010; Tang, Daolin/ABD-5062-2021	Kang, Rui/0000-0003-2725-1574; Tang, Daolin/0000-0002-1903-6180; Amoscato, Andrew/0000-0002-1340-9150; Tracey, Kevin J/0000-0003-1884-6314	NIH [1 P01 CA 101944-04]; NATIONAL CANCER INSTITUTE [P01CA101944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062508] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was funded by a grant from the NIH 1 P01 CA 101944-04 (Michael T. Lotze) integrating NK and DC into Cancer Therapy from the National Cancer Institute. Thoughtful discussions and review of this work with Timothy Billiar and Sarah Berman at the University of Pittsburgh and with external colleagues Guido Kroemer, Douglas Green, Matthew Albert and Beth Levine are much appreciated.	Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]; Bell CW, 2006, AM J PHYSIOL-CELL PH, V291, pC1318, DOI 10.1152/ajpcell.00616.2005; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Choi JJ, 2004, SCAND J IMMUNOL, V60, P159, DOI 10.1111/j.0300-9475.2004.01470.x; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Geft D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003238; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200; Hoppe G, 2006, EXP CELL RES, V312, P3526, DOI 10.1016/j.yexcr.2006.07.020; Ito N, 2007, J LEUKOCYTE BIOL, V81, P75, DOI 10.1189/jlb.0306169; Kang R, 2010, LEUKEMIA, V24, P177, DOI 10.1038/leu.2009.224; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983; Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tang DL, 2007, J IMMUNOL, V178, P7376, DOI 10.4049/jimmunol.178.11.7376; Tang DL, 2007, J LEUKOCYTE BIOL, V81, P741, DOI 10.1189/jlb.0806540; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Tang DL, 2009, AM J RESP CELL MOL, V41, P651, DOI 10.1165/rcmb.2008-0119OC; Tang DL, 2005, SHOCK, V23, P434, DOI 10.1097/01.shk.0000159556.95285.df; Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269; Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	49	356	379	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5299	5310		10.1038/onc.2010.261	http://dx.doi.org/10.1038/onc.2010.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622903	Green Accepted			2022-12-28	WOS:000282089100008
J	Dash, R; Su, ZZ; Lee, SG; Azab, B; Boukerche, H; Sarkar, D; Fisher, PB				Dash, R.; Su, Z-Z; Lee, S-G; Azab, B.; Boukerche, H.; Sarkar, D.; Fisher, P. B.			Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1	ONCOGENE			English	Article						CCN1; SARI; transcriptional regulation; AP-1; c-Jun	HUMAN BREAST-CANCER; DIFFERENTIATION-ASSOCIATED GENE-7; TISSUE GROWTH-FACTOR; ACTIVATOR PROTEIN-1; CELL-PROLIFERATION; NUDE-MICE; C-JUN; CYR61; EXPRESSION; TRANSCRIPTION	Enhanced expression of the CCN family of secretory integrin-binding proteins correlates with many essential components of the cancerous state, including tumor cell adhesion, proliferation, invasion and migration. Consequently, CCN1 expression is elevated in various cancers, including breast cancer, and its expression directly correlates with poor patient prognosis. Using subtraction-hybridization, combined with induction of cancer cell terminal differentiation, we cloned SARI (suppressor of activator protein (AP)-1, regulated by interferon (IFN)), an IFN-beta-inducible, potent tumor suppressor gene that exerts cancer-selective growth inhibitory effects. Forced expression of SARI using an adenovirus (Ad. SARI) inhibits AP-1 function and downregulates CCN1 expression in multiple cancer lineages, resulting in a profound inhibition in anchorage-independent cell growth and tumor cell invasion. Overexpression of SARI reduces CCN1-promoter activity through inhibition of AP-1 binding. Accordingly, SARI selectively blocks expression of the transformed state in rat embryo fibroblast cells that stably overexpress c-Jun. These results illustrate that SARI inhibits AP-1 transactivating factor binding to the cis-element of the CCN1 promoter, possibly through its interaction with c-Jun. Overall, SARI can directly inhibit CCN1-induced transformation by inhibiting the transcription of CCN1, as well as indirectly by inhibiting the expression of c-Jun (and hence blocking AP-1 activity). In these contexts, transformed cells 'addicted' to AP-1 activity are rendered susceptible to SARI-mediated inhibition of expression of the transformed phenotype. Oncogene (2010) 29, 4412-4423; doi: 10.1038/onc.2010.194; published online 7 June 2010	[Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, VCU Inst Mol Med, Richmond, VA 23298 USA; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23298 USA; [Lee, S-G] Kyung Hee Univ, Canc Prevent Mat Dev Res Ctr, Coll Oriental Med, Seoul, South Korea; [Boukerche, H.] Univ Lyon 1, INSERM, F-69365 Lyon, France	Virginia Commonwealth University; Virginia Commonwealth University; Kyung Hee University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, VCU Inst Mol Med, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	pbfisher@vcu.edu	Azab, Belal/AAJ-5652-2021; Lee, Seok-Geun/B-3408-2011	Azab, Belal/0000-0003-0293-6489; Lee, Seok-Geun/0000-0002-0060-5777; dash, rupesh/0000-0001-5740-7053	National Institutes of Health [R01 CA097318, P01 CA104177]; National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [P01CA104177, R01CA097318] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by National Institutes of Health Grants R01 CA097318 and P01 CA104177; and by the National Foundation for Cancer Research. DS is a Harrison Endowed Scholar in Cancer Research. PBF holds the Thelma Newmeyer Corman Chair in Cancer Research.	ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DASH R, 2010, CANC GENE THER; Echlin DR, 2000, ONCOGENE, V19, P1752, DOI 10.1038/sj.onc.1203491; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Grotendorst GR, 2000, ENDOCRINOLOGY, V141, P2254, DOI 10.1210/en.141.6.2254; Han JS, 2003, EUR J BIOCHEM, V270, P3408, DOI 10.1046/j.1432-1033.2003.03723.x; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATTHEW GF, 1907, T ROYAL SOC CANADA, V1, P7; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; O'Kelly J, 2008, INT J ONCOL, V33, P59; OKELLY KH, 2005, CCN PROTEINS; Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417; RYSECK RP, 1991, ONCOGENE, V6, P533; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Shimizu T, 2005, ONCOL REP, V14, P441; Su Z, 2001, NUCLEIC ACIDS RES, V29, P1661, DOI 10.1093/nar/29.8.1661; Su ZZ, 2008, P NATL ACAD SCI USA, V105, P20906, DOI 10.1073/pnas.0807975106; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Taddei I, 2003, J MAMMARY GLAND BIOL, V8, P383, DOI 10.1023/B:JOMG.0000017426.74915.b9; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vellon L, 2005, ONCOGENE, V24, P3759, DOI 10.1038/sj.onc.1208452; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Zullo AJ, 2007, J IMMUNOL, V178, P58, DOI 10.4049/jimmunol.178.1.58	44	39	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2010	29	31					4412	4423		10.1038/onc.2010.194	http://dx.doi.org/10.1038/onc.2010.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20531301				2022-12-28	WOS:000280559100005
J	Gonzalvez, F; Ashkenazi, A				Gonzalvez, F.; Ashkenazi, A.			New insights into apoptosis signaling by Apo2L/TRAIL	ONCOGENE			English	Review						DR4; DR5; glycosylation; caspase-8; cullin 3; p62	TRAIL-INDUCED APOPTOSIS; NF-KAPPA-B; DEATH RECEPTOR 5; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LIGAND (TRAIL)-INDUCED APOPTOSIS; FLICE-INHIBITORY PROTEINS; FADD-DEPENDENT APOPTOSIS; CYTOCHROME-C RELEASE; INDUCED CELL-DEATH; CANCER-CELLS	Apoptosis ligand 2 tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to a small subset of proapoptotic protein ligands in the TNF superfamily. This subset, which also includes Fas ligand and TNF-alpha, can activate the extrinsic apoptotic cell death pathway on binding to cognate death receptors at the cell surface. Over the past 10 years, Apo2L/TRAIL has emerged as a promising candidate for cancer therapy, on the basis of its unique ability to trigger apoptosis in various types of cancer cells without significant toxicity toward normal cells. Herein, we review key advances in understanding the molecular events that control apoptosis signaling by Apo2L/TRAIL, which may aid in the development of cancer therapies based on the extrinsic apoptotic pathway. Oncogene (2010) 29, 4752-4765; doi:10.1038/onc.2010.221; published online 7 June 2010	[Gonzalvez, F.; Ashkenazi, A.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365, DOI 10.1053/j.gastro.2009.02.071; Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Ashkenazi A, 2008, J CLIN ONCOL, V26, P3621, DOI 10.1200/JCO.2007.15.7198; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Beraza N, 2009, J EXP MED, V206, P1727, DOI 10.1084/jem.20082152; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Casella C R, 1997, Curr Opin Hematol, V4, P24; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaigne-Delalande B, 2009, CELL DEATH DIFFER, V16, P1654, DOI 10.1038/cdd.2009.111; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen M, 2002, J BIOL CHEM, V277, P50761, DOI 10.1074/jbc.M210356200; Chen XF, 2003, CANCER RES, V63, P1059; Chowdhury I, 2006, CELL MOL BIOL LETT, V11, P506, DOI 10.2478/s11658-006-0041-3; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cretney E, 2005, IMMUNOL CELL BIOL, V83, P511, DOI 10.1111/j.1440-1711.2005.01358.x; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Dumitru CA, 2007, APOPTOSIS, V12, P1533, DOI 10.1007/s10495-007-0081-9; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Eimon PM, 2006, CELL DEATH DIFFER, V13, P1619, DOI 10.1038/sj.cdd.4402015; Elnemr A, 2001, INT J ONCOL, V18, P311; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Green D R, 1998, Results Probl Cell Differ, V24, P45; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa K, 2002, CIRCULATION, V105, P3039, DOI 10.1161/01.CIR.0000018651.89208.69; Hilliard B, 2001, J IMMUNOL, V166, P1314, DOI 10.4049/jimmunol.166.2.1314; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Labrinidis A, 2008, BLOOD, V111, P5411, DOI 10.1182/blood-2008-03-144261; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Laguinge LM, 2008, CANCER RES, V68, P909, DOI 10.1158/0008-5472.CAN-06-1806; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Lee SH, 1999, CANCER RES, V59, P5683; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lluis JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008620; Lub-de Hooge MN, 2005, ANN RHEUM DIS, V64, P854, DOI 10.1136/ard.2004.029058; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martin S, 2005, CANCER RES, V65, P11447, DOI 10.1158/0008-5472.CAN-05-1494; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mejia ROS, 2001, NEUROSCIENTIST, V7, P480, DOI 10.1177/107385840100700604; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Nuutinen U, 2009, LEUKEMIA RES, V33, P829, DOI 10.1016/j.leukres.2008.09.025; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Ou D, 2005, HUM IMMUNOL, V66, P799, DOI 10.1016/j.humimm.2005.03.009; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prasad KV, 2003, AUTOIMMUNITY, V36, P323, DOI 10.1080/08916930310001604207; Prunell GF, 2005, CNS NEUROL DISORD-DR, V4, P51, DOI 10.2174/1568007053005082; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rossin A, 2009, BIOCHEM J, V419, P185, DOI 10.1042/BJ20081212; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Said TM, 2004, HUM REPROD UPDATE, V10, P39, DOI 10.1093/humupd/dmh003; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2006, J CLIN INVEST, V116, P2901, DOI 10.1172/JCI23771; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Scorrano L, 2008, J CELL BIOL, V183, P579, DOI 10.1083/jcb.200810125; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Varfolomeev E, 2008, CELL CYCLE, V7, P1511, DOI 10.4161/cc.7.11.5959; Varfolomeev E, 2009, J BIOL CHEM, V284, P34553, DOI 10.1074/jbc.M109.040139; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Wu GS, 1999, CANCER RES, V59, P2770; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida T, 2007, ONCOL REP, V18, P1239; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yue HH, 2005, CELL DEATH DIFFER, V12, P94, DOI 10.1038/sj.cdd.4401523; Zauli G, 2004, BLOOD, V104, P2044, DOI 10.1182/blood-2004-03-1196; Zauli G, 2008, J CELL PHYSIOL, V214, P117, DOI 10.1002/jcp.21165; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhao XX, 2009, BIOCHEM BIOPH RES CO, V378, P21, DOI 10.1016/j.bbrc.2008.10.123; Zheng SJ, 2004, J IMMUNOL, V173, P5652, DOI 10.4049/jimmunol.173.9.5652	176	270	282	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4752	4765		10.1038/onc.2010.221	http://dx.doi.org/10.1038/onc.2010.221			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20531300				2022-12-28	WOS:000281326400002
J	Wang, S; Huang, X; Lee, CK; Liu, B				Wang, S.; Huang, X.; Lee, C-K; Liu, B.			Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin	ONCOGENE			English	Article						erbB3; erbB2; Survivin; paclitaxel resistance; breast cancer	GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY; ESTROGEN-RECEPTOR; SIGNALING PATHWAY; ACTIVATION LEADS; TAXOL; OVEREXPRESSION; TRASTUZUMAB; MECHANISMS	The coexpression of erbB3 and erbB2 is frequently observed in breast cancer; and erbB3 has a critical role in erbB2 promotion of breast cancer progression and anti-estrogen resistance. In this study, we determine the role of erbB3 in erbB2-mediated paclitaxel resistance in breast cancer cells. The overexpression of exogenous erbB3 via either stable or transient transfection in erbB2-overexpressing, but not epidermal growth factor receptor (EGFR)-expressing, breast cancer cells significantly decreases paclitaxel-induced growth inhibition and apoptosis. Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase ( PARP) cleavage and activation of caspase- 3 and -8. Furthermore, while forced overexpression of erbB3 increases, specific knockdown of erbB3 decreases the expression levels of Survivin only in the erbB2-overexpressing breast cancer cells. Targeting Survivin with specific shRNA overcomes paclitaxel resistance without effect on the expression levels of either erbB2 or erbB3. Mechanistic studies indicate that the specific phosphoinositide 3-kinase (PI-3K), Akt and mammalian target of rapamycin (mTOR) inhibitors, but not the mitogen-activated protein kinase kinase (MEK) inhibitor, not only abrogate erbB3-mediated upregulation of Survivin, but also reinforce the erbB2/erbB3-coexpressing breast cancer cells to paclitaxel-induced growth inhibition. These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin. Our studies suggest that new strategies targeting erbB3 or Survivin may enhance the efficacy of chemotherapeutic agents against erbB2-overexpressing breast cancer. Oncogene (2010) 29, 4225-4236; doi: 10.1038/onc.2010.180; published online 24 May 2010	[Wang, S.; Huang, X.; Liu, B.] Univ Colorado Denver, Sch Med, Dept Pathol, Aurora, CO 80045 USA; [Lee, C-K] Univ Colorado Denver, Sch Med, Dept Med, Myeloma & Amyloidosis Program, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Liu, B (corresponding author), Univ Colorado Denver, Sch Med, Dept Pathol, MS-8104,POB 6511,12801 E 17th Ave, Aurora, CO 80045 USA.	bolin.liu@ucdenver.edu	Wang, Shuiliang/R-4080-2019	Wang, Shuiliang/0000-0002-5054-9064; Liu, Bolin/0000-0003-0150-8650	Susan G Komen for the Cure	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation)	We thank Dr Haihua Gu for providing the pLKO.1-ErbB3shRNA expression vector and lentivirus packaging plasmids pCMV-VSVG and pCMV-DA. 9. We also thank Ms Lisa Litzenberger for her excellent art preparation. This work was supported in part by a research Grant from Susan G Komen for the Cure (to BL).	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Ferlini C, 2007, CURR CANCER DRUG TAR, V7, P704, DOI 10.2174/156800907783220453; Grupka NL, 2004, ARCH PATHOL LAB MED, V128, P974; Hawthorne VS, 2009, MOL CANCER RES, V7, P592, DOI 10.1158/1541-7786.MCR-08-0316; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321; Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Kim A, 2005, BREAST CANCER RES, V7, pR708, DOI 10.1186/bcr1281; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Liu BL, 2009, MOL CANCER RES, V7, P1882, DOI 10.1158/1541-7786.MCR-08-0509; Liu Q, 2008, CANCER BIOL THER, V7, P1053, DOI 10.4161/cbt.7.7.6100; Lu J, 2009, CLIN CANCER RES, V15, P1326, DOI 10.1158/1078-0432.CCR-08-0954; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Morris PG, 2009, EXPERT REV ANTICANC, V9, P175, DOI 10.1586/14737140.9.2.175; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Oh SH, 2008, CLIN CANCER RES, V14, P1581, DOI 10.1158/1078-0432.CCR-07-0952; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pack SD, 2004, CANCER RES, V64, P789, DOI 10.1158/0008-5472.CAN-03-1982; Saloustros E, 2008, EXPERT OPIN PHARMACO, V9, P2603, DOI [10.1517/14656566.9.15.2603, 10.1517/14656566.9.15.2603 ]; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Seve P, 2008, LANCET ONCOL, V9, P168, DOI 10.1016/S1470-2045(08)70029-9; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; THOR AD, 1989, CANCER RES, V49, P7147; Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094; van Amerongen R, 2006, GENE DEV, V20, P1975, DOI 10.1101/gad.1460806; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359	49	94	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4225	4236		10.1038/onc.2010.180	http://dx.doi.org/10.1038/onc.2010.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498641				2022-12-28	WOS:000280151500010
J	Liu, PS; Jong, TH; Maa, MC; Leu, TH				Liu, P-S; Jong, T-H; Maa, M-C; Leu, T-H			The interplay between Eps8 and IRSp53 contributes to Src-mediated transformation	ONCOGENE			English	Article						IRSp53; Eps8; v-Src; Stat3; oncogenic proteins; cancer cells	TYROSINE KINASE SUBSTRATE; MISSING-IN-METASTASIS; INSULIN-RECEPTOR; STRUCTURAL BASIS; HOMOLOGY DOMAIN; SH3 DOMAIN; V-SRC; EXPRESSION; PHOSPHORYLATION; ACTIVATION	As an oncoprotein, Eps8 participates in v-Src-induced cellular transformation. To delineate the underlying mechanism, we conducted a yeast two-hybrid screening and identified IRSp53S, a protein critical in cell mobilization, as one of the Eps8-binding partners from a human brain cDNA library. The association was mediated by the multiple proline-rich regions of Eps8 and the C-terminal SH3-WWB containing domains of IRSp53S. In this study, we observed that Eps8 modulated the expression of IRSp53 in v-Src-transformed cells (IV5), raising the question of whether Eps8/IRSp53 interaction was crucial in carcinogenesis. To address this issue, we generated IV5-expressing irsp53 siRNA cells. Attenuation of IRSp53 reduced cell proliferation of IV5 in culture dish and tumor formation in mice, which could be partly rescued by ectopically expressed human IRSp53S. In addition, IRSp53 knockdown impaired activity of phosphatidylinositol 3-kinase (as reflected by Pi-Ser473 AKT) and Stat3 (as reflected by Pi-Tyr705 Stat3), and reduced cyclin D1 expression that culminated to impede G(1)-phase cell-cycle progression. Ectopically expressed human IRSp53S, but not its Eps8-binding defective mutants (that is, Delta 363 and PPPDA), rescued these defects and partly restored cell proliferation. Remarkably, through activation of Src, EGF increased the formation of Eps8/IRSp53 complex and Stat3 activation in HeLa cells. With these results, we show for the first time that IRSp53, through its interaction with Eps8, not only affects cell migration but also dictates cellular growth in cancer cells. Oncogene (2010) 29, 3977-3989; doi:10.1038/onc.2010.144; published online 26 April 2010	[Jong, T-H; Leu, T-H] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Liu, P-S; Leu, T-H] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Maa, M-C] China Med Univ, Inst Med Sci, Taichung, Taiwan; [Maa, M-C] China Med Univ, Inst Mol Syst Biomed, Taichung, Taiwan; [Leu, T-H] Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; China Medical University Taiwan; China Medical University Taiwan; National Cheng Kung University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	mcmaa@mail.cmu.edu.tw; tzengleu@mail.ncku.edu.tw			National Science Council [NSC98-2311-B-039-002-MY3, NSC97-2320-B-006-024-MY3, NSC 94-3112-B-001-003, NSC 94-3112-B-001-018-Y]; NHRI [NHRI-EX-98-9828BI]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH99-TD-B-111-004]; China Medical University [CMU98-C-05]	National Science Council(Ministry of Science and Technology, Taiwan); NHRI(National Health Research Institutes - Taiwan); Taiwan Department of Health Clinical Trial and Research Center of Excellence; China Medical University(China Medical University)	This work was supported by National Science Council grants to M-CM (NSC98-2311-B-039-002-MY3) and T-HL (NSC97-2320-B-006-024-MY3). Additional support came from NHRI (NHRI-EX-98-9828BI to T-H Leu), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH99-TD-B-111-004 to M-C Maa) and China Medical University (CMU98-C-05 to M-C Maa). The DNA constructs of pLKO.1-mirsp53-b and pLKO.1-mirsp53-c were provided by the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 94-3112-B-001-003 and NSC 94-3112-B-001-018-Y).	Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Aitio O, 2008, J MOL BIOL, V382, P167, DOI 10.1016/j.jmb.2008.07.008; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Chen YJ, 2008, MOL CANCER THER, V7, P1376, DOI 10.1158/1535-7163.MCT-07-2388; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Leu TH, 2004, J BIOL CHEM, V279, P9875, DOI 10.1074/jbc.M309884200; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Miyahara A, 2003, J HUM GENET, V48, P410, DOI 10.1007/s10038-003-0047-x; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Oda K, 1999, CYTOGENET CELL GENET, V84, P75, DOI 10.1159/000015219; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Okamura-Oho Y, 2001, BIOCHEM BIOPH RES CO, V289, P957, DOI 10.1006/bbrc.2001.6102; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2008, TRENDS CELL BIOL, V18, P52, DOI 10.1016/j.tcb.2007.12.002; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Suetsugu S, 2006, J BIOL CHEM, V281, P35347, DOI 10.1074/jbc.M606814200; Xu M, 2009, ENDOCRINOLOGY, V150, P2064, DOI 10.1210/en.2008-1265; Yap LF, 2009, ONCOGENE, V28, P2524, DOI 10.1038/onc.2009.105; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921	30	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3977	3989		10.1038/onc.2010.144	http://dx.doi.org/10.1038/onc.2010.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20418908				2022-12-28	WOS:000279603200010
J	Chen, Z; Li, Y; Zhang, H; Huang, P; Luthra, R				Chen, Z.; Li, Y.; Zhang, H.; Huang, P.; Luthra, R.			Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression	ONCOGENE			English	Article						miR-210; mitochondria; hypoxia; COX10; ISCU; ROS	CANCER-CELLS; DNA-REPAIR; INHIBITION; STRATEGY	The mechanisms of compromised mitochondrial function under various pathological conditions, including hypoxia, remain largely unknown. Recent studies have shown that microRNA-210 (miR-210) is induced by hypoxia under the regulation of hypoxia-inducible factor-1 alpha and has an important role in cell survival under hypoxic microenvironment. Hence, we hypothesized that miR-210 has a role in regulating mitochondrial metabolism and investigated miR-210 effects on mitochondrial function in cancer cell lines under normal and hypoxic conditions. Our results demonstrate that miR-210 decreases mitochondrial function and upregulates the glycolysis, thus make cancer cells more sensitive to glycolysis inhibitor. miR-210 can also activate the generation of reactive oxygen species (ROS). ISCU (iron-sulfur cluster scaffold homolog) and COX10 (cytochrome c oxidase assembly protein), two important factors of the mitochondria electron transport chain and the tricarboxylic acid cycle have been identified as potential targets of miR-210. The unique means by which miR-210 regulates mitochondrial function reveals an miRNA-mediated link between microenvironmental stress, oxidative phosphorylation, ROS and iron homeostasis. Oncogene (2010) 29, 4362-4368; doi:10.1038/onc.2010.193; published online 24 May 2010	[Chen, Z.; Li, Y.; Luthra, R.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77054 USA; [Zhang, H.; Huang, P.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Luthra, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 8515 Fannin St,NAO1-061A, Houston, TX 77054 USA.	rluthra@mdanderson.org						Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Diaz F, 2006, MOL CELL BIOL, V26, P4872, DOI 10.1128/MCB.01767-05; Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Luthra R, 2008, ONCOGENE, V27, P6667, DOI 10.1038/onc.2008.256; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Xu RH, 2005, CANCER RES, V65, P613	20	283	305	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4362	4368		10.1038/onc.2010.193	http://dx.doi.org/10.1038/onc.2010.193			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498629				2022-12-28	WOS:000280547900012
J	Yan, Y; Cao, PT; Greer, PM; Nagengast, ES; Kolb, RH; Mumby, MC; Cowan, KH				Yan, Y.; Cao, P. T.; Greer, P. M.; Nagengast, E. S.; Kolb, R. H.; Mumby, M. C.; Cowan, K. H.			Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response	ONCOGENE			English	Article						PP2A; ATM/ATR; Chk1/2; irradiation and G2/M arrest	CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; SERINE/THREONINE PHOSPHATASES; OKADAIC ACID; CALYCULIN-A; PHOSPHORYLATION; KINASE; ATR; CHK1	G2/M checkpoint activation after DNA damage results in G2/M cell cycle arrest that allows time for DNA repair before the entry of cells into mitosis. Activation of G2/M checkpoint involves a series of signaling events, which include activation of ataxia telangiectecia-mutated and Rad3-related (ATR) and Chk1 kinases and inhibition of Cdc2/Cyclin B activity. Studies presented in this report show that serine (Ser)/threonine (Thr) protein phosphatase 2A (PP2A) has an important role in G2/M checkpoint activation in response to gamma-irradiation (IR) exposure. Using PP2A inhibitors, as well as siRNA targeting various forms of Ser/Thr protein phosphatases, results presented in this report show that specific PP2A inhibition abrogates IR-induced activation of ATR and Chk1 kinases, as well as phosphorylation of Cdc2-Tyr15, and attenuates IR-induced G2/M arrest. These results suggest an important regulation of PP2A on IR-induced G2/M checkpoint signaling response. Oncogene (2010) 29, 4317-4329; doi:10.1038/onc.2010.187; published online 24 May 2010	[Yan, Y.; Cao, P. T.; Greer, P. M.; Nagengast, E. S.; Kolb, R. H.; Cowan, K. H.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Mumby, M. C.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA	University of Nebraska System; University of Nebraska Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cowan, KH (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	kcowan@unmc.edu		Kolb, Ryan/0000-0001-6305-2885	Nebraska [DHHS-LB506, 2007-45]; NCI [NCI T32 CA009476]; NCI Cancer Center Support Grant [P30CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER	Nebraska; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michel Ouellette for providing HPNE cells, Dr Helen Piwnica Worms for GST-Cdc25C construct, Dr Charles Kuzynski, Victoria Smith and Megan Michalak for assistance on the flow cytometry analysis, and Dr Janina Baranowska-Kortylewicz for assistance on the operation of Mark I 68A Cesium-137 Irradiator. This work was supported by Nebraska DHHS-LB506 grant 2007-45 to YY, NCI Training Grant (NCI T32 CA009476) to RK and NCI Cancer Center Support Grant (P30CA036727) to KC.	Ahn JY, 2000, CANCER RES, V60, P5934; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cho US, 2007, PLOS BIOL, V5, P1810, DOI 10.1371/journal.pbio.0050202; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Cohen PTW, 2002, J CELL SCI, V115, P241; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jang YJ, 2007, J BIOL CHEM, V282, P2473, DOI 10.1074/jbc.M605480200; Janssens IA, 2005, BIOGEOSCIENCES, V2, P15, DOI 10.5194/bg-2-15-2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Li G, 2007, J BIOL CHEM, V282, P7287, DOI 10.1074/jbc.M607951200; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Liu QH, 2000, GENE DEV, V14, P1448; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; McConnell JL, 2009, MOL PHARMACOL, V75, P1249, DOI 10.1124/mol.108.053140; Nagasawa H, 1998, CANCER RES, V58, P2036; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Swingle Mark, 2007, V365, P23; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	49	48	54	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4317	4329		10.1038/onc.2010.187	http://dx.doi.org/10.1038/onc.2010.187			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498628	Green Accepted			2022-12-28	WOS:000280547900008
J	Wen, KW; Damania, B				Wen, K. W.; Damania, B.			Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1	ONCOGENE			English	Article						KSHV; K1; heat shock proteins; Hsp90; Hsp40; lytic replication	SARCOMA-ASSOCIATED HERPESVIRUS; MULTICENTRIC CASTLEMANS-DISEASE; HEAT-SHOCK PROTEINS; KAPOSIS-SARCOMA; DNA-SEQUENCES; SIGNALING PATHWAY; STEROID-RECEPTOR; GENE-PRODUCT; IN-VIVO; GELDANAMYCIN	Kaposi sarcoma-associated herpesvirus (KSHV) is a member of the gammaherpesvirus family. It is the etiological agent of three different human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman disease. The far left end of the KSHV genome encodes a unique transmembrane glycoprotein called K1. K1 possesses the ability to transform rodent fibroblasts and block apoptosis. K1 has also been shown to activate the PI3K/Akt/mTOR pathway in different cells. Using tandem affinity purification, we identified heat shock protein 90 beta (Hsp90 beta) and endoplasmic reticulum-associated Hsp40 (Erdj3/DnaJB11), as cellular binding partners of K1. Interactions of K1 with Hsp90 beta and Hsp40 were confirmed by co-immunoprecipitation in both directions. Furthermore, K1 also interacted with the Hsp90 alpha isoform. We report that small-interfering RNAs directed against Hsp90 and Hsp40/Erdj3, as well as pharmacological inhibitors of Hsp90, dramatically reduced K1 expression, suggesting that K1 is a client protein of these chaperones. In addition, both Hsp90 and Hsp40/Erdj3 were essential for K1's antiapoptotic function. Finally, we report that the Hsp90 inhibitors, 17-AAG and 17-DMAG, can suppress the proliferation of KSHV-positive PEL cell lines and exhibited IC(50) values of 50 nM and below. Oncogene (2010) 29, 3532-3544; doi:10.1038/onc.2010.124; published online 26 April 2010	[Wen, K. W.; Damania, B.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Wen, K. W.; Damania, B.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Damania, B (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	damania@med.unc.edu			NIH [CA096500]; University of Pennsylvania [P30-AI045008]; NIAID [T32-AI007001]; MSTP [T32-GM008719]; NATIONAL CANCER INSTITUTE [R01CA096500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007001, P30AI045008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MSTP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Prasanna Bhende for help with immunohistochemistry and cell-cycle analysis and Stuart Krall for technical assistance. We thank Dr Jae Jung for providing us with the anti-K1 antibody and members of the Damania and Dittmer lab for informative discussions. We also thank the UNC Proteomics Center for processing of the protein samples and subsequent mass spectroscopy analysis. BD is a Leukemia & Lymphoma Society Scholar, American Heart Association established investigator, and a Burroughs Wellcome Fund Investigator in Infectious Disease. This work was supported by grant CA096500 from NIH and a University of Pennsylvania CFAR pilot project grant (P30-AI045008) to BD. KWW was supported in part by NIAID training Grant T32-AI007001 and MSTP Grant T32-GM008719. BD is a Leukemia & Lymphoma Society Scholar and Burroughs Welcome Fund Investigator in Infectious Disease.	Berkova Z, 2009, JNCI-J NATL CANCER I, V101, P399, DOI 10.1093/jnci/djn516; Bowser BS, 2002, J VIROL, V76, P12574, DOI 10.1128/JVI.76.24.12574-12583.2002; Burch AD, 2005, J VIROL, V79, P10740, DOI 10.1128/JVI.79.16.10740-10749.2005; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANDRIANI S, 2010, J VIROL MAR; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Damania B, 1999, J VIROL, V73, P5123, DOI 10.1128/JVI.73.6.5123-5131.1999; Damania B, 2000, J VIROL, V74, P2721, DOI 10.1128/JVI.74.6.2721-2730.2000; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Gessain A, 1996, BLOOD, V87, P414; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; Hollingshead M, 2005, CANCER CHEMOTH PHARM, V56, P115, DOI 10.1007/s00280-004-0939-2; Ivy P. S., 2004, ONCOLOGY HUNTINGT, V18, P619; Ivy PS, 2004, ONCOLOGY-NY, V18, P610; Lagunoff M, 1997, VIROLOGY, V236, P147, DOI 10.1006/viro.1997.8713; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Lee BS, 2000, J EXP MED, V192, P11, DOI 10.1084/jem.192.1.11; Lee BS, 2005, J VIROL, V79, P12173, DOI 10.1128/JVI.79.19.12173-12184.2005; Lee BS, 2003, J VIROL, V77, P8072, DOI 10.1128/JVI.77.14.8072-8086.2003; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; Lee H, 1998, MOL CELL BIOL, V18, P5219, DOI 10.1128/MCB.18.9.5219; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li W, 2007, EMBO J, V26, P1221, DOI 10.1038/sj.emboj.7601579; Livingston CM, 2008, J VIROL, V82, P6324, DOI 10.1128/JVI.00455-08; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Ohji G, 2006, J BIOCHEM, V139, P129, DOI 10.1093/jb/mvj008; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Pedersen CB, 2003, J BIOL CHEM, V278, P47449, DOI 10.1074/jbc.M309514200; Picard D, 2004, NAT CELL BIOL, V6, P479, DOI 10.1038/ncb0604-479; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Prakash O, 2005, BLOOD, V105, P3987, DOI 10.1182/blood-2004-07-2781; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Samaniego F, 2001, J Natl Cancer Inst Monogr, P15; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Shen Y, 2005, MOL BIOL CELL, V16, P40, DOI 10.1091/mbc.E04-05-0434; Shinozaki F, 2006, J BIOL CHEM, V281, P16361, DOI 10.1074/jbc.M600891200; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Tomlinson CC, 2008, J VIROL, V82, P6514, DOI 10.1128/JVI.02637-07; Trentin L, 2008, BLOOD, V112, P4665, DOI 10.1182/blood-2008-02-139139; Wang L, 2006, CANCER RES, V66, P3658, DOI 10.1158/0008-5472.CAN-05-3680; Wang L, 2004, CANCER RES, V64, P2774, DOI 10.1158/0008-5472.CAN-03-3653; Wang SZ, 2007, BLOOD, V109, P2174, DOI 10.1182/blood-2006-02-003178; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Xu WP, 2003, CANCER RES, V63, P7777; Zhang C, 2005, PLANT PHYSIOL BIOCH, V43, P13, DOI 10.1016/j.plaphy.2004.10.006	55	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3532	3544		10.1038/onc.2010.124	http://dx.doi.org/10.1038/onc.2010.124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418907	Green Accepted, Green Submitted			2022-12-28	WOS:000278835400008
J	Ansieau, S; Morel, AP; Hinkal, G; Bastid, J; Puisieux, A				Ansieau, S.; Morel, A-P; Hinkal, G.; Bastid, J.; Puisieux, A.			TWISTing an embryonic transcription factor into an oncoprotein	ONCOGENE			English	Review						TWIST; embryogenesis; EMT; failsafe program escape; cell dissemination	EPITHELIAL-MESENCHYMAL TRANSITION; SAETHRE-CHOTZEN-SYNDROME; HUMAN BREAST-CANCER; LYMPH-NODE METASTASIS; E-CADHERIN EXPRESSION; BHLH PROTEIN TWIST; GROWTH-FACTOR-BETA; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; STEM-CELLS	Over the past decade, the reactivation of TWIST embryonic transcription factors has been described as a frequent event and a marker of poor prognosis in an impressive array of human cancers. Growing evidence now supports the premise that these cancers hijack TWIST's embryonic functions, granting oncogenic and metastatic properties. In this review, we report on the history and recent breakthroughs in understanding TWIST protein functions and the emerging role of the associated epithelial-mesenchymal transition (EMT) in tumorigenesis. We then broaden the discussion to address the general contribution of reactivating embryonic programs in cancerogenesis. Oncogene (2010) 29, 3173-3184; doi: 10.1038/onc.2010.92; published online 12 April 2010	[Ansieau, S.; Puisieux, A.] Ctr Leon Berard, INSERM, U590, F-69008 Lyon, France; [Bastid, J.; Puisieux, A.] Univ Lyon 1, Inst Sci Pharmaceut & Biol, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ansieau, S (corresponding author), Ctr Leon Berard, INSERM, U590, 28 Rue Laennec, F-69008 Lyon, France.	ansieau@lyon.fnclcc.fr; puisieux@lyon.fnclcc.fr	MOREL, Anne-Pierre/AAN-7072-2021; Ansieau, Stephane/I-6195-2016	ANSIEAU, Stephane/0000-0003-0989-2108; PUISIEUX, Alain/0000-0002-9938-3798	Ligue contre le Cancer (Comites de l'Ain, de la Drome et Rhone-Alpes); l'Association pour la Recherche sur le Cancer (ARC); l'Institut National du Cancer (INCa); la Fondation de France; la Fondation Albert et Jeanne Rollet du Coudray	Ligue contre le Cancer (Comites de l'Ain, de la Drome et Rhone-Alpes); l'Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); l'Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); la Fondation de France(Fondation de France); la Fondation Albert et Jeanne Rollet du Coudray	Because of size restriction, unfortunately we could not refer to all significant contributions in this field. We therefore apologize to non-cited scientists. Our researches are supported by the Ligue contre le Cancer (Comites de l'Ain, de la Drome et Rhone-Alpes), l'Association pour la Recherche sur le Cancer (ARC), l'Institut National du Cancer (INCa), la Fondation de France and la Fondation Albert et Jeanne Rollet du Coudray.	Alborzi A, 1996, J CRAN GENET DEV BIO, V16, P94; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Ansieau S, 2008, CELL CYCLE, V7, P3659, DOI 10.4161/cc.7.23.7049; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BATE M, 1991, DEVELOPMENT, V113, P79; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brouzes E, 2004, BIOL CELL, V96, P471, DOI 10.1016/j.biolcel.2004.04.009; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Castanon I, 2001, DEVELOPMENT, V128, P3145; Cates JMM, 2008, APPL IMMUNOHISTO M M, V16, P251, DOI 10.1097/PAI.0b013e318156e9b4; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Connerney J, 2008, DEV BIOL, V318, P323, DOI 10.1016/j.ydbio.2008.03.037; Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717; Cripps RM, 1998, DEV BIOL, V203, P106, DOI 10.1006/dbio.1998.9040; Demontis S, 2006, CELL DEATH DIFFER, V13, P335, DOI 10.1038/sj.cdd.4401744; Desprat N, 2008, DEV CELL, V15, P470, DOI 10.1016/j.devcel.2008.07.009; DI CE, 1999, LAB INVEST, V79, P1261; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dong YF, 2007, MOL ENDOCRINOL, V21, P2805, DOI 10.1210/me.2007-0199; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; ElGhouzzi V, 1997, NAT GENET, V15, P42; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; Fendrich V, 2009, EUR J ENDOCRINOL, V160, P695, DOI 10.1530/EJE-08-0662; Feng Y, 2009, ORAL SURG ORAL MED O, V108, P565, DOI 10.1016/j.tripleo.2009.05.041; Firulli AB, 2008, CURR MED CHEM, V15, P2641, DOI 10.2174/092986708785908987; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Fondrevelle ME, 2009, UROL ONCOL-SEMIN ORI, V27, P268, DOI 10.1016/j.urolonc.2007.12.012; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gort EH, 2008, ONCOGENE, V27, P1501, DOI 10.1038/sj.onc.1210795; Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hasselblatt M, 2009, CANCER RES, V69, P2219, DOI 10.1158/0008-5472.CAN-08-3176; Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hinoi E, 2006, GENE DEV, V20, P2937, DOI 10.1101/gad.1482906; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933; Hosono S, 2007, BRIT J CANCER, V96, P314, DOI 10.1038/sj.bjc.6603533; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu L, 2008, CANCER RES, V68, P4296, DOI 10.1158/0008-5472.CAN-08-0067; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Kajiyama H, 2006, ONCOLOGY-BASEL, V71, P394, DOI 10.1159/000107108; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kojc N, 2009, VIRCHOWS ARCH, V454, P549, DOI 10.1007/s00428-009-0771-5; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Kyo S, 2006, HUM PATHOL, V37, P431, DOI 10.1016/j.humpath.2005.12.021; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Li Chang-hai, 2006, Zhonghua Wai Ke Za Zhi, V44, P1353; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Man TK, 2005, CANCER RES, V65, P8142, DOI 10.1158/0008-5472.CAN-05-0985; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Matsuo N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-240; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakaya Y, 2008, DEV GROWTH DIFFER, V50, P755, DOI 10.1111/j.1440-169X.2008.01070.x; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; Niesner U, 2008, J EXP MED, V205, P1889, DOI 10.1084/jem.20072468; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Niu RF, 2007, J EXP CLIN CANC RES, V26, P385; Ohuchida K, 2007, INT J CANCER, V120, P1634, DOI 10.1002/ijc.22295; OKA H, 1993, CANCER RES, V53, P1696; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ou DL, 2008, ANTICANCER RES, V28, P1355; Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Rice DPC, 2000, DEVELOPMENT, V127, P1845; Rodrigues CO, 2008, DEVELOPMENT, V135, P1903, DOI 10.1242/dev.011296; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Satoh K, 2008, AM J PATHOL, V172, P926, DOI 10.2353/ajpath.2008.070346; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shibata K, 2008, ANN ONCOL, V19, P81, DOI 10.1093/annonc/mdm344; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Smit MA, 2008, CANCER CELL, V14, P5, DOI 10.1016/j.ccr.2008.06.012; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Song LB, 2006, CANCER LETT, V242, P258, DOI 10.1016/j.canlet.2005.11.013; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; UMBAS R, 1994, CANCER RES, V54, P3929; Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Waldmann J, 2009, ANN SURG ONCOL, V16, P1997, DOI 10.1245/s10434-009-0480-y; Wang SM, 1997, GENE, V187, P83, DOI 10.1016/S0378-1119(96)00727-5; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Watanabe O, 2004, ANTICANCER RES, V24, P3851; Whitehead J, 2008, HFSP J, V2, P286, DOI 10.2976/1.2955566; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; Wong MC, 2008, DEV BIOL, V317, P417, DOI 10.1016/j.ydbio.2008.02.020; Xie FW, 2009, CLIN EXP METASTAS, V26, P1025, DOI 10.1007/s10585-009-9292-5; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu J, 2007, J HUAZHONG U SCI-MED, V27, P668, DOI 10.1007/s11596-007-0612-1; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang L, 2008, WD SCI P COMP ENG, V1, P295, DOI 10.1142/9789812799470_0048; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; Yoshida J, 2009, MED MOL MORPHOL, V42, P82, DOI 10.1007/s00795-008-0436-5; Yuen HF, 2007, J CLIN PATHOL, V60, P510, DOI 10.1136/jcp.2006.039099; Zhang YQ, 2007, PATHOLOGY, V39, P470, DOI 10.1080/00313020701570053; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004; Zhu Q, 2008, J HUAZHONG U SCI-MED, V28, P144, DOI 10.1007/s11596-008-0207-5; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	150	130	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3173	3184		10.1038/onc.2010.92	http://dx.doi.org/10.1038/onc.2010.92			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20383196				2022-12-28	WOS:000278321100001
J	Ooki, A; Yamashita, K; Kikuchi, S; Sakuramoto, S; Katada, N; Kokubo, K; Kobayashi, H; Kim, MS; Sidransky, D; Watanabe, M				Ooki, A.; Yamashita, K.; Kikuchi, S.; Sakuramoto, S.; Katada, N.; Kokubo, K.; Kobayashi, H.; Kim, M. S.; Sidransky, D.; Watanabe, M.			Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer	ONCOGENE			English	Article						HOP homeobox; gastric cancer; methylation; prognosis	ABERRANT METHYLATION; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; ESTROGEN; PGP9.5; INACTIVATION; CHEMOTHERAPY; MANAGEMENT; SCORE	HOP homeobox (HOPX) is an unusual homeobox gene encoding three spliced transcript variants, among which the only HOPX-beta promoter harbors CpG islands. The characteristics of its promoter methylation was analyzed using bisulfite sequencing and quantitative-methylation-specific polymerase chain reaction (Q-MSP), and the effects of HOPX expression were also examined. HOPX-beta expression was silenced in all gastric cancer cell lines tested; its expression could be restored by treatment with demethylating agent. On Q-MSP, HOPX-beta hypermethylation (cut-off value of 3.55) was found in 84% (67 out of 80) of primary tumor tissues and 10% (8 out of 80) of the corresponding normal tissues and could discriminate normal from tumor tissues (P<0.0001). The prognosis of the advanced cases with HOPX-beta hypermethylation was as poor as those with stage IV disease when cut-off value was set at 11.28. This finding was validated in an independent cohort of 90 advanced gastric cancers. The HOPX-beta hypermethylation was also an independent prognostic factor (P = 0.029) on multivariate analysis. Exogenous HOPX expression significantly inhibited cell proliferation, colony formation and invasion as well as enhanced apoptosis. Taken together, HOPX-beta promoter methylation is a frequent and cancer-specific event in gastric cancer. Quantitative assessment of HOPX-beta methylation has great clinical potential as a marker of tumor aggressiveness. Oncogene (2010) 29, 3263-3275; doi: 10.1038/onc.2010.76; published online 15 March 2010	[Ooki, A.; Yamashita, K.; Kikuchi, S.; Sakuramoto, S.; Katada, N.; Watanabe, M.] Kitasato Univ Hosp, Dept Surg, Kanagawa, Japan; [Kokubo, K.; Kobayashi, H.] Kitasato Univ, Sch Allied Hlth Sci, Dept Med Engn & Technol, Kanagawa 2288555, Japan; [Kim, M. S.; Sidransky, D.] Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Inst, Baltimore, MD USA	Kitasato University; Kitasato University; Johns Hopkins University	Ooki, A (corresponding author), Kitasato Univ, Dept Surg, Kitasato 1-15-1, Kanagawa 2288555, Japan.	sp9y9tq9@piano.ocn.ne.jp; gekaw@med.kitasato-u.ac.jp	Kokubo, Kenichi/E-6667-2011	Kokubo, Kenichi/0000-0003-0922-7933	Ministry of Health, Labour and Welfare of Japan; Japanese Foundation for Multidisciplinary Treatment of Cancer	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japanese Foundation for Multidisciplinary Treatment of Cancer(Japanese Foundation for Multidisciplinary Treatment of Cancer)	This work was supported, in part, by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan and by the Japanese Foundation for Multidisciplinary Treatment of Cancer.	Brena RM, 2006, J MOL MED, V84, P365, DOI 10.1007/s00109-005-0034-0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen Y, 2007, INT J CANCER, V121, P1021, DOI 10.1002/ijc.22753; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Kee HJ, 2007, J BIOL CHEM, V282, P7700, DOI 10.1074/jbc.M611198200; Kook H, 2006, BIOCHEMISTRY-US, V45, P10584, DOI 10.1021/bi060641s; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lehnert T, 2002, BRIT J SURG, V89, P471, DOI 10.1046/j.0007-1323.2002.02067.x; Liu JW, 2007, INT J CANCER, V121, P1994, DOI 10.1002/ijc.22934; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowy AM, 1999, ANN SURG, V229, P303, DOI 10.1097/00000658-199903000-00001; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Nakajima Toshifusa, 2002, Gastric Cancer, V5, P1, DOI 10.1007/s101200200000; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; OOKI A, 2009, INT J CANC IN PRESS; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; REMMELE W, 1987, PATHOLOGE, V8, P138; REMMELE W, 1993, PATHOL RES PRACT, V189, P862; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Tokumaru Y, 2008, INT J CANCER, V123, P753, DOI 10.1002/ijc.23354; Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yamaguchi S, 2009, INT J CANCER, V124, P2577, DOI 10.1002/ijc.24217; Yamashita K, 2006, CANCER RES, V66, P3921, DOI 10.1158/0008-5472.CAN-05-1511; Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213; Yamashita K, 2009, CANCER SCI, V100, P195, DOI 10.1111/j.1349-7006.2008.01022.x; Zhang YJ, 2008, J GASTROEN HEPATOL, V23, P856, DOI 10.1111/j.1440-1746.2007.05140.x; Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050	39	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3263	3275		10.1038/onc.2010.76	http://dx.doi.org/10.1038/onc.2010.76			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20228841				2022-12-28	WOS:000278321100009
J	Aziz, MH; Hafeez, BB; Sand, JM; Pierce, DB; Aziz, SW; Dreckschmidt, NE; Verma, AK				Aziz, M. H.; Hafeez, B. B.; Sand, J. M.; Pierce, D. B.; Aziz, S. W.; Dreckschmidt, N. E.; Verma, A. K.			Protein kinase C epsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2)	ONCOGENE			English	Article						PKC epsilon; Stat3; human cancer	INDUCED CUTANEOUS DAMAGE; EPIDERMAL JB6 CELLS; PROSTATE-CANCER; TRANSGENIC MICE; BREAST-CANCER; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; STAT3; CARCINOMA; ACTIVATION	Protein kinase C epsilon (PKC epsilon), a novel calcium-independent PKC isoform, has been shown to be a transforming oncogene. PKC epsilon-mediated oncogenic activity is linked to its ability to promote cell survival. However, the mechanisms by which PKC epsilon signals cell survival remain elusive. We found that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, is a protein partner of PKC epsilon. Stat3 has two conserved amino-acid (Tyr705 and Ser727) residues, which are phosphorylated during Stat3 activation. PKC epsilon interacts with Stat3 alpha isoform, which has Ser727, and not with Stat3 beta isoform, which lacks Ser727. PKC epsilon-Stat3 interaction and Stat3-Ser727 phosphorylation was initially observed during induction of squamous cell carcinomas and in prostate cancer. Now we present that (1) PKC epsilon physically interacts with Stat3 alpha isoform in various human cancer cells: skin melanomas (MeWo and WM266-4), gliomas (T98G and MO59K), bladder (RT-4 and UM-UC-3), colon (Caco-2), lung (H1650), pancreatic (PANC-1), and breast (MCF-7 and MDA: MB-231); (2) inhibition of PKC epsilon expression using specific siRNA inhibits Stat3Ser727 phosphorylation, Stat3-DNA binding, Stat3-regulated gene expression as well as cell invasion; and (3) PKC epsilon mediates Stat3Ser727 phosphorylation through integration with the MAPK cascade (RAF-1, MEK1/2, and ERK1/2). The results indicate that PKC epsilon-mediated Stat3Ser727 phosphorylation is essential for constitutive activation of Stat3 and cell invasion in various human cancers. Oncogene (2010) 29, 3100-3109; doi: 10.1038/onc.2010.63; published online 15 March 2010	[Aziz, M. H.; Hafeez, B. B.; Sand, J. M.; Pierce, D. B.; Aziz, S. W.; Dreckschmidt, N. E.; Verma, A. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Paul P Carbone Comprehens Canc,WIMR, Madison, WI 53792 USA; [Sand, J. M.] Wisconsin Inst Med Res, Mol & Environm Toxicol Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Verma, AK (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Paul P Carbone Comprehens Canc,WIMR, Room 7103,1111 Highland Ave, Madison, WI 53792 USA.	akverma@facstaff.wisc.edu			DOD [W81XWH]; NIH [CA35368]; NATIONAL CANCER INSTITUTE [R01CA035368] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in parts by DOD Grant W81XWH and NIH Grant CA35368 to AKV.	Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Aziz MH, 2007, MOL CARCINOGEN, V46, P646, DOI 10.1002/mc.20356; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Aziz MH, 2007, CANCER RES, V67, P1385, DOI 10.1158/0008-5472.CAN-06-3350; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Burger AM, 2005, CANCER RES, V65, P10401, DOI 10.1158/0008-5472.CAN-05-2103; Burger A, 2006, NEOPLASIA, V8, P689, DOI 10.1593/neo.06469; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chen D, 2007, J BIOL CHEM, V282, P33776, DOI 10.1074/jbc.M703320200; Christine R, 2005, CANCER RES, V65, P195; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jansen AP, 2001, CANCER RES, V61, P808; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Li L, 2004, BIOCHEM BIOPH RES CO, V322, P1005, DOI 10.1016/j.bbrc.2004.08.014; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nikitakis NG, 2004, CURR CANCER DRUG TAR, V4, P637, DOI 10.2174/1568009043332736; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Reddig PJ, 2000, CANCER RES, V60, P595; Stephanou A, 2005, GROWTH FACTORS, V23, P177, DOI 10.1080/08977190500178745; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Wheeler DL, 2005, PHOTOCHEM PHOTOBIOL, V81, P9, DOI 10.1562/2004-08-12-RA-271.1; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Wheeler DL, 2003, CANCER RES, V63, P6547; Wu DQ, 2004, ONCOGENE, V23, P8659, DOI 10.1038/sj.onc.1207900; Wu DQ, 2002, CANCER RES, V62, P2423; Xuan YT, 2005, CIRCULATION, V112, P1971, DOI 10.1161/CIRCULATIONAHA.105.561522; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zykova TA, 2005, CARCINOGENESIS, V26, P331, DOI 10.1093/carcin/bgh334	43	88	89	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3100	3109		10.1038/onc.2010.63	http://dx.doi.org/10.1038/onc.2010.63			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20228845	Green Accepted			2022-12-28	WOS:000278133100007
J	Sloss, CM; Wang, F; Palladino, MA; Cusack, JC				Sloss, C. M.; Wang, F.; Palladino, M. A.; Cusack, J. C., Jr.			Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells	ONCOGENE			English	Article						proteasome inhibition; NPI-0052; EGFR; HB-EGF; pancreatic cancer	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; BORTEZOMIB; RESISTANCE; P38; CHEMOTHERAPY; CONTRIBUTES; SENSITIVITY; ERLOTINIB	Resistance to drug treatments underlies the high lethality of pancreatic ductal adenocarcinoma. Along with others, we have recently identified that proteasome inhibition is a promising therapeutic option in this highly refractory disease. The pleiotropic effects of proteasome inhibition include the activation of apoptotic signaling pathways and also antiapoptotic signaling pathways such as EGFR, AKT and the MAP kinases that reduce the apoptotic potential of this class of drug. In this study, we sought to determine the mechanism behind the activation of EGFR in response to proteasome inhibition in pancreatic cancer cells. We found that the second-generation proteasome inhibitor NPI-0052 induced the mRNA transcription of several EGFR family ligands (EGF, HB-EGF and epiregulin), however only increases in HB-EGF were detected at the protein level. Using both pharmacological inhibitors and lentiviral-mediated shRNA knockdown of EGFR ligand expression, we discovered that ligand cleavage by MMP/ADAMs and HB-EGF expression is required for activation of EGFR in response to proteasome inhibition. Furthermore, we discover that induction of HB-EGF is dependent on reactive oxygen species and p38-MAPK signaling but not ERK and that the transcription factor SP-1 is involved in NPI-0052-induced HB-EGF transcription. Together, these results indicate that stress signaling leading to induction of HB-EGF expression and increases in MMP/ADAM-dependent HB-EGF cleavage are responsible for proteasome inhibitor-induced activation of EGFR in pancreatic cancer cells. Oncogene (2010) 29, 3146-3152; doi: 10.1038/onc.2010.52; published online 8 March 2010	[Sloss, C. M.; Wang, F.; Cusack, J. C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Boston, MA 02114 USA; [Palladino, M. A.] Nereus Pharmaceut, San Diego, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Cusack, JC (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Yawkey Bldg 7th Floor,55 Fruit St, Boston, MA 02114 USA.	jcusack@partners.org			NIH [CA98871]; NATIONAL CANCER INSTITUTE [R01CA098871] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Grant no. CA98871 (JC Cusack).	Blaine SA, 2009, AM J PHYSIOL-GASTR L, V297, pG434, DOI 10.1152/ajpgi.00152.2009; Buck E, 2006, MOL CANCER THER, V5, P2051, DOI 10.1158/1535-7163.MCT-06-0007; Codony-Servat J, 2006, MOL CANCER THER, V5, P665, DOI 10.1158/1535-7163.MCT-05-0147; D'Addario M, 2006, GENE, V379, P51, DOI 10.1016/j.gene.2006.04.012; Edwards JP, 2009, J IMMUNOL, V182, P1929, DOI 10.4049/jimmunol.0802703; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Giovannetti E, 2006, MOL CANCER THER, V5, P1387, DOI 10.1158/1535-7163.MCT-06-0004; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; Ingram JL, 2003, AM J PHYSIOL-LUNG C, V284, pL774, DOI 10.1152/ajplung.00189.2002; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274; Lorch JH, 2007, CANCER RES, V67, P727, DOI 10.1158/0008-5472.CAN-06-2162; McConkey DJ, 2008, DRUG RESIST UPDATE, V11, P164, DOI 10.1016/j.drup.2008.08.002; Means AL, 2003, GASTROENTEROLOGY, V124, P1020, DOI 10.1053/gast.2003.50150; Milano A, 2007, EUR J CANCER, V43, P1125, DOI 10.1016/j.ejca.2007.01.038; Miyamoto H, 2004, PANCREAS, V28, P38, DOI 10.1097/00006676-200401000-00006; Miyamoto S, 2006, CANCER SCI, V97, P341, DOI 10.1111/j.1349-7006.2006.00188.x; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Shi YY, 2006, BREAST CANCER RES TR, V100, P33, DOI 10.1007/s10549-006-9232-x; Sloss CM, 2008, CLIN CANCER RES, V14, P5116, DOI 10.1158/1078-0432.CCR-07-4506; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Wang F, 2007, ONCOGENE, V26, P2006, DOI 10.1038/sj.onc.1209999; Wang F, 2007, CANCER RES, V67, P8486, DOI 10.1158/0008-5472.CAN-07-0498; Zhu KY, 2009, CANCER RES, V69, P1836, DOI 10.1158/0008-5472.CAN-08-4103; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	30	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3146	3152		10.1038/onc.2010.52	http://dx.doi.org/10.1038/onc.2010.52			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20208558	Green Accepted			2022-12-28	WOS:000278133100011
J	Wang, Y; Klumpp, S; Amin, HM; Liang, H; Li, J; Estrov, Z; Zweidler-McKay, P; Brandt, SJ; Agulnick, A; Nagarajan, L				Wang, Y.; Klumpp, S.; Amin, H. M.; Liang, H.; Li, J.; Estrov, Z.; Zweidler-McKay, P.; Brandt, S. J.; Agulnick, A.; Nagarajan, L.			SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability	ONCOGENE			English	Article						tumor suppressor; null mouse; LIM code; p53; lymphoma; SSBP2	DNA-BINDING PROTEINS; B-CELL; TRANSCRIPTION FACTOR; LIM-DOMAIN; MYELOGENOUS LEUKEMIA; GENE-EXPRESSION; DIFFERENTIATION; SURVIVAL; PROLIFERATION; ABUNDANCE	SSBP proteins bind and stabilize transcriptional cofactor LIM domain-binding protein1 (LDB1) from proteosomal degradation to promote tissue-specific transcription through an evolutionarily conserved pathway. The human SSBP2 gene was isolated as a candidate tumor suppressor from a critical region of loss in chromosome 5q14.1. By gene targeting, we show increased predisposition to B-cell lymphomas and carcinomas in Ssbp2(-/-) mice. Remarkably, loss of Ssbp2 causes increased LDB1 turnover in the thymus, a pathway exploited in Trp53(-/-) Ssbp2(-/-) mice to develop highly aggressive, immature thymic lymphomas. Using T-cell differentiation as a model, we report a stage-specific upregulation of Ssbp2 expression, which in turn regulates LDB1 turnover under physiological conditions. Furthermore, transcript levels of pT alpha, a target of LDB1-containing complex, and a critical regulator T-cell differentiation are reduced in Ssbp2(-/-) immature thymocytes. Our findings suggest that disruption of the SSBP2-regulated pathways may be an infrequent but critical step in malignant transformation of multiple tissues. Oncogene (2010) 29, 3044-3053; doi: 10.1038/onc.2010.78; published online 29 March 2010	[Wang, Y.; Liang, H.; Li, J.; Nagarajan, L.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Klumpp, S.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Amin, H. M.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Estrov, Z.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Zweidler-McKay, P.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; [Brandt, S. J.] Vanderbilt Univ, Dept Med, Nashville, TN USA; [Brandt, S. J.] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN USA; [Brandt, S. J.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA; [Brandt, S. J.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Agulnick, A.] Novocell Inc, La Jolla, CA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Nagarajan, L (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, Box 45,1515 Holcombe Blvd, Houston, TX 77030 USA.	lnagaraj@mdanderson.org		Zweidler-McKay, Patrick/0000-0001-6621-523X	NCI [CA16672];  [HL744409]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449, R01HL049118] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Xiaoping Ma and Mayur Patel for expert technical assistance, Samuel Pfaff and Dong Er Zhang for housing the Ssbp2<SUP>-/-</SUP> mice in the early stages of these investigations, Gigi Lozano, Richard Behringer, present and former members of the Nagarajan laboratory for helpful discussions, Kim-Anh Vu for assistance with the histology photographs. These studies were supported by HL744409 to LN. The genotyping, flow cytometry facilities and veterinary services were supported by NCI core Grant CA16672.	Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Baseta JG, 2000, J IMMUNOL, V165, P5621, DOI 10.4049/jimmunol.165.10.5621; Cai Y, 2008, BIOCHEM BIOPH RES CO, V373, P303, DOI 10.1016/j.bbrc.2008.06.027; Capron C, 2006, BLOOD, V107, P4678, DOI 10.1182/blood-2005-08-3145; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Cerretini R, 2006, EUR J HAEMATOL, V76, P284, DOI 10.1111/j.1600-0609.2005.00616.x; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Fleisig HB, 2007, ONCOGENE, V26, P4797, DOI 10.1038/sj.onc.1210281; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Gungor C, 2007, P NATL ACAD SCI USA, V104, P15000, DOI 10.1073/pnas.0703738104; Haks MC, 1999, IMMUNITY, V11, P91, DOI 10.1016/S1074-7613(00)80084-9; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnsen SA, 2009, CANCER RES, V69, P128, DOI 10.1158/0008-5472.CAN-08-1630; Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2; Lecuyer E, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703939200; Liang H, 2005, ONCOGENE, V24, P2625, DOI 10.1038/sj.onc.1208167; Liu JW, 2008, CLIN CANCER RES, V14, P3754, DOI 10.1158/1078-0432.CCR-07-4763; Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; Natkunam Y, 2008, J CLIN ONCOL, V26, P447, DOI 10.1200/JCO.2007.13.0690; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Poitras JL, 2008, GENE CHROMOSOME CANC, V47, P884, DOI 10.1002/gcc.20585; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Rothenberg EV, 2007, NAT IMMUNOL, V8, P441, DOI 10.1038/ni1461; Rothenberg EV, 2007, CURR OPIN HEMATOL, V14, P322, DOI 10.1097/MOH.0b013e3281de72a8; Ryu CJ, 2006, CANCER CELL, V9, P109, DOI 10.1016/j.ccr.2006.01.004; Smith KS, 1999, MOL CELL BIOL, V19, P4443; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Wu HK, 1996, ONCOGENE, V12, P1205; Xu ZX, 2007, GENE DEV, V21, P942, DOI 10.1101/gad.1528507; Zhang XB, 2008, J CLIN INVEST, V118, P1502, DOI 10.1172/JCI34371	38	22	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3044	3053		10.1038/onc.2010.78	http://dx.doi.org/10.1038/onc.2010.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20348955	Green Accepted			2022-12-28	WOS:000278133100002
J	Jeffery, JM; Urquhart, AJ; Subramaniam, VN; Parton, RG; Khanna, KK				Jeffery, J. M.; Urquhart, A. J.; Subramaniam, V. N.; Parton, R. G.; Khanna, K. K.			Centrobin regulates the assembly of functional mitotic spindles	ONCOGENE			English	Article						Centrobin; mitosis; mitotic spindle; spindle assembly checkpoint	CENTROSOME INTEGRITY; CG-NAP; CHECKPOINT; PROTEIN; PHOSPHORYLATION; ANAPHASE; NEK2; NIP2/CENTROBIN; ORGANIZATION; SUBSTRATE	The proper function of the spindle is crucial to the high fidelity of chromosome segregation and is indispensable for tumor suppression in humans. Centrobin is a recently identified centrosomal protein that has a role in stabilizing the microtubule structure. Here we functionally characterize the defects in centrosome integrity and spindle assembly in Centrobin-depleted cells. Centrobin-depleted cells show a range of spindle abnormalities including unfocused poles that are not associated with centrosomes, S-shaped spindles and mini spindles. These cells undergo mitotic arrest and subsequently often die by apoptosis, as determined by live cell imaging. Co-depletion of Mad2 relieves the mitotic arrest, indicating that cells arrest due to a failure to silence the spindle checkpoint in metaphase. Consistent with this, Centrobin-depleted metaphase cells stained positive for BubR1 and BubR1 S676. Staining with a panel of centrosome markers showed a loss of centrosome anchoring to the mitotic spindle. Furthermore, these cells show less cold-stable microtubules and a shorter distance between kinetochore pairs. These results show a requirement of Centrobin in maintaining centrosome integrity, which in turn promotes anchoring of mitotic spindle to the centrosomes. Furthermore, this anchoring is required for the stability of microtubule-kinetochore attachments and biogenesis of tension-ridden and properly functioning mitotic spindle. Oncogene (2010) 29, 2649-2658; doi:10.1038/onc.2010.37; published online 1 March 2010	[Jeffery, J. M.; Urquhart, A. J.; Khanna, K. K.] Queensland Inst Med Res, Signal Transduct Lab, Canc & Cell Biol Div, Brisbane, Qld 4006, Australia; [Subramaniam, V. N.] Queensland Inst Med Res, Membrane Transport Lab, Canc & Cell Biol Div, Brisbane, Qld 4006, Australia; [Parton, R. G.] Univ Queensland, Mol Cell Biol Div, Inst Mol Biosci, Brisbane, Qld, Australia; [Parton, R. G.] Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Khanna, KK (corresponding author), Queensland Inst Med Res, Signal Transduct Lab, Canc & Cell Biol Div, 300 Herston Rd, Brisbane, Qld 4006, Australia.	kumkum.khanna@qimr.edu.au	Parton, Robert G/C-5673-2009; Subramaniam, V. Nathan/A-1901-2010; Khanna, Kum Kum/I-1747-2013	Parton, Robert G/0000-0002-7494-5248; Subramaniam, V. Nathan/0000-0002-4583-7790; Khanna, Kum Kum/0000-0001-8650-5381	National Health and Research Council of Australia	National Health and Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Sabine Elowe for the BubR1 S676 antibody, Duane Compton for the NuMA antibody, Andreas Merdes for the PCM1 antibody, Yoshitaka Ono for CG-NAP nd Kendrin antibodies, and Kunsoo Rhee for the myc-Centrobin constructs. We also thank Randy Poon and Uttam Surana for critical reading of the article and helpful suggestions. This work is supported in part by Program grant from the National Health and Research Council of Australia (K Khanna).	Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Emdad L, 2005, FRONT BIOSCI-LANDMRK, V10, P728; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Jeong Y, 2007, J CELL SCI, V120, P2106, DOI 10.1242/jcs.03458; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Lawo S, 2009, CURR BIOL, V19, P816, DOI 10.1016/j.cub.2009.04.033; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Morrison EE, 2001, EUR J CELL BIOL, V80, P749, DOI 10.1078/0171-9335-00221; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Oshimori N, 2006, NAT CELL BIOL, V8, P1095, DOI 10.1038/ncb1474; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Roh M, 2003, CANCER RES, V63, P8079; Shimizu H, 2009, J CELL SCI, V122, P3145, DOI 10.1242/jcs.052795; Sonn S, 2009, MOL REPROD DEV, V76, P587, DOI 10.1002/mrd.20990; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tang CJC, 2009, NAT CELL BIOL, V11, P825, DOI 10.1038/ncb1889; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Zou CZ, 2005, J CELL BIOL, V171, P437, DOI 10.1083/jcb.200506185	32	29	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2649	2658		10.1038/onc.2010.37	http://dx.doi.org/10.1038/onc.2010.37			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190801				2022-12-28	WOS:000277354600005
J	Li, Z; Zhang, Q; Mao, JH; Weise, A; Mrasek, K; Fan, X; Zhang, X; Liehr, T; Lu, KH; Balmain, A; Cai, WW				Li, Z.; Zhang, Q.; Mao, J-H; Weise, A.; Mrasek, K.; Fan, X.; Zhang, X.; Liehr, T.; Lu, K. H.; Balmain, A.; Cai, W-W			An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis	ONCOGENE			English	Article						radiation; p21; acetylation; carcinogenesis	HISTONE-DEACETYLASE INHIBITORS; FRAGILE SITE FRA16D; REPEAT INSTABILITY; IONIZING-RADIATION; BREAST-CANCER; DEGRADATION; EXPRESSION; COMMON; ATM; P53	There is a gap between the initial formation of cells carrying radiation-induced genetic damage and their contribution to cancer development. Herein, we reveal a previously uncharacterized gene FATS through a genome-wide approach and demonstrate its essential role in regulating the abundance of p21 in surveillance of genome integrity. A large exon coding the NH2-terminal domain of FATS, deleted in spontaneous mouse lymphomas, is much more frequently deleted in radiation-induced mouse lymphomas. Its human counterpart is a fragile site gene at a previously identified loss of heterozygosity site. FATS is essential for maintaining steady-state level of p21 protein and sustaining DNA damage checkpoint. Furthermore, the NH2-terminal FATS physically interacts with histone deacetylase 1 (HDAC1) to enhance the acetylation of endogenous p21, leading to the stabilization of p21. Our results reveal a molecular linkage between p21 abundance and radiation-induced carcinogenesis. Oncogene (2010) 29, 2659-2671; doi:10.1038/onc.2010.19; published online 15 February 2010	[Li, Z.; Fan, X.; Zhang, X.; Liehr, T.] Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Key Lab,Minist Educ Breast Canc Prevent & Treatme, Tianjin 300030, Peoples R China; [Zhang, Q.; Lu, K. H.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; [Mao, J-H; Balmain, A.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; [Weise, A.; Mrasek, K.; Liehr, T.] Inst Human Genet & Anthropol, Jena, Germany; [Cai, W-W] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Tianjin Medical University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; Baylor College of Medicine	Li, Z (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Key Lab,Minist Educ Breast Canc Prevent & Treatme, Huan Hu Xi Rd, Tianjin 300030, Peoples R China.	zhengli@tijmu.edu.cn	Liehr, Thomas/H-2852-2019; Weise, Anja/H-6669-2019; Mao, Jian-Hua/EIZ-8595-2022	Liehr, Thomas/0000-0003-1672-3054; Weise, Anja/0000-0003-3988-8919; Mao, Jian-Hua/0000-0001-9320-6021	Tianjin Medical University Cancer Institute and Hospital [08Y01]; Ministry of Science and Technology of China 973 [2009CB526407]; Tianjin Municipal Science and Technology Foundation; Department of defense of United States [FG02-03ER63630]; IZKF Jena Start-up S16	Tianjin Medical University Cancer Institute and Hospital; Ministry of Science and Technology of China 973(Ministry of Science and Technology, ChinaNational Basic Research Program of China); Tianjin Municipal Science and Technology Foundation; Department of defense of United States(United States Department of Defense); IZKF Jena Start-up S16	We are grateful to Mien-Chi Hung for critical discussions. We thank Xiangwei He and Qi Gao for assistance in microscopic imaging; Tao Jiang and Qian Li for technical assistance. This study was supported in part by the following grants: Tianjin Medical University Cancer Institute and Hospital Start-up 08Y01 (to Z Li); Ministry of Science and Technology of China 973-program Concept Award 2009CB526407 (to Z Li); Tianjin Municipal Science and Technology Foundation ( to Z Li); Department of defense of United States FG02-03ER63630 (to A Balmain); IZKF Jena Start-up S16 (to T Liehr).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bichara M, 2006, MUTAT RES-FUND MOL M, V598, P144, DOI 10.1016/j.mrfmmm.2006.01.020; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cen B, 2008, CANCER RES, V68, P5355, DOI 10.1158/0008-5472.CAN-07-6869; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Efeyan A, 2007, ONCOGENE, V26, P1645, DOI 10.1038/sj.onc.1209972; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; HOLM LE, 1990, INT J RADIAT ONCOL, V19, P1303, DOI 10.1016/0360-3016(90)90249-J; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li Z, 2004, CANCER RES, V64, P9080, DOI 10.1158/0008-5472.CAN-04-2419; Liehr Thomas, 2002, Expert Rev Mol Diagn, V2, P217, DOI 10.1586/14737159.2.3.217; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Magrath IT, 1997, ANN ONCOL, V8, P7, DOI 10.1023/A:1008225127815; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mao JH, 2005, ONCOGENE, V24, P7924, DOI 10.1038/sj.onc.1208926; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Nagase S, 1997, CANCER RES, V57, P1630; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Schellong G, 1998, ANN ONCOL, V9, P115, DOI 10.1023/A:1008482728545; Schwartz M, 2006, CANCER LETT, V232, P13, DOI 10.1016/j.canlet.2005.07.039; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Wei Q, 2003, MOL CELL BIOL, V23, P4035, DOI 10.1128/MCB.23.12.4035-4045.2003; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Zhang H, 2007, MOL CELL, V27, P367, DOI 10.1016/j.molcel.2007.06.012; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06	58	16	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2659	2671		10.1038/onc.2010.19	http://dx.doi.org/10.1038/onc.2010.19			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154723				2022-12-28	WOS:000277354600006
J	Ndisang, D; Khan, A; Lorenzato, F; Sindos, M; Singer, A; Latchman, DS				Ndisang, D.; Khan, A.; Lorenzato, F.; Sindos, M.; Singer, A.; Latchman, D. S.			The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix	ONCOGENE			English	Article						Brn-3a cellular transactivator; nicotine; environmental smoking-related substance; HPV variants; cervical intraepithelial neoplasia	HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION; CANCER CELLS; FACTOR PLAYS; NONSMOKERS; PROMOTER; SMOKERS; GROWTH; SMEARS	The cellular transcription factor Brn-3a differentially regulates different human papilloma virus (HPV)-16 variants that are associated with different risks of progression to cervical carcinoma in infected humans. The upstream regulatory regions (URRs) of high- and intermediate-risk HPV-16 variants are activated by the cellular transcription factor Brn-3a, whereas the URR of a low-risk HPV-16 variant is not. In this study, we show in transfection assays that Brn-3a and the smoking-related substance nicotine produce stronger responsiveness of the URR of the low- and high-risk variants than with either factor alone, but not the intermediate-risk variant. We determined that this synergistic activity of Brn-3a/nicotine is due to two nucleotide differences in the URR, crucial for oncogenic E6/E7 transactivation. Mutant constructs in which the nucleotide residues were substituted alter Brn-3a/nicotine responsiveness. Importantly, women smokers with high levels of Brn-3a infected with low- or high-risk HPV-16 variants have augmented E6 levels, and were more frequently diagnosed with higher grades of cervical intraepithelial neoplasia (CIN) and cancer, as compared with non-smokers who were infected with similar variants and expressed similar levels of Brn-3a. Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not. Oncogene (2010) 29, 2701-2711; doi:10.1038/onc.2010.33; published online 1 March 2010	[Ndisang, D.; Khan, A.; Sindos, M.; Latchman, D. S.] UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; [Lorenzato, F.] Whittington Hosp, Dept Womens & Childrens Hlth, London N19 5NF, England; [Latchman, D. S.] Univ London, London, England	University of London; University College London; University of London; University College London; University of London	Ndisang, D (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St,Guilford St, London WC1N 1EH, England.	d.ndisang@ich.ucl.ac.uk			Association for International Cancer Research (AICR)	Association for International Cancer Research (AICR)	This study was funded by the Association for International Cancer Research (AICR).	ANTHONY SG, 2006, CANCER EPIDEM BIOMAR, V15, P2141; Bible JM, 2000, J GEN VIROL, V81, P1517, DOI 10.1099/0022-1317-81-6-1517; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGHARDT E, 1991, CANCER-AM CANCER SOC, V67, P1037, DOI 10.1002/1097-0142(19910215)67:4<1037::AID-CNCR2820670429>3.0.CO;2-2; COX MF, 1986, LANCET, V2, P157; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103; Dasgupta P, 2006, J CLIN INVEST, V116, P2208, DOI 10.1172/JCI28164; Harkness PC, 2002, J NEUROSCI, V22, P10172; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; Lane D, 2005, AM J REPROD IMMUNOL, V53, P153, DOI 10.1111/j.1600-0897.2005.00259.x; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; Miller AB, 2001, LANCET, V357, P1816, DOI 10.1016/S0140-6736(00)05008-X; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MORRIS PJ, 1993, NUCLEIC ACIDS RES, V21, P1019, DOI 10.1093/nar/21.4.1019; Ndisang D, 2006, ONCOGENE, V25, P51, DOI 10.1038/sj.onc.1209006; Ndisang D, 2006, GYNECOL ONCOL, V100, P89, DOI 10.1016/j.ygyno.2005.07.109; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisang D, 2001, ONCOGENE, V20, P4899, DOI 10.1038/sj.onc.1204634; Prokopczyk B, 1997, J NATL CANCER I, V89, P868, DOI 10.1093/jnci/89.12.868; Sindos M, 2003, GYNECOL ONCOL, V90, P366, DOI 10.1016/S0090-8258(03)00261-0; Sindos M, 2003, INT J GYNECOL CANCER, V13, P515, DOI 10.1046/j.1525-1438.2003.13303.x; Tsai HT, 2007, GYNECOL ONCOL, V105, P181, DOI 10.1016/j.ygyno.2006.11.012; zur Hausen H, 2009, VIROLOGY, V392, P1, DOI 10.1016/j.virol.2009.06.001	27	5	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2701	2711		10.1038/onc.2010.33	http://dx.doi.org/10.1038/onc.2010.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190800				2022-12-28	WOS:000277354600010
J	Morris, MR; Ricketts, C; Gentle, D; Abdulrahman, M; Clarke, N; Brown, M; Kishida, T; Yao, M; Latif, F; Maher, ER				Morris, M. R.; Ricketts, C.; Gentle, D.; Abdulrahman, M.; Clarke, N.; Brown, M.; Kishida, T.; Yao, M.; Latif, F.; Maher, E. R.			Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; methylation; epigenetics	HIPPEL-LINDAU-DISEASE; CLEAR-CELL; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; TARGET GENES; EPIGENETIC INACTIVATION; BASEMENT-MEMBRANE; DNA METHYLATION; POOR-PROGNOSIS; MULTIPLE GENES	Promoter region hyermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many types of human cancers. Functional epigenetic studies, in which gene expression is induced by treatment with demethylating agents, may identify novel genes with tumour-specific methylation. We used high-density gene expression microarrays in a functional epigenetic study of 11 renal cell carcinoma (RCC) cell lines. Twenty-eight genes were then selected for analysis of promoter methylation status in cell lines and primary RCC. Eight genes (BNC1, PDLIM4, RPRM, CST6, SFRP1, GREM1, COL14A1 and COL15A1) showed frequent (>30% of RCC tested) tumour-specific promoter region methylation. Hypermethylation was associated with transcriptional silencing. Re-expression of BNC1, CST6, RPRM and SFRP1 suppressed the growth of RCC cell lines and RNA interference knock-down of BNC1, SFRP1 and COL14A1 increased the growth of RCC cell lines. Methylation of BNC1 or COL14A1 was associated with a poorer prognosis independent of tumour size, stage or grade. The identification of these epigenetically inactivated candidate RCC TSGs can provide insights into renal tumourigenesis and a basis for developing novel therapies and biomarkers for prognosis and detection. Oncogene (2010) 29, 2104-2117; doi: 10.1038/onc.2009.493; published online 15 February 2010	[Morris, M. R.; Ricketts, C.; Gentle, D.; Abdulrahman, M.; Latif, F.; Maher, E. R.] Univ Birmingham, Dept Med & Mol Genet, Inst Biomedi Res W, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Morris, M. R.; Ricketts, C.; Gentle, D.; Latif, F.; Maher, E. R.] Univ Birmingham, Canc Res UK Renal Mol Oncol Grp, Birmingham B15 2TT, W Midlands, England; [Clarke, N.; Brown, M.] Univ Manchester, Genito Urinary Canc Res Grp, Paterson Inst Canc Res, Manchester, Lancs, England; [Kishida, T.; Yao, M.] Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan; [Maher, E. R.] Birmingham Womens Hosp, W Midlands Reg Gent Serv, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; Paterson Institute for Cancer Research; University of Manchester; Yokohama City University; Birmingham Women's Hospital	Maher, ER (corresponding author), Univ Birmingham, Dept Med & Mol Genet, Inst Biomedi Res W, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	MAHER, EAMONN R/A-9507-2008; Brown, Mick/A-1308-2012; Brown, Mick D/N-6521-2015; Morris, Mark/C-6413-2008; Ricketts, Christopher/AAV-9580-2020	MAHER, EAMONN R/0000-0002-6226-6918; Brown, Mick D/0000-0003-1322-4671; Morris, Mark/0000-0002-0700-355X; Clarke, Noel/0000-0001-7776-8059; Abdulrahman, Mahera/0000-0001-6271-3776	Cancer Research UK; MRC [G0900871] Funding Source: UKRI; Medical Research Council [G0900871] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Cancer Research UK for financial support.	Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Amenta PS, 2005, J HISTOCHEM CYTOCHEM, V53, P165, DOI 10.1369/jhc.4A6376.2005; Awakura Y, 2008, ONCOL REP, V20, P1257, DOI 10.3892/or_00000138; Battagli C, 2003, CANCER RES, V63, P8695; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Boumber YA, 2007, CANCER RES, V67, P1997, DOI 10.1158/0008-5472.CAN-06-3093; Brandan E, 2006, J BIOL CHEM, V281, P31562, DOI 10.1074/jbc.M602919200; Breault JE, 2005, CLIN CANCER RES, V11, P557; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Chowdhury S, 2008, EUR J CANCER, V44, P2152, DOI 10.1016/j.ejca.2008.06.028; Christoph F, 2006, CLIN CANCER RES, V12, P5040, DOI 10.1158/1078-0432.CCR-06-0144; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Costa VL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-133; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Ehnis T, 1997, J BIOL CHEM, V272, P20414, DOI 10.1074/jbc.272.33.20414; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gonzalgo ML, 2004, CLIN CANCER RES, V10, P7276, DOI 10.1158/1078-0432.CCR-03-0692; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Harris A, 2007, MOL CANCER RES, V5, P1241, DOI 10.1158/1541-7786.MCR-07-0200; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mancini V, 2008, UROL ONCOL-SEMIN ORI, V26, P225, DOI 10.1016/j.urolonc.2007.05.017; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Morrissey C, 2001, CANCER RES, V61, P7277; Nomoto S, 2007, BRIT J CANCER, V97, P1260, DOI 10.1038/sj.bjc.6604016; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2006, CANCER-AM CANCER SOC, V107, P251, DOI 10.1002/cncr.21977; Schaefer L, 2007, AM J PATHOL, V170, P301, DOI 10.2353/ajpath.2007.060497; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340; Smits KM, 2008, CLIN CANCER RES, V14, P782, DOI 10.1158/1078-0432.CCR-07-1753; Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837; Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910; Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194; Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198; Wistuba II, 2007, CURR MOL MED, V7, P3, DOI 10.2174/156652407779940468; Yamada D, 2006, INT J CANCER, V118, P916, DOI 10.1002/ijc.21450; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	57	120	128	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2104	2117		10.1038/onc.2009.493	http://dx.doi.org/10.1038/onc.2009.493			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20154727	Green Accepted, Green Submitted, Green Published			2022-12-28	WOS:000276402800009
J	Munro, S; Khaire, N; Inche, A; Carr, S; La Thangue, NB				Munro, S.; Khaire, N.; Inche, A.; Carr, S.; La Thangue, N. B.			Lysine methylation regulates the pRb tumour suppressor protein	ONCOGENE			English	Article						tumour suppressor; pRb; lysine methylation; Set7/9; HP1	RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR; HISTONE METHYLATION; MUSCLE-CELLS; IN-VIVO; DIFFERENTIATION; E2F; ACETYLATION; BINDING	The pRb tumour suppressor protein has a central role in coordinating early cell cycle progression. An important level of control imposed on pRb occurs through post-translational modi. cation, for example, phosphorylation. We describe here a new level of regulation on pRb, mediated through the targeted methylation of lysine residues, by the methyltransferase Set7/9. Set7/9 methylates the C-terminal region of pRb, both in vitro and in cells, and methylated pRb interacts with heterochromatin protein HP1. pRb methylation is required for pRb-dependent cell cycle arrest and transcriptional repression, as well as pRb-dependent differentiation. Our results indicate that methylation can influence the properties of pRb, and raise the interesting possibility that methylation modulates pRb tumour suppressor activity. Oncogene (2010) 29, 2357-2367; doi:10.1038/onc.2009.511; published online 8 February 2010	[Munro, S.; Khaire, N.; Inche, A.; Carr, S.; La Thangue, N. B.] Univ Oxford, Canc Biol Lab, Dept Clin Pharmacol, Div Med Sci, Oxford OX3 7DQ, England	University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Canc Biol Lab, Dept Clin Pharmacol, Div Med Sci, Old Rd Campus Res Bldg,Old Rd Campus, Oxford OX3 7DQ, England.	Nick.LaThangue@clinpharm.ox.ac.uk			CRUK; EU; LRF; MRC; AICR; MRC [G9400953, G0500905] Funding Source: UKRI; Medical Research Council [G0500905, G9400953] Funding Source: researchfish	CRUK(Cancer Research UK); EU(European Commission); LRF; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the CRUK, EU, LRF, MRC and AICR for supporting this work and R Williams for assistance in preparing the paper.	BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kinkade R, 2008, CANCER RES, V68, P3810, DOI 10.1158/0008-5472.CAN-07-6672; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; LEE SW, 1992, BIOCHIM BIOPHYS ACTA, V1135, P115, DOI 10.1016/0167-4889(92)90126-V; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 2000, CANCER RES, V60, P3689; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Vandromme M, 2008, MOL CANCER RES, V6, P418, DOI 10.1158/1541-7786.MCR-07-0381; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Xiao B, 2003, CURR OPIN STRUC BIOL, V13, P699, DOI 10.1016/j.sbi.2003.10.003; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	46	82	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2357	2367		10.1038/onc.2009.511	http://dx.doi.org/10.1038/onc.2009.511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20140018				2022-12-28	WOS:000276951500005
J	Wang, M; Wang, M; Yuan, L; Wu, D; Zhang, Z; Yin, C; Fu, G; Wei, Q; Zhang, Z				Wang, M.; Wang, M.; Yuan, L.; Wu, D.; Zhang, Z.; Yin, C.; Fu, G.; Wei, Q.; Zhang, Z.			A novel XPF-357A > C polymorphism predicts risk and recurrence of bladder cancer	ONCOGENE			English	Article						genetic variation; XPF; bladder cancer; recurrence; molecular epidemiology	EXCISION-REPAIR GENES; DNA-REPAIR; MDM2 PROMOTER; LUNG-CANCER; SUSCEPTIBILITY; PROTEIN; ERCC4; MELANOMA; PATHWAY	Xeroderma pigmentosum group F (XPF) has an essential role in the nucleotide excision repair pathway that removes a wide variety of DNA lesions. We hypothesized that genetic variants in XPF are associated with bladder cancer risk and recurrence. We selected three tagging single nucleotide polymorphisms (tagSNPs) from the HapMap database for the Chinese and genotyped them in a two-stage case-control study to evaluate the association and further examined the functionality of a novel polymorphism in the promoter. The two-stage analysis found that the rs744154 tagSNP in the XPF intron 1, which was linkage disequilibrium with the -357A > C polymorphism in the promoter region, was associated with a protective effect on bladder cancer risk. Electrophoretic mobility shift assay (EMSA) further revealed that the -357C allele decreased the binding ability of transcriptional factors to the XPF promoter. The vector construct containing the -357C allele had a lower luciferase expression than did the -357A allele. The -357C allele in the transcription factor-binding site was also associated with decreased expression levels of both XPF mRNA and protein in bladder cancer tissues. Furthermore, patients with the -357C allele had a shorter overall recurrence-free survival than did patients with the -357A allele. Our results suggest that the XPF promoter -357A > C polymorphism may regulate the expression of XPF and thereby contribute to susceptibility to and prognosis of bladder cancer. Further larger studies with different populations are warranted to confirm these findings. Oncogene (2010) 29, 1920-1928; doi:10.1038/onc.2009.484; published online 11 January 2010	[Wang, M.; Wang, M.; Yuan, L.; Wu, D.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Mol Toxicol, Nanjing 210029, Peoples R China; [Wang, M.; Wang, M.; Yuan, L.; Wu, D.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Genet Toxicol, Nanjing 210029, Peoples R China; [Zhang, Z.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Epidemiol, Nanjing 210029, Peoples R China; [Zhang, Z.; Zhang, Z.] Nanjing Med Univ, Ctr Canc, Dept Biostat, Nanjing 210029, Peoples R China; [Yin, C.] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing 210029, Peoples R China; [Fu, G.] Nanjing Med Univ, Huai An Affiliated Hosp 1, Dept Urol, Huaian, Peoples R China; [Wei, Q.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, Z (corresponding author), Nanjing Med Univ, Dept Mol & Genet Toxicol, Sch Publ Hlth, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.	drzdzhang@gmail.com			National Natural Science Foundation of China [30872084, 30800926, 30972444]; Key Program for Basic Research of Jiangsu Provincial Department of Education [08KJA330001]; 'Qinglan Project' Foundation for the Young Academic Leader of Jiangsu Province; Jiangsu Provincial Graduates Innovative Project [CX08B-183Z]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program for Basic Research of Jiangsu Provincial Department of Education; 'Qinglan Project' Foundation for the Young Academic Leader of Jiangsu Province; Jiangsu Provincial Graduates Innovative Project	This study was partly supported by the National Natural Science Foundation of China (30872084, 30800926 and 30972444), the Key Program for Basic Research of Jiangsu Provincial Department of Education (08KJA330001), 'Qinglan Project' Foundation for the Young Academic Leader of Jiangsu Province (Z Zhang), and Jiangsu Provincial Graduates Innovative Project (CX08B-183Z).	An J, 2007, CANCER EPIDEM BIOMAR, V16, P1633, DOI 10.1158/1055-9965.EPI-07-0252; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; COHEN SM, 1992, UROL CLIN N AM, V19, P421; Cohen SM, 2000, SCAND J UROL NEPHROL, V34, P105, DOI 10.1080/00365590050509869; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x; Garcia-Closas M, 2006, CANCER EPIDEM BIOMAR, V15, P536, DOI 10.1158/1055-9965.EPI-05-0749; Gu J, 2005, CLIN CANCER RES, V11, P1408, DOI 10.1158/1078-0432.CCR-04-1101; Han JL, 2009, BREAST CANCER RES TR, V115, P613, DOI 10.1007/s10549-008-0089-z; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Kim WJ, 2008, CANCER SCI, V99, P646, DOI 10.1111/j.1349-7006.2008.00735.x; Kornguth DG, 2005, INT J RADIAT ONCOL, V62, P665, DOI 10.1016/j.ijrobp.2004.11.026; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Laser H, 2000, P NATL ACAD SCI USA, V97, P13732, DOI 10.1073/pnas.250400997; Lee OKE, 2005, WORLDV EVID-BASED NU, V2, P4, DOI 10.1111/j.1524-475X.2005.04085.x; McWilliams RR, 2008, CANCER RES, V68, P4928, DOI 10.1158/0008-5472.CAN-07-5539; Milne RL, 2006, CANCER RES, V66, P9420, DOI 10.1158/0008-5472.CAN-06-1418; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009; Shaoa MH, 2008, LUNG CANCER, V60, P332, DOI 10.1016/j.lungcan.2007.10.023; Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Smith TR, 2003, CANCER EPIDEM BIOMAR, V12, P1200; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Sun T, 2007, NAT GENET, V39, P605, DOI 10.1038/ng2030; Theodorescu D, 2003, HISTOL HISTOPATHOL, V18, P259, DOI 10.14670/HH-18.259; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Tsodikov OV, 2005, P NATL ACAD SCI USA, V102, P11236, DOI 10.1073/pnas.0504341102; Wang ML, 2008, CLIN CANCER RES, V14, P3633, DOI 10.1158/1078-0432.CCR-07-5155; WATANABE F, 1994, BBA-MOL CELL RES, V1223, P255, DOI 10.1016/0167-4889(94)90234-8; Winsey SL, 2000, CANCER RES, V60, P5612; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154	38	32	35	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1920	1928		10.1038/onc.2009.484	http://dx.doi.org/10.1038/onc.2009.484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062074				2022-12-28	WOS:000276199600005
J	Wu, S; Huang, S; Ding, J; Zhao, Y; Liang, L; Liu, T; Zhan, R; He, X				Wu, S.; Huang, S.; Ding, J.; Zhao, Y.; Liang, L.; Liu, T.; Zhan, R.; He, X.			Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3 ' untranslated region	ONCOGENE			English	Article						miRNA; p21Cip1/Waf1; 3 ' untranslated region	P21; INHIBITOR; MECHANISM; KINASES; CANCER; GENES	Cyclin-dependent kinase inhibitor 1A ( CDKN1A), also known as p21Cip1/Waf1, is a master downstream effector of tumor suppressors.In this study, we experimentally demonstrate through a high-throughput luciferase reporter screen that p21Cip1/Waf1 can be directly targeted by nearly 28 microRNAs ( miRNAs). The results were further confirmed by a series of mutational analyses and luciferase reporter assays. These 28 miRNAs can substantially inhibit p21Cip1/Waf1 expression, predominantly at translational level. Many of these miRNAs were upregulated in cancers and might serve as modulators of oncogenesis. Furthermore, 8 of these 28 p21-regulating miRNAs are located in the chromosome 19 miRNA cluster, the largest miRNA gene cluster in humans, and they can clearly promote cell proliferation and cell-cycle progression in choriocarcinoma cells. In conclusion, our screening strategy provides an alternative approach to uncovering miRNA modulators of an individual mRNA, and it has identified multiple miRNAs that can suppress p21Cip1/Waf1 expression by directly targeting its 30 untranslated region. Oncogene (2010) 29, 2302-2308; doi: 10.1038/onc.2010.34; published online 1 March 2010	[Wu, S.; Huang, S.; Ding, J.; Zhao, Y.; Liang, L.; He, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China; [Wu, S.; Zhan, R.] Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Dept Hematol, Fuzhou 350001, Peoples R China; [Liu, T.] Shanghai Jiao Tong Univ, Sch Med, Int Peace Matern & Child Hlth Hosp, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University; Fujian Medical University; Shanghai Jiao Tong University	He, X (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, 25 Ln 2200,Xie Tu Rd, Shanghai 200032, Peoples R China.	deanzhanrong@yahoo.com.cn; xhhe@shsci.org	liang, linhui/AAW-4176-2021; He, Xianghuo/I-1497-2014; Huang, Shenglin/N-9472-2018	He, Xianghuo/0000-0001-8872-668X; Huang, Shenglin/0000-0003-1279-0794	Science & Technology Commission of Shanghai Municipality [07DJ14006]; Ministry of Health of China [2008ZX10002-017]; Ministry of Human Resources and Social Security of China [2007-170]; Doctoral Program of Higher Education of China [200802480076]	Science & Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Ministry of Health of China; Ministry of Human Resources and Social Security of China; Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	We are most grateful for Dr T Didier's gifts of the pWPXL, psPAX2 and pMD2. G lentivirus plasmids. This work was supported by grants from the Science & Technology Commission of Shanghai Municipality (07DJ14006), the Ministry of Health of China (2008ZX10002-017), the Ministry of Human Resources and Social Security of China (2007-170) and the Doctoral Program of Higher Education of China (200802480076).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bortolin-Cavaille ML, 2009, NUCLEIC ACIDS RES, V37, P3464, DOI 10.1093/nar/gkp205; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; HARPER JW, 1993, CELL, V75, P805; Hausser J, 2009, NUCLEIC ACIDS RES, V37, pW266, DOI 10.1093/nar/gkp412; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lionetti M, 2009, BLOOD, V114, pE20, DOI 10.1182/blood-2009-08-237495; Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	23	288	303	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2302	2308		10.1038/onc.2010.34	http://dx.doi.org/10.1038/onc.2010.34			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20190813				2022-12-28	WOS:000276685200015
J	Sirvent, A; Benistant, C; Pannequin, J; Veracini, L; Simon, V; Bourgaux, JF; Hollande, F; Cruzalegui, F; Roche, S				Sirvent, A.; Benistant, C.; Pannequin, J.; Veracini, L.; Simon, V.; Bourgaux, J-F; Hollande, F.; Cruzalegui, F.; Roche, S.			Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization	ONCOGENE			English	Article						tyrosine kinase Src; oncogenic signalling; colorectal cancer; invasion; Csk	ADAPTER PROTEIN; DOWN-REGULATION; BREAST-CANCER; ENRICHED MICRODOMAINS; C-SRC; GROWTH; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; ASSOCIATION	The nonreceptor tyrosine kinases of the Src family (SFK) are frequently deregulated in human colorectal cancer (CRC), and they have been implicated in tumour growth and metastasis. How SFK are activated in this cancer has not been clearly established. Here, we show that the SFK-dependent invasion is induced by inactivation of the negative regulator C-terminal Src kinase, Csk. While the level of Csk was inconsistent with SFK activity in colon cancer cells, its membrane translocation, needed for efficient regulation of membrane-localized SFK activity, was impaired. Accordingly, Csk downregulation did not affect SFK oncogenic activity in these cells, whereas expression of a membrane-localized form of this kinase affected their invasive activity. Downregulation of the transmembrane and rafts-localized Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain (PAG), was instrumental for the cytoplasmic accumulation of Csk. Re-expression of PAG in cells from late-stage CRC inhibited SFK invasive activity in a Csk-dependent manner. Conversely, inactivation of its residual expression in early-stage CRC cells promoted SFK invasive activity. Finally, this mechanism was specific to CRC as Csk coupling to SFK was readily detected in breast cancer cells. Therefore, Csk mis-localization defines a novel mechanism for SFK oncogenic activation in CRC cells. Oncogene (2010) 29, 1303-1315; doi:10.1038/onc.2009.450; published online 14 December 2009	[Sirvent, A.; Benistant, C.; Veracini, L.; Simon, V.; Roche, S.] Univ Montpellier I, CNRS, CRBM, UMR5237,Equipe Labellisee Ligue Natl Canc, F-34293 Montpellier 05, France; [Pannequin, J.; Hollande, F.] Univ Montpellier 2, IGF, Montpellier, France; [Pannequin, J.; Hollande, F.] Univ Montpellier I, INSERM, U661, UMR5203, F-34293 Montpellier 05, France; [Bourgaux, J-F] CHU Caremeau, Serv Hepatogastroenterol, Nimes, France; [Cruzalegui, F.] Inst Rech Servier, Div Canc Res & Drug Discovery, Croissy Sur Seine, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Nimes; Servier; Institut de Recherches Internationales Servier	Roche, S (corresponding author), Univ Montpellier I, CNRS, CRBM, UMR5237,Equipe Labellisee Ligue Natl Canc, 1919 Route Mende, F-34293 Montpellier 05, France.	serge.roche@crbm.cnrs.fr	Benistant, Christine/M-5771-2018; Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022	Hollande, Frederic/0000-0002-7046-8392; pannequin, julie/0000-0002-9956-373X; roche, serge/0000-0003-3413-3859	Servier Laboratories; la Ligue Nationale Contre le Cancer; CNRS; University of Montpellier 1 and 2; l'Association pour la Recherche contre le Cancer (ARC); INCa;  [4025]	Servier Laboratories; la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); CNRS(Centre National de la Recherche Scientifique (CNRS)); University of Montpellier 1 and 2; l'Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); INCa(Institut National du Cancer (INCA) France); 	We thank M Okada, S Parsons, P Mangeat and N Morin for various reagents; C Naudin, G Collin and C Leroy for technical assistance; Sylvain De Rossi and Virginie Georget (Montpellier RIO Imaging platform) for confocal microscopy analysis; and J Hickmann for helpful discussion. This work was supported by Servier Laboratories, la Ligue Nationale Contre le Cancer, the CNRS, the University of Montpellier 1 and 2 and l'Association pour la Recherche contre le Cancer (ARC, n<SUP>o</SUP> 4025). AS was supported by Servier Laboratories and by the INCa. SR and CB are INSERM investigators.	Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Benistant C, 2001, CANCER RES, V61, P1415; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Causeret M, 2005, MOL BIOL CELL, V16, P2168, DOI 10.1091/mbc.E04-09-0829; Collin G, 2007, MOL CELL BIOL, V27, P7631, DOI 10.1128/MCB.00543-07; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; Kunte DP, 2005, FEBS LETT, V579, P3497, DOI 10.1016/j.febslet.2005.05.030; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Miyagi T, 2008, BBA-GEN SUBJECTS, V1780, P532, DOI 10.1016/j.bbagen.2007.09.016; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Nusrat A, 2000, J CELL SCI, V113, P1771; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Pannequin J, 2007, GASTROENTEROLOGY, V133, P1554, DOI 10.1053/j.gastro.2007.08.023; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Saito K, 2008, BIOCHEM BIOPH RES CO, V366, P969, DOI 10.1016/j.bbrc.2007.12.055; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Smida M, 2007, BLOOD, V110, P596, DOI 10.1182/blood-2006-07-038752; Solheim SA, 2008, J BIOL CHEM, V283, P2773, DOI 10.1074/jbc.M705215200; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Veracini L, 2008, J CELL BIOL, V182, P603, DOI 10.1083/jcb.200705102; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhao MM, 2006, MOL CELL BIOL, V26, P2479, DOI 10.1128/MCB.26.7.2479-2489.2006; Zheng X, 2008, INT J CANCER, V122, P1999, DOI 10.1002/ijc.23321; Zhu S, 2008, ONCOGENE, V27, P2027, DOI 10.1038/sj.onc.1210838; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	47	47	47	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1303	1315		10.1038/onc.2009.450	http://dx.doi.org/10.1038/onc.2009.450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20010872	Green Submitted			2022-12-28	WOS:000275170600006
J	Baert, JL; Monte, D; Verreman, K; Degerny, C; Coutte, L; Launoit, Y				Baert, J-L; Monte, D.; Verreman, K.; Degerny, C.; Coutte, L.; de Launoit, Y.			The E3 ubiquitin ligase complex component COP1 regulates PEA3 group member stability and transcriptional activity	ONCOGENE			English	Article						ETS; ERM; transcription factor; Ub-modification; COP1; DET1	PHOTOMORPHOGENESIS; IDENTIFICATION; DOMAIN; JUN	In this study, we report that the PEA3 group members interact with the mammalian really interesting new gene (RING) E3 ubiquitin ligase constitutive photomorphogenetic 1 (COP1), which mediates ubiquitylation and subsequent proteasome degradation of the p53 and c-Jun transcription factors. This interaction is mediated by the central region of COP1 including the coiled-coil domain and two COP1-interacting consensus motifs localized in the well-conserved N-terminal transactivation domain of the PEA3 group members. At the transcriptional level, COP1 reduces the transcriptional activity of ERM and the two other PEA3 group proteins on Ets-responsive reporter genes; this effect being dependent on the RING domain of COP1 and the two COP1-interacting motifs of ERM. Reduced transcriptional activity was, however, not related to COP1-induced changes in ERM stability. In fact, increased ubiquitylation and subsequent proteasome-mediated degradation of ERM is achieved only when COP1 is expressed with DET1, a key COP1 partner within the ubiquitylation complex. Conversely, we show that the depletion of COP1 or DET1 by small interference RNA (siRNA) in U2OS cells stabilizes endogenous ERM whereas only COP1 knockdown enhances expression of ICAM-1, a gene regulated by this transcription factor. These results indicate that COP1 is a complex regulator of ERM and the two other PEA3 group members. Oncogene (2010) 29, 1810-1820; doi:10.1038/onc.2009.471; published online 11 January 2010	[Baert, J-L] Univ Lille Nord France, Inst Biol, Inst Pasteur, CNRS,UMR 8161,IFR 142, F-59021 Lille, France; [Degerny, C.] Univ Paris 11, Inst Andre Lwoff, CNRS, FRE 2944, Villejuif, France; [Coutte, L.] Univ Paris 11, Fac Sci, Lab Biol Anim, Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Baert, JL (corresponding author), Univ Lille Nord France, Inst Biol, Inst Pasteur, CNRS,UMR 8161,IFR 142, BP 447,1 Rue Calmette, F-59021 Lille, France.	jean-luc.baert@ibl.fr; yvan.delaunoit@ibl.fr		de Launoit, Yvan/0000-0003-1837-9808; coutte, laurent/0000-0002-0031-4742; monte, didier/0000-0002-0613-6203	'Ligue Nationale Contre le Cancer' (Comite Nord, France); 'Association pour la Recherche contre le Cancer' (France); 'Conseil Regional Nord/Pas-de-Calais' (France); European Regional Development Fund	'Ligue Nationale Contre le Cancer' (Comite Nord, France); 'Association pour la Recherche contre le Cancer' (France)(Fondation ARC pour la Recherche sur le Cancer); 'Conseil Regional Nord/Pas-de-Calais' (France)(Region Hauts-de-France); European Regional Development Fund(European Commission)	This work was carried out thanks to grants awarded by the 'Ligue Nationale Contre le Cancer' (Comite Nord, France), the 'Association pour la Recherche contre le Cancer' (France), the 'Conseil Regional Nord/Pas-de-Calais' (France) and the European Regional Development Fund (Intergenes program). We thank E Bianchi and VM Dixit for kind gifts of plasmids.	Baert JL, 2007, ONCOGENE, V26, P415, DOI 10.1038/sj.onc.1209801; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Di Bacco A, 2006, CELL CYCLE, V5, P2310, DOI 10.4161/cc.5.20.3367; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gocke CB, 2005, J BIOL CHEM, V280, P5004, DOI 10.1074/jbc.M411718200; Holm M, 2001, EMBO J, V20, P118, DOI 10.1093/emboj/20.1.118; Kato S, 2008, J BIOL CHEM, V283, P35464, DOI 10.1074/jbc.M801011200; Liu Y, 2006, MOL CELL BIOL, V26, P3114, DOI 10.1128/MCB.26.8.3114-3123.2006; Sharrocks AD, 2006, GENE DEV, V20, P754, DOI 10.1101/gad.1421006; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007	20	35	35	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1810	1820		10.1038/onc.2009.471	http://dx.doi.org/10.1038/onc.2009.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062082	Green Published			2022-12-28	WOS:000276022800010
J	Dhillon, J; Astanehe, A; Lee, C; Fotovati, A; Hu, K; Dunn, SE				Dhillon, J.; Astanehe, A.; Lee, C.; Fotovati, A.; Hu, K.; Dunn, S. E.			The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44(+) cells	ONCOGENE			English	Article						YB-1; trastuzumab; resistance; CD44; tumor-initiating cells	GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; TUMOR-GROWTH; CHEMOTHERAPY; HER-2; YB-1; EFFICACY; RELAPSE; SAFETY	The development of acquired resistance to trastuzumab remains a prevalent challenge in the treatment of patients whose tumors express human epidermal growth factor 2 (HER2). We previously reported that HER2 overexpressing breast cancers are dependent on Y-box binding protein-1 (YB-1) for growth and survival. As YB-1 is also linked to drug resistance in other types of cancer, we address its possible role in trastuzumab insensitivity. Employing an in vivo model of acquired resistance, we demonstrate that resistant cell lines have elevated levels of P-YB-1(S102) and its activating kinase P-RSK and these levels are sustained following trastuzumab treatment. Further, to demonstrate the importance of YB-1 in mediating drug resistance, the expression of the active mutant YB-1(S102D) rendered the BT474 cell line insensitive to trastuzumab. Questioning the role of tumor-initiating cells (TIC) and their ability to escape cancer therapies, we investigate YB-1's role in inducing the cancer stem cell marker CD44. Notably, the resistant cells express more CD44 mRNA and protein compared with BT474 cells, which correlated with increased mammosphere formation. Expression of YB-1S102D in the BT474 cells increase CD44 protein levels, resulting in enhanced mammosphere formation. Further, exposing BT474 cells to trastuzumab selected for a resistant sub-population enriched for CD44. Conversely, small intefering RNA inhibition of CD44 restored trastuzumab sensitivity in the resistant cell lines. Our findings provide insight on a novel mechanism employed by tumor cells to acquire the ability to escape the effects of trastuzumab and suggest that targeting YB-1 may overcome resistance by eliminating the unresponsive TIC population, rendering the cancer sensitive to therapy. Oncogene (2010) 29, 6294-6300; doi:10.1038/onc.2010.365; published online 30 August 2010	[Dhillon, J.; Astanehe, A.; Lee, C.; Fotovati, A.; Hu, K.; Dunn, S. E.] Univ British Columbia, Dept Paediat, Child & Family Res Inst, Lab Oncogenom Res, Vancouver, BC V5Z 4H4, Canada; [Dhillon, J.; Astanehe, A.; Lee, C.; Dunn, S. E.] Expt Med Program, Dept Med, Vancouver, BC, Canada	Child & Family Research Institute; University of British Columbia	Dunn, SE (corresponding author), Univ British Columbia, Dept Paediat, Child & Family Res Inst, Lab Oncogenom Res, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca			Canadian Breast Cancer Research Alliance; National Cancer Institute of Canada; Child and Family Research Institute; Canadian Institute of Health Research; Michael Smith Foundation for Health Research	Canadian Breast Cancer Research Alliance; National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Child and Family Research Institute; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	We thank Spencer Freeman from the Life Sciences Centre, UBC for his assistance with confocal microscopy. This work was supported by the Canadian Breast Cancer Research Alliance and the National Cancer Institute of Canada (SED). JD was a recipient of the Child and Family Research Institute Graduate Studentship and AA was a recipient of Canadian Institute of Health Research MD/PhD and the Michael Smith Foundation for Health Research Studentships.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Gluz O, 2009, J CLIN ONCOL, V27, P6144, DOI 10.1200/JCO.2008.19.6261; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Marangoni E, 2009, BRIT J CANCER, V100, P918, DOI 10.1038/sj.bjc.6604953; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561	21	32	35	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	47					6294	6300		10.1038/onc.2010.365	http://dx.doi.org/10.1038/onc.2010.365			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802512				2022-12-28	WOS:000284601700010
J	Lizardi, PM				Lizardi, P. M.			As we bring demethylating drugs to the clinic, we better know the DICE being cast	ONCOGENE			English	Editorial Material							ELEMENTS; CELLS; TRANSCRIPTOME; PROMOTER		Yale Univ, Sch Med, Dept Pathol, Interdept Computat Biol & Bioinformat Program, New Haven, CT 06520 USA	Yale University	Lizardi, PM (corresponding author), Yale Univ, Sch Med, Dept Pathol, Interdept Computat Biol & Bioinformat Program, 310 Cedar St, New Haven, CT 06520 USA.	paul.lizardi@mac.com						Apostolou E, 2008, CELL, V134, P85, DOI 10.1016/j.cell.2008.05.052; Comfort NC, 2001, ENDEAVOUR, V25, P127, DOI 10.1016/S0160-9327(00)01370-3; Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Penzkofer T, 2005, NUCLEIC ACIDS RES, V33, pD498, DOI 10.1093/nar/gki044; Rangwala SH, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r100; Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866; Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Szpakowski S, 2009, GENE, V448, P151, DOI 10.1016/j.gene.2009.08.006; Weber B, 2010, ONCOGENE, V29, P5775, DOI 10.1038/onc.2010.227; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917	12	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5772	5774		10.1038/onc.2010.372	http://dx.doi.org/10.1038/onc.2010.372			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20729909				2022-12-28	WOS:000283586200002
J	Wimmer, P; Schreiner, S; Everett, RD; Sirma, H; Groitl, P; Dobner, T				Wimmer, P.; Schreiner, S.; Everett, R. D.; Sirma, H.; Groitl, P.; Dobner, T.			SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML	ONCOGENE			English	Article						HAdV5 E1B-55K; PML isoforms; SUMO	ACUTE PROMYELOCYTIC LEUKEMIA; E4 ORF3 PROTEIN; REGION-1B 55-KDA ONCOPROTEIN; ADENOVIRUS E4ORF6 PROTEIN; NUCLEAR-BODY FORMATION; SIMPLEX-VIRUS TYPE-1; TRANSFORMED-CELLS; RAR-ALPHA; PREMATURE SENESCENCE; DNA-DAMAGE	The E1B-55K product from human adenovirus is a substrate of the small ubiquitin-related modifier (SUMO)-conjugation system. SUMOylation of E1B-55K is required to transform primary mammalian cells in cooperation with adenovirus E1A and to repress p53 tumour suppressor functions. The biochemical consequences of SUMO1 conjugation of 55K have so far remained elusive. Here, we report that E1B-55K physically interacts with different isoforms of the tumour suppressor protein promyelocytic leukaemia (PML). We show that E1B-55K binds to PML isoforms IV and V in a SUMO1-dependent and -independent manner. Interaction with PML-IV promotes the localization of 55K to PML-containing subnuclear structures (PML-NBs). In virus-infected cells, this process is negatively regulated by other viral proteins, indicating that binding to PML is controlled through reversible SUMOylation in a timely coordinated manner. These results together with earlier work are consistent with the idea that SUMOylation regulates targeting of E1B-55K to PML-NBs, known to control transcriptional regulation, tumour suppression, DNA repair and apoptosis. Furthermore, they suggest that SUMO1-dependent modulation of p53-dependent growth suppression through E1B-55K PML-IV interaction has a key role in adenovirus-mediated cell transformation. Oncogene (2010) 29, 5511-5522; doi:10.1038/onc.2010.284; published online 19 July 2010	[Wimmer, P.; Schreiner, S.; Groitl, P.; Dobner, T.] Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, D-20251 Hamburg, Germany; [Sirma, H.] Univ Med Ctr, Inst Pathol, Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dobner, T (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de		Schreiner, Sabrina/0000-0002-5744-7159	Studienstiftung des Deutschen Volkes e.V., Bonn, Germany [41, 53175]; Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Deutsche Forschungsgemeinschaft (DFG); Stiftung fur neurovirale Erkrankungen; MRC [MC_U130169966] Funding Source: UKRI; Medical Research Council [MC_U130169966] Funding Source: researchfish	Studienstiftung des Deutschen Volkes e.V., Bonn, Germany; Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Stiftung fur neurovirale Erkrankungen; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	PW was supported by grants from the 'Studienstiftung des Deutschen Volkes e.V.', Ahrstrasse 41, 53175 Bonn, Germany. We thank Philippe Gripon for providing the described HepaRG cell line and Roel van Driel/Ineke van der Kraan for the 5E10 antibody. The Heinrich-Pette-Institute is supported by the 'Freie und Hansestadt Hamburg' and the 'Bundesministerium fur Gesundheit'. This work was supported by grants from the 'Deutsche Forschungsgemeinschaft (DFG)' and by the 'Stiftung fur neurovirale Erkrankungen' to HS.	ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2009, FRONT BIOSCI-LANDMRK, V14, P497, DOI 10.2741/3258; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cerec V, 2007, HEPATOLOGY, V45, P957, DOI 10.1002/hep.21536; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 2008, J VIROL, V82, P2661, DOI 10.1128/JVI.02308-07; Everett RD, 2007, BIOCHIMIE, V89, P819, DOI 10.1016/j.biochi.2007.01.004; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GODDARD AD, 1992, LEUKEMIA, V6, pS117; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Groitl Peter, 2007, Methods Mol Med, V130, P29; Guccione E, 2004, ONCOGENE, V23, P4662, DOI 10.1038/sj.onc.1207631; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hoppe A, 2006, J VIROL, V80, P3042, DOI 10.1128/JVI.80.6.3042-3049.2006; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Kindsmuller K, 2009, J VIROL, V83, P9045, DOI 10.1128/JVI.00728-09; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724; LEE K, 1995, SMALL SCALE PREPARAT; Leppard KN, 2009, J GEN VIROL, V90, P95, DOI 10.1099/vir.0.005512-0; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864; Lukashchuk V, 2010, J VIROL, V84, P4026, DOI 10.1128/JVI.02597-09; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Melnick A, 1999, LEUKEMIA, V13, P1534, DOI 10.1038/sj.leu.2401513; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Regad T, 2009, NAT NEUROSCI, V12, P132, DOI 10.1038/nn.2251; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2009, CELL DEATH DIFFER, V16, P1083, DOI 10.1038/cdd.2009.63; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schreck KC, 2009, NAT NEUROSCI, V12, P108, DOI 10.1038/nn0209-108; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Stracker TH, 2005, J VIROL, V79, P6664, DOI 10.1128/JVI.79.11.6664-6673.2005; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; STUURMAN N, 1992, J CELL SCI, V101, P773; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tavalai N, 2008, BBA-MOL CELL RES, V1783, P2207, DOI 10.1016/j.bbamcr.2008.08.004; Torok D, 2009, FRONT BIOSCI-LANDMRK, V14, P1325, DOI 10.2741/3311; Ullman AJ, 2008, J VIROL, V82, P7325, DOI 10.1128/JVI.00723-08; Ullman AJ, 2007, J VIROL, V81, P4744, DOI 10.1128/JVI.02385-06; Van Damme E, 2010, INT J BIOL SCI, V6, P51, DOI 10.7150/ijbs.6.51; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOUNGHUSBAND HB, 1985, CAN J BIOCHEM CELL B, V63, P654, DOI 10.1139/o85-083; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	93	39	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	40					5511	5522		10.1038/onc.2010.284	http://dx.doi.org/10.1038/onc.2010.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20639899				2022-12-28	WOS:000282945800008
J	Cantelmo, AR; Cammarota, R; Noonan, DM; Focaccetti, C; Comoglio, PM; Prat, M; Albini, A				Cantelmo, A. R.; Cammarota, R.; Noonan, D. M.; Focaccetti, C.; Comoglio, P. M.; Prat, M.; Albini, A.			Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth	ONCOGENE			English	Article						Met; cell-penetrating peptides; Antennapedia; Tat; angiogenesis; cancer	FACTOR SCATTER FACTOR; SMALL-MOLECULE INHIBITOR; FACTOR/SCATTER FACTOR; C-MET; PENETRATING PEPTIDES; IN-VIVO; TYROSINE KINASE; INVASIVE GROWTH; FACTOR-RECEPTOR; HGF RECEPTOR	Hepatocyte growth factor (HGF) and its receptor Met are responsible for a wide variety of cellular responses, both physiologically during embryo development and tissue homeostasis, and pathologically, particularly during tumor growth and dissemination. In cancer, Met can act as an oncogene on tumor cells, as well as a pro-angiogenic factor activating endothelial cells and inducing new vessel formation. Molecules interfering with Met activity could be valuable therapeutic agents. Here we have investigated the antiangiogenic properties of a synthetic peptide mimicking the docking site of the Met carboxyl-terminal tail, which was delivered into the cells by fusion with the internalization sequences from Antennapedia or HIV-Tat. We showed that these peptides inhibit ligand-dependent endothelial cell proliferation, motility, invasiveness and morphogenesis in vitro to an even greater extent and with much less toxicity than the Met inhibitor PHA-665752, which correlated with interference of HGF-dependent downstream signaling. In vivo, the peptides inhibited HGF-induced angiogenesis in the matrigel sponge assay and impaired xenograft tumor growth and vascularization in Kaposi's sarcoma. These data show that interference with the Met receptor intracellular sequence impairs HGF-induced angiogenesis, suggesting the use of antidocking site compounds as a therapeutic strategy to counteract angiogenesis in cancer as well as in other diseases. Oncogene (2010) 29, 5286-5298; doi:10.1038/onc.2010.267; published online 5 July 2010	[Cantelmo, A. R.; Cammarota, R.; Noonan, D. M.; Focaccetti, C.; Albini, A.] Casa Cura MultiMed IRCCS, I-20138 Milan, Italy; [Noonan, D. M.] Univ Insubria, Dept Expt Med, Varese, Italy; [Comoglio, P. M.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Candiolo, Italy; [Prat, M.] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy	IRCCS Multimedica; University of Insubria; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Eastern Piedmont Amedeo Avogadro	Albini, A (corresponding author), MultiMed Castellanza, Via Piemonte 70, I-21053 Castellanza, VA, Italy.	adriana.albini@multimedica.it	Noonan, Douglas M/A-8620-2010; Focaccetti, Chiara/AAD-9378-2019; Cantelmo, Anna Rita/G-6766-2018	Noonan, Douglas M/0000-0001-8058-0719; Focaccetti, Chiara/0000-0002-7334-3966; Cantelmo, Anna Rita/0000-0002-2748-264X; Comoglio, Paolo/0000-0002-7056-5328; Albini, Adriana/0000-0002-9624-5103	AIRC (Associazione Italiana per la Ricerca sul Cancro); ISS; Compagnia San Paolo; MIUR	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); ISS; Compagnia San Paolo(Compagnia di San Paolo); MIUR(Ministry of Education, Universities and Research (MIUR))	These studies were supported by AIRC (Associazione Italiana per la Ricerca sul Cancro), ISS, Compagnia San Paolo and the MIUR. We thank Drs Monica Morini and Raffaella Dell'Eva (Istituto Nazionale per la Ricerca sul Cancro, Genova) for preliminary observations. We are indebted to Dr Paola Corradino (CBA, Genova) for literature searches and Alessandra Panvini-Rosati (Multimedica, Milan) for assistance. ARC is a PhD student at the Department of Structural and Functional Biology, Via Dunant 5, Varese, CF is a MIUR 'Grande Progetto Strategico' fellow.	Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; Albini A, 2001, CANCER RES, V61, P8171; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli C, 2005, BIOCHEM BIOPH RES CO, V334, P1172, DOI 10.1016/j.bbrc.2005.07.020; Berthou S, 2004, ONCOGENE, V23, P5387, DOI 10.1038/sj.onc.1207691; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Cao RH, 2006, BLOOD, V107, P3531, DOI 10.1182/blood-2005-06-2538; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Christensen JG, 2003, CANCER RES, V63, P7345; Chu SH, 2009, J NEURO-ONCOL, V93, P183, DOI 10.1007/s11060-008-9772-5; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Dong G, 2001, CANCER RES, V61, P5911; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Foged C, 2008, EXPERT OPIN DRUG DEL, V5, P105, DOI 10.1517/17425247.5.1.105; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Gherardi E, 2006, P NATL ACAD SCI USA, V103, P4046, DOI 10.1073/pnas.0509040103; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Jun HT, 2007, CLIN CANCER RES, V13, P6735, DOI 10.1158/1078-0432.CCR-06-2969; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007; LONGATI P, 1994, ONCOGENE, V9, P49; Lou XQ, 2009, MOL CANCER THER, V8, P1126, DOI 10.1158/1535-7163.MCT-08-0904; Matsumoto K, 2003, CANCER SCI, V94, P321, DOI 10.1111/j.1349-7006.2003.tb01440.x; Mazzone M, 2004, J CLIN INVEST, V114, P1418, DOI 10.1172/JCI200422235; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Paranjpe S, 2007, HEPATOLOGY, V45, P1471, DOI 10.1002/hep.21570; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Prat M, 1998, J CELL SCI, V111, P237; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sengupta S, 2003, ARTERIOSCL THROM VAS, V23, P69, DOI 10.1161/01.ATV.0000048701.86621.D0; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; You WK, 2008, BMB REP, V41, P833, DOI 10.5483/BMBRep.2008.41.12.833; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	69	16	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5286	5298		10.1038/onc.2010.267	http://dx.doi.org/10.1038/onc.2010.267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20603611	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000282089100007
J	Liu, W; Zabirnyk, O; Wang, H; Shiao, YH; Nickerson, ML; Khalil, S; Anderson, LM; Perantoni, AO; Phang, JM				Liu, W.; Zabirnyk, O.; Wang, H.; Shiao, Y-H; Nickerson, M. L.; Khalil, S.; Anderson, L. M.; Perantoni, A. O.; Phang, J. M.			miR-23b*targets proline oxidase, a novel tumor suppressor protein in renal cancer	ONCOGENE			English	Article						proline oxidase; miR-23b*; renal cancer; ROS; tumor suppressor	CELL CARCINOMA; DOWN-REGULATION; EXPRESSION; GENE; MICRORNAS; APOPTOSIS; HYPOXIA; MYC; BIOGENESIS; BINDING	Proline oxidase (POX) is a novel mitochondrial tumor suppressor that can suppress proliferation and induce apoptosis through the generation of reactive oxygen species (ROS) and decreasing hypoxia-inducible factor (HIF) signaling. Recent studies have shown the absence of expression of POX in human cancer tissues, including renal cancer. However, the mechanism for the loss of POX remains obscure. No genetic or epigenetic variation of POX gene was found. In this study, we identified the upregulated miR-23b* in renal cancer as an important regulator of POX. Ectopic overexpression of miR-23b* in normal renal cells resulted in striking downregulation of POX, whereas POX expression increased markedly when endogenous miR-23b* was knocked down by its antagomirs in renal cancer cells. Consistent with the POX-mediated tumor suppression pathway, these antagomirs induced ROS, inhibited HIF signaling and increased apoptosis. Furthermore, we confirmed the regulation of miR-23b* on POX and its function in the DLD1 Tet-off POX cell system. Using a luciferase reporter system, we verified the direct binding of miR-23b* to the POX mRNA 3'-untranslated region. In addition, pairs of human renal carcinoma and normal tissues showed a negative correlation between miR-23b* and POX protein expression, providing its clinical corroboration. Taken together, our results suggested that miR-23b*, by targeting POX, could function as an oncogene; decreasing miR-23b* expression may prove to be an effective way of inhibiting kidney tumor growth. Oncogene (2010) 29, 4914-4924; doi: 10.1038/onc.2010.237; published online 21 June 2010	[Liu, W.; Zabirnyk, O.; Shiao, Y-H; Khalil, S.; Anderson, L. M.; Phang, J. M.] NCI, Lab Comparat Carcinogenesis, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Wang, H.; Perantoni, A. O.] NCI, Lab Canc & Dev Biol, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Nickerson, M. L.] NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, W (corresponding author), NCI, Lab Comparat Carcinogenesis, Ctr Canc Res, NIH, Bldg 538,Room 144, Frederick, MD 21702 USA.	liuwei3@mail.nih.gov; phangj@mail.nih.gov	Shiao, Yih-Horng/ABC-7262-2021; liu, wei/E-7340-2012	Shiao, Yih-Horng/0000-0001-9841-7784	NIH; National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010744, ZIABC010743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Anna E Maciag for insightful comments, Dr Matthew J Fivash for statistical analysis, Dr Miriam R Anver for evaluating POX immunohistochemical staining and miR-23b* in situ hybridization, Dr Chang H Kim for his help with the miRNA microarray. This research was supported (in part) by the Intramural Research Program of the NIH, the National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Chow TFF, 2010, CLIN BIOCHEM, V43, P150, DOI 10.1016/j.clinbiochem.2009.07.020; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Donald SP, 2001, CANCER RES, V61, P1810; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Girgin C, 2001, UROL INT, V66, P78, DOI 10.1159/000056575; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guimbellot JS, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-15; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu Y, 2008, ONCOGENE, V27, P6729, DOI 10.1038/onc.2008.322; Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nakada C, 2008, J PATHOL, V216, P418, DOI 10.1002/path.2437; Nass D, 2009, BRAIN PATHOL, V19, P375, DOI 10.1111/j.1750-3639.2008.00184.x; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Phang JM, 2008, J NUTR, V138, p2008S, DOI 10.1093/jn/138.10.2008S; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Smaldone MC, 2009, UROL ONCOL-SEMIN ORI, V27, P238, DOI 10.1016/j.urolonc.2007.12.001; Sowter HM, 2003, CANCER RES, V63, P6130; SUZUKI Y, 1992, JPN J CANCER RES, V83, P233, DOI 10.1111/j.1349-7006.1992.tb00091.x; Williams AE, 2008, CELL MOL LIFE SCI, V65, P545, DOI 10.1007/s00018-007-7355-9; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	43	121	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4914	4924		10.1038/onc.2010.237	http://dx.doi.org/10.1038/onc.2010.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562915	Green Accepted			2022-12-28	WOS:000281578700006
J	Whittaker, S; Marais, R; Zhu, AX				Whittaker, S.; Marais, R.; Zhu, A. X.			The role of signaling pathways in the development and treatment of hepatocellular carcinoma	ONCOGENE			English	Review						epidermal growth factor receptor; hepatocellular carcinoma; multikinase inhibitor; signaling; sorafenib; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; ACTIVATED PROTEIN-KINASES; MESSENGER-RNA EXPRESSION; C-MET PROTOONCOGENE; PHASE-II TRIAL; FACTOR-RECEPTOR; TUMOR-GROWTH; HEPATITIS-B; PROGNOSTIC-SIGNIFICANCE	Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a multifaceted molecular pathogenesis. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins (for example, alcohol or aflatoxin) or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These pathways are of interest from a therapeutic perspective, because targeting them may help to reverse, delay or prevent tumorigenesis. In this review, we explore some of the major pathways implicated in HCC. These include the RAF/MEK/ERK pathway, phosphatidylinositol-3 kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway, WNT/beta-catenin pathway, insulin-like growth factor pathway, hepatocyte growth factor/c-MET pathway and growth factor-regulated angiogenic signaling. We focus on the role of these pathways in hepatocarcinogenesis, how they are altered, and the consequences of these abnormalities. In addition, we also review the latest preclinical and clinical data on the rationally designed targeted agents that are now being directed against these pathways, with early evidence of success. Oncogene (2010) 29, 4989-5005; doi:10.1038/onc.2010.236; published online 19 July 2010	[Zhu, A. X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA; [Whittaker, S.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Whittaker, S.] Broad Inst, Cambridge, MA USA; [Marais, R.] Inst Canc Res, London SW3 6JB, England	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Zhu, AX (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Lawrence House,POB 232,55 Fruit St, Boston, MA 02114 USA.	azhu@partners.org	Whittaker, Steven/AAS-9874-2020	Whittaker, Steven/0000-0001-9062-7947; Marais, Richard/0000-0001-7484-4183	Bayer HealthCare Pharmaceuticals; Genentech, Inc.	Bayer HealthCare Pharmaceuticals(Bayer AGBayer Healthcare Pharmaceuticals); Genentech, Inc.(Roche HoldingGenentech)	We would like to thank John D Zoidis, MD (Bayer HealthCare Pharmaceuticals, Montville, NJ, USA), and Anna Hunt and Catherine Crookes (GeoMed, Macclesfield, Cheshire, UK) for writing and editorial support, with funding from Bayer HealthCare Pharmaceuticals.; Steven Whittaker and Richard Marais have no competing financial interests in relation to this work. RichardMarais is on the editorial board of Oncogene. Andrew X Zhu has participated in advisory activities and has received research support from Bayer HealthCare Pharmaceuticals and Genentech, Inc.	Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; ABOUALFA GK, 2008, ASCO GASTR CANC S OR; Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Albert DH, 2006, MOL CANCER THER, V5, P995, DOI 10.1158/1535-7163.MCT-05-0410; ALBERTS SR, 2007, ASCO GASTR CANC S OR; Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029; Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550; Bangoura G, 2007, WORLD J GASTROENTERO, V13, P3176, DOI 10.3748/wjg.v13.i23.3176; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Bugianesi E, 2005, ALIMENT PHARM THER, V22, P40, DOI 10.1111/j.1365-2036.2005.02594.x; Burgess T, 2006, CANCER RES, V66, P1721, DOI 10.1158/0008-5472.CAN-05-3329; Burtrum D, 2003, CANCER RES, V63, P8912; CARIANI E, 1988, CANCER RES, V48, P6844; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; Chao Y, 2003, ANN SURG ONCOL, V10, P355, DOI 10.1245/ASO.2003.10.002; Chen Wong L., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P575, DOI 10.2174/156801105774574649; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; DESOUZA AT, 1995, ONCOGENE, V10, P1725; Dhar DK, 2002, ANTICANCER RES, V22, P379; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; El-Assal ON, 1998, HEPATOLOGY, V27, P1554, DOI 10.1002/hep.510270613; Faivre S, 2009, LANCET ONCOL, V10, P794, DOI 10.1016/S1470-2045(09)70171-8; Feitelson MA, 2004, SURG CLIN N AM, V84, P339, DOI 10.1016/S0039-6109(03)00226-3; Feng DY, 2001, WORLD J GASTROENTERO, V7, P33; FLAHERTY K, 2009, J CLIN ONCOL, V27, pS461; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GRUENWALD V, 2007, J CLIN ONCOL S, V25, pS222; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; Harden TK, 2006, ANNU REV PHARMACOL, V46, P355, DOI 10.1146/annurev.pharmtox.46.120604.141223; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Himmelsbach K, 2009, GUT, V58, P1644, DOI 10.1136/gut.2009.182212; Hopfner M, 2006, BIOCHEM PHARMACOL, V71, P1435, DOI 10.1016/j.bcp.2006.02.006; Hopfner M, 2004, J HEPATOL, V41, P1008, DOI 10.1016/j.jhep.2004.08.024; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Hsu CH, 2010, BRIT J CANCER, V102, P981, DOI 10.1038/sj.bjc.6605580; Hu TH, 2003, CANCER, V97, P1929, DOI 10.1002/cncr.11266; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huether A, 2005, J HEPATOL, V43, P661, DOI 10.1016/j.jhep.2005.02.040; Huether A, 2006, WORLD J GASTROENTERO, V12, P5160; Huynh H, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-19; Huynh H, 2007, MOL CANCER THER, V6, P2468, DOI 10.1158/1535-7163.MCT-07-0162; Huynh H, 2007, MOL CANCER THER, V6, P138, DOI 10.1158/1535-7163.MCT-06-0436; Hwang YH, 2004, HEPATOL RES, V29, P113, DOI 10.1016/j.hepres.2004.02.009; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Ito Y, 2001, ONCOL REP, V8, P903; Johnston SRD, 2006, DRUG TODAY, V42, P441, DOI 10.1358/dot.2006.42.7.985637; Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kira S, 1997, LIVER, V17, P177; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Kneteman NM, 2004, LIVER TRANSPLANT, V10, P1301, DOI 10.1002/lt.20237; Koch I, 2005, J CLIN ONCOL, V23, p341S; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Leicht DT, 2007, BBA-MOL CELL RES, V1773, P1196, DOI 10.1016/j.bbamcr.2007.05.001; Li XM, 1998, J EXP CLIN CANC RES, V17, P13; Lian ZR, 2007, HEPATOLOGY, V45, P1390, DOI 10.1002/hep.21610; Lierman E, 2006, BLOOD, V108, P1374, DOI 10.1182/blood-2006-02-004457; Liu YQ, 2005, CANCER RES, V65, P3691, DOI 10.1158/0008-5472.CAN-04-3462; Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lund P, 2004, CANCER LETT, V206, P85, DOI 10.1016/j.canlet.2003.10.018; Ma PC, 2005, CLIN CANCER RES, V11, P2312, DOI 10.1158/1078-0432.CCR-04-1708; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; MALKA D, 2007, J CLIN ONCOL S, V18, pS215; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marotta F, 2004, Clin Ter, V155, P187; Mas VR, 2007, TRANSPLANTATION, V84, P1262, DOI 10.1097/01.tp.0000287596.91520.1a; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Matsuo M, 2003, MOL CANCER THER, V2, P557; McKillop IH, 1997, HEPATOLOGY, V26, P1484; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Mulcahy Mary F, 2005, Curr Treat Options Oncol, V6, P423, DOI 10.1007/s11864-005-0045-7; Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68; Nakanishi K, 2005, CANCER-AM CANCER SOC, V103, P307, DOI 10.1002/cncr.20774; Ng IOL, 2001, AM J CLIN PATHOL, V116, P838; O'Dwyer PJ, 2006, J CLIN ONCOL, V24, p213S; Okano J, 2006, J GASTROENTEROL, V41, P166, DOI 10.1007/s00535-005-1736-3; Pang R, 2007, GASTROENTEROLOGY, V132, P1088, DOI 10.1053/j.gastro.2006.12.030; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Philip PA, 2005, J CLIN ONCOL, V23, P6657, DOI 10.1200/JCO.2005.14.696; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pons-Renedo Fernando, 2003, MedGenMed, V5, P11; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Poon RTP, 2004, BRIT J SURG, V91, P1354, DOI 10.1002/bjs.4594; Poon RTP, 2004, ONCOL REP, V11, P1077; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Presta LG, 1997, CANCER RES, V57, P4593; Ramanathan RK, 2006, J CLIN ONCOL, V24, p181S; Ramanathan RK, 2009, CANCER CHEMOTH PHARM, V64, P777, DOI 10.1007/s00280-009-0927-7; RAOUL JL, 2009, J CLIN ONCOL S, V27, pS15; Roberts Lewis R, 2006, Expert Opin Emerg Drugs, V11, P469, DOI 10.1517/14728214.11.3.469; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sananbenesi F, 2002, MOL CELL NEUROSCI, V21, P463, DOI 10.1006/mcne.2002.1188; Scharovsky OG, 2000, J BIOMED SCI, V7, P292, DOI 10.1007/BF02253247; Schiffer E, 2005, HEPATOLOGY, V41, P307, DOI 10.1002/hep.20538; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt VA, 2008, MOL CELL BIOL, V28, P1489, DOI 10.1128/MCB.01090-07; Schmitz KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018; Schuierer MM, 2006, ONCOL REP, V16, P451; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartz GK, 2009, J CLIN ONCOL S, V27, p15s; Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006; Semela D, 2007, J HEPATOL, V46, P840, DOI 10.1016/j.jhep.2006.11.021; Shimamura T, 2000, J GASTROEN HEPATOL, V15, P640, DOI 10.1046/j.1440-1746.2000.02201.x; Siegel AB, 2008, J CLIN ONCOL, V26, P2992, DOI 10.1200/JCO.2007.15.9947; Sieghart W, 2007, TRANSPLANTATION, V83, P425, DOI 10.1097/01.tp.0000252780.42104.95; Simonetti RG, 1997, ANN ONCOL, V8, P117, DOI 10.1023/A:1008285123736; Stockl L, 2003, ONCOGENE, V22, P2604, DOI 10.1038/sj.onc.1206320; Su MC, 2006, CANCER LETT, V235, P34, DOI 10.1016/j.canlet.2005.03.059; Sun XF, 2007, IEEE J SEL AREA COMM, V25, P18, DOI 10.1109/JSAC-OCN.2007.023305; SUZUKI K, 1994, HEPATOLOGY, V20, P1231; Tanaka Y, 2006, ONCOGENE, V25, P2950, DOI 10.1038/sj.onc.1209311; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tavian D, 2000, INT J CANCER, V87, P644, DOI 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.3.CO;2-N; Thomas MB, 2005, J CLIN ONCOL, V23, P8093, DOI 10.1200/JCO.2004.00.1537; Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886; Thomas MB, 2009, J CLIN ONCOL, V27, P843, DOI 10.1200/JCO.2008.18.3301; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; To MD, 2005, CELL CYCLE, V4, P1185, DOI 10.4161/cc.4.9.2039; TOH H, 2009, J CLIN ONCOL S, V27, pS15; Ueda S, 2006, CANCER RES, V66, P5346, DOI 10.1158/0008-5472.CAN-05-3684; Ueki T, 1997, HEPATOLOGY, V25, P619, DOI 10.1002/hep.510250321; Villanueva A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wang XW, 2002, TOXICOLOGY, V181, P43, DOI 10.1016/S0300-483X(02)00253-6; Watanabe S, 2005, HEPATOL RES, V33, P161, DOI 10.1016/j.hepres.2005.09.026; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409; *WELLC TRUST GEN C, 2008, CAT SOM MUT CANC COS; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wood JM, 2000, CANCER RES, V60, P2178; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Xaus J, 2001, IMMUNOBIOLOGY, V204, P543, DOI 10.1078/0171-2985-00091; Yamaguchi R, 1998, HEPATOLOGY, V28, P68, DOI 10.1002/hep.510280111; YEH YC, 1987, CANCER RES, V47, P896; Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635; Zhang YC, 2006, WORLD J GASTROENTERO, V12, P3977, DOI 10.3748/wjg.v12.i25.3977; Zhou J, 2000, J CANCER RES CLIN, V126, P57, DOI 10.1007/s004320050009; Zhu AX, 2008, CANCER-AM CANCER SOC, V112, P250, DOI 10.1002/cncr.23175; Zhu AX, 2007, CANCER-AM CANCER SOC, V110, P581, DOI 10.1002/cncr.22829; Zhu AX, 2006, ONCOLOGIST, V11, P790, DOI 10.1634/theoncologist.11-7-790; Zhu AX, 2009, J CLIN ONCOL, V27, P3027, DOI 10.1200/JCO.2008.20.9908; Zhu AX, 2006, J CLIN ONCOL, V24, P1898, DOI 10.1200/JCO.2005.04.9130	164	656	679	0	213	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					4989	5005		10.1038/onc.2010.236	http://dx.doi.org/10.1038/onc.2010.236			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20639898				2022-12-28	WOS:000281620100001
J	Gkika, D; Flourakis, M; Lemonnier, L; Prevarskaya, N				Gkika, D.; Flourakis, M.; Lemonnier, L.; Prevarskaya, N.			PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression	ONCOGENE			English	Article						prostate cancer; ion channel regulation; kallikrein; cell migration	BRADYKININ B-2 RECEPTOR; BINDING PROTEIN-3; EPITHELIAL-CELLS; SEMINAL PLASMA; CHANNEL; ANTIGEN; GROWTH; IDENTIFICATION; KALLIKREINS; ACTIVATION	Although the transient receptor potential melastatin 8 (TRPM8) cold receptor is highly expressed in prostate cancer (PCa) and constitutes a promising diagnostic and prognostic indicator, the natural agonists of this channel in the prostate, as well as its physiological and pathological functions, remain unknown. In this study, we identified the well-known PCa marker, prostate-specific antigen (PSA), as a physiological TRPM8 agonist. Electrophysiological and Ca(2+) imaging studies demonstrated that PSA activated TRPM8-mediated current by the bradykinin 2 receptor signaling pathway. Further investigation of this mechanism by cell-surface biotinylation revealed that the increase in TRPM8 current induced by PSA was due to an increase in the number of functional TRPM8 channels on the plasma membrane. Importantly, wound-healing and migration assays revealed that TRPM8 activation by PSA reduced motility of the PC3 PCa cell line, suggesting that plasma membrane TRPM8 has a protective role in PCa progression. Consequently, PSA was identified as a natural TRPM8 agonist in the prostate and we propose a putative physiological role for both of these proteins in carcinogenesis, making this pathway a potentially important target for anticancer agent development. Oncogene (2010) 29, 4611-4616; doi: 10.1038/onc.2010.210; published online 7 June 2010	[Prevarskaya, N.] USTL, INSERM, Lab Physiol Cellulaire, Equipe Labellisee Ligue Natl Canc,U1003, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), USTL, INSERM, Lab Physiol Cellulaire, Equipe Labellisee Ligue Natl Canc,U1003, Batiment SN3, F-59655 Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.fr	Lemonnier, Loic/L-7289-2018; Gkika, Dimitra/S-3054-2019	Lemonnier, Loic/0000-0001-6200-5382; Gkika, Dimitra/0000-0001-8612-0836; Prevarskaya, natacha/0000-0003-0316-197X; Flourakis, Matthieu/0000-0002-5366-9125	Institut national de la Sante et de la Recherche Medicale (INSERM); Ministere de l'education nationale and the Ligue Nationale contre le cancer; Institut National du Cancer (INCa) [07/3d1616/pdoc-110-18/ng-nc]	Institut national de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ministere de l'education nationale and the Ligue Nationale contre le cancer; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France)	This study was supported by grants from the Institut national de la Sante et de la Recherche Medicale (INSERM), Ministere de l'education nationale and the Ligue Nationale contre le cancer. Dr D Gkika was supported by a grant from the Institut National du Cancer (INCa) (Grant No: 07/3d1616/pdoc-110-18/ng-nc).	BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bidaux G, 2007, J CLIN INVEST, V117, P1647, DOI 10.1172/JCI30168; Bindukumar B, 2005, NEOPLASIA, V7, P241, DOI 10.1593/neo.04529; Blaukat A, 2003, ANDROLOGIA, V35, P17, DOI 10.1046/j.1439-0272.2003.00533.x; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gkika D, 2006, EMBO J, V25, P4707, DOI 10.1038/sj.emboj.7601357; Gkika D, 2009, BBA-MOL CELL RES, V1793, P953, DOI 10.1016/j.bbamcr.2008.11.010; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Henshall SM, 2003, CANCER RES, V63, P4196; Kramarenko II, 2009, BIOCHEM PHARMACOL, V77, P269, DOI 10.1016/j.bcp.2008.09.027; Lilja H, 2003, UROLOGY, V62, P27, DOI 10.1016/S0090-4295(03)00775-1; LILJA H, 1988, PROSTATE, V12, P29, DOI 10.1002/pros.2990120105; Monet M, 2009, BBA-MOL CELL RES, V1793, P528, DOI 10.1016/j.bbamcr.2009.01.003; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Platz EA, 2005, CANCER CAUSE CONTROL, V16, P255, DOI 10.1007/s10552-004-3484-8; Premkumar LS, 2005, J NEUROSCI, V25, P11322, DOI 10.1523/JNEUROSCI.3006-05.2005; Robertson SA, 2005, CELL TISSUE RES, V322, P43, DOI 10.1007/s00441-005-1127-3; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Srinivasan D, 2004, EUR J PHARMACOL, V504, P155, DOI 10.1016/j.ejphar.2004.10.004; Thebault S, 2005, J BIOL CHEM, V280, P39423, DOI 10.1074/jbc.M503544200; Tsavaler L, 2001, CANCER RES, V61, P3760; Yang ZH, 2009, ASIAN J ANDROL, V11, P157, DOI 10.1038/aja.2009.1; Zhang L, 2006, ENDOCR-RELAT CANCER, V13, P27, DOI 10.1677/erc.1.01093	28	74	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2010	29	32					4611	4616		10.1038/onc.2010.210	http://dx.doi.org/10.1038/onc.2010.210			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531306				2022-12-28	WOS:000280862300011
J	Vetter, G; Saumet, A; Moes, M; Vallar, L; Le Bechec, A; Laurini, C; Sabbah, M; Arar, K; Theillet, C; Lecellier, CH; Friederich, E				Vetter, G.; Saumet, A.; Moes, M.; Vallar, L.; Le Bechec, A.; Laurini, C.; Sabbah, M.; Arar, K.; Theillet, C.; Lecellier, C-H; Friederich, E.			RETRACTED: miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers (Retracted article. See vol. 35, pg. 670, 2016)	ONCOGENE			English	Article; Retracted Publication						EMT; miR-661; SNAI1; StarD10; Nectin-1; breast cancer cell invasion	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; GENE-EXPRESSION; MIR-200 FAMILY; REPRESSORS ZEB1; METASTASIS; PHENOTYPE; MICRORNA; RECEPTORS; SIGNATURE	Epithelial to mesenchymal transition (EMT) is a key step toward metastasis. MCF7 breast cancer cells conditionally expressing the EMT master regulator SNAI1 were used to identify early expressed microRNAs (miRNAs) and their targets that may contribute to the EMT process. Potential targets of miRNAs were identified by matching lists of in silico predicted targets and of inversely expressed mRNAs. MiRNAs were ranked based on the number of predicted hits, highlighting miR-661, a miRNA with so far no reported role in EMT. MiR-661 was found required for efficient invasion of breast cancer cells by destabilizing two of its predicted mRNA targets, the cell-cell adhesion protein Nectin-1 and the lipid transferase StarD10, resulting, in turn, in the downregulation of epithelial markers. Reexpression of Nectin-1 or StarD10 lacking the 3'-untranslated region counteracted SNAI1-induced invasion. Importantly, analysis of public transcriptomic data from a cohort of 295 well-characterized breast tumor specimen revealed that expression of StarD10 is highly associated with markers of luminal subtypes whereas its loss negatively correlated with the EMT-related, basal-like subtype. Collectively, our non-a priori approach revealed a nonpredicted link between SNAI1-triggered EMT and the down-regulation of Nectin-1 and StarD10 through the up-regulation of miR-661, which may contribute to the invasion of breast cancer cells and poor disease outcome. Oncogene (2010) 29, 4436-4448; doi: 10.1038/onc.2010.181; published online 14 June 2010	[Vetter, G.; Moes, M.; Le Bechec, A.; Laurini, C.; Friederich, E.] Univ Luxembourg, FSTC, Life Sci Res Unit, Cytoskeleton & Cell Plast Lab, L-1511 Luxembourg, Luxembourg; [Saumet, A.; Theillet, C.] INSERM, Inst Rech Cancerol Montpellier, U896, Montpellier, France; [Vallar, L.] Ctr Rech Publ Sante, Microarray Ctr, Luxembourg, Luxembourg; [Sabbah, M.] Hop Saint Antoine, INSERM, U938, Paris, France; [Arar, K.] Sigma Aldrich, Evry, France; [Lecellier, C-H] CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 122, Montpellier, France	University of Luxembourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Luxembourg Institute of Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Merck KGaA; MilliporeSigma; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Friederich, E (corresponding author), Univ Luxembourg, FSTC, Life Sci Res Unit, Cytoskeleton & Cell Plast Lab, L-1511 Luxembourg, Luxembourg.	evelyne.friederich@uni.lu	Theillet, Charles/O-7634-2018	Vallar, Laurent/0000-0002-4404-1010; Theillet, Charles/0000-0001-5555-2759	Fond National de la Recherche (FNR) du Luxembourg (BIOSAN); Fondation Luxembourgeoise Contre le Cancer; Human Frontier Science Program [RGP0058/2005]; INSERM; CNRS, France; Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Luxembourg [BFR 08/046]; Fond National de la Recherche, Luxembourg	Fond National de la Recherche (FNR) du Luxembourg (BIOSAN)(Luxembourg National Research Fund); Fondation Luxembourgeoise Contre le Cancer; Human Frontier Science Program(Human Frontier Science Program); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS, France(Centre National de la Recherche Scientifique (CNRS)); Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Luxembourg; Fond National de la Recherche, Luxembourg(Luxembourg National Research Fund)	We thank M Yatskou, P Nazarov and A Muller (CRP-Sante, Luxembourg) for their help with the microarray data analysis. We thank C Hoffmann-Laporte (CRP-Sante, Luxembourg) for her help with confocal microscopy observations. We especially thank E Schaffner-Reckinger for critical reading of the article and P Savagner for helpful discussions. This work was supported by grants from the Fond National de la Recherche (FNR) du Luxembourg (BIOSAN), the Fondation Luxembourgeoise Contre le Cancer, Human Frontier Science Program (RGP0058/2005), INSERM and CNRS, France. A Saumet is a recipient of a fellowship from the Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Luxembourg (BFR 08/046). M Moes and A Le Bechec are supported by AFR grants from the Fond National de la Recherche, Luxembourg.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Brakeman PR, 2009, AM J PHYSIOL-RENAL, V296, pF564, DOI 10.1152/ajprenal.90328.2008; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cano A, 2008, TRENDS CELL BIOL, V18, P357, DOI 10.1016/j.tcb.2008.05.005; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; De Wever O, 2008, HISTOCHEM CELL BIOL, V130, P481, DOI 10.1007/s00418-008-0464-1; Divijendra S, 2009, CANCER RES, V69, P5639, DOI 10.1158/0008-5472.CAN-09-0898; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P1033, DOI 10.1677/ERC-06-0001; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Murphy NC, 2010, INT J CANCER, V126, P1445, DOI 10.1002/ijc.24826; Olayioye MA, 2005, J BIOL CHEM, V280, P27436, DOI 10.1074/jbc.M413330200; Olayioye MA, 2004, CANCER RES, V64, P3538, DOI 10.1158/0008-5472.CAN-03-3731; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Sakisaka T, 2007, CURR OPIN CELL BIOL, V19, P593, DOI 10.1016/j.ceb.2007.09.007; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Saumet A, 2009, BLOOD, V113, P412, DOI 10.1182/blood-2008-05-158139; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vetter G, 2009, BIOCHEM BIOPH RES CO, V385, P485, DOI 10.1016/j.bbrc.2009.05.025	34	109	117	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4436	4448		10.1038/onc.2010.181	http://dx.doi.org/10.1038/onc.2010.181			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20543867	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000280559100007
J	Weiss, MB; Vitolo, MI; Mohseni, M; Rosen, DM; Denmeade, SR; Park, BH; Weber, DJ; Bachman, KE				Weiss, M. B.; Vitolo, M. I.; Mohseni, M.; Rosen, D. M.; Denmeade, S. R.; Park, B. H.; Weber, D. J.; Bachman, K. E.			Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response	ONCOGENE			English	Article						p53; TP53; chromosomal instability; Doxorubicin; MCF-10A	BREAST-CANCER PATIENTS; TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; CONTINUOUS-INFUSION; P53-DEFICIENT MICE; IN-VITRO; MUTATIONS; AMPLIFICATION; CHEMOTHERAPY; ANEUPLOIDY	The TP53 tumor suppressor gene is the most commonly mutated gene in human cancers. To evaluate the biological and clinical relevance of p53 loss, human somatic cell gene targeting was used to delete the TP53 gene in the non-tumorigenic epithelial cell line, MCF-10A. In all four p53-/- clones generated, cells acquired the capability for epidermal growth factor-independent growth and were defective in appropriate downstream signaling and cell cycle checkpoints in response to DNA damage. Interestingly, p53 loss induced chromosomal instability leading to features of transformation and the selection of clones with varying phenotypes. For example, p53-deficient clones were heterogeneous in their capacity for anchorage-independent growth and invasion. In addition, and of clinical importance, the cohort of p53-null clones showed sensitivity to chemotherapeutic interventions that varied depending not only on the type of chemotherapeutic agent, but also on the treatment schedule. In conclusion, deletion of the TP53 gene from MCF-10A cells eliminated p53 functions, as well as produced p53-/- clones with varying phenotypes possibly stemming from the distinct chromosomal changes observed. Such a model system will be useful to further understand the cancer-specific phenotypic changes that accompany p53 loss, as well as help to provide future treatment strategies for human malignancies that harbor aberrant p53. Oncogene (2010) 29, 4715-4724; doi:10.1038/onc.2010.220; published online 21 June 2010	[Weiss, M. B.; Vitolo, M. I.; Weber, D. J.; Bachman, K. E.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Weiss, M. B.] Univ Maryland, Grad Program Mol Med, Baltimore, MD 21201 USA; [Mohseni, M.] Johns Hopkins Univ, Sch Med, Dept Human Genet, Baltimore, MD USA; [Rosen, D. M.; Denmeade, S. R.; Park, B. H.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA; [Weber, D. J.; Bachman, K. E.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Bachman, KE (corresponding author), GlaxoSmithKline Inc, Dept Oncol, 1250 S Collegeville Rd,UP1340, Collegeville, PA 19426 USA.	bpark2@jhmi.edu; dweber@umaryland.edu; kurtis.e.bachman@gsk.com	Weber, David J/B-5349-2011	Weber, David J/0000-0002-8824-1110; Vitolo, Michele/0000-0001-8055-9645	NIH [T32DK067872]; Susan G Komen Breast Cancer Foundation [PDF104506]; DOD [BC083057]; Avon Foundation [R01CA109274]; Breast Cancer Research Foundation [R01CA107331, R01GM58888]; Maryland Cigarette Restitution Fund; NATIONAL CANCER INSTITUTE [R01CA109274, R01CA107331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058888] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); DOD(United States Department of Defense); Avon Foundation; Breast Cancer Research Foundation; Maryland Cigarette Restitution Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Fred Bunz for providing TP53 knockout vectors and advice, and Joel Greschock for advice on copy number analysis. This work was supported by: NIH grant T32DK067872 (MBW), Susan G Komen Breast Cancer Foundation PDF104506 (MIV), DOD Breast Cancer Pre-doctoral Training Award BC083057 (MM), The Avon Foundation, R01CA109274, The Breast Cancer Research Foundation (BHP), R01CA107331 and R01GM58888 (DJW) and Maryland Cigarette Restitution Fund (KEB).	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bomme L, 2001, INT J CANCER, V92, P816, DOI 10.1002/ijc.1275; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Calistri D, 2006, CELL ONCOL, V28, P161; Campomenosi P, 1998, ANAL CELL PATHOL, V17, P1; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Dutt A, 2007, CURR OPIN ONCOL, V19, P43, DOI 10.1097/CCO.0b013e328011a8c1; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Formenti SC, 1997, INT J RADIAT ONCOL, V39, P1059, DOI 10.1016/S0360-3016(97)00506-3; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greshock J, 2007, CANCER RES, V67, P10173, DOI 10.1158/0008-5472.CAN-07-2102; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hyman E, 2002, CANCER RES, V62, P6240; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Papa V, 1997, J ENDOCRINOL INVEST, V20, P531, DOI 10.1007/BF03348015; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rozan S, 1998, INT J CANCER, V79, P27, DOI 10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.3.CO;2-8; Sengelov L, 1997, J CANCER RES CLIN, V123, P565, DOI 10.1007/s004320050106; SOULE HD, 1990, CANCER RES, V50, P6075; THORLACIUS S, 1993, CANCER RES, V53, P1637; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Varis A, 2003, BRIT J CANCER, V88, P1914, DOI 10.1038/sj.bjc.6600969; Vitolo MI, 2009, CANCER RES, V69, P8275, DOI 10.1158/0008-5472.CAN-09-1067; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Willmarth NE, 2006, J BIOL CHEM, V281, P37728, DOI 10.1074/jbc.M606532200; Wolmark N, 1998, J CLIN ONCOL, V16, P301; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249	49	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4715	4724		10.1038/onc.2010.220	http://dx.doi.org/10.1038/onc.2010.220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20562907	Green Accepted			2022-12-28	WOS:000281127400010
J	Mittendorf, EA; Liu, Y; Tucker, SL; McKenzie, T; Qiao, N; Akli, S; Biernacka, A; Liu, Y; Meijer, L; Keyomarsi, K; Hunt, KK				Mittendorf, E. A.; Liu, Y.; Tucker, S. L.; McKenzie, T.; Qiao, N.; Akli, S.; Biernacka, A.; Liu, Y.; Meijer, L.; Keyomarsi, K.; Hunt, K. K.			A novel interaction between HER2/neu and cyclin E in breast cancer	ONCOGENE			English	Article						breast cancer; HER2/neu; cell cycle regulation; cyclin E	MOLECULAR-WEIGHT FORMS; RECEPTOR STATUS; EXPRESSION; OVEREXPRESSION; AMPLIFICATION; TRASTUZUMAB; INHIBITION; HER-2/NEU; C-ERBB-2; ANTIBODY	HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two. HER2 and cyclin E expression levels were determined in 395 breast cancer patients. Patients with HER2-overexpression and high levels of cyclin E had decreased 5-year disease-specific survival compared with low levels of cyclin E (14% versus 89%, P < 0.0001). In vitro studies were performed in which HER2-mediated activity in HER2-overexpressing breast cancer cell lines was downregulated by transfection with HER2 small interfering RNA or treatment with trastuzumab. Cyclin E expression levels were determined by western blot analysis, and functional effects analyzed using kinase assays, MTT assays were used to assess cell viability as a marker of proliferation and fluorescence-activated cell sorting analysis was used to determine cell cycle profiles. Decreased HER2-mediated signaling resulted in decreased expression of cyclin E, particularly the low molecular weight (LMW) isoforms. Decreased HER2 and LMW cyclin E expression had functional consequences, including decreased cyclin E-associated kinase activity and decreased proliferation, because of increased apoptosis and an increased accumulation of cells in the G1 phase. In vivo studies performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzumab on cyclin E expression. Given the relationship between HER2 and cyclin E, in vitro clonogenic assays were performed to assess combination therapy targeting both proteins. Isobologram analysis showed a synergistic interaction between the two agents (trastuzumab targeting HER2 and roscovitine targeting cyclin E). Taken together, these studies show that HER2-mediated signaling effects LMW cyclin E expression, which in turn deregulates the cell cycle. LMW cyclin E has prognostic and predictive roles in HER2-overexpressing breast cancer, warranting further study of its potential as a therapeutic target. Oncogene (2010) 29, 3896-3907; doi:10.1038/onc.2010.151; published online 10 May 2010	[Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, Houston, TX 77030 USA; [Tucker, S. L.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat, Houston, TX 77030 USA; [Tucker, S. L.] Univ Texas MD Anderson Canc Ctr, Dept Computat Biol, Houston, TX 77030 USA; [Akli, S.; Biernacka, A.; Liu, Y.; Keyomarsi, K.; Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Meijer, L.] CNRS, Biol Stn, Roscoff, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Centre National de la Recherche Scientifique (CNRS)	Hunt, KK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kkeyomar@mdanderson.org; khunt@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; , laurent/0000-0003-3511-4916	NIH [T32 CA009599, CA87458, 1K99CA133244-01]; AACR; Susan G Komen for the Cure [PDF0707621]; Clayton Foundation for Research; NCI [P50CA116199]; Susan G Komen Breast Cancer Foundation [BCTR0504200]; NATIONAL CANCER INSTITUTE [R01CA087548, R01CA152228, K99CA133244, T32CA009599, P50CA116199] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR; Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Clayton Foundation for Research; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH T32 CA009599 (Mittendorf); AACR (Mittendorf); Susan G Komen for the Cure PDF0707621 (Keyomarsi and Mittendorf); Clayton Foundation for Research (Keyomarsi); NIH CA87458 (Keyomarsi); NCI P50CA116199 (Keyomarsi); Susan G Komen Breast Cancer Foundation BCTR0504200 (Hunt) and NIH 1K99CA133244-01 (Mittendorf).	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2003, CANCER BIOL THER, V2, pS38; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; BACUS SS, 1992, CANCER RES, V52, P2580; Brockhoff G, 2007, CELL PROLIFERAT, V40, P488, DOI 10.1111/j.1365-2184.2007.00449.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Harwell RM, 2000, CANCER RES, V60, P481; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333; Le XF, 2006, CELL CYCLE, V5, P1654, DOI 10.4161/cc.5.15.3007; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; MCCANN AH, 1991, CANCER RES, V51, P3296; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Potemski P, 2006, J EXP CLIN CANC RES, V25, P59; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Roh H, 2000, CANCER RES, V60, P560; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wingate H, 2005, J BIOL CHEM, V280, P15148, DOI 10.1074/jbc.M409789200; WRIGHT C, 1989, CANCER RES, V49, P2087; Yakes FM, 2002, CANCER RES, V62, P4132; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	40	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3896	3907		10.1038/onc.2010.151	http://dx.doi.org/10.1038/onc.2010.151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453888	Green Accepted			2022-12-28	WOS:000279603200003
J	Freeman, MR; Di Vizio, D; Solomon, KR				Freeman, M. R.; Di Vizio, D.; Solomon, K. R.			The Rafts of the Medusa: cholesterol targeting in cancer therapy	ONCOGENE			English	Editorial Material							PROSTATE-CANCER; CELLS; AKT	In this issue of Oncogene, Mollinedo and co-workers present promising evidence that cholesterol-sensitive signaling pathways involving lipid rafts can be therapeutically targeted in multiple myeloma. Because the pathways considered in their study are used by other types of tumor cells, one implication of this report is that cholesterol-targeting approaches may be applicable to other malignancies. Oncogene (2010) 29, 3745-3747; doi: 10.1038/onc.2010.132; published online 3 May 2010	[Freeman, M. R.; Di Vizio, D.; Solomon, K. R.] Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA; [Freeman, M. R.; Di Vizio, D.; Solomon, K. R.] Harvard Univ, Childrens Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA; [Freeman, M. R.; Di Vizio, D.] Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; [Freeman, M. R.] Harvard Univ, Childrens Hosp, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Solomon, K. R.] Harvard Univ, Childrens Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Freeman, MR (corresponding author), Childrens Hosp, Urol Dis Res Ctr, Enders 1161,300 Longwood Ave, Boston, MA 02115 USA.	michael.freeman@childrens.harvard.edu						Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Caldieri G, 2010, TRENDS CELL BIOL, V20, P64, DOI 10.1016/j.tcb.2009.10.006; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mollinedo F, 2010, ONCOGENE, V29, P3748, DOI 10.1038/onc.2010.131; Mondul AM, 2010, CANCER CAUSE CONTROL, V21, P61, DOI 10.1007/s10552-009-9434-8; Platz EA, 2006, JNCI-J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499; Solomon KR, 2009, AM J PATHOL, V174, P1017, DOI 10.2353/ajpath.2009.080551; Zhuang LY, 2005, J CLIN INVEST, V115, P959	10	18	20	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3745	3747		10.1038/onc.2010.132	http://dx.doi.org/10.1038/onc.2010.132			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440260				2022-12-28	WOS:000279385200002
J	Kuzontkoski, PM; Mulligan-Kehoe, MJ; Harris, BT; Israel, MA				Kuzontkoski, P. M.; Mulligan-Kehoe, M. J.; Harris, B. T.; Israel, M. A.			Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels	ONCOGENE			English	Article						ID4; MGP; angiogenesis; glioblastoma; vascularization	HUMAN-ENDOTHELIAL-CELLS; LOOP-HELIX PROTEINS; ID PROTEINS; TUMOR ANGIOGENESIS; ASTROCYTIC TUMORS; MESSENGER-RNA; BREAST-CANCER; IN-VITRO; EXPRESSION; DIFFERENTIATION	Inhibitor of differentiation-4 is highly expressed in glioblastoma multiforme (GBM). We report a novel pro-angiogenic function for inhibitor of differentiation-4 in the growth of glioblastoma xenografts. Tumor-derived cell cultures expressing elevated levels of ID4 produced enlarged xenografts in immunosuppressed mice that were better vascularized than corresponding control tumors and expressed elevated matrix GLA protein (MGP) that mediated enhanced tumor angiogenesis. Inhibition of MGP resulted in smaller and less vascularized xenografts. Our finding shows a novel function for ID4 in tumor angiogenesis, and identifies ID4 and MGP as possible therapeutic targets for GBM. Oncogene (2010) 29, 3793-3802; doi: 10.1038/onc.2010.147; published online 10 May 2010	[Kuzontkoski, P. M.; Israel, M. A.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pediat, Lebanon, NH 03756 USA; [Kuzontkoski, P. M.; Israel, M. A.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA; [Mulligan-Kehoe, M. J.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Surg, Vasc Sect, Lebanon, NH 03756 USA; [Harris, B. T.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pathol, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Israel, MA (corresponding author), Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pediat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Mark.A.Israel@Dartmouth.edu			Theodora B. Betz Foundation; Jordan & Kyra Foundation	Theodora B. Betz Foundation; Jordan & Kyra Foundation	Many thanks to Dr Kristina I Bostrom for lending her expertise, sharing reagents, and fielding generously many questions about MGP. This work was supported by funding from the Theodora B. Betz Foundation (MAI) and the Jordan & Kyra Foundation (MAI).	AndresBarquin PJ, 1997, CANCER RES, V57, P215; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Bellido M, 2003, HAEMATOLOGICA, V88, P994; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bostrom K, 2004, J BIOL CHEM, V279, P52904, DOI 10.1074/jbc.M406868200; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; CHEN L, 1990, ONCOGENE, V5, P1391; de Candia P, 2006, HUM PATHOL, V37, P1032, DOI 10.1016/j.humpath.2006.03.004; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Havrda MC, 2008, J NEUROSCI, V28, P14074, DOI 10.1523/JNEUROSCI.3188-08.2008; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Itahana Y, 2003, CANCER RES, V63, P7098; Jeon HM, 2008, GENE DEV, V22, P2028, DOI 10.1101/gad.1668708; Kargiotis O, 2006, J NEURO-ONCOL, V78, P281, DOI 10.1007/s11060-005-9097-6; Kleihues P., 1997, PATHOLOGY GENETICS T; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lampugnani MG, 1999, METH MOL B, V96, P177; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; Liang Y, 2005, BMC CLIN PATHOL, V5, DOI 10.1186/1472-6890-5-6; Ling MT, 2005, CARCINOGENESIS, V26, P1668, DOI 10.1093/carcin/bgi128; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mikkola HKA, 2003, BLOOD, V101, P508, DOI 10.1182/blood-2002-06-1699; Newman B, 2001, J CELL BIOL, V154, P659, DOI 10.1083/jcb.200106040; Ozawa T, 1998, IN VIVO, V12, P369; Proudfoot D, 2006, NEPHROLOGY, V11, P455, DOI 10.1111/j.1440-1797.2006.00660.x; Russell RG, 2004, CANCER RES, V64, P7220, DOI 10.1158/0008-5472.CAN-04-2095; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; St Croix B, 2000, SCIENCE, V289, P1197; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; VERMEER C, 2001, PATENT COOPERATION T, P1; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Yun K, 2004, DEVELOPMENT, V131, P5441, DOI 10.1242/dev.01430	49	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3793	3802		10.1038/onc.2010.147	http://dx.doi.org/10.1038/onc.2010.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453881				2022-12-28	WOS:000279385200007
J	Lu, Y; Bertran, S; Samuels, TA; Mira-y-Lopez, R; Farias, EF				Lu, Y.; Bertran, S.; Samuels, T-A; Mira-y-Lopez, R.; Farias, E. F.			Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RAR alpha agonist AM580	ONCOGENE			English	Article						RAR alpha; RAR gamma; AM580; MMTV-neu; MMTV-wnt1; breast cancer	HUMAN-BREAST-CANCER; ACID RECEPTOR-ALPHA; CHANGES FOLLOWING DEPRIVATION; SQUAMOUS-CELL CARCINOMA; RETINOIC ACID; BETA-CATENIN; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; EXPRESSION; GAMMA	We hypothesized that specific activation of a single retinoic acid receptor-alpha (RAR alpha), without direct and concurrent activation of RAR beta and gamma, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer. A total of 50 uniparous mouse mammary tumor virus (MMTV)-neu and 50 nuliparous MMTV-wnt1 transgenic mice were treated with RAR alpha agonist (retinobenzoic acid, Am580) that was added to the diet for 40 (neu) and 35 weeks (wnt1), respectively. Among the shared antitumor effects was the inhibition of epithelial hyperplasia, a significant increase (P<0.05) in tumor-free survival and a reduction in tumor incidence and in the growth of established tumors. In both models, the mechanisms responsible for these effects involved inhibition of proliferation and survival pathways, and induction of apoptosis. The treatment was more effective in the MMTV-wnt1 model in which Am580 also induced differentiation, in both in vivo and three-dimensional (3D) cultures. In these tumors Am580 inhibited the wnt pathway, measured by loss of nuclear beta-catenin, suggesting partial oncogene dependence of therapy. Am580 treatment increased RAR beta and lowered the level of RAR gamma, an isotype whose expression we linked with tumor proliferation. The anticancer effect of RAR alpha, together with the newly discovered pro-proliferative role of RAR gamma, suggests that specific activation of RAR alpha and inhibition of RAR gamma might be effective in breast cancer therapy. Oncogene (2010) 29, 3665-3676; doi: 10.1038/onc.2010.119; published online 10 May 2010	[Lu, Y.; Bertran, S.; Samuels, T-A; Mira-y-Lopez, R.; Farias, E. F.] Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Tisch Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Farias, EF (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Tisch Canc Ctr, 1 Gustave Levy Pl, New York, NY 10029 USA.	Eduardo.farias@mssm.edu			NCI [R01-CA119018]; Samuel Waxman Cancer Research Foundation (SWCRF); NIH-NCI [5R24-CA095823-04]; NSF [DBI-972404]; NIH [1S10-RR0-9145-01]; NATIONAL CANCER INSTITUTE [R01CA119018, R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Samuel Waxman Cancer Research Foundation (SWCRF); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs W Muller and HE Varmus, respectively, for the gift of MMTV-neu and MMTV-wnt1 mice, Dr K Shudo for generous gift of AM580 in amounts sufficient to complete these extensive in vivo studies, and Drs L Ossowski, S Waxman and J Aguirre-Ghiso for helpful advice. This work was supported by the NCI Grant R01-CA119018, the Samuel Waxman Cancer Research Foundation (SWCRF) and the NIH-NCI shared resources Grant 5R24-CA095823-04, NSF Major Research Instrumentation Grant DBI-972404, the NIH shared instrumentation Grant 1S10-RR0-9145-01 to MSSM's Microscopy Shared Resources Facility.	ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; Berry DC, 2007, PPAR RES, V2007, DOI 10.1155/2007/73256; Borriello A, 2006, CANCER RES, V66, P4240, DOI 10.1158/0008-5472.CAN-05-2759; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Bukholm IK, 2000, J PATHOL, V190, P15; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chapellier B, 2002, EMBO J, V21, P3402, DOI 10.1093/emboj/cdf331; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Collins SJ, 2008, CURR OPIN HEMATOL, V15, P346, DOI 10.1097/MOH.0b013e3283007edf; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Gantenbein-Ritter B, 2008, TISSUE ENG PART C-ME, V14, P353, DOI 10.1089/ten.tec.2008.0313; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Klaassen I, 2001, BRIT J CANCER, V85, P630, DOI 10.1054/bjoc.2001.1952; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Marcotte R, 2008, J MAMMARY GLAND BIOL, V13, P323, DOI 10.1007/s10911-008-9087-3; MOON RC, 1990, METHOD ENZYMOL, V190, P395; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Noy N, 2007, BIOCHEMISTRY-US, V46, P13461, DOI 10.1021/bi7018699; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; Patatanian E, 2008, J CLIN PHARM THER, V33, P331, DOI 10.1111/j.1365-2710.2008.00935.x; Polakis P, 2000, GENE DEV, V14, P1837; Purton LE, 2006, J EXP MED, V203, P1283, DOI 10.1084/jem.20052105; Radu M, 2008, J CELL PHYSIOL, V217, P558, DOI 10.1002/jcp.21532; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Schneider SM, 2000, CANCER RES, V60, P5479; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shin DM, 2001, J CLIN ONCOL, V19, P3010, DOI 10.1200/JCO.2001.19.12.3010; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1976, FED PROC, V35, P1332; Su D, 2008, BIOCHEM PHARMACOL, V75, P1129, DOI 10.1016/j.bcp.2007.11.006; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151; Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOLBACH SB, 1978, NUTR REV, V36, P16; Wolf G, 2000, NUTR REV, V58, P211, DOI 10.1111/j.1753-4887.2000.tb01865.x; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621	55	22	22	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3665	3676		10.1038/onc.2010.119	http://dx.doi.org/10.1038/onc.2010.119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20453882	Green Accepted			2022-12-28	WOS:000279108600007
J	Liu, Y; Karaca, M; Zhang, Z; Gioeli, D; Earp, HS; Whang, YE				Liu, Y.; Karaca, M.; Zhang, Z.; Gioeli, D.; Earp, H. S.; Whang, Y. E.			Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases	ONCOGENE			English	Article						androgen receptor; phosphorylation; Ack1 kinase; dasatinib; prostate cancer	RECURRENT PROSTATE-CANCER; ACTIVATION; RESISTANT; GROWTH; INTERLEUKIN-6; INDEPENDENCE; PROGRESSION; EXPRESSION; PATHWAY	Activation of androgen receptor (AR) may have a role in the development of castration-resistant prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in castrated animals. However, the upstream signals that activate these kinases and lead to AR activation are incompletely characterized. In this study, we investigated AR phosphorylation in response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6. Small interfering RNA-mediated knockdown of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation, whereas Src mediates Tyr-534 phosphorylation induced by EGF, IL-6 and bombesin. Dasatinib, a Src inhibitor, blocked EGF-induced Tyr-534 phosphorylation. In addition, we showed that dasatinib also inhibited Ack1 kinase. Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib may exert antitumor activity in prostate cancer through inhibition of Ack1. Oncogene (2010) 29, 3208-3216; doi: 10.1038/onc.2010.103; published online 12 April 2010	[Liu, Y.; Zhang, Z.; Earp, H. S.; Whang, Y. E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Karaca, M.; Whang, Y. E.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Gioeli, D.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; [Earp, H. S.; Whang, Y. E.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Earp, H. S.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Whang, YE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Campus Box 7295, Chapel Hill, NC 27599 USA.	ywhang@med.unc.edu	, Animal Studies Core/AAF-4432-2022; , Animal Studies Core/ADK-4234-2022; Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NIH [R01CA120921, R01CA120304, T32ES007017]; NATIONAL CANCER INSTITUTE [R01CA120921, R01CA120304, R01CA124706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Francis Lee of Bristol-Myers-Squibb for providing dasatinib, Charlene Ross and staff of the UNC Lineberger Animal Studies Facility for assistance in xenograft tumor experiments, Dominic Moore for statistical analysis and Nupam Mahajan for discussions and sharing unpublished papers. This study was supported by grants from NIH R01CA120921 (YEW), NIH R01CA120304 (HSE) and NIH T32ES007017 (MK).	Araujo J, 2009, J CLIN ONCOL, V27; Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998; Brave M, 2008, CLIN CANCER RES, V14, P352, DOI 10.1158/1078-0432.CCR-07-4175; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; DaSilva J, 2009, CANCER RES, V69, P7402, DOI 10.1158/0008-5472.CAN-08-4687; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Galisteo ML, 2006, P NATL ACAD SCI USA, V103, P9796, DOI 10.1073/pnas.0603714103; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gong J, 2006, ONCOGENE, V25, P2011, DOI 10.1038/sj.onc.1209231; Gregory CW, 2005, CLIN CANCER RES, V11, P1704, DOI 10.1158/1078-0432.CCR-04-1158; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Liu YB, 2005, CANCER RES, V65, P3404, DOI 10.1158/0008-5472.CAN-04-4292; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Pao-Chun L, 2009, J BIOL CHEM, V284, P34954, DOI 10.1074/jbc.M109.072660; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Yang JC, 2009, CANCER RES, V69, P151, DOI 10.1158/0008-5472.CAN-08-0442; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	35	70	77	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3208	3216		10.1038/onc.2010.103	http://dx.doi.org/10.1038/onc.2010.103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20383201	Green Accepted, Green Submitted			2022-12-28	WOS:000278321100004
J	Szabo, PM; Tamasi, V; Molnar, V; Andrasfalvy, M; Tombol, Z; Farkas, R; Kovesdi, K; Patocs, A; Toth, M; Szalai, C; Falus, A; Racz, K; Igaz, P				Szabo, P. M.; Tamasi, V.; Molnar, V.; Andrasfalvy, M.; Tombol, Z.; Farkas, R.; Kovesdi, K.; Patocs, A.; Toth, M.; Szalai, C.; Falus, A.; Racz, K.; Igaz, P.			Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed	ONCOGENE			English	Article						adrenocortical tumour; meta-analysis; mRNA profiling; comparative genome hybridization; pathway analysis	GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; MOLECULAR CLASSIFICATION; HYBRIDIZATION ANALYSIS; RETINOIC ACID; ADRENAL-GLAND; RECEPTOR; CANCER; MICROARRAY; MALIGNANCY	Sporadic adrenocortical tumours are common, but their pathogenesis is poorly elucidated. In this study, we present a meta-analysis and review of gene expression microarray and comparative genome hybridization (CGH) studies performed to date on these tumours, including our own data. Data of whole genome microarray studies from altogether 164 tumours (97 benign, 67 malignant) and 18 normal tissues were reclassified and reanalysed. Significant gene sets and cytogenetic changes from publications without available genomic data were also examined including 269 benign, 215 malignant tumour and 30 normal tissues. In our experimental study, 11 tumour and four normal samples were analysed by parallel mRNA and CGH profiling. Data were examined by an integrative bioinformatics approach (GeneSpring, Gene Set Enrichment Analysis and Ingenuity Pathway Analysis softwares) searching for common gene expression changes and paralleling chromosome aberrations. Both meta-analysis of available mRNA and CGH profiling data and our experimental study revealed three major pathogenetic pathways: (1) cell cycle, (2) retinoic acid signalling (including lipopolysaccharide/Toll like receptor 4 pathway), (3) complement system and antigen presentation. These pathways include novel, previously undescribed pathomechanisms of adrenocortical tumours, and associated gene products may serve as diagnostic markers of malignancy and therapeutic targets. Oncogene (2010) 29, 3163-3172; doi: 10.1038/onc.2010.80; published online 22 March 2010	[Szabo, P. M.; Tombol, Z.; Farkas, R.; Kovesdi, K.; Toth, M.; Racz, K.; Igaz, P.] Semmelweis Univ, Fac Med, Dept Med 2, H-1088 Budapest, Hungary; [Tamasi, V.; Molnar, V.; Falus, A.] Semmelweis Univ, Fac Med, Dept Genet Cell & Immunobiol, H-1088 Budapest, Hungary; [Andrasfalvy, M.] Kromat Ltd, Budapest, Hungary; [Patocs, A.] Hungarian Acad Sci, Mol Med Res Grp, Budapest, Hungary; [Szalai, C.; Falus, A.] Hungarian Acad Sci, Inflammat Biol & Immune Genom Res Grp, Budapest, Hungary; [Szalai, C.] Heim Pal Pediat Hosp, Mol Biol Lab, Budapest, Hungary	Semmelweis University; Semmelweis University; Hungarian Academy of Sciences; Hungarian Academy of Sciences	Igaz, P (corresponding author), Semmelweis Univ, Fac Med, Dept Med 2, Szentkiralyi Str 46, H-1088 Budapest, Hungary.	igapet@bel2.sote.hu	Igaz, Peter/D-3081-2014	Igaz, Peter/0000-0003-2192-554X; Patocs, Attila/0000-0001-7506-674X; Falus, Andras/0000-0002-6843-6789	Hungarian Scientific Research Fund (OTKA) [PD72306]; Hungarian Ministry of Health [ETT 040/09]	Hungarian Scientific Research Fund (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Hungarian Ministry of Health	This work was supported by the Hungarian Scientific Research Fund (OTKA, PD72306) and the Hungarian Ministry of Health (ETT 040/09).	Bertherat J, 2003, CANCER RES, V63, P5308; Betz MJ, 2005, J CLIN ENDOCR METAB, V90, P3886, DOI 10.1210/jc.2004-1267; Bourcigaux N, 2000, J CLIN ENDOCR METAB, V85, P322, DOI 10.1210/jc.85.1.322; Cummins CL, 2006, J CLIN INVEST, V116, P1902, DOI 10.1172/JCI28400; de Fraipont F, 2005, J CLIN ENDOCR METAB, V90, P1819, DOI 10.1210/jc.2004-1075; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Dohna M, 2000, GENE CHROMOSOME CANC, V28, P145, DOI 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.0.CO;2-7; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Faggad A, 2009, MODERN PATHOL, V22, P579, DOI 10.1038/modpathol.2009.14; Fernandez-Ranvier GG, 2008, ARCH SURG-CHICAGO, V143, P841, DOI 10.1001/archsurg.143.9.841; Fernandez-Ranvier GG, 2008, WORLD J SURG, V32, P873, DOI 10.1007/s00268-008-9521-0; Ferruzzi P, 2005, J CLIN ENDOCR METAB, V90, P1332, DOI 10.1210/jc.2004-0978; Figueiredo BC, 2005, J CLIN ENDOCR METAB, V90, P615, DOI 10.1210/jc.2004-0942; Figueiredo BC, 1999, J CLIN ENDOCR METAB, V84, P1116, DOI 10.1210/jc.84.3.1116; Ghose Romi, 2004, Nucl Recept, V2, P4, DOI 10.1186/1478-1336-2-4; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Haselbeck RJ, 1997, ENDOCRINOLOGY, V138, P3035, DOI 10.1210/en.138.7.3035; Hong FX, 2008, BIOINFORMATICS, V24, P374, DOI 10.1093/bioinformatics/btm620; Kanczkowski W, 2009, MOL CELL ENDOCRINOL, V300, P57, DOI 10.1016/j.mce.2008.10.028; Kjellman M, 1996, CANCER RES, V56, P4219; Laurell C, 2009, EUR J ENDOCRINOL, V161, P141, DOI 10.1530/EJE-09-0068; Libe R, 2007, ENDOCR-RELAT CANCER, V14, P13, DOI 10.1677/erc.1.01130; Marx C, 1996, J CLIN ENDOCR METAB, V81, P4488, DOI 10.1210/jc.81.12.4488; Ondrey F, 2009, CLIN CANCER RES, V15, P2, DOI 10.1158/1078-0432.CCR-08-0326; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Patalano A, 2009, HORM RES, V71, P99, DOI 10.1159/000178049; Russell AJ, 1999, BRIT J CANCER, V81, P684, DOI 10.1038/sj.bjc.6690748; Scripture CD, 2005, LANCET ONCOL, V6, P780, DOI 10.1016/S1470-2045(05)70388-0; Shimizu M, 2009, CANCER SCI, V100, P369, DOI 10.1111/j.1349-7006.2008.01045.x; Sidhu S, 2002, J CLIN ENDOCR METAB, V87, P3467, DOI 10.1210/jc.87.7.3467; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Slater EP, 2006, EUR J ENDOCRINOL, V154, P587, DOI 10.1530/eje.1.02116; Soon PSH, 2009, ENDOCR-RELAT CANCER, V16, P573, DOI 10.1677/ERC-08-0237; Soon PSH, 2008, ONCOLOGIST, V13, P548, DOI 10.1634/theoncologist.2007-0243; Stephan EA, 2008, MOL CANCER THER, V7, P425, DOI 10.1158/1535-7163.MCT-07-0267; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorngate FE, 2002, J LIPID RES, V43, P1920, DOI 10.1194/jlr.M200205-JLR200; Tombol Z, 2009, ENDOCR-RELAT CANCER, V16, P895, DOI 10.1677/ERC-09-0096; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Vakharia K, 2005, ENDOCRINOLOGY, V146, P1398, DOI 10.1210/en.2004-0882; Velazquez-Fernandez D, 2005, SURGERY, V138, P1087, DOI 10.1016/j.surg.2005.09.031; West AN, 2007, CANCER RES, V67, P600, DOI 10.1158/0008-5472.CAN-06-3767; Wolkersdorfer GW, 2005, J CLIN ENDOCR METAB, V90, P1768, DOI 10.1210/jc.2004-1406; Ye P, 2007, J ENDOCRINOL, V195, P39, DOI 10.1677/JOE-07-0037; Zacharowski K, 2006, P NATL ACAD SCI USA, V103, P6392, DOI 10.1073/pnas.0601527103; Zhao JM, 1999, AM J PATHOL, V155, P1039, DOI 10.1016/S0002-9440(10)65205-4; Zhao JM, 2002, GENE CHROMOSOME CANC, V34, P48, DOI 10.1002/gcc.10035	49	58	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3163	3172		10.1038/onc.2010.80	http://dx.doi.org/10.1038/onc.2010.80			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20305693				2022-12-28	WOS:000278133100013
J	Turner, N; Lambros, MB; Horlings, HM; Pearson, A; Sharpe, R; Natrajan, R; Geyer, FC; van Kouwenhove, M; Kreike, B; Mackay, A; Ashworth, A; de Vijver, MJV; Reis-Filho, JS				Turner, N.; Lambros, M. B.; Horlings, H. M.; Pearson, A.; Sharpe, R.; Natrajan, R.; Geyer, F. C.; van Kouwenhove, M.; Kreike, B.; Mackay, A.; Ashworth, A.; de Vijver, M. J. van; Reis-Filho, J. S.			Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets	ONCOGENE			English	Article						triple negative breast cancer; microarrays; gene expression; comparative genomic hybridization; FGFR2	COMPARATIVE GENOMIC HYBRIDIZATION; COPY-NUMBER ALTERATIONS; MICROARRAY PLATFORMS; IN-SITU; EXPRESSION; PATTERNS; GENES; CELLS; ARRAY; RESOLUTION	Triple negative breast cancers (TNBCs) have a relatively poor prognosis and cannot be effectively treated with current targeted therapies. We searched for genes that have the potential to be therapeutic targets by identifying genes consistently overexpressed when amplified. Fifty-six TNBCs were subjected to high-resolution microarray-based comparative genomic hybridization (aCGH), of which 24 were subjected to genome-wide gene expression analysis. TNBCs were genetically heterogeneous; no individual focal amplification was present at high frequency, although 78.6% of TNBCs harboured at least one focal amplification. Integration of aCGH and expression data revealed 40 genes significantly overexpressed when amplified, including the known oncogenes and potential therapeutic targets, FGFR2 (10q26.3), BUB3 (10q26.3), RAB20 (13q34), PKN1 (19p13.12) and NOTCH3 (19p13.12). We identified two TNBC cell lines with FGFR2 amplification, which both had constitutive activation of FGFR2. Amplified cell lines were highly sensitive to FGFR inhibitor PD173074, and to RNAi silencing of FGFR2. Treatment with PD173074 induced apoptosis resulting partly from inhibition of PI3K-AKT signalling. Independent validation using publicly available aCGH data sets revealed FGFR2 gene was amplified in 4% (6/165) of TNBC, but not in other subtypes (0/214, P = 0.0065). Our analysis demonstrates that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours. Oncogene (2010) 29, 2013-2023; doi: 10.1038/onc.2009.489; published online 18 January 2010	[Turner, N.; Lambros, M. B.; Pearson, A.; Sharpe, R.; Natrajan, R.; Geyer, F. C.; Mackay, A.; Ashworth, A.; Reis-Filho, J. S.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Horlings, H. M.; van Kouwenhove, M.; de Vijver, M. J. van] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Horlings, H. M.; de Vijver, M. J. van] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; [Kreike, B.] Netherlands Canc Inst, Div Radiat Oncol, NL-1066 CX Amsterdam, Netherlands	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Netherlands Cancer Institute	Turner, N (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	nicholas.turner@icr.ac.uk; jorge.reis-filho@icr.ac.uk		Turner, Nicholas/0000-0001-8937-0873; Natrajan, Rachael/0000-0002-9987-2946; van de Vijver, Marc/0000-0002-0385-4787; Kreike, Bas/0000-0003-0030-8200	Cancer Research UK and Breakthrough Breast Cancer; NHS	Cancer Research UK and Breakthrough Breast Cancer; NHS	This work was supported by grants from Cancer Research UK and Breakthrough Breast Cancer. Dr Nicholas Turner is a CRUK clinician scientist. We acknowledge NHS funding to the NIHR Biomedical Research Centre.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Agrawal G, 2007, J CLIN ONCOL, V25, P2618, DOI 10.1200/JCO.2007.11.3084; Andre F, 2009, CLIN CANCER RES, V15, P441, DOI 10.1158/1078-0432.CCR-08-1791; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360; Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518; Byron SA, 2008, CANCER RES, V68, P6902, DOI 10.1158/0008-5472.CAN-08-0770; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Garcia-Closas M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000054; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gunnarsson R, 2008, GENE CHROMOSOME CANC, V47, P697, DOI 10.1002/gcc.20575; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; Hannemann J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1613; Harris LN, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1622; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Lambros MBK, 2006, LAB INVEST, V86, P398, DOI 10.1038/labinvest.3700390; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; NATRAJAN R, 2009, BREAST CANC RES TREA; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Ng G, 2006, J MOL DIAGN, V8, P449, DOI 10.2353/jmoldx.2006.060033; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Reis-Filho JS, 2008, NAT GENET, V40, P809, DOI 10.1038/ng0708-809b; Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164; Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208; Tan DSP, 2007, LAB INVEST, V87, P737, DOI 10.1038/labinvest.3700593; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	47	295	304	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2013	2023		10.1038/onc.2009.489	http://dx.doi.org/10.1038/onc.2009.489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101236	Green Submitted, Green Accepted			2022-12-28	WOS:000276402800001
J	Lochhead, PA; Wickman, G; Mezna, M; Olson, MF				Lochhead, P. A.; Wickman, G.; Mezna, M.; Olson, M. F.			Activating ROCK1 somatic mutations in human cancer	ONCOGENE			English	Article						ROCK; kinase; Rho; actin; cytoskeleton; cancer	RHO-ASSOCIATED KINASE; CASPASE-MEDIATED ACTIVATION; PROGRESSION; INHIBITOR; TUMOR; METASTASIS; INVASION; PATHWAY; GTPASES; DOWNSTREAM	Cancer cells acquire characteristics of deregulated growth, survival and increased metastatic potential. Genetic mutations that provide a selective advantage by promoting these characteristics have been termed 'drivers,' whereas mutations that do not contribute to disease initiation/progression are termed 'passengers.' The advent of high-throughput methodologies has facilitated large-scale screening of cancer genomes and the subsequent identification of novel somatic mutations. Although this approach has generated valuable results, the data remain incomplete until the functional consequences of these mutations are determined to differentiate potential drivers from passengers. ROCK1 is an essential effector kinase downstream of Rho GTPases, an important pathway involved in cell migration. The Cancer Genome Project identified three nonsynonymous mutations in the ROCK1 gene. We now show that these somatic ROCK1 mutations lead to elevated kinase activity and drive actin cytoskeleton rearrangements that promote increased motility and decreased adhesion, characteristics of cancer progression. Mapping of the kinase-interacting regions of the carboxy terminus combined with structural modeling provides an insight into how these mutations likely affect the regulation of ROCK1. Consistent with the frequency of ROCK1 mutations in human cancer, these results support the conclusion that there is selective pressure for the ROCK1 gene to acquire 'driver' mutations that result in kinase activation. Oncogene (2010) 29, 2591-2598; doi:10.1038/onc.2010.3; published online 8 February 2010	[Lochhead, P. A.; Wickman, G.; Mezna, M.; Olson, M. F.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Olson, MF (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.olson@beatson.gla.ac.uk	Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 	Cancer Research UK; NIH [CA030721]; NATIONAL CANCER INSTITUTE [R01CA030721] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Cancer Research UK and by a grant to MFO from the NIH (CA030721). Assistance with protein modeling was provided by Felix Krueger (Babraham Institute).	Abe H, 2008, BIOMED RES-TOKYO, V29, P155, DOI 10.2220/biomedres.29.155; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; DOKI Y, 1993, CANCER RES, V53, P3421; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jacobs M, 2006, J BIOL CHEM, V281, P260, DOI 10.1074/jbc.M508847200; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakajima M, 2003, CANCER CHEMOTH PHARM, V52, P319, DOI 10.1007/s00280-003-0641-9; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Ogawa T, 2007, AM J TRANSPLANT, V7, P347, DOI 10.1111/j.1600-6143.2006.01647.x; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Wen WY, 2008, J BIOL CHEM, V283, P26263, DOI 10.1074/jbc.M803417200; Xue F, 2008, HEPATOL RES, V38, P810, DOI 10.1111/j.1872-034X.2008.00333.x; Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535-7163.MCT-05-0440	24	74	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2591	2598		10.1038/onc.2010.3	http://dx.doi.org/10.1038/onc.2010.3			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140017				2022-12-28	WOS:000277169400014
J	Song, J; Sandoval, R; Pilkinton, MA; Tian, X; Raychaudhuri, P; Colamonici, OR				Song, J.; Sandoval, R.; Pilkinton, M. A.; Tian, X.; Raychaudhuri, P.; Colamonici, O. R.			ARF-induced downregulation of Mip130/LIN-9 protein levels mediates a positive feedback that leads to increased expression of p16(Ink4a) and p19(Arf)	ONCOGENE			English	Article						LIN-9; ARF; p53; senescence and cell cycle	CELL-CYCLE ARREST; GROWTH SUPPRESSION; ONCOGENIC RAS; CDKN2A LOCUS; G(1) CONTROL; B-MYB; SENESCENCE; P53; P14(ARF); GENE	The ARF-MDM2-p53 pathway constitutes one of the most important mechanisms of surveillance against oncogenic transformation, and its inactivation occurs in a large proportion of cancers. Here, we show that ARF regulates Mip130/LIN-9 by inducing its translocation to the nucleolus and decreasing the expression of the Mip130/LIN-9 protein through a post-transcriptional mechanism. The knockdown of Mip130/LIN-9 in p53(-/-) and Arf(-/-) mouse embryonic fibroblasts (MEFs) mimics some effects of ARF, such as the downregulation of B-Myb, impaired induction of G2/M genes, and a decrease in cell proliferation. Importantly, although the knockdown of Mip130/LIN-9 reduced the proliferation of p53 or Arf-null MEFs, only p53(-/-) MEFs showed a senescence-like state and an increase in the expression of Arf and p16. Interestingly, the increase in p16 and ARF is indirect because the Mip130/LIN-9 knockdown decreased the transcription of negative regulators of the Ink4a/Arf locus, such as BUBR1 and CDC6. Chromatin immunoprecipitation assays also reveal that Mip130/LIN-9 occupies the promoters of the BubR1 and cdc6 genes, suggesting that Mip130/LIN-9 is necessary for the expression of these genes. Altogether, these results indicate that there is a feedback mechanism between ARF and Mip130/LIN-9 in which either the increase of ARF or the decrease in Mip130/LIN-9 causes a further increase in the expression of Arf and p16. Oncogene (2010) 29, 1976-1986; doi:10.1038/onc.2009.485; published online 18 January 2010	[Song, J.; Sandoval, R.; Pilkinton, M. A.; Colamonici, O. R.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; [Tian, X.] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; [Raychaudhuri, P.] Univ Illinois, Dept Biochem Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,MC868,Rm E403, Chicago, IL 60612 USA.	ocolamon@uic.edu			National Institutes of Health [RO1 GM81562, NCI-KO1CA127862, T32]; Ruth L Kirschstein National Research Service Award [NOT-OD-06-093]; Training Program in Signal Transduction and Cellular Endocrinology [DK07739]; NATIONAL CANCER INSTITUTE [K01CA127862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081562] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Training Program in Signal Transduction and Cellular Endocrinology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs Charles Sherr and Martine Roussel, St Jude Children's Research Hospital, for the Arf and p53 plasmid constructs and Arf<SUP>-/-</SUP> and p53<SUP>-/-</SUP> MEFs. This work was supported by Public Health Service Grants RO1 GM81562 (ORC) and NCI-KO1CA127862 (RS) from the National Institutes of Health. JS and MP were supported by NIH Institutional T32 training grants, Ruth L Kirschstein National Research Service Award NOT-OD-06-093 and Training Program in Signal Transduction and Cellular Endocrinology DK07739, respectively.	Baker DJ, 2008, CELL CYCLE, V7, P2795, DOI 10.4161/cc.7.18.6687; Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744; Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Blagosklonny MV, 2006, J CELL PHYSIOL, V209, P592, DOI 10.1002/jcp.20750; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Datta A, 2005, MOL CELL BIOL, V25, P8024, DOI 10.1128/MCB.25.18.8024-8036.2005; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gazzeri S, 1998, CANCER RES, V58, P3926; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hartman TK, 2007, NEUROBIOL AGING, V28, P921, DOI 10.1016/j.neurobiolaging.2006.05.012; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hong Z, 2007, J CELL PHYSIOL, V210, P567, DOI 10.1002/jcp.20919; Isono K, 2005, MOL CELL BIOL, V25, P6694, DOI 10.1128/MCB.25.15.6694-6706.2005; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Modestou M, 2001, CANCER RES, V61, P3145; Muller H, 1997, MOL CELL BIOL, V17, P5508; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; QUELLE DE, 1995, CELL, V83, P993; Saadatmandi N, 2002, CANCER GENE THER, V9, P830, DOI 10.1038/sj.cgt.7700505; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sandoval R, 2006, EXP CELL RES, V312, P2465, DOI 10.1016/j.yexcr.2006.04.002; Sandoval R, 2009, EXP CELL RES, V315, P2914, DOI 10.1016/j.yexcr.2009.07.014; Schmunis GA, 2007, ISBT SCI SERIES, V2, P6, DOI 10.1111/j.1751-2824.2007.00052.x; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	63	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1976	1986		10.1038/onc.2009.485	http://dx.doi.org/10.1038/onc.2009.485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101237	Green Accepted			2022-12-28	WOS:000276199600010
J	Torosyan, Y; Dobi, A; Glasman, M; Mezhevaya, K; Naga, S; Huang, W; Paweletz, C; Leighton, X; Pollard, HB; Srivastava, M				Torosyan, Y.; Dobi, A.; Glasman, M.; Mezhevaya, K.; Naga, S.; Huang, W.; Paweletz, C.; Leighton, X.; Pollard, H. B.; Srivastava, M.			Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells	ONCOGENE			English	Article						Annexin A7, ANXA7 (or synexin); heterogeneous nuclear ribonucleoprotein; hnRNP; prostate cancer; DNA affinity enrichment/identification of nuclear proteins; mass spectrometry	ELEMENT-BINDING-PROTEIN; ANNEXIN-VII GENE; IN-VIVO; RIBONUCLEOPROTEIN-K; ANDROGEN RECEPTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID-RECEPTOR; CORE PROMOTER; EXPRESSION	Annexin-A7 (ANXA7) tumor suppressor role has been shown in various tumors, and ANXA7 expression has been particularly lost in androgen-resistant prostate cancers. In this study, we studied ANXA7 regulation in normal prostate versus androgen-sensitive and -resistant prostate cancer cells. Deletion mapping analysis showed lowest ANXA7-promoter activities in androgen-sensitive LNCaP prostate cancer cells. Genomatix analysis of ANXA7 promoter identified a cluster of steroid nuclear hormone receptor elements, including V$GREF (V$GRE.02/ARE.02). Gelshift analysis clearly indicated distinct nuclear protein occupancy at this ANXA7-promoter site (-1086/-890) in prostate cancer (LNCaP, DU145, and PC3) versus normal prostate (PrEC) cells. In matrix-assisted laser desorption time-of-light mass spectrometry-based search for ANXA7 nuclear regulators, we identified several heterogeneous nuclear ribonucleoproteins (hnRNPs) (A1, A2/B1 and K) attached to the steroid-associated ANXA7-promoter site in the androgen-resistant PC3 prostate cancer cells with high ANXA7 gene copy number, but not in PrEC. The hnPNP role in ANXA7 regulation (that was validated by hnRNPA2/B1 antibody interference) resulted in multiple ANXA7 cDNA and protein products in PC3, but not in PrEC. Ingenuity pathways analysis showed plausible molecular paths between ANXA7 and the hnRNP-associated network in prostate cancer progression. Thus, a multi-hnRNP complex can be responsible for aberrant ANXA7 transcription and splicing, thereby affecting ANXA7 expression pattern and tumor suppressor function in prostate cancer. Oncogene (2010) 29, 2457-2466; doi:10.1038/onc.2010.2; published online 1 March 2010	[Torosyan, Y.; Glasman, M.; Mezhevaya, K.; Naga, S.; Huang, W.; Paweletz, C.; Leighton, X.; Pollard, H. B.; Srivastava, M.] Uniformed Serv Univ Sch Med USUHS, Dept Anat Physiol & Genet, Inst Mol Med, Bethesda, MD USA; [Dobi, A.] CPDR, Sect Gene Regulat & Bioinformat, Rockville, MD USA		Srivastava, M (corresponding author), USU Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd,B2-034, Bethesda, MD 20814 USA.	msrivastava@usuhs.mil			US Department of Defense (DoD)	US Department of Defense (DoD)(United States Department of Defense)	We thank Dr Gideon Dreyfuss (University of Pennsylvania School of Medicine) for providing hnRNPA2/B1 antibody. This work was supported by grants funded by the US Department of Defense (DoD).	Adachi K, 1999, ENDOCRINOLOGY, V140, P618, DOI 10.1210/en.140.2.618; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Barboro P, 2009, BRIT J CANCER, V100, P1608, DOI 10.1038/sj.bjc.6605057; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; Caron D, 2008, J PROTEOME RES, V7, P4492, DOI 10.1021/pr8002497; Carpenter B, 2006, BBA-REV CANCER, V1765, P85, DOI 10.1016/j.bbcan.2005.10.002; Chen H, 2005, ENDOCRINOLOGY, V146, P4266, DOI 10.1210/en.2005-0160; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Chen TC, 2000, CLIN CANCER RES, V6, P901; Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011; Courchet J, 2008, J BIOL CHEM, V283, P32131, DOI 10.1074/jbc.M802927200; Dobi A, 2002, BIOTECHNIQUES, V33, P868, DOI 10.2144/02334rr03; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Graveley BR, 2009, NAT STRUCT MOL BIOL, V16, P13, DOI 10.1038/nsmb0109-13; He YW, 2005, J CELL SCI, V118, P3173, DOI 10.1242/jcs.02448; Heemers HV, 2006, MOL ENDOCRINOL, V20, P2265, DOI 10.1210/me.2005-0479; Hellwinkel OJC, 2008, BJU INT, V101, P1454, DOI 10.1111/j.1464-410X.2008.07540.x; Hilbe W, 2004, EUR J CANCER PREV, V13, P425, DOI 10.1097/00008469-200410000-00011; Juven-Gershon T, 2008, CURR OPIN CELL BIOL, V20, P253, DOI 10.1016/j.ceb.2008.03.003; Kang HS, 2007, PHYSIOL GENOMICS, V31, P281, DOI 10.1152/physiolgenomics.00098.2007; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kimura E, 2003, BIOSCI BIOTECH BIOCH, V67, P1786, DOI 10.1271/bbb.67.1786; Lee BJ, 2006, CELL, V126, P543, DOI 10.1016/j.cell.2006.05.049; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; Mikula M, 2006, PROTEOMICS, V6, P2395, DOI 10.1002/pmic.200500632; Mukhopadhyay NK, 2009, CANCER RES, V69, P2210, DOI 10.1158/0008-5472.CAN-08-2308; Myslinski E, 2006, J BIOL CHEM, V281, P39953, DOI 10.1074/jbc.M608507200; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Patry C, 2003, CANCER RES, V63, P7679; Pollard H B, 1998, Adv Pharmacol, V42, P81; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rizzo G, 2006, CURR OPIN PHARMACOL, V6, P421, DOI 10.1016/j.coph.2006.03.012; Rozanov DV, 2008, CANCER RES, V68, P4086, DOI 10.1158/0008-5472.CAN-07-6458; Sakaguchi M, 2007, J BIOL CHEM, V282, P35679, DOI 10.1074/jbc.M707538200; Shi LH, 2008, J BIOL CHEM, V283, P36474, DOI 10.1074/jbc.M805980200; Shi Y, 2007, MOL CELL, V28, P79, DOI 10.1016/j.molcel.2007.08.028; SHIRVAN A, 1994, BIOCHEMISTRY-US, V33, P6888, DOI 10.1021/bi00188a019; Srivastava M, 2003, P NATL ACAD SCI USA, V100, P14287, DOI 10.1073/pnas.2235927100; Srivastava M, 2000, CELL BIOL INT, V24, P475, DOI 10.1006/cbir.2000.0511; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Srivastava M, 2007, INT J CANCER, V121, P2628, DOI 10.1002/ijc.23008; Tokusumi Y, 2007, MOL CELL BIOL, V27, P1844, DOI 10.1128/MCB.01363-06; Torosyan Y, 2006, CANCER RES, V66, P9609, DOI 10.1158/0008-5472.CAN-06-1574; Torosyan Y, 2009, INT J CANCER, V125, P2528, DOI 10.1002/ijc.24592; Yemelyanov A, 2007, ONCOGENE, V26, P1885, DOI 10.1038/sj.onc.1209991; Zheng Z, 2006, J BIOL CHEM, V281, P4002, DOI 10.1074/jbc.M509260200	51	25	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2457	2466		10.1038/onc.2010.2	http://dx.doi.org/10.1038/onc.2010.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20190808				2022-12-28	WOS:000277169400001
J	Giglio, S; Mancini, F; Pellegrino, M; Di Conza, G; Puxeddu, E; Sacchi, A; Pontecorvi, A; Moretti, F				Giglio, S.; Mancini, F.; Pellegrino, M.; Di Conza, G.; Puxeddu, E.; Sacchi, A.; Pontecorvi, A.; Moretti, F.			Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity	ONCOGENE			English	Article						p53; MDM4; MDM2; p76(MDM2); p90(MDM2)	DEGRADATION; HDMX; PHOSPHORYLATION; UBIQUITINATION; TRANSCRIPTS; STABILITY; REVEALS; ABILITY; ATM	Under basal growth conditions, p53 function is tightly controlled by the members of MDM family, MDM2 and MDM4. The Mdm2 gene codes, in addition to the full-length p90(MDM2), for a short protein, p76(MDM2) that lacks the p53-binding domain. Despite this property and at variance with p90(MDM2), this protein acts positively toward p53, although the molecular mechanism remains elusive. Here, we report that p76(MDM2) antagonizes MDM4 inhibitory function. We show that p76(MDM2) possesses intrinsic ubiquitinating and degrading activity, and through these activities controls MDM4 levels. Furthermore, the presence of p76(MDM2) decreases the association of MDM4 with p53 and p90(MDM2), and antagonizes p53 degradation by the heterodimer MDM4/ p90(MDM2). The p76(MDM2)-mediated regulation of MDM4 occurs in the cytoplasm, under basal growth conditions. Conversely, upon DNA damage, phosphorylation of MDM4Ser403 dissociates p76(MDM2) and prevents MDM4 degradation. The overall negative control of MDM4 by p76(MDM2) reflects on p53 function as p76(MDM2) impairs MDM4-mediated inhibition of p53 activity. In agreement with the positive role of p76(MDM2) toward p53, the p76(MDM2)/p90(MDM2) ratio significantly decreases in a group of thyroid tumor samples compared with normal counterparts. Overall, these findings reveal a new mechanism in the control of p53 basal activity that may account for the distinct sensitivity of tissues to stress signals depending on the balance among MDM proteins. Moreover, these data suggest an onco-suppressive function for a product of the Mdm2 gene. Oncogene (2010) 29, 5935-5945; doi:10.1038/onc.2010.324; published online 9 August 2010	[Giglio, S.; Mancini, F.; Pellegrino, M.; Di Conza, G.; Moretti, F.] CNR, Inst Neurobiol & Mol Med, Fdn Santa Lucia, I-6400143 Rome, Italy; [Giglio, S.; Mancini, F.; Pontecorvi, A.] Catholic Univ, Inst Med Pathol, Rome, Italy; [Di Conza, G.] Univ Messina, Dept Expt Clin Med & Pharmacol, Messina, Italy; [Puxeddu, E.] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy; [Sacchi, A.] Regina Elena Inst Canc Res, Lab Mol Oncogenesis, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Santa Lucia; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Messina; University of Perugia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Moretti, F (corresponding author), CNR, Inst Neurobiol & Mol Med, Fdn Santa Lucia, Via Fosso di Fiorano, I-6400143 Rome, Italy.	moretti@inmm.cnr.it	Mancini, Francesca/AAZ-1672-2021; Moretti, Fabiola/I-5647-2013; Puxeddu, Efisio/I-8188-2012; Pellegrino, Marsha/K-4500-2016; Di Conza, Giusy/GPP-1438-2022; mancini, francesca/K-6062-2016	Mancini, Francesca/0000-0002-2459-8815; Moretti, Fabiola/0000-0002-2691-1254; Pellegrino, Marsha/0000-0002-9002-3622; mancini, francesca/0000-0002-2459-8815; Di Conza, Giusy/0000-0003-1353-5867	Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita	Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita(Fondazione AIRC per la ricerca sul cancro)	The work was supported by research grants from Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita. We are grateful to Dr Lozano for Mdm2<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs, to Dr JC Marine for Mdm4<SUP>-/-</SUP> Mdm2<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs and to Dr Jochemsen for phosphorylation-defective human MDM4S403A coding plasmid. We are also especially grateful to Dr Jochemsen for critical review and helpful comments to the paper.	BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cheng TH, 2007, MOL CELL BIOL, V27, P111, DOI 10.1128/MCB.00235-06; Dimitriadi M, 2008, BRIT J CANCER, V99, P1144, DOI 10.1038/sj.bjc.6604643; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; Mancini F, 2009, CURR GENOMICS, V10, P42, DOI 10.2174/138920209787581280; Mancini F, 2009, CELL CYCLE, V8, P3854, DOI 10.4161/cc.8.23.10089; Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Ohtsubo C, 2009, CANCER SCI, V100, P1291, DOI 10.1111/j.1349-7006.2009.01180.x; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pikkarainen S, 2009, J BIOL CHEM, V284, P27195, DOI 10.1074/jbc.M109.037887; Prodosmo A, 2008, J MOL MED-JMM, V86, P585, DOI 10.1007/s00109-008-0322-6; Ralhan R, 2000, AM J PATHOL, V157, P587, DOI 10.1016/S0002-9440(10)64569-5; Salem MMAEL, 2009, FASEB J, V23, P3790, DOI 10.1096/fj.09-132621; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wang YYV, 2009, CELL CYCLE, V8, P3443, DOI 10.4161/cc.8.21.9744; Zhou JX, 2009, J IMMUNOL, V183, P3188, DOI 10.4049/jimmunol.0803693	35	11	12	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5935	5945		10.1038/onc.2010.324	http://dx.doi.org/10.1038/onc.2010.324			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697359				2022-12-28	WOS:000283843400007
J	Ma, Z; Liu, Z; Wu, RF; Terada, LS				Ma, Z.; Liu, Z.; Wu, R-F; Terada, L. S.			p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior	ONCOGENE			English	Article						anoikis; Shc; pRB; metastasis; small cell lung cancer	PAPILLOMAVIRUS TYPE-16 E7; CELL-CYCLE; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; K-RAS; ACTIVATION; ANOIKIS; KINASE; PATHWAY; DIFFERENTIATION	Normal tissue cells survive and proliferate only while anchored to solid substrate. Conversely, transformed cells both survive and proliferate following detachment, having lost attachment context through unclear mechanisms. p66(Shc) is a focal adhesion-associated protein that reports cell attachment through a RhoA-dependent mechanosensory test. We find that human small cell lung cancer (SCLC) cells and mouse Lewis lung carcinoma (LLC), which display aggressive metastatic behavior, lack both p66(Shc) and retinoblastoma (pRB) and bypass anoikis. Re-expression of p66(Shc) in these cells restores anoikis and provides striking protection from metastasis by LLC cells in vivo. Notably, knockdown of p66(Shc) in normal epithelial cells leads to unrestrained Ras activation, preventing anoikis through downstream suppression of RhoA but blocking proliferation in a pRB-dependent manner, thus mimicking oncogenic Ras. Conversely, LLC and SCLC cells display constitutive Ras activation necessary to bypass anoikis, which is reversed by re-expression of p66(Shc). p66(Shc) therefore coordinates Ras-dependent control of proliferation and anchorage sensation, which can be defeated in the evolution of highly metastatic tumors by combined loss of both p66(Shc) and pRB. Oncogene (2010) 29, 5559-5567; doi:10.1038/onc.2010.326; published online 2 August 2010	[Ma, Z.; Liu, Z.; Wu, R-F; Terada, L. S.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Pulm & Crit Care, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Univ Texas SW, Dept Internal Med, 5323 Harry Hines Blvd,MC 8558, Dallas, TX 75390 USA.	Lance.Terada@utsouthwestern.edu		Terada, Lance/0000-0001-7441-9734	NHLBI [R01-HL067256, R01-HL061897]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061897, R01HL067256] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful to Dr John Shelton for assistance with histology and Drs Ralph P Mason and Li Liu for technical support with in vivo GFP imaging. This work was supported by grants to LST by the NHLBI (R01-HL067256 and R01-HL061897).	Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grignani F, 1998, CANCER RES, V58, P14; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wu RF, 2007, J BIOL CHEM, V282, P37412, DOI 10.1074/jbc.M704481200	26	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5559	5567		10.1038/onc.2010.326	http://dx.doi.org/10.1038/onc.2010.326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676142	Green Accepted			2022-12-28	WOS:000282946900003
J	Oram, SH; Thoms, JAI; Pridans, C; Janes, ME; Kinston, SJ; Anand, S; Landry, JR; Lock, RB; Jayaraman, PS; Huntly, BJ; Pimanda, JE; Gottgens, B				Oram, S. H.; Thoms, J. A. I.; Pridans, C.; Janes, M. E.; Kinston, S. J.; Anand, S.; Landry, J-R; Lock, R. B.; Jayaraman, P-S; Huntly, B. J.; Pimanda, J. E.; Goettgens, B.			A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients	ONCOGENE			English	Article						LMO2; leukaemia; transcriptional regulation; human; ChIP-on-chip; chromatin immunoprecipitation	LIM-PROTEIN RBTN2; GENE-THERAPY; CELL LEUKEMIA; ETS; ONCOGENE; DOMAIN; ERG; ELEMENTS; SCL; TRANSLOCATIONS	The T-cell oncogene Lim-only 2 (LMO2) critically influences both normal and malignant haematopoiesis. LMO2 is not normally expressed in T cells, yet ectopic expression is seen in the majority of T-acute lymphoblastic leukaemia (T-ALL) patients with specific translocations involving LMO2 in only a subset of these patients. Ectopic lmo2 expression in thymocytes of transgenic mice causes T-ALL, and retroviral vector integration into the LMO2 locus was implicated in the development of clonal T-cell disease in patients undergoing gene therapy. Using array-based chromatin immunoprecipitation, we now demonstrate that in contrast to B-acute lymphoblastic leukaemia, human T-ALL samples largely use promoter elements with little influence from distal enhancers. Active LMO2 promoter elements in T-ALL included a previously unrecognized third promoter, which we demonstrate to be active in cell lines, primary T-ALL patients and transgenic mice. The ETS factors ERG and FLI1 previously implicated in lmo2-dependent mouse models of T-ALL bind to the novel LMO2 promoter in human T-ALL samples, while in return LMO2 binds to blood stem/progenitor enhancers in the FLI1 and ERG gene loci. Moreover, LMO2, ERG and FLI1 all regulate the +1 enhancer of HHEX/PRH, which was recently implicated as a key mediator of early progenitor expansion in LMO2-driven T-ALL. Our data therefore suggest that a self-sustaining triad of LMO2/ERG/FLI1 stabilizes the expression of important mediators of the leukaemic phenotype such as HHEX/PRH. Oncogene (2010) 29, 5796-5808; doi: 10.1038/onc.2010.320; published online 2 August 2010	[Oram, S. H.; Pridans, C.; Kinston, S. J.; Anand, S.; Huntly, B. J.; Goettgens, B.] Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Thoms, J. A. I.; Janes, M. E.; Pimanda, J. E.] Univ New S Wales, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Thoms, J. A. I.; Janes, M. E.; Pimanda, J. E.] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Landry, J-R] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada; [Lock, R. B.] Univ New S Wales, Childrens Canc Inst Australia, Sydney, NSW, Australia; [Jayaraman, P-S] Univ Birmingham, Birmingham Univ Stem Cell Ctr, Birmingham, W Midlands, England	University of Cambridge; University of New South Wales Sydney; University of New South Wales Sydney; Universite de Montreal; Children's Cancer Institute; University of New South Wales Sydney; University of Birmingham	Gottgens, B (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 0XY, England.	BG200@CAM.AC.UK	Thoms, Julie/H-6123-2019; Lock, Richard/G-4253-2013; huntly, brian JP/E-6725-2014; Pridans, Clare/AAF-9953-2020	Thoms, Julie/0000-0002-4876-7230; huntly, brian JP/0000-0003-0312-161X; Pridans, Clare/0000-0001-9423-557X; Lock, Richard/0000-0002-3436-9071; Gottgens, Berthold/0000-0001-6302-5705; /0000-0002-6500-9095	Kay Kendall Leukaemia Fund; Medical Research Council; Cancer Research UK; National Health and Research Council of Australia; National Institute for Health Research Cambridge Biomedical Research Centre; Leukaemia and Lymphoma Research UK; MRC [G0800784, G116/187] Funding Source: UKRI; Medical Research Council [G116/187, G0800784, G0800784B] Funding Source: researchfish; National Centre for the Replacement [G0900729/1] Funding Source: researchfish	Kay Kendall Leukaemia Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); National Health and Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Leukaemia and Lymphoma Research UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement	We thank the Kay Kendall Leukaemia Fund, Medical Research Council, Cancer Research UK, National Health and Research Council of Australia, the National Institute for Health Research Cambridge Biomedical Research Centre and Leukaemia and Lymphoma Research UK for grant funding. We are grateful to Michelle Hammet and Tina Hamilton for assistance with pronuclear microinjections and to Professor Sally Kinsey, Leeds Teaching Hospitals, for assistance with sourcing patient material.	Appert A, 2009, CANCER RES, V69, P4784, DOI 10.1158/0008-5472.CAN-08-4774; Asnafi V, 2004, BLOOD, V104, P4173, DOI 10.1182/blood-2003-11-3944; Baldus CD, 2007, J CLIN ONCOL, V25, P3739, DOI 10.1200/JCO.2007.11.5253; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; Chiaretti S, 2004, BLOOD, V103, P2771, DOI 10.1182/blood-2003-09-3243; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; CRIST WM, 1993, STEM CELLS, V11, P81, DOI 10.1002/stem.5530110202; Dave UP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000491; Donaldson IJ, 2005, HUM MOL GENET, V14, P595, DOI 10.1093/hmg/ddi056; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Follows GA, 2006, GENOME RES, V16, P1310, DOI 10.1101/gr.5373606; Garand R, 1993, Recent Results Cancer Res, V131, P283; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hammond SM, 2005, LEUKEMIA RES, V29, P89, DOI 10.1016/j.leukres.2004.05.013; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Huang XL, 2006, BLOOD, V107, P3153, DOI 10.1182/blood-2005-08-3206; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kruse EA, 2009, P NATL ACAD SCI USA, V106, P13814, DOI 10.1073/pnas.0906556106; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Landry JR, 2005, BLOOD, V106, P2680, DOI 10.1182/blood-2004-12-4755; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100; MacArthur BD, 2009, NAT REV MOL CELL BIO, V10, P672, DOI 10.1038/nrm2766; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Noy P, 2010, MOL CELL BIOL, V30, P2120, DOI 10.1128/MCB.01511-09; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P17692, DOI 10.1073/pnas.0707045104; Rabbitts T. H., 1997, Leukemia (Basingstoke), V11, P271; RAIMONDI SC, 2007, ATLAS GENET CYTOGENE, V11, P69; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Valge-Archer V, 1998, ONCOGENE, V17, P3199, DOI 10.1038/sj.onc.1202353; van Grotel M, 2008, LEUKEMIA, V22, P124, DOI 10.1038/sj.leu.2404957; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wilson NK, 2009, BLOOD, V113, P5456, DOI 10.1182/blood-2009-01-200048; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	46	32	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5796	5808		10.1038/onc.2010.320	http://dx.doi.org/10.1038/onc.2010.320			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20676125	Green Published			2022-12-28	WOS:000283586200005
J	Hartmann, C; Muller, N; Blaukat, A; Koch, J; Benhar, I; Wels, WS				Hartmann, C.; Mueller, N.; Blaukat, A.; Koch, J.; Benhar, I.; Wels, W. S.			Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response	ONCOGENE			English	Article						epidermal growth factor receptor; therapeutic antibody; phage display; peptide mimotope	GROWTH-FACTOR RECEPTOR; TUMOR-CELL GROWTH; MONOCLONAL-ANTIBODY; ERBB-2 RECEPTOR; CANCER; DISPLAY; TOXIN; INHIBITION; CARCINOMA; LIBRARIES	Aberrant activation of the epidermal growth factor receptor (EGFR) has been found in human cancers of various origins, and has been implicated in cancer pathogenesis. The therapeutic anti-EGFR antibodies cetuximab and matuzumab inhibit both ligand-induced receptor activation and growth of EGFR-expressing tumor cells. The efficacy of such EGFR-targeted therapies may be further enhanced by induction of functionally equivalent endogenous antibody responses. Here we describe novel peptide sequences selected from random peptide libraries for binding to single-chain antibody fragments of cetuximab or matuzumab. Two of these peptides characterized by KTL and YPLG motifs are recognized equally well by cetuximab and matuzumab, although nonoverlapping epitopes were previously reported for these antibodies. Immunization of experimental animals with synthetic KTL-and YPLG-containing peptides led to induction of antibodies that cross-react with human EGFR, and prevent binding of natural EGFR ligands, ligand-induced receptor activation and tumor cell growth in a manner similar to cetuximab and matuzumab. Our findings show that these peptide mimotopes can induce anti-EGFR antibodies with antitumoral activity, which may have implications for EGFR-specific cancer immunotherapy. Oncogene (2010) 29, 4517-4527; doi: 10.1038/onc.2010.195; published online 31 May 2010	[Hartmann, C.; Mueller, N.; Koch, J.; Wels, W. S.] Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; [Blaukat, A.] Merck KGaA, Merck Serono Res, TA Oncol, Darmstadt, Germany; [Benhar, I.] Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, Ramat Aviv, Israel	Merck KGaA; EMD Serono Inc.; Tel Aviv University	Wels, WS (corresponding author), Chemotherapeut Forschungsinst, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	wels@em.uni-frankfurt.de		Benhar, Itai/0000-0002-0824-7177; Wels, Winfried/0000-0001-9858-3643	Merck KGaA	Merck KGaA(Merck & Company)	We thank Dr Jens Oliver Funk, Merck KGaA for support of this project; Thorsten Geyer, Georg-Speyer-Haus for preparing plasmid pIB-Tx-scFv(225); Dr John Mendelsohn, MD Anderson Cancer Center, Houston for monoclonal antibody cetuximab; Dr Nancy Hynes, Friedrich Miescher Institute, Basel for 15E anti-EGFR antibody; Christian Brendel, Georg-Speyer-Haus for help with CLSM experiments and Dr Stephen Hyland, Georg-Speyer-Haus and Dr Arne Sutter, Merck KGaA for helpful discussions. This work was supported in part by a grant from Merck KGaA.	Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO;2-8; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Benhar I, 2000, J MOL BIOL, V301, P893, DOI 10.1006/jmbi.2000.4021; Brandt O, 2009, CURR CHEM BIOL, V3, P171; Cochran JR, 2004, J IMMUNOL METHODS, V287, P147, DOI 10.1016/j.jim.2004.01.024; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Groner B, 2004, CURR MOL MED, V4, P539, DOI 10.2174/1566524043360483; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773; Leahy DJ, 2008, CANCER CELL, V13, P291, DOI 10.1016/j.ccr.2008.03.010; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; Mayrose I, 2007, BIOINFORMATICS, V23, P3244, DOI 10.1093/bioinformatics/btm493; Mayrose I, 2007, NUCLEIC ACIDS RES, V35, P69, DOI 10.1093/nar/gkl975; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Partidos CD, 2000, CURR OPIN MOL THER, V2, P74; Rao S, 2008, BRIT J CANCER, V99, P868, DOI 10.1038/sj.bjc.6604622; Riemer AB, 2005, JNCI-J NATL CANCER I, V97, P1663, DOI 10.1093/jnci/dji373; Riemer AB, 2004, J IMMUNOL, V173, P394, DOI 10.4049/jimmunol.173.1.394; Sato J D, 1983, Mol Biol Med, V1, P511; Schmidt M, 1996, BRIT J CANCER, V74, P853, DOI 10.1038/bjc.1996.448; Schmidt M, 1999, ONCOGENE, V18, P1711, DOI 10.1038/sj.onc.1202489; Schmiedel J, 2008, CANCER CELL, V13, P365, DOI 10.1016/j.ccr.2008.02.019; Seiden MV, 2007, GYNECOL ONCOL, V104, P727, DOI 10.1016/j.ygyno.2006.10.019; Shomura H, 2004, BRIT J CANCER, V90, P1563, DOI 10.1038/sj.bjc.6601728; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, CANCER RES, V52, P6310; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	28	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4517	4527		10.1038/onc.2010.195	http://dx.doi.org/10.1038/onc.2010.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20514015				2022-12-28	WOS:000280862300003
J	Plaza-Menacho, I; Morandi, A; Robertson, D; Pancholi, S; Drury, S; Dowsett, M; Martin, LA; Isacke, CM				Plaza-Menacho, I.; Morandi, A.; Robertson, D.; Pancholi, S.; Drury, S.; Dowsett, M.; Martin, L-A; Isacke, C. M.			Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance	ONCOGENE			English	Article						RET; breast cancer; endocrine therapy; tamoxifen; estrogen receptor; endocrine resistance	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; MCF-7 CELLS; MEDIATED TRANSCRIPTION; THERAPY RESISTANCE; GENE-EXPRESSION; CROSS-TALK; SERINE 118; S6 KINASE	Endocrine therapy is the main therapeutic option for patients with estrogen receptor (ER alpha)-positive breast cancer. Resistance to this treatment is often associated with estrogen-independent activation of ER alpha. In this study, we show that in ER alpha-positive breast cancer cells, activation of the receptor tyrosine kinase RET (REarranged during Transfection) by its ligand GDNF results in increased ER alpha phosphorylation on Ser118 and Ser167 and estrogen-independent activation of ER alpha transcriptional activity. Further, we identify mTOR as a key component in this downstream signaling pathway. In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug. In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity. Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ER alpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of wRET-positive tumors. Together these findings identify RET as a potentially important therapeutic target in ER alpha-positive breast cancers and in particular in tamoxifen-resistant tumors. Oncogene (2010) 29, 4648-4657; doi:10.1038/onc.2010.209; published online 7 June 2010	[Plaza-Menacho, I.; Morandi, A.; Robertson, D.; Pancholi, S.; Drury, S.; Dowsett, M.; Martin, L-A; Isacke, C. M.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Drury, S.; Dowsett, M.] Royal Marsden Hosp Trust, Acad Dept Biochem, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk	Piris, Alejandro/D-3830-2014; Martin, Lesley-Ann/AAA-1841-2020; Plaza-Menacho, Ivan/K-8517-2017	Pancholi, Sunil/0000-0002-0880-1588; Morandi, Andrea/0000-0002-9222-5332; Plaza-Menacho, Ivan/0000-0003-4666-9431; Isacke, Clare/0000-0002-9222-3345	Breakthrough Breast Cancer; Association of International Cancer Research [09-0533]; Mary-Jean Mitchell Green Foundation; Ministerio de Educacion y Ciencia (MEC) of Spain [EX2006-1341]; NHS; Worldwide Cancer Research [09-0533] Funding Source: researchfish	Breakthrough Breast Cancer; Association of International Cancer Research; Mary-Jean Mitchell Green Foundation; Ministerio de Educacion y Ciencia (MEC) of Spain(Spanish Government); NHS; Worldwide Cancer Research	This work was supported by Breakthrough Breast Cancer (CMI, L-AM and MD), the Association of International Cancer Research (grant 09-0533; CMI, AM and IP-M), the Mary-Jean Mitchell Green Foundation (L-AM and MD) and the Ministerio de Educacion y Ciencia (MEC) of Spain (grant EX2006-1341; IP-M). We acknowledge NHS funding to the NIHR Biomedical Research Centre. We thank Anne E Lykkesfeldt for the TAM<SUP>R</SUP>-1 cells, Jorge Reis-Filho, Suzanne Parry, Kay Savage, Margaret Hills and Janine Salter for their help with the TMA staining and analysis, and to Ana Maria Pereira for her advice on the tamoxifen response experiments.	Abe Y, 2009, J BIOL CHEM, V284, P14939, DOI 10.1074/jbc.M900097200; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Arpino G, 2007, JNCI-J NATL CANCER I, V99, P694, DOI 10.1093/jnci/djk151; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chang SB, 2007, J SURG RES, V138, P37, DOI 10.1016/j.jss.2006.07.003; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Dowsett M, 2006, ANN ONCOL, V17, P818, DOI 10.1093/annonc/mdl016; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Ghayad SE, 2008, CANCER SCI, V99, P1992, DOI 10.1111/j.1349-7006.2008.00955.x; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Howell A, 2004, BREAST CANCER RES, V6, P269, DOI 10.1186/bcr945; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; Johnston SRD, 2009, CLIN BREAST CANCER, V9, pS28, DOI 10.3816/CBC.2009.s.003; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kok M, 2009, JNCI-J NATL CANCER I, V101, P1725, DOI 10.1093/jnci/djp412; Kurokawa H, 2000, CANCER RES, V60, P5887; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; Macedo LF, 2008, CANCER RES, V68, P3516, DOI 10.1158/0008-5472.CAN-07-6807; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P29230, DOI 10.1074/jbc.M703461200; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P6415, DOI 10.1074/jbc.M608952200; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186	54	103	111	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4648	4657		10.1038/onc.2010.209	http://dx.doi.org/10.1038/onc.2010.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531297				2022-12-28	WOS:000281127400004
J	Favre, C; Zhdanov, A; Leahy, M; Papkovsky, D; O'Connor, R				Favre, C.; Zhdanov, A.; Leahy, M.; Papkovsky, D.; O'Connor, R.			Mitochondrial pyrimidine nucleotide carrier (PNC1) regulates mitochondrial biogenesis and the invasive phenotype of cancer cells	ONCOGENE			English	Article						PNC1; IGF-I; mitochondria; ROS; EMT in cancer; metabolism	ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-I; AEROBIC GLYCOLYSIS; SKELETAL-MUSCLE; OXIDATIVE STRESS; DNA-REPLICATION; INSULIN; METABOLISM; OXYGEN	The insulin-like growth factor (IGF-I) signalling pathway is essential for metabolism, cell growth and survival. It induces expression of the mitochondrial pyrimidine nucleotide carrier 1 (PNC1) in transformed cells, but the consequences of this for cell phenotype are unknown. Here we show that PNC1 is necessary to maintain mitochondrial function by controlling mitochondrial DNA replication and the ratio of transcription of mitochondrial genes relative to nuclear genes. PNC1 suppression causes reduced oxidative phosphorylation and leakage of reactive oxygen species (ROS), which activates the AMPK-PGC1 alpha signalling pathway and promotes mitochondrial biogenesis. Overexpression of PNC1 suppresses mitochondrial biogenesis. Suppression of PNC1 causes a profound ROS-dependent epithelial-mesenchymal transition (EMT), whereas overexpression of PNC1 suppresses both basal EMT and induction of EMT by TGF-beta. Overall, our findings indicate that PNC1 is essential for mitochondria maintenance and suggest that its induction by IGF-I facilitates cell growth whereas protecting cells from an ROS-promoted differentiation programme that arises from mitochondrial dysfunction. Oncogene (2010) 29, 3964-3976; doi:10.1038/onc.2010.146; published online 10 May 2010	[Favre, C.; Leahy, M.; O'Connor, R.] Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland; [Zhdanov, A.; Papkovsky, D.] Univ Coll Cork, Dept Biochem, Lab Biophys & Bioanal, Cork, Ireland	University College Cork; University College Cork	O'Connor, R (corresponding author), Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422; Papkovsky, Dmitri/0000-0003-1556-1145; Zhdanov, Alexander/0000-0001-5787-2035	Science Foundation Ireland; Health Research Board	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board	We thank Kurt Tidmore for assistance with illustrations and to our colleagues in the Cell Biology Laboratory for helpful discussions. This work was funded by Science Foundation Ireland and the Health Research Board.	Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028; Ferraro D, 2006, ONCOGENE, V25, P3689, DOI 10.1038/sj.onc.1209409; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Floyd S, 2007, MOL BIOL CELL, V18, P3545, DOI 10.1091/mbc.e06-12-1109; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Hynes J, 2009, ANAL BIOCHEM, V390, P21, DOI 10.1016/j.ab.2009.04.016; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200; Jeng JY, 2008, J CELL BIOCHEM, V103, P347, DOI 10.1002/jcb.21625; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; Marshall Stephen, 2006, Sci STKE, V2006, pre7; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Naito A, 2008, CANCER SCI, V99, P1584, DOI 10.1111/j.1349-7006.2008.00879.x; Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50; Pankratz SL, 2009, J BIOL CHEM, V284, P2031, DOI 10.1074/jbc.M804776200; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Perez R, 2008, WORLD J GASTROENTERO, V14, P2731, DOI 10.3748/wjg.14.2731; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Unterluggauer Hermann, 2008, Biotechnology Journal, V3, P813, DOI 10.1002/biot.200700254; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Will Y, 2006, NAT PROTOC, V1, P2563, DOI 10.1038/nprot.2006.351; Witczak CA, 2008, CELL MOL LIFE SCI, V65, P3737, DOI 10.1007/s00018-008-8244-6; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Zhdanov AV, 2008, J BIOL CHEM, V283, P5650, DOI 10.1074/jbc.M706439200	46	59	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3964	3976		10.1038/onc.2010.146	http://dx.doi.org/10.1038/onc.2010.146			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453889				2022-12-28	WOS:000279603200009
J	Sparks, CA; Guertin, DA				Sparks, C. A.; Guertin, D. A.			Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy	ONCOGENE			English	Review						mTOR; mTORC2; AKT; SGK; rapamycin; Rictor	AKT/PROTEIN-KINASE-B; MAMMALIAN TARGET; TOR COMPLEX-2; CELL-GROWTH; MOTIF PHOSPHORYLATION; ACTIN CYTOSKELETON; TSC1-TSC2 COMPLEX; BINDING PARTNER; PROTEINS SLM1; SIGNAL RELAY	Small molecule inhibitors that selectively target cancer cells and not normal cells would be valuable anti-cancer therapeutics. The mammalian target of rapamycin complex 2 (mTORC2) is emerging as a promising candidate target for such an inhibitor. Recent studies in cancer biology indicate that mTORC2 activity is essential for the transformation and vitality of a number of cancer cell types, but in many normal cells, mTORC2 activity is less essential. These studies are intensifying interest in developing inhibitors that specifically target mTORC2. However, there are many open questions regarding the function and regulation of mTORC2 and its function in both normal and cancer cells. Here, we summarize exciting new research into the biology of mTORC2 signaling and highlight the current state and future prospects for mTOR-targeted therapy. Oncogene (2010) 29, 3733-3744; doi: 10.1038/onc.2010.139; published online 26 April 2010	[Sparks, C. A.; Guertin, D. A.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Guertin, DA (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	david.guertin@umassmed.edu			National Institutes of Health [R00 CA129613]; Charles Hood Foundation; UMass Center for Clinical and Translational Sciences; NATIONAL CANCER INSTITUTE [R00CA129613] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles Hood Foundation; UMass Center for Clinical and Translational Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DAG is supported by grants from the National Institutes of Health (R00 CA129613), the Charles Hood Foundation, and the UMass Center for Clinical and Translational Sciences.	Acosta-Jaquez HA, 2009, MOL CELL BIOL, V29, P4308, DOI 10.1128/MCB.01665-08; Akcakanat A, 2007, BIOCHEM BIOPH RES CO, V362, P330, DOI 10.1016/j.bbrc.2007.07.151; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Barquilla A, 2008, P NATL ACAD SCI USA, V105, P14579, DOI 10.1073/pnas.0802668105; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Berchtold D, 2009, MOL BIOL CELL, V20, P1565, DOI 10.1091/mbc.E08-10-1001; Bozulic L, 2009, CURR OPIN CELL BIOL, V21, P256, DOI 10.1016/j.ceb.2009.02.002; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Cybulski N, 2009, P NATL ACAD SCI USA, V106, P9902, DOI 10.1073/pnas.0811321106; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; EFEYAN A, 2009, CURR OPIN CELL BIOL, V22, P1; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hayashi T, 2007, GENES CELLS, V12, P1357, DOI 10.1111/j.1365-2443.2007.01141.x; Hietakangas V, 2007, GENE DEV, V21, P632, DOI 10.1101/gad.416307; Hietakangas V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-282; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2008, BIOCHEM J, V410, P19, DOI 10.1042/BJ20071518; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim E, 2009, CELL CYCLE, V8, P1014, DOI 10.4161/cc.8.7.8124; Koike-Kumagai M, 2009, EMBO J, V28, P3879, DOI 10.1038/emboj.2009.312; Kumar A, 2008, MOL CELL BIOL, V28, P61, DOI 10.1128/MCB.01405-07; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Lee S, 1999, MOL BIOL CELL, V10, P2829, DOI 10.1091/mbc.10.9.2829; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Nardella C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000189; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Recher C, 2005, CELL CYCLE, V4, P1540; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schroder W, 2005, CELL SIGNAL, V17, P761, DOI 10.1016/j.cellsig.2004.10.015; Schroder WA, 2007, CELL SIGNAL, V19, P1279, DOI 10.1016/j.cellsig.2007.01.013; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Shor B, 2008, CANCER RES, V68, P2934, DOI 10.1158/0008-5472.CAN-07-6487; Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Sturgill TW, 2008, EUKARYOT CELL, V7, P1819, DOI 10.1128/EC.00088-08; Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05; Tessier M, 2006, J CELL BIOCHEM, V98, P1391, DOI 10.1002/jcb.20894; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Treins C, 2010, ONCOGENE, V29, P1003, DOI 10.1038/onc.2009.401; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Witzig TE, 2005, J CLIN ONCOL, V23, P5347, DOI 10.1200/JCO.2005.13.466; Witzig Thomas E, 2006, Curr Treat Options Oncol, V7, P285, DOI 10.1007/s11864-006-0038-1; Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Yuan RR, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-45; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	103	241	256	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3733	3744		10.1038/onc.2010.139	http://dx.doi.org/10.1038/onc.2010.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418915	Green Accepted			2022-12-28	WOS:000279385200001
J	Wiebusch, L; Hagemeier, C				Wiebusch, L.; Hagemeier, C.			p53-and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress	ONCOGENE			English	Article						APC/C; p53; p21; Emi1; senescence; apoptosis	ANAPHASE-PROMOTING COMPLEX; NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE-RESPONSE; HUMAN CANCER-CELLS; S-PHASE; TRANSCRIPTIONAL REPRESSION; ANTICANCER AGENTS; TUMOR-SUPPRESSION; UBIQUITIN LIGASE; DOWN-REGULATION	The long-term cellular response to DNA damage is controlled by the tumor suppressor p53. It results in cell-cycle arrest followed by DNA repair and, depending on the degree of damage inflicted, premature senescence or apoptotic cell death. Here we show that in normal diploid fibroblasts the ubiquitin ligase anaphase-promoting complex or cyclosome (APC/C)-Cdh1 becomes prematurely activated in G2 as part of the sustained long-term but not the rapid short-term response to genotoxic stress and results in the degradation of numerous APC/C substrates. Using HCT116 somatic knockout cells we show that mechanistically premature APC/C activation depends on p53 and its transcriptional target p21 that mediates the signal through downregulation of the APC/C inhibitor Emi1. Cdc14B is dispensable in this setting but might function redundantly. Our data suggest an unexpected role for the APC/C in executing a part of the p53-dependent DNA damage response that leads to premature senescence. Oncogene (2010) 29, 3477-3489; doi:10.1038/onc.2010.99; published online 12 April 2010	[Wiebusch, L.; Hagemeier, C.] Charite, Childrens Hosp, Mol Biol Lab, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wiebusch, L (corresponding author), Charite, Childrens Hosp, Mol Biol Lab, Ziegelstr 5-9, D-10117 Berlin, Germany.	lueder.wiebusch@charite.de; christian.hagemeier@charite.de	Wiebusch, Lüder/AAR-6668-2021	Wiebusch, Lüder/0000-0002-7210-6731	Deutsche Forschungsgemeinschaft (DFG) [HA1575/2-1, WI2043/2-2]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank Eli Berdougo, Philipp Haemmati, Christoph Hanski, Hans-Jurgen Heidebrecht, Prasad Jallepalli, Bert Vogelstein and Ralph Wasch for the generous supply of reagents. We acknowledge Matthias Truss for help with lentivirus production and Ralf Uecker for excellent technical assistance. This work was supported by Grants HA1575/2-1 and WI2043/2-2 from the Deutsche Forschungsgemeinschaft (DFG).	Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Andreassen PR, 2001, CANCER RES, V61, P7660; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Banerjee T, 2009, NUCLEIC ACIDS RES, V37, P2688, DOI 10.1093/nar/gkp110; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Berdougo E, 2008, CELL CYCLE, V7, P1184, DOI 10.4161/cc.7.9.5792; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 1999, CANCER RES, V59, P3761; Demidenko ZN, 2008, CELL CYCLE, V7, P3355, DOI 10.4161/cc.7.21.6919; Di Fiore B, 2007, J CELL BIOL, V177, P425, DOI 10.1083/jcb.200611166; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; Gillis LD, 2009, CELL CYCLE, V8, P253, DOI 10.4161/cc.8.2.7550; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; HARPER JW, 1993, CELL, V75, P805; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Janicke RU, 2007, CELL CYCLE, V6, P407; Kan QM, 2008, P NATL ACAD SCI USA, V105, P4757, DOI 10.1073/pnas.0706392105; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kob R, 2009, CELL CYCLE, V8, P2041, DOI 10.4161/cc.8.13.8850; Kurose A, 2006, CELL PROLIFERAT, V39, P231, DOI 10.1111/j.1365-2184.2006.00380.x; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; Liu WJ, 2007, MOL CELL BIOL, V27, P2967, DOI 10.1128/MCB.01830-06; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Matthew EM, 2007, CELL CYCLE, V6, P2571, DOI 10.4161/cc.6.20.5079; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2000, GENE DEV, V14, P655; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rodier G, 2008, EMBO J, V27, P679, DOI 10.1038/emboj.2008.6; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Summers MK, 2008, MOL CELL, V31, P544, DOI 10.1016/j.molcel.2008.07.014; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang W, 2005, BIOCHEMISTRY-US, V44, P14553, DOI 10.1021/bi051071j; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	60	54	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3477	3489		10.1038/onc.2010.99	http://dx.doi.org/10.1038/onc.2010.99			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383190				2022-12-28	WOS:000278835400003
J	Yin, G; Chen, R; Alvero, AB; Fu, HH; Holmberg, J; Glackin, C; Rutherford, T; Mor, G				Yin, G.; Chen, R.; Alvero, A. B.; Fu, H-H; Holmberg, J.; Glackin, C.; Rutherford, T.; Mor, G.			TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214	ONCOGENE			English	Article						ovarian CSCs; Twist1; miR-199a/214 cluster; IKK beta	KAPPA-B ACTIVITY; SURFACE EPITHELIUM; IN-VIVO; DIFFERENTIATION; MICRORNAS; ONCOGENESIS; ACTIVATION; EXPRESSION; RESISTANCE; SURVIVAL	Cancer stem cells are responsible for sustaining the tumor and giving rise to proliferating and progressively differentiating cells. However, the molecular mechanisms regulating the process of cancer stem cell (CSC) differentiation is not clearly understood. Recently, we reported the isolation of the epithelial ovarian cancer (EOC) stem cells (type I/CD44+). In this study, we show that type I/CD44+ cells are characterized by low levels of both miR-199a and miR-214, whereas mature EOC cells (type II/CD44-) have higher levels of miR-199a and miR-214. Moreover, these two micro RNAs (miRNAs) are regulated as a cluster on pri-miR-199a2 within the human Dnm3os gene (GenBank FJ623959). This study identify Twist1 as a regulator of this unique miRNA cluster responsible for the regulation of the IKK beta/NF-kappa beta and PTEN/AKT pathways and its association of ovarian CSC differentiation. Our data suggest that Twist1 may be an important regulator of 'stemness' in EOC cells. The regulation of MIR199A2/214 expression may be used as a potential therapeutic approach in EOC patients. Oncogene (2010) 29, 3545-3553; doi:10.1038/onc.2010.111; published online 19 April 2010	[Mor, G.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, New Haven, CT 06520 USA; [Glackin, C.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA USA	Yale University; City of Hope; Beckman Research Institute of City of Hope	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, 333 Cedar St,LSOG 305A, New Haven, CT 06520 USA.	gil.mor@yale.edu	Yin, Gang/H-3289-2011	Holmberg, Jennie/0000-0002-1106-4718; Alvero, Ayesha/0000-0002-6593-3595	NCI/NIH [RO1CA127913, RO1CA118678]; Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; NATIONAL CANCER INSTITUTE [R01CA118678, R01CA127913] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by grants from NCI/NIH RO1CA127913, RO1CA118678, the Janet Burros Memorial Foundation, the Sands Family Foundation and the Discovery To Cure Research Program.	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Alison MR, 2008, CELL TISSUE RES, V331, P109, DOI 10.1007/s00441-007-0510-7; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Koga K, 2009, AM J REPROD IMMUNOL, V61, P196, DOI 10.1111/j.1600-0897.2008.00682.x; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; Lee MS, 2000, BONE, V27, P591, DOI 10.1016/S8756-3282(00)00380-X; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Loebel DAF, 2002, GENESIS, V33, P103, DOI 10.1002/gene.10091; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; ODWYER PJ, 1994, CANCER RES, V54, P724; Ota MS, 2004, DEV DYNAM, V230, P216, DOI 10.1002/dvdy.20047; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Papagiannakopoulos T, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-15; Salamanca CM, 2004, J SOC GYNECOL INVEST, V11, P241, DOI 10.1016/j.jsgi.2003.10.010; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; WOOLAS RP, 1993, JNCI-J NATL CANCER I, V85, P1748, DOI 10.1093/jnci/85.21.1748; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	42	170	186	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3545	3553		10.1038/onc.2010.111	http://dx.doi.org/10.1038/onc.2010.111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400975	Green Accepted			2022-12-28	WOS:000278835400009
J	Iejima, D; Minegishi, Y; Takenaka, K; Siswanto, A; Watanabe, M; Huang, L; Watanabe, T; Tanaka, F; Kuroda, M; Gotoh, N				Iejima, D.; Minegishi, Y.; Takenaka, K.; Siswanto, A.; Watanabe, M.; Huang, L.; Watanabe, T.; Tanaka, F.; Kuroda, M.; Gotoh, N.			FRS2 beta, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding	ONCOGENE			English	Article						FRS2; SNT2; FRS3; HER; NSCLC; prognosis	DOCKING-PROTEIN FRS2-ALPHA; FRS2 FAMILY; MAP KINASE; ACTIVATION; MUTATIONS; EXPRESSION; SITES; MOTIF	An adaptor protein FRS2b inhibits epidermal growth factor-receptor (EGFR) tyrosine kinase without being phosphorylated at tyrosine residues after EGF stimulation. Although binding to ERK appears to be important for this inhibition, the precise molecular mechanisms and the role of FRS2b in signal transduction mediated by other EGFR family members, as well as its role in human cancer, remain unclear. In this study, we demonstrate that FRS2b inhibits anchorage-independent cell growth induced by oncogenic ErbB2, another member of EGFR family, and that it inhibits heterodimer formation between EGFR and ErbB2. We mapped the residues important for the FRS2b and ERK interaction to two docking (D) domain-like sequences on FRS2b and two aspartic acid residues in the common docking (CD) domain of ERK. Moreover, in response to EGF, ERK translocated to the plasma membrane in cells expressing FRS2b but not an FRS2b mutant in which four arginine residues in the D domains were replaced with alanines, suggesting that FRS2b serves as a plasma membrane anchor for activated ERK. Finally, a low mRNA expression level of FRS2b was significantly correlated with poor prognosis in a cohort of 60 non-small cell lung cancer patients. Therefore, we have identified the molecular mechanisms by which FRS2b acts as a feedback inhibitor of EGFR family members and suggest a role for FRS2b as a tumor suppressor. Oncogene (2010) 29, 3087-3099; doi: 10.1038/onc.2010.69; published online 15 March 2010	[Iejima, D.; Minegishi, Y.; Siswanto, A.; Watanabe, M.; Gotoh, N.] Univ Tokyo, Inst Med Sci, Dept Syst Biomed Technol, Minato Ku, Tokyo 1088639, Japan; [Takenaka, K.; Tanaka, F.] Kyoto Univ, Sch Med, Dept Thorac Surg, Kyoto 606, Japan; [Takenaka, K.] Koseikai Takeda Hosp, Dept Thorac Surg, Kyoto, Japan; [Siswanto, A.; Watanabe, T.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Minato Ku, Tokyo 1088639, Japan; [Huang, L.] RIKEN, Cellular Biochem Lab, Wako, Saitama, Japan; [Tanaka, F.] Hyogo Coll Med, Dept Thorac Surg, Nishinomiya, Hyogo, Japan; [Kuroda, M.] Tokyo Med Univ, Dept Pathol, Tokyo, Japan	University of Tokyo; Kyoto University; University of Tokyo; RIKEN; Hyogo College of Medicine; Tokyo Medical University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Dept Syst Biomed Technol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@ims.u-tokyo.ac.jp	Huang, Lin/AAI-5740-2020		Ministry of Health, Labor and Welfare of Japan; Naito Foundation; Cell Science Research Foundation	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Naito Foundation(Naito Memorial Foundation); Cell Science Research Foundation(Cell Science Research Foundation, Japan)	We are grateful to Dr Toshio Kitamura for valuable reagents for retrovirus expression system and Dr Tadashi Yamamoto for NIH3T3 cells expressing oncogenic ErbB2 and for expression vectors for ErbB2 and VE mutant. This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan for the 3rd-term Comprehensive 10-year Strategy for Cancer Control; from the Naito Foundation; and Cell Science Research Foundation to NG.	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Butch ER, 1996, J BIOL CHEM, V271, P4230; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gotoh N, 2005, MOL CELL BIOL, V25, P4105, DOI 10.1128/MCB.25.10.4105-4116.2005; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Gotoh N, 2009, INT J BIOCHEM CELL B, V41, P511, DOI 10.1016/j.biocel.2008.06.019; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Huang L, 2006, ONCOGENE, V25, P6457, DOI 10.1038/sj.onc.1209656; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Sato T, 2009, EXPERT OPIN THER TAR, V13, P689, DOI 10.1517/14728220902942330; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sonobe M, 2005, BRIT J CANCER, V93, P355, DOI 10.1038/sj.bjc.6602707; Sonobe M, 2006, J MOL DIAGN, V8, P351, DOI 10.2353/jmoldx.2006.050132; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Yamamoto S, 2005, P NATL ACAD SCI USA, V102, P15983, DOI 10.1073/pnas.0507961102; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	30	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3087	3099		10.1038/onc.2010.69	http://dx.doi.org/10.1038/onc.2010.69			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20228838				2022-12-28	WOS:000278133100006
J	Siegel, PM; Muller, WJ				Siegel, P. M.; Muller, W. J.			Transcription factor regulatory networks in mammary epithelial development and tumorigenesis	ONCOGENE			English	Review						mammary gland development; transcription factor networks; STAT; Elf; GATA-3; breast cancer	BREAST-CANCER METASTASIS; LUMINAL CELL FATE; GENE-EXPRESSION; STEM-CELLS; GLAND DEVELOPMENT; C/EBP-DELTA; MOUSE MODEL; IN-VIVO; GATA-3; DIFFERENTIATION	The mouse mammary gland is composed of three epithelial cell types, which include ductal, alveolar and myoepithelial cells. A hierarchy in which the mammary stem cell compartment gives rise to progressively restricted progenitors that ultimately form the luminal (ductal and alveolar) and myoepithelial lineages is now emerging. Although very little is known about the mechanisms controlling the differentiation of the myoepithelial cell lineage, a growing body of work reveals that the luminal cell fate is specified by a network of transcription factors. The precise roles of specific transcription factors in promoting differentiation of luminal progenitors into ductal or alveolar cells are now being elucidated. This review will discuss the importance of these recent observations and place them within the context of other transcription factor networks involved in mammary gland development and tumorigenesis. Oncogene (2010) 29, 2753-2759; doi: 10.1038/onc.2010.43; published online 29 March 2010	[Muller, W. J.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; McGill Univ, Dept Med, Goodman Canc Ctr, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Dept Biochem, 1160 Ave Pins Ouest,Room 516, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca			National Cancer Institute of Canada/Terry Fox Foundation [017003]	National Cancer Institute of Canada/Terry Fox Foundation	We thank Dr Josie Ursini-Siegel and Rob Annan for their critical reading of the manuscript. Work carried out in the laboratory of Dr WJ Muller was supported by a grant from the National Cancer Institute of Canada/Terry Fox Foundation Program Project Grant (# 017003). PMS is a research scientist of the Canadian Cancer Society and WJM holds a Canada Research Chair in Molecular Oncology.	Asselin-Labat ML, 2008, COLD SH Q B, V73, P469, DOI 10.1101/sqb.2008.73.020; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032; Clevenger Charles V, 2003, Breast Dis, V18, P75; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Fang SH, 2009, J SURG RES, V157, P290, DOI 10.1016/j.jss.2008.07.015; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; Jackson-Fisher AJ, 2006, ONCOGENE, V25, P5664, DOI 10.1038/sj.onc.1209574; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; LAMARCA HL, 2010, STEM CELLS; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; McDaniel SM, 2006, AM J PATHOL, V168, P608, DOI 10.2353/ajpath.2006.050677; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Molyneux G, 2007, CELL MOL LIFE SCI, V64, P3248, DOI 10.1007/s00018-007-7391-5; Naylor MJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1661; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pensa S, 2009, J MAMMARY GLAND BIOL, V14, P121, DOI 10.1007/s10911-009-9124-x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Polyak K, 2007, STEM CELL REV, V3, P107, DOI 10.1007/s12015-007-0020-8; Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schedin P, 2007, J MAMMARY GLAND BIOL, V12, P71, DOI 10.1007/s10911-007-9039-3; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2006, CELL CYCLE, V5, P1519, DOI 10.4161/cc.5.14.2983; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Tiffen PG, 2008, MOL ENDOCRINOL, V22, P2677, DOI 10.1210/me.2008-0097; Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	57	32	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2753	2759		10.1038/onc.2010.43	http://dx.doi.org/10.1038/onc.2010.43			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20348953				2022-12-28	WOS:000277591900001
J	Macurek, L; Lindqvist, A; Voets, O; Kool, J; Vos, HR; Medema, RH				Macurek, L.; Lindqvist, A.; Voets, O.; Kool, J.; Vos, H. R.; Medema, R. H.			Wip1 phosphatase is associated with chromatin and dephosphorylates gamma H2AX to promote checkpoint inhibition	ONCOGENE			English	Article						DNA damage; checkpoint inhibition; phosphatase; cancer	DOUBLE-STRAND BREAKS; DNA-DAMAGE CHECKPOINT; HISTONE H2AX PHOSPHORYLATION; ACTIVATION IN-VIVO; PROTEIN PHOSPHATASE; ATM ACTIVATION; RADIOSENSITIZING AGENT; IONIZING-RADIATION; SIGNALING PATHWAYS; REPAIR PROTEINS	DNA double-stranded breaks (DSBs) elicit a checkpoint response that causes a delay in cell cycle progression. Early in the checkpoint response, histone H2AX is phosphorylated in the chromatin region flanking the DSB by ATM/ATR and DNA-PK kinases. The resulting foci of phosphorylated H2AX (gamma-H2AX) serve as a platform for recruitment and retention of additional components of the checkpoint-signaling cascade that enhance checkpoint signaling and DSB repair. Upon repair, both the assembled protein complexes and the chromatin modifications are removed to quench the checkpoint signal. In this study, we show that the DNA damage-responsive Wip1 phosphatase is bound to chromatin. Moreover, Wip1 directly dephosphorylates gamma-H2AX and cells depleted of Wip1 fail to dephosphorylate gamma-H2AX during checkpoint recovery. Conversely, premature activation of Wip1 leads to displacement of MDC1 from damage foci and prevents activation of the checkpoint. Taken together, our data show that Wip1 has an essential role in dephosphorylation of gamma-H2AX to silence the checkpoint and restore chromatin structure once DNA damage is repaired. Oncogene (2010) 29, 2281-2291; doi: 10.1038/onc.2009.501; published online 25 January 2010	[Macurek, L.; Lindqvist, A.; Voets, O.; Kool, J.; Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CG Utrecht, Netherlands; [Macurek, L.; Lindqvist, A.; Voets, O.; Kool, J.; Vos, H. R.; Medema, R. H.] Univ Med Ctr Utrecht, Canc Genom Ctr, NL-3584 CG Utrecht, Netherlands; [Macurek, L.] Acad Sci Czech Republic, Inst Mol Genet, Dept Genome Integr, Vvi, Prague, Czech Republic; [Vos, H. R.] Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, Univ Sweg 100,Str 2-118, NL-3584 CG Utrecht, Netherlands.	r.h.medema@umcutrecht.nl	Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013; Lindqvist, Arne/B-6792-2008; Macurek, Libor/C-7865-2014	Macurek, Libor/0000-0002-0987-1238; Lindqvist, Arne/0000-0002-0141-1579; Medema, Rene/0000-0002-6754-0381; Vos, Harmjan/0000-0002-4696-6068	Netherlands Genomics Initiative of NWO; Dutch Cancer Society [UU2006-3579]; Grant Agency of the Czech Republic [P305/10/P420]; Wenner-Gren foundation; Netherlands Organization for Scientific Research (NWO) [ZonMw 916.86.083]; Center for Translational Molecular Medicine (CTMM)	Netherlands Genomics Initiative of NWO; Dutch Cancer Society(KWF Kankerbestrijding); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Wenner-Gren foundation; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Center for Translational Molecular Medicine (CTMM)	We are thankful to Dr Lukas for providing MDC-EGFP plasmid, Dr Donehower for Wip1-FLAG, Dr Dansen and P Charitou for providing reagents, Livio Kleij for maintenance of the microscopes and Monica Alvarez for critical reading of the article. RHM and LM were funded by the Netherlands Genomics Initiative of NWO and the Dutch Cancer Society (UU2006-3579), LM by Grant Agency of the Czech Republic (P305/10/P420), AL by the Wenner-Gren foundation and by the Netherlands Organization for Scientific Research (NWO) (ZonMw 916.86.083) and HV by the Center for Translational Molecular Medicine (CTMM).	Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Chowdhury D, 2008, MOL CELL, V31, P33, DOI 10.1016/j.molcel.2008.05.016; Chuman Y, 2009, J BIOCHEM, V145, P1, DOI 10.1093/jb/mvn135; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; Dinant C, 2007, J CELL SCI, V120, P2731, DOI 10.1242/jcs.004523; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lindqvist A, 2007, PLOS BIOL, V5, P1127, DOI 10.1371/journal.pbio.0050123; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Nakada S, 2008, EMBO REP, V9, P1019, DOI 10.1038/embor.2008.162; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Svetlova M, 2007, BIOCHEM BIOPH RES CO, V358, P650, DOI 10.1016/j.bbrc.2007.04.188; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s	59	113	116	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2281	2291		10.1038/onc.2009.501	http://dx.doi.org/10.1038/onc.2009.501			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101220				2022-12-28	WOS:000276685200013
J	Zhang, W; Zeng, X; Briggs, KJ; Beaty, R; Simons, B; Yen, RWC; Tyler, MA; Tsai, HC; Ye, Y; Gesell, GS; Herman, JG; Baylin, SB; Watkins, DN				Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.			A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1	ONCOGENE			English	Article						Hic1; ephrin-A1; EphA2; EphA4	MILLER-DIEKER-SYNDROME; EPHA2 RECEPTOR; CELL-MIGRATION; COLORECTAL-CANCER; GENE; EXPRESSION; LIGAND; MICE; HYPERMETHYLATED-IN-CANCER-1; PROGRESSION	The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically inactivated in various human cancers. In this study, we show that HIC1 is a direct transcriptional repressor of the gene encoding ephrin-A1, a cell surface ligand implicated in the pathogenesis of epithelial cancers. We also show that mouse embryos lacking both Hic1 alleles manifest developmental defects spatially associated with the misexpression of ephrin-A1, and that overexpression of ephrin-A1 is a feature of tumors arising in Hic1 heterozygous mice in which the remaining wild-type allele is epigenetically silenced. In breast cancer, we find that ephrin-A1 expression is common in vivo, but that in cell culture, expression of the EphA receptors is predominant. Restoration of HIC1 function in breast cancer cells leads to a reduction in tumor growth in vivo, an effect that can be partially rescued by co-overexpression of ephrin-A1. Interestingly, overexpression of ephrin-A1 in vitro triggers downregulation of EphA2 and EphA4 levels, resulting in an expression pattern similar to that seen in vivo. We conclude that Hic1 spatially restricts ephrin-A1 expression in development, and that upregulated expression of ephrin-A1 resulting from epigenetic silencing of HIC1 in cancer cells may be an important mechanism in epithelial malignancy. Oncogene (2010) 29, 2467-2476; doi:10.1038/onc.2010.12; published online 15 February 2010	[Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; [Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; [Zeng, X.; Briggs, K. J.; Tsai, H-C] Johns Hopkins Univ, Sch Med, Grad Training Program Cellular & Mol Med, Baltimore, MD 21231 USA; [Watkins, D. N.] Monash Univ, Ctr Canc Res, Monash Inst Med Res, Clayton, Vic, Australia	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Monash University	Watkins, DN (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB I 541, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu; neil.watkins@med.monash.edu.au	Tsai, Hsing-Chen/AAE-7530-2021; zhang, wei/A-7015-2011; Simons, Brian W./G-7352-2015; Watkins, David N/I-6113-2013	Tsai, Hsing-Chen/0000-0002-7057-9084; Simons, Brian W./0000-0003-0644-211X; 	National Cancer Institute [R01 CA43318]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute Grant R01 CA43318 (SB Baylin) and an American Cancer Society Postdoctoral Fellowship (W Zhang). We thank Craig D Peacock, Leslie Meszler and Lillian Dasko-Vincent for technical assistance, Leander Van Neste for biostatistical support and Kathy Bender for the preparation and submission of this paper.	Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Hirotsune S, 1997, GENOME RES, V7, P625, DOI 10.1101/gr.7.6.625; Holder N, 1999, DEVELOPMENT, V126, P2033; Iida H, 2005, GUT, V54, P843, DOI 10.1136/gut.2004.049486; Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9; Shi L, 2008, ONCOGENE, V27, P3265, DOI 10.1038/sj.onc.1210992; Takai N, 2001, ONCOL REP, V8, P567; Tang XX, 1999, CLIN CANCER RES, V5, P1491; Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244; Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349	44	35	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2467	2476		10.1038/onc.2010.12	http://dx.doi.org/10.1038/onc.2010.12			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154726	Green Accepted			2022-12-28	WOS:000277169400002
J	Zheng, J; Machida, K; Antoku, S; Ng, KY; Claffey, KP; Mayer, BJ				Zheng, J.; Machida, K.; Antoku, S.; Ng, K. Y.; Claffey, K. P.; Mayer, B. J.			Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation	ONCOGENE			English	Article						SH3 domain; SH2/SH3 adaptor; Abl family kinase; SOS1; C3G	PHOSPHOINOSITIDE 3-KINASE/AKT PATHWAY; NUCLEOTIDE-RELEASING FACTOR; FOCAL ADHESION KINASE; ABL TYROSINE KINASE; V-CRK; ADAPTER PROTEIN; MALIGNANT FEATURE; CELL-MIGRATION; POSITIVE CELLS; SH3 DOMAIN	The v-Crk oncogene product consists of two protein interaction modules, a Src homology 2 (SH2) domain and a Src homology 3 (SH3) domain. Overexpression of CrkI, the cellular homolog of v-Crk, transforms mouse fibroblasts, and elevated CrkI expression is observed in several human cancers. The SH2 and SH3 domains of Crk are required for transformation, but the identity of the critical cellular binding partners is not known. A number of candidate Crk SH3-binding proteins have been identified, including the nonreceptor tyrosine kinases c-Abl and Arg, and the guanine nucleotide exchange proteins C3G, SOS1 and DOCK180. The aim of this study is to determine which of these are required for transformation by CrkI. We found that short hairpin RNA-mediated knockdown of C3G or SOS1 suppressed anchorage-independent growth of NIH-3T3 cells over-expressing CrkI, whereas knockdown of SOS1 alone was sufficient to suppress tumor formation by these cells in nude mice. Knockdown of C3G was sufficient to revert morphological changes induced by CrkI expression. By contrast, knockdown of Abl family kinases or their inhibition with imatinib enhanced anchorage-independent growth and tumorigenesis induced by Crk. These results show that SOS1 is essential for CrkI-induced fibroblast transformation, and also reveal a surprising negative role for Abl kinases in Crk transformation. Oncogene (2010) 29, 6378-6389; doi:10.1038/onc.2010.369; published online 23 August 2010	[Zheng, J.; Machida, K.; Antoku, S.; Ng, K. Y.; Mayer, B. J.] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, Farmington, CT 06030 USA; [Claffey, K. P.] Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; [Claffey, K. P.] Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut; University of Connecticut	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	bmayer@neuron.uchc.edu			National Institutes of Health [CA82258, CA064436]; NATIONAL CANCER INSTITUTE [R01CA064436, R01CA082258, R29CA064436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michiyuki Matsuda (Kyoto University) for providing the shRNAs targeting DOCK180 and the antibody against DOCK180, Dr Peter Davies (Albert Einstein College of Medicine) for Arg antibody and Novartis Pharmaceuticals for imatinib. We thank Kathryn Phoenix and Frank Vumbaca for the technical help. This work was supported by grants CA82258 (to BJM) and CA064436 (to KPC) from the National Institutes of Health.	Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Antoku S, 2009, J CELL SCI, V122, P4228, DOI 10.1242/jcs.054627; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Cipres A, 2007, CELL SIGNAL, V19, P1662, DOI 10.1016/j.cellsig.2007.02.011; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2009, NAT MED, V15, P1149, DOI 10.1038/nm1009-1149; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hemmeryckx B, 2001, CANCER RES, V61, P1398; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Iwahara T, 2004, P NATL ACAD SCI USA, V101, P17693, DOI 10.1073/pnas.0408413102; Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nievers MG, 1997, J CELL SCI, V110, P389; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Riggins RB, 2003, MOL CANCER RES, V1, P428; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Sharma A, 2004, PRIN PRACT, P165, DOI 10.1109/ICTTA.2004.1307673; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Stam JC, 2001, J BIOL CHEM, V276, P25176, DOI 10.1074/jbc.M009825200; Takino T, 2003, CANCER RES, V63, P2335; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang L, 2007, BIOCHEM BIOPH RES CO, V362, P976, DOI 10.1016/j.bbrc.2007.08.106; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006	55	7	9	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6378	6389		10.1038/onc.2010.369	http://dx.doi.org/10.1038/onc.2010.369			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20729917	Green Accepted			2022-12-28	WOS:000284874700008
J	Kanai, M; Crowe, MS; Zheng, Y; Vande Woude, GF; Fukasawa, K				Kanai, M.; Crowe, M. S.; Zheng, Y.; Vande Woude, G. F.; Fukasawa, K.			RhoA and RhoC are both required for the ROCK II-dependent promotion of centrosome duplication	ONCOGENE			English	Article						centrosome; Rho; ROCK II; CDK2; cyclin E; NPM/B23	CDK2/CYCLIN E; KINASE; GTPASES; NUCLEOPHOSMIN/B23; INVOLVEMENT; TARGET; CYCLE; CDK2	CDK2-cyclin E triggers centrosome duplication, and nucleophosmin (NPM/B23) is found to be one of its targets. NPM/B23 phosphorylated by CDK2-cyclin E acquires a high binding affinity to Rho-associated kinase (ROCK II), and physically associates with ROCK II. The NPM/B23-binding results in superactivation of ROCK II, which is a critical event for initiation of centrosome duplication. The activation of ROCK II also requires the binding of Rho small GTPase to the auto-inhibitory region; hence the availability of the active Rho protein is an important aspect of the centrosomally localized ROCK II to properly initiate centrosome duplication. There are three isoforms of Rho (RhoA, B and C), all of which are capable of binding to and priming the activation of ROCK II. Here, we investigated which Rho isoform(s) are involved in the activation of ROCK II in respect to the initiation of centrosome duplication. We found that both RhoA and RhoC, but not RhoB, were required for initiation of centrosome duplication, and overactivation of RhoA, as well as RhoC, but not RhoB, promoted centrosome duplication and centrosome amplification. Oncogene (2010) 29, 6040 6050; doi:10.1038/onc.2010.328; published online 9 August 2010	[Kanai, M.; Crowe, M. S.; Fukasawa, K.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; [Zheng, Y.] Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH USA; [Zheng, Y.] Univ Cincinnati, Childrens Hosp Res Fdn, Mol Dev Biol Program, Cincinnati, OH USA; [Vande Woude, G. F.] Van Andel Res Inst, Grand Rapids, MI USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Van Andel Institute	Fukasawa, K (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr,SRB 2, Tampa, FL 33612 USA.	Kenji.Fukasawa@moffitt.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; Crowe, Matthew/0000-0001-5251-0238	National Institute of Health [CA90522]; James & Esther King Biomedical Research Program [09KN-05-23139]; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087328] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James & Esther King Biomedical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M Rowland and B Nepon-Sixt for technical assistance and core staff at the analytical microscopy core facility and molecular biology core facility in H Lee Moffitt Cancer Center. We also thank Dr Sebti for providing RhoB cDNA. This study is supported by the National Institute of Health (CA90522 to KF) and James & Esther King Biomedical Research Program (09KN-05-23139 to MK).	Aoki T, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-56; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Canguilhem B, 2005, J BIOL CHEM, V280, P43257, DOI 10.1074/jbc.M508650200; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Chevrier V, 2002, J CELL BIOL, V157, P807, DOI 10.1083/jcb.200203034; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Ho TTG, 2008, J BIOL CHEM, V283, P21588, DOI 10.1074/jbc.M710033200; Kabuyama Y, 2009, MOL CELL PROTEOMICS, V8, P2308, DOI 10.1074/mcp.M900178-MCP200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Milia J, 2005, CELL DEATH DIFFER, V12, P492, DOI 10.1038/sj.cdd.4401586; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Reed SI, 1997, CANCER SURV, V29, P7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Salisbury JL, 2007, J CELL PHYSIOL, V213, P420, DOI 10.1002/jcp.21226; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang L, 2003, J BIOL CHEM, V278, P44617, DOI 10.1074/jbc.M308929200; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504	39	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6040	6050		10.1038/onc.2010.328	http://dx.doi.org/10.1038/onc.2010.328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20697357	Green Accepted			2022-12-28	WOS:000284108700006
J	Liu, Y; Chen, N; Cui, X; Zheng, X; Deng, L; Price, S; Karantza, V; Minden, A				Liu, Y.; Chen, N.; Cui, X.; Zheng, X.; Deng, L.; Price, S.; Karantza, V.; Minden, A.			The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis	ONCOGENE			English	Article						Pak4; mammary epithelial cells; breast cancer; apoptosis; cell survival	ANCHORAGE-INDEPENDENT GROWTH; EPITHELIAL ACINI; CELL POLARITY; CANCER; APOPTOSIS; RECEPTOR; ACTIVATION; SURVIVAL; BINDING; MODEL	The Pak4 serine/threonine kinase is highly expressed in many cancer cell lines and human tumors. Although several studies have addressed the role for Pak4 in transformation of fibroblasts, most human cancers are epithelial in origin. Epithelial cancers are associated not only with changes in cell growth but also with changes in the cellular organization within the three-dimensional (3D) architecture of the affected tissues. In this study we used immortalized mouse mammary epithelial cells (iMMECs) as a model system to study the role for Pak4 in mammary tumorigenesis. iMMECs are an excellent model system for studying breast cancer, as they can grow in 3D-epithelial cell culture, in which they form acinar structures that recapitulate in vivo mammary morphogenesis. Although Pak4 is expressed at low levels in wild-type iMMECs, it is overexpressed in response to oncogenes, such as oncogenic Ras and Her2/neu. In this study we found that overexpression of Pak4 in iMMECs leads to changes in 3D acinar architecture that are consistent with oncogenic transformation. These include decreased central acinar cell death, abrogation of lumen formation, cell polarity alterations and deregulation of acinar size and cell number. Furthermore, iMMECs overexpressing Pak4 form tumors when implanted into the fat pads of athymic mice. Our results suggest that overexpression of Pak4 triggers events that are important for the transformation of mammary epithelial cells. This is likely to be owing to the ability of Pak4 to inhibit apoptosis and promote cell survival and thus subsequent uncontrolled proliferation, and to its ability to deregulate cell shape and polarity. Oncogene (2010) 29, 5883-5894; doi:10.1038/onc.2010.329; published online 9 August 2010	[Liu, Y.; Cui, X.; Zheng, X.; Minden, A.] Rutgers State Univ, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA; [Chen, N.; Price, S.; Karantza, V.] Canc Inst New Jersey, Dept Med, New Brunswick, NJ USA; [Chen, N.; Karantza, V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Med Oncol, Dept Internal Med, Piscataway, NJ 08854 USA; [Deng, L.] Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Minden, A (corresponding author), Rutgers State Univ, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Ernest Mario Sch Pharm, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	aminden@rci.rutgers.edu	Chen, Ning/AAM-9513-2021	Chen, Ning/0000-0002-8191-6744	 [R01 CA076342];  [R00 CA133181]; NATIONAL CANCER INSTITUTE [R00CA133181, R01CA076342] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Chung S Yang and Dr Zhihong Yang for providing human colon cancer cell lines. This work was supported by R01 CA076342 to AM and R00 CA133181 to VK.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chandramouly G, 2007, J CELL SCI, V120, P1596, DOI 10.1242/jcs.03439; Chen SY, 2008, COMMUN COMPUT PHYS, V4, pI; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Degenhardt K, 2006, CLIN CANCER RES, V12, P5298, DOI 10.1158/1078-0432.CCR-06-0439; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Konska G, 1998, INT J ONCOL, V12, P361; Li XF, 2005, J BIOL CHEM, V280, P41192, DOI 10.1074/jbc.M506884200; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	22	50	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	44					5883	5894		10.1038/onc.2010.329	http://dx.doi.org/10.1038/onc.2010.329			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697354	Green Accepted			2022-12-28	WOS:000283843400003
J	Planel, S; Salomon, A; Jalinot, P; Feige, JJ; Cherradi, N				Planel, S.; Salomon, A.; Jalinot, P.; Feige, J-J; Cherradi, N.			A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1	ONCOGENE			English	Article						tumor angiogenesis; VEGF; ZFP36L1; tristetraprolin; mRNA stability; multitarget therapy	ENDOTHELIAL GROWTH-FACTOR; CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; HORMONAL-REGULATION; IN-VIVO; TRISTETRAPROLIN; DELIVERY; TRANSDUCTION; ANGIOGENESIS; EXPRESSION	Angiogenesis inhibitors have shown clinical benefits in patients with advanced cancer, but further therapeutic improvement is needed. We have previously shown that the zinc finger protein 36, C3H type-like 1 (ZFP36L1) enhances vascular endothelial growth factor (VEGF) mRNA decay through its interaction with AU-rich elements within VEGF 3'-untranslated region. In this study, we evaluated the possibility to develop an antiangiogenic and antitumoral strategy using the mRNA-destabilizing activity of ZFP36L1. We engineered a cell-penetrating ZFP36L1, by fusing it to the protein transduction domains (PTDs) TAT derived from HIV, or the polyarginine peptides R7 or R9. PTD-ZFP36L1 fusion proteins were expressed in bacterial cells and affinity-purified to homogeneity. TAT-, R7- and R9-ZFP36L1 were efficiently internalized into living cells and decreased both endogenous VEGF mRNA half-life and VEGF protein levels in vitro. Importantly, a single injection of R9-TIS11b fusion protein into a high-VEGF expressing tissue in vivo (in this study, the mouse adrenal gland) markedly decreased VEGF expression. We further evaluated the effect of R9-ZFP36L1 on tumor growth using Lewis Lung Carcinoma (LL/2) cells implanted subcutaneously into nude mice. Intratumoral injection of R9-ZFP36L1 significantly reduced tumor growth and markedly decreased the expression of multiple angiogenic and inflammatory cytokines, including VEGF, acidic fibroblast growth factor, tumor necrosis factor alpha, interleukin (IL)-1 alpha and IL-6, with a concomitant obliteration of tumor vascularization. These findings indicate that R9-ZFP36L1 fusion protein may represent a novel antiangiogenic and antitumoral agent, and supports the emerging idea that modulation of mRNA stability represents a promising therapeutic approach to treat cancer. Oncogene (2010) 29, 5989-6003; doi:10.1038/onc.2010.341; published online 30 August 2010	[Cherradi, N.] CEA Grenoble, INSERM, U878, LPAV,iRTSV, F-38054 Grenoble 09, Rhone Alpes, France; [Planel, S.; Salomon, A.; Feige, J-J; Cherradi, N.] Univ Grenoble 1, Grenoble, France; [Jalinot, P.] ENS Lyon, LBMC CNRS UMR5239, Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Cherradi, N (corresponding author), CEA Grenoble, INSERM, U878, LPAV,iRTSV, 17 Rue Martyrs, F-38054 Grenoble 09, Rhone Alpes, France.	nadia.cherradi@cea.fr	Feige, Jean-Jacques/M-8905-2017; Cherradi, Nadia/K-9695-2016; Jalinot, Pierre/M-7940-2014	Feige, Jean-Jacques/0000-0002-1354-7692; Cherradi, Nadia/0000-0002-4292-774X; 	Institut National de la Sante et de la Recherche Medicale (INSERM) [U878]; Commissariat a l'Energie Atomique (iRTSV/LAPV); Institut du Cancer (INCa); Canceropole Rhone-Alpes (CLARA); Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie; Association pour la Recherche sur le Cancer; Fondation pour la Recherche Medicale	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Commissariat a l'Energie Atomique (iRTSV/LAPV)(French Atomic Energy Commission); Institut du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Rhone-Alpes (CLARA); Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM, U878), the Commissariat a l'Energie Atomique (iRTSV/LAPV), the Institut du Cancer (INCa, Program 'Emergence des Canceropoles 2004'), the Canceropole Rhone-Alpes (CLARA) and the Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie. We also thank the Association pour la Recherche sur le Cancer and the Fondation pour la Recherche Medicale for their financial support to SP. We thank Dr Didier Grunwald (LTS, iRTSV, CEA-Grenoble) for helping us with the laser confocal microscopy platform of our institute. We also thank Dr Maryline Herbet and Dr Michael Thomas (INSERM U878, iRTSV, CEA-Grenoble) for their assistance in the 'in vivo' experiments and Dr Jean-Luc Coll (INSERM U883, UJF, Grenoble, France) for his generous gift of the LL/2-luciferase cell line.	Asoh S, 2008, ADV DRUG DELIVER REV, V60, P499, DOI 10.1016/j.addr.2007.09.011; Baou M, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/634520; Bell SE, 2006, DEV DYNAM, V235, P3144, DOI 10.1002/dvdy.20949; Benjamin D, 2007, EXPERT OPIN BIOL TH, V7, P1515, DOI 10.1517/14712598.7.10.1515; Benjamin D, 2006, MOL CELL BIOL, V26, P9497, DOI 10.1128/MCB.01099-06; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bigelow RLH, 2009, BREAST CANCER RES TR, V117, P31, DOI 10.1007/s10549-008-0170-7; Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011; Cao H, 2008, BIOTECHNOL PROGR, V24, P326, DOI 10.1021/bp070269n; Cao HP, 2009, BIOTECHNOL PROGR, V25, P461, DOI 10.1002/btpr.121; Cao HP, 2004, BIOCHEMISTRY-US, V43, P13724, DOI 10.1021/bi049014y; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031; Cherradi N, 2006, MOL ENDOCRINOL, V20, P916, DOI 10.1210/me.2005-0121; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Dirkx AEM, 2006, J LEUKOCYTE BIOL, V80, P1183, DOI 10.1189/jlb.0905495; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fittipaldi A, 2005, ADV DRUG DELIVER REV, V57, P597, DOI 10.1016/j.addr.2004.10.011; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gariano RF, 2006, GENE EXPR PATTERNS, V6, P187, DOI 10.1016/j.modgep.2005.06.008; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Ho A, 2001, CANCER RES, V61, P474; Jalonen U, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/40691; Kuvaja P, 2005, ONCOLOGY-BASEL, V68, P196, DOI 10.1159/000086774; Lee SK, 2005, INT J CANCER, V117, P32, DOI 10.1002/ijc.21133; Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6; Li B, 2009, CANCER RES, V69, P338, DOI 10.1158/0008-5472.CAN-08-1565; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Offenberg H, 2008, MOL ONCOL, V2, P233, DOI 10.1016/j.molonc.2008.06.003; Ogilvie RL, 2009, J BIOL CHEM, V284, P11216, DOI 10.1074/jbc.M901229200; Onesto C, 2004, J BIOL CHEM, V279, P34217, DOI 10.1074/jbc.M400219200; Petrelli A, 2008, CURR MED CHEM, V15, P422; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Saidi A, 2009, INT J CANCER, V125, P1054, DOI 10.1002/ijc.24380; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Snyder EL, 2004, PHARM RES-DORDR, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stumpo DJ, 2009, BLOOD, V114, P2401, DOI 10.1182/blood-2009-04-214619; Stumpo DJ, 2004, MOL CELL BIOL, V24, P6445, DOI 10.1128/MCB.24.14.6445-6455.2004; Thomas M, 2004, ENDOCRINOLOGY, V145, P4320, DOI 10.1210/en.2004-0179; Tudor C, 2009, FEBS LETT, V583, P1933, DOI 10.1016/j.febslet.2009.04.039; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	50	26	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					5989	6003		10.1038/onc.2010.341	http://dx.doi.org/10.1038/onc.2010.341			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20802528				2022-12-28	WOS:000284108700002
J	Titz, B; Low, T; Komisopoulou, E; Chen, SS; Rubbi, L; Graeber, TG				Titz, B.; Low, T.; Komisopoulou, E.; Chen, S. S.; Rubbi, L.; Graeber, T. G.			The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization	ONCOGENE			English	Article						adaptor protein; BCR-ABL1; phospho-complex; quantitative mass spectrometry; signaling network; systems biology	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL KINASE; ADAPTER PROTEIN; PARKINSONS-DISEASE; NEGATIVE REGULATOR; MASS-SPECTROMETRY; TYROSINE KINASE; BINDING-SITE	BCR-ABL1 is a fusion tyrosine kinase, which causes multiple types of leukemia. We used an integrated proteomic approach that includes label-free quantitative protein complex and phosphorylation profiling by mass spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal BCR-ABL1 signaling network shows a modular and layered organization with an inner core of three leukemia transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/Dok2 complex). We introduced an 'interaction directionality' analysis, which annotates static protein networks with information on the directionality of phosphorylation-dependent interactions. In this analysis, the observed network structure was consistent with a step-wise phosphorylation-dependent assembly of the Grb2/Gab2/Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 core. The CrkI complex demonstrated a different directionality, which supports a candidate assembly on the Nedd9 (Hef1, CasL) scaffold. As adaptor protein family members can compensate for each other in leukemic transformation, we compared members of the Dok and Crk protein families and found both overlapping and differential binding patterns. We identified an additional level of regulation for the CrkII protein via binding to 14-3-3 proteins, which was independent from its inhibitory phosphorylation. We also identified novel components of the inner core complexes, including the kinases Pragmin (Sgk223) and Lrrk1 (Lrrk2 paralog). Pragmin was found as a component of the CrkI complex and is a potential link between BCR-ABL1/CrkI and RhoA signaling. Lrrk1 is an unusual kinase with a GTPase domain. We detected Lrrk1 as a component of the Grb2/Gab2/Shc1 complex and found that it functionally interacts with the regulator of small GTPases Arap1 (Centd2) and possibly participates in the mitogen-activated protein kinase response to cellular stresses. This modular and phosphorylation-driven interaction network provides a framework for the integration of pleiotropic signaling effects of BCR-ABL1 toward leukemic transformation. Oncogene (2010) 29, 5895-5910; doi:10.1038/onc.2010.331; published online 9 August 2010	[Titz, B.; Low, T.; Komisopoulou, E.; Chen, S. S.; Rubbi, L.; Graeber, T. G.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Calif Nanosyst Inst,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Graeber, TG (corresponding author), Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Calif Nanosyst Inst,Jonsson Comprehens Canc Ctr, 570 Westwood Plaza,Bldg 114, Los Angeles, CA 90095 USA.	tgraeber@mednet.ucla.edu	Titz, Bjoern/G-6317-2017; Titz, Björn/B-9516-2008	Titz, Bjoern/0000-0003-4414-4105; Graeber, Thomas/0000-0001-8574-9181	NIH NHGRI [HG002807]; University of California, Cancer Research Coordinating Committee; German Academic Exchange Service; UCLA, USHHS [T32 CA009056]; NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG002807] Funding Source: NIH RePORTER	NIH NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); University of California, Cancer Research Coordinating Committee(University of California System); German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); UCLA, USHHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was funded by grants to TGG from the NIH NHGRI (HG002807) and the University of California, Cancer Research Coordinating Committee, and by postdoctoral fellowships of the German Academic Exchange Service to BT and the UCLA Tumor Biology Program USHHS Ruth L Kirschstein Institutional National Research Service Award # T32 CA009056 to SSC. TGG is an Alfred P Sloan Research Fellow. We thank M Negishi, D Korr and T Burckstummer for kindly providing plasmids. Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research Flow Cytometry Core.	Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; BAIER T, 2009, R D COM SERVER; Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Brehme M, 2009, P NATL ACAD SCI USA, V106, P7414, DOI 10.1073/pnas.0900653106; Burckstummer T, 2006, NAT METHODS, V3, P1013, DOI 10.1038/nmeth968; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Caplan AJ, 2007, TRENDS CELL BIOL, V17, P87, DOI 10.1016/j.tcb.2006.12.002; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Daniele T, 2008, TRAFFIC, V9, P2221, DOI 10.1111/j.1600-0854.2008.00823.x; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Diella F, 2008, FRONT BIOSCI-LANDMRK, V13, P6580, DOI 10.2741/3175; Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Faisal A, 2004, J BIOL CHEM, V279, P3202, DOI 10.1074/jbc.M310010200; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gautreau A, 2004, P NATL ACAD SCI USA, V101, P4379, DOI 10.1073/pnas.0400628101; Gilks WP, 2005, LANCET, V365, P415, DOI 10.1016/S0140-6736(05)17830-1; Gloeckner CJ, 2009, J NEUROCHEM, V109, P959, DOI 10.1111/j.1471-4159.2009.06024.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goss VL, 2006, BLOOD, V107, P4888, DOI 10.1182/blood-2005-08-3399; Goudreault M, 2009, MOL CELL PROTEOMICS, V8, P157, DOI 10.1074/mcp.M800266-MCP200; Graeber TG, 2010, P NATL ACAD SCI USA, V107, P6112, DOI 10.1073/pnas.1001149107; Harada JN, 2005, GENOME RES, V15, P1136, DOI 10.1101/gr.3889305; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Heo HY, 2010, EXP CELL RES, V316, P649, DOI 10.1016/j.yexcr.2009.09.014; Hornbeck PV, 2004, PROTEOMICS, V4, P1551, DOI 10.1002/pmic.200300772; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Hughan SC, 2007, J THROMB HAEMOST, V5, P387, DOI 10.1111/j.1538-7836.2007.02307.x; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Johnson KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007439; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Kantarjian HM, 2007, CLIN CANCER RES, V13, P1089, DOI 10.1158/1078-0432.CCR-06-2147; Kerrien S, 2007, NUCLEIC ACIDS RES, V35, pD561, DOI 10.1093/nar/gkl958; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Korr D, 2006, CELL SIGNAL, V18, P910, DOI 10.1016/j.cellsig.2005.08.015; Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102; Liou AKF, 2008, NEUROBIOL DIS, V32, P116, DOI 10.1016/j.nbd.2008.06.016; Marchler-Bauer A, 2009, NUCLEIC ACIDS RES, V37, pD205, DOI 10.1093/nar/gkn845; McGavin MKH, 2001, J EXP MED, V194, P1777, DOI 10.1084/jem.194.12.1777; Million RP, 2000, BLOOD, V96, P664; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Neduva V, 2006, CURR OPIN BIOTECH, V17, P465, DOI 10.1016/j.copbio.2006.08.002; NICHOLS GL, 1994, BLOOD, V84, P2912; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; ODA T, 1994, J BIOL CHEM, V269, P22925; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Pawson T, 2007, CURR OPIN CELL BIOL, V19, P112, DOI 10.1016/j.ceb.2007.02.013; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pflieger D, 2008, MOL CELL PROTEOMICS, V7, P326, DOI 10.1074/mcp.M700282-MCP200; Prakash A, 2006, MOL CELL PROTEOMICS, V5, P423, DOI 10.1074/mcp.M500133-MCP200; Prosser DC, 2008, J CELL SCI, V121, P3052, DOI 10.1242/jcs.028696; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; R Core Team, 2020, R LANG ENV STAT COMP; Raetz EA, 2008, J CLIN ONCOL, V26, P3971, DOI 10.1200/JCO.2008.16.1414; Ramshaw HS, 2007, BLOOD, V110, P3582, DOI 10.1182/blood-2007-01-070391; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sarmann J, 2009, J BIOL CHEM, V284, P16482, DOI 10.1074/jbc.M808255200; Saha S, 2009, J NEUROSCI, V29, P9210, DOI 10.1523/JNEUROSCI.2281-09.2009; Sasaoka T, 2001, ENDOCRINOLOGY, V142, P5226, DOI 10.1210/en.142.12.5226; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Skaggs BJ, 2006, P NATL ACAD SCI USA, V103, P19466, DOI 10.1073/pnas.0609239103; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; Stuart JR, 2006, J BIOL CHEM, V281, P31290, DOI 10.1074/jbc.M602389200; Tanaka H, 2006, J BIOL CHEM, V281, P10355, DOI 10.1074/jbc.M511314200; Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522; Titz B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002292; Trinkle-Mulcahy L, 2008, J CELL BIOL, V183, P223, DOI 10.1083/jcb.200805092; Wang LZ, 2008, J NEUROSCI, V28, P3384, DOI 10.1523/JNEUROSCI.0185-08.2008; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Yasuda T, 2004, J EXP MED, V200, P1681, DOI 10.1084/jem.20041247; Yasuda T, 2007, INT IMMUNOL, V19, P487, DOI 10.1093/intimm/dxm015; Yoon HY, 2008, TRAFFIC, V9, P2236, DOI 10.1111/j.1600-0854.2008.00839.x; Yu WD, 2008, CARCINOGENESIS, V29, P1717, DOI 10.1093/carcin/bgn098; Zimman A, 2010, J PROTEOME RES, V9, P2812, DOI 10.1021/pr901194x; Zipfel PA, 2006, CURR BIOL, V16, P35, DOI 10.1016/j.cub.2005.12.024	92	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5895	5910		10.1038/onc.2010.331	http://dx.doi.org/10.1038/onc.2010.331			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697350	Green Accepted			2022-12-28	WOS:000283843400004
J	Zenvirt, S; Kravchenko-Balasha, N; Levitzki, A				Zenvirt, S.; Kravchenko-Balasha, N.; Levitzki, A.			Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents	ONCOGENE			English	Article						CHK1; checkpoint; cancer; p53	DNA-DAMAGE; S-PHASE; CHECKPOINT KINASES; MITOTIC CATASTROPHE; G(2)/M TRANSITION; PATHWAY; THERAPY; ARREST; ABROGATION; ATM	DNA damage checkpoints cause cell cycle arrest, allowing DNA repair before resumption of the cell cycle. These checkpoints can be activated through several signaling pathways. Checkpoint activators include p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 and/or MAPKAP kinase 2 (MK2). Many cancer cells lack p53 activity and, therefore, depend on alternative checkpoint activators to arrest the cell cycle following DNA damage. Inhibition of these pathways is expected to specifically sensitize these p53-deficient cells to DNA damage caused by chemotherapy. Using isogenic p53-proficient and p53-deficient cancer cell lines, we show that inactivation of CHK1, but not MK2, abrogates cell cycle arrest following chemotherapy, specifically in p53-deficient cells. However, we show that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive than p53-deficient cells to CHK1 inhibition in the presence of DNA damage. Thus, combining CHK1 inhibition with DNA damage does not lead to preferential killing of p53-deficient over p53-proficient cells, and inhibiting CHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy. Oncogene (2010) 29, 6149-6159; doi:10.1038/onc.2010.343; published online 23 August 2010	[Zenvirt, S.; Kravchenko-Balasha, N.; Levitzki, A.] Hebrew Univ Jerusalem, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	Levitzki@vms.huji.ac.il	Kravchenko-Balasha, Nataly/D-7683-2016	Kravchenko-Balasha, Nataly/0000-0001-6943-7479	Lady Davis Fellowship Trust; Algen Biopharmaceuticals, Ltd.	Lady Davis Fellowship Trust; Algen Biopharmaceuticals, Ltd.	We would like to thank Dr Shoshana Klein for discussions and editing. This work was partially supported by the Lady Davis Fellowship Trust and by Algen Biopharmaceuticals, Ltd.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashwell S, 2008, EXPERT OPIN INV DRUG, V17, P1331, DOI [10.1517/13543784.17.9.1331, 10.1517/13543784.17.9.1331 ]; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; DENT MF, 1995, CYTOTECHNOLOGY, V17, P27, DOI 10.1007/BF00749218; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hirose Y, 2001, CANCER RES, V61, P5843; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kravchenko-Balasha N, 2009, J BIOL CHEM, V284, P11717, DOI 10.1074/jbc.M900217200; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Lieberman HB, 2008, CURR MED CHEM, V15, P360, DOI 10.2174/092986708783497328; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Shao RG, 1997, CANCER RES, V57, P4029; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227; Tao YG, 2009, CELL CYCLE, V8, P1196, DOI 10.4161/cc.8.8.8203; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2003, CANCER BIOL THER, V2, pS16; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6149	6159		10.1038/onc.2010.343	http://dx.doi.org/10.1038/onc.2010.343			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729914	Bronze			2022-12-28	WOS:000284356500007
J	Behrens, ME; Grandgenett, PM; Bailey, JM; Singh, PK; Yi, CH; Yu, F; Hollingsworth, MA				Behrens, M. E.; Grandgenett, P. M.; Bailey, J. M.; Singh, P. K.; Yi, C-H; Yu, F.; Hollingsworth, M. A.			The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF	ONCOGENE			English	Article						MUC1; CTGF; signal transduction; transcriptional activation; pancreatic cancer	TISSUE-GROWTH-FACTOR; CARCINOMA-ASSOCIATED ANTIGEN; CYTOPLASMIC TAIL; IN-VITRO; C-SRC; CANCER; BETA; EXPRESSION; CELLS; P53	The MUC1 cytoplasmic tail (MUC1.CT) conducts signals from spatial and extracellular cues (growth factor and cytokine stimulation) to evoke a reprogramming of the cellular transcriptional profile. Specific phosphorylated forms of the MUC1.CT achieve this function by differentially associating with transcription factors and redirecting their transcriptional regulatory capabilities at specific gene regulatory elements. The specificity of interaction between MUC1.CT and several transcription factors is dictated by the phosphorylation pattern of the 18 potential phosphorylation motifs within the MUC1.CT. To better appreciate the scope of differential gene expression triggered by MUC1.CT activation, we performed microarray gene expression analysis and chromatin immunoprecipitation (ChIP)-chip promoter analysis and identified the genome-wide transcriptional targets of MUC1.CT signaling in pancreatic cancer. On a global scale, MUC1.CT preferentially targets genes related to invasion, angiogenesis and metastasis, suggesting that MUC1.CT signaling contributes to establishing a reactive tumor microenvironment during tumor progression to metastatic disease. We examined in detail the molecular mechanisms of MUC1.CT signaling that induces the expression of connective tissue growth factor (CTGF/CCN2), a potent mediator of ECM remodeling and angiogenesis. We demonstrate a robust induction of CTGF synthesis and secretion in response to serum factors that is enabled only when MUC1 is highly expressed. We demonstrate the requirement of phosphorylation at distinct tyrosine motifs within the MUC1.CT for MUC1-induced CTGF expression and demonstrate a phosphorylation-specific localization of MUC1.CT to the CTGF promoter. We found that MUC1 reorganizes transcription factor occupancy of genomic regions upstream of the CTGF gene, directing beta-catenin and mutant p53 to CTGF gene regulatory elements to promote CTGF expression and destabilizing the interaction at these regions of the transcriptional repressor, c-Jun. With this example we illustrate the capacity of MUC1.CT to mediate transcription factor activity in a context-dependent manner to achieve wide spread and robust changes in gene expression and facilitate creation of the reactive tumor microenvironment. Oncogene (2010) 29, 5667-5677; doi:10.1038/onc.2010.327; published online 9 August 2010	[Behrens, M. E.; Grandgenett, P. M.; Bailey, J. M.; Singh, P. K.; Yi, C-H; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Behrens, M. E.; Singh, P. K.; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Yu, F.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Hollingsworth, MA (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	mahollin@unmc.edu	Yu, Fang/B-9874-2013	Bailey-Lundberg, Jennifer/0000-0002-4750-106X; Singh, Pankaj/0000-0001-8903-0131	NCI NIH HHS [P50 CA127297, R01 CA057362, U01 CA111294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA127297, U01CA111294, R01CA057362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Aikawa T, 2006, MOL CANCER THER, V5, P1108, DOI 10.1158/1535-7163.MCT-05-0516; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Gao JC, 2009, INT J ONCOL, V35, P337, DOI 10.3892/ijo_00000345; Gatto M, 2008, LAB INVEST, V88, P986, DOI 10.1038/labinvest.2008.63; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; Kohlgraf KG, 2003, CANCER RES, V63, P5011; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Masaki Y, 1999, HEPATO-GASTROENTEROL, V46, P2240; Masuko Kayo, 2010, BMC Res Notes, V3, P5, DOI 10.1186/1756-0500-3-5; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; Pemberton LF, 1996, J BIOL CHEM, V271, P2332, DOI 10.1074/jbc.271.4.2332; Qu CF, 2004, BRIT J CANCER, V91, P2086, DOI 10.1038/sj.bjc.6602232; Raina D, 2008, CANCER BIOL THER, V7, P1959, DOI 10.4161/cbt.7.12.6956; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Sun YB, 2004, J CELL BIOCHEM, V92, P258, DOI 10.1002/jcb.20044; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Tsutsumida H, 2006, CLIN CANCER RES, V12, P2976, DOI 10.1158/1078-0432.CCR-05-1197; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; Yang DH, 1998, J CLIN ENDOCR METAB, V83, P2593, DOI 10.1210/jc.83.7.2593; Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478; Yuan ZL, 2009, J SURG RES, V157, pE39, DOI 10.1016/j.jss.2008.09.005; Zarrinkalam KH, 2003, KIDNEY INT, V64, P331, DOI 10.1046/j.1523-1755.2003.00069.x	39	59	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5667	5677		10.1038/onc.2010.327	http://dx.doi.org/10.1038/onc.2010.327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20697347	Green Accepted			2022-12-28	WOS:000283262500003
J	Wu, WKK; Lee, CW; Cho, CH; Fan, D; Wu, K; Yu, J; Sung, JJY				Wu, W. K. K.; Lee, C. W.; Cho, C. H.; Fan, D.; Wu, K.; Yu, J.; Sung, J. J. Y.			MicroRNA dysregulation in gastric cancer: a new player enters the game	ONCOGENE			English	Review						microRNA; gastric cancer; signaling pathway; proliferation; apoptosis; metastasis	MIGRATION INHIBITORY FACTOR; EPSTEIN-BARR-VIRUS; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; HELICOBACTER-PYLORI; INCREASED RISK; DECREASED EXPRESSION; TRANSCRIPTION FACTOR; INDUCE APOPTOSIS; EPITHELIAL-CELLS	Gastric carcinogenesis is a multistep process involving genetic and epigenetic alteration of protein-coding proto-oncogenes and tumor-suppressor genes. Recent discoveries have shed new light on the involvement of a class of noncoding RNA known as microRNA (miRNA) in gastric cancer. A substantial number of miRNAs show differential expression in gastric cancer tissues. Genes coding for these miRNAs have been characterized as novel proto-oncogenes and tumor-suppressor genes based on findings that these miRNAs control malignant phenotypes of gastric cancer cells. In this connection, miRNA dysregulation promotes cell-cycle progression, confers resistance to apoptosis, and enhances invasiveness and metastasis. Moreover, certain polymorphisms in miRNA genes are associated with increased risks for atrophic gastritis and gastric cancer, whereas circulating levels of miRNAs may serve as biomarkers for early diagnosis. Several miRNAs have also been shown to correlate with gastric cancer progression, and thus may be used as prognostic markers. Elucidating the biological aspects of miRNA dysregulation may help us better understand the pathogenesis of gastric cancer and promote the development of miRNA-directed therapeutics against this deadly disease. Oncogene (2010) 29, 5761-5771; doi: 10.1038/onc.2010.352; published online 30 August 2010	[Wu, W. K. K.; Lee, C. W.; Cho, C. H.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, LKS Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, W. K. K.; Lee, C. W.; Cho, C. H.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Cho, C. H.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Fan, D.; Wu, K.] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Fan, D.; Wu, K.] Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian 710032, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Air Force Military Medical University; Air Force Military Medical University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, LKS Inst Hlth Sci, 7-F LKS Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk; joesung@cuhk.edu.hk	Wu, William K.K./A-3277-2009; wu, william/HII-5817-2022; Sung, Joseph J. Y./R-3203-2018; Xiao, Yang/B-5668-2012; Cho, Chi Hin/C-6543-2014; Yu, Jun/D-8569-2015	Wu, William K.K./0000-0002-5662-5240; Sung, Joseph J. Y./0000-0003-3125-5199; Cho, Chi Hin/0000-0002-7658-3260; Yu, Jun/0000-0001-5008-2153	National Basic Research Program of China (973 Program) [2010CB529305]; CUHK [3110043]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); CUHK(Chinese University of Hong Kong)	This work was supported by research grant from the National Basic Research Program of China (973 Program, 2010CB529305). CUHK Group Research Scheme (3110043) and CUHK Focused Investments Scheme-Scheme C.	Agrawal S, 2007, BLOOD, V109, P3895, DOI 10.1182/blood-2006-08-040147; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Araya M, 1997, J SURG ONCOL, V65, P232, DOI 10.1002/(SICI)1096-9098(199708)65:4<232::AID-JSO2>3.0.CO;2-6; Arisawa T, 2007, DIGEST DIS SCI, V52, P1691, DOI 10.1007/s10620-006-9648-5; Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Bernard D, 2006, ONCOGENE, V25, P1358, DOI 10.1038/sj.onc.1209179; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Beswick EJ, 2008, INFECT IMMUN, V76, P3233, DOI 10.1128/IAI.01534-07; Beswick EJ, 2006, J IMMUNOL, V176, P6794, DOI 10.4049/jimmunol.176.11.6794; BLASER MJ, 1995, CANCER RES, V55, P2111; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Catalano V, 2009, CRIT REV ONCOL HEMAT, V71, P127, DOI 10.1016/j.critrevonc.2009.01.004; Chan SH, 2008, ANTICANCER RES, V28, P907; Che XM, 2000, CANCER LETT, V148, P181, DOI 10.1016/S0304-3835(99)00335-3; Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiosea S, 2007, CANCER RES, V67, P2345, DOI 10.1158/0008-5472.CAN-06-3533; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; di Mario F, 2008, DIGEST LIVER DIS, V40, P523, DOI 10.1016/j.dld.2008.02.028; Diaz-Meco MT, 2009, CELL CYCLE, V8, P2518, DOI 10.4161/cc.8.16.9384; Du Y, 2009, J GASTROENTEROL, V44, P556, DOI 10.1007/s00535-009-0037-7; Faber C, 2009, VIRCHOWS ARCH, V454, P359, DOI 10.1007/s00428-009-0751-9; Fehri LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009500; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gao CP, 2010, CANCER-AM CANCER SOC, V116, P41, DOI 10.1002/cncr.24743; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Gorouhi F, 2008, BRIT J CANCER, V98, P1443, DOI 10.1038/sj.bjc.6604277; Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x; Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Humar B, 2002, ONCOGENE, V21, P8192, DOI 10.1038/sj.onc.1205921; Hwang HW, 2009, P NATL ACAD SCI USA, V106, P7016, DOI 10.1073/pnas.0811523106; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Jiang Z, 2010, J GASTROENTEROL, V45, P17, DOI 10.1007/s00535-009-0135-6; Jonjic N, 1997, ANTICANCER RES, V17, P3883; Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179; Kikuyama S, 1998, ONCOL REP, V5, P867; Kim DN, 2007, J VIROL, V81, P1033, DOI 10.1128/JVI.02271-06; Kim MS, 2010, J PATHOL, V221, P139, DOI 10.1002/path.2683; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lai KW, 2010, EUR J CANCER, V46, P1456, DOI 10.1016/j.ejca.2010.01.036; Lazzaretti D, 2009, RNA, V15, P1059, DOI 10.1261/rna.1606309; Lee EJ, 2008, RNA, V14, P35, DOI 10.1261/rna.804508; Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lee Y, 2006, COLD SPRING HARB SYM, V71, P51, DOI 10.1101/sqb.2006.71.041; Legesse-Miller A, 2009, J BIOL CHEM, V284, P6605, DOI 10.1074/jbc.C900002200; Li GQ, 2009, WORLD J GASTROENTERO, V15, P5541, DOI 10.3748/wjg.15.5541; Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Maeda K, 1998, ONCOLOGY-BASEL, V55, P594, DOI 10.1159/000011918; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; Matsushima K, 2011, INT J CANCER, V128, P361, DOI 10.1002/ijc.25348; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Motoyama K, 2010, INT J ONCOL, V36, P1089, DOI 10.3892/ijo_00000590; Mott JL, 2009, HEPATOLOGY, V50, P630, DOI 10.1002/hep.23010; NEKARDA H, 1994, CANCER RES, V54, P2900; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Pateras IS, 2009, MOL CANCER RES, V7, P1902, DOI 10.1158/1541-7786.MCR-09-0317; Peng S, 2010, DIGEST DIS SCI, V55, P2288, DOI 10.1007/s10620-009-1007-x; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pfannkuche K, 2009, STEM CELL REV REP, V5, P224, DOI 10.1007/s12015-009-9078-9; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Poon TCW, 2006, GASTROENTEROLOGY, V130, P1858, DOI 10.1053/j.gastro.2006.02.011; Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329; Qiao L, 2009, DRUG RESIST UPDATE, V12, P55, DOI 10.1016/j.drup.2009.02.002; Rachagani S, 2010, CANCER LETT, V292, P8, DOI 10.1016/j.canlet.2009.11.010; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Rocha GA, 2005, INT J CANCER, V115, P678, DOI 10.1002/ijc.20935; Romano MF, 2009, IDRUGS, V12, P253; Saadat M, 2006, CANCER SCI, V97, P505, DOI 10.1111/j.1349-7006.2006.00207.x; Saito H, 1999, ONCOLOGY-BASEL, V56, P253, DOI 10.1159/000011973; Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140; Sakuma K, 2005, INT J CANCER, V115, P93, DOI 10.1002/ijc.20903; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0; Shah KM, 2009, CLIN MICROBIOL INFEC, V15, P982, DOI 10.1111/j.1469-0691.2009.03033.x; Shen HM, 2009, APOPTOSIS, V14, P348, DOI 10.1007/s10495-009-0315-0; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Shen WW, 2007, NEOPLASIA, V9, P812, DOI 10.1593/neo.07403; Shinozaki A, 2010, CANCER RES, V70, P4719, DOI 10.1158/0008-5472.CAN-09-4620; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; Squillaro T, 2010, FASEB J, V24, P1593, DOI 10.1096/fj.09-143057; Stella MC, 2009, MOL BIOL CELL, V20, P642, DOI 10.1091/mbc.E08-03-0321; Sun L, 2008, EUR J CANCER PREV, V17, P446, DOI 10.1097/CEJ.0b013e328305a140; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; Theiss AL, 2009, MOL BIOL CELL, V20, P4412, DOI 10.1091/mbc.E09-05-0361; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Vogiatzi P, 2006, CANCER BIOL THER, V5, P371, DOI 10.4161/cbt.5.4.2748; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126; Wan HY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-16; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang QZ, 2009, CURR CANCER DRUG TAR, V9, P572, DOI 10.2174/156800909788486731; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wu J, 2010, ONCOGENE, V29, P1987, DOI 10.1038/onc.2009.481; Wu Q, 2010, BIOCHEM BIOPH RES CO, V392, P340, DOI 10.1016/j.bbrc.2009.12.182; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Xiang SL, 2006, NAT BIOTECHNOL, V24, P697, DOI 10.1038/nbt1211; Xiao BX, 2009, CLIN CHIM ACTA, V400, P97, DOI 10.1016/j.cca.2008.10.021; Yamaguchi N, 2001, LANCET ONCOL, V2, P88, DOI 10.1016/S1470-2045(00)00225-4; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; YONEMURA Y, 1994, ONCOLOGY, V51, P251; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z; Yuasa-Kawada J, 2009, P NATL ACAD SCI USA, V106, P14530, DOI 10.1073/pnas.0801262106; Zambon CF, 2004, GASTROENTEROLOGY, V126, P382, DOI 10.1053/j.gastro.2003.08.042; Zhang HH, 2007, WORLD J GASTROENTERO, V13, P2883, DOI 10.3748/wjg.v13.i20.2883; Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659; Zhang XL, 2010, BIOCHEM BIOPH RES CO, V395, P275, DOI 10.1016/j.bbrc.2010.04.005; ZHANG Y, 2009, MED ONCOL; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zheng ZH, 2007, CHINESE MED J-PEKING, V120, P2099, DOI 10.1097/00029330-200712010-00007; Zhou H, 2010, J MOL MED, V88, P709, DOI 10.1007/s00109-010-0617-2; Zhou Y, 2007, INT J CANCER, V121, P1481, DOI 10.1002/ijc.22833; ZHU W, 2010, INT J CANC	143	246	266	0	51	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5761	5771		10.1038/onc.2010.352	http://dx.doi.org/10.1038/onc.2010.352			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20802530				2022-12-28	WOS:000283586200001
J	Bartkova, J; Hamerlik, P; Stockhausen, MT; Ehrmann, J; Hlobilkova, A; Laursen, H; Kalita, O; Kolar, Z; Poulsen, HS; Broholm, H; Lukas, J; Bartek, J				Bartkova, J.; Hamerlik, P.; Stockhausen, M-T; Ehrmann, J.; Hlobilkova, A.; Laursen, H.; Kalita, O.; Kolar, Z.; Poulsen, H. S.; Broholm, H.; Lukas, J.; Bartek, J.			Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas	ONCOGENE			English	Article						glioblastoma multiforme; DNA replication stress; oxidative DNA lesions; DNA damage checkpoints; p53 aberrations	ONCOGENE-INDUCED SENESCENCE; CANCER; REPAIR; CHECKPOINT; 53BP1; RADIORESISTANCE; PATHWAYS; BARRIER; BIOLOGY	Malignant gliomas, the deadliest of brain neoplasms, show rampant genetic instability and resistance to genotoxic therapies, implicating potentially aberrant DNA damage response (DDR) in glioma pathogenesis and treatment failure. Here, we report on gross, aberrant constitutive activation of DNA damage signalling in low-and high-grade human gliomas, and analyze the sources of such endogenous genotoxic stress. Based on analyses of human glioblastoma multiforme (GBM) cell lines, normal astrocytes and clinical specimens from grade II astrocytomas (n=41) and grade IV GBM (n=60), we conclude that the DDR machinery is constitutively activated in gliomas, as documented by phosphorylated histone H2AX (gamma H2AX), activation of the ATM-Chk2-p53 pathway, 53BP1 foci and other markers. Oxidative DNA damage (8-oxoguanine) was high in some GBM cell lines and many GBM tumors, while it was low in normal brain and grade II astrocytomas, despite the degree of DDR activation was higher in grade II tumors. Markers indicative of ongoing DNA replication stress (Chk1 activation, Rad17 phosphorylation, replication protein A foci and single-stranded DNA) were present in GBM cells under high-or low-oxygen culture conditions and in clinical specimens of both low-and high-grade tumors. The observed global checkpoint signaling, in contrast to only focal areas of overabundant p53 (indicative of p53 mutation) in grade II astrocytomas, are consistent with DDR activation being an early event in gliomagenesis, initially limiting cell proliferation (low Ki-67 index) and selecting for mutations of p53 and likely other genes that allow escape (higher Ki-67 index) from the checkpoint and facilitate tumor progression. Overall, these results support the potential role of the DDR machinery as a barrier to gliomagenesis and indicate that replication stress, rather than oxidative stress, fuels the DNA damage signalling in early stages of astrocytoma development. Oncogene (2010) 29, 5095-5102; doi:10.1038/onc.2010.249; published online 28 June 2010	[Bartkova, J.; Hamerlik, P.; Lukas, J.; Bartek, J.] Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; [Bartkova, J.; Hamerlik, P.; Lukas, J.; Bartek, J.] Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark; [Hamerlik, P.; Bartek, J.] Palacky Univ, Inst Mol & Translat Med, Lab Genome Integr, CR-77147 Olomouc, Czech Republic; [Stockhausen, M-T; Poulsen, H. S.] Copenhagen Univ Hosp, Dept Radiat Biol, Copenhagen, Denmark; [Laursen, H.; Broholm, H.] Copenhagen Univ Hosp, Dept Neuropathol, Copenhagen, Denmark; [Kalita, O.] Univ Hosp, Dept Neurosurg, Olomouc, Czech Republic	Danish Cancer Society; Danish Cancer Society; Palacky University Olomouc; University of Copenhagen; University of Copenhagen; University Hospital Olomouc	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jil@cancer.dk; jb@cancer.dk	Ehrmann, Jiri/C-9074-2009; Kolar, Zdenek/A-4597-2008; Bartek, Jiri/G-5870-2014; , Petra/U-2260-2019; Kalita, Ondrej/I-8815-2016	Ehrmann, Jiri/0000-0002-8419-3414; Kolar, Zdenek/0000-0003-1838-5925; , Petra/0000-0002-5856-0161; Lukas, Jiri/0000-0001-9087-506X; Kalita, Ondrej/0000-0002-1356-023X	Danish Cancer Society; Danish National Research Foundation; Danish Research Council; Vilhelm Pedersen and Hustrus Mindelegat; Czech Ministry of Education [MSMT6198959216]; Grant Agency of the Czech Ministry of Health [NS10282-3/2009]; Lundbeck Foundation [R13-A1287]; European Commission [CZ.1.05/2.1.00/01.0030]	Danish Cancer Society(Danish Cancer Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Research Council(Det Frie Forskningsrad (DFF)); Vilhelm Pedersen and Hustrus Mindelegat; Czech Ministry of Education(Ministry of Education, Youth & Sports - Czech Republic); Grant Agency of the Czech Ministry of Health; Lundbeck Foundation(Lundbeckfonden); European Commission(European CommissionEuropean Commission Joint Research Centre)	We thank J Darling, University of Wolverhampton and CV Bree, University of Amsterdam for donating the SS859 and Gli-6 cells, respectively and MyungHee Lee for excellent technical assistance. Grant support was obtained from Danish Cancer Society, Danish National Research Foundation, Danish Research Council, Vilhelm Pedersen and Hustrus Mindelegat, Czech Ministry of Education (MSMT6198959216), Grant Agency of the Czech Ministry of Health (NS10282-3/2009), Lundbeck Foundation (R13-A1287) and European Commission (projects: CZ.1.05/2.1.00/01.0030, Active p53, Infla-Care, GENICA).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2007, ONCOGENE, V26, P7414, DOI 10.1038/sj.onc.1210553; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Knizetova P, 2008, CELL CYCLE, V7, P2553, DOI 10.4161/cc.7.16.6442; Li DD, 2005, EUR J NEUROSCI, V22, P1319, DOI 10.1111/j.1460-9568.2005.04335.x; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016; Mistrik M, 2009, CELL CYCLE, V8, P2592, DOI 10.4161/cc.8.16.9331; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	30	136	137	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5095	5102		10.1038/onc.2010.249	http://dx.doi.org/10.1038/onc.2010.249			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581868				2022-12-28	WOS:000281620100009
J	Shang, X; Vasudevan, SA; Yu, Y; Ge, N; Ludwig, AD; Wesson, CL; Wang, K; Burlingame, SM; Zhao, YJ; Rao, PH; Lu, X; Russell, HV; Okcu, MF; Hicks, MJ; Shohet, JM; Donehower, LA; Nuchtern, JG; Yang, J				Shang, X.; Vasudevan, S. A.; Yu, Y.; Ge, N.; Ludwig, A. D.; Wesson, C. L.; Wang, K.; Burlingame, S. M.; Zhao, Y-j; Rao, P. H.; Lu, X.; Russell, H. V.; Okcu, M. F.; Hicks, M. J.; Shohet, J. M.; Donehower, L. A.; Nuchtern, J. G.; Yang, J.			Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; DUSP26; MKP8; doxorubicin; p53; phosphatase	IN-VIVO; PATHWAY; PROTEIN; CANCER; PHOSPHORYLATION; TARGET; MDM2; THERAPY; KINASE; GROWTH	Chemoresistance is a major cause of treatment failure and poor outcome in neuroblastoma. In this study, we investigated the expression and function of dual-specificity phosphatase 26 (DUSP26), also known as mitogen-activated protein kinase phophatase-8, in human neuroblastoma. We found that DUSP26 was expressed in a majority of neuroblastoma cell lines and tissue specimens. Importantly, we found that DUSP26 promotes the resistance of human neuroblastoma to doxorubicin-induced apoptosis by acting as a p53 phosphatase to downregulate p53 tumor suppressor function in neuroblastoma cells. Inhibiting DUSP26 expression in the IMR-32 neuroblastoma cell line enhanced doxorubicin-induced p53 phosphorylation at Ser20 and Ser37, p21, Puma, Bax expression as well as apoptosis. In contrast, DUSP26 overexpression in the SK-N-SH cell line inhibited doxorubicin-induced p53 phosphorylation at Ser20 and Ser37, p21, Puma, Bax expression and apoptosis. Using in vitro and in vivo assays, we found that DUSP26 binds to p53 and dephosphorylates p53 at Ser20 and Ser37. In this report, we show that DUSP26 functions as a p53 phosphatase, which suppresses downstream p53 activity in response to genotoxic stress. This suggests that inhibition of this phosphatase may increase neuroblastoma chemosensitivity and DUSP26 is a novel therapeutic target for this aggressive pediatric malignancy. Oncogene (2010) 29, 4938-4946; doi: 10.1038/onc.2010.244; published online 21 June 2010	[Shang, X.; Vasudevan, S. A.; Wesson, C. L.; Burlingame, S. M.; Nuchtern, J. G.] Baylor Coll Med, Michael E DeBakey Dept Surg, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Shang, X.; Yu, Y.; Ge, N.; Ludwig, A. D.; Wang, K.; Burlingame, S. M.; Zhao, Y-j; Rao, P. H.; Russell, H. V.; Okcu, M. F.; Shohet, J. M.; Nuchtern, J. G.; Yang, J.] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Lu, X.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Hicks, M. J.] Baylor Coll Med, Dept Pathol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Donehower, L. A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Baylor College of Medicine; Baylor College of Medicine	Nuchtern, JG (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Dan L Duncan Canc Ctr, 6621 Fannin,CC650-00, Houston, TX 77030 USA.	nuchtern@bcm.edu; jianhuay@bcm.edu			Hope Street Kids Foundation; Bear Necessities Pediatric Cancer Foundation; American Cancer Society [RSG-06-070-01-TBE]; Society of University Surgeons; NIH/NCI-NRSA [1F32CA113059-01A1]; NATIONAL CANCER INSTITUTE [F32CA113059] Funding Source: NIH RePORTER	Hope Street Kids Foundation; Bear Necessities Pediatric Cancer Foundation; American Cancer Society(American Cancer Society); Society of University Surgeons; NIH/NCI-NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Xiangwei Wu for providing GFP-p53 expression plasmid and Mdm2-Luc reporter. The work was supported in part by the grants from the Hope Street Kids Foundation (to JY), the Bear Necessities Pediatric Cancer Foundation (to JY), the American Cancer Society Grant RSG-06-070-01-TBE (to JY), the Society of University Surgeons Ethicon Resident Scholarship (SAV) and the NIH/NCI-NRSA training grant 1F32CA113059-01A1 (SAV).	Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen L, 2007, CELL CYCLE, V6, P2685, DOI 10.4161/cc.6.21.4853; Eischen CM, 2009, CANCER CELL, V15, P161, DOI 10.1016/j.ccr.2009.02.004; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; London WB, 2005, J CLIN ONCOL, V23, P6459, DOI 10.1200/JCO.2005.05.571; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; Pestell KE, 2000, ONCOGENE, V19, P6607, DOI 10.1038/sj.onc.1204084; Shang XY, 2009, MOL CANCER THER, V8, P2461, DOI 10.1158/1535-7163.MCT-08-0857; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Vasudevan SA, 2009, MOL CANCER THER, V8, P2478, DOI 10.1158/1535-7163.MCT-08-1132; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899; Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200	34	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4938	4946		10.1038/onc.2010.244	http://dx.doi.org/10.1038/onc.2010.244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562916	Green Accepted			2022-12-28	WOS:000281578700008
J	Barbachano, A; Ordonez-Moran, P; Garcia, JM; Sanchez, A; Pereira, F; Larriba, MJ; Martinez, N; Hernandez, J; Landolfi, S; Bonilla, F; Palmer, HG; Rojas, JM; Munoz, A				Barbachano, A.; Ordonez-Moran, P.; Garcia, J. M.; Sanchez, A.; Pereira, F.; Larriba, M. J.; Martinez, N.; Hernandez, J.; Landolfi, S.; Bonilla, F.; Palmer, H. G.; Rojas, J. M.; Munoz, A.			SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity	ONCOGENE			English	Article						colon cancer; E-cadherin; SPROUTY-2; vitamin D; ZEB1	TRANSCRIPTION FACTOR SNAIL; VITAMIN-D-RECEPTOR; ACTIVATED PROTEIN-KINASE; EPITHELIAL TUMOR-CELLS; CARCINOMA-CELLS; GENE-EXPRESSION; DOWN-REGULATION; BETA-CATENIN; EPIGENETIC INACTIVATION; GROWTH	SPROUTY-2 (SPRY2) regulates receptor tyrosine kinase signalling and therefore cell growth and differentiation. In this study, we show that SPRY2 expression in colon cancer cells is inhibited by the active vitamin D metabolite 1 alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through E-cadherin-dependent and -independent mechanisms. In turn, SPRY2 represses both basal and 1,25(OH)(2)D(3)-induced E-cadherin expression. In line with this, SPRY2 induces ZEB1 RNA and protein, but not that of other epithelial-to-mesenchymal transition inducers that repress the CDH1/E-cadherin promoter. Consistently, SPRY2 and E-cadherin protein levels inversely correlate in colon cancer cell lines and xenografted tumours. Moreover, SPRY2 knockdown by small hairpin RNA increases CDH1/E-cadherin expression and, reciprocally, CDH1/E-cadherin knockdown increases that of SPRY2. In colon cancer patients, SPRY2 is upregulated in undifferentiated high-grade tumours and at the invasive front of low-grade carcinomas. Quantification of protein expression in 34 tumours confirmed an inverse correlation between SPRY2 and E-cadherin. Our data demonstrate a tumourigenic action of SPRY2 that is based on the repression of E-cadherin, probably by the induction of ZEB1, and a reciprocal regulation of SPRY2 and E-cadherin that dictates cell phenotype. We propose SPRY2 as a candidate novel marker for high-grade tumours and a target of therapeutic intervention in colon cancer. Oncogene (2010) 29, 4800-4813; doi:10.1038/onc.2010.225; published online 14 June 2010	[Barbachano, A.; Ordonez-Moran, P.; Pereira, F.; Larriba, M. J.; Munoz, A.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, E-28049 Madrid, Spain; [Garcia, J. M.; Bonilla, F.] Hosp Univ Puerta Hierro, Madrid, Spain; [Sanchez, A.; Martinez, N.; Rojas, J. M.] Inst Salud Carlos III, Unidad Biol Celular, Area Biol Celular & Desarrollo, Ctr Nacl Microbiol, Madrid, Spain; [Hernandez, J.; Landolfi, S.] Hosp Univ Vall dHebron, Serv Anat Patol, Barcelona, Spain; [Palmer, H. G.] Vall dHebron Inst Oncol, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, Arturo Duperier 4, E-28049 Madrid, Spain.	amunoz@iib.uam.es	Munoz, Alberto/O-6393-2014; Barbachano, Antonio/O-7731-2015; Palmer, Héctor G./AAG-8332-2019; Rojas, José M/D-3718-2018; LARRIBA, MARIA JESUS/O-4652-2014; Rojas, José M./AAA-3354-2021; Seoane, Joan/AAG-9173-2019; Ordonez-Moran, Paloma/B-6371-2016	Munoz, Alberto/0000-0003-3890-4251; Barbachano, Antonio/0000-0002-1248-5143; Rojas, José M/0000-0002-5383-3482; LARRIBA, MARIA JESUS/0000-0001-9035-7414; Rojas, José M./0000-0002-7547-2825; Seoane, Joan/0000-0002-6541-5974; Landolfi, Stefania/0000-0002-1059-635X; Palmer, Hector/0000-0002-9823-5638; Ordonez-Moran, Paloma/0000-0001-7688-1252; Pires Pereira, Fabio/0000-0002-9991-2805	Ministerio de Ciencia e Innovacion of Spain; Fondo Europeo de Desarrollo Regional [SAF2007-60341, RD06/0020/0009, RD06/0020/0020, SAF2006-04247, RD06/0020/0003, PS09/00562]; Comunidad de Madrid [S-GEN-0266/2006]; Spanish Association Against Cancer; European Union [MRTN-CT-2005-019496]	Ministerio de Ciencia e Innovacion of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fondo Europeo de Desarrollo Regional(European Commission); Comunidad de Madrid(Comunidad de Madrid); Spanish Association Against Cancer; European Union(European Commission)	We thank Drs R Bouillon, A Verstuyf, JP van de Velde, A Fabra, H Clevers, C Carlberg, E Batlle, L Sastre and A Garcia de Herreros for kindly providing us reagents, Dr M Pollan for help with statistical analysis, T Martinez for technical assistance, and R Rycroft for help with the English language editing of the paper. This study was supported by the Ministerio de Ciencia e Innovacion of Spain and Fondo Europeo de Desarrollo Regional (SAF2007-60341 and RD06/0020/0009 to AM, RD06/0020/0020 to FB, and SAF2006-04247, RD06/0020/0003 and FIS-Intrasalud (PS09/00562) to JMR), Comunidad de Madrid (S-GEN-0266/2006 to AM and FB), Spanish Association Against Cancer (to JMR), and European Union (MRTN-CT-2005-019496, NucSys, to AM).	Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Campbell MJ, 2006, EXPERT OPIN THER TAR, V10, P735, DOI 10.1517/14728222.10.5.735; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Ding W, 2007, J CELL PHYSIOL, V212, P796, DOI 10.1002/jcp.21078; Eelen G, 2007, CURR MED CHEM, V14, P1893; Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; *IARC, 2008, INT AGENCY RES CANC, V5, P305; *IARC, 2008, INT AGENCY RES CANC, V5, P186; IARC, 2008, IARC WORK GROUP REP, V5, P1; *IARC, 2008, INT AGENCY RES CANC, V5, P216; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Kim HJ, 2007, CURR BIOL, V17, P455, DOI 10.1016/j.cub.2007.01.059; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Martinez N, 2007, CELL SIGNAL, V19, P2277, DOI 10.1016/j.cellsig.2007.07.008; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Miyaki M, 1995, ONCOGENE, V11, P2547; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ordonez-Moran P, 2008, J CELL BIOL, V183, P697, DOI 10.1083/jcb.200803020; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2003, CANCER RES, V63, P7799; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Pike JW, 2007, J STEROID BIOCHEM, V103, P389, DOI 10.1016/j.jsbmb.2006.12.050; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sanchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Swat A, 2009, MOL CELL BIOL, V29, P3332, DOI 10.1128/MCB.01955-08; TOMITA N, 1992, CANCER RES, V52, P6840; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493	51	58	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4800	4813		10.1038/onc.2010.225	http://dx.doi.org/10.1038/onc.2010.225			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543868	Green Submitted			2022-12-28	WOS:000281326400006
J	Kurita, S; Mott, JL; Almada, LL; Bronk, SF; Werneburg, NW; Sun, SY; Roberts, LR; Fernandez-Zapico, ME; Gores, GJ				Kurita, S.; Mott, J. L.; Almada, L. L.; Bronk, S. F.; Werneburg, N. W.; Sun, S-Y; Roberts, L. R.; Fernandez-Zapico, M. E.; Gores, G. J.			GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis	ONCOGENE			English	Article						apoptosis; cholangiocarcinoma; GLI transcription factors; TRAIL	BASAL-CELL CARCINOMA; CHOLANGIOCARCINOMA CELLS; SIGNALING PATHWAY; DEATH RECEPTOR-4; SONIC HEDGEHOG; CYTOCHROME-C; EXPRESSION; RESISTANCE; CANCER; REQUIREMENT	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis through its cognate receptors death receptor 4 (DR4) and death receptor 5 (DR5), preferentially in malignant cells. However, many malignant cells remain resistant to TRAIL cytotoxicity by poorly characterized mechanisms. Here, using cholangiocarcinoma cells, as a model for TRAIL resistance, we identified a role for the oncogenic Hedgehog (Hh)-GLI pathway in the regulation of TRAIL cytotoxicity. Blockade of Hh using pharmacological and genetic tools sensitizes the cells to TRAIL cytotoxicity. Restoration of apoptosis sensitivity coincided with upregulation of DR4 expression, while expression of other death effector proteins remained unaltered. Knockdown of DR4 mimics Hh-mediated resistance to TRAIL cytotoxicity. Hh regulates the expression of DR4 by modulating the activity of its promoter. Luciferase, chromatin immunoprecipitation and expression assays show that the transcription factor GLI3 binds to the DR4 promoter and Hh requires an intact GLI3-repression activity to silence DR4 expression. Finally, small interfering RNA (siRNA)-targeted knockdown of GLI3, but not GLI1 or GLI2, restores DR4 expression and TRAIL sensitivity, indicating that the Hh effect is exclusively mediated by this transcription factor. In conclusion, these data provide evidence of a regulatory mechanism, which modulates TRAIL signaling in cancer cells and suggest new therapeutic approaches for TRAIL-resistant neoplasms. Oncogene (2010) 29, 4848-4858; doi:10.1038/onc.2010.235; published online 21 June 2010	[Kurita, S.; Mott, J. L.; Almada, L. L.; Bronk, S. F.; Werneburg, N. W.; Roberts, L. R.; Fernandez-Zapico, M. E.; Gores, G. J.] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; [Almada, L. L.; Fernandez-Zapico, M. E.] Mayo Clin, Schulze Ctr Novel Therapeut, Div Oncol Res, Rochester, MN 55905 USA; [Sun, S-Y] Emory Univ, Sch Med, Dept Hematol, Winship Canc Inst, Atlanta, GA USA; [Sun, S-Y] Emory Univ, Sch Med, Dept Med Oncol, Winship Canc Inst, Atlanta, GA USA	Mayo Clinic; Mayo Clinic; Emory University; Emory University	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Mott, Justin/0000-0002-2927-6962; Roberts, Lewis/0000-0001-7885-8574	NIH [DK59427, CA136526, CA100882, P30 DK 84567]; Mayo Foundation; Mayo Clinic [P50 CA102701]; NATIONAL CANCER INSTITUTE [P50CA102701, R01CA100882, R56CA100882, R01CA136526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK079875, R01DK059427, R56DK059427, P30DK084567] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; Mayo Clinic; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Erin Nystuen-Bungum for her excellent secretarial assistance. This work was supported by NIH R01 Grants DK59427 (GJG), CA136526, (MEF-Z), CA100882 (LRR), the Clinical and Optical Microscopy Cores for P30 DK 84567, Mayo Clinic Pancreatic SPORE P50 CA102701 (MEF-Z), and the Mayo Foundation.	Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365, DOI 10.1053/j.gastro.2009.02.071; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen MH, 2009, GENE DEV, V23, P1910, DOI 10.1101/gad.1794109; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Eggert A, 2001, CANCER RES, V61, P1314; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Kump E, 2008, ONCOGENE, V27, P3856, DOI 10.1038/onc.2008.5; Lees C, 2005, GASTROENTEROLOGY, V129, P1696, DOI 10.1053/j.gastro.2005.05.010; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mendoza FJ, 2008, APOPTOSIS, V13, P756, DOI 10.1007/s10495-008-0210-0; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Parkin CA, 2008, AM J PHYSIOL-GASTR L, V294, pG363, DOI 10.1152/ajpgi.00457.2007; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wehbe H, 2006, J PHARMACOL EXP THER, V319, P1153, DOI 10.1124/jpet.106.109835; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	33	41	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4848	4858		10.1038/onc.2010.235	http://dx.doi.org/10.1038/onc.2010.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562908	Green Accepted			2022-12-28	WOS:000281326400010
J	Braun, J; Hoang-Vu, C; Dralle, H; Huettelmaier, S				Braun, J.; Hoang-Vu, C.; Dralle, H.; Huettelmaier, S.			Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas	ONCOGENE			English	Article						ATC; microRNA; TGF beta; EMT; TGFBR1; SMAD2	MESENCHYMAL TRANSITION; MIR-200 FAMILY; E-CADHERIN; CANCER-CELLS; EXPRESSION; ZEB1; METASTASIS; GROWTH; TUMORS; GENES	Anaplastic thyroid carcinomas (ATCs) arise from epithelial thyroid cells by mesenchymal de-/transdifferentiation and rapidly invade the adjacent tissue. Specific microRNA signatures were suggested to distinguish ATCs from normal thyroid tissue and other thyroid carcinomas of follicular origin. Whether distinct microRNA patterns correlate with de-/transdifferentiation and invasion of ATCs remained elusive. We identified two significantly decreased microRNA families that unambiguously distinguish ATCs from papillary and follicular thyroid carcinomas: miR-200 and miR-30. Expression of these microRNAs in mesenchymal ATC-derived cells reduced their invasive potential and induced mesenchymal-epithelial transition (MET) by regulating the expression of MET marker proteins. Supporting the role of transforming growth factor (TGF)beta signaling in modulating MET/epithelial- mesenchymal transition (EMT), expression of SMAD2 and TGFBR1, upregulated in most primary ATCs, was controlled by members of the miR-30 and/or miR-200 families in ATC-derived cells. Inhibition of TGF beta receptor 1 (TGFBR1) in these cells induced MET and reduction of prometastatic miR-21, but caused an increase of the miR-200 family. These findings identify altered microRNA signatures as potent markers for ATCs that promote de-/transdifferentiation (EMT) and invasion of these neoplasias. Hence, TGFBR1 inhibition could have a significant potential for the treatment of ATCs and possibly other invasive tumors. Oncogene (2010) 29, 4237-4244; doi: 10.1038/onc.2010.169; published online 24 May 2010	[Huettelmaier, S.] Univ Halle Wittenberg, Dept Mol Cell Biol, ZAMED, D-06120 Halle, Sachsen Anhalt, Germany; [Hoang-Vu, C.; Dralle, H.] Univ Halle Wittenberg, Dept Gen Visceral & Vasc Surg, D-06120 Halle, Sachsen Anhalt, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Huettelmaier, S (corresponding author), Univ Halle Wittenberg, Dept Mol Cell Biol, ZAMED, Heinrich Damerow Str 1, D-06120 Halle, Sachsen Anhalt, Germany.	stefan.huettelmaier@medizin.uni-halle.de	Hüttelmaier, Stefan/AAQ-1203-2021; Dralle, Henning/ABD-4454-2020	Braun, Juliane/0000-0002-2491-5788	DFG; BMBF [FKZ 01ZZ0404]	DFG(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF))	This work was supported by DFG and BMBF (FKZ 01ZZ0404) funding to Stefan Huttelmaier.	BRABANT G, 1993, CANCER RES, V53, P4987; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guzinska-Ustymowicz K, 2005, WORLD J GASTROENTERO, V11, P1193, DOI 10.3748/wjg.v11.i8.1193; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Piek E, 1999, J CELL SCI, V112, P4557; Resnick MB, 1998, MODERN PATHOL, V11, P735; Rocha AS, 2003, HISTOPATHOLOGY, V42, P580, DOI 10.1046/j.1365-2559.2003.01642.x; Safina A, 2007, ONCOGENE, V26, P2407, DOI 10.1038/sj.onc.1210046; Schwertheim S, 2009, HORM METAB RES, V41, P475, DOI 10.1055/s-0029-1215593; Shao ES, 2009, BLOOD, V114, P2197, DOI 10.1182/blood-2009-01-199166; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	26	242	257	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2010	29	29					4237	4244		10.1038/onc.2010.169	http://dx.doi.org/10.1038/onc.2010.169			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498632				2022-12-28	WOS:000280151500011
J	Li, YJ; Stark, JM; Chen, DJ; Ann, DK; Chen, Y				Li, Y-J; Stark, J. M.; Chen, D. J.; Ann, D. K.; Chen, Y.			Role of SUMO:SIM-mediated protein-protein interaction in non-homologous end joining	ONCOGENE			English	Article						SUMO; NHEJ; SUMO-interacting motif; SBM; inhibitor; DNA repair	STRAND BREAK REPAIR; UBIQUITIN-LIKE PROTEINS; DNA-DAMAGE; BINDING MOTIF; LIGASE; XRCC4; IDENTIFICATION; RECOMBINATION; LOCALIZATION; NUCLEUS	Although post-translational modi. cations by the small ubiquitin-like modifiers (SUMO) are known to be important in DNA damage response, it is unclear whether they have a role in double-strand break (DSB) repair by non-homologous end joining (NHEJ). Here, we analyzed various DSB repair pathways upon inhibition of SUMO-mediated protein-protein interactions using peptides that contain the SUMO-interaction motif (SIM) and discriminate between mono-and SUMO-chain modi. cations. The SIM peptides specifically inhibit NHEJ as shown by in vivo repair assays and radio-sensitivity of cell lines deficient in different DSB repair pathways. Furthermore, mono-SUMO, instead of SUMO-chain, modi. cations appear to be involved in NHEJ. Immunoprecipitation experiments also showed that the SIM peptide interacted with SUMOylated Ku70 after radiation. This study is the first to show an important role for SUMO: SIM-mediated protein-protein interactions in NHEJ, and provides a mechanistic basis for the role of SIM peptide in sensitizing genotoxic stress of cancer cells. Oncogene (2010) 29, 3509-3518; doi:10.1038/onc.2010.108; published online 19 April 2010	[Li, Y-J; Chen, Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Stark, J. M.] City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Biol, Duarte, CA 91010 USA; [Chen, D. J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Ann, D. K.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Clin & Mol Pharmacol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; University of Texas System; University of Texas Southwestern Medical Center Dallas; City of Hope; Beckman Research Institute of City of Hope	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.	ychen@coh.org		Li, Yi-Jia/0000-0002-8791-8097	NIH [R01GM074748, R01GM-086171, RO1CA120954, R37CA050519-20, F32CA134180]; NATIONAL CANCER INSTITUTE [F32CA134180, R01CA120954, R37CA050519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086171, R01GM074748] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is funded by NIH Grants R01GM074748 and R01GM-086171 to Y Chen, RO1CA120954 to JM Stark, R37CA050519-20 to DJ Chen and R01DE14183 to DK Ann. Y-J Li is a recipient of the NIH National Research Service Award (F32CA134180).	Andrews EA, 2005, MOL CELL BIOL, V25, P185, DOI 10.1128/MCB.25.1.185-196.2005; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Carson JP, 2004, CANCER RES, V64, P2096, DOI 10.1158/0008-5472.CAN-03-2029; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Krebber H, 2000, METHOD ENZYMOL, V327, P283, DOI 10.1016/S0076-6879(00)27284-4; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sacher M, 2006, NAT CELL BIOL, V8, P1284, DOI 10.1038/ncb1488; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; TATHAM MH, 2001, J BIOL CHEM, V12, P12; Uzunova K, 2007, J BIOL CHEM, V282, P34167, DOI 10.1074/jbc.M706505200; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; Xie Y, 2007, J BIOL CHEM, V282, P34176, DOI 10.1074/jbc.M706025200; Yano K, 2008, CELL CYCLE, V7, P1321, DOI 10.4161/cc.7.10.5898; Yano KI, 2008, EMBO REP, V9, P91, DOI 10.1038/sj.embor.7401137; Yurchenko V, 2006, MOL CELL BIOL, V26, P1786, DOI 10.1128/MCB.26.5.1786-1794.2006; Yurchenko V, 2008, BIOCHEM BIOPH RES CO, V366, P263, DOI 10.1016/j.bbrc.2007.11.136; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	35	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3509	3518		10.1038/onc.2010.108	http://dx.doi.org/10.1038/onc.2010.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400978	Green Accepted			2022-12-28	WOS:000278835400006
J	Wang, Z; Pedersen, E; Basse, A; Lefever, T; Peyrollier, K; Kapoor, S; Mei, Q; Karlsson, R; Chrostek-Grashoff, A; Brakebusch, C				Wang, Z.; Pedersen, E.; Basse, A.; Lefever, T.; Peyrollier, K.; Kapoor, S.; Mei, Q.; Karlsson, R.; Chrostek-Grashoff, A.; Brakebusch, C.			Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo	ONCOGENE			English	Article						Rac1; tumor; Pak	ACTIVATOR TIAM1; ERK; PHOSPHORYLATION; PROLIFERATION; REQUIREMENT; DELETION; PAK	Rac1 has a role in proliferation and survival of tumor cells in vitro. The exact effects of Rac1 on growth, apoptosis and corresponding signaling pathways during tumorigenesis in vivo, however, have not been explored yet. Using mice with a keratinocyte-restricted deletion of the Rac1 gene, we found that Rac1 is essential for DMBA/TPA-induced skin tumor formation. This corresponded to a decreased keratinocyte hyperproliferation, although apoptosis was not detectably altered. Activated Rac1 promoted Erk-dependent hyperproliferation by Pak1-mediated Mek activation independent of Mek1 phosporylation at serine 298. Rac1 was furthermore required for Pak2-dependent hyperactivation of Akt, which under in vivo condition was restricted to the suprabasal cell layers corresponding to a suprabasal-specific expression of Pak2. It is surprising that none of these signaling pathways was altered in untreated Rac1-deficient skin, indicating a hyperproliferation- specific function of Rac1 in vivo. These data suggest that blocking of Rac1 function might allow tumor-specific growth repression, as Rac1 is not required for normal growth and growth signaling controlling pathways in skin in vivo. Oncogene (2010) 29, 3362-3373; doi:10.1038/onc.2010.95; published online 12 April 2010	[Wang, Z.; Pedersen, E.; Basse, A.; Lefever, T.; Peyrollier, K.; Kapoor, S.; Karlsson, R.; Brakebusch, C.] Univ Copenhagen, Inst Biomed, BRIC, DK-2200 Copenhagen, Denmark; [Wang, Z.; Mei, Q.] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Peoples R China; [Lefever, T.] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium; [Chrostek-Grashoff, A.] Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA USA	University of Copenhagen; Air Force Military Medical University; Ghent University; University of Virginia	Brakebusch, C (corresponding author), Univ Copenhagen, Inst Biomed, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	cord.brakebusch@bric.dk	Basse, Astrid L/M-4630-2014	Basse, Astrid L/0000-0002-6532-9232; Brakebusch, Cord/0000-0002-9342-1634	Danish Cancer Foundation; Novo Nordisk Foundation	Danish Cancer Foundation(Danish Cancer Society); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	We thank Dr Peter Staller and Dr Chris Marshall for advice, Dr Anders Lund for providing the plasmids, Volkan Turan for excellent technical help, Anna Fossum for FACS, and Sahar Abelechian and Anita Friismose for help with mouse handling. This work was supported by the Danish Cancer Foundation and the Novo Nordisk Foundation.	Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Espina C, 2008, AM J PATHOL, V172, P156, DOI 10.2353/ajpath.2008.070561; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Maruta Hiroshi, 2002, Methods Mol Biol, V189, P75; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Thomas EK, 2007, CANCER CELL, V12, P467, DOI 10.1016/j.ccr.2007.10.015; Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	24	86	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3362	3373		10.1038/onc.2010.95	http://dx.doi.org/10.1038/onc.2010.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383193				2022-12-28	WOS:000278622700005
J	Gandhi, M; Dillon, LW; Pramanik, S; Nikiforov, YE; Wang, YH				Gandhi, M.; Dillon, L. W.; Pramanik, S.; Nikiforov, Y. E.; Wang, Y-H			DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells	ONCOGENE			English	Article						fragile site; RET/PTC rearrangement; FRA10C/FRA10G; papillary thyroid carcinomas	HUMAN-CHROMOSOME 7; IN-VITRO; TRINUCLEOTIDE REPEATS; RET REARRANGEMENTS; LATE REPLICATION; COMMON; CARCINOMAS; INDUCTION; RADIATION; CANCER	Human chromosomal fragile sites are regions of the genome that are prone to DNA breakage, and are classified as common or rare, depending on their frequency in the population. Common fragile sites frequently coincide with the location of genes involved in carcinogenic chromosomal translocations, suggesting their role in cancer formation. However, there has been no direct evidence linking breakage at fragile sites to the formation of a cancer-specific translocation. Here, we studied the involvement of fragile sites in the formation of RET/PTC rearrangements, which are frequently found in papillary thyroid carcinoma (PTC). These rearrangements are commonly associated with radiation exposure; however, most of the tumors found in adults are not linked to radiation. In this study, we provide structural and biochemical evidence that the RET, CCDC6 and NCOA4 genes participating in two major types of RET/PTC rearrangements, are located in common fragile sites FRA10C and FRA10G, and undergo DNA breakage after exposure to fragile site-inducing chemicals. Moreover, exposure of human thyroid cells to these chemicals results in the formation of cancer-specific RET/PTC rearrangements. These results provide the direct evidence for the involvement of chromosomal fragile sites in the generation of cancer-specific rearrangements in human cells. Oncogene (2010) 29, 2272-2280; doi: 10.1038/onc.2009.502; published online 25 January 2010	[Dillon, L. W.; Pramanik, S.; Wang, Y-H] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; [Gandhi, M.; Nikiforov, Y. E.] Univ Pittsburgh, Dept Pathol & Lab Med, Pittsburgh, PA USA	Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, YH (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, 1 Med Ctr Blvd,2051 Hanes Bldg, Winston Salem, NC 27157 USA.	ywang@wfubmc.edu	Pramanik, Sreemanta/AAK-3772-2020; Pramanik, Sreemanta/E-2800-2013	Pramanik, Sreemanta/0000-0003-0448-2118; Pramanik, Sreemanta/0000-0003-0448-2118	National Cancer Institute [CA113863]; NATIONAL CANCER INSTITUTE [R01CA113863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM095440] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Cancer Institute (CA113863 to Y-H Wang and YE Nikiforov).	Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Burrow AA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-59; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Casper AM, 2004, AM J HUM GENET, V75, P654, DOI 10.1086/422701; Caudill CM, 2005, J CLIN ENDOCR METAB, V90, P2364, DOI 10.1210/jc.2004-1811; Ciampi R, 2005, ENDOCR PATHOL, V16, P99, DOI 10.1385/EP:16:2:099; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Corbin S, 2002, CANCER RES, V62, P3477; Durkin SG, 2008, P NATL ACAD SCI USA, V105, P246, DOI 10.1073/pnas.0708097105; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Fenton CL, 2000, J CLIN ENDOCR METAB, V85, P1170, DOI 10.1210/jc.85.3.1170; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GACY AM, 1995, CELL, V81, P533; Gasparini P, 2007, J CELL BIOCHEM, V102, P320, DOI 10.1002/jcb.21481; Glover TW, 2006, CANCER LETT, V232, P4, DOI 10.1016/j.canlet.2005.08.032; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Handt O, 2000, CHROMOSOME RES, V8, P677, DOI 10.1023/A:1026737203447; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hewett DR, 1998, MOL CELL, V1, P773, DOI 10.1016/S1097-2765(00)80077-5; Klugbauer S, 2001, GENOMICS, V73, P149, DOI 10.1006/geno.2000.6434; Kong QZ, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.6.e33; KUWANO A, 1987, HUM GENET, V75, P75; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; MITELMAN F, 2008, MITELMAN DATABASE CH; Motomura T, 1998, THYROID, V8, P485, DOI 10.1089/thy.1998.8.485; MURANO I, 1989, HUM GENET, V83, P45, DOI 10.1007/BF00274145; Musio A, 1997, ENVIRON MOL MUTAGEN, V29, P250, DOI 10.1002/(SICI)1098-2280(1997)29:3&lt;250::AID-EM4&gt;3.0.CO;2-G; Nikiforov YE, 1999, ONCOGENE, V18, P6330, DOI 10.1038/sj.onc.1203019; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/modpathol.2008.10; Nikiforova MN, 2008, EXPERT REV MOL DIAGN, V8, P83, DOI 10.1586/14737159.8.1.83; Palakodeti A, 2004, GENE CHROMOSOME CANC, V39, P71, DOI 10.1002/gcc.10290; Pelliccia F, 2008, CYTOGENET GENOME RES, V121, P196, DOI 10.1159/000138885; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Santoro M, 2006, EUR J ENDOCRINOL, V155, P645, DOI 10.1530/eje.1.02289; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; SUTHERLAND GR, 1985, HUM GENET, V69, P233, DOI 10.1007/BF00293031; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Zhang H, 2007, MOL CELL, V27, P367, DOI 10.1016/j.molcel.2007.06.012; Zlotorynski E, 2003, MOL CELL BIOL, V23, P7143, DOI 10.1128/MCB.23.20.7143-7151.2003	51	64	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2272	2280		10.1038/onc.2009.502	http://dx.doi.org/10.1038/onc.2009.502			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101222	Green Accepted			2022-12-28	WOS:000276685200012
J	Dennemarker, J; Lohmuller, T; Mayerle, J; Tacke, M; Lerch, MM; Coussens, LM; Peters, C; Reinheckel, T				Dennemaerker, J.; Lohmueller, T.; Mayerle, J.; Tacke, M.; Lerch, M. M.; Coussens, L. M.; Peters, C.; Reinheckel, T.			Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis	ONCOGENE			English	Article						skin cancer; mouse model; protease; cathepsin	TRANSGENIC MICE; EMERGING ROLES; CANCER; EXPRESSION; CARCINOGENESIS; ANGIOGENESIS; CELLS; INVASION; MATRIX; GROWTH	To define a functional role for the endosomal/lysosomal cysteine protease cathepsin L (Ctsl) during squamous carcinogenesis, we generated mice harboring a constitutive Ctsl deficiency in addition to epithelial expression of the human papillomavirus type 16 oncogenes (human cytokeratin 14 (K14)-HPV16). We found enhanced tumor progression and metastasis in the absence of Ctsl. As tumor progression in K14 -HPV16 mice is dependent on inflammation and angiogenesis, we examined immune cell infiltration and vascularization without finding any effect of the Ctsl genotype. In contrast, keratinocyte-specific transgenic expression of cathepsin V, the human orthologue of mouse Ctsl, in otherwise Ctsl-deficient K14 HPV16 mice restored the phenotype observed in the control HPV16 skin. To better understand this phenotype at the molecular level, we measured several oncogenic signal transduction pathways in primary keratinocytes on stimulation with keratinocyte-conditioned cell culture medium. We found increased activation of protein kinase B/Akt and mitogen-activated protein kinase pathways in protease-deficient cells, especially if treated with media conditioned by Ctsl-deficient keratinocytes. Similarly, the level of active GTP-Ras was increased in Ctsl-deficient epidermis. We conclude that Ctsl is critical for the termination of growth factor signaling in the endosomal/lysosomal compartment of keratinocytes and, therefore, functions as an anti-tumor protease. Oncogene (2010) 29, 1611-1621; doi:10.1038/onc.2009.466; published online 21 December 2009	[Dennemaerker, J.; Lohmueller, T.; Tacke, M.; Peters, C.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; [Mayerle, J.; Lerch, M. M.] Ernst Moritz Arndt Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, Greifswald, Germany; [Coussens, L. M.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; [Coussens, L. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ctr Biol Signalling Studies, Freiburg, Germany; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ludwig Heilmeyer Comprehens Canc Ctr, Freiburg, Germany	University of Freiburg; Ernst Moritz Arndt Universitat Greifswald; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Freiburg; University of Freiburg	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, Stefan Meier Str 17, D-79104 Freiburg, Germany.	Thomas.Reinheckel@uniklinik-freiburg.de	Coussens, Lisa/ABH-9834-2020; Lerch, Markus M./E-2206-2016; Mayerle, Julia/W-7907-2019; Reinheckel, Thomas/AAL-9761-2021	Lerch, Markus M./0000-0002-9643-8263; Reinheckel, Thomas/0000-0001-9866-9105; Mayerle, Julia/0000-0002-3666-6459	Deutsche Krebshilfe [Re106977]; Excellence Initiative of the German Federal and State Governments [EXC 294]; European Union [201279]; NATIONAL CANCER INSTITUTE [R01CA130980] Funding Source: NIH RePORTER	Deutsche Krebshilfe(Deutsche Krebshilfe); Excellence Initiative of the German Federal and State Governments; European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ulrike Reif and Susanne Dollwet-Mack for excellent technical assistance and Dr Marie Follo for comments on the paper. The work was supported by a grant from the Deutsche Krebshilfe (Re106977) and in part by the Excellence Initiative of the German Federal and State Governments (EXC 294) and the European Union Framework Program (FP7 'MICRO-ENVIMET' No 201279).	Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bernard D, 2003, J INVEST DERMATOL, V120, P592, DOI 10.1046/j.1523-1747.2003.12086.x; Bethel PA, 2009, BIOORG MED CHEM LETT, V19, P4622, DOI 10.1016/j.bmcl.2009.06.090; Boudreau F, 2007, FASEB J, V21, P3853, DOI 10.1096/fj.07-8113com; Bromme D., 2004, HDB PROTEOLYTIC ENZY, P1107; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 1996, AM J PATHOL, V149, P1899; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gondi CS, 2004, CANCER RES, V64, P4069, DOI 10.1158/0008-5472.CAN-04-1243; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Gutierrez-Fernandez A, 2008, CANCER RES, V68, P2755, DOI 10.1158/0008-5472.CAN-07-5154; Hagemann S, 2004, EUR J CELL BIOL, V83, P775, DOI 10.1078/0171-9335-00404; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Martin MD, 2007, CANCER METAST REV, V26, P717, DOI 10.1007/s10555-007-9089-4; Mayerle J, 2005, GASTROENTEROLOGY, V129, P1251, DOI 10.1053/j.gastro.2005.08.002; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Navab R, 2008, ONCOGENE, V27, P4973, DOI 10.1038/onc.2008.144; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nyberg P, 2008, FRONT BIOSCI, V13, P6537, DOI 10.2741/3173; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Tolosa E, 2003, J CLIN INVEST, V112, P517, DOI 10.1172/JCI200318028; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Walz M, 2007, EXP DERMATOL, V16, P715, DOI 10.1111/j.1600-0625.2007.00579.x; Zheng X, 2004, CANCER RES, V64, P1773, DOI 10.1158/0008-5472.CAN-03-0820	48	86	88	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1611	1621		10.1038/onc.2009.466	http://dx.doi.org/10.1038/onc.2009.466			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20023699	Green Accepted			2022-12-28	WOS:000275694700006
J	Morawska-Onyszczuk, M; Bienkowska-Szewczyk, K; Dobbelstein, M				Morawska-Onyszczuk, M.; Bienkowska-Szewczyk, K.; Dobbelstein, M.			Self-association of adenovirus type 5 E1B-55kDa as well as p53 is essential for their mutual interaction	ONCOGENE			English	Article						p53; E1B-55kDa; oligomerization; adenovirus	E1B 55-KILODALTON PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; E4ORF3 PROTEIN; TUMOR-ANTIGEN; DNA; DEGRADATION; BINDING; ONCOPROTEINS; IDENTIFICATION	The adenovirus type 5 E1B-55kDa oncoprotein forms a complex with the tumor suppressor p53 and inactivates it. E1B-55kDa and p53 are each capable of forming oligomers. We mapped the oligomerization domain of E1B-55kDa to the central portion of the protein. Disturbing E1B-55kDa self-association by point mutations at residues 285/286 or 307 not only impairs its intracellular localization to the cytoplasmic clusters, but in addition, its association with p53. Strikingly, tetramerization of p53 is also required for efficient association with E1B-55kDa. Moreover, two different E1B-55kDa mutants defective for p53 binding but proficient for oligomerization can trans-complement each other for p53 relocalization. We propose that the homo-oligomerization of each component enables efficient interaction between E1B-55kDa and p53 through increased avidity. Oncogene (2010) 29, 1773-1786; doi:10.1038/onc.2009.461; published online 21 December 2009	[Morawska-Onyszczuk, M.; Dobbelstein, M.] Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, D-37077 Gottingen, Germany; [Morawska-Onyszczuk, M.; Bienkowska-Szewczyk, K.] Univ Gdansk, Dept Mol Virol, Intercoll Fac Biotechnol, PL-80952 Gdansk, Poland; [Morawska-Onyszczuk, M.; Bienkowska-Szewczyk, K.] Med Univ Gdansk, Gdansk, Poland	University of Gottingen; Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; Medical University Gdansk	Dobbelstein, M (corresponding author), Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, Ernst Caspari Haus,Justus Liebig Weg 11, D-37077 Gottingen, Germany.	mdobbel@uni-goettingen.de		Morawska, Magdalena/0000-0003-0449-5226; Bienkowska-szewczyk, Krystyna/0000-0003-3650-2902; Dobbelstein, Matthias/0000-0001-5052-3967	German Cancer Aid/Dr Mildred Scheel Stiftung; EU; German Research Foundation (DFG); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society; Fonden til Laegevidenskabens Fremme; Novonordisk fonden; University of Gottingen; Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB)	German Cancer Aid/Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); EU(European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society(Danish Cancer Society); Fonden til Laegevidenskabens Fremme; Novonordisk fonden(Novo Nordisk Foundation); University of Gottingen; Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB)	We thank C Hippel and A Dickmanns for excellent technical assistance. We thank M Oren (Rehovot) and K Vousden (Glasgow) for plasmids and cells. Our work was supported by the German Cancer Aid/Dr Mildred Scheel Stiftung, the EU 6th Framework Program (Integrated Project Active p53), the German Research Foundation (DFG), the Wilhelm Sander Stiftung, the Statens Sundhedsvidenskabelige Forskningsrad of Denmark, the Danish Cancer Society, the Fonden til Laegevidenskabens Fremme, the Novonordisk fonden, the MSc/PhD Molecular Biology Program at the University of Gottingen, and The Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB).	Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DISSANAYAKE S, 1977, IMMUNOLOGY, V32, P309; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fleisig HB, 2007, ONCOGENE, V26, P4797, DOI 10.1038/sj.onc.1210281; Gonzalez RA, 2002, J VIROL, V76, P4507, DOI 10.1128/JVI.76.9.4507-4519.2002; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAND RJA, 1995, VIROLOGY, V207, P255, DOI 10.1006/viro.1995.1074; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Horridge JJ, 1998, J VIROL, V72, P9374, DOI 10.1128/JVI.72.11.9374-9379.1998; Konig C, 1999, J VIROL, V73, P2253; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Marshall LJ, 2008, J VIROL, V82, P6395, DOI 10.1128/JVI.00043-08; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schwartz RA, 2008, J VIROL, V82, P9043, DOI 10.1128/JVI.00925-08; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003	48	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1773	1786		10.1038/onc.2009.461	http://dx.doi.org/10.1038/onc.2009.461			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023703				2022-12-28	WOS:000276022800007
J	Punj, V; Matta, H; Schamus, S; Tamewitz, A; Anyang, B; Chaudhary, PM				Punj, V.; Matta, H.; Schamus, S.; Tamewitz, A.; Anyang, B.; Chaudhary, P. M.			Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a	ONCOGENE			English	Article						KSHV; vFLIP; K13; NF-kB; CXCR4; mir-146a	NF-KAPPA-B; MICROVASCULAR ENDOTHELIAL-CELLS; CELLULAR MICRORNA MIR-146A; GENE-EXPRESSION; LYTIC REPLICATION; INDUCED APOPTOSIS; KINASE COMPLEX; ACTIVATION; HUMAN-HERPESVIRUS-8; TRANSFORMATION	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV)encoded viral FLICE inhibitory protein (vFLIP) K13 is a potent activator of the nuclear factor-kappa B (NF-kappa B) pathway. In this study, we show that infection with KHSV and ectopic expression of K13, but not its NF-kappa B-defective mutant, suppressed the expression of CXCR4. Suppression of CXCR4 by KSHV and K13 was associated with upregulated expression of miR-146a, a microRNA that is known to bind to the 3'-untranslated region of CXCR4 mRNA. Reporter studies identified two NF-kappa B sites in the promoter of miR-146a that were essential for its activation by K13. Accordingly, ectopic expression of K13, but not its NF-kappa B-defective mutant or other vFLIPs, strongly stimulated the miR-146a promoter activity, which could be blocked by specific genetic and pharmacological inhibitors of the NF-kappa B pathway. Finally, expression of CXCR4 was downregulated in clinical samples of KS and this was accompanied by an increased expression of miR-146a. Our results show that K13-induced NF-kappa B activity suppresses CXCR4 through upregulation of miR-146a. Downregulation of CXCR4 expression by K13 may contribute to KS development by promoting premature release of KSHV-infected endothelial progenitors into the circulation. Oncogene (2010) 29, 1835-1844; doi:10.1038/onc.2009.460; published online 21 December 2009	[Punj, V.; Matta, H.; Schamus, S.; Tamewitz, A.; Anyang, B.; Chaudhary, P. M.] Univ Pittsburgh, Dept Med, Div Hematol Oncol, Hillman Canc Ctr,Canc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chaudhary, PM (corresponding author), Univ Pittsburgh, Dept Med, Div Hematol Oncol, Hillman Canc Ctr,Canc Inst, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		National Institutes of Health [CA85177, CA124621]; Leukemia & Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA124621, R01CA085177] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr David Baltimore (California Institute of Technology) for the miR-146a promoter reporter constructs, Dr Parkash Gill for SLK cells, the NIH AIDS Research and Reference Reagent Program for CXCR4 antibodies and the Cancer Specimen Resources at the University of California, San Francisco and George Washington University, Washington, for providing patient samples. This work was supported by grants from the National Institutes of Health (CA85177 and CA124621) and the Leukemia & Lymphoma Society.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary Preet M., 2008, V1, P186, DOI 10.1159/000141519; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Dorak T, 2006, REAL TIME PCR; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2008, ONCOGENE, V27, P5243, DOI 10.1038/onc.2008.150; Matta H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Motsch N, 2007, RNA BIOL, V4, P131, DOI 10.4161/rna.4.3.5206; Naranatt PP, 2004, CANCER RES, V64, P72, DOI 10.1158/0008-5472.CAN-03-2767; Pellet C, 2006, J INVEST DERMATOL, V126, P621, DOI 10.1038/sj.jid.5700083; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Poole LJ, 2002, J VIROL, V76, P3395, DOI 10.1128/JVI.76.7.3395-3420.2002; Punj V, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-50; Punj V, 2009, BLOOD, V113, P5660, DOI 10.1182/blood-2008-10-186403; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sakakibara S, 2009, J VIROL, V83, P2140, DOI 10.1128/JVI.01871-08; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 2000, J ANTIMICROB CHEMOTH, V45, P15, DOI 10.1093/jac/45.suppl_4.15; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thurau M, 2009, J VIROL, V83, P598, DOI 10.1128/JVI.00629-08; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Williams AE, 2008, BIOCHEM SOC T, V36, P1211, DOI 10.1042/BST0361211; Xu YY, 2007, J GEN VIROL, V88, P46, DOI 10.1099/vir.0.82375-0; Ye FC, 2008, J VIROL, V82, P4235, DOI 10.1128/JVI.02370-07; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067	49	51	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1835	1844		10.1038/onc.2009.460	http://dx.doi.org/10.1038/onc.2009.460			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023696	Green Accepted			2022-12-28	WOS:000276022800012
J	Ocak, S; Yamashita, H; Udyavar, AR; Miller, AN; Gonzalez, AL; Zou, Y; Jiang, A; Yi, Y; Shyr, Y; Estrada, L; Quaranta, V; Massion, PP				Ocak, S.; Yamashita, H.; Udyavar, A. R.; Miller, A. N.; Gonzalez, A. L.; Zou, Y.; Jiang, A.; Yi, Y.; Shyr, Y.; Estrada, L.; Quaranta, V.; Massion, P. P.			DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway	ONCOGENE			English	Article						array CGH; copy number alterations; pathway analysis; FAK; adhesion; spreading	COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE INHIBITOR; GENE-EXPRESSION; CARCINOMAS; PROTEIN; OVEREXPRESSION; SIGNATURES; TUMORS	Small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer in its clinical behavior, with a 5-year overall survival as low as 5%. Despite years of research in the field, molecular determinants of SCLC behavior are still poorly understood, and this deficiency has translated into an absence of specific diagnostics and targeted therapeutics. We hypothesized that tumor DNA copy number alterations would allow the identification of molecular pathways involved in SCLC progression. Array comparative genomic hybridization was performed on DNA extracted from 46 formalin-fixed paraffin-embedded SCLC tissue specimens. Genomic profiling of tumor and sex-matched control DNA allowed the identification of 70 regions of copy number gain and 55 regions of copy number loss. Using molecular pathway analysis, we found a strong enrichment in these regions of copy number alterations for 11 genes associated with the focal adhesion pathway. We verified these findings at the genomic, gene expression and protein level. Focal Adhesion Kinase (FAK), one of the central genes represented in this pathway, was commonly expressed in SCLC tumors and constitutively phosphorylated in SCLC cell lines. Those were poorly adherent to most substrates but not to laminin-322. Inhibition of FAK phosphorylation at Tyr(397) by a small-molecule inhibitor, PF-573,228, induced a dose-dependent decrease of adhesion and an increase of spreading in SCLC cell lines on laminin-322. Cells that tended to spread also showed a decrease in focal adhesions, as demonstrated by a decreased vinculin expression. These results support the concept that pathway analysis of genes in regions of copy number alterations may uncover molecular mechanisms of disease progression and demonstrate a new role of FAK and associated adhesion pathways in SCLC. Further investigations of FAK at the functional level may lead to a better understanding of SCLC progression and may have therapeutic implications. Oncogene (2010) 29, 6331-6342; doi:10.1038/onc.2010.362; published online 30 August 2010	[Massion, P. P.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Yamashita, H.; Udyavar, A. R.; Estrada, L.; Quaranta, V.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Gonzalez, A. L.] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; [Jiang, A.; Shyr, Y.] Vanderbilt Univ, Canc Biostat Ctr, Nashville, TN 37232 USA; [Yi, Y.] Vanderbilt Univ, Div Med Genet, Nashville, TN 37232 USA; [Miller, A. N.; Massion, P. P.] Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Massion, PP (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Div Allergy Pulm & Crit Care Med, 2220 Pierce Ave,Preston Res Bldg 640, Nashville, TN 37232 USA.	pierre.massion@vanderbilt.edu	Quaranta, Vito/G-6512-2016; Wang, Weili/D-1546-2011	Quaranta, Vito/0000-0001-7491-8672; Estrada, Lourdes/0000-0002-3645-4456; Yamashita, Hironobu/0000-0003-2587-7100; Jiang, Aixiang/0000-0002-6153-7595	Cancer Center Support [5P30 CA068485]; Department of Veterans Affairs; IASLC; Universite Catholique de Louvain (Bourse Clinicien-Chercheur), Belgium; NATIONAL CANCER INSTITUTE [U54CA113007, P30CA068485] Funding Source: NIH RePORTER	Cancer Center Support; Department of Veterans Affairs(US Department of Veterans Affairs); IASLC; Universite Catholique de Louvain (Bourse Clinicien-Chercheur), Belgium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kathy Taylor, Director of the Research Institute at St Thomas Health Services, Nashville, TN, for sharing archived SCLC tissue blocks; Dr Coe for providing array CGH data (Coe et al., 2006); and Vanderbilt's Immunohistochemistry Core (supported by a Cancer Center Support Grant 5P30 CA068485) for their contribution. We also thank Steven K Hanks, Alissa M Weaver and Donna J Webb for their useful input in the interpretation of the paper. This work was supported by a Merit Review grant from the Department of Veterans Affairs. Dr Ocak was supported by an IASLC Young Investigator Fellowship Award and by a grant from Universite Catholique de Louvain (Bourse Clinicien-Chercheur), Belgium.	Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167; Cooper S, 2006, RESPIROLOGY, V11, P241, DOI 10.1111/j.1440-1843.2006.00850.x; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gallia GL, 2006, MOL CANCER RES, V4, P709, DOI 10.1158/1541-7786.MCR-06-0172; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kirov SA, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-72; LEVIN NA, 1994, CANCER RES, V54, P5086; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Massion PP, 2008, AM J RESP CRIT CARE, V178, P1164, DOI 10.1164/rccm.200801-142OC; Massion PP, 2003, CANCER RES, V63, P7113; Massion PP, 2002, CANCER RES, V62, P3636; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MIURA I, 1992, CANCER RES, V52, P1322; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Peng WX, 2005, CANCER SCI, V96, P661, DOI 10.1111/j.1349-7006.2005.00092.x; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Qian J, 2009, MOL CANCER THER, V8, P101, DOI 10.1158/1535-7163.MCT-08-0973; RIED T, 1994, CANCER RES, V54, P1801; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shi Q, 2007, MOL CARCINOGEN, V46, P488, DOI 10.1002/mc.20297; SIDHU GS, 1979, AM J PATHOL, V96, P5; Siesser PMF, 2006, CLIN CANCER RES, V12, P3233, DOI 10.1158/1078-0432.CCR-06-0456; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; SOZZI G, 1987, CANCER GENET CYTOGEN, V27, P45, DOI 10.1016/0165-4608(87)90259-7; Taniwaki M, 2006, INT J ONCOL, V29, P567; Tanno S, 2004, LUNG CANCER, V46, P11, DOI 10.1016/j.lungcan.2004.03.006; Ullmann R, 1998, HUM PATHOL, V29, P1145, DOI 10.1016/S0046-8177(98)90428-2; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	46	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	48					6331	6342		10.1038/onc.2010.362	http://dx.doi.org/10.1038/onc.2010.362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20802517	Green Accepted			2022-12-28	WOS:000284874700004
J	Leber, B; Lin, J; Andrews, DW				Leber, B.; Lin, J.; Andrews, D. W.			Still embedded together binding to membranes regulates Bcl-2 protein interactions	ONCOGENE			English	Review						apoptosis; model; membranes; Bcl-2; Bcl-XL; Bax	CONFORMATIONAL-CHANGE; BAX ACTIVATION; CELL-SURVIVAL; APOPTOSIS; BCL-X(L); BH3; BIM; MITOCHONDRIA; CANCER; FAMILY	The dysregulation of apoptosis is a key step in developing tumours, and mediates resistance to cancer therapy. Many different signals for cell death converge on permeabilization of the outer mitochondrial membrane, which is controlled by the Bcl-2 family of proteins. The importance of this step is becoming increasingly relevant as the first generation of small molecules that inhibit the interaction of Bcl-2 family proteins enters clinical trials as anticancer agents. The Bcl-2 family can be divided into three classes: BH3-only proteins that are activated by various forms of cellular stress, Bax and Bak proteins that mediate mitochondrial membrane permeabilization, and inhibitory proteins such as Bcl-2 and Bcl-XL. The recently proposed embedded together model emphasizes the fact that many of the regulatory interactions between different classes of Bcl-2 family members occur at intracellular membranes, and binding to membranes causes conformational changes in the proteins that dictate functions in a dynamic manner. Within this context, recent results indicate that Bcl-XL functions as a dominant-negative Bax, a concept that resolves the paradox of similar structures but opposite functions of Bcl-XL and Bax. We have also shown that the conformational change that allows Bax to insert into the outer mitochondrial membrane is the rate-limiting step in the multistep process of Bax activation. Nevertheless, investigating the structure of activated Bax or Bak as monomers and as components of the oligomeric structures that mediate membrane permeabilization is the focus of ongoing research (and controversy) at many laboratories worldwide. Oncogene (2010) 29, 5221-5230; doi:10.1038/onc.2010.283; published online 19 July 2010	[Leber, B.; Andrews, D. W.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Leber, B.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Lin, J.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	McMaster University; McMaster University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St W,Room 4H-41, Hamilton, ON L8N 3Z5, Canada.	andrewsd@dwalab.ca		Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157	Canadian Institute of Health Research (CIHR) [FRN12517]; Tier-I Canada Research Chair in Membrane Biogenesis; NIH [GM062964]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Tier-I Canada Research Chair in Membrane Biogenesis(Canada Research Chairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Work from our laboratories cited in this review was supported by a Canadian Institute of Health Research (CIHR FRN12517) Grant to DWA and BL, by a Tier-I Canada Research Chair in Membrane Biogenesis to DWA and by NIH Grant GM062964 to JL.	Albeck JG, 2008, PLOS BIOL, V6, P2831, DOI 10.1371/journal.pbio.0060299; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Billen LP, 2008, ONCOGENE, V27, pS93, DOI 10.1038/onc.2009.47; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Brunelle JK, 2009, J CELL BIOL, V187, P429, DOI 10.1083/jcb.200904049; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Chonghaile TN, 2008, ONCOGENE, V27, pS149, DOI 10.1038/onc.2009.52; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Czabotar PE, 2009, CELL DEATH DIFFER, V16, P1187, DOI 10.1038/cdd.2009.83; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Denisov AY, 2007, BIOCHEMISTRY-US, V46, P734, DOI 10.1021/bi062080a; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Dewson G, 2009, MOL CELL, V36, P696, DOI 10.1016/j.molcel.2009.11.008; Dewson G, 2009, J CELL SCI, V122, P2801, DOI 10.1242/jcs.038166; Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; George NM, 2007, GENE DEV, V21, P1937, DOI 10.1101/gad.1553607; Green DR, 2008, NATURE, V455, P1047, DOI 10.1038/4551047a; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hekman M, 2006, J BIOL CHEM, V281, P17321, DOI 10.1074/jbc.M600292200; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Ivashyna O, 2009, J BIOL CHEM, V284, P23935, DOI 10.1074/jbc.M109.023853; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Merino D, 2009, J CELL BIOL, V186, P355, DOI 10.1083/jcb.200905153; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; Peng J, 2006, J BIOL CHEM, V281, P35802, DOI 10.1074/jbc.M608303200; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Ploner C, 2008, ONCOGENE, V27, pS84, DOI 10.1038/onc.2009.46; Polzien L, 2009, J BIOL CHEM, V284, P28004, DOI 10.1074/jbc.M109.010702; Roy SS, 2009, MOL CELL, V33, P377, DOI 10.1016/j.molcel.2009.01.018; Schafer B, 2009, MOL BIOL CELL, V20, P2276, DOI 10.1091/mbc.E08-10-1056; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Terrones O, 2008, J BIOL CHEM, V283, P7790, DOI 10.1074/jbc.M708814200; Wang H, 2009, J STRUCT BIOL, V166, P32, DOI 10.1016/j.jsb.2008.12.003; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang Z, 2004, J BIOL CHEM, V279, P43920, DOI 10.1074/jbc.M406412200; Zhang Z, 2010, J BIOL CHEM, V285, P17614, DOI 10.1074/jbc.M110.113456; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	61	112	121	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5221	5230		10.1038/onc.2010.283	http://dx.doi.org/10.1038/onc.2010.283			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20639903	Green Accepted			2022-12-28	WOS:000282089100001
J	Wang, M; Hossain, MS; Tan, W; Coolman, B; Zhou, J; Liu, S; Casey, PJ				Wang, M.; Hossain, M. S.; Tan, W.; Coolman, B.; Zhou, J.; Liu, S.; Casey, P. J.			Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth	ONCOGENE			English	Article						isoprenylcysteine carboxylmethyltransferase (Icmt); prenylation; farnesylation; autophagy; apoptosis; cancer therapy	PROGRAMMED CELL-DEATH; SMALL-MOLECULE INHIBITOR; CARBOXYL METHYLTRANSFERASE; PROTEIN PRENYLATION; K-RAS; OVARIAN; CYTOTOXICITY; MECHANISMS; HOMOLOG; LC3	Inhibition of isoprenylcysteine carboxylmethyltransferase (Icmt), which catalyzes the final step in the post-translational C-terminal processing of prenylated proteins, suppresses tumor cell growth and induces cell death. Icmt inhibition by either a small molecule inhibitor termed as cysmethynil or inhibitory RNA induces marked autophagy leading to cell death. HepG2 cells were used to investigate the function of autophagy in tumor cell death. Suppression of autophagy, either pharmacologically or through knockdown of the autophagy essential proteins, Atg5 or Atg1, inhibits not only cysmethynil-induced autophagy, but also apoptosis in HepG2 cells. The dependence of cysmethynil-induced apoptosis on autophagy was further shown using autophagy-deficient mouse embryonic fibroblast (MEF) cells. Atg5(-/-) MEF cells were found to be resistant to cysmethynil-induced apoptosis, whereas wild-type MEFs showed high sensitivity to apoptosis induction. These data indicate that inhibition of Icmt can elicit cell death through two linked mechanisms, autophagy and apoptosis, and that autophagy can be an active player upstream of apoptosis in cell types capable of apoptotic cell death, such as HepG2 and MEFs. Further, treatment of mice-bearing HepG2-derived tumors with cysmethynil resulted in marked inhibition of tumor growth; analysis of tumor tissue from these mice revealed markers consistent with autophagy induction and cell growth arrest. Oncogene (2010) 29, 4959-4970; doi: 10.1038/onc.2010.247; published online 12 July 2010	[Wang, M.; Hossain, M. S.; Tan, W.; Zhou, J.; Liu, S.; Casey, P. J.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Coolman, B.; Casey, P. J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA	National University of Singapore; Duke University	Wang, M (corresponding author), Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg	Hossain, Mohammad Sorowar/AAX-2009-2020	Hossain, Mohammad Sorowar/0000-0001-7143-2909; Wang, Mei/0000-0001-6887-6840; Casey, Patrick/0000-0002-7366-9309	Singapore Ministry of Health; Agency for Science, Technology, and Research	Singapore Ministry of Health(Ministry of Health-Singapore); Agency for Science, Technology, and Research(Agency for Science Technology & Research (A*STAR))	We are grateful to Noboru Mizushima for the generous gift of Atg5 knockout cells. This paper is dedicated to the spirit of Block C, an aging nursing school dormitory retrofitted as the Duke-NUS interim research facility in which some of these studies were conducted. Financial support was provided by awards from the Singapore Ministry of Health and the Agency for Science, Technology, and Research.	Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083; Anderson JL, 2005, J BIOL CHEM, V280, P29454, DOI 10.1074/jbc.M504982200; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Baron RA, 2007, BIOCHEMISTRY-US, V46, P554, DOI 10.1021/bi060344n; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Blum R, 2008, RECENT PAT ANTI-CANC, V3, P31; Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; CLIBY W, 1993, GYNECOL ONCOL, V50, P34, DOI 10.1006/gyno.1993.1160; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Di X, 2009, BIOCHEM PHARMACOL, V77, P1139, DOI 10.1016/j.bcp.2008.12.016; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; ECCLES DM, 1992, ONCOGENE, V7, P2069; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818; Gewirtz DA, 2009, RADIOTHER ONCOL, V92, P323, DOI 10.1016/j.radonc.2009.05.022; Gorka M, 2005, ANTI-CANCER DRUG, V16, P777; Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511; Juhasz G, 2003, FEBS LETT, V543, P154, DOI 10.1016/S0014-5793(03)00431-9; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kang C, 2007, GENE DEV, V21, P2161, DOI 10.1101/gad.1573107; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kramer K, 2003, MOL BIOL CELL, V14, P848, DOI 10.1091/mbc.E02-07-0390; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333; Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; Nair U, 2005, J BIOL CHEM, V280, P41785, DOI 10.1074/jbc.R500016200; Olie RA, 1998, CURR BIOL, V8, P955, DOI 10.1016/S0960-9822(98)70395-1; Roisin-Bouffay C, 2004, J BIOL CHEM, V279, P11489, DOI 10.1074/jbc.M312741200; SAITO H, 1993, CANCER RES, V53, P3382; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Sousa SF, 2008, CURR MED CHEM, V15, P1478, DOI 10.2174/092986708784638825; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood-2007-06-094060; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Wright LP, 2009, MOL CELL BIOL, V29, P1826, DOI 10.1128/MCB.01719-08; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	49	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4959	4970		10.1038/onc.2010.247	http://dx.doi.org/10.1038/onc.2010.247			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20622895				2022-12-28	WOS:000281578700010
J	Lee, SH; Shen, GN; Jung, YS; Lee, SJ; Chung, JY; Kim, HS; Xu, Y; Choi, Y; Lee, JW; Ha, NC; Song, GY; Park, BJ				Lee, S-H; Shen, G-N; Jung, Y. S.; Lee, S-J; Chung, J-Y; Kim, H-S; Xu, Y.; Choi, Y.; Lee, J-W; Ha, N-C; Song, G. Y.; Park, B-J			Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells	ONCOGENE			English	Article						anticancer drug; p53; K-Ras; Snail; pancreatic cancer	PANCREATIC-CANCER; IN-VIVO; P53; EXPRESSION; BREAST; RESTORATION; SENESCENCE; MUTATIONS; PATHWAY; CATENIN	p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Raswild- type cells. Moreover, GN25 can selectively activate wild-type p53 in p53(WT/MT) cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers. Oncogene (2010) 29, 4576-4587; doi: 10.1038/onc.2010.208; published online 7 June 2010	[Lee, S-H; Jung, Y. S.; Lee, S-J; Chung, J-Y; Park, B-J] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Lee, S-H; Shen, G-N; Choi, Y.] Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea; [Shen, G-N; Song, G. Y.] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea; [Kim, H-S; Xu, Y.; Lee, J-W; Ha, N-C] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Pusan National University; Korea University; Chungnam National University; Pusan National University	Park, BJ (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	gysong@cnu.ac.kr; bjpark1219@pusan.ac.kr	Kim, Heui-Soo/ABF-3773-2021; Choi, Yongseok/F-8375-2012; Lee, Jaewon/N-9064-2013; Lee, Sang Joon/AAG-2448-2019	Kim, Heui-Soo/0000-0002-5226-6594; Choi, Yongseok/0000-0002-3622-3439; Lee, Jaewon/0000-0003-3203-2130; Song, Gyu Yong/0000-0001-6058-5790	national cancer center of Korea [0920250]; Pusan National University [PNU-2008-101-20080596000]; Ministry of Education, Science and Technology [2009-0093815]	national cancer center of Korea; Pusan National University(Pusan National University); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by national cancer center of Korea (0920250; BJP), by the Bio-Scientific Research Grant funded by the Pusan National University (PNU-2008-101-20080596000; BJP) and by the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815; GYS).	Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Butz J, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-11; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kumaravel TS, 2005, BREAST CANCER RES TR, V91, P89, DOI 10.1007/s10549-004-5780-0; Lee SH, 2009, ONCOGENE, V28, P2005, DOI 10.1038/onc.2009.67; Lee SJ, 2009, INT J ONCOL, V34, P1637, DOI 10.3892/ijo_00000294; Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006; Leslie A, 2003, CANCER RES, V63, P4656; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Park BJ, 2005, CELL, V120, P209, DOI 10.1016/j.cell.2004.11.054; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; WEINBERG RA, 2001, BIOL CANC, P311; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yan WS, 2009, J BIOL CHEM, V284, P12178, DOI 10.1074/jbc.M900994200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508	25	33	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2010	29	32					4576	4587		10.1038/onc.2010.208	http://dx.doi.org/10.1038/onc.2010.208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531295				2022-12-28	WOS:000280862300008
J	Zauner, L; Melroe, GT; Sigrist, JA; Rechsteiner, MP; Dorner, M; Arnold, M; Berger, C; Bernasconi, M; Schaefer, BW; Speck, RF; Nadal, D				Zauner, L.; Melroe, G. T.; Sigrist, J. A.; Rechsteiner, M. P.; Dorner, M.; Arnold, M.; Berger, C.; Bernasconi, M.; Schaefer, B. W.; Speck, R. F.; Nadal, D.			TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification	ONCOGENE			English	Article						TLR9; Burkitt's lymphoma; Epstein-Barr virus; Plasmodium falciparum; histone modification	EPSTEIN-BARR-VIRUS; TOLL-LIKE RECEPTOR-9; NF-KAPPA-B; IMMUNE ACTIVATION; LYTIC CYCLE; CPG DNA; INDUCTION; INFECTION; LATENT; REPLICATION	Endemic Burkitt's lymphoma (BL) is considered to preferentially develop in equatorial Africa because of chronic co-infection with Epstein-Barr virus (EBV) and the malaria pathogen Plasmodium falciparum. The interaction and contribution of both pathogens in the oncogenic process are poorly understood. Earlier, we showed that immune activation with a synthetic Toll-like receptor 9 (TLR9) ligand suppresses the initiation of EBV lytic replication in primary human B cells. In this study we investigate the mechanism involved in the suppression of EBV lytic gene expression in BL cell lines. We show that this suppression is dependent on functional TLR9 and MyD88 signaling but independent of downstream signaling elements, including phosphatidylinositol-3 kinase, mitogen-activated protein kinases and nuclear factor-kappa B. We identified TLR9 triggering resulting in histone modifications to negatively affect the activation of the promoter of EBV's master regulatory lytic gene BZLF1. Finally, we show that P. falciparum hemozoin, a natural TLR9 ligand, suppresses induction of EBV lytic gene expression in a dose-dependent manner. Thus, we provide evidence for a possible interaction between P. falciparum and EBV at the B-cell level and the mechanism involved in suppressing lytic and thereby reinforcing latent EBV that has unique oncogenic potential. Oncogene (2010) 29, 4588-4598; doi: 10.1038/onc.2010.203; published online 31 May 2010	[Zauner, L.; Melroe, G. T.; Sigrist, J. A.; Rechsteiner, M. P.; Dorner, M.; Arnold, M.; Berger, C.; Bernasconi, M.; Nadal, D.] Univ Zurich, Univ Childrens Hosp Zurich, Div Infect Dis & Hosp Epidemiol, Lab Expt Infect Dis & Canc Res, Zurich, Switzerland; [Schaefer, B. W.] Univ Zurich, Univ Childrens Hosp Zurich, Div Oncol, Zurich, Switzerland; [Speck, R. F.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich; University Children's Hospital Zurich; University of Zurich; University of Zurich; University Zurich Hospital	Nadal, D (corresponding author), Univ Childrens Hosp, Div Infect Dis & Hosp Epidemiol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	david.nadal@kispi.uzh.ch	Bernasconi, Michele/GOH-1815-2022; Bernasconi, Michele/CAG-2492-2022; Bernasconi, Michele/C-6734-2008; Dorner, Marcus/B-1398-2010; Speck, Roberto F/O-2433-2016	Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Schafer, Beat/0000-0001-5988-2915; Speck, Roberto/0000-0002-8453-1137; Dorner, Marcus/0000-0003-0321-4226	Cancer League of the Canton Zurich; Swiss National Foundation [310040-114118]; Oncosuisse; Forschungskredit of the University of Zurich [54192002]	Cancer League of the Canton Zurich; Swiss National Foundation(Swiss National Science Foundation (SNSF)); Oncosuisse; Forschungskredit of the University of Zurich	We thank Jurg Tschopp, Hans-Peter Beck and Sebastian Rusch for providing reagents. This work was supported by grants from the Cancer League of the Canton Zurich, the Swiss National Foundation (no. 310040-114118), Oncosuisse, the Forschungskredit of the University of Zurich (no. 54192002) and UBS donation by a client.	Alazard N, 2003, J VIROL, V77, P8166, DOI 10.1128/JVI.77.14.8166-8172.2003; Ashman RF, 2005, INT IMMUNOL, V17, P411, DOI 10.1093/intimm/dxh222; Berger C, 2001, J MED VIROL, V64, P505, DOI 10.1002/jmv.1078; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Chene A, 2007, PLOS PATHOG, V3, P826, DOI 10.1371/journal.ppat.0030080; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; Countryman JK, 2008, J VIROL, V82, P4706, DOI 10.1128/JVI.00116-08; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DIRENZO L, 1994, INT J CANCER, V57, P914, DOI 10.1002/ijc.2910570623; Duramad O, 2005, J IMMUNOL, V174, P5193, DOI 10.4049/jimmunol.174.9.5193; FLEMINGTON EK, 1991, J VIROL, V65, P7073, DOI 10.1128/JVI.65.12.7073-7077.1991; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Heeg K, 2008, INT J MED MICROBIOL, V298, P33, DOI 10.1016/j.ijmm.2007.07.007; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003; Iwakiri D, 2004, J IMMUNOL, V172, P1561, DOI 10.4049/jimmunol.172.3.1561; Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000; Klein E, 2007, ONCOGENE, V26, P1297, DOI 10.1038/sj.onc.1210240; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; Kumagai Y, 2008, ADV DRUG DELIVER REV, V60, P795, DOI 10.1016/j.addr.2007.12.004; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Ladell K, 2007, CELL MICROBIOL, V9, P2055, DOI 10.1111/j.1462-5822.2007.00937.x; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; NOVAK EJ, 1994, CYTOMETRY, V17, P135, DOI 10.1002/cyto.990170205; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Rechsteiner MP, 2008, J VIROL, V82, P1739, DOI 10.1128/JVI.01723-07; Rechsteiner MP, 2007, J GEN VIROL, V88, P1454, DOI 10.1099/vir.0.82790-0; Rickinson A, 2007, FIELDS VIROLOGY; Rochford R, 2005, NAT REV MICROBIOL, V3, P182, DOI 10.1038/nrmicro1089; Ryan JL, 2004, DIAGN MOL PATHOL, V13, P61, DOI 10.1097/00019606-200406000-00001; Sanjuan MA, 2006, J CELL BIOL, V172, P1057, DOI 10.1083/jcb.200508058; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; Takeshita F, 2004, SEMIN IMMUNOL, V16, P17, DOI 10.1016/j.smim.2003.10.009; TOVEY MG, 1978, NATURE, V276, P270, DOI 10.1038/276270a0; Tsurumi T, 2005, REV MED VIROL, V15, P3, DOI 10.1002/rmv.441; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yuan J, 2006, J VIROL, V80, P2548, DOI 10.1128/JVI.80.5.2548-2565.2006; ZURHAUSEN H, 1978, NATURE, V272, P373	41	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4588	4598		10.1038/onc.2010.203	http://dx.doi.org/10.1038/onc.2010.203			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20514021				2022-12-28	WOS:000280862300009
J	Niu, Y; Chang, TM; Yeh, S; Ma, WL; Wang, YZ; Chang, C				Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Wang, Y. Z.; Chang, C.			Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails	ONCOGENE			English	Review						prostate metastasis; anti-androgen therapy; androgen replacement therapy	TESTOSTERONE REPLACEMENT THERAPY; GROWTH-IN-VIVO; TUMOR-SUPPRESSOR; MOLECULAR CHARACTERIZATION; STROMAL MICROENVIRONMENT; EPITHELIAL INTERACTIONS; XENOGRAFT MODELS; CASTRATION; INHIBITION; PROGRESSION	Prostate cancer is one of the major causes of cancer-related death in the western world. Androgen-deprivation therapy (ADT) for the suppression of androgens binding to the androgen receptor (AR) has been the norm of prostate cancer treatment. Despite early success to suppress prostate tumor growth, ADT eventually fails leading to recurrent tumor growth in a hormone-refractory manner, even though AR remains to function in hormone-refractory prostate cancer. Interestingly, some prostate cancer survivors who received androgen replacement therapy had improved quality of life without adverse effect on their cancer progression. These contrasting clinical data suggest that differential androgen/AR signals in individual cells of prostate tumors can exist in the same or different patients, and may be used to explain why ADT of prostate cancer fails. Such a hypothesis is supported by the results obtained from transgenic mice with selective knockout of AR in prostatic stromal vs epithelial cells and orthotopic transplants of various human prostate cancer cell lines with AR overexpression or knockout. These studies concluded that AR functions as a stimulator for prostate cancer proliferation and metastasis in stromal cells, as a survival factor of prostatic cancer epithelial luminal cells, and as a suppressor for prostate cancer basal intermediate cell growth and metastasis. These dual yet opposite functions of the stromal and epithelial AR may challenge the current ADT to battle prostate cancer and should be taken into consideration when developing new AR-targeting therapies in selective prostate cancer cells. Oncogene (2010) 29, 3593-3604; doi: 10.1038/onc.2010.121; published online 3 May 2010	[Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; [Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; [Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; [Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Niu, Y.] Tianjin Med Univ, Tianjin Inst Urol, Sex Hormone Res Ctr, Tianjin, Peoples R China; [Ma, W-L] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan; [Wang, Y. Z.] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Tianjin Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of British Columbia	Chang, C (corresponding author), Univ Rochester Med, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Ma, Wen-Lung/O-2745-2015	Ma, Wen-Lung/0000-0002-5571-3302; Wang, Yuzhuo/0000-0002-9749-8591	George Whipple Professorship; NIH [CA122840]; NSFC [30872587]; NATIONAL CANCER INSTITUTE [R01CA122840] Funding Source: NIH RePORTER	George Whipple Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the George Whipple Professorship and NIH grant CA122840 and NSFC grant project 30872587.	Agarwal PK, 2005, J UROLOGY, V173, P533, DOI 10.1097/01.ju.0000143942.55896.64; AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; Altuwaijri S, 2007, ASIAN J ANDROL, V9, P181, DOI 10.1111/j.1745-7262.2007.00258.x; ANDERSON KM, 1968, NATURE, V219, P277, DOI 10.1038/219277a0; Banach-Petrosky W, 2007, CANCER RES, V67, P9089, DOI 10.1158/0008-5472.CAN-07-2887; Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214; Basaria S, 2008, J ANDROL, V29, P534, DOI 10.2164/jandrol.108.005454; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bouzin C, 2007, DRUG RESIST UPDATE, V10, P109, DOI 10.1016/j.drup.2007.03.001; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; BRUCHOVSKY N, 1990, CANCER RES, V50, P2275; BRUCHOVSKY N, 1993, CANC MED, P884; Buchanan G, 2001, CANCER METAST REV, V20, P207, DOI 10.1023/A:1015531326689; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008-5472.CAN-06-0632; Condon MS, 2005, SEMIN CANCER BIOL, V15, P132, DOI 10.1016/j.semcancer.2004.08.002; Crook JM, 1999, UROLOGY, V53, P530, DOI 10.1016/S0090-4295(98)00547-0; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ferreira U, 2006, PROSTATE CANCER P D, V9, P39, DOI 10.1038/sj.pcan.4500833; FOWLER JE, 1981, J UROLOGY, V126, P372, DOI 10.1016/S0022-5347(17)54531-0; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; George DJ, 1999, CANCER RES, V59, P2395; GINGRICH JR, 1991, CANCER RES, V57, P4687; GLEAVE M, 1991, CANCER RES, V51, P3753; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Halin S, 2007, PROSTATE, V67, P370, DOI 10.1002/pros.20473; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hobisch A, 1996, PROSTATE, V28, P129; Hofmeister V, 2008, CANCER IMMUNOL IMMUN, V57, P1, DOI 10.1007/s00262-007-0365-5; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Hurtado-Coll A, 2002, UROLOGY, V60, P52, DOI 10.1016/S0090-4295(02)01572-8; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Inui S, 2002, FASEB J, V16, P1967, DOI 10.1096/fj.02-0043fje; Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255; Johansson A, 2007, PROSTATE, V67, P1664, DOI 10.1002/pros.20657; Johnson MA, 2005, PROSTATE, V62, P322, DOI 10.1002/pros.20148; Joly-Pharaboz MO, 2000, J STEROID BIOCHEM, V73, P237, DOI 10.1016/S0960-0760(00)00076-5; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kaufman JM, 2004, J UROLOGY, V172, P920, DOI 10.1097/01.ju.0000136269.10161.32; Khera M, 2009, J SEX MED, V6, P1165, DOI 10.1111/j.1743-6109.2009.01161.x; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Litvinov IV, 2004, PROSTATE, V61, P299, DOI 10.1002/pros.20187; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483; Liu AY, 2004, AM J PATHOL, V165, P1543, DOI 10.1016/S0002-9440(10)63412-8; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Mathew P, 2008, ANN ONCOL, V19, P395, DOI 10.1093/annonc/mdm568; Mercader M, 2001, P NATL ACAD SCI USA, V98, P14565, DOI 10.1073/pnas.251140998; Mirosevich J, 1999, J ENDOCRINOL, V162, P341, DOI 10.1677/joe.0.1620341; Miyamoto H, 2005, MOL CARCINOGEN, V44, P1, DOI 10.1002/mc.20121; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Morris MJ, 2009, EUR UROL, V56, P237, DOI 10.1016/j.eururo.2009.03.073; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nelius T, 2007, INT J CANCER, V121, P999, DOI 10.1002/ijc.22802; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; OLEA N, 1990, ENDOCRINOLOGY, V126, P1457, DOI 10.1210/endo-126-3-1457; Olumi AF, 1999, CANCER RES, V59, P5002; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pinkas J, 2006, BIOCHEM PHARMACOL, V72, P523, DOI 10.1016/j.bcp.2006.03.004; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricke WA, 2006, INT J CANCER, V118, P2123, DOI 10.1002/ijc.21614; Roy AK, 1999, VITAM HORM, V55, P309; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Schmitt B, 2001, UROLOGY, V57, P727, DOI 10.1016/S0090-4295(00)01086-4; SHIMAZAKI JUN, 1965, GUNMA J MED SCI, V14, P313; Soto AM, 1995, ONCOL RES, V7, P545; Szmulewitz R, 2009, EUR UROL, V56, P97, DOI 10.1016/j.eururo.2009.02.022; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283; Thalmann GN, 2000, PROSTATE, V44, P91; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van Leenders GJLH, 2003, CRIT REV ONCOL HEMAT, V46, pS3, DOI 10.1016/S1040-8428(03)00059-3; van Leenders GJLH, 2001, J PATHOL, V195, P563, DOI 10.1002/path.993; van Weerden WM, 2000, PROSTATE, V43, P263; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang XD, 2006, DEV BIOL, V290, P66, DOI 10.1016/j.ydbio.2005.11.009; Wang YZ, 2001, CANCER RES, V61, P6064; Webber MM, 1999, CARCINOGENESIS, V20, P1185, DOI 10.1093/carcin/20.7.1185; Wu CT, 2007, P NATL ACAD SCI USA, V104, P12679, DOI 10.1073/pnas.0704940104; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Zhou JR, 2004, INT J CANCER, V110, P800, DOI 10.1002/ijc.20206	104	103	107	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3593	3604		10.1038/onc.2010.121	http://dx.doi.org/10.1038/onc.2010.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440270				2022-12-28	WOS:000279108600001
J	Redmond, KL; Crawford, NT; Farmer, H; D'Costa, ZC; O'Brien, GJ; Buckley, NE; Kennedy, RD; Johnston, PG; Harkin, DP; Mullan, PB				Redmond, K. L.; Crawford, N. T.; Farmer, H.; D'Costa, Z. C.; O'Brien, G. J.; Buckley, N. E.; Kennedy, R. D.; Johnston, P. G.; Harkin, D. P.; Mullan, P. B.			T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells	ONCOGENE			English	Article						TBX2; NDRG1; EGR1; breast cancer	P53-DEPENDENT APOPTOSIS; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; GENE; TBX2; P53; SENESCENCE; EXPRESSION; GROWTH; BRCA1	T-box 2 (TBX2) is a transcription factor involved in mammary development and is known to be overexpressed in a subset of aggressive breast cancers. TBX2 has previously been shown to repress growth control genes such as p14(ARF) and p21(WAF1/cip1). In this study we show that TBX2 drives proliferation in breast cancer cells and this is abrogated after TBX2 small interfering RNA (siRNA) knockdown or after the expression of a dominant-negative TBX2 protein. Using microarray analysis we identified a large cohort of novel TBX2-repressed target genes including the breast tumour suppressor NDRG1 (N-myc downregulated gene 1). We show that TBX2 targets NDRG1 through a previously undescribed mechanism involving the recruitment of early growth response 1 (EGR1). We show EGR1 is required for the ability of TBX2 to repress NDRG1 and drive cell proliferation. We show that TBX2 interacts with EGR1 and that TBX2 requires EGR1 to target the NDRG1 proximal promoter. Abrogation of either TBX2 or EGR1 expression is accompanied by the upregulation of cell senescence and apoptotic markers. NDRG1 can recapitulate these effects when transfected into TBX2-expressing cells. Together, these data identify a novel mechanism for TBX2-driven oncogenesis and highlight the importance of NDRG1 as a growth control gene in breast tissue. Oncogene (2010) 29, 3252-3262; doi: 10.1038/onc.2010.84; published online 29 March 2010	[Redmond, K. L.; Crawford, N. T.; Farmer, H.; D'Costa, Z. C.; Buckley, N. E.; Johnston, P. G.; Harkin, D. P.; Mullan, P. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [O'Brien, G. J.; Kennedy, R. D.; Harkin, D. P.] Almac Diagnost, Craigavon, North Ireland	Queens University Belfast	Mullan, PB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, CCRCB Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	p.mullan@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513	Department of Employment and Learning Northern Ireland; Breast Cancer Campaign; Action Cancer; OSF; Cancer Research UK; Research and Development Northern Ireland	Department of Employment and Learning Northern Ireland; Breast Cancer Campaign; Action Cancer; OSF; Cancer Research UK(Cancer Research UK); Research and Development Northern Ireland	Special thanks to Dr James Murray (CCRCB, QUB) for gift of sheep anti-human NDRG1 antibody, Professor Carlos Caldas (University of Cambridge) for TBX2-expressing breast cancer cell lines and Professor Max Costa (University of New York) for NDRG1 promoter luciferase constructs. We also thank Professor Neil Perkins (University of Bristol) for reading this manuscript. This study was supported by the Department of Employment and Learning Northern Ireland (KLR), Breast Cancer Campaign (NTC, PBM), Action Cancer (HF, PBM), OSF (ZCD'C), Cancer Research UK (GJO'B, PGJ, DPH) and Research and Development Northern Ireland (NEB).	Boogerd KJ, 2008, CARDIOVASC RES, V78, P485, DOI 10.1093/cvr/cvn049; Buckley NE, 2007, MOL CANCER RES, V5, P261, DOI 10.1158/1541-7786.MCR-06-0250; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Ismail A, 2009, CANCER LETT, V278, P230, DOI 10.1016/j.canlet.2009.01.006; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Le NTV, 2004, BLOOD, V104, P2967, DOI 10.1182/blood-2004-05-1866; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Lu Shaolei, 2008, Endocrinology, V149, P4809, DOI 10.1210/en.2008-0035; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Ronski K, 2005, CANCER-AM CANCER SOC, V104, P925, DOI 10.1002/cncr.21262; Roylance R, 1999, CANCER RES, V59, P1433; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sinclair CS, 2002, CANCER RES, V62, P3587; Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029; Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461; Zhang J, 2008, GENE, V417, P5, DOI 10.1016/j.gene.2008.03.002; Zhang P, 2007, CANCER RES, V67, P9125, DOI 10.1158/0008-5472.CAN-07-1525	30	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3252	3262		10.1038/onc.2010.84	http://dx.doi.org/10.1038/onc.2010.84			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20348948				2022-12-28	WOS:000278321100008
J	Liu, Q; Basu, S; Qiu, Y; Tang, F; Dong, F				Liu, Q.; Basu, S.; Qiu, Y.; Tang, F.; Dong, F.			A role of Miz-1 in Gfi-1-mediated transcriptional repression of CDKN1A	ONCOGENE			English	Article						Gfi-1; Miz-1; CKD inhibitors; proliferation	ZINC-FINGER PROTEIN; GROWTH-FACTOR INDEPENDENCE-1; HEMATOPOIETIC STEM-CELLS; TGF-BETA RECEPTOR; C-MYC; T-CELLS; FACTOR GFI1; DIFFERENTIATION; EXPRESSION; SMAD	Zinc-finger (ZF) transcriptional repressor growth factor independence 1 (Gfi-1) has an important role in hematopoiesis and inner ear development, and also functions as an oncoprotein that cooperates with c-Myc in lymphomagenesis. Gfi-1 represses transcription by directly binding to conserved sequences in the promoters of its target genes. CDKN1A encoding p21(Cip1) has been identified as a Gfi-1 target gene and has been shown to contain Gfi-1 binding sites in the upstream promoter region. We show here that Gfi-1 represses CDKN1A in a manner that is independent of its DNA binding activity. Gfi-1 interacts with POZ-ZF transcription factor Miz-1, originally shown to be a c-Myc-interacting partner, and through Miz-1 binds to the CDKN1A core promoter. Interestingly, Gfi-1 and c-Myc, through Miz-1, form a ternary complex on the CDKN1A promoter, and function in collaboration to repress CDKN1A. Gfi-1 knockdown results in enhanced levels of p21(Cip1) and attenuated cell proliferation. Notably, similar to c-Myc, the expression of Gfi-1 is downregulated by transforming growth factor-beta (TGF beta) and the level of Gfi-1 influences the response of cells to the cytostatic effect of TGF beta(.) Our data reveal an important mechanism by which Gfi-1 regulates cell proliferation and may also have implications for understanding the role of Gfi-1 in lymphomagenesis. Oncogene (2010) 29, 2843-2852; doi: 10.1038/onc.2010.48; published online 1 March 2010	[Liu, Q.; Basu, S.; Qiu, Y.; Tang, F.; Dong, F.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Dong, F (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St,MS 601, Toledo, OH 43606 USA.	fdong@utnet.utoledo.edu			National Institutes of Health [R15HL091511]; American Cancer Society [RSG-08-307-01]; Ohio Cancer Research Associates Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL091511] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Ohio Cancer Research Associates Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Drs M Eilers, PN Tsichlis, XF Wang and Jinfang Zhu for providing the reagents used in this study, and Dr A Quinn and S Rasche for help with [3H] thymidine incorporation assays. This work was supported in part by grants R15HL091511 (FD) from the National Institutes of Health, RSG-08-307-01 (FD) from The American Cancer Society and a grant (FD) from Ohio Cancer Research Associates Inc.	Basu S, 2009, P NATL ACAD SCI USA, V106, P1433, DOI 10.1073/pnas.0804863106; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Dwivedi PP, 2005, ENDOCR-RELAT CANCER, V12, P351, DOI 10.1677/erc.1.00920; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Horman SR, 2009, BLOOD, V113, P5466, DOI 10.1182/blood-2008-09-179747; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; Letterio JJ, 2005, ONCOGENE, V24, P5701, DOI 10.1038/sj.onc.1208922; Lin HK, 2005, ONCOGENE, V24, P5693, DOI 10.1038/sj.onc.1208923; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; Moroy T, 2005, INT J BIOCHEM CELL B, V37, P541, DOI 10.1016/j.biocel.2004.08.011; Pargmann D, 2007, EUR J IMMUNOL, V37, P3551, DOI 10.1002/eji.200737130; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Wallis D, 2003, DEVELOPMENT, V130, P221, DOI 10.1242/dev.00190; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5; Zhu JF, 2006, P NATL ACAD SCI USA, V103, P18214, DOI 10.1073/pnas.0608981103; Zhu JF, 2009, J EXP MED, V206, P329, DOI 10.1084/jem.20081666; Zhuang DZ, 2006, J BIOL CHEM, V281, P10745, DOI 10.1074/jbc.M510924200; Zornig M, 1996, ONCOGENE, V12, P1789	45	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2843	2852		10.1038/onc.2010.48	http://dx.doi.org/10.1038/onc.2010.48			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190815	Green Accepted			2022-12-28	WOS:000277591900009
J	van Dieck, J; Brandt, T; Teufel, DP; Veprintsev, DB; Joerger, AC; Fersht, AR				van Dieck, J.; Brandt, T.; Teufel, D. P.; Veprintsev, D. B.; Joerger, A. C.; Fersht, A. R.			Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73	ONCOGENE			English	Article						S100; p63; p73; tumor suppressor; protein-protein interaction	SQUAMOUS-CELL CARCINOMA; CALCIUM-BINDING PROTEIN; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; KINASE-C; FAMILY; CANCER; EXPRESSION; GENE	S100 proteins modulate p53 activity by interacting with its tetramerization (p53TET, residues 325-355) and transactivation (residues 1-57) domains. In this study, we characterized biophysically the binding of S100A1, S100A2, S100A4, S100A6 and S100B to homologous domains of p63 and p73 in vitro by fluorescence anisotropy, analytical ultracentrifugation and analytical gel filtration. We found that S100A1, S100A2, S100A4, S100A6 and S100B proteins bound different p63 and p73 tetramerization domain variants and naturally occurring isoforms with varying affinities in a calcium-dependent manner. Additional interactions were observed with peptides derived from the p63 and p73 N-terminal transactivation domains. Importantly, S100 proteins bound p63 and p73 with different affinities in their different oligomeric states, similarly to the differential modes of binding to p53. On the basis of our data, we hypothesize that S100 proteins regulate the oligomerization state of all three p53 family members and their isoforms, with a potential physiological relevance in developmental and disease-related processes. The regulation of the p53 family by S100 is complicated and depends on the target preference of each individual S100 protein, the concentration of the proteins and calcium, as well as the splicing variation of p63 or p73. Our results outlining the complexity of the interaction should be considered when studying the functional effects of S100 proteins in their biological context. Oncogene (2010) 29, 2024-2035; doi: 10.1038/onc.2009.490; published online 8 February 2010	[van Dieck, J.; Brandt, T.; Teufel, D. P.; Veprintsev, D. B.; Joerger, A. C.; Fersht, A. R.] Univ Cambridge, MRC Ctr Prot Engn, Cambridge CB2 0QH, Cambs, England	MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, MRC Ctr Prot Engn, Hills Rd, Cambridge CB2 0QH, Cambs, England.	arf25@cam.ac.uk	Veprintsev, Dmitry B/H-2228-2012; Fersht, Alan R/B-2189-2008	Veprintsev, Dmitry B/0000-0002-3583-5409; Teufel, Daniel/0000-0002-6527-2117; Joerger, Andreas/0000-0002-1232-0138	Medical Research Council [MC_U105474168] Funding Source: Medline; MRC [MC_U105474168] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Boldrup L, 2009, J PATHOL, V218, P428, DOI 10.1002/path.2560; Brandt T, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-628; Buckiova D, 2009, J COMP NEUROL, V513, P469, DOI 10.1002/cne.21967; Burge S, 2009, P NATL ACAD SCI USA, V106, P3142, DOI 10.1073/pnas.0900383106; Chan WY, 2003, MICROSC RES TECHNIQ, V60, P600, DOI 10.1002/jemt.10302; Danilova N, 2008, MECH DEVELOP, V125, P919, DOI 10.1016/j.mod.2008.09.003; Dean B, 2006, AUST NZ J PSYCHIAT, V40, P217, DOI 10.1080/j.1440-1614.2006.01777.x; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dotto JE, 2006, J CUTAN PATHOL, V33, P413, DOI 10.1111/j.0303-6987.2006.00477.x; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Fernandez-Fernandez MR, 2008, PROTEIN SCI, V17, P1663, DOI 10.1110/ps.035527.108; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Finlan LE, 2007, CELL CYCLE, V6, P1062, DOI 10.4161/cc.6.9.4162; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Joerger AC, 2009, P NATL ACAD SCI USA, V106, P17705, DOI 10.1073/pnas.0905867106; Kirschner RD, 2008, NUCLEIC ACIDS RES, V36, P2969, DOI 10.1093/nar/gkn132; Langenbacher A, 2008, DEV DYNAM, V237, P3491, DOI 10.1002/dvdy.21704; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; Lauriola L, 2000, INT J CANCER, V89, P345, DOI 10.1002/1097-0215(20000720)89:4<345::AID-IJC5>3.0.CO;2-T; Lin J, 2004, J BIOL CHEM, V279, P34071, DOI 10.1074/jbc.M405419200; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; MacGregor IK, 2004, BIOPHYS CHEM, V108, P165, DOI 10.1016/j.bpc.2003.10.018; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Mueller A, 2005, J BIOL CHEM, V280, P29186, DOI 10.1074/jbc.M505000200; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Pruneri G, 2002, LAB INVEST, V82, P1327, DOI 10.1097/01.LAB.0000032373.99569.73; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Scoumanne A, 2005, CANCER BIOL THER, V4, P1178, DOI 10.4161/cbt.4.11.2254; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Slomnicki LP, 2009, INT J BIOCHEM CELL B, V41, P784, DOI 10.1016/j.biocel.2008.08.007; Teufel DP, 2007, P NATL ACAD SCI USA, V104, P7009, DOI 10.1073/pnas.0702010104; van Dieck J, 2009, J BIOL CHEM, V284, P13804, DOI 10.1074/jbc.M901351200; Vigliano FA, 2009, FISH SHELLFISH IMMUN, V26, P146, DOI 10.1016/j.fsi.2008.02.016; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Whitaker M, 2008, PHILOS T R SOC B, V363, P1401, DOI 10.1098/rstb.2008.2259; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297	56	40	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2024	2035		10.1038/onc.2009.490	http://dx.doi.org/10.1038/onc.2009.490			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20140014	Bronze			2022-12-28	WOS:000276402800002
J	Chuan, YC; Iglesias-Gato, D; Fernandez-Perez, L; Cedazo-Minguez, A; Pang, ST; Norstedt, G; Pousette, A; Flores-Morales, A				Chuan, Y-C; Iglesias-Gato, D.; Fernandez-Perez, L.; Cedazo-Minguez, A.; Pang, S-T; Norstedt, G.; Pousette, A.; Flores-Morales, A.			Ezrin mediates c-Myc actions in prostate cancer cell invasion	ONCOGENE			English	Article						ezrin; c-Myc; metastasis; cell invasion; androgen	ANDROGEN RECEPTOR; GENE-EXPRESSION; AKT ACTIVITY; IN-VIVO; PROGRESSION; ACTIVATION; SUPPRESSOR; PATHWAYS; GROWTH; PTEN	The forced overexpression of c-Myc in mouse prostate and in normal human prostate epithelial cells results in tumor transformation with an invasive phenotype. How c-Myc regulates cell invasion is poorly understood. In this study, we have investigated the interplay of c-Myc and androgens in the regulation of prostate cancer cell invasion. We found that c-Myc induces cell invasion and anchorage-independent growth by regulating ezrin protein expression in the presence of androgens. The activity of the ezrin promoter is controlled by androgens through c-Myc, which binds to a phylogenetically conserved E-Box located in the proximal promoter region. Besides, we also show that ezrin is an important regulator of c-Myc protein levels. These effects are achieved through androgen-induced changes in ezrin phosphorylation, which results in the regulation of downstream signals. These downstream signals involve the modulation of Akt and GSK-3 beta activity resulting in increased c-Myc protein synthesis and inhibition of its degradation. In summary, we have shown a key role for ezrin as a mediator of c-Myc-induced tumorigenesis in prostate cancer cells. Oncogene (2010) 29, 1531-1542; doi:10.1038/onc.2009.442; published online 14 December 2009	[Chuan, Y-C] Univ Copenhagen, Fac Hlth Sci, Ctr Prot Res, Novo Nordisk Fdn, DK-2200 Copenhagen, Denmark; [Chuan, Y-C; Iglesias-Gato, D.; Norstedt, G.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Fernandez-Perez, L.] Univ Las Palmas GC, Dept Clin Sci, Las Palmas Gran Canaria, Spain; [Fernandez-Perez, L.] Canary Inst Canc Res, Las Palmas Gran Canaria, Spain; [Cedazo-Minguez, A.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Pang, S-T] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Surg,Div Urol, Tao Yuan, Taiwan; [Pousette, A.] Karolinska Inst, Androl Ctr, Stockholm, Sweden	Novo Nordisk Foundation; University of Copenhagen; Karolinska Institutet; Universidad de Las Palmas de Gran Canaria; Karolinska Institutet; Chang Gung Memorial Hospital; Chang Gung University; Karolinska Institutet	Chuan, YC (corresponding author), Univ Copenhagen, Fac Hlth Sci, Ctr Prot Res, Novo Nordisk Fdn, DK-2200 Copenhagen, Denmark.	yin.choy.chuan@cpr.ku.dk	Fernandez-Perez, Leandro/H-1493-2015; Cedazo-Minguez, Angel/C-6707-2012; Iglesias-Gato, Diego/R-1794-2016	Fernandez-Perez, Leandro/0000-0001-7802-465X; Cedazo-Minguez, Angel/0000-0003-4626-4864; Iglesias-Gato, Diego/0000-0002-8982-9936; Norstedt, Gunnar/0000-0002-7759-3241	Novo Nordisk Foundation Center for Protein Research; Karolinska Institutet, Cancerfonden [45576-B01-01XAB]; Swedish Research Council [VR- 529-2002-6766]; Robert Lundberg Memorial Foundation [2007Lund0045]	Novo Nordisk Foundation Center for Protein Research; Karolinska Institutet, Cancerfonden(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Robert Lundberg Memorial Foundation	We thank Maria Henriksson for providing the c-Myc expression plasmid. The work carried out in this study was in part supported by the Novo Nordisk Foundation Center for Protein Research, Karolinska Institutet, Cancerfonden (45576-B01-01XAB), Swedish Research Council (VR- 529-2002-6766) and the Robert Lundberg Memorial Foundation (2007Lund0045).	Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bonaccorsi L, 2000, ENDOCRINOLOGY, V141, P3172, DOI 10.1210/en.141.9.3172; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; D'Angelo R, 2007, MOL BIOL CELL, V18, P4780, DOI 10.1091/mbc.E06-12-1144; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; Hellerstedt BA, 2003, UROL ONCOL-SEMIN ORI, V21, P272, DOI 10.1016/S1078-1439(03)00046-2; Jenkins RB, 1997, CANCER RES, V57, P524; JOSHUA AM, 2007, BIOCH BIOPHYS ACTA; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Liu J, 2006, CURR TOP MICROBIOL, V302, P1; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Pang ST, 2004, ONCOL REP, V11, P1187; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; Prag S, 2007, MOL BIOL CELL, V18, P2935, DOI 10.1091/mbc.E06-11-1031; SADI MV, 1991, CANCER, V67, P3065, DOI 10.1002/1097-0142(19910615)67:12<3065::AID-CNCR2820671222>3.0.CO;2-U; Sawyer TK, 2004, EXPERT OPIN INV DRUG, V13, P1; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Sun JS, 2007, PROSTATE, V67, P692, DOI 10.1002/pros.20543; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791; Valdman A, 2005, EUR UROL, V48, P852, DOI 10.1016/j.eururo.2005.03.013; Vidal OM, 2007, MOL ENDOCRINOL, V21, P293, DOI 10.1210/me.2006-0096; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Williams K, 2005, PROSTATE, V63, P369, DOI 10.1002/pros.20200; Wu YM, 2004, CANCER RES, V64, P7311, DOI 10.1158/0008-5472.CAN-04-0972	40	49	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1531	1542		10.1038/onc.2009.442	http://dx.doi.org/10.1038/onc.2009.442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20010876				2022-12-28	WOS:000275392400011
J	Wendt, MK; Smith, JA; Schiemann, WP				Wendt, M. K.; Smith, J. A.; Schiemann, W. P.			Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression	ONCOGENE			English	Article						EGFR; TGF-beta; FAK; breast cancer; metastasis; invasion	FOCAL ADHESION KINASE; FACTOR RECEPTOR INHIBITION; MAMMARY-CARCINOMA CELLS; TGF-BETA; GENE-EXPRESSION; TUMOR; METASTASIS; ACTIVATION; LINES; PROLIFERATION	Transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) have critical roles in regulating the metastasis of aggressive breast cancers, yet the impact of epithelial-mesenchymal transition (EMT) induced by TGF-beta in altering the response of breast cancer cells to EGF remains unknown. We show in this study that murine metastatic 4T1 breast cancer cells formed compact and dense spheroids when cultured under three-dimensional (3D) conditions, which was in sharp contrast to the branching phenotypes exhibited by their nonmetastatic counterparts. Using the human MCF10A series, we show that epithelial-type and nonmetastatic breast cancer cells were unable to invade to EGF, whereas their mesenchymal-type and metastatic counterparts readily invaded to EGF. Furthermore, EMT induced by TGF-beta was sufficient to manifest dense spheroid morphologies, a phenotype that increased primary tumor exit and invasion to EGF. Post-EMT invasion to EGF was dependent on increased activation of EGF receptor (EGFR) and p38 mitogen-activated protein kinase, all of which could be abrogated either by pharmacologic (PF-562271) or by genetic (shRNA) targeting of focal adhesion kinase (FAK). Mechanistically, EMT induced by TGF-beta increased cell-surface levels of EGFR and prevented its physical interaction with E-cadherin, leading instead to the formation of oncogenic signaling complexes with T beta R-II. Elevated EGFR expression was sufficient to transform normal mammary epithelial cells, and to progress their 3D morphology from that of hollow acini to branched structures characteristic of nonmetastatic breast cancer cells. Importantly, we show that TGF-beta stimulation of EMT enabled this EGFR-driven breast cancer model to abandon their inherent branching architecture and form large, undifferentiated masses that were hyperinvasive to EGF and showed increased pulmonary tumor growth upon tail vein injection. Finally, chemotherapeutic targeting of FAK was sufficient to revert the aggressive behaviors of these structures. Collectively, this investigation has identified a novel EMT-based approach to neutralize the oncogenic activities of EGF and TGF-beta in aggressive and invasive forms of breast cancer. Oncogene (2010) 29, 6485-6498; doi:10.1038/onc.2010.377; published online 30 August 2010	[Wendt, M. K.; Smith, J. A.; Schiemann, W. P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Schiemann, WP (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	william.schiemann@case.edu		Wendt, Mike/0000-0002-3665-7413	National Institutes of Health [CA129359]; Susan G Komen for the Cure Foundation [BCTR0706967]; Department of Defense [BC084561]; American Cancer Society [PF-09-120-01]; NATIONAL CANCER INSTITUTE [R01CA129359] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Pfizer for graciously providing the novel small molecule FAK inhibitor, PF-562271. We also thank Dr Alexander D Sorkin for providing the retroviral construct that encoded human EGFR. WPS was supported in part by grants from the National Institutes of Health (CA129359) and the Susan G Komen for the Cure Foundation (BCTR0706967) and the Department of Defense (BC084561), whereas MKW was supported by a fellowship from the American Cancer Society (PF-09-120-01).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Cicchini C, 2008, EXP CELL RES, V314, P143, DOI 10.1016/j.yexcr.2007.09.005; Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Ding Q, 2008, J BIOL CHEM, V283, P26839, DOI 10.1074/jbc.M803645200; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Joo CK, 2008, ONCOGENE, V27, P614, DOI 10.1038/sj.onc.1210649; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Thomson S, 2008, CLIN EXP METASTAS, V25, P843, DOI 10.1007/s10585-008-9200-4; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751; Wendt MK, 2009, J BIOL CHEM, V284, P34145, DOI 10.1074/jbc.M109.023614; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Wilding J, 1996, CANCER RES, V56, P5285; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	48	152	157	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6485	6498		10.1038/onc.2010.377	http://dx.doi.org/10.1038/onc.2010.377			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802523	Green Accepted			2022-12-28	WOS:000285138900008
J	Kralova, J; Sheely, JI; Liss, AS; Bose, HR				Kralova, J.; Sheely, J. I.; Liss, A. S.; Bose, H. R., Jr.			ERK and JNK activation is essential for oncogenic transformation by v-Rel	ONCOGENE			English	Article						v-Rel; NF-kappa B; transformation; oncogenesis; MAPK	NF-KAPPA-B; SIGNAL-REGULATED KINASE; CELL-CYCLE ARREST; C-REL; TRANSCRIPTION FACTOR; CANCER PROGRESSION; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; JUN KINASE	v-Rel is the acutely oncogenic member of the NF-kappa B family of transcription factors. Infection with retroviruses expressing v-Rel rapidly induces fatal lymphomas in birds and transforms primary lymphocytes and fibroblasts in vitro. We have previously shown that AP-1 transcriptional activity contributes to v-Rel-mediated transformation. Although v-Rel increases the expression of these factors, their activity may also be induced through phosphorylation by the mitogen-activated protein kinases (MAPKs). The expression of v-Rel results in the strong and sustained activation of the ERK and JNK MAPK pathways. This induction is critical for the v-Rel-transformed phenotype, as suppression of MAPK activity with chemical inhibitors or small interfering RNA severely impairs colony formation of v-Rel-transformed lymphoid cell lines. However, signaling must be maintained within an optimal range in these cells, as strong additional activation of either pathway beyond the levels induced by v-Rel through the expression of constitutively active MAPK proteins attenuates the transformed phenotype. MAPK signaling also has an important role in the initial transformation of primary spleen cells by v-Rel, although distinct requirements for MAPK activity at different stages of v-Rel-mediated transformation were identified. We also show that the ability of v-Rel to induce MAPK signaling more strongly than c-Rel contributes to its greater oncogenicity. Oncogene (2010) 29, 6267-6279; doi:10.1038/onc.2010.359; published online 30 August 2010	[Kralova, J.; Sheely, J. I.; Liss, A. S.; Bose, H. R., Jr.] Univ Texas Austin, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas Austin, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	National Cancer Institute [CA33192, CA098151]; Grant Agency of the Academy of Sciences of the Czech Republic [KAN200200651]; NATIONAL CANCER INSTITUTE [R01CA098151, R01CA033192] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grant Agency of the Academy of Sciences of the Czech Republic(Czech Academy of SciencesGrant Agency of the Czech Republic); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the laboratories of Natalie Ahn and Aming Lin for generously providing the CA MKK constructs. This work was supported by Public Health Service grants CA33192 and CA098151 from the National Cancer Institute. Jarmila Kralova was supported, in part, by grant KAN200200651 from the Grant Agency of the Academy of Sciences of the Czech Republic. We also thank R Hrdlickova and J Nehyba for their critical reading of the manuscript.	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bubendorf L, 1999, CANCER RES, V59, P803; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Chen NY, 2001, CANCER RES, V61, P3908; Corzo C, 2006, CANCER GENET CYTOGEN, V165, P151, DOI 10.1016/j.cancergencyto.2005.08.013; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Fujii M, 1996, ONCOGENE, V12, P2193; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gupta N, 2008, CANCER RES, V68, P808, DOI 10.1158/0008-5472.CAN-07-3169; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Houben R, 2008, J INVEST DERMATOL, V128, P2003, DOI 10.1038/jid.2008.30; Karakosta A, 2005, J EXP CLIN CANC RES, V24, P505; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 1996, ONCOGENE, V12, P2595; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liss AS, 2010, ONCOGENE, V29, P4925, DOI 10.1038/onc.2010.239; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Nelson DM, 1998, HUM GENE THER, V9, P2401, DOI 10.1089/hum.1998.9.16-2401; Nielsen C, 2007, CANCER RES, V67, P178, DOI 10.1158/0008-5472.CAN-06-2801; OKUNO H, 1991, ONCOGENE, V6, P1491; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Potapova O, 2002, CANCER RES, V62, P3257; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Skarpen E, 2008, FASEB J, V22, P466, DOI 10.1096/fj.07-8650com; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200; Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	50	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6267	6279		10.1038/onc.2010.359	http://dx.doi.org/10.1038/onc.2010.359			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802521	Green Accepted			2022-12-28	WOS:000284601700008
J	Hildebrandt, MAT; Gu, J; Lin, J; Ye, Y; Tan, W; Tamboli, P; Wood, CG; Wu, X				Hildebrandt, M. A. T.; Gu, J.; Lin, J.; Ye, Y.; Tan, W.; Tamboli, P.; Wood, C. G.; Wu, X.			Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; microRNA; methylation; metastasis; miR-9	HUMAN BREAST-CANCER; MICRORNAS; EXPRESSION; MIR-9	The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value <0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30-26.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsa-miR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence. Oncogene (2010) 29, 5724-5728; doi:10.1038/onc.2010.305; published online 2 August 2010	[Wu, X.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, Houston, TX 77030 USA; [Tamboli, P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Wood, C. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wu, X (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, 1155 Pressler Blvd, Houston, TX 77030 USA.	xwu@mdanderson.org	Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	National Institute of Health [R01 CA098897]; NATIONAL CANCER INSTITUTE [R01CA098897, K07CA134831] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported, in part, by National Institute of Health Grant R01 CA098897.	Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CELL CYCLE, V6, P1455; Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	15	177	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5724	5728		10.1038/onc.2010.305	http://dx.doi.org/10.1038/onc.2010.305			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676129				2022-12-28	WOS:000283262500008
J	Kang, X; Li, J; Zou, Y; Yi, J; Zhang, H; Cao, M; Yeh, ETH; Cheng, J				Kang, X.; Li, J.; Zou, Y.; Yi, J.; Zhang, H.; Cao, M.; Yeh, E. T. H.; Cheng, J.			PIASy stimulates HIF1 alpha SUMOylation and negatively regulates HIF1 alpha activity in response to hypoxia	ONCOGENE			English	Article						HIF1 alpha; hypoxia; PIASy; SUMOylation	TRANSCRIPTIONAL ACTIVITY; INDUCIBLE-FACTOR; TUMOR ANGIOGENESIS; CONJUGATING ENZYME; SUMO MODIFICATION; GENE-ACTIVATION; NUCLEAR-BODIES; HIF-ALPHA; PROTEIN; FAMILY	Hypoxia-inducible factor-1 alpha (HIF1 alpha) is a crucial regulator of the cellular response to hypoxia through its regulation of genes that control erythropoiesis, angiogenesis and anaerobic metabolism. We have previously shown that HIF1 alpha stability is regulated by SUMOylation under the hypoxic condition. However, how HIF1 alpha became SUMOylated during hypoxia is still unknown. In this study we identify PIASy as a specific E3 ligase for hypoxia-induced HIF1 alpha SUMOylation. Hypoxia promotes translocation of HIF1 alpha to the nucleus to facilitate its binding to PIASy, enabling the conjugation of HIF1 alpha by SUMO1. We further show that PIASy negatively regulates hypoxia-induced HIF1 alpha stability and transactivation. Knocking down PIASy increases the angiogenic activity of endothelial cells. Moreover, we show an inverse relationship between expression of PIASy and tumor angiogenesis in colon cancer. Thus, we define an important role of PIASy in hypoxia signaling through promoting HIF1 alpha SUMOylation. Oncogene (2010) 29, 5568-5578; doi:10.1038/onc.2010.297; published online 26 July 2010	[Cheng, J.] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Dept Mol & Cell Biol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200025, Peoples R China; [Kang, X.; Li, J.; Zou, Y.; Yi, J.; Cao, M.; Cheng, J.] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, E Inst Shanghai Municipal Educ Commiss, Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China; [Zhang, H.] Chinese Acad Med Sci, Canc Hosp, Dept Abdominal Surg, Beijing 100037, Peoples R China; [Zhang, H.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Yeh, E. T. H.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; [Yeh, E. T. H.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Texas System; UTMD Anderson Cancer Center; Saint Lukes Episcopal Hospital; Texas Heart Institute	Cheng, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, Dept Mol & Cell Biol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200025, Peoples R China.	jkcheng@shsmu.edu.cn			National Natural Science Foundation of China [30772462, 30800579]; National Key Scientific Program in China [2009CB918403]; State Key Laboratory of Oncogenes and Related Genes [91-08-06]; E-Institutes of Shanghai Municipal Education Commission [E09013]; NIH [CA239520]; NATIONAL CANCER INSTITUTE [R01CA139520] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Program in China; State Key Laboratory of Oncogenes and Related Genes; E-Institutes of Shanghai Municipal Education Commission; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Natural Science Foundation of China (30772462, to JC; 30800579 to XK), National Key Scientific Program in China (2009CB918403, to JC), State Key Laboratory of Oncogenes and Related Genes (91-08-06, to JC), E-Institutes of Shanghai Municipal Education Commission (E09013, to JC) and NIH grants (CA239520, to ETHY). ETHY is the McNair Scholar of the Texas Heart Institute, St Luke Episcopal Hospital.	Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Berta MA, 2007, BIOCHEM BIOPH RES CO, V360, P646, DOI 10.1016/j.bbrc.2007.06.103; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Branzei D, 2006, CELL, V127, P509, DOI 10.1016/j.cell.2006.08.050; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gruber M, 2006, CURR OPIN HEMATOL, V13, P169, DOI 10.1097/01.moh.0000219663.88409.35; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Matsuura T, 2005, EXP CELL RES, V308, P65, DOI 10.1016/j.yexcr.2005.04.022; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shao RJ, 2004, FEBS LETT, V569, P293, DOI 10.1016/j.febslet.2004.05.079; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; van Hagen M, 2010, NUCLEIC ACIDS RES, V38, P1922, DOI 10.1093/nar/gkp1157; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200	44	48	54	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5568	5578		10.1038/onc.2010.297	http://dx.doi.org/10.1038/onc.2010.297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20661221				2022-12-28	WOS:000282946900004
J	Chock, K; Allison, JMS; ElShamy, WM				Chock, K.; Allison, J. M. S.; ElShamy, W. M.			BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells	ONCOGENE			English	Article						BRCA1-IRIS; p53; p38MAPK; WIP1; UVC; etoposide; H2O2	ACTIVATED PROTEIN-KINASE; CYCLIN D1 EXPRESSION; BREAST-CANCER CELLS; NF-KAPPA-B; P38 MAPK; INDUCED PHOSPHORYLATION; FACTOR HUR; P53; WIP1; PHOSPHATASE	Cells' ability to evade cell death and to proliferate post geno-/cell-toxic stresses likely leads to formation of cancer. Activation of p38MAPK and p53 following these stresses helps protect cells against cancer development by initiating apoptosis. The duration of p38MAPK and p53 activation is regulated by the WIP1 phosphatase. BRCA1-IRIS triggers WIP1 expression in a p53-dependent and -independent manner. BRCA1-IRIS triggers the expression and cytoplasmic localization of the mRNA stabilization and translation inducer, HuR, that binds p53 and PPM1D mRNA. Hence, BRCA1-IRIS overexpression inactivates p38MAPK and/or p53 by upregulating WIP1 expression. BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses. This mechanism represents a new link between geno-/cell-toxic stress and aggressive breast cancer formation in p53 wild-type cells. Oncogene (2010) 29, 5274-5285; doi:10.1038/onc.2010.262; published online 12 July 2010	[ElShamy, W. M.] Univ Hawaii, Dept Pathol, John A Burns Sch Med, Honolulu, HI 96813 USA; Canc Ctr Hawaii, Honolulu, HI USA	University of Hawaii System; Cancer Research Center of Hawaii	ElShamy, WM (corresponding author), Univ Hawaii, Dept Pathol, John A Burns Sch Med, 651 Ilalo St,BSB-119A, Honolulu, HI 96813 USA.	welshamy@crch.hawaii.edu	ElShamy, Wael/AAF-2867-2019; ElShamy, Wael M./L-1090-2018		University of Hawaii; Hawaii Community Foundation	University of Hawaii; Hawaii Community Foundation	This research was supported in part by a start-up support from the University of Hawaii, and in part by a Grant from the Hawaii Community Foundation to WMeS. Wael M ElShamy is a Dr Lawrence and Mrs Bo Hing Chen Tsue American Cancer Society Scholar.	Al-Mohanna MA, 2007, NUCLEIC ACIDS RES, V35, P223, DOI 10.1093/nar/gkl1075; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FORNACE A, 1999, EMBO J, V18, P6845; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Hao L, 2007, INT J CANCER, V121, P39, DOI 10.1002/ijc.22597; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hasegawa H, 2009, BRIT J CANCER, V100, P1943, DOI 10.1038/sj.bjc.6605084; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickson JA, 2007, MOL REPROD DEV, V74, P821, DOI 10.1002/mrd.20688; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Im JS, 2008, J BIOL CHEM, V283, P25171, DOI 10.1074/jbc.M802851200; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; LI I, 2007, ACTA BIOCH BIOPH SIN, V39, P181; Licata LA, 2010, BREAST CANCER RES TR, V122, P55, DOI 10.1007/s10549-009-0517-8; Lim SJ, 2009, CANCER RES TREAT, V41, P87, DOI 10.4143/crt.2009.41.2.87; Lowe JM, 2010, J BIOL CHEM, V285, P5249, DOI 10.1074/jbc.M109.034579; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Marechal R, 2009, EXPERT REV ANTICANC, V9, P1439, DOI [10.1586/era.09.119, 10.1586/ERA.09.119]; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; Nakuci E, 2006, EXP CELL RES, V312, P3120, DOI 10.1016/j.yexcr.2006.06.021; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rodriguez-Bravo V, 2007, CANCER RES, V67, P11648, DOI 10.1158/0008-5472.CAN-07-3100; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sakuma T, 2008, J NEURO-ONCOL, V88, P143, DOI 10.1007/s11060-008-9559-8; She QB, 2001, CANCER RES, V61, P1604; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sturgill TW, 2008, BIOCHEM BIOPH RES CO, V371, P1, DOI 10.1016/j.bbrc.2008.04.002; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Sykes SM, 2009, J BIOL CHEM, V284, P20197, DOI 10.1074/jbc.M109.026096; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tong X, 2009, MOL CARCINOGEN, V48, P118, DOI 10.1002/mc.20460; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604	51	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5274	5285		10.1038/onc.2010.262	http://dx.doi.org/10.1038/onc.2010.262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622893				2022-12-28	WOS:000282089100006
J	Lucas, JT; Salimath, BP; Slomiany, MG; Rosenzweig, SA				Lucas, J. T., Jr.; Salimath, B. P.; Slomiany, M. G.; Rosenzweig, S. A.			Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent	ONCOGENE			English	Article						VEGF; invadopodia; cell migration; invasion; HEF1; NEDD9	SQUAMOUS-CELL CARCINOMA; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX DEGRADATION; BREAST-CANCER METASTASIS; TYROSINE PHOSPHORYLATION; NECK-CANCER; 11Q13 AMPLIFICATION; FACTOR RECEPTOR; HEAD; CORTACTIN	We previously reported a vascular endothelial growth factor (VEGF) autocrine loop in head and neck squamous cell carcinoma (HNSCC) cell lines, supporting a role for VEGF in HNSCC tumorigenesis. Using a phosphotyrosine proteomics approach, we screened the HNSCC cell line, squamous cell carcinoma-9 for effectors of VEGFR2 signaling. A cluster of proteins involved in cell migration and invasion, including the p130Cas paralog, human enhancer of filamentation 1 (HEF1/Cas-L/Nedd9) was identified. HEF1 silencing and overexpression studies revealed a role for VEGF in regulating cell migration, invasion and matrix metalloproteinase (MMP) expression in a HEF1-dependent manner. Moreover, cells plated on extracellular matrix-coated coverslips showed enhanced invadopodia formation in response to VEGF that was HEF1-dependent. Immunolocalization revealed that HEF1 colocalized to invadopodia with MT1-MMP. Analysis of HNSCC tissue microarrays for HEF1 immunoreactivity revealed a 6.5-fold increase in the odds of having a metastasis with a high HEF1 score compared with a low HEF1 score. These findings suggest that HEF1 may be prognostic for advanced stage HNSCC. They also show for the first time that HEF1 is required for VEGF-mediated HNSCC cell migration and invasion, consistent with HEF1's recent identification as a metastatic regulator. These results support a strategy targeting VEGF: VEGFR2 in HNSCC therapeutics. Oncogene (2010) 29, 4449-4459; doi: 10.1038/onc.2010.185; published online 24 May 2010	[Lucas, J. T., Jr.; Salimath, B. P.; Rosenzweig, S. A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Slomiany, M. G.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; [Rosenzweig, S. A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Rosenzweig, SA (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,MSC 505, Charleston, SC 29425 USA.	rosenzsa@musc.edu	Lucas, John T./K-5243-2013; Rosenzweig, Steven A/O-5062-2018	Lucas, John T./0000-0002-4139-4160; Rosenzweig, Steven/0000-0002-7022-6086	MUSC; PhRMA Foundation; Abney Foundation; Southeastern Pre-Doctoral Training in Clinical Research [T32]; NIH [CA78887, CA134845]; DOD [N6311601MD10004]; American Health Assistance Foundation; NATIONAL CANCER INSTITUTE [R01CA078887, R55CA078887, P30CA138313, R01CA134845] Funding Source: NIH RePORTER	MUSC; PhRMA Foundation; Abney Foundation; Southeastern Pre-Doctoral Training in Clinical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Health Assistance Foundation(BrightFocus Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Amanda M Brock for excellent technical assistance, Jennifer Bethard and Dr Kevin Schey (MUSC Mass Spectrometry Facility), the HCC Cell and Molecular Imaging Shared Resource, the HCC Tissue Biorepository and Dr Elizabeth Garrett-Mayer, Director (HCC Biostatistics Shared Resource) for aid and consultations. We are indebted to Drs Terry Day and M Boyd Gillespie for human specimens and Drs Silvio Gutkind and Alfredo Molinolo (NIDCR) for tissue microarrays. This work was supported by a MUSC Summer Health Research Fellowship, a Paul Calabresi Fellowship (PhRMA Foundation), an Abney Foundation Award, the Southeastern Pre-Doctoral Training in Clinical Research T32 (JTL), NIH grants CA78887 and CA134845 (SAR), DOD award (N6311601MD10004) to HCC and the American Health Assistance Foundation (SAR). Portions of this work were presented at the Annual Meeting of the AACR, 2008, San Diego, CA, USA and the Annual Meeting of the Endocrine Society, 2008, San Francisco, CA, USA.	Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Bachelder RE, 2003, CANCER RES, V63, P5230; Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088; Bigbee WL, 2007, CLIN CANCER RES, V13, P3107, DOI 10.1158/1078-0432.CCR-07-0746; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Canel M, 2006, CLIN CANCER RES, V12, P3272, DOI 10.1158/1078-0432.CCR-05-1583; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Cohen LA, 2005, CURR CANCER DRUG TAR, V5, P629, DOI 10.2174/156800905774932798; Cooney MM, 2005, CANCER CHEMOTH PHARM, V55, P295, DOI 10.1007/s00280-004-0871-5; Descamps FJ, 2002, LAB INVEST, V82, P1607, DOI 10.1097/01.LAB.0000038556.54069.73; Fashena SJ, 2002, J CELL SCI, V115, P99; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Kyzas PA, 2005, MODERN PATHOL, V18, P485, DOI 10.1038/modpathol.3800295; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Michi Y, 2000, ORAL ONCOL, V36, P81, DOI 10.1016/S1368-8375(99)00059-7; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Mon NN, 2006, ANN NY ACAD SCI, V1086, P199, DOI 10.1196/annals.1377.019; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Patel AM, 1996, ONCOGENE, V12, P31; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ries L, 2004, SEER CANC STAT REV 1; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sabe H, 2006, CURR OPIN CELL BIOL, V18, P558, DOI 10.1016/j.ceb.2006.08.002; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Singh MK, 2008, MOL BIOL CELL, V19, P1627, DOI 10.1091/mbc.E07-09-0953; Singh MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI 10.1007/s12013-007-0036-3; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sloan EK, 2002, CELL MOL LIFE SCI, V59, P1491, DOI 10.1007/s00018-002-8524-5; Slomiany MG, 2007, CANCER LETT, V248, P269, DOI 10.1016/j.canlet.2006.08.004; Slomiany MG, 2006, BIOCHEM BIOPH RES CO, V342, P851, DOI 10.1016/j.bbrc.2006.02.043; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011; WEAVER AM, 2008, CANC LETT, V265, P15912; Yu YH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003215	58	57	58	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4449	4459		10.1038/onc.2010.185	http://dx.doi.org/10.1038/onc.2010.185			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20498643	Green Accepted			2022-12-28	WOS:000280559100008
J	Basu, D; Nguyen, TTK; Montone, KT; Zhang, G; Wang, LP; Diehl, JA; Rustgi, AK; Lee, JT; Weinstein, GS; Herlyn, M				Basu, D.; Nguyen, T-T K.; Montone, K. T.; Zhang, G.; Wang, L-P; Diehl, J. A.; Rustgi, A. K.; Lee, J. T.; Weinstein, G. S.; Herlyn, M.			Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity	ONCOGENE			English	Article						epithelial to mesenchymal transition; squamous cell carcinoma; head and neck; chemotherapy resistance; tumor heterogeneity	CANCER CELLS; TRANSITION PHENOTYPE; ACQUIRED-RESISTANCE; EGFR INHIBITORS; COPY NUMBER; HEAD; SENSITIVITY; SNAIL; LINES; EXPRESSION	Variable drug responses among malignant cells within individual tumors may represent a barrier to their eradication using chemotherapy. Carcinoma cells expressing mesenchymal markers resist conventional and epidermal growth factor receptor (EGFR)-targeted chemotherapy. In this study, we evaluated whether mesenchymal-like sub-populations within human squamous cell carcinomas (SCCs) with predominantly epithelial features contribute to overall therapy resistance. We identified a mesenchymal-like subset expressing low E-cadherin (Ecad-lo) and high vimentin within the upper aerodigestive tract SCCs. This subset was both isolated from the cell lines and was identified in xenografts and primary clinical specimens. The Ecad-lo subset contained more low-turnover cells, correlating with resistance to the conventional chemotherapeutic paclitaxel in vitro. Epidermal growth factor induced less stimulation of the mitogen-activated protein kinase and phosphatidylinositol-3-kinase pathways in Ecad-lo cells, which was likely due to lower EGFR expression in this subset and correlated with in vivo resistance to the EGFR-targeted antibody, cetuximab. The Ecad-lo and high E-cadherin subsets were dynamic in phenotype, showing the capacity to repopulate each other from single-cell clones. Taken together, these results provide evidence for a low-turnover, mesenchymal-like sub-population in SCCs with diminished EGFR pathway function and intrinsic resistance to conventional and EGFR-targeted chemotherapies. Oncogene ( 2010) 29, 4170-4182; doi: 10.1038/onc.2010.170; published online 24 May 2010	[Basu, D.; Nguyen, T-T K.; Zhang, G.; Lee, J. T.; Herlyn, M.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Basu, D.; Weinstein, G. S.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Basu, D.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA; [Montone, K. T.; Wang, L-P] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Basu, D (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	devraj.basu@uphs.upenn.edu; herlynm@wistar.org	Zhang, Gao/D-3471-2017		NIH [NCI P01 CA098101]; Wistar Cancer Center [P30 CA10815]; American Cancer Society [IRG-78-002-30]; Philadelphia VA Medical Center; NATIONAL CANCER INSTITUTE [P01CA098101, P30CA010815, P30CA016520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wistar Cancer Center; American Cancer Society(American Cancer Society); Philadelphia VA Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Fredrick Keeny in the Wistar Institute Microscopy Core for assistance with digital image processing and Ademi Santiago-Walker, PhD for critical review of the paper. This work is supported by grants from the NIH (NCI P01 CA098101 to M Herlyn, A Rustgi and D Basu), the Wistar Cancer Center Core Grant (P30 CA10815), and the American Cancer Society (IRG-78-002-30 to D Basu). This work is also supported in part with resources and use of facilities at the Philadelphia VA Medical Center.	Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bianco R, 2005, ENDOCR-RELAT CANCER, V12, pS159, DOI 10.1677/erc.1.00999; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Cooper JB, 2009, HEAD NECK-J SCI SPEC, V31, P1086, DOI 10.1002/hed.21109; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Frederick BA, 2007, MOL CANCER THER, V6, P1683, DOI 10.1158/1535-7163.MCT-07-0138; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Ghoul A, 2009, CANCER RES, V69, P4260, DOI 10.1158/0008-5472.CAN-08-2837; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Haddad Y, 2009, CLIN CANCER RES, V15, P532, DOI 10.1158/1078-0432.CCR-08-1733; Herbst RS, 2005, J CLIN ONCOL, V23, P5578, DOI 10.1200/JCO.2005.07.120; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kawaguchi Y, 2007, BRIT J CANCER, V97, P494, DOI 10.1038/sj.bjc.6603885; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; MANCANIELLO D, 2008, CURR PROTOC CYTOM, P168; Mandal M, 2008, CANCER-AM CANCER SOC, V112, P2088, DOI 10.1002/cncr.23410; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Opitz OG, 1998, J BIOL CHEM, V273, P23912, DOI 10.1074/jbc.273.37.23912; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shrader M, 2007, MOL CANCER THER, V6, P277, DOI 10.1158/1535-7163.MCT-06-0513; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Strauss R, 2009, CANCER RES, V69, P5115, DOI 10.1158/0008-5472.CAN-09-0645; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Temam S, 2007, J CLIN ONCOL, V25, P2164, DOI 10.1200/JCO.2006.06.6605; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	47	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4170	4182		10.1038/onc.2010.170	http://dx.doi.org/10.1038/onc.2010.170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498638	Green Accepted			2022-12-28	WOS:000280151500005
J	Albero, MP; Vaquer, JM; Andreu, EJ; Villanueva, JJ; Franch, L; Ivorra, C; Poch, E; Agirre, X; Prosper, F; Perez-Roger, I				Albero, M. P.; Vaquer, J. M.; Andreu, E. J.; Villanueva, J. J.; Franch, L.; Ivorra, C.; Poch, E.; Agirre, X.; Prosper, F.; Perez-Roger, I.			Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells	ONCOGENE			English	Article						Bortezomib; CML; Bcr-Abl1; Imatinib resistance; Rb; apoptosis	PHILADELPHIA-CHROMOSOME; PROTEASOME INHIBITION; PROLIFERATION; LYMPHOMA; THERAPY; CYCLINS; DRUGS; DEATH; TRANSFORMATION; DEGRADATION	The use of c-abl-specific inhibitors such as Imatinib (IM) or Dasatinib has revolutionized the treatment of chronic myeloid leukemia (CML). However, a significant percentage of patients become resistant to IM. In this report, we have analyzed the possibility of using the proteasome as a molecular target in CML. Our results show that cells that express Bcr-Abl1 are more sensitive to the inhibition of the proteasome with Bortezomib (Btz) than control cells. This treatment reduces the proliferation of Bcr-Abl1-expressing cells, by inactivating NF-kappa B2 and decreasing the phosphorylation of Rb, eventually leading to an increase in caspase-dependent apoptosis. Furthermore, we show that Btz also induces cell-cycle arrest and apoptosis in cells expressing Bcr-Abl1 mutants that are resistant to IM. These results unravel a new molecular target of Btz, that is the Rb pathway, and open new possibilities in the treatment of CML especially for patients that become resistant to IM because of the presence of the T315I mutation. Oncogene (2010) 29, 3276-3286; doi: 10.1038/onc.2010.81; published online 22 March 2010	[Albero, M. P.; Vaquer, J. M.; Villanueva, J. J.; Franch, L.; Ivorra, C.; Poch, E.; Perez-Roger, I.] Cardenal Herrera CEU Univ, Dept Chem Biochem & Mol Biol, Moncada, Spain; [Andreu, E. J.; Agirre, X.; Prosper, F.] Univ Navarra, Fdn Appl Med Res, Univ Navarra Clin, Dept Hematol, E-31080 Pamplona, Spain; [Andreu, E. J.; Agirre, X.; Prosper, F.] Univ Navarra, Fdn Appl Med Res, Univ Navarra Clin, Area Cell Therapy, E-31080 Pamplona, Spain	Universidad CEU Cardenal Herrera; University of Navarra; University of Navarra	Perez-Roger, I (corresponding author), Cardenal Herrera CEU Univ, Dept Chem Biochem & Mol Biol, Edif Seminario,Av Seminario, Valencia 46113, Spain.	iperez@uch.ceu.es	Poch, Enric/C-5258-2013; Agirre, Xabier/ABE-4110-2020; Pérez Roger, Ignacio/K-1346-2014; Andreu, Enrique J/F-9813-2016; Prosper, Felipe/H-6859-2017	Pérez Roger, Ignacio/0000-0002-5564-6912; Andreu, Enrique J/0000-0001-5317-9989; Prosper, Felipe/0000-0001-6115-8790; Vaquer Santamaria, Juana Maria/0000-0002-4070-602X; Ivorra, Carmen/0000-0002-4699-6689	Instituto de Salud Carlos III [PI060285, PI070602, RD06/0020]; Conselleria de Sanitat; Cardenal Herrera-CEU University; 'UTE project CIMA'; Generalitat Valenciana; Ramon y Cajal; Ministerio de Ciencia e Innovacion	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Conselleria de Sanitat; Cardenal Herrera-CEU University; 'UTE project CIMA'; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Ramon y Cajal(Spanish Government); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank Dr Elisabeth Buchdunger at Novartis for providing us with Imatinib and Millenium Pharmaceuticals for the kind gift of Bortezomib. We also thank Dr BJ Druker for the mutant Bcr-Abl1-expressing BaF/3 cells. The study was supported by grants from the Instituto de Salud Carlos III PI060285, PI070602 and RD06/0020 to IPR, FP and EJA; from the Conselleria de Sanitat to IPR; from the Cardenal Herrera-CEU University (PRUCH and Santander-Copernicus) to IPR and 'UTE project CIMA'. Fellowships were from the Cardenal Herrera-CEU University to MPA and JJV and from the Generalitat Valenciana to JMV. EJA is supported by the program Ramon y Cajal from the Ministerio de Ciencia e Innovacion.	Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Andreu EJ, 2005, CANCER RES, V65, P3264, DOI 10.1158/0008-5472.CAN-04-1357; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Brignole C, 2006, J NATL CANCER I, V98, P1142, DOI 10.1093/jnci/djj309; Chauhan D, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S1; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Crawford LJ, 2009, EXP HEMATOL, V37, P357, DOI 10.1016/j.exphem.2008.11.004; Dai Y, 2004, BLOOD, V104, P509, DOI 10.1182/blood-2003-12-4121; Dasmahapatra G, 2006, LEUKEMIA RES, V30, P1263, DOI 10.1016/j.leukres.2006.01.005; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Galimberti S, 2008, LEUKEMIA RES, V32, P103, DOI 10.1016/j.leukres.2007.05.023; Gatto S, 2003, HAEMATOLOGICA, V88, P853; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Heaney NB, 2010, BLOOD, V115, P2241, DOI 10.1182/blood-2008-06-164582; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Joazeiro CAP, 2006, CANCER RES, V66, P7840, DOI 10.1158/0008-5472.CAN-06-2033; Kano Y, 2007, INVEST NEW DRUG, V25, P31, DOI 10.1007/s10637-006-9000-0; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Markovina S, 2008, MOL CANCER RES, V6, P1356, DOI 10.1158/1541-7786.MCR-08-0108; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Poch E, 2007, EXP CELL RES, V313, P719, DOI 10.1016/j.yexcr.2006.11.006; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Ramirez P, 2008, ONCOLOGIST, V13, P424, DOI 10.1634/theoncologist.2007-0170; Roman-Gomez J, 2007, HAEMATOLOGICA, V92, P153, DOI 10.3324/haematol.10782; Sartore-Bianchi A, 2007, CLIN CANCER RES, V13, P5942, DOI 10.1158/1078-0432.CCR-07-0536; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P45, DOI 10.3109/10428199309047862; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stapnes C, 2007, BRIT J HAEMATOL, V136, P814, DOI 10.1111/j.1365-2141.2007.06504.x; Strauss SJ, 2007, CANCER RES, V67, P2783, DOI 10.1158/0008-5472.CAN-06-3254; Van Phan Nguyen Thanh, 2005, Hum Cell, V18, P25; Vink J, 2006, BRIT J HAEMATOL, V134, P253, DOI 10.1111/j.1365-2141.2006.06170.x; Wei AH, 2008, LEUKEMIA LYMPHOMA, V49, P657, DOI 10.1080/10428190801942378; Yan H, 2007, LEUKEMIA, V21, P1488, DOI 10.1038/sj.leu.2404735; Yang DT, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-40; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737; Zhao XX, 2008, LEUKEMIA RES, V32, P275, DOI 10.1016/j.leukres.2007.05.024	42	17	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3276	3286		10.1038/onc.2010.81	http://dx.doi.org/10.1038/onc.2010.81			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305692	Green Published			2022-12-28	WOS:000278321100010
J	Cobbold, LC; Wilson, LA; Sawicka, K; King, HA; Kondrashov, AV; Spriggs, KA; Bushell, M; Willis, AE				Cobbold, L. C.; Wilson, L. A.; Sawicka, K.; King, H. A.; Kondrashov, A. V.; Spriggs, K. A.; Bushell, M.; Willis, A. E.			Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1	ONCOGENE			English	Article						translation; IRES; c-myc; protein synthesis	BINDING-PROTEIN; SITE FUNCTION; CELL-LINE; SEGMENT; TRANSLATION; INITIATION; IDENTIFICATION; MECHANISM; FAMILY; GROWTH	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment (IRES) and c-myc translation can therefore be initiated by internal ribosome entry as well as by cap-dependent mechanisms. It has been shown previously that in patients with multiple myeloma (MM) and in MM-derived cell lines there is a C to T mutation in the c-myc IRES that increases IRES activity and the corresponding synthesis of c-myc protein although it is not fully understood how this occurs. Our data show that two recently identified c-myc IRES transacting factors, Y-box binding protein 1 (YB-1) and polypyrimidine tract-binding protein 1 (PTB-1), bind more strongly (approximately 3.5- and 2-fold respectively) to the mutated version of the c-myc IRES and in vitro these proteins exert their effect synergistically to stimulate IRES activity of the mutant IRES 4.5-fold more than the wild-type version. Importantly, we show that there is a strong correlation between the expression of PTB-1, YB-1 and c-myc in MM-derived cell lines, suggesting that by reducing either PTB-1 or YB-1 protein levels it is possible to decrease c-myc expression and inhibit cell proliferation of MM-derived cell lines. Oncogene (2010) 29, 2884-2891; doi: 10.1038/onc.2010.31; published online 1 March 2010	[Cobbold, L. C.; Wilson, L. A.; Sawicka, K.; King, H. A.; Kondrashov, A. V.; Spriggs, K. A.; Bushell, M.; Willis, A. E.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England	University of Nottingham	Willis, AE (corresponding author), Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Univ Pk, Nottingham NG7 2RD, England.	anne.willis@nottingham.ac.uk		Kondrashov, Alexander/0000-0003-3428-5975; Sawicka, Kirsty/0000-0003-4195-6327; Willis, Anne/0000-0002-1470-8531	BBSRC; CRUK; Biotechnology and Biological Sciences Research Council [BB/F006926/1] Funding Source: researchfish; Medical Research Council [MC_UP_A600_1023] Funding Source: researchfish; BBSRC [BB/F006926/1] Funding Source: UKRI; MRC [MC_UP_A600_1023] Funding Source: UKRI	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CRUK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by grants from the BBSRC (LCC, HAK) and CRUK (LAW, AVK). Martin Bushell is a BBSRC David Philips fellow and Anne Willis holds a BBSRC professorial fellowship. We thank Professor Dalton (Moffitt Cancer Center, Florida, USA) for providing the cell line 8226/R5.	Bader AG, 2008, ONCOGENE, V27, P1179, DOI 10.1038/sj.onc.1210719; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chatterjee M, 2008, BLOOD, V111, P3714, DOI 10.1182/blood-2007-05-089151; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; DALTON WS, 1986, CANCER RES, V46, P5125; Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Ho P Joy, 2002, Rev Clin Exp Hematol, V6, P276, DOI 10.1046/j.1468-0734.2002.00081.x; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Mitchell SA, 2005, GENE DEV, V19, P1556, DOI 10.1101/gad.339105; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spriggs KA, 2009, MOL CELL BIOL, V29, P1565, DOI 10.1128/MCB.01283-08; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang C, 2008, J BIOL CHEM, V283, P20277, DOI 10.1074/jbc.M803682200	33	76	80	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2884	2891		10.1038/onc.2010.31	http://dx.doi.org/10.1038/onc.2010.31			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190818				2022-12-28	WOS:000277591900013
J	Cooper, SJ; Zou, H; LeGrand, SN; Marlow, LA; von Roemeling, CA; Radisky, DC; Wu, KJ; Hampel, N; Margulis, V; Tun, HW; Blobe, GC; Wood, CG; Copland, JA				Cooper, S. J.; Zou, H.; LeGrand, S. N.; Marlow, L. A.; von Roemeling, C. A.; Radisky, D. C.; Wu, K. J.; Hampel, N.; Margulis, V.; Tun, H. W.; Blobe, G. C.; Wood, C. G.; Copland, J. A.			Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma	ONCOGENE			English	Article						transcriptional regulation; GATA3; type III transforming growth factor-beta receptor; methylation; clear cell renal cell carcinoma	TGF-BETA; BETAGLYCAN EXPRESSION; CANCER; GENE; DIFFERENTIATION; INVASIVENESS; INHIBITION; MOTILITY	Loss of transforming growth factor-beta receptor III (TbRIII) correlates with loss of transforming growth factor-beta (TGF-beta) responsiveness and suggests a role for dysregulated TGF-beta signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TbRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TbRIII expression in human cells. We localize GATA3's binding to a 10-bp region of the TbRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TbRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TbRIII expression during ccRCC progression. Oncogene (2010) 29, 2905-2915; doi:10.1038/onc.2010.64; published online 8 March 2010	[Copland, J. A.] Mayo Clin, Dept Canc Biol, Mayo Clin Comprehens Canc Ctr, Coll Med, Jacksonville, FL 32224 USA; [Zou, H.] Mayo Clin Rochester, Dept Gastroenterol & Hepatol, Rochester, MN USA; [Wu, K. J.] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA; [Hampel, N.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; [Hampel, N.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; [Margulis, V.; Wood, C. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Tun, H. W.] Mayo Clin, Dept Hematol & Oncol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Duke University; Duke University; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic	Copland, JA (corresponding author), Mayo Clin, Dept Canc Biol, Mayo Clin Comprehens Canc Ctr, Coll Med, 4500 San Pablo Rd,Griffin Bld Rm 309, Jacksonville, FL 32224 USA.	copland.john@mayo.edu	Hempel, Nadine/F-1700-2014; Blobe, Gerard/AAJ-5945-2020; Radisky, Derek/B-6569-2018	Hempel, Nadine/0000-0002-5574-8783; Blobe, Gerard/0000-0002-4274-8901; Radisky, Derek/0000-0002-1962-8784; Marlow, Laura/0000-0002-4726-9889; von Roemeling, Christina/0000-0002-3754-5544	NIH [CA104505, 3RO1CA104505-05S1, CA106307]; Dr Ellis and Dona Brunton Rare Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA104505, R01CA106307] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr Ellis and Dona Brunton Rare Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Holly Hammond for her close editing of the manuscript. We also thank Tam How, Brandy Edenfield and Gregory Kennedy for their technical support. This work was funded in part by NIH Grant CA104505 (JAC and CGW), 3RO1CA104505-05S1 (JAC), Dr Ellis and Dona Brunton Rare Cancer Research Fund ( JAC), NIH Grant CA106307 (GCB) and a generous gift from Susan A Olde, OBE.	Chakravarthy D, 1999, INT J ONCOL, V15, P187; Cooper S, 2005, MOL CARCINOGEN, V43, P108, DOI 10.1002/mc.20101; Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267; Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Florio P, 2005, EUR J ENDOCRINOL, V152, P277, DOI 10.1530/eje.1.01849; Gordon KJ, 2008, CARCINOGENESIS, V29, P252, DOI 10.1093/carcin/bgm249; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Gulbinas A, 2006, J HISTOCHEM CYTOCHEM, V54, P161, DOI 10.1369/jhc.5A6626.2005; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hempel N, 2008, CARCINOGENESIS, V29, P905, DOI 10.1093/carcin/bgn049; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; LABASTIE MC, 1995, KIDNEY INT, V47, P1597, DOI 10.1038/ki.1995.223; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Margulis V, 2008, CLIN CANCER RES, V14, P5722, DOI 10.1158/1078-0432.CCR-08-0546; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCarthy TL, 2007, MOL ENDOCRINOL, V21, P2713, DOI 10.1210/me.2007-0210; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6; Sharifi N, 2007, PROSTATE, V67, P301, DOI 10.1002/pros.20526; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tavares TS, 2008, CANCER BIOL THER, V7, P1607, DOI 10.4161/cbt.7.10.6584; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; Wood CG, 2007, CLIN CANCER RES, V13, p697S, DOI 10.1158/1078-0432.CCR-06-2109; You HJ, 2009, CARCINOGENESIS, V30, P1281, DOI 10.1093/carcin/bgp071	35	37	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2905	2915		10.1038/onc.2010.64	http://dx.doi.org/10.1038/onc.2010.64			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208565	Green Accepted			2022-12-28	WOS:000277890400002
J	Nilsson, MB; Zage, PE; Zeng, L; Xu, L; Cascone, T; Wu, HK; Saigal, B; Zweidler-McKay, PA; Heymach, JV				Nilsson, M. B.; Zage, P. E.; Zeng, L.; Xu, L.; Cascone, T.; Wu, H. K.; Saigal, B.; Zweidler-McKay, P. A.; Heymach, J. V.			Multiple receptor tyrosine kinases regulate HIF-1 alpha and HIF-2 alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors	ONCOGENE			English	Article						neuroblastoma; sunitinib; sorafenib; HIF-1 alpha; HIF-2 alpha; RTKs	EPIDERMAL-GROWTH-FACTOR; BONE-MARROW-TRANSPLANTATION; TUMOR ANGIOGENESIS; PROSTATE-CANCER; FACTOR VEGF; EXPRESSION; CELLS; ACTIVATION; PATHWAY; ANTITUMOR	Novel treatment approaches are needed for children with advanced neuroblastoma. Studies with neuroblastoma cells have indicated the presence of a hypoxiadriven vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-1 autocrine loop modulating hypoxia-inducible factor-1alpha (HIF-1 alpha). Whether other receptor tyrosine kinases (RTKs) are capable of modulating HIF-1 alpha levels and whether RTKs can regulate HIF-2 alpha as well is largely unknown. We evaluated neuroblastoma cell lines for expression of various RTKs. Although cell lines were heterogeneous in the expression of VEGFR-1, -3, c-Kit and RET, most cells expressed PDGFR-alpha and -beta. Ligand-induced activation of multiple RTKs upregulated HIF-1 alpha levels, whereas activation of VEGFR-1 alone upregulated HIF-2 alpha. Multitargeted tyrosine kinase inhibitor sunitinib reduced hypoxia-induced rises in HIF-1 alpha and HIF-2 alpha through mechanisms involving effects on both mRNA levels and protein stability. In addition, sunitinib and sorafenib had direct effects on tumor cell viability in vitro. In a neuroblastoma xenograft model, tumor growth inhibition by sunitinib was associated with inhibition of angiogenesis and reduced HIF-1 alpha levels. These findings show that multiple RTKs may regulate the HIF axis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects not only by direct effects on endothelial cells, but also by blocking compensatory hypoxia- and ligand-induced changes in HIF-1 alpha and HIF-2 alpha. Oncogene (2010) 29, 2938-2949; doi:10.1038/onc.2010.60; published online 8 March 2010	[Nilsson, M. B.; Xu, L.; Cascone, T.; Wu, H. K.; Saigal, B.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Zage, P. E.; Zeng, L.; Zweidler-McKay, P. A.] Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Div Pediat, Houston, TX 77030 USA; [Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Heymach, JV (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	jheymach@mdanderson.org	Heymach, John/AAG-2361-2019	Heymach, John/0000-0001-9068-8942; Zweidler-McKay, Patrick/0000-0001-6621-523X	Damon Runyon Cancer Research Foundation [CI 24-04]; MD Anderson Cancer Center Physician Scientist; Lorrie Olivier Neuroblastoma Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Damon Runyon Cancer Research Foundation; MD Anderson Cancer Center Physician Scientist; Lorrie Olivier Neuroblastoma Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JVH is a Damon Runyon-Lilly Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI 24-04) and the MD Anderson Cancer Center Physician Scientist Award. This work was also supported in part by the Lorrie Olivier Neuroblastoma Research Fund.	Beaudry P, 2008, MOL CANCER THER, V7, P418, DOI 10.1158/1535-7163.MCT-07-0568; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bruns CJ, 2000, CANCER RES, V60, P2926; Canete A, 2000, J CLIN ONCOL, V18, P27, DOI 10.1200/JCO.2000.18.1.27; COHEN PS, 1994, BLOOD, V84, P3465; Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575; Donfrancesco A, 2004, ACTA PAEDIATR, V93, P6, DOI 10.0180/08035320310021165; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Fakhari M, 2002, J PEDIATR SURG, V37, P582, DOI 10.1053/jpsu.2002.31614; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hishiki T, 1998, CANCER RES, V58, P2158; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kane RC, 2009, ONCOLOGIST, V14, P95, DOI 10.1634/theoncologist.2008-0185; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Katzenstein HM, 2001, MED PEDIATR ONCOL, V36, P190, DOI 10.1002/1096-911X(20010101)36:1<190::AID-MPO1045>3.0.CO;2-I; Kaushal V, 2005, CLIN CANCER RES, V11, P584; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Komuro H, 2001, J CANCER RES CLIN, V127, P739; Kushner BH, 2000, MED PEDIATR ONCOL, V35, P468, DOI 10.1002/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P; Ladenstein R, 1998, J CLIN ONCOL, V16, P953, DOI 10.1200/JCO.1998.16.3.953; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lesslie DP, 2006, BRIT J CANCER, V94, P1710, DOI 10.1038/sj.bjc.6603143; Maris JM, 2008, PEDIATR BLOOD CANCER, V50, P581, DOI 10.1002/pbc.21232; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Peddinti R, 2007, CLIN CANCER RES, V13, P3499, DOI 10.1158/1078-0432.CCR-07-0237; Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Pickering LM, 2009, NAT CLIN PRACT ONCOL, V6, P6, DOI 10.1038/ncponc1283; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shusterman S, 2005, CANCER LETT, V228, P171, DOI 10.1016/j.canlet.2005.01.049; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Wey JS, 2005, CANCER-AM CANCER SOC, V104, P427, DOI 10.1002/cncr.21145; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Witte D, 2002, ANTICANCER RES, V22, P1463; Yamagata K, 2002, GLIA, V37, P1, DOI 10.1002/glia.10003; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang JC, 2004, CLIN CANCER RES, V10, p6367S, DOI 10.1158/1078-0432.CCR-050006; Yoshida D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0; Zhang LB, 2009, NEOPLASIA, V11, P426, DOI 10.1593/neo.09166; Zhong H, 2000, CANCER RES, V60, P1541	49	58	64	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2938	2949		10.1038/onc.2010.60	http://dx.doi.org/10.1038/onc.2010.60			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208561				2022-12-28	WOS:000277890400005
J	Alvarez-Moya, B; Lopez-Alcala, C; Drosten, M; Bachs, O; Agell, N				Alvarez-Moya, B.; Lopez-Alcala, C.; Drosten, M.; Bachs, O.; Agell, N.			K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function	ONCOGENE			English	Article						calmodulin; K-Ras; PKC; phosphorylation	C-MEDIATED PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; CELL-CYCLE; N-RAS; H-RAS; SIGNAL; GROWTH; RAF-1; GENE; PKC	Fine tuning of Ras activity is widely known as a mechanism to induce different cellular responses. Recently, we have shown that calmodulin (CaM) binds to K-Ras and that K-Ras phosphorylation inhibits its interaction with CaM. In this study we report that CaM inhibits K-Ras phosphorylation at Ser181 by protein kinase C (PKC) in vivo, and this is a mechanism to modulate K-Ras activity and signaling. Although CaM inhibition increased the activation of endogenous K-Ras, PKC inhibition decreased its activation status. We demonstrate that K-Ras phosphorylation decreased susceptibility to p120GAP activity. Accordingly, we also observed that non-phosphorylable K-Ras mutant exhibits a less sustained activation profile and do not efficiently activate AKT at low growth factor doses compared with wild-type K-Ras. It is interesting that the physiological responses induced by K-Ras are affected by this phosphorylation; when K-Ras cannot be phosphorylated it exhibits a remarkably decreased ability to stimulate proliferation in non-saturated serum conditions. Finally, we demonstrate that phosphorylation also regulates oncogenic K-Ras functions, as focus formation capacity, mobility and apoptosis resistance upon adriamycin treatment of cells expressing oncogenic K-Ras that cannot be phosphorylated are highly compromised. Moreover, at low serum concentration proliferation and survival is practically inhibited when cells cannot phosphorylate oncogenic K-Ras. In this condition, K-Ras phosphorylation is essential to ensure a proper activation of mitogen-activated protein kinase and PI3K/AKT pathways. In summary, our findings suggest that the interplay between CaM interaction and PKC phosphorylation is essential to regulate non-oncogenic and oncogenic K-Ras activity and functionality. Oncogene (2010) 29, 5911-5922; doi:10.1038/onc.2010.298; published online 30 August 2010	[Alvarez-Moya, B.; Lopez-Alcala, C.; Bachs, O.; Agell, N.] Univ Barcelona, Dept Biol Cellular Immunol & Neurociencies, Inst Invest Biomed August Pi & Sunyer, Fac Med, E-08036 Barcelona, Spain; [Drosten, M.] CNIO, Mol Oncol Programme, Madrid, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Centro Nacional de Investigaciones Oncologicas (CNIO)	Agell, N (corresponding author), Univ Barcelona, Dept Biol Cellular Immunol & Neurociencies, Inst Invest Biomed August Pi & Sunyer, Fac Med, C Casanova 143, E-08036 Barcelona, Spain.	neusagell@ub.edu	Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074; Drosten, Matthias/0000-0002-3205-456X; Alvarez Moya, Blanca/0000-0003-2573-7909	Ministerio de Educacion y Ciencia (Spain) [SAF2007-60491]; Generalitat de Catalunya (Spain)	Ministerio de Educacion y Ciencia (Spain)(Spanish Government); Generalitat de Catalunya (Spain)(Generalitat de Catalunya)	We thank Dr M Barbacid (CNIO, Spain) for the generous gift of Rasless and K-Ras<SUP>-/-</SUP> MEFs. We are also indebt with Anna Bosch and Maria Calvo (Confocal microscopy facility, SCT-University of Barcelona) for their help of performing the cell mobility assays. This study was supported by grant SAF2007-60491 from the Ministerio de Educacion y Ciencia (Spain). Blanca Alvarez-Moya was recipient of a pre-doctoral fellowship from the Generalitat de Catalunya (Spain).	Agell N, 2006, CELL CYCLE, V5, P3, DOI 10.4161/cc.5.1.2270; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Ashery U, 2006, CELL MOL NEUROBIOL, V26, P471, DOI 10.1007/s10571-006-9059-3; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; BOS JL, 1989, CANCER RES, V49, P4682; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1996, CANCER SURV, V27, P87; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Liao JH, 2006, J BIOL CHEM, V281, P29730, DOI 10.1074/jbc.M600668200; Liou JS, 2004, J CELL PHYSIOL, V198, P277, DOI 10.1002/jcp.10409; Lopez-Alcala C, 2008, J BIOL CHEM, V283, P10621, DOI 10.1074/jbc.M706238200; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Moreto J, 2008, CELL SIGNAL, V20, P1092, DOI 10.1016/j.cellsig.2008.01.022; Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8; Plowman SJ, 2008, MOL CELL BIOL, V28, P4377, DOI 10.1128/MCB.00050-08; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rodriguez-Vilarrupla A, 2005, MOL CELL BIOL, V25, P7364, DOI 10.1128/MCB.25.16.7364-7374.2005; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHALOMFEUERSTEI.R, 2008, RES, V68, P6608; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VEIGL ML, 1982, FED PROC, V41, P2283; Villalonga P, 2002, J BIOL CHEM, V277, P37929, DOI 10.1074/jbc.M202245200; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Xia SH, 2009, CELL SIGNAL, V21, P502, DOI 10.1016/j.cellsig.2008.12.002; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	43	46	46	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5911	5922		10.1038/onc.2010.298	http://dx.doi.org/10.1038/onc.2010.298			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20802526				2022-12-28	WOS:000283843400005
J	Antico-Arciuch, VG; Dima, M; Liao, XH; Refetoff, S; Di Cristofano, A				Antico-Arciuch, V. G.; Dima, M.; Liao, X-H; Refetoff, S.; Di Cristofano, A.			Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females	ONCOGENE			English	Article						thyroid cancer; Pten; estrogen	GENETIC ALTERATIONS; CANCER CELLS; MOLECULAR-MECHANISMS; TARGETED EXPRESSION; PAPILLARY; PATHWAY; MICE; GROWTH; TUMORS; PROLIFERATION	It is well known that thyroid disease is more frequent in women than in men; however, the molecular basis for this gender-based difference is still poorly understood. The activation of phosphoinositide 3-kinase (PI3K), through different mechanisms including loss of the PTEN tumor suppressor, is being increasingly recognized as a major player in the development of thyroid neoplastic lesions. Loss of Pten in the mouse thyroid results in a significant increase in the thyrocyte proliferative index, which is more prominent in the female mice. In this study, we show that 52% of the Pten(-/-) female mice, but only 12% of the males, develop follicular adenomas by 1 year of age. In addition, 50% of female mutants, but only 35% of males older than 1 year of age develop invasive, and often metastatic, follicular carcinomas. Mutant females have a significantly shorter overall survival compared with male mutants. Hormonal manipulation experiments established a direct role of estrogens in controlling the increased thyrocyte proliferation index in mutant females. Further-more, while genetic ablation of one Cdkn1b allele accelerated the development of neoplastic lesions, it also abolished the gender differences in survival and reduced the difference in neoplastic lesion development rate, underlining a key role of p27 in mediating estrogen action in the thyroid follicular cells. These data, based on a clinically relevant model of thyroid follicular carcinoma, provide, to the best of our knowledge, for the first time in vivo evidence that circulating estrogens are directly responsible for the increased female susceptibility to thyroid disease, at least on activation of the PI3K pathway, and provide new insights into the gender-based differences characterizing thyroid neoplastic disorders. Oncogene (2010) 29, 5678-5686; doi:10.1038/onc.2010.308; published online 2 August 2010	[Di Cristofano, A.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Price Ctr Genet & Translat Med, Bronx, NY 10461 USA; [Liao, X-H; Refetoff, S.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Refetoff, S.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Refetoff, S.] Univ Chicago, Comm Genet, Chicago, IL 60637 USA	Yeshiva University; Albert Einstein College of Medicine; University of Chicago; University of Chicago; University of Chicago	Di Cristofano, A (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Price Ctr Genet & Translat Med, 1301 Morris Pk Ave,Room 302, Bronx, NY 10461 USA.	antonio.dicristofano@einstein.yu.edu	Di Cristofano, Antonio/B-4148-2016; Refetoff, Samuel/ABB-1263-2021; di cristofano, antonio/AAJ-3796-2020	Refetoff, Samuel/0000-0003-0164-8231; di cristofano, antonio/0000-0003-2537-3228	AECC; NIH [CA97097, CA128943, DK15070, DK20595]; NATIONAL CANCER INSTITUTE [R01CA128943, R01CA097097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020595, R01DK015070, P60DK020595, R37DK015070] Funding Source: NIH RePORTER	AECC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the Animal Housing and the Histotechnology and Comparative Pathology Facilities of Albert Einstein College of Medicine. This study was supported by the AECC Core Grant, and by NIH grants to ADC (CA97097 and CA128943) and SR (DK15070 and DK20595).	Chen GG, 2008, CURR CANCER DRUG TAR, V8, P367, DOI 10.2174/156800908785133150; Foster JS, 2003, J BIOL CHEM, V278, P41355, DOI 10.1074/jbc.M302830200; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Hou P, 2008, CANCER, V113, P2440, DOI 10.1002/cncr.23869; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Kumar A, 2010, INT J ONCOL, V36, P1067, DOI 10.3892/ijo_00000588; Lacroix L, 2001, THYROID, V11, P1017, DOI 10.1089/105072501753271699; Libutti SK, 2005, CANCER J, V11, P104, DOI 10.1097/00130404-200503000-00003; Lu CX, 2010, ENDOCRINOLOGY, V151, P1929, DOI 10.1210/en.2009-1017; Manole D, 2001, J CLIN ENDOCR METAB, V86, P1072, DOI 10.1210/jc.86.3.1072; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; Rajoria S, 2010, THYROID, V20, P33, DOI 10.1089/thy.2009.0296; Sodre AKMB, 2008, J CLIN ENDOCR METAB, V93, P4141, DOI 10.1210/jc.2007-0353; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Vasko VV, 2007, CURR OPIN ONCOL, V19, P11, DOI 10.1097/CCO.0b013e328011ab86; Vitagliano D, 2006, ONCOGENE, V25, P5467, DOI 10.1038/sj.onc.1209527; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Wang YG, 2007, J CLIN ENDOCR METAB, V92, P2387, DOI 10.1210/jc.2006-2019; Yeager N, 2008, CANCER RES, V68, P444, DOI 10.1158/0008-5472.CAN-07-3030; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524	24	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5678	5686		10.1038/onc.2010.308	http://dx.doi.org/10.1038/onc.2010.308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676139	Green Accepted			2022-12-28	WOS:000283262500004
J	Kreis, NN; Sanhaji, M; Kramer, A; Sommer, K; Rodel, F; Strebhardt, K; Yuan, J				Kreis, N. N.; Sanhaji, M.; Kraemer, A.; Sommer, K.; Roedel, F.; Strebhardt, K.; Yuan, J.			Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells	ONCOGENE			English	Article						targeting cyclin B1; p53 stabilization; HPV 16/18; p14ARF and Ser315 phosphorylation of p53	INHIBITS PROLIFERATION; E6; PHOSPHORYLATION; DEGRADATION; ACTIVATION; INCREASES; APOPTOSIS; PROTEIN; MDM2; ARF	Abrogation of functional p53 is responsible for malignant cell transformation and the maintenance of malignant state of human papillomavirus-infected cancer cells. Thus, restoration of p53 has been regarded as an important strategy for molecular intervention combating papillomavirus-associated malignancies. We show here that depleting cyclin B1 stabilizes and reactivates p53 in papillomavirus-infected cervical cancer cell lines HeLa and CaSki. HeLa cells depleted of cyclin B1 exhibit mitotic defects in spindle formation and chromosome alignment. Downregulation of cyclin B1 increases p14 alternative reading frame of p16, the positive regulator of p53, and decreases phosphorylation of Ser315 in p53. Whereas RO-3306, a selective inhibitor of cyclin-dependent kinase 1 (Cdk1), suppresses this phosphorylation at Ser315 of p53, ZM447439, targeting Aurora A/B kinases, shows no effect. Further analyses in HeLa cells and HCT116 p53(-/-) cells suggest that the Ser315 phosphorylation by Cdk1 regulates negatively the protein stability and the function of p53. Moreover, increased p53 in HeLa cells is functional by showing its increased downstream effectors p21, mouse double minute 2 and Bax. Restoration of p53 and silencing cyclin B1 render cervical carcinoma cells more susceptible to DNA damage agent camptothecin. Taken together, targeting cyclin B1 might be an attractive strategy for preventing and treating papillomavirus-associated cancer by reactivating p53 and by reducing the Cdk1 activity. Oncogene (2010) 29, 5591-5603; doi:10.1038/onc.2010.290; published online 26 July 2010	[Kreis, N. N.; Sanhaji, M.; Kraemer, A.; Strebhardt, K.; Yuan, J.] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; [Sommer, K.] Goethe Univ Frankfurt, Sch Med, Dept Traumatol & Reconstruct Surg, D-60590 Frankfurt, Germany; [Roedel, F.] Goethe Univ Frankfurt, Sch Med, Dept Radiotherapy & Oncol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Kreis, Nina-Naomi/AAF-5407-2019; Strebhardt, Klaus/E-8765-2011	Kreis, Nina-Naomi/0000-0003-4304-0160; Strebhardt, Klaus/0000-0003-2173-9763	Deutsche Krebshilfe [107594, 108553]	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work is supported by the Deutsche Krebshilfe (# 107594 and # 108553). We are grateful to Dr B Vogelstein, Ludwig Center at Johns Hopkins, Howard Hughes Medical Institute, Baltimore, for HCT116 p53(+ / +) and p53(- / -) cell lines, and Dr K Hoppe-Seyler, Deutsches Krebsforschungszentrum, Heidelberg, for CaSki cell line. We thank Ms Roth and Ms Zimmer for their excellent technical support.	Androic I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-391; Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; BUTZ K, 1995, ONCOGENE, V10, P927; Cho NH, 2006, CANCER LETT, V232, P170, DOI 10.1016/j.canlet.2005.02.026; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Dickson MA, 2009, CURR ONCOL, V16, P120; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kreis NN, 2009, CELL CYCLE, V8, P460, DOI 10.4161/cc.8.3.7651; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lu WG, 2001, ONCOGENE, V20, P3206, DOI 10.1038/sj.onc.1204412; Pathirana D, 2009, VACCINE, V27, P4551, DOI 10.1016/j.vaccine.2009.03.086; Pluquet O, 2005, MOL CELL BIOL, V25, P9392, DOI 10.1128/MCB.25.21.9392-9405.2005; Radhakrishnan SK, 2006, CELL CYCLE, V5, P519, DOI 10.4161/cc.5.5.2514; Rampias T, 2009, JNCI-J NATL CANCER I, V101, P412, DOI 10.1093/jnci/djp017; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhao M., 2006, Experimental Oncology, V28, P44	32	40	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5591	5603		10.1038/onc.2010.290	http://dx.doi.org/10.1038/onc.2010.290			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20661218				2022-12-28	WOS:000282946900006
J	Teissier, S; Pang, CL; Thierry, F				Teissier, S.; Pang, C. L.; Thierry, F.			The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells	ONCOGENE			English	Article						papillomavirus; transcription; HPV; E2F; cell cycle	MITOTIC PATHWAY; PROTEIN; CYCLE; IDENTIFICATION; ENHANCEOSOME; REPLICATION; EXPRESSION; HMG-I(Y); FAMILY; E6	High-risk papillomavirus type 18 (HPV18) is one of the less represented HPV types in low-grade lesions of the anogenital tract, whereas it occupies the second place in cervical cancer, where it can be found in 16% of the cases worldwide, after HPV16 present in 54% of them. These epidemiological data indicate that HPV18 infection is more prone to carcinogenic progression. The main oncogenic proteins, E6 and E7 of HPV18, are functionally comparable to the homologous proteins of the other high-risk viruses, including HPV16. In this work, we investigated the possibility that the higher oncogenic potential of HPV18 might be due to transcriptional regulation of the E6/E7 oncogenes. By comparing the E6/E7 promoter and enhancer sequences of the mucosal HPV genomes, we identified E2F binding sites specific for HPV18. The E2F family of transcription factors contains activators (E2F1-3) and repressors (E2F4-8) that regulate the transcription of S-phase and mitotic genes and thereby have a crucial role in cell-cycle progression. Surprisingly, we identified E2F5 as a direct activator of HPV18 E6/E7 transcription by sequential silencing of E2F members in HeLa cells. In addition, we could show that E2F5 positively regulates S-phase entry in HeLa cells and that this activation of the cell cycle by a member of the E2F repressor family is specific for HPV18-expressing cells. Diverting the function of E2F5 from a cell-cycle repressor into an activator might contribute to the higher oncogenic potential of HPV18 when compared with other high-risk HPV types. Oncogene (2010) 29, 5061-5070; doi:10.1038/onc.2010.246; published online 19 July 2010	[Teissier, S.; Thierry, F.] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Pang, C. L.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National University of Singapore	Thierry, F (corresponding author), ASTAR, Inst Med Biol, Immunos 06-05,8A Biomed Grove, Singapore 138648, Singapore.	francoise.thierry@imb.a-star.edu.sg						Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Bouallaga I, 2003, MOL CELL BIOL, V23, P2329, DOI 10.1128/MCB.23.7.2329-2340.2003; Caracciolo V, 2007, J CELL PHYSIOL, V212, P96, DOI 10.1002/jcp.21005; CASTELLSAGUE X, 2007, VACCINE, V25; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; Kuner R, 2007, J MOL MED, V85, P1253, DOI 10.1007/s00109-007-0230-1; Linhart C, 2005, CELL CYCLE, V4, P1788, DOI 10.4161/cc.4.12.2173; McLaughlin-Drubin ME, 2008, J VIROL, V82, P8695, DOI 10.1128/JVI.00579-08; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Reed SA, 2007, J CELL BIOCHEM, V101, P1394, DOI 10.1002/jcb.21256; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Teissier S, 2007, J VIROL, V81, P9368, DOI 10.1128/JVI.00427-07; Thierry F, 2004, CANCER RES, V64, P895, DOI 10.1158/0008-5472.CAN-03-2349; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thierry F, 2009, VIROLOGY, V384, P375, DOI 10.1016/j.virol.2008.11.014; VILLA LL, 1991, VIROLOGY, V181, P374; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	31	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5061	5070		10.1038/onc.2010.246	http://dx.doi.org/10.1038/onc.2010.246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20639900				2022-12-28	WOS:000281620100006
J	Ling, H; Sylvestre, JR; Jolicoeur, P				Ling, H.; Sylvestre, J-R; Jolicoeur, P.			Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors	ONCOGENE			English	Article						mammary tumors; stem cells; Notch1	HEMATOPOIETIC STEM-CELLS; NOTCH PROMOTES SURVIVAL; HUMAN BREAST-CANCER; SIGNALING PATHWAY; TRANSGENIC MICE; UP-REGULATION; C-MYC; D1; TRANSFORMATION; ONCOGENESIS	Members of the Notch family are involved in the development of breast cancer in animal models and in humans. In young transgenic mice, expressing intracellular activated Notch1 (N1(IC)) in mammary cells, we found that CD24(+) CD29(high) progenitor cells had enhanced survival, and were expanded through a cyclin D1-dependent pathway. This expansion positively correlated with the later cyclin D1-dependent formation of basal-like ductal tumors. This expanded population exhibited abnormal differentiation skewed toward the basal cells, showed signs of pre-malignancy (low PTEN/p53 and high c-myc) and contained stem cells with impaired self-renewal in vivo, and more numerous multipotent, ductal-restricted progenitors. Our data suggest that N1(IC) can favor transformation of progenitor cells early in life through a cyclin D1-dependent pathway. Oncogene (2010) 29, 4543-4554; doi: 10.1038/onc.2010.186; published online 21 June 2010	[Ling, H.; Sylvestre, J-R; Jolicoeur, P.] Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; [Jolicoeur, P.] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Jolicoeur, P.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	paul.jolicoeur@ircm.qc.ca			Canadian Institute of Heath Research (CIHR); Canada Research Chair	Canadian Institute of Heath Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by grant to PJ from the Canadian Institute of Heath Research (CIHR). PJ is a recipient of a Canada Research Chair and HL of a Postdoctoral Fellowship from CIHR Training grant in cancer. We are grateful to Annie Lavallee as well as to Eric Massicotte and Martine Dupuis for excellent assistance with tissue sections and flow cytometry, respectively, and to Dominic Filion for image analysis.	Ahmed KM, 2008, ONCOGENE, V27, P6738, DOI 10.1038/onc.2008.265; Asselin-Labat ML, 2006, J NATL CANCER I, V98, P1011, DOI 10.1093/jnci/djj267; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Brown JM, 1999, CANCER RES, V59, P1391; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; DEOME KB, 1959, CANCER RES, V19, P515; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hanna Z, 2009, J VIROL, V83, P9743, DOI 10.1128/JVI.00125-09; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200; Martinez-Rumayor A, 2008, AM J CARDIOL, V101, p3A, DOI 10.1016/j.amjcard.2007.11.012; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Michels KB, 2004, NEW ENGL J MED, V351, P1679, DOI 10.1056/NEJMe048229; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Roue G, 2008, ONCOGENE, V27, P4909, DOI 10.1038/onc.2008.126; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stahl M, 2006, CANCER RES, V66, P7562, DOI 10.1158/0008-5472.CAN-06-0974; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	42	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4543	4554		10.1038/onc.2010.186	http://dx.doi.org/10.1038/onc.2010.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20562911				2022-12-28	WOS:000280862300005
J	Toomey, EC; Schiffman, JD; Lessnick, SL				Toomey, E. C.; Schiffman, J. D.; Lessnick, S. L.			Recent advances in the molecular pathogenesis of Ewing's sarcoma	ONCOGENE			English	Review						Ewing's sarcoma; EWS/FLI; ETS; microsatellites	GROWTH-FACTOR-I; MESENCHYMAL PROGENITOR CELLS; COMPARATIVE GENOMIC HYBRIDIZATION; EWS/FLI-1 FUSION GENE; PRIMITIVE NEUROECTODERMAL TUMORS; EWS-ETS ONCOPROTEINS; EMBRYONIC STEM-CELLS; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; DNA-BINDING	Tumor development is a complex process resulting from interplay between mutations in oncogenes and tumor suppressors, host susceptibility factors, and cellular context. Great advances have been made by studying rare tumors with unique clinical, genetic, or molecular features. Ewing's sarcoma serves as an excellent paradigm for understanding tumorigenesis because it exhibits some very useful and important characteristics. For example, nearly all cases of Ewing's sarcoma contain the (11;22)(q24;q12) chromosomal translocation that encodes the EWS/FLI oncoprotein. Besides the t(11;22), however, many cases have otherwise simple karyotypes with no other demonstrable abnormalities. Furthermore, it seems that an underlying genetic susceptibility to Ewing's sarcoma, if it exists, must be rare. These two features suggest that EWS/FLI is the primary mutation that drives the development of this tumor. Finally, Ewing's sarcoma is an aggressive tumor that requires aggressive treatment. Thus, improved understanding of the pathogenesis of this tumor will not only be of academic interest, but may also lead to new therapeutic approaches for individuals afflicted with this disease. The purpose of this review is to highlight recent advances in understanding the molecular pathogenesis of Ewing's sarcoma, while considering the questions surrounding this disease that still remain and how this knowledge may be applied to developing new treatments for patients with this highly aggressive disease. Oncogene (2010) 29, 4504-4516; doi: 10.1038/onc.2010.205; published online 14 June 2010	[Toomey, E. C.; Schiffman, J. D.; Lessnick, S. L.] Huntsman Canc Inst, Ctr Childrens Canc Res, Salt Lake City, UT 84112 USA; [Toomey, E. C.; Schiffman, J. D.; Lessnick, S. L.] Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Schiffman, J. D.; Lessnick, S. L.] Univ Utah, Sch Med, Div Pediat Hematol Oncol, Salt Lake City, UT USA	Huntsman Cancer Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Huntsman Canc Inst, Ctr Childrens Canc Res, 2000 Circle Hope,Room 4242, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu		Wiles, Elizabeth/0000-0001-7269-7466	St Baldrick's Foundation; The Harriet H Samuelsson Foundation; National Cancer Institute [R01CA140394, R21CA138295]; American Cancer Society [RSG0618801MGO]; Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Terri Anna Perine Sarcoma Fund; Huntsman Cancer Institute; Huntsman Cancer Foundation; NIH [P30CA042014]; NATIONAL CANCER INSTITUTE [P30CA042014, R01CA140394, R21CA138295] Funding Source: NIH RePORTER	St Baldrick's Foundation; The Harriet H Samuelsson Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Terri Anna Perine Sarcoma Fund; Huntsman Cancer Institute; Huntsman Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize for the omission of many important topics and references due to space constraints. JDS acknowledges support from St Baldrick's Foundation and The Harriet H Samuelsson Foundation. SLL acknowledges support from the National Cancer Institute (R01CA140394 and R21CA138295), the American Cancer Society (RSG0618801MGO), Alex's Lemonade Stand Foundation, the Liddy Shriver Sarcoma Initiative, the Terri Anna Perine Sarcoma Fund, and the Huntsman Cancer Institute and Huntsman Cancer Foundation. We also acknowledge NIH support to the Huntsman Cancer Institute (P30CA042014).	AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Amiel A, 2003, CANCER GENET CYTOGEN, V140, P107, DOI 10.1016/S0165-4608(02)00659-3; Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Bachmaier R, 2009, ONCOGENE, V28, P1280, DOI 10.1038/onc.2008.484; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Benini S, 2001, CLIN CANCER RES, V7, P1790; BENJAMIN RS, 2007, CONN TISS ONC SOC 14; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Brisset S, 2001, CANCER GENET CYTOGEN, V130, P57, DOI 10.1016/S0165-4608(01)00454-X; Brownhill SC, 2007, BRIT J CANCER, V96, P1914, DOI 10.1038/sj.bjc.6603819; Burdach S, 2009, CELL CYCLE, V8, P1991, DOI 10.4161/cc.8.13.8929; Cavazzana A O, 1988, Prog Clin Biol Res, V271, P487; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; Codrington R, 2005, PLOS BIOL, V3, P1459, DOI 10.1371/journal.pbio.0030242; COMSTOCK KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P487, DOI 10.1006/abbi.1994.1266; DAHLIN DC, 1961, J BONE JOINT SURG AM, V43, P185, DOI 10.2106/00004623-196143020-00004; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; DICKMAN PS, 1982, LAB INVEST, V47, P375; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; Ferreira BI, 2008, ONCOGENE, V27, P2084, DOI 10.1038/sj.onc.1210845; Fuchs B, 2004, CLIN ORTHOP RELAT R, P64, DOI 10.1097/01.blo.0000141385.77071.8d; Fuchs B, 2004, CLIN CANCER RES, V10, P1344, DOI 10.1158/1078-0432.CCR-03-0038; GANGWAL K, 2010, GENES CANC, V2, P177; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Guillon N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004932; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; HAMILTON G, 1991, THYMUS, V18, P33; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Horowitz Marc E., 1997, P831; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081; JEON IS, 1995, ONCOGENE, V10, P1229; Joo J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007608; KADIN ME, 1971, CANCER-AM CANCER SOC, V27, P257, DOI 10.1002/1097-0142(197102)27:2<257::AID-CNCR2820270203>3.0.CO;2-8; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kinsey M, 2009, CANCER RES, V69, P9047, DOI 10.1158/0008-5472.CAN-09-1540; Klevernic IV, 2009, BIOCHEM J, V418, P625, DOI 10.1042/BJ20082097; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; KOVAR H, 1990, ONCOGENE, V5, P1067; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kovar H, 2006, CANCER RES, V66, P9786, DOI 10.1158/0008-5472.CAN-06-0205; Kurmasheva RT, 2009, CANCER RES, V69, P7662, DOI 10.1158/0008-5472.CAN-09-1693; Lee G, 2007, NAT BIOTECHNOL, V25, P1468, DOI 10.1038/nbt1365; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin PP, 2008, CANCER RES, V68, P8968, DOI 10.1158/0008-5472.CAN-08-0573; Linabery AM, 2008, CANCER-AM CANCER SOC, V113, P2575, DOI 10.1002/cncr.23866; LIPINSKI M, 1986, J CELL BIOCHEM, V31, P289, DOI 10.1002/jcb.240310406; LIPINSKI M, 1987, INT J CANCER, V40, P81, DOI 10.1002/ijc.2910400115; LIPINSKI M, 1987, CANCER RES, V47, P183; Luo W, 2009, ONCOGENE, V28, P4126, DOI 10.1038/onc.2009.262; Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078-0432.CCR-09-0816; MAO XH, 1994, J BIOL CHEM, V269, P18216; Maurici D, 1998, CANCER GENET CYTOGEN, V100, P106, DOI 10.1016/S0165-4608(97)00028-9; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Meyers P A, 2000, Curr Treat Options Oncol, V1, P247, DOI 10.1007/s11864-000-0036-7; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078-0432.CCR-07-5090; Ng TL, 2007, J MOL DIAGN, V9, P459, DOI 10.2353/jmoldx.2007.070009; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; OHNO T, 1993, CANCER RES, V53, P5859; Olmos D, 2010, LANCET ONCOL, V11, P129, DOI 10.1016/S1470-2045(09)70354-7; Olsen RJ, 2001, ONCOGENE, V20, P1756, DOI 10.1038/sj.onc.1204268; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2009, EXPERT REV ANTICANC, V9, P1025, DOI 10.1586/ERA.09.81; Roberts P, 2008, GENE CHROMOSOME CANC, V47, P207, DOI 10.1002/gcc.20523; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Savola S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-17; Schuck A, 2002, STRAHLENTHER ONKOL, V178, P701, DOI 10.1007/s00066-002-0992-x; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 1998, CANCER RES, V58, P4127; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Scotlandi K, 2009, J CLIN ONCOL, V27, P2209, DOI 10.1200/JCO.2008.19.2542; Selvarajah S, 2007, CANCER GENET CYTOGEN, V174, P35, DOI 10.1016/j.cancergencyto.2006.11.011; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shing DC, 2003, CANCER RES, V63, P4568; Shing DC, 2002, CYTOGENET GENOME RES, V97, P20, DOI 10.1159/000064063; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028; Tan AY, 2009, J MOL CELL BIOL, V1, P82, DOI 10.1093/jmcb/mjp025; Tarkkanen M, 1999, CANCER GENET CYTOGEN, V114, P35, DOI 10.1016/S0165-4608(99)00031-X; Teitell MA, 1999, LAB INVEST, V79, P1535; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; TOLCHER AW, 2007, J CLIN ONCOL S, P3002; Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792; Torchia EC, 2003, CANCER RES, V63, P3464; Torchia EC, 2007, MOL CELL BIOL, V27, P7918, DOI 10.1128/MCB.00099-07; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; TRICHE TJ, 1987, MAJOR PROBLEMS PATHO, P145; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; WANG CC, 1953, NEW ENGL J MED, V248, P571, DOI 10.1056/NEJM195304022481401; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zwerner JP, 2008, ONCOGENE, V27, P3282, DOI 10.1038/sj.onc.1210991	152	124	133	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4504	4516		10.1038/onc.2010.205	http://dx.doi.org/10.1038/onc.2010.205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20543858	Green Accepted			2022-12-28	WOS:000280862300002
J	Sidhu, SS; Nawroth, R; Retz, M; Lemjabbar-Alaoui, H; Dasari, V; Basbaum, C				Sidhu, S. S.; Nawroth, R.; Retz, M.; Lemjabbar-Alaoui, H.; Dasari, V.; Basbaum, C.			EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis	ONCOGENE			English	Article						CD147; EMMPRIN; beta-catenin; Wnt; lung cancer	MATRIX-METALLOPROTEINASE INDUCER; FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN; COLORECTAL-CANCER; GROWTH-FACTOR; STEM-CELLS; WNT; EXPRESSION; CD147; ACTIVATION	Advances in the field of tumor biology have identified that tumor cells co-opt developmental signaling pathways of embryonic stem cells and thus gain the ability to proliferate, differentiate and alter cell-cell interactions. One such pathway is the Wnt/beta-catenin signaling pathway. High levels of EMMPRIN expression have been shown to correlate with poor prognosis and metastasis in a broad range of tumors. Although a variety of functions are attributed to EMMPRIN in tumorigenesis, the specific mechanism(s) through which it can exert its effects have not been elucidated, until now. In this study, we identify EMMPRIN as a novel regulator of the canonical Wnt/beta-catenin signaling pathway in lung cancer. Increasing EMMPRIN expression levels in lung cancer epithelial cells upregulated the beta-catenin signaling pathway and silencing EMMPRIN inhibited beta-catenin signaling, cell migration, proliferation, anchorage-independent growth and tumor growth in a mouse tumor xenograft model. These results provide a compelling rationale for targeting EMMPRIN for anticancer therapies. Understanding the molecular mechanisms driving EMMPRIN-induced lung tumorigenesis will provide enormous benefits in developing new therapeutic treatments for this and other forms of cancer. Oncogene ( 2010) 29, 4145-4156; doi: 10.1038/onc.2010.166; published online 31 May 2010	[Sidhu, S. S.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA; [Sidhu, S. S.] Univ Calif San Francisco, Dept Med, Div Allergy Immunol, San Francisco, CA 94143 USA; [Sidhu, S. S.; Nawroth, R.; Retz, M.; Lemjabbar-Alaoui, H.; Dasari, V.; Basbaum, C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Sidhu, S. S.; Nawroth, R.; Retz, M.; Lemjabbar-Alaoui, H.; Dasari, V.; Basbaum, C.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Nawroth, R.; Retz, M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D-8000 Munich, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Technical University of Munich	Sidhu, SS (corresponding author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, HSE 1350,513 Parnassus Ave, San Francisco, CA 94143 USA.	ssidhu@ucsf.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	National Institutes of Health [PPG P01 HL024136]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the National Institutes of Health (PPG P01 HL024136). The authors would like to thank Anatol Sucher for technical support and Dr Zena Werb for critical reading of the paper. The authors also dedicate this paper to the memory of Dr Carol Basbaum (mentor and friend).	Als AB, 2007, CLIN CANCER RES, V13, P4407, DOI 10.1158/1078-0432.CCR-07-0109; Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9; Bartscherer K, 2008, EMBO REP, V9, P977, DOI 10.1038/embor.2008.167; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Betsuyaku T, 2003, AM J RESP CRIT CARE, V168, P222, DOI 10.1164/rccm.200301-103OC; BISWAS C, 1995, CANCER RES, V55, P434; Bonner AE, 2003, J MED GENET, V40, P408, DOI 10.1136/jmg.40.6.408; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Daniel VC, 2006, RESPIROLOGY, V11, P234, DOI 10.1111/j.1440-1843.2006.00838.x; Davidson B, 2003, CLIN EXP METASTAS, V20, P161, DOI 10.1023/A:1022696012668; Deora AA, 2005, P NATL ACAD SCI USA, V102, P16245, DOI 10.1073/pnas.0504419102; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023; Gagliardi M, 2008, TRAFFIC, V9, P1, DOI 10.1111/j.1600-0854.2007.00662.x; Guo HM, 1997, J BIOL CHEM, V272, P24; Huang ZQ, 2008, BIOCHEM BIOPH RES CO, V374, P517, DOI 10.1016/j.bbrc.2008.07.058; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Klein CA, 2002, NAT BIOTECHNOL, V20, P387, DOI 10.1038/nbt0402-387; Koornstra JJ, 2005, CANCER EPIDEM BIOMAR, V14, P1608, DOI 10.1158/1055-9965.EPI-05-0112; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar-Alaoui H, 2010, ONCOGENE, V29, P635, DOI 10.1038/onc.2009.365; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lowy AM, 2006, CANCER RES, V66, P4734, DOI 10.1158/0008-5472.CAN-05-4268; McEntee MF, 1999, CARCINOGENESIS, V20, P635, DOI 10.1093/carcin/20.4.635; Millimaggi D, 2007, NEOPLASIA, V9, P349, DOI 10.1593/neo.07133; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morrisey EE, 2003, AM J PATHOL, V162, P1393, DOI 10.1016/S0002-9440(10)64271-X; Nabeshima K, 2006, PATHOL INT, V56, P359, DOI 10.1111/j.1440-1827.2006.01972.x; Nawroth R, 2008, UROLOGE, V47, P1152, DOI 10.1007/s00120-008-1828-9; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Reimers N, 2004, CLIN CANCER RES, V10, P3422, DOI 10.1158/1078-0432.CCR-03-0610; Renno T, 2002, J IMMUNOL, V168, P4946, DOI 10.4049/jimmunol.168.10.4946; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Riethdorf S, 2006, INT J CANCER, V119, P1800, DOI 10.1002/ijc.22062; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070; Sienel W, 2008, MODERN PATHOL, V21, P1130, DOI 10.1038/modpathol.2008.102; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Sun JX, 2001, CANCER RES, V61, P2276; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tang Y, 2006, MOL CANCER RES, V4, P371, DOI 10.1158/1541-7786.MCR-06-0042; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Van Scoyk M, 2008, TRANSL RES, V151, P175, DOI 10.1016/j.trsl.2007.12.011; Wang WJ, 2008, CHEMOTHERAPY, V54, P291, DOI 10.1159/000151225; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Yang JM, 2006, J BIOL CHEM, V281, P9719, DOI 10.1074/jbc.M508421200; Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200; Yurchenko V, 2005, J BIOL CHEM, V280, P17013, DOI 10.1074/jbc.M412851200	63	51	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4145	4156		10.1038/onc.2010.166	http://dx.doi.org/10.1038/onc.2010.166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20514014				2022-12-28	WOS:000280151500003
J	Fotheringham, JA; Mazzucca, S; Raab-Traub, N				Fotheringham, J. A.; Mazzucca, S.; Raab-Traub, N.			Epstein-Barr virus latent membrane protein-2A-induced Delta Np63 alpha expression is associated with impaired epithelial-cell differentiation	ONCOGENE			English	Article						Epstein-Barr virus; nasopharyngeal carcinoma; differentiation; p63; latent membrane protein 2A	NASOPHARYNGEAL CARCINOMA; PROTEIN 2A; KERATINOCYTE DIFFERENTIATION; UBIQUITIN LIGASE; STEM-CELLS; PY MOTIFS; P63; LMP2A; TRANSCRIPTION; DEGRADATION	Epstein-Barr virus (EBV) is an oncogenic gamma-herpes virus associated with malignancies that develop in both lymphoid and epithelial cells including nasopharyngeal carcinoma (NPC). The EBV protein, latent membrane protein 2A (LMP2A), is expressed in NPC and can modulate epithelial proliferation, transformation and differentiation, and as such may promote malignancy. A key regulator of epithelial-cell differentiation is the transcription factor p63, a member of the p53 family. This study examines the potential contribution of p63 to LMP2A-mediated inhibition of epithelial-cell differentiation. Stable expression of LMP2A increased the protein level and stability of the Delta Np63 alpha isoform and in two epithelial cell lines, LMP2A interacted with Delta Np63 alpha under stable-and transient-expression systems. LMP2A and Delta Np63 alpha were localized to the cytoplasm and nuclear membrane and co-immunoprecipitated in the same fractions. Following induction of epithelial-cell differentiation by calcium, expression of differentiation markers was impaired in both Delta Np63 alpha- and LMP2A-expressing cells. Induction of p63 alpha, association of p63 alpha with LMP2A and impairment of differentiation required the PY and immunoreceptor tyrosine-based activation motif (ITAM) signaling motif of LMP2A. By associating with and being regulated by LMP2A, Delta Np63 alpha may function as a unique regulator of LMP2A effects on epithelial differentiation and contribute to EBV-associated epithelial cancers. Oncogene (2010) 29, 4287-4296; doi:10.1038/onc.2010.175; published online 24 May 2010	[Fotheringham, J. A.; Mazzucca, S.; Raab-Traub, N.] Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu	Ariel, Pablo/AGJ-4118-2022	Mazzucca, Stephanie/0000-0001-6908-0780	National Institutes of Health [CA19014, CA32979, CA103634]; NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979, R01CA103634] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors gratefully acknowledge Dr M Oren for providing the Delta Np63 alpha plasmid and Dr R Longnecker for providing the LMP2A PY mutant. Funding for this study was provided by the National Institutes of Health grants CA19014, CA32979 and CA103634.	Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; Bultema R, 2009, ONCOGENE, V28, P1471, DOI 10.1038/onc.2008.492; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Deyrieux AF, 2007, CYTOTECHNOLOGY, V54, P77, DOI 10.1007/s10616-007-9076-1; Fukuda M, 2007, J VIROL, V81, P9299, DOI 10.1128/JVI.00537-07; Guo C, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-23; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; Longnecker R, 2000, EXP CELL RES, V257, P332, DOI 10.1006/excr.2000.4900; Medawar A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003441; Melino G, 2006, CELL CYCLE, V5, P1735; Merchant M, 2001, Int Rev Immunol, V20, P805, DOI 10.3109/08830180109045591; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Ogawa E, 2008, J BIOL CHEM, V283, P34241, DOI 10.1074/jbc.M804101200; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; RAABTRAUB N, 1992, INFECT AGENT DIS, V1, P173; Rossi M, 2006, CELL CYCLE, V5, P1816, DOI 10.4161/cc.5.16.2861; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Testoni B, 2006, NUCLEIC ACIDS RES, V34, P928, DOI 10.1093/nar/gkj477; Truong AB, 2007, CELL CYCLE, V6, P295, DOI 10.4161/cc.6.3.3753; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wu GJ, 2003, CANCER RES, V63, P2351; Yip YL, 2008, INT J ONCOL, V33, P713, DOI 10.3892/ijo_00000057; Young L S, 1992, Semin Cancer Biol, V3, P273	35	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4287	4296		10.1038/onc.2010.175	http://dx.doi.org/10.1038/onc.2010.175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498633	Green Accepted, Green Submitted			2022-12-28	WOS:000280547900005
J	Haller, BK; Brave, A; Wallgard, E; Roswall, P; Sunkari, VG; Mattson, U; Hallengard, D; Catrina, SB; Hellstrom, M; Pietras, K				Haller, B. K.; Brave, A.; Wallgard, E.; Roswall, P.; Sunkari, V. G.; Mattson, U.; Hallengard, D.; Catrina, S-B; Hellstrom, M.; Pietras, K.			Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma	ONCOGENE			English	Article						angiogenesis; DNA vaccination; breast cancer; Delta-like ligand 4; endothelial tip cell	INHIBITS TUMOR-GROWTH; CANCER VACCINES; DLL4; ANGIOGENESIS; BLOCKADE; EXPRESSION; CHALLENGE; PROTECTS; TRIAL; COLON	The Notch ligand delta-like ligand 4 (DLL4) is an essential component expressed by endothelial tip cells during angiogenic sprouting. We have described a conceptually novel therapeutic strategy for targeting tumor angiogenesis and endothelial tip cells based on DNA vaccination against DLL4. Immunization with DLL4-encoding plasmid DNA by in vivo electroporation severely retarded the growth of orthotopically implanted mammary carcinomas in mice by induction of a nonproductive angiogenic response. Mechanistically, vaccination brought about a break in tolerance against the self-antigen, DLL4, as evidenced by the production of inhibitory and inherently therapeutic antibodies against mouse DLL4. Importantly, no evidence for a delayed wound healing response, or for toxicity associated with pharmacological blockade of DLL4 signaling, was noted in mice immunized with the DLL4 vaccine. We have thus developed a well-tolerated DNA vaccination strategy targeting the endothelial tip cells and the antigen DLL4 with proven therapeutic efficacy in mouse models of mammary carcinoma; a disease that has been reported to dramatically induce the expression of DLL4. Conceivably, induction of immunity toward principal mediators of pathological angiogenesis could provide protection against recurrent malignant disease in the adjuvant setting. Oncogene (2010) 29, 4276-4286; doi: 10.1038/onc.2010.176; published online 24 May 2010	[Wallgard, E.; Roswall, P.; Pietras, K.] Karolinska Inst, Div Vasc Biol, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; [Haller, B. K.; Brave, A.; Hallengard, D.] Swedish Inst Infect Dis Control, Dept Virol, Stockholm, Sweden; [Haller, B. K.; Brave, A.; Hallengard, D.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; [Sunkari, V. G.; Catrina, S-B] Karolinska Inst, Dept Mol Med & Surg, SE-17177 Stockholm, Sweden; [Mattson, U.; Hellstrom, M.] Bioinvent Int, Lund, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; Karolinska Institutet	Pietras, K (corresponding author), Karolinska Inst, Div Vasc Biol, Dept Med Biochem & Biophys, House A4,Level 4,Scheeles Vag 2, SE-17177 Stockholm, Sweden.	kristian.pietras@ki.se	Pietras, Kristian/ABG-2097-2021; Pietras, Kristian/ABE-8727-2020	Pietras, Kristian/0000-0001-6738-4705; Haller, Kristian/0000-0002-9060-0928; Catrina, Sergiu/0000-0002-6914-3902; Sunkari, Vivekananda/0000-0003-4599-5120; Hellstrom, Mats/0000-0002-7088-9533	Swedish Cancer Society; Swedish Research Council; Karolinska Institutet Cancer network; Ake Wiberg's foundation; Jeansson's foundation; Swedish National Board of Health and Welfare; Alex and Eva Wallstrom foundation; Magn. Bergvall foundation; Karolinska Institute Research foundations	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet Cancer network; Ake Wiberg's foundation; Jeansson's foundation; Swedish National Board of Health and Welfare; Alex and Eva Wallstrom foundation; Magn. Bergvall foundation; Karolinska Institute Research foundations(Karolinska Institutet)	We are grateful to Cyto Pulse Sciences, Inc., Glen Burnie, MD, USA for providing the technology for in vivo electroporation. This study was supported by grants to KP from the Swedish Cancer Society (Young Investigator Award and project grant), the Swedish Research Council (including a Linnaeus grant for the STARGET consortium), by a strategic grant from the Karolinska Institutet Cancer network, Ake Wiberg's foundation and Jeansson's foundation. BKH recieved support from the The Swedish National Board of Health and Welfare, The Alex and Eva Wallstrom foundation, The Magn. Bergvall foundation and Karolinska Institute Research foundations.	Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bergman PJ, 2003, CLIN CANCER RES, V9, P1284; Botusan IR, 2008, P NATL ACAD SCI USA, V105, P19426, DOI 10.1073/pnas.0805230105; Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Holmgren L, 2006, P NATL ACAD SCI USA, V103, P9208, DOI 10.1073/pnas.0603110103; Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061; Jubb AM, 2009, BRIT J CANCER, V101, P1749, DOI 10.1038/sj.bjc.6605368; Jubb AM, 2010, AM J PATHOL, V176, P2019, DOI 10.2353/ajpath.2010.090908; Kaplan CD, 2006, VACCINE, V24, P6994, DOI 10.1016/j.vaccine.2006.04.071; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Liu MA, 2006, HUM GENE THER, V17, P1051, DOI 10.1089/hum.2006.17.1051; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pejawar-Gaddy S, 2008, CRIT REV ONCOL HEMAT, V67, P93, DOI 10.1016/j.critrevonc.2008.02.010; Plum SM, 2004, IMMUNOPHARM IMMUNOT, V26, P29, DOI 10.1081/IPH-120029942; Pourgholami Mohammad H., 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P343, DOI 10.2174/187152508785909528; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Schlom J, 2007, CLIN CANCER RES, V13, P3776, DOI 10.1158/1078-0432.CCR-07-0588; Segarra M, 2008, BLOOD, V112, P1904, DOI 10.1182/blood-2007-11-126045; Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104; Ullenhag GJ, 2004, CLIN CANCER RES, V10, P3273, DOI 10.1158/1078-0432.CCR-03-0706; Wei WZ, 1999, INT J CANCER, V81, P748, DOI 10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751	27	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4276	4286		10.1038/onc.2010.176	http://dx.doi.org/10.1038/onc.2010.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498640				2022-12-28	WOS:000280547900004
J	Mollinedo, F; de la Iglesia-Vicente, J; Gajate, C; de Mendoza, AEH; Villa-Pulgarin, JA; Campanero, MA; Blanco-Prieto, MJ				Mollinedo, F.; de la Iglesia-Vicente, J.; Gajate, C.; Estella-Hermoso de Mendoza, A.; Villa-Pulgarin, J. A.; Campanero, M. A.; Blanco-Prieto, M. J.			Lipid raft-targeted therapy in multiple myeloma	ONCOGENE			English	Article						lipid raft; cholesterol; phospholipid ether; edelfosine; apoptosis; MM	ETHER PHOSPHOLIPID EDELFOSINE; ET-18-OCH3 EDELFOSINE; CANCER-CELLS; DEATH RECEPTOR; TUMOR-TISSUES; APOPTOSIS; CHOLESTEROL; FAS/CD95; FAS; INVOLVEMENT	Despite recent advances in treatment, multiple myeloma (MM) remains an incurable malignancy. By using in vitro, ex vivo and in vivo approaches, we have identified here that lipid rafts constitute a new target in MM. We have found that the phospholipid ether edelfosine targets and accumulates in MM cell membrane rafts, inducing apoptosis through co-clustering of rafts and death receptors. Raft disruption by cholesterol depletion inhibited drug uptake by tumor cells as well as cell killing. Cholesterol replenishment restored MM cell ability to take up edelfosine and to undergo drug-induced apoptosis. Ceramide addition displaced cholesterol from rafts, and inhibited edelfosine-induced apoptosis. In an MM animal model, edelfosine oral administration showed a potent in vivo antimyeloma activity, and the drug accumulated preferentially and dramatically in the tumor. A decrease in tumor cell cholesterol, a major raft component, inhibited the in vivo antimyeloma action of edelfosine and reduced drug uptake by the tumor. The results reported here provide the proof-of-principle and rationale for further clinical evaluation of edelfosine and for this raft-targeted therapy to improve patient outcome in MM. Our data reveal cholesterol-containing lipid rafts as a novel and efficient therapeutic target in MM, opening a new avenue in cancer treatment. Oncogene (2010) 29, 3748-3757; doi: 10.1038/onc.2010.131; published online 26 April 2010	[Mollinedo, F.; de la Iglesia-Vicente, J.; Gajate, C.; Villa-Pulgarin, J. A.] Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain; [Gajate, C.] Hosp Univ Salamanca, Unidad Invest, E-37007 Salamanca, Spain; [Estella-Hermoso de Mendoza, A.; Blanco-Prieto, M. J.] Univ Navarra, Fac Farm, Dept Farm & Tecnol Farmaceut, E-31080 Pamplona, Spain; [Campanero, M. A.] Clin Univ, Serv Farmacol Clin, Pamplona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Navarra; University of Navarra	Mollinedo, F (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es; cgajate@usal.es	IBSAL, Secretaría/H-3719-2011; Estella-Hermoso de Mendoza, Ander/E-9201-2011; Maria, Blanco-Prieto/E-6665-2017; Estella-Hermoso de Mendoza, Ander/M-7194-2016; Villa-Pulgarin, Janny A/AAW-4592-2020	Maria, Blanco-Prieto/0000-0003-0710-899X; Estella-Hermoso de Mendoza, Ander/0000-0001-9855-4527; Villa-Pulgarin, Janny A/0000-0002-9916-5977; Gajate, Consuelo/0000-0003-0604-6459	Ministerio de Ciencia e Innovacion [SAF2007-61261, SAF2008-02251, PCT-0901002007-27, RD06/0020/1037]; Fondo de Investigacion Sanitaria; European Commission [FIS-FEDER 06/0813, PS09/01915]; Junta de Castilla y Leon; Caja Navarra Foundation; Department of Health of the Navarra Government; Department of Education of the Basque Government [BF106.37]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); European Commission(European CommissionEuropean Commission Joint Research Centre); Junta de Castilla y Leon(Junta de Castilla y Leon); Caja Navarra Foundation; Department of Health of the Navarra Government; Department of Education of the Basque Government	This work was supported by grants from Ministerio de Ciencia e Innovacion (SAF2007-61261, SAF2008-02251, PCT-0901002007-27, RD06/0020/1037 from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III), Fondo de Investigacion Sanitaria and European Commission (FIS-FEDER 06/0813, PS09/01915), Junta de Castilla y Leon (GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Project 2009) and Caja Navarra Foundation, Department of Health of the Navarra Government ('Ortiz de Landazuri, 2009' project). CG is supported by the Ramon y Cajal Program from the Ministerio de Ciencia e Innovacion of Spain. AEHdM is supported by a research grant (BF106.37) from the Department of Education of the Basque Government.	Auer J, 2002, CURR MED CHEM, V9, P1831, DOI 10.2174/0929867023369024; Ausili A, 2008, J PHYS CHEM B, V112, P11643, DOI 10.1021/jp802165n; Barnes K, 2004, BIOCHEM J, V378, P343, DOI 10.1042/BJ20031186; Blanco-Prieto MJ, 2004, J CHROMATOGR B, V810, P85, DOI 10.1016/j.jchromb.2004.07.013; Busto Jon V, 2008, J Chem Biol, V1, P89, DOI 10.1007/s12154-008-0009-z; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Christian AE, 1997, J LIPID RES, V38, P2264; DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F; Dimberg LY, 2005, BLOOD, V106, P1346, DOI 10.1182/blood-2004-04-1322; Elahi MM, 2008, HYPERTENSION, V51, P939, DOI 10.1161/HYPERTENSIONAHA.107.100982; de Mendoza AEH, 2009, CLIN CANCER RES, V15, P858, DOI 10.1158/1078-0432.CCR-08-1654; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044; Gajate C, 2009, BIOCHEM BIOPH RES CO, V380, P780, DOI 10.1016/j.bbrc.2009.01.147; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Hussein MA, 2002, CURR OPIN ONCOL, V14, P31, DOI 10.1097/00001622-200201000-00006; Jasinska M, 2007, PHARMACOL REP, V59, P483; Karasavvas N, 1996, EUR J BIOCHEM, V236, P729, DOI 10.1111/j.1432-1033.1996.00729.x; KOGA T, 1990, BIOCHIM BIOPHYS ACTA, V1045, P115, DOI 10.1016/0005-2760(90)90139-O; Kolanjiappan K, 2003, CLIN BIOCHEM, V36, P61, DOI 10.1016/S0009-9120(02)00421-6; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; MEGHA LE, 2004, J BIOL CHEM, V279, P9997; Mihelic R, 2007, LEUKEMIA, V21, P1150, DOI 10.1038/sj.leu.2404633; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; Mollinedo F, 2007, EXPERT OPIN THER PAT, V17, P385, DOI 10.1517/13543776.17.4.385; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Mollinedo F, 2008, CONTEMP HEMATOL, P393; Mollinedo F, 2009, J PHARMACOL EXP THER, V329, P439, DOI 10.1124/jpet.108.148254; Mollinedo Faustino, 2006, P13; Nieto-Miguel T, 2006, J BIOL CHEM, V281, P14833, DOI 10.1074/jbc.M511251200; Nybond S, 2005, BBA-BIOMEMBRANES, V1718, P61, DOI 10.1016/j.bbamem.2005.10.009; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Quesada E, 2004, J MED CHEM, V47, P5333, DOI 10.1021/jm049808a; Rouquette-Jazdanian AK, 2007, CELL SIGNAL, V19, P1404, DOI 10.1016/j.cellsig.2007.01.015; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tosi MR, 2005, CLIN CHIM ACTA, V359, P27, DOI 10.1016/j.cccn.2005.04.003; Zerp SF, 2008, ANTI-CANCER DRUG, V19, P65, DOI 10.1097/CAD.0b013e3282f16d36; Zhuang LY, 2005, J CLIN INVEST, V115, P959	51	95	97	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3748	3757		10.1038/onc.2010.131	http://dx.doi.org/10.1038/onc.2010.131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418917				2022-12-28	WOS:000279385200003
J	Orr, SJ; Gaymes, T; Ladon, D; Chronis, C; Czepulkowski, B; Wang, R; Mufti, GJ; Marcotte, EM; Thomas, NSB				Orr, S. J.; Gaymes, T.; Ladon, D.; Chronis, C.; Czepulkowski, B.; Wang, R.; Mufti, G. J.; Marcotte, E. M.; Thomas, N. S. B.			Reducing MCM levels in human primary T cells during the G(0)-> G(1) transition causes genomic instability during the first cell cycle	ONCOGENE			English	Article						cell cycle; MCM; chromosomal abnormalities; DNA damage; premature chromatid separation	MINICHROMOSOME MAINTENANCE PROTEINS; SISTER-CHROMATID COHESION; MOSAIC VARIEGATED ANEUPLOIDY; DNA-REPLICATION; S-PHASE; SACCHAROMYCES-CEREVISIAE; GENETIC INSTABILITY; MAMMALIAN-CELLS; CANCER-CELLS; RECOMBINATION	DNA replication is tightly regulated, but paradoxically there is reported to be an excess of MCM DNA replication proteins over the number of replication origins. Here, we show that MCM levels in primary human T cells are induced during the G(0)-> G(1) transition and are not in excess in proliferating cells. The level of induction is critical as we show that a 50% reduction leads to increased centromere separation, premature chromatid separation (PCS) and gross chromosomal abnormalities typical of genomic instability syndromes. We investigated the mechanisms involved and show that a reduction in MCM levels causes dose-dependent DNA damage involving activation of ATR & ATM and Chk1 & Chk2. There is increased DNA mis-repair by non-homologous end joining (NHEJ) and both NHEJ and homologous recombination are necessary for Mcm7-depleted cells to progress to metaphase. Therefore, a simple reduction in MCM loading onto DNA, which occurs in cancers as a result of aberrant cell cycle control, is sufficient to cause PCS and gross genomic instability within one cell cycle. Oncogene (2010) 29, 3803-3814; doi: 10.1038/onc.2010.138; published online 3 May 2010	[Orr, S. J.; Gaymes, T.; Ladon, D.; Chronis, C.; Czepulkowski, B.; Mufti, G. J.; Thomas, N. S. B.] Kings Coll London, Dept Haematol Med, Leukaemia Sci Labs, Rayne Inst, London SE5 9NU, England; [Wang, R.; Marcotte, E. M.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of London; King's College London; University of Texas System; University of Texas Austin	Thomas, NSB (corresponding author), Kings Coll London, Dept Haematol Med, Leukaemia Sci Labs, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	nicholas.s.thomas@kcl.ac.uk		Marcotte, Edward/0000-0001-8808-180X	Leukaemia Research Fund; Department of Trade and Industry (dti); British Society for Haematology; Welch and Packard Foundations; National Institutes of Health (NIH); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067779] Funding Source: NIH RePORTER	Leukaemia Research Fund; Department of Trade and Industry (dti); British Society for Haematology; Welch and Packard Foundations; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We sincerely thank Hye Kyung Hong, Kai Stoeber and Gareth Williams, UCL for the Mcm2 plasmid and advice on expressing recombinant Mcm2. We also thank our colleagues for helpful comments. This work was supported by grants from the Leukaemia Research Fund (LRF, now Leukaemia and Lymphoma Research (LLR)), Department of Trade and Industry (dti), the British Society for Haematology, the Welch and Packard Foundations and the National Institutes of Health (NIH).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bailis JM, 2008, MOL CELL BIOL, V28, P1724, DOI 10.1128/MCB.01717-07; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Bruemmer D, 2003, BIOCHEM BIOPH RES CO, V303, P251, DOI 10.1016/S0006-291X(03)00343-7; Budman J, 2007, J BIOL CHEM, V282, P11950, DOI 10.1074/jbc.M610058200; Chong J P, 1996, Prog Cell Cycle Res, V2, P83; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; Crevel G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000833; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Feng DR, 2003, CANCER RES, V63, P7356; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; FRANCON P, 2006, ENCY LIFE SCI; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; Gaymes TJ, 2002, CANCER RES, V62, P2791; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gillespie PJ, 2004, CURR BIOL, V14, P1598, DOI 10.1016/j.cub.2004.07.053; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; HOWELL RT, 1992, HUMAN CYTOGENETICS P, P209; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Kajii T, 1998, AM J MED GENET, V78, P245, DOI 10.1002/(SICI)1096-8628(19980707)78:3<245::AID-AJMG7>3.0.CO;2-O; Kajii T, 2001, AM J MED GENET, V104, P57, DOI 10.1002/ajmg.1580; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lea NC, 2003, MOL CELL BIOL, V23, P2351, DOI 10.1128/MCB.23.7.2351-2361.2003; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lengronne A, 2006, MOL CELL, V23, P787, DOI 10.1016/j.molcel.2006.08.018; Liang DT, 1999, J CELL SCI, V112, P559; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Moldovan GL, 2006, MOL CELL, V23, P723, DOI 10.1016/j.molcel.2006.07.007; Nakanishi M, 2006, CANCER SCI, V97, P984, DOI 10.1111/j.1349-7006.2006.00289.x; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Shimada K, 2007, CELL, V128, P85, DOI 10.1016/j.cell.2006.11.045; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Shukla A, 2005, BIOCHEM BIOPH RES CO, V329, P1240, DOI 10.1016/j.bbrc.2005.02.106; Smith AE, 2009, GENOME RES, V19, P1325, DOI 10.1101/gr.085530.108; Stoeber K, 2001, J CELL SCI, V114, P2027; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi TS, 2004, NAT CELL BIOL, V6, P991, DOI 10.1038/ncb1177; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Williams GH, 2007, CURR OPIN CELL BIOL, V19, P672, DOI 10.1016/j.ceb.2007.10.005	52	28	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3803	3814		10.1038/onc.2010.138	http://dx.doi.org/10.1038/onc.2010.138			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440261	Green Accepted			2022-12-28	WOS:000279385200008
J	Zuntini, M; Pedrini, E; Parra, A; Sgariglia, F; Gentile, FV; Pandolfi, M; Alberghini, M; Sangiorgi, L				Zuntini, M.; Pedrini, E.; Parra, A.; Sgariglia, F.; Gentile, F. V.; Pandolfi, M.; Alberghini, M.; Sangiorgi, L.			Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation	ONCOGENE			English	Article						solitary osteochondroma; multiple osteochondroma; chondrosarcoma; EXT genes; tumor suppressor; mutation screening	MULTIPLE EXOSTOSES; NATURAL-HISTORY; MUTATIONS; HETEROZYGOSITY; POINT; LOCI	Osteochondroma, the most common benign bone tumor, may occur as a sporadic lesion or as multiple neoplasms in the context of multiple osteochondromas syndrome. The most severe complication is malignant transformation into peripheral secondary chondrosarcoma. Although both benign conditions have been linked to defects in EXT1 or EXT2 genes, contradictory reports are present in the literature regarding the requirement of their biallelic inactivation for osteochondroma development. A major limitation of these studies is represented by the small number of samples available for the screening. Taking advantage of a large series of tissues, our aim was to contribute to the definition of a genetic model for osteochondromas onset and transformation. EXT genes point mutations and big deletions were analyzed in 64 tissue samples. A double hit was found in 5 out of 35 hereditary cases, 6 out of 16 chondrosarcomas and 2 recurrences; none of the 11 sporadic osteochondromas showed two somatic mutations. Our results clearly indicate that, in most cases, biallelic inactivation of EXT genes does not account for osteochondromas formation; this mechanism should be regarded as a common feature for hereditary osteochondromas transformation and as an event that occurs later in tumor progression of solitary cases. These findings suggest that mechanisms alternative to EXT genetic alteration likely have a role in osteochondromas pathogenesis. Oncogene (2010) 29, 3827-3834; doi: 10.1038/onc.2010.135; published online 26 April 2010	[Zuntini, M.; Pedrini, E.; Parra, A.; Sgariglia, F.; Gentile, F. V.; Pandolfi, M.; Sangiorgi, L.] Ist Ortoped Rizzoli, Dept Med Genet & Skeletal Rare Dis, I-40136 Bologna, Italy; [Alberghini, M.] Ist Ortoped Rizzoli, Dept Anat Pathol & Histol, I-40136 Bologna, Italy	IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli	Sangiorgi, L (corresponding author), Ist Ortoped Rizzoli, Dept Med Genet & Skeletal Rare Dis, Via Barbiano 1-10, I-40136 Bologna, Italy.	luca.sangiorgi@ior.it	Sangiorgi, Luca/AHI-1694-2022; Parra, Alessandro/C-7967-2019; Pandolfi, Margareth/H-7616-2016; PEDRINI, ELENA/E-6340-2019	Parra, Alessandro/0000-0002-4482-0612; PEDRINI, ELENA/0000-0001-9980-7741; Sangiorgi, Luca/0000-0003-3658-1209	European Project EuroBoNeT	European Project EuroBoNeT	This research was supported by the European Project EuroBoNeT.	Bernard MA, 2001, CELL MOTIL CYTOSKEL, V48, P149, DOI 10.1002/1097-0169(200102)48:2<149::AID-CM1005>3.0.CO;2-3; Bovee JVMG, 1999, GENE CHROMOSOME CANC, V26, P237; Bovee JVMG, 1999, AM J HUM GENET, V65, P689, DOI 10.1086/302532; Bridge JA, 1998, CANCER-AM CANCER SOC, V82, P1657, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1657::AID-CNCR10>3.0.CO;2-3; Cheung PK, 2001, AM J HUM GENET, V69, P55, DOI 10.1086/321278; Essadki B, 2000, Acta Orthop Belg, V66, P146; Farach-Carson MC, 2005, CRIT REV EUKAR GENE, V15, P29, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i1.30; Hall CR, 2002, AM J MED GENET, V112, P1, DOI 10.1002/ajmg.10635; Hameetman L, 2007, JNCI-J NATL CANCER I, V99, P396, DOI 10.1093/jnci/djk067; HECHT JT, 1995, AM J HUM GENET, V56, P1125; HENNEKAM RCM, 1991, J MED GENET, V28, P262, DOI 10.1136/jmg.28.4.262; Huvos A, 1991, BONE TUMORS DIAGNOSI; Jennes I, 2009, HUM MUTAT, V30, P1620, DOI 10.1002/humu.21123; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lonie Lorne, 2006, Hum Mutat, V27, P1160, DOI 10.1002/humu.9467; Ludecke HJ, 1997, GENOMICS, V40, P351, DOI 10.1006/geno.1996.4577; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MERTENS F, 1994, GENE CHROMOSOME CANC, V9, P8, DOI 10.1002/gcc.2870090103; Pedrini E, 2005, HUM MUTAT, V26, DOI 10.1002/humu.9359; Porter DE, 1999, J PATHOL, V188, P119; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Rohlin A, 2009, HUM MUTAT, V30, P1012, DOI 10.1002/humu.20980; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; SOLOMON L, 1964, AM J HUM GENET, V16, P351; Springfield DS, 1996, AAOS INSTR COURS LEC, V45, P417; Traeger-Synodinos Joanne, 2006, Molecular Aspects of Medicine, V27, P176, DOI 10.1016/j.mam.2005.12.004; Trebicz-Geffen M, 2008, INT J EXP PATHOL, V89, P321, DOI 10.1111/j.1365-2613.2008.00589.x; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 2000, HUM MUTAT, V15, P220, DOI 10.1002/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K; Wuyts W, 1998, AM J HUM GENET, V62, P346, DOI 10.1086/301726; WUYTS W, 1995, AM J HUM GENET, V57, P382	33	32	32	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3827	3834		10.1038/onc.2010.135	http://dx.doi.org/10.1038/onc.2010.135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418910				2022-12-28	WOS:000279385200010
J	Krapf, G; Kaindl, U; Kilbey, A; Fuka, G; Inthal, A; Joas, R; Mann, G; Neil, JC; Haas, OA; Panzer-Grumayer, ER				Krapf, G.; Kaindl, U.; Kilbey, A.; Fuka, G.; Inthal, A.; Joas, R.; Mann, G.; Neil, J. C.; Haas, O. A.; Panzer-Gruemayer, E. R.			ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1	ONCOGENE			English	Article						ETV6/RUNX1; t(12;21); acute lymphoblastic leukemia; mitotic checkpoint MAD2L1; tetraploidy	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROMOTES ANEUPLOIDY; NEAR-TETRAPLOIDY; CBF ONCOPROTEINS; CELL BIOLOGY; DNA-BINDING; FUSION; CANCER; PROTEIN; GENE	Approximately 25% of childhood B-cell precursor acute lymphoblastic leukemia have an ETV6/RUNX1 (E/R) gene fusion that results from a t(12;21). This genetic subgroup of leukemia is associated with near-triploidy, near-tetraploidy, and trisomy 21 as rather specific types of secondary changes. Here, we show that, unlike various controls, E/R-expressing Ba/F3 clones acquire a tetraploid karyotype on prolonged culture, corroborating the assumption that E/R may attenuate the mitotic checkpoint (MC). Consistent with this notion, E/R-expressing diploid murine and human cell lines have decreased proportions of cells with 4N DNA content and a lower mitotic index when treated with spindle toxins. Moreover, both RUNX1 and E/R regulate mitotic arrest-deficient 2 L1 (MAD2L1), an essential MC component, by binding to promoter-inherent RUNX1 sites, which results in down-regulation of MAD2L1 mRNA and protein in E/R-expressing cells. Forced expression of E/R also abolishes RUNX1-induced reporter activation, whereas E/R with a mutant DNA-binding site leads to only minor effects. Our data link for the first time E/R, MC, and MAD2L1 and provide new insights into the function of the E/R fusion gene product. Although tetraploidy is an almost exclusive feature of E/R-positive leukemias, its rarity within this particular subgroup implies that further yet unknown factors are required for its manifestation. Oncogene (2010) 29, 3307-3312; doi: 10.1038/onc.2010.53; published online 1 March 2010	[Panzer-Gruemayer, E. R.] Childrens Canc Res Inst, Leukemia Biol Grp, A-1090 Vienna, Austria; [Kilbey, A.; Neil, J. C.] Fac Vet Med, Inst Comparat Med, Mol Oncol Lab, Glasgow, Lanark, Scotland; [Mann, G.; Haas, O. A.; Panzer-Gruemayer, E. R.] St Anna Childrens Hosp, Vienna, Austria	Saint Anna Children's Hospital; University of Glasgow; Saint Anna Children's Hospital	Panzer-Grumayer, ER (corresponding author), Childrens Canc Res Inst, Leukemia Biol Grp, Zimmermannpl 10, A-1090 Vienna, Austria.	renate.panzer@ccri.at	Haas, Oskar/AAM-5794-2020		FWF [P17551-B14]; Austrian Ministry for Education, Science and Culture; St Anna Kinderkrebsforschung; Leukaemia Research Fund	FWF(Austrian Science Fund (FWF)); Austrian Ministry for Education, Science and Culture; St Anna Kinderkrebsforschung; Leukaemia Research Fund	We thank O Williams for expression vectors containing E/R or the mutant E/R, D-E Zhang for the RUNX1-expression vector, A Friedman for CBFb-expression vector, D Guardavaccaro for the luciferase reporter plasmid for the MAD2L1 promoter in pGL3, JD Rowley for AT-2 cell line, L Orel for the Myc-ETV6/RUNX1 vector, Idriss M Bennani-Baiti for stimulating discussions, and Marion Zavadil for proofreading the paper. This study was supported in part by a grant from the FWF P17551-B14 and the Austrian Ministry for Education, Science and Culture (GENAU-Ch.I.L.D) and the St Anna Kinderkrebsforschung to ER P-G. A Kilbey is funded by the Leukaemia Research Fund. GK participated in the design of the study, performed experiments, interpreted data, and wrote the paper. UK, GF, AI, RJ performed research and interpreted data. AK performed and interpreted ChIP experiments. JCN participated in study design and interpretation of ChIP data. GM contributed patient samples. OAH participated in the interpretation of data and writing of the paper. ER P-G designed and supervised research and wrote the paper.	Attarbaschi A, 2006, GENE CHROMOSOME CANC, V45, P608, DOI 10.1002/gcc.20324; Attarbaschi A, 2004, LEUKEMIA, V18, P1611, DOI 10.1038/sj.leu.2403471; Boyapati A, 2007, BLOOD, V109, P3963, DOI 10.1182/blood-2006-09-045583; Diakos C, 2007, BLOOD, V109, P2607, DOI 10.1182/blood-2006-04-019612; Fang Y, 2006, ONCOGENE, V25, P3598, DOI 10.1038/sj.onc.1209392; Ford AM, 2009, J CLIN INVEST, V119, P826, DOI 10.1172/JCI36428; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Ha GH, 2007, CANCER RES, V67, P7155, DOI 10.1158/0008-5472.CAN-06-3392; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Li Z, 2003, J BIOL CHEM, V278, P33088, DOI 10.1074/jbc.M303973200; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Michel L, 2004, CELL CYCLE, V3, P990; Morrow M, 2007, ONCOGENE, V26, P4404, DOI 10.1038/sj.onc.1210227; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Peters JM, 2007, NATURE, V446, P868, DOI 10.1038/446868a; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Raimondi SC, 2006, CANCER GENET CYTOGEN, V169, P50, DOI 10.1016/j.cancergencyto.2006.04.006; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Roudaia L, 2009, BLOOD, V113, P3070, DOI 10.1182/blood-2008-03-147207; Sasaki A, 2004, BIOCHEM BIOPH RES CO, V317, P1128, DOI 10.1016/j.bbrc.2004.03.172; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672	32	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3307	3312		10.1038/onc.2010.53	http://dx.doi.org/10.1038/onc.2010.53			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20190817	Green Accepted			2022-12-28	WOS:000278321100013
J	Liu, Y; Yan, S; Wondimu, A; Bob, D; Weiss, M; Sliwinski, K; Villar, J; Notario, V; Sutherland, M; Colberg-Poley, AM; Ladisch, S				Liu, Y.; Yan, S.; Wondimu, A.; Bob, D.; Weiss, M.; Sliwinski, K.; Villar, J.; Notario, V.; Sutherland, M.; Colberg-Poley, A. M.; Ladisch, S.			Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth	ONCOGENE			English	Article						ganglioside synthesis; ganglioside depletion; tumor model; c-Myc/H-Ras transformation; tumorigenesis	GLUCOSYLCERAMIDE SYNTHASE; CANCER CELLS; KAPPA-B; ACTIVATION; EXPRESSION; PROLIFERATION; CONVERSION; INHIBITOR; MIGRATION; ADHESION	Biologically active membrane gangliosides, expressed and released by many human tumors, are hypothesized to significantly impact tumor progression. Lack of a model of complete and specific tumor ganglioside depletion in vivo, however, has hampered elucidation of their role. Here, we report the creation of a novel, stable, genetically induced tumor cell system resulting in specific and complete blockade of ganglioside synthesis. Wild-type (WT) and GM3 synthase/GM2 synthase double knockout (DKO) murine embryonic fibroblasts were transformed using amphotropic retrovirus-transduced oncogenes (pBABE-c-Myc(T58A) + H-RasG12V). The transformed cells, WTt and DKOt respectively, evidenced comparable integrated copy numbers and oncogene expression. Ganglioside synthesis was completely blocked in the DKOt cells, importantly without triggering an alternate pathway of ganglioside synthesis. Ganglioside depletion (to <0.5 nmol/10(7) cells from 9 to 11 nmol/10(7) WTt or untransfected normal fibroblasts) did not adversely affect cell proliferation kinetics but did reduce cell migration on fibronectin-coated wells, consistent with our previous observations in ganglioside-depleted normal human fibroblasts. Strikingly, despite similar oncogene expression and growth kinetics, DKOt cells evidenced significantly impaired tumor growth in syngeneic immunocompetent mice, underscoring the pivotal role of tumor cell gangliosides and providing an ideal system for probing their mechanisms of action in vivo. Oncogene (2010) 29, 3297-3306; doi: 10.1038/onc.2010.85; published online 22 March 2010	[Liu, Y.; Yan, S.; Wondimu, A.; Bob, D.; Weiss, M.; Sliwinski, K.; Sutherland, M.; Colberg-Poley, A. M.; Ladisch, S.] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, NW, Washington, DC 20010 USA; [Liu, Y.; Colberg-Poley, A. M.; Ladisch, S.] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; [Villar, J.; Notario, V.] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med, Washington, DC 20007 USA; [Colberg-Poley, A. M.; Ladisch, S.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA	Children's National Health System; George Washington University; Georgetown University; George Washington University	Ladisch, S (corresponding author), Childrens Natl Med Ctr, Ctr Canc & Immunol Res, NW, 111 Michigan Ave NW,Suite 5200, Washington, DC 20010 USA.	sladisch@cnmc.org	/AAB-6461-2022; /AFP-0764-2022		NIH [CA61010, CA42361, CA64472, GM62116]; NATIONAL CANCER INSTITUTE [R01CA042361, R01CA064472, R01CA061010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rick Proia for the GM3S mice. This work was supported by NIH grants CA61010 and CA42361 to SL, CA64472 to VN, and GM62116 to the Consortium for Functional Glycomics.	Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; Buggins AGS, 2001, J IMMUNOL, V167, P6021, DOI 10.4049/jimmunol.167.10.6021; Cazet A, 2009, BIOL CHEM, V390, P601, DOI 10.1515/BC.2009.054; Deng W, 2002, GLYCOBIOLOGY, V12, P145, DOI 10.1093/glycob/12.3.145; FLOUTSIS G, 1989, INT J CANCER, V43, P6, DOI 10.1002/ijc.2910430103; Hakomori S, 1973, Adv Cancer Res, V18, P265, DOI 10.1016/S0065-230X(08)60755-1; Hakomori S, 1996, CANCER RES, V56, P5309; Hyuga S, 1999, INT J CANCER, V83, P685, DOI 10.1002/(SICI)1097-0215(19991126)83:5<685::AID-IJC20>3.0.CO;2-4; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; Jeyakumar M, 2002, NEUROPATH APPL NEURO, V28, P343, DOI 10.1046/j.1365-2990.2002.00422.x; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; LADISCH S, 1983, CANCER RES, V43, P3808; Ladisch S, 2004, CURR CLIN ONCOL, P145; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; LI RX, 1991, BIOCHIM BIOPHYS ACTA, V1083, P57, DOI 10.1016/0005-2760(91)90124-Z; Liu YH, 2004, J BIOL CHEM, V279, P36481, DOI 10.1074/jbc.M402880200; Liu YH, 2008, GLYCOBIOLOGY, V18, P593, DOI 10.1093/glycob/cwn039; Liu YH, 2006, CANCER RES, V66, P10408, DOI 10.1158/0008-5472.CAN-06-1572; Mitsuzuka K, 2005, J BIOL CHEM, V280, P35545, DOI 10.1074/jbc.M505630200; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; Saha S., 2005, Indian Journal of Experimental Biology, V43, P1130; Schenck M, 2007, ARCH BIOCHEM BIOPHYS, V462, P171, DOI 10.1016/j.abb.2007.03.031; Shevchuk NA, 2007, BBA-MOL CELL BIOL L, V1771, P1226, DOI 10.1016/j.bbalip.2007.05.008; Shurin GV, 2001, CANCER RES, V61, P363; Simpson MA, 2004, NAT GENET, V36, P1225, DOI 10.1038/ng1460; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Todeschini AR, 2008, BBA-GEN SUBJECTS, V1780, P421, DOI 10.1016/j.bbagen.2007.10.008; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; VALENTINO L, 1990, BLOOD, V75, P1564; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Villar J, 2007, CANCER RES, V67, P10859, DOI 10.1158/0008-5472.CAN-07-2041; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yamashita T, 2005, P NATL ACAD SCI USA, V102, P2725, DOI 10.1073/pnas.0407785102	38	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3297	3306		10.1038/onc.2010.85	http://dx.doi.org/10.1038/onc.2010.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305696	Green Accepted			2022-12-28	WOS:000278321100012
J	Li, P; Wang, D; Yao, H; Doret, P; Hao, G; Shen, Q; Qiu, H; Zhang, X; Wang, Y; Chen, G; Wang, Y				Li, P.; Wang, D.; Yao, H.; Doret, P.; Hao, G.; Shen, Q.; Qiu, H.; Zhang, X.; Wang, Y.; Chen, G.; Wang, Y.			Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression	ONCOGENE			English	Article						histone citrullination; histone deacetylation; PAD4; HDAC2; p53	TRANSCRIPTIONAL REGULATION; CHROMATIN MODIFICATIONS; ARGININE METHYLATION; STRUCTURAL BASIS; HISTONE; P53; ACTIVATION; ACETYLATION; NUCLEOSOME; REPRESSION	Histone Arg methylation and Lys acetylation have been found to cooperatively regulate the expression of p53-target genes. Peptidylarginine deiminase 4 (PAD4) is an enzyme that citrullinates histone arginine and monomethyl-arginine residues thereby regulating histone Arg methylation. We have recently found that PAD4 serves as a p53 corepressor to regulate histone Arg methylation at the p53-target gene p21/WAF1/CIP1 promoter. However, it has not been tested whether histone Arg citrullination coordinates with other histone modifications to repress transcription. Here, we show that histone deacetylase (HDAC2) and PAD4 interact with p53 through distinct domains and simultaneously associate with the p21 promoter to regulate gene expression. After DNA damage, PAD4 and HDAC2 dissociate from several p53-target gene promoters (for example, p21, GADD45, and PUMA) with a concomitant increase in histone Lys acetylation and Arg methylation at these promoters. Furthermore, PAD4 promoter association and histone Arg modifications are regulated by p53 and HDAC activity. In contrast, HDAC2 promoter association and histone Lys acetylation are affected by p53 and PAD4 activity at minor degrees. Importantly, PAD4 inhibitor Cl-amidine and HDAC inhibitor suberoylanilide hydroxamic acid show additive effects in inducing p21, GADD45, and PUMA expression and inhibiting cancer cell growth in a p53-dependent manner. Our results unveil an important crosstalk between histone deacetylation and citrullination, suggesting that a combination of PAD4 and HDAC2 inhibitors as a potential strategy for cancer treatment. Oncogene (2010) 29, 3153-3162; doi: 10.1038/onc.2010.51; published online 1 March 2010	[Li, P.; Wang, D.; Yao, H.; Doret, P.; Shen, Q.; Wang, Y.] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, 454 N Frear, University Pk, PA 16802 USA; [Hao, G.] Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; [Qiu, H.; Wang, Y.] Univ Calif Riverside, Dept Chem 027, Riverside, CA 92521 USA; [Zhang, X.] Univ S Florida, Coll Med, Dept Pathol & Cell Biol, Tampa, FL USA; [Chen, G.] Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Cornell University; University of California System; University of California Riverside; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wang, Y (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, 454 N Frear, University Pk, PA 16802 USA.	yuw12@psu.edu	Chen, Gong/A-8063-2013	Chen, Gong/0000-0002-5067-9889; Wang, Yanming/0000-0002-0710-043X	PSU; NIH [R01 CA136856, R01 CA116522]; NATIONAL CANCER INSTITUTE [R01CA116522, R01CA136856] Funding Source: NIH RePORTER	PSU; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs JC Reese, DS Gilmour, BF Pugh, and S Tan for discussions and helpful comments. Research is supported in part by a PSU start-up fund and NIH Grants R01 CA136856 to YW (PSU) and R01 CA116522 to YW (UC Riverside).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Arita K, 2004, NAT STRUCT MOL BIOL, V11, P777, DOI 10.1038/nsmb799; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Causey CP, 2008, TETRAHEDRON LETT, V49, P4383, DOI 10.1016/j.tetlet.2008.05.021; Chang XT, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-40; Chang XT, 2006, MOL CARCINOGEN, V45, P183, DOI 10.1002/mc.20169; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Levesque AA, 2007, CARCINOGENESIS, V28, P13, DOI 10.1093/carcin/bgl214; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li PX, 2008, MOL CELL BIOL, V28, P4745, DOI 10.1128/MCB.01747-07; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Yao HJ, 2008, J BIOL CHEM, V283, P20060, DOI 10.1074/jbc.M802940200	38	91	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3153	3162		10.1038/onc.2010.51	http://dx.doi.org/10.1038/onc.2010.51			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20190809	Green Accepted			2022-12-28	WOS:000278133100012
J	Gao, Y; Yao, A; Zhang, W; Lu, S; Yu, Y; Deng, L; Yin, A; Xia, Y; Sun, B; Wang, X				Gao, Y.; Yao, A.; Zhang, W.; Lu, S.; Yu, Y.; Deng, L.; Yin, A.; Xia, Y.; Sun, B.; Wang, X.			Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice	ONCOGENE			English	Article						mesenchymal stem cells; PEDF; lentiviral vectors; hepatocellular carcinoma; angiogenesis	LUNG METASTASIS MODEL; GENE-THERAPY; TARGETED-DELIVERY; FACTOR EXPRESSION; PROSTATE-CANCER; INTERFERON-BETA; TUMOR STROMA; IN-VITRO; ANGIOGENESIS; GROWTH	The poor outcome of cancer gene therapy in clinical trials relates in part to insufficient gene delivery to tumor sites. Mesenchymal stem cells (MSCs) represent a new tool for the delivery of therapeutic agents to tumor cells. This study used an orthotopic nude mice model of hepatocellular carcinoma (HCC) to evaluate the potential of genetically modified human MSCs (hMSCs), to function as an effective delivery vehicle for therapeutic genes. hMSCs derived from the bone marrow were efficiently engineered to express human pigment epithelium-derived factor (PEDF) by lentiviral transduction, then tested in vitro for high-level expression and bioactivity of the transgenic protein. The preferential homing of hMSCs toward HCC was confirmed by in vitro and in vivo migration assays. in vivo efficacy experiments showed that intravenous (i.v.) injection of PEDF-expressing hMSCs significantly suppressed both the growth of primary liver tumors and the development of pulmonary metastases. Moreover, hMSCs-based PEDF gene delivery moderately increased the systemic levels of human PEDF. Immunohistochemistry of primary liver tumors demonstrated lower microvessel density in mice treated with hMSCs-PEDF than in control mice. This is the first study to show the potential of hMSCs as an effective delivery vehicle for therapeutic genes in the treatment of HCC. Oncogene (2010) 29, 2784-2794; doi: 10.1038/onc.2010.38; published online 1 March 2010	[Wang, X.] Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; Nanjing Med Univ, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Wang, X (corresponding author), Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.	sunbc@njmu.edu.cn; wangxh@njmu.edu.cn			Jiangsu Province's Outstanding Medical Academic Leader program [RC2007057]; Jiangsu Province's Key Medical Centre [2006-50]; Natural Science Foundation of China [30672367, 30772003]; Ministry of Health, China [Wkj2006-2-021]; New Century Excellent Talents in University; Ministry of Education	Jiangsu Province's Outstanding Medical Academic Leader program; Jiangsu Province's Key Medical Centre; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health, China; New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Ministry of Education	This study was supported by grants from Jiangsu Province's Outstanding Medical Academic Leader program (RC2007057 to BS and YG), Jiangsu Province's Key Medical Centre (2006-50 to XW) and grants from the Natural Science Foundation of China (30672367 and 30772003 to BS), Ministry of Health, China (Wkj2006-2-021 to BS), New Century Excellent Talents in University, the Ministry of Education (To BS).	Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Cai J, 2006, CLIN CANCER RES, V12, P3510, DOI 10.1158/1078-0432.CCR-06-0094; Chang CJ, 2007, HEPATOLOGY, V45, P746, DOI 10.1002/hep.21560; Chen QR, 2001, MOL GENET METAB, V74, P120, DOI 10.1006/mgme.2001.3223; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Ek ETH, 2007, CANCER GENE THER, V14, P616, DOI 10.1038/sj.cgt.7701044; Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744; Fritz V, 2008, CURR STEM CELL RES T, V3, P32, DOI 10.2174/157488808783489462; GAO Yun, 2009, Zhonghua Gan Zang Bing Za Zhi, V17, P363; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Guan M, 2003, J CLIN PATHOL, V56, P277, DOI 10.1136/jcp.56.4.277; Halin S, 2004, CANCER RES, V64, P5664, DOI 10.1158/0008-5472.CAN-04-0835; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Kanehira M, 2007, CANCER GENE THER, V14, P894, DOI 10.1038/sj.cgt.7701079; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kikuchi E, 2004, CLIN CANCER RES, V10, P1835, DOI 10.1158/1078-0432.CCR-03-0099; Komarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535-7163.MCT-05-0334; Lau WY, 2008, HEPATOB PANCREAT DIS, V7, P237; Lee TK, 2005, CLIN CANCER RES, V11, P8458, DOI 10.1158/1078-0432.CCR-05-0447; Matsumoto K, 2004, HEPATOLOGY, V40, P252, DOI 10.1002/hep.20259; Mittler J, 2008, TRANSPLANTATION, V86, P895, DOI 10.1097/TP.0b013e318186ad7a; Mizuguchi H, 2005, BIOCHEM BIOPH RES CO, V332, P1101, DOI 10.1016/j.bbrc.2005.05.055; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Ou-Yang F, 2006, CANCER RES, V66, P378, DOI 10.1158/0008-5472.CAN-05-1578; Persano L, 2007, MOL ASPECTS MED, V28, P87, DOI 10.1016/j.mam.2006.12.005; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ren C, 2008, GENE THER, V15, P1446, DOI 10.1038/gt.2008.101; Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008-0084; Sotiropoulou PA, 2006, STEM CELLS, V24, P462, DOI 10.1634/stemcells.2004-0331; Streck CJ, 2005, J PEDIATR SURG, V40, P236, DOI 10.1016/j.jpedsurg.2004.09.049; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Studeny M, 2002, CANCER RES, V62, P3603; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; Uehara H, 2004, CANCER RES, V64, P3533, DOI 10.1158/0008-5472.CAN-03-3725; Van Damme A, 2006, STEM CELLS, V24, P896, DOI 10.1634/stemcells.2003-0106; Yang ZF, 2008, ANAT REC, V291, P721, DOI 10.1002/ar.20668; Yoon SK, 2001, CANCER GENE THER, V8, P573, DOI 10.1038/sj.cgt.7700345	40	75	92	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2784	2794		10.1038/onc.2010.38	http://dx.doi.org/10.1038/onc.2010.38			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190814				2022-12-28	WOS:000277591900004
J	Gustafson, WC; Weiss, WA				Gustafson, W. C.; Weiss, W. A.			Myc proteins as therapeutic targets	ONCOGENE			English	Review						myc; mycn; neuroblastoma; N-myc; mTor; PI3K	ANAPLASTIC LYMPHOMA KINASE; INITIAL TESTING STAGE-1; ARF TUMOR-SUPPRESSOR; C-MYC; N-MYC; GENE-EXPRESSION; DNA-BINDING; CELL-LINES; TRANSCRIPTIONAL CONTROL; MALIGNANT PROGRESSION	Myc proteins (c-myc, Mycn and Mycl) target proliferative and apoptotic pathways vital for progression in cancer. Amplification of the MYCN gene has emerged as one of the clearest indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the most common extracranial solid tumor of childhood. Phosphorylation and ubiquitin-mediated modulation of Myc protein influence stability and represent potential targets for therapeutic intervention. Phosphorylation of Myc proteins is controlled in-part by the receptor tyrosine kinase/phosphatidylinositol 3-kinase/Akt/mTOR signaling, with additional contributions from Aurora A kinase. Myc proteins regulate apoptosis in part through interactions with the p53/Mdm2/Arf signaling pathway. Mutation in p53 is commonly observed in patients with relapsed neuroblastoma, contributing to both biology and therapeutic resistance. This review examines Myc function and regulation in neuroblastoma, and discusses emerging therapies that target Mycn. Oncogene (2010) 29, 1249-1259; doi:10.1038/onc.2009.512; published online 25 January 2010	[Gustafson, W. C.; Weiss, W. A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA; [Gustafson, W. C.] Univ Calif San Francisco, Div Pediat Hematol Oncol, San Francisco, CA 94143 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gustafson, WC (corresponding author), Univ Calif San Francisco, Dept Pediat, Helen Diller Family Canc Res Bldg,1450 3rd St, San Francisco, CA 94158 USA.	GustafsonC@peds.ucsf.edu		Weiss, William/0000-0003-2230-9132	NIH [CA133091, NS055750, CA102321, CA097257, CA128583]; Burroughs Wellcome Fund; American Brain Tumor Association; Brain Tumor Society; Accelerate Brain Cancer Cure; Alex's Lemonade Stand Foundation; Children's National Brain Tumor Foundation; Wallace H. Coulter Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Samuel G Waxman Foundation; V Foundation; NATIONAL CANCER INSTITUTE [R01CA102321, R01CA133091, R01CA148699, P01CA081403, T32CA128583, P50CA097257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055750] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Brain Tumor Association; Brain Tumor Society; Accelerate Brain Cancer Cure; Alex's Lemonade Stand Foundation; Children's National Brain Tumor Foundation; Wallace H. Coulter Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Samuel G Waxman Foundation; V Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Chris Hackett and Theo Nicolaides for critical review. We acknowledge support from NIH grants CA133091, NS055750, CA102321, CA097257, CA128583; Burroughs Wellcome Fund, American Brain Tumor Association, The Brain Tumor Society, Accelerate Brain Cancer Cure; Alex's Lemonade Stand, Children's National Brain Tumor, Wallace H. Coulter, Katie Dougherty, Pediatric Brain Tumor, Samuel G Waxman and V Foundations.	Alaminos M, 2003, CANCER RES, V63, P4538; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amente S, 2007, FEBS LETT, V581, P821, DOI 10.1016/j.febslet.2007.01.062; ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; ASKEW DS, 1991, ONCOGENE, V6, P1915; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bell E, 2007, CELL CYCLE, V6, P1249, DOI 10.4161/cc.6.10.4222; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Berg T, 2008, CURR OPIN CHEM BIOL, V12, P464, DOI 10.1016/j.cbpa.2008.07.023; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brooks TA, 2009, NAT REV CANCER, V9, P849, DOI 10.1038/nrc2733; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cheng AJ, 2007, EUR J CANCER, V43, P1467, DOI 10.1016/j.ejca.2007.03.008; Chesler L, 2008, NEOPLASIA, V10, P1268, DOI 10.1593/neo.08778; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; CLAUSEN N, 1989, ACTA PAEDIATR SCAND, V78, P736, DOI 10.1111/j.1651-2227.1989.tb11135.x; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Cotterman R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005799; Coutts AS, 2009, DNA REPAIR, V8, P483, DOI 10.1016/j.dnarep.2009.01.008; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2009, CURR CANCER DRUG TAR, V9, P729, DOI 10.2174/156800909789271521; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Gingras AC, 2001, GENE DEV, V15, P2852; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Hackett CS, 2003, CANCER RES, V63, P5266; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Ho R, 2002, CANCER RES, V62, P6462; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hossain MS, 2008, ONCOGENE, V27, P6075, DOI 10.1038/onc.2008.200; Houghton PJ, 2008, PEDIATR BLOOD CANCER, V50, P799, DOI 10.1002/pbc.21296; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Ikegaki N, 2007, CLIN CANCER RES, V13, P6001, DOI 10.1158/1078-0432.CCR-07-0071; Inge TH, 2002, SURGERY, V132, P232, DOI 10.1067/msy.2002.125387; Jacobs JFM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-239; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kanemaru KK, 2008, PEDIATR BLOOD CANCER, V50, P806, DOI 10.1002/pbc.21273; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Keshelava N, 1998, CANCER RES, V58, P5396; Keshelava N, 1997, EUR J CANCER, V33, P2002, DOI 10.1016/S0959-8049(97)00213-X; Keshelava N, 2000, MED PEDIATR ONCOL, V35, P563, DOI 10.1002/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koppen A, 2007, CANCER LETT, V256, P218, DOI 10.1016/j.canlet.2007.06.011; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu T, 2009, EUR J CANCER, V45, P1846, DOI 10.1016/j.ejca.2009.03.002; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Manohar CF, 2004, ONCOGENE, V23, P753, DOI 10.1038/sj.onc.1207151; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Maris JM, 2008, PEDIATR BLOOD CANCER, V51, P42, DOI 10.1002/pbc.21535; Maris JM, 2008, NEW ENGL J MED, V358, P2585, DOI 10.1056/NEJMoa0708698; Maris JM, 2009, CANCER CELL, V15, P5, DOI 10.1016/j.ccr.2008.12.008; Marques M, 2008, MOL CELL BIOL, V28, P2803, DOI 10.1128/MCB.01786-07; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Martins RAP, 2008, GENE DEV, V22, P179, DOI 10.1101/gad.1608008; Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Moore HC, 2008, J CLIN PATHOL, V61, P1098, DOI 10.1136/jcp.2007.054627; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Norris MD, 2000, MED PEDIATR ONCOL, V35, P585, DOI 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.3.CO;2-G; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Ota S, 2007, DEVELOPMENT, V134, P1583, DOI 10.1242/dev.000703; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Paffhausen T, 2007, CANCER LETT, V250, P17, DOI 10.1016/j.canlet.2006.09.010; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1994, ONCOGENE, V9, P59; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Rohrer T, 2002, PEDIATR PULM, V33, P71, DOI 10.1002/ppul.10031; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; SAKSELA K, 1992, ONCOGENE, V7, P347; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schramm A, 2009, CANCER LETT, V282, P55, DOI 10.1016/j.canlet.2009.02.052; Schulte JH, 2009, CANCER LETT, V274, P10, DOI 10.1016/j.canlet.2008.06.010; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shang XY, 2009, MOL CANCER THER, V8, P2461, DOI 10.1158/1535-7163.MCT-08-0857; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Slack A, 2005, CANCER LETT, V228, P21, DOI 10.1016/j.canlet.2005.01.050; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Trochet D, 2005, AM J HUM GENET, V76, P421, DOI 10.1086/428366; Tweddle DA, 2001, CANCER RES, V61, P8; Ushmorov A, 2008, ONCOGENE, V27, P3424, DOI 10.1038/sj.onc.1211017; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Van Maerken T, 2009, CELL DEATH DIFFER, V16, P1563, DOI 10.1038/cdd.2009.138; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VOGAN K, 1993, CANCER RES, V53, P5269; Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094; Walkley CR, 2005, NAT CELL BIOL, V7, P172, DOI 10.1038/ncb1214; Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weiss WA, 2000, CANCER RES, V60, P2483; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Witt O, 2009, CURR PHARM DESIGN, V15, P436, DOI 10.2174/138161209787315774; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zask A, 2009, J MED CHEM, V52, P5013, DOI 10.1021/jm900851f; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	199	148	154	1	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1249	1259		10.1038/onc.2009.512	http://dx.doi.org/10.1038/onc.2009.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20101214	Green Accepted			2022-12-28	WOS:000275170600001
J	Fernandez, AF; Esteller, M				Fernandez, A. F.; Esteller, M.			Viral epigenomes in human tumorigenesis	ONCOGENE			English	Review						epigenetics; DNA methylation; histone modification; virus; viral oncogenes; human cancer	EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; HEPATITIS-B-VIRUS; T-CELL LEUKEMIA; HUMAN-PAPILLOMAVIRUS TYPE-16; IMMEDIATE-EARLY PROMOTER; DNA METHYLTRANSFERASE DNMT3A; LATENT NUCLEAR ANTIGEN; HUMAN CANCER-CELLS; CPG METHYLATION	Viruses are associated with 15-20% of human cancers worldwide. In the last century, many studies were directed towards elucidating the molecular mechanisms and genetic alterations by which viruses cause cancer. The importance of epigenetics in the regulation of gene expression has prompted the investigation of virus and host interactions not only at the genetic level but also at the epigenetic level. In this study, we summarize the published epigenetic information relating to the genomes of viruses directly or indirectly associated with the establishment of tumorigenic processes. We also review aspects such as viral replication and latency associated with epigenetic changes and summarize what is known about epigenetic alterations in host genomes and the implications of these for the tumoral process. The advances made in characterizing epigenetic features in cancer-causing viruses have improved our understanding of their functional mechanisms. Knowledge of the epigenetic changes that occur in the genome of these viruses should provide us with markers for following cancer progression, as well as new tools for cancer therapy. Oncogene (2010) 29, 1405-1420; doi:10.1038/onc.2009.517; published online 25 January 2010	[Esteller, M.] Hosp Duran & Reynals, PEBC, Bellvitge Biomed Res Inst, IDIBELL, Barcelona 08907, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, PEBC, Bellvitge Biomed Res Inst, IDIBELL, 3rd Floor,Gran Via 199-203, Barcelona 08907, Catalonia, Spain.	mesteller@iconcologia.net	Esteller, Manel/L-5956-2014; Fernandez, Agustin F./N-7302-2014	Esteller, Manel/0000-0003-4490-6093; Fernandez, Agustin F./0000-0002-3792-4085	Spanish Association Against Cancer (AECC); Fundacion Mutua Madrilena; Swiss Bridge Award;  [MCYT08-03]; ICREA Funding Source: Custom	Spanish Association Against Cancer (AECC); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Swiss Bridge Award; ; ICREA(ICREA)	This study was supported by grants I+D+I MCYT08-03, Spanish Association Against Cancer (AECC), Fundacion Mutua Madrilena and the Swiss Bridge Award. ME is an ICREA (Institucio Catalana de Recerca i Estudis Avancats) Research Professor.	Ambinder RF, 1999, SEMIN CANCER BIOL, V9, P369, DOI 10.1006/scbi.1999.0137; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Areste C, 2009, TRENDS MICROBIOL, V17, P119, DOI 10.1016/j.tim.2008.12.001; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Badal S, 2004, VIROLOGY, V324, P483, DOI 10.1016/j.virol.2004.04.002; Badal V, 2003, J VIROL, V77, P6227, DOI 10.1128/JVI.77.11.6227-6234.2003; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Barozzi P, 2007, AUTOIMMUN REV, V7, P132, DOI 10.1016/j.autrev.2007.02.018; Beck J, 2007, WORLD J GASTROENTERO, V13, P48, DOI 10.3748/wjg.v13.i1.48; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; Bernat A, 2003, ONCOGENE, V22, P7871, DOI 10.1038/sj.onc.1206896; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bhattacharjee B, 2006, VIROLOGY, V354, P280, DOI 10.1016/j.virol.2006.06.018; Bhende PM, 2005, J VIROL, V79, P7338, DOI 10.1128/JVI.79.12.7338-7348.2005; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brandsma JL, 2009, VIROLOGY, V389, P100, DOI 10.1016/j.virol.2009.03.029; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Breitbart M, 2005, TRENDS MICROBIOL, V13, P278, DOI 10.1016/j.tim.2005.04.003; Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Cai Xuezhong, 2006, PLoS Pathogens, V2, P236, DOI 10.1371/journal.ppat.0020023; Carbone A, 2007, INT J BIOL MARKER, V22, P161, DOI 10.1177/172460080702200211; Carbone A, 2005, BRIT J HAEMATOL, V130, P662, DOI 10.1111/j.1365-2141.2005.05613.x; Carbone A, 2009, CURR OPIN HIV AIDS, V4, P3, DOI 10.1097/COH.0b013e32831a722b; Chang Y, 2006, J VIROL, V80, P7748, DOI 10.1128/JVI.02608-05; Chen J, 2001, P NATL ACAD SCI USA, V98, P4119, DOI 10.1073/pnas.051004198; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684; Cinati J, 2004, TRENDS MOL MED, V10, P19, DOI 10.1016/j.molmed.2003.11.002; Cinatl J, 1996, INTERVIROLOGY, V39, P259, DOI 10.1159/000150527; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200; Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9; Countryman JK, 2008, J VIROL, V82, P4706, DOI 10.1128/JVI.00116-08; Cuevas-Bennett C, 2008, J VIROL, V82, P9525, DOI 10.1128/JVI.00946-08; Cullen BR, 2009, NATURE, V457, P421, DOI 10.1038/nature07757; Damania B, 2007, TRENDS MICROBIOL, V15, P38, DOI 10.1016/j.tim.2006.11.002; DANOS O, 1980, EUR J BIOCHEM, V109, P457, DOI 10.1111/j.1432-1033.1980.tb04815.x; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DeCaprio JA, 2009, VIROLOGY, V384, P274, DOI 10.1016/j.virol.2008.12.010; Derse D, 2007, J VIROL, V81, P6731, DOI 10.1128/JVI.02752-06; Di Bartolo DL, 2008, BLOOD, V111, P4731, DOI 10.1182/blood-2007-09-110544; Dickerson SJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000356; Dolken L, 2009, VIRUS GENES, V38, P355, DOI 10.1007/s11262-009-0347-0; Doerfler W, 1996, BBA-REV CANCER, V1288, pF79, DOI 10.1016/0304-419X(96)00024-8; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; Doi K, 2005, BLOOD, V106, P1048, DOI 10.1182/blood-2004-11-4350; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Duverger A, 2009, J VIROL, V83, P3078, DOI 10.1128/JVI.02058-08; DYSON PJ, 1985, J GEN VIROL, V66, P1931, DOI 10.1099/0022-1317-66-9-1931; de Oliveira DE, 2007, CANCER LETT, V247, P182, DOI 10.1016/j.canlet.2006.05.010; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Fejer G, 2008, J GEN VIROL, V89, P1364, DOI 10.1099/vir.0.83594-0; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fernandez AF, 2009, GENOME RES, V19, P438, DOI 10.1101/gr.083550.108; Ferrari R, 2009, NAT REV GENET, V10, P290, DOI 10.1038/nrg2539; Flanagan JM, 2007, BRIT J CANCER, V96, P183, DOI 10.1038/sj.bjc.6603516; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Fukayama M, 2008, CANCER SCI, V99, P1726, DOI 10.1111/j.1349-7006.2008.00888.x; GEORG WB, 2009, INT J CANCER, V124, P1745; Gerle B, 2007, J VIROL, V81, P13242, DOI 10.1128/JVI.01396-07; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Goel A, 2006, GASTROENTEROLOGY, V130, P1950, DOI 10.1053/j.gastro.2006.02.061; Gottwein E, 2008, CELL HOST MICROBE, V3, P375, DOI 10.1016/j.chom.2008.05.002; Gray KS, 2009, J VIROL, V83, P314, DOI 10.1128/JVI.01444-08; Grey F, 2008, MED MICROBIOL IMMUN, V197, P261, DOI 10.1007/s00430-007-0070-1; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Guo YH, 2009, J MED VIROL, V81, P1177, DOI 10.1002/jmv.21525; Gurtsevitch VE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P504, DOI 10.1134/S0006297908050039; Han YF, 2008, CELL HOST MICROBE, V4, P134, DOI 10.1016/j.chom.2008.06.008; HAUSEN HZ, 1977, CURR TOP MICROBIOL, P1; Heather J, 2009, J GEN VIROL, V90, P1450, DOI 10.1099/vir.0.007922-0; Herceg Z, 2009, J HEPATOL, V50, P252, DOI 10.1016/j.jhep.2008.11.013; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Horenstein MG, 2008, J CUTAN PATHOL, V35, P40, DOI 10.1111/j.1600-0560.2008.01118.x; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Hublarova P, 2009, INT J GYNECOL CANCER, V19, P321, DOI 10.1111/IGC.0b013e31819d8a5c; Ioudinkova E, 2006, GENE, V384, P120, DOI 10.1016/j.gene.2006.07.021; Ishida T, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-69; Javier RT, 2008, CANCER RES, V68, P7693, DOI 10.1158/0008-5472.CAN-08-3301; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Jiang GC, 2007, J VIROL, V81, P10914, DOI 10.1128/JVI.01208-07; Jiang MX, 2009, VIROLOGY, V384, P266, DOI 10.1016/j.virol.2008.09.027; Jin WB, 2007, COMPUT BIOL CHEM, V31, P124, DOI 10.1016/j.compbiolchem.2007.01.005; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jung JK, 2007, CANCER RES, V67, P5771, DOI 10.1158/0008-5472.CAN-07-0529; Kalantari M, 2004, J VIROL, V78, P12762, DOI 10.1128/JVI.78.23.12762-12772.2004; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kim K, 2003, J VIROL, V77, P12450, DOI 10.1128/JVI.77.23.12450-12459.2003; Kinlen L, 2004, ONCOGENE, V23, P6341, DOI 10.1038/sj.onc.1207898; Klein E, 2007, ONCOGENE, V26, P1297, DOI 10.1038/sj.onc.1210240; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lenasi T, 2008, CELL HOST MICROBE, V4, P123, DOI 10.1016/j.chom.2008.05.016; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Li H, 2003, ADV CANCER RES, V89, P133, DOI 10.1016/S0065-230X(03)01004-2; Li HP, 2005, CELL RES, V15, P262, DOI 10.1038/sj.cr.7290295; Li QH, 2008, VIROLOGY, V379, P234, DOI 10.1016/j.virol.2008.06.043; Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813; Liu Y, 2009, CHINESE MED J-PEKING, V122, P10, DOI 10.3760/cma.j.issn.0366-6999.2009.01.003; Lu F, 2006, J VIROL, V80, P5273, DOI 10.1128/JVI.02541-05; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; McLaughlin-Drubin ME, 2008, BBA-MOL BASIS DIS, V1782, P127, DOI 10.1016/j.bbadis.2007.12.005; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; Mehta AK, 2009, GENE, V428, P20, DOI 10.1016/j.gene.2008.09.033; Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178; MILLER RH, 1983, P NATL ACAD SCI-BIOL, V80, P2534, DOI 10.1073/pnas.80.9.2534; Minarovits J, 2006, CURR TOP MICROBIOL, V310, P61; Mok HP, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-228; Nair V, 2006, TRENDS MICROBIOL, V14, P169, DOI 10.1016/j.tim.2006.02.007; Niemhom S, 2008, CANCER DETECT PREV, V32, P127, DOI 10.1016/j.cdp.2008.05.005; Niller HH, 2008, AUTOIMMUNITY, V41, P298, DOI 10.1080/08916930802024772; Pantry SN, 2009, SEMIN CANCER BIOL, V19, P153, DOI 10.1016/j.semcancer.2009.02.010; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Park JH, 2007, BIOCHEM BIOPH RES CO, V358, P513, DOI 10.1016/j.bbrc.2007.04.169; Park JJ, 2007, J GEN VIROL, V88, P3214, DOI 10.1099/vir.0.83171-0; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Paulson EJ, 1999, J VIROL, V73, P9959, DOI 10.1128/JVI.73.12.9959-9968.1999; Payer B, 2008, ANNU REV GENET, V42, P733, DOI 10.1146/annurev.genet.42.110807.091711; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pollicino T, 2006, GASTROENTEROLOGY, V130, P823, DOI 10.1053/j.gastro.2006.01.001; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Prosch S, 1996, BIOL CHEM H-S, V377, P195, DOI 10.1515/bchm3.1996.377.3.195; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Reeves M, 2006, J VIROL, V80, P9998, DOI 10.1128/JVI.01297-06; Reshmi G, 2008, FEBS LETT, V582, P4113, DOI 10.1016/j.febslet.2008.11.011; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Robertson KD, 1997, BLOOD, V90, P4480, DOI 10.1182/blood.V90.11.4480.4480_4480_4484; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Sakakibara S, 2004, J VIROL, V78, P7299, DOI 10.1128/JVI.78.14.7299-7310.2004; Salamon D, 2001, J VIROL, V75, P2584, DOI 10.1128/JVI.75.6.2584-2596.2001; Samols MA, 2007, PLOS PATHOG, V3, P611, DOI 10.1371/journal.ppat.0030065; Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Seo GJ, 2008, J VIROL, V82, P9823, DOI 10.1128/JVI.01144-08; Shamay M, 2006, P NATL ACAD SCI USA, V103, P14554, DOI 10.1073/pnas.0604469103; Sharara AI, 1996, ANN INTERN MED, V125, P658, DOI 10.7326/0003-4819-125-8-199610150-00006; SHAW JE, 1979, J VIROL, V29, P657, DOI 10.1128/JVI.29.2.657-665.1979; Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006; Soderberg-Naucler C, 2006, J INTERN MED, V259, P219, DOI 10.1111/j.1365-2796.2006.01618.x; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; Stuber G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-28; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2003, CLIN IMMUNOL, V109, P53, DOI 10.1016/S1521-6616(03)00198-0; Thain A, 1996, J VIROL, V70, P7233, DOI 10.1128/JVI.70.10.7233-7235.1996; Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741; Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194; Turan T, 2007, VIROLOGY, V361, P185, DOI 10.1016/j.virol.2006.11.010; Turan T, 2006, VIROLOGY, V349, P175, DOI 10.1016/j.virol.2005.12.033; Verma SC, 2007, J VIROL, V81, P3402, DOI 10.1128/JVI.01607-06; Vivekanandan P, 2008, J VIRAL HEPATITIS, V15, P103, DOI 10.1111/j.1365-2893.2007.00905.x; Vivekanandan P, 2009, J INFECT DIS, V199, P1286, DOI 10.1086/597614; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; Whitby D, 2009, NAT GENET, V41, P7, DOI 10.1038/ng0109-7; Whiteside MA, 2008, CANCER-AM CANCER SOC, V113, P2981, DOI 10.1002/cncr.23750; Wiencke JK, 2008, ONCOGENE, V27, P2412, DOI 10.1038/sj.onc.1210895; Williams H, 2006, BLOOD, V107, P862, DOI 10.1182/blood-2005-07-2702; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Yasunaga JI, 2007, REV MED VIROL, V17, P301, DOI 10.1002/rmv.548; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yokosuka O, 2006, MED MOL MORPHOL, V39, P113, DOI 10.1007/s00795-006-0328-5; Yoshioka M, 2003, J MED VIROL, V70, P410, DOI 10.1002/jmv.10411; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971; zur Hausen H., 2006, INFECT CAUSING HUMAN; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	195	63	68	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1405	1420		10.1038/onc.2009.517	http://dx.doi.org/10.1038/onc.2009.517			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20101211				2022-12-28	WOS:000275392400001
J	Luo, J; Yang, J; Yu, BY; Liu, W; Li, M; Zhuang, SM				Luo, J.; Yang, J.; Yu, B-Y; Liu, W.; Li, M.; Zhuang, S-M			Identification of Siah-interacting protein as a potential regulator of apoptosis and curcumin resistance	ONCOGENE			English	Article						Siah-interacting protein; SIP; curcumin; apoptosis	CALCYCLIN-BINDING-PROTEIN; KINASE-C; ACQUIRED-RESISTANCE; CANCER-THERAPY; UP-REGULATION; BETA-CATENIN; CELLS; PHOSPHORYLATION; TRANSLOCATION; S100A6	The mechanism underlying curcumin (diferuloylmethane) resistance is still largely unknown. Here we employed proteomic approach to identify the Siah-interacting protein (SIP) as a candidate for detailed study, because the spot intensity of SIP on a two-dimensional gel displayed 70-90% reduction in curcumin-sensitive cells, but remained unchanged in curcumin-resistant sublines, after curcumin treatment. Both gain-and loss-of-function studies revealed that SIP promoted curcumin-induced apoptosis. Moreover, SIP underwent phosphorylation and nuclear translocation in curcumin-sensitive but not resistant cells, upon curcumin exposure. The nuclear translocation of SIP was remarkably impaired when a putative nuclear localization sequence (NLS, amino acid (aa) 143-159) was deleted or the serine 141 was mutated into alanine, whereas truncation of the N-terminal region (aa 1-43) obviously increased the nuclear import of SIP. In accordance with their nuclear localization, N-terminal truncation significantly enhanced the proapoptotic effect of SIP, whereas NLS deletion or Ser141Ala mutation attenuated the apoptosis-promoting activity of both wild-type- and N-terminal truncated-SIP. These data suggest that SIP plays a role in apoptosis and curcumin resistance, and the function of SIP may be regulated by different motifs, such as the NLS, N-terminal region and serine 141. Our findings provide new insights into the biological significance of SIP and the mechanisms of drug resistance. Oncogene (2010) 29, 6357-6366; doi:10.1038/onc.2010.358; published online 23 August 2010	[Luo, J.; Yang, J.; Yu, B-Y; Zhuang, S-M] Sun Yat Sen Univ, Sch Life Sci, Minist Educ, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China; [Liu, W.; Li, M.] Sun Yat Sen Univ, Zhongshan Sch Med, Prote Ctr, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhuang, SM (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Minist Educ, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.	zhuangshimei@163.com		Yang, Jin-E/0000-0002-7511-1042; Zhuang, Shi-Mei/0000-0002-2512-3942	National Natural Science Foundation of China [30470664]; Ministry of Science and Technology of China [2010CB912803, 2005CB724600]; Ministry of Education of China [105136]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Education of China(Ministry of Education, China)	This study was supported by grants from the National Natural Science Foundation of China (30470664), Ministry of Science and Technology of China (2010CB912803, 2005CB724600) and Ministry of Education of China (105136).	Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192; Bhandarkar SS, 2007, ADV EXP MED BIOL, V595, P185; Bhattacharya S, 2005, BIOCHEMISTRY-US, V44, P9462, DOI 10.1021/bi0502689; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Daouti S, 2009, CANCER RES, V69, P1924, DOI 10.1158/0008-5472.CAN-08-2627; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Filipek A, 2002, J BIOL CHEM, V277, P21103, DOI 10.1074/jbc.M111010200; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hsieh HL, 2002, J CELL SCI, V115, P3149; Huang HD, 2005, NUCLEIC ACIDS RES, V33, pD80; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Joo JH, 2008, J CELL BIOCHEM, V103, P1183, DOI 10.1002/jcb.21496; Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081; Kawamori T, 1999, CANCER RES, V59, P597; Kilanczyk E, 2009, BIOCHEM BIOPH RES CO, V380, P54, DOI 10.1016/j.bbrc.2009.01.026; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Li N, 2002, CARCINOGENESIS, V23, P1307, DOI 10.1093/carcin/23.8.1307; Lotfi K, 2002, BIOCHEM BIOPH RES CO, V293, P1489, DOI 10.1016/S0006-291X(02)00415-1; Mahmmoud YA, 2007, BRIT J PHARMACOL, V150, P200, DOI 10.1038/sj.bjp.0706970; Mansson E, 2002, BIOCHEM BIOPH RES CO, V298, P338, DOI 10.1016/S0006-291X(02)02471-3; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Ning XX, 2007, MOL CANCER RES, V5, P1254, DOI 10.1158/1541-7786.MCR-06-0426; O'Connor R, 2009, CURR CANCER DRUG TAR, V9, P273, DOI 10.2174/156800909788166583; Orre LM, 2007, MOL CELL PROTEOMICS, V6, P2122, DOI 10.1074/mcp.M700202-MCP200; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Shankar E, 2008, ONCOGENE, V27, P3957, DOI 10.1038/onc.2008.39; Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744; Sun SR, 2007, BIOCHEM BIOPH RES CO, V356, P864, DOI 10.1016/j.bbrc.2007.03.080; Takigawa Y, 2008, CURR DRUG TARGETS, V9, P1013, DOI 10.2174/138945008786786127; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Wang WZ, 2008, FEBS LETT, V582, P2689, DOI 10.1016/j.febslet.2008.06.048; Wu J, 2003, J BIOCHEM MOL BIOL, V36, P354; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; Yang YJ, 2006, LIFE SCI, V78, P753, DOI 10.1016/j.lfs.2005.05.100	41	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6357	6366		10.1038/onc.2010.358	http://dx.doi.org/10.1038/onc.2010.358			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20729913				2022-12-28	WOS:000284874700006
J	Li, H; Wang, W; Liu, X; Paulson, KE; Yee, AS; Zhang, X				Li, H.; Wang, W.; Liu, X.; Paulson, K. E.; Yee, A. S.; Zhang, X.			Transcriptional factor HBP1 targets P16(INK4A), upregulating its expression and consequently is involved in Ras-induced premature senescence	ONCOGENE			English	Article						Ras; HBP1; p16(INK4A); senescence; transformation	BREAST-CANCER CELLS; HUMAN MELANOCYTE; REPRESSOR HBP1; CYCLE ARREST; LIFE-SPAN; PROTEIN; KINASE; GENE; PATHWAY; TRANSFORMATION	Oncogene-mediated premature senescence has emerged as a potential tumor-suppressive mechanism in early cancer transitions. Many studies showed that Ras and p38 mitogen-activated protein kinase (MAPK) participate in premature senescence. Our previous work indicated that the HMG box-containing protein 1 (HBP1) transcription factor is involved in Ras- and p38 MAPK-induced premature senescence, but the mechanism of which has not yet been identified. Here, we showed that the p16(INK4A) cyclin-dependent kinase inhibitor is a novel target of HBP1 participating in Ras-induced premature senescence. The promoter of the p16(INK4A) gene contains an HBP1-binding site at position -426 to -433 bp from the transcriptional start site. HBP1 regulates the expression of the endogenous p16(INK4A) gene through direct sequence-specific binding. With HBP1 expression and the subsequent increase of p16(INK4A) gene expression, Ras induces premature senescence in primary cells. The data suggest a model in which Ras and p38 MAPK signaling engage HBP1 and p16(INK4A) to trigger premature senescence. In addition, we report that HBP1 knockdown is also required for Ras-induced transformation. All the data indicate that the mechanism of HBP1-mediated transcriptional regulation is important for not only premature senescence but also tumorigenesis. Oncogene (2010) 29, 5083-5094; doi:10.1038/onc.2010.252; published online 28 June 2010	[Li, H.; Wang, W.; Liu, X.; Zhang, X.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100191, Peoples R China; [Paulson, K. E.] Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA USA; [Yee, A. S.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Peking University; Tufts Medical Center; Tufts University	Zhang, X (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Xueyuan Rd 38, Beijing 100191, Peoples R China.	xiaoweizhang@bjmu.edu.cn			National Natural Science Foundation of China [30770442]; National Basic Research Programs of China [2007CB507400]; NIH/NCI [CA94187, CA104236]; Susan B Komen Foundation for the Cure [BCTR0504367]; NATIONAL CANCER INSTITUTE [R01CA104236, R01CA094187] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Programs of China(National Basic Research Program of China); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan B Komen Foundation for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Natural Science Foundation of China (no. 30770442) to Xiaowei Zhang, and from the National Basic Research Programs of China (no. 2007CB507400) to Tanjun Tong; from the NIH/NCI (CA94187 and CA104236) to Amy S Yee and the Susan B Komen Foundation for the Cure (BCTR0504367) to K Eric Paulson. We thank Dr Wengong Wang for helpful discussion on the paper.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Haferkamp S, 2008, AGING CELL, V7, P733, DOI 10.1111/j.1474-9726.2008.00422.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Haq R, 2002, CANCER RES, V62, P5076; Hornsby PJ, 2007, J CLIN ONCOL, V25, P1852, DOI 10.1200/JCO.2006.10.3101; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kim JE, 2008, INT J MOL MED, V22, P651, DOI 10.3892/ijmm_00000068; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Muscarella P, 2008, GENE EXPRESSION, V14, P207, DOI 10.3727/105221608786883825; Nelyudova A, 2007, CELL CYCLE, V6, P2171, DOI 10.4161/cc.6.17.4610; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Signer RAJ, 2008, GENE DEV, V22, P3115, DOI 10.1101/gad.1715808; Smith JM, 2004, DEV DYNAM, V230, P366, DOI 10.1002/dvdy.20053; Sokol JP, 2005, BREAST CANCER RES, V7, pR844, DOI 10.1186/bcr1312; Swanson KA, 2004, NAT STRUCT MOL BIOL, V11, P738, DOI 10.1038/nsmb798; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; Yee AS, 1999, PEDIATR PATHOL MOL M, V18, P275; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	48	43	49	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5083	5094		10.1038/onc.2010.252	http://dx.doi.org/10.1038/onc.2010.252			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581871				2022-12-28	WOS:000281620100008
J	Ye, X; Li, Y; Stawicki, S; Couto, S; Eastham-Anderson, J; Kallop, D; Weimer, R; Wu, Y; Pei, L				Ye, X.; Li, Y.; Stawicki, S.; Couto, S.; Eastham-Anderson, J.; Kallop, D.; Weimer, R.; Wu, Y.; Pei, L.			An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies	ONCOGENE			English	Article						monoclonal antibody; tumor stroma; combination therapies	RECEPTOR TYROSINE KINASE; CELL LUNG-CANCER; BREAST-CANCER; THERAPEUTIC TARGET; PROLONGS SURVIVAL; MYELOID-LEUKEMIA; EXPRESSION; INFLAMMATION; PROGRESSION; METASTASIS	Axl is expressed in various types of cancer and is involved in multiple processes of tumorigenesis, including promoting tumor cell growth, migration, invasion, metastasis as well as angiogenesis. To evaluate further the mechanisms involved in the expression/activation of Axl in various aspects of tumorigenesis, especially its roles in modulating tumor stromal functions, we have developed a phage-derived mAb (YW327.6S2) that recognizes both human and murine Axl. YW327.6S2 binds to both human and murine Axl with high affinity. It blocks the ligand Gas6 binding to the receptor, downregulates receptor expression, inhibits receptor activation and downstream signaling. In A549 non-small-cell lung cancer (NSCLC) and MDA-MB-231 breast cancer models, YW327.6S2 attenuates xenograft tumor growth and potentiates the effect of anti-VEGF treatment. In NSCLC models, YW327.6S2 also enhances the effect of erlotinib and chemotherapy in reducing tumor growth. Furthermore, YW327.6S2 reduces the metastasis of MDA-MB-231 breast cancer cells to distant organs. YW327.6S2 induces tumor cell apoptosis in NSCLC, reduces tumor-associated vascular density and inhibits the secretion of inflammatory cytokines and chemokines from tumor-associated macrophages in the breast cancer model. In conclusion, anti-Axl mAb can enhance the therapeutic efficacy of anti-VEGF, EGFR small-molecule inhibitors as well as chemotherapy. Axl mAb affects not only tumor cells but also tumor stroma through its modulation of tumor-associated vasculature and immune cell functions. Oncogene (2010) 29, 5254-5264; doi:10.1038/onc.2010.268; published online 5 July 2010	[Ye, X.; Li, Y.; Pei, L.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Stawicki, S.; Wu, Y.] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; [Couto, S.; Eastham-Anderson, J.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Kallop, D.; Weimer, R.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Pei, L (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	lpei@gene.com						Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Giaccone G, 2005, J CLIN ONCOL, V23, P3235, DOI 10.1200/JCO.2005.08.409; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Loges S, 2010, BLOOD, V115, P2264, DOI 10.1182/blood-2009-06-228684; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Meric F, 2002, CLIN CANCER RES, V8, P361; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Sidhu SS, 2004, J MOL BIOL, V338, P299, DOI 10.1016/j.jmb.2004.02.050; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	44	155	179	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5254	5264		10.1038/onc.2010.268	http://dx.doi.org/10.1038/onc.2010.268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20603615				2022-12-28	WOS:000282089100004
J	Lecomte, S; Desmots, F; Le Masson, F; Le Goff, P; Michel, D; Christians, ES; Le Drean, Y				Lecomte, S.; Desmots, F.; Le Masson, F.; Le Goff, P.; Michel, D.; Christians, E. S.; Le Drean, Y.			Roles of heat shock factor 1 and 2 in response to proteasome inhibition: consequence on p53 stability	ONCOGENE			English	Article						heat shock factor; MG132; proteasome; gankyrin; p53	TRANSCRIPTION FACTOR-1; EXPRESSION; GENE; ACTIVATION; STRESS; SYSTEM; DISRUPTION; RESISTANCE; APOPTOSIS; PROTEINS	A single heat shock factor (HSF), mediating the heat shock response, exists from yeast to Drosophila, whereas several related HSFs have been found in mammals. This raises the question of the specific or redundant functions of the different members of the HSF family and in particular of HSF1 and HSF2, which are both ubiquitously expressed. Using immortalized mouse embryonic fibroblasts (iMEFs) derived from wild-type, Hsf1(-/-), Hsf2(-/-) or double-mutant mice, we observed the distinctive behaviors of these mutants with respect to proteasome inhibition. This proteotoxic stress reduces to the same extent the viability of Hsf1(-/-)- and Hsf2(-/-)-deficient cells, but through different underlying mechanisms. Contrary to Hsf2(-/-) cells, Hsf1(-/-) cells are unable to induce pro-survival heat shock protein expression. Conversely, proteasome activity is lower in Hsf2(-/-) cells and the expression of some proteasome subunits, such as Psmb5 and gankyrin, is decreased. As gankyrin is an oncoprotein involved in p53 degradation, we analyzed the status of p53 in HSF-deficient iMEFs and observed that it was strongly stabilized in Hsf2(-/-) cells. This study points a new role for HSF2 in the regulation of protein degradation and suggests that pan-HSF inhibitors could be valuable tools to reduce chemoresistance to proteasome inhibition observed in cancer therapy. Oncogene ( 2010) 29, 4216-4224; doi: 10.1038/onc.2010.171; published online 24 May 2010	[Lecomte, S.; Desmots, F.; Le Goff, P.; Michel, D.; Le Drean, Y.] Univ Rennes 1, IFR Genom Fonct Agron & Sante 140, CNRS, UMR 6026, F-35042 Rennes, France; [Le Masson, F.; Christians, E. S.] Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Le Drean, Y (corresponding author), Univ Rennes 1, IFR Genom Fonct Agron & Sante 140, CNRS, UMR 6026, Bat 13,Campus Beaulieu, F-35042 Rennes, France.	yves.le-drean@univ-rennes1.fr	Le Dréan, Yves/L-4822-2015; LE GOFF, PASCALE/K-1842-2015; Lecomte, Sylvain/K-1745-2015	LE GOFF, PASCALE/0000-0002-3931-2197; 	Canceropole Grand Ouest; CNRS; French Ministry of Higher Education and Research (MENRT); 'Association pour la Recherche sur le Cancer' (ARC)	Canceropole Grand Ouest; CNRS(Centre National de la Recherche Scientifique (CNRS)); French Ministry of Higher Education and Research (MENRT); 'Association pour la Recherche sur le Cancer' (ARC)(Fondation ARC pour la Recherche sur le Cancer)	This work was supported by Canceropole Grand Ouest and CNRS. SL and FLM were supported by a fellowship from the French Ministry of Higher Education and Research (MENRT), and FD by a fellowship from the 'Association pour la Recherche sur le Cancer' (ARC). We thank Dr V Mezger (UMR CNRS 7216, Paris, France) for the gift of immortalized MEFs, and V Noel for the help in in silico analysis. We also thank Frederic Percevault for the establishment of a stable clone expressing HSF2 from Hsf2<SUP>-/-</SUP> iMEFs.	Akerfelt M, 2007, ANN NY ACAD SCI, V1113, P15, DOI 10.1196/annals.1391.005; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bush KT, 1997, J BIOL CHEM, V272, P9086; Busse A, 2008, CANCER, V112, P659, DOI 10.1002/cncr.23224; Cantalupo PG, 2009, VIROLOGY, V386, P183, DOI 10.1016/j.virol.2008.12.038; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Fuchs D, 2008, J CELL BIOCHEM, V103, P270, DOI 10.1002/jcb.21405; Hahn JS, 2006, MOL MICROBIOL, V60, P240, DOI 10.1111/j.1365-2958.2006.05097.x; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; Jin XJ, 2009, J CELL BIOCHEM, V107, P504, DOI 10.1002/jcb.22151; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kisselev AF, 2005, METHOD ENZYMOL, V398, P364, DOI 10.1016/S0076-6879(05)98030-0; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nencioni A, 2007, LEUKEMIA, V21, P30, DOI 10.1038/sj.leu.2404444; Oerlemans R, 2008, BLOOD, V112, P2489, DOI 10.1182/blood-2007-08-104950; Ostling P, 2007, J BIOL CHEM, V282, P7077, DOI 10.1074/jbc.M607556200; Paul S, 2008, BIOESSAYS, V30, P1172, DOI 10.1002/bies.20852; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; Ruckrich T, 2009, LEUKEMIA, V23, P1098, DOI 10.1038/leu.2009.8; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; Sato Y, 2009, BIOCHEM BIOPH RES CO, V378, P795, DOI 10.1016/j.bbrc.2008.11.125; Schwartz AL, 1999, ANNU REV MED, V50, P57; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Taylor DM, 2005, CELL STRESS CHAPERON, V10, P230, DOI 10.1379/CSC-119R.1; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Tsirigotis M, 2001, BIOTECHNIQUES, V31, P120, DOI 10.2144/01311rr03; Twombly R, 2003, J NATL CANCER I, V95, P845, DOI 10.1093/jnci/95.12.845; Wilkerson DC, 2007, CELL STRESS CHAPERON, V12, P283, DOI 10.1379/CSC-250.1; Xing HY, 2005, SCIENCE, V307, P421, DOI 10.1126/science.1106478; Yamamoto N, 2009, FEBS J, V276, P1962, DOI 10.1111/j.1742-4658.2009.06923.x; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692	45	31	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4216	4224		10.1038/onc.2010.171	http://dx.doi.org/10.1038/onc.2010.171			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498630	Green Submitted			2022-12-28	WOS:000280151500009
J	Wu, Q; Sahasrabudhe, RM; Luo, LZ; Lewis, DW; Gollin, SM; Saunders, WS				Wu, Q.; Sahasrabudhe, R. M.; Luo, L. Z.; Lewis, D. W.; Gollin, S. M.; Saunders, W. S.			Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells	ONCOGENE			English	Article						cytokinesis; myosin light-chain kinase; multinucleation; multipolar spindles; myosin phosphatase; myosin regulatory light chain	RHO-ASSOCIATED KINASE; SMOOTH-MUSCLE MYOSIN; CHROMOSOMAL INSTABILITY; CLEAVAGE FURROW; CITRON-KINASE; CENTROSOME; LINES; CONSEQUENCES; PHOSPHATASE; INVASION	Cancer cells often have unstable genomes and increased centrosome and chromosome numbers, which are an important part of malignant transformation in the most recent model of tumorigenesis. However, very little is known about divisional failures in cancer cells that may lead to chromosomal and centrosomal amplifications. In this study, we show that cancer cells often failed at cytokinesis because of decreased phosphorylation of the myosin regulatory light chain (MLC), a key regulatory component of cortical contraction during division. Reduced MLC phosphorylation was associated with high expression of myosin phosphatase and/or reduced myosin light-chain kinase levels. Furthermore, expression of phosphomimetic MLC largely prevented cytokinesis failure in the tested cancer cells. When myosin light-chain phosphorylation was restored to normal levels by phosphatase knockdown, multinucleation and multipolar mitosis were markedly reduced, resulting in enhanced genome stabilization. Furthermore, both overexpression of myosin phosphatase or inhibition of the myosin light-chain kinase in nonmalignant cells could recapitulate some of the mitotic defects of cancer cells, including multinucleation and multipolar spindles, indicating that these changes are sufficient to reproduce the cytokinesis failures we see in cancer cells. These results for the first time define the molecular defects leading to divisional failure in cancer cells. Oncogene ( 2010) 29, 4183-4193; doi: 10.1038/onc.2010.165; published online 24 May 2010	[Wu, Q.; Sahasrabudhe, R. M.; Saunders, W. S.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Luo, L. Z.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; [Lewis, D. W.; Gollin, S. M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA; [Lewis, D. W.; Gollin, S. M.; Saunders, W. S.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City of Hope; Beckman Research Institute of City of Hope; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Saunders, WS (corresponding author), Univ Pittsburgh, Dept Biol Sci, 258 Crawford Hall, Pittsburgh, PA 15260 USA.	wsaund@pitt.edu		Luo, Li/0000-0002-8680-4119; Gollin, Susanne/0000-0001-5438-6808	NIH [R01DE016086, R01DE14729, P30CA47904]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014729] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr David J Hartshorne (University of Arizona) for kindly providing the UPCI:SCC103 cell line and HEK293 with the MYPT1 expression cell line, respectively. We are also grateful to Dr Jeffrey D Hildebrand (University of Pittsburgh), Dr Anne R Bresnick (Albert Einstein College of Medicine), Dr Kathleen Kelly (National Cancer Institute), Dr David J Hartshorne (University of Arizona) and Dr James T Stull (University of Texas Southwestern Medical Center) for plasmids and antibodies. We also thank Dr Xiaojing Wang (University of Pittsburgh) for helpful discussions regarding statistical analysis and Dr Jian Huang (University of Texas Southwestern Medical Center) for helpful suggestions about urea glycerol electrophoresis. This study was supported in part by NIH grants R01DE016086 to WSS and SMG and R01DE14729 to SMG and WSS. Cytogenetic analyses were carried out in the UPCI Cytogenetics Facility, supported in part by NIH grant P30CA47904 to Ronald B Herberman/SMG.	Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Eda M, 2001, J CELL SCI, V114, P3273; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gu LZ, 2006, EUR J CANCER, V42, P948, DOI 10.1016/j.ejca.2005.12.017; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Kaneko K, 2002, PANCREAS, V24, P34, DOI 10.1097/00006676-200201000-00005; King RW, 2008, BBA-REV CANCER, V1786, P4, DOI 10.1016/j.bbcan.2008.07.007; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lemez P, 1998, LEUKEMIA RES, V22, P581, DOI 10.1016/S0145-2126(97)00177-X; Lothschutz D, 2002, INFLAMM RES, V51, P416, DOI 10.1007/PL00000323; Lucero A, 2006, MOL BIOL CELL, V17, P4093, DOI 10.1091/mbc.E06-02-0119; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; PARK SH, 1995, CANCER GENET CYTOGEN, V83, P127, DOI 10.1016/0165-4608(95)00040-V; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silverman-Gavrila RV, 2001, CELL MOTIL CYTOSKEL, V50, P180, DOI 10.1002/cm.10006; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Takanishi DM, 1996, ARCH SURG-CHICAGO, V131, P587; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Tohtong R, 2003, PROSTATE CANCER P D, V6, P212, DOI 10.1038/sj.pcan.4500663; VANELDIK LJ, 1984, MOL CELL BIOL, V4, P2224, DOI 10.1128/MCB.4.10.2224; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; White JS, 2007, ORAL ONCOL, V43, P701, DOI 10.1016/j.oraloncology.2006.09.001; WORD RA, 1991, AM J PHYSIOL, V260, pC861, DOI 10.1152/ajpcell.1991.260.4.C861; Xia DL, 2005, EXP CELL RES, V304, P506, DOI 10.1016/j.yexcr.2004.11.025	36	33	34	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4183	4193		10.1038/onc.2010.165	http://dx.doi.org/10.1038/onc.2010.165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498637	Green Accepted			2022-12-28	WOS:000280151500006
J	Fishler, T; Li, YY; Wang, RH; Kim, HS; Sengupta, K; Vassilopoulos, A; Lahusen, T; Xu, X; Lee, MH; Liu, Q; Elledge, SJ; Ried, T; Deng, CX				Fishler, T.; Li, Y-Y; Wang, R-H; Kim, H-S; Sengupta, K.; Vassilopoulos, A.; Lahusen, T.; Xu, X.; Lee, M-H; Liu, Q.; Elledge, S-J; Ried, T.; Deng, C-X			Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53	ONCOGENE			English	Article						Chk1; mitotic catastrophe; genome integrity; mammary cancer; SB-218078	CELL-CYCLE CHECKPOINT; PHASE-I TRIAL; DNA-DAMAGE; SPINDLE CHECKPOINT; BRCA1; KINASE; BREAST; INHIBITOR; LACKING; ARREST	Checkpoint kinase 1 (Chk1) is a key element in the DNA-damage response pathway that is required for maintaining genomic stability. To study the potential role of Chk1 in mammary tumorigenesis, we disrupted it using a Cre/loxP system. We showed that although Chk1 heterozygosity caused abnormal development of the mammary gland, it was not sufficient to induce tumorigenesis. Simultaneous deletion of one copy of p53 failed to rescue the developmental defects; however, it synergistically induced mammary tumor formation in Chk(;)(1+/-) MMTV-Cre animals with a median time to tumor latency of about 10 months. Chk1 deficiency caused a preponderance of abnormalities, including prolongation, multipolarity, misalignment, mitotic catastrophe and loss of spindle checkpoint, that are accompanied by reduced expression of several cell cycle regulators, including Mad2. On the other hand, we also showed that Chk1 deficiency inhibited mammary tumor formation in mice carrying a homozygous deletion of p53, uncovering a complex relationship between Chk1 and p53. Furthermore, inhibition of Chk1 with a specific inhibitor, SB-218078, or acute deletion of Chk1 using small hairpin RNA killed mammary tumor cells effectively. These data show that Chk1 is critical for maintaining genome integrity and serves as a double-edged sword for cancer: although its inhibition kills cancer cells, it also triggers tumorigenesis when favorable mutations are accumulated for cell growth. Oncogene (2010) 29, 4007-4017; doi:10.1038/onc.2010.163; published online 17 May 2010	[Deng, C-X] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Sengupta, K.; Ried, T.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Liu, Q.; Elledge, S-J] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Rm 9N105, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016	Lee, Mi-Hye/0000-0002-5484-3383	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; NATIONAL CANCER INSTITUTE [ZIABC010836, ZIABC010835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056004, ZIADK056011, ZIADK056001, ZIADK056010, ZIADK056009] Funding Source: NIH RePORTER	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We gratefully acknowledge members of Deng laboratory for a critical reading of the article. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blagden S, 2005, CURR DRUG TARGETS, V6, P325, DOI 10.2174/1389450053765824; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Carrassa L, 2009, J CELL MOL MED, V13, P1565, DOI [10.1111/j.1582-4934.2008.00362.x, 10.1111/j.1582-4934.2009.00362.x]; Collura A, 2005, MOL CELL BIOL, V25, P7889, DOI 10.1128/MCB.25.17.7889-7899.2005; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Durkin SG, 2006, ONCOGENE, V25, P4381, DOI 10.1038/sj.onc.1209466; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuse E, 1998, CANCER RES, V58, P3248; HARPER JW, 1993, CELL, V75, P805; Hotte SJ, 2006, ANN ONCOL, V17, P334, DOI 10.1093/annonc/mdj076; Jackson JR, 2000, CANCER RES, V60, P566; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kortmansky J, 2005, J CLIN ONCOL, V23, P1875, DOI 10.1200/JCO.2005.03.116; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Li W, 2007, ONCOGENE, V26, P7204, DOI 10.1038/sj.onc.1210527; Liu QH, 2000, GENE DEV, V14, P1448; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takai H, 2000, GENE DEV, V14, P1439; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yarden RI, 2001, J CELL BIOCHEM, V83, P521, DOI 10.1002/jcb.1257; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	48	39	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2010	29	28					4007	4017		10.1038/onc.2010.163	http://dx.doi.org/10.1038/onc.2010.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473325	Green Accepted			2022-12-28	WOS:000279892400002
J	Heublein, S; Kazi, S; Ogmundsdottir, MH; Attwood, EV; Kala, S; Boyd, CAR; Wilson, C; Goberdhan, DCI				Heublein, S.; Kazi, S.; Oegmundsdottir, M. H.; Attwood, E. V.; Kala, S.; Boyd, C. A. R.; Wilson, C.; Goberdhan, D. C. I.			Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation	ONCOGENE			English	Article						SLC36; PAT; mTORC1; amino-acid sensing; transporter; transceptor	XENOPUS-LAEVIS OOCYTES; PI3K PATHWAY; RAG GTPASES; CANCER; GROWTH; RAPAMYCIN; KINASE; TARGET; LOCALIZATION; METABOLISM	The phosphoinositide3-kinase (PI3K)/Akt and downstream mammalian target of rapamycin complex 1 (mTORC1) signalling cascades promote normal growth and are frequently hyperactivated in tumour cells. mTORC1 is also regulated by local nutrients, particularly amino acids, but the mechanisms involved are poorly understood. Unexpectedly, members of the proton-assisted amino-acid transporter (PAT or SLC36) family emerged from in vivo genetic screens in Drosophila as transporters with uniquely potent effects on mTORC1-mediated growth. In this study, we show the two human PATs that are widely expressed in normal tissues and cancer cell lines, namely PAT1 and PAT4, behave similarly to fly PATs when expressed in Drosophila. Small interfering RNA knockdown shows that these molecules are required for the activation of mTORC1 targets and for proliferation in human MCF-7 breast cancer and HEK-293 embryonic kidney cell lines. Furthermore, activation of mTORC1 in starved HEK-293 cells stimulated by amino acids requires PAT1 and PAT4, and is elevated in PAT1-overexpressing cells. Importantly, in HEK-293 cells, PAT1 is highly concentrated in intracellular compartments, including endosomes, wherein mTOR shuttles upon amino-acid stimulation. Therefore our data are consistent with a model in which PATs modulate the activity of mTORC1 not by transporting amino acids into the cell but by modulating the intracellular response to amino acids. Oncogene (2010) 29, 4068-4079; doi:10.1038/onc.2010.177; published online 24 May 2010	[Heublein, S.; Kazi, S.; Oegmundsdottir, M. H.; Attwood, E. V.; Kala, S.; Boyd, C. A. R.; Wilson, C.; Goberdhan, D. C. I.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England	University of Oxford	Goberdhan, DCI (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Le Gros Clark Bldg,S Parks Rd, Oxford OX1 3QX, England.	deborah.goberdhan@dpag.ox.ac.uk			Cancer Research-UK [C19591/A9093, C191591/A6181, C7713/A6174]; Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; University of Oxford; Newton Abraham Studentship and Overseas Research	Cancer Research-UK(Cancer Research UK); Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; University of Oxford; Newton Abraham Studentship and Overseas Research	We thank Toshiro Aigaki, Hugo Bellen and the Bloomington Stock Centre for fly strains, Robert Edwards (UCSF) for generously providing the PAT1 antisera and Vuk Stambolic (Toronto) for the GFP-Rheb construct. We are grateful to Dr David Meredith (Oxford Brookes University) for helpful discussion and to Bass Hassan and Claudia Buehnemann for comments on the paper. This work was supported by Cancer Research-UK grants (C19591/A9093, C191591/A6181 and C7713/A6174), funding from the Studienstiftung des deutschen Volkes and the Max Weber Programm Bayern to SH and a University of Oxford, Newton Abraham Studentship and Overseas Research Student Award to MHO.	Atkins MB, 2009, NAT REV DRUG DISCOV, V8, P535, DOI 10.1038/nrd2924; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Bermingham JR, 2004, MAMM GENOME, V15, P114, DOI 10.1007/s00335-003-2319-3; Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Chang YY, 2009, BIOCHEM SOC T, V37, P232, DOI 10.1042/BST0370232; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Cohen A, 2009, CELL, V136, P399, DOI 10.1016/j.cell.2009.01.021; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Findlay GM, 2007, BIOCHEM J, V403, P13, DOI 10.1042/BJ20061881; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Gao MG, 2006, NAT CELL BIOL, V8, P657, DOI 10.1038/ncb1419; Goberdhan DCI, 2005, DEVELOPMENT, V132, P2365, DOI 10.1242/dev.01821; Goberdhan DCI, 2003, DIFFERENTIATION, V71, P375, DOI 10.1046/j.1432-0436.2003.7107001.x; Goberdhan DCI, 2009, BIOCHEM SOC T, V37, P248, DOI 10.1042/BST0370248; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hafen E, 2004, SWISS MED WKLY, V134, P711; Hietakangas V, 2009, ANNU REV GENET, V43, P389, DOI 10.1146/annurev-genet-102108-134815; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Hundal HS, 2009, AM J PHYSIOL-ENDOC M, V296, pE603, DOI 10.1152/ajpendo.91002.2008; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Kim RH, 2006, BRIT J CANCER, V94, P620, DOI 10.1038/sj.bjc.6602994; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Panitsas KE, 2006, PFLUG ARCH EUR J PHY, V452, P53, DOI 10.1007/s00424-005-0002-0; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Reynolds B, 2007, BIOCHEM SOC T, V35, P1215, DOI 10.1042/BST0351215; Rubio-Aliaga I, 2004, J BIOL CHEM, V279, P2754, DOI 10.1074/jbc.M305556200; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Toivonen JM, 2009, MOL CELL ENDOCRINOL, V299, P39, DOI 10.1016/j.mce.2008.07.005; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zinzalla V, 2008, NATURE, V454, P287, DOI 10.1038/454287a	48	111	116	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4068	4079		10.1038/onc.2010.177	http://dx.doi.org/10.1038/onc.2010.177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20498635	Green Accepted			2022-12-28	WOS:000279892400007
J	Osborne, LC; Duthie, KA; Seo, JH; Gascoyne, RD; Abraham, N				Osborne, L. C.; Duthie, K. A.; Seo, J. H.; Gascoyne, R. D.; Abraham, N.			Selective ablation of the YxxM motif of IL-7R alpha suppresses lymphomagenesis but maintains lymphocyte development	ONCOGENE			English	Article						lymphoma; haploinsufficiency; IL-7; c-myc; knock-in mouse models	ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL RECEPTOR; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; INTERLEUKIN (IL)-7; IL-7; ACTIVATION; BCL-2; PROLIFERATION; EXPRESSION	Tumor progression is a multiple step process in which, in addition to oncogenic mutation, other supporting factors can contribute to transformation. The role these factors have in cancer is an open question. Using the E mu-myc model of B-cell transformation, we evaluated the contribution of the cytokine interleukin-7 (IL-7) in supporting lymphomagenesis. We have previously shown that disruption of the Y449xxM motif of the IL-7 receptor alpha (IL-7R alpha) in a knock-in mouse model (IL-7R alpha(449F)) has minor effects on lymphocyte production, but interferes with the activation of survival effectors. To address the hypothesis that targeted signal ablation would selectively affect lymphocyte transformation, IL-7R alpha(449F) mice were crossed with two lymphomagenesis models, transgenic (Tg) IL-7 and E mu-myc mice. We found that the loss of IL-7R alpha Y449 signaling prevented Tg IL-7-mediated T-and B-lymphocyte transformation and decreased the development of E mu-myc-induced B-cell tumors. We showed that the IL-7R alpha(449F) mutation prevented increased survival of Tg IL-7 CD8 T cells, and decreased viability of bone marrow progenitor B cells, as well as E mu-myc-induced proliferation. This study shows that IL-7R alpha Y449 is important for lymphocyte transformation, and that unlike deficiencies in pre-B cell receptor signaling, Myc overexpression cannot compensate for the loss of IL-7R alpha signals in early B-cell development. Oncogene (2010) 29, 3854-3864; doi: 10.1038/onc.2010.133; published online 3 May 2010	[Abraham, N.] Univ British Columbia, Dept Microbiol & Immunol, Dept Zool, Inst Life Sci, Vancouver, BC V5T 2L9, Canada; [Gascoyne, R. D.] Univ British Columbia, BC Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5T 2L9, Canada; [Abraham, N.] Univ British Columbia, Inst Life Sci, Dept Zool, Vancouver, BC V5T 2L9, Canada	University of British Columbia; British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Abraham, N (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Dept Zool, Inst Life Sci, 3552-2350 Hlth Sci Mall, Vancouver, BC V5T 2L9, Canada.	ninan@interchange.ubc.ca	Abraham, Ninan/K-5572-2012; Gascoyne, Randy D/A-6009-2013; Osborne, Lisa/K-3027-2015	Abraham, Ninan/0000-0002-2747-1246; Gascoyne, Randy D/0000-0002-2610-5690; Osborne, Lisa/0000-0002-7170-3235	Canadian Institutes for Health Research (CIHR) [MOP-67005, MOP-84532]; Michael Smith Foundation for Health Research (MSFHR); Natural Sciences and Engineering Research Council (NSERC); CIHR/MSFHR	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); Natural Sciences and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR/MSFHR(Michael Smith Foundation for Health ResearchCanadian Institutes of Health Research (CIHR))	We thank Dr Robert Kay, Martin Richer and Caylib Durand for critical reading of the paper; Jill Miners, Eric Ma Asavee and Rachel Kim for animal colony maintenance and genotyping; Dr Sarah Gaffen for technical assistance; Nadia Gale and staff at the Centre for Translational and Applied Genomics; Dr Christine Eischen for providing C57BL/6 E mu-myc mice; Dr Bart Vanhaesebroeck for providing C57BL/6 p110 delta<SUP>D910A</SUP> mice; Dr Philippa Marrack for providing anti-Bim-producing Ham151 cells and the Wesbrook Animal Unit staff for animal husbandry. This work is supported by the Canadian Institutes for Health Research (CIHR) (MOP-67005 and MOP-84532 to N Abraham). LCO was supported by studentships from the Michael Smith Foundation for Health Research (MSFHR), the Natural Sciences and Engineering Research Council (NSERC) and the CIHR/MSFHR Strategic Training Program in Transplantation Research. KAD was supported by an NSERC Postgraduate scholarship. NA holds CIHR New Investigator and MSFHR Career Investigator awards.	Abraham N, 2005, ONCOGENE, V24, P5252, DOI 10.1038/sj.onc.1208726; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Cattaruzza L, 2009, INT J CANCER, V125, P1092, DOI 10.1002/ijc.24389; Duthie KA, 2007, MOL CELL PROTEOMICS, V6, P1700, DOI 10.1074/mcp.M600468-MCP200; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; El Kassar N, 2004, BLOOD, V104, P1419, DOI 10.1182/blood-2004-01-0201; Fleming HE, 2002, SEMIN IMMUNOL, V14, P423, DOI 10.1016/S1044532302000775; FOSS HD, 1995, AM J PATHOL, V146, P33; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Juarez J, 2007, HAEMATOLOGICA, V92, P450, DOI 10.3324/haematol.10621; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kotani A, 2007, P NATL ACAD SCI USA, V104, P1616, DOI 10.1073/pnas.0610732104; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Lali FV, 2004, J IMMUNOL, V172, P3527, DOI 10.4049/jimmunol.172.6.3527; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LONG BW, 1995, P NATL ACAD SCI USA, V92, P1416, DOI 10.1073/pnas.92.5.1416; Marshall AJ, 1998, J IMMUNOL, V161, P6038; *NAT CANC I CAN CA, 2008, CAN CANC STAT; Nepal RM, 2008, ONCOGENE, V27, P4752, DOI 10.1038/onc.2008.111; Nilsson LM, 2007, ONCOGENE, V26, P2833, DOI 10.1038/sj.onc.1210104; Osborne LC, 2007, J EXP MED, V204, P619, DOI 10.1084/jem.20061871; Pallard C, 1999, IMMUNITY, V10, P525, DOI 10.1016/S1074-7613(00)80052-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Sasson SC, 2010, CYTOKINE, V50, P58, DOI 10.1016/j.cyto.2009.12.001; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Scupoli MT, 2007, HAEMATOLOGICA, V92, P264, DOI 10.3324/haematol.10356; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wei CJ, 2000, J IMMUNOL, V164, P1961, DOI 10.4049/jimmunol.164.4.1961; Wen RR, 2006, MOL CELL BIOL, V26, P9364, DOI 10.1128/MCB.00839-06; Wofford JA, 2008, BLOOD, V111, P2101, DOI 10.1182/blood-2007-06-096297; Yasuda T, 2008, IMMUNITY, V28, P499, DOI 10.1016/j.immuni.2008.02.015	40	9	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3854	3864		10.1038/onc.2010.133	http://dx.doi.org/10.1038/onc.2010.133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440272				2022-12-28	WOS:000279385200013
J	Damiano, L; Di Stefano, P; Leal, MPC; Barba, M; Mainiero, F; Cabodi, S; Tordella, L; Sapino, A; Castellano, I; Canel, M; Frame, M; Turco, E; Defilippi, P				Damiano, L.; Di Stefano, P.; Leal, M. P. Camacho; Barba, M.; Mainiero, F.; Cabodi, S.; Tordella, L.; Sapino, A.; Castellano, I.; Canel, M.; Frame, M.; Turco, E.; Defilippi, P.			p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation	ONCOGENE			English	Article						cell motility; p140Cap; Ras; Src; tumour growth	BREAST-CANCER; EGF RECEPTOR; GROWTH; TUMORIGENESIS; PROGRESSION; ACTIVATION	The adaptor protein p140Cap/SNIP is a novel Src-binding protein that regulates Src activation through C-terminal Src kinase (Csk). Here, by gain and loss of function approaches in breast and colon cancer cells, we report that p140Cap immobilizes E-cadherin at the cell membrane and inhibits EGFR and Erk1/2 signalling, blocking scatter and proliferation of cancer cells. p140Cap-dependent regulation of E-cadherin/EGFR cross-talk and cell motility is due to the inhibition of Src kinase. However, rescue of Src activity is not sufficient to restore Erk1/2 phosphorylation and proliferation. Indeed, p140Cap also impairs Erk1/2 phosphorylation by affecting Ras activity, downstream to the EGFR. In conclusion, p140Cap stabilizes adherens junctions and inhibits EGFR and Ras signalling through the dual control of both Src and Ras activities, thus affecting crucial cancer properties such as invasion and growth. Interestingly, p140Cap expression is lost in more aggressive human breast cancers, showing an inverse correlation with EGFR expression. Therefore, p140Cap mechanistically behaves as a tumour suppressor that inhibits signalling pathways leading to aggressive phenotypes. Oncogene (2010) 29, 3677-3690; doi: 10.1038/onc.2010.128; published online 10 May 2010	[Damiano, L.; Di Stefano, P.; Leal, M. P. Camacho; Cabodi, S.; Tordella, L.; Turco, E.; Defilippi, P.] Univ Turin, Dept Genet Biol & Biochem, I-10125 Turin, TO, Italy; [Damiano, L.; Di Stefano, P.; Leal, M. P. Camacho; Cabodi, S.; Tordella, L.; Turco, E.; Defilippi, P.] Univ Turin, Ctr Mol Biotechnol, I-10125 Turin, TO, Italy; [Barba, M.; Mainiero, F.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; [Sapino, A.; Castellano, I.] Univ Turin, Dept Biomed Sci & Human Oncol, I-10125 Turin, TO, Italy; [Frame, M.] Western Gen Hosp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Turin; University of Turin; Sapienza University Rome; University of Turin; University of Edinburgh	Defilippi, P (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Via Nizza 52, I-10125 Turin, TO, Italy.	paola.defilippi@unito.it	Sapino, Anna/J-4113-2018; Sapino, Anna/AGY-9901-2022; DEFILIPPI, Paola/L-2232-2014; Castellano, Isabella/K-1888-2018	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571; Cabodi, Sara/0000-0003-1248-6549; Frame, Margaret/0000-0001-5882-1942; Tordella, Luca/0000-0002-0542-7834; Castellano, isabella/0000-0002-9072-1615; Mainiero, Fabrizio/0000-0002-7136-9839; Defilippi, Paola/0000-0001-6427-4906	AIRC; AICR; EU; MUR; Progetto Alfieri; Regione Piemonte (Oncoprot, Druidi, PiStem and BioTher); Regione Piemonte Sanita	AIRC(Fondazione AIRC per la ricerca sul cancro); AICR; EU(European Commission); MUR(Ministry of Education, Universities and Research (MIUR)); Progetto Alfieri; Regione Piemonte (Oncoprot, Druidi, PiStem and BioTher)(Regione Piemonte); Regione Piemonte Sanita	We thank PP Pandolfi (Boston, MA), A Sorkin (Denver, Co), J Stow (Brisbane, Australia), C Sasaki (Baltimore, Maryland) and K Nishida (Osaka, Japan) for reagent gifts. This work was supported by grants from the AIRC, AICR, EU FP7 Metafight program, MUR, Progetto Alfieri, Regione Piemonte (Oncoprot, Druidi, PiStem and BioTher), Regione Piemonte Sanita. MP Camacho Leal is supported by the AICR.	Alema S, 2007, BBA-MOL CELL RES, V1773, P47, DOI 10.1016/j.bbamcr.2006.06.001; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Di Stefano P, 2004, MOL BIOL CELL, V15, P787, DOI 10.1091/mbc.E03-09-0689; Di Stefano P, 2007, EMBO J, V26, P2843, DOI 10.1038/sj.emboj.7601724; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Glynn RW, 2010, CANCER TREAT REV, V36, P224, DOI 10.1016/j.ctrv.2009.12.007; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Kennedy S, 2008, BRIT J CANCER, V98, P1641, DOI 10.1038/sj.bjc.6604365; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; Reynolds AB, 2007, BBA-MOL CELL RES, V1773, P2, DOI 10.1016/j.bbamcr.2006.09.019; Sasaki CY, 2000, CANCER RES, V60, P7057; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284	32	42	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3677	3690		10.1038/onc.2010.128	http://dx.doi.org/10.1038/onc.2010.128			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20453886				2022-12-28	WOS:000279108600008
J	Ye, Y; Pringle, LM; Lau, AW; Riquelme, DN; Wang, H; Jiang, T; Lev, D; Welman, A; Blobel, GA; Oliveira, AM; Chou, MM				Ye, Y.; Pringle, L. M.; Lau, A. W.; Riquelme, D. N.; Wang, H.; Jiang, T.; Lev, D.; Welman, A.; Blobel, G. A.; Oliveira, A. M.; Chou, M. M.			TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappa B	ONCOGENE			English	Article						TRE17/USP6; aneurysmal bone cyst; MMP-9; Arf6; NF-kappa B; RhoA	ENDOTHELIAL GROWTH-FACTOR; IN-SITU HYBRIDIZATION; DEUBIQUITINATING ENZYME; MATRIX-METALLOPROTEINASE-9 EXPRESSION; STROMELYSIN-2 MMP-10; UBIQUITIN LIGASE; CARCINOMA CELLS; CDC42 GTPASES; RHO-GTPASES; PATHWAY	Aneurysmal bone cyst (ABC) is an aggressive, pediatric bone tumor characterized by extensive destruction of the surrounding bone. Although first described over 60 years ago, its molecular etiology remains poorly understood. Recent work revealed that ABCs harbor translocation of TRE17/USP6, leading to its transcriptional upregulation. TRE17 encodes a ubiquitin-specific protease (USP), and a TBC domain that mediates binding to the Arf6 GTPase. However, the mechanisms by which TRE17 overexpression contributes to tumor pathogenesis, and the role of its USP and TBC domains, are unknown. ABCs are characterized by osteolysis, inflammatory recruitment and extensive vascularization, the processes in which matrix proteases have a prominent role. This led us to explore whether TRE17 regulates the production of matrix metalloproteinases ( MMPs). In this study we show that TRE17 is sufficient to induce expression of MMP-9 and MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6. TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappa B (NF-kappa B), mediated in part by the GTPase RhoA and its effector kinase, ROCK. Furthermore, xenograft studies show that TRE17 induces formation of tumors that reproduce multiple features of ABC, including a high degree of vascularization, with an essential role for the USP domain. In sum, these studies reveal that TRE17 is sufficient to initiate tumorigenesis, identify MMPs as novel TRE17 effectors that likely contribute to ABC pathogenesis and define the underlying signaling mechanism of their induction. Oncogene ( 2010) 29, 3619-3629; doi: 10.1038/onc.2010.116; published online 26 April 2010	[Ye, Y.; Pringle, L. M.; Lau, A. W.; Riquelme, D. N.; Chou, M. M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wang, H.; Blobel, G. A.] Univ Penn, Childrens Hosp Philadelphia, Div Pediat, Sch Med, Philadelphia, PA 19104 USA; [Jiang, T.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Lev, D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Welman, A.] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland; [Oliveira, A. M.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Edinburgh; Mayo Clinic	Chou, MM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Sch Med, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu			NIH [CA081415, DK58044, P30 AR050950]; Mayo Foundation; Pennsylvania Muscle Institute; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK058044, R01DK058044] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; Pennsylvania Muscle Institute; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the NIH Grants CA081415 (MMC), DK58044 (GAB) and P30 AR050950 (Penn Center for Musculoskeletal Disorders). Additional support was from the Mayo Foundation CR20 Program (AMO), the Pennsylvania Muscle Institute Pilot Project Grant (MMC) and the Pennsylvania Department of Health (MMC), which specifically disclaims responsibility for any analysis, interpretations or conclusions. We thank Yvette Liu for invaluable assistance with bioluminescence imaging.	Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Barksby HE, 2006, ARTHRITIS RHEUM-US, V54, P3244, DOI 10.1002/art.22167; Benitah SA, 2003, MOL BIOL CELL, V14, P3041, DOI 10.1091/mbc.E03-01-0016; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bizimungu C, 2005, BIOCHEM BIOPH RES CO, V335, P883, DOI 10.1016/j.bbrc.2005.07.159; Bizimungu C, 2007, BIOTECHNOL LETT, V29, P1927, DOI 10.1007/s10529-007-9475-6; Bord S, 1998, BONE, V23, P7, DOI 10.1016/S8756-3282(98)00064-7; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bryan B, 2005, FEBS LETT, V579, P1015, DOI 10.1016/j.febslet.2004.12.074; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cottalorda J, 2007, ARCH ORTHOP TRAUM SU, V127, P105, DOI 10.1007/s00402-006-0223-5; Cui RW, 2006, CIRC RES, V99, P723, DOI 10.1161/01.RES.0000244015.10655.3f; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Genersch E, 2000, J CELL SCI, V113, P4319; Ghajar CM, 2008, CRIT REV EUKAR GENE, V18, P251, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.30; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Haeusler G, 2005, CALCIFIED TISSUE INT, V76, P326, DOI 10.1007/s00223-004-0161-6; Han SW, 2006, J BIOL CHEM, V281, P29614, DOI 10.1074/jbc.M604013200; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Kanangat S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2086; Kim KC, 2005, ARCH PHARM RES, V28, P1257, DOI 10.1007/BF02978209; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krampert M, 2004, MOL BIOL CELL, V15, P5242, DOI 10.1091/mbc.E04-02-0109; Kumta SM, 2003, LIFE SCI, V73, P1427, DOI 10.1016/S0024-3205(03)00434-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Nakakuki T, 2005, ARTERIOSCL THROM VAS, V25, P2088, DOI 10.1161/01.ATV.0000183607.50230.9f; NAKAMURA T, 1992, ONCOGENE, V7, P733; Nielsen GP, 2002, AM J SURG PATHOL, V26, P64, DOI 10.1097/00000478-200201000-00007; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Saccomanni B, 2008, ARCH ORTHOP TRAUM SU, V128, P1145, DOI 10.1007/s00402-007-0477-6; Sebban H, 2006, TRENDS CELL BIOL, V16, P569, DOI 10.1016/j.tcb.2006.09.004; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Shinde A, 2006, PEDIATR DEVEL PATHOL, V9, P38, DOI 10.2350/06-05-0070.1; Singhal S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S3; Solt LA, 2007, J BIOL CHEM, V282, P8724, DOI 10.1074/jbc.M609613200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Welman A, 2006, NEOPLASIA, V8, P905, DOI 10.1593/neo.06475; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamaguchi T, 2007, J BIOL CHEM, V282, P33943, DOI 10.1074/jbc.M706282200; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	67	102	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3619	3629		10.1038/onc.2010.116	http://dx.doi.org/10.1038/onc.2010.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418905	Green Accepted			2022-12-28	WOS:000279108600003
J	van Eekelen, M; Sasportas, LS; Kasmieh, R; Yip, S; Figueiredo, JL; Louis, DN; Weissleder, R; Shah, K				van Eekelen, M.; Sasportas, L. S.; Kasmieh, R.; Yip, S.; Figueiredo, J-L; Louis, D. N.; Weissleder, R.; Shah, K.			Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors	ONCOGENE			English	Article						brain tumor; glioma; human neural stem cells; TSP-1; endothelial cells; angiogenesis; in vivo imaging	IN-VIVO; MALIGNANT GLIOMA; THERAPY; CANCER; ABT-510; GROWTH; APOPTOSIS; ENDOSTATIN; INHIBITOR; MIGRATION	Novel therapeutic agents combined with innovative modes of delivery and non-invasive imaging of drug delivery, pharmacokinetics and efficacy are crucial in developing effective clinical anticancer therapies. In this study, we have created and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that comprises unique regions of three type-I-repeats of TSP-1 and used engineered human neural stem cells (hNSC) to provide sustained on-site delivery of secretable aaTSP-1 to tumor-vasculature. We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microvascular endothelial cells co-cultured with established glioma cells and CD133+ glioma-initiating cells. Using human glioma cells and hNSC engineered with different combinations of fluorescent and bioluminescent marker proteins and employing multi-modality imaging techniques, we show that aaTSP-1 targets the vascular-component of gliomas and a single administration of hNSC-aaTSP-1 markedly reduces tumor vessel-density that results in inhibition of tumor-progression and increased survival in mice bearing highly malignant human gliomas. We also show that therapeutic hNSC do not proliferate and remain in an un-differentiated state in the brains of glioma-bearing mice. This study provides a platform for accelerated development of future cell-based therapies for cancer. Oncogene (2010) 29, 3185-3195; doi: 10.1038/onc.2010.75; published online 22 March 2010	[van Eekelen, M.; Sasportas, L. S.; Kasmieh, R.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA USA; [van Eekelen, M.; Sasportas, L. S.; Kasmieh, R.; Figueiredo, J-L; Weissleder, R.; Shah, K.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Louis, D. N.; Shah, K.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Yip, S.; Louis, D. N.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Yip, S.; Louis, D. N.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Figueiredo, J-L; Weissleder, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Shah, K (corresponding author), Harvard Univ, Mol Neurotherapy & Imaging Lab, Massachusetts Gen Hosp, Dept Radiol & Neurol,Med Sch, Rm 5403,149,13th St, Charlestown, MA 02129 USA.	kshah@helix.mgh.harvard.edu	Yip, Stephen/E-9994-2012; van Eekelen, Mark/A-6225-2010	Yip, Stephen/0000-0002-8514-9861; /0000-0003-0828-4143	American Cancer Society; Goldhirsh foundation; Alliance for Cancer Gene Therapy [P50 CA86355, R21CA131980]; NATIONAL CANCER INSTITUTE [P50CA086355, R21CA131980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071197] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Goldhirsh foundation; Alliance for Cancer Gene Therapy; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by American Cancer Society (KS), Goldhirsh foundation (KS), Alliance for Cancer Gene Therapy (KS), P50 CA86355 (KS, RW), R21CA131980 (KS). We thank Dr Rainer Koehler for his help with intravital microscopy and Dr Claudio Vinegoni for his help with processing images. We also thank Dr Jack Lawler (Beth Israel Deaconess Hospital, Boston) for providing us with TSP-1 cDNA construct and Dr Paul van Bergen en Henegouwen (Utrecht University, The Netherlands) for his constructive comments.	Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Anderson JC, 2007, CANCER BIOL THER, V6, P454, DOI 10.4161/cbt.6.3.3630; ASAISHI K, 1981, CANCER RES, V41, P1898; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Capillo M, 2003, CLIN CANCER RES, V9, P377; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Corsten MF, 2008, LANCET ONCOL, V9, P376, DOI 10.1016/S1470-2045(08)70099-8; Drixler TA, 2000, CANCER RES, V60, P1761; Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001; Ehtesham M, 2002, CANCER RES, V62, P7170; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Guerin C, 1997, EXS, V79, P47; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoekstra R, 2006, EUR J CANCER, V42, P467, DOI 10.1016/j.ejca.2005.08.040; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kisker O, 2001, CANCER RES, V61, P7669; Kock N, 2007, NEOPLASIA, V9, P435, DOI 10.1593/neo.07223; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Liu P, 2003, LEUKEMIA RES, V27, P701, DOI 10.1016/S0145-2126(02)00346-6; Markovic SN, 2007, AM J CLIN ONCOL-CANC, V30, P303, DOI 10.1097/01.coc.0000256104.80089.35; Montet X, 2007, RADIOLOGY, V242, P751, DOI 10.1148/radiol.2423052065; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Rusk A, 2006, CLIN CANCER RES, V12, P7444, DOI 10.1158/1078-0432.CCR-06-0109; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Shah K, 2004, CANCER RES, V64, P3236, DOI 10.1158/0008-5472.CAN-03-3516; Shah K, 2003, ONCOGENE, V22, P6865, DOI 10.1038/sj.onc.1206748; Shah K, 2008, J NEUROSCI, V28, P4406, DOI 10.1523/JNEUROSCI.0296-08.2008; Tang Y, 2003, HUM GENE THER, V14, P1247, DOI 10.1089/104303403767740786; Tuettenberg J, 2006, CRIT REV ONCOL HEMAT, V59, P181, DOI 10.1016/j.critrevonc.2006.01.004; Verhaegen M, 2002, ANAL CHEM, V74, P4378, DOI 10.1021/ac025742k; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088; Zhang XF, 2007, CANCER LETT, V247, P143, DOI 10.1016/j.canlet.2006.04.003	37	50	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3185	3195		10.1038/onc.2010.75	http://dx.doi.org/10.1038/onc.2010.75			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305695	Green Accepted			2022-12-28	WOS:000278321100002
J	Zhao, F; Mancuso, A; Bui, TV; Tong, X; Gruber, JJ; Swider, CR; Sanchez, PV; Lum, JJ; Sayed, N; Melo, JV; Perl, AE; Carroll, M; Tuttle, SW; Thompson, CB				Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Swider, C. R.; Sanchez, P. V.; Lum, J. J.; Sayed, N.; Melo, J. V.; Perl, A. E.; Carroll, M.; Tuttle, S. W.; Thompson, C. B.			Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1 alpha-induced metabolic reprograming	ONCOGENE			English	Article						imatinib (Gleevec, STI571); resistance; HIF-1 alpha; pentose phosphate pathway; glucose metabolism; cell survival	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR; EXPRESSION LEVELS; POSITIVE CELLS; CLINICAL RESISTANCE; PENTOSE-PHOSPHATE; CYCLE ACTIVITY; GROWTH-FACTOR; SENSITIVITY	As chronic myeloid leukemia (CML) progresses from the chronic phase to blast crisis, the levels of BCR-ABL increase. In addition, blast-transformed leukemic cells display enhanced resistance to imatinib in the absence of BCR-ABL-resistance mutations. In this study, we show that when BCR-ABL-transformed cell lines were selected for imatinib resistance in vitro, the cells that grew out displayed a higher BCR-ABL expression comparable to the increase seen in accelerated forms of the disease. This enhanced expression of BCR-ABL was associated with an increased rate of glycolysis but with a decreased rate of proliferation. The higher level of BCR-ABL expression in the selected cells correlated with a nonhypoxic induction of hypoxia-inducible factor-1 alpha (HIF-1 alpha) that was required for cells to tolerate enhanced BCR-ABL signaling. HIF-1 alpha induction resulted in an enhanced rate of glycolysis but with reduced glucose flux through both the tricarboxylic acid cycle and the oxidative arm of the pentose phosphate pathway (PPP). The reduction in oxidative PPP-mediated ribose synthesis was compensated by the HIF1 alpha-dependent activation of the nonoxidative PPP enzyme, transketolase, in imatinib-resistant CML cells. In both primary cultures of cells from patients exhibiting blast transformation and in vivo xenograft tumors, use of oxythiamine, which can inhibit both the pyruvate dehydrogenase complex and transketolase, resulted in enhanced imatinib sensitivity of tumor cells. Together, these results suggest that oxythiamine can enhance imatinib efficacy in patients who present an accelerated form of the disease. Oncogene (2010) 29, 2962-2972; doi:10.1038/onc.2010.67; published online 15 March 2010	[Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Sayed, N.; Thompson, C. B.] Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Swider, C. R.; Sanchez, P. V.; Perl, A. E.; Carroll, M.] Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; [Lum, J. J.] BC Canc Agcy, Trev & Joyce Deeley Res Ctr, Victoria, BC, Canada; [Melo, J. V.] SA Pathol, Div Haematol, Adelaide, SA, Australia; [Melo, J. V.] Ctr Canc Biol, Adelaide, SA, Australia; [Tuttle, S. W.] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; British Columbia Cancer Agency; SA Pathology; Centre for Cancer Biology; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Ctr, 421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Mancuso, Anthony/AAP-9358-2020	Lum, Julian/0000-0002-5624-3541	NCI; NIH; NATIONAL CANCER INSTITUTE [R01CA105463, P01CA104838, R01CA092660, K01CA129151] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Thompson laboratory, especially Tullia Lindsten, Mondira Kundu, Uma Sachdeva and Scott Olejniczak, for helpful suggestions during the study and careful critique of the paper. We thank Dr E Buchdunger (Novartis, Basel, Switzerland) for providing imatinib and Dr EP Reddy (Temple University, Philadelphia) for providing cell lines expressing either the WT or mutant (T315I) form of BCR-ABL. We are grateful to Dr MC Simon (University of Pennsylvania), Dr JL Riley (University of Pennsylvania) and Dr DA Tuveson (Cancer Research UK Cambridge Research Institute, UK) for providing experimental reagents. This work was supported in part by grants from the NCI and NIH.	Barnes DJ, 2005, CANCER RES, V65, P8912, DOI 10.1158/0008-5472.CAN-05-0076; Barnes K, 2005, ONCOGENE, V24, P3257, DOI 10.1038/sj.onc.1208461; Bell EL, 2007, ESSAYS BIOCHEM, V43, P17, DOI 10.1042/bse0430017; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chamberlain BR, 1996, ANN CLIN BIOCHEM, V33, P352, DOI 10.1177/000456329603300413; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dewar AL, 2005, IMMUNOL CELL BIOL, V83, P48, DOI 10.1111/j.1440-1711.2004.01296.x; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Giuntoli S, 2006, LEUKEMIA, V20, P1291, DOI 10.1038/sj.leu.2404224; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; Gumireddy K, 2005, P NATL ACAD SCI USA, V102, P1992, DOI 10.1073/pnas.0408283102; Gupte SA, 2006, AM J PHYSIOL-HEART C, V290, pH2228, DOI 10.1152/ajpheart.00615.2005; Haseloff RF, 2006, PROTEOMICS, V6, P1803, DOI 10.1002/pmic.200500182; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; Khorashad JS, 2006, LEUKEMIA, V20, P658, DOI 10.1038/sj.leu.2404137; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kominsky DJ, 2009, CLIN CANCER RES, V15, P3442, DOI 10.1158/1078-0432.CCR-08-3291; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Modi H, 2007, BLOOD, V109, P5411, DOI 10.1182/blood-2006-06-032490; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Sherbenou DW, 2007, J CLIN INVEST, V117, P2067, DOI 10.1172/JCI31988; Thompson JE, 2007, EXP HEMATOL, V35, P21, DOI 10.1016/j.exphem.2006.08.017; Tuttle SW, 2007, J BIOL CHEM, V282, P36790, DOI 10.1074/jbc.M700327200; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; ZAHAREVITZ DW, 1992, EUR J BIOCHEM, V210, P293, DOI 10.1111/j.1432-1033.1992.tb17420.x; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	36	134	139	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					2962	2972		10.1038/onc.2010.67	http://dx.doi.org/10.1038/onc.2010.67			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20228846	Green Accepted			2022-12-28	WOS:000277890400007
J	Shimizu, S; Konishi, A; Nishida, Y; Mizuta, T; Nishina, H; Yamamoto, A; Tsujimoto, Y				Shimizu, S.; Konishi, A.; Nishida, Y.; Mizuta, T.; Nishina, H.; Yamamoto, A.; Tsujimoto, Y.			Involvement of JNK in the regulation of autophagic cell death	ONCOGENE			English	Article						JNK; autophagic cell death; Atg5	SIGNAL-TRANSDUCTION; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; BAX; TRANSLOCATION; MITOCHONDRIA	Programmed cell death is a crucial process in the normal development and physiology of metazoans, and it can be divided into several categories that include type I death (apoptosis) and type II death (autophagic cell death). The Bcl-2 family proteins are well-characterized regulators of apoptosis, among which multidomain pro-apoptotic members (such as Bax and Bak) function as a mitochondrial gateway at which various apoptotic signals converge. Although embryonic fibroblasts from Bax/Bak double-knockout (DKO) mice are resistant to apoptosis, we have previously reported that these cells still die by autophagy in response to various death stimuli. In this study, we found that jun N-terminal kinase (JNK) was activated in etoposide-and staurosporine-treated, but not serum-starved, Bax/Bak DKO cells, and that autophagic cell death was suppressed by the addition of a JNK inhibitor and by a dominant-negative mutant of JNK. Studies with sek1(-/-)mkk7(-/-) cells revealed that disruption of JNK prevented the induction of autophagic cell death. Co-activation of JNK and autophagy induced autophagic cell death. Activation of JNK occurred downstream of the induction of autophagy, and was dependent on the autophagic process. These results indicate that JNK activation is crucial for the autophagic death of Bax/Bak DKO cells. Oncogene (2010) 29, 2070-2082; doi: 10.1038/onc.2009.487; published online 18 January 2010	[Shimizu, S.; Nishida, Y.; Mizuta, T.] Tokyo Med & Dent Univ, Med Res Inst, Dept Pathol Cell Biol, Bunkyo Ku, Tokyo 1035802, Japan; [Shimizu, S.; Nishida, Y.; Tsujimoto, Y.] Osaka Univ, Sch Med, Dept Med Genet, Suita, Osaka 565, Japan; [Konishi, A.] Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Bunkyo Ku, Tokyo 1035802, Japan; [Nishina, H.] Tokyo Med & Dent Univ, Med Res Inst, Dept Dev & Regenerat Biol, Bunkyo Ku, Tokyo 1035802, Japan; [Yamamoto, A.] Nagahama Inst Biosci & Technol, Dept Biosci, Nagahama, Japan	Tokyo Medical & Dental University (TMDU); Osaka University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Shimizu, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Pathol Cell Biol, Bunkyo Ku, Yushima 1-5-45, Tokyo 1035802, Japan.	shimizu.pcb@mri.tmd.ac.jp; tsujimot@gene.med.osaka-u.ac.jp	Konishi, Akimitsu/J-4024-2019	Konishi, Akimitsu/0000-0002-3291-0821	National Institute of Biomedical Innovation (NIBIO); Japanese Ministry of Education, Science, Sports and Culture; Japanese Ministry of Health, Labor and Welfare; Uehara Memorial Foundation; Naito Foundation	National Institute of Biomedical Innovation (NIBIO)(National Institute of Biomedical Innovation); Japanese Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Uehara Memorial Foundation(Uehara Memorial Foundation); Naito Foundation(Naito Memorial Foundation)	We thank Dr N Mizushima for providing us with MEFs from Atg5 <SUP>/</SUP> and Atg5<SUP>+/+</SUP> mice and pCAGGS-GFP-LC3 plasmid. We also thank Drs R Davis and Y Gotoh for providing PCMV5-JNK1 APF plasmid and pCDNA3 MKK7-JNK1 WT plasmid, respectively. This study was partly supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO); a grant for Scientific Research on Priority Areas, SORST of Japan Science and Technology Corp; a grant for the 21st Century COE Program; a grant for Creative Scientific Research from the Japanese Ministry of Education, Science, Sports and Culture; and a grant for Comprehensive Research on Aging and Health from the Japanese Ministry of Health, Labor and Welfare. This study was also supported by grants from the Uehara Memorial Foundation and the Naito Foundation.	Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cheng Y, 2008, BIOCHEM BIOPH RES CO, V376, P483, DOI 10.1016/j.bbrc.2008.09.018; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harris CA, 2001, J BIOL CHEM, V276, P37754; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; KLINONSKY DJ, 2005, CURR BIOL, V15, pR282; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shimizu S, 1996, ONCOGENE, V12, P2251; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103	28	132	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2070	2082		10.1038/onc.2009.487	http://dx.doi.org/10.1038/onc.2009.487			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101227				2022-12-28	WOS:000276402800006
J	Andrieu, C; Taieb, D; Baylot, V; Ettinger, S; Soubeyran, P; De-Thonel, A; Nelson, C; Garrido, C; So, A; Fazli, L; Bladou, F; Gleave, M; Iovanna, JL; Rocchi, P				Andrieu, C.; Taieb, D.; Baylot, V.; Ettinger, S.; Soubeyran, P.; De-Thonel, A.; Nelson, C.; Garrido, C.; So, A.; Fazli, L.; Bladou, F.; Gleave, M.; Iovanna, J. L.; Rocchi, P.			Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E	ONCOGENE			English	Article						prostate cancer; androgen independence; heat shock protein 27; eukaryotic translational initiation factor; ubiquitination	INITIATION-FACTOR 4E; INDEPENDENT PROGRESSION; PROTEASOMAL DEGRADATION; 4E-BINDING PROTEIN-1; LNCAP TUMORS; CYCLIN D1; TRANSLATION; GROWTH; HEAT-SHOCK-PROTEIN-27; APOPTOSIS	One strategy to improve therapies in advanced prostate cancer (PC) involves targeting genes that are activated by androgen withdrawal to delay the emergence of the androgen-independent (AI) phenotype. Heat shock protein 27 (Hsp27) expression becomes highly upregulated in PC cells after androgen withdrawal or chemotherapy, in which it functions as a cytoprotective chaperone to confer broadspectrum treatment resistance. The purpose of this study is to elucidate anti-apoptotic pathways regulated by Hsp27 that are activated during PC progression. Using two-hybrid experiment, we found that Hsp27 was having a major role in the protein translational initiation process. Furthermore, using complementary DNA (cDNA) microarray analysis, 4E binding protein 1 was identified as being proportionately and highly regulated by Hsp27. These data led us to analyze the protein synthesis initiation pathway, which is a prerequisite for cell growth and proliferation. Using northern and western blot analysis, we found that Hsp27 downregulation decreased eukaryotic translation initiation factor 4E (eIF4E) expression at the protein, but not mRNA, level. The cytoprotection afforded by Hsp27 overexpression was attenuated by eIF4E knockdown using specific eIF4E short interfering RNA (siRNA). Co-immunoprecipitation and co-immunofluorescence confirmed that Hsp27 colocalizes and interacts directly with eIF4E. Hsp27-eIF4E interaction decreases eIF4E ubiquitination and proteasomal degradation. By chaperoning eIF4E, Hsp27 seems to protect the protein synthesis initiation process to enhance cell survival during cell stress induced by castration or chemotherapy. Forced overexpression of eIF4E induces resistance to androgen-withdrawal and paclitaxel treatment in the prostate LNCaP cells in vitro. These findings identify Hsp27 as a modulator of eIF4E and establish a potential mechanism for the eIF4E-regulated apoptosis after androgen ablation and chemotherapy. Targeting Hsp27-eIF4E interaction may serve as a therapeutic target in advanced PC. Oncogene (2010) 29, 1883-1896; doi:10.1038/onc.2009.479; published online 18 January 2010	[Andrieu, C.; Taieb, D.; Baylot, V.; Soubeyran, P.; Iovanna, J. L.; Rocchi, P.] INSERM, Stress Cellulaire U624, F-13009 Marseille, France; [Andrieu, C.; Taieb, D.; Baylot, V.; Soubeyran, P.; Iovanna, J. L.; Rocchi, P.] Aix Marseille Univ, Marseille, France; [Ettinger, S.; Nelson, C.; So, A.; Fazli, L.; Gleave, M.] Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada; [De-Thonel, A.; Garrido, C.] INSERM, U866, Fac Med, Dijon, France; [Bladou, F.] Hop St Marguerite, Serv Urol, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of British Columbia; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Rocchi, P (corresponding author), INSERM, U624, Prostate Canc Res Project, Parc Sci & Technol Luminy,163 Ave Luminy, F-13009 Marseille, Provence, France.	palma.rocchi@inserm.fr	Baylot, Virginie/AAR-1416-2021; Soubeyran, Philippe/P-1758-2018; Andrieu, Claudia/O-4432-2017; Taieb, Pr. David/M-5219-2017; Garrido, Carolina/GWM-5557-2022; Baylot, Virginie/HCI-7158-2022; Iovanna, Juan/M-9805-2017; Rocchi, Palma/P-5455-2014; Garrido, carmen/G-1633-2018	Baylot, Virginie/0000-0003-1313-2857; Iovanna, Juan/0000-0003-1822-2237; Rocchi, Palma/0000-0002-4383-4684; Garrido, carmen/0000-0003-1368-1493; de Thonel, Aurelie/0000-0003-0405-0745; Soubeyran, Philippe/0000-0002-5876-3217	l'Institut National de la Sante et de la Recherche Medicale ( INSERM); l'Association pour la Recherche sur le Cancer (ARC); l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	l'Institut National de la Sante et de la Recherche Medicale ( INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); l'Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	We thank Dr Valentina Evdokimova (British Columbia Cancer Agency, Canada) for her helpful advice on eIF4E experiments. We thank Dr Takayuki Murata (McGill University, Canada) for providing the pcDNA3.1 FLAG-tagged eIF4E vectors. We thank Virginia Yago and Paul Jugpal (Prostate Centre, Canada) for their excellent technical assistance in animal and laboratory experimentation. We thank Dr Jonathan Nowak (Inserm U624, France) for his excellent help in confocal microscopy. This work was supported from grants by l'Institut National de la Sante et de la Recherche Medicale (INSERM), l'Association pour la Recherche sur le Cancer (ARC) and l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP).	Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Arora S, 2005, CANCER RES, V65, P3806, DOI 10.1158/0008-5472.CAN-04-4036; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Cornford PA, 2000, CANCER RES, V60, P7099; Frankfurt OS, 1997, CLIN CANCER RES, V3, P465; Fusi A, 2004, TUMORI J, V90, P535, DOI 10.1177/030089160409000601; Gallagher Eva, 2006, Clin J Oncol Nurs, V10, P233, DOI 10.1188/06.CJON.233-240; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; HOTTE SJ, 2009, J CLIN ONCOL S, V27, pS15; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kamada M, 2007, MOL CANCER THER, V6, P299, DOI 10.1158/1535-7163.MCT-06-0417; Kiyama S, 2003, CANCER RES, V63, P3575; Liang JJN, 2000, FEBS LETT, V484, P98, DOI 10.1016/S0014-5793(00)02136-0; Lucas A, 2006, J UROLOGY, V176, pS72, DOI 10.1016/j.juro.2006.06.077; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meli M, 2006, J MED CHEM, V49, P7721, DOI 10.1021/jm060836y; Miller H, 2005, ARTERIOSCL THROM VAS, V25, pE10, DOI 10.1161/01.ATV.0000156536.89752.8e; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2000, CANCER RES, V60, P3058; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Oridate N, 2005, CANCER BIOL THER, V4, P318, DOI 10.4161/cbt.4.3.1504; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, ONCOGENE, V23, P9111, DOI 10.1038/sj.onc.1208154; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369	48	109	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1883	1896		10.1038/onc.2009.479	http://dx.doi.org/10.1038/onc.2009.479			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101233				2022-12-28	WOS:000276199600002
J	Lauring, J; Cosgrove, DP; Fontana, S; Gustin, JP; Konishi, H; Abukhdeir, AM; Garay, JP; Mohseni, M; Wang, GM; Higgins, MJ; Gorkin, D; Reis, M; Vogelstein, B; Polyak, K; Cowherd, M; Buckhaults, PJ; Park, BH				Lauring, J.; Cosgrove, D. P.; Fontana, S.; Gustin, J. P.; Konishi, H.; Abukhdeir, A. M.; Garay, J. P.; Mohseni, M.; Wang, G. M.; Higgins, M. J.; Gorkin, D.; Reis, M.; Vogelstein, B.; Polyak, K.; Cowherd, M.; Buckhaults, P. J.; Park, B. H.			Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations	ONCOGENE			English	Article						Akt1; oncogene; knock in; gene targeting; breast epithelial cells	PLECKSTRIN HOMOLOGY DOMAIN; PTEN LOSS; PHOSPHOINOSITIDE 3-KINASE; HIGH-FREQUENCY; CANCER; ACTIVATION; CARCINOMA; GENE; CORRELATE; PATHWAY	An oncogenic mutation (G49A:E17K) in the AKT1 gene has been described recently in human breast, colon, and ovarian cancers. The low frequency of this mutation and perhaps other selective pressures have prevented the isolation of human cancer cell lines that harbor this mutation thereby limiting functional analysis. Here, we create a physiologic in vitro model to study the effects of this mutation by using somatic cell gene targeting using the nontumorigenic human breast epithelial cell line, MCF10A. Surprisingly, knock in of E17K into the AKT1 gene had minimal phenotypic consequences and importantly, did not recapitulate the biochemical and growth characteristics seen with somatic cell knock in of PIK3CA hotspot mutations. These results suggest that mutations in critical genes within the PI3-kinase (PI3K) pathway are not functionally equivalent, and that other cooperative genetic events may be necessary to achieve oncogenic PI3K pathway activation in cancers that contain the AKT1 E17K mutation. Oncogene (2010) 29, 2337-2345; doi:10.1038/onc.2009.516; published online 25 January 2010	[Lauring, J.; Cosgrove, D. P.; Fontana, S.; Gustin, J. P.; Konishi, H.; Abukhdeir, A. M.; Garay, J. P.; Mohseni, M.; Wang, G. M.; Higgins, M. J.; Gorkin, D.; Reis, M.; Vogelstein, B.; Park, B. H.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD 21231 USA; [Polyak, K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Cowherd, M.; Buckhaults, P. J.] Univ S Carolina, Sch Med, Columbia, SC USA	Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Lauring, J (corresponding author), Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Sch Med, 1650 Orleans St,Room 146, Baltimore, MD 21231 USA.	jlaurin1@jhmi.edu; bpark2@jhmi.edu	Reis, Marcelo Martins/H-9370-2012	Reis, Marcelo Martins/0000-0002-4706-1041; Abukhdeir, Abde/0000-0003-1172-5819; Higgins, Michaela Jane/0000-0002-9065-8652; Lauring, Josh/0000-0002-4312-704X; Konishi, Hiroyuki/0000-0003-1131-4905; Gorkin, David/0000-0003-4944-4107	Flight Attendant Medical Research Institute (FAMRI); V Foundation; Maryland Cigarette Restitution Fund; National Institutes of Health [CA88843, CA088843-08, T32 CA09071-27, CA109274]; trust of Ruby J Nelson in loving memory of Charlotte R Nelson; Avon Foundation; American Society of Clinical Oncology Foundation; Department of Defense [W81XWH-06-1-0325, BC083057]; FAMRI; Susan G Komen Foundation; Medical Scientist Training Program Fellowship; Mary Kay Ash Charitable Foundation; Stewart Trust Fund; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R37CA043460, T32CA009071, R55CA109274, P50CA088843, R01CA109274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute (FAMRI); V Foundation; Maryland Cigarette Restitution Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); trust of Ruby J Nelson in loving memory of Charlotte R Nelson; Avon Foundation; American Society of Clinical Oncology Foundation; Department of Defense(United States Department of Defense); FAMRI; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Medical Scientist Training Program Fellowship; Mary Kay Ash Charitable Foundation; Stewart Trust Fund; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	JL receives support from the Flight Attendant Medical Research Institute (FAMRI), the V Foundation, and the Maryland Cigarette Restitution Fund, National Institutes of Health Grants CA88843, CA088843-08, The Susan G Komen for the Cure Career Catalyst Grant funded by the trust of Ruby J Nelson in loving memory of Charlotte R Nelson, and the Avon Foundation. DC receives support from National Institutes of Health Grant T32 CA09071-27 and a Young Investigator Award from the American Society of Clinical Oncology Foundation. JP Gustin is a recipient of a Department of Defense Breast Cancer Research Program Predoctoral Fellowship Award W81XWH-06-1-0325. JP Garay is a recipient of a Research Supplement to promote diversity in health-related research. HK is a recipient of a Young Clinical Scientist Award from FAMRI. AMA is supported by a Susan G Komen Foundation Postdoctoral Fellowship Award. GW is a recipient of a Medical Scientist Training Program Fellowship. MM is recipient of a Department of Defense Breast Cancer Predoctoral Training Award (BC083057). BHP acknowledges support from the Avon Foundation, Susan G Komen for the Cure, the Mary Kay Ash Charitable Foundation, the Stewart Trust Fund, National Institutes of Health Grants CA109274 and CA88843, FAMRI, and the Breast Cancer Research Foundation.	Abubaker J, 2007, LEUKEMIA, V21, P2368, DOI 10.1038/sj.leu.2404873; Abukhdeir AM, 2006, BREAST CANCER RES TR, V99, P23, DOI 10.1007/s10549-006-9177-0; Arena S, 2007, CANCER RES, V67, P8468, DOI 10.1158/0008-5472.CAN-07-1126; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cohen Y, 2010, GYNECOL ONCOL, V116, P88, DOI 10.1016/j.ygyno.2009.09.038; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denley A, 2008, METHOD ENZYMOL, V438, P291, DOI 10.1016/S0076-6879(07)38020-8; Di Nicolantonio F, 2008, P NATL ACAD SCI USA, V105, P20864, DOI 10.1073/pnas.0808757105; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Hayes MP, 2006, CLIN CANCER RES, V12, P5932, DOI 10.1158/1078-0432.CCR-06-1375; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Konishi H, 2007, NAT PROTOC, V2, P2865, DOI 10.1038/nprot.2007.409; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Workman P, 2004, BIOCHEM SOC T, V32, P393, DOI 10.1042/BST0320393; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6	30	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2337	2345		10.1038/onc.2009.516	http://dx.doi.org/10.1038/onc.2009.516			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101210	Green Accepted			2022-12-28	WOS:000276951500003
J	Xie, J; Litman, R; Wang, S; Peng, M; Guillemette, S; Rooney, T; Cantor, SB				Xie, J.; Litman, R.; Wang, S.; Peng, M.; Guillemette, S.; Rooney, T.; Cantor, S. B.			Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to pol eta-dependent bypass	ONCOGENE			English	Article						BRCA1; FANCJ; DNA repair	DNA-POLYMERASE-ETA; HOMOLOGY-DIRECTED REPAIR; FANCONI-ANEMIA PATHWAY; BREAST-CANCER; HELICASE BRIP1; PROTEIN; DAMAGE; BRCA1; CELLS; BACH1	BRCA1 and the DNA helicase FANCJ (also known as BACH1 or BRIP1) have common functions in breast cancer suppression and DNA repair. However, the functional significance of the direct interaction between BRCA1 and FANCJ remains unclear. Here, we have discovered that BRCA1 binding to FANCJ regulates DNA damage repair choice. Thus, when FANCJ binding to BRCA1 is ablated, the molecular mechanism chosen for the repair of damaged DNA is dramatically altered. Specifically, a FANCJ protein that cannot be phosphorylated at serine 990 or bind BRCA1 inhibits DNA repair via homologous recombination and promotes pol eta-dependent bypass. Furthermore, the pol eta-dependent bypass promoted by FANCJ requires the direct binding to the mismatch repair (MMR) protein, MLH1. Together, our findings implicate that in human cells BRCA1 binding to FANCJ is critical to regulate DNA repair choice and promote genomic stability. Moreover, unregulated FANCJ function could be associated with cancer and/or chemoresistance. Oncogene (2010) 29, 2499-2508; doi:10.1038/onc.2010.18; published online 22 February 2010	[Xie, J.; Litman, R.; Wang, S.; Peng, M.; Guillemette, S.; Rooney, T.; Cantor, S. B.] Univ Massachusetts, UMASS Mem Canc Ctr, Dept Canc Biol, Womens Cancers Program,Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University Massachusetts Worcester Hospital	Cantor, SB (corresponding author), UMASS Med Sch, Dept Canc Biol, 364 Plantat St,LRB Rm 415, Worcester, MA 01605 USA.	Sharon.Cantor@umassmed.edu			NIH [R01 CA129514-01A1]; NATIONAL CANCER INSTITUTE [R01CA129514] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Larry Thompson, Alan Lehmann, and Roger Greenberg for critical comments. We also thank Maria Jasin for the DR-U2OS cells and Alan Lehmann for the XPV-vector and pol eta-complemented lines as well as pol eta-GFP construct, Hans Joenje for FA-J cells, and Claire Baldwin for readership comments. This study was supported by NIH R01 CA129514-01A1 and from charitable contributions from Mr and Mrs Edward T Vitone Jr.	Albertella MR, 2005, CANCER RES, V65, P9799, DOI 10.1158/0008-5472.CAN-05-1095; Alt A, 2007, SCIENCE, V318, P967, DOI 10.1126/science.1148242; Barber LJ, 2008, CELL, V135, P261, DOI 10.1016/j.cell.2008.08.016; Barbour L, 2003, MUTAT RES-FUND MOL M, V532, P137, DOI 10.1016/j.mrfmmm.2003.08.014; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cantor SB, 2006, CELL CYCLE, V5, P164, DOI 10.4161/cc.5.2.2338; Delacote F, 2007, MUTAT RES-FUND MOL M, V615, P125, DOI 10.1016/j.mrfmmm.2006.11.028; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Dupaigne P, 2008, MOL CELL, V29, P243, DOI 10.1016/j.molcel.2007.11.033; Eelen G, 2008, ONCOGENE, V27, P4233, DOI 10.1038/onc.2008.51; Gupta R, 2005, J BIOL CHEM, V280, P25450, DOI 10.1074/jbc.M501995200; Hinz JM, 2006, DNA REPAIR, V5, P875, DOI 10.1016/j.dnarep.2006.05.039; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kawamoto T, 2005, MOL CELL, V20, P793, DOI 10.1016/j.molcel.2005.10.016; Kim HT, 2008, MOL CELLS, V25, P457; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Niedernhofer LJ, 2005, CELL, V123, P1191, DOI 10.1016/j.cell.2005.12.009; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Papouli E, 2005, MOL CELL, V19, P123, DOI 10.1016/j.molcel.2005.06.001; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Peng M, 2007, EMBO J, V26, P3238, DOI 10.1038/sj.emboj.7601754; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902; Shen X, 2009, MOL CELL, V35, P716, DOI 10.1016/j.molcel.2009.06.034; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Sommers JA, 2009, J BIOL CHEM, V284, P7505, DOI 10.1074/jbc.M809019200; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	43	50	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2499	2508		10.1038/onc.2010.18	http://dx.doi.org/10.1038/onc.2010.18			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20173781	Green Accepted			2022-12-28	WOS:000277169400005
J	Draheim, KM; Chen, HB; Tao, Q; Moore, N; Roche, M; Lyle, S				Draheim, K. M.; Chen, H-B; Tao, Q.; Moore, N.; Roche, M.; Lyle, S.			ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta 4	ONCOGENE			English	Article						ARRDC3; breast cancer; integrin beta 4; TLIMP	ALPHA-6-BETA-4 INTEGRIN; CARCINOMA-CELLS; SIGNALING PATHWAYS; EPIDERMAL-GROWTH; MIGRATING CELLS; TUMOR-GROWTH; RECEPTOR; ENDOCYTOSIS; INVASION; PROTEIN	Large-scale genetic analyses of human tumor samples have been used to identify novel oncogenes, tumor suppressors and prognostic factors, but the functions and molecular interactions of many individual genes have not been determined. In this study we examined the cellular effects and molecular mechanism of the arrestin family member, ARRDC3, a gene preferentially lost in a subset of breast cancers. Oncomine data revealed that the expression of ARRDC3 decreases with tumor grade, metastases and recurrences. ARRDC3 overexpression represses cancer cell proliferation, migration, invasion, growth in soft agar and in vivo tumorigenicity, whereas downregulation of ARRCD3 has the opposite effects. Mechanistic studies showed that ARRDC3 functions in a novel regulatory pathway that controls the cell surface adhesion molecule, beta-4 integrin (ITG beta 4), a protein associated with aggressive tumor behavior. Our data indicates ARRDC3 directly binds to a phosphorylated form of ITG beta 4 leading to its internalization, ubiquitination and ultimate degradation. The results identify the ARRCD3-ITG beta 4 pathway as a new therapeutic target in breast cancer and show the importance of connecting genetic arrays with mechanistic studies in the search for new treatments. Oncogene (2010) 29, 5032-5047; doi:10.1038/onc.2010.250; published online 5 July 2010	[Draheim, K. M.; Chen, H-B; Moore, N.; Roche, M.; Lyle, S.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Tao, Q.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Beth Israel Deaconess Medical Center	Lyle, S (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,LRB 411, Worcester, MA 01605 USA.	stephen.lyle@umassmed.edu		Roche, Michael/0000-0001-8064-3556	National Cancer Institute of the National Institutes of Health [CA118916]; Worcester Foundation for Biotechnology Research; NATIONAL CANCER INSTITUTE [R01CA118916] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Worcester Foundation for Biotechnology Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding: this work was supported by the National Cancer Institute of the National Institutes of Health (grant number CA118916) and The Worcester Foundation for Biotechnology Research (SRL).	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Alvarez CE, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-222; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Aubry L, 2009, CURR GENOMICS, V10, P133, DOI 10.2174/138920209787847014; Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009; Bhandari D, 2007, J BIOL CHEM, V282, P36971, DOI 10.1074/jbc.M705085200; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Diaz LK, 2005, MODERN PATHOL, V18, P1165, DOI 10.1038/modpathol.3800411; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dutta U, 2008, CANCER RES, V68, P8779, DOI 10.1158/0008-5472.CAN-08-2125; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; FALCIONI R, 1989, MOL CARCINOGEN, V2, P361, DOI 10.1002/mc.2940020611; Fuchs E, 1997, CURR OPIN GENET DEV, V7, P672, DOI 10.1016/S0959-437X(97)80016-0; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; Germain EC, 2009, MOL BIOL CELL, V20, P56, DOI 10.1091/mbc.E08-06-0646; Gurevich EV, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-236; Hemler ME, 2001, DEV CELL, V1, P728, DOI 10.1016/S1534-5807(01)00102-2; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kendall RT, 2009, CELL MOL LIFE SCI, V66, P2953, DOI 10.1007/s00018-009-0088-1; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Luttrell LM, 2002, J CELL SCI, V115, P455; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oka S, 2006, ENDOCRINOLOGY, V147, P733, DOI 10.1210/en.2005-0679; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rabinovitz I, 2004, MOL CELL BIOL, V24, P4351, DOI 10.1128/MCB.24.10.4351-4360.2004; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Raghuwanshi SK, 2008, J IMMUNOL, V180, P5699, DOI 10.4049/jimmunol.180.8.5699; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510; Raymond K, 2007, MOL BIOL CELL, V18, P4210, DOI 10.1091/mbc.E06-08-0720; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shi F, 2008, J CELL SCI, V121, P2360, DOI 10.1242/jcs.014977; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Vicente-Manzanares M, 2009, J CELL SCI, V122, P199, DOI 10.1242/jcs.018564; Voduc D, 2008, CLIN BREAST CANCER, V8, pS171, DOI 10.3816/CBC.2008.s.014; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Wilhelmsen K, 2007, MOL BIOL CELL, V18, P3512, DOI 10.1091/mbc.E07-04-0306; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Zhang ZP, 2009, CELL SIGNAL, V21, P1195, DOI 10.1016/j.cellsig.2009.03.010	56	82	85	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5032	5047		10.1038/onc.2010.250	http://dx.doi.org/10.1038/onc.2010.250			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20603614	hybrid, Green Published			2022-12-28	WOS:000281620100004
J	Lovric, MM; Hawkins, CJ				Lovric, M. M.; Hawkins, C. J.			TRAIL treatment provokes mutations in surviving cells	ONCOGENE			English	Article						late effects; second malignancies; Apo-2L; DNA damage; mutagenesis; HPRT	APOPTOSIS-INDUCING LIGAND; CASPASE-ACTIVATED DNASE; DOUBLE-STRAND BREAKS; IN-VIVO; CONVERTING-ENZYME; HUMAN HEPATOCYTES; MAMMALIAN-CELLS; TUMOR-GROWTH; CANCER; DEATH	Chemotherapy and radiotherapy commonly damage DNA and trigger p53-dependent apoptosis through intrinsic apoptotic pathways. Two unfortunate consequences of this mechanism are resistance due to blockade of p53 or intrinsic apoptosis pathways, and mutagenesis of nonmalignant surviving cells which can impair cellular function or provoke second malignancies. Death ligand-based drugs, such as tumor necrosis factor-related apoptosis inducing ligand (TRAIL), stimulate extrinsic apoptotic signaling, and may overcome resistance to treatments that induce intrinsic apoptosis. As death receptor ligation does not damage DNA as a primary mechanism of pro-apoptotic action, we hypothesized that surviving cells would remain genetically unscathed, suggesting that death ligand-based therapies may avoid some of the adverse effects associated with traditional cancer treatments. Surprisingly, however, treatment with sub-lethal concentrations of TRAIL or FasL was mutagenic. Mutations arose in viable cells that contained active caspases, and overexpression of the caspase-8 inhibitor crmA or silencing of caspase-8 abolished TRAIL-mediated mutagenesis. Downregulation of the apoptotic nuclease caspase-activated DNAse (CAD)/DNA fragmentation factor 40 (DFF40) prevented the DNA damage associated with TRAIL treatment. Although death ligands do not need to damage DNA in order to induce apoptosis, surviving cells nevertheless incur DNA damage after treatment with these agents. Oncogene (2010) 29, 5048-5060; doi:10.1038/onc.2010.242; published online 19 July 2010	[Lovric, M. M.; Hawkins, C. J.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Bundoora, Vic 3083, Australia; [Hawkins, C. J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Childrens Canc Ctr, Parkville, Vic 3052, Australia	La Trobe University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Hawkins, CJ (corresponding author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem, Kingsbury Dr, Bundoora, Vic 3083, Australia.	c.hawkins@latrobe.edu.au	Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071; Green, Maja/0000-0002-7982-2503	Cancer Council Victoria [384400]; La Trobe University; National Health and Medical Research Council [541930]; Australian Research Council [FT0991464]	Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); La Trobe University; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	This study was funded by a Cancer Council Victoria Grant-in-Aid (#384400), a La Trobe University Postgraduate scholarship to MML, a National Health and Medical Research Council Career Development Award (#541930) and Australian Research Council Future Fellowship (#FT0991464) to CJH. We are grateful to Anissa Jabbour for the MEF cells and advice, to Rebecca Bilardi for assistance in establishing the gamma H2AX assay and to Lahiru Gangoda for help with fluorescence microscopy. We thank Tanja Kitevska for proofreading, Delara Pantaki, Sarah Roberts, Sunil Kumar and Livleen Kaur for technical assistance and members of the Hawkins laboratory and Children's Cancer Centre for advice and suggestions.	Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Ashley DM, 2008, BRIT J CANCER, V99, P294, DOI 10.1038/sj.bjc.6604459; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; DEMARS R, 1971, FED PROC, V30, P944; Dickerman JD, 2007, PEDIATRICS, V119, P554, DOI 10.1542/peds.2006-2826; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evens AM, 2008, NAT CLIN PRACT ONCOL, V5, P543, DOI 10.1038/ncponc1186; Frankenberg-Schwager M, 2005, TOXICOLOGY, V212, P175, DOI 10.1016/j.tox.2005.04.015; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Gocke E, 2009, TOXICOL LETT, V190, P254, DOI 10.1016/j.toxlet.2009.03.016; Hao CH, 2004, CANCER RES, V64, P8502, DOI 10.1158/0008-5472.CAN-04-2599; Hartlerode AJ, 2009, BIOCHEM J, V423, P157, DOI 10.1042/BJ20090942; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Jabbour AM, 2009, CELL DEATH DIFFER, V16, P555, DOI 10.1038/cdd.2008.179; Jeha S, 2009, SEMIN HEMATOL, V46, P76, DOI 10.1053/j.seminhematol.2008.09.009; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Knight MJ, 2004, MOL CARCINOGEN, V39, P173, DOI 10.1002/mc.20011; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuo LJ, 2008, IN VIVO, V22, P305; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Leverkus M, 2000, CANCER RES, V60, P553; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; MacPhail SH, 2003, INT J RADIAT BIOL, V79, P351, DOI 10.1080/0955300032000093128; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; Meadows AT, 2009, J CLIN ONCOL, V27, P2356, DOI 10.1200/JCO.2008.21.1920; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Olive PL, 2009, CYTOM PART B-CLIN CY, V76B, P79, DOI 10.1002/cyto.b.20450; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rice SC, 2004, CANCER RES, V64, P4464, DOI 10.1158/0008-5472.CAN-03-3940; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; Veld CWOH, 1997, MUTAGENESIS, V12, P417, DOI 10.1093/mutage/12.6.417; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Watters GP, 2009, MUTAT RES-GEN TOX EN, V679, P50, DOI 10.1016/j.mrgentox.2009.07.007; Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2000, ACTA BIOCHIM POL, V47, P1037; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Winer E, 2009, J CLIN ONCOL, V27, P812, DOI 10.1200/JCO.2008.21.2134; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45	53	61	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	36					5048	5060		10.1038/onc.2010.242	http://dx.doi.org/10.1038/onc.2010.242			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20639907	hybrid, Green Published			2022-12-28	WOS:000281620100005
J	Stagg, J; Smyth, MJ				Stagg, J.; Smyth, M. J.			Extracellular adenosine triphosphate and adenosine in cancer	ONCOGENE			English	Review						immunosuppression; adenosine; ecto-nucleotidases; inflammasome; ATP	HUMAN DENDRITIC CELLS; REGULATORY T-CELLS; INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; P2X(7) RECEPTOR EXPRESSION; C6 GLIOMA-CELLS; MEMORY B-CELLS; NF-KAPPA-B; BREAST-CANCER; ENDOTHELIAL-CELLS	Adenosine triphosphate (ATP) is actively released in the extracellular environment in response to tissue damage and cellular stress. Through the activation of P2X and P2Y receptors, extracellular ATP enhances tissue repair, promotes the recruitment of immune phagocytes and dendritic cells, and acts as a co-activator of NLR family, pyrin domain-containing 3 (NLRP3) inflammasomes. The conversion of extracellular ATP to adenosine, in contrast, essentially through the enzymatic activity of the ecto-nucleotidases CD39 and CD73, acts as a negative-feedback mechanism to prevent excessive immune responses. Here we review the effects of extracellular ATP and adenosine on tumorigenesis. First, we summarize the functions of extracellular ATP and adenosine in the context of tumor immunity. Second, we present an overview of the immunosuppressive and pro-angiogenic effects of extracellular adenosine. Third, we present experimental evidence that extracellular ATP and adenosine receptors are expressed by tumor cells and enhance tumor growth. Finally, we discuss recent studies, including our own work, which suggest that therapeutic approaches that promote ATP-mediated activation of inflammasomes, or inhibit the accumulation of tumor-derived extracellular adenosine, may constitute effective new means to induce anticancer activity. Oncogene (2010) 29, 5346-5358; doi: 10.1038/onc.2010.292; published online 26 July 2010	[Stagg, J.; Smyth, M. J.] Peter MacCallum Canc Ctr, Canc Immunol Program, Sir Donald & Lady Trescowthick Lab, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Stagg, J (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Program, Sir Donald & Lady Trescowthick Lab, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	john.stagg@petermac.org; smyth@petermac.org	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240	Canadian Institutes of Health Research (CIHR); Susan G Komen Breast Cancer Foundation; Victorian Breast Cancer Research Consortium; Victorian Cancer Agency; National Health and Medical Research Council of Australia (NHMRC)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Victorian Breast Cancer Research Consortium; Victorian Cancer Agency; National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	JS is supported by a Canadian Institutes of Health Research (CIHR) Fellowship. MJS is supported by the Susan G Komen Breast Cancer Foundation, the Victorian Breast Cancer Research Consortium, the Victorian Cancer Agency, and by a National Health and Medical Research Council of Australia (NH&MRC) Australia Fellowship and Program Grant.	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Ahmad A, 2009, P NATL ACAD SCI USA, V106, P10684, DOI 10.1073/pnas.0901326106; Airas L, 2000, J IMMUNOL, V165, P5411, DOI 10.4049/jimmunol.165.10.5411; Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Anderson SM, 2007, J EXP MED, V204, P2103, DOI 10.1084/jem.20062571; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Axtell RC, 2010, NAT MED, V16, P406, DOI 10.1038/nm.2110; Bavaresco L, 2008, MOL CELL BIOCHEM, V319, P61, DOI 10.1007/s11010-008-9877-3; Beldi G, 2008, HEPATOLOGY, V48, P841, DOI 10.1002/hep.22401; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Boucher I, 2007, EXP EYE RES, V85, P130, DOI 10.1016/j.exer.2007.03.009; Bouma MG, 1997, J IMMUNOL, V158, P5400; Bournazou I, 2009, J CLIN INVEST, V119, P20, DOI 10.1172/JCI36226; Burnstock G, 2006, TRENDS PHARMACOL SCI, V27, P166, DOI 10.1016/j.tips.2006.01.005; BURNSTOCK G, 1970, BRIT J PHARMACOL, V40, P668, DOI 10.1111/j.1476-5381.1970.tb10646.x; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Cho JH, 2007, GASTROENTEROLOGY, V133, P1327, DOI 10.1053/j.gastro.2007.08.032; CHRISTENSEN LD, 1992, SCAND J IMMUNOL, V35, P407, DOI 10.1111/j.1365-3083.1992.tb02875.x; Clark AN, 2007, CIRC RES, V101, P1130, DOI 10.1161/CIRCRESAHA.107.150110; Colgan Sean P, 2006, Purinergic Signal, V2, P351, DOI 10.1007/s11302-005-5302-5; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; Csoka B, 2008, FASEB J, V22, P3491, DOI 10.1096/fj.08-107458; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; DIECKHOFF J, 1986, FEBS LETT, V195, P82, DOI 10.1016/0014-5793(86)80135-1; DURAK I, 1994, CANCER LETT, V84, P199, DOI 10.1016/0304-3835(94)90376-X; Dwyer KM, 2007, PURINERG SIGNAL, V3, P171, DOI 10.1007/s11302-006-9050-y; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; EPPELL BA, 1989, J IMMUNOL, V143, P4141; Eroglu A, 2000, MED ONCOL, V17, P319, DOI 10.1007/BF02782198; Etique N, 2009, ONCOL REP, V21, P977, DOI 10.3892/or_00000311; Feng YH, 2005, AM J PHYSIOL-CELL PH, V288, pC1342, DOI 10.1152/ajpcell.00315.2004; Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; FIRESTEIN GS, 1995, J IMMUNOL, V154, P326; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Fountain SJ, 2007, NATURE, V448, P200, DOI 10.1038/nature05926; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; Friedman DJ, 2009, P NATL ACAD SCI USA, V106, P16788, DOI 10.1073/pnas.0902869106; Fukuda K, 2004, BRIT J CANCER, V91, P1543, DOI 10.1038/sj.bjc.6602187; Gallos G, 2005, AM J PHYSIOL-RENAL, V289, pF369, DOI 10.1152/ajprenal.00470.2004; Gessi S, 2008, PHARMACOL THERAPEUT, V117, P123, DOI 10.1016/j.pharmthera.2007.09.002; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Gonzales E, 2010, J HEPATOL, V52, P54, DOI 10.1016/j.jhep.2009.10.005; GOTO T, 1983, J IMMUNOL, V130, P1350; Greig AVH, 2003, J INVEST DERMATOL, V121, P1145, DOI 10.1046/j.1523-1747.2003.12567.x; Guerra AN, 2003, J ENDOTOXIN RES, V9, P256, DOI 10.1179/096805103225001468; Gunosewoyo H, 2007, CURR MED CHEM, V14, P1505, DOI 10.2174/092986707780831023; Harish A, 2003, INT J ONCOL, V23, P1245; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hasko G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/sj.bjp.0703134; Hasko G, 1996, J IMMUNOL, V157, P4634; Hilaire CS, 2008, BIOCHEM BIOPH RES CO, V375, P292, DOI 10.1016/j.bbrc.2008.07.059; Hochhauser Edith, 2007, Interact Cardiovasc Thorac Surg, V6, P363, DOI 10.1510/icvts.2006.136317; Hyman MC, 2009, J CLIN INVEST, V119, P1136, DOI 10.1172/JCI36433; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Jantaratnotai N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-442; Jin DC, 2010, CANCER RES, V70, P2245, DOI 10.1158/0008-5472.CAN-09-3109; Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Kim SY, 2006, PLANT PHYSIOL, V142, P984, DOI 10.1104/pp.106.085670; Kitakaze M, 1996, CIRCULATION, V93, P781, DOI 10.1161/01.CIR.93.4.781; Kolachala V, 2005, CELL MOL LIFE SCI, V62, P2647, DOI 10.1007/s00018-005-5328-4; Kondo T, 2006, HISTOPATHOLOGY, V48, P612, DOI 10.1111/j.1365-2559.2005.02277.x; Lane HA, 2001, ANN ONCOL, V12, P21, DOI 10.1023/A:1011155606333; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Lee H, 2003, INT J CANCER, V107, P528, DOI 10.1002/ijc.11428; Leth-Larsen R, 2009, MOL CELL PROTEOMICS, V8, P1436, DOI 10.1074/mcp.M800061-MCP200; LeWitt PA, 2008, ANN NEUROL, V63, P295, DOI 10.1002/ana.21315; Li X, 2006, CANCER EPIDEM BIOMAR, V15, P1906, DOI 10.1158/1055-9965.EPI-06-0407; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Lin Z, 2010, ONCOGENE, V29, P1114, DOI 10.1038/onc.2009.409; Ludwig HC, 1999, ANTICANCER RES, V19, P1747; Madi L, 2004, CLIN CANCER RES, V10, P4472, DOI 10.1158/1078-0432.CCR-03-0651; Majumdar S, 2003, ONCOGENE, V22, P1206, DOI 10.1038/sj.onc.1206184; Mandapathil M, 2010, J BIOL CHEM, V285, P7176, DOI 10.1074/jbc.M109.047423; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Marteau F, 2005, BLOOD, V106, P3860, DOI 10.1182/blood-2005-05-1843; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; MASSAIA M, 1990, J IMMUNOL, V145, P1664; Mikhailov A, 2008, J IMMUNOL, V181, P464, DOI 10.4049/jimmunol.181.1.464; Mills JH, 2008, P NATL ACAD SCI USA, V105, P9325, DOI 10.1073/pnas.0711175105; Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524; Mirza A, 2005, CANCER BIOL THER, V4, P1355, DOI 10.4161/cbt.4.12.2196; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Morello S, 2008, CANCER BIOL THER, V7, P278, DOI 10.4161/cbt.7.2.5301; Myers TJ, 2009, MOL BIOL CELL, V20, P5236, DOI 10.1091/mbc.E08-12-1256; Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720; Niemela J, 2004, J IMMUNOL, V172, P1646, DOI 10.4049/jimmunol.172.3.1646; Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood-2008-02-136325; Nowak M, 2010, EUR J IMMUNOL, V40, P682, DOI 10.1002/eji.200939897; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Ohta A, 2009, J IMMUNOL, V183, P5487, DOI 10.4049/jimmunol.0901247; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105; PRIEBE T, 1990, CELL IMMUNOL, V130, P513, DOI 10.1016/0008-8749(90)90291-X; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Reichelt ME, 2005, CIRC RES, V96, P363, DOI 10.1161/01.RES.0000156075.00127.C3; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Richard CL, 2006, INT J CANCER, V119, P2044, DOI 10.1002/ijc.22084; Ring S, 2010, J IMMUNOL, V184, P3408, DOI 10.4049/jimmunol.0901751; Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5; Rodrigues S, 2007, ONCOGENE, V26, P5615, DOI 10.1038/sj.onc.1210347; Ryzhov S, 2004, J IMMUNOL, V172, P7726, DOI 10.4049/jimmunol.172.12.7726; Ryzhov S, 2008, NEOPLASIA, V10, P987, DOI 10.1593/neo.08478; Sadej R, 2006, MELANOMA RES, V16, P213, DOI 10.1097/01.cmr.0000215030.69823.11; Sauer H, 2001, FASEB J, V15, P2539, DOI 10.1096/fj.01-0360fje; SAVIC V, 1990, IMMUNOLOGY, V70, P321; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; Schnurr M, 2005, BLOOD, V105, P1582, DOI 10.1182/blood-2004-05-1718; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; Slater M, 2004, HISTOPATHOLOGY, V44, P206, DOI 10.1111/j.0309-0167.2004.01798.x; Solini A, 2008, ENDOCRINOLOGY, V149, P389, DOI 10.1210/en.2007-1223; Spychala J, 2004, EXP CELL RES, V296, P99, DOI 10.1016/j.yexcr.2003.11.001; Spychala J, 2004, CLIN CANCER RES, V10, P708, DOI 10.1158/1078-0432.CCR-0811-03; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Stella J, 2010, UROL ONCOL-SEMIN ORI, V28, P260, DOI 10.1016/j.urolonc.2009.01.035; Strater Norbert, 2006, Purinergic Signal, V2, P343, DOI 10.1007/s11302-006-9000-8; SU C, 1971, SCIENCE, V173, P336, DOI 10.1126/science.173.3994.336; Swann JB, 2009, BLOOD, V113, P6382, DOI 10.1182/blood-2009-01-198564; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Takedachi M, 2008, J IMMUNOL, V180, P6288, DOI 10.4049/jimmunol.180.9.6288; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Tomayko MM, 2008, J IMMUNOL, V181, P27, DOI 10.4049/jimmunol.181.1.27; Ujhazy P, 1996, INT J CANCER, V68, P493, DOI 10.1002/(SICI)1097-0215(19961115)68:4<493::AID-IJC15>3.0.CO;2-6; Wei W, 2008, CANCER LETT, V260, P79, DOI 10.1016/j.canlet.2007.10.025; Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Wu PY, 2009, CELL SIGNAL, V21, P881, DOI 10.1016/j.cellsig.2009.01.036; Xaus J, 1999, J IMMUNOL, V162, P3607; Yu LQ, 2004, BRAIN RES, V1000, P156, DOI 10.1016/j.brainres.2003.11.072; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646; Zhang H, 2004, J IMMUNOL, V173, P932, DOI 10.4049/jimmunol.173.2.932; Zhi XL, 2007, CLIN EXP METASTAS, V24, P439, DOI 10.1007/s10585-007-9081-y; Zhou LY, 2008, J BIOL CHEM, V283, P28274, DOI 10.1074/jbc.M802663200	153	418	445	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5346	5358		10.1038/onc.2010.292	http://dx.doi.org/10.1038/onc.2010.292			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20661219				2022-12-28	WOS:000282944500002
J	Tessema, M; Klinge, DM; Yingling, CM; Do, K; Van Neste, L; Belinsky, SA				Tessema, M.; Klinge, D. M.; Yingling, C. M.; Do, K.; Van Neste, L.; Belinsky, S. A.			Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis	ONCOGENE			English	Article						CXCL14; chemokines; lung cancer; DNA methylation; CXCL5; CXCL12	SQUAMOUS-CELL CARCINOMA; PROMOTER HYPERMETHYLATION; DNA METHYLATION; SUPPRESSOR GENES; CHEMOKINE CXCL14; DENDRITIC CELLS; DOWN-REGULATION; MULTIPLE GENES; IN-VIVO; EXPRESSION	Chemokines are important regulators of directional cell migration and tumor metastasis. A genome-wide transcriptome array designed to uncover novel genes silenced by methylation in lung cancer identified the CXCsubfamily of chemokines. Expression of 11 of the 16 known human CXC-chemokines was increased in lung adenocarcinoma cell lines after treatment with 5-aza-2'-deoxycytidine (DAC). Tumor-specific methylation leading to silencing of CXCL5, 12 and 14 was found in over 75% of primary lung adenocarcinomas and DAC treatment restored the expression of each of the silenced gene. Forced expression of CXCL14 in H23 cells, where this gene is silenced by methylation, increased cell death in vitro and dramatically reduced the in vivo growth of lung tumor xenografts through necrosis of up to 90% of the tumor mass. CXCL14 re-expression had a profound effect on the genome altering the transcription of over 1000 genes, including increased expression of 30 cell-cycle inhibitor and pro-apoptosis genes. In addition, CXCL14 methylation in sputum from asymptomatic early-stage lung cancer cases was associated with a 2.9-fold elevated risk for this disease compared with controls, substantiating its potential as a biomarker for early detection of lung cancer. Together, these findings identify CXCL14 as an important tumor suppressor gene epigenetically silenced during lung carcinogenesis. Oncogene (2010) 29, 5159-5170; doi:10.1038/onc.2010.255; published online 21 June 2010	[Tessema, M.; Klinge, D. M.; Yingling, C. M.; Do, K.; Belinsky, S. A.] Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA; [Van Neste, L.] Univ Ghent, Dept Mol Biotechnol, Fac Biosci Engn, B-9000 Ghent, Belgium	Lovelace Respiratory Research Institute; Ghent University	Belinsky, SA (corresponding author), Lovelace Resp Res Inst, Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	sbelinsk@LRRI.org			NIH [R01 ES008801, P50 CA58184]; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008801] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Grant support: supported largely by NIH Grant R01 ES008801 and in part by P50 CA58184.	Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Cirincione R, 2006, INT J CANCER, V118, P1248, DOI 10.1002/ijc.21473; Darash-Yahana M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006695; Deng T, 2009, BIOCHEM BIOPH RES CO, V387, P611, DOI 10.1016/j.bbrc.2009.07.093; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hromas R, 1999, BIOCHEM BIOPH RES CO, V255, P703, DOI 10.1006/bbrc.1999.0257; Hsu HS, 2007, J PATHOL, V213, P412, DOI 10.1002/path.2246; Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855; McKinnon CM, 2008, ONCOGENE, V27, P6856, DOI 10.1038/onc.2008.317; Meissner A, 2006, NATURE, V439, P212, DOI 10.1038/nature04257; Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Mu X, 2009, ACTA BIOCH BIOPH SIN, V41, P631, DOI 10.1093/abbs/gmp051; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ozawa S, 2006, BIOCHEM BIOPH RES CO, V348, P406, DOI 10.1016/j.bbrc.2006.07.070; Ozawa S, 2009, CANCER SCI, V100, P2202, DOI 10.1111/j.1349-7006.2009.01281.x; Palmisano WA, 2003, CANCER RES, V63, P4620; Parsanejad R, 2008, J INTERF CYTOK RES, V28, P703, DOI 10.1089/jir.2008.0139; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Schwarze SR, 2005, PROSTATE, V64, P67, DOI 10.1002/pros.20215; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shellenberger TD, 2004, CANCER RES, V64, P8262, DOI 10.1158/0008-5472.CAN-04-2056; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; Speetjens FM, 2008, CLIN CANCER RES, V14, P2276, DOI 10.1158/1078-0432.CCR-07-4045; Strieter RM, 2004, ANN NY ACAD SCI, V1028, P351, DOI 10.1196/annals.1322.041; Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325; Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114; Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751; Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505; Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385; Yoshino M, 2009, INT J ONCOL, V35, P1201, DOI 10.3892/ijo_00000437; Yuvaraj S, 2009, MOL CANCER RES, V7, P1399, DOI 10.1158/1541-7786.MCR-08-0589; Zhou W, 2008, J NEUROSCI RES, V86, P3002, DOI 10.1002/jnr.21746	45	86	92	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5159	5170		10.1038/onc.2010.255	http://dx.doi.org/10.1038/onc.2010.255			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20562917	Green Accepted			2022-12-28	WOS:000281867200005
J	Guo, X; Liu, W; Pan, Y; Ni, P; Ji, J; Guo, L; Zhang, J; Wu, J; Jiang, J; Chen, X; Cai, Q; Li, J; Zhang, J; Gu, Q; Liu, B; Zhu, Z; Yu, Y				Guo, X.; Liu, W.; Pan, Y.; Ni, P.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.			Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma	ONCOGENE			English	Article						epigenetic; gastric carcinoma; homeobox genes; IRX1; tumor suppressor	SQUAMOUS-CELL CARCINOMA; PROTEOMICS TECHNOLOGY; EPIGENETIC THERAPY; ENDOTHELIAL-CELLS; LUNG DEVELOPMENT; DNA METHYLATION; IROQUOIS GENES; BREAST-CANCER; EXPRESSION; IDENTIFICATION	The IRX1 tumor suppressor gene is located on 5p15.33, a cancer susceptibility locus. Loss of heterozygosity of 5p15.33 in gastric cancer was identified in our previous work. In this study, we analyzed the molecular features and function of IRX1. We found that IRX1 expression was lost or reduced in gastric cancer. However, no mutations were identified in IRX1-encoding regions. IRX1 transcription was suppressed by hypermethylation, and the expression of IRX1 mRNA was partially restored in gastric cancer cells after 5-Aza-dC treatment. Restoring IRX1 expression in SGC-7901 and NCI-N87 gastric cancer cells inhibited growth, invasion and tumorigenesis in vitro and in vivo. We identified a number of target genes by global microarray analysis after IRX1 transfection combined with real-time PCR and chromatin immunoprecipitation assay. BDKRB2, an angiogenesis-related gene, HIST2H2BE and FGF7, cell proliferation and invasion-related genes, were identified as direct IRX1 target genes. The hypermethylation of IRX1 was not only detected in primary gastric cancer tissues but also in the peripheral blood of gastric cancer patients, suggesting IRX1 could potentially serve as a biomarker for gastric cancer. Oncogene (2010) 29, 3908-3920; doi:10.1038/onc.2010.143; published online 3 May 2010	[Guo, X.; Liu, W.; Pan, Y.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.] Shanghai Ruijin Hosp, Dept Surg, Shanghai, Peoples R China; [Guo, X.; Liu, W.; Pan, Y.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.] Shanghai Inst Digest Surg, Shanghai, Peoples R China; [Ni, P.] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Biochem, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.	surgeryzhu@yahoo.com.cn; yingyan3y@yahoo.com.cn	Liu, Bingya/GMW-5655-2022		National Natural Science Foundation of China [30572127, 30770961, 30973486]; Chinese National High Tech Program [863-2006AA02A402, 2006AA02A301]; Shanghai Pu Jiang Project [PJ200700367]; Shanghai Science and Technology Commission [09DZ1950101, 09JC1409600]; Shanghai Charity Foundation for Cancer Research	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National High Tech Program(National High Technology Research and Development Program of China); Shanghai Pu Jiang Project(Shanghai Pujiang Program); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Charity Foundation for Cancer Research	This work was supported, in part by grants from the National Natural Science Foundation of China (30572127, 30770961 and 30973486), the Chinese National High Tech Program (863-2006AA02A402, 2006AA02A301), the Shanghai Pu Jiang Project (PJ200700367), Key Research Project from Shanghai Science and Technology Commission (09DZ1950101 and 09JC1409600), and Shanghai Charity Foundation for Cancer Research.	Alarcon P, 2008, DEVELOPMENT, V135, P3197, DOI 10.1242/dev.023697; Asaka SI, 2006, SURG TODAY, V36, P793, DOI 10.1007/s00595-006-3261-2; Becker MB, 2001, MECH DEVELOP, V106, P155, DOI 10.1016/S0925-4773(01)00412-9; Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509; Bergman Y, 1998, BIOL CHEM, V379, P401; Cairns Paul, 2009, V507, P165, DOI 10.1007/978-1-59745-522-0_13; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Do Jee C, 2009, EUR J CANCER, V45, P1282, DOI 10.1016/j.ejca.2008.12.027; Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; Hao Y, 2008, J PROTEOME RES, V7, P3668, DOI 10.1021/pr700638k; Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032; Huang QJ, 2008, J CANCER RES CLIN, V134, P1219, DOI 10.1007/s00432-008-0398-y; Hurtubise A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-16; Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589; Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120; Ishihara K, 2002, INT IMMUNOPHARMACOL, V2, P499, DOI 10.1016/S1567-5769(01)00193-X; Ishihara K, 2001, JPN J PHARMACOL, V87, P318, DOI 10.1254/jjp.87.318; Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090; KAMEI M, 1992, BIOTHERAPY, V4, P17, DOI 10.1007/BF02171705; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kuga D, 2008, NEURO-ONCOLOGY, V10, P995, DOI 10.1215/15228517-2008-064; Lai IR, 2002, HEPATO-GASTROENTEROL, V49, P1157; Lemaire M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-128; Lewis MT, 1999, CELL TISSUE RES, V296, P549, DOI 10.1007/s004410051316; Lu Y, 2005, CANCER LETT, V224, P329, DOI 10.1016/j.canlet.2004.11.057; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Perez-Diez A, 2007, ADV EXP MED BIOL, V593, P74; Plendl J, 2000, BIOL CHEM, V381, P1103, DOI 10.1515/BC.2000.135; Quackenbush J, 2006, NEW ENGL J MED, V354, P2463, DOI 10.1056/NEJMra042342; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q; Schneider-Stock R, 2007, IDRUGS, V10, P557; Shaker S, 2004, ONCOL REP, V11, P1253; Shaoul R, 2006, BIOCHEM BIOPH RES CO, V350, P825, DOI 10.1016/j.bbrc.2006.08.198; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; Tocchi A, 1998, J CANCER RES CLIN, V124, P450, DOI 10.1007/s004320050198; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Toyota M, 2005, SEMIN ONCOL, V32, P521, DOI 10.1053/j.seminoncol.2005.07.003; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6; van Tuyl M, 2006, AM J PHYSIOL-LUNG C, V290, pL777, DOI 10.1152/ajplung.00293.2005; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Ychou M, 2000, DIS MARKERS, V16, P105, DOI 10.1155/2000/595492; Yu Ying-yan, 2006, Zhonghua Zhongliu Zazhi, V28, P84; Zhao HJ, 2005, PROSTATE, V63, P187, DOI 10.1002/pros.20158	54	70	80	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3908	3920		10.1038/onc.2010.143	http://dx.doi.org/10.1038/onc.2010.143			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20440264				2022-12-28	WOS:000279603200004
J	Hernandez, I; Moreno, JL; Zandueta, C; Montuenga, L; Lecanda, F				Hernandez, I.; Moreno, J. L.; Zandueta, C.; Montuenga, L.; Lecanda, F.			Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer	ONCOGENE			English	Article						microenvironment; tumor-stroma; splicing; osteolysis; colonization	METALLOPROTEASE-DISINTEGRIN ADAM8; OSTEOCLAST-STIMULATING FACTOR; RENAL-CELL CARCINOMA; INCREASED EXPRESSION; CATALYTIC-ACTIVITY; INTEGRIN; ADHESION; PROTEIN; FAMILY; INTERLEUKIN-8	ADAMs (a disintegrin and metalloprotease) are transmembrane proteins involved in a variety of physiological processes and tumorigenesis. Recently, ADAM8 has been associated with poor prognosis of lung cancer. However, its contribution to tumorigenesis in the context of lung cancer metastasis remains unknown. Native ADAM8 expression levels were lower in lung cancer cell lines. In contrast, we identified and characterized two novel spliced isoforms encoding truncated proteins, Delta 18a and Delta 14', which were present in several tumor cell lines and not in normal cells. Overexpression of Delta 18a protein resulted in enhanced invasive activity in vitro. ADAM8 and its Delta 14' isoform expression levels were markedly increased in lung cancer cells, in conditions mimicking tumor microenvironment. Moreover, addition of supernatants from Delta 14'-overexpressing cells resulted in a significant increase in tartrate-resistant acid phosphatase+ cells in osteoclast cultures in vitro. These findings were associated with increased pro-osteoclastogenic cytokines interleukin (IL)-8 and IL-6 protein levels. Furthermore, lung cancer cells overexpressing Delta 14' increased prometastatic activity with a high tumor burden and increased osteolysis in a murine model of bone metastasis. Thus, the expression of truncated forms of ADAM8 by the lung cancer cells may result in the specific upregulation of their invasive and osteoclastogenic activities in the bone microenvironment. These findings suggest a novel mechanism of tumor-induced osteolysis in metastatic bone colonization. Oncogene (2010) 29, 3758-3769; doi: 10.1038/onc.2010.130; published online 10 May 2010	[Hernandez, I.; Zandueta, C.; Lecanda, F.] Univ Navarra, Adhes & Metastasis Lab, Div Oncol, E-31080 Pamplona, Spain; [Moreno, J. L.] Univ Maryland, Sch Med, Dept Orthopaed, Baltimore, MD 21201 USA; [Montuenga, L.] Univ Navarra, Sch Med, Dept Histol & Pathol, E-31080 Pamplona, Spain; [Montuenga, L.] Univ Navarra, Biomarkers Lab, Ctr Appl Biomed Res CIMA, E-31080 Pamplona, Spain	University of Navarra; University System of Maryland; University of Maryland Baltimore; University of Navarra; University of Navarra	Lecanda, F (corresponding author), Univ Navarra, Adhes & Metastasis Lab, Div Oncol, Ctr Appl Biomed Res CIMA, Pio 12-55, Navarra 31080, Spain.	flecanda@unav.es	Montuenga, Luis M/AAF-7783-2020	Montuenga, Luis M/0000-0002-8739-1387; Zandueta Pascual, Carolina/0000-0002-7931-8649	'UTE project FIMA'; I3 Program; 'La Caixa Foundation'; Government of Navarra [67/2005];  [RTICCC C03/10];  [FIT-090100-2005-46];  [PI042284];  [PI070031];  [SAF-2009-11280]	'UTE project FIMA'; I3 Program; 'La Caixa Foundation'(La Caixa Foundation); Government of Navarra; ; ; ; ; 	We thank especially S Martinez and the members of the Morphology and Animal Core Facilities. C Berasain for critical reading of the article. This work was supported by 'UTE project FIMA' agreement, and RTICCC C03/10, FIT-090100-2005-46, PI042284, PI070031 and SAF-2009-11280 (to FL). FL is also supported by funds from the I3 Program, 'La Caixa Foundation', and is a recipient of the 'Ortiz de Landazuri' award (67/2005, Government of Navarra).	Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cao Y, 2001, BIOCHEM J, V357, P353, DOI 10.1042/0264-6021:3570353; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gee JMW, 2003, BREAST CANCER RES, V5, P223, DOI 10.1186/bcr637; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gomez-Gaviro M, 2007, J IMMUNOL, V178, P8053, DOI 10.4049/jimmunol.178.12.8053; Gonzalez I, 2007, J MOL MED, V85, P1015, DOI 10.1007/s00109-007-0202-5; Haidl ID, 2002, GENE, V283, P163, DOI 10.1016/S0378-1119(01)00871-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Hinkle CL, 2006, J NEUROBIOL, V66, P1378, DOI 10.1002/neu.20257; Hooper NM, 2005, ADAM FAMILY PROTEASE; Ishikawa N, 2004, CLIN CANCER RES, V10, P8363, DOI 10.1158/1078-0432.CCR-04-1436; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Karadag A, 2006, BLOOD, V107, P3271, DOI 10.1182/blood-2005-09-3830; Kelly K, 2005, DEV DYNAM, V232, P221, DOI 10.1002/dvdy.20221; Kim T, 2006, BIOL REPROD, V74, P744, DOI 10.1095/biolreprod.105.048892; King NE, 2004, AM J RESP CELL MOL, V31, P257, DOI 10.1165/rcmb.2004-0026OC; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Lu X., 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P29; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Mandelin J, 2003, J RHEUMATOL, V30, P2033; Matsuno O, 2006, IMMUNOL LETT, V102, P67, DOI 10.1016/j.imlet.2005.07.006; Matsuno O, 2007, INT ARCH ALLERGY IMM, V142, P285, DOI 10.1159/000097359; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Naus S, 2006, BIOL CHEM, V387, P337, DOI 10.1515/BC.2006.045; Naus S, 2004, J BIOL CHEM, V279, P16083, DOI 10.1074/jbc.M400560200; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Ohtsuka T, 2006, INT J CANCER, V118, P263, DOI 10.1002/ijc.21324; Rao HW, 2006, J BONE MINER RES, V21, P1657, DOI 10.1359/JBMR.060718; Reiss K, 2006, PHARMACOL THERAPEUT, V111, P985, DOI 10.1016/j.pharmthera.2006.02.009; Roemer A, 2004, J UROLOGY, V172, P2162, DOI 10.1097/01.ju.0000144602.01322.49; Roemer A, 2004, ONCOL REP, V11, P529; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Stautz D, 2010, EXP CELL RES, V316, P55, DOI 10.1016/j.yexcr.2009.09.017; Takeda S, 2007, FEBS LETT, V581, P5859, DOI 10.1016/j.febslet.2007.11.062; Valkovskaya N, 2007, J CELL MOL MED, V11, P1162, DOI 10.1111/j.1582-4934.2007.00082.x; Verrier S, 2004, BONE, V35, P34, DOI 10.1016/j.bone.2003.12.029; Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008-5472.CAN-07-6493; Wildeboer D, 2006, J NEUROPATH EXP NEUR, V65, P516, DOI 10.1097/01.jnen.0000229240.51490.d3; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	50	34	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3758	3769		10.1038/onc.2010.130	http://dx.doi.org/10.1038/onc.2010.130			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453887				2022-12-28	WOS:000279385200004
J	Kunnev, D; Rusiniak, ME; Kudla, A; Freeland, A; Cady, GK; Pruitt, SC				Kunnev, D.; Rusiniak, M. E.; Kudla, A.; Freeland, A.; Cady, G. K.; Pruitt, S. C.			DNA damage response and tumorigenesis in Mcm2-deficient mice	ONCOGENE			English	Article						minichromosome maintenance protein; p53; licensing factor; cancer tumor spectrum; loss of heterozygosity	MCM PROTEINS; HUMAN-CELLS; REPLICATION; EXPRESSION; ORIGINS	Minichromosome maintenance proteins (Mcm's) are components of the DNA replication licensing complex. In vivo, reduced expression or activity of Mcm's has been shown to result in highly penetrant early onset cancers (Shima et al., 2007; Pruitt et al., 2007) and stem cell deficiencies ( Pruitt et al., 2007). Here we use mouse embryonic fibroblasts from an Mcm2-deficient strain of mice to show by DNA fiber analysis that origin usage is decreased in Mcm2-deficient cells under conditions of hydroxyurea (HU)-mediated replication stress. DNA damage responses (DDRs) resulting from HU and additional replication-dependent and replication-independent genotoxic agents were also examined and shown to function at wild-type (wt) levels. Further, basal levels of many components of the DDR were expressed at wt levels, showing that there is no acute replicative stress under normal growth conditions. Only very modest, 1.5- to 2-fold increases in the basal levels of gamma-H2AX, p21(cip1) and 53bp foci were found, consistent with a slight chronic elevation in DDR pathways. The one condition in which a larger difference between wt- and Mcm2-deficient cells was found occurred after ultraviolet irradiation and may reflect the role of Chk1-mediated suppression of dormant origins. In vivo, abrogating p53-mediated DDR in Mcm2-deficient mice results in increased embryonic lethality and accelerated cancer formation in surviving mice. Further, p53 mutation rescues the negative effect of Mcm2 deficiency on the survival of neural stem cells in vitro; however, the enhanced survival correlates with increased genetic damage relative to Mcm2 wt cells carrying the p53 mutation. Together these results show that even relatively minor perturbations to primary or dormant replication origin usage contribute to accelerated genetic damage in vivo. In addition, these studies show that tumor types resulting from Mcm2 deficiency are strongly affected by interaction with both genetic background and p53. Oncogene ( 2010) 29, 3630-3638; doi: 10.1038/onc.2010.125; published online 3 May 2010	[Kunnev, D.; Rusiniak, M. E.; Kudla, A.; Freeland, A.; Cady, G. K.; Pruitt, S. C.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Pruitt, SC (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	steven.pruitt@roswellpark.org			NIH-NCI; Ellison Medical Foundation; NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE [R01CA130995] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ellison Medical Foundation(Lawrence Ellison Foundation); NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	BALB/c:p53<SUP>null/wt</SUP> mice were a generous gift of Dr Peter Demant.This work was supported by grants from the NIH-NCI, the Ellison Medical Foundation, and NYSTEM to SCP. Cost of animal maintenance and flow cytometry was supported in part by an NCI-CCS grant to RPCI.	Bailey KJ, 2004, AGING CELL, V3, P391, DOI 10.1111/j.1474-9728.2004.00128.x; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Heffernan TP, 2007, J BIOL CHEM, V282, P9458, DOI 10.1074/jbc.M611292200; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Liu PJ, 2009, CELL CYCLE, V8, P125, DOI 10.4161/cc.8.1.7528; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Maslov AY, 2007, STEM CELLS, V25, P132, DOI 10.1634/stemcells.2006-0032; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Nevis KR, 2009, CELL CYCLE, V8, P1952, DOI 10.4161/cc.8.12.8811; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649	21	68	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3630	3638		10.1038/onc.2010.125	http://dx.doi.org/10.1038/onc.2010.125			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440269	Green Accepted			2022-12-28	WOS:000279108600004
J	Chen, YC; Zhang, XW; Niu, XH; Xin, DQ; Zhao, WP; Na, YQ; Mao, ZB				Chen, Y. C.; Zhang, X. W.; Niu, X. H.; Xin, D. Q.; Zhao, W. P.; Na, Y. Q.; Mao, Z. B.			Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer	ONCOGENE			English	Article						HBP1; MIF; cancer	RETINOBLASTOMA PROTEIN; PROGENITOR CELLS; FACTOR HBP1; EXPRESSION; GROWTH; GENE; ADENOCARCINOMA; CARCINOMA; EFFECTORS; PATHWAY	Macrophage migration inhibitory factor (MIF) is a well-described proinflammatory mediator. MIF overexpression has been observed in many tumors and is implicated in oncogenic transformation and tumor progression. However, the molecular mechanisms responsible for regulating MIF expression remain poorly understood. In this study, we showed that the transcriptional repressor HBP1 (HMG box-containing protein 1) negatively regulates MIF expression. We first identified a large high-affinity HBP1 DNA-binding element at positions -811 to -792 from the transcriptional start site within the MIF promoter by computer analysis. Reporter analyses showed that this element was required for HBP1-mediated transcriptional repression. Furthermore, HBP1 associated with the MIF promoter in vivo and repressed endogenous MIF gene expression. Consistent with HBP1-mediated repression of MIF, low levels of HBP1 expression were associated with high levels of MIF expression in prostate cancer samples. Importantly, HBP1-mediated repression of MIF inhibited tumorigenic growth and invasion, and the repressive effect of HBP1 on tumorigenic growth and invasion could be partially rescued by the addition of recombinant MIF to the culture medium. Finally, prostate tumor samples with low HBP1 and high MIF expression were associated with a significant decrease in relapse-free survival. Taken together, these results indicated that HBP1 directly inhibited MIF gene transcription, and suggested that the loss of HBP1 expression or activity may contribute to the upregulation of MIF expression in prostate tumor tissue. Oncogene (2010) 29, 3067-3078; doi: 10.1038/onc.2010.97; published online 12 April 2010	[Zhang, X. W.; Mao, Z. B.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; [Chen, Y. C.; Niu, X. H.; Xin, D. Q.; Na, Y. Q.] Peking Univ, Peking Univ Hosp 1, Dept Urol, Beijing 100083, Peoples R China; [Chen, Y. C.; Niu, X. H.; Xin, D. Q.; Na, Y. Q.] Peking Univ, Inst Urol, Beijing 100083, Peoples R China; [Zhao, W. P.] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China	Peking University; Peking University; Peking University; Zhejiang University	Mao, ZB (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 XueyuanRd, Beijing 100083, Peoples R China.	zbmao@bjmu.edu.cn			National Science Foundation of China	National Science Foundation of China(National Natural Science Foundation of China (NSFC))	Our work has been funded by the National Science Foundation of China. Most parts of this research were completed in Dr Mao's laboratory. Dr Mao was the corresponding author.	Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin KM, 2001, LEUKEMIA, V15, P601, DOI 10.1038/sj.leu.2402071; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Lu XF, 2005, J BIOL CHEM, V280, P22606, DOI 10.1074/jbc.M412073200; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567; Petrenko O, 2003, J BIOL CHEM, V278, P11078, DOI 10.1074/jbc.M211985200; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Walsh PC, 2002, CAMPBELLS UROLOGY; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	27	45	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3067	3078		10.1038/onc.2010.97	http://dx.doi.org/10.1038/onc.2010.97			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20383199				2022-12-28	WOS:000278133100004
J	Lievre, A; Blons, H; Laurent-Puig, P				Lievre, A.; Blons, H.; Laurent-Puig, P.			Oncogenic mutations as predictive factors in colorectal cancer	ONCOGENE			English	Review						colorectal cancer; EGFR; cetuximab; panitumumab; KRAS; personalized medicine	GROWTH-FACTOR RECEPTOR; CETUXIMAB PLUS IRINOTECAN; ISLAND METHYLATOR PHENOTYPE; POPULATION-BASED SERIES; KIRSTEN RAS MUTATIONS; GENE COPY NUMBER; PHASE-III TRIAL; K-RAS; BRAF MUTATION; PIK3CA MUTATIONS	The anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and panitumumab have been demonstrated to be new therapeutic options for metastatic colorectal cancer (mCRC). Oncogenic activation of intracellular signalling pathways downstream of EGFR has a major role in colorectal carcinogenesis but has also been reported to be an important mechanism of resistance to anti-EGFR antibodies. Among the activating mutations found in colorectal cancers, tumour KRAS mutations, which are found in B40% of the cases, have been widely demonstrated as a major predictive marker of resistance to cetuximab or panitumumab, therefore, opening the way to individualized treatment for patients with mCRC. Other oncogenic mutations, such as BRAF or PIK3CA mutations or loss of PTEN expression, may also be additional interesting predictive markers of response to anti-EGFR monoclonal antibodies but required further evaluation before being incorporated in clinical practice. The identification of these molecular markers involved in the resistance of antiEGFR antibodies will allow the development of new therapies that should target 'escape mechanisms' used by tumours to circumvent a pathway that has been pharmacologically blocked by anti-EGFR. Oncogene (2010) 29, 3033-3043; doi: 10.1038/onc.2010.89; published online 12 April 2010	[Lievre, A.; Blons, H.; Laurent-Puig, P.] INSERM, UMR S Mol Basis Response Xenobiot 775, F-75006 Paris, France; [Lievre, A.] Hop Ambroise Pare, AP HP, Serv Hepatogastroenterol & Oncol Digest, Boulogne, France; [Lievre, A.] Univ Versailles St Quentin En Yvelines, Versailles, France; [Blons, H.; Laurent-Puig, P.] Univ Paris 05, Paris, France; [Blons, H.; Laurent-Puig, P.] Hop Europeen Georges Pompidou, AP HP, Serv Biochim, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Laurent-Puig, P (corresponding author), INSERM, Mol Basis Response Xenobiot U775, 45 Rue St Peres, F-75006 Paris, France.	pierre.laurent-puig@parisdescartes.fr	Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013	Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459; Blons, Helene/0000-0002-0572-8426	Institut National du Cancer [2009-1-RT03]; Region Ile de France	Institut National du Cancer(Institut National du Cancer (INCA) France); Region Ile de France(Region Ile-de-France)	We thank Institut National du Cancer (N degrees 2009-1-RT03) and the Region Ile de France for their financial support.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Artale S, 2008, J CLIN ONCOL, V26, P4217, DOI 10.1200/JCO.2008.18.7286; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Bokemeyer C, 2007, J CLIN ONCOL, V25; BOKEMEYER C, 2009, EJC SUPPL, V7, P345; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; BOS JL, 1989, CANCER RES, V49, P4682; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439; Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; de Vogel S, 2009, ANN ONCOL, V20, P1216, DOI 10.1093/annonc/mdn782; Di Fiore F, 2008, BRIT J CANCER, V99, P551, DOI 10.1038/sj.bjc.6604451; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Etienne-Grimaldi MC, 2008, CLIN CANCER RES, V14, P4830, DOI 10.1158/1078-0432.CCR-07-4906; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; Finkelstein SD, 1993, ARCH SURG-CHICAGO, V128, P531; FINOCCHIARO G, 2007, P AN M AM SOC CLIN, V25, P4021; Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009; French AJ, 2008, CLIN CANCER RES, V14, P3408, DOI 10.1158/1078-0432.CCR-07-1489; Gnanasampanthan G, 2001, J PATHOL, V195, P543, DOI 10.1002/path.990; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Harbison CT, 2008, J CLIN ONCOL, V26, P2230, DOI 10.1200/JCO.2008.16.0473; He YJ, 2009, CLIN CANCER RES, V15, P6956, DOI 10.1158/1078-0432.CCR-09-1165; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; Italiano A, 2008, ANN SURG ONCOL, V15, P649, DOI 10.1245/s10434-007-9667-2; Jacobs B, 2009, J CLIN ONCOL, V27, P5068, DOI 10.1200/JCO.2008.21.3744; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kim JH, 2009, VIRCHOWS ARCH, V455, P485, DOI 10.1007/s00428-009-0857-0; Kohne C, 2009, J CLIN ONCOL, V27; Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796; Lea IA, 2009, MUTAT RES-FUND MOL M, V670, P96, DOI 10.1016/j.mrfmmm.2009.06.011; Lenz HJ, 2006, J CLIN ONCOL, V24, P4914, DOI 10.1200/JCO.2006.06.7595; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177; Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moroni M, 2008, LANCET ONCOL, V9, P402, DOI 10.1016/S1470-2045(08)70109-8; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698; Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438; Ogino S, 2009, J CLIN ONCOL, V27, P1477, DOI 10.1200/JCO.2008.18.6544; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541; Personeni N, 2005, SEMIN ONCOL, V32, pS59, DOI 10.1053/j.seminoncol.2005.04.029; Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Razis E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-234; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Sauer T, 2005, HISTOPATHOLOGY, V47, P560, DOI 10.1111/j.1365-2559.2005.02252.x; Scartozzi M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-303; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shia J, 2005, MODERN PATHOL, V18, P1350, DOI 10.1038/modpathol.3800417; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Souglakos J, 2009, BRIT J CANCER, V101, P465, DOI 10.1038/sj.bjc.6605164; Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618; Tejpar S, 2009, EJC SUPPL, V7, P322, DOI 10.1016/S1359-6349(09)71100-0; Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536; Van Cutsem E, 2009, EJC SUPPL, V7, P345, DOI 10.1016/S1359-6349(09)71172-3; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; VANCUTSEM E, 2007, P AN M AM SOC CLIN, V25, P4000; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Yen LC, 2009, CLIN CANCER RES, V15, P4508, DOI 10.1158/1078-0432.CCR-08-3179; ZLOBEC I, 2009, INT J CANC	100	86	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3033	3043		10.1038/onc.2010.89	http://dx.doi.org/10.1038/onc.2010.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20383189				2022-12-28	WOS:000278133100001
J	Caldwell, SA; Jackson, SR; Shahriari, KS; Lynch, TP; Sethi, G; Walker, S; Vosseller, K; Reginato, MJ				Caldwell, S. A.; Jackson, S. R.; Shahriari, K. S.; Lynch, T. P.; Sethi, G.; Walker, S.; Vosseller, K.; Reginato, M. J.			Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1	ONCOGENE			English	Article						O-GlcNAc; OGT; FoxM1; breast cancer; glucose metabolism; p27(Kip1)	LINKED N-ACETYLGLUCOSAMINE; INSULIN-RESISTANCE; NUCLEOCYTOPLASMIC PROTEINS; GLYCOSYLATION; CELLS; BETA; PHOSPHORYLATION; INHIBITORS; EXPRESSION; GLUCOSE	Cancer cells upregulate glycolysis, increasing glucose uptake to meet energy needs. A small fraction of a cell's glucose enters the hexosamine biosynthetic pathway (HBP), which regulates levels of O-linked beta-N-acetylglucosamine (O-GlcNAc), a carbohydrate posttranslational modification of diverse nuclear and cytosolic proteins. We discovered that breast cancer cells upregulate the HBP, including increased O-GlcNAcation and elevated expression of O-GlcNAc transferase (OGT), which is the enzyme catalyzing the addition of O-GlcNAc to proteins. Reduction of O-GlcNAcation through RNA interference of OGT in breast cancer cells leads to inhibition of tumor growth both in vitro and in vivo and is associated with decreased cell-cycle progression and increased expression of the cell-cycle inhibitor p27(Kip1). Elevation of p27(Kip1) was associated with decreased expression and activity of the oncogenic transcription factor FoxM1, a known regulator of p27(Kip1) stability through transcriptional control of Skp2. Reducing O-GlcNAc levels in breast cancer cells decreased levels of FoxM1 protein and caused a decrease in multiple FoxM1-specific targets, including Skp2. Moreover, reducing O-GlcNAcation decreased cancer cell invasion and was associated with the downregulation of matrix metallo-proteinase- 2, a known FoxM1 target. Finally, pharmacological inhibition of OGT in breast cancer cells had similar anti-growth and anti-invasion effects. These findings identify O-GlcNAc as a novel mechanism through which alterations in glucose metabolism regulate cancer growth and invasion and suggest that OGT may represent novel therapeutic targets for breast cancer. Oncogene (2010) 29, 2831-2842; doi: 10.1038/onc.2010.41; published online 1 March 2010	[Caldwell, S. A.; Jackson, S. R.; Shahriari, K. S.; Lynch, T. P.; Sethi, G.; Vosseller, K.; Reginato, M. J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA; [Walker, S.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Drexel University; Harvard University; Harvard Medical School	Reginato, MJ (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St, Philadelphia, PA 19104 USA.	Mauricio.Reginato@drexelmed.edu	Reginato, Mauricio/I-6155-2013; Sethi, Gautam/F-2372-2011	Reginato, Mauricio/0000-0002-7541-4094; Sethi, Gautam/0000-0002-8677-8475	Department of Defense [BC086596, BC074374]	Department of Defense(United States Department of Defense)	This study was supported by the Department of Defense, Breast Cancer Research Program Concept Award: BC086596 to MJR and Synergistic Idea Award: BC074374 to MJR and KV.	Bektas N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-42; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184; Gartel AL, 2008, EXPERT OPIN THER TAR, V12, P663, DOI 10.1517/14728222.12.6.663 ; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Housley MP, 2008, J BIOL CHEM, V283, P16283, DOI 10.1074/jbc.M802240200; Kawauchi K, 2009, P NATL ACAD SCI USA, V106, P3431, DOI 10.1073/pnas.0813210106; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Macauley MS, 2005, J BIOL CHEM, V280, P25313, DOI 10.1074/jbc.M413819200; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Marshall Stephen, 2006, Sci STKE, V2006, pre7; Myatt SS, 2008, NAT REV CANCER, V8, P244, DOI 10.1038/nrc2223-c2; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Yakes FM, 2002, CANCER RES, V62, P4132; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	47	277	300	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2831	2842		10.1038/onc.2010.41	http://dx.doi.org/10.1038/onc.2010.41			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190804				2022-12-28	WOS:000277591900008
J	Rocher-Ros, V; Marco, S; Mao, JH; Gines, S; Metzger, D; Chambon, P; Balmain, A; Saura, CA				Rocher-Ros, V.; Marco, S.; Mao, J-H; Gines, S.; Metzger, D.; Chambon, P.; Balmain, A.; Saura, C. A.			Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7	ONCOGENE			English	Article						carcinogenesis; epidermis; Fbw7; Notch; gamma-secretase	GROWTH-FACTOR RECEPTOR; AMYLOID PRECURSOR PROTEIN; TUMOR-SUPPRESSOR; NEGATIVE REGULATOR; DOWN-REGULATION; NOTCH; DEGRADATION; SEL-10; ENDOCYTOSIS; ACTIVATION	The epidermal growth factor receptor (EGFR) and Notch signaling pathways have antagonistic roles during epidermal differentiation and carcinogenesis. The molecular mechanisms regulating the crosstalk between EGFR and Notch during epidermal transformation are largely unknown. We found enhanced EGFR-dependent signaling, proliferation and oncogenic transformation caused by loss of presenilins (PS), the catalytic components of gamma-secretase that generates the Notch1 intracellular domain (NICD). The underlying mechanism for abnormal EGFR signaling in PS-deficient cells involves gamma-secretase-independent transcriptional upregulation of the E3 ubiquitin ligase Fbw7. Fbw7 alpha, which targets NICD for degradation, regulates positively EGFR by affecting a proteasome-dependent ubiquitination step essential for constitutive degradation and stability of EGFR. To investigate the pathological relevance of this findings in vivo, we generated a novel epidermal conditional PS-deficient (ePS cDKO) mouse by deleting both PS in keratinocytes of the basal layer of the epidermis. The ePS cDKO mice develop epidermal hyperplasia associated with enhanced expression of both EGFR and Fbw7 and reduced NICD levels in keratinocytes. These findings establish a novel role for PS on epidermal growth and transformation by reciprocally regulating the EGFR and Notch signaling pathways through Fbw7. Oncogene (2010) 29, 2950-2961; doi:10.1038/onc.2010.57; published online 8 March 2010	[Saura, C. A.] Univ Autonoma Barcelona, Inst Neurociencies, Dept Bioquim & Biol Mol,Fac Med M2 120, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08193 Barcelona, Spain; [Mao, J-H; Balmain, A.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; [Gines, S.] Univ Barcelona, Dept Biol Cellular Inmunol & Neurociencies, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain; [Metzger, D.; Chambon, P.] Univ Strasbourg, Strasbourg, France; [Metzger, D.; Chambon, P.] Coll France, Dept Funct Genom, Inst Genet & Biol Mol & Cellulaire, Inserm U964,CNRS, Illkirch Graffenstaden, France	Autonomous University of Barcelona; CIBERNED; University of California System; University of California San Francisco; CIBERNED; University of Barcelona; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Saura, CA (corresponding author), Univ Autonoma Barcelona, Inst Neurociencies, Dept Bioquim & Biol Mol,Fac Med M2 120, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08193 Barcelona, Spain.	carlos.saura@uab.es	Mao, Jian-Hua/EIZ-8595-2022; Saura, Carlos A/D-2727-2011; Saura, Carlos A/AFM-9239-2022; Gines, Silvia/L-1943-2015	Mao, Jian-Hua/0000-0001-9320-6021; Saura, Carlos A/0000-0003-3692-5657; Gines, Silvia/0000-0002-9479-8185; Metzger, Daniel/0000-0002-5555-046X; Marco, Sergi/0000-0002-9747-0388	Fundacio Marato-TV3 [050710]; Spanish Ministerio de Ciencia e Innovacion [SAF2007-64115, CIBERNED CB06/05/0042]; European Union [IRG-014860]; Generalitat de Catalunya; NATIONAL CANCER INSTITUTE [R01CA116481] Funding Source: NIH RePORTER	Fundacio Marato-TV3; Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); European Union(European Commission); Generalitat de Catalunya(Generalitat de Catalunya); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B De Strooper for providing the immortalized PS fibroblasts, J Shen for PS1 (f/f); PS2-/- mice, G Thinakaran for the pAG3zeo-PS1 Delta loop plasmid, R Kopan for the mNICD-myc plasmid, BE Clurman for the Fbw7 alpha/beta-Flag cDNAs and A Johnson for the pER1-luc plasmid. We thank S Aznar-Benitah for histological expertise advice and E Martin and M Castillo for technical assistance. We thank Servei de Microscopia and Servei de Genomica de la UAB for the excellent technical support. This study was supported by grants from Fundacio Marato-TV3 (050710), Spanish Ministerio de Ciencia e Innovacion (SAF2007-64115, CIBERNED CB06/05/0042 and Programa Ramon y Cajal) and 6th Framework Programme of the European Union (Marie Curie International Reintegration Grant IRG-014860). VRR received a doctoral fellowship from Generalitat de Catalunya.	Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; de Souza N, 2007, DEVELOPMENT, V134, P691, DOI 10.1242/dev.02767; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Deng Y, 2006, J NEUROSCI, V26, P3845, DOI 10.1523/JNEUROSCI.5384-05.2006; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Grim JE, 2008, J CELL BIOL, V181, P913, DOI 10.1083/jcb.200802076; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Jost M, 2000, EUR J DERMATOL, V10, P505; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lefort K, 2004, SEMIN CANCER BIOL, V14, P374, DOI 10.1016/j.semcancer.2004.04.017; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Li T, 2007, J BIOL CHEM, V282, P32264, DOI 10.1074/jbc.M703649200; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Perez-Losada J, 2005, CANCER RES, V65, P6488, DOI 10.1158/0008-5472.CAN-05-1294; Pirrone A, 2004, METH MOL B, V289, P3; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Repetto E, 2007, J BIOL CHEM, V282, P31504, DOI 10.1074/jbc.M704273200; Rikiyama T, 2003, BBA-GENE STRUCT EXPR, V1629, P15, DOI 10.1016/S0167-4781(03)00156-8; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; To MD, 2006, ONCOGENE, V25, P3557, DOI 10.1038/sj.onc.1209397; Tournoy J, 2004, HUM MOL GENET, V13, P1321, DOI 10.1093/hmg/ddh151; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Zhang YW, 2007, P NATL ACAD SCI USA, V104, P10613, DOI 10.1073/pnas.0703903104	54	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2950	2961		10.1038/onc.2010.57	http://dx.doi.org/10.1038/onc.2010.57			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208556	Green Accepted			2022-12-28	WOS:000277890400006
J	Schneider, G; Henrich, A; Greiner, G; Wolf, V; Lovas, A; Wieczorek, M; Wagner, T; Reichardt, S; von Werder, A; Schmid, RM; Weih, F; Heinzel, T; Saur, D; Kramer, OH				Schneider, G.; Henrich, A.; Greiner, G.; Wolf, V.; Lovas, A.; Wieczorek, M.; Wagner, T.; Reichardt, S.; von Werder, A.; Schmid, R. M.; Weih, F.; Heinzel, T.; Saur, D.; Kraemer, O. H.			Cross talk between stimulated NF-kappa B and the tumor suppressor p53	ONCOGENE			English	Article						NF-kappa B; p53; S-phase; hydroxyurea; TNF-alpha; apoptosis	ACID PHENETHYL ESTER; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; CELL-CYCLE; INDUCED APOPTOSIS; GENE-EXPRESSION; MOUSE MODEL; ACTIVATION; CANCER; PATHWAY	Nuclear factor-kappa B (NF-kappa B) and p53 critically determine cancer development and progression. Defining the cross talk between these transcription factors can expand our knowledge on molecular mechanisms of tumorigenesis. Here, we show that induction of replicational stress activates NF-kappa B p65 and triggers its interaction with p53 in the nucleus. Experiments with knockout cells show that p65 and p53 are both required for enhanced NF-kappa B activity during S-phase checkpoint activation involving ataxiatelangiectasia mutated and checkpoint kinase-1. Accordingly, the pro-inflammatory cytokine tumor necrosis factora alpha (TNF-alpha) also triggers formation of a transcriptionally active complex containing nuclear p65 and p53 on jB response elements. Gene expression analyses revealed that, independent of NF-kappa B activation in the cytosol, TNFinduced NF-kappa B-directed gene expression relies on p53. Hence, p53 is unexpectedly necessary for NF-kappa B-mediated gene expression induced by atypical and classical stimuli. Remarkably, data from gain- and loss-of function approaches argue that anti-apoptotic NF-kappa B p65 activity is constitutively evoked by a p53 hot-spot mutant frequently found in tumors. Our observations suggest explanations for the outstanding question why p53 mutations rather than p53 deletions arise in tumors of various origins. Oncogene (2010) 29, 2795-2806; doi: 10.1038/onc.2010.46; published online 1 March 2010	[Greiner, G.; Wolf, V.; Wieczorek, M.; Wagner, T.; Reichardt, S.; Heinzel, T.; Kraemer, O. H.] Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Dept Biochem, D-07743 Jena, Germany; [Schneider, G.; Henrich, A.; von Werder, A.; Schmid, R. M.; Saur, D.] Tech Univ Munich, Med Klin, Klinikum Rechts Isar 2, Munich, Germany; [Lovas, A.; Weih, F.] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany	Friedrich Schiller University of Jena; Technical University of Munich; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Kramer, OH (corresponding author), Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Dept Biochem, Hans Knoll Str 2, D-07743 Jena, Germany.	oliver.kraemer@uni-jena.de	Heinzel, Thorsten/B-1013-2015; Krämer, Oliver H/L-9266-2015; Saur, Dieter/G-4629-2011; Saur, Dieter/O-8355-2015	Krämer, Oliver H/0000-0003-3973-045X; Saur, Dieter/0000-0001-5874-0210	DFG [SCHN 959/1-2, SFB456]; Landesprogramm 'ProExzellenz' [PE 123-2-1]; Deutsche Krebshilfe	DFG(German Research Foundation (DFG)); Landesprogramm 'ProExzellenz'; Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Dr B Vogelstein for HCT-116 cells, Dr A Hoffmann for wild-type and Rel A/ MEFs, Dr T Jacks and Dr D Tuveson for LSL-KRAS<SUP>G12D</SUP> and LSL-p53<SUP>R172H</SUP> mice, Dr A Berns for TP53<SUP>lox/lox</SUP> mice, Dr H Nakhai for Ptf1a/p48<SUP>ex1Cre/+</SUP> mice, Dr R Bernards and Dr R Agami for shRNA against p53, M Buchwald for help with electroporation, Dr A Licht for help with EMSAs, Dr Z-Q Wang and Dr W-K Min for wild-type and p53/ MEFs and very helpful discussions and suggestions. This study was supported by DFG (SCHN 959/1-2) and SFB456 grants to GS, Landesprogramm 'ProExzellenz' (PE 123-2-1) to OHK, and a grant from Deutsche Krebshilfe to GS and OHK.	Alsafadi S, 2009, CURR MED CHEM, V16, P4328, DOI 10.2174/092986709789578196; Ansari SA, 2001, EXP CELL RES, V265, P221, DOI 10.1006/excr.2001.5168; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Armstrong MB, 2006, NEOPLASIA, V8, P967, DOI 10.1593/neo.06574; Bar J, 2009, ONCOGENE, V28, P933, DOI 10.1038/onc.2008.445; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Deppert W, 2007, ONCOGENE, V26, P2142, DOI 10.1038/sj.onc.1210276; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Gapuzan MER, 2005, ONCOGENE, V24, P6574, DOI 10.1038/sj.onc.1208809; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Grallert B, 2008, CELL CYCLE, V7, P2315, DOI 10.4161/cc.6389; Ha J, 2009, INT IMMUNOPHARMACOL, V9, P774, DOI 10.1016/j.intimp.2009.03.001; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi T, 2007, J IMMUNOL, V178, P7385, DOI 10.4049/jimmunol.178.11.7385; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ho CC, 2006, CANCER RES, V66, P2233, DOI 10.1158/0008-5472.CAN-05-1790; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Hung MW, 2003, ANTICANCER RES, V23, P4773; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Kaustov L, 2006, CELL CYCLE, V5, P489, DOI 10.4161/cc.5.5.2489; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kawauchi K, 2008, BIOCHEM BIOPH RES CO, V372, P137, DOI 10.1016/j.bbrc.2008.05.021; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Kramer OH, 2008, ONCOGENE, V27, P732, DOI 10.1038/sj.onc.1210677; Kramer OH, 2009, TRENDS PHARMACOL SCI, V30, P647, DOI 10.1016/j.tips.2009.09.007; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Lee YJ, 2003, BIOCHEM PHARMACOL, V66, P2281, DOI 10.1016/j.bcp.2003.07.014; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Li J, 2007, J CLIN INVEST, V117, P3283, DOI 10.1172/JCI31772; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marusyk A, 2007, CELL CYCLE, V6, P2148, DOI 10.4161/cc.6.17.4732; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Nesic D, 2008, MOL CANCER RES, V6, P1193, DOI 10.1158/1541-7786.MCR-07-2125; O'Brien DI, 2005, EXPERT OPIN THER TAR, V9, P1031, DOI 10.1517/14728222.9.5.1031; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Ravi R, 1998, CANCER RES, V58, P4531; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schafer T, 2003, FASEB J, V17, P660, DOI 10.1096/fj.02-0774com; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259; Schrell UMH, 1996, LANCET, V348, P888, DOI 10.1016/S0140-6736(05)64757-5; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027; Szoltysek K, 2008, ACTA BIOCHIM POL, V55, P741; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023; Tsai CJ, 2009, TRENDS BIOCHEM SCI, V34, P594, DOI 10.1016/j.tibs.2009.07.007; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wietek C, 2007, TRENDS BIOCHEM SCI, V32, P311, DOI 10.1016/j.tibs.2007.05.003; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127; Yan B, 2006, CANCER RES, V66, P11565, DOI 10.1158/0008-5472.CAN-06-2540; Yazdanpanah B, 2009, NATURE, V460, P1159, DOI 10.1038/nature08206; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yoshida K, 2008, ONCOGENE, V27, P1183, DOI 10.1038/sj.onc.1210722; Zhang XP, 2009, P NATL ACAD SCI USA, V106, P12245, DOI 10.1073/pnas.0813088106	82	112	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2795	2806		10.1038/onc.2010.46	http://dx.doi.org/10.1038/onc.2010.46			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190799				2022-12-28	WOS:000277591900005
J	Schonherr, C; Yang, HL; Vigny, M; Palmer, RH; Hallberg, B				Schoenherr, C.; Yang, H-L; Vigny, M.; Palmer, R. H.; Hallberg, B.			Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells	ONCOGENE			English	Article						ALK; PC12 cells; neurite outgrowth; small GTPase; Rap1; neuroblastoma	RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; NON-HODGKINS-LYMPHOMA; MAP KINASE; NEURONAL DIFFERENTIATION; DROSOPHILA-MELANOGASTER; SUSTAINED ACTIVATION; PHOSPHORYLATED RAP1B; CANCER METASTASIS	Many different types of cancer originate from aberrant signaling from the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), arising through different translocation events and overexpression. Further, activating point mutations in the ALK domain have been recently reported in neuroblastoma. To characterize signaling in the context of the full-length receptor, we have examined whether ALK is able to activate Rap1 and contribute to differentiation/proliferation processes. We show that ALK activates Rap1 via the Rap1-specific guanine-nucleotide exchange factor C3G, which binds in a constitutive complex with CrkL to activated ALK. The activation of the C3G/Rap1 pathway results in neurite outgrowth of PC12 cells, which is inhibited by either overexpression of Rap1GAP or siRNA-mediated knockdown of Rap1 itself or the guanine nucleotide exchange factor C3G. Significantly, this pathway also appears to function in the regulation of proliferation of neuroblastoma cells such as SK-N-SH and SH-SY5Y, because abrogation of Rap1 activity by Rap1-specific siRNA or overexpression of Rap1GAP reduces cellular growth. These results suggest that ALK activation of Rap1 may contribute to cell proliferation and oncogenesis of neuroblastoma driven by gain-of-function mutant ALK receptors. Oncogene (2010) 29, 2817-2830; doi: 10.1038/onc.2010.27; published online 1 March 2010	[Schoenherr, C.; Palmer, R. H.; Hallberg, B.] Umea Univ, Dept Mol Biol, S-90187 Umea, Norrland, Sweden; [Yang, H-L] Beijing Forestry Univ, Coll Biol Sci & Biotechnol, Beijing, Peoples R China; [Vigny, M.] UPMC, INSERM, IFM, U839, Paris, France	Umea University; Beijing Forestry University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Hallberg, B (corresponding author), Umea Univ, Dept Mol Biol, Buil 6L, S-90187 Umea, Norrland, Sweden.	Bengt.Hallberg@molbiol.umu.se			Swedish Cancer Foundation [08-0597]; Lions Cancer Research Foundation, Umea; Swedish Childhood Cancer Foundation [08/084]; Swedish Research Council [621-2003-3399]; Association for International Cancer Research [AICR 08-0177]	Swedish Cancer Foundation; Lions Cancer Research Foundation, Umea; Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Association for International Cancer Research	We thank Caroline Grabbe for comments and critical reading of the paper and Lovisa Olofsson for initial experiments. BH is supported by a Grant (08-0597) from the Swedish Cancer Foundation, Lions Cancer Research Foundation, Umea, and Grant (08/084) from the Swedish Childhood Cancer Foundation. RHP is a Swedish Cancer Foundation Research Fellow and is supported by grants from the Swedish Research Council (621-2003-3399), the Swedish Childhood Cancer Foundation (08/074) and the Association for International Cancer Research (AICR 08-0177).	Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bazigou E, 2007, CELL, V128, P961, DOI 10.1016/j.cell.2007.02.024; Bilsland JG, 2008, NEUROPSYCHOPHARMACOL, V33, P685, DOI 10.1038/sj.npp.1301446; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Degoutin J, 2007, FEBS LETT, V581, P727, DOI 10.1016/j.febslet.2007.01.039; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; FELLER SM, 1995, ONCOGENE, V10, P1465; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Gouzi JY, 2005, J CELL SCI, V118, P5811, DOI 10.1242/jcs.02695; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Guerrero C, 2004, ONCOGENE, V23, P4885, DOI 10.1038/sj.onc.1207622; Gyan E, 2005, LEUKEMIA, V19, P1678, DOI 10.1038/sj.leu.2403882; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Hemmeryckx B, 2001, CANCER RES, V61, P1398; Henriksson ML, 2002, BIOCHEM J, V367, P617, DOI 10.1042/BJ20020714; Hisata S, 2007, J CELL BIOL, V178, P843, DOI 10.1083/jcb.200610073; Hong K, 2008, J BIOL CHEM, V283, P23129, DOI 10.1074/jbc.M800478200; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Ishihara T, 2002, CELL, V109, P639, DOI 10.1016/S0092-8674(02)00748-1; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Liao EH, 2004, NATURE, V430, P345, DOI 10.1038/nature02647; Lin YL, 2000, FEBS LETT, V467, P184, DOI 10.1016/S0014-5793(00)01150-9; Lopes SS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000026; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuse M, 2009, ENDOCR J, V56, P161, DOI 10.1507/endocrj.K08E-244; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Minato N, 2009, CANCER SCI, V100, P17, DOI 10.1111/j.1349-7006.2008.01011.x; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Piccinini G, 2002, J BIOL CHEM, V277, P22231, DOI 10.1074/jbc.M111145200; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Raaijmakers JH, 2009, J BIOL CHEM, V284, P10995, DOI 10.1074/jbc.R800061200; Radha V, 2008, J NEUROCHEM, V107, P1424, DOI 10.1111/j.1471-4159.2008.05710.x; Reiner DJ, 2008, CURR BIOL, V18, P1101, DOI 10.1016/j.cub.2008.06.060; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; SHIOTA M, 1994, ONCOGENE, V9, P1567; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Shirinian M, 2007, DIFFERENTIATION, V75, P418, DOI 10.1111/j.1432-0436.2006.00148.x; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Stute C, 2004, DEVELOPMENT, V131, P743, DOI 10.1242/dev.00972; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Varshney GK, 2006, BIOCHEM BIOPH RES CO, V351, P839, DOI 10.1016/j.bbrc.2006.10.117; Vernersson E, 2006, GENE EXPR PATTERNS, V6, P448, DOI 10.1016/j.modgep.2005.11.006; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Voss AK, 2008, DEVELOPMENT, V135, P2139, DOI 10.1242/dev.016725; Voss AK, 2006, EMBO J, V25, P3652, DOI 10.1038/sj.emboj.7601234; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yang HL, 2007, J EXP ZOOL PART B, V308B, P269, DOI 10.1002/jez.b.21146; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zemojtel T, 2006, LEUKEMIA, V20, P145, DOI 10.1038/sj.leu.2404040; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	86	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2817	2830		10.1038/onc.2010.27	http://dx.doi.org/10.1038/onc.2010.27			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190816				2022-12-28	WOS:000277591900007
J	Garamszegi, N; Garamszegi, SP; Samavarchi-Tehrani, P; Walford, E; Schneiderbauer, MM; Wrana, JL; Scully, SP				Garamszegi, N.; Garamszegi, S. P.; Samavarchi-Tehrani, P.; Walford, E.; Schneiderbauer, M. M.; Wrana, J. L.; Scully, S. P.			Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics	ONCOGENE			English	Article						attachment-independent signaling; extracellular matrix; gene expressional plasticity; Smads; TGF-beta and integrin receptors	TGF-BETA; ARTICULAR CHONDROCYTES; II COLLAGEN; CELLS; TGF-BETA-1; ADHESION; SUPERFAMILY; SPECIFICITY; ACTIVATION; TRANSDUCTION	Matrix remodeling, degradation, inflammation and invasion liberate peptide fragments that can subsequently interact with cells in an attachment-independent manner. Such 'soluble' matrix components, including collagens, fibronectin and laminin, induced Smad activation (termed crosstalk signaling), which follows a similar chronological sequence and R-Smad specificity as induced by transforming growth factor (TGF)-beta 1. Smad4 nuclear translocation occurred in response to collagen binding, indicating downstream signal propagation. TGF-beta scavenging antibody affected only TGF-beta 1, but not crosstalk-induced responses. TGF-beta type II receptor mutation (DR26 Delta 25), which is deficient in TGF-beta type I receptor recruitment to the ligand, induced a heterotetramer signaling complex, and propagated Smad2 activation only through collagen induction and not TGF-beta signaling. Consequentially, TGF-beta ligand participation is not required for crosstalk signaling. This signaling requires a functional integrin beta 1 receptor as showed by RNA interference. Co-immunoprecipitation (co-IP) and fluorescent microscopy indicate the involvement of focal adhesion kinase (FAK) and Src activity in collagen-induced signal propagation, and suggest a membrane signaling complex formation that includes both TGF-beta receptors and integrins. The related gene expressional responses are distinct from that evoked by TGF-beta 1, supporting its separate function. This signaling mechanism expands and partially explains TGF-beta receptor dynamics and consequential signaling diversity-related gene expressional plasticity. Oncogene (2010) 29, 2368-2380; doi:10.1038/onc.2009.514; published online 25 January 2010	[Garamszegi, N.; Schneiderbauer, M. M.; Scully, S. P.] Univ Miami, Dept Orthopaed, Leonard M Miller Sch Med, Miami, FL 33136 USA; [Garamszegi, N.; Garamszegi, S. P.; Walford, E.; Scully, S. P.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Samavarchi-Tehrani, P.; Wrana, J. L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Miami; University of Miami; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Garamszegi, N (corresponding author), Univ Miami, Dept Orthopaed, Leonard M Miller Sch Med, Room 218,Papanicolau Bldg,Med Campus Locator M877, Miami, FL 33136 USA.	ngaramszegi@med.miami.edu	Wrana, Jeffrey/F-8857-2013		National Institutes of Health [CA-66088Y]; American Cancer Society [ACS 66105H]; Woman's Cancer Association [WCA 66461Y]; University of Miami Orthopaedics Department; Sylvester Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [S15CA066088] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Woman's Cancer Association; University of Miami Orthopaedics Department; Sylvester Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Edward B Leof for the pSmad3-specific antibody, as well as for CCL 64 and R1B cells, Joan Massague for DR26 cells, Mary Goldring for C28 cells and Joel A Block for JJ012 cells. This work was supported by Grants CA-66088Y to SPS from National Institutes of Health, ACS 66105H to NG from the American Cancer Society and by the Woman's Cancer Association Madelon Ravlin Memorial Award WCA 66461Y to NG and SPS. Further support was provided by the University of Miami Orthopaedics Department, and the Sylvester Comprehensive Cancer Center.	Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumont N, 2002, DIFFERENTIATION, V70, P574, DOI 10.1046/j.1432-0436.2002.700910.x; Evans JG, 2006, EUR J CELL BIOL, V85, P145, DOI 10.1016/j.ejcb.2005.08.006; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Franz CM, 2005, J CELL SCI, V118, P5315, DOI 10.1242/jcs.02653; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; Garamszegi N, 2001, MOL BIOL CELL, V12, P2881, DOI 10.1091/mbc.12.9.2881; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; HILL D J, 1992, Progress in Growth Factor Research, V4, P45, DOI 10.1016/0955-2235(92)90004-2; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Jones J, 1996, ONCOGENE, V12, P119; Kracklauer Martin P, 2003, Mol Cancer, V2, P28, DOI 10.1186/1476-4598-2-28; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Lee MS, 2005, MOL CELL BIOL, V25, P6921, DOI 10.1128/MCB.25.16.6921-6936.2005; Madan R, 2006, HUM PATHOL, V37, P9, DOI 10.1016/j.humpath.2005.09.024; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; PARSONS JT, 1994, J CELL SCI, P109; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Qi WN, 2003, J ORTHOPAED RES, V21, P282, DOI 10.1016/S0736-0266(02)00136-5; Qi WN, 1998, EXP CELL RES, V241, P142, DOI 10.1006/excr.1998.4032; Qi WN, 1997, J ORTHOPAED RES, V15, P483, DOI 10.1002/jor.1100150402; Qi WN, 2000, J ORTHOPAED RES, V18, P928, DOI 10.1002/jor.1100180612; Rechtman MM, 2009, J BIOL CHEM, V284, P7843, DOI 10.1074/jbc.M809215200; ROSIER RN, 1989, CONNECT TISSUE RES, V20, P295, DOI 10.3109/03008208909023900; Schneiderbauer MM, 2004, CELL SIGNAL, V16, P1133, DOI 10.1016/j.cellsig.2004.03.004; SEGARINI PR, 1990, ANN NY ACAD SCI, V593, P73, DOI 10.1111/j.1749-6632.1990.tb16101.x; Sheppard D, 2004, CURR OPIN CELL BIOL, V16, P552, DOI 10.1016/j.ceb.2004.06.017; SUZUKI F, 1992, ADV EXP MED BIOL, V324, P101; THORP BH, 1992, DEVELOPMENT, V114, P907; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	54	57	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2368	2380		10.1038/onc.2009.514	http://dx.doi.org/10.1038/onc.2009.514			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101206				2022-12-28	WOS:000276951500006
J	Wang, J; Kim, J; Roh, M; Franco, OE; Hayward, SW; Wills, ML; Abdulkadir, SA				Wang, J.; Kim, J.; Roh, M.; Franco, O. E.; Hayward, S. W.; Wills, M. L.; Abdulkadir, S. A.			Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma	ONCOGENE			English	Article						Pim1; c-MYC; prostate cancer; mouse model; neuroendocrine	INDUCED NEUROENDOCRINE DIFFERENTIATION; UROGENITAL SINUS MESENCHYME; TRANSGENIC MOUSE MODEL; CANCER CELLS; INTRAEPITHELIAL NEOPLASIA; ONCOGENIC TRANSFORMATION; SIGNALING PATHWAY; MURINE PROSTATE; TUMOR-CELLS; PROTEIN	The oncogenic PIM1 kinase has been implicated as a cofactor for c-MYC in prostate carcinogenesis. In this study, we show that in human prostate tumors, coexpression of c-MYC and PIM1 is associated with higher Gleason grades. Using a tissue recombination model coupled with lentiviral-mediated gene transfer we find that Pim1 is weakly oncogenic in naive adult mouse prostatic epithelium. However, it cooperates dramatically with c-MYC to induce prostate cancer within 6-weeks. Importantly, c-MYC/Pim1 synergy is critically dependent on Pim1 kinase activity. c-MYC/Pim1 tumors showed increased levels of the active serine-62 (S62) phosphorylated form of c-MYC. Grafts expressing a phosphomimetic c-MYCS62D mutant had higher rates of proliferation than grafts expressing wild type c-MYC but did not form tumors like c-MYC/Pim1 grafts, indicating that Pim1 cooperativity with c-MYC in vivo involves additional mechanisms other than enhancement of c-MYC activity by S62 phosphorylation. c-MYC/Pim1-induced prostate carcinomas show evidence of neuroendocrine (NE) differentiation. Additional studies, including the identification of tumor cells coexpressing androgen receptor and NE cell markers synaptophysin and Ascl1 suggested that NE tumors arose from adenocarcinoma cells through transdifferentiation. These results directly show functional cooperativity between c-MYC and PIM1 in prostate tumorigenesis in vivo and support efforts for targeting PIM1 in prostate cancer. Oncogene (2010) 29, 2477-2487; doi:10.1038/onc.2010.10; published online 8 February 2010	[Kim, J.; Roh, M.; Wills, M. L.; Abdulkadir, S. A.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Wang, J.; Hayward, S. W.; Abdulkadir, S. A.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Franco, O. E.; Hayward, S. W.] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol, B33321A MCN,1161 21st Ave S, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu	Hayward, Simon/A-1688-2011	Kim, Jongchan/0000-0002-9733-9881; Hayward, Simon/0000-0002-6059-6550	NIH [CA123484]; NATIONAL CANCER INSTITUTE [R01CA123484] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert Matusik, Vito Quaranta, Fritz Parl and Susan Kasper for helpful discussions. This work was supported by NIH Grant CA123484 (SAA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Bachmann M, 2006, INT J BIOCHEM CELL B, V38, P430, DOI 10.1016/j.biocel.2005.10.010; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cindolo L, 2007, UROL INT, V79, P287, DOI 10.1159/000109711; CUNHA GR, 1978, J EXP ZOOL, V205, P181, DOI 10.1002/jez.1402050203; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DISANTAGNESE PA, 1987, HUM PATHOL, V18, P849; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Hansel DE, 2009, PROSTATE, V69, P603, DOI 10.1002/pros.20910; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Hu Y, 2004, P NATL ACAD SCI USA, V101, P5559, DOI 10.1073/pnas.0306988101; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kim J, 2002, CANCER RES, V62, P1549; Kim J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000542; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Pinski J, 2006, PROSTATE, V66, P1136, DOI 10.1002/pros.20440; Roh M, 2005, J BIOL CHEM, V280, P40568, DOI 10.1074/jbc.M509369200; Roh M, 2003, CANCER RES, V63, P8079; Roh M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002572; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Sauer CG, 2006, PROSTATE, V66, P227, DOI 10.1002/pros.20338; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vias M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-17; Wafa LA, 2007, HUM PATHOL, V38, P161, DOI 10.1016/j.humpath.2006.07.003; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	45	102	111	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2477	2487		10.1038/onc.2010.10	http://dx.doi.org/10.1038/onc.2010.10			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140016	Green Accepted			2022-12-28	WOS:000277169400003
J	Ye, Y; Xiao, Y; Wang, W; Yearsley, K; Gao, JX; Shetuni, B; Barsky, SH				Ye, Y.; Xiao, Y.; Wang, W.; Yearsley, K.; Gao, J. X.; Shetuni, B.; Barsky, S. H.			ER alpha signaling through slug regulates E-cadherin and EMT	ONCOGENE			English	Article						ER alpha; slug; E-cadherin; EMT; ER alpha/N-CoR/HDAC1 corepressor complex	BREAST-CANCER CELLS; GLYCOGEN-SYNTHASE KINASE-3; ESTROGEN-RECEPTOR-ALPHA; EPITHELIAL-MESENCHYMAL TRANSITION; SEMIAUTOMATED IMAGING-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVITY; DOWN-REGULATION; BETA-CATENIN; EXPRESSION	The ER alpha signaling pathway is one of the most important and most studied pathways in human breast cancer, yet numerous questions still exist such as how hormonally responsive cancers progress to a more aggressive and hormonally independent phenotype. We have noted that human breast cancers exhibit a strong direct correlation between ER alpha and E-cadherin expression by immunohistochemistry, suggesting that ER alpha signaling might regulate E-cadherin and implying that this regulation might influence epithelial-mesenchymal transition (EMT) and tumor progression. To investigate this hypothesis and the mechanisms behind it, we studied the effects of ER alpha signaling in ER alpha-transfected ER alpha-negative breast carcinoma cell lines, the MDA-MB-468 and the MDA-MB-231 and the effects of ER alpha knockdown in naturally expressing ER alpha-positive lines, MCF-7 and T47D. When ER alpha was overexpressed in the ER alpha-negative lines, 17 beta-estradiol (E2) decreased slug and increased E-cadherin. Clones maximally exhibiting these changes grew more in clumps and became less invasive in Matrigel. When ER alpha was knocked down in the ER alpha-positive lines, slug increased, E-cadherin decreased, cells became spindly and exhibited increased Matrigel invasion. ER alpha signaling decreased slug expression by two different mechanisms: directly, by repression of slug transcription by the formation of a corepressor complex of ligand-activated ER alpha, HDAC inhibitor (HDAC1), and nuclear receptor corepressor (N-CoR) that bound the slug promoter in three half-site estrogen response elements (EREs); indirectly by phosphorylation and inactivation of GSK-3 beta through phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt). The GSK-3 beta inactivation, in turn, repressed slug expression and increased E-cadherin. In human breast cancer cases, there was a strong inverse correlation between slug and ER alpha and E-cadherin immunoreactivity. Our findings indicate that ER alpha signaling through slug regulates E-cadherin and EMT. Oncogene (2010) 29, 1451-1462; doi:10.1038/onc.2009.433; published online 18 January 2010	[Ye, Y.; Barsky, S. H.] Univ Nevada, Sch Med, Dept Pathol, Reno, NV 89557 USA; [Ye, Y.; Barsky, S. H.] Nevada Canc Inst, Dept Pathol, Las Vegas, NV USA; [Xiao, Y.; Wang, W.; Yearsley, K.; Gao, J. X.; Shetuni, B.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of California System; University of California San Diego; University System of Ohio; Ohio State University	Barsky, SH (corresponding author), Univ Nevada, Sch Med, Dept Pathol, 1 Manville Med Bldg, Reno, NV 89557 USA.	sbarsky@medicine.nevada.edu			Department of Defense Breast Cancer Research Program [W81XWH-06-1-0631]; Ohio State Strategic Initiative Grant Program; Donald A Senhauser Endowment	Department of Defense Breast Cancer Research Program(United States Department of Defense); Ohio State Strategic Initiative Grant Program; Donald A Senhauser Endowment	This study was supported by the Department of Defense Breast Cancer Research Program Grant W81XWH-06-1-0631, the Ohio State Strategic Initiative Grant Program and The Donald A Senhauser Endowment.	Alpaugh ML, 2002, AM J PATHOL, V161, P619, DOI 10.1016/S0002-9440(10)64217-4; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barsky SH, 2003, EXP MOL PATHOL, V74, P113, DOI 10.1016/S0014-4800(03)00011-X; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; DEGROOT RP, 1993, ONCOGENE, V8, P841; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Grisouard J, 2007, MOL ENDOCRINOL, V21, P2427, DOI 10.1210/me.2007-0129; Hajra KM, 2002, CANCER RES, V62, P1613; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Hayashida Y, 2005, CANCER RES, V65, P8836, DOI 10.1158/0008-5472.CAN-05-0718; Hiraguri S, 1998, CANCER RES, V58, P1972; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Hyder SM, 1996, CANCER RES, V56, P3954; Joshi AS, 2007, CYTOM PART A, V71A, P273, DOI 10.1002/cyto.a.20374; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Mendez P, 2006, ENDOCRINOLOGY, V147, P3027, DOI 10.1210/en.2005-1224; Moggs JG, 2005, J MOL ENDOCRINOL, V34, P535, DOI 10.1677/jme.1.01677; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; Nam JS, 2006, CANCER RES, V66, P7176, DOI 10.1158/0008-5472.CAN-06-0825; Natsugoe S, 2007, ONCOL REP, V17, P517; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Oesterreich S, 2003, CANCER RES, V63, P5203; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15; Sasaki CY, 2000, CANCER RES, V60, P7057; Sharangpani GM, 2007, J MICROSC-OXFORD, V226, P244, DOI 10.1111/j.1365-2818.2007.01772.x; Tomlinson JS, 2001, CANCER RES, V61, P5231; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Voss TC, 2005, MOL CELL ENDOCRINOL, V231, P33, DOI 10.1016/j.mce.2004.12.003; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yang S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-211; Ye Y, 2008, BIOCHEM J, V416, P179, DOI 10.1042/BJ20080328; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	54	143	155	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1451	1462		10.1038/onc.2009.433	http://dx.doi.org/10.1038/onc.2009.433			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20101232				2022-12-28	WOS:000275392400004
J	Kreisler, A; Strissel, PL; Strick, R; Neumann, SB; Schumacher, U; Becker, CM				Kreisler, A.; Strissel, P. L.; Strick, R.; Neumann, S. B.; Schumacher, U.; Becker, C-M			Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer	ONCOGENE			English	Article						NRSF/REST; CREB; AKT2; small-cell lung cancer; methylation	RESTRICTIVE SILENCER FACTOR; GLYCINE RECEPTOR; FIBRONECTIN GENE; CYCLIC-AMP; EXPRESSION; TRANSCRIPTION; REST; REPRESSOR; DIFFERENTIATION; CARCINOMA	The neuron-restrictive silencer factor/RE1-silencing transcription factor (NRSF/REST) is a negative regulator of gene expression restricting the expression of neuronal genes to the nervous system. NRSF/REST is highly expressed in non-neuronal tissues like the lung. In previous work, we identified small-cell lung cancer (SCLC) cell lines with no detectable NRSF/REST expression that, as a consequence, expressed neuronal markers like L1-cell adhesion molecule (L1-CAM) and neural cell adhesion molecule (NCAM). The loss of NRSF/REST expression was linked to malignant progression; however, its mechanistic role remained elusive. Here, we show that NRSF/REST itself, rather than one of its regulated genes, acts like a classic tumour suppressor, being in part regulated by methylation. In SCLCs, NRSF/REST is positively regulated by CREB, with an NRSF/REST promoter fragment showing cell type specificity. Downstream, NRSF/REST directly regulates AKT2, in which NRSF/REST loss leads to an epidermal growth factor-mediated de-regulation of AKT-Serine473 phosphorylation, important for cellular proliferation and survival. Assaying anchorage-independent growth, we observed that with reduced NRSF/REST expression, proliferation was significantly enhanced, whereas NRSF/REST rescue decreased the potential of cells to grow anchorage independently. Our observations support the fact that NRSF/REST may act as an important modulator of malignant progression in SCLC. Oncogene (2010) 29, 5828-5838; doi: 10.1038/onc.2010.321; published online 9 August 2010	[Strissel, P. L.; Strick, R.; Neumann, S. B.] Univ Klinikum Erlangen, Mol Med Lab, Frauenklin, D-91054 Erlangen, Germany; [Kreisler, A.; Becker, C-M] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Erlangen, Germany; [Schumacher, U.] Univ Klinikum Hamburg Eppendorf, Zentrum Expt Med, Inst Anat 2, Hamburg, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Strissel, PL (corresponding author), Univ Klinikum Erlangen, Mol Med Lab, Frauenklin, Univ Str 21-23, D-91054 Erlangen, Germany.	pamela.strissel@uk-erlangen.de	Wang, Weili/D-1546-2011		Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of University of Erlangen-Nurnberg; Johannes und Frieda Marohn-Stiftung	Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of University of Erlangen-Nurnberg; Johannes und Frieda Marohn-Stiftung	We thank Barbara Orlicz-Welcz, Rosa Weber, Florentine Koppitz, Sonja Oeser and Eli Stiegler for dedicated technical assistance and the group of Michael Wegner for their help with the luciferase assays. We thank Magnus von Knebel-Doeberitz from the University of Heidelberg for the NRSF/REST expression vector pcNRSFwt. This project was supported by a grant from the Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of University of Erlangen-Nurnberg to CM Becker and PL Strissel and a grant from the Johannes und Frieda Marohn-Stiftung.	Anbazhagan R, 1999, CANCER RES, V59, P5119; Arboleda MJ, 2003, CANCER RES, V63, P196; BARCO A, 2006, ROLE CREB CBP BRAIN; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; CARNEY DN, 1985, CANCER RES, V45, P2913; Chong S, 2006, RADIOGRAPHICS, V26, P41, DOI 10.1148/rg.261055057; Ciombor Kristen Keon, 2006, Curr Treat Options Oncol, V7, P59, DOI 10.1007/s11864-006-0032-7; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Coulson JM, 2000, CANCER RES, V60, P1840; Ekici M, 2008, J BIOL CHEM, V283, P9257, DOI 10.1074/jbc.M709388200; FERGUSON AT, 1995, CANCER RES, V55, P2279; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; Fuller GN, 2005, MOL CANCER THER, V4, P343; GAZDAR AF, 1980, CANCER RES, V40, P3502; GRIFFIN CA, 1985, CANCER RES, V45, P272; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Gurrola-Diaz C, 2003, ONCOGENE, V22, P5636, DOI 10.1038/sj.onc.1206790; Kitamura H, 2009, ENDOCR PATHOL, V20, P101, DOI 10.1007/s12022-009-9072-4; Koenigsberger C, 2000, P NATL ACAD SCI USA, V97, P2291, DOI 10.1073/pnas.050578797; Kojima T, 2001, MOL BRAIN RES, V90, P174, DOI 10.1016/S0169-328X(01)00107-3; Laufs TL, 2004, NEUROSCI LETT, V362, P83, DOI 10.1016/j.neulet.2004.02.072; Lee BH, 1998, EXP MOL MED, V30, P240, DOI 10.1038/emm.1998.35; Lenz B, 2006, EXP CELL RES, V312, P4049, DOI 10.1016/j.yexcr.2006.09.004; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; Magin A, 2002, NEUROCHEM INT, V40, P195, DOI 10.1016/S0197-0186(01)00091-2; Moss AC, 2009, CLIN CANCER RES, V15, P274, DOI 10.1158/1078-0432.CCR-08-1163; Neumann SB, 2004, MOL BRAIN RES, V120, P173, DOI 10.1016/j.molbrainres.2003.10.021; Ng RK, 2008, CELL CYCLE, V7, P1173, DOI 10.4161/cc.7.9.5791; Onganer PU, 2005, BRIT J CANCER, V93, P1197, DOI 10.1038/sj.bjc.6602857; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Otto SJ, 2007, J NEUROSCI, V27, P6729, DOI 10.1523/JNEUROSCI.0091-07.2007; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Palm K, 1998, J NEUROSCI, V18, P1280; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Pio R, 2009, J THORAC ONCOL, V4, P674, DOI 10.1097/JTO.0b013e3181a520dc; Rasband W., 2006, IMAGEJ; Reddy BY, 2009, P NATL ACAD SCI USA, V106, P4408, DOI 10.1073/pnas.0809130106; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schug J, 2003, CURRENT PROTOCOLS BI; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; Smith B, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S15; Strick R, 2007, J MOL MED, V85, P23, DOI 10.1007/s00109-006-0104-y; Strissel PL, 2008, INT J CANCER, V123, P2871, DOI 10.1002/ijc.23900; Strissel PL, 2000, HUM MOL GENET, V9, P1671, DOI 10.1093/hmg/9.11.1671; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Wu J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r85; Zimmermann S, 1997, CANCER IMMUNOL IMMUN, V44, P1, DOI 10.1007/s002620050348	54	55	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5828	5838		10.1038/onc.2010.321	http://dx.doi.org/10.1038/onc.2010.321			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20697351				2022-12-28	WOS:000283586200008
J	Shimizu, T; Ishikawa, T; Sugihara, E; Kuninaka, S; Miyamoto, T; Mabuchi, Y; Matsuzaki, Y; Tsunoda, T; Miya, F; Morioka, H; Nakayama, R; Kobayashi, E; Toyama, Y; Kawai, A; Ichikawa, H; Hasegawa, T; Okada, S; Ito, T; Ikeda, Y; Suda, T; Saya, H				Shimizu, T.; Ishikawa, T.; Sugihara, E.; Kuninaka, S.; Miyamoto, T.; Mabuchi, Y.; Matsuzaki, Y.; Tsunoda, T.; Miya, F.; Morioka, H.; Nakayama, R.; Kobayashi, E.; Toyama, Y.; Kawai, A.; Ichikawa, H.; Hasegawa, T.; Okada, S.; Ito, T.; Ikeda, Y.; Suda, T.; Saya, H.			c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis	ONCOGENE			English	Article						osteosarcoma; differentiation; animal model; PPAR gamma	MESENCHYMAL STEM-CELLS; TRANSCRIPTIONAL REGULATION; OSTEOBLAST LINEAGE; EXPRESSION; DIFFERENTIATION; PROTEIN; CANCER; GENE; MICE; PATHOGENESIS	The development of cancer is due to the growth and proliferation of transformed normal cells. Recent evidence suggests that the nature of oncogenic stress and the state of the cell of origin critically affect both tumorigenic activity and tumor histological type. However, this mechanistic relationship in mesenchymal tumors is currently largely unexplored. To clarify these issues, we established a mouse osteosarcoma (OS) model through overexpression of c-MYC in bone marrow stromal cells (BMSCs) derived from Ink4a/Arf (-/-) mice. Single-cell cloning revealed that c-MYC-expressing BMSCs are composed of two distinctly different clones: highly tumorigenic cells, similar to bipotent-committed osteo-chondral progenitor cells, and low-tumorigenic tripotent cells, similar to mesenchymal stem cells (MSCs). It is noteworthy that both bipotent and tripotent cells were capable of generating histologically similar, lethal OS, suggesting that both committed progenitor cells and MSCs can become OS cells of origin. Shifting mesenchymal differentiation by depleting PPAR gamma in tripotent MSC-like cells and overexpressing PPAR gamma in bipotent cells affected cell proliferation and tumorigenic activity. Our findings indicate that differentiation potential has a key role in OS tumorigenic activity, and that the suppression of adipogenic ability is a critical factor for the development of OS. Oncogene (2010) 29, 5687-5699; doi:10.1038/onc.2010.312; published online 2 August 2010	[Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo 1608582, Japan; [Shimizu, T.; Sugihara, E.; Saya, H.] Japan Sci & Technol Agcy, CREST, Tokyo, Japan; [Ishikawa, T.] Daiichi Sankyo Co Ltd, Kasai R& Ctr, Tokyo, Japan; [Miyamoto, T.; Morioka, H.; Nakayama, R.; Kobayashi, E.; Toyama, Y.] Keio Univ, Dept Orthoped Surg, Tokyo 1608582, Japan; [Miyamoto, T.] Japan Sci & Technol Agcy, Saitama, Japan; [Mabuchi, Y.; Matsuzaki, Y.] Keio Univ, Dept Physiol, Tokyo 1608582, Japan; [Tsunoda, T.; Miya, F.] RIKEN, Ctr Genom Med, Yokohama, Kanagawa, Japan; [Kawai, A.] Natl Canc Ctr, Orthoped Div, Tokyo, Japan; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Tokyo 104, Japan; [Hasegawa, T.] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido, Japan; [Okada, S.] Kumamoto Univ, Grad Sch Med Sci, Ctr AIDS Res, Div Hemopoiesis, Kumamoto, Japan; [Ito, T.] Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, Kumamoto, Japan; [Ikeda, Y.] Keio Univ, Dept Internal Med, Tokyo 1608582, Japan; [Suda, T.] Keio Univ, Sakaguchi Lab, Dept Cell Differentiat, Tokyo 1608582, Japan	Keio University; Japan Science & Technology Agency (JST); Daiichi Sankyo Company Limited; Keio University; Japan Science & Technology Agency (JST); Keio University; RIKEN; National Cancer Center - Japan; National Cancer Center - Japan; Sapporo Medical University; Kumamoto University; Kumamoto University; Keio University; Keio University	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013; Okada, Seiji/F-5785-2013; Sugihara, Eiji/J-8058-2013; Mabuchi, Yo/L-1535-2013; Tsunoda, Tatsuhiko/K-2061-2014; Toyama, Yoshiaki/K-5743-2013; Suda, Toshio/H-6761-2013	Mabuchi, Yo/0000-0001-8008-3966; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Suda, Toshio/0000-0001-7540-1771; Sugihara, Eiji/0000-0002-3233-1045; Miya, Fuyuki/0000-0001-6758-2015; Saya, Hideyuki/0000-0001-6610-1902	Ministry of Education, Science, Sports, and Culture of Japan; National Institute of Biomedical Innovation, Japan	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation, Japan(National Institute of Biomedical Innovation)	We are grateful to I Ishimatsu and N Suzuki for technical assistance. We thank K Arai for secretarial assistance. This work was partly supported by grants from the Ministry of Education, Science, Sports, and Culture of Japan (TS and HS) and a grant from the National Institute of Biomedical Innovation, Japan (HS).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; BARRIOS C, 1994, AM J CLIN ONCOL-CANC, V17, P273, DOI 10.1097/00000421-199406000-00019; Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585-006-9046-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712; Fletcher C.D.M, 2002, OSTEOGENIC TUMOURS W; Fujino RS, 2006, MOL ENDOCRINOL, V20, P904, DOI 10.1210/me.2005-0423; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gregory CA, 2005, EXP CELL RES, V306, P330, DOI 10.1016/j.yexcr.2005.03.018; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Li H, 2008, DEV BIOL, V316, P458, DOI 10.1016/j.ydbio.2008.01.001; Li N, 2009, CANCER-AM CANCER SOC, V115, P4795, DOI 10.1002/cncr.24519; Lopez-Guerrero JA, 2004, DIAGN MOL PATHOL, V13, P81; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Mandal D, 2007, GENE, V386, P131, DOI 10.1016/j.gene.2006.08.030; Miller SFC, 2007, GENE EXPR PATTERNS, V7, P635, DOI 10.1016/j.modgep.2006.12.002; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Riggi N, 2006, CANCER RES, V66, P7016, DOI 10.1158/0008-5472.CAN-05-3979; Rosen ED, 2000, GENE DEV, V14, P1293; Shibata KR, 2007, STEM CELLS, V25, P2371, DOI 10.1634/stemcells.2007-0225; Thomas G, 2003, J BIOL CHEM, V278, P50563, DOI 10.1074/jbc.M307310200; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Zang X, 2007, P NATL ACAD SCI USA, V104, P19458, DOI 10.1073/pnas.0709802104	50	113	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5687	5699		10.1038/onc.2010.312	http://dx.doi.org/10.1038/onc.2010.312			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676132				2022-12-28	WOS:000283262500005
J	White, RA; Malkoski, SP; Wang, XJ				White, R. A.; Malkoski, S. P.; Wang, X-J			TGF beta signaling in head and neck squamous cell carcinoma	ONCOGENE			English	Review						TGF beta; Smad; head and neck cancer	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; II RECEPTOR GENE; DOWN-REGULATION; IMMUNE-RESPONSE; SKIN TUMORS; T-CELLS; CANCER; EXPRESSION; SMAD4	Transforming growth factor beta (TGF beta) is a key regulator of epithelial cell proliferation, immune function and angiogenesis. Because TGF beta signaling maintains epithelial homeostasis, dysregulated TGF beta signaling is common in many malignancies, including head and neck squamous cell carcinoma (HNSCC). Defective TGF beta signaling in epithelial cells causes hyperproliferation, reduced apoptosis and increased genomic instability, and the compensatory increase in TGF beta production by tumor epithelial cells with TGF beta signaling defects further promotes tumor growth and metastases by increasing angiogenesis and inflammation in tumor stromal cells. Here, we review the mouse models that we used to study TGF beta signaling in HNSCC. Oncogene (2010) 29, 5437-5446; doi:10.1038/onc.2010.306; published online 2 August 2010	[Wang, X-J] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [White, R. A.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; [Malkoski, S. P.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Wang, XJ (corresponding author), Univ Colorado Denver, Dept Pathol, AMC 12800 E 19th Ave, Aurora, CO 80045 USA.	xj.wang@ucdenver.edu			NIH [CA87849, CA79998, DE15953, CA131483]; NATIONAL CANCER INSTITUTE [R01CA079998, R01CA087849, K08CA131483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank our laboratory members for their contributions and Pamela Garl for proofreading. Work from the Wang laboratory was supported by NIH grants CA87849, CA79998, DE15953 and CA131483.	Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Berton TR, 2003, ONCOGENE, V22, P5415, DOI 10.1038/sj.onc.1206825; Bharathy S, 2008, CANCER RES, V68, P1656, DOI 10.1158/0008-5472.CAN-07-5089; Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Boucek J, 2010, J CELL MOL MED, V14, P426, DOI 10.1111/j.1582-4934.2008.00650.x; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHANG SE, 1991, INT J CANCER, V48, P409, DOI 10.1002/ijc.2910480318; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Curado MP, 2009, CURR OPIN ONCOL, V21, P194, DOI 10.1097/CCO.0b013e32832a68ca; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guasch G, 2007, CANCER CELL, V12, P313, DOI 10.1016/j.ccr.2007.08.020; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAWKINS BL, 1994, HEAD NECK-J SCI SPEC, V16, P424, DOI 10.1002/hed.2880160506; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Honjo Y, 2007, CELL CYCLE, V6, P1360, DOI 10.4161/cc.6.11.4268; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Iamaroon Anak, 2006, J Oral Sci, V48, P105, DOI 10.2334/josnusd.48.105; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karamouzis MV, 2007, JAMA-J AM MED ASSOC, V298, P70, DOI 10.1001/jama.298.1.70; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Kim SK, 1996, CANCER RES, V56, P2519; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCaul JA, 2002, LANCET ONCOL, V3, P280, DOI 10.1016/S1470-2045(02)00729-5; Moutsopoulos NM, 2008, CURR OPIN IMMUNOL, V20, P234, DOI 10.1016/j.coi.2008.04.003; Muro-Cacho CA, 1999, CLIN CANCER RES, V5, P1243; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Owens P, 2010, AM J PATHOL, V176, P122, DOI 10.2353/ajpath.2010.090081; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; Pardali K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Prime SS, 2001, ORAL ONCOL, V37, P1, DOI 10.1016/S1368-8375(00)00055-5; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIN DM, 1994, CANCER RES, V54, P3153; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Sparano A, 2006, LARYNGOSCOPE, V116, P735, DOI 10.1097/01.mlg.0000205141.54471.7f; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takebayashi S, 2000, CANCER RES, V60, P3397; Tannehill-Gregg SH, 2004, VET PATHOL, V41, P278, DOI 10.1354/vp.41-3-278; Teicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; van Oijen M G, 1998, Oral Dis, V4, P4; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; Weeks BH, 2001, CANCER RES, V61, P7435; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Xie W, 2003, ONCOL RES, V14, P61, DOI 10.3727/000000003108748612; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; YUAN B, 1994, CANCER RES, V54, P5310; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	110	69	69	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5437	5446		10.1038/onc.2010.306	http://dx.doi.org/10.1038/onc.2010.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20676130	Green Accepted			2022-12-28	WOS:000282945800001
J	Holgren, C; Dougherty, U; Edwin, F; Cerasi, D; Taylor, I; Fichera, A; Joseph, L; Bissonnette, M; Khare, S				Holgren, C.; Dougherty, U.; Edwin, F.; Cerasi, D.; Taylor, I.; Fichera, A.; Joseph, L.; Bissonnette, M.; Khare, S.			Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas	ONCOGENE			English	Article						sprouty-2; colon; cancer; metastasis; Ras; c-Met	HEPATOCYTE GROWTH-FACTOR; PROTEIN-KINASE PATHWAY; COLORECTAL-CANCER; URSODEOXYCHOLIC ACID; TYROSINE KINASE; HEPATOCELLULAR-CARCINOMA; ORTHOTOPIC IMPLANTATION; LIVER METASTASES; PROSTATE-CANCER; RAS ACTIVATION	Sprouty negatively regulates receptor tyrosine kinase signals by inhibiting Ras/extracellular signal-regulated kinase (ERK) pathways. Sprouty is downregulated in breast, prostate and liver cancers and appears to function as a tumor suppressor. The role of sprouty in colonic neoplasia, however, has not been investigated. Sprouty-2 protein and mRNA transcripts were significantly upregulated in human colonic adenocarcinomas. Strikingly, the c-Met receptor was also upregulated in tumors with increased sprouty-2. To delineate a potential causal relationship between sprouty-2 and c-Met, K-ras mutant HCT-116 colon cancer cells were transduced with purified TAT-sprouty-2 protein or stably transfected with full-length human sprouty-2 gene. Sprouty-2 upregulation significantly increased cell proliferation by accelerating cell cycle transition. Sprouty-2 transfectants showed strong upregulation of c-Met protein and mRNA transcripts and hepatocyte growth factor-stimulated ERK and Akt phosphorylation and enhanced cell migration and invasion. In contrast, knockdown of c-Met by small interfering RNA (siRNA) significantly decreased cell proliferation, migration and invasion in sprouty-2 transfectants. Further, knockdown of sprouty-2 by siRNA in parental HT-29 and LS-174T colon cancer cells also decreased cell invasion. Sprouty-2 transfectants formed significantly larger tumor xenografts and showed increased proliferation and angiogenesis and suppressed apoptosis. Sprouty-2 tumors metastasized to the liver from cecal orthotopic implants, suggesting that sprouty-2 might also enhance metastatic signals. Thus, in colon cancer sprouty functions as an oncogene and its effects are mediated in part by c-Met upregulation. Oncogene (2010) 29, 5241-5253; doi:10.1038/onc.2010.264; published online 26 July 2010	[Holgren, C.; Khare, S.] Loyola Univ Chicago, Dept Med, Maywood, IL 60153 USA; [Holgren, C.; Khare, S.] Hines Vet Affairs Med Ctr, Hines, IL USA; [Dougherty, U.; Cerasi, D.; Taylor, I.; Bissonnette, M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Edwin, F.] Loyola Univ Chicago, Dept Pharmacol, Maywood, IL 60153 USA; [Fichera, A.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA; [Joseph, L.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Chicago; Loyola University Chicago; University of Chicago; University of Chicago	Khare, S (corresponding author), Loyola Univ Chicago, Dept Med, Bldg 54,2160 S 1st Ave, Maywood, IL 60153 USA.	skhare@lumc.edu			VA merit award;  [CA036745]; NATIONAL CANCER INSTITUTE [R03CA097540, R37CA036745, R01CA036745] Funding Source: NIH RePORTER	VA merit award(US Department of Veterans Affairs); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were funded in part by Grant CA036745 (to M Bissonnette) and VA merit award (to S Khare).	Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Brett D, 2001, ONCOGENE, V20, P4581, DOI 10.1038/sj.onc.1204610; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; Dougherty U, 2009, CLIN CANCER RES, V15, P6780, DOI 10.1158/1078-0432.CCR-09-1678; Edwin F, 2006, J BIOL CHEM, V281, P4816, DOI 10.1074/jbc.M508300200; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Fujita S, 1997, JPN J CLIN ONCOL, V27, P378, DOI 10.1093/jjco/27.6.378; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kanayama M, 2007, AM J PHYSIOL-GASTR L, V293, pG230, DOI 10.1152/ajpgi.00068.2007; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Khare S, 2003, CANCER RES, V63, P3517; Khare S, 2008, NUTR CANCER, V60, P389, DOI 10.1080/01635580701883003; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kwabi-Addo B, 2004, CANCER RES, V64, P4728, DOI 10.1158/0008-5472.CAN-03-3759; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee M, 2006, BIOCHEM BIOPH RES CO, V350, P450, DOI 10.1016/j.bbrc.2006.09.067; Li N, 2007, J BIOL CHEM, V282, P16764, DOI 10.1074/jbc.M610835200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Lito P, 2008, J BIOL CHEM, V283, P2002, DOI 10.1074/jbc.M709046200; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Minowada G, 2009, AM J RESP CELL MOL, V40, P31, DOI 10.1165/rcmb.2008-0147OC; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Pelletier G, 2003, HEPATOLOGY, V37, P887, DOI 10.1053/jhep.2003.50118; Poppleton HM, 2004, BIOCHEM BIOPH RES CO, V323, P98, DOI 10.1016/j.bbrc.2004.08.070; Rozen S, 2000, Methods Mol Biol, V132, P365; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Shoji T, 2003, CANCER LETT, V195, P235, DOI 10.1016/S0304-3835(02)00108-8; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Sutterluty H, 2007, MOL CANCER RES, V5, P509, DOI 10.1158/1541-7786.MCR-06-0273; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Teranishi N, 2007, INT J ONCOL, V30, P593; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Vaculova A, 2006, FEBS LETT, V580, P6565, DOI 10.1016/j.febslet.2006.11.004; Wang L., 2008, Experimental Oncology, V30, P42; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049; Zeng ZS, 2004, CLIN EXP METASTAS, V21, P409, DOI 10.1007/s10585-005-1617-4	57	57	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5241	5253		10.1038/onc.2010.264	http://dx.doi.org/10.1038/onc.2010.264			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20661223	Green Accepted			2022-12-28	WOS:000282089100003
J	Tromp, JM; Tonino, SH; Elias, JA; Jaspers, A; Luijks, DM; Kater, AP; van Lier, RAW; van Oers, MHJ; Eldering, E				Tromp, J. M.; Tonino, S. H.; Elias, J. A.; Jaspers, A.; Luijks, D. M.; Kater, A. P.; van Lier, R. A. W.; van Oers, M. H. J.; Eldering, E.			Dichotomy in NF-kappa B signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering	ONCOGENE			English	Article						CLL; CD40; TLR9; NF-kappa B; Bcl-X-L; IgVH mutation status	CHRONIC LYMPHOCYTIC-LEUKEMIA; IMMUNOSTIMULATORY CPG-OLIGONUCLEOTIDES; CD40 STIMULATION; SURVIVAL; EXPRESSION; PHENOTYPE; APOPTOSIS; RECEPTOR; GENE; PROLIFERATION	Chronic lymphocytic leukemia (CLL) cells circulating in peripheral blood (PB) differ from the leukemic fraction in lymph nodes (LNs) with respect to cell division and drug sensitivity. CD40 stimulation of PB CLL cells in vitro results in chemoresistance and provides a partial model for the LN microenvironment. The TLR9 ligand CpG induces proliferation in immunoglobulin variable heavy-chain- unmutated CLL, but apoptosis in immunoglobulin variable heavy-chain-mutated CLL. To juxtapose proliferative with antiapoptotic signals, we investigated the effects of CpG in the context of CD40 ligation in mutated versus unmutated CLL cells in this study. Prolonged CD40 ligation induced classical, followed by alternative nuclear factor-kappa B (NF-kappa B), activity in both subgroups, correlating with enhanced Bfl-1 and Bcl-X-L levels, respectively. A dichotomy in NF-kappa B signaling occurred on combined CD40/TLR9 triggering. This induced declining p52 and Bcl-X-L levels, and reversed chemoresistance only in mutated cells, whereas unmutated cells proliferated, maintained p52 and Bcl-X-L and remained chemoresistant. The pivotal contribution of Bcl-X-L to chemoresistance was shown by the BH3 mimetic ABT-737 and RNA interference. Finally, in ex vivo LN samples, p52, p65 and Bcl-X-L levels were highly expressed, corroborating the in vitro findings. Thus, a distinction in NF-kappa B activation and drug susceptibility in mutated versus unmutated (LN-like) CLL cells was uncovered, which was causally linked to Bcl-X-L levels. Oncogene (2010) 29, 5071-5082; doi:10.1038/onc.2010.248; published online 28 June 2010	[Tromp, J. M.; Tonino, S. H.; Elias, J. A.; Jaspers, A.; van Lier, R. A. W.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Noord Holland, Netherlands; [Tromp, J. M.; Tonino, S. H.; Elias, J. A.; Luijks, D. M.; Kater, A. P.; van Oers, M. H. J.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Noord Holland, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Tromp, JM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands.	j.m.tromp@amc.uva.nl		van Lier, Rene/0000-0002-3201-7144	Dutch Cancer Society (KWF) [UvA 2007-3856]	Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	We thank professor Carel JM van Noessel and Dr Richard Bende (department of pathology, AMC) for obtaining lymph node material of CLL patients. We are very grateful to the patients for donating blood samples. ABT-737, a BH3 mimetic, was obtained under MTA from Abbott (Abbott Park, courtesy Dr S Rosenberg). This work was supported by the Dutch Cancer Society (KWF), Grant no. UvA 2007-3856.	Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Caligaris-Cappio F, 2008, J CLIN ONCOL, V26, P4497, DOI 10.1200/JCO.2007.15.4393; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Chiorazzi N, 2007, BEST PRACT RES CL HA, V20, P399, DOI 10.1016/j.beha.2007.03.007; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Damle RN, 2002, BLOOD, V99, P4087, DOI 10.1182/blood.V99.11.4087; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Decker T, 2000, BLOOD, V95, P999, DOI 10.1182/blood.V95.3.999.003k10_999_1006; Decker T, 2001, LEUKEMIA LYMPHOMA, V42, P301, DOI 10.3109/10428190109064586; Endo T, 2007, BLOOD, V109, P703, DOI 10.1182/blood-2006-06-027755; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Fakler M, 2008, BLOOD, V112, P317; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghia P, 2005, CURR TOP MICROBIOL, V294, P135, DOI 10.1007/3-540-29933-5_8; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hewamana S, 2008, BLOOD, V111, P4681, DOI 10.1182/blood-2007-11-125278; Homig-Holzel C, 2008, J EXP MED, V205, P1317, DOI 10.1084/jem.20080238; Kater AP, 2004, BRIT J HAEMATOL, V127, P404, DOI 10.1111/j.1365-2141.2004.05225.x; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; KEATING MJ, 2003, HEMATOL-AM SOC HEMAT, V5, P153; Kipps TJ, 2007, BEST PRACT RES CL HA, V20, P415, DOI 10.1016/j.beha.2007.04.001; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; LANKESTER AC, 1995, BLOOD, V86, P1090; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417; Lopez-Guerra M, 2009, CLIN CANCER RES, V15, P2767, DOI 10.1158/1078-0432.CCR-08-2382; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI200523409; Nedellec S, 2005, J IMMUNOL, V174, P3749, DOI 10.4049/jimmunol.174.6.3749; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Pleyer L, 2009, NAT REV CLIN ONCOL, V6, P405, DOI 10.1038/nrclinonc.2009.72; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Rodriguez A, 2004, CLIN CANCER RES, V10, P6796, DOI 10.1158/1078-0432.CCR-04-0753; Romano MF, 1998, BLOOD, V92, P990; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Silke J, 2010, CELL DEATH DIFFER, V17, P35, DOI 10.1038/cdd.2009.114; Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003; Tas SW, 2007, BLOOD, V110, P1540, DOI 10.1182/blood-2006-11-056010; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Gent R, 2008, CANCER RES, V68, P10137, DOI 10.1158/0008-5472.CAN-08-2325; Wierda WG, 2003, BRIT J HAEMATOL, V120, P452, DOI 10.1046/j.1365-2141.2003.04118.x; Willimott S, 2007, BRIT J HAEMATOL, V138, P721, DOI 10.1111/j.1365-2141.2007.06717.x; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676	54	61	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5071	5082		10.1038/onc.2010.248	http://dx.doi.org/10.1038/onc.2010.248			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581863				2022-12-28	WOS:000281620100007
J	Zeng, X; Shaikh, FY; Harrison, MK; Adon, AM; Trimboli, AJ; Carroll, KA; Sharma, N; Timmers, C; Chodosh, LA; Leone, G; Saavedra, HI				Zeng, X.; Shaikh, F. Y.; Harrison, M. K.; Adon, A. M.; Trimboli, A. J.; Carroll, K. A.; Sharma, N.; Timmers, C.; Chodosh, L. A.; Leone, G.; Saavedra, H. I.			The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2	ONCOGENE			English	Article						Ras; centrosome amplification; mammary cancers; cyclin D1; Cdk4; Nek2	IN-SITU HYBRIDIZATION; BREAST-CANCER; C-MYC; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; TRANSGENIC MICE; MMTV-RAS; P21(WAF1/CIP1) DEFICIENCY; GENOMIC INSTABILITY; PROTEIN-KINASE	Centrosome amplification (CA) contributes to carcinogenesis by generating aneuploidy. Elevated frequencies of CA in most benign breast lesions and primary tumors suggest a causative role for CA in breast cancers. Clearly, identifying which and how altered signal transduction pathways contribute to CA is crucial to breast cancer control. Although a causative and cooperative role for c-Myc and Ras in mammary tumorigenesis is well documented, their ability to generate CA during mammary tumor initiation remains unexplored. To answer that question, K-Ras(G12D) and c-Myc were induced in mouse mammary glands. Although CA was observed in mammary tumors initiated by c-Myc or K-Ras(G12D), it was detected only in premalignant mammary lesions expressing K-Ras(G12D). CA, both in vivo and in vitro, was associated with increased expression of the centrosome-regulatory proteins, cyclin D1 and Nek2. Abolishing the expression of cyclin D1, Cdk4 or Nek2 in MCF10A human mammary epithelial cells expressing H-Ras(G12V) abrogated Ras-induced CA, whereas silencing cyclin E1 or B2 had no effect. Thus, we conclude that CA precedes mammary tumorigenesis, and interfering with centrosome-regulatory targets suppresses CA. Oncogene (2010) 29, 5103-5112; doi:10.1038/onc.2010.253; published online 28 June 2010	[Zeng, X.; Harrison, M. K.; Adon, A. M.; Saavedra, H. I.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Zeng, X.; Harrison, M. K.; Adon, A. M.; Saavedra, H. I.] Emory Winship Canc Inst, Atlanta, GA USA; [Shaikh, F. Y.; Trimboli, A. J.; Sharma, N.; Timmers, C.; Leone, G.] Program Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH USA; [Carroll, K. A.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Chodosh, L. A.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Chodosh, L. A.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Emory University; Emory University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Saavedra, HI (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365C Clifton Rd,Room C3084, Atlanta, GA 30322 USA.	hsaaved@emory.edu			Georgia Cancer Coalition Distinguished Scholar Award;  [NIH R01CA98371];  [DOD BCRP W81XWH-05-1-0405];  [NIH U01 CA105490];  [R01CA85619];  [R01HD042619];  [R01CA121275];  [R01HD047470];  [P01CA097189];  [K01CA104079]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042619, R01HD047470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA085619, K01CA104079, R01CA098371, R01CA121275, U01CA105490, P01CA097189, R01CA151521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER	Georgia Cancer Coalition Distinguished Scholar Award; ; ; ; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Rene Opavsky, Paul W Doetsch, Ya Wang and Hui Wang for manuscript discussions. We also thank Ms Carla G Saavedra and Meredith Roberts for editing; Dr Harold Varmus for providing tetO-K-Ras<SUP>G12D</SUP> mice; Dr J Brugge for nontransformed MCF10A cells; and Jana Opavska, Joi Carmichael and Stacy Sannem for technical assistance. We thank Dr Adam Marcus (from the Emory Imaging Core) and Mr Alan Bakaletz, for imaging advice. Lewis A Chodosh was funded by NIH R01CA98371, DOD BCRP W81XWH-05-1-0405 and NIH U01 CA105490, Gustavo Leone by R01CA85619, R01HD042619, R01CA121275, R01HD047470 and P01CA097189, Harold Saavedra by K01CA104079, and a Georgia Cancer Coalition Distinguished Scholar Award.	Adon AM, 2010, MOL CELL BIOL, V30, P694, DOI 10.1128/MCB.00253-09; BAILLY E, 1992, J CELL SCI, V101, P529; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bearss DJ, 2002, CANCER RES, V62, P2077; Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051; BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I; Blakely CM, 2005, DEVELOPMENT, V132, P1147, DOI 10.1242/dev.01655; Blancato J, 2004, BRIT J CANCER, V90, P1612, DOI 10.1038/sj.bjc.6601703; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Castellanos E, 2008, CURR BIOL, V18, P1209, DOI 10.1016/j.cub.2008.07.029; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; CLAIR T, 1987, CANCER RES, V47, P5290; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fleisch MC, 2006, MICROSC RES TECHNIQ, V69, P964, DOI 10.1002/jemt.20372; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Guo HQ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1752; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hundley JE, 1997, CANCER RES, V57, P600; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; JANES PW, 1994, ONCOGENE, V9, P3601; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MANGUES R, 1990, ONCOGENE, V5, P1491; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Omer CA, 2000, CANCER RES, V60, P2680; Pihan GA, 1998, CANCER RES, V58, P3974; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Rummukainen JK, 2001, MODERN PATHOL, V14, P1030, DOI 10.1038/modpathol.3880431; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schneeweiss A, 2003, INT J CANCER, V107, P346, DOI 10.1002/ijc.11408; Shackney SE, 2004, CLIN CANCER RES, V10, P3042, DOI 10.1158/1078-0432.CCR-0401-3; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	70	62	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5103	5112		10.1038/onc.2010.253	http://dx.doi.org/10.1038/onc.2010.253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581865	Green Accepted			2022-12-28	WOS:000281620100010
J	Puca, R; Nardinocchi, L; Givol, D; D'Orazi, G				Puca, R.; Nardinocchi, L.; Givol, D.; D'Orazi, G.			Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells	ONCOGENE			English	Review						HIPK2; p53; post-translational modifications; protein conformation; apoptosis; chemoresistance	INTERACTING PROTEIN KINASE-2; ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; TUMOR-SUPPRESSOR; IN-VIVO; P53SER46 PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; GENE-EXPRESSION	The p53 protein is the most studied tumor suppressor and the p53 pathway has been shown to mediate cellular stress responses that are disrupted when cancer develops. After DNA damage, p53 is activated as transcription factor to directly induce the expression of target genes involved in cell-cycle arrest, DNA repair, senescence and, importantly, apoptosis. Post-translational modifications of p53 are essential for the activation of p53 and for selection of target genes. The tumor suppressor homeodomain-interacting protein kinase-2 (HIPK2) is a crucial regulator of p53 apoptotic function by phosphorylating its N-terminal serine 46 (Ser46) and facilitating Lys382 acetylation at the C-terminus. HIPK2 is activated by numerous genotoxic agents and can be deregulated in tumors by several conditions including hypoxia. Recent findings suggest that HIPK2 active/inactive protein can affect p53 function in multiple and unexpected ways. This makes p53 as well as HIPK2 interesting targets for cancer therapy. Hence, understanding the role of HIPK2 as p53 activator may provide important insights in the process of tumor progression, and may also serve as the crucial point in the diagnostic and therapeutical aspects of cancer. Oncogene (2010) 29, 4378-4387; doi: 10.1038/onc.2010.183; published online 31 May 2010	[Puca, R.; Nardinocchi, L.; D'Orazi, G.] Natl Canc Inst Regina Elena, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy; [Puca, R.; Nardinocchi, L.; D'Orazi, G.] Univ G DAnnunzio, Dept Oncol & Neurosci, Sch Med, I-66013 Chieti, Italy; [Givol, D.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	G d'Annunzio University of Chieti-Pescara; Weizmann Institute of Science	D'Orazi, G (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Sch Med, Via Vestini 31, I-66013 Chieti, Italy.	gdorazi@unich.it	D'Orazi, Gabriella/T-2792-2019	D'Orazi, Gabriella/0000-0001-6876-9105	Italian Association for Cancer Research; University 'Gd'Annunzio'; Italian Foundation for Cancer Research (FIRC)	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); University 'Gd'Annunzio'; Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This research conducted in our laboratory is supported by Grants from Italian Association for Cancer Research and from University 'Gd'Annunzio'. RP is a recipient of a fellowship from Italian Foundation for Cancer Research (FIRC).	Al-Beiti MAM, 2008, AUST NZ J OBSTET GYN, V48, P329, DOI 10.1111/j.1479-828X.2008.00874.x; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Calzado MA, 2009, BIOL CHEM, V390, P1079, DOI 10.1515/BC.2009.112; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi DW, 2008, J BIOL CHEM, V283, P4682, DOI 10.1074/jbc.M708873200; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2006, CLIN CANCER RES, V12, P735, DOI 10.1158/1078-0432.CCR-05-1557; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; Di Stefana V, 2005, FEBS LETT, V579, P5473, DOI 10.1016/j.febslet.2005.09.008; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINAUT P, 1993, CANCER RES, V53, P1739; Haldar SM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000502; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; JOENGER AC, 2007, ONCOGENE, V26, P2226; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Komiyama S, 2004, BIOCHEM BIOPH RES CO, V323, P816, DOI 10.1016/j.bbrc.2004.08.161; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Krieghoff-Henning E, 2008, BBA-MOL CELL RES, V1783, P2185, DOI 10.1016/j.bbamcr.2008.07.002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lanni C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010171; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mantovani F, 2007, NAT STRUCT MOL BIOL, V14, P912, DOI 10.1038/nsmb1306; Marchetti A, 2004, CELL DEATH DIFFER, V11, P596, DOI 10.1038/sj.cdd.4401368; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Moehlenbrink J, 2010, CANCER LETT, V292, P119, DOI 10.1016/j.canlet.2009.11.016; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Moller A, 2003, CANCER RES, V63, P4310; Nardinocchi L, 2010, CELL CYCLE, V9, P1270, DOI 10.4161/cc.9.7.11125; Nardinocchi L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006819; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2002, BIOCHEM BIOPH RES CO, V290, P942, DOI 10.1006/bbrc.2001.6310; Pistritto G, 2007, CELL DEATH DIFFER, V14, P1837, DOI 10.1038/sj.cdd.4402186; Puca R, 2008, GYNECOL ONCOL, V109, P403, DOI 10.1016/j.ygyno.2008.02.018; Puca R, 2008, CANCER RES, V68, P3707, DOI 10.1158/0008-5472.CAN-07-6776; Puca R, 2010, FREE RADICAL BIO MED, V48, P1338, DOI 10.1016/j.freeradbiomed.2010.02.015; Puca R, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-85; Puca R, 2009, EXP CELL RES, V315, P67, DOI 10.1016/j.yexcr.2008.10.018; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rinaldo C, 2009, CANCER RES, V69, P6241, DOI 10.1158/0008-5472.CAN-09-0337; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shmueli A, 2007, MOL CELL, V25, P794, DOI 10.1016/j.molcel.2007.03.006; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yoshida K, 2006, J BIOL CHEM, V281, P5734, DOI 10.1074/jbc.M512074200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	99	109	114	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4378	4387		10.1038/onc.2010.183	http://dx.doi.org/10.1038/onc.2010.183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514025				2022-12-28	WOS:000280559100002
J	Yousef, AF; Fonseca, GJ; Pelka, P; Ablack, JNG; Walsh, C; Dick, FA; Bazett-Jones, DP; Shaw, GS; Mymryk, JS				Yousef, A. F.; Fonseca, G. J.; Pelka, P.; Ablack, J. N. G.; Walsh, C.; Dick, F. A.; Bazett-Jones, D. P.; Shaw, G. S.; Mymryk, J. S.			Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase UBC9 and likely interferes with polySUMOylation	ONCOGENE			English	Article						E1A; UBC9; SUMO; adenovirus	PML NUCLEAR-BODIES; UBIQUITIN LIGASE; SEQUENCE-ANALYSIS; ADENOVIRUS E1A; PROTEIN; YEAST; MOTIF; RNF4; TRANSFORMATION; SUMOYLATION	Hub proteins have central roles in regulating cellular processes. By targeting a single cellular hub, a viral oncogene may gain control over an entire module in the cellular interaction network that is potentially comprised of hundreds of proteins. The adenovirus E1A oncoprotein is a viral hub that interacts with many cellular hub proteins by short linear motifs/molecular recognition features (MoRFs). These interactions transform the architecture of the cellular protein interaction network and virtually reprogram the cell. To identify additional MoRFs within E1A, we screened portions of E1A for their ability to activate yeast pseudohyphal growth or differentiation. This identified a novel functional region within E1A conserved region 2 comprised of the sequence EVIDLT. This MoRF is necessary and sufficient to bind the N-terminal region of the SUMO conjugase UBC9, which also interacts with SUMO noncovalently and is involved in polySUMOylation. Our results suggest that E1A interferes with polySUMOylation, but not with monoSUMOylation. These data provide the first insight into the consequences of the interaction of E1A with UBC9, which was initially described in 1996. We further demonstrate that polySUMOylation regulates pseudohyphal growth and promyelocytic leukemia body reorganization by E1A. In conclusion, the interaction of the E1A oncogene with UBC9 mimics the normal binding between SUMO and UBC9 and represents a novel mechanism to modulate polySUMOylation. Oncogene (2010) 29, 4693-4704; doi:10.1038/onc.2010.226; published online 14 June 2010	[Yousef, A. F.; Fonseca, G. J.; Ablack, J. N. G.; Walsh, C.; Mymryk, J. S.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada; [Pelka, P.; Dick, F. A.; Mymryk, J. S.] Univ Western Ontario, Dept Oncol, London Reg Canc Program, London, ON N6A 4L6, Canada; [Dick, F. A.; Shaw, G. S.] Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada; [Bazett-Jones, D. P.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Mymryk, JS (corresponding author), Univ Western Ontario, Dept Microbiol, London Reg Canc Program, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	jmymryk@uwo.ca	Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625; Yousef, Ahmed F./0000-0001-5734-489X	Canadian Institutes of Health Research [MOP-75647]; OGS award; OGSST award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); OGS award; OGSST award	This work was supported by a grant from the Canadian Institutes of Health Research to JSM (MOP-75647). AFY and PP were supported by CIHR Strategic Training Program in Cancer Research and Technology Transfer awards. GJF and JNA held OGS and OGSST awards. We thank Drs C Brandl, R Hay, J Taylor, K Uzunova, J Dohmen, A Strunnikov, G Fink, E Yeh and O Janne for generously providing reagents essential for this study.	Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Capili AD, 2007, J MOL BIOL, V369, P608, DOI 10.1016/j.jmb.2007.04.006; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dunnebier T, 2009, INT J CANCER, V125, P596, DOI 10.1002/ijc.24286; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Knipscheer P, 2007, EMBO J, V26, P2797, DOI 10.1038/sj.emboj.7601711; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mo YY, 2005, EXPERT OPIN THER TAR, V9, P1203, DOI 10.1517/14728222.9.6.1203; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Mullen JR, 2008, J BIOL CHEM, V283, P19912, DOI 10.1074/jbc.M802690200; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; O'Connor MJ, 1999, J VIROL, V73, P3574; Pelka P, 2008, J VIROL, V82, P7252, DOI 10.1128/JVI.00104-08; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; Prudden J, 2009, NAT STRUCT MOL BIOL, V16, P509, DOI 10.1038/nsmb.1582; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Sekiyama N, 2010, PROTEINS, V78, P1491, DOI 10.1002/prot.22667; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; Uzunova K, 2007, J BIOL CHEM, V282, P34167, DOI 10.1074/jbc.M706505200; Wang JH, 2007, MOL CELL, V27, P228, DOI 10.1016/j.molcel.2007.05.023; Weisshaar SR, 2008, FEBS LETT, V582, P3174, DOI 10.1016/j.febslet.2008.08.008; Xie Y, 2007, J BIOL CHEM, V282, P34176, DOI 10.1074/jbc.M706025200; Yousef AF, 2008, INT J CANCER, V122, P942, DOI 10.1002/ijc.23174; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699; Zhu S, 2010, ONCOGENE, V29, P1763, DOI 10.1038/onc.2009.459	58	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4693	4704		10.1038/onc.2010.226	http://dx.doi.org/10.1038/onc.2010.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543865				2022-12-28	WOS:000281127400008
J	Ogba, N; Doughman, YQ; Chaplin, LJ; Hu, Y; Gargesha, M; Watanabe, M; Montano, MM				Ogba, N.; Doughman, Y. Q.; Chaplin, L. J.; Hu, Y.; Gargesha, M.; Watanabe, M.; Montano, M. M.			HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland	ONCOGENE			English	Article						HEXIM1; VEGF; HIF-1 alpha; P-TEFb; angiogenesis; mammary tumors	ESTROGEN-RECEPTOR-ALPHA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CANCER CELLS; GENE-EXPRESSION; DOWN-REGULATION; RAT UTERUS; IN-VIVO; VEGF; ESTRADIOL; TRANSCRIPTION	Recently, we found that mutation of the C-terminus of transcription factor hexamethylene bisacetamide-inducible protein 1 (HEXIM1) in mice leads to abnormalities in cardiovascular development because of aberrant vascular endothelial growth factor ( VEGF) expression. HEXIM1 regulation of some genes has also been shown to be positive transcription elongation factor b ( P-TEFb) dependent. However, it is not known whether HEXIM1 regulates VEGF in the mammary gland. We demonstrate that HEXIM1 regulates estrogen-induced VEGF transcription through inhibition of estrogen receptor-alpha recruitment to the VEGF promoter in a P-TEFb-independent manner in MCF-7 cells. Under hypoxic conditions, HEXIM1 inhibits estrogen-induced hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein expression and recruitment of HIF-1 alpha to the hypoxia-response element in the VEGF promoter. In the mouse mammary gland, increased HEXIM1 expression decreased estrogen-driven VEGF and HIF-1 alpha expression. Conversely, a mutation in the C-terminus of HEXIM1 ( HEXIM1(1- 312)) led to increased VEGF and HIF-1 alpha expression and vascularization in mammary glands of heterozygous HEXIM1(1-312) mice when compared with their wild-type littermates. In addition, HEXIM1(1-312) mice have a higher incidence of carcinogen-induced mammary tumors with increased vascularization, suggesting an inhibitory role for HEXIM1 during angiogenesis. Taken together, our data provide evidence to suggest a novel role for HEXIM1 in cancer progression. Oncogene ( 2010) 29, 3639-3649; doi: 10.1038/onc.2010.110; published online 10 May 2010	[Ogba, N.; Chaplin, L. J.; Hu, Y.; Montano, M. M.] Rainbow Babies & Childrens Hosp, Dept Pharmacol, Cleveland, OH 44106 USA; [Doughman, Y. Q.; Watanabe, M.] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Gargesha, M.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu	Ogba, Ndiya/K-8429-2014	Ogba, Ndiya/0000-0003-0453-3763	National Institute of Health [CA92440]; American Heart Association; Department of Defense [W81XWH-06-1-0426]; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Anthony J Berdis and Jay Prendergast for reagents and their help with kinase and ELISA assays. This work was supported by the National Institute of Health Grant CA92440 and the American Heart Association Grant to MMM and a Department of Defense predoctoral Fellowship W81XWH-06-1-0426 to NO.	Bogin L, 2002, CANCER RES, V62, P1948; Bos R, 2004, BREAST CANCER RES, V6, pR450, DOI 10.1186/bcr813; Buteau-Lozano H, 2002, CANCER RES, V62, P4977; Cho JY, 2005, MOL ENDOCRINOL, V19, P1191, DOI 10.1210/me.2004-0162; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Garvin S, 2005, BRIT J CANCER, V93, P1005, DOI 10.1038/sj.bjc.6602824; Higgins KJ, 2006, ENDOCRINOLOGY, V147, P3285, DOI 10.1210/EN.2006-0081; Hyder SM, 2006, ENDOCR-RELAT CANCER, V13, P667, DOI 10.1677/erc.1.00931; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388; Kazi AA, 2007, ENDOCRINOLOGY, V148, P2363, DOI 10.1210/en.2006-1394; Kazi AA, 2009, BIOL REPROD, V81, P378, DOI 10.1095/biolreprod.109.076117; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lydon JP, 1999, CANCER RES, V59, P4276; Maity A, 2001, BREAST CANCER RES TR, V67, P51, DOI 10.1023/A:1010662905549; Molitoris KH, 2009, ENDOCRINOLOGY, V150, P5405, DOI 10.1210/en.2009-0884; Montano MM, 2008, CIRC RES, V102, P415, DOI 10.1161/CIRCRESAHA.107.157859; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Qiang Z, 2006, MICROBIOL MOL BIOL R, V70, P646, DOI 10.1128/MMBR.00011-06; Rossiter H, 2007, FASEB J, V21, P3994, DOI 10.1096/fj.07-8720com; Rugo HS, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-suppl_1-43; Seifeddine R, 2007, J STEROID BIOCHEM, V104, P169, DOI 10.1016/j.jsbmb.2007.03.025; Shimizu N, 2005, P NATL ACAD SCI USA, V102, P8555, DOI 10.1073/pnas.0409863102; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Wittmann BM, 2003, CANCER RES, V63, P5151; Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456	33	22	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3639	3649		10.1038/onc.2010.110	http://dx.doi.org/10.1038/onc.2010.110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20453883	Green Accepted			2022-12-28	WOS:000279108600005
J	Pandey, RN; Rani, R; Yeo, EJ; Spencer, M; Hu, S; Lang, RA; Hegde, RS				Pandey, R. N.; Rani, R.; Yeo, E-J; Spencer, M.; Hu, S.; Lang, R. A.; Hegde, R. S.			The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells	ONCOGENE			English	Article						EYA; cell migration; cell invasion; metastasis; tyrosine phosphatase	EXTRASKELETAL MYXOID CHONDROSARCOMAS; FATE DETERMINATION FACTOR; TYROSINE-PHOSPHATASE; BREAST-CANCER; ENDOTHELIAL MIGRATION; SIX1 HOMEOPROTEIN; GENE-EXPRESSION; MATRIX ADHESION; GROWTH; DEPHOSPHORYLATION	The Eyes Absent (EYA) proteins combine transactivation, tyrosine phosphatase, and threonine phosphatase activities in their function as part of a conserved regulatory cascade involved in embryonic organ development. EYA tyrosine phosphatase activity contributes to fly eye development, and vertebrate EYA is involved in promoting DNA damage repair subsequent to genotoxic stress. EYAs are known to be expressed at elevated levels in ovarian and breast cancers. Here, we show that the tyrosine phosphatase activity of the EYAs promotes tumor cell migration, invasion, and transformation. These cellular effects are accompanied by alterations of the actin cytoskeleton and increased levels of active Rac and Cdc42. The invasiveness conferred by EYA is reflected in vivo by inhibition of metastasis seen when EYA3 expression is silenced in the invasive breast cancer cell line MDA-MB-231. Together, our data directly associate the tyrosine phosphatase activity of the EYAs with the oncogenesis-associated cellular properties of motility and invasiveness. Oncogene (2010) 29, 3715-3722; doi: 10.1038/onc.2010.122; published online 26 April 2010	[Hegde, R. S.] Cincinnati Childrens Hosp Res Fdn, Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Pandey, R. N.; Rani, R.; Yeo, E-J; Spencer, M.; Hu, S.; Hegde, R. S.] Univ Cincinnati, Dept Pediat, Sch Med, Cincinnati, OH 45221 USA; [Yeo, E-J; Lang, R. A.] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Dept Ophthalmol,Div Pediat Ophthalmol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hegde, RS (corresponding author), Cincinnati Childrens Hosp Res Fdn, Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	rashmi.hegde@cchmc.org	Lang, Richard/E-5578-2011; Hu, Shengyong/C-2798-2012	Lang, Richard/0000-0002-5212-254X	NIH [RO1-EY014648, R21-EY19125]; NATIONAL EYE INSTITUTE [R01EY014648, R21EY019125] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Dr Steve Danzer for help with confocal microscopy. Viral vectors were produced by the Viral Vector Core at the Translational Core Laboratories, Cincinnati Children's Hospital Research Foundation. This study was supported by NIH grants RO1-EY014648 and R21-EY19125 to RSH.	Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Bacac M, 2006, J PATHOL, V208, P543, DOI 10.1002/path.1915; Bonini NM, 1997, DEVELOPMENT, V124, P4819; Castiglioni S, 2007, BIOCHEM BIOPH RES CO, V364, P534, DOI 10.1016/j.bbrc.2007.10.022; Christensen KL, 2007, ONCOGENE, V26, P3406, DOI 10.1038/sj.onc.1210122; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Hanson IM, 2001, SEMIN CELL DEV BIOL, V12, P475, DOI 10.1006/scdb.2001.0271; Hisaoka M, 2004, CANCER GENET CYTOGEN, V152, P101, DOI 10.1016/j.cancergencyto.2003.11.011; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Jemc J, 2007, DEV BIOL, V310, P416, DOI 10.1016/j.ydbio.2007.07.024; Kriebel M, 2007, DEV DYNAM, V236, P1526, DOI 10.1002/dvdy.21170; Krishnan N, 2009, J BIOL CHEM, V284, P16066, DOI 10.1074/jbc.C900032200; Laflamme C, 2003, CANCER RES, V63, P449; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Liang FB, 2005, J BIOL CHEM, V280, P24857, DOI 10.1074/jbc.M502780200; Mariotti M, 2009, INT J BIOCHEM CELL B, V41, P687, DOI 10.1016/j.biocel.2008.08.005; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Pauli T, 2005, DEVELOPMENT, V132, P2771, DOI 10.1242/dev.01841; Rayapureddi JP, 2006, FEBS LETT, V580, P3853, DOI 10.1016/j.febslet.2006.06.009; Rayapureddi JP, 2005, BIOCHEMISTRY-US, V44, P751, DOI 10.1021/bi0481794; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Richert MM, 2005, BREAST CANCER RES, V7, pR819, DOI 10.1186/bcr1292; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Takamatsu N, 1998, Nihon Ronen Igakkai Zasshi, V35, P535; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Winchester C, 2000, J CLIN PATHOL, V53, P212, DOI 10.1136/jcp.53.3.212; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu KM, 2007, MOL BIOL CELL, V18, P755, DOI 10.1091/mbc.E06-09-0793; Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06; Xiong WJ, 2009, DEV CELL, V16, P271, DOI 10.1016/j.devcel.2008.12.005; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang L, 2005, CANCER RES, V65, P925; Zhang TY, 2006, DEVELOPMENT, V133, P4881, DOI 10.1242/dev.02669	44	79	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3715	3722		10.1038/onc.2010.122	http://dx.doi.org/10.1038/onc.2010.122			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418914	Green Accepted			2022-12-28	WOS:000279108600011
J	Odvody, J; Vincent, T; Arrate, MP; Grieb, B; Wang, S; Garriga, J; Lozano, G; Iwakuma, T; Haines, DS; Eischen, CM				Odvody, J.; Vincent, T.; Arrate, M. P.; Grieb, B.; Wang, S.; Garriga, J.; Lozano, G.; Iwakuma, T.; Haines, D. S.; Eischen, C. M.			A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis	ONCOGENE			English	Article						MTBP; Myc; Mdm2; p53; lymphoma	C-MYC; APOPTOSIS; MTBP; P53; HAPLOINSUFFICIENCY; INSTABILITY; MICE	Mdm2 binding protein (MTBP) has been implicated in cell-cycle arrest and the Mdm2/p53 tumor suppressor pathway through its interaction with Mdm2. To determine the function of MTBP in tumorigenesis and its potential role in the Mdm2/p53 pathway, we crossed Mtbp-deficient mice to E mu-myc transgenic mice, in which overexpression of the oncogene c-Myc induces B-cell lymphomas primarily through inactivation of the Mdm2/p53 pathway. We report that Myc-induced B-cell lymphoma development in Mtbp heterozygous mice was profoundly delayed. Surprisingly, reduced levels of Mtbp did not lead to an increase in B-cell apoptosis or affect Mdm2. Instead, an Mtbp deficiency inhibited Myc-induced proliferation and the upregulation of Myc target genes necessary for cell growth. Consistent with a role in proliferation, Mtbp expression was induced by Myc and other factors that promote cell-cycle progression and was elevated in lymphomas from humans and mice. Therefore, Mtbp functioned independent of Mdm2 and was a limiting factor for the proliferative and transforming functions of Myc. Thus, Mtbp is a previously unrecognized regulator of Myc-induced tumorigenesis. Oncogene (2010) 29, 3287-3296; doi: 10.1038/onc.2010.82; published online 22 March 2010	[Eischen, C. M.] Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, Nashville, TN 37232 USA; [Wang, S.; Haines, D. S.] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA; [Garriga, J.; Haines, D. S.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA; [Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; [Iwakuma, T.] Louisiana State Univ, Dept Genet, Hlth Sci Ctr, New Orleans, LA USA	Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Eischen, CM (corresponding author), Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, C3321 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	christine.eischen@vanderbilt.edu		Grieb, Brian/0000-0003-3980-8050	NCI [R01CA098139, R01CA117935, P30CA068485]; Leukemia & Lymphoma Society;  [P01CA095569]; NATIONAL CANCER INSTITUTE [R01CA098139, P01CA095569, R01CA117935, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Silvia Plaza, Brandon Metge, Jane Kennedy, and Dr Chris Carbone for expert technical assistance, Dr Xavier Grana for assistance with the adenoviruses and the H1299 cell-cycle studies, and Dr William Dupont and Dale Plummer for Kaplan-Meier analysis. We also thank the following individuals for providing recombinant adenoviruses: Dr Joseph Nevins (Duke University) E2F1 and c-Myc, Dr Juan Fueyo (MD Anderson Cancer Center) p16, Dr Wafik El-Deiry (University of Pennsylvania) p21, and Dr Ruiz-Lozano (Burnham Institute) GFP. This work was supported by NCI Grants R01CA098139, R01CA117935 and P30CA068485 (CME); the Leukemia & Lymphoma Society (CME) and P01CA095569 (DH and JG).	Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Iwakuma T, 2008, ONCOGENE, V27, P1813, DOI 10.1038/sj.onc.1210827; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Martin ES, 2007, CANCER RES, V67, P10736, DOI 10.1158/0008-5472.CAN-07-2742; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	19	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3287	3296		10.1038/onc.2010.82	http://dx.doi.org/10.1038/onc.2010.82			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305689	Green Accepted			2022-12-28	WOS:000278321100011
J	Komiya, T; Coxon, A; Park, Y; Chen, WD; Zajac-Kaye, M; Meltzer, P; Karpova, T; Kaye, FJ				Komiya, T.; Coxon, A.; Park, Y.; Chen, W-D; Zajac-Kaye, M.; Meltzer, P.; Karpova, T.; Kaye, F. J.			Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer	ONCOGENE			English	Article						Crtc1; LKB1; lung cancer; Mect1/Torc1; NR4A2	SENSITIVE COINCIDENCE DETECTOR; PEUTZ-JEGHERS-SYNDROME; MUCOEPIDERMOID CARCINOMA; SALIVARY-GLAND; MAMMALIAN-CELLS; WARTHINS TUMORS; GENE-EXPRESSION; RECEPTOR NR4A2; FUSION; ACTIVATION	Activation of Crtc1 (also known as Mect1/Torc1) by a t(11; 19) chromosomal rearrangement underlies the etiology of malignant salivary gland tumors. As LKB1 is a target for mutational inactivation in lung cancer and was recently shown to regulate hepatic Crtc2/CREB transcriptional activity in mice, we now present evidence suggesting disruption of an LKB1/Crtc pathway in cancer. Although Crtc1 is preferentially expressed in adult brain tissues, we observed elevated levels of steady-state Crtc1 in thoracic tumors. In addition, we show that somatic loss of LKB1 is associated with underphosphorylation of endogenous Crtc1, enhanced Crtc1 nuclear localization and enhanced expression of the Crtc prototypic target gene, NR4A2/Nurr1. Inhibition of NR4A2 was associated with growth suppression of LKB1 null tumors, but showed little effect on LKB1-wildtype cells. These data strengthen the role of dysregulated Crtc as a bona. de cancer gene, present a new element to the complex LKB1 tumorigenic axis, and suggest that Crtc genes may be aberrantly activated in a wider range of common adult malignancies. Oncogene (2010) 29, 1672-1680; doi:10.1038/onc.2009.453; published online 14 December 2009	[Komiya, T.; Coxon, A.; Park, Y.; Chen, W-D; Meltzer, P.; Kaye, F. J.] NCI, Genet Branch, Bethesda, MD 20892 USA; [Komiya, T.; Coxon, A.; Park, Y.; Chen, W-D; Zajac-Kaye, M.; Meltzer, P.; Karpova, T.; Kaye, F. J.] Natl Naval Med Ctr, Bethesda, MD USA; [Zajac-Kaye, M.] NCI, Med Oncol Branch, Bethesda, MD 20892 USA; [Karpova, T.] NCI, Lab Receptor Biol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaye, FJ (corresponding author), Univ Florida Coll, Canc Genet Res Ctr, Dept Med, Rm 364,1376 Mowry Rd, Gainesville, FL 32610 USA.	fkaye@ufl.edu	kaye, frederic/E-2437-2011; CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515; Karpova, Tatiana/0000-0001-6025-2128	NATIONAL CANCER INSTITUTE [ZIASC007256, Z01SC007256, ZIABC011091] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 SC007256-20] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Achcar RDD, 2009, HUM PATHOL, V40, P854, DOI 10.1016/j.humpath.2008.11.007; Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Camelo-Piragua SI, 2009, HUM PATHOL, V40, P887, DOI 10.1016/j.humpath.2008.11.004; Carling D, 2006, TRENDS MOL MED, V12, P144, DOI 10.1016/j.molmed.2006.02.003; Cheng HL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000369; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Fu A, 2008, CELL CYCLE, V7, P3823, DOI 10.4161/cc.7.24.7241; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Kaye FJ, 2006, CLIN CANCER RES, V12, P3878, DOI 10.1158/1078-0432.CCR-06-0791; Kaye FJ, 2009, MOL CANCER THER, V8, P1399, DOI 10.1158/1535-7163.MCT-09-0135; Kazakov DV, 2007, AM J DERMATOPATH, V29, P457, DOI 10.1097/DAD.0b013e318156d76f; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Lennerz JKM, 2009, AM J SURG PATHOL, V33, P835, DOI 10.1097/PAS.0b013e318190cf5b; Li QX, 2006, HISTOL HISTOPATHOL, V21, P533, DOI 10.14670/HH-21.533; Li SA, 2009, J NEUROSCI, V29, P2334, DOI 10.1523/JNEUROSCI.2296-08.2009; Li XL, 2009, CARCINOGENESIS, V30, P1606, DOI 10.1093/carcin/bgp161; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shah U, 2008, CANCER RES, V68, P3562, DOI 10.1158/0008-5472.CAN-07-6620; Shaw RJ, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.286pe55; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wallen-Mackenzie A, 2003, GENE DEV, V17, P3036, DOI 10.1101/gad.276003; Wang B, 2008, CELL METAB, V7, P434, DOI 10.1016/j.cmet.2008.02.010; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Zhou Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000016	48	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1672	1680		10.1038/onc.2009.453	http://dx.doi.org/10.1038/onc.2009.453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20010869	Green Accepted			2022-12-28	WOS:000275694700012
J	Nogueira, C; Kim, KH; Sung, H; Paraiso, KHT; Dannenberg, JH; Bosenberg, M; Chin, L; Kim, M				Nogueira, C.; Kim, K-H; Sung, H.; Paraiso, K. H. T.; Dannenberg, J-H; Bosenberg, M.; Chin, L.; Kim, M.			Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis	ONCOGENE			English	Article						melanoma; PTEN; RAS; E-cadherin; AKT2; mouse model	TUMOR-SUPPRESSOR GENE; PTEN/MMAC1 ALTERATIONS; MALIGNANT-MELANOMA; BRAF MUTATIONS; UP-REGULATION; KINASE-B; BREAST; LEADS; INACTIVATION; NEOPLASIA	Mitogen-activated protein kinase (MAPK) and AKT pathways are frequently co-activated in melanoma through overexpression of receptor tyrosine kinases, mutations in their signaling surrogates, such as RAS and BRAF, or loss of negative regulators such as PTEN. As RAS can be a positive upstream regulator of PI3-K, it has been proposed that the loss of PTEN and the activation of RAS are redundant events in melanoma pathogenesis. Here, in genetically engineered mouse models of cutaneous melanomas, we sought to better understand the genetic interactions between HRAS activation and PTEN inactivation in melanoma genesis and progression in vivo. We showed that HRAS activation cooperates with Pten+/- and Ink4a/Arf-/- to increase melanoma penetrance and promote metastasis. Correspondingly, gain-and loss-of-function studies established that Pten loss increases invasion and migration of melanoma cells and non-transformed melanocytes, and such biological activity correlates with a shift to phosphorylation of AKT2 isoform and E-cadherin down-regulation. Thus, Pten inactivation can drive the genesis and promote the metastatic progression of RAS activated Ink4a/Arf deficient melanomas. Oncogene (2010) 29, 6222-6232; doi:10.1038/onc.2010.349; published online 16 August 2010	[Chin, L.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Chin, L.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Nogueira, C.; Dannenberg, J-H; Chin, L.; Kim, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Nogueira, C.] Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP Med Fac, P-4100 Oporto, Portugal; [Kim, K-H; Sung, H.; Paraiso, K. H. T.; Kim, M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr,Mol Oncol Dept, Tampa, FL 33612 USA; [Bosenberg, M.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Universidade do Porto; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Vermont	Chin, L (corresponding author), Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, 44 Binney St, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu; Minjung.Kim@moffitt.org	Nogueira, Cristina/N-4574-2015	Nogueira, Cristina/0000-0002-0853-5304; Kim, Minjung/0000-0002-5682-6640; KIM, KWAN HYUN/0000-0003-4975-2839	FCT [PRAXIS/BD/21794/99]; Claudia Adams Barr Program; Dermatology Foundation; Melanoma Research Foundation; Damon-Runyon Cancer Research Foundation; Dutch Cancer Society; NIH [UO1 CA84313, RO1 CA93947]; Bankhead Coley Pilot Research Award; American Cancer Society [93-032-13]; NATIONAL CANCER INSTITUTE [U01CA084313, R01CA093947] Funding Source: NIH RePORTER	FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Claudia Adams Barr Program; Dermatology Foundation; Melanoma Research Foundation; Damon-Runyon Cancer Research Foundation; Dutch Cancer Society(KWF Kankerbestrijding); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bankhead Coley Pilot Research Award; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	C Nogueira was supported by a fellowship from FCT (PRAXIS/BD/21794/99). M Kim was supported by the Claudia Adams Barr Program, the Dermatology Foundation, and Melanoma Research Foundation. JH Dannenberg was supported by Damon-Runyon Cancer Research Foundation and the Dutch Cancer Society. This work was supported by grants from the NIH (UO1 CA84313; RO1 CA93947) to L Chin and from the Bankhead Coley Pilot Research Award and American Cancer Society Institutional Research Grant (#93-032-13) to M Kim. We thank Dr Jin Q Cheng (Moffitt Cancer Center) for helpful discussion and adenoviruses for PTEN and DN-AKT2 expression, and Dr Ronald A DePinho for critical reading of this paper.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arboleda MJ, 2003, CANCER RES, V63, P196; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Dhawan P, 2002, CANCER RES, V62, P7335; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Forbes SA, 2008, CURR PROTOC HUM GENE, V57, DOI DOI 10.11.1-10.11.26; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Guldberg P, 1997, CANCER RES, V57, P3660; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Ikeda T, 2000, ONCOL REP, V7, P567; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; JAFARI M, 1995, J CANCER RES CLIN, V121, P23, DOI 10.1007/BF01202725; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Lahtz C, 2010, J INVEST DERMATOL, V130, P620, DOI 10.1038/jid.2009.226; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Sviderskaya EV, 1997, J INVEST DERMATOL, V108, P30, DOI 10.1111/1523-1747.ep12285621; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2000, CANCER RES, V60, P1800; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	58	71	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6222	6232		10.1038/onc.2010.349	http://dx.doi.org/10.1038/onc.2010.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	21686270	Green Accepted			2022-12-28	WOS:000284601700004
